[{"text": "The hypotensive effect of 100 mg/kg alpha-methyldopa was also partially reversed by naloxone.", "entity_list": [{"name": "hypotensive", "ent_type": "Disease", "char_span": [4, 15], "ent_id": "D007022", "tok_span": [1, 3]}, {"name": "alpha-methyldopa", "ent_type": "Chemical", "char_span": [36, 52], "ent_id": "D008750", "tok_span": [9, 14]}, {"name": "naloxone", "ent_type": "Chemical", "char_span": [84, 92], "ent_id": "D009270", "tok_span": [19, 22]}], "relation_list": [{"subject": "alpha-methyldopa", "object": "hypotensive", "sbj_char_span": [36, 52], "obj_char_span": [4, 15], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 14], "obj_tok_span": [1, 3]}], "umls_entity_list": []}, {"text": "Lidocaine-induced cardiac asystole.", "entity_list": [{"name": "Lidocaine", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D008012", "tok_span": [0, 3]}, {"name": "cardiac asystole", "ent_type": "Disease", "char_span": [18, 34], "ent_id": "D006323", "tok_span": [5, 9]}], "relation_list": [{"subject": "Lidocaine", "object": "cardiac asystole", "sbj_char_span": [0, 9], "obj_char_span": [18, 34], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "Suxamethonium infusion rate and observed fasciculations.", "entity_list": [{"name": "Suxamethonium", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D013390", "tok_span": [0, 5]}, {"name": "fasciculations", "ent_type": "Disease", "char_span": [41, 55], "ent_id": "D005207", "tok_span": [9, 12]}], "relation_list": [{"subject": "Suxamethonium", "object": "fasciculations", "sbj_char_span": [0, 13], "obj_char_span": [41, 55], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [9, 12]}], "umls_entity_list": []}, {"text": "Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.", "entity_list": [{"name": "hyoscine", "ent_type": "Chemical", "char_span": [170, 178], "ent_id": "D012601", "tok_span": [37, 40]}, {"name": "scopolamine", "ent_type": "Chemical", "char_span": [157, 168], "ent_id": "D012601", "tok_span": [33, 36]}, {"name": "overdosage", "ent_type": "Disease", "char_span": [180, 190], "ent_id": "D062787", "tok_span": [41, 44]}, {"name": "Galanthamine hydrobromide", "ent_type": "Chemical", "char_span": [0, 25], "ent_id": "D005702", "tok_span": [0, 7]}], "relation_list": [{"subject": "scopolamine", "object": "overdosage", "sbj_char_span": [157, 168], "obj_char_span": [180, 190], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 36], "obj_tok_span": [41, 44]}, {"subject": "hyoscine", "object": "overdosage", "sbj_char_span": [170, 178], "obj_char_span": [180, 190], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 40], "obj_tok_span": [41, 44]}], "umls_entity_list": []}, {"text": "Effects of uninephrectomy and high protein feeding on lithium-induced chronic renal failure in rats.", "entity_list": [{"name": "chronic renal failure", "ent_type": "Disease", "char_span": [70, 91], "ent_id": "D007676", "tok_span": [13, 16]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [54, 61], "ent_id": "D008094", "tok_span": [10, 11]}], "relation_list": [{"subject": "lithium", "object": "chronic renal failure", "sbj_char_span": [54, 61], "obj_char_span": [70, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "Lithium also caused proteinuria and systolic hypertension in absence of glomerulosclerosis.", "entity_list": [{"name": "hypertension", "ent_type": "Disease", "char_span": [45, 57], "ent_id": "D006973", "tok_span": [7, 8]}, {"name": "proteinuria", "ent_type": "Disease", "char_span": [20, 31], "ent_id": "D011507", "tok_span": [4, 5]}, {"name": "glomerulosclerosis", "ent_type": "Disease", "char_span": [72, 90], "ent_id": "D005921", "tok_span": [11, 15]}, {"name": "Lithium", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "D008094", "tok_span": [0, 2]}], "relation_list": [{"subject": "Lithium", "object": "proteinuria", "sbj_char_span": [0, 7], "obj_char_span": [20, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [4, 5]}, {"subject": "Lithium", "object": "hypertension", "sbj_char_span": [0, 7], "obj_char_span": [45, 57], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [7, 8]}], "umls_entity_list": []}, {"text": "The results indicate that Li-induced nephropathy, even when the GFR is only modestly reduced, is associated with proteinuria and arterial systolic hypertension.", "entity_list": [{"name": "hypertension", "ent_type": "Disease", "char_span": [147, 159], "ent_id": "D006973", "tok_span": [26, 27]}, {"name": "nephropathy", "ent_type": "Disease", "char_span": [37, 48], "ent_id": "D007674", "tok_span": [7, 8]}, {"name": "Li", "ent_type": "Chemical", "char_span": [26, 28], "ent_id": "D008094", "tok_span": [4, 5]}, {"name": "proteinuria", "ent_type": "Disease", "char_span": [113, 124], "ent_id": "D011507", "tok_span": [22, 23]}], "relation_list": [{"subject": "Li", "object": "hypertension", "sbj_char_span": [26, 28], "obj_char_span": [147, 159], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [26, 27]}, {"subject": "Li", "object": "proteinuria", "sbj_char_span": [26, 28], "obj_char_span": [113, 124], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [22, 23]}], "umls_entity_list": []}, {"text": "Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction, ischemia, and bundle branch block.", "entity_list": [{"name": "cocaine", "ent_type": "Chemical", "char_span": [14, 21], "ent_id": "D003042", "tok_span": [4, 5]}, {"name": "myocardial infarction", "ent_type": "Disease", "char_span": [116, 137], "ent_id": "D009203", "tok_span": [21, 23]}, {"name": "bundle branch block", "ent_type": "Disease", "char_span": [153, 172], "ent_id": "D002037", "tok_span": [27, 30]}, {"name": "ischemia", "ent_type": "Disease", "char_span": [139, 147], "ent_id": "D007511", "tok_span": [24, 25]}, {"name": "myocardial injury", "ent_type": "Disease", "char_span": [87, 104], "ent_id": "D009202", "tok_span": [17, 19]}], "relation_list": [{"subject": "cocaine", "object": "myocardial infarction", "sbj_char_span": [14, 21], "obj_char_span": [116, 137], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [21, 23]}, {"subject": "cocaine", "object": "bundle branch block", "sbj_char_span": [14, 21], "obj_char_span": [153, 172], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [27, 30]}], "umls_entity_list": []}, {"text": "Sulpiride-induced tardive dystonia.", "entity_list": [{"name": "Sulpiride", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D013469", "tok_span": [0, 3]}, {"name": "tardive dystonia", "ent_type": "Disease", "char_span": [18, 34], "ent_id": "D004421", "tok_span": [5, 10]}], "relation_list": [{"subject": "Sulpiride", "object": "tardive dystonia", "sbj_char_span": [0, 9], "obj_char_span": [18, 34], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 10]}], "umls_entity_list": []}, {"text": "We studied a 37-year-old man who developed persistent segmental dystonia within 2 months after starting sulpiride therapy.", "entity_list": [{"name": "sulpiride", "ent_type": "Chemical", "char_span": [104, 113], "ent_id": "D013469", "tok_span": [20, 23]}, {"name": "dystonia", "ent_type": "Disease", "char_span": [64, 72], "ent_id": "D004421", "tok_span": [13, 15]}], "relation_list": [{"subject": "sulpiride", "object": "dystonia", "sbj_char_span": [104, 113], "obj_char_span": [64, 72], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "We could not find any previous reports of sulpiride-induced tardive dystonia.", "entity_list": [{"name": "tardive dystonia", "ent_type": "Disease", "char_span": [60, 76], "ent_id": "D004421", "tok_span": [13, 18]}, {"name": "sulpiride", "ent_type": "Chemical", "char_span": [42, 51], "ent_id": "D013469", "tok_span": [8, 11]}], "relation_list": [{"subject": "sulpiride", "object": "tardive dystonia", "sbj_char_span": [42, 51], "obj_char_span": [60, 76], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [13, 18]}], "umls_entity_list": []}, {"text": "Myasthenia gravis presenting as weakness after magnesium administration.", "entity_list": [{"name": "magnesium", "ent_type": "Chemical", "char_span": [47, 56], "ent_id": "D008274", "tok_span": [10, 11]}, {"name": "Myasthenia gravis", "ent_type": "Disease", "char_span": [0, 17], "ent_id": "D009157", "tok_span": [0, 6]}], "relation_list": [{"subject": "magnesium", "object": "Myasthenia gravis", "sbj_char_span": [47, 56], "obj_char_span": [0, 17], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [0, 6]}], "umls_entity_list": []}, {"text": "Although paralysis after magnesium administration has been described in patients with known myasthenia gravis, it has not previously been reported to be the initial or only manifestation of the disease.", "entity_list": [{"name": "paralysis", "ent_type": "Disease", "char_span": [9, 18], "ent_id": "D010243", "tok_span": [1, 3]}, {"name": "myasthenia gravis", "ent_type": "Disease", "char_span": [92, 109], "ent_id": "D009157", "tok_span": [13, 19]}, {"name": "magnesium", "ent_type": "Chemical", "char_span": [25, 34], "ent_id": "D008274", "tok_span": [4, 5]}], "relation_list": [{"subject": "magnesium", "object": "myasthenia gravis", "sbj_char_span": [25, 34], "obj_char_span": [92, 109], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [13, 19]}], "umls_entity_list": []}, {"text": "Twenty common migraine patients received a one sided frontotemporal application of nitroglycerin (10 patients) or placebo ointment (10 patients) in a double blind study.", "entity_list": [{"name": "nitroglycerin", "ent_type": "Chemical", "char_span": [83, 96], "ent_id": "D005996", "tok_span": [13, 16]}, {"name": "migraine", "ent_type": "Disease", "char_span": [14, 22], "ent_id": "D008881", "tok_span": [2, 3]}], "relation_list": [{"subject": "nitroglycerin", "object": "migraine", "sbj_char_span": [83, 96], "obj_char_span": [14, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [2, 3]}], "umls_entity_list": []}, {"text": "Early onset migraine attacks were induced by nitroglycerin in seven out of 10 patients versus no patient in the placebo group.", "entity_list": [{"name": "nitroglycerin", "ent_type": "Chemical", "char_span": [45, 58], "ent_id": "D005996", "tok_span": [7, 10]}, {"name": "migraine", "ent_type": "Disease", "char_span": [12, 20], "ent_id": "D008881", "tok_span": [2, 3]}], "relation_list": [{"subject": "nitroglycerin", "object": "migraine", "sbj_char_span": [45, 58], "obj_char_span": [12, 20], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [2, 3]}], "umls_entity_list": []}, {"text": "Subsequently 20 migraine patients, who developed an early onset attack with frontotemporal nitroglycerin, received the drug in a second induction test at other body areas.", "entity_list": [{"name": "nitroglycerin", "ent_type": "Chemical", "char_span": [91, 104], "ent_id": "D005996", "tok_span": [14, 17]}, {"name": "migraine", "ent_type": "Disease", "char_span": [16, 24], "ent_id": "D008881", "tok_span": [2, 3]}], "relation_list": [{"subject": "nitroglycerin", "object": "migraine", "sbj_char_span": [91, 104], "obj_char_span": [16, 24], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [2, 3]}], "umls_entity_list": []}, {"text": "Thus the migraine-inducing effect of nitroglycerin seems to depend on direct stimulation of the habitual site of pain, suggesting that the frontotemporal region is of crucial importance in the development of a migraine crisis.", "entity_list": [{"name": "migraine", "ent_type": "Disease", "char_span": [210, 218], "ent_id": "D008881", "tok_span": [39, 40]}, {"name": "nitroglycerin", "ent_type": "Chemical", "char_span": [37, 50], "ent_id": "D005996", "tok_span": [7, 10]}, {"name": "migraine", "ent_type": "Disease", "char_span": [9, 17], "ent_id": "D008881", "tok_span": [2, 3]}, {"name": "pain", "ent_type": "Disease", "char_span": [113, 117], "ent_id": "D010146", "tok_span": [22, 23]}], "relation_list": [{"subject": "nitroglycerin", "object": "migraine", "sbj_char_span": [37, 50], "obj_char_span": [9, 17], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [2, 3]}, {"subject": "nitroglycerin", "object": "migraine", "sbj_char_span": [37, 50], "obj_char_span": [210, 218], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [39, 40]}], "umls_entity_list": []}, {"text": "Clotiazepam-induced acute hepatitis.", "entity_list": [{"name": "hepatitis", "ent_type": "Disease", "char_span": [26, 35], "ent_id": "D056486", "tok_span": [7, 8]}, {"name": "Clotiazepam", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "C084599", "tok_span": [0, 4]}], "relation_list": [{"subject": "Clotiazepam", "object": "hepatitis", "sbj_char_span": [0, 11], "obj_char_span": [26, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [7, 8]}], "umls_entity_list": []}, {"text": "We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.", "entity_list": [{"name": "hepatitis", "ent_type": "Disease", "char_span": [52, 61], "ent_id": "D056486", "tok_span": [10, 11]}, {"name": "clotiazepam", "ent_type": "Chemical", "char_span": [148, 159], "ent_id": "C084599", "tok_span": [24, 27]}, {"name": "thienodiazepine", "ent_type": "Chemical", "char_span": [163, 178], "ent_id": "C013295", "tok_span": [29, 34]}, {"name": "extensive hepatocellular necrosis", "ent_type": "Disease", "char_span": [67, 100], "ent_id": "D047508", "tok_span": [12, 15]}], "relation_list": [{"subject": "clotiazepam", "object": "hepatitis", "sbj_char_span": [148, 159], "obj_char_span": [52, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 27], "obj_tok_span": [10, 11]}], "umls_entity_list": []}, {"text": "The administration of several benzodiazepines, chemically related to clotiazepam, did not interfere with recovery and did not induce any relapse of hepatitis.", "entity_list": [{"name": "benzodiazepines", "ent_type": "Chemical", "char_span": [30, 45], "ent_id": "D001569", "tok_span": [4, 9]}, {"name": "hepatitis", "ent_type": "Disease", "char_span": [148, 157], "ent_id": "D056486", "tok_span": [29, 30]}, {"name": "clotiazepam", "ent_type": "Chemical", "char_span": [69, 80], "ent_id": "C084599", "tok_span": [13, 16]}], "relation_list": [{"subject": "clotiazepam", "object": "hepatitis", "sbj_char_span": [69, 80], "obj_char_span": [148, 157], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [29, 30]}], "umls_entity_list": []}, {"text": "This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.", "entity_list": [{"name": "clotiazepam", "ent_type": "Chemical", "char_span": [126, 137], "ent_id": "C084599", "tok_span": [21, 24]}, {"name": "clotiazepam", "ent_type": "Chemical", "char_span": [28, 39], "ent_id": "C084599", "tok_span": [4, 7]}, {"name": "hepatitis", "ent_type": "Disease", "char_span": [57, 66], "ent_id": "D056486", "tok_span": [10, 11]}, {"name": "benzodiazepines", "ent_type": "Chemical", "char_span": [150, 165], "ent_id": "D001569", "tok_span": [26, 31]}, {"name": "hepatotoxicity", "ent_type": "Disease", "char_span": [103, 117], "ent_id": "D056486", "tok_span": [18, 20]}], "relation_list": [{"subject": "clotiazepam", "object": "hepatotoxicity", "sbj_char_span": [126, 137], "obj_char_span": [103, 117], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [18, 20]}, {"subject": "clotiazepam", "object": "hepatitis", "sbj_char_span": [28, 39], "obj_char_span": [57, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [10, 11]}, {"subject": "clotiazepam", "object": "hepatitis", "sbj_char_span": [126, 137], "obj_char_span": [57, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [10, 11]}, {"subject": "clotiazepam", "object": "hepatotoxicity", "sbj_char_span": [28, 39], "obj_char_span": [103, 117], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [18, 20]}], "umls_entity_list": []}, {"text": "Arterial hypertension as a complication of prolonged ketoconazole treatment.", "entity_list": [{"name": "hypertension", "ent_type": "Disease", "char_span": [9, 21], "ent_id": "D006973", "tok_span": [2, 3]}, {"name": "ketoconazole", "ent_type": "Chemical", "char_span": [53, 65], "ent_id": "D007654", "tok_span": [8, 11]}], "relation_list": [{"subject": "ketoconazole", "object": "hypertension", "sbj_char_span": [53, 65], "obj_char_span": [9, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [2, 3]}], "umls_entity_list": []}, {"text": "Two of 14 patients with Cushing's syndrome treated on a long-term basis with ketoconazole developed sustained hypertension.", "entity_list": [{"name": "Cushing's syndrome", "ent_type": "Disease", "char_span": [24, 42], "ent_id": "D003480", "tok_span": [5, 11]}, {"name": "ketoconazole", "ent_type": "Chemical", "char_span": [77, 89], "ent_id": "D007654", "tok_span": [19, 22]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [110, 122], "ent_id": "D006973", "tok_span": [24, 25]}], "relation_list": [{"subject": "ketoconazole", "object": "hypertension", "sbj_char_span": [77, 89], "obj_char_span": [110, 122], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 22], "obj_tok_span": [24, 25]}], "umls_entity_list": []}, {"text": "In both cases normal plasma and urinary free cortisol levels had been achieved following ketoconazole therapy, yet continuous blood pressure monitoring demonstrated hypertension 31 (patient 1) and 52 weeks (patient 2) after treatment.", "entity_list": [{"name": "ketoconazole", "ent_type": "Chemical", "char_span": [89, 101], "ent_id": "D007654", "tok_span": [14, 17]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [165, 177], "ent_id": "D006973", "tok_span": [25, 26]}, {"name": "cortisol", "ent_type": "Chemical", "char_span": [45, 53], "ent_id": "D006854", "tok_span": [8, 9]}], "relation_list": [{"subject": "ketoconazole", "object": "hypertension", "sbj_char_span": [89, 101], "obj_char_span": [165, 177], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [25, 26]}], "umls_entity_list": []}, {"text": "Our findings show that long-term treatment with high doses of ketoconazole may induce enzyme blockade leading to mineralocorticoid-related hypertension.", "entity_list": [{"name": "hypertension", "ent_type": "Disease", "char_span": [139, 151], "ent_id": "D006973", "tok_span": [26, 27]}, {"name": "ketoconazole", "ent_type": "Chemical", "char_span": [62, 74], "ent_id": "D007654", "tok_span": [12, 15]}], "relation_list": [{"subject": "ketoconazole", "object": "hypertension", "sbj_char_span": [62, 74], "obj_char_span": [139, 151], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [26, 27]}], "umls_entity_list": []}, {"text": "Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.", "entity_list": [{"name": "tranexamic acid", "ent_type": "Chemical", "char_span": [99, 114], "ent_id": "D014148", "tok_span": [15, 19]}, {"name": "trauma", "ent_type": "Disease", "char_span": [213, 219], "ent_id": "D014947", "tok_span": [37, 38]}, {"name": "sepsis", "ent_type": "Disease", "char_span": [223, 229], "ent_id": "D018805", "tok_span": [39, 40]}, {"name": "intravascular coagulation", "ent_type": "Disease", "char_span": [13, 38], "ent_id": "D004211", "tok_span": [2, 5]}, {"name": "AMCA", "ent_type": "Chemical", "char_span": [116, 120], "ent_id": "D014148", "tok_span": [20, 22]}, {"name": "pulmonary and renal insufficiency", "ent_type": "Disease", "char_span": [147, 180], "ent_id": "D01166", "tok_span": [29, 33]}], "relation_list": [{"subject": "AMCA", "object": "intravascular coagulation", "sbj_char_span": [116, 120], "obj_char_span": [13, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 22], "obj_tok_span": [2, 5]}, {"subject": "tranexamic acid", "object": "intravascular coagulation", "sbj_char_span": [99, 114], "obj_char_span": [13, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 19], "obj_tok_span": [2, 5]}], "umls_entity_list": []}, {"text": "A randomized comparison of labetalol and nitroprusside for induced hypotension.", "entity_list": [{"name": "labetalol", "ent_type": "Chemical", "char_span": [27, 36], "ent_id": "D007741", "tok_span": [4, 7]}, {"name": "nitroprusside", "ent_type": "Chemical", "char_span": [41, 54], "ent_id": "D009599", "tok_span": [8, 12]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [67, 78], "ent_id": "D007022", "tok_span": [14, 15]}], "relation_list": [{"subject": "nitroprusside", "object": "hypotension", "sbj_char_span": [41, 54], "obj_char_span": [67, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [14, 15]}, {"subject": "labetalol", "object": "hypotension", "sbj_char_span": [27, 36], "obj_char_span": [67, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [14, 15]}], "umls_entity_list": []}, {"text": "In a randomized study, labetalol-induced hypotension and nitroprusside-induced hypotension were compared in 20 patients (10 in each group) scheduled for major orthopedic procedures.", "entity_list": [{"name": "nitroprusside", "ent_type": "Chemical", "char_span": [57, 70], "ent_id": "D009599", "tok_span": [12, 16]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [79, 90], "ent_id": "D007022", "tok_span": [18, 19]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [41, 52], "ent_id": "D007022", "tok_span": [10, 11]}, {"name": "labetalol", "ent_type": "Chemical", "char_span": [23, 32], "ent_id": "D007741", "tok_span": [5, 8]}], "relation_list": [{"subject": "nitroprusside", "object": "hypotension", "sbj_char_span": [57, 70], "obj_char_span": [79, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 16], "obj_tok_span": [18, 19]}, {"subject": "labetalol", "object": "hypotension", "sbj_char_span": [23, 32], "obj_char_span": [41, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [10, 11]}, {"subject": "nitroprusside", "object": "hypotension", "sbj_char_span": [57, 70], "obj_char_span": [41, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 16], "obj_tok_span": [10, 11]}, {"subject": "labetalol", "object": "hypotension", "sbj_char_span": [23, 32], "obj_char_span": [79, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [18, 19]}], "umls_entity_list": []}, {"text": "Nitroprusside infusion was associated with a significant (p less than 0.05) increase in heart rate and cardiac output; rebound hypertension was observed in three patients after discontinuation of nitroprusside.", "entity_list": [{"name": "increase in heart rate and cardiac output", "ent_type": "Disease", "char_span": [76, 117], "ent_id": "D016534", "tok_span": [18, 25]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [127, 139], "ent_id": "D006973", "tok_span": [28, 29]}, {"name": "nitroprusside", "ent_type": "Chemical", "char_span": [196, 209], "ent_id": "D009599", "tok_span": [37, 41]}], "relation_list": [{"subject": "nitroprusside", "object": "increase in heart rate and cardiac output", "sbj_char_span": [196, 209], "obj_char_span": [76, 117], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 41], "obj_tok_span": [18, 25]}], "umls_entity_list": []}, {"text": "Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).", "entity_list": [{"name": "hexafluorodiethyl ether", "ent_type": "Chemical", "char_span": [20, 43], "ent_id": "D005481", "tok_span": [5, 11]}, {"name": "Seizures", "ent_type": "Disease", "char_span": [0, 8], "ent_id": "D012640", "tok_span": [0, 3]}, {"name": "HFDE", "ent_type": "Chemical", "char_span": [45, 49], "ent_id": "D005481", "tok_span": [12, 14]}, {"name": "seizures", "ent_type": "Disease", "char_span": [124, 132], "ent_id": "D012640", "tok_span": [30, 31]}, {"name": "CBZ", "ent_type": "Chemical", "char_span": [115, 118], "ent_id": "D002220", "tok_span": [27, 29]}], "relation_list": [{"subject": "hexafluorodiethyl ether", "object": "seizures", "sbj_char_span": [20, 43], "obj_char_span": [124, 132], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 11], "obj_tok_span": [30, 31]}, {"subject": "hexafluorodiethyl ether", "object": "Seizures", "sbj_char_span": [20, 43], "obj_char_span": [0, 8], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 11], "obj_tok_span": [0, 3]}, {"subject": "HFDE", "object": "Seizures", "sbj_char_span": [45, 49], "obj_char_span": [0, 8], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 14], "obj_tok_span": [0, 3]}, {"subject": "HFDE", "object": "seizures", "sbj_char_span": [45, 49], "obj_char_span": [124, 132], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 14], "obj_tok_span": [30, 31]}], "umls_entity_list": []}, {"text": "Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment.", "entity_list": [{"name": "HFDE", "ent_type": "Chemical", "char_span": [121, 125], "ent_id": "D005481", "tok_span": [24, 26]}, {"name": "weight gain", "ent_type": "Disease", "char_span": [182, 193], "ent_id": "D015430", "tok_span": [36, 38]}, {"name": "seizures", "ent_type": "Disease", "char_span": [134, 142], "ent_id": "D012640", "tok_span": [28, 29]}, {"name": "CBZ", "ent_type": "Chemical", "char_span": [23, 26], "ent_id": "D002220", "tok_span": [3, 5]}], "relation_list": [{"subject": "HFDE", "object": "seizures", "sbj_char_span": [121, 125], "obj_char_span": [134, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 26], "obj_tok_span": [28, 29]}], "umls_entity_list": []}, {"text": "Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.", "entity_list": [{"name": "nitroglycerin", "ent_type": "Chemical", "char_span": [442, 455], "ent_id": "D005996", "tok_span": [136, 139]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [404, 415], "ent_id": "D007022", "tok_span": [128, 129]}, {"name": "tachycardia", "ent_type": "Disease", "char_span": [258, 269], "ent_id": "D013610", "tok_span": [97, 98]}, {"name": "norepinephrine", "ent_type": "Chemical", "char_span": [297, 311], "ent_id": "D009638", "tok_span": [103, 104]}, {"name": "hydralazine", "ent_type": "Chemical", "char_span": [427, 438], "ent_id": "D006830", "tok_span": [131, 135]}], "relation_list": [{"subject": "nitroglycerin", "object": "hypotension", "sbj_char_span": [442, 455], "obj_char_span": [404, 415], "rel_type": "chemical-induced disease", "sbj_tok_span": [136, 139], "obj_tok_span": [128, 129]}, {"subject": "hydralazine", "object": "hypotension", "sbj_char_span": [427, 438], "obj_char_span": [404, 415], "rel_type": "chemical-induced disease", "sbj_tok_span": [131, 135], "obj_tok_span": [128, 129]}], "umls_entity_list": []}, {"text": "Impotence was more common among male patients than controls and was found to be associated with co-morbidity and the taking of methotrexate.", "entity_list": [{"name": "Impotence", "ent_type": "Disease", "char_span": [0, 9], "ent_id": "D007172", "tok_span": [0, 3]}, {"name": "methotrexate", "ent_type": "Chemical", "char_span": [127, 139], "ent_id": "D008727", "tok_span": [25, 27]}], "relation_list": [{"subject": "methotrexate", "object": "Impotence", "sbj_char_span": [127, 139], "obj_char_span": [0, 9], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 27], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.", "entity_list": [{"name": "renal papillary necrosis", "ent_type": "Disease", "char_span": [23, 47], "ent_id": "D007681", "tok_span": [4, 7]}, {"name": "cancer of the renal pelvis, ureter or bladder", "ent_type": "Disease", "char_span": [51, 96], "ent_id": "D00768", "tok_span": [8, 18]}, {"name": "phenacetin", "ent_type": "Chemical", "char_span": [135, 145], "ent_id": "D010615", "tok_span": [23, 26]}, {"name": "paracetamol", "ent_type": "Chemical", "char_span": [149, 160], "ent_id": "D000082", "tok_span": [27, 31]}], "relation_list": [{"subject": "phenacetin", "object": "renal papillary necrosis", "sbj_char_span": [135, 145], "obj_char_span": [23, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [4, 7]}], "umls_entity_list": []}, {"text": "The risk of renal papillary necrosis was increased nearly 20-fold by consumption of phenacetin, which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer.", "entity_list": [{"name": "renal papillary necrosis", "ent_type": "Disease", "char_span": [12, 36], "ent_id": "D007681", "tok_span": [3, 6]}, {"name": "phenacetin", "ent_type": "Chemical", "char_span": [84, 94], "ent_id": "D010615", "tok_span": [15, 18]}, {"name": "ureteric cancer", "ent_type": "Disease", "char_span": [181, 196], "ent_id": "D014516", "tok_span": [35, 39]}, {"name": "cancer of the renal pelvis and bladder", "ent_type": "Disease", "char_span": [130, 168], "ent_id": "D00768", "tok_span": [25, 32]}], "relation_list": [{"subject": "phenacetin", "object": "renal papillary necrosis", "sbj_char_span": [84, 94], "obj_char_span": [12, 36], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [3, 6]}], "umls_entity_list": []}, {"text": "Dapsone-associated Heinz body hemolytic anemia in a Cambodian woman with hemoglobin E trait.", "entity_list": [{"name": "Dapsone", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "D003622", "tok_span": [0, 3]}, {"name": "hemolytic anemia", "ent_type": "Disease", "char_span": [30, 46], "ent_id": "D000743", "tok_span": [8, 11]}], "relation_list": [{"subject": "Dapsone", "object": "hemolytic anemia", "sbj_char_span": [0, 7], "obj_char_span": [30, 46], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [8, 11]}], "umls_entity_list": []}, {"text": "A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis.", "entity_list": [{"name": "hemolysis", "ent_type": "Disease", "char_span": [179, 188], "ent_id": "D006461", "tok_span": [44, 46]}, {"name": "hemolytic anemia", "ent_type": "Disease", "char_span": [82, 98], "ent_id": "D000743", "tok_span": [22, 25]}, {"name": "dapsone", "ent_type": "Chemical", "char_span": [122, 129], "ent_id": "D003622", "tok_span": [30, 33]}, {"name": "leprosy", "ent_type": "Disease", "char_span": [51, 58], "ent_id": "D007918", "tok_span": [14, 17]}], "relation_list": [{"subject": "dapsone", "object": "hemolytic anemia", "sbj_char_span": [122, 129], "obj_char_span": [82, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 33], "obj_tok_span": [22, 25]}], "umls_entity_list": []}, {"text": "Thus, AE RBCs appear to have an increased sensitivity to oxidant stress both in vitro and in vivo, since dapsone does not cause hemolytic anemia at this dose in hematologically normal individuals.", "entity_list": [{"name": "hemolytic anemia", "ent_type": "Disease", "char_span": [128, 144], "ent_id": "D000743", "tok_span": [29, 32]}, {"name": "dapsone", "ent_type": "Chemical", "char_span": [105, 112], "ent_id": "D003622", "tok_span": [23, 26]}], "relation_list": [{"subject": "dapsone", "object": "hemolytic anemia", "sbj_char_span": [105, 112], "obj_char_span": [128, 144], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [29, 32]}], "umls_entity_list": []}, {"text": "Triazolam-induced brief episodes of secondary mania in a depressed patient.", "entity_list": [{"name": "Triazolam", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D014229", "tok_span": [0, 3]}, {"name": "mania", "ent_type": "Disease", "char_span": [46, 51], "ent_id": "D001714", "tok_span": [9, 11]}, {"name": "depressed", "ent_type": "Disease", "char_span": [57, 66], "ent_id": "D003866", "tok_span": [13, 14]}], "relation_list": [{"subject": "Triazolam", "object": "mania", "sbj_char_span": [0, 9], "obj_char_span": [46, 51], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "Large doses of triazolam repeatedly induced brief episodes of mania in a depressed elderly woman.", "entity_list": [{"name": "triazolam", "ent_type": "Chemical", "char_span": [15, 24], "ent_id": "D014229", "tok_span": [3, 6]}, {"name": "mania", "ent_type": "Disease", "char_span": [62, 67], "ent_id": "D001714", "tok_span": [11, 13]}, {"name": "depressed", "ent_type": "Disease", "char_span": [73, 82], "ent_id": "D003866", "tok_span": [15, 16]}], "relation_list": [{"subject": "triazolam", "object": "mania", "sbj_char_span": [15, 24], "obj_char_span": [62, 67], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [11, 13]}], "umls_entity_list": []}, {"text": "Manic excitement was coincident with the duration of action of triazolam.", "entity_list": [{"name": "triazolam", "ent_type": "Chemical", "char_span": [63, 72], "ent_id": "D014229", "tok_span": [13, 16]}, {"name": "Manic", "ent_type": "Disease", "char_span": [0, 5], "ent_id": "D001714", "tok_span": [0, 2]}], "relation_list": [{"subject": "triazolam", "object": "Manic", "sbj_char_span": [63, 72], "obj_char_span": [0, 5], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "On the mechanisms of the development of tolerance to the muscular rigidity produced by morphine in rats.", "entity_list": [{"name": "morphine", "ent_type": "Chemical", "char_span": [87, 95], "ent_id": "D009020", "tok_span": [14, 15]}, {"name": "muscular rigidity", "ent_type": "Disease", "char_span": [57, 74], "ent_id": "D009127", "tok_span": [10, 12]}], "relation_list": [{"subject": "morphine", "object": "muscular rigidity", "sbj_char_span": [87, 95], "obj_char_span": [57, 74], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "The development of tolerance to the muscular rigidity produced by morphine was studied in rats.", "entity_list": [{"name": "morphine", "ent_type": "Chemical", "char_span": [66, 74], "ent_id": "D009020", "tok_span": [10, 11]}, {"name": "muscular rigidity", "ent_type": "Disease", "char_span": [36, 53], "ent_id": "D009127", "tok_span": [6, 8]}], "relation_list": [{"subject": "morphine", "object": "muscular rigidity", "sbj_char_span": [66, 74], "obj_char_span": [36, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "Saline-pretreated controls given a test dose of morphine (20 mg/kg i.p.) showed a pronounced rigidity recorded as tonic activity in the electromyogram.", "entity_list": [{"name": "morphine", "ent_type": "Chemical", "char_span": [48, 56], "ent_id": "D009020", "tok_span": [10, 11]}, {"name": "rigidity", "ent_type": "Disease", "char_span": [93, 101], "ent_id": "D009127", "tok_span": [24, 25]}], "relation_list": [{"subject": "morphine", "object": "rigidity", "sbj_char_span": [48, 56], "obj_char_span": [93, 101], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [24, 25]}], "umls_entity_list": []}, {"text": "Rats treated for 11 days with morphine and withdrawn for 36-40 h showed differences in the development of tolerance: about half of the animals showed a rigidity after the test dose of morphine that was not significantly less than in the controls and were akinetic (A group).", "entity_list": [{"name": "rigidity", "ent_type": "Disease", "char_span": [152, 160], "ent_id": "D009127", "tok_span": [29, 30]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [30, 38], "ent_id": "D009020", "tok_span": [6, 7]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [184, 192], "ent_id": "D009020", "tok_span": [35, 36]}, {"name": "akinetic", "ent_type": "Disease", "char_span": [255, 263], "ent_id": "D018476", "tok_span": [47, 49]}], "relation_list": [{"subject": "morphine", "object": "rigidity", "sbj_char_span": [184, 192], "obj_char_span": [152, 160], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 36], "obj_tok_span": [29, 30]}, {"subject": "morphine", "object": "rigidity", "sbj_char_span": [30, 38], "obj_char_span": [152, 160], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [29, 30]}, {"subject": "morphine", "object": "akinetic", "sbj_char_span": [184, 192], "obj_char_span": [255, 263], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 36], "obj_tok_span": [47, 49]}, {"subject": "morphine", "object": "akinetic", "sbj_char_span": [30, 38], "obj_char_span": [255, 263], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [47, 49]}], "umls_entity_list": []}, {"text": "In a further series of experiments, haloperidol (0.2 mg/kg i.p.) was used in order to block the dopaminergic activation and to estimate the real degree of the tolerance to the rigidity without any dopaminergic interference.", "entity_list": [{"name": "haloperidol", "ent_type": "Chemical", "char_span": [36, 47], "ent_id": "D006220", "tok_span": [7, 10]}, {"name": "rigidity", "ent_type": "Disease", "char_span": [176, 184], "ent_id": "D009127", "tok_span": [42, 43]}], "relation_list": [{"subject": "haloperidol", "object": "rigidity", "sbj_char_span": [36, 47], "obj_char_span": [176, 184], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [42, 43]}], "umls_entity_list": []}, {"text": "Haloperidol enhanced the rigidity in the A group.", "entity_list": [{"name": "Haloperidol", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D006220", "tok_span": [0, 3]}, {"name": "rigidity", "ent_type": "Disease", "char_span": [25, 33], "ent_id": "D009127", "tok_span": [5, 6]}], "relation_list": [{"subject": "Haloperidol", "object": "rigidity", "sbj_char_span": [0, 11], "obj_char_span": [25, 33], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 6]}], "umls_entity_list": []}, {"text": "The results suggest that rigidity, which is assumed to be due to an action of morphine in the striatum, can be antagonized by another process leading to dopaminergic activation in the striatum.", "entity_list": [{"name": "morphine", "ent_type": "Chemical", "char_span": [78, 86], "ent_id": "D009020", "tok_span": [16, 17]}, {"name": "rigidity", "ent_type": "Disease", "char_span": [25, 33], "ent_id": "D009127", "tok_span": [4, 5]}], "relation_list": [{"subject": "morphine", "object": "rigidity", "sbj_char_span": [78, 86], "obj_char_span": [25, 33], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 17], "obj_tok_span": [4, 5]}], "umls_entity_list": []}, {"text": "However, compression neuropathy due to fibrotic muscle affected by pentazocine-induced myopathy has not previously been reported.", "entity_list": [{"name": "compression neuropathy", "ent_type": "Disease", "char_span": [9, 31], "ent_id": "D009408", "tok_span": [2, 4]}, {"name": "pentazocine", "ent_type": "Chemical", "char_span": [67, 78], "ent_id": "D010423", "tok_span": [11, 14]}, {"name": "myopathy", "ent_type": "Disease", "char_span": [87, 95], "ent_id": "D009135", "tok_span": [16, 18]}], "relation_list": [{"subject": "pentazocine", "object": "myopathy", "sbj_char_span": [67, 78], "obj_char_span": [87, 95], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [16, 18]}, {"subject": "pentazocine", "object": "compression neuropathy", "sbj_char_span": [67, 78], "obj_char_span": [9, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [2, 4]}], "umls_entity_list": []}, {"text": "Recurrent reversible acute renal failure from amphotericin.", "entity_list": [{"name": "acute renal failure", "ent_type": "Disease", "char_span": [21, 40], "ent_id": "D058186", "tok_span": [3, 6]}, {"name": "amphotericin", "ent_type": "Chemical", "char_span": [46, 58], "ent_id": "D000666", "tok_span": [7, 10]}], "relation_list": [{"subject": "amphotericin", "object": "acute renal failure", "sbj_char_span": [46, 58], "obj_char_span": [21, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [3, 6]}], "umls_entity_list": []}, {"text": "A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions.", "entity_list": [{"name": "sporotrichosis", "ent_type": "Disease", "char_span": [54, 68], "ent_id": "D013174", "tok_span": [8, 12]}, {"name": "acute renal failure", "ent_type": "Disease", "char_span": [79, 98], "ent_id": "D058186", "tok_span": [13, 16]}, {"name": "cirrhosis", "ent_type": "Disease", "char_span": [27, 36], "ent_id": "D005355", "tok_span": [5, 6]}, {"name": "amphotericin B", "ent_type": "Chemical", "char_span": [143, 157], "ent_id": "D000666", "tok_span": [21, 25]}], "relation_list": [{"subject": "amphotericin B", "object": "acute renal failure", "sbj_char_span": [143, 157], "obj_char_span": [79, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 25], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "We propose that amphotericin, in the setting of reduced effective arterial volume, may activate tubuloglomerular feedback, thereby contributing to acute renal failure.", "entity_list": [{"name": "amphotericin", "ent_type": "Chemical", "char_span": [16, 28], "ent_id": "D000666", "tok_span": [3, 6]}, {"name": "acute renal failure", "ent_type": "Disease", "char_span": [147, 166], "ent_id": "D058186", "tok_span": [28, 31]}], "relation_list": [{"subject": "amphotericin", "object": "acute renal failure", "sbj_char_span": [16, 28], "obj_char_span": [147, 166], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [28, 31]}], "umls_entity_list": []}, {"text": "Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis, immediate withdrawal of amiodarone, and prompt but continued steroid therapy to ensure full recovery.", "entity_list": [{"name": "steroid", "ent_type": "Chemical", "char_span": [172, 179], "ent_id": "D013256", "tok_span": [34, 35]}, {"name": "amiodarone", "ent_type": "Chemical", "char_span": [87, 97], "ent_id": "D000638", "tok_span": [14, 18]}, {"name": "amiodarone", "ent_type": "Chemical", "char_span": [135, 145], "ent_id": "D000638", "tok_span": [25, 29]}, {"name": "pneumonitis", "ent_type": "Disease", "char_span": [98, 109], "ent_id": "D011014", "tok_span": [18, 21]}], "relation_list": [{"subject": "amiodarone", "object": "pneumonitis", "sbj_char_span": [135, 145], "obj_char_span": [98, 109], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 29], "obj_tok_span": [18, 21]}, {"subject": "amiodarone", "object": "pneumonitis", "sbj_char_span": [87, 97], "obj_char_span": [98, 109], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 18], "obj_tok_span": [18, 21]}], "umls_entity_list": []}, {"text": "We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy.", "entity_list": [{"name": "hyperkalemia", "ent_type": "Disease", "char_span": [61, 73], "ent_id": "D006947", "tok_span": [12, 16]}, {"name": "renal failure", "ent_type": "Disease", "char_span": [42, 55], "ent_id": "D051437", "tok_span": [9, 11]}, {"name": "ascites", "ent_type": "Disease", "char_span": [103, 110], "ent_id": "D001201", "tok_span": [22, 23]}, {"name": "cirrhosis", "ent_type": "Disease", "char_span": [92, 101], "ent_id": "D005355", "tok_span": [20, 21]}, {"name": "indomethacin", "ent_type": "Chemical", "char_span": [136, 148], "ent_id": "D007213", "tok_span": [30, 33]}, {"name": "cor pulmonale", "ent_type": "Disease", "char_span": [116, 129], "ent_id": "D011660", "tok_span": [25, 29]}], "relation_list": [{"subject": "indomethacin", "object": "hyperkalemia", "sbj_char_span": [136, 148], "obj_char_span": [61, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 33], "obj_tok_span": [12, 16]}, {"subject": "indomethacin", "object": "ascites", "sbj_char_span": [136, 148], "obj_char_span": [103, 110], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 33], "obj_tok_span": [22, 23]}, {"subject": "indomethacin", "object": "cirrhosis", "sbj_char_span": [136, 148], "obj_char_span": [92, 101], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 33], "obj_tok_span": [20, 21]}, {"subject": "indomethacin", "object": "cor pulmonale", "sbj_char_span": [136, 148], "obj_char_span": [116, 129], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 33], "obj_tok_span": [25, 29]}], "umls_entity_list": []}, {"text": "Prompt restoration of renal function followed drug withdrawal, while re-exposure to a single dose of indomethacin caused recurrence of acute reversible oliguria.", "entity_list": [{"name": "indomethacin", "ent_type": "Chemical", "char_span": [101, 113], "ent_id": "D007213", "tok_span": [19, 22]}, {"name": "oliguria", "ent_type": "Disease", "char_span": [152, 160], "ent_id": "D009846", "tok_span": [27, 29]}], "relation_list": [{"subject": "indomethacin", "object": "oliguria", "sbj_char_span": [101, 113], "obj_char_span": [152, 160], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 22], "obj_tok_span": [27, 29]}], "umls_entity_list": []}, {"text": "There was pain on i.m. injection of flunitrazepam significantly more often than with isotonic saline.", "entity_list": [{"name": "pain", "ent_type": "Disease", "char_span": [10, 14], "ent_id": "D010146", "tok_span": [2, 3]}, {"name": "flunitrazepam", "ent_type": "Chemical", "char_span": [36, 49], "ent_id": "D005445", "tok_span": [10, 15]}], "relation_list": [{"subject": "flunitrazepam", "object": "pain", "sbj_char_span": [36, 49], "obj_char_span": [10, 14], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 15], "obj_tok_span": [2, 3]}], "umls_entity_list": []}, {"text": "Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.", "entity_list": [{"name": "vitamin D3", "ent_type": "Chemical", "char_span": [26, 36], "ent_id": "D002762", "tok_span": [5, 8]}, {"name": "vitamin D3", "ent_type": "Chemical", "char_span": [160, 170], "ent_id": "D002762", "tok_span": [40, 43]}, {"name": "hypercalcemia", "ent_type": "Disease", "char_span": [103, 116], "ent_id": "D006934", "tok_span": [28, 31]}, {"name": "hyperphosphatemia", "ent_type": "Disease", "char_span": [118, 135], "ent_id": "D054559", "tok_span": [32, 35]}, {"name": "vitamin D3", "ent_type": "Chemical", "char_span": [60, 70], "ent_id": "D002762", "tok_span": [20, 23]}], "relation_list": [{"subject": "vitamin D3", "object": "hypercalcemia", "sbj_char_span": [160, 170], "obj_char_span": [103, 116], "rel_type": "chemical-induced disease", "sbj_tok_span": [40, 43], "obj_tok_span": [28, 31]}, {"subject": "vitamin D3", "object": "hypercalcemia", "sbj_char_span": [26, 36], "obj_char_span": [103, 116], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [28, 31]}, {"subject": "vitamin D3", "object": "hyperphosphatemia", "sbj_char_span": [26, 36], "obj_char_span": [118, 135], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [32, 35]}, {"subject": "vitamin D3", "object": "hyperphosphatemia", "sbj_char_span": [160, 170], "obj_char_span": [118, 135], "rel_type": "chemical-induced disease", "sbj_tok_span": [40, 43], "obj_tok_span": [32, 35]}, {"subject": "vitamin D3", "object": "hypercalcemia", "sbj_char_span": [60, 70], "obj_char_span": [103, 116], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [28, 31]}, {"subject": "vitamin D3", "object": "hyperphosphatemia", "sbj_char_span": [60, 70], "obj_char_span": [118, 135], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [32, 35]}], "umls_entity_list": []}, {"text": "Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.", "entity_list": [{"name": "Peripheral neuropathy", "ent_type": "Disease", "char_span": [0, 21], "ent_id": "D010523", "tok_span": [0, 2]}, {"name": "nutritional deficiency", "ent_type": "Disease", "char_span": [29, 51], "ent_id": "D044342", "tok_span": [4, 6]}, {"name": "sensori-motor neuropathy", "ent_type": "Disease", "char_span": [134, 158], "ent_id": "D010523", "tok_span": [27, 32]}, {"name": "riboflavin", "ent_type": "Chemical", "char_span": [68, 78], "ent_id": "D012256", "tok_span": [10, 13]}, {"name": "thiamine", "ent_type": "Chemical", "char_span": [55, 63], "ent_id": "D013831", "tok_span": [7, 9]}], "relation_list": [{"subject": "riboflavin", "object": "sensori-motor neuropathy", "sbj_char_span": [68, 78], "obj_char_span": [134, 158], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [27, 32]}, {"subject": "thiamine", "object": "Peripheral neuropathy", "sbj_char_span": [55, 63], "obj_char_span": [0, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 9], "obj_tok_span": [0, 2]}, {"subject": "thiamine", "object": "sensori-motor neuropathy", "sbj_char_span": [55, 63], "obj_char_span": [134, 158], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 9], "obj_tok_span": [27, 32]}, {"subject": "riboflavin", "object": "Peripheral neuropathy", "sbj_char_span": [68, 78], "obj_char_span": [0, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.", "entity_list": [{"name": "amitriptyline", "ent_type": "Chemical", "char_span": [163, 176], "ent_id": "D000639", "tok_span": [33, 38]}, {"name": "dry mouth", "ent_type": "Disease", "char_span": [88, 97], "ent_id": "D014987", "tok_span": [16, 18]}, {"name": "dothiepin", "ent_type": "Chemical", "char_span": [143, 152], "ent_id": "D004308", "tok_span": [27, 31]}, {"name": "blurred vision", "ent_type": "Disease", "char_span": [72, 86], "ent_id": "D014786", "tok_span": [12, 15]}], "relation_list": [{"subject": "amitriptyline", "object": "dry mouth", "sbj_char_span": [163, 176], "obj_char_span": [88, 97], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 38], "obj_tok_span": [16, 18]}, {"subject": "amitriptyline", "object": "blurred vision", "sbj_char_span": [163, 176], "obj_char_span": [72, 86], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 38], "obj_tok_span": [12, 15]}], "umls_entity_list": []}, {"text": "Both drugs impaired immediate free recall but the decrease was greater for diazepam than propranolol.", "entity_list": [{"name": "propranolol", "ent_type": "Chemical", "char_span": [89, 100], "ent_id": "D011433", "tok_span": [16, 20]}, {"name": "diazepam", "ent_type": "Chemical", "char_span": [75, 83], "ent_id": "D003975", "tok_span": [12, 15]}, {"name": "impaired immediate free recall", "ent_type": "Disease", "char_span": [11, 41], "ent_id": "D008569", "tok_span": [2, 6]}], "relation_list": [{"subject": "propranolol", "object": "impaired immediate free recall", "sbj_char_span": [89, 100], "obj_char_span": [11, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 20], "obj_tok_span": [2, 6]}, {"subject": "diazepam", "object": "impaired immediate free recall", "sbj_char_span": [75, 83], "obj_char_span": [11, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [2, 6]}], "umls_entity_list": []}, {"text": "The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.", "entity_list": [{"name": "aspirin", "ent_type": "Chemical", "char_span": [25, 32], "ent_id": "D001241", "tok_span": [5, 6]}, {"name": "bladder carcinomas", "ent_type": "Disease", "char_span": [149, 167], "ent_id": "D001749", "tok_span": [50, 52]}, {"name": "forestomach tumors", "ent_type": "Disease", "char_span": [199, 217], "ent_id": "D013274", "tok_span": [57, 61]}, {"name": "N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide", "ent_type": "Chemical", "char_span": [38, 83], "ent_id": "D005200", "tok_span": [7, 32]}, {"name": "FANFT", "ent_type": "Chemical", "char_span": [85, 90], "ent_id": "D005200", "tok_span": [33, 36]}, {"name": "FANFT", "ent_type": "Chemical", "char_span": [135, 140], "ent_id": "D005200", "tok_span": [45, 48]}], "relation_list": [{"subject": "FANFT", "object": "forestomach tumors", "sbj_char_span": [85, 90], "obj_char_span": [199, 217], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 36], "obj_tok_span": [57, 61]}, {"subject": "FANFT", "object": "forestomach tumors", "sbj_char_span": [135, 140], "obj_char_span": [199, 217], "rel_type": "chemical-induced disease", "sbj_tok_span": [45, 48], "obj_tok_span": [57, 61]}, {"subject": "N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide", "object": "bladder carcinomas", "sbj_char_span": [38, 83], "obj_char_span": [149, 167], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 32], "obj_tok_span": [50, 52]}, {"subject": "FANFT", "object": "bladder carcinomas", "sbj_char_span": [135, 140], "obj_char_span": [149, 167], "rel_type": "chemical-induced disease", "sbj_tok_span": [45, 48], "obj_tok_span": [50, 52]}, {"subject": "FANFT", "object": "bladder carcinomas", "sbj_char_span": [85, 90], "obj_char_span": [149, 167], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 36], "obj_tok_span": [50, 52]}, {"subject": "N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide", "object": "forestomach tumors", "sbj_char_span": [38, 83], "obj_char_span": [199, 217], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 32], "obj_tok_span": [57, 61]}], "umls_entity_list": []}, {"text": "Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy?", "entity_list": [{"name": "hypotension", "ent_type": "Disease", "char_span": [24, 35], "ent_id": "D007022", "tok_span": [4, 5]}, {"name": "diabetic autonomic neuropathy", "ent_type": "Disease", "char_span": [56, 85], "ent_id": "D003929", "tok_span": [10, 13]}, {"name": "nitroglycerin", "ent_type": "Chemical", "char_span": [39, 52], "ent_id": "D005996", "tok_span": [6, 9]}], "relation_list": [{"subject": "nitroglycerin", "object": "hypotension", "sbj_char_span": [39, 52], "obj_char_span": [24, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [4, 5]}], "umls_entity_list": []}, {"text": "Pituitary tumors were induced in F344 female rats by chronic treatment with diethylstilbestrol (DES, 8-10 mg) implanted subcutaneously in silastic capsules.", "entity_list": [{"name": "Pituitary tumors", "ent_type": "Disease", "char_span": [0, 16], "ent_id": "D010911", "tok_span": [0, 3]}, {"name": "DES", "ent_type": "Chemical", "char_span": [96, 99], "ent_id": "D004054", "tok_span": [22, 23]}, {"name": "diethylstilbestrol", "ent_type": "Chemical", "char_span": [76, 94], "ent_id": "D004054", "tok_span": [15, 21]}], "relation_list": [{"subject": "DES", "object": "Pituitary tumors", "sbj_char_span": [96, 99], "obj_char_span": [0, 16], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [0, 3]}, {"subject": "diethylstilbestrol", "object": "Pituitary tumors", "sbj_char_span": [76, 94], "obj_char_span": [0, 16], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 21], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "Triamterene nephrolithiasis complicating dyazide therapy.", "entity_list": [{"name": "dyazide", "ent_type": "Chemical", "char_span": [41, 48], "ent_id": "C020743", "tok_span": [10, 13]}, {"name": "nephrolithiasis", "ent_type": "Disease", "char_span": [12, 27], "ent_id": "D053040", "tok_span": [4, 8]}, {"name": "Triamterene", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D014223", "tok_span": [0, 4]}], "relation_list": [{"subject": "Triamterene", "object": "nephrolithiasis", "sbj_char_span": [0, 11], "obj_char_span": [12, 27], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "A case of triamterene nephrolithiasis is reported in a man after 4 years of hydrochlorothiazide-triamterene therapy for hypertension.", "entity_list": [{"name": "hydrochlorothiazide-triamterene", "ent_type": "Chemical", "char_span": [76, 107], "ent_id": "C020743", "tok_span": [20, 29]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [120, 132], "ent_id": "D006973", "tok_span": [31, 32]}, {"name": "nephrolithiasis", "ent_type": "Disease", "char_span": [22, 37], "ent_id": "D053040", "tok_span": [7, 11]}, {"name": "triamterene", "ent_type": "Chemical", "char_span": [10, 21], "ent_id": "D014223", "tok_span": [3, 7]}], "relation_list": [{"subject": "triamterene", "object": "nephrolithiasis", "sbj_char_span": [10, 21], "obj_char_span": [22, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 7], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "Factors affecting triamterene nephrolithiasis are discussed and 2 previously reported cases are reviewed.", "entity_list": [{"name": "triamterene", "ent_type": "Chemical", "char_span": [18, 29], "ent_id": "D014223", "tok_span": [2, 6]}, {"name": "nephrolithiasis", "ent_type": "Disease", "char_span": [30, 45], "ent_id": "D053040", "tok_span": [6, 10]}], "relation_list": [{"subject": "triamterene", "object": "nephrolithiasis", "sbj_char_span": [18, 29], "obj_char_span": [30, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [6, 10]}], "umls_entity_list": []}, {"text": "Metabolic involvement in adriamycin cardiotoxicity.", "entity_list": [{"name": "adriamycin", "ent_type": "Chemical", "char_span": [25, 35], "ent_id": "D004317", "tok_span": [3, 7]}, {"name": "cardiotoxicity", "ent_type": "Disease", "char_span": [36, 50], "ent_id": "D066126", "tok_span": [7, 9]}], "relation_list": [{"subject": "adriamycin", "object": "cardiotoxicity", "sbj_char_span": [25, 35], "obj_char_span": [36, 50], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 7], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "The cardiotoxic effects of adriamycin were studied in mammalian myocardial cells in culture as a model system.", "entity_list": [{"name": "cardiotoxic", "ent_type": "Disease", "char_span": [4, 15], "ent_id": "D066126", "tok_span": [1, 3]}, {"name": "adriamycin", "ent_type": "Chemical", "char_span": [27, 37], "ent_id": "D004317", "tok_span": [5, 9]}], "relation_list": [{"subject": "adriamycin", "object": "cardiotoxic", "sbj_char_span": [27, 37], "obj_char_span": [4, 15], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [1, 3]}], "umls_entity_list": []}, {"text": "Abnormal movements and deafness occurred only in rats treated during the preweaning period; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11-17 and 5 to 11 days of age, respectively, indicating that the cochlea is more sensitive to streptomycin than the site (vestibular or central) responsible for the dyskinesias.", "entity_list": [{"name": "dyskinesias", "ent_type": "Disease", "char_span": [346, 357], "ent_id": "D004409", "tok_span": [65, 69]}, {"name": "streptomycin", "ent_type": "Chemical", "char_span": [275, 287], "ent_id": "D013307", "tok_span": [53, 54]}, {"name": "deafness", "ent_type": "Disease", "char_span": [23, 31], "ent_id": "D003638", "tok_span": [3, 5]}, {"name": "Abnormal movements", "ent_type": "Disease", "char_span": [0, 18], "ent_id": "D004409", "tok_span": [0, 2]}], "relation_list": [{"subject": "streptomycin", "object": "deafness", "sbj_char_span": [275, 287], "obj_char_span": [23, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [53, 54], "obj_tok_span": [3, 5]}, {"subject": "streptomycin", "object": "Abnormal movements", "sbj_char_span": [275, 287], "obj_char_span": [0, 18], "rel_type": "chemical-induced disease", "sbj_tok_span": [53, 54], "obj_tok_span": [0, 2]}, {"subject": "streptomycin", "object": "dyskinesias", "sbj_char_span": [275, 287], "obj_char_span": [346, 357], "rel_type": "chemical-induced disease", "sbj_tok_span": [53, 54], "obj_tok_span": [65, 69]}], "umls_entity_list": []}, {"text": "Crescentic fibrillary glomerulonephritis associated with intermittent rifampin therapy for pulmonary tuberculosis.", "entity_list": [{"name": "rifampin", "ent_type": "Chemical", "char_span": [70, 78], "ent_id": "D012293", "tok_span": [14, 17]}, {"name": "pulmonary tuberculosis", "ent_type": "Disease", "char_span": [91, 113], "ent_id": "D014397", "tok_span": [19, 21]}, {"name": "glomerulonephritis", "ent_type": "Disease", "char_span": [22, 40], "ent_id": "D005921", "tok_span": [6, 11]}], "relation_list": [{"subject": "rifampin", "object": "glomerulonephritis", "sbj_char_span": [70, 78], "obj_char_span": [22, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [6, 11]}], "umls_entity_list": []}, {"text": "This case study reveals an unusual finding of rapidly proliferative crescentic glomerulonephritis in a patient treated with rifampin who had no other identifiable causes for developing this disease.", "entity_list": [{"name": "rifampin", "ent_type": "Chemical", "char_span": [124, 132], "ent_id": "D012293", "tok_span": [24, 27]}, {"name": "glomerulonephritis", "ent_type": "Disease", "char_span": [79, 97], "ent_id": "D005921", "tok_span": [14, 19]}], "relation_list": [{"subject": "rifampin", "object": "glomerulonephritis", "sbj_char_span": [124, 132], "obj_char_span": [79, 97], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 27], "obj_tok_span": [14, 19]}], "umls_entity_list": []}, {"text": "This patient underwent a 10-month regimen of rifampin and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy.", "entity_list": [{"name": "renal failure", "ent_type": "Disease", "char_span": [148, 161], "ent_id": "D051437", "tok_span": [29, 31]}, {"name": "pulmonary tuberculosis", "ent_type": "Disease", "char_span": [72, 94], "ent_id": "D014397", "tok_span": [18, 20]}, {"name": "rifampin", "ent_type": "Chemical", "char_span": [45, 53], "ent_id": "D012293", "tok_span": [9, 12]}, {"name": "isoniazid", "ent_type": "Chemical", "char_span": [58, 67], "ent_id": "D007538", "tok_span": [13, 17]}], "relation_list": [{"subject": "rifampin", "object": "renal failure", "sbj_char_span": [45, 53], "obj_char_span": [148, 161], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [29, 31]}], "umls_entity_list": []}, {"text": "This report documents the unusual occurrence of rapidly progressive glomerulonephritis with crescents and fibrillar glomerulonephritis in a patient treated with rifampin.", "entity_list": [{"name": "glomerulonephritis", "ent_type": "Disease", "char_span": [116, 134], "ent_id": "D005921", "tok_span": [21, 26]}, {"name": "rifampin", "ent_type": "Chemical", "char_span": [161, 169], "ent_id": "D012293", "tok_span": [31, 34]}, {"name": "glomerulonephritis", "ent_type": "Disease", "char_span": [68, 86], "ent_id": "D005921", "tok_span": [9, 14]}], "relation_list": [{"subject": "rifampin", "object": "glomerulonephritis", "sbj_char_span": [161, 169], "obj_char_span": [68, 86], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 34], "obj_tok_span": [9, 14]}, {"subject": "rifampin", "object": "glomerulonephritis", "sbj_char_span": [161, 169], "obj_char_span": [116, 134], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 34], "obj_tok_span": [21, 26]}], "umls_entity_list": []}, {"text": "Time course of lipid peroxidation in puromycin aminonucleoside-induced nephropathy.", "entity_list": [{"name": "nephropathy", "ent_type": "Disease", "char_span": [71, 82], "ent_id": "D007674", "tok_span": [13, 14]}, {"name": "puromycin aminonucleoside", "ent_type": "Chemical", "char_span": [37, 62], "ent_id": "D011692", "tok_span": [6, 11]}], "relation_list": [{"subject": "puromycin aminonucleoside", "object": "nephropathy", "sbj_char_span": [37, 62], "obj_char_span": [71, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 11], "obj_tok_span": [13, 14]}], "umls_entity_list": []}, {"text": "Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-induced nephropathy, with antioxidants significantly reducing the proteinuria.", "entity_list": [{"name": "PAN", "ent_type": "Chemical", "char_span": [101, 104], "ent_id": "D011692", "tok_span": [18, 19]}, {"name": "oxygen", "ent_type": "Chemical", "char_span": [9, 15], "ent_id": "D010100", "tok_span": [2, 3]}, {"name": "puromycin aminonucleoside", "ent_type": "Chemical", "char_span": [74, 99], "ent_id": "D011692", "tok_span": [12, 17]}, {"name": "nephropathy", "ent_type": "Disease", "char_span": [114, 125], "ent_id": "D007674", "tok_span": [22, 23]}, {"name": "proteinuria", "ent_type": "Disease", "char_span": [172, 183], "ent_id": "D011507", "tok_span": [29, 30]}], "relation_list": [{"subject": "PAN", "object": "proteinuria", "sbj_char_span": [101, 104], "obj_char_span": [172, 183], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [29, 30]}, {"subject": "puromycin aminonucleoside", "object": "nephropathy", "sbj_char_span": [74, 99], "obj_char_span": [114, 125], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 17], "obj_tok_span": [22, 23]}, {"subject": "PAN", "object": "nephropathy", "sbj_char_span": [101, 104], "obj_char_span": [114, 125], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [22, 23]}, {"subject": "puromycin aminonucleoside", "object": "proteinuria", "sbj_char_span": [74, 99], "obj_char_span": [172, 183], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 17], "obj_tok_span": [29, 30]}], "umls_entity_list": []}, {"text": "This study supports the role of lipid peroxidation in mediating the proteinuric injury in PAN nephropathy.", "entity_list": [{"name": "proteinuric injury", "ent_type": "Disease", "char_span": [68, 86], "ent_id": "D011507", "tok_span": [11, 14]}, {"name": "nephropathy", "ent_type": "Disease", "char_span": [94, 105], "ent_id": "D007674", "tok_span": [16, 17]}, {"name": "PAN", "ent_type": "Chemical", "char_span": [90, 93], "ent_id": "D011692", "tok_span": [15, 16]}], "relation_list": [{"subject": "PAN", "object": "proteinuric injury", "sbj_char_span": [90, 93], "obj_char_span": [68, 86], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 16], "obj_tok_span": [11, 14]}, {"subject": "PAN", "object": "nephropathy", "sbj_char_span": [90, 93], "obj_char_span": [94, 105], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 16], "obj_tok_span": [16, 17]}], "umls_entity_list": []}, {"text": "Clomipramine-induced sleep disturbance does not impair its prolactin-releasing action.", "entity_list": [{"name": "Clomipramine", "ent_type": "Chemical", "char_span": [0, 12], "ent_id": "D002997", "tok_span": [0, 4]}, {"name": "sleep disturbance", "ent_type": "Disease", "char_span": [21, 38], "ent_id": "D012893", "tok_span": [6, 8]}], "relation_list": [{"subject": "Clomipramine", "object": "sleep disturbance", "sbj_char_span": [0, 12], "obj_char_span": [21, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "The present study was undertaken to examine the role of sleep disturbance, induced by clomipramine administration, on the secretory rate of prolactin (PRL) in addition to the direct drug effect.", "entity_list": [{"name": "clomipramine", "ent_type": "Chemical", "char_span": [86, 98], "ent_id": "D002997", "tok_span": [15, 19]}, {"name": "sleep disturbance", "ent_type": "Disease", "char_span": [56, 73], "ent_id": "D012893", "tok_span": [10, 12]}], "relation_list": [{"subject": "clomipramine", "object": "sleep disturbance", "sbj_char_span": [86, 98], "obj_char_span": [56, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 19], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Angioedema following the intravenous administration of metoprolol.", "entity_list": [{"name": "Angioedema", "ent_type": "Disease", "char_span": [0, 10], "ent_id": "D000799", "tok_span": [0, 4]}, {"name": "metoprolol", "ent_type": "Chemical", "char_span": [55, 65], "ent_id": "D008790", "tok_span": [9, 12]}], "relation_list": [{"subject": "metoprolol", "object": "Angioedema", "sbj_char_span": [55, 65], "obj_char_span": [0, 10], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "A history of angioedema secondary to lisinopril therapy was elicited.", "entity_list": [{"name": "lisinopril", "ent_type": "Chemical", "char_span": [37, 47], "ent_id": "D017706", "tok_span": [9, 13]}, {"name": "angioedema", "ent_type": "Disease", "char_span": [13, 23], "ent_id": "D000799", "tok_span": [3, 7]}], "relation_list": [{"subject": "lisinopril", "object": "angioedema", "sbj_char_span": [37, 47], "obj_char_span": [13, 23], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "During the first day of hospitalization (while intubated), intravenous metoprolol was given, resulting in severe angioedema.", "entity_list": [{"name": "metoprolol", "ent_type": "Chemical", "char_span": [71, 81], "ent_id": "D008790", "tok_span": [14, 17]}, {"name": "angioedema", "ent_type": "Disease", "char_span": [113, 123], "ent_id": "D000799", "tok_span": [23, 27]}], "relation_list": [{"subject": "metoprolol", "object": "angioedema", "sbj_char_span": [71, 81], "obj_char_span": [113, 123], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [23, 27]}], "umls_entity_list": []}, {"text": "However, coniine has failed to produce arthrogryposis in rats or mice and is only weakly teratogenic in rabbits.", "entity_list": [{"name": "arthrogryposis", "ent_type": "Disease", "char_span": [39, 53], "ent_id": "D001176", "tok_span": [9, 13]}, {"name": "coniine", "ent_type": "Chemical", "char_span": [9, 16], "ent_id": "C007112", "tok_span": [2, 5]}], "relation_list": [{"subject": "coniine", "object": "arthrogryposis", "sbj_char_span": [9, 16], "obj_char_span": [39, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [9, 13]}], "umls_entity_list": []}, {"text": "No histopathological alterations or differences in bone formation were seen in the limbs or toes of any chicks from any group; however, extensive cranial hemorrhage occurred in all nicotine sulfate-treated chicks.", "entity_list": [{"name": "nicotine", "ent_type": "Chemical", "char_span": [181, 189], "ent_id": "D009538", "tok_span": [33, 34]}, {"name": "cranial hemorrhage", "ent_type": "Disease", "char_span": [146, 164], "ent_id": "D002543", "tok_span": [28, 30]}], "relation_list": [{"subject": "nicotine", "object": "cranial hemorrhage", "sbj_char_span": [181, 189], "obj_char_span": [146, 164], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 34], "obj_tok_span": [28, 30]}], "umls_entity_list": []}, {"text": "In summary, the chick embryo provides a reliable and simple experimental animal model of coniine-induced arthrogryposis.", "entity_list": [{"name": "arthrogryposis", "ent_type": "Disease", "char_span": [105, 119], "ent_id": "D001176", "tok_span": [20, 24]}, {"name": "coniine", "ent_type": "Chemical", "char_span": [89, 96], "ent_id": "C007112", "tok_span": [15, 18]}], "relation_list": [{"subject": "coniine", "object": "arthrogryposis", "sbj_char_span": [89, 96], "obj_char_span": [105, 119], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "Epidural blood flow during prostaglandin E1 or trimethaphan induced hypotension.", "entity_list": [{"name": "trimethaphan", "ent_type": "Chemical", "char_span": [47, 59], "ent_id": "D014294", "tok_span": [9, 13]}, {"name": "prostaglandin E1", "ent_type": "Chemical", "char_span": [27, 43], "ent_id": "D000527", "tok_span": [5, 8]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [68, 79], "ent_id": "D007022", "tok_span": [14, 15]}], "relation_list": [{"subject": "prostaglandin E1", "object": "hypotension", "sbj_char_span": [27, 43], "obj_char_span": [68, 79], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [14, 15]}, {"subject": "trimethaphan", "object": "hypotension", "sbj_char_span": [47, 59], "obj_char_span": [68, 79], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [14, 15]}], "umls_entity_list": []}, {"text": "To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.", "entity_list": [{"name": "prostaglandin E1", "ent_type": "Chemical", "char_span": [26, 42], "ent_id": "D000527", "tok_span": [5, 8]}, {"name": "TMP", "ent_type": "Chemical", "char_span": [67, 70], "ent_id": "D014294", "tok_span": [18, 20]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [80, 91], "ent_id": "D007022", "tok_span": [22, 23]}, {"name": "PGE1", "ent_type": "Chemical", "char_span": [44, 48], "ent_id": "D000527", "tok_span": [9, 11]}, {"name": "trimethaphan", "ent_type": "Chemical", "char_span": [53, 65], "ent_id": "D014294", "tok_span": [13, 17]}, {"name": "isoflurane", "ent_type": "Chemical", "char_span": [261, 271], "ent_id": "D007530", "tok_span": [57, 59]}], "relation_list": [{"subject": "trimethaphan", "object": "hypotension", "sbj_char_span": [53, 65], "obj_char_span": [80, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [22, 23]}, {"subject": "PGE1", "object": "hypotension", "sbj_char_span": [44, 48], "obj_char_span": [80, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 11], "obj_tok_span": [22, 23]}, {"subject": "TMP", "object": "hypotension", "sbj_char_span": [67, 70], "obj_char_span": [80, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 20], "obj_tok_span": [22, 23]}, {"subject": "prostaglandin E1", "object": "hypotension", "sbj_char_span": [26, 42], "obj_char_span": [80, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [22, 23]}], "umls_entity_list": []}, {"text": "After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.", "entity_list": [{"name": "PGE1", "ent_type": "Chemical", "char_span": [15, 19], "ent_id": "D000527", "tok_span": [2, 4]}, {"name": "PGE1", "ent_type": "Chemical", "char_span": [170, 174], "ent_id": "D000527", "tok_span": [40, 42]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [151, 162], "ent_id": "D007022", "tok_span": [37, 38]}, {"name": "TMP", "ent_type": "Chemical", "char_span": [23, 26], "ent_id": "D014294", "tok_span": [5, 7]}], "relation_list": [{"subject": "PGE1", "object": "hypotension", "sbj_char_span": [170, 174], "obj_char_span": [151, 162], "rel_type": "chemical-induced disease", "sbj_tok_span": [40, 42], "obj_tok_span": [37, 38]}, {"subject": "TMP", "object": "hypotension", "sbj_char_span": [23, 26], "obj_char_span": [151, 162], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 7], "obj_tok_span": [37, 38]}, {"subject": "PGE1", "object": "hypotension", "sbj_char_span": [15, 19], "obj_char_span": [151, 162], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 4], "obj_tok_span": [37, 38]}], "umls_entity_list": []}, {"text": "These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF.", "entity_list": [{"name": "PGE1", "ent_type": "Chemical", "char_span": [27, 31], "ent_id": "D000527", "tok_span": [4, 6]}, {"name": "TMP", "ent_type": "Chemical", "char_span": [111, 114], "ent_id": "D014294", "tok_span": [20, 22]}, {"name": "TMP", "ent_type": "Chemical", "char_span": [53, 56], "ent_id": "D014294", "tok_span": [10, 12]}, {"name": "hypotensive", "ent_type": "Disease", "char_span": [61, 72], "ent_id": "D007022", "tok_span": [13, 15]}], "relation_list": [{"subject": "PGE1", "object": "hypotensive", "sbj_char_span": [27, 31], "obj_char_span": [61, 72], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 6], "obj_tok_span": [13, 15]}, {"subject": "TMP", "object": "hypotensive", "sbj_char_span": [53, 56], "obj_char_span": [61, 72], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 12], "obj_tok_span": [13, 15]}, {"subject": "TMP", "object": "hypotensive", "sbj_char_span": [111, 114], "obj_char_span": [61, 72], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 22], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "Infarcts in substantia nigra pars reticulata were evoked by prolonged pilocarpine-induced status epilepticus.", "entity_list": [{"name": "status epilepticus", "ent_type": "Disease", "char_span": [90, 108], "ent_id": "D013226", "tok_span": [22, 25]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [70, 81], "ent_id": "D010862", "tok_span": [17, 20]}, {"name": "Infarcts in substantia nigra pars reticulata", "ent_type": "Disease", "char_span": [0, 44], "ent_id": "D002544", "tok_span": [0, 13]}], "relation_list": [{"subject": "pilocarpine", "object": "status epilepticus", "sbj_char_span": [70, 81], "obj_char_span": [90, 108], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [22, 25]}, {"subject": "pilocarpine", "object": "Infarcts in substantia nigra pars reticulata", "sbj_char_span": [70, 81], "obj_char_span": [0, 44], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [0, 13]}], "umls_entity_list": []}, {"text": "Increase of Parkinson disability after fluoxetine medication.", "entity_list": [{"name": "Parkinson disability", "ent_type": "Disease", "char_span": [12, 32], "ent_id": "D009069", "tok_span": [3, 5]}, {"name": "fluoxetine", "ent_type": "Chemical", "char_span": [39, 49], "ent_id": "D005473", "tok_span": [6, 9]}], "relation_list": [{"subject": "fluoxetine", "object": "Parkinson disability", "sbj_char_span": [39, 49], "obj_char_span": [12, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "We report the increased amount of motor disability in four patients with idiopathic Parkinson's disease after exposure to the antidepressant fluoxetine.", "entity_list": [{"name": "fluoxetine", "ent_type": "Chemical", "char_span": [141, 151], "ent_id": "D005473", "tok_span": [22, 25]}, {"name": "antidepressant", "ent_type": "Chemical", "char_span": [126, 140], "ent_id": "D000928", "tok_span": [21, 22]}, {"name": "idiopathic Parkinson's disease", "ent_type": "Disease", "char_span": [73, 103], "ent_id": "D010300", "tok_span": [12, 17]}, {"name": "motor disability", "ent_type": "Disease", "char_span": [34, 50], "ent_id": "D009069", "tok_span": [6, 8]}], "relation_list": [{"subject": "fluoxetine", "object": "motor disability", "sbj_char_span": [141, 151], "obj_char_span": [34, 50], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 25], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "Acetaminophen-induced hypotension.", "entity_list": [{"name": "Acetaminophen", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D000082", "tok_span": [0, 3]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [22, 33], "ent_id": "D007022", "tok_span": [5, 6]}], "relation_list": [{"subject": "Acetaminophen", "object": "hypotension", "sbj_char_span": [0, 13], "obj_char_span": [22, 33], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 6]}], "umls_entity_list": []}, {"text": "However, acetaminophen has been demonstrated to produce symptoms of anaphylaxis, including hypotension, in sensitive individuals.", "entity_list": [{"name": "hypotension", "ent_type": "Disease", "char_span": [91, 102], "ent_id": "D007022", "tok_span": [17, 18]}, {"name": "acetaminophen", "ent_type": "Chemical", "char_span": [9, 22], "ent_id": "D000082", "tok_span": [2, 5]}, {"name": "anaphylaxis", "ent_type": "Disease", "char_span": [68, 79], "ent_id": "D000707", "tok_span": [12, 15]}], "relation_list": [{"subject": "acetaminophen", "object": "hypotension", "sbj_char_span": [9, 22], "obj_char_span": [91, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [17, 18]}], "umls_entity_list": []}, {"text": "This article describes two critically ill patients in whom transient episodes of hypotension reproducibly developed after administration of acetaminophen.", "entity_list": [{"name": "hypotension", "ent_type": "Disease", "char_span": [81, 92], "ent_id": "D007022", "tok_span": [12, 13]}, {"name": "acetaminophen", "ent_type": "Chemical", "char_span": [140, 153], "ent_id": "D000082", "tok_span": [19, 22]}, {"name": "critically ill", "ent_type": "Disease", "char_span": [27, 41], "ent_id": "D016638", "tok_span": [4, 6]}], "relation_list": [{"subject": "acetaminophen", "object": "hypotension", "sbj_char_span": [140, 153], "obj_char_span": [81, 92], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 22], "obj_tok_span": [12, 13]}], "umls_entity_list": []}, {"text": "The reports illustrate the need for clinicians to consider acetaminophen in patients with hypotension of unknown origin.", "entity_list": [{"name": "acetaminophen", "ent_type": "Chemical", "char_span": [59, 72], "ent_id": "D000082", "tok_span": [9, 12]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [90, 101], "ent_id": "D007022", "tok_span": [15, 16]}], "relation_list": [{"subject": "acetaminophen", "object": "hypotension", "sbj_char_span": [59, 72], "obj_char_span": [90, 101], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [15, 16]}], "umls_entity_list": []}, {"text": "Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone.", "entity_list": [{"name": "ceftriaxone", "ent_type": "Chemical", "char_span": [84, 95], "ent_id": "D002443", "tok_span": [16, 20]}, {"name": "autoimmune hemolytic anemia", "ent_type": "Disease", "char_span": [17, 44], "ent_id": "D000744", "tok_span": [3, 7]}, {"name": "erythroblastocytopenia", "ent_type": "Disease", "char_span": [50, 72], "ent_id": "-1", "tok_span": [9, 14]}, {"name": "hepatitis", "ent_type": "Disease", "char_span": [6, 15], "ent_id": "D056486", "tok_span": [1, 2]}], "relation_list": [{"subject": "ceftriaxone", "object": "hepatitis", "sbj_char_span": [84, 95], "obj_char_span": [6, 15], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 20], "obj_tok_span": [1, 2]}, {"subject": "ceftriaxone", "object": "autoimmune hemolytic anemia", "sbj_char_span": [84, 95], "obj_char_span": [17, 44], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 20], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "An 80-yr-old man developed acute hepatitis shortly after ingesting oral ceftriaxone.", "entity_list": [{"name": "ceftriaxone", "ent_type": "Chemical", "char_span": [72, 83], "ent_id": "D002443", "tok_span": [15, 19]}, {"name": "hepatitis", "ent_type": "Disease", "char_span": [33, 42], "ent_id": "D056486", "tok_span": [9, 10]}], "relation_list": [{"subject": "ceftriaxone", "object": "hepatitis", "sbj_char_span": [72, 83], "obj_char_span": [33, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 19], "obj_tok_span": [9, 10]}], "umls_entity_list": []}, {"text": "The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).", "entity_list": [{"name": "EPS", "ent_type": "Disease", "char_span": [47, 50], "ent_id": "D001480", "tok_span": [9, 10]}, {"name": "clozapine", "ent_type": "Chemical", "char_span": [274, 283], "ent_id": "D003024", "tok_span": [55, 58]}, {"name": "weight gain", "ent_type": "Disease", "char_span": [154, 165], "ent_id": "D015430", "tok_span": [29, 31]}, {"name": "seizure", "ent_type": "Disease", "char_span": [212, 219], "ent_id": "D012640", "tok_span": [39, 40]}, {"name": "sexual dysfunction", "ent_type": "Disease", "char_span": [167, 185], "ent_id": "D012735", "tok_span": [32, 34]}, {"name": "agranulocytosis", "ent_type": "Disease", "char_span": [257, 272], "ent_id": "D000380", "tok_span": [49, 54]}, {"name": "clozapine", "ent_type": "Chemical", "char_span": [241, 250], "ent_id": "D003024", "tok_span": [43, 46]}], "relation_list": [{"subject": "clozapine", "object": "agranulocytosis", "sbj_char_span": [241, 250], "obj_char_span": [257, 272], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 46], "obj_tok_span": [49, 54]}, {"subject": "clozapine", "object": "agranulocytosis", "sbj_char_span": [274, 283], "obj_char_span": [257, 272], "rel_type": "chemical-induced disease", "sbj_tok_span": [55, 58], "obj_tok_span": [49, 54]}], "umls_entity_list": []}, {"text": "The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.", "entity_list": [{"name": "EP", "ent_type": "Chemical", "char_span": [144, 146], "ent_id": "D004837", "tok_span": [27, 28]}, {"name": "epinephrine", "ent_type": "Chemical", "char_span": [131, 142], "ent_id": "D004837", "tok_span": [23, 26]}, {"name": "TET", "ent_type": "Chemical", "char_span": [63, 66], "ent_id": "C009438", "tok_span": [10, 12]}, {"name": "blood coagulation", "ent_type": "Disease", "char_span": [186, 203], "ent_id": "D001778", "tok_span": [36, 38]}, {"name": "FAN", "ent_type": "Chemical", "char_span": [71, 74], "ent_id": "C060802", "tok_span": [13, 15]}, {"name": "thrombosis", "ent_type": "Disease", "char_span": [95, 105], "ent_id": "D013927", "tok_span": [18, 19]}, {"name": "platelet aggregation", "ent_type": "Disease", "char_span": [161, 181], "ent_id": "D001791", "tok_span": [33, 35]}], "relation_list": [{"subject": "epinephrine", "object": "thrombosis", "sbj_char_span": [131, 142], "obj_char_span": [95, 105], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [18, 19]}, {"subject": "EP", "object": "thrombosis", "sbj_char_span": [144, 146], "obj_char_span": [95, 105], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 28], "obj_tok_span": [18, 19]}], "umls_entity_list": []}, {"text": "Warfarin-induced artery calcification is accelerated by growth and vitamin D.\n The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.", "entity_list": [{"name": "artery calcification", "ent_type": "Disease", "char_span": [169, 189], "ent_id": "D061205", "tok_span": [29, 31]}, {"name": "Warfarin", "ent_type": "Chemical", "char_span": [224, 232], "ent_id": "D014859", "tok_span": [37, 40]}, {"name": "vitamin D", "ent_type": "Chemical", "char_span": [127, 136], "ent_id": "D014807", "tok_span": [22, 24]}, {"name": "vitamin D", "ent_type": "Chemical", "char_span": [67, 76], "ent_id": "D014807", "tok_span": [12, 14]}, {"name": "artery calcification", "ent_type": "Disease", "char_span": [17, 37], "ent_id": "D061205", "tok_span": [5, 7]}, {"name": "Warfarin", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D014859", "tok_span": [0, 3]}, {"name": "calcification", "ent_type": "Disease", "char_span": [289, 302], "ent_id": "D002114", "tok_span": [53, 54]}], "relation_list": [{"subject": "Warfarin", "object": "artery calcification", "sbj_char_span": [224, 232], "obj_char_span": [169, 189], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 40], "obj_tok_span": [29, 31]}, {"subject": "Warfarin", "object": "artery calcification", "sbj_char_span": [224, 232], "obj_char_span": [17, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 40], "obj_tok_span": [5, 7]}, {"subject": "Warfarin", "object": "artery calcification", "sbj_char_span": [0, 8], "obj_char_span": [17, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 7]}, {"subject": "Warfarin", "object": "artery calcification", "sbj_char_span": [0, 8], "obj_char_span": [169, 189], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [29, 31]}], "umls_entity_list": []}, {"text": "The first series of experiments examined the influence of age and growth status on artery calcification in Warfarin-treated rats.", "entity_list": [{"name": "Warfarin", "ent_type": "Chemical", "char_span": [107, 115], "ent_id": "D014859", "tok_span": [17, 20]}, {"name": "artery calcification", "ent_type": "Disease", "char_span": [83, 103], "ent_id": "D061205", "tok_span": [14, 16]}], "relation_list": [{"subject": "Warfarin", "object": "artery calcification", "sbj_char_span": [107, 115], "obj_char_span": [83, 103], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "Treatment for 2 weeks with Warfarin caused massive focal calcification of the artery media in 20-day-old rats and less extensive focal calcification in 42-day-old rats.", "entity_list": [{"name": "Warfarin", "ent_type": "Chemical", "char_span": [27, 35], "ent_id": "D014859", "tok_span": [5, 8]}, {"name": "calcification of the artery", "ent_type": "Disease", "char_span": [57, 84], "ent_id": "D061205", "tok_span": [11, 15]}, {"name": "calcification", "ent_type": "Disease", "char_span": [135, 148], "ent_id": "D002114", "tok_span": [27, 28]}], "relation_list": [{"subject": "Warfarin", "object": "calcification of the artery", "sbj_char_span": [27, 35], "obj_char_span": [57, 84], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "In contrast, no artery calcification could be detected in 10-month-old adult rats even after 4 weeks of Warfarin treatment.", "entity_list": [{"name": "Warfarin", "ent_type": "Chemical", "char_span": [104, 112], "ent_id": "D014859", "tok_span": [22, 25]}, {"name": "artery calcification", "ent_type": "Disease", "char_span": [16, 36], "ent_id": "D061205", "tok_span": [4, 6]}], "relation_list": [{"subject": "Warfarin", "object": "artery calcification", "sbj_char_span": [104, 112], "obj_char_span": [16, 36], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 25], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "To directly examine the importance of growth to Warfarin-induced artery calcification in animals of the same age, 20-day-old rats were fed for 2 weeks either an ad libitum diet or a 6-g/d restricted diet that maintains weight but prevents growth.", "entity_list": [{"name": "Warfarin", "ent_type": "Chemical", "char_span": [48, 56], "ent_id": "D014859", "tok_span": [8, 11]}, {"name": "artery calcification", "ent_type": "Disease", "char_span": [65, 85], "ent_id": "D061205", "tok_span": [13, 15]}], "relation_list": [{"subject": "Warfarin", "object": "artery calcification", "sbj_char_span": [48, 56], "obj_char_span": [65, 85], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "Concurrent treatment of both dietary groups with Warfarin produced massive focal calcification of the artery media in the ad libitum-fed rats but no detectable artery calcification in the restricted-diet, growth-inhibited group.", "entity_list": [{"name": "calcification of the artery", "ent_type": "Disease", "char_span": [81, 108], "ent_id": "D061205", "tok_span": [14, 18]}, {"name": "artery calcification", "ent_type": "Disease", "char_span": [160, 180], "ent_id": "D061205", "tok_span": [29, 31]}, {"name": "Warfarin", "ent_type": "Chemical", "char_span": [49, 57], "ent_id": "D014859", "tok_span": [8, 11]}], "relation_list": [{"subject": "Warfarin", "object": "calcification of the artery", "sbj_char_span": [49, 57], "obj_char_span": [81, 108], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [14, 18]}, {"subject": "Warfarin", "object": "artery calcification", "sbj_char_span": [49, 57], "obj_char_span": [160, 180], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [29, 31]}], "umls_entity_list": []}, {"text": "Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.", "entity_list": [{"name": "artery calcification", "ent_type": "Disease", "char_span": [383, 403], "ent_id": "D061205", "tok_span": [65, 67]}, {"name": "phosphate", "ent_type": "Chemical", "char_span": [183, 192], "ent_id": "D010710", "tok_span": [27, 28]}, {"name": "phosphate", "ent_type": "Chemical", "char_span": [269, 278], "ent_id": "D010710", "tok_span": [41, 42]}, {"name": "artery calcification", "ent_type": "Disease", "char_span": [53, 73], "ent_id": "D061205", "tok_span": [7, 9]}, {"name": "Warfarin", "ent_type": "Chemical", "char_span": [366, 374], "ent_id": "D014859", "tok_span": [60, 63]}, {"name": "artery calcification", "ent_type": "Disease", "char_span": [215, 235], "ent_id": "D061205", "tok_span": [31, 33]}], "relation_list": [{"subject": "Warfarin", "object": "artery calcification", "sbj_char_span": [366, 374], "obj_char_span": [53, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [60, 63], "obj_tok_span": [7, 9]}, {"subject": "Warfarin", "object": "artery calcification", "sbj_char_span": [366, 374], "obj_char_span": [215, 235], "rel_type": "chemical-induced disease", "sbj_tok_span": [60, 63], "obj_tok_span": [31, 33]}, {"subject": "Warfarin", "object": "artery calcification", "sbj_char_span": [366, 374], "obj_char_span": [383, 403], "rel_type": "chemical-induced disease", "sbj_tok_span": [60, 63], "obj_tok_span": [65, 67]}], "umls_entity_list": []}, {"text": "This observation suggests that increased susceptibility to Warfarin-induced artery calcification could be related to higher serum phosphate levels.", "entity_list": [{"name": "Warfarin", "ent_type": "Chemical", "char_span": [59, 67], "ent_id": "D014859", "tok_span": [7, 10]}, {"name": "phosphate", "ent_type": "Chemical", "char_span": [130, 139], "ent_id": "D010710", "tok_span": [20, 21]}, {"name": "artery calcification", "ent_type": "Disease", "char_span": [76, 96], "ent_id": "D061205", "tok_span": [12, 14]}], "relation_list": [{"subject": "Warfarin", "object": "artery calcification", "sbj_char_span": [59, 67], "obj_char_span": [76, 96], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [12, 14]}], "umls_entity_list": []}, {"text": "The second set of experiments examined the possible synergy between vitamin D and Warfarin in artery calcification.", "entity_list": [{"name": "Warfarin", "ent_type": "Chemical", "char_span": [82, 90], "ent_id": "D014859", "tok_span": [14, 17]}, {"name": "artery calcification", "ent_type": "Disease", "char_span": [94, 114], "ent_id": "D061205", "tok_span": [18, 20]}, {"name": "vitamin D", "ent_type": "Chemical", "char_span": [68, 77], "ent_id": "D014807", "tok_span": [11, 13]}], "relation_list": [{"subject": "Warfarin", "object": "artery calcification", "sbj_char_span": [82, 90], "obj_char_span": [94, 114], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [18, 20]}], "umls_entity_list": []}, {"text": "High doses of the vitamin K antagonist Warfarin are also known to cause calcification of the artery media, but at treatment times of 2 weeks or longer yet not at 1 week.", "entity_list": [{"name": "vitamin K", "ent_type": "Chemical", "char_span": [18, 27], "ent_id": "D014812", "tok_span": [4, 6]}, {"name": "Warfarin", "ent_type": "Chemical", "char_span": [39, 47], "ent_id": "D014859", "tok_span": [7, 10]}, {"name": "calcification of the artery", "ent_type": "Disease", "char_span": [72, 99], "ent_id": "D061205", "tok_span": [15, 19]}], "relation_list": [{"subject": "Warfarin", "object": "calcification of the artery", "sbj_char_span": [39, 47], "obj_char_span": [72, 99], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [15, 19]}], "umls_entity_list": []}, {"text": "High levels of matrix Gla protein are found at sites of artery calcification in rats treated with vitamin D plus Warfarin, and chemical analysis showed that the protein that accumulated was indeed not gamma-carboxylated.", "entity_list": [{"name": "artery calcification", "ent_type": "Disease", "char_span": [56, 76], "ent_id": "D061205", "tok_span": [12, 14]}, {"name": "gamma-carboxylated", "ent_type": "Chemical", "char_span": [201, 219], "ent_id": "D015055", "tok_span": [37, 41]}, {"name": "Warfarin", "ent_type": "Chemical", "char_span": [113, 121], "ent_id": "D014859", "tok_span": [21, 24]}, {"name": "vitamin D", "ent_type": "Chemical", "char_span": [98, 107], "ent_id": "D014807", "tok_span": [18, 20]}], "relation_list": [{"subject": "Warfarin", "object": "artery calcification", "sbj_char_span": [113, 121], "obj_char_span": [56, 76], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [12, 14]}], "umls_entity_list": []}, {"text": "Antidepressant-induced mania in bipolar patients: identification of risk factors.", "entity_list": [{"name": "Antidepressant", "ent_type": "Chemical", "char_span": [0, 14], "ent_id": "D000928", "tok_span": [0, 3]}, {"name": "bipolar", "ent_type": "Disease", "char_span": [32, 39], "ent_id": "D001714", "tok_span": [8, 9]}, {"name": "mania", "ent_type": "Disease", "char_span": [23, 28], "ent_id": "D001714", "tok_span": [5, 7]}], "relation_list": [{"subject": "Antidepressant", "object": "bipolar", "sbj_char_span": [0, 14], "obj_char_span": [32, 39], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [8, 9]}, {"subject": "Antidepressant", "object": "mania", "sbj_char_span": [0, 14], "obj_char_span": [23, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "BACKGROUND: Concerns about possible risks of switching to mania associated with antidepressants continue to interfere with the establishment of an optimal treatment paradigm for bipolar depression.", "entity_list": [{"name": "mania", "ent_type": "Disease", "char_span": [58, 63], "ent_id": "D001714", "tok_span": [10, 12]}, {"name": "antidepressants", "ent_type": "Chemical", "char_span": [80, 95], "ent_id": "D000928", "tok_span": [14, 16]}, {"name": "bipolar depression", "ent_type": "Disease", "char_span": [178, 196], "ent_id": "D001714", "tok_span": [28, 30]}], "relation_list": [{"subject": "antidepressants", "object": "bipolar depression", "sbj_char_span": [80, 95], "obj_char_span": [178, 196], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [28, 30]}, {"subject": "antidepressants", "object": "mania", "sbj_char_span": [80, 95], "obj_char_span": [58, 63], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.", "entity_list": [{"name": "serotonin reuptake inhibitors", "ent_type": "Chemical", "char_span": [333, 362], "ent_id": "D017367", "tok_span": [67, 72]}, {"name": "antidepressant", "ent_type": "Chemical", "char_span": [278, 292], "ent_id": "D000928", "tok_span": [59, 60]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [407, 414], "ent_id": "D008094", "tok_span": [87, 88]}, {"name": "DSM-IV bipolar I", "ent_type": "Disease", "char_span": [142, 158], "ent_id": "D001714", "tok_span": [28, 33]}, {"name": "hypomanic", "ent_type": "Disease", "char_span": [36, 45], "ent_id": "D001714", "tok_span": [7, 10]}, {"name": "bipolar II", "ent_type": "Disease", "char_span": [163, 173], "ent_id": "D001714", "tok_span": [35, 37]}, {"name": "manic", "ent_type": "Disease", "char_span": [27, 32], "ent_id": "D001714", "tok_span": [4, 6]}, {"name": "manic", "ent_type": "Disease", "char_span": [195, 200], "ent_id": "D001714", "tok_span": [42, 44]}, {"name": "SSRIs", "ent_type": "Chemical", "char_span": [364, 369], "ent_id": "D017367", "tok_span": [73, 76]}, {"name": "antidepressant", "ent_type": "Chemical", "char_span": [219, 233], "ent_id": "D000928", "tok_span": [48, 49]}], "relation_list": [{"subject": "serotonin reuptake inhibitors", "object": "hypomanic", "sbj_char_span": [333, 362], "obj_char_span": [36, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [67, 72], "obj_tok_span": [7, 10]}, {"subject": "antidepressant", "object": "manic", "sbj_char_span": [219, 233], "obj_char_span": [195, 200], "rel_type": "chemical-induced disease", "sbj_tok_span": [48, 49], "obj_tok_span": [42, 44]}, {"subject": "SSRIs", "object": "manic", "sbj_char_span": [364, 369], "obj_char_span": [195, 200], "rel_type": "chemical-induced disease", "sbj_tok_span": [73, 76], "obj_tok_span": [42, 44]}, {"subject": "antidepressant", "object": "hypomanic", "sbj_char_span": [219, 233], "obj_char_span": [36, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [48, 49], "obj_tok_span": [7, 10]}, {"subject": "antidepressant", "object": "DSM-IV bipolar I", "sbj_char_span": [219, 233], "obj_char_span": [142, 158], "rel_type": "chemical-induced disease", "sbj_tok_span": [48, 49], "obj_tok_span": [28, 33]}, {"subject": "antidepressant", "object": "hypomanic", "sbj_char_span": [278, 292], "obj_char_span": [36, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [59, 60], "obj_tok_span": [7, 10]}, {"subject": "serotonin reuptake inhibitors", "object": "manic", "sbj_char_span": [333, 362], "obj_char_span": [195, 200], "rel_type": "chemical-induced disease", "sbj_tok_span": [67, 72], "obj_tok_span": [42, 44]}, {"subject": "antidepressant", "object": "manic", "sbj_char_span": [219, 233], "obj_char_span": [27, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [48, 49], "obj_tok_span": [4, 6]}, {"subject": "antidepressant", "object": "DSM-IV bipolar I", "sbj_char_span": [278, 292], "obj_char_span": [142, 158], "rel_type": "chemical-induced disease", "sbj_tok_span": [59, 60], "obj_tok_span": [28, 33]}, {"subject": "serotonin reuptake inhibitors", "object": "bipolar II", "sbj_char_span": [333, 362], "obj_char_span": [163, 173], "rel_type": "chemical-induced disease", "sbj_tok_span": [67, 72], "obj_tok_span": [35, 37]}, {"subject": "SSRIs", "object": "manic", "sbj_char_span": [364, 369], "obj_char_span": [27, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [73, 76], "obj_tok_span": [4, 6]}, {"subject": "antidepressant", "object": "manic", "sbj_char_span": [278, 292], "obj_char_span": [195, 200], "rel_type": "chemical-induced disease", "sbj_tok_span": [59, 60], "obj_tok_span": [42, 44]}, {"subject": "serotonin reuptake inhibitors", "object": "DSM-IV bipolar I", "sbj_char_span": [333, 362], "obj_char_span": [142, 158], "rel_type": "chemical-induced disease", "sbj_tok_span": [67, 72], "obj_tok_span": [28, 33]}, {"subject": "SSRIs", "object": "bipolar II", "sbj_char_span": [364, 369], "obj_char_span": [163, 173], "rel_type": "chemical-induced disease", "sbj_tok_span": [73, 76], "obj_tok_span": [35, 37]}, {"subject": "serotonin reuptake inhibitors", "object": "manic", "sbj_char_span": [333, 362], "obj_char_span": [27, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [67, 72], "obj_tok_span": [4, 6]}, {"subject": "SSRIs", "object": "DSM-IV bipolar I", "sbj_char_span": [364, 369], "obj_char_span": [142, 158], "rel_type": "chemical-induced disease", "sbj_tok_span": [73, 76], "obj_tok_span": [28, 33]}, {"subject": "SSRIs", "object": "hypomanic", "sbj_char_span": [364, 369], "obj_char_span": [36, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [73, 76], "obj_tok_span": [7, 10]}, {"subject": "antidepressant", "object": "bipolar II", "sbj_char_span": [278, 292], "obj_char_span": [163, 173], "rel_type": "chemical-induced disease", "sbj_tok_span": [59, 60], "obj_tok_span": [35, 37]}, {"subject": "antidepressant", "object": "bipolar II", "sbj_char_span": [219, 233], "obj_char_span": [163, 173], "rel_type": "chemical-induced disease", "sbj_tok_span": [48, 49], "obj_tok_span": [35, 37]}, {"subject": "antidepressant", "object": "manic", "sbj_char_span": [278, 292], "obj_char_span": [27, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [59, 60], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.", "entity_list": [{"name": "mania", "ent_type": "Disease", "char_span": [34, 39], "ent_id": "D001714", "tok_span": [10, 12]}, {"name": "hypomanic", "ent_type": "Disease", "char_span": [217, 226], "ent_id": "D001714", "tok_span": [67, 70]}, {"name": "hypomania", "ent_type": "Disease", "char_span": [21, 30], "ent_id": "D001714", "tok_span": [6, 9]}, {"name": "manic", "ent_type": "Disease", "char_span": [173, 178], "ent_id": "D001714", "tok_span": [54, 56]}, {"name": "SSRIs", "ent_type": "Chemical", "char_span": [134, 139], "ent_id": "D017367", "tok_span": [36, 39]}], "relation_list": [{"subject": "SSRIs", "object": "mania", "sbj_char_span": [134, 139], "obj_char_span": [34, 39], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 39], "obj_tok_span": [10, 12]}, {"subject": "SSRIs", "object": "manic", "sbj_char_span": [134, 139], "obj_char_span": [173, 178], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 39], "obj_tok_span": [54, 56]}, {"subject": "SSRIs", "object": "hypomanic", "sbj_char_span": [134, 139], "obj_char_span": [217, 226], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 39], "obj_tok_span": [67, 70]}, {"subject": "SSRIs", "object": "hypomania", "sbj_char_span": [134, 139], "obj_char_span": [21, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 39], "obj_tok_span": [6, 9]}], "umls_entity_list": []}, {"text": "We describe a 25-year-old woman with pre-existing mitral valve prolapse who developed intractable ventricular fibrillation after consuming a \"natural energy\" guarana health drink containing a high concentration of caffeine.", "entity_list": [{"name": "caffeine", "ent_type": "Chemical", "char_span": [214, 222], "ent_id": "D002110", "tok_span": [40, 41]}, {"name": "mitral valve prolapse", "ent_type": "Disease", "char_span": [50, 71], "ent_id": "D008945", "tok_span": [13, 17]}, {"name": "ventricular fibrillation", "ent_type": "Disease", "char_span": [98, 122], "ent_id": "D014693", "tok_span": [21, 23]}], "relation_list": [{"subject": "caffeine", "object": "ventricular fibrillation", "sbj_char_span": [214, 222], "obj_char_span": [98, 122], "rel_type": "chemical-induced disease", "sbj_tok_span": [40, 41], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "Bladder retention of urine as a result of continuous intravenous infusion of fentanyl: 2 case reports.", "entity_list": [{"name": "fentanyl", "ent_type": "Chemical", "char_span": [77, 85], "ent_id": "D005283", "tok_span": [13, 16]}, {"name": "retention of urine", "ent_type": "Disease", "char_span": [8, 26], "ent_id": "D016055", "tok_span": [2, 5]}], "relation_list": [{"subject": "fentanyl", "object": "retention of urine", "sbj_char_span": [77, 85], "obj_char_span": [8, 26], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [2, 5]}], "umls_entity_list": []}, {"text": "Various reported side effects of fentanyl administration include chest wall rigidity, hypotension, respiratory depression, and bradycardia.", "entity_list": [{"name": "fentanyl", "ent_type": "Chemical", "char_span": [33, 41], "ent_id": "D005283", "tok_span": [5, 8]}, {"name": "chest wall rigidity", "ent_type": "Disease", "char_span": [65, 84], "ent_id": "D009127", "tok_span": [10, 13]}, {"name": "respiratory depression", "ent_type": "Disease", "char_span": [99, 121], "ent_id": "D012131", "tok_span": [16, 18]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [86, 97], "ent_id": "D007022", "tok_span": [14, 15]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [127, 138], "ent_id": "D001919", "tok_span": [20, 24]}], "relation_list": [{"subject": "fentanyl", "object": "hypotension", "sbj_char_span": [33, 41], "obj_char_span": [86, 97], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [14, 15]}, {"subject": "fentanyl", "object": "respiratory depression", "sbj_char_span": [33, 41], "obj_char_span": [99, 121], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [16, 18]}, {"subject": "fentanyl", "object": "bradycardia", "sbj_char_span": [33, 41], "obj_char_span": [127, 138], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "Here, 2 cases of urinary bladder retention leading to renal pelvocalyceal dilatation mimicking hydronephrosis as a result of continuous infusion of fentanyl are reported.", "entity_list": [{"name": "urinary bladder retention", "ent_type": "Disease", "char_span": [17, 42], "ent_id": "D001745", "tok_span": [5, 8]}, {"name": "hydronephrosis", "ent_type": "Disease", "char_span": [95, 109], "ent_id": "D006869", "tok_span": [20, 24]}, {"name": "fentanyl", "ent_type": "Chemical", "char_span": [148, 156], "ent_id": "D005283", "tok_span": [31, 34]}], "relation_list": [{"subject": "fentanyl", "object": "urinary bladder retention", "sbj_char_span": [148, 156], "obj_char_span": [17, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 34], "obj_tok_span": [5, 8]}], "umls_entity_list": []}, {"text": "Oral contraceptives and the risk of myocardial infarction.", "entity_list": [{"name": "Oral contraceptives", "ent_type": "Chemical", "char_span": [0, 19], "ent_id": "D003276", "tok_span": [0, 3]}, {"name": "myocardial infarction", "ent_type": "Disease", "char_span": [36, 57], "ent_id": "D009203", "tok_span": [7, 9]}], "relation_list": [{"subject": "Oral contraceptives", "object": "myocardial infarction", "sbj_char_span": [0, 19], "obj_char_span": [36, 57], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "BACKGROUND: An association between the use of oral contraceptives and the risk of myocardial infarction has been found in some, but not all, studies.", "entity_list": [{"name": "myocardial infarction", "ent_type": "Disease", "char_span": [82, 103], "ent_id": "D009203", "tok_span": [15, 17]}, {"name": "oral contraceptives", "ent_type": "Chemical", "char_span": [46, 65], "ent_id": "D003276", "tok_span": [8, 11]}], "relation_list": [{"subject": "oral contraceptives", "object": "myocardial infarction", "sbj_char_span": [46, 65], "obj_char_span": [82, 103], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.", "entity_list": [{"name": "levonorgestrel", "ent_type": "Chemical", "char_span": [162, 176], "ent_id": "D016912", "tok_span": [43, 48]}, {"name": "estrogen", "ent_type": "Chemical", "char_span": [211, 219], "ent_id": "D004967", "tok_span": [56, 57]}, {"name": "myocardial infarction", "ent_type": "Disease", "char_span": [424, 445], "ent_id": "D009203", "tok_span": [102, 104]}, {"name": "oral contraceptives", "ent_type": "Chemical", "char_span": [178, 197], "ent_id": "D003276", "tok_span": [49, 52]}, {"name": "desogestrel", "ent_type": "Chemical", "char_span": [107, 118], "ent_id": "D017135", "tok_span": [24, 28]}, {"name": "myocardial infarction", "ent_type": "Disease", "char_span": [508, 529], "ent_id": "D009203", "tok_span": [118, 120]}, {"name": "gestodene", "ent_type": "Chemical", "char_span": [122, 131], "ent_id": "C033273", "tok_span": [29, 32]}, {"name": "progestagen", "ent_type": "Chemical", "char_span": [59, 70], "ent_id": "D011372", "tok_span": [10, 13]}], "relation_list": [{"subject": "oral contraceptives", "object": "myocardial infarction", "sbj_char_span": [178, 197], "obj_char_span": [508, 529], "rel_type": "chemical-induced disease", "sbj_tok_span": [49, 52], "obj_tok_span": [118, 120]}, {"subject": "oral contraceptives", "object": "myocardial infarction", "sbj_char_span": [178, 197], "obj_char_span": [424, 445], "rel_type": "chemical-induced disease", "sbj_tok_span": [49, 52], "obj_tok_span": [102, 104]}], "umls_entity_list": []}, {"text": "An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS: The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive, as compared with nonusers, was 2.0 (95 percent confidence interval, 1.5 to 2.8).", "entity_list": [{"name": "myocardial infarction", "ent_type": "Disease", "char_span": [156, 177], "ent_id": "D009203", "tok_span": [36, 38]}, {"name": "oral contraceptive", "ent_type": "Chemical", "char_span": [220, 238], "ent_id": "D003276", "tok_span": [46, 48]}], "relation_list": [{"subject": "oral contraceptive", "object": "myocardial infarction", "sbj_char_span": [220, 238], "obj_char_span": [156, 177], "rel_type": "chemical-induced disease", "sbj_tok_span": [46, 48], "obj_tok_span": [36, 38]}], "umls_entity_list": []}, {"text": "Among women who used oral contraceptives, the odds ratio was 2.1 (95 percent confidence interval, 1.5 to 3.0) for those without a prothrombotic mutation and 1.9 (95 percent confidence interval, 0.6 to 5.5) for those with a mutation CONCLUSIONS: The risk of myocardial infarction was increased among women who used second-generation oral contraceptives.", "entity_list": [{"name": "oral contraceptives", "ent_type": "Chemical", "char_span": [21, 40], "ent_id": "D003276", "tok_span": [4, 7]}, {"name": "myocardial infarction", "ent_type": "Disease", "char_span": [257, 278], "ent_id": "D009203", "tok_span": [66, 68]}, {"name": "oral contraceptives", "ent_type": "Chemical", "char_span": [332, 351], "ent_id": "D003276", "tok_span": [77, 80]}], "relation_list": [{"subject": "oral contraceptives", "object": "myocardial infarction", "sbj_char_span": [332, 351], "obj_char_span": [257, 278], "rel_type": "chemical-induced disease", "sbj_tok_span": [77, 80], "obj_tok_span": [66, 68]}, {"subject": "oral contraceptives", "object": "myocardial infarction", "sbj_char_span": [21, 40], "obj_char_span": [257, 278], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [66, 68]}], "umls_entity_list": []}, {"text": "The risk of myocardial infarction was similar among women who used oral contraceptives whether or not they had a prothrombotic mutation.", "entity_list": [{"name": "oral contraceptives", "ent_type": "Chemical", "char_span": [67, 86], "ent_id": "D003276", "tok_span": [11, 14]}, {"name": "myocardial infarction", "ent_type": "Disease", "char_span": [12, 33], "ent_id": "D009203", "tok_span": [3, 5]}], "relation_list": [{"subject": "oral contraceptives", "object": "myocardial infarction", "sbj_char_span": [67, 86], "obj_char_span": [12, 33], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "Effects of 5-HT1B receptor ligands microinjected into the accumbal shell or core on the cocaine-induced locomotor hyperactivity in rats.", "entity_list": [{"name": "locomotor hyperactivity", "ent_type": "Disease", "char_span": [104, 127], "ent_id": "D009069", "tok_span": [23, 26]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [88, 95], "ent_id": "D003042", "tok_span": [20, 21]}], "relation_list": [{"subject": "cocaine", "object": "locomotor hyperactivity", "sbj_char_span": [88, 95], "obj_char_span": [104, 127], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 21], "obj_tok_span": [23, 26]}], "umls_entity_list": []}, {"text": "The present study was designed to examine the effect of 5-HT1B receptor ligands microinjected into the subregions of the nucleus accumbens (the shell and the core) on the locomotor hyperactivity induced by cocaine in rats.", "entity_list": [{"name": "cocaine", "ent_type": "Chemical", "char_span": [206, 213], "ent_id": "D003042", "tok_span": [43, 44]}, {"name": "locomotor hyperactivity", "ent_type": "Disease", "char_span": [171, 194], "ent_id": "D009069", "tok_span": [38, 41]}], "relation_list": [{"subject": "cocaine", "object": "locomotor hyperactivity", "sbj_char_span": [206, 213], "obj_char_span": [171, 194], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 44], "obj_tok_span": [38, 41]}], "umls_entity_list": []}, {"text": "GR 55562 (0.1-10 microg/side), administered intra-accumbens shell prior to cocaine, dose-dependently attenuated the psychostimulant-induced locomotor hyperactivity.", "entity_list": [{"name": "locomotor hyperactivity", "ent_type": "Disease", "char_span": [140, 163], "ent_id": "D009069", "tok_span": [37, 40]}, {"name": "GR 55562", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "C103477", "tok_span": [0, 4]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [75, 82], "ent_id": "D003042", "tok_span": [24, 25]}], "relation_list": [{"subject": "cocaine", "object": "locomotor hyperactivity", "sbj_char_span": [75, 82], "obj_char_span": [140, 163], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 25], "obj_tok_span": [37, 40]}], "umls_entity_list": []}, {"text": "Our findings indicate that cocaine induced hyperlocomotion is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively.", "entity_list": [{"name": "hyperlocomotion", "ent_type": "Disease", "char_span": [43, 58], "ent_id": "D009069", "tok_span": [6, 10]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [27, 34], "ent_id": "D003042", "tok_span": [4, 5]}, {"name": "GR 55562", "ent_type": "Chemical", "char_span": [255, 263], "ent_id": "C103477", "tok_span": [51, 55]}, {"name": "CP 93129", "ent_type": "Chemical", "char_span": [278, 286], "ent_id": "C065046", "tok_span": [59, 62]}], "relation_list": [{"subject": "cocaine", "object": "hyperlocomotion", "sbj_char_span": [27, 34], "obj_char_span": [43, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [6, 10]}, {"subject": "CP 93129", "object": "hyperlocomotion", "sbj_char_span": [278, 286], "obj_char_span": [43, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [59, 62], "obj_tok_span": [6, 10]}], "umls_entity_list": []}, {"text": "Our patients developed jaundice following treatment with ticlopidine and showed the clinical and laboratory characteristics of cholestatic hepatitis, which resolved after discontinuation of the drug.", "entity_list": [{"name": "jaundice", "ent_type": "Disease", "char_span": [23, 31], "ent_id": "D007565", "tok_span": [3, 6]}, {"name": "cholestatic hepatitis", "ent_type": "Disease", "char_span": [127, 148], "ent_id": "D00277", "tok_span": [22, 26]}, {"name": "ticlopidine", "ent_type": "Chemical", "char_span": [57, 68], "ent_id": "D013988", "tok_span": [9, 14]}], "relation_list": [{"subject": "ticlopidine", "object": "jaundice", "sbj_char_span": [57, 68], "obj_char_span": [23, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 14], "obj_tok_span": [3, 6]}], "umls_entity_list": []}, {"text": "The mechanisms of this ticlopidine-induced cholestasis are unclear.", "entity_list": [{"name": "ticlopidine", "ent_type": "Chemical", "char_span": [23, 34], "ent_id": "D013988", "tok_span": [4, 9]}, {"name": "cholestasis", "ent_type": "Disease", "char_span": [43, 54], "ent_id": "D002779", "tok_span": [11, 14]}], "relation_list": [{"subject": "ticlopidine", "object": "cholestasis", "sbj_char_span": [23, 34], "obj_char_span": [43, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 9], "obj_tok_span": [11, 14]}], "umls_entity_list": []}, {"text": "Epithelial sodium channel (ENaC) subunit mRNA and protein expression in rats with puromycin aminonucleoside-induced nephrotic syndrome.", "entity_list": [{"name": "nephrotic syndrome", "ent_type": "Disease", "char_span": [116, 134], "ent_id": "D009404", "tok_span": [24, 27]}, {"name": "puromycin aminonucleoside", "ent_type": "Chemical", "char_span": [82, 107], "ent_id": "D011692", "tok_span": [17, 22]}, {"name": "sodium", "ent_type": "Chemical", "char_span": [11, 17], "ent_id": "D012964", "tok_span": [2, 3]}], "relation_list": [{"subject": "puromycin aminonucleoside", "object": "nephrotic syndrome", "sbj_char_span": [82, 107], "obj_char_span": [116, 134], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 22], "obj_tok_span": [24, 27]}], "umls_entity_list": []}, {"text": "We examined the abundance of ENaC subunit mRNAs and proteins in puromycin aminonucleoside (PAN)-induced nephrotic syndrome.", "entity_list": [{"name": "PAN", "ent_type": "Chemical", "char_span": [91, 94], "ent_id": "D011692", "tok_span": [19, 20]}, {"name": "puromycin aminonucleoside", "ent_type": "Chemical", "char_span": [64, 89], "ent_id": "D011692", "tok_span": [13, 18]}, {"name": "nephrotic syndrome", "ent_type": "Disease", "char_span": [104, 122], "ent_id": "D009404", "tok_span": [23, 26]}], "relation_list": [{"subject": "puromycin aminonucleoside", "object": "nephrotic syndrome", "sbj_char_span": [64, 89], "obj_char_span": [104, 122], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 18], "obj_tok_span": [23, 26]}, {"subject": "PAN", "object": "nephrotic syndrome", "sbj_char_span": [91, 94], "obj_char_span": [104, 122], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 20], "obj_tok_span": [23, 26]}], "umls_entity_list": []}, {"text": "The time courses of urinary sodium excretion, plasma aldosterone concentration and proteinuria were studied in male Sprague-Dawley rats treated with a single dose of either PAN or vehicle.", "entity_list": [{"name": "aldosterone", "ent_type": "Chemical", "char_span": [53, 64], "ent_id": "D000450", "tok_span": [9, 11]}, {"name": "proteinuria", "ent_type": "Disease", "char_span": [83, 94], "ent_id": "D011507", "tok_span": [13, 14]}, {"name": "sodium", "ent_type": "Chemical", "char_span": [28, 34], "ent_id": "D012964", "tok_span": [5, 6]}, {"name": "PAN", "ent_type": "Chemical", "char_span": [173, 176], "ent_id": "D011692", "tok_span": [30, 31]}], "relation_list": [{"subject": "PAN", "object": "proteinuria", "sbj_char_span": [173, 176], "obj_char_span": [83, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 31], "obj_tok_span": [13, 14]}], "umls_entity_list": []}, {"text": "In conclusion, ENaC mRNA expression, especially alphaENaC, is increased in the very early phase of the experimental model of PAN-induced nephrotic syndrome in rats, but appears to escape from the regulation by aldosterone after day 3.", "entity_list": [{"name": "PAN", "ent_type": "Chemical", "char_span": [125, 128], "ent_id": "D011692", "tok_span": [27, 28]}, {"name": "aldosterone", "ent_type": "Chemical", "char_span": [210, 221], "ent_id": "D000450", "tok_span": [44, 46]}, {"name": "nephrotic syndrome", "ent_type": "Disease", "char_span": [137, 155], "ent_id": "D009404", "tok_span": [30, 33]}], "relation_list": [{"subject": "PAN", "object": "nephrotic syndrome", "sbj_char_span": [125, 128], "obj_char_span": [137, 155], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 28], "obj_tok_span": [30, 33]}], "umls_entity_list": []}, {"text": "Coronary aneurysm after implantation of a paclitaxel-eluting stent.", "entity_list": [{"name": "paclitaxel", "ent_type": "Chemical", "char_span": [42, 52], "ent_id": "D017239", "tok_span": [6, 7]}, {"name": "Coronary aneurysm", "ent_type": "Disease", "char_span": [0, 17], "ent_id": "D003323", "tok_span": [0, 2]}], "relation_list": [{"subject": "paclitaxel", "object": "Coronary aneurysm", "sbj_char_span": [42, 52], "obj_char_span": [0, 17], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "We present a 43-year-old man who developed a coronary aneurysm in the right coronary artery 6 months after receiving a paclitaxel-eluting stent.", "entity_list": [{"name": "coronary aneurysm", "ent_type": "Disease", "char_span": [45, 62], "ent_id": "D003323", "tok_span": [12, 14]}, {"name": "paclitaxel", "ent_type": "Chemical", "char_span": [119, 129], "ent_id": "D017239", "tok_span": [24, 25]}], "relation_list": [{"subject": "paclitaxel", "object": "coronary aneurysm", "sbj_char_span": [119, 129], "obj_char_span": [45, 62], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 25], "obj_tok_span": [12, 14]}], "umls_entity_list": []}, {"text": "Whatever was the dose, the central administration of U-II had no effect on body temperature, nociception, apomorphine-induced penile erection and climbing behavior, and stress-induced plasma corticosterone level.", "entity_list": [{"name": "U-II", "ent_type": "Chemical", "char_span": [53, 57], "ent_id": "D014579", "tok_span": [10, 13]}, {"name": "penile erection", "ent_type": "Disease", "char_span": [126, 141], "ent_id": "D010409", "tok_span": [30, 35]}, {"name": "apomorphine", "ent_type": "Chemical", "char_span": [106, 117], "ent_id": "D001058", "tok_span": [23, 28]}, {"name": "corticosterone", "ent_type": "Chemical", "char_span": [191, 205], "ent_id": "D003345", "tok_span": [45, 47]}], "relation_list": [{"subject": "apomorphine", "object": "penile erection", "sbj_char_span": [106, 117], "obj_char_span": [126, 141], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 28], "obj_tok_span": [30, 35]}], "umls_entity_list": []}, {"text": "Recurrent dysphonia and acitretin.", "entity_list": [{"name": "dysphonia", "ent_type": "Disease", "char_span": [10, 19], "ent_id": "D055154", "tok_span": [2, 4]}, {"name": "acitretin", "ent_type": "Chemical", "char_span": [24, 33], "ent_id": "D017255", "tok_span": [5, 8]}], "relation_list": [{"subject": "acitretin", "object": "dysphonia", "sbj_char_span": [24, 33], "obj_char_span": [10, 19], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [2, 4]}], "umls_entity_list": []}, {"text": "We report the case of a woman complaining of dysphonia while she was treated by acitretin.", "entity_list": [{"name": "acitretin", "ent_type": "Chemical", "char_span": [80, 89], "ent_id": "D017255", "tok_span": [17, 20]}, {"name": "dysphonia", "ent_type": "Disease", "char_span": [45, 54], "ent_id": "D055154", "tok_span": [10, 12]}], "relation_list": [{"subject": "acitretin", "object": "dysphonia", "sbj_char_span": [80, 89], "obj_char_span": [45, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "To our knowledge, this is the first case of acitretin-induced dysphonia.", "entity_list": [{"name": "acitretin", "ent_type": "Chemical", "char_span": [44, 53], "ent_id": "D017255", "tok_span": [10, 13]}, {"name": "dysphonia", "ent_type": "Disease", "char_span": [62, 71], "ent_id": "D055154", "tok_span": [15, 17]}], "relation_list": [{"subject": "acitretin", "object": "dysphonia", "sbj_char_span": [44, 53], "obj_char_span": [62, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "Using functional magnetic resonance imaging (fMRI) in normal volunteers, we studied the gabapentin-induced modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and capsaicin-induced secondary hyperalgesia.", "entity_list": [{"name": "gabapentin", "ent_type": "Chemical", "char_span": [88, 98], "ent_id": "C040029", "tok_span": [15, 19]}, {"name": "secondary hyperalgesia", "ent_type": "Disease", "char_span": [223, 245], "ent_id": "D006930", "tok_span": [41, 46]}, {"name": "capsaicin", "ent_type": "Chemical", "char_span": [205, 214], "ent_id": "D002211", "tok_span": [36, 39]}], "relation_list": [{"subject": "capsaicin", "object": "secondary hyperalgesia", "sbj_char_span": [205, 214], "obj_char_span": [223, 245], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 39], "obj_tok_span": [41, 46]}], "umls_entity_list": []}, {"text": "MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes.", "entity_list": [{"name": "impaired social and emotional judgement processes", "ent_type": "Disease", "char_span": [85, 134], "ent_id": "D003072", "tok_span": [14, 21]}, {"name": "MDMA", "ent_type": "Chemical", "char_span": [0, 4], "ent_id": "D018817", "tok_span": [0, 2]}], "relation_list": [{"subject": "MDMA", "object": "impaired social and emotional judgement processes", "sbj_char_span": [0, 4], "obj_char_span": [85, 134], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [14, 21]}], "umls_entity_list": []}, {"text": "The events are consistent with a severe reaction to calcium chelation by sodium citrate anticoagulant resulting in symptomatic systemic hypocalcemia.", "entity_list": [{"name": "sodium citrate", "ent_type": "Chemical", "char_span": [73, 87], "ent_id": "C102006", "tok_span": [13, 15]}, {"name": "calcium", "ent_type": "Chemical", "char_span": [52, 59], "ent_id": "D002118", "tok_span": [9, 10]}, {"name": "hypocalcemia", "ent_type": "Disease", "char_span": [136, 148], "ent_id": "D006996", "tok_span": [20, 23]}], "relation_list": [{"subject": "sodium citrate", "object": "hypocalcemia", "sbj_char_span": [73, 87], "obj_char_span": [136, 148], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [20, 23]}], "umls_entity_list": []}, {"text": "We conclude that careful screening for medications and underlying conditions predisposing to hypocalcemia is recommended to help prevent severe reactions due to citrate toxicity.", "entity_list": [{"name": "toxicity", "ent_type": "Disease", "char_span": [169, 177], "ent_id": "D064420", "tok_span": [26, 27]}, {"name": "hypocalcemia", "ent_type": "Disease", "char_span": [93, 105], "ent_id": "D006996", "tok_span": [13, 16]}, {"name": "citrate", "ent_type": "Chemical", "char_span": [161, 168], "ent_id": "C102006", "tok_span": [25, 26]}], "relation_list": [{"subject": "citrate", "object": "hypocalcemia", "sbj_char_span": [161, 168], "obj_char_span": [93, 105], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 26], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "Proteinuria after conversion to sirolimus in renal transplant recipients.", "entity_list": [{"name": "sirolimus", "ent_type": "Chemical", "char_span": [32, 41], "ent_id": "D020123", "tok_span": [5, 7]}, {"name": "Proteinuria", "ent_type": "Disease", "char_span": [0, 11], "ent_id": "D011507", "tok_span": [0, 2]}], "relation_list": [{"subject": "sirolimus", "object": "Proteinuria", "sbj_char_span": [32, 41], "obj_char_span": [0, 11], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 7], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "More recently, proteinuria has been reported as a consequence of sirolimus therapy, although the mechanism has remained unclear.", "entity_list": [{"name": "proteinuria", "ent_type": "Disease", "char_span": [15, 26], "ent_id": "D011507", "tok_span": [3, 4]}, {"name": "sirolimus", "ent_type": "Chemical", "char_span": [65, 74], "ent_id": "D020123", "tok_span": [11, 13]}], "relation_list": [{"subject": "sirolimus", "object": "proteinuria", "sbj_char_span": [65, 74], "obj_char_span": [15, 26], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 13], "obj_tok_span": [3, 4]}], "umls_entity_list": []}, {"text": "We retrospectively examined the records of 25 renal transplant patients, who developed or displayed increased proteinuria after SRL conversion.", "entity_list": [{"name": "SRL", "ent_type": "Chemical", "char_span": [128, 131], "ent_id": "D020123", "tok_span": [18, 20]}, {"name": "proteinuria", "ent_type": "Disease", "char_span": [110, 121], "ent_id": "D011507", "tok_span": [16, 17]}], "relation_list": [{"subject": "SRL", "object": "proteinuria", "sbj_char_span": [128, 131], "obj_char_span": [110, 121], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 20], "obj_tok_span": [16, 17]}], "umls_entity_list": []}, {"text": "Heavy proteinuria was common after the use of SRL as rescue therapy for renal transplantation.", "entity_list": [{"name": "SRL", "ent_type": "Chemical", "char_span": [46, 49], "ent_id": "D020123", "tok_span": [9, 11]}, {"name": "proteinuria", "ent_type": "Disease", "char_span": [6, 17], "ent_id": "D011507", "tok_span": [2, 3]}], "relation_list": [{"subject": "SRL", "object": "proteinuria", "sbj_char_span": [46, 49], "obj_char_span": [6, 17], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 11], "obj_tok_span": [2, 3]}], "umls_entity_list": []}, {"text": "In vitro characterization of parasympathetic and sympathetic responses in cyclophosphamide-induced cystitis in the rat.", "entity_list": [{"name": "cystitis", "ent_type": "Disease", "char_span": [99, 107], "ent_id": "D003556", "tok_span": [17, 19]}, {"name": "cyclophosphamide", "ent_type": "Chemical", "char_span": [74, 90], "ent_id": "D003520", "tok_span": [12, 15]}], "relation_list": [{"subject": "cyclophosphamide", "object": "cystitis", "sbj_char_span": [74, 90], "obj_char_span": [99, 107], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [17, 19]}], "umls_entity_list": []}, {"text": "In cyclophosphamide-induced cystitis in the rat, detrusor function is impaired and the expression and effects of muscarinic receptors altered.", "entity_list": [{"name": "cyclophosphamide", "ent_type": "Chemical", "char_span": [3, 19], "ent_id": "D003520", "tok_span": [1, 4]}, {"name": "cystitis", "ent_type": "Disease", "char_span": [28, 36], "ent_id": "D003556", "tok_span": [6, 8]}], "relation_list": [{"subject": "cyclophosphamide", "object": "cystitis", "sbj_char_span": [3, 19], "obj_char_span": [28, 36], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 4], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay.", "entity_list": [{"name": "BZDs", "ent_type": "Chemical", "char_span": [16, 20], "ent_id": "D001569", "tok_span": [4, 7]}, {"name": "tiredness", "ent_type": "Disease", "char_span": [102, 111], "ent_id": "D005221", "tok_span": [26, 29]}, {"name": "dizziness", "ent_type": "Disease", "char_span": [45, 54], "ent_id": "D004244", "tok_span": [13, 16]}, {"name": "inability to sleep", "ent_type": "Disease", "char_span": [56, 74], "ent_id": "D007319", "tok_span": [17, 20]}, {"name": "depressive symptoms", "ent_type": "Disease", "char_span": [181, 200], "ent_id": "D003866", "tok_span": [42, 44]}], "relation_list": [{"subject": "BZDs", "object": "dizziness", "sbj_char_span": [16, 20], "obj_char_span": [45, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [13, 16]}, {"subject": "BZDs", "object": "tiredness", "sbj_char_span": [16, 20], "obj_char_span": [102, 111], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [26, 29]}, {"subject": "BZDs", "object": "inability to sleep", "sbj_char_span": [16, 20], "obj_char_span": [56, 74], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [17, 20]}, {"subject": "BZDs", "object": "depressive symptoms", "sbj_char_span": [16, 20], "obj_char_span": [181, 200], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [42, 44]}], "umls_entity_list": []}, {"text": "Acute vocal fold palsy after acute disulfiram intoxication.", "entity_list": [{"name": "vocal fold palsy", "ent_type": "Disease", "char_span": [6, 22], "ent_id": "D014826", "tok_span": [1, 4]}, {"name": "disulfiram", "ent_type": "Chemical", "char_span": [35, 45], "ent_id": "D004221", "tok_span": [6, 10]}], "relation_list": [{"subject": "disulfiram", "object": "vocal fold palsy", "sbj_char_span": [35, 45], "obj_char_span": [6, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 10], "obj_tok_span": [1, 4]}], "umls_entity_list": []}, {"text": "Acute peripheral neuropathy caused by a disulfiram overdose is very rare and there is no report of it leading to vocal fold palsy.", "entity_list": [{"name": "peripheral neuropathy", "ent_type": "Disease", "char_span": [6, 27], "ent_id": "D010523", "tok_span": [1, 3]}, {"name": "vocal fold palsy", "ent_type": "Disease", "char_span": [113, 129], "ent_id": "D014826", "tok_span": [24, 27]}, {"name": "disulfiram", "ent_type": "Chemical", "char_span": [40, 50], "ent_id": "D004221", "tok_span": [6, 10]}, {"name": "overdose", "ent_type": "Disease", "char_span": [51, 59], "ent_id": "D062787", "tok_span": [10, 12]}], "relation_list": [{"subject": "disulfiram", "object": "peripheral neuropathy", "sbj_char_span": [40, 50], "obj_char_span": [6, 27], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 10], "obj_tok_span": [1, 3]}, {"subject": "disulfiram", "object": "vocal fold palsy", "sbj_char_span": [40, 50], "obj_char_span": [113, 129], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 10], "obj_tok_span": [24, 27]}], "umls_entity_list": []}, {"text": "Higher optical density of an antigen assay predicts thrombosis in patients with heparin-induced thrombocytopenia.", "entity_list": [{"name": "heparin", "ent_type": "Chemical", "char_span": [80, 87], "ent_id": "D006493", "tok_span": [12, 13]}, {"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [96, 112], "ent_id": "D013921", "tok_span": [15, 17]}, {"name": "thrombosis", "ent_type": "Disease", "char_span": [52, 62], "ent_id": "D013927", "tok_span": [8, 9]}], "relation_list": [{"subject": "heparin", "object": "thrombosis", "sbj_char_span": [80, 87], "obj_char_span": [52, 62], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [8, 9]}, {"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [80, 87], "obj_char_span": [96, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "OBJECTIVES: To correlate optical density and percent inhibition of a two-step heparin-induced thrombocytopenia (HIT) antigen assay with thrombosis; the assay utilizes reaction inhibition characteristics of a high heparin concentration.", "entity_list": [{"name": "HIT", "ent_type": "Disease", "char_span": [112, 115], "ent_id": "D013921", "tok_span": [20, 22]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [213, 220], "ent_id": "D006493", "tok_span": [37, 38]}, {"name": "thrombosis", "ent_type": "Disease", "char_span": [136, 146], "ent_id": "D013927", "tok_span": [26, 27]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [78, 85], "ent_id": "D006493", "tok_span": [14, 15]}, {"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [94, 110], "ent_id": "D013921", "tok_span": [17, 19]}], "relation_list": [{"subject": "heparin", "object": "HIT", "sbj_char_span": [213, 220], "obj_char_span": [112, 115], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 38], "obj_tok_span": [20, 22]}, {"subject": "heparin", "object": "HIT", "sbj_char_span": [78, 85], "obj_char_span": [112, 115], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [20, 22]}, {"subject": "heparin", "object": "thrombosis", "sbj_char_span": [78, 85], "obj_char_span": [136, 146], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [26, 27]}, {"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [78, 85], "obj_char_span": [94, 110], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [17, 19]}, {"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [213, 220], "obj_char_span": [94, 110], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 38], "obj_tok_span": [17, 19]}, {"subject": "heparin", "object": "thrombosis", "sbj_char_span": [213, 220], "obj_char_span": [136, 146], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 38], "obj_tok_span": [26, 27]}], "umls_entity_list": []}, {"text": "PATIENTS AND METHODS: Patients with more than 50% decrease in platelet count or thrombocytopenia (<150 x 10(9)/L) after exposure to heparin, who had a positive two-step antigen assay [optical density (OD) >0.4 and >50 inhibition with high concentration of heparin] were included in the study.", "entity_list": [{"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [80, 96], "ent_id": "D013921", "tok_span": [16, 18]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [256, 263], "ent_id": "D006493", "tok_span": [61, 62]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [132, 139], "ent_id": "D006493", "tok_span": [32, 33]}], "relation_list": [{"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [256, 263], "obj_char_span": [80, 96], "rel_type": "chemical-induced disease", "sbj_tok_span": [61, 62], "obj_tok_span": [16, 18]}, {"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [132, 139], "obj_char_span": [80, 96], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 33], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "Central retinal vein occlusion associated with clomiphene-induced ovulation.", "entity_list": [{"name": "retinal vein occlusion", "ent_type": "Disease", "char_span": [8, 30], "ent_id": "D012170", "tok_span": [1, 4]}, {"name": "clomiphene", "ent_type": "Chemical", "char_span": [47, 57], "ent_id": "D002996", "tok_span": [6, 10]}], "relation_list": [{"subject": "clomiphene", "object": "retinal vein occlusion", "sbj_char_span": [47, 57], "obj_char_span": [8, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 10], "obj_tok_span": [1, 4]}], "umls_entity_list": []}, {"text": "OBJECTIVE: To report a case of central retinal vein occlusion associated with clomiphene citrate (CC).", "entity_list": [{"name": "CC", "ent_type": "Chemical", "char_span": [98, 100], "ent_id": "D002996", "tok_span": [19, 20]}, {"name": "clomiphene citrate", "ent_type": "Chemical", "char_span": [78, 96], "ent_id": "D002996", "tok_span": [13, 18]}, {"name": "retinal vein occlusion", "ent_type": "Disease", "char_span": [39, 61], "ent_id": "D012170", "tok_span": [8, 11]}], "relation_list": [{"subject": "clomiphene citrate", "object": "retinal vein occlusion", "sbj_char_span": [78, 96], "obj_char_span": [39, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 18], "obj_tok_span": [8, 11]}, {"subject": "CC", "object": "retinal vein occlusion", "sbj_char_span": [98, 100], "obj_char_span": [39, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 20], "obj_tok_span": [8, 11]}], "umls_entity_list": []}, {"text": "MAIN OUTCOME MEASURE(S): Central retinal vein occlusion after ovulation induction with CC.", "entity_list": [{"name": "CC", "ent_type": "Chemical", "char_span": [87, 89], "ent_id": "D002996", "tok_span": [20, 21]}, {"name": "retinal vein occlusion", "ent_type": "Disease", "char_span": [33, 55], "ent_id": "D012170", "tok_span": [12, 15]}], "relation_list": [{"subject": "CC", "object": "retinal vein occlusion", "sbj_char_span": [87, 89], "obj_char_span": [33, 55], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 21], "obj_tok_span": [12, 15]}], "umls_entity_list": []}, {"text": "RESULT(S): A 36-year-old Chinese woman developed central retinal vein occlusion after eight courses of CC.", "entity_list": [{"name": "CC", "ent_type": "Chemical", "char_span": [103, 105], "ent_id": "D002996", "tok_span": [23, 24]}, {"name": "retinal vein occlusion", "ent_type": "Disease", "char_span": [57, 79], "ent_id": "D012170", "tok_span": [16, 19]}], "relation_list": [{"subject": "CC", "object": "retinal vein occlusion", "sbj_char_span": [103, 105], "obj_char_span": [57, 79], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 24], "obj_tok_span": [16, 19]}], "umls_entity_list": []}, {"text": "A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication, although mild visual disturbance after CC intake is not uncommon.", "entity_list": [{"name": "CC", "ent_type": "Chemical", "char_span": [66, 68], "ent_id": "D002996", "tok_span": [11, 12]}, {"name": "thromboembolic", "ent_type": "Disease", "char_span": [34, 48], "ent_id": "D013923", "tok_span": [7, 9]}, {"name": "CC", "ent_type": "Chemical", "char_span": [162, 164], "ent_id": "D002996", "tok_span": [26, 27]}, {"name": "visual disturbance", "ent_type": "Disease", "char_span": [137, 155], "ent_id": "D014786", "tok_span": [23, 25]}], "relation_list": [{"subject": "CC", "object": "visual disturbance", "sbj_char_span": [66, 68], "obj_char_span": [137, 155], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [23, 25]}, {"subject": "CC", "object": "visual disturbance", "sbj_char_span": [162, 164], "obj_char_span": [137, 155], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 27], "obj_tok_span": [23, 25]}], "umls_entity_list": []}, {"text": "CONCLUSION(S): This is the first reported case of central retinal vein occlusion after treatment with CC.", "entity_list": [{"name": "CC", "ent_type": "Chemical", "char_span": [102, 104], "ent_id": "D002996", "tok_span": [19, 20]}, {"name": "retinal vein occlusion", "ent_type": "Disease", "char_span": [58, 80], "ent_id": "D012170", "tok_span": [13, 16]}], "relation_list": [{"subject": "CC", "object": "retinal vein occlusion", "sbj_char_span": [102, 104], "obj_char_span": [58, 80], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 20], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "Nicotine-induced nystagmus correlates with midpontine activation.", "entity_list": [{"name": "nystagmus", "ent_type": "Disease", "char_span": [17, 26], "ent_id": "D009759", "tok_span": [4, 8]}, {"name": "Nicotine", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D009538", "tok_span": [0, 2]}], "relation_list": [{"subject": "Nicotine", "object": "nystagmus", "sbj_char_span": [0, 8], "obj_char_span": [17, 26], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "The pathomechanism of nicotine-induced nystagmus (NIN) is unknown.", "entity_list": [{"name": "nystagmus", "ent_type": "Disease", "char_span": [39, 48], "ent_id": "D009759", "tok_span": [9, 13]}, {"name": "nicotine", "ent_type": "Chemical", "char_span": [22, 30], "ent_id": "D009538", "tok_span": [6, 7]}, {"name": "NIN", "ent_type": "Disease", "char_span": [50, 53], "ent_id": "D009759", "tok_span": [14, 16]}], "relation_list": [{"subject": "nicotine", "object": "nystagmus", "sbj_char_span": [22, 30], "obj_char_span": [39, 48], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [9, 13]}, {"subject": "nicotine", "object": "NIN", "sbj_char_span": [22, 30], "obj_char_span": [50, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.", "entity_list": [{"name": "gastric hemorrhage", "ent_type": "Disease", "char_span": [191, 209], "ent_id": "D006471", "tok_span": [35, 37]}, {"name": "atherosclerosis", "ent_type": "Disease", "char_span": [233, 248], "ent_id": "D050197", "tok_span": [42, 43]}, {"name": "histamine", "ent_type": "Chemical", "char_span": [87, 96], "ent_id": "D006632", "tok_span": [19, 20]}, {"name": "ulcer", "ent_type": "Disease", "char_span": [214, 219], "ent_id": "D014456", "tok_span": [38, 39]}, {"name": "vitamin D2", "ent_type": "Chemical", "char_span": [280, 290], "ent_id": "D004872", "tok_span": [48, 51]}, {"name": "cholesterol", "ent_type": "Chemical", "char_span": [295, 306], "ent_id": "D002784", "tok_span": [52, 53]}], "relation_list": [{"subject": "vitamin D2", "object": "ulcer", "sbj_char_span": [280, 290], "obj_char_span": [214, 219], "rel_type": "chemical-induced disease", "sbj_tok_span": [48, 51], "obj_tok_span": [38, 39]}, {"subject": "cholesterol", "object": "atherosclerosis", "sbj_char_span": [295, 306], "obj_char_span": [233, 248], "rel_type": "chemical-induced disease", "sbj_tok_span": [52, 53], "obj_tok_span": [42, 43]}, {"subject": "cholesterol", "object": "ulcer", "sbj_char_span": [295, 306], "obj_char_span": [214, 219], "rel_type": "chemical-induced disease", "sbj_tok_span": [52, 53], "obj_tok_span": [38, 39]}, {"subject": "cholesterol", "object": "gastric hemorrhage", "sbj_char_span": [295, 306], "obj_char_span": [191, 209], "rel_type": "chemical-induced disease", "sbj_tok_span": [52, 53], "obj_tok_span": [35, 37]}, {"subject": "vitamin D2", "object": "gastric hemorrhage", "sbj_char_span": [280, 290], "obj_char_span": [191, 209], "rel_type": "chemical-induced disease", "sbj_tok_span": [48, 51], "obj_tok_span": [35, 37]}, {"subject": "vitamin D2", "object": "atherosclerosis", "sbj_char_span": [280, 290], "obj_char_span": [233, 248], "rel_type": "chemical-induced disease", "sbj_tok_span": [48, 51], "obj_tok_span": [42, 43]}], "umls_entity_list": []}, {"text": "Male Wistar rats were challenged intragastrically once daily for 9 days with 1.0 ml/kg of corn oil containing vitamin D2 and cholesterol to induce atherosclerosis.", "entity_list": [{"name": "atherosclerosis", "ent_type": "Disease", "char_span": [147, 162], "ent_id": "D050197", "tok_span": [32, 33]}, {"name": "cholesterol", "ent_type": "Chemical", "char_span": [125, 136], "ent_id": "D002784", "tok_span": [29, 30]}, {"name": "vitamin D2", "ent_type": "Chemical", "char_span": [110, 120], "ent_id": "D004872", "tok_span": [25, 28]}], "relation_list": [{"subject": "cholesterol", "object": "atherosclerosis", "sbj_char_span": [125, 136], "obj_char_span": [147, 162], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 30], "obj_tok_span": [32, 33]}, {"subject": "vitamin D2", "object": "atherosclerosis", "sbj_char_span": [110, 120], "obj_char_span": [147, 162], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 28], "obj_tok_span": [32, 33]}], "umls_entity_list": []}, {"text": "Elevated atherosclerotic parameters, such as serum calcium, total cholesterol and low-density lipoprotein concentration were obtained in atherosclerotic rats.", "entity_list": [{"name": "cholesterol", "ent_type": "Chemical", "char_span": [66, 77], "ent_id": "D002784", "tok_span": [11, 12]}, {"name": "atherosclerotic", "ent_type": "Disease", "char_span": [137, 152], "ent_id": "D050197", "tok_span": [21, 22]}, {"name": "atherosclerotic", "ent_type": "Disease", "char_span": [9, 24], "ent_id": "D050197", "tok_span": [2, 3]}, {"name": "calcium", "ent_type": "Chemical", "char_span": [51, 58], "ent_id": "D002118", "tok_span": [8, 9]}], "relation_list": [{"subject": "cholesterol", "object": "atherosclerotic", "sbj_char_span": [66, 77], "obj_char_span": [9, 24], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [2, 3]}, {"subject": "cholesterol", "object": "atherosclerotic", "sbj_char_span": [66, 77], "obj_char_span": [137, 152], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [21, 22]}], "umls_entity_list": []}, {"text": "Adriamycin-induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure.", "entity_list": [{"name": "death", "ent_type": "Disease", "char_span": [44, 49], "ent_id": "D003643", "tok_span": [10, 11]}, {"name": "Adriamycin", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D004317", "tok_span": [0, 4]}, {"name": "heart failure", "ent_type": "Disease", "char_span": [92, 105], "ent_id": "D006333", "tok_span": [20, 22]}], "relation_list": [{"subject": "Adriamycin", "object": "heart failure", "sbj_char_span": [0, 10], "obj_char_span": [92, 105], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [20, 22]}], "umls_entity_list": []}, {"text": "BACKGROUND: The mechanisms underlying heart failure induced by adriamycin are very complicated and still unclear.", "entity_list": [{"name": "adriamycin", "ent_type": "Chemical", "char_span": [63, 73], "ent_id": "D004317", "tok_span": [9, 13]}, {"name": "heart failure", "ent_type": "Disease", "char_span": [38, 51], "ent_id": "D006333", "tok_span": [5, 7]}], "relation_list": [{"subject": "adriamycin", "object": "heart failure", "sbj_char_span": [63, 73], "obj_char_span": [38, 51], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by adriamycin, so that we can develop a novel treatment strategy for heart failure.", "entity_list": [{"name": "heart failure", "ent_type": "Disease", "char_span": [94, 107], "ent_id": "D006333", "tok_span": [16, 18]}, {"name": "adriamycin", "ent_type": "Chemical", "char_span": [119, 129], "ent_id": "D004317", "tok_span": [20, 24]}, {"name": "heart failure", "ent_type": "Disease", "char_span": [185, 198], "ent_id": "D006333", "tok_span": [35, 37]}], "relation_list": [{"subject": "adriamycin", "object": "heart failure", "sbj_char_span": [119, 129], "obj_char_span": [94, 107], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 24], "obj_tok_span": [16, 18]}, {"subject": "adriamycin", "object": "heart failure", "sbj_char_span": [119, 129], "obj_char_span": [185, 198], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 24], "obj_tok_span": [35, 37]}], "umls_entity_list": []}, {"text": "METHODS: 3-methyladenine (3MA), a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin.", "entity_list": [{"name": "3-methyladenine", "ent_type": "Chemical", "char_span": [9, 24], "ent_id": "C025946", "tok_span": [2, 7]}, {"name": "3MA", "ent_type": "Chemical", "char_span": [26, 29], "ent_id": "C025946", "tok_span": [8, 10]}, {"name": "adriamycin", "ent_type": "Chemical", "char_span": [119, 129], "ent_id": "D004317", "tok_span": [28, 32]}, {"name": "heart failure", "ent_type": "Disease", "char_span": [80, 93], "ent_id": "D006333", "tok_span": [21, 23]}], "relation_list": [{"subject": "adriamycin", "object": "heart failure", "sbj_char_span": [119, 129], "obj_char_span": [80, 93], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 32], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "CONCLUSION: Autophagic cardiomyocyte death plays an important role in the pathogenesis of heart failure in rats induced by adriamycin.", "entity_list": [{"name": "adriamycin", "ent_type": "Chemical", "char_span": [123, 133], "ent_id": "D004317", "tok_span": [22, 26]}, {"name": "heart failure", "ent_type": "Disease", "char_span": [90, 103], "ent_id": "D006333", "tok_span": [16, 18]}, {"name": "death", "ent_type": "Disease", "char_span": [37, 42], "ent_id": "D003643", "tok_span": [7, 8]}], "relation_list": [{"subject": "adriamycin", "object": "heart failure", "sbj_char_span": [123, 133], "obj_char_span": [90, 103], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 26], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "Mitochondrial injury may be involved in the progression of heart failure caused by adriamycin via the autophagy pathway.", "entity_list": [{"name": "heart failure", "ent_type": "Disease", "char_span": [59, 72], "ent_id": "D006333", "tok_span": [9, 11]}, {"name": "adriamycin", "ent_type": "Chemical", "char_span": [83, 93], "ent_id": "D004317", "tok_span": [13, 17]}], "relation_list": [{"subject": "adriamycin", "object": "heart failure", "sbj_char_span": [83, 93], "obj_char_span": [59, 72], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "Confusion, a rather serious adverse drug reaction with valproic acid: a review of the French Pharmacovigilance database.", "entity_list": [{"name": "valproic acid", "ent_type": "Chemical", "char_span": [55, 68], "ent_id": "D014635", "tok_span": [10, 14]}, {"name": "Confusion", "ent_type": "Disease", "char_span": [0, 9], "ent_id": "D003221", "tok_span": [0, 2]}], "relation_list": [{"subject": "valproic acid", "object": "Confusion", "sbj_char_span": [55, 68], "obj_char_span": [0, 9], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "INTRODUCTION: Confusion is an adverse drug reaction frequently observed with valproic acid.", "entity_list": [{"name": "Confusion", "ent_type": "Disease", "char_span": [14, 23], "ent_id": "D003221", "tok_span": [2, 4]}, {"name": "valproic acid", "ent_type": "Chemical", "char_span": [77, 90], "ent_id": "D014635", "tok_span": [12, 16]}], "relation_list": [{"subject": "valproic acid", "object": "Confusion", "sbj_char_span": [77, 90], "obj_char_span": [14, 23], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 16], "obj_tok_span": [2, 4]}], "umls_entity_list": []}, {"text": "METHODS: Using the French Pharmacovigilance database, we selected the cases of confusion reported since 1985 with valproic acid.", "entity_list": [{"name": "valproic acid", "ent_type": "Chemical", "char_span": [114, 127], "ent_id": "D014635", "tok_span": [22, 26]}, {"name": "confusion", "ent_type": "Disease", "char_span": [79, 88], "ent_id": "D003221", "tok_span": [17, 18]}], "relation_list": [{"subject": "valproic acid", "object": "confusion", "sbj_char_span": [114, 127], "obj_char_span": [79, 88], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 26], "obj_tok_span": [17, 18]}], "umls_entity_list": []}, {"text": "RESULTS: 272 cases of confusion were reported with valproic acid: 153 women and 119 men.", "entity_list": [{"name": "confusion", "ent_type": "Disease", "char_span": [22, 31], "ent_id": "D003221", "tok_span": [6, 7]}, {"name": "valproic acid", "ent_type": "Chemical", "char_span": [51, 64], "ent_id": "D014635", "tok_span": [10, 14]}], "relation_list": [{"subject": "valproic acid", "object": "confusion", "sbj_char_span": [51, 64], "obj_char_span": [22, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [6, 7]}], "umls_entity_list": []}, {"text": "Confusion mostly occurred during the two first weeks following valproic acid exposure (39.7%).", "entity_list": [{"name": "valproic acid", "ent_type": "Chemical", "char_span": [63, 76], "ent_id": "D014635", "tok_span": [10, 14]}, {"name": "Confusion", "ent_type": "Disease", "char_span": [0, 9], "ent_id": "D003221", "tok_span": [0, 2]}], "relation_list": [{"subject": "valproic acid", "object": "Confusion", "sbj_char_span": [63, 76], "obj_char_span": [0, 9], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "CONCLUSION: This work shows that confusion with valproic acid is a serious, rather frequent but reversible adverse drug reaction.", "entity_list": [{"name": "confusion", "ent_type": "Disease", "char_span": [33, 42], "ent_id": "D003221", "tok_span": [6, 7]}, {"name": "valproic acid", "ent_type": "Chemical", "char_span": [48, 61], "ent_id": "D014635", "tok_span": [8, 12]}], "relation_list": [{"subject": "valproic acid", "object": "confusion", "sbj_char_span": [48, 61], "obj_char_span": [33, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [6, 7]}], "umls_entity_list": []}, {"text": "Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome.", "entity_list": [{"name": "Antituberculosis", "ent_type": "Chemical", "char_span": [0, 16], "ent_id": "D000995", "tok_span": [0, 5]}, {"name": "acute liver failure", "ent_type": "Disease", "char_span": [33, 52], "ent_id": "D017114", "tok_span": [8, 11]}], "relation_list": [{"subject": "Antituberculosis", "object": "acute liver failure", "sbj_char_span": [0, 16], "obj_char_span": [33, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [8, 11]}], "umls_entity_list": []}, {"text": "Antituberculosis therapy (ATT)-associated acute liver failure (ATT-ALF) is the commonest drug-induced ALF in South Asia.", "entity_list": [{"name": "Antituberculosis", "ent_type": "Chemical", "char_span": [0, 16], "ent_id": "D000995", "tok_span": [0, 5]}, {"name": "ALF", "ent_type": "Disease", "char_span": [67, 70], "ent_id": "D017114", "tok_span": [19, 21]}, {"name": "ALF", "ent_type": "Disease", "char_span": [102, 105], "ent_id": "D017114", "tok_span": [29, 31]}, {"name": "acute liver failure", "ent_type": "Disease", "char_span": [42, 61], "ent_id": "D017114", "tok_span": [12, 15]}], "relation_list": [{"subject": "Antituberculosis", "object": "acute liver failure", "sbj_char_span": [0, 16], "obj_char_span": [42, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [12, 15]}, {"subject": "Antituberculosis", "object": "ALF", "sbj_char_span": [0, 16], "obj_char_span": [102, 105], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [29, 31]}, {"subject": "Antituberculosis", "object": "ALF", "sbj_char_span": [0, 16], "obj_char_span": [67, 70], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [19, 21]}], "umls_entity_list": []}, {"text": "The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome.", "entity_list": [{"name": "stomatitis", "ent_type": "Disease", "char_span": [89, 99], "ent_id": "D013280", "tok_span": [19, 21]}, {"name": "diarrhea", "ent_type": "Disease", "char_span": [61, 69], "ent_id": "D003967", "tok_span": [13, 14]}, {"name": "vomiting", "ent_type": "Disease", "char_span": [79, 87], "ent_id": "D014839", "tok_span": [17, 18]}, {"name": "capecitabine", "ent_type": "Chemical", "char_span": [44, 56], "ent_id": "C110904", "tok_span": [7, 12]}, {"name": "hand-foot syndrome", "ent_type": "Disease", "char_span": [104, 122], "ent_id": "D060831", "tok_span": [22, 26]}, {"name": "nausea", "ent_type": "Disease", "char_span": [71, 77], "ent_id": "D009325", "tok_span": [15, 16]}], "relation_list": [{"subject": "capecitabine", "object": "hand-foot syndrome", "sbj_char_span": [44, 56], "obj_char_span": [104, 122], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 12], "obj_tok_span": [22, 26]}, {"subject": "capecitabine", "object": "stomatitis", "sbj_char_span": [44, 56], "obj_char_span": [89, 99], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 12], "obj_tok_span": [19, 21]}, {"subject": "capecitabine", "object": "diarrhea", "sbj_char_span": [44, 56], "obj_char_span": [61, 69], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 12], "obj_tok_span": [13, 14]}, {"subject": "capecitabine", "object": "vomiting", "sbj_char_span": [44, 56], "obj_char_span": [79, 87], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 12], "obj_tok_span": [17, 18]}, {"subject": "capecitabine", "object": "nausea", "sbj_char_span": [44, 56], "obj_char_span": [71, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 12], "obj_tok_span": [15, 16]}], "umls_entity_list": []}, {"text": "Effects of pallidal neurotensin on haloperidol-induced parkinsonian catalepsy: behavioral and electrophysiological studies.", "entity_list": [{"name": "neurotensin", "ent_type": "Chemical", "char_span": [20, 31], "ent_id": "D009496", "tok_span": [4, 6]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [35, 46], "ent_id": "D006220", "tok_span": [7, 10]}, {"name": "parkinsonian catalepsy", "ent_type": "Disease", "char_span": [55, 77], "ent_id": "D002375", "tok_span": [12, 18]}], "relation_list": [{"subject": "haloperidol", "object": "parkinsonian catalepsy", "sbj_char_span": [35, 46], "obj_char_span": [55, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [12, 18]}], "umls_entity_list": []}, {"text": "RESULTS: Bilateral infusions of neurotensin into the globus pallidus reversed haloperidol-induced parkinsonian catalepsy in rats.", "entity_list": [{"name": "haloperidol", "ent_type": "Chemical", "char_span": [78, 89], "ent_id": "D006220", "tok_span": [17, 20]}, {"name": "parkinsonian catalepsy", "ent_type": "Disease", "char_span": [98, 120], "ent_id": "D002375", "tok_span": [22, 28]}, {"name": "neurotensin", "ent_type": "Chemical", "char_span": [32, 43], "ent_id": "D009496", "tok_span": [7, 9]}], "relation_list": [{"subject": "haloperidol", "object": "parkinsonian catalepsy", "sbj_char_span": [78, 89], "obj_char_span": [98, 120], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [22, 28]}], "umls_entity_list": []}, {"text": "This was accounted for by a significant number of depressions occurring in methyl dopa treated patients with psychiatric histories.", "entity_list": [{"name": "methyl dopa", "ent_type": "Chemical", "char_span": [75, 86], "ent_id": "D008750", "tok_span": [13, 16]}, {"name": "depressions", "ent_type": "Disease", "char_span": [50, 61], "ent_id": "D003866", "tok_span": [9, 11]}, {"name": "psychiatric", "ent_type": "Disease", "char_span": [109, 120], "ent_id": "D001523", "tok_span": [19, 20]}], "relation_list": [{"subject": "methyl dopa", "object": "depressions", "sbj_char_span": [75, 86], "obj_char_span": [50, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "Pulmonary shunt and cardiovascular responses to CPAP during nitroprusside-induced hypotension.", "entity_list": [{"name": "nitroprusside", "ent_type": "Chemical", "char_span": [60, 73], "ent_id": "D009599", "tok_span": [9, 13]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [82, 93], "ent_id": "D007022", "tok_span": [15, 16]}], "relation_list": [{"subject": "nitroprusside", "object": "hypotension", "sbj_char_span": [60, 73], "obj_char_span": [82, 93], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [15, 16]}], "umls_entity_list": []}, {"text": "Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.", "entity_list": [{"name": "decreased cardiac output", "ent_type": "Disease", "char_span": [144, 168], "ent_id": "D002303", "tok_span": [27, 30]}, {"name": "nitroprusside", "ent_type": "Chemical", "char_span": [23, 36], "ent_id": "D009599", "tok_span": [8, 12]}, {"name": "H2O", "ent_type": "Chemical", "char_span": [7, 10], "ent_id": "D014867", "tok_span": [2, 5]}, {"name": "decrease in arterial blood pressure", "ent_type": "Disease", "char_span": [65, 100], "ent_id": "D007022", "tok_span": [16, 21]}], "relation_list": [{"subject": "nitroprusside", "object": "decrease in arterial blood pressure", "sbj_char_span": [23, 36], "obj_char_span": [65, 100], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [16, 21]}], "umls_entity_list": []}, {"text": "Nitroprusside caused significant decreases in arterial blood pressure and systemic vascular resistance and increases in heart rate, but did not change cardiac output or QS/QT.", "entity_list": [{"name": "Nitroprusside", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D009599", "tok_span": [0, 4]}, {"name": "decreases in arterial blood pressure", "ent_type": "Disease", "char_span": [33, 69], "ent_id": "D007022", "tok_span": [6, 11]}], "relation_list": [{"subject": "Nitroprusside", "object": "decreases in arterial blood pressure", "sbj_char_span": [0, 13], "obj_char_span": [33, 69], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [6, 11]}], "umls_entity_list": []}, {"text": "In addition, reflex bradycardia caused by injected norepinephrine was significantly enhanced by L-dopa, DL-Threo-dihydroxyphenylserine had no effect on blood pressure, heart rate or reflex responses to norepinephrine.", "entity_list": [{"name": "DL-Threo-dihydroxyphenylserine", "ent_type": "Chemical", "char_span": [104, 134], "ent_id": "D015103", "tok_span": [21, 32]}, {"name": "norepinephrine", "ent_type": "Chemical", "char_span": [51, 65], "ent_id": "D009638", "tok_span": [11, 12]}, {"name": "L-dopa", "ent_type": "Chemical", "char_span": [96, 102], "ent_id": "D007980", "tok_span": [16, 20]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [20, 31], "ent_id": "D001919", "tok_span": [4, 8]}, {"name": "norepinephrine", "ent_type": "Chemical", "char_span": [202, 216], "ent_id": "D009638", "tok_span": [45, 46]}], "relation_list": [{"subject": "norepinephrine", "object": "bradycardia", "sbj_char_span": [202, 216], "obj_char_span": [20, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [45, 46], "obj_tok_span": [4, 8]}, {"subject": "norepinephrine", "object": "bradycardia", "sbj_char_span": [51, 65], "obj_char_span": [20, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "However, L-dopa restored the bradycardia caused by norepinephrine in addition to decreasing blood pressure and heart rate. 5-HTP (5 mg/kg i.v.) decreased blood pressure and heart rate and decreased the reflex bradycardia to norepinephrine.", "entity_list": [{"name": "L-dopa", "ent_type": "Chemical", "char_span": [9, 15], "ent_id": "D007980", "tok_span": [2, 6]}, {"name": "norepinephrine", "ent_type": "Chemical", "char_span": [224, 238], "ent_id": "D009638", "tok_span": [54, 55]}, {"name": "5-HTP", "ent_type": "Chemical", "char_span": [123, 128], "ent_id": "D006916", "tok_span": [25, 29]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [29, 40], "ent_id": "D001919", "tok_span": [8, 12]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [209, 220], "ent_id": "D001919", "tok_span": [49, 53]}, {"name": "norepinephrine", "ent_type": "Chemical", "char_span": [51, 65], "ent_id": "D009638", "tok_span": [14, 15]}], "relation_list": [{"subject": "norepinephrine", "object": "bradycardia", "sbj_char_span": [51, 65], "obj_char_span": [209, 220], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [49, 53]}, {"subject": "norepinephrine", "object": "bradycardia", "sbj_char_span": [51, 65], "obj_char_span": [29, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [8, 12]}, {"subject": "norepinephrine", "object": "bradycardia", "sbj_char_span": [224, 238], "obj_char_span": [209, 220], "rel_type": "chemical-induced disease", "sbj_tok_span": [54, 55], "obj_tok_span": [49, 53]}, {"subject": "norepinephrine", "object": "bradycardia", "sbj_char_span": [224, 238], "obj_char_span": [29, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [54, 55], "obj_tok_span": [8, 12]}], "umls_entity_list": []}, {"text": "Cocaine-induced myocardial infarction: clinical observations and pathogenetic considerations.", "entity_list": [{"name": "Cocaine", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "D003042", "tok_span": [0, 3]}, {"name": "myocardial infarction", "ent_type": "Disease", "char_span": [16, 37], "ent_id": "D009203", "tok_span": [5, 7]}], "relation_list": [{"subject": "Cocaine", "object": "myocardial infarction", "sbj_char_span": [0, 7], "obj_char_span": [16, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "Clinical and experimental data published to date suggest several possible mechanisms by which cocaine may result in acute myocardial infarction.", "entity_list": [{"name": "acute myocardial infarction", "ent_type": "Disease", "char_span": [116, 143], "ent_id": "D009203", "tok_span": [17, 20]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [94, 101], "ent_id": "D003042", "tok_span": [13, 14]}], "relation_list": [{"subject": "cocaine", "object": "acute myocardial infarction", "sbj_char_span": [94, 101], "obj_char_span": [116, 143], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 14], "obj_tok_span": [17, 20]}], "umls_entity_list": []}, {"text": "In individuals with preexisting, high-grade coronary arterial narrowing, acute myocardial infarction may result from an increase in myocardial oxygen demand associated with cocaine-induced increase in rate-pressure product.", "entity_list": [{"name": "oxygen", "ent_type": "Chemical", "char_span": [143, 149], "ent_id": "D010100", "tok_span": [23, 24]}, {"name": "acute myocardial infarction", "ent_type": "Disease", "char_span": [73, 100], "ent_id": "D009203", "tok_span": [13, 16]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [173, 180], "ent_id": "D003042", "tok_span": [27, 28]}], "relation_list": [{"subject": "cocaine", "object": "acute myocardial infarction", "sbj_char_span": [173, 180], "obj_char_span": [73, 100], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 28], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "Renal papillary necrosis (RPN) and a decreased urinary concentrating ability developed during continuous long-term treatment with aspirin and paracetamol in female Fischer 344 rats.", "entity_list": [{"name": "Renal papillary necrosis", "ent_type": "Disease", "char_span": [0, 24], "ent_id": "D007681", "tok_span": [0, 3]}, {"name": "paracetamol", "ent_type": "Chemical", "char_span": [142, 153], "ent_id": "D000082", "tok_span": [24, 28]}, {"name": "aspirin", "ent_type": "Chemical", "char_span": [130, 137], "ent_id": "D001241", "tok_span": [22, 23]}, {"name": "RPN", "ent_type": "Disease", "char_span": [26, 29], "ent_id": "D007681", "tok_span": [4, 6]}], "relation_list": [{"subject": "paracetamol", "object": "RPN", "sbj_char_span": [142, 153], "obj_char_span": [26, 29], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 28], "obj_tok_span": [4, 6]}, {"subject": "aspirin", "object": "RPN", "sbj_char_span": [130, 137], "obj_char_span": [26, 29], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [4, 6]}, {"subject": "aspirin", "object": "Renal papillary necrosis", "sbj_char_span": [130, 137], "obj_char_span": [0, 24], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [0, 3]}, {"subject": "paracetamol", "object": "Renal papillary necrosis", "sbj_char_span": [142, 153], "obj_char_span": [0, 24], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 28], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "Lithium-induced polyuria seems to be related to extrarenal as well as to renal effects.", "entity_list": [{"name": "polyuria", "ent_type": "Disease", "char_span": [16, 24], "ent_id": "D011141", "tok_span": [4, 6]}, {"name": "Lithium", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "D008094", "tok_span": [0, 2]}], "relation_list": [{"subject": "Lithium", "object": "polyuria", "sbj_char_span": [0, 7], "obj_char_span": [16, 24], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "Prazosin-induced stress incontinence.", "entity_list": [{"name": "Prazosin", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D011224", "tok_span": [0, 3]}, {"name": "stress incontinence", "ent_type": "Disease", "char_span": [17, 36], "ent_id": "D014550", "tok_span": [5, 7]}], "relation_list": [{"subject": "Prazosin", "object": "stress incontinence", "sbj_char_span": [0, 8], "obj_char_span": [17, 36], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "A case of genuine stress incontinence due to prazosin, a common antihypertensive drug, is presented.", "entity_list": [{"name": "prazosin", "ent_type": "Chemical", "char_span": [45, 53], "ent_id": "D011224", "tok_span": [8, 11]}, {"name": "stress incontinence", "ent_type": "Disease", "char_span": [18, 37], "ent_id": "D014550", "tok_span": [4, 6]}], "relation_list": [{"subject": "prazosin", "object": "stress incontinence", "sbj_char_span": [45, 53], "obj_char_span": [18, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "Patients who present with stress incontinence while taking prazosin should change their antihypertensive medication before considering surgery, because their incontinence may resolve spontaneously with a change in drug therapy.", "entity_list": [{"name": "incontinence", "ent_type": "Disease", "char_span": [158, 170], "ent_id": "D014549", "tok_span": [23, 24]}, {"name": "prazosin", "ent_type": "Chemical", "char_span": [59, 67], "ent_id": "D011224", "tok_span": [8, 11]}, {"name": "stress incontinence", "ent_type": "Disease", "char_span": [26, 45], "ent_id": "D014550", "tok_span": [4, 6]}], "relation_list": [{"subject": "prazosin", "object": "stress incontinence", "sbj_char_span": [59, 67], "obj_char_span": [26, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "Myocardial infarction following sublingual administration of isosorbide dinitrate.", "entity_list": [{"name": "Myocardial infarction", "ent_type": "Disease", "char_span": [0, 21], "ent_id": "D009203", "tok_span": [0, 3]}, {"name": "isosorbide dinitrate", "ent_type": "Chemical", "char_span": [61, 81], "ent_id": "D007548", "tok_span": [9, 15]}], "relation_list": [{"subject": "isosorbide dinitrate", "object": "Myocardial infarction", "sbj_char_span": [61, 81], "obj_char_span": [0, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 15], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually.", "entity_list": [{"name": "necrosis", "ent_type": "Disease", "char_span": [33, 41], "ent_id": "D009336", "tok_span": [10, 11]}, {"name": "isosorbide dinitrate", "ent_type": "Chemical", "char_span": [138, 158], "ent_id": "D007548", "tok_span": [24, 30]}, {"name": "myocardial infarction", "ent_type": "Disease", "char_span": [63, 84], "ent_id": "D009203", "tok_span": [14, 16]}], "relation_list": [{"subject": "isosorbide dinitrate", "object": "myocardial infarction", "sbj_char_span": [138, 158], "obj_char_span": [63, 84], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 30], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "Fluoxetine-induced akathisia: clinical and theoretical implications.", "entity_list": [{"name": "Fluoxetine", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D005473", "tok_span": [0, 3]}, {"name": "akathisia", "ent_type": "Disease", "char_span": [19, 28], "ent_id": "D017109", "tok_span": [5, 9]}], "relation_list": [{"subject": "Fluoxetine", "object": "akathisia", "sbj_char_span": [0, 10], "obj_char_span": [19, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.", "entity_list": [{"name": "fluoxetine", "ent_type": "Chemical", "char_span": [24, 34], "ent_id": "D005473", "tok_span": [3, 6]}, {"name": "major depression", "ent_type": "Disease", "char_span": [89, 105], "ent_id": "D003865", "tok_span": [16, 18]}, {"name": "obsessive compulsive disorder", "ent_type": "Disease", "char_span": [56, 85], "ent_id": "D009771", "tok_span": [10, 15]}, {"name": "akathisia", "ent_type": "Disease", "char_span": [116, 125], "ent_id": "D017109", "tok_span": [19, 23]}], "relation_list": [{"subject": "fluoxetine", "object": "akathisia", "sbj_char_span": [24, 34], "obj_char_span": [116, 125], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "The typical fluoxetine-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia.", "entity_list": [{"name": "akathisia", "ent_type": "Disease", "char_span": [194, 203], "ent_id": "D017109", "tok_span": [40, 44]}, {"name": "anxiety", "ent_type": "Disease", "char_span": [129, 136], "ent_id": "D001008", "tok_span": [27, 28]}, {"name": "fluoxetine", "ent_type": "Chemical", "char_span": [12, 22], "ent_id": "D005473", "tok_span": [2, 5]}], "relation_list": [{"subject": "fluoxetine", "object": "akathisia", "sbj_char_span": [12, 22], "obj_char_span": [194, 203], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [40, 44]}], "umls_entity_list": []}, {"text": "Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.", "entity_list": [{"name": "akathisia", "ent_type": "Disease", "char_span": [126, 135], "ent_id": "D017109", "tok_span": [28, 32]}, {"name": "akathisia", "ent_type": "Disease", "char_span": [55, 64], "ent_id": "D017109", "tok_span": [11, 15]}, {"name": "fluoxetine", "ent_type": "Chemical", "char_span": [107, 117], "ent_id": "D005473", "tok_span": [23, 26]}], "relation_list": [{"subject": "fluoxetine", "object": "akathisia", "sbj_char_span": [107, 117], "obj_char_span": [55, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [11, 15]}, {"subject": "fluoxetine", "object": "akathisia", "sbj_char_span": [107, 117], "obj_char_span": [126, 135], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.", "entity_list": [{"name": "Akathisia", "ent_type": "Disease", "char_span": [0, 9], "ent_id": "D017109", "tok_span": [0, 4]}, {"name": "propranolol", "ent_type": "Chemical", "char_span": [138, 149], "ent_id": "D011433", "tok_span": [28, 32]}, {"name": "fluoxetine", "ent_type": "Chemical", "char_span": [49, 59], "ent_id": "D005473", "tok_span": [12, 15]}], "relation_list": [{"subject": "fluoxetine", "object": "Akathisia", "sbj_char_span": [49, 59], "obj_char_span": [0, 9], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced \"jitteriness\" may be identical.", "entity_list": [{"name": "antidepressant", "ent_type": "Chemical", "char_span": [217, 231], "ent_id": "D000928", "tok_span": [43, 44]}, {"name": "fluoxetine", "ent_type": "Chemical", "char_span": [25, 35], "ent_id": "D005473", "tok_span": [4, 7]}, {"name": "fluoxetine", "ent_type": "Chemical", "char_span": [174, 184], "ent_id": "D005473", "tok_span": [31, 34]}, {"name": "akathisia", "ent_type": "Disease", "char_span": [193, 202], "ent_id": "D017109", "tok_span": [36, 40]}, {"name": "akathisia", "ent_type": "Disease", "char_span": [44, 53], "ent_id": "D017109", "tok_span": [9, 13]}], "relation_list": [{"subject": "fluoxetine", "object": "akathisia", "sbj_char_span": [174, 184], "obj_char_span": [44, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 34], "obj_tok_span": [9, 13]}, {"subject": "fluoxetine", "object": "akathisia", "sbj_char_span": [25, 35], "obj_char_span": [193, 202], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [36, 40]}, {"subject": "fluoxetine", "object": "akathisia", "sbj_char_span": [174, 184], "obj_char_span": [193, 202], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 34], "obj_tok_span": [36, 40]}, {"subject": "fluoxetine", "object": "akathisia", "sbj_char_span": [25, 35], "obj_char_span": [44, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [9, 13]}], "umls_entity_list": []}, {"text": "Although generally well-tolerated, asymptomatic abnormalities of liver function have been recorded and, less commonly, severe hepatitis induced by diclofenac.", "entity_list": [{"name": "diclofenac", "ent_type": "Chemical", "char_span": [147, 157], "ent_id": "D004008", "tok_span": [23, 27]}, {"name": "hepatitis", "ent_type": "Disease", "char_span": [126, 135], "ent_id": "D056486", "tok_span": [20, 21]}, {"name": "abnormalities of liver function", "ent_type": "Disease", "char_span": [48, 79], "ent_id": "D056486", "tok_span": [7, 11]}], "relation_list": [{"subject": "diclofenac", "object": "hepatitis", "sbj_char_span": [147, 157], "obj_char_span": [126, 135], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 27], "obj_tok_span": [20, 21]}, {"subject": "diclofenac", "object": "abnormalities of liver function", "sbj_char_span": [147, 157], "obj_char_span": [48, 79], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 27], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.", "entity_list": [{"name": "stroke", "ent_type": "Disease", "char_span": [227, 233], "ent_id": "D020521", "tok_span": [47, 48]}, {"name": "cerebral infarction", "ent_type": "Disease", "char_span": [433, 452], "ent_id": "D002544", "tok_span": [82, 84]}, {"name": "stroke", "ent_type": "Disease", "char_span": [55, 61], "ent_id": "D020521", "tok_span": [11, 12]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [349, 356], "ent_id": "D003042", "tok_span": [69, 70]}, {"name": "stroke", "ent_type": "Disease", "char_span": [168, 174], "ent_id": "D020521", "tok_span": [35, 36]}, {"name": "intracranial hemorrhage", "ent_type": "Disease", "char_span": [393, 416], "ent_id": "D020300", "tok_span": [77, 79]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [199, 206], "ent_id": "D003042", "tok_span": [41, 42]}, {"name": "intracranial aneurysms", "ent_type": "Disease", "char_span": [282, 304], "ent_id": "D002532", "tok_span": [55, 57]}, {"name": "stroke", "ent_type": "Disease", "char_span": [123, 129], "ent_id": "D020521", "tok_span": [25, 26]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [104, 111], "ent_id": "D003042", "tok_span": [22, 23]}, {"name": "stroke", "ent_type": "Disease", "char_span": [368, 374], "ent_id": "D020521", "tok_span": [72, 73]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [240, 247], "ent_id": "D003042", "tok_span": [49, 50]}, {"name": "arteriovenous malformations", "ent_type": "Disease", "char_span": [309, 336], "ent_id": "D001165", "tok_span": [58, 63]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [73, 80], "ent_id": "D003042", "tok_span": [14, 15]}], "relation_list": [{"subject": "cocaine", "object": "cerebral infarction", "sbj_char_span": [240, 247], "obj_char_span": [433, 452], "rel_type": "chemical-induced disease", "sbj_tok_span": [49, 50], "obj_tok_span": [82, 84]}, {"subject": "cocaine", "object": "cerebral infarction", "sbj_char_span": [349, 356], "obj_char_span": [433, 452], "rel_type": "chemical-induced disease", "sbj_tok_span": [69, 70], "obj_tok_span": [82, 84]}, {"subject": "cocaine", "object": "cerebral infarction", "sbj_char_span": [199, 206], "obj_char_span": [433, 452], "rel_type": "chemical-induced disease", "sbj_tok_span": [41, 42], "obj_tok_span": [82, 84]}, {"subject": "cocaine", "object": "cerebral infarction", "sbj_char_span": [73, 80], "obj_char_span": [433, 452], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [82, 84]}, {"subject": "cocaine", "object": "cerebral infarction", "sbj_char_span": [104, 111], "obj_char_span": [433, 452], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [82, 84]}], "umls_entity_list": []}, {"text": "Glyburide-induced hepatitis.", "entity_list": [{"name": "Glyburide", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D005905", "tok_span": [0, 3]}, {"name": "hepatitis", "ent_type": "Disease", "char_span": [18, 27], "ent_id": "D056486", "tok_span": [5, 6]}], "relation_list": [{"subject": "Glyburide", "object": "hepatitis", "sbj_char_span": [0, 9], "obj_char_span": [18, 27], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 6]}], "umls_entity_list": []}, {"text": "For glyburide, a second-generation sulfonylurea, only two brief reports of hepatotoxicity exist.", "entity_list": [{"name": "glyburide", "ent_type": "Chemical", "char_span": [4, 13], "ent_id": "D005905", "tok_span": [1, 4]}, {"name": "hepatotoxicity", "ent_type": "Disease", "char_span": [75, 89], "ent_id": "D056486", "tok_span": [18, 20]}, {"name": "sulfonylurea", "ent_type": "Chemical", "char_span": [35, 47], "ent_id": "D013453", "tok_span": [9, 12]}], "relation_list": [{"subject": "glyburide", "object": "hepatotoxicity", "sbj_char_span": [4, 13], "obj_char_span": [75, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 4], "obj_tok_span": [18, 20]}], "umls_entity_list": []}, {"text": "Two patients with type II diabetes mellitus developed an acute hepatitis-like syndrome soon after initiation of glyburide therapy.", "entity_list": [{"name": "glyburide", "ent_type": "Chemical", "char_span": [112, 121], "ent_id": "D005905", "tok_span": [18, 21]}, {"name": "type II diabetes mellitus", "ent_type": "Disease", "char_span": [18, 43], "ent_id": "D003924", "tok_span": [3, 7]}, {"name": "acute hepatitis-like syndrome", "ent_type": "Disease", "char_span": [57, 86], "ent_id": "D056486", "tok_span": [9, 14]}], "relation_list": [{"subject": "glyburide", "object": "acute hepatitis-like syndrome", "sbj_char_span": [112, 121], "obj_char_span": [57, 86], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [9, 14]}], "umls_entity_list": []}, {"text": "Glyburide can produce an acute hepatitis-like illness in some persons.", "entity_list": [{"name": "Glyburide", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D005905", "tok_span": [0, 3]}, {"name": "acute hepatitis-like illness", "ent_type": "Disease", "char_span": [25, 53], "ent_id": "D056486", "tok_span": [6, 11]}], "relation_list": [{"subject": "Glyburide", "object": "acute hepatitis-like illness", "sbj_char_span": [0, 9], "obj_char_span": [25, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [6, 11]}], "umls_entity_list": []}, {"text": "Systolic pressure variation is greater during hemorrhage than during sodium nitroprusside-induced hypotension in ventilated dogs.", "entity_list": [{"name": "hypotension", "ent_type": "Disease", "char_span": [98, 109], "ent_id": "D007022", "tok_span": [17, 18]}, {"name": "hemorrhage", "ent_type": "Disease", "char_span": [46, 56], "ent_id": "D006470", "tok_span": [7, 8]}, {"name": "sodium nitroprusside", "ent_type": "Chemical", "char_span": [69, 89], "ent_id": "D009599", "tok_span": [10, 15]}], "relation_list": [{"subject": "sodium nitroprusside", "object": "hypotension", "sbj_char_span": [69, 89], "obj_char_span": [98, 109], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 15], "obj_tok_span": [17, 18]}], "umls_entity_list": []}, {"text": "During HEM-induced hypotension the cardiac output was significantly lower and systemic vascular resistance higher compared with that in the SNP group.", "entity_list": [{"name": "HEM", "ent_type": "Disease", "char_span": [7, 10], "ent_id": "D006470", "tok_span": [1, 3]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [19, 30], "ent_id": "D007022", "tok_span": [5, 6]}, {"name": "SNP", "ent_type": "Chemical", "char_span": [140, 143], "ent_id": "D009599", "tok_span": [22, 23]}], "relation_list": [{"subject": "SNP", "object": "hypotension", "sbj_char_span": [140, 143], "obj_char_span": [19, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [5, 6]}], "umls_entity_list": []}, {"text": "The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).", "entity_list": [{"name": "HEM", "ent_type": "Disease", "char_span": [57, 60], "ent_id": "D006470", "tok_span": [19, 21]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [15, 26], "ent_id": "D007022", "tok_span": [4, 5]}, {"name": "SNP", "ent_type": "Chemical", "char_span": [107, 110], "ent_id": "D009599", "tok_span": [38, 39]}], "relation_list": [{"subject": "SNP", "object": "hypotension", "sbj_char_span": [107, 110], "obj_char_span": [15, 26], "rel_type": "chemical-induced disease", "sbj_tok_span": [38, 39], "obj_tok_span": [4, 5]}], "umls_entity_list": []}, {"text": "The delta down, which is the measure of decrease of SBP after a mechanical breath, was 20.3 +/- 8.4 and 10.1 +/- 3.8 mm Hg in the HEM and SNP groups, respectively, during hypotension (P less than 0.02).", "entity_list": [{"name": "HEM", "ent_type": "Disease", "char_span": [130, 133], "ent_id": "D006470", "tok_span": [41, 43]}, {"name": "SNP", "ent_type": "Chemical", "char_span": [138, 141], "ent_id": "D009599", "tok_span": [44, 45]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [171, 182], "ent_id": "D007022", "tok_span": [50, 51]}], "relation_list": [{"subject": "SNP", "object": "hypotension", "sbj_char_span": [138, 141], "obj_char_span": [171, 182], "rel_type": "chemical-induced disease", "sbj_tok_span": [44, 45], "obj_tok_span": [50, 51]}], "umls_entity_list": []}, {"text": "Cerebral blood flow and metabolism during isoflurane-induced hypotension in patients subjected to surgery for cerebral aneurysms.", "entity_list": [{"name": "hypotension", "ent_type": "Disease", "char_span": [61, 72], "ent_id": "D007022", "tok_span": [11, 12]}, {"name": "cerebral aneurysms", "ent_type": "Disease", "char_span": [110, 128], "ent_id": "D002532", "tok_span": [18, 20]}, {"name": "isoflurane", "ent_type": "Chemical", "char_span": [42, 52], "ent_id": "D007530", "tok_span": [7, 9]}], "relation_list": [{"subject": "isoflurane", "object": "hypotension", "sbj_char_span": [42, 52], "obj_char_span": [61, 72], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 9], "obj_tok_span": [11, 12]}], "umls_entity_list": []}, {"text": "Cerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.", "entity_list": [{"name": "isoflurane", "ent_type": "Chemical", "char_span": [80, 90], "ent_id": "D007530", "tok_span": [13, 15]}, {"name": "cerebral aneurysm", "ent_type": "Disease", "char_span": [168, 185], "ent_id": "D002532", "tok_span": [30, 32]}, {"name": "oxygen", "ent_type": "Chemical", "char_span": [52, 58], "ent_id": "D010100", "tok_span": [9, 10]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [99, 110], "ent_id": "D007022", "tok_span": [17, 18]}], "relation_list": [{"subject": "isoflurane", "object": "hypotension", "sbj_char_span": [80, 90], "obj_char_span": [99, 110], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [17, 18]}], "umls_entity_list": []}, {"text": "Controlled hypotension to an average MAP of 50-55 mm Hg was induced by increasing the dose of isoflurane, and maintained at an inspired concentration of 2.2 +/- 0.2%.", "entity_list": [{"name": "Hg", "ent_type": "Chemical", "char_span": [53, 55], "ent_id": "D008628", "tok_span": [11, 12]}, {"name": "isoflurane", "ent_type": "Chemical", "char_span": [94, 104], "ent_id": "D007530", "tok_span": [19, 21]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [11, 22], "ent_id": "D007022", "tok_span": [1, 2]}], "relation_list": [{"subject": "isoflurane", "object": "hypotension", "sbj_char_span": [94, 104], "obj_char_span": [11, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 21], "obj_tok_span": [1, 2]}], "umls_entity_list": []}, {"text": "An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.", "entity_list": [{"name": "impaired renal function", "ent_type": "Disease", "char_span": [203, 226], "ent_id": "D007674", "tok_span": [37, 40]}, {"name": "carcinoma of the oral cavity", "ent_type": "Disease", "char_span": [140, 168], "ent_id": "D009062", "tok_span": [25, 30]}, {"name": "allergic reaction", "ent_type": "Disease", "char_span": [3, 20], "ent_id": "D004342", "tok_span": [1, 3]}, {"name": "cirrhosis", "ent_type": "Disease", "char_span": [170, 179], "ent_id": "D005355", "tok_span": [31, 32]}, {"name": "cisplatin", "ent_type": "Chemical", "char_span": [185, 194], "ent_id": "D002945", "tok_span": [34, 35]}, {"name": "angioneurotic edema", "ent_type": "Disease", "char_span": [35, 54], "ent_id": "D000799", "tok_span": [5, 10]}, {"name": "5-fluorouracil", "ent_type": "Chemical", "char_span": [88, 102], "ent_id": "D005472", "tok_span": [14, 19]}], "relation_list": [{"subject": "5-fluorouracil", "object": "angioneurotic edema", "sbj_char_span": [88, 102], "obj_char_span": [35, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 19], "obj_tok_span": [5, 10]}], "umls_entity_list": []}, {"text": "Amiodarone-induced sinoatrial block.", "entity_list": [{"name": "sinoatrial block", "ent_type": "Disease", "char_span": [19, 35], "ent_id": "D012848", "tok_span": [6, 10]}, {"name": "Amiodarone", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D000638", "tok_span": [0, 4]}], "relation_list": [{"subject": "Amiodarone", "object": "sinoatrial block", "sbj_char_span": [0, 10], "obj_char_span": [19, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [6, 10]}], "umls_entity_list": []}, {"text": "We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and supraventricular tachycardia.", "entity_list": [{"name": "supraventricular tachycardia", "ent_type": "Disease", "char_span": [154, 182], "ent_id": "D013617", "tok_span": [34, 39]}, {"name": "Wolff-Parkinson-White syndrome", "ent_type": "Disease", "char_span": [119, 149], "ent_id": "D014927", "tok_span": [26, 33]}, {"name": "amiodarone", "ent_type": "Chemical", "char_span": [44, 54], "ent_id": "D000638", "tok_span": [9, 13]}, {"name": "primary cardiomyopathy", "ent_type": "Disease", "char_span": [95, 117], "ent_id": "D009202", "tok_span": [23, 25]}, {"name": "sinoatrial block", "ent_type": "Disease", "char_span": [12, 28], "ent_id": "D012848", "tok_span": [2, 6]}], "relation_list": [{"subject": "amiodarone", "object": "sinoatrial block", "sbj_char_span": [44, 54], "obj_char_span": [12, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [2, 6]}], "umls_entity_list": []}, {"text": "Reduction in the dosage of amiodarone resulted in the disappearance of the sinoatrial block and the persistence of asymptomatic sinus bradycardia.", "entity_list": [{"name": "sinus bradycardia", "ent_type": "Disease", "char_span": [128, 145], "ent_id": "D012804", "tok_span": [24, 29]}, {"name": "amiodarone", "ent_type": "Chemical", "char_span": [27, 37], "ent_id": "D000638", "tok_span": [5, 9]}, {"name": "sinoatrial block", "ent_type": "Disease", "char_span": [75, 91], "ent_id": "D012848", "tok_span": [15, 19]}], "relation_list": [{"subject": "amiodarone", "object": "sinoatrial block", "sbj_char_span": [27, 37], "obj_char_span": [75, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [15, 19]}], "umls_entity_list": []}, {"text": "Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.", "entity_list": [{"name": "DTIC", "ent_type": "Chemical", "char_span": [56, 60], "ent_id": "D003606", "tok_span": [13, 15]}, {"name": "Veno-occlusive liver disease", "ent_type": "Disease", "char_span": [0, 28], "ent_id": "D006504", "tok_span": [0, 7]}, {"name": "dacarbazine", "ent_type": "Chemical", "char_span": [35, 46], "ent_id": "D003606", "tok_span": [8, 11]}, {"name": "melanoma", "ent_type": "Disease", "char_span": [66, 74], "ent_id": "D008545", "tok_span": [17, 18]}], "relation_list": [{"subject": "dacarbazine", "object": "Veno-occlusive liver disease", "sbj_char_span": [35, 46], "obj_char_span": [0, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [0, 7]}, {"subject": "DTIC", "object": "Veno-occlusive liver disease", "sbj_char_span": [56, 60], "obj_char_span": [0, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [0, 7]}], "umls_entity_list": []}, {"text": "A case of veno-occlusive disease of the liver with fatal outcome after dacarbazine (DTIC) therapy for melanoma is reported.", "entity_list": [{"name": "DTIC", "ent_type": "Chemical", "char_span": [84, 88], "ent_id": "D003606", "tok_span": [20, 22]}, {"name": "veno-occlusive disease of the liver", "ent_type": "Disease", "char_span": [10, 45], "ent_id": "D006504", "tok_span": [3, 12]}, {"name": "melanoma", "ent_type": "Disease", "char_span": [102, 110], "ent_id": "D008545", "tok_span": [25, 26]}, {"name": "dacarbazine", "ent_type": "Chemical", "char_span": [71, 82], "ent_id": "D003606", "tok_span": [16, 19]}], "relation_list": [{"subject": "DTIC", "object": "veno-occlusive disease of the liver", "sbj_char_span": [84, 88], "obj_char_span": [10, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 22], "obj_tok_span": [3, 12]}, {"subject": "dacarbazine", "object": "veno-occlusive disease of the liver", "sbj_char_span": [71, 82], "obj_char_span": [10, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [3, 12]}], "umls_entity_list": []}, {"text": "A case of tardive dyskinesia caused by metoclopramide.", "entity_list": [{"name": "metoclopramide", "ent_type": "Chemical", "char_span": [39, 53], "ent_id": "D008787", "tok_span": [12, 17]}, {"name": "tardive dyskinesia", "ent_type": "Disease", "char_span": [10, 28], "ent_id": "D004409", "tok_span": [3, 10]}], "relation_list": [{"subject": "metoclopramide", "object": "tardive dyskinesia", "sbj_char_span": [39, 53], "obj_char_span": [10, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 17], "obj_tok_span": [3, 10]}], "umls_entity_list": []}, {"text": "Abnormal involuntary movements appeared in the mouth, tongue, neck and abdomen of a 64-year-old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days.", "entity_list": [{"name": "metoclopramide", "ent_type": "Chemical", "char_span": [123, 137], "ent_id": "D008787", "tok_span": [26, 31]}, {"name": "Abnormal involuntary movements", "ent_type": "Disease", "char_span": [0, 30], "ent_id": "D004409", "tok_span": [0, 4]}, {"name": "gastrointestinal disorder", "ent_type": "Disease", "char_span": [142, 167], "ent_id": "D005767", "tok_span": [32, 35]}], "relation_list": [{"subject": "metoclopramide", "object": "Abnormal involuntary movements", "sbj_char_span": [123, 137], "obj_char_span": [0, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 31], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "When the metoclopramide administration was discontinued, the abnormal movements gradually improved to a considerable extent.", "entity_list": [{"name": "metoclopramide", "ent_type": "Chemical", "char_span": [9, 23], "ent_id": "D008787", "tok_span": [2, 7]}, {"name": "abnormal movements", "ent_type": "Disease", "char_span": [61, 79], "ent_id": "D004409", "tok_span": [12, 14]}], "relation_list": [{"subject": "metoclopramide", "object": "abnormal movements", "sbj_char_span": [9, 23], "obj_char_span": [61, 79], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 7], "obj_tok_span": [12, 14]}], "umls_entity_list": []}, {"text": "A case is presented of a reversible intra-Hisian block occurring under amiodarone treatment for atrial tachycardia in a patient without clear intraventricular conduction abnormalities.", "entity_list": [{"name": "amiodarone", "ent_type": "Chemical", "char_span": [71, 81], "ent_id": "D000638", "tok_span": [14, 18]}, {"name": "intraventricular conduction abnormalities", "ent_type": "Disease", "char_span": [142, 183], "ent_id": "D006345", "tok_span": [27, 31]}, {"name": "intra-Hisian block", "ent_type": "Disease", "char_span": [36, 54], "ent_id": "D006327", "tok_span": [7, 12]}, {"name": "atrial tachycardia", "ent_type": "Disease", "char_span": [96, 114], "ent_id": "D013617", "tok_span": [20, 22]}], "relation_list": [{"subject": "amiodarone", "object": "intra-Hisian block", "sbj_char_span": [71, 81], "obj_char_span": [36, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 18], "obj_tok_span": [7, 12]}], "umls_entity_list": []}, {"text": "The similarity between the histologic appearances of busulfan cystitis and both radiation and cyclophosphamide-induced cystitis is discussed and the world literature reviewed.", "entity_list": [{"name": "cystitis", "ent_type": "Disease", "char_span": [119, 127], "ent_id": "D003556", "tok_span": [22, 24]}, {"name": "cyclophosphamide", "ent_type": "Chemical", "char_span": [94, 110], "ent_id": "D003520", "tok_span": [17, 20]}, {"name": "cystitis", "ent_type": "Disease", "char_span": [62, 70], "ent_id": "D003556", "tok_span": [11, 13]}, {"name": "busulfan", "ent_type": "Chemical", "char_span": [53, 61], "ent_id": "D002066", "tok_span": [8, 11]}], "relation_list": [{"subject": "busulfan", "object": "cystitis", "sbj_char_span": [53, 61], "obj_char_span": [62, 70], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [11, 13]}, {"subject": "busulfan", "object": "cystitis", "sbj_char_span": [53, 61], "obj_char_span": [119, 127], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [22, 24]}], "umls_entity_list": []}, {"text": "The role of the renin--angiotensin system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside (SNP)-induced hypotension was evaluated.", "entity_list": [{"name": "SNP", "ent_type": "Chemical", "char_span": [133, 136], "ent_id": "D009599", "tok_span": [27, 28]}, {"name": "sodium nitroprusside", "ent_type": "Chemical", "char_span": [111, 131], "ent_id": "D009599", "tok_span": [21, 26]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [146, 157], "ent_id": "D007022", "tok_span": [31, 32]}, {"name": "angiotensin", "ent_type": "Chemical", "char_span": [23, 34], "ent_id": "D000809", "tok_span": [7, 8]}, {"name": "halothane", "ent_type": "Chemical", "char_span": [86, 95], "ent_id": "D006221", "tok_span": [16, 19]}], "relation_list": [{"subject": "sodium nitroprusside", "object": "hypotension", "sbj_char_span": [111, 131], "obj_char_span": [146, 157], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 26], "obj_tok_span": [31, 32]}, {"subject": "halothane", "object": "hypotension", "sbj_char_span": [86, 95], "obj_char_span": [146, 157], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [31, 32]}, {"subject": "SNP", "object": "hypotension", "sbj_char_span": [133, 136], "obj_char_span": [146, 157], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 28], "obj_tok_span": [31, 32]}], "umls_entity_list": []}, {"text": "This demonstrates the participation of the renin--angiotensin system in antagonizing the combined hypotensive effects of halothane and SNP.", "entity_list": [{"name": "hypotensive", "ent_type": "Disease", "char_span": [98, 109], "ent_id": "D007022", "tok_span": [16, 18]}, {"name": "angiotensin", "ent_type": "Chemical", "char_span": [50, 61], "ent_id": "D000809", "tok_span": [9, 10]}, {"name": "halothane", "ent_type": "Chemical", "char_span": [121, 130], "ent_id": "D006221", "tok_span": [20, 23]}, {"name": "SNP", "ent_type": "Chemical", "char_span": [135, 138], "ent_id": "D009599", "tok_span": [24, 25]}], "relation_list": [{"subject": "SNP", "object": "hypotensive", "sbj_char_span": [135, 138], "obj_char_span": [98, 109], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 25], "obj_tok_span": [16, 18]}, {"subject": "halothane", "object": "hypotensive", "sbj_char_span": [121, 130], "obj_char_span": [98, 109], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "Toxic hepatitis induced by antithyroid drugs: four cases including one with cross-reactivity between carbimazole and benzylthiouracil.", "entity_list": [{"name": "carbimazole", "ent_type": "Chemical", "char_span": [101, 112], "ent_id": "D002231", "tok_span": [18, 22]}, {"name": "benzylthiouracil", "ent_type": "Chemical", "char_span": [117, 133], "ent_id": "C019269", "tok_span": [23, 28]}, {"name": "Toxic hepatitis", "ent_type": "Disease", "char_span": [0, 15], "ent_id": "D056486", "tok_span": [0, 2]}], "relation_list": [{"subject": "carbimazole", "object": "Toxic hepatitis", "sbj_char_span": [101, 112], "obj_char_span": [0, 15], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 22], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Two others had a mixed (cholestatic and cytolytic) hepatitis following carbimazole.", "entity_list": [{"name": "carbimazole", "ent_type": "Chemical", "char_span": [71, 82], "ent_id": "D002231", "tok_span": [15, 19]}, {"name": "hepatitis", "ent_type": "Disease", "char_span": [51, 60], "ent_id": "D056486", "tok_span": [13, 14]}, {"name": "cholestatic", "ent_type": "Disease", "char_span": [24, 35], "ent_id": "D002779", "tok_span": [6, 9]}], "relation_list": [{"subject": "carbimazole", "object": "cholestatic", "sbj_char_span": [71, 82], "obj_char_span": [24, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 19], "obj_tok_span": [6, 9]}, {"subject": "carbimazole", "object": "hepatitis", "sbj_char_span": [71, 82], "obj_char_span": [51, 60], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 19], "obj_tok_span": [13, 14]}], "umls_entity_list": []}, {"text": "One of the latter two patients further experienced a cytolytic hepatitis which appeared after Benzylthiouracil (Basd  ne) had replaced carbimazole.", "entity_list": [{"name": "hepatitis", "ent_type": "Disease", "char_span": [63, 72], "ent_id": "D056486", "tok_span": [11, 12]}, {"name": "Benzylthiouracil", "ent_type": "Chemical", "char_span": [94, 110], "ent_id": "C019269", "tok_span": [15, 20]}, {"name": "Basd  ne", "ent_type": "Chemical", "char_span": [112, 120], "ent_id": "C019269", "tok_span": [21, 24]}, {"name": "carbimazole", "ent_type": "Chemical", "char_span": [135, 146], "ent_id": "D002231", "tok_span": [27, 31]}], "relation_list": [{"subject": "carbimazole", "object": "hepatitis", "sbj_char_span": [135, 146], "obj_char_span": [63, 72], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 31], "obj_tok_span": [11, 12]}], "umls_entity_list": []}, {"text": "A prospective, randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine (ZDV)-induced bone marrow suppression.", "entity_list": [{"name": "vitamin B12", "ent_type": "Chemical", "char_span": [70, 81], "ent_id": "D014805", "tok_span": [12, 15]}, {"name": "ZDV", "ent_type": "Chemical", "char_span": [141, 144], "ent_id": "D015215", "tok_span": [28, 30]}, {"name": "bone marrow suppression", "ent_type": "Disease", "char_span": [154, 177], "ent_id": "D001855", "tok_span": [33, 36]}, {"name": "zidovudine", "ent_type": "Chemical", "char_span": [129, 139], "ent_id": "D015215", "tok_span": [22, 27]}, {"name": "folinic acid", "ent_type": "Chemical", "char_span": [86, 98], "ent_id": "D002955", "tok_span": [16, 19]}], "relation_list": [{"subject": "ZDV", "object": "bone marrow suppression", "sbj_char_span": [141, 144], "obj_char_span": [154, 177], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 30], "obj_tok_span": [33, 36]}, {"subject": "zidovudine", "object": "bone marrow suppression", "sbj_char_span": [129, 139], "obj_char_span": [154, 177], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 27], "obj_tok_span": [33, 36]}], "umls_entity_list": []}, {"text": "Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced myelotoxicity in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.", "entity_list": [{"name": "folinic acid", "ent_type": "Chemical", "char_span": [16, 28], "ent_id": "D002955", "tok_span": [4, 7]}, {"name": "ZDV", "ent_type": "Chemical", "char_span": [48, 51], "ent_id": "D015215", "tok_span": [9, 11]}, {"name": "myelotoxicity", "ent_type": "Disease", "char_span": [119, 132], "ent_id": "D001855", "tok_span": [24, 26]}, {"name": "ZDV", "ent_type": "Chemical", "char_span": [107, 110], "ent_id": "D015215", "tok_span": [20, 22]}, {"name": "Vitamin B12", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D014805", "tok_span": [0, 3]}], "relation_list": [{"subject": "ZDV", "object": "myelotoxicity", "sbj_char_span": [107, 110], "obj_char_span": [119, 132], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 22], "obj_tok_span": [24, 26]}, {"subject": "ZDV", "object": "myelotoxicity", "sbj_char_span": [48, 51], "obj_char_span": [119, 132], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 11], "obj_tok_span": [24, 26]}], "umls_entity_list": []}, {"text": "Acute confusion induced by a high-dose infusion of 5-fluorouracil and folinic acid.", "entity_list": [{"name": "folinic acid", "ent_type": "Chemical", "char_span": [70, 82], "ent_id": "D002955", "tok_span": [16, 19]}, {"name": "confusion", "ent_type": "Disease", "char_span": [6, 15], "ent_id": "D003221", "tok_span": [1, 2]}, {"name": "5-fluorouracil", "ent_type": "Chemical", "char_span": [51, 65], "ent_id": "D005472", "tok_span": [10, 15]}], "relation_list": [{"subject": "5-fluorouracil", "object": "confusion", "sbj_char_span": [51, 65], "obj_char_span": [6, 15], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 15], "obj_tok_span": [1, 2]}, {"subject": "folinic acid", "object": "confusion", "sbj_char_span": [70, 82], "obj_char_span": [6, 15], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [1, 2]}], "umls_entity_list": []}, {"text": "He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.", "entity_list": [{"name": "coma", "ent_type": "Disease", "char_span": [121, 125], "ent_id": "D003128", "tok_span": [22, 24]}, {"name": "disorientation", "ent_type": "Disease", "char_span": [60, 74], "ent_id": "D003221", "tok_span": [9, 11]}, {"name": "folinic acid", "ent_type": "Chemical", "char_span": [214, 226], "ent_id": "D002955", "tok_span": [45, 48]}, {"name": "irritability", "ent_type": "Disease", "char_span": [79, 91], "ent_id": "D001523", "tok_span": [12, 14]}, {"name": "confusion", "ent_type": "Disease", "char_span": [49, 58], "ent_id": "D003221", "tok_span": [7, 8]}, {"name": "5-fluorouracil", "ent_type": "Chemical", "char_span": [195, 209], "ent_id": "D005472", "tok_span": [39, 44]}], "relation_list": [{"subject": "folinic acid", "object": "coma", "sbj_char_span": [214, 226], "obj_char_span": [121, 125], "rel_type": "chemical-induced disease", "sbj_tok_span": [45, 48], "obj_tok_span": [22, 24]}, {"subject": "folinic acid", "object": "disorientation", "sbj_char_span": [214, 226], "obj_char_span": [60, 74], "rel_type": "chemical-induced disease", "sbj_tok_span": [45, 48], "obj_tok_span": [9, 11]}, {"subject": "5-fluorouracil", "object": "coma", "sbj_char_span": [195, 209], "obj_char_span": [121, 125], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 44], "obj_tok_span": [22, 24]}, {"subject": "5-fluorouracil", "object": "confusion", "sbj_char_span": [195, 209], "obj_char_span": [49, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 44], "obj_tok_span": [7, 8]}, {"subject": "folinic acid", "object": "confusion", "sbj_char_span": [214, 226], "obj_char_span": [49, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [45, 48], "obj_tok_span": [7, 8]}, {"subject": "5-fluorouracil", "object": "disorientation", "sbj_char_span": [195, 209], "obj_char_span": [60, 74], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 44], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "Erythema multiforme and hypersensitivity myocarditis caused by ampicillin.", "entity_list": [{"name": "ampicillin", "ent_type": "Chemical", "char_span": [63, 73], "ent_id": "D000667", "tok_span": [13, 15]}, {"name": "Erythema multiforme", "ent_type": "Disease", "char_span": [0, 19], "ent_id": "D004892", "tok_span": [0, 6]}, {"name": "hypersensitivity myocarditis", "ent_type": "Disease", "char_span": [24, 52], "ent_id": "D009205", "tok_span": [7, 11]}], "relation_list": [{"subject": "ampicillin", "object": "Erythema multiforme", "sbj_char_span": [63, 73], "obj_char_span": [0, 19], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [0, 6]}, {"subject": "ampicillin", "object": "hypersensitivity myocarditis", "sbj_char_span": [63, 73], "obj_char_span": [24, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "OBJECTIVE: To report a case of erythema multiforme and hypersensitivity myocarditis caused by ampicillin.", "entity_list": [{"name": "ampicillin", "ent_type": "Chemical", "char_span": [94, 104], "ent_id": "D000667", "tok_span": [19, 21]}, {"name": "hypersensitivity myocarditis", "ent_type": "Disease", "char_span": [55, 83], "ent_id": "D009205", "tok_span": [13, 17]}, {"name": "erythema multiforme", "ent_type": "Disease", "char_span": [31, 50], "ent_id": "D004892", "tok_span": [7, 12]}], "relation_list": [{"subject": "ampicillin", "object": "erythema multiforme", "sbj_char_span": [94, 104], "obj_char_span": [31, 50], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 21], "obj_tok_span": [7, 12]}, {"subject": "ampicillin", "object": "hypersensitivity myocarditis", "sbj_char_span": [94, 104], "obj_char_span": [55, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 21], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "Immediate allergic reactions to amoxicillin.", "entity_list": [{"name": "allergic reactions", "ent_type": "Disease", "char_span": [10, 28], "ent_id": "D004342", "tok_span": [3, 5]}, {"name": "amoxicillin", "ent_type": "Chemical", "char_span": [32, 43], "ent_id": "D000658", "tok_span": [6, 9]}], "relation_list": [{"subject": "amoxicillin", "object": "allergic reactions", "sbj_char_span": [32, 43], "obj_char_span": [10, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.", "entity_list": [{"name": "allergic", "ent_type": "Disease", "char_span": [159, 167], "ent_id": "D004342", "tok_span": [34, 35]}, {"name": "allergic", "ent_type": "Disease", "char_span": [219, 227], "ent_id": "D004342", "tok_span": [44, 45]}, {"name": "penicillin", "ent_type": "Chemical", "char_span": [292, 302], "ent_id": "D010406", "tok_span": [62, 63]}, {"name": "amoxicillin", "ent_type": "Chemical", "char_span": [241, 252], "ent_id": "D000658", "tok_span": [47, 50]}, {"name": "beta-lactam", "ent_type": "Chemical", "char_span": [171, 182], "ent_id": "D047090", "tok_span": [36, 40]}, {"name": "AX", "ent_type": "Chemical", "char_span": [254, 256], "ent_id": "D000658", "tok_span": [51, 53]}], "relation_list": [{"subject": "AX", "object": "allergic", "sbj_char_span": [254, 256], "obj_char_span": [219, 227], "rel_type": "chemical-induced disease", "sbj_tok_span": [51, 53], "obj_tok_span": [44, 45]}, {"subject": "amoxicillin", "object": "allergic", "sbj_char_span": [241, 252], "obj_char_span": [159, 167], "rel_type": "chemical-induced disease", "sbj_tok_span": [47, 50], "obj_tok_span": [34, 35]}, {"subject": "amoxicillin", "object": "allergic", "sbj_char_span": [241, 252], "obj_char_span": [219, 227], "rel_type": "chemical-induced disease", "sbj_tok_span": [47, 50], "obj_tok_span": [44, 45]}, {"subject": "AX", "object": "allergic", "sbj_char_span": [254, 256], "obj_char_span": [159, 167], "rel_type": "chemical-induced disease", "sbj_tok_span": [51, 53], "obj_tok_span": [34, 35]}], "umls_entity_list": []}, {"text": "We selected the 54 (30.5%) cases of immediate AX allergy with good tolerance of PG.", "entity_list": [{"name": "AX", "ent_type": "Chemical", "char_span": [46, 48], "ent_id": "D000658", "tok_span": [13, 15]}, {"name": "PG", "ent_type": "Chemical", "char_span": [80, 82], "ent_id": "D010400", "tok_span": [20, 21]}, {"name": "allergy", "ent_type": "Disease", "char_span": [49, 56], "ent_id": "D004342", "tok_span": [15, 16]}], "relation_list": [{"subject": "AX", "object": "allergy", "sbj_char_span": [46, 48], "obj_char_span": [49, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [15, 16]}], "umls_entity_list": []}, {"text": "Challenge tests with AX were performed in 23 subjects (43%) to establish the diagnosis of immediate allergic reaction to AX, and in 15 cases (28%) both skin test and RAST for AX were negative.", "entity_list": [{"name": "AX", "ent_type": "Chemical", "char_span": [21, 23], "ent_id": "D000658", "tok_span": [4, 6]}, {"name": "AX", "ent_type": "Chemical", "char_span": [121, 123], "ent_id": "D000658", "tok_span": [24, 26]}, {"name": "AX", "ent_type": "Chemical", "char_span": [175, 177], "ent_id": "D000658", "tok_span": [42, 44]}, {"name": "allergic reaction", "ent_type": "Disease", "char_span": [100, 117], "ent_id": "D004342", "tok_span": [21, 23]}], "relation_list": [{"subject": "AX", "object": "allergic reaction", "sbj_char_span": [21, 23], "obj_char_span": [100, 117], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 6], "obj_tok_span": [21, 23]}, {"subject": "AX", "object": "allergic reaction", "sbj_char_span": [175, 177], "obj_char_span": [100, 117], "rel_type": "chemical-induced disease", "sbj_tok_span": [42, 44], "obj_tok_span": [21, 23]}, {"subject": "AX", "object": "allergic reaction", "sbj_char_span": [121, 123], "obj_char_span": [100, 117], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 26], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "We describe the largest group of AX-allergic patients who have tolerated PG reported so far.", "entity_list": [{"name": "allergic", "ent_type": "Disease", "char_span": [36, 44], "ent_id": "D004342", "tok_span": [9, 10]}, {"name": "PG", "ent_type": "Chemical", "char_span": [73, 75], "ent_id": "D010400", "tok_span": [14, 15]}, {"name": "AX", "ent_type": "Chemical", "char_span": [33, 35], "ent_id": "D000658", "tok_span": [6, 8]}], "relation_list": [{"subject": "AX", "object": "allergic", "sbj_char_span": [33, 35], "obj_char_span": [36, 44], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [9, 10]}], "umls_entity_list": []}, {"text": "Persistent paralysis after prolonged use of atracurium in the absence of corticosteroids.", "entity_list": [{"name": "paralysis", "ent_type": "Disease", "char_span": [11, 20], "ent_id": "D010243", "tok_span": [2, 4]}, {"name": "atracurium", "ent_type": "Chemical", "char_span": [44, 54], "ent_id": "D001279", "tok_span": [8, 11]}], "relation_list": [{"subject": "atracurium", "object": "paralysis", "sbj_char_span": [44, 54], "obj_char_span": [11, 20], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [2, 4]}], "umls_entity_list": []}, {"text": "Reports of persistent paralysis after the discontinuance of these drugs have most often involved aminosteroid-based NMBAs such as vecuronium bromide, especially when used in conjunction with corticosteroids.", "entity_list": [{"name": "vecuronium bromide", "ent_type": "Chemical", "char_span": [130, 148], "ent_id": "D014673", "tok_span": [26, 30]}, {"name": "paralysis", "ent_type": "Disease", "char_span": [22, 31], "ent_id": "D010243", "tok_span": [3, 5]}], "relation_list": [{"subject": "vecuronium bromide", "object": "paralysis", "sbj_char_span": [130, 148], "obj_char_span": [22, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 30], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "Atracurium besylate, a short-acting benzylisoquinolinium NMBA that is eliminated independently of renal or hepatic function, has also been associated with persistent paralysis, but only when used with corticosteroids.", "entity_list": [{"name": "Atracurium besylate", "ent_type": "Chemical", "char_span": [0, 19], "ent_id": "D001279", "tok_span": [0, 5]}, {"name": "benzylisoquinolinium", "ent_type": "Chemical", "char_span": [36, 56], "ent_id": "-1", "tok_span": [10, 16]}, {"name": "paralysis", "ent_type": "Disease", "char_span": [166, 175], "ent_id": "D010243", "tok_span": [34, 36]}], "relation_list": [{"subject": "Atracurium besylate", "object": "paralysis", "sbj_char_span": [0, 19], "obj_char_span": [166, 175], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [34, 36]}], "umls_entity_list": []}, {"text": "We report a case of atracurium-related paralysis persisting for approximately 50 hours in a patient who was not treated with corticosteroids.", "entity_list": [{"name": "atracurium", "ent_type": "Chemical", "char_span": [20, 30], "ent_id": "D001279", "tok_span": [5, 8]}, {"name": "paralysis", "ent_type": "Disease", "char_span": [39, 48], "ent_id": "D010243", "tok_span": [10, 12]}], "relation_list": [{"subject": "atracurium", "object": "paralysis", "sbj_char_span": [20, 30], "obj_char_span": [39, 48], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Habitual use of acetaminophen as a risk factor for chronic renal failure: a comparison with phenacetin.", "entity_list": [{"name": "chronic renal failure", "ent_type": "Disease", "char_span": [51, 72], "ent_id": "D007676", "tok_span": [13, 16]}, {"name": "acetaminophen", "ent_type": "Chemical", "char_span": [16, 29], "ent_id": "D000082", "tok_span": [5, 8]}, {"name": "phenacetin", "ent_type": "Chemical", "char_span": [92, 102], "ent_id": "D010615", "tok_span": [20, 23]}], "relation_list": [{"subject": "phenacetin", "object": "chronic renal failure", "sbj_char_span": [92, 102], "obj_char_span": [51, 72], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end-stage renal disease (ESRD), with a relative risk in the range of 4 to 19.", "entity_list": [{"name": "ESRD", "ent_type": "Disease", "char_span": [188, 192], "ent_id": "D007676", "tok_span": [35, 37]}, {"name": "chronic renal failure", "ent_type": "Disease", "char_span": [137, 158], "ent_id": "D007676", "tok_span": [25, 28]}, {"name": "end-stage renal disease", "ent_type": "Disease", "char_span": [163, 186], "ent_id": "D007676", "tok_span": [29, 34]}, {"name": "phenacetin", "ent_type": "Chemical", "char_span": [88, 98], "ent_id": "D010615", "tok_span": [16, 19]}], "relation_list": [{"subject": "phenacetin", "object": "chronic renal failure", "sbj_char_span": [88, 98], "obj_char_span": [137, 158], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [25, 28]}, {"subject": "phenacetin", "object": "end-stage renal disease", "sbj_char_span": [88, 98], "obj_char_span": [163, 186], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [29, 34]}, {"subject": "phenacetin", "object": "ESRD", "sbj_char_span": [88, 98], "obj_char_span": [188, 192], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [35, 37]}], "umls_entity_list": []}, {"text": "These studies suggest that both phenacetin and acetaminophen may contribute to the burden of ESRD, with the risk of the latter being somewhat less than that of the former.", "entity_list": [{"name": "phenacetin", "ent_type": "Chemical", "char_span": [32, 42], "ent_id": "D010615", "tok_span": [5, 8]}, {"name": "ESRD", "ent_type": "Disease", "char_span": [93, 97], "ent_id": "D007676", "tok_span": [18, 20]}, {"name": "acetaminophen", "ent_type": "Chemical", "char_span": [47, 60], "ent_id": "D000082", "tok_span": [9, 12]}], "relation_list": [{"subject": "phenacetin", "object": "ESRD", "sbj_char_span": [32, 42], "obj_char_span": [93, 97], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [18, 20]}], "umls_entity_list": []}, {"text": "Reduction of heparan sulphate-associated anionic sites in the glomerular basement membrane of rats with streptozotocin-induced diabetic nephropathy.", "entity_list": [{"name": "diabetic nephropathy", "ent_type": "Disease", "char_span": [127, 147], "ent_id": "D003928", "tok_span": [24, 26]}, {"name": "streptozotocin", "ent_type": "Chemical", "char_span": [104, 118], "ent_id": "D013311", "tok_span": [18, 22]}, {"name": "heparan sulphate", "ent_type": "Chemical", "char_span": [13, 29], "ent_id": "D006497", "tok_span": [2, 5]}], "relation_list": [{"subject": "streptozotocin", "object": "diabetic nephropathy", "sbj_char_span": [104, 118], "obj_char_span": [127, 147], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 22], "obj_tok_span": [24, 26]}], "umls_entity_list": []}, {"text": "Lithium-associated cognitive and functional deficits reduced by a switch to divalproex sodium: a case series.", "entity_list": [{"name": "divalproex sodium", "ent_type": "Chemical", "char_span": [76, 93], "ent_id": "D014635", "tok_span": [13, 18]}, {"name": "cognitive and functional deficits", "ent_type": "Disease", "char_span": [19, 52], "ent_id": "D003072", "tok_span": [4, 8]}, {"name": "Lithium", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "D008094", "tok_span": [0, 2]}], "relation_list": [{"subject": "Lithium", "object": "cognitive and functional deficits", "sbj_char_span": [0, 7], "obj_char_span": [19, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.", "entity_list": [{"name": "tremor", "ent_type": "Disease", "char_span": [120, 126], "ent_id": "D014202", "tok_span": [22, 24]}, {"name": "loss of creativity", "ent_type": "Disease", "char_span": [189, 207], "ent_id": "D003072", "tok_span": [35, 38]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [140, 147], "ent_id": "D008094", "tok_span": [27, 28]}, {"name": "functional impairments", "ent_type": "Disease", "char_span": [213, 235], "ent_id": "D003072", "tok_span": [40, 42]}, {"name": "polyuria", "ent_type": "Disease", "char_span": [107, 115], "ent_id": "D011141", "tok_span": [19, 21]}, {"name": "cognitive deficits", "ent_type": "Disease", "char_span": [169, 187], "ent_id": "D003072", "tok_span": [32, 34]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [90, 97], "ent_id": "D008094", "tok_span": [15, 16]}], "relation_list": [{"subject": "lithium", "object": "functional impairments", "sbj_char_span": [140, 147], "obj_char_span": [213, 235], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 28], "obj_tok_span": [40, 42]}, {"subject": "lithium", "object": "loss of creativity", "sbj_char_span": [90, 97], "obj_char_span": [189, 207], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 16], "obj_tok_span": [35, 38]}, {"subject": "lithium", "object": "cognitive deficits", "sbj_char_span": [90, 97], "obj_char_span": [169, 187], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 16], "obj_tok_span": [32, 34]}, {"subject": "lithium", "object": "cognitive deficits", "sbj_char_span": [140, 147], "obj_char_span": [169, 187], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 28], "obj_tok_span": [32, 34]}, {"subject": "lithium", "object": "functional impairments", "sbj_char_span": [90, 97], "obj_char_span": [213, 235], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 16], "obj_tok_span": [40, 42]}, {"subject": "lithium", "object": "loss of creativity", "sbj_char_span": [140, 147], "obj_char_span": [189, 207], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 28], "obj_tok_span": [35, 38]}], "umls_entity_list": []}, {"text": "This report summarizes our experience in switching bipolar patients from lithium to divalproex sodium to alleviate such cognitive and functional impairments.", "entity_list": [{"name": "bipolar", "ent_type": "Disease", "char_span": [51, 58], "ent_id": "D001714", "tok_span": [7, 8]}, {"name": "divalproex sodium", "ent_type": "Chemical", "char_span": [84, 101], "ent_id": "D014635", "tok_span": [12, 17]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [73, 80], "ent_id": "D008094", "tok_span": [10, 11]}, {"name": "cognitive and functional impairments", "ent_type": "Disease", "char_span": [120, 156], "ent_id": "D003072", "tok_span": [20, 24]}], "relation_list": [{"subject": "lithium", "object": "cognitive and functional impairments", "sbj_char_span": [73, 80], "obj_char_span": [120, 156], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients.", "entity_list": [{"name": "cognitive, motivational, or creative deficits", "ent_type": "Disease", "char_span": [150, 195], "ent_id": "D003072", "tok_span": [28, 35]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [53, 60], "ent_id": "D008094", "tok_span": [9, 10]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [210, 217], "ent_id": "D008094", "tok_span": [37, 38]}, {"name": "bipolar", "ent_type": "Disease", "char_span": [225, 232], "ent_id": "D001714", "tok_span": [40, 41]}, {"name": "divalproex sodium", "ent_type": "Chemical", "char_span": [94, 111], "ent_id": "D014635", "tok_span": [17, 22]}], "relation_list": [{"subject": "lithium", "object": "cognitive, motivational, or creative deficits", "sbj_char_span": [53, 60], "obj_char_span": [150, 195], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [28, 35]}, {"subject": "lithium", "object": "cognitive, motivational, or creative deficits", "sbj_char_span": [210, 217], "obj_char_span": [150, 195], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 38], "obj_tok_span": [28, 35]}], "umls_entity_list": []}, {"text": "CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.", "entity_list": [{"name": "cognitive deficits", "ent_type": "Disease", "char_span": [129, 147], "ent_id": "D003072", "tok_span": [22, 24]}, {"name": "bipolar", "ent_type": "Disease", "char_span": [99, 106], "ent_id": "D001714", "tok_span": [19, 20]}, {"name": "loss of creativity", "ent_type": "Disease", "char_span": [149, 167], "ent_id": "D003072", "tok_span": [25, 28]}, {"name": "divalproex sodium", "ent_type": "Chemical", "char_span": [40, 57], "ent_id": "D014635", "tok_span": [7, 12]}, {"name": "functional impairments", "ent_type": "Disease", "char_span": [173, 195], "ent_id": "D003072", "tok_span": [30, 32]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [88, 95], "ent_id": "D008094", "tok_span": [17, 18]}], "relation_list": [{"subject": "lithium", "object": "functional impairments", "sbj_char_span": [88, 95], "obj_char_span": [173, 195], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 18], "obj_tok_span": [30, 32]}, {"subject": "lithium", "object": "loss of creativity", "sbj_char_span": [88, 95], "obj_char_span": [149, 167], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 18], "obj_tok_span": [25, 28]}, {"subject": "lithium", "object": "cognitive deficits", "sbj_char_span": [88, 95], "obj_char_span": [129, 147], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 18], "obj_tok_span": [22, 24]}], "umls_entity_list": []}, {"text": "The male Wistar rats consuming a diet that contained LiCl (60 mmol/kg) for 4 weeks developed marked polyuria.", "entity_list": [{"name": "polyuria", "ent_type": "Disease", "char_span": [100, 108], "ent_id": "D011141", "tok_span": [22, 24]}, {"name": "LiCl", "ent_type": "Chemical", "char_span": [53, 57], "ent_id": "D018021", "tok_span": [9, 11]}], "relation_list": [{"subject": "LiCl", "object": "polyuria", "sbj_char_span": [53, 57], "obj_char_span": [100, 108], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 11], "obj_tok_span": [22, 24]}], "umls_entity_list": []}, {"text": "Suxamethonium-induced cardiac arrest and death following 5 days of immobilization.", "entity_list": [{"name": "Suxamethonium", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D013390", "tok_span": [0, 5]}, {"name": "death", "ent_type": "Disease", "char_span": [41, 46], "ent_id": "D003643", "tok_span": [10, 11]}, {"name": "cardiac arrest", "ent_type": "Disease", "char_span": [22, 36], "ent_id": "D006323", "tok_span": [7, 9]}], "relation_list": [{"subject": "Suxamethonium", "object": "cardiac arrest", "sbj_char_span": [0, 13], "obj_char_span": [22, 36], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "The present report describes a case of cardiac arrest and subsequent death as a result of hyperkalaemia following the use of suxamethonium in a 23-year-old Malawian woman.", "entity_list": [{"name": "suxamethonium", "ent_type": "Chemical", "char_span": [125, 138], "ent_id": "D013390", "tok_span": [24, 29]}, {"name": "hyperkalaemia", "ent_type": "Disease", "char_span": [90, 103], "ent_id": "D006947", "tok_span": [16, 20]}, {"name": "death", "ent_type": "Disease", "char_span": [69, 74], "ent_id": "D003643", "tok_span": [11, 12]}, {"name": "cardiac arrest", "ent_type": "Disease", "char_span": [39, 53], "ent_id": "D006323", "tok_span": [7, 9]}], "relation_list": [{"subject": "suxamethonium", "object": "hyperkalaemia", "sbj_char_span": [125, 138], "obj_char_span": [90, 103], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 29], "obj_tok_span": [16, 20]}, {"subject": "suxamethonium", "object": "cardiac arrest", "sbj_char_span": [125, 138], "obj_char_span": [39, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 29], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "Forty seconds after injection of suxamethonium, bradycardia and cardiac arrest occurred.", "entity_list": [{"name": "suxamethonium", "ent_type": "Chemical", "char_span": [33, 46], "ent_id": "D013390", "tok_span": [5, 10]}, {"name": "cardiac arrest", "ent_type": "Disease", "char_span": [64, 78], "ent_id": "D006323", "tok_span": [16, 18]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [48, 59], "ent_id": "D001919", "tok_span": [11, 15]}], "relation_list": [{"subject": "suxamethonium", "object": "cardiac arrest", "sbj_char_span": [33, 46], "obj_char_span": [64, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 10], "obj_tok_span": [16, 18]}, {"subject": "suxamethonium", "object": "bradycardia", "sbj_char_span": [33, 46], "obj_char_span": [48, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 10], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "Apart from the reduction in the patient's level of consciousness, there were no signs of motor neurone damage or of any of the other known predisposing conditions for hyperkalaemia following the administration of suxamethonium.", "entity_list": [{"name": "hyperkalaemia", "ent_type": "Disease", "char_span": [167, 180], "ent_id": "D006947", "tok_span": [33, 37]}, {"name": "suxamethonium", "ent_type": "Chemical", "char_span": [213, 226], "ent_id": "D013390", "tok_span": [41, 46]}], "relation_list": [{"subject": "suxamethonium", "object": "hyperkalaemia", "sbj_char_span": [213, 226], "obj_char_span": [167, 180], "rel_type": "chemical-induced disease", "sbj_tok_span": [41, 46], "obj_tok_span": [33, 37]}], "umls_entity_list": []}, {"text": "It is postulated that her death was caused by hypersensitivity to suxamethonium, associated with her 5-day immobilization.", "entity_list": [{"name": "suxamethonium", "ent_type": "Chemical", "char_span": [66, 79], "ent_id": "D013390", "tok_span": [12, 17]}, {"name": "hypersensitivity", "ent_type": "Disease", "char_span": [46, 62], "ent_id": "D004342", "tok_span": [9, 11]}, {"name": "death", "ent_type": "Disease", "char_span": [26, 31], "ent_id": "D003643", "tok_span": [5, 6]}], "relation_list": [{"subject": "suxamethonium", "object": "hypersensitivity", "sbj_char_span": [66, 79], "obj_char_span": [46, 62], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 17], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.", "entity_list": [{"name": "increase in blood pressure", "ent_type": "Disease", "char_span": [3, 29], "ent_id": "D006973", "tok_span": [1, 5]}, {"name": "incomprehensible shouts", "ent_type": "Disease", "char_span": [78, 101], "ent_id": "D019954", "tok_span": [14, 20]}, {"name": "mepivacaine", "ent_type": "Chemical", "char_span": [267, 278], "ent_id": "D008619", "tok_span": [50, 54]}, {"name": "adrenaline", "ent_type": "Chemical", "char_span": [297, 307], "ent_id": "D004837", "tok_span": [58, 60]}, {"name": "Dupuytren's contracture", "ent_type": "Disease", "char_span": [336, 359], "ent_id": "D004387", "tok_span": [68, 76]}, {"name": "atrial fibrillation", "ent_type": "Disease", "char_span": [46, 65], "ent_id": "D001281", "tok_span": [8, 10]}, {"name": "loss of consciousness", "ent_type": "Disease", "char_span": [106, 127], "ent_id": "D014474", "tok_span": [21, 24]}, {"name": "agitation", "ent_type": "Disease", "char_span": [67, 76], "ent_id": "D011595", "tok_span": [11, 13]}], "relation_list": [{"subject": "mepivacaine", "object": "atrial fibrillation", "sbj_char_span": [267, 278], "obj_char_span": [46, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [50, 54], "obj_tok_span": [8, 10]}, {"subject": "mepivacaine", "object": "increase in blood pressure", "sbj_char_span": [267, 278], "obj_char_span": [3, 29], "rel_type": "chemical-induced disease", "sbj_tok_span": [50, 54], "obj_tok_span": [1, 5]}, {"subject": "adrenaline", "object": "atrial fibrillation", "sbj_char_span": [297, 307], "obj_char_span": [46, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [58, 60], "obj_tok_span": [8, 10]}, {"subject": "adrenaline", "object": "increase in blood pressure", "sbj_char_span": [297, 307], "obj_char_span": [3, 29], "rel_type": "chemical-induced disease", "sbj_tok_span": [58, 60], "obj_tok_span": [1, 5]}], "umls_entity_list": []}, {"text": "Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).", "entity_list": [{"name": "FK506", "ent_type": "Chemical", "char_span": [8, 13], "ent_id": "D016559", "tok_span": [1, 3]}, {"name": "focal segmental glomerulosclerosis", "ent_type": "Disease", "char_span": [163, 197], "ent_id": "D005923", "tok_span": [35, 41]}, {"name": "interstitial fibrosis", "ent_type": "Disease", "char_span": [235, 256], "ent_id": "D005355", "tok_span": [51, 53]}, {"name": "nephropathy", "ent_type": "Disease", "char_span": [14, 25], "ent_id": "D007674", "tok_span": [3, 4]}], "relation_list": [{"subject": "FK506", "object": "focal segmental glomerulosclerosis", "sbj_char_span": [8, 13], "obj_char_span": [163, 197], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 3], "obj_tok_span": [35, 41]}], "umls_entity_list": []}, {"text": "In the mouse passive-avoidance test, PG-9 (10-30 mg/kg, i.p.), administered 20 min before the training session, prevented amnesia induced by both the non selective antimuscarinic drug scopolamine and the M1-selective antagonist S-(-)-ET-126.", "entity_list": [{"name": "scopolamine", "ent_type": "Chemical", "char_span": [184, 195], "ent_id": "D012601", "tok_span": [48, 51]}, {"name": "amnesia", "ent_type": "Disease", "char_span": [122, 129], "ent_id": "D000647", "tok_span": [34, 37]}, {"name": "PG-9", "ent_type": "Chemical", "char_span": [37, 41], "ent_id": "C087567", "tok_span": [8, 11]}, {"name": "S-(-)-ET-126", "ent_type": "Chemical", "char_span": [228, 240], "ent_id": "C098725", "tok_span": [58, 67]}], "relation_list": [{"subject": "S-(-)-ET-126", "object": "amnesia", "sbj_char_span": [228, 240], "obj_char_span": [122, 129], "rel_type": "chemical-induced disease", "sbj_tok_span": [58, 67], "obj_tok_span": [34, 37]}, {"subject": "scopolamine", "object": "amnesia", "sbj_char_span": [184, 195], "obj_char_span": [122, 129], "rel_type": "chemical-induced disease", "sbj_tok_span": [48, 51], "obj_tok_span": [34, 37]}], "umls_entity_list": []}, {"text": "Angioedema due to ACE inhibitors: common and inadequately diagnosed.", "entity_list": [{"name": "Angioedema", "ent_type": "Disease", "char_span": [0, 10], "ent_id": "D000799", "tok_span": [0, 4]}, {"name": "ACE inhibitors", "ent_type": "Chemical", "char_span": [18, 32], "ent_id": "D000806", "tok_span": [6, 8]}], "relation_list": [{"subject": "ACE inhibitors", "object": "Angioedema", "sbj_char_span": [18, 32], "obj_char_span": [0, 10], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "The estimated incidence of angioedema during angiotensin-converting enzyme (ACE) inhibitor treatment is between 1 and 7 per thousand patients.", "entity_list": [{"name": "angioedema", "ent_type": "Disease", "char_span": [27, 37], "ent_id": "D000799", "tok_span": [4, 8]}, {"name": "angiotensin-converting enzyme (ACE) inhibitor", "ent_type": "Chemical", "char_span": [45, 90], "ent_id": "D000806", "tok_span": [9, 17]}], "relation_list": [{"subject": "angiotensin-converting enzyme (ACE) inhibitor", "object": "angioedema", "sbj_char_span": [45, 90], "obj_char_span": [27, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 17], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "Recurrent use of newer oral contraceptives and the risk of venous thromboembolism.", "entity_list": [{"name": "oral contraceptives", "ent_type": "Chemical", "char_span": [23, 42], "ent_id": "D003276", "tok_span": [5, 8]}, {"name": "venous thromboembolism", "ent_type": "Disease", "char_span": [59, 81], "ent_id": "D054556", "tok_span": [12, 15]}], "relation_list": [{"subject": "oral contraceptives", "object": "venous thromboembolism", "sbj_char_span": [23, 42], "obj_char_span": [59, 81], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [12, 15]}], "umls_entity_list": []}, {"text": "The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.", "entity_list": [{"name": "VTE", "ent_type": "Disease", "char_span": [78, 81], "ent_id": "D054556", "tok_span": [12, 14]}, {"name": "oral contraceptives", "ent_type": "Chemical", "char_span": [105, 124], "ent_id": "D003276", "tok_span": [18, 21]}, {"name": "OC", "ent_type": "Chemical", "char_span": [126, 128], "ent_id": "D003276", "tok_span": [22, 23]}, {"name": "venous thromboembolism", "ent_type": "Disease", "char_span": [54, 76], "ent_id": "D054556", "tok_span": [8, 11]}, {"name": "OC", "ent_type": "Chemical", "char_span": [170, 172], "ent_id": "D003276", "tok_span": [30, 31]}], "relation_list": [{"subject": "oral contraceptives", "object": "venous thromboembolism", "sbj_char_span": [105, 124], "obj_char_span": [54, 76], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [8, 11]}, {"subject": "OC", "object": "VTE", "sbj_char_span": [170, 172], "obj_char_span": [78, 81], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 31], "obj_tok_span": [12, 14]}, {"subject": "oral contraceptives", "object": "VTE", "sbj_char_span": [105, 124], "obj_char_span": [78, 81], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [12, 14]}, {"subject": "OC", "object": "venous thromboembolism", "sbj_char_span": [126, 128], "obj_char_span": [54, 76], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [8, 11]}, {"subject": "OC", "object": "VTE", "sbj_char_span": [126, 128], "obj_char_span": [78, 81], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [12, 14]}, {"subject": "OC", "object": "venous thromboembolism", "sbj_char_span": [170, 172], "obj_char_span": [54, 76], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 31], "obj_tok_span": [8, 11]}], "umls_entity_list": []}, {"text": "The adjusted rate ratio of VTE for repeat users of third generation OC was 0.6 (95% CI:0.3-1.2) relative to repeat users of second generation pills, whereas it was 1.3 (95% CI:0.7-2.4) for switchers from second to third generation pills relative to switchers from third to second generation pills.", "entity_list": [{"name": "OC", "ent_type": "Chemical", "char_span": [68, 70], "ent_id": "D003276", "tok_span": [13, 14]}, {"name": "VTE", "ent_type": "Disease", "char_span": [27, 30], "ent_id": "D054556", "tok_span": [5, 7]}], "relation_list": [{"subject": "OC", "object": "VTE", "sbj_char_span": [68, 70], "obj_char_span": [27, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 14], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "Development of apomorphine-induced aggressive behavior: comparison of adult male and female Wistar rats.", "entity_list": [{"name": "apomorphine", "ent_type": "Chemical", "char_span": [15, 26], "ent_id": "D001058", "tok_span": [2, 7]}, {"name": "aggressive behavior", "ent_type": "Disease", "char_span": [35, 54], "ent_id": "D010554", "tok_span": [9, 11]}], "relation_list": [{"subject": "apomorphine", "object": "aggressive behavior", "sbj_char_span": [15, 26], "obj_char_span": [35, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 7], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "The development of apomorphine-induced (1.0 mg/kg s.c. once daily) aggressive behavior of adult male and female Wistar rats obtained from the same breeder was studied in two consecutive sets.", "entity_list": [{"name": "aggressive behavior", "ent_type": "Disease", "char_span": [67, 86], "ent_id": "D010554", "tok_span": [24, 26]}, {"name": "apomorphine", "ent_type": "Chemical", "char_span": [19, 30], "ent_id": "D001058", "tok_span": [3, 8]}], "relation_list": [{"subject": "apomorphine", "object": "aggressive behavior", "sbj_char_span": [19, 30], "obj_char_span": [67, 86], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 8], "obj_tok_span": [24, 26]}], "umls_entity_list": []}, {"text": "In male animals, repeated apomorphine treatment induced a gradual development of aggressive behavior as evidenced by the increased intensity of aggressiveness and shortened latency before the first attack toward the opponent.", "entity_list": [{"name": "aggressiveness", "ent_type": "Disease", "char_span": [144, 158], "ent_id": "D010554", "tok_span": [25, 27]}, {"name": "apomorphine", "ent_type": "Chemical", "char_span": [26, 37], "ent_id": "D001058", "tok_span": [5, 10]}, {"name": "aggressive behavior", "ent_type": "Disease", "char_span": [81, 100], "ent_id": "D010554", "tok_span": [16, 18]}], "relation_list": [{"subject": "apomorphine", "object": "aggressive behavior", "sbj_char_span": [26, 37], "obj_char_span": [81, 100], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 10], "obj_tok_span": [16, 18]}, {"subject": "apomorphine", "object": "aggressiveness", "sbj_char_span": [26, 37], "obj_char_span": [144, 158], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 10], "obj_tok_span": [25, 27]}], "umls_entity_list": []}, {"text": "In conclusion, the present study demonstrates gender differences in the development of the apomorphine-induced aggressive behavior and indicates that the female rats do not fill the validation criteria for use in this method.", "entity_list": [{"name": "aggressive behavior", "ent_type": "Disease", "char_span": [111, 130], "ent_id": "D010554", "tok_span": [21, 23]}, {"name": "apomorphine", "ent_type": "Chemical", "char_span": [91, 102], "ent_id": "D001058", "tok_span": [14, 19]}], "relation_list": [{"subject": "apomorphine", "object": "aggressive behavior", "sbj_char_span": [91, 102], "obj_char_span": [111, 130], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 19], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "Serotonergic antidepressants and urinary incontinence.", "entity_list": [{"name": "Serotonergic antidepressants", "ent_type": "Chemical", "char_span": [0, 28], "ent_id": "D018490", "tok_span": [0, 5]}, {"name": "urinary incontinence", "ent_type": "Disease", "char_span": [33, 53], "ent_id": "D014549", "tok_span": [6, 8]}], "relation_list": [{"subject": "Serotonergic antidepressants", "object": "urinary incontinence", "sbj_char_span": [0, 28], "obj_char_span": [33, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "entity_list": [{"name": "incontinence", "ent_type": "Disease", "char_span": [46, 58], "ent_id": "D014549", "tok_span": [7, 8]}, {"name": "venlafaxine", "ent_type": "Chemical", "char_span": [72, 83], "ent_id": "C047426", "tok_span": [10, 15]}], "relation_list": [{"subject": "venlafaxine", "object": "incontinence", "sbj_char_span": [72, 83], "obj_char_span": [46, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 15], "obj_tok_span": [7, 8]}], "umls_entity_list": []}, {"text": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "entity_list": [{"name": "incontinence", "ent_type": "Disease", "char_span": [74, 86], "ent_id": "D014549", "tok_span": [12, 13]}, {"name": "venlafaxine", "ent_type": "Chemical", "char_span": [224, 235], "ent_id": "C047426", "tok_span": [41, 46]}, {"name": "paroxetine", "ent_type": "Chemical", "char_span": [144, 154], "ent_id": "D017374", "tok_span": [22, 25]}, {"name": "sertraline", "ent_type": "Chemical", "char_span": [159, 169], "ent_id": "D020280", "tok_span": [26, 29]}, {"name": "serotonin", "ent_type": "Chemical", "char_span": [114, 123], "ent_id": "D012701", "tok_span": [17, 18]}], "relation_list": [{"subject": "venlafaxine", "object": "incontinence", "sbj_char_span": [224, 235], "obj_char_span": [74, 86], "rel_type": "chemical-induced disease", "sbj_tok_span": [41, 46], "obj_tok_span": [12, 13]}, {"subject": "sertraline", "object": "incontinence", "sbj_char_span": [159, 169], "obj_char_span": [74, 86], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 29], "obj_tok_span": [12, 13]}, {"subject": "paroxetine", "object": "incontinence", "sbj_char_span": [144, 154], "obj_char_span": [74, 86], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 25], "obj_tok_span": [12, 13]}], "umls_entity_list": []}, {"text": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "entity_list": [{"name": "incontinence", "ent_type": "Disease", "char_span": [131, 143], "ent_id": "D014549", "tok_span": [26, 27]}, {"name": "lithium carbonate", "ent_type": "Chemical", "char_span": [50, 67], "ent_id": "D016651", "tok_span": [11, 13]}], "relation_list": [{"subject": "lithium carbonate", "object": "incontinence", "sbj_char_span": [50, 67], "obj_char_span": [131, 143], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 13], "obj_tok_span": [26, 27]}], "umls_entity_list": []}, {"text": "Animal studies suggest that incontinence secondary to serotonergic antidepressants could be mediated by the 5HT4 receptors found on the bladder.", "entity_list": [{"name": "incontinence", "ent_type": "Disease", "char_span": [28, 40], "ent_id": "D014549", "tok_span": [4, 5]}, {"name": "serotonergic antidepressants", "ent_type": "Chemical", "char_span": [54, 82], "ent_id": "D018490", "tok_span": [7, 11]}], "relation_list": [{"subject": "serotonergic antidepressants", "object": "incontinence", "sbj_char_span": [54, 82], "obj_char_span": [28, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [4, 5]}], "umls_entity_list": []}, {"text": "Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension.", "entity_list": [{"name": "hypertension", "ent_type": "Disease", "char_span": [132, 144], "ent_id": "D006973", "tok_span": [23, 24]}, {"name": "angiotensin", "ent_type": "Chemical", "char_span": [80, 91], "ent_id": "D000809", "tok_span": [17, 18]}, {"name": "tizanidine", "ent_type": "Chemical", "char_span": [40, 50], "ent_id": "C023754", "tok_span": [6, 11]}, {"name": "Hypotension", "ent_type": "Disease", "char_span": [0, 11], "ent_id": "D007022", "tok_span": [0, 2]}], "relation_list": [{"subject": "tizanidine", "object": "Hypotension", "sbj_char_span": [40, 50], "obj_char_span": [0, 11], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 11], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.", "entity_list": [{"name": "spasticity", "ent_type": "Disease", "char_span": [248, 258], "ent_id": "D009128", "tok_span": [50, 53]}, {"name": "tizanidine", "ent_type": "Chemical", "char_span": [195, 205], "ent_id": "C023754", "tok_span": [34, 39]}, {"name": "lisinopril", "ent_type": "Chemical", "char_span": [63, 73], "ent_id": "D017706", "tok_span": [13, 17]}, {"name": "angiotensin", "ent_type": "Chemical", "char_span": [78, 89], "ent_id": "D000809", "tok_span": [19, 20]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [157, 168], "ent_id": "D007022", "tok_span": [29, 30]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [130, 142], "ent_id": "D006973", "tok_span": [26, 27]}], "relation_list": [{"subject": "lisinopril", "object": "hypotension", "sbj_char_span": [63, 73], "obj_char_span": [157, 168], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [29, 30]}, {"subject": "tizanidine", "object": "hypotension", "sbj_char_span": [195, 205], "obj_char_span": [157, 168], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 39], "obj_tok_span": [29, 30]}], "umls_entity_list": []}, {"text": "These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.", "entity_list": [{"name": "thrombotic microangiopathy", "ent_type": "Disease", "char_span": [51, 77], "ent_id": "D057049", "tok_span": [8, 13]}, {"name": "glomerulonephritis", "ent_type": "Disease", "char_span": [135, 153], "ent_id": "D005921", "tok_span": [31, 36]}, {"name": "Henoch-Schonlein nephritis", "ent_type": "Disease", "char_span": [96, 122], "ent_id": "D011695", "tok_span": [18, 26]}, {"name": "acute renal failure", "ent_type": "Disease", "char_span": [175, 194], "ent_id": "D058186", "tok_span": [41, 44]}, {"name": "malignant hypertension", "ent_type": "Disease", "char_span": [27, 49], "ent_id": "D006974", "tok_span": [5, 7]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [159, 166], "ent_id": "D003042", "tok_span": [38, 39]}, {"name": "lupus nephritis", "ent_type": "Disease", "char_span": [79, 94], "ent_id": "D008181", "tok_span": [14, 17]}], "relation_list": [{"subject": "cocaine", "object": "acute renal failure", "sbj_char_span": [159, 166], "obj_char_span": [175, 194], "rel_type": "chemical-induced disease", "sbj_tok_span": [38, 39], "obj_tok_span": [41, 44]}], "umls_entity_list": []}, {"text": "In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated cocaine-induced convulsions and lethality.", "entity_list": [{"name": "BD1063", "ent_type": "Chemical", "char_span": [58, 64], "ent_id": "C093337", "tok_span": [14, 17]}, {"name": "convulsions", "ent_type": "Disease", "char_span": [116, 127], "ent_id": "D012640", "tok_span": [26, 29]}, {"name": "LR132", "ent_type": "Chemical", "char_span": [69, 74], "ent_id": "-1", "tok_span": [19, 21]}, {"name": "BD1018", "ent_type": "Chemical", "char_span": [50, 56], "ent_id": "-1", "tok_span": [10, 13]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [100, 107], "ent_id": "D003042", "tok_span": [23, 24]}], "relation_list": [{"subject": "cocaine", "object": "convulsions", "sbj_char_span": [100, 107], "obj_char_span": [116, 127], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 24], "obj_tok_span": [26, 29]}], "umls_entity_list": []}, {"text": "To further validate the hypothesis that the anti-cocaine effects of the novel ligands involved antagonism of sigma receptors, an antisense oligodeoxynucleotide against sigma1 receptors was also shown to significantly attenuate the convulsive and locomotor stimulatory effects of cocaine.", "entity_list": [{"name": "oligodeoxynucleotide", "ent_type": "Chemical", "char_span": [139, 159], "ent_id": "D009838", "tok_span": [24, 29]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [49, 56], "ent_id": "D003042", "tok_span": [9, 10]}, {"name": "convulsive", "ent_type": "Disease", "char_span": [231, 241], "ent_id": "D012640", "tok_span": [40, 42]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [279, 286], "ent_id": "D003042", "tok_span": [48, 49]}], "relation_list": [{"subject": "cocaine", "object": "convulsive", "sbj_char_span": [49, 56], "obj_char_span": [231, 241], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [40, 42]}, {"subject": "cocaine", "object": "convulsive", "sbj_char_span": [279, 286], "obj_char_span": [231, 241], "rel_type": "chemical-induced disease", "sbj_tok_span": [48, 49], "obj_tok_span": [40, 42]}], "umls_entity_list": []}, {"text": "TDP is a side-effect that has led to withdrawal of several drugs from the market (e.g. terfenadine and terodiline). 2.", "entity_list": [{"name": "terfenadine", "ent_type": "Chemical", "char_span": [87, 98], "ent_id": "D016593", "tok_span": [23, 27]}, {"name": "terodiline", "ent_type": "Chemical", "char_span": [103, 113], "ent_id": "C010637", "tok_span": [28, 31]}, {"name": "TDP", "ent_type": "Disease", "char_span": [0, 3], "ent_id": "D016171", "tok_span": [0, 2]}], "relation_list": [{"subject": "terodiline", "object": "TDP", "sbj_char_span": [103, 113], "obj_char_span": [0, 3], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 31], "obj_tok_span": [0, 2]}, {"subject": "terfenadine", "object": "TDP", "sbj_char_span": [87, 98], "obj_char_span": [0, 3], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 27], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.", "entity_list": [{"name": "cisapride", "ent_type": "Chemical", "char_span": [103, 112], "ent_id": "D020117", "tok_span": [23, 27]}, {"name": "terfenadine", "ent_type": "Chemical", "char_span": [78, 89], "ent_id": "D016593", "tok_span": [14, 18]}, {"name": "TDP", "ent_type": "Disease", "char_span": [55, 58], "ent_id": "D016171", "tok_span": [9, 11]}, {"name": "E4031", "ent_type": "Chemical", "char_span": [117, 122], "ent_id": "C063968", "tok_span": [28, 31]}, {"name": "terodiline", "ent_type": "Chemical", "char_span": [91, 101], "ent_id": "C010637", "tok_span": [19, 22]}], "relation_list": [{"subject": "terfenadine", "object": "TDP", "sbj_char_span": [78, 89], "obj_char_span": [55, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 18], "obj_tok_span": [9, 11]}, {"subject": "terodiline", "object": "TDP", "sbj_char_span": [91, 101], "obj_char_span": [55, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 22], "obj_tok_span": [9, 11]}, {"subject": "cisapride", "object": "TDP", "sbj_char_span": [103, 112], "obj_char_span": [55, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 27], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "For compounds that have shown TDP in the clinic (terfenadine, terodiline, cisapride) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man (< 10-fold) reflecting their limited safety margins.", "entity_list": [{"name": "cisapride", "ent_type": "Chemical", "char_span": [74, 83], "ent_id": "D020117", "tok_span": [20, 24]}, {"name": "terfenadine", "ent_type": "Chemical", "char_span": [49, 60], "ent_id": "D016593", "tok_span": [11, 15]}, {"name": "terodiline", "ent_type": "Chemical", "char_span": [62, 72], "ent_id": "C010637", "tok_span": [16, 19]}, {"name": "TDP", "ent_type": "Disease", "char_span": [30, 33], "ent_id": "D016171", "tok_span": [5, 7]}], "relation_list": [{"subject": "terfenadine", "object": "TDP", "sbj_char_span": [49, 60], "obj_char_span": [30, 33], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [5, 7]}, {"subject": "cisapride", "object": "TDP", "sbj_char_span": [74, 83], "obj_char_span": [30, 33], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 24], "obj_tok_span": [5, 7]}, {"subject": "terodiline", "object": "TDP", "sbj_char_span": [62, 72], "obj_char_span": [30, 33], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "Intravenous administration of prochlorperazine by 15-minute infusion versus 2-minute bolus does not affect the incidence of akathisia: a prospective, randomized, controlled trial.", "entity_list": [{"name": "prochlorperazine", "ent_type": "Chemical", "char_span": [30, 46], "ent_id": "D011346", "tok_span": [5, 11]}, {"name": "akathisia", "ent_type": "Disease", "char_span": [124, 133], "ent_id": "D017109", "tok_span": [27, 31]}], "relation_list": [{"subject": "prochlorperazine", "object": "akathisia", "sbj_char_span": [30, 46], "obj_char_span": [124, 133], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 11], "obj_tok_span": [27, 31]}], "umls_entity_list": []}, {"text": "STUDY OBJECTIVE: We sought to compare the rate of akathisia after administration of intravenous prochlorperazine as a 2-minute bolus or 15-minute infusion.", "entity_list": [{"name": "akathisia", "ent_type": "Disease", "char_span": [50, 59], "ent_id": "D017109", "tok_span": [10, 14]}, {"name": "prochlorperazine", "ent_type": "Chemical", "char_span": [96, 112], "ent_id": "D011346", "tok_span": [18, 24]}], "relation_list": [{"subject": "prochlorperazine", "object": "akathisia", "sbj_char_span": [96, 112], "obj_char_span": [50, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 24], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "CONCLUSION: A 50% reduction in the incidence of akathisia when prochlorperazine was administered by means of 15-minute intravenous infusion versus a 2-minute intravenous push was not detected.", "entity_list": [{"name": "akathisia", "ent_type": "Disease", "char_span": [48, 57], "ent_id": "D017109", "tok_span": [10, 14]}, {"name": "prochlorperazine", "ent_type": "Chemical", "char_span": [63, 79], "ent_id": "D011346", "tok_span": [15, 21]}], "relation_list": [{"subject": "prochlorperazine", "object": "akathisia", "sbj_char_span": [63, 79], "obj_char_span": [48, 57], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 21], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "Antithymocyte globulin in the treatment of D-penicillamine-induced aplastic anemia.", "entity_list": [{"name": "D-penicillamine", "ent_type": "Chemical", "char_span": [43, 58], "ent_id": "D010396", "tok_span": [11, 18]}, {"name": "aplastic anemia", "ent_type": "Disease", "char_span": [67, 82], "ent_id": "D000741", "tok_span": [20, 23]}, {"name": "Antithymocyte globulin", "ent_type": "Chemical", "char_span": [0, 22], "ent_id": "D000961", "tok_span": [0, 7]}], "relation_list": [{"subject": "D-penicillamine", "object": "aplastic anemia", "sbj_char_span": [43, 58], "obj_char_span": [67, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 18], "obj_tok_span": [20, 23]}], "umls_entity_list": []}, {"text": "A patient who received antithymocyte globulin therapy for aplastic anemia due to D-penicillamine therapy is described.", "entity_list": [{"name": "aplastic anemia", "ent_type": "Disease", "char_span": [58, 73], "ent_id": "D000741", "tok_span": [13, 16]}, {"name": "D-penicillamine", "ent_type": "Chemical", "char_span": [81, 96], "ent_id": "D010396", "tok_span": [18, 25]}, {"name": "antithymocyte globulin", "ent_type": "Chemical", "char_span": [23, 45], "ent_id": "D000961", "tok_span": [4, 11]}], "relation_list": [{"subject": "D-penicillamine", "object": "aplastic anemia", "sbj_char_span": [81, 96], "obj_char_span": [58, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 25], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "Use of antithymocyte globulin may be the optimal treatment of D-penicillamine-induced aplastic anemia.", "entity_list": [{"name": "antithymocyte globulin", "ent_type": "Chemical", "char_span": [7, 29], "ent_id": "D000961", "tok_span": [2, 9]}, {"name": "aplastic anemia", "ent_type": "Disease", "char_span": [86, 101], "ent_id": "D000741", "tok_span": [24, 27]}, {"name": "D-penicillamine", "ent_type": "Chemical", "char_span": [62, 77], "ent_id": "D010396", "tok_span": [15, 22]}], "relation_list": [{"subject": "D-penicillamine", "object": "aplastic anemia", "sbj_char_span": [62, 77], "obj_char_span": [86, 101], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 22], "obj_tok_span": [24, 27]}], "umls_entity_list": []}, {"text": "RESULTS: Sensitivity to several convulsion endpoints induced by nicotine, carbachol, and neostigmine were significantly greater in WSR versus WSP mice.", "entity_list": [{"name": "nicotine", "ent_type": "Chemical", "char_span": [64, 72], "ent_id": "D009538", "tok_span": [10, 11]}, {"name": "neostigmine", "ent_type": "Chemical", "char_span": [89, 100], "ent_id": "D009388", "tok_span": [17, 21]}, {"name": "carbachol", "ent_type": "Chemical", "char_span": [74, 83], "ent_id": "D002217", "tok_span": [12, 15]}, {"name": "convulsion", "ent_type": "Disease", "char_span": [32, 42], "ent_id": "D012640", "tok_span": [5, 7]}], "relation_list": [{"subject": "neostigmine", "object": "convulsion", "sbj_char_span": [89, 100], "obj_char_span": [32, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [5, 7]}, {"subject": "carbachol", "object": "convulsion", "sbj_char_span": [74, 83], "obj_char_span": [32, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [5, 7]}, {"subject": "nicotine", "object": "convulsion", "sbj_char_span": [64, 72], "obj_char_span": [32, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "Prenatal dexamethasone programs hypertension and renal injury in the rat.", "entity_list": [{"name": "hypertension", "ent_type": "Disease", "char_span": [32, 44], "ent_id": "D006973", "tok_span": [4, 5]}, {"name": "renal injury", "ent_type": "Disease", "char_span": [49, 61], "ent_id": "D007674", "tok_span": [6, 8]}, {"name": "dexamethasone", "ent_type": "Chemical", "char_span": [9, 22], "ent_id": "D003907", "tok_span": [2, 3]}], "relation_list": [{"subject": "dexamethasone", "object": "renal injury", "sbj_char_span": [9, 22], "obj_char_span": [49, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 3], "obj_tok_span": [6, 8]}, {"subject": "dexamethasone", "object": "hypertension", "sbj_char_span": [9, 22], "obj_char_span": [32, 44], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 3], "obj_tok_span": [4, 5]}], "umls_entity_list": []}, {"text": "The purpose of the present study was to determine if prenatal dexamethasone programmed a progressive increase in blood pressure and renal injury in rats.", "entity_list": [{"name": "dexamethasone", "ent_type": "Chemical", "char_span": [62, 75], "ent_id": "D003907", "tok_span": [11, 12]}, {"name": "renal injury", "ent_type": "Disease", "char_span": [132, 144], "ent_id": "D007674", "tok_span": [20, 22]}, {"name": "increase in blood pressure", "ent_type": "Disease", "char_span": [101, 127], "ent_id": "D006973", "tok_span": [15, 19]}], "relation_list": [{"subject": "dexamethasone", "object": "increase in blood pressure", "sbj_char_span": [62, 75], "obj_char_span": [101, 127], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [15, 19]}, {"subject": "dexamethasone", "object": "renal injury", "sbj_char_span": [62, 75], "obj_char_span": [132, 144], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [20, 22]}], "umls_entity_list": []}, {"text": "Offspring of rats administered dexamethasone on days 15 and 16 gestation had a 20% reduction in glomerular number compared with control at 6 to 9 months of age (22 527+/-509 versus 28 050+/-561, P<0.05), which was comparable to the percent reduction in glomeruli measured at 3 weeks of age.", "entity_list": [{"name": "reduction in glomerular number", "ent_type": "Disease", "char_span": [83, 113], "ent_id": "D007674", "tok_span": [16, 20]}, {"name": "dexamethasone", "ent_type": "Chemical", "char_span": [31, 44], "ent_id": "D003907", "tok_span": [5, 6]}], "relation_list": [{"subject": "dexamethasone", "object": "reduction in glomerular number", "sbj_char_span": [31, 44], "obj_char_span": [83, 113], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 6], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "Male rats that received prenatal dexamethasone on days 15 and 16, 17 and 18, and 13 and 14 of gestation had elevated blood pressures at 6 months of age; the latter group did not have a reduction in glomerular number.", "entity_list": [{"name": "reduction in glomerular number", "ent_type": "Disease", "char_span": [185, 215], "ent_id": "D007674", "tok_span": [39, 43]}, {"name": "elevated blood pressures", "ent_type": "Disease", "char_span": [108, 132], "ent_id": "D006973", "tok_span": [23, 26]}, {"name": "dexamethasone", "ent_type": "Chemical", "char_span": [33, 46], "ent_id": "D003907", "tok_span": [5, 6]}], "relation_list": [{"subject": "dexamethasone", "object": "reduction in glomerular number", "sbj_char_span": [33, 46], "obj_char_span": [185, 215], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 6], "obj_tok_span": [39, 43]}, {"subject": "dexamethasone", "object": "elevated blood pressures", "sbj_char_span": [33, 46], "obj_char_span": [108, 132], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 6], "obj_tok_span": [23, 26]}], "umls_entity_list": []}, {"text": "This study shows that prenatal dexamethasone in rats results in a reduction in glomerular number, glomerulosclerosis, and hypertension when administered at specific points during gestation.", "entity_list": [{"name": "glomerulosclerosis", "ent_type": "Disease", "char_span": [98, 116], "ent_id": "D005921", "tok_span": [16, 20]}, {"name": "reduction in glomerular number", "ent_type": "Disease", "char_span": [66, 96], "ent_id": "D007674", "tok_span": [11, 15]}, {"name": "dexamethasone", "ent_type": "Chemical", "char_span": [31, 44], "ent_id": "D003907", "tok_span": [5, 6]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [122, 134], "ent_id": "D006973", "tok_span": [22, 23]}], "relation_list": [{"subject": "dexamethasone", "object": "hypertension", "sbj_char_span": [31, 44], "obj_char_span": [122, 134], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 6], "obj_tok_span": [22, 23]}, {"subject": "dexamethasone", "object": "reduction in glomerular number", "sbj_char_span": [31, 44], "obj_char_span": [66, 96], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 6], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.", "entity_list": [{"name": "venous thromboembolism", "ent_type": "Disease", "char_span": [12, 34], "ent_id": "D054556", "tok_span": [3, 6]}, {"name": "cyproterone acetate", "ent_type": "Chemical", "char_span": [55, 74], "ent_id": "D017373", "tok_span": [9, 14]}, {"name": "ethinyl estradiol", "ent_type": "Chemical", "char_span": [95, 112], "ent_id": "D004997", "tok_span": [17, 21]}], "relation_list": [{"subject": "cyproterone acetate", "object": "venous thromboembolism", "sbj_char_span": [55, 74], "obj_char_span": [12, 34], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 14], "obj_tok_span": [3, 6]}, {"subject": "ethinyl estradiol", "object": "venous thromboembolism", "sbj_char_span": [95, 112], "obj_char_span": [12, 34], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [3, 6]}], "umls_entity_list": []}, {"text": "Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).", "entity_list": [{"name": "EE", "ent_type": "Chemical", "char_span": [105, 107], "ent_id": "D004997", "tok_span": [20, 21]}, {"name": "CPA", "ent_type": "Chemical", "char_span": [101, 104], "ent_id": "D017373", "tok_span": [17, 19]}, {"name": "VTE", "ent_type": "Disease", "char_span": [80, 83], "ent_id": "D054556", "tok_span": [12, 14]}, {"name": "oral contraceptives", "ent_type": "Chemical", "char_span": [144, 163], "ent_id": "D003276", "tok_span": [25, 28]}, {"name": "venous thromboembolism", "ent_type": "Disease", "char_span": [56, 78], "ent_id": "D054556", "tok_span": [8, 11]}], "relation_list": [{"subject": "EE", "object": "venous thromboembolism", "sbj_char_span": [105, 107], "obj_char_span": [56, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 21], "obj_tok_span": [8, 11]}, {"subject": "CPA", "object": "VTE", "sbj_char_span": [101, 104], "obj_char_span": [80, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 19], "obj_tok_span": [12, 14]}, {"subject": "CPA", "object": "venous thromboembolism", "sbj_char_span": [101, 104], "obj_char_span": [56, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 19], "obj_tok_span": [8, 11]}, {"subject": "EE", "object": "VTE", "sbj_char_span": [105, 107], "obj_char_span": [80, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 21], "obj_tok_span": [12, 14]}], "umls_entity_list": []}, {"text": "METHODS: Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.", "entity_list": [{"name": "EE", "ent_type": "Chemical", "char_span": [250, 252], "ent_id": "D004997", "tok_span": [53, 54]}, {"name": "PCOS", "ent_type": "Disease", "char_span": [197, 201], "ent_id": "D011085", "tok_span": [39, 41]}, {"name": "CPA", "ent_type": "Chemical", "char_span": [246, 249], "ent_id": "D017373", "tok_span": [50, 52]}, {"name": "VTE", "ent_type": "Disease", "char_span": [226, 229], "ent_id": "D054556", "tok_span": [46, 48]}, {"name": "acne", "ent_type": "Disease", "char_span": [178, 182], "ent_id": "D000152", "tok_span": [31, 33]}, {"name": "hirsutism", "ent_type": "Disease", "char_span": [184, 193], "ent_id": "D006628", "tok_span": [34, 38]}], "relation_list": [{"subject": "EE", "object": "VTE", "sbj_char_span": [250, 252], "obj_char_span": [226, 229], "rel_type": "chemical-induced disease", "sbj_tok_span": [53, 54], "obj_tok_span": [46, 48]}, {"subject": "CPA", "object": "VTE", "sbj_char_span": [246, 249], "obj_char_span": [226, 229], "rel_type": "chemical-induced disease", "sbj_tok_span": [50, 52], "obj_tok_span": [46, 48]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.", "entity_list": [{"name": "VTE", "ent_type": "Disease", "char_span": [55, 58], "ent_id": "D054556", "tok_span": [9, 11]}, {"name": "hirsutism", "ent_type": "Disease", "char_span": [113, 122], "ent_id": "D006628", "tok_span": [26, 30]}, {"name": "EE", "ent_type": "Chemical", "char_span": [90, 92], "ent_id": "D004997", "tok_span": [19, 20]}, {"name": "acne", "ent_type": "Disease", "char_span": [107, 111], "ent_id": "D000152", "tok_span": [23, 25]}, {"name": "CPA", "ent_type": "Chemical", "char_span": [86, 89], "ent_id": "D017373", "tok_span": [16, 18]}, {"name": "PCOS", "ent_type": "Disease", "char_span": [126, 130], "ent_id": "D011085", "tok_span": [31, 33]}], "relation_list": [{"subject": "EE", "object": "VTE", "sbj_char_span": [90, 92], "obj_char_span": [55, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 20], "obj_tok_span": [9, 11]}, {"subject": "CPA", "object": "VTE", "sbj_char_span": [86, 89], "obj_char_span": [55, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 18], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB).", "entity_list": [{"name": "flutamide", "ent_type": "Chemical", "char_span": [107, 116], "ent_id": "D005485", "tok_span": [30, 34]}, {"name": "leuprolide acetate", "ent_type": "Chemical", "char_span": [27, 45], "ent_id": "D016729", "tok_span": [5, 10]}, {"name": "LHRH-A", "ent_type": "Chemical", "char_span": [47, 53], "ent_id": "D016729", "tok_span": [11, 15]}, {"name": "anemia", "ent_type": "Disease", "char_span": [154, 160], "ent_id": "D000740", "tok_span": [45, 46]}], "relation_list": [{"subject": "leuprolide acetate", "object": "anemia", "sbj_char_span": [27, 45], "obj_char_span": [154, 160], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 10], "obj_tok_span": [45, 46]}, {"subject": "flutamide", "object": "anemia", "sbj_char_span": [107, 116], "obj_char_span": [154, 160], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 34], "obj_tok_span": [45, 46]}, {"subject": "LHRH-A", "object": "anemia", "sbj_char_span": [47, 53], "obj_char_span": [154, 160], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [45, 46]}], "umls_entity_list": []}, {"text": "Reversible dilated cardiomyopathy related to amphotericin B therapy.", "entity_list": [{"name": "dilated cardiomyopathy", "ent_type": "Disease", "char_span": [11, 33], "ent_id": "D002311", "tok_span": [2, 4]}, {"name": "amphotericin B", "ent_type": "Chemical", "char_span": [45, 59], "ent_id": "D000666", "tok_span": [6, 10]}], "relation_list": [{"subject": "amphotericin B", "object": "dilated cardiomyopathy", "sbj_char_span": [45, 59], "obj_char_span": [11, 33], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 10], "obj_tok_span": [2, 4]}], "umls_entity_list": []}, {"text": "We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.", "entity_list": [{"name": "AmB", "ent_type": "Chemical", "char_span": [144, 147], "ent_id": "D000666", "tok_span": [26, 28]}, {"name": "amphotericin B", "ent_type": "Chemical", "char_span": [128, 142], "ent_id": "D000666", "tok_span": [21, 25]}, {"name": "coccidioidomycosis", "ent_type": "Disease", "char_span": [166, 184], "ent_id": "D003047", "tok_span": [31, 37]}, {"name": "heart failure", "ent_type": "Disease", "char_span": [83, 96], "ent_id": "D006333", "tok_span": [13, 15]}, {"name": "dilated cardiomyopathy", "ent_type": "Disease", "char_span": [36, 58], "ent_id": "D002311", "tok_span": [6, 8]}], "relation_list": [{"subject": "amphotericin B", "object": "dilated cardiomyopathy", "sbj_char_span": [128, 142], "obj_char_span": [36, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 25], "obj_tok_span": [6, 8]}, {"subject": "AmB", "object": "dilated cardiomyopathy", "sbj_char_span": [144, 147], "obj_char_span": [36, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 28], "obj_tok_span": [6, 8]}, {"subject": "amphotericin B", "object": "heart failure", "sbj_char_span": [128, 142], "obj_char_span": [83, 96], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 25], "obj_tok_span": [13, 15]}, {"subject": "AmB", "object": "heart failure", "sbj_char_span": [144, 147], "obj_char_span": [83, 96], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 28], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB.", "entity_list": [{"name": "AmB", "ent_type": "Chemical", "char_span": [102, 105], "ent_id": "D000666", "tok_span": [15, 17]}, {"name": "posaconazole", "ent_type": "Chemical", "char_span": [69, 81], "ent_id": "C101425", "tok_span": [9, 12]}, {"name": "heart failure", "ent_type": "Disease", "char_span": [40, 53], "ent_id": "D006333", "tok_span": [5, 7]}], "relation_list": [{"subject": "AmB", "object": "heart failure", "sbj_char_span": [102, 105], "obj_char_span": [40, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 17], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "Numerous anecdotal reports suggest that products containing quinine may produce neurological complications, including confusion, altered mental status, seizures, and coma, particularly in older women.", "entity_list": [{"name": "quinine", "ent_type": "Chemical", "char_span": [60, 67], "ent_id": "D011803", "tok_span": [10, 12]}, {"name": "neurological complications", "ent_type": "Disease", "char_span": [80, 106], "ent_id": "D002493", "tok_span": [14, 16]}, {"name": "coma", "ent_type": "Disease", "char_span": [166, 170], "ent_id": "D003128", "tok_span": [27, 29]}, {"name": "confusion", "ent_type": "Disease", "char_span": [118, 127], "ent_id": "D003221", "tok_span": [18, 19]}, {"name": "seizures", "ent_type": "Disease", "char_span": [152, 160], "ent_id": "D012640", "tok_span": [24, 25]}], "relation_list": [{"subject": "quinine", "object": "confusion", "sbj_char_span": [60, 67], "obj_char_span": [118, 127], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 12], "obj_tok_span": [18, 19]}, {"subject": "quinine", "object": "coma", "sbj_char_span": [60, 67], "obj_char_span": [166, 170], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 12], "obj_tok_span": [27, 29]}, {"subject": "quinine", "object": "seizures", "sbj_char_span": [60, 67], "obj_char_span": [152, 160], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 12], "obj_tok_span": [24, 25]}], "umls_entity_list": []}, {"text": "In sham-operated rats, rilmenidine or alpha-methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure.", "entity_list": [{"name": "alpha-methyldopa", "ent_type": "Chemical", "char_span": [38, 54], "ent_id": "D008750", "tok_span": [12, 17]}, {"name": "rilmenidine", "ent_type": "Chemical", "char_span": [23, 34], "ent_id": "C032302", "tok_span": [6, 11]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [72, 83], "ent_id": "D007022", "tok_span": [19, 20]}], "relation_list": [{"subject": "alpha-methyldopa", "object": "hypotension", "sbj_char_span": [38, 54], "obj_char_span": [72, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 17], "obj_tok_span": [19, 20]}, {"subject": "rilmenidine", "object": "hypotension", "sbj_char_span": [23, 34], "obj_char_span": [72, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 11], "obj_tok_span": [19, 20]}], "umls_entity_list": []}, {"text": "Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on rilmenidine hypotension.", "entity_list": [{"name": "hypotension", "ent_type": "Disease", "char_span": [113, 124], "ent_id": "D007022", "tok_span": [26, 27]}, {"name": "rilmenidine", "ent_type": "Chemical", "char_span": [101, 112], "ent_id": "C032302", "tok_span": [21, 26]}, {"name": "alpha-methyldopa", "ent_type": "Chemical", "char_span": [55, 71], "ent_id": "D008750", "tok_span": [9, 14]}, {"name": "hypotensive", "ent_type": "Disease", "char_span": [31, 42], "ent_id": "D007022", "tok_span": [5, 7]}], "relation_list": [{"subject": "alpha-methyldopa", "object": "hypotensive", "sbj_char_span": [55, 71], "obj_char_span": [31, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 14], "obj_tok_span": [5, 7]}, {"subject": "rilmenidine", "object": "hypotension", "sbj_char_span": [101, 112], "obj_char_span": [113, 124], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 26], "obj_tok_span": [26, 27]}, {"subject": "rilmenidine", "object": "hypotensive", "sbj_char_span": [101, 112], "obj_char_span": [31, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 26], "obj_tok_span": [5, 7]}, {"subject": "alpha-methyldopa", "object": "hypotension", "sbj_char_span": [55, 71], "obj_char_span": [113, 124], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 14], "obj_tok_span": [26, 27]}], "umls_entity_list": []}, {"text": "The enhanced alpha-methyldopa hypotension in Ovx rats was paralleled with further reduction in SDRR and a reduced locomotor activity.", "entity_list": [{"name": "a reduced locomotor activity", "ent_type": "Disease", "char_span": [104, 132], "ent_id": "D001523", "tok_span": [22, 26]}, {"name": "alpha-methyldopa", "ent_type": "Chemical", "char_span": [13, 29], "ent_id": "D008750", "tok_span": [2, 7]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [30, 41], "ent_id": "D007022", "tok_span": [7, 8]}], "relation_list": [{"subject": "alpha-methyldopa", "object": "hypotension", "sbj_char_span": [13, 29], "obj_char_span": [30, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 7], "obj_tok_span": [7, 8]}], "umls_entity_list": []}, {"text": "These findings suggest that estrogen downregulates alpha2- but not I1-receptor-mediated hypotension and highlight a role for the cardiac autonomic control in alpha-methyldopa-estrogen interaction.", "entity_list": [{"name": "estrogen", "ent_type": "Chemical", "char_span": [175, 183], "ent_id": "D004967", "tok_span": [36, 37]}, {"name": "alpha-methyldopa", "ent_type": "Chemical", "char_span": [158, 174], "ent_id": "D008750", "tok_span": [30, 35]}, {"name": "estrogen", "ent_type": "Chemical", "char_span": [28, 36], "ent_id": "D004967", "tok_span": [4, 5]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [88, 99], "ent_id": "D007022", "tok_span": [19, 20]}], "relation_list": [{"subject": "alpha-methyldopa", "object": "hypotension", "sbj_char_span": [158, 174], "obj_char_span": [88, 99], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 35], "obj_tok_span": [19, 20]}], "umls_entity_list": []}, {"text": "Cardioprotective effect of tincture of Crataegus on isoproterenol-induced myocardial infarction in rats.", "entity_list": [{"name": "tincture of Crataegus", "ent_type": "Chemical", "char_span": [27, 48], "ent_id": "C007145", "tok_span": [4, 12]}, {"name": "myocardial infarction", "ent_type": "Disease", "char_span": [74, 95], "ent_id": "D009203", "tok_span": [19, 21]}, {"name": "isoproterenol", "ent_type": "Chemical", "char_span": [52, 65], "ent_id": "D007545", "tok_span": [13, 17]}], "relation_list": [{"subject": "isoproterenol", "object": "myocardial infarction", "sbj_char_span": [52, 65], "obj_char_span": [74, 95], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [19, 21]}], "umls_entity_list": []}, {"text": "RESULTS: During a mean follow-up of 3.3 years, raloxifene was associated with an increased risk for venous thromboembolism (relative risk [RR] 2.1; 95% confidence interval [CI] 1.2-3.8).", "entity_list": [{"name": "venous thromboembolism", "ent_type": "Disease", "char_span": [100, 122], "ent_id": "D054556", "tok_span": [26, 29]}, {"name": "raloxifene", "ent_type": "Chemical", "char_span": [47, 57], "ent_id": "D020849", "tok_span": [14, 19]}], "relation_list": [{"subject": "raloxifene", "object": "venous thromboembolism", "sbj_char_span": [47, 57], "obj_char_span": [100, 122], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 19], "obj_tok_span": [26, 29]}], "umls_entity_list": []}, {"text": "CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.", "entity_list": [{"name": "cataracts", "ent_type": "Disease", "char_span": [125, 134], "ent_id": "D002386", "tok_span": [25, 27]}, {"name": "gallbladder disease", "ent_type": "Disease", "char_span": [136, 155], "ent_id": "D005705", "tok_span": [28, 31]}, {"name": "endometrial hyperplasia", "ent_type": "Disease", "char_span": [157, 180], "ent_id": "D004714", "tok_span": [32, 34]}, {"name": "Raloxifene", "ent_type": "Chemical", "char_span": [12, 22], "ent_id": "D020849", "tok_span": [2, 7]}, {"name": "endometrial cancer", "ent_type": "Disease", "char_span": [185, 203], "ent_id": "D016889", "tok_span": [36, 38]}, {"name": "venous thromboembolism", "ent_type": "Disease", "char_span": [65, 87], "ent_id": "D054556", "tok_span": [14, 17]}], "relation_list": [{"subject": "Raloxifene", "object": "venous thromboembolism", "sbj_char_span": [12, 22], "obj_char_span": [65, 87], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 7], "obj_tok_span": [14, 17]}], "umls_entity_list": []}, {"text": "Ceftriaxone-associated biliary pseudolithiasis in paediatric surgical patients.", "entity_list": [{"name": "Ceftriaxone", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D002443", "tok_span": [0, 5]}, {"name": "biliary pseudolithiasis", "ent_type": "Disease", "char_span": [23, 46], "ent_id": "D001660", "tok_span": [7, 12]}], "relation_list": [{"subject": "Ceftriaxone", "object": "biliary pseudolithiasis", "sbj_char_span": [0, 11], "obj_char_span": [23, 46], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [7, 12]}], "umls_entity_list": []}, {"text": "It is well known that ceftriaxone leads to pseudolithiasis in some patients.", "entity_list": [{"name": "pseudolithiasis", "ent_type": "Disease", "char_span": [43, 58], "ent_id": "D001660", "tok_span": [11, 15]}, {"name": "ceftriaxone", "ent_type": "Chemical", "char_span": [22, 33], "ent_id": "D002443", "tok_span": [5, 9]}], "relation_list": [{"subject": "ceftriaxone", "object": "pseudolithiasis", "sbj_char_span": [22, 33], "obj_char_span": [43, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "In this study, we prospectively evaluated the incidence and clinical importance of pseudolithiasis in paediatric surgical patients receiving ceftriaxone treatment, who often had to fast in the post-operative period.", "entity_list": [{"name": "ceftriaxone", "ent_type": "Chemical", "char_span": [141, 152], "ent_id": "D002443", "tok_span": [22, 26]}, {"name": "pseudolithiasis", "ent_type": "Disease", "char_span": [83, 98], "ent_id": "D001660", "tok_span": [13, 17]}], "relation_list": [{"subject": "ceftriaxone", "object": "pseudolithiasis", "sbj_char_span": [141, 152], "obj_char_span": [83, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 26], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "Significant blockade of cocaine toxicity was observed with the higher dose of GNC92H2 (190 mg/kg), where premorbid behaviors were reduced up to 40%, seizures up to 77% and death by 72%.", "entity_list": [{"name": "death", "ent_type": "Disease", "char_span": [172, 177], "ent_id": "D003643", "tok_span": [41, 42]}, {"name": "seizures", "ent_type": "Disease", "char_span": [149, 157], "ent_id": "D012640", "tok_span": [35, 36]}, {"name": "GNC92H2", "ent_type": "Chemical", "char_span": [78, 85], "ent_id": "-1", "tok_span": [12, 17]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [24, 31], "ent_id": "D003042", "tok_span": [3, 4]}, {"name": "toxicity", "ent_type": "Disease", "char_span": [32, 40], "ent_id": "D064420", "tok_span": [4, 5]}], "relation_list": [{"subject": "cocaine", "object": "seizures", "sbj_char_span": [24, 31], "obj_char_span": [149, 157], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [35, 36]}], "umls_entity_list": []}, {"text": "CONCLUSION: We suggest that the increased risk of venous thromboembolism due to raloxifene treatment may be related to increased tPA levels, but not TAFI levels.", "entity_list": [{"name": "venous thromboembolism", "ent_type": "Disease", "char_span": [50, 72], "ent_id": "D054556", "tok_span": [9, 12]}, {"name": "raloxifene", "ent_type": "Chemical", "char_span": [80, 90], "ent_id": "D020849", "tok_span": [14, 19]}], "relation_list": [{"subject": "raloxifene", "object": "venous thromboembolism", "sbj_char_span": [80, 90], "obj_char_span": [50, 72], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 19], "obj_tok_span": [9, 12]}], "umls_entity_list": []}, {"text": "Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug.", "entity_list": [{"name": "Ketoconazole", "ent_type": "Chemical", "char_span": [0, 12], "ent_id": "D007654", "tok_span": [0, 5]}, {"name": "torsades de pointes", "ent_type": "Disease", "char_span": [21, 40], "ent_id": "D016171", "tok_span": [6, 11]}], "relation_list": [{"subject": "Ketoconazole", "object": "torsades de pointes", "sbj_char_span": [0, 12], "obj_char_span": [21, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [6, 11]}], "umls_entity_list": []}, {"text": "We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.", "entity_list": [{"name": "TdP", "ent_type": "Disease", "char_span": [119, 122], "ent_id": "D016171", "tok_span": [22, 25]}, {"name": "ketoconazole", "ent_type": "Chemical", "char_span": [137, 149], "ent_id": "D007654", "tok_span": [28, 31]}, {"name": "fungal infection", "ent_type": "Disease", "char_span": [167, 183], "ent_id": "D009181", "tok_span": [34, 36]}, {"name": "torsades de pointes", "ent_type": "Disease", "char_span": [98, 117], "ent_id": "D016171", "tok_span": [16, 21]}, {"name": "coronary artery disease", "ent_type": "Disease", "char_span": [23, 46], "ent_id": "D003324", "tok_span": [5, 8]}, {"name": "prolonged QT interval", "ent_type": "Disease", "char_span": [72, 93], "ent_id": "D008133", "tok_span": [12, 15]}], "relation_list": [{"subject": "ketoconazole", "object": "torsades de pointes", "sbj_char_span": [137, 149], "obj_char_span": [98, 117], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 31], "obj_tok_span": [16, 21]}, {"subject": "ketoconazole", "object": "TdP", "sbj_char_span": [137, 149], "obj_char_span": [119, 122], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 31], "obj_tok_span": [22, 25]}, {"subject": "ketoconazole", "object": "prolonged QT interval", "sbj_char_span": [137, 149], "obj_char_span": [72, 93], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 31], "obj_tok_span": [12, 15]}], "umls_entity_list": []}, {"text": "We postulate that by virtue of its direct blocking action on IKr, ketoconazole alone may prolong QT interval and induce TdP.", "entity_list": [{"name": "TdP", "ent_type": "Disease", "char_span": [120, 123], "ent_id": "D016171", "tok_span": [25, 28]}, {"name": "ketoconazole", "ent_type": "Chemical", "char_span": [66, 78], "ent_id": "D007654", "tok_span": [15, 18]}], "relation_list": [{"subject": "ketoconazole", "object": "TdP", "sbj_char_span": [66, 78], "obj_char_span": [120, 123], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [25, 28]}], "umls_entity_list": []}, {"text": "This calls for attention when ketoconazole is administered to patients with risk factors for acquired long QT syndrome.", "entity_list": [{"name": "ketoconazole", "ent_type": "Chemical", "char_span": [30, 42], "ent_id": "D007654", "tok_span": [5, 8]}, {"name": "long QT syndrome", "ent_type": "Disease", "char_span": [102, 118], "ent_id": "D008133", "tok_span": [17, 20]}], "relation_list": [{"subject": "ketoconazole", "object": "long QT syndrome", "sbj_char_span": [30, 42], "obj_char_span": [102, 118], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [17, 20]}], "umls_entity_list": []}, {"text": "Diazepam-, scopolamine- and ageing-induced amnesia served as the interoceptive behavioral models.", "entity_list": [{"name": "Diazepam", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D003975", "tok_span": [0, 3]}, {"name": "amnesia", "ent_type": "Disease", "char_span": [43, 50], "ent_id": "D000647", "tok_span": [13, 16]}, {"name": "scopolamine", "ent_type": "Chemical", "char_span": [11, 22], "ent_id": "D012601", "tok_span": [5, 8]}], "relation_list": [{"subject": "Diazepam", "object": "amnesia", "sbj_char_span": [0, 8], "obj_char_span": [43, 50], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [13, 16]}, {"subject": "scopolamine", "object": "amnesia", "sbj_char_span": [11, 22], "obj_char_span": [43, 50], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "Furthermore, DCE reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.).", "entity_list": [{"name": "DCE", "ent_type": "Chemical", "char_span": [13, 16], "ent_id": "D010936", "tok_span": [2, 4]}, {"name": "diazepam", "ent_type": "Chemical", "char_span": [83, 91], "ent_id": "D003975", "tok_span": [28, 31]}, {"name": "scopolamine", "ent_type": "Chemical", "char_span": [49, 60], "ent_id": "D012601", "tok_span": [11, 14]}, {"name": "amnesia", "ent_type": "Disease", "char_span": [30, 37], "ent_id": "D000647", "tok_span": [6, 9]}], "relation_list": [{"subject": "diazepam", "object": "amnesia", "sbj_char_span": [83, 91], "obj_char_span": [30, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 31], "obj_tok_span": [6, 9]}, {"subject": "scopolamine", "object": "amnesia", "sbj_char_span": [49, 60], "obj_char_span": [30, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [6, 9]}], "umls_entity_list": []}, {"text": "The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine.", "entity_list": [{"name": "bupivacaine", "ent_type": "Chemical", "char_span": [115, 126], "ent_id": "D002045", "tok_span": [23, 27]}, {"name": "triamcinolone", "ent_type": "Chemical", "char_span": [97, 110], "ent_id": "D014221", "tok_span": [18, 22]}, {"name": "cauda equina syndrome", "ent_type": "Disease", "char_span": [34, 55], "ent_id": "D011128", "tok_span": [7, 12]}], "relation_list": [{"subject": "bupivacaine", "object": "cauda equina syndrome", "sbj_char_span": [115, 126], "obj_char_span": [34, 55], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 27], "obj_tok_span": [7, 12]}], "umls_entity_list": []}, {"text": "High-dose testosterone is associated with atherosclerosis in postmenopausal women.", "entity_list": [{"name": "testosterone", "ent_type": "Chemical", "char_span": [10, 22], "ent_id": "D013739", "tok_span": [3, 4]}, {"name": "atherosclerosis", "ent_type": "Disease", "char_span": [42, 57], "ent_id": "D050197", "tok_span": [7, 8]}], "relation_list": [{"subject": "testosterone", "object": "atherosclerosis", "sbj_char_span": [10, 22], "obj_char_span": [42, 57], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [7, 8]}], "umls_entity_list": []}, {"text": "METHODS: In a population-based study in 513 naturally postmenopausal women aged 54-67 years, we studied the association between self-reported intramuscularly administered high-dose estrogen-testosterone therapy (estradiol- and testosterone esters) and aortic atherosclerosis.", "entity_list": [{"name": "atherosclerosis", "ent_type": "Disease", "char_span": [259, 274], "ent_id": "D050197", "tok_span": [47, 48]}, {"name": "testosterone", "ent_type": "Chemical", "char_span": [190, 202], "ent_id": "D013739", "tok_span": [36, 37]}, {"name": "estradiol- and testosterone esters", "ent_type": "Chemical", "char_span": [212, 246], "ent_id": "C032109", "tok_span": [39, 44]}, {"name": "estrogen", "ent_type": "Chemical", "char_span": [181, 189], "ent_id": "D004967", "tok_span": [34, 35]}], "relation_list": [{"subject": "testosterone", "object": "atherosclerosis", "sbj_char_span": [190, 202], "obj_char_span": [259, 274], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 37], "obj_tok_span": [47, 48]}], "umls_entity_list": []}, {"text": "CONCLUSION: Our results suggest that high-dose testosterone therapy may adversely affect atherosclerosis in postmenopausal women and indicate that androgen replacement in these women may not be harmless.", "entity_list": [{"name": "testosterone", "ent_type": "Chemical", "char_span": [47, 59], "ent_id": "D013739", "tok_span": [9, 10]}, {"name": "atherosclerosis", "ent_type": "Disease", "char_span": [89, 104], "ent_id": "D050197", "tok_span": [14, 15]}], "relation_list": [{"subject": "testosterone", "object": "atherosclerosis", "sbj_char_span": [47, 59], "obj_char_span": [89, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [14, 15]}], "umls_entity_list": []}, {"text": "Sirolimus-associated proteinuria and renal dysfunction.", "entity_list": [{"name": "Sirolimus", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D020123", "tok_span": [0, 3]}, {"name": "proteinuria", "ent_type": "Disease", "char_span": [21, 32], "ent_id": "D011507", "tok_span": [5, 6]}, {"name": "renal dysfunction", "ent_type": "Disease", "char_span": [37, 54], "ent_id": "D007674", "tok_span": [7, 9]}], "relation_list": [{"subject": "Sirolimus", "object": "renal dysfunction", "sbj_char_span": [0, 9], "obj_char_span": [37, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [7, 9]}, {"subject": "Sirolimus", "object": "proteinuria", "sbj_char_span": [0, 9], "obj_char_span": [21, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 6]}], "umls_entity_list": []}, {"text": "Sirolimus represents a major therapeutic advance in the prevention of acute renal allograft rejection and chronic allograft nephropathy.", "entity_list": [{"name": "Sirolimus", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D020123", "tok_span": [0, 3]}, {"name": "nephropathy", "ent_type": "Disease", "char_span": [124, 135], "ent_id": "D007674", "tok_span": [19, 20]}], "relation_list": [{"subject": "Sirolimus", "object": "nephropathy", "sbj_char_span": [0, 9], "obj_char_span": [124, 135], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [19, 20]}], "umls_entity_list": []}, {"text": "Because sirolimus does not share the vasomotor renal adverse effects exhibited by calcineurin inhibitors, it has been designated a 'non-nephrotoxic drug'.", "entity_list": [{"name": "sirolimus", "ent_type": "Chemical", "char_span": [8, 17], "ent_id": "D020123", "tok_span": [1, 3]}, {"name": "nephrotoxic", "ent_type": "Disease", "char_span": [136, 147], "ent_id": "D007674", "tok_span": [27, 30]}], "relation_list": [{"subject": "sirolimus", "object": "nephrotoxic", "sbj_char_span": [8, 17], "obj_char_span": [136, 147], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 3], "obj_tok_span": [27, 30]}], "umls_entity_list": []}, {"text": "However, clinical reports suggest that, under some circumstances, sirolimus is associated with proteinuria and acute renal dysfunction.", "entity_list": [{"name": "acute renal dysfunction", "ent_type": "Disease", "char_span": [111, 134], "ent_id": "D058186", "tok_span": [18, 21]}, {"name": "sirolimus", "ent_type": "Chemical", "char_span": [66, 75], "ent_id": "D020123", "tok_span": [11, 13]}, {"name": "proteinuria", "ent_type": "Disease", "char_span": [95, 106], "ent_id": "D011507", "tok_span": [16, 17]}], "relation_list": [{"subject": "sirolimus", "object": "proteinuria", "sbj_char_span": [66, 75], "obj_char_span": [95, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 13], "obj_tok_span": [16, 17]}], "umls_entity_list": []}, {"text": "The mechanisms of sirolimus-associated proteinuria are multifactorial and may be due to an increase in glomerular capillary pressure following calcineurin inhibitor withdrawal.", "entity_list": [{"name": "proteinuria", "ent_type": "Disease", "char_span": [39, 50], "ent_id": "D011507", "tok_span": [7, 8]}, {"name": "sirolimus", "ent_type": "Chemical", "char_span": [18, 27], "ent_id": "D020123", "tok_span": [3, 5]}], "relation_list": [{"subject": "sirolimus", "object": "proteinuria", "sbj_char_span": [18, 27], "obj_char_span": [39, 50], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 5], "obj_tok_span": [7, 8]}], "umls_entity_list": []}, {"text": "Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.", "entity_list": [{"name": "proteinuria", "ent_type": "Disease", "char_span": [234, 245], "ent_id": "D011507", "tok_span": [41, 42]}, {"name": "sirolimus", "ent_type": "Chemical", "char_span": [168, 177], "ent_id": "D020123", "tok_span": [31, 33]}, {"name": "sirolimus", "ent_type": "Chemical", "char_span": [132, 141], "ent_id": "D020123", "tok_span": [22, 24]}, {"name": "proteinuria", "ent_type": "Disease", "char_span": [353, 364], "ent_id": "D011507", "tok_span": [59, 60]}, {"name": "angiotensin", "ent_type": "Chemical", "char_span": [273, 284], "ent_id": "D000809", "tok_span": [48, 49]}, {"name": "angiotensin II", "ent_type": "Chemical", "char_span": [317, 331], "ent_id": "D000804", "tok_span": [54, 56]}], "relation_list": [{"subject": "sirolimus", "object": "proteinuria", "sbj_char_span": [168, 177], "obj_char_span": [353, 364], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 33], "obj_tok_span": [59, 60]}, {"subject": "sirolimus", "object": "proteinuria", "sbj_char_span": [132, 141], "obj_char_span": [353, 364], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 24], "obj_tok_span": [59, 60]}, {"subject": "sirolimus", "object": "proteinuria", "sbj_char_span": [132, 141], "obj_char_span": [234, 245], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 24], "obj_tok_span": [41, 42]}, {"subject": "sirolimus", "object": "proteinuria", "sbj_char_span": [168, 177], "obj_char_span": [234, 245], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 33], "obj_tok_span": [41, 42]}], "umls_entity_list": []}, {"text": "Progressive myopathy with up-regulation of MHC-I associated with statin therapy.", "entity_list": [{"name": "myopathy", "ent_type": "Disease", "char_span": [12, 20], "ent_id": "D009135", "tok_span": [2, 4]}, {"name": "statin", "ent_type": "Chemical", "char_span": [65, 71], "ent_id": "D019821", "tok_span": [14, 15]}], "relation_list": [{"subject": "statin", "object": "myopathy", "sbj_char_span": [65, 71], "obj_char_span": [12, 20], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [2, 4]}], "umls_entity_list": []}, {"text": "Statins can cause a necrotizing myopathy and hyperCKaemia which is reversible on cessation of the drug.", "entity_list": [{"name": "hyperCKaemia", "ent_type": "Disease", "char_span": [45, 57], "ent_id": "-1", "tok_span": [11, 14]}, {"name": "myopathy", "ent_type": "Disease", "char_span": [32, 40], "ent_id": "D009135", "tok_span": [8, 10]}, {"name": "Statins", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "D019821", "tok_span": [0, 2]}], "relation_list": [{"subject": "Statins", "object": "myopathy", "sbj_char_span": [0, 7], "obj_char_span": [32, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "What is less well known is a phenomenon whereby statins may induce a myopathy, which persists or may progress after stopping the drug.", "entity_list": [{"name": "statins", "ent_type": "Chemical", "char_span": [48, 55], "ent_id": "D019821", "tok_span": [9, 10]}, {"name": "myopathy", "ent_type": "Disease", "char_span": [69, 77], "ent_id": "D009135", "tok_span": [13, 15]}], "relation_list": [{"subject": "statins", "object": "myopathy", "sbj_char_span": [48, 55], "obj_char_span": [69, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "These observations suggest that statins may initiate an immune-mediated myopathy that persists after withdrawal of the drug and responds to immunosuppressive therapy.", "entity_list": [{"name": "statins", "ent_type": "Chemical", "char_span": [32, 39], "ent_id": "D019821", "tok_span": [4, 5]}, {"name": "myopathy", "ent_type": "Disease", "char_span": [72, 80], "ent_id": "D009135", "tok_span": [11, 13]}], "relation_list": [{"subject": "statins", "object": "myopathy", "sbj_char_span": [32, 39], "obj_char_span": [72, 80], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [11, 13]}], "umls_entity_list": []}, {"text": "The mechanism of this myopathy is uncertain but may involve the induction by statins of an endoplasmic reticulum stress response with associated up-regulation of MHC-I expression and antigen presentation by muscle fibres.", "entity_list": [{"name": "statins", "ent_type": "Chemical", "char_span": [77, 84], "ent_id": "D019821", "tok_span": [14, 15]}, {"name": "myopathy", "ent_type": "Disease", "char_span": [22, 30], "ent_id": "D009135", "tok_span": [4, 6]}], "relation_list": [{"subject": "statins", "object": "myopathy", "sbj_char_span": [77, 84], "obj_char_span": [22, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "Clonidine-induced bradycardia in conscious alpha2ABC-/- mice was 32.3% (10 microg/kg) and 26.6% (100 microg/kg) of the effect in wild-type mice.", "entity_list": [{"name": "bradycardia", "ent_type": "Disease", "char_span": [18, 29], "ent_id": "D001919", "tok_span": [6, 10]}, {"name": "Clonidine", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D003000", "tok_span": [0, 4]}], "relation_list": [{"subject": "Clonidine", "object": "bradycardia", "sbj_char_span": [0, 9], "obj_char_span": [18, 29], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [6, 10]}], "umls_entity_list": []}, {"text": "The influence of smoking during pregnancy on the developing cochlea has not been estimated, although smoking has been positively associated with hearing loss in adults.", "entity_list": [{"name": "hearing loss", "ent_type": "Disease", "char_span": [145, 157], "ent_id": "D034381", "tok_span": [24, 26]}, {"name": "smoking", "ent_type": "Chemical", "char_span": [17, 24], "ent_id": "D012906", "tok_span": [3, 4]}, {"name": "smoking", "ent_type": "Chemical", "char_span": [101, 108], "ent_id": "D012906", "tok_span": [18, 19]}], "relation_list": [{"subject": "smoking", "object": "hearing loss", "sbj_char_span": [17, 24], "obj_char_span": [145, 157], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [24, 26]}, {"subject": "smoking", "object": "hearing loss", "sbj_char_span": [101, 108], "obj_char_span": [145, 157], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [24, 26]}], "umls_entity_list": []}, {"text": "Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats: implications for autism.", "entity_list": [{"name": "autism", "ent_type": "Disease", "char_span": [110, 116], "ent_id": "D001321", "tok_span": [18, 19]}, {"name": "Neuroinflammation", "ent_type": "Disease", "char_span": [0, 17], "ent_id": "D020078", "tok_span": [0, 4]}, {"name": "terbutaline", "ent_type": "Chemical", "char_span": [62, 73], "ent_id": "D013726", "tok_span": [9, 12]}, {"name": "behavioral abnormalities", "ent_type": "Disease", "char_span": [22, 46], "ent_id": "D001523", "tok_span": [5, 7]}], "relation_list": [{"subject": "terbutaline", "object": "autism", "sbj_char_span": [62, 73], "obj_char_span": [110, 116], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [18, 19]}], "umls_entity_list": []}, {"text": "Terbutaline, a beta2-adrenoceptor agonist used to arrest preterm labor, has been associated with increased concordance for autism in dizygotic twins.", "entity_list": [{"name": "Terbutaline", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D013726", "tok_span": [0, 3]}, {"name": "preterm labor", "ent_type": "Disease", "char_span": [57, 70], "ent_id": "D007752", "tok_span": [15, 17]}, {"name": "autism", "ent_type": "Disease", "char_span": [123, 129], "ent_id": "D001321", "tok_span": [25, 26]}], "relation_list": [{"subject": "Terbutaline", "object": "autism", "sbj_char_span": [0, 11], "obj_char_span": [123, 129], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [25, 26]}], "umls_entity_list": []}, {"text": "Acute myocarditis associated with clozapine.", "entity_list": [{"name": "myocarditis", "ent_type": "Disease", "char_span": [6, 17], "ent_id": "D009205", "tok_span": [1, 3]}, {"name": "clozapine", "ent_type": "Chemical", "char_span": [34, 43], "ent_id": "D003024", "tok_span": [5, 8]}], "relation_list": [{"subject": "clozapine", "object": "myocarditis", "sbj_char_span": [34, 43], "obj_char_span": [6, 17], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [1, 3]}], "umls_entity_list": []}, {"text": "OBJECTIVE: A case of acute myocarditis associated with the commencement of clozapine is described, highlighting the onset, course and possible contributing factors.", "entity_list": [{"name": "clozapine", "ent_type": "Chemical", "char_span": [75, 84], "ent_id": "D003024", "tok_span": [15, 18]}, {"name": "myocarditis", "ent_type": "Disease", "char_span": [27, 38], "ent_id": "D009205", "tok_span": [6, 8]}], "relation_list": [{"subject": "clozapine", "object": "myocarditis", "sbj_char_span": [75, 84], "obj_char_span": [27, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "RESULTS: A 20-year-old male with schizophrenia developed a sudden onset of myocarditis after commencement of clozapine.", "entity_list": [{"name": "myocarditis", "ent_type": "Disease", "char_span": [75, 86], "ent_id": "D009205", "tok_span": [16, 18]}, {"name": "schizophrenia", "ent_type": "Disease", "char_span": [33, 46], "ent_id": "D012559", "tok_span": [10, 11]}, {"name": "clozapine", "ent_type": "Chemical", "char_span": [109, 118], "ent_id": "D003024", "tok_span": [23, 26]}], "relation_list": [{"subject": "clozapine", "object": "myocarditis", "sbj_char_span": [109, 118], "obj_char_span": [75, 86], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Myocarditis is an increasingly recognized complication associated with the use of clozapine.", "entity_list": [{"name": "clozapine", "ent_type": "Chemical", "char_span": [95, 104], "ent_id": "D003024", "tok_span": [15, 18]}, {"name": "Myocarditis", "ent_type": "Disease", "char_span": [13, 24], "ent_id": "D009205", "tok_span": [2, 5]}], "relation_list": [{"subject": "clozapine", "object": "Myocarditis", "sbj_char_span": [95, 104], "obj_char_span": [13, 24], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [2, 5]}], "umls_entity_list": []}, {"text": "Encephalopathy induced by levetiracetam added to valproate.", "entity_list": [{"name": "Encephalopathy", "ent_type": "Disease", "char_span": [0, 14], "ent_id": "D001927", "tok_span": [0, 3]}, {"name": "valproate", "ent_type": "Chemical", "char_span": [49, 58], "ent_id": "D014635", "tok_span": [13, 16]}, {"name": "levetiracetam", "ent_type": "Chemical", "char_span": [26, 39], "ent_id": "C026098", "tok_span": [5, 11]}], "relation_list": [{"subject": "levetiracetam", "object": "Encephalopathy", "sbj_char_span": [26, 39], "obj_char_span": [0, 14], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 11], "obj_tok_span": [0, 3]}, {"subject": "valproate", "object": "Encephalopathy", "sbj_char_span": [49, 58], "obj_char_span": [0, 14], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "BACKGROUND: We report on the manifestation of a levetiracetam (LEV)-induced encephalopathy.", "entity_list": [{"name": "levetiracetam", "ent_type": "Chemical", "char_span": [48, 61], "ent_id": "C026098", "tok_span": [9, 15]}, {"name": "LEV", "ent_type": "Chemical", "char_span": [63, 66], "ent_id": "C026098", "tok_span": [16, 18]}, {"name": "encephalopathy", "ent_type": "Disease", "char_span": [76, 90], "ent_id": "D001927", "tok_span": [21, 23]}], "relation_list": [{"subject": "LEV", "object": "encephalopathy", "sbj_char_span": [63, 66], "obj_char_span": [76, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 18], "obj_tok_span": [21, 23]}, {"subject": "levetiracetam", "object": "encephalopathy", "sbj_char_span": [48, 61], "obj_char_span": [76, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 15], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "Norepinephrine signaling through beta-adrenergic receptors is critical for expression of cocaine-induced anxiety.", "entity_list": [{"name": "cocaine", "ent_type": "Chemical", "char_span": [89, 96], "ent_id": "D003042", "tok_span": [16, 17]}, {"name": "Norepinephrine", "ent_type": "Chemical", "char_span": [0, 14], "ent_id": "D009638", "tok_span": [0, 4]}, {"name": "anxiety", "ent_type": "Disease", "char_span": [105, 112], "ent_id": "D001008", "tok_span": [19, 20]}], "relation_list": [{"subject": "cocaine", "object": "anxiety", "sbj_char_span": [89, 96], "obj_char_span": [105, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 17], "obj_tok_span": [19, 20]}], "umls_entity_list": []}, {"text": "While the mechanisms underlying cocaine's rewarding effects have been studied extensively, less attention has been paid to the unpleasant behavioral states induced by cocaine, such as anxiety.", "entity_list": [{"name": "anxiety", "ent_type": "Disease", "char_span": [184, 191], "ent_id": "D001008", "tok_span": [33, 34]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [167, 174], "ent_id": "D003042", "tok_span": [29, 30]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [32, 39], "ent_id": "D003042", "tok_span": [4, 5]}], "relation_list": [{"subject": "cocaine", "object": "anxiety", "sbj_char_span": [167, 174], "obj_char_span": [184, 191], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 30], "obj_tok_span": [33, 34]}, {"subject": "cocaine", "object": "anxiety", "sbj_char_span": [32, 39], "obj_char_span": [184, 191], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [33, 34]}], "umls_entity_list": []}, {"text": "METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety.", "entity_list": [{"name": "dopamine", "ent_type": "Chemical", "char_span": [56, 64], "ent_id": "D004298", "tok_span": [11, 12]}, {"name": "NE", "ent_type": "Chemical", "char_span": [134, 136], "ent_id": "D009638", "tok_span": [31, 32]}, {"name": "anxiety", "ent_type": "Disease", "char_span": [245, 252], "ent_id": "D001008", "tok_span": [55, 56]}, {"name": "norepinephrine", "ent_type": "Chemical", "char_span": [118, 132], "ent_id": "D009638", "tok_span": [29, 30]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [229, 236], "ent_id": "D003042", "tok_span": [52, 53]}], "relation_list": [{"subject": "cocaine", "object": "anxiety", "sbj_char_span": [229, 236], "obj_char_span": [245, 252], "rel_type": "chemical-induced disease", "sbj_tok_span": [52, 53], "obj_tok_span": [55, 56]}], "umls_entity_list": []}, {"text": "RESULTS: We found that cocaine dose-dependently increased anxiety-like behavior in control (Dbh +/-) mice, as measured by a decrease in open arm exploration.", "entity_list": [{"name": "anxiety", "ent_type": "Disease", "char_span": [58, 65], "ent_id": "D001008", "tok_span": [11, 12]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [23, 30], "ent_id": "D003042", "tok_span": [5, 6]}], "relation_list": [{"subject": "cocaine", "object": "anxiety", "sbj_char_span": [23, 30], "obj_char_span": [58, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 6], "obj_tok_span": [11, 12]}], "umls_entity_list": []}, {"text": "Cocaine-induced anxiety was also attenuated in Dbh +/- mice following administration of disulfiram, a dopamine beta-hydroxylase (DBH) inhibitor.", "entity_list": [{"name": "disulfiram", "ent_type": "Chemical", "char_span": [88, 98], "ent_id": "D004221", "tok_span": [20, 24]}, {"name": "Cocaine", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "D003042", "tok_span": [0, 3]}, {"name": "anxiety", "ent_type": "Disease", "char_span": [16, 23], "ent_id": "D001008", "tok_span": [5, 6]}, {"name": "dopamine", "ent_type": "Chemical", "char_span": [102, 110], "ent_id": "D004298", "tok_span": [26, 27]}], "relation_list": [{"subject": "Cocaine", "object": "anxiety", "sbj_char_span": [0, 7], "obj_char_span": [16, 23], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 6]}], "umls_entity_list": []}, {"text": "In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.", "entity_list": [{"name": "propranolol", "ent_type": "Chemical", "char_span": [126, 137], "ent_id": "D011433", "tok_span": [20, 24]}, {"name": "yohimbine", "ent_type": "Chemical", "char_span": [291, 300], "ent_id": "D015016", "tok_span": [68, 72]}, {"name": "anxiety", "ent_type": "Disease", "char_span": [162, 169], "ent_id": "D001008", "tok_span": [28, 29]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [146, 153], "ent_id": "D003042", "tok_span": [25, 26]}, {"name": "prazosin", "ent_type": "Chemical", "char_span": [254, 262], "ent_id": "D011224", "tok_span": [58, 61]}], "relation_list": [{"subject": "cocaine", "object": "anxiety", "sbj_char_span": [146, 153], "obj_char_span": [162, 169], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 26], "obj_tok_span": [28, 29]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: These results indicate that noradrenergic signaling via beta-adrenergic receptors is required for cocaine-induced anxiety in mice.", "entity_list": [{"name": "cocaine", "ent_type": "Chemical", "char_span": [111, 118], "ent_id": "D003042", "tok_span": [18, 19]}, {"name": "anxiety", "ent_type": "Disease", "char_span": [127, 134], "ent_id": "D001008", "tok_span": [21, 22]}], "relation_list": [{"subject": "cocaine", "object": "anxiety", "sbj_char_span": [111, 118], "obj_char_span": [127, 134], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [21, 22]}], "umls_entity_list": []}, {"text": "RESULTS: There were more incidents of bradycardia in subjects treated with clonidine compared with those not treated with clonidine (17.5% versus 3.4%; p =.02), but no other significant group differences regarding electrocardiogram and other cardiovascular outcomes.", "entity_list": [{"name": "clonidine", "ent_type": "Chemical", "char_span": [75, 84], "ent_id": "D003000", "tok_span": [15, 17]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [38, 49], "ent_id": "D001919", "tok_span": [7, 11]}, {"name": "clonidine", "ent_type": "Chemical", "char_span": [122, 131], "ent_id": "D003000", "tok_span": [23, 25]}], "relation_list": [{"subject": "clonidine", "object": "bradycardia", "sbj_char_span": [75, 84], "obj_char_span": [38, 49], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 17], "obj_tok_span": [7, 11]}, {"subject": "clonidine", "object": "bradycardia", "sbj_char_span": [122, 131], "obj_char_span": [38, 49], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 25], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "Physicians prescribing clonidine should monitor for bradycardia and advise patients about the high likelihood of initial drowsiness.", "entity_list": [{"name": "clonidine", "ent_type": "Chemical", "char_span": [23, 32], "ent_id": "D003000", "tok_span": [2, 4]}, {"name": "drowsiness", "ent_type": "Disease", "char_span": [121, 131], "ent_id": "D006970", "tok_span": [21, 24]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [52, 63], "ent_id": "D001919", "tok_span": [7, 11]}], "relation_list": [{"subject": "clonidine", "object": "bradycardia", "sbj_char_span": [23, 32], "obj_char_span": [52, 63], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 4], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "A 45-year-old man, an admitted frequent cocaine user, presented to the Emergency Department (ED) on two separate occasions with a history of priapism after cocaine use.", "entity_list": [{"name": "cocaine", "ent_type": "Chemical", "char_span": [40, 47], "ent_id": "D003042", "tok_span": [11, 12]}, {"name": "priapism", "ent_type": "Disease", "char_span": [141, 149], "ent_id": "D011317", "tok_span": [30, 33]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [156, 163], "ent_id": "D003042", "tok_span": [34, 35]}], "relation_list": [{"subject": "cocaine", "object": "priapism", "sbj_char_span": [156, 163], "obj_char_span": [141, 149], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 35], "obj_tok_span": [30, 33]}, {"subject": "cocaine", "object": "priapism", "sbj_char_span": [40, 47], "obj_char_span": [141, 149], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [30, 33]}], "umls_entity_list": []}, {"text": "Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats.", "entity_list": [{"name": "green tea", "ent_type": "Chemical", "char_span": [10, 19], "ent_id": "D010936", "tok_span": [2, 4]}, {"name": "isoproterenol", "ent_type": "Chemical", "char_span": [49, 62], "ent_id": "D007545", "tok_span": [9, 13]}, {"name": "myocardial infarction", "ent_type": "Disease", "char_span": [71, 92], "ent_id": "D009203", "tok_span": [14, 16]}, {"name": "vitamin E", "ent_type": "Chemical", "char_span": [24, 33], "ent_id": "D014810", "tok_span": [5, 7]}], "relation_list": [{"subject": "isoproterenol", "object": "myocardial infarction", "sbj_char_span": [49, 62], "obj_char_span": [71, 92], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.", "entity_list": [{"name": "myocardial infarction", "ent_type": "Disease", "char_span": [245, 266], "ent_id": "D009203", "tok_span": [47, 49]}, {"name": "green tea", "ent_type": "Chemical", "char_span": [67, 76], "ent_id": "D010936", "tok_span": [11, 13]}, {"name": "ISO", "ent_type": "Chemical", "char_span": [232, 235], "ent_id": "D007545", "tok_span": [43, 44]}, {"name": "vitamin E", "ent_type": "Chemical", "char_span": [81, 90], "ent_id": "D014810", "tok_span": [14, 16]}, {"name": "isoproterenol", "ent_type": "Chemical", "char_span": [217, 230], "ent_id": "D007545", "tok_span": [38, 42]}], "relation_list": [{"subject": "ISO", "object": "myocardial infarction", "sbj_char_span": [232, 235], "obj_char_span": [245, 266], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 44], "obj_tok_span": [47, 49]}, {"subject": "isoproterenol", "object": "myocardial infarction", "sbj_char_span": [217, 230], "obj_char_span": [245, 266], "rel_type": "chemical-induced disease", "sbj_tok_span": [38, 42], "obj_tok_span": [47, 49]}], "umls_entity_list": []}, {"text": "These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.", "entity_list": [{"name": "myocardial infarction", "ent_type": "Disease", "char_span": [104, 125], "ent_id": "D009203", "tok_span": [16, 18]}, {"name": "green tea", "ent_type": "Chemical", "char_span": [61, 70], "ent_id": "D010936", "tok_span": [8, 10]}, {"name": "ISO", "ent_type": "Chemical", "char_span": [92, 95], "ent_id": "D007545", "tok_span": [14, 15]}, {"name": "vitamin E", "ent_type": "Chemical", "char_span": [75, 84], "ent_id": "D014810", "tok_span": [11, 13]}], "relation_list": [{"subject": "ISO", "object": "myocardial infarction", "sbj_char_span": [92, 95], "obj_char_span": [104, 125], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.\n A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).", "entity_list": [{"name": "chronic hepatitis C", "ent_type": "Disease", "char_span": [89, 108], "ent_id": "D019698", "tok_span": [18, 21]}, {"name": "ocular myasthenia", "ent_type": "Disease", "char_span": [15, 32], "ent_id": "D009157", "tok_span": [2, 7]}, {"name": "ribavirin", "ent_type": "Chemical", "char_span": [233, 242], "ent_id": "D012254", "tok_span": [51, 54]}, {"name": "pegylated interferon (IFN) alpha-2b", "ent_type": "Chemical", "char_span": [193, 228], "ent_id": "C417083", "tok_span": [39, 50]}, {"name": "chronic hepatitis C", "ent_type": "Disease", "char_span": [247, 266], "ent_id": "D019698", "tok_span": [55, 58]}, {"name": "pegylated interferon", "ent_type": "Chemical", "char_span": [40, 60], "ent_id": "C417083", "tok_span": [8, 12]}, {"name": "ribavirin", "ent_type": "Chemical", "char_span": [65, 74], "ent_id": "D012254", "tok_span": [13, 16]}, {"name": "CHC", "ent_type": "Disease", "char_span": [268, 271], "ent_id": "D019698", "tok_span": [59, 61]}, {"name": "diplopia", "ent_type": "Disease", "char_span": [149, 157], "ent_id": "D004172", "tok_span": [31, 33]}], "relation_list": [{"subject": "pegylated interferon", "object": "ocular myasthenia", "sbj_char_span": [40, 60], "obj_char_span": [15, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [2, 7]}, {"subject": "ribavirin", "object": "ocular myasthenia", "sbj_char_span": [65, 74], "obj_char_span": [15, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [2, 7]}, {"subject": "pegylated interferon (IFN) alpha-2b", "object": "ocular myasthenia", "sbj_char_span": [193, 228], "obj_char_span": [15, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 50], "obj_tok_span": [2, 7]}, {"subject": "ribavirin", "object": "ocular myasthenia", "sbj_char_span": [233, 242], "obj_char_span": [15, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [51, 54], "obj_tok_span": [2, 7]}], "umls_entity_list": []}, {"text": "The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.", "entity_list": [{"name": "IFN", "ent_type": "Chemical", "char_span": [213, 216], "ent_id": "C417083", "tok_span": [46, 47]}, {"name": "pegylated IFN alpha-2b", "ent_type": "Chemical", "char_span": [61, 83], "ent_id": "C417083", "tok_span": [11, 19]}, {"name": "ocular myasthenia", "ent_type": "Disease", "char_span": [4, 21], "ent_id": "D009157", "tok_span": [1, 6]}, {"name": "CHC", "ent_type": "Disease", "char_span": [102, 105], "ent_id": "D019698", "tok_span": [24, 26]}, {"name": "ribavirin", "ent_type": "Chemical", "char_span": [88, 97], "ent_id": "D012254", "tok_span": [20, 23]}], "relation_list": [{"subject": "IFN", "object": "ocular myasthenia", "sbj_char_span": [213, 216], "obj_char_span": [4, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [46, 47], "obj_tok_span": [1, 6]}, {"subject": "ribavirin", "object": "ocular myasthenia", "sbj_char_span": [88, 97], "obj_char_span": [4, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [1, 6]}, {"subject": "pegylated IFN alpha-2b", "object": "ocular myasthenia", "sbj_char_span": [61, 83], "obj_char_span": [4, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 19], "obj_tok_span": [1, 6]}], "umls_entity_list": []}, {"text": "This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).", "entity_list": [{"name": "NMDA", "ent_type": "Chemical", "char_span": [229, 233], "ent_id": "D016202", "tok_span": [51, 52]}, {"name": "hyperactivity", "ent_type": "Disease", "char_span": [129, 142], "ent_id": "D006948", "tok_span": [25, 27]}, {"name": "MK-801", "ent_type": "Chemical", "char_span": [197, 203], "ent_id": "D016291", "tok_span": [40, 44]}, {"name": "SSR103800", "ent_type": "Chemical", "char_span": [81, 90], "ent_id": "-1", "tok_span": [13, 17]}, {"name": "amphetamine", "ent_type": "Chemical", "char_span": [181, 192], "ent_id": "D000661", "tok_span": [35, 39]}], "relation_list": [{"subject": "amphetamine", "object": "hyperactivity", "sbj_char_span": [181, 192], "obj_char_span": [129, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 39], "obj_tok_span": [25, 27]}, {"subject": "MK-801", "object": "hyperactivity", "sbj_char_span": [197, 203], "obj_char_span": [129, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [40, 44], "obj_tok_span": [25, 27]}], "umls_entity_list": []}, {"text": "Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.", "entity_list": [{"name": "hyperactivity", "ent_type": "Disease", "char_span": [170, 183], "ent_id": "D006948", "tok_span": [40, 42]}, {"name": "NMDA", "ent_type": "Chemical", "char_span": [187, 191], "ent_id": "D016202", "tok_span": [43, 44]}, {"name": "NMDA", "ent_type": "Chemical", "char_span": [102, 106], "ent_id": "D016202", "tok_span": [28, 29]}, {"name": "hyperactivity", "ent_type": "Disease", "char_span": [57, 70], "ent_id": "D006948", "tok_span": [20, 22]}, {"name": "MK-801", "ent_type": "Chemical", "char_span": [128, 134], "ent_id": "D016291", "tok_span": [32, 36]}, {"name": "SSR103800", "ent_type": "Chemical", "char_span": [20, 29], "ent_id": "-1", "tok_span": [3, 7]}], "relation_list": [{"subject": "MK-801", "object": "hyperactivity", "sbj_char_span": [128, 134], "obj_char_span": [57, 70], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 36], "obj_tok_span": [20, 22]}, {"subject": "MK-801", "object": "hyperactivity", "sbj_char_span": [128, 134], "obj_char_span": [170, 183], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 36], "obj_tok_span": [40, 42]}], "umls_entity_list": []}, {"text": "In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).", "entity_list": [{"name": "amphetamine", "ent_type": "Chemical", "char_span": [65, 76], "ent_id": "D000661", "tok_span": [14, 18]}, {"name": "SSR103800", "ent_type": "Chemical", "char_span": [13, 22], "ent_id": "-1", "tok_span": [3, 7]}, {"name": "hyperactivity", "ent_type": "Disease", "char_span": [40, 53], "ent_id": "D006948", "tok_span": [10, 12]}, {"name": "dopamine", "ent_type": "Chemical", "char_span": [102, 110], "ent_id": "D004298", "tok_span": [22, 23]}], "relation_list": [{"subject": "amphetamine", "object": "hyperactivity", "sbj_char_span": [65, 76], "obj_char_span": [40, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 18], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Phenylephrine but not ephedrine reduces frontal lobe oxygenation following anesthesia-induced hypotension.", "entity_list": [{"name": "Phenylephrine", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D010656", "tok_span": [0, 3]}, {"name": "ephedrine", "ent_type": "Chemical", "char_span": [22, 31], "ent_id": "D004809", "tok_span": [5, 8]}, {"name": "reduces frontal lobe oxygenation", "ent_type": "Disease", "char_span": [32, 64], "ent_id": "D002534", "tok_span": [8, 12]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [94, 105], "ent_id": "D007022", "tok_span": [16, 17]}], "relation_list": [{"subject": "Phenylephrine", "object": "reduces frontal lobe oxygenation", "sbj_char_span": [0, 13], "obj_char_span": [32, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [8, 12]}], "umls_entity_list": []}, {"text": "RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.", "entity_list": [{"name": "Clomipramine", "ent_type": "Chemical", "char_span": [9, 21], "ent_id": "D002997", "tok_span": [2, 6]}, {"name": "behavioral inflexibility", "ent_type": "Disease", "char_span": [175, 199], "ent_id": "-1", "tok_span": [31, 35]}, {"name": "anxiety", "ent_type": "Disease", "char_span": [126, 133], "ent_id": "D001008", "tok_span": [19, 20]}, {"name": "hoarding", "ent_type": "Disease", "char_span": [338, 346], "ent_id": "D060845", "tok_span": [66, 68]}, {"name": "corticostriatal dysfunction", "ent_type": "Disease", "char_span": [352, 379], "ent_id": "-1", "tok_span": [70, 75]}, {"name": "memory impairment", "ent_type": "Disease", "char_span": [292, 309], "ent_id": "D008569", "tok_span": [52, 54]}], "relation_list": [{"subject": "Clomipramine", "object": "hoarding", "sbj_char_span": [9, 21], "obj_char_span": [338, 346], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [66, 68]}, {"subject": "Clomipramine", "object": "anxiety", "sbj_char_span": [9, 21], "obj_char_span": [126, 133], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [19, 20]}, {"subject": "Clomipramine", "object": "memory impairment", "sbj_char_span": [9, 21], "obj_char_span": [292, 309], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [52, 54]}], "umls_entity_list": []}, {"text": "A case is reported of the hemolytic uremic syndrome (HUS) in a woman taking oral contraceptives.", "entity_list": [{"name": "HUS", "ent_type": "Disease", "char_span": [53, 56], "ent_id": "D006463", "tok_span": [12, 14]}, {"name": "hemolytic uremic syndrome", "ent_type": "Disease", "char_span": [26, 51], "ent_id": "D006463", "tok_span": [6, 11]}, {"name": "oral contraceptives", "ent_type": "Chemical", "char_span": [76, 95], "ent_id": "D003276", "tok_span": [19, 22]}], "relation_list": [{"subject": "oral contraceptives", "object": "hemolytic uremic syndrome", "sbj_char_span": [76, 95], "obj_char_span": [26, 51], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 22], "obj_tok_span": [6, 11]}, {"subject": "oral contraceptives", "object": "HUS", "sbj_char_span": [76, 95], "obj_char_span": [53, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 22], "obj_tok_span": [12, 14]}], "umls_entity_list": []}, {"text": "Effects of acetylsalicylic acid, dipyridamole, and hydrocortisone on epinephrine-induced myocardial injury in dogs.", "entity_list": [{"name": "hydrocortisone", "ent_type": "Chemical", "char_span": [51, 65], "ent_id": "D006854", "tok_span": [15, 19]}, {"name": "myocardial injury", "ent_type": "Disease", "char_span": [89, 106], "ent_id": "D009202", "tok_span": [25, 27]}, {"name": "dipyridamole", "ent_type": "Chemical", "char_span": [33, 45], "ent_id": "D004176", "tok_span": [8, 13]}, {"name": "acetylsalicylic acid", "ent_type": "Chemical", "char_span": [11, 31], "ent_id": "D001241", "tok_span": [2, 7]}, {"name": "epinephrine", "ent_type": "Chemical", "char_span": [69, 80], "ent_id": "D004837", "tok_span": [20, 23]}], "relation_list": [{"subject": "epinephrine", "object": "myocardial injury", "sbj_char_span": [69, 80], "obj_char_span": [89, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [25, 27]}], "umls_entity_list": []}, {"text": "A reproducible model for producing diffuse myocardial injury (epinephrine infusion) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute myocardial infarction.", "entity_list": [{"name": "myocardial infarction", "ent_type": "Disease", "char_span": [205, 226], "ent_id": "D009203", "tok_span": [35, 37]}, {"name": "myocardial injury", "ent_type": "Disease", "char_span": [43, 60], "ent_id": "D009202", "tok_span": [6, 8]}, {"name": "epinephrine", "ent_type": "Chemical", "char_span": [62, 73], "ent_id": "D004837", "tok_span": [9, 12]}], "relation_list": [{"subject": "epinephrine", "object": "myocardial injury", "sbj_char_span": [62, 73], "obj_char_span": [43, 60], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "Eight glaucomatous patients chronically treated with timolol 0.5%/12h, suffering from depression diagnosed through DMS-III-R criteria, were included in the study.", "entity_list": [{"name": "glaucomatous", "ent_type": "Disease", "char_span": [6, 18], "ent_id": "D005901", "tok_span": [1, 4]}, {"name": "depression", "ent_type": "Disease", "char_span": [86, 96], "ent_id": "D003866", "tok_span": [21, 22]}, {"name": "timolol", "ent_type": "Chemical", "char_span": [53, 60], "ent_id": "D013999", "tok_span": [8, 11]}], "relation_list": [{"subject": "timolol", "object": "depression", "sbj_char_span": [53, 60], "obj_char_span": [86, 96], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [21, 22]}], "umls_entity_list": []}, {"text": "In a double blind cross-over study with control group, the patients under timolol treatment presented higher depression values measured through the Beck and the Zung-Conde scales (p < 0.001 vs control).", "entity_list": [{"name": "timolol", "ent_type": "Chemical", "char_span": [74, 81], "ent_id": "D013999", "tok_span": [15, 18]}, {"name": "depression", "ent_type": "Disease", "char_span": [109, 119], "ent_id": "D003866", "tok_span": [21, 22]}], "relation_list": [{"subject": "timolol", "object": "depression", "sbj_char_span": [74, 81], "obj_char_span": [109, 119], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [21, 22]}], "umls_entity_list": []}, {"text": "These results suggest that betaxolol could be less of a depression-inducer than timolol in predisposed patients.", "entity_list": [{"name": "timolol", "ent_type": "Chemical", "char_span": [80, 87], "ent_id": "D013999", "tok_span": [18, 21]}, {"name": "depression", "ent_type": "Disease", "char_span": [56, 66], "ent_id": "D003866", "tok_span": [13, 14]}, {"name": "betaxolol", "ent_type": "Chemical", "char_span": [27, 36], "ent_id": "D015784", "tok_span": [4, 8]}], "relation_list": [{"subject": "timolol", "object": "depression", "sbj_char_span": [80, 87], "obj_char_span": [56, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [13, 14]}], "umls_entity_list": []}, {"text": "Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report.", "entity_list": [{"name": "renal toxicity", "ent_type": "Disease", "char_span": [34, 48], "ent_id": "D007674", "tok_span": [12, 14]}, {"name": "malignant mesenchymal tumors", "ent_type": "Disease", "char_span": [73, 101], "ent_id": "C535700", "tok_span": [18, 21]}, {"name": "ifosfamide", "ent_type": "Chemical", "char_span": [23, 33], "ent_id": "D007069", "tok_span": [7, 12]}], "relation_list": [{"subject": "ifosfamide", "object": "renal toxicity", "sbj_char_span": [23, 33], "obj_char_span": [34, 48], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 12], "obj_tok_span": [12, 14]}], "umls_entity_list": []}, {"text": "Evidence for an involvement of D1 and D2 dopamine receptors in mediating nicotine-induced hyperactivity in rats.", "entity_list": [{"name": "dopamine", "ent_type": "Chemical", "char_span": [41, 49], "ent_id": "D004298", "tok_span": [10, 11]}, {"name": "nicotine", "ent_type": "Chemical", "char_span": [73, 81], "ent_id": "D009538", "tok_span": [14, 15]}, {"name": "hyperactivity", "ent_type": "Disease", "char_span": [90, 103], "ent_id": "D006948", "tok_span": [17, 19]}], "relation_list": [{"subject": "nicotine", "object": "hyperactivity", "sbj_char_span": [73, 81], "obj_char_span": [90, 103], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [17, 19]}], "umls_entity_list": []}, {"text": "Nicotine (1.0 mg/kg) caused a significant increase in locomotor activity in rats that were habituated to the test environment, but had only a weak and delayed stimulant action in rats that were unfamiliar with the test environment.", "entity_list": [{"name": "increase in locomotor activity", "ent_type": "Disease", "char_span": [42, 72], "ent_id": "D006948", "tok_span": [13, 17]}, {"name": "Nicotine", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D009538", "tok_span": [0, 2]}], "relation_list": [{"subject": "Nicotine", "object": "increase in locomotor activity", "sbj_char_span": [0, 8], "obj_char_span": [42, 72], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.", "entity_list": [{"name": "SCH 23390", "ent_type": "Chemical", "char_span": [74, 83], "ent_id": "C534628", "tok_span": [14, 17]}, {"name": "raclopride", "ent_type": "Chemical", "char_span": [113, 123], "ent_id": "D020891", "tok_span": [23, 27]}, {"name": "hyperactivity", "ent_type": "Disease", "char_span": [17, 30], "ent_id": "D006948", "tok_span": [4, 6]}, {"name": "fluphenazine", "ent_type": "Chemical", "char_span": [149, 161], "ent_id": "D005476", "tok_span": [35, 38]}, {"name": "Nicotine", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D009538", "tok_span": [0, 2]}], "relation_list": [{"subject": "Nicotine", "object": "hyperactivity", "sbj_char_span": [0, 8], "obj_char_span": [17, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "Pretreatment with the D2 agonist PHNO enhanced nicotine-induced hyperactivity, whereas the D1 agonist SKF 38393 had no effect.", "entity_list": [{"name": "nicotine", "ent_type": "Chemical", "char_span": [47, 55], "ent_id": "D009538", "tok_span": [10, 11]}, {"name": "SKF 38393", "ent_type": "Chemical", "char_span": [102, 111], "ent_id": "D015647", "tok_span": [21, 26]}, {"name": "PHNO", "ent_type": "Chemical", "char_span": [33, 37], "ent_id": "-1", "tok_span": [7, 9]}, {"name": "hyperactivity", "ent_type": "Disease", "char_span": [64, 77], "ent_id": "D006948", "tok_span": [13, 15]}], "relation_list": [{"subject": "nicotine", "object": "hyperactivity", "sbj_char_span": [47, 55], "obj_char_span": [64, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "The results indicate that acute nicotine injection induces a pronounced hyperactivity in rats habituated to the test environment.", "entity_list": [{"name": "hyperactivity", "ent_type": "Disease", "char_span": [72, 85], "ent_id": "D006948", "tok_span": [10, 12]}, {"name": "nicotine", "ent_type": "Chemical", "char_span": [32, 40], "ent_id": "D009538", "tok_span": [5, 6]}], "relation_list": [{"subject": "nicotine", "object": "hyperactivity", "sbj_char_span": [32, 40], "obj_char_span": [72, 85], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 6], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Reduction in injection pain using buffered lidocaine as a local anesthetic before cardiac catheterization.", "entity_list": [{"name": "pain", "ent_type": "Disease", "char_span": [23, 27], "ent_id": "D010146", "tok_span": [3, 4]}, {"name": "lidocaine", "ent_type": "Chemical", "char_span": [43, 52], "ent_id": "D008012", "tok_span": [6, 8]}], "relation_list": [{"subject": "lidocaine", "object": "pain", "sbj_char_span": [43, 52], "obj_char_span": [23, 27], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [3, 4]}], "umls_entity_list": []}, {"text": "Previous reports have suggested that pain associated with the injection of lidocaine is related to the acidic pH of the solution.", "entity_list": [{"name": "pain", "ent_type": "Disease", "char_span": [37, 41], "ent_id": "D010146", "tok_span": [5, 6]}, {"name": "lidocaine", "ent_type": "Chemical", "char_span": [75, 84], "ent_id": "D008012", "tok_span": [11, 13]}], "relation_list": [{"subject": "lidocaine", "object": "pain", "sbj_char_span": [75, 84], "obj_char_span": [37, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 13], "obj_tok_span": [5, 6]}], "umls_entity_list": []}, {"text": "To determine if the addition of a buffering solution to adjust the pH of lidocaine into the physiologic range would reduce pain during injection, we performed a blinded randomized study in patients undergoing cardiac catheterization.", "entity_list": [{"name": "lidocaine", "ent_type": "Chemical", "char_span": [73, 82], "ent_id": "D008012", "tok_span": [15, 17]}, {"name": "pain", "ent_type": "Disease", "char_span": [123, 127], "ent_id": "D010146", "tok_span": [23, 24]}], "relation_list": [{"subject": "lidocaine", "object": "pain", "sbj_char_span": [73, 82], "obj_char_span": [123, 127], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 17], "obj_tok_span": [23, 24]}], "umls_entity_list": []}, {"text": "Twenty patients were asked to quantify the severity of pain after receiving standard lidocaine in one femoral area and buffered lidocaine in the opposite femoral area.", "entity_list": [{"name": "lidocaine", "ent_type": "Chemical", "char_span": [85, 94], "ent_id": "D008012", "tok_span": [13, 15]}, {"name": "pain", "ent_type": "Disease", "char_span": [55, 59], "ent_id": "D010146", "tok_span": [9, 10]}, {"name": "lidocaine", "ent_type": "Chemical", "char_span": [128, 137], "ent_id": "D008012", "tok_span": [21, 23]}], "relation_list": [{"subject": "lidocaine", "object": "pain", "sbj_char_span": [128, 137], "obj_char_span": [55, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 23], "obj_tok_span": [9, 10]}, {"subject": "lidocaine", "object": "pain", "sbj_char_span": [85, 94], "obj_char_span": [55, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [9, 10]}], "umls_entity_list": []}, {"text": "The mean pain score for buffered lidocaine was significantly lower than the mean score for standard lidocaine (2.7 +/- 1.9 vs. 3.8 +/- 2.2, P = 0.03).", "entity_list": [{"name": "lidocaine", "ent_type": "Chemical", "char_span": [100, 109], "ent_id": "D008012", "tok_span": [17, 19]}, {"name": "pain", "ent_type": "Disease", "char_span": [9, 13], "ent_id": "D010146", "tok_span": [2, 3]}, {"name": "lidocaine", "ent_type": "Chemical", "char_span": [33, 42], "ent_id": "D008012", "tok_span": [6, 8]}], "relation_list": [{"subject": "lidocaine", "object": "pain", "sbj_char_span": [33, 42], "obj_char_span": [9, 13], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [2, 3]}, {"subject": "lidocaine", "object": "pain", "sbj_char_span": [100, 109], "obj_char_span": [9, 13], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 19], "obj_tok_span": [2, 3]}], "umls_entity_list": []}, {"text": "The pH adjustment of standard lidocaine can be accomplished easily in the catheterization laboratory before injection and results in a reduction of the pain occurring during the infiltration of tissues.", "entity_list": [{"name": "pain", "ent_type": "Disease", "char_span": [152, 156], "ent_id": "D010146", "tok_span": [25, 26]}, {"name": "lidocaine", "ent_type": "Chemical", "char_span": [30, 39], "ent_id": "D008012", "tok_span": [5, 7]}], "relation_list": [{"subject": "lidocaine", "object": "pain", "sbj_char_span": [30, 39], "obj_char_span": [152, 156], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 7], "obj_tok_span": [25, 26]}], "umls_entity_list": []}, {"text": "Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.", "entity_list": [{"name": "decreased appetite", "ent_type": "Disease", "char_span": [47, 65], "ent_id": "D001068", "tok_span": [10, 12]}, {"name": "mazindol", "ent_type": "Chemical", "char_span": [29, 37], "ent_id": "D008454", "tok_span": [5, 9]}, {"name": "mazindol", "ent_type": "Chemical", "char_span": [152, 160], "ent_id": "D008454", "tok_span": [40, 44]}, {"name": "gastrointestinal symptoms", "ent_type": "Disease", "char_span": [119, 144], "ent_id": "D012817", "tok_span": [32, 35]}, {"name": "dry mouth", "ent_type": "Disease", "char_span": [73, 82], "ent_id": "D014987", "tok_span": [17, 19]}], "relation_list": [{"subject": "mazindol", "object": "gastrointestinal symptoms", "sbj_char_span": [29, 37], "obj_char_span": [119, 144], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [32, 35]}, {"subject": "mazindol", "object": "dry mouth", "sbj_char_span": [29, 37], "obj_char_span": [73, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [17, 19]}, {"subject": "mazindol", "object": "gastrointestinal symptoms", "sbj_char_span": [152, 160], "obj_char_span": [119, 144], "rel_type": "chemical-induced disease", "sbj_tok_span": [40, 44], "obj_tok_span": [32, 35]}, {"subject": "mazindol", "object": "decreased appetite", "sbj_char_span": [152, 160], "obj_char_span": [47, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [40, 44], "obj_tok_span": [10, 12]}, {"subject": "mazindol", "object": "dry mouth", "sbj_char_span": [152, 160], "obj_char_span": [73, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [40, 44], "obj_tok_span": [17, 19]}, {"subject": "mazindol", "object": "decreased appetite", "sbj_char_span": [29, 37], "obj_char_span": [47, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Pentoxifylline (Trental) does not inhibit dipyridamole-induced coronary hyperemia: implications for dipyridamole-thallium-201 myocardial imaging.", "entity_list": [{"name": "dipyridamole", "ent_type": "Chemical", "char_span": [100, 112], "ent_id": "D004176", "tok_span": [27, 32]}, {"name": "hyperemia", "ent_type": "Disease", "char_span": [72, 81], "ent_id": "D006940", "tok_span": [22, 24]}, {"name": "Trental", "ent_type": "Chemical", "char_span": [16, 23], "ent_id": "D010431", "tok_span": [7, 10]}, {"name": "Pentoxifylline", "ent_type": "Chemical", "char_span": [0, 14], "ent_id": "D010431", "tok_span": [0, 6]}, {"name": "dipyridamole", "ent_type": "Chemical", "char_span": [42, 54], "ent_id": "D004176", "tok_span": [14, 19]}, {"name": "thallium", "ent_type": "Chemical", "char_span": [113, 121], "ent_id": "D013793", "tok_span": [33, 36]}], "relation_list": [{"subject": "dipyridamole", "object": "hyperemia", "sbj_char_span": [42, 54], "obj_char_span": [72, 81], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 19], "obj_tok_span": [22, 24]}, {"subject": "dipyridamole", "object": "hyperemia", "sbj_char_span": [100, 112], "obj_char_span": [72, 81], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 32], "obj_tok_span": [22, 24]}], "umls_entity_list": []}, {"text": "Many of these patients are taking pentoxifylline (Trental), a methylxanthine derivative which may improve intermittent claudication.", "entity_list": [{"name": "methylxanthine", "ent_type": "Chemical", "char_span": [62, 76], "ent_id": "C008514", "tok_span": [18, 22]}, {"name": "intermittent claudication", "ent_type": "Disease", "char_span": [106, 131], "ent_id": "D007383", "tok_span": [26, 30]}, {"name": "pentoxifylline", "ent_type": "Chemical", "char_span": [34, 48], "ent_id": "D010431", "tok_span": [6, 11]}, {"name": "Trental", "ent_type": "Chemical", "char_span": [50, 57], "ent_id": "D010431", "tok_span": [12, 15]}], "relation_list": [{"subject": "pentoxifylline", "object": "intermittent claudication", "sbj_char_span": [34, 48], "obj_char_span": [106, 131], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 11], "obj_tok_span": [26, 30]}, {"subject": "Trental", "object": "intermittent claudication", "sbj_char_span": [50, 57], "obj_char_span": [106, 131], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [26, 30]}], "umls_entity_list": []}, {"text": "Whether pentoxifylline inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown.", "entity_list": [{"name": "thallium", "ent_type": "Chemical", "char_span": [164, 172], "ent_id": "D013793", "tok_span": [40, 43]}, {"name": "dipyridamole", "ent_type": "Chemical", "char_span": [151, 163], "ent_id": "D004176", "tok_span": [34, 39]}, {"name": "theophylline", "ent_type": "Chemical", "char_span": [107, 119], "ent_id": "D013806", "tok_span": [25, 28]}, {"name": "dipyridamole", "ent_type": "Chemical", "char_span": [32, 44], "ent_id": "D004176", "tok_span": [7, 12]}, {"name": "methylxanthines", "ent_type": "Chemical", "char_span": [83, 98], "ent_id": "C008514", "tok_span": [19, 23]}, {"name": "pentoxifylline", "ent_type": "Chemical", "char_span": [8, 22], "ent_id": "D010431", "tok_span": [1, 6]}, {"name": "hyperemia", "ent_type": "Disease", "char_span": [62, 71], "ent_id": "D006940", "tok_span": [15, 17]}], "relation_list": [{"subject": "dipyridamole", "object": "hyperemia", "sbj_char_span": [32, 44], "obj_char_span": [62, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 12], "obj_tok_span": [15, 17]}, {"subject": "dipyridamole", "object": "hyperemia", "sbj_char_span": [151, 163], "obj_char_span": [62, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 39], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "Neither dose of pentoxifylline significantly decreased the dipyridamole-induced hyperemia, while peak coronary blood flow was significantly lower after theophylline (p less than 0.01).", "entity_list": [{"name": "theophylline", "ent_type": "Chemical", "char_span": [152, 164], "ent_id": "D013806", "tok_span": [30, 33]}, {"name": "dipyridamole", "ent_type": "Chemical", "char_span": [59, 71], "ent_id": "D004176", "tok_span": [11, 16]}, {"name": "hyperemia", "ent_type": "Disease", "char_span": [80, 89], "ent_id": "D006940", "tok_span": [18, 20]}, {"name": "pentoxifylline", "ent_type": "Chemical", "char_span": [16, 30], "ent_id": "D010431", "tok_span": [3, 8]}], "relation_list": [{"subject": "dipyridamole", "object": "hyperemia", "sbj_char_span": [59, 71], "obj_char_span": [80, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 16], "obj_tok_span": [18, 20]}], "umls_entity_list": []}, {"text": "We conclude that pentoxyifylline does not inhibit dipyridamole-induced coronary hyperemia even at high doses.", "entity_list": [{"name": "dipyridamole", "ent_type": "Chemical", "char_span": [50, 62], "ent_id": "D004176", "tok_span": [11, 16]}, {"name": "hyperemia", "ent_type": "Disease", "char_span": [80, 89], "ent_id": "D006940", "tok_span": [19, 21]}, {"name": "pentoxyifylline", "ent_type": "Chemical", "char_span": [17, 32], "ent_id": "D010431", "tok_span": [3, 8]}], "relation_list": [{"subject": "dipyridamole", "object": "hyperemia", "sbj_char_span": [50, 62], "obj_char_span": [80, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 16], "obj_tok_span": [19, 21]}], "umls_entity_list": []}, {"text": "The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.", "entity_list": [{"name": "cerebral haemorrhage", "ent_type": "Disease", "char_span": [21, 41], "ent_id": "D002543", "tok_span": [4, 7]}, {"name": "hypotensive", "ent_type": "Disease", "char_span": [115, 126], "ent_id": "D007022", "tok_span": [22, 24]}, {"name": "death", "ent_type": "Disease", "char_span": [56, 61], "ent_id": "D003643", "tok_span": [11, 12]}, {"name": "noradrenaline", "ent_type": "Chemical", "char_span": [189, 202], "ent_id": "D009638", "tok_span": [37, 40]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [137, 145], "ent_id": "D007980", "tok_span": [26, 29]}, {"name": "parkinsonian", "ent_type": "Disease", "char_span": [217, 229], "ent_id": "D010300", "tok_span": [43, 46]}, {"name": "hypotensive", "ent_type": "Disease", "char_span": [152, 163], "ent_id": "D007022", "tok_span": [31, 33]}, {"name": "Parkinson's disease", "ent_type": "Disease", "char_span": [79, 98], "ent_id": "D010300", "tok_span": [15, 19]}], "relation_list": [{"subject": "levodopa", "object": "hypotensive", "sbj_char_span": [137, 145], "obj_char_span": [152, 163], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 29], "obj_tok_span": [31, 33]}, {"subject": "levodopa", "object": "hypotensive", "sbj_char_span": [137, 145], "obj_char_span": [115, 126], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 29], "obj_tok_span": [22, 24]}], "umls_entity_list": []}, {"text": "From these results, we conclude that ribavirin has an antiviral effect in advanced cases of AHF, and that anemia, the only secondary reaction observed, can be easily managed.", "entity_list": [{"name": "ribavirin", "ent_type": "Chemical", "char_span": [37, 46], "ent_id": "D012254", "tok_span": [7, 10]}, {"name": "AHF", "ent_type": "Disease", "char_span": [92, 95], "ent_id": "D006478", "tok_span": [18, 20]}, {"name": "anemia", "ent_type": "Disease", "char_span": [106, 112], "ent_id": "D000740", "tok_span": [23, 24]}], "relation_list": [{"subject": "ribavirin", "object": "anemia", "sbj_char_span": [37, 46], "obj_char_span": [106, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [23, 24]}], "umls_entity_list": []}, {"text": "Angina and ischemic electrocardiographic changes occurred after administration of oral dipyridamole in four patients awaiting urgent myocardial revascularization procedures.", "entity_list": [{"name": "dipyridamole", "ent_type": "Chemical", "char_span": [87, 99], "ent_id": "D004176", "tok_span": [12, 17]}, {"name": "Angina", "ent_type": "Disease", "char_span": [0, 6], "ent_id": "D000787", "tok_span": [0, 2]}], "relation_list": [{"subject": "dipyridamole", "object": "Angina", "sbj_char_span": [87, 99], "obj_char_span": [0, 6], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 17], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Nitroprusside-induced hypotension evokes ACTH secretion which is primarily mediated by enhanced secretion of immunoreactive corticotropin-releasing factor (irCRF) into the hypophysial-portal circulation.", "entity_list": [{"name": "hypotension", "ent_type": "Disease", "char_span": [22, 33], "ent_id": "D007022", "tok_span": [6, 7]}, {"name": "Nitroprusside", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D009599", "tok_span": [0, 4]}], "relation_list": [{"subject": "Nitroprusside", "object": "hypotension", "sbj_char_span": [0, 13], "obj_char_span": [22, 33], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [6, 7]}], "umls_entity_list": []}, {"text": "Suppression of irCRF secretion in response to nitroprusside-induced hypotension is observed and occurs at a plasma corticosterone level between 8-12 micrograms/dl.", "entity_list": [{"name": "corticosterone", "ent_type": "Chemical", "char_span": [115, 129], "ent_id": "D003345", "tok_span": [24, 26]}, {"name": "nitroprusside", "ent_type": "Chemical", "char_span": [46, 59], "ent_id": "D009599", "tok_span": [10, 14]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [68, 79], "ent_id": "D007022", "tok_span": [16, 17]}], "relation_list": [{"subject": "nitroprusside", "object": "hypotension", "sbj_char_span": [46, 59], "obj_char_span": [68, 79], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [16, 17]}], "umls_entity_list": []}, {"text": "Noradrenergic involvement in catalepsy induced by delta 9-tetrahydrocannabinol.", "entity_list": [{"name": "catalepsy", "ent_type": "Disease", "char_span": [29, 38], "ent_id": "D002375", "tok_span": [4, 7]}, {"name": "delta 9-tetrahydrocannabinol", "ent_type": "Chemical", "char_span": [50, 78], "ent_id": "D013759", "tok_span": [9, 18]}], "relation_list": [{"subject": "delta 9-tetrahydrocannabinol", "object": "catalepsy", "sbj_char_span": [50, 78], "obj_char_span": [29, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 18], "obj_tok_span": [4, 7]}], "umls_entity_list": []}, {"text": "These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by THC, whereas dopaminergic neurons are important in catalepsy induced by haloperidol.", "entity_list": [{"name": "THC", "ent_type": "Chemical", "char_span": [118, 121], "ent_id": "D013759", "tok_span": [20, 22]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [169, 178], "ent_id": "D002375", "tok_span": [29, 32]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [97, 106], "ent_id": "D002375", "tok_span": [15, 18]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [190, 201], "ent_id": "D006220", "tok_span": [34, 37]}], "relation_list": [{"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [190, 201], "obj_char_span": [169, 178], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 37], "obj_tok_span": [29, 32]}, {"subject": "THC", "object": "catalepsy", "sbj_char_span": [118, 121], "obj_char_span": [97, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 22], "obj_tok_span": [15, 18]}, {"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [190, 201], "obj_char_span": [97, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 37], "obj_tok_span": [15, 18]}, {"subject": "THC", "object": "catalepsy", "sbj_char_span": [118, 121], "obj_char_span": [169, 178], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 22], "obj_tok_span": [29, 32]}], "umls_entity_list": []}, {"text": "Intracranial pressure increases during alfentanil-induced rigidity.", "entity_list": [{"name": "rigidity", "ent_type": "Disease", "char_span": [58, 66], "ent_id": "D009127", "tok_span": [13, 14]}, {"name": "alfentanil", "ent_type": "Chemical", "char_span": [39, 49], "ent_id": "D015760", "tok_span": [7, 11]}], "relation_list": [{"subject": "alfentanil", "object": "rigidity", "sbj_char_span": [39, 49], "obj_char_span": [58, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [13, 14]}], "umls_entity_list": []}, {"text": "Intracranial pressure (ICP) was measured during alfentanil-induced rigidity in rats.", "entity_list": [{"name": "alfentanil", "ent_type": "Chemical", "char_span": [48, 58], "ent_id": "D015760", "tok_span": [11, 15]}, {"name": "rigidity", "ent_type": "Disease", "char_span": [67, 75], "ent_id": "D009127", "tok_span": [17, 18]}], "relation_list": [{"subject": "alfentanil", "object": "rigidity", "sbj_char_span": [48, 58], "obj_char_span": [67, 75], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [17, 18]}], "umls_entity_list": []}, {"text": "These observations suggest that rigidity should be prevented when alfentanil, and, presumably, other opiates, are used in the anesthetic management of patients with ICP problems.", "entity_list": [{"name": "alfentanil", "ent_type": "Chemical", "char_span": [66, 76], "ent_id": "D015760", "tok_span": [9, 13]}, {"name": "rigidity", "ent_type": "Disease", "char_span": [32, 40], "ent_id": "D009127", "tok_span": [4, 5]}], "relation_list": [{"subject": "alfentanil", "object": "rigidity", "sbj_char_span": [66, 76], "obj_char_span": [32, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [4, 5]}], "umls_entity_list": []}, {"text": "It is concluded that patients on 5-FU treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed.", "entity_list": [{"name": "tachyarrhythmia", "ent_type": "Disease", "char_span": [145, 160], "ent_id": "D013610", "tok_span": [26, 31]}, {"name": "chest pain", "ent_type": "Disease", "char_span": [131, 141], "ent_id": "D002637", "tok_span": [23, 25]}, {"name": "5-FU", "ent_type": "Chemical", "char_span": [33, 37], "ent_id": "D005472", "tok_span": [6, 9]}], "relation_list": [{"subject": "5-FU", "object": "chest pain", "sbj_char_span": [33, 37], "obj_char_span": [131, 141], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [23, 25]}], "umls_entity_list": []}, {"text": "Verapamil-induced carbamazepine neurotoxicity.", "entity_list": [{"name": "Verapamil", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D014700", "tok_span": [0, 3]}, {"name": "neurotoxicity", "ent_type": "Disease", "char_span": [32, 45], "ent_id": "D020258", "tok_span": [9, 11]}, {"name": "carbamazepine", "ent_type": "Chemical", "char_span": [18, 31], "ent_id": "D002220", "tok_span": [5, 9]}], "relation_list": [{"subject": "Verapamil", "object": "neurotoxicity", "sbj_char_span": [0, 9], "obj_char_span": [32, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [9, 11]}, {"subject": "carbamazepine", "object": "neurotoxicity", "sbj_char_span": [18, 31], "obj_char_span": [32, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "Two patients with signs of carbamazepine neurotoxicity after combined treatment with verapamil showed complete recovery after discontinuation of the calcium entry blocker.", "entity_list": [{"name": "verapamil", "ent_type": "Chemical", "char_span": [85, 94], "ent_id": "D014700", "tok_span": [15, 18]}, {"name": "neurotoxicity", "ent_type": "Disease", "char_span": [41, 54], "ent_id": "D020258", "tok_span": [9, 11]}, {"name": "calcium", "ent_type": "Chemical", "char_span": [149, 156], "ent_id": "D002118", "tok_span": [25, 26]}, {"name": "carbamazepine", "ent_type": "Chemical", "char_span": [27, 40], "ent_id": "D002220", "tok_span": [5, 9]}], "relation_list": [{"subject": "verapamil", "object": "neurotoxicity", "sbj_char_span": [85, 94], "obj_char_span": [41, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [9, 11]}, {"subject": "carbamazepine", "object": "neurotoxicity", "sbj_char_span": [27, 40], "obj_char_span": [41, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "In contrast, dosages of Mipafox (less than or equal to 5 mg/kg) which inhibited mean NTE activity in spinal cord less than or equal to 61% and brain less than or equal to 60% produced this degree of cord damage in only 9% of the animals.", "entity_list": [{"name": "Mipafox", "ent_type": "Chemical", "char_span": [24, 31], "ent_id": "C005238", "tok_span": [6, 10]}, {"name": "cord damage", "ent_type": "Disease", "char_span": [199, 210], "ent_id": "D013118", "tok_span": [50, 52]}], "relation_list": [{"subject": "Mipafox", "object": "cord damage", "sbj_char_span": [24, 31], "obj_char_span": [199, 210], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 10], "obj_tok_span": [50, 52]}], "umls_entity_list": []}, {"text": "Cerebral infarction with a single oral dose of phenylpropanolamine.", "entity_list": [{"name": "Cerebral infarction", "ent_type": "Disease", "char_span": [0, 19], "ent_id": "D002544", "tok_span": [0, 3]}, {"name": "phenylpropanolamine", "ent_type": "Chemical", "char_span": [47, 66], "ent_id": "D010665", "tok_span": [9, 13]}], "relation_list": [{"subject": "phenylpropanolamine", "object": "Cerebral infarction", "sbj_char_span": [47, 66], "obj_char_span": [0, 19], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "We report the case of a young woman who suffered a cerebral infarction after taking a single oral dose of PPA.", "entity_list": [{"name": "PPA", "ent_type": "Chemical", "char_span": [106, 109], "ent_id": "D010665", "tok_span": [20, 22]}, {"name": "cerebral infarction", "ent_type": "Disease", "char_span": [51, 70], "ent_id": "D002544", "tok_span": [11, 13]}], "relation_list": [{"subject": "PPA", "object": "cerebral infarction", "sbj_char_span": [106, 109], "obj_char_span": [51, 70], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 22], "obj_tok_span": [11, 13]}], "umls_entity_list": []}, {"text": "Maternal lithium and neonatal Ebstein's anomaly: evaluation with cross-sectional echocardiography.", "entity_list": [{"name": "lithium", "ent_type": "Chemical", "char_span": [9, 16], "ent_id": "D008094", "tok_span": [1, 2]}, {"name": "Ebstein's anomaly", "ent_type": "Disease", "char_span": [30, 47], "ent_id": "D004437", "tok_span": [4, 9]}], "relation_list": [{"subject": "lithium", "object": "Ebstein's anomaly", "sbj_char_span": [9, 16], "obj_char_span": [30, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 2], "obj_tok_span": [4, 9]}], "umls_entity_list": []}, {"text": "The effects of exercise on the severity of isoproterenol-induced myocardial infarction were studied in female albino rats of 20,40,60 and 80 weeks of age.", "entity_list": [{"name": "isoproterenol", "ent_type": "Chemical", "char_span": [43, 56], "ent_id": "D007545", "tok_span": [8, 12]}, {"name": "myocardial infarction", "ent_type": "Disease", "char_span": [65, 86], "ent_id": "D009203", "tok_span": [14, 16]}], "relation_list": [{"subject": "isoproterenol", "object": "myocardial infarction", "sbj_char_span": [43, 56], "obj_char_span": [65, 86], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "Light microscopic analysis showed a significant protection against ADR-induced cardiac morphological alterations.", "entity_list": [{"name": "ADR", "ent_type": "Chemical", "char_span": [67, 70], "ent_id": "D004317", "tok_span": [8, 10]}, {"name": "cardiac morphological alterations", "ent_type": "Disease", "char_span": [79, 112], "ent_id": "D009202", "tok_span": [12, 15]}], "relation_list": [{"subject": "ADR", "object": "cardiac morphological alterations", "sbj_char_span": [67, 70], "obj_char_span": [79, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [12, 15]}], "umls_entity_list": []}, {"text": "Intrarenal infusion of noradrenaline caused hypertension at doses which did not do so when infused intravenously.", "entity_list": [{"name": "noradrenaline", "ent_type": "Chemical", "char_span": [23, 36], "ent_id": "D009638", "tok_span": [4, 7]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [44, 56], "ent_id": "D006973", "tok_span": [8, 9]}], "relation_list": [{"subject": "noradrenaline", "object": "hypertension", "sbj_char_span": [23, 36], "obj_char_span": [44, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [8, 9]}], "umls_entity_list": []}, {"text": "These results suggest that hypertension after chronic intrarenal noradrenaline infusion is produced by relatively higher levels of circulating noradrenaline and by triggering of an additional intrarenal pressor mechanism.", "entity_list": [{"name": "hypertension", "ent_type": "Disease", "char_span": [27, 39], "ent_id": "D006973", "tok_span": [4, 5]}, {"name": "noradrenaline", "ent_type": "Chemical", "char_span": [143, 156], "ent_id": "D009638", "tok_span": [21, 24]}, {"name": "noradrenaline", "ent_type": "Chemical", "char_span": [65, 78], "ent_id": "D009638", "tok_span": [9, 12]}], "relation_list": [{"subject": "noradrenaline", "object": "hypertension", "sbj_char_span": [143, 156], "obj_char_span": [27, 39], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [4, 5]}, {"subject": "noradrenaline", "object": "hypertension", "sbj_char_span": [65, 78], "obj_char_span": [27, 39], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [4, 5]}], "umls_entity_list": []}, {"text": "There was only one case of dementia possibly due to cimetidine (with a drug level of 1.9 microgram/ml 6 hr after a dose) in a group of 13 patients without liver or kidney disease who had cimetidine levels above 1.25 microgram/ml.", "entity_list": [{"name": "cimetidine", "ent_type": "Chemical", "char_span": [52, 62], "ent_id": "D002927", "tok_span": [10, 13]}, {"name": "dementia", "ent_type": "Disease", "char_span": [27, 35], "ent_id": "D003704", "tok_span": [6, 7]}, {"name": "cimetidine", "ent_type": "Chemical", "char_span": [187, 197], "ent_id": "D002927", "tok_span": [45, 48]}, {"name": "liver or kidney disease", "ent_type": "Disease", "char_span": [155, 178], "ent_id": "D00810", "tok_span": [39, 43]}], "relation_list": [{"subject": "cimetidine", "object": "dementia", "sbj_char_span": [187, 197], "obj_char_span": [27, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [45, 48], "obj_tok_span": [6, 7]}, {"subject": "cimetidine", "object": "dementia", "sbj_char_span": [52, 62], "obj_char_span": [27, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [6, 7]}], "umls_entity_list": []}, {"text": "Thus, high cimetidine levels alone do not always induce dementia.", "entity_list": [{"name": "cimetidine", "ent_type": "Chemical", "char_span": [11, 21], "ent_id": "D002927", "tok_span": [3, 6]}, {"name": "dementia", "ent_type": "Disease", "char_span": [56, 64], "ent_id": "D003704", "tok_span": [12, 13]}], "relation_list": [{"subject": "cimetidine", "object": "dementia", "sbj_char_span": [11, 21], "obj_char_span": [56, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [12, 13]}], "umls_entity_list": []}, {"text": "Development of clear cell adenocarcinoma in DES-exposed offspring under observation.", "entity_list": [{"name": "DES", "ent_type": "Chemical", "char_span": [44, 47], "ent_id": "D004054", "tok_span": [6, 7]}, {"name": "clear cell adenocarcinoma", "ent_type": "Disease", "char_span": [15, 40], "ent_id": "D018262", "tok_span": [2, 5]}], "relation_list": [{"subject": "DES", "object": "clear cell adenocarcinoma", "sbj_char_span": [44, 47], "obj_char_span": [15, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [2, 5]}], "umls_entity_list": []}, {"text": "Phenobarbitone-induced enlargement of the liver in the rat: its relationship to carbon tetrachloride-induced cirrhosis.", "entity_list": [{"name": "enlargement of the liver", "ent_type": "Disease", "char_span": [23, 47], "ent_id": "D006529", "tok_span": [6, 10]}, {"name": "Phenobarbitone", "ent_type": "Chemical", "char_span": [0, 14], "ent_id": "D010634", "tok_span": [0, 4]}, {"name": "cirrhosis", "ent_type": "Disease", "char_span": [109, 118], "ent_id": "D005355", "tok_span": [24, 25]}, {"name": "carbon tetrachloride", "ent_type": "Chemical", "char_span": [80, 100], "ent_id": "D002251", "tok_span": [17, 22]}], "relation_list": [{"subject": "Phenobarbitone", "object": "enlargement of the liver", "sbj_char_span": [0, 14], "obj_char_span": [23, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [6, 10]}], "umls_entity_list": []}, {"text": "The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial \"calibrating\" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.", "entity_list": [{"name": "phenobarbitone", "ent_type": "Chemical", "char_span": [476, 490], "ent_id": "D010634", "tok_span": [112, 116]}, {"name": "atrophy", "ent_type": "Disease", "char_span": [225, 232], "ent_id": "D001284", "tok_span": [54, 55]}, {"name": "carbon tetrachloride", "ent_type": "Chemical", "char_span": [285, 305], "ent_id": "D002251", "tok_span": [64, 69]}, {"name": "phenobarbitone", "ent_type": "Chemical", "char_span": [336, 350], "ent_id": "D010634", "tok_span": [76, 80]}, {"name": "enlargement of the liver", "ent_type": "Disease", "char_span": [499, 523], "ent_id": "D006529", "tok_span": [118, 122]}, {"name": "cirrhosis of the liver", "ent_type": "Disease", "char_span": [20, 42], "ent_id": "D008103", "tok_span": [4, 8]}, {"name": "ascites", "ent_type": "Disease", "char_span": [116, 123], "ent_id": "D001201", "tok_span": [26, 27]}, {"name": "splenomegaly", "ent_type": "Disease", "char_span": [179, 191], "ent_id": "D013163", "tok_span": [43, 46]}, {"name": "carbon tetrachloride", "ent_type": "Chemical", "char_span": [436, 456], "ent_id": "D002251", "tok_span": [102, 107]}], "relation_list": [{"subject": "phenobarbitone", "object": "cirrhosis of the liver", "sbj_char_span": [476, 490], "obj_char_span": [20, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [112, 116], "obj_tok_span": [4, 8]}, {"subject": "phenobarbitone", "object": "enlargement of the liver", "sbj_char_span": [476, 490], "obj_char_span": [499, 523], "rel_type": "chemical-induced disease", "sbj_tok_span": [112, 116], "obj_tok_span": [118, 122]}, {"subject": "phenobarbitone", "object": "cirrhosis of the liver", "sbj_char_span": [336, 350], "obj_char_span": [20, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [76, 80], "obj_tok_span": [4, 8]}, {"subject": "carbon tetrachloride", "object": "cirrhosis of the liver", "sbj_char_span": [436, 456], "obj_char_span": [20, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [102, 107], "obj_tok_span": [4, 8]}, {"subject": "phenobarbitone", "object": "enlargement of the liver", "sbj_char_span": [336, 350], "obj_char_span": [499, 523], "rel_type": "chemical-induced disease", "sbj_tok_span": [76, 80], "obj_tok_span": [118, 122]}, {"subject": "carbon tetrachloride", "object": "cirrhosis of the liver", "sbj_char_span": [285, 305], "obj_char_span": [20, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [64, 69], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "Attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride in rats.", "entity_list": [{"name": "diabetes-insipidus-like syndrome", "ent_type": "Disease", "char_span": [35, 67], "ent_id": "D003919", "tok_span": [8, 17]}, {"name": "amiloride", "ent_type": "Chemical", "char_span": [71, 80], "ent_id": "D000584", "tok_span": [18, 22]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [19, 26], "ent_id": "D008094", "tok_span": [5, 6]}], "relation_list": [{"subject": "lithium", "object": "diabetes-insipidus-like syndrome", "sbj_char_span": [19, 26], "obj_char_span": [35, 67], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 6], "obj_tok_span": [8, 17]}], "umls_entity_list": []}, {"text": "In all the experiments, the attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level.", "entity_list": [{"name": "diabetes-insipidus-like syndrome", "ent_type": "Disease", "char_span": [63, 95], "ent_id": "D003919", "tok_span": [12, 21]}, {"name": "amiloride", "ent_type": "Chemical", "char_span": [99, 108], "ent_id": "D000584", "tok_span": [22, 26]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [47, 54], "ent_id": "D008094", "tok_span": [9, 10]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [165, 172], "ent_id": "D008094", "tok_span": [36, 37]}, {"name": "potassium", "ent_type": "Chemical", "char_span": [267, 276], "ent_id": "D011188", "tok_span": [55, 56]}], "relation_list": [{"subject": "lithium", "object": "diabetes-insipidus-like syndrome", "sbj_char_span": [47, 54], "obj_char_span": [63, 95], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [12, 21]}, {"subject": "lithium", "object": "diabetes-insipidus-like syndrome", "sbj_char_span": [165, 172], "obj_char_span": [63, 95], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 37], "obj_tok_span": [12, 21]}], "umls_entity_list": []}, {"text": "Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.", "entity_list": [{"name": "impaired memory", "ent_type": "Disease", "char_span": [212, 227], "ent_id": "D008569", "tok_span": [47, 49]}, {"name": "weight loss", "ent_type": "Disease", "char_span": [229, 240], "ent_id": "D015431", "tok_span": [50, 52]}, {"name": "alprazolam", "ent_type": "Chemical", "char_span": [32, 42], "ent_id": "D000525", "tok_span": [5, 9]}, {"name": "irritability", "ent_type": "Disease", "char_span": [198, 210], "ent_id": "D001523", "tok_span": [44, 46]}, {"name": "enuresis", "ent_type": "Disease", "char_span": [112, 120], "ent_id": "D004775", "tok_span": [25, 28]}, {"name": "depression", "ent_type": "Disease", "char_span": [100, 110], "ent_id": "D003866", "tok_span": [23, 24]}, {"name": "aggression", "ent_type": "Disease", "char_span": [140, 150], "ent_id": "D001523", "tok_span": [33, 34]}, {"name": "ataxia", "ent_type": "Disease", "char_span": [245, 251], "ent_id": "D001259", "tok_span": [53, 55]}], "relation_list": [{"subject": "alprazolam", "object": "enuresis", "sbj_char_span": [32, 42], "obj_char_span": [112, 120], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [25, 28]}, {"subject": "alprazolam", "object": "impaired memory", "sbj_char_span": [32, 42], "obj_char_span": [212, 227], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [47, 49]}, {"subject": "alprazolam", "object": "depression", "sbj_char_span": [32, 42], "obj_char_span": [100, 110], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [23, 24]}, {"subject": "alprazolam", "object": "weight loss", "sbj_char_span": [32, 42], "obj_char_span": [229, 240], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [50, 52]}, {"subject": "alprazolam", "object": "ataxia", "sbj_char_span": [32, 42], "obj_char_span": [245, 251], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [53, 55]}], "umls_entity_list": []}, {"text": "The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.", "entity_list": [{"name": "Dup 753", "ent_type": "Chemical", "char_span": [241, 248], "ent_id": "D019808", "tok_span": [42, 46]}, {"name": "proteinuria", "ent_type": "Disease", "char_span": [46, 57], "ent_id": "D011507", "tok_span": [8, 9]}, {"name": "angiotensin II", "ent_type": "Chemical", "char_span": [269, 283], "ent_id": "D000804", "tok_span": [53, 55]}, {"name": "nephrotic syndromes", "ent_type": "Disease", "char_span": [18, 37], "ent_id": "D009404", "tok_span": [3, 6]}, {"name": "puromycin aminonucleoside", "ent_type": "Chemical", "char_span": [166, 191], "ent_id": "D011692", "tok_span": [30, 35]}, {"name": "losartan", "ent_type": "Chemical", "char_span": [250, 258], "ent_id": "D019808", "tok_span": [47, 49]}, {"name": "hypoalbuminemia", "ent_type": "Disease", "char_span": [59, 74], "ent_id": "D034141", "tok_span": [10, 13]}, {"name": "hypercholesterolemia", "ent_type": "Disease", "char_span": [76, 96], "ent_id": "D006937", "tok_span": [14, 17]}, {"name": "blood nitrogen urea", "ent_type": "Chemical", "char_span": [113, 132], "ent_id": "D001806", "tok_span": [20, 23]}], "relation_list": [{"subject": "puromycin aminonucleoside", "object": "hypercholesterolemia", "sbj_char_span": [166, 191], "obj_char_span": [76, 96], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 35], "obj_tok_span": [14, 17]}, {"subject": "puromycin aminonucleoside", "object": "hypoalbuminemia", "sbj_char_span": [166, 191], "obj_char_span": [59, 74], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 35], "obj_tok_span": [10, 13]}, {"subject": "puromycin aminonucleoside", "object": "nephrotic syndromes", "sbj_char_span": [166, 191], "obj_char_span": [18, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 35], "obj_tok_span": [3, 6]}, {"subject": "puromycin aminonucleoside", "object": "proteinuria", "sbj_char_span": [166, 191], "obj_char_span": [46, 57], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 35], "obj_tok_span": [8, 9]}], "umls_entity_list": []}, {"text": "Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients.", "entity_list": [{"name": "gallstone", "ent_type": "Disease", "char_span": [107, 116], "ent_id": "D042882", "tok_span": [22, 24]}, {"name": "octreotide", "ent_type": "Chemical", "char_span": [67, 77], "ent_id": "D015282", "tok_span": [13, 16]}, {"name": "acromegalic", "ent_type": "Disease", "char_span": [138, 149], "ent_id": "D000172", "tok_span": [27, 30]}], "relation_list": [{"subject": "octreotide", "object": "gallstone", "sbj_char_span": [67, 77], "obj_char_span": [107, 116], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [22, 24]}], "umls_entity_list": []}, {"text": "During treatment with octreotide, 17 patients developed sludge, 10 had gallstones, and 1 developed acute cholecystitis requiring surgery.", "entity_list": [{"name": "octreotide", "ent_type": "Chemical", "char_span": [22, 32], "ent_id": "D015282", "tok_span": [3, 6]}, {"name": "acute cholecystitis", "ent_type": "Disease", "char_span": [99, 118], "ent_id": "D041881", "tok_span": [21, 25]}, {"name": "gallstones", "ent_type": "Disease", "char_span": [71, 81], "ent_id": "D042882", "tok_span": [14, 17]}], "relation_list": [{"subject": "octreotide", "object": "acute cholecystitis", "sbj_char_span": [22, 32], "obj_char_span": [99, 118], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [21, 25]}, {"subject": "octreotide", "object": "gallstones", "sbj_char_span": [22, 32], "obj_char_span": [71, 81], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [14, 17]}], "umls_entity_list": []}, {"text": "After withdrawal of octreotide in 10 patients without gallstones, 8 patients assessed had return of normal gallbladder contractility within 1 month.", "entity_list": [{"name": "octreotide", "ent_type": "Chemical", "char_span": [20, 30], "ent_id": "D015282", "tok_span": [3, 6]}, {"name": "gallstones", "ent_type": "Disease", "char_span": [54, 64], "ent_id": "D042882", "tok_span": [10, 13]}], "relation_list": [{"subject": "octreotide", "object": "gallstones", "sbj_char_span": [20, 30], "obj_char_span": [54, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [10, 13]}], "umls_entity_list": []}, {"text": "Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge, gallstones, and cholecystitis during octreotide therapy in Chinese acromegalic patients.", "entity_list": [{"name": "acromegalic", "ent_type": "Disease", "char_span": [194, 205], "ent_id": "D000172", "tok_span": [37, 40]}, {"name": "cholecystitis", "ent_type": "Disease", "char_span": [143, 156], "ent_id": "D002764", "tok_span": [27, 30]}, {"name": "octreotide", "ent_type": "Chemical", "char_span": [164, 174], "ent_id": "D015282", "tok_span": [31, 34]}, {"name": "gallstones", "ent_type": "Disease", "char_span": [127, 137], "ent_id": "D042882", "tok_span": [22, 25]}], "relation_list": [{"subject": "octreotide", "object": "gallstones", "sbj_char_span": [164, 174], "obj_char_span": [127, 137], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 34], "obj_tok_span": [22, 25]}], "umls_entity_list": []}, {"text": "Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease.", "entity_list": [{"name": "propranolol", "ent_type": "Chemical", "char_span": [46, 57], "ent_id": "D011433", "tok_span": [12, 16]}, {"name": "dyskinesia", "ent_type": "Disease", "char_span": [32, 42], "ent_id": "D004409", "tok_span": [7, 11]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [15, 23], "ent_id": "D007980", "tok_span": [2, 5]}, {"name": "Parkinson's disease", "ent_type": "Disease", "char_span": [61, 80], "ent_id": "D010300", "tok_span": [17, 21]}], "relation_list": [{"subject": "levodopa", "object": "dyskinesia", "sbj_char_span": [15, 23], "obj_char_span": [32, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "This study suggests that administration of low doses of beta-blockers may improve levodopa-induced ballistic and choreic dyskinesia in PD.", "entity_list": [{"name": "levodopa", "ent_type": "Chemical", "char_span": [82, 90], "ent_id": "D007980", "tok_span": [14, 17]}, {"name": "PD", "ent_type": "Disease", "char_span": [135, 137], "ent_id": "D010300", "tok_span": [30, 31]}, {"name": "dyskinesia", "ent_type": "Disease", "char_span": [121, 131], "ent_id": "D004409", "tok_span": [25, 29]}], "relation_list": [{"subject": "levodopa", "object": "dyskinesia", "sbj_char_span": [82, 90], "obj_char_span": [121, 131], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [25, 29]}], "umls_entity_list": []}, {"text": "Morphological features of encephalopathy after chronic administration of the antiepileptic drug valproate to rats.", "entity_list": [{"name": "valproate", "ent_type": "Chemical", "char_span": [96, 105], "ent_id": "D014635", "tok_span": [16, 19]}, {"name": "encephalopathy", "ent_type": "Disease", "char_span": [26, 40], "ent_id": "D001927", "tok_span": [4, 6]}], "relation_list": [{"subject": "valproate", "object": "encephalopathy", "sbj_char_span": [96, 105], "obj_char_span": [26, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral \"Polfa\") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (\"valproate encephalopathy\").", "entity_list": [{"name": "neurological disorders", "ent_type": "Disease", "char_span": [193, 215], "ent_id": "D009422", "tok_span": [56, 58]}, {"name": "sodium valproate", "ent_type": "Chemical", "char_span": [61, 77], "ent_id": "D014635", "tok_span": [14, 18]}, {"name": "encephalopathy", "ent_type": "Disease", "char_span": [257, 271], "ent_id": "D001927", "tok_span": [66, 68]}, {"name": "cerebellum damage", "ent_type": "Disease", "char_span": [227, 244], "ent_id": "D002526", "tok_span": [59, 61]}, {"name": "valproate", "ent_type": "Chemical", "char_span": [247, 256], "ent_id": "D014635", "tok_span": [63, 66]}], "relation_list": [{"subject": "valproate", "object": "encephalopathy", "sbj_char_span": [247, 256], "obj_char_span": [257, 271], "rel_type": "chemical-induced disease", "sbj_tok_span": [63, 66], "obj_tok_span": [66, 68]}, {"subject": "sodium valproate", "object": "encephalopathy", "sbj_char_span": [61, 77], "obj_char_span": [257, 271], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 18], "obj_tok_span": [66, 68]}], "umls_entity_list": []}, {"text": "The possible influence of the hepatic damage, mainly hyperammonemia, upon the development of valproate encephalopathy is discussed.", "entity_list": [{"name": "valproate", "ent_type": "Chemical", "char_span": [93, 102], "ent_id": "D014635", "tok_span": [18, 21]}, {"name": "hyperammonemia", "ent_type": "Disease", "char_span": [53, 67], "ent_id": "D022124", "tok_span": [9, 13]}, {"name": "encephalopathy", "ent_type": "Disease", "char_span": [103, 117], "ent_id": "D001927", "tok_span": [21, 23]}, {"name": "hepatic damage", "ent_type": "Disease", "char_span": [30, 44], "ent_id": "D056486", "tok_span": [5, 7]}], "relation_list": [{"subject": "valproate", "object": "encephalopathy", "sbj_char_span": [93, 102], "obj_char_span": [103, 117], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.", "entity_list": [{"name": "vancomycin", "ent_type": "Chemical", "char_span": [103, 113], "ent_id": "D014640", "tok_span": [20, 21]}, {"name": "amikacin", "ent_type": "Chemical", "char_span": [39, 47], "ent_id": "D000583", "tok_span": [8, 11]}, {"name": "streptococcal endophthalmitis", "ent_type": "Disease", "char_span": [135, 164], "ent_id": "D013290", "tok_span": [26, 33]}, {"name": "retinal toxicity", "ent_type": "Disease", "char_span": [48, 64], "ent_id": "D012164", "tok_span": [11, 13]}, {"name": "amikacin", "ent_type": "Chemical", "char_span": [90, 98], "ent_id": "D000583", "tok_span": [16, 19]}], "relation_list": [{"subject": "amikacin", "object": "retinal toxicity", "sbj_char_span": [39, 47], "obj_char_span": [48, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [11, 13]}, {"subject": "amikacin", "object": "retinal toxicity", "sbj_char_span": [90, 98], "obj_char_span": [48, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [11, 13]}], "umls_entity_list": []}, {"text": "Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff-Parkinson-White syndrome and idiopathic dilated cardiomyopathy.", "entity_list": [{"name": "atrioventricular reentrant tachycardia", "ent_type": "Disease", "char_span": [35, 73], "ent_id": "D013611", "tok_span": [7, 16]}, {"name": "idiopathic dilated cardiomyopathy", "ent_type": "Disease", "char_span": [165, 198], "ent_id": "D002311", "tok_span": [35, 38]}, {"name": "verapamil", "ent_type": "Chemical", "char_span": [80, 89], "ent_id": "D014700", "tok_span": [17, 20]}, {"name": "Wolff-Parkinson-White syndrome", "ent_type": "Disease", "char_span": [130, 160], "ent_id": "D014927", "tok_span": [27, 34]}], "relation_list": [{"subject": "verapamil", "object": "atrioventricular reentrant tachycardia", "sbj_char_span": [80, 89], "obj_char_span": [35, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [7, 16]}], "umls_entity_list": []}, {"text": "QRS without preexcitation, caused by junctional escape beats after verapamil or unidirectional antegrade block of accessory pathway after catheter ablation, established frequent AVRT attack.", "entity_list": [{"name": "verapamil", "ent_type": "Chemical", "char_span": [67, 76], "ent_id": "D014700", "tok_span": [14, 17]}, {"name": "AVRT", "ent_type": "Disease", "char_span": [178, 182], "ent_id": "D013611", "tok_span": [34, 36]}], "relation_list": [{"subject": "verapamil", "object": "AVRT", "sbj_char_span": [67, 76], "obj_char_span": [178, 182], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [34, 36]}], "umls_entity_list": []}, {"text": "We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).", "entity_list": [{"name": "1,1-dichloro-2,2,2-trifluoroethane", "ent_type": "Chemical", "char_span": [129, 163], "ent_id": "C067411", "tok_span": [22, 40]}, {"name": "liver disease", "ent_type": "Disease", "char_span": [31, 44], "ent_id": "D008107", "tok_span": [5, 7]}, {"name": "HCFC 123", "ent_type": "Chemical", "char_span": [165, 173], "ent_id": "C067411", "tok_span": [41, 44]}, {"name": "1-chloro-1,2,2,2-tetrafluoroethane", "ent_type": "Chemical", "char_span": [179, 213], "ent_id": "C072959", "tok_span": [46, 64]}, {"name": "HCFC 124", "ent_type": "Chemical", "char_span": [215, 223], "ent_id": "C072959", "tok_span": [65, 68]}], "relation_list": [{"subject": "HCFC 124", "object": "liver disease", "sbj_char_span": [215, 223], "obj_char_span": [31, 44], "rel_type": "chemical-induced disease", "sbj_tok_span": [65, 68], "obj_tok_span": [5, 7]}, {"subject": "1,1-dichloro-2,2,2-trifluoroethane", "object": "liver disease", "sbj_char_span": [129, 163], "obj_char_span": [31, 44], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 40], "obj_tok_span": [5, 7]}, {"subject": "1-chloro-1,2,2,2-tetrafluoroethane", "object": "liver disease", "sbj_char_span": [179, 213], "obj_char_span": [31, 44], "rel_type": "chemical-induced disease", "sbj_tok_span": [46, 64], "obj_tok_span": [5, 7]}, {"subject": "HCFC 123", "object": "liver disease", "sbj_char_span": [165, 173], "obj_char_span": [31, 44], "rel_type": "chemical-induced disease", "sbj_tok_span": [41, 44], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "Patients given prilocaine were more likely to develop hearing loss (10 out of 22) than those given bupivacaine (4 out of 22) (P < 0.05).", "entity_list": [{"name": "prilocaine", "ent_type": "Chemical", "char_span": [15, 25], "ent_id": "D011318", "tok_span": [2, 4]}, {"name": "hearing loss", "ent_type": "Disease", "char_span": [54, 66], "ent_id": "D034381", "tok_span": [9, 11]}, {"name": "bupivacaine", "ent_type": "Chemical", "char_span": [99, 110], "ent_id": "D002045", "tok_span": [20, 24]}], "relation_list": [{"subject": "bupivacaine", "object": "hearing loss", "sbj_char_span": [99, 110], "obj_char_span": [54, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 24], "obj_tok_span": [9, 11]}, {"subject": "prilocaine", "object": "hearing loss", "sbj_char_span": [15, 25], "obj_char_span": [54, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 4], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "The average hearing loss for speech frequencies was about 10 dB after prilocaine and 15 dB after bupivacaine.", "entity_list": [{"name": "hearing loss", "ent_type": "Disease", "char_span": [12, 24], "ent_id": "D034381", "tok_span": [2, 4]}, {"name": "prilocaine", "ent_type": "Chemical", "char_span": [70, 80], "ent_id": "D011318", "tok_span": [12, 14]}, {"name": "bupivacaine", "ent_type": "Chemical", "char_span": [97, 108], "ent_id": "D002045", "tok_span": [18, 22]}], "relation_list": [{"subject": "prilocaine", "object": "hearing loss", "sbj_char_span": [70, 80], "obj_char_span": [12, 24], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 14], "obj_tok_span": [2, 4]}, {"subject": "bupivacaine", "object": "hearing loss", "sbj_char_span": [97, 108], "obj_char_span": [12, 24], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 22], "obj_tok_span": [2, 4]}], "umls_entity_list": []}, {"text": "Pethidine-associated seizure in a healthy adolescent receiving pethidine for postoperative pain control.", "entity_list": [{"name": "pethidine", "ent_type": "Chemical", "char_span": [63, 72], "ent_id": "D008614", "tok_span": [12, 16]}, {"name": "seizure", "ent_type": "Disease", "char_span": [21, 28], "ent_id": "D012640", "tok_span": [6, 7]}, {"name": "Pethidine", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D008614", "tok_span": [0, 4]}, {"name": "postoperative pain", "ent_type": "Disease", "char_span": [77, 95], "ent_id": "D010149", "tok_span": [17, 19]}], "relation_list": [{"subject": "pethidine", "object": "seizure", "sbj_char_span": [63, 72], "obj_char_span": [21, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 16], "obj_tok_span": [6, 7]}, {"subject": "Pethidine", "object": "seizure", "sbj_char_span": [0, 9], "obj_char_span": [21, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [6, 7]}], "umls_entity_list": []}, {"text": "A previously healthy child who developed acute, severe, rapidly progressive vanishing bile duct syndrome shortly after Stevens-Johnson syndrome is described; this was temporally associated with ibuprofen use.", "entity_list": [{"name": "ibuprofen", "ent_type": "Chemical", "char_span": [194, 203], "ent_id": "D007052", "tok_span": [30, 34]}, {"name": "vanishing bile duct syndrome", "ent_type": "Disease", "char_span": [76, 104], "ent_id": "D001649", "tok_span": [12, 16]}, {"name": "Stevens-Johnson syndrome", "ent_type": "Disease", "char_span": [119, 143], "ent_id": "D013262", "tok_span": [18, 22]}], "relation_list": [{"subject": "ibuprofen", "object": "Stevens-Johnson syndrome", "sbj_char_span": [194, 203], "obj_char_span": [119, 143], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 34], "obj_tok_span": [18, 22]}], "umls_entity_list": []}, {"text": "High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium.", "entity_list": [{"name": "primary pulmonary hypertension", "ent_type": "Disease", "char_span": [18, 48], "ent_id": "D006976", "tok_span": [3, 6]}, {"name": "appetite suppressants", "ent_type": "Chemical", "char_span": [65, 86], "ent_id": "D001067", "tok_span": [8, 11]}], "relation_list": [{"subject": "appetite suppressants", "object": "primary pulmonary hypertension", "sbj_char_span": [65, 86], "obj_char_span": [18, 48], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [3, 6]}], "umls_entity_list": []}, {"text": "Primary pulmonary hypertension is a rare, progressive and incurable disease, which has been associated with the intake of appetite suppressant drugs.", "entity_list": [{"name": "Primary pulmonary hypertension", "ent_type": "Disease", "char_span": [0, 30], "ent_id": "D006976", "tok_span": [0, 3]}, {"name": "appetite suppressant", "ent_type": "Chemical", "char_span": [122, 142], "ent_id": "D001067", "tok_span": [21, 24]}], "relation_list": [{"subject": "appetite suppressant", "object": "Primary pulmonary hypertension", "sbj_char_span": [122, 142], "obj_char_span": [0, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "In 8 patients the diagnosis of primary pulmonary hypertension was uncertain, 5 of them had taken appetite suppressants.", "entity_list": [{"name": "appetite suppressants", "ent_type": "Chemical", "char_span": [97, 118], "ent_id": "D001067", "tok_span": [17, 20]}, {"name": "primary pulmonary hypertension", "ent_type": "Disease", "char_span": [31, 61], "ent_id": "D006976", "tok_span": [6, 9]}], "relation_list": [{"subject": "appetite suppressants", "object": "primary pulmonary hypertension", "sbj_char_span": [97, 118], "obj_char_span": [31, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [6, 9]}], "umls_entity_list": []}, {"text": "A policy of unrestricted prescription of appetite suppressants may lead to a high incidence of associated primary pulmonary hypertension.", "entity_list": [{"name": "primary pulmonary hypertension", "ent_type": "Disease", "char_span": [106, 136], "ent_id": "D006976", "tok_span": [17, 20]}, {"name": "appetite suppressants", "ent_type": "Chemical", "char_span": [41, 62], "ent_id": "D001067", "tok_span": [6, 9]}], "relation_list": [{"subject": "appetite suppressants", "object": "primary pulmonary hypertension", "sbj_char_span": [41, 62], "obj_char_span": [106, 136], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [17, 20]}], "umls_entity_list": []}, {"text": "Choreoathetoid movements associated with rapid adjustment to methadone.", "entity_list": [{"name": "Choreoathetoid movements", "ent_type": "Disease", "char_span": [0, 24], "ent_id": "D002819", "tok_span": [0, 7]}, {"name": "methadone", "ent_type": "Chemical", "char_span": [61, 70], "ent_id": "D008691", "tok_span": [12, 15]}], "relation_list": [{"subject": "methadone", "object": "Choreoathetoid movements", "sbj_char_span": [61, 70], "obj_char_span": [0, 24], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [0, 7]}], "umls_entity_list": []}, {"text": "This is a case report of euphoria and choreoathetoid movements both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing heroine and cocaine.", "entity_list": [{"name": "cocaine", "ent_type": "Chemical", "char_span": [209, 216], "ent_id": "D003042", "tok_span": [43, 44]}, {"name": "methadone", "ent_type": "Chemical", "char_span": [152, 161], "ent_id": "D008691", "tok_span": [31, 34]}, {"name": "choreoathetoid movements", "ent_type": "Disease", "char_span": [38, 62], "ent_id": "D002819", "tok_span": [10, 17]}, {"name": "heroine", "ent_type": "Chemical", "char_span": [197, 204], "ent_id": "D003932", "tok_span": [40, 42]}], "relation_list": [{"subject": "methadone", "object": "choreoathetoid movements", "sbj_char_span": [152, 161], "obj_char_span": [38, 62], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 34], "obj_tok_span": [10, 17]}, {"subject": "cocaine", "object": "choreoathetoid movements", "sbj_char_span": [209, 216], "obj_char_span": [38, 62], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 44], "obj_tok_span": [10, 17]}], "umls_entity_list": []}, {"text": "Cocaine-induced mood disorder: prevalence rates and psychiatric symptoms in an outpatient cocaine-dependent sample.", "entity_list": [{"name": "cocaine", "ent_type": "Chemical", "char_span": [90, 97], "ent_id": "D003042", "tok_span": [16, 17]}, {"name": "Cocaine", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "D003042", "tok_span": [0, 3]}, {"name": "psychiatric", "ent_type": "Disease", "char_span": [52, 63], "ent_id": "D001523", "tok_span": [11, 12]}, {"name": "mood disorder", "ent_type": "Disease", "char_span": [16, 29], "ent_id": "D019964", "tok_span": [5, 7]}], "relation_list": [{"subject": "Cocaine", "object": "mood disorder", "sbj_char_span": [0, 7], "obj_char_span": [16, 29], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 7]}, {"subject": "cocaine", "object": "mood disorder", "sbj_char_span": [90, 97], "obj_char_span": [16, 29], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 17], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "This paper attempts to examine and compare prevalence rates and symptom patterns of DSM substance-induced and other mood disorders. 243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.", "entity_list": [{"name": "mood disorders", "ent_type": "Disease", "char_span": [215, 229], "ent_id": "D019964", "tok_span": [40, 42]}, {"name": "mood disorders", "ent_type": "Disease", "char_span": [116, 130], "ent_id": "D019964", "tok_span": [19, 21]}, {"name": "mood disorder", "ent_type": "Disease", "char_span": [187, 200], "ent_id": "D019964", "tok_span": [32, 34]}, {"name": "CIMD", "ent_type": "Disease", "char_span": [202, 206], "ent_id": "D019970", "tok_span": [35, 37]}, {"name": "mood disorder", "ent_type": "Disease", "char_span": [237, 250], "ent_id": "D019964", "tok_span": [45, 47]}, {"name": "psychiatric", "ent_type": "Disease", "char_span": [280, 291], "ent_id": "D001523", "tok_span": [52, 53]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [136, 143], "ent_id": "D003042", "tok_span": [23, 24]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [171, 178], "ent_id": "D003042", "tok_span": [29, 30]}], "relation_list": [{"subject": "cocaine", "object": "mood disorder", "sbj_char_span": [136, 143], "obj_char_span": [187, 200], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 24], "obj_tok_span": [32, 34]}, {"subject": "cocaine", "object": "mood disorder", "sbj_char_span": [171, 178], "obj_char_span": [237, 250], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 30], "obj_tok_span": [45, 47]}, {"subject": "cocaine", "object": "mood disorder", "sbj_char_span": [171, 178], "obj_char_span": [187, 200], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 30], "obj_tok_span": [32, 34]}, {"subject": "cocaine", "object": "mood disorder", "sbj_char_span": [136, 143], "obj_char_span": [237, 250], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 24], "obj_tok_span": [45, 47]}, {"subject": "cocaine", "object": "mood disorders", "sbj_char_span": [171, 178], "obj_char_span": [215, 229], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 30], "obj_tok_span": [40, 42]}, {"subject": "cocaine", "object": "mood disorders", "sbj_char_span": [136, 143], "obj_char_span": [215, 229], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 24], "obj_tok_span": [40, 42]}, {"subject": "cocaine", "object": "mood disorders", "sbj_char_span": [171, 178], "obj_char_span": [116, 130], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 30], "obj_tok_span": [19, 21]}, {"subject": "cocaine", "object": "mood disorders", "sbj_char_span": [136, 143], "obj_char_span": [116, 130], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 24], "obj_tok_span": [19, 21]}], "umls_entity_list": []}, {"text": "Hemolysis of human erythrocytes induced by tamoxifen is related to disruption of membrane structure.", "entity_list": [{"name": "tamoxifen", "ent_type": "Chemical", "char_span": [43, 52], "ent_id": "D013629", "tok_span": [7, 8]}, {"name": "Hemolysis", "ent_type": "Disease", "char_span": [0, 9], "ent_id": "D006461", "tok_span": [0, 2]}], "relation_list": [{"subject": "tamoxifen", "object": "Hemolysis", "sbj_char_span": [43, 52], "obj_char_span": [0, 9], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Tamoxifen (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, induces changes in normal discoid shape of erythrocytes and hemolytic anemia.", "entity_list": [{"name": "hemolytic anemia", "ent_type": "Disease", "char_span": [162, 178], "ent_id": "D000743", "tok_span": [31, 34]}, {"name": "TAM", "ent_type": "Chemical", "char_span": [11, 14], "ent_id": "D013629", "tok_span": [3, 4]}, {"name": "breast cancer", "ent_type": "Disease", "char_span": [87, 100], "ent_id": "D001943", "tok_span": [18, 20]}, {"name": "Tamoxifen", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D013629", "tok_span": [0, 2]}], "relation_list": [{"subject": "Tamoxifen", "object": "hemolytic anemia", "sbj_char_span": [0, 9], "obj_char_span": [162, 178], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [31, 34]}, {"subject": "TAM", "object": "hemolytic anemia", "sbj_char_span": [11, 14], "obj_char_span": [162, 178], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [31, 34]}], "umls_entity_list": []}, {"text": "This work evaluates the effects of TAM on isolated human erythrocytes, attempting to identify the underlying mechanisms on TAM-induced hemolytic anemia and the involvement of biomembranes in its cytostatic action mechanisms.", "entity_list": [{"name": "TAM", "ent_type": "Chemical", "char_span": [123, 126], "ent_id": "D013629", "tok_span": [19, 20]}, {"name": "TAM", "ent_type": "Chemical", "char_span": [35, 38], "ent_id": "D013629", "tok_span": [6, 7]}, {"name": "hemolytic anemia", "ent_type": "Disease", "char_span": [135, 151], "ent_id": "D000743", "tok_span": [22, 25]}], "relation_list": [{"subject": "TAM", "object": "hemolytic anemia", "sbj_char_span": [35, 38], "obj_char_span": [135, 151], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [22, 25]}, {"subject": "TAM", "object": "hemolytic anemia", "sbj_char_span": [123, 126], "obj_char_span": [135, 151], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 20], "obj_tok_span": [22, 25]}], "umls_entity_list": []}, {"text": "TAM induces hemolysis of erythrocytes as a function of concentration.", "entity_list": [{"name": "hemolysis", "ent_type": "Disease", "char_span": [12, 21], "ent_id": "D006461", "tok_span": [2, 4]}, {"name": "TAM", "ent_type": "Chemical", "char_span": [0, 3], "ent_id": "D013629", "tok_span": [0, 1]}], "relation_list": [{"subject": "TAM", "object": "hemolysis", "sbj_char_span": [0, 3], "obj_char_span": [12, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 1], "obj_tok_span": [2, 4]}], "umls_entity_list": []}, {"text": "The extension of hemolysis is variable with erythrocyte samples, but 12.5 microM TAM induces total hemolysis of all tested suspensions.", "entity_list": [{"name": "hemolysis", "ent_type": "Disease", "char_span": [17, 26], "ent_id": "D006461", "tok_span": [3, 5]}, {"name": "TAM", "ent_type": "Chemical", "char_span": [81, 84], "ent_id": "D013629", "tok_span": [17, 18]}, {"name": "hemolysis", "ent_type": "Disease", "char_span": [99, 108], "ent_id": "D006461", "tok_span": [20, 22]}], "relation_list": [{"subject": "TAM", "object": "hemolysis", "sbj_char_span": [81, 84], "obj_char_span": [17, 26], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 18], "obj_tok_span": [3, 5]}, {"subject": "TAM", "object": "hemolysis", "sbj_char_span": [81, 84], "obj_char_span": [99, 108], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 18], "obj_tok_span": [20, 22]}], "umls_entity_list": []}, {"text": "The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.", "entity_list": [{"name": "hydroxyl", "ent_type": "Chemical", "char_span": [158, 166], "ent_id": "D017665", "tok_span": [40, 41]}, {"name": "hemolysis", "ent_type": "Disease", "char_span": [196, 205], "ent_id": "D006461", "tok_span": [47, 49]}, {"name": "TAM", "ent_type": "Chemical", "char_span": [24, 27], "ent_id": "D013629", "tok_span": [5, 6]}, {"name": "hemolytic", "ent_type": "Disease", "char_span": [4, 13], "ent_id": "D006461", "tok_span": [1, 3]}, {"name": "alpha-tocopherol", "ent_type": "Chemical", "char_span": [66, 82], "ent_id": "D024502", "tok_span": [12, 18]}, {"name": "TAM", "ent_type": "Chemical", "char_span": [184, 187], "ent_id": "D013629", "tok_span": [44, 45]}, {"name": "alpha-TAc", "ent_type": "Chemical", "char_span": [123, 132], "ent_id": "D024502", "tok_span": [32, 36]}, {"name": "alpha-T", "ent_type": "Chemical", "char_span": [84, 91], "ent_id": "D024502", "tok_span": [19, 22]}, {"name": "alpha-tocopherol acetate", "ent_type": "Chemical", "char_span": [97, 121], "ent_id": "D024502", "tok_span": [24, 31]}], "relation_list": [{"subject": "TAM", "object": "hemolytic", "sbj_char_span": [184, 187], "obj_char_span": [4, 13], "rel_type": "chemical-induced disease", "sbj_tok_span": [44, 45], "obj_tok_span": [1, 3]}, {"subject": "TAM", "object": "hemolytic", "sbj_char_span": [24, 27], "obj_char_span": [4, 13], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 6], "obj_tok_span": [1, 3]}, {"subject": "TAM", "object": "hemolysis", "sbj_char_span": [24, 27], "obj_char_span": [196, 205], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 6], "obj_tok_span": [47, 49]}, {"subject": "TAM", "object": "hemolysis", "sbj_char_span": [184, 187], "obj_char_span": [196, 205], "rel_type": "chemical-induced disease", "sbj_tok_span": [44, 45], "obj_tok_span": [47, 49]}], "umls_entity_list": []}, {"text": "This was further evidenced by absence of oxygen consumption and hemoglobin oxidation both determined in parallel with TAM-induced hemolysis.", "entity_list": [{"name": "oxygen", "ent_type": "Chemical", "char_span": [41, 47], "ent_id": "D010100", "tok_span": [7, 8]}, {"name": "TAM", "ent_type": "Chemical", "char_span": [118, 121], "ent_id": "D013629", "tok_span": [17, 18]}, {"name": "hemolysis", "ent_type": "Disease", "char_span": [130, 139], "ent_id": "D006461", "tok_span": [20, 22]}], "relation_list": [{"subject": "TAM", "object": "hemolysis", "sbj_char_span": [118, 121], "obj_char_span": [130, 139], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 18], "obj_tok_span": [20, 22]}], "umls_entity_list": []}, {"text": "Hemolysis caused by TAM was not preceded by the leakage of K(+) from the cells, also excluding a colloid-osmotic type mechanism of hemolysis, according to the effects on osmotic fragility curves.", "entity_list": [{"name": "K", "ent_type": "Chemical", "char_span": [59, 60], "ent_id": "D011188", "tok_span": [12, 13]}, {"name": "hemolysis", "ent_type": "Disease", "char_span": [131, 140], "ent_id": "D006461", "tok_span": [30, 32]}, {"name": "TAM", "ent_type": "Chemical", "char_span": [20, 23], "ent_id": "D013629", "tok_span": [4, 5]}, {"name": "Hemolysis", "ent_type": "Disease", "char_span": [0, 9], "ent_id": "D006461", "tok_span": [0, 2]}], "relation_list": [{"subject": "TAM", "object": "Hemolysis", "sbj_char_span": [20, 23], "obj_char_span": [0, 9], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [0, 2]}, {"subject": "TAM", "object": "hemolysis", "sbj_char_span": [20, 23], "obj_char_span": [131, 140], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [30, 32]}], "umls_entity_list": []}, {"text": "These effects suggest that the protection from hemolysis by tocopherols is related to a decreased TAM incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided.", "entity_list": [{"name": "TAM", "ent_type": "Chemical", "char_span": [98, 101], "ent_id": "D013629", "tok_span": [19, 20]}, {"name": "tocopherols", "ent_type": "Chemical", "char_span": [60, 71], "ent_id": "D024505", "tok_span": [10, 14]}, {"name": "hemolysis", "ent_type": "Disease", "char_span": [47, 56], "ent_id": "D006461", "tok_span": [7, 9]}], "relation_list": [{"subject": "TAM", "object": "hemolysis", "sbj_char_span": [98, 101], "obj_char_span": [47, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 20], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "Therefore, TAM-induced hemolysis results from a structural perturbation of red cell membrane, leading to changes in the framework of the erythrocyte membrane and its cytoskeleton caused by its high partition in the membrane.", "entity_list": [{"name": "TAM", "ent_type": "Chemical", "char_span": [11, 14], "ent_id": "D013629", "tok_span": [2, 3]}, {"name": "hemolysis", "ent_type": "Disease", "char_span": [23, 32], "ent_id": "D006461", "tok_span": [5, 7]}], "relation_list": [{"subject": "TAM", "object": "hemolysis", "sbj_char_span": [11, 14], "obj_char_span": [23, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 3], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "These defects explain the abnormal erythrocyte shape and decreased mechanical stability promoted by TAM, resulting in hemolytic anemia.", "entity_list": [{"name": "hemolytic anemia", "ent_type": "Disease", "char_span": [118, 134], "ent_id": "D000743", "tok_span": [17, 20]}, {"name": "TAM", "ent_type": "Chemical", "char_span": [100, 103], "ent_id": "D013629", "tok_span": [13, 14]}], "relation_list": [{"subject": "TAM", "object": "hemolytic anemia", "sbj_char_span": [100, 103], "obj_char_span": [118, 134], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 14], "obj_tok_span": [17, 20]}], "umls_entity_list": []}, {"text": "Changes of sodium and ATP affinities of the cardiac (Na,K)-ATPase during and after nitric oxide deficient hypertension.", "entity_list": [{"name": "ATP", "ent_type": "Chemical", "char_span": [22, 25], "ent_id": "D000255", "tok_span": [4, 5]}, {"name": "sodium", "ent_type": "Chemical", "char_span": [11, 17], "ent_id": "D012964", "tok_span": [2, 3]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [106, 118], "ent_id": "D006973", "tok_span": [22, 23]}, {"name": "K", "ent_type": "Chemical", "char_span": [56, 57], "ent_id": "D011188", "tok_span": [12, 13]}, {"name": "nitric oxide", "ent_type": "Chemical", "char_span": [83, 95], "ent_id": "D009569", "tok_span": [19, 21]}, {"name": "Na", "ent_type": "Chemical", "char_span": [53, 55], "ent_id": "D012964", "tok_span": [10, 11]}], "relation_list": [{"subject": "nitric oxide", "object": "hypertension", "sbj_char_span": [83, 95], "obj_char_span": [106, 118], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 21], "obj_tok_span": [22, 23]}], "umls_entity_list": []}, {"text": "Inhibition of NO synthesis induces sustained hypertension.", "entity_list": [{"name": "hypertension", "ent_type": "Disease", "char_span": [45, 57], "ent_id": "D006973", "tok_span": [6, 7]}, {"name": "NO", "ent_type": "Chemical", "char_span": [14, 16], "ent_id": "D009569", "tok_span": [2, 3]}], "relation_list": [{"subject": "NO", "object": "hypertension", "sbj_char_span": [14, 16], "obj_char_span": [45, 57], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 3], "obj_tok_span": [6, 7]}], "umls_entity_list": []}, {"text": "To assess the molecular basis of disturbances in transmembraneous transport of Na+, we studied the response of cardiac (Na,K)-ATPase to NO-deficient hypertension induced in rats by NO-synthase inhibition with 40 mg/kg/day N(G)-nitro-L-arginine methyl ester (L-NAME) for 4 four weeks.", "entity_list": [{"name": "hypertension", "ent_type": "Disease", "char_span": [149, 161], "ent_id": "D006973", "tok_span": [32, 33]}, {"name": "L-NAME", "ent_type": "Chemical", "char_span": [258, 264], "ent_id": "D019331", "tok_span": [61, 65]}, {"name": "K", "ent_type": "Chemical", "char_span": [123, 124], "ent_id": "D011188", "tok_span": [24, 25]}, {"name": "Na", "ent_type": "Chemical", "char_span": [79, 81], "ent_id": "D012964", "tok_span": [12, 13]}, {"name": "NO", "ent_type": "Chemical", "char_span": [181, 183], "ent_id": "D009569", "tok_span": [37, 38]}, {"name": "Na", "ent_type": "Chemical", "char_span": [120, 122], "ent_id": "D012964", "tok_span": [22, 23]}, {"name": "NO", "ent_type": "Chemical", "char_span": [136, 138], "ent_id": "D009569", "tok_span": [29, 30]}, {"name": "N(G)-nitro-L-arginine methyl ester", "ent_type": "Chemical", "char_span": [222, 256], "ent_id": "D019331", "tok_span": [48, 60]}], "relation_list": [{"subject": "NO", "object": "hypertension", "sbj_char_span": [136, 138], "obj_char_span": [149, 161], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 30], "obj_tok_span": [32, 33]}, {"subject": "NO", "object": "hypertension", "sbj_char_span": [181, 183], "obj_char_span": [149, 161], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 38], "obj_tok_span": [32, 33]}], "umls_entity_list": []}, {"text": "Inhibition of NO-synthase induced a reversible hypertension accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.", "entity_list": [{"name": "depressed", "ent_type": "Disease", "char_span": [75, 84], "ent_id": "D003866", "tok_span": [11, 12]}, {"name": "NO", "ent_type": "Chemical", "char_span": [14, 16], "ent_id": "D009569", "tok_span": [2, 3]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [47, 59], "ent_id": "D006973", "tok_span": [8, 9]}, {"name": "Na", "ent_type": "Chemical", "char_span": [182, 184], "ent_id": "D012964", "tok_span": [34, 35]}, {"name": "Na", "ent_type": "Chemical", "char_span": [85, 87], "ent_id": "D012964", "tok_span": [12, 13]}, {"name": "K", "ent_type": "Chemical", "char_span": [185, 186], "ent_id": "D011188", "tok_span": [36, 37]}, {"name": "Na", "ent_type": "Chemical", "char_span": [151, 153], "ent_id": "D012964", "tok_span": [26, 27]}], "relation_list": [{"subject": "NO", "object": "hypertension", "sbj_char_span": [14, 16], "obj_char_span": [47, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 3], "obj_tok_span": [8, 9]}], "umls_entity_list": []}, {"text": "Effects of long-term pretreatment with isoproterenol on bromocriptine-induced tachycardia in conscious rats.", "entity_list": [{"name": "tachycardia", "ent_type": "Disease", "char_span": [78, 89], "ent_id": "D013610", "tok_span": [18, 19]}, {"name": "bromocriptine", "ent_type": "Chemical", "char_span": [56, 69], "ent_id": "D001971", "tok_span": [12, 16]}, {"name": "isoproterenol", "ent_type": "Chemical", "char_span": [39, 52], "ent_id": "D007545", "tok_span": [7, 11]}], "relation_list": [{"subject": "bromocriptine", "object": "tachycardia", "sbj_char_span": [56, 69], "obj_char_span": [78, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 16], "obj_tok_span": [18, 19]}], "umls_entity_list": []}, {"text": "It has been shown that bromocriptine-induced tachycardia, which persisted after adrenalectomy, is (i) mediated by central dopamine D2 receptor activation and (ii) reduced by 5-day isoproterenol pretreatment, supporting therefore the hypothesis that this effect is dependent on sympathetic outflow to the heart.", "entity_list": [{"name": "dopamine", "ent_type": "Chemical", "char_span": [122, 130], "ent_id": "D004298", "tok_span": [26, 27]}, {"name": "tachycardia", "ent_type": "Disease", "char_span": [45, 56], "ent_id": "D013610", "tok_span": [11, 12]}, {"name": "isoproterenol", "ent_type": "Chemical", "char_span": [180, 193], "ent_id": "D007545", "tok_span": [40, 44]}, {"name": "bromocriptine", "ent_type": "Chemical", "char_span": [23, 36], "ent_id": "D001971", "tok_span": [5, 9]}], "relation_list": [{"subject": "bromocriptine", "object": "tachycardia", "sbj_char_span": [23, 36], "obj_char_span": [45, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [11, 12]}], "umls_entity_list": []}, {"text": "This study was conducted to examine whether prolonged pretreatment with isoproterenol could abolish bromocriptine-induced tachycardia in conscious rats.", "entity_list": [{"name": "isoproterenol", "ent_type": "Chemical", "char_span": [72, 85], "ent_id": "D007545", "tok_span": [10, 14]}, {"name": "tachycardia", "ent_type": "Disease", "char_span": [122, 133], "ent_id": "D013610", "tok_span": [23, 24]}, {"name": "bromocriptine", "ent_type": "Chemical", "char_span": [100, 113], "ent_id": "D001971", "tok_span": [17, 21]}], "relation_list": [{"subject": "bromocriptine", "object": "tachycardia", "sbj_char_span": [100, 113], "obj_char_span": [122, 133], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [23, 24]}], "umls_entity_list": []}, {"text": "Isoproterenol pretreatment for 15 days caused cardiac hypertrophy without affecting baseline blood pressure and heart rate.", "entity_list": [{"name": "cardiac hypertrophy", "ent_type": "Disease", "char_span": [46, 65], "ent_id": "D006332", "tok_span": [9, 11]}, {"name": "Isoproterenol", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D007545", "tok_span": [0, 4]}], "relation_list": [{"subject": "Isoproterenol", "object": "cardiac hypertrophy", "sbj_char_span": [0, 13], "obj_char_span": [46, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "In control rats, intravenous bromocriptine (150 microg/kg) induced significant hypotension and tachycardia.", "entity_list": [{"name": "hypotension", "ent_type": "Disease", "char_span": [79, 90], "ent_id": "D007022", "tok_span": [18, 19]}, {"name": "tachycardia", "ent_type": "Disease", "char_span": [95, 106], "ent_id": "D013610", "tok_span": [20, 21]}, {"name": "bromocriptine", "ent_type": "Chemical", "char_span": [29, 42], "ent_id": "D001971", "tok_span": [5, 9]}], "relation_list": [{"subject": "bromocriptine", "object": "tachycardia", "sbj_char_span": [29, 42], "obj_char_span": [95, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [20, 21]}, {"subject": "bromocriptine", "object": "hypotension", "sbj_char_span": [29, 42], "obj_char_span": [79, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [18, 19]}], "umls_entity_list": []}, {"text": "Bromocriptine-induced hypotension was unaffected by isoproterenol pretreatment, while tachycardia was reversed to significant bradycardia, an effect that was partly reduced by i.v. domperidone (0.5 mg/kg).", "entity_list": [{"name": "tachycardia", "ent_type": "Disease", "char_span": [86, 97], "ent_id": "D013610", "tok_span": [17, 18]}, {"name": "domperidone", "ent_type": "Chemical", "char_span": [181, 192], "ent_id": "D004294", "tok_span": [38, 41]}, {"name": "isoproterenol", "ent_type": "Chemical", "char_span": [52, 65], "ent_id": "D007545", "tok_span": [10, 14]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [126, 137], "ent_id": "D001919", "tok_span": [22, 26]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [22, 33], "ent_id": "D007022", "tok_span": [6, 7]}, {"name": "Bromocriptine", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D001971", "tok_span": [0, 4]}], "relation_list": [{"subject": "domperidone", "object": "bradycardia", "sbj_char_span": [181, 192], "obj_char_span": [126, 137], "rel_type": "chemical-induced disease", "sbj_tok_span": [38, 41], "obj_tok_span": [22, 26]}, {"subject": "isoproterenol", "object": "bradycardia", "sbj_char_span": [52, 65], "obj_char_span": [126, 137], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [22, 26]}, {"subject": "Bromocriptine", "object": "tachycardia", "sbj_char_span": [0, 13], "obj_char_span": [86, 97], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [17, 18]}, {"subject": "Bromocriptine", "object": "hypotension", "sbj_char_span": [0, 13], "obj_char_span": [22, 33], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [6, 7]}], "umls_entity_list": []}, {"text": "These results show that 15-day isoproterenol pretreatment not only abolished but reversed bromocriptine-induced tachycardia to bradycardia, an effect that is mainly related to further cardiac beta-adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart.", "entity_list": [{"name": "bradycardia", "ent_type": "Disease", "char_span": [127, 138], "ent_id": "D001919", "tok_span": [25, 29]}, {"name": "isoproterenol", "ent_type": "Chemical", "char_span": [31, 44], "ent_id": "D007545", "tok_span": [7, 11]}, {"name": "tachycardia", "ent_type": "Disease", "char_span": [112, 123], "ent_id": "D013610", "tok_span": [23, 24]}, {"name": "bromocriptine", "ent_type": "Chemical", "char_span": [90, 103], "ent_id": "D001971", "tok_span": [17, 21]}], "relation_list": [{"subject": "isoproterenol", "object": "bradycardia", "sbj_char_span": [31, 44], "obj_char_span": [127, 138], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [25, 29]}, {"subject": "bromocriptine", "object": "tachycardia", "sbj_char_span": [90, 103], "obj_char_span": [112, 123], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [23, 24]}], "umls_entity_list": []}, {"text": "They suggest that, in normal conscious rats, the central tachycardia of bromocriptine appears to predominate and to mask the bradycardia of this agonist at peripheral dopamine D2 receptors.", "entity_list": [{"name": "dopamine", "ent_type": "Chemical", "char_span": [167, 175], "ent_id": "D004298", "tok_span": [34, 35]}, {"name": "tachycardia", "ent_type": "Disease", "char_span": [57, 68], "ent_id": "D013610", "tok_span": [11, 12]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [125, 136], "ent_id": "D001919", "tok_span": [25, 29]}, {"name": "bromocriptine", "ent_type": "Chemical", "char_span": [72, 85], "ent_id": "D001971", "tok_span": [13, 17]}], "relation_list": [{"subject": "bromocriptine", "object": "tachycardia", "sbj_char_span": [72, 85], "obj_char_span": [57, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [11, 12]}], "umls_entity_list": []}, {"text": "Given that sympathetic neural dominance exhibits a similar developmental pattern, and given that clonidine induces sympathetic withdrawal and bradycardia, we hypothesized that clonidine's developmental effects on cardiac rate and ultrasound production would mirror each other.", "entity_list": [{"name": "clonidine", "ent_type": "Chemical", "char_span": [176, 185], "ent_id": "D003000", "tok_span": [28, 30]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [142, 153], "ent_id": "D001919", "tok_span": [20, 24]}, {"name": "clonidine", "ent_type": "Chemical", "char_span": [97, 106], "ent_id": "D003000", "tok_span": [14, 16]}], "relation_list": [{"subject": "clonidine", "object": "bradycardia", "sbj_char_span": [97, 106], "obj_char_span": [142, 153], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [20, 24]}, {"subject": "clonidine", "object": "bradycardia", "sbj_char_span": [176, 185], "obj_char_span": [142, 153], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 30], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "Age-related changes in ultrasound production corresponded with changes in cardiovascular variables, including baseline cardiac rate and clonidine-induced bradycardia.", "entity_list": [{"name": "bradycardia", "ent_type": "Disease", "char_span": [154, 165], "ent_id": "D001919", "tok_span": [23, 27]}, {"name": "clonidine", "ent_type": "Chemical", "char_span": [136, 145], "ent_id": "D003000", "tok_span": [19, 21]}], "relation_list": [{"subject": "clonidine", "object": "bradycardia", "sbj_char_span": [136, 145], "obj_char_span": [154, 165], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 21], "obj_tok_span": [23, 27]}], "umls_entity_list": []}, {"text": "Differential effects of systemically administered ketamine and lidocaine on dynamic and static hyperalgesia induced by intradermal capsaicin in humans.", "entity_list": [{"name": "lidocaine", "ent_type": "Chemical", "char_span": [63, 72], "ent_id": "D008012", "tok_span": [8, 10]}, {"name": "hyperalgesia", "ent_type": "Disease", "char_span": [95, 107], "ent_id": "D006930", "tok_span": [14, 18]}, {"name": "ketamine", "ent_type": "Chemical", "char_span": [50, 58], "ent_id": "D007649", "tok_span": [6, 7]}, {"name": "capsaicin", "ent_type": "Chemical", "char_span": [131, 140], "ent_id": "D002211", "tok_span": [23, 26]}], "relation_list": [{"subject": "capsaicin", "object": "hyperalgesia", "sbj_char_span": [131, 140], "obj_char_span": [95, 107], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [14, 18]}], "umls_entity_list": []}, {"text": "We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked (dynamic) pain and punctate-evoked (static) hyperalgesia induced by capsaicin.", "entity_list": [{"name": "lidocaine", "ent_type": "Chemical", "char_span": [71, 80], "ent_id": "D008012", "tok_span": [11, 13]}, {"name": "ketamine", "ent_type": "Chemical", "char_span": [58, 66], "ent_id": "D007649", "tok_span": [9, 10]}, {"name": "capsaicin", "ent_type": "Chemical", "char_span": [165, 174], "ent_id": "D002211", "tok_span": [35, 38]}, {"name": "pain", "ent_type": "Disease", "char_span": [107, 111], "ent_id": "D010146", "tok_span": [20, 21]}, {"name": "hyperalgesia", "ent_type": "Disease", "char_span": [141, 153], "ent_id": "D006930", "tok_span": [29, 33]}], "relation_list": [{"subject": "capsaicin", "object": "pain", "sbj_char_span": [165, 174], "obj_char_span": [107, 111], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 38], "obj_tok_span": [20, 21]}, {"subject": "capsaicin", "object": "hyperalgesia", "sbj_char_span": [165, 174], "obj_char_span": [141, 153], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 38], "obj_tok_span": [29, 33]}], "umls_entity_list": []}, {"text": "Cyclosporine and tacrolimus-associated thrombotic microangiopathy.", "entity_list": [{"name": "tacrolimus", "ent_type": "Chemical", "char_span": [17, 27], "ent_id": "D016559", "tok_span": [4, 6]}, {"name": "Cyclosporine", "ent_type": "Chemical", "char_span": [0, 12], "ent_id": "D016572", "tok_span": [0, 3]}, {"name": "thrombotic microangiopathy", "ent_type": "Disease", "char_span": [39, 65], "ent_id": "D057049", "tok_span": [8, 13]}], "relation_list": [{"subject": "Cyclosporine", "object": "thrombotic microangiopathy", "sbj_char_span": [0, 12], "obj_char_span": [39, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [8, 13]}, {"subject": "tacrolimus", "object": "thrombotic microangiopathy", "sbj_char_span": [17, 27], "obj_char_span": [39, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 6], "obj_tok_span": [8, 13]}], "umls_entity_list": []}, {"text": "The development of thrombotic microangiopathy (TMA) associated with the use of cyclosporine has been well documented.", "entity_list": [{"name": "cyclosporine", "ent_type": "Chemical", "char_span": [79, 91], "ent_id": "D016572", "tok_span": [17, 19]}, {"name": "TMA", "ent_type": "Disease", "char_span": [47, 50], "ent_id": "D057049", "tok_span": [9, 11]}, {"name": "thrombotic microangiopathy", "ent_type": "Disease", "char_span": [19, 45], "ent_id": "D057049", "tok_span": [3, 8]}], "relation_list": [{"subject": "cyclosporine", "object": "thrombotic microangiopathy", "sbj_char_span": [79, 91], "obj_char_span": [19, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 19], "obj_tok_span": [3, 8]}, {"subject": "cyclosporine", "object": "TMA", "sbj_char_span": [79, 91], "obj_char_span": [47, 50], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 19], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "As a result, switching to tacrolimus has been reported to be a viable therapeutic option in the setting of cyclosporine-induced TMA.", "entity_list": [{"name": "cyclosporine", "ent_type": "Chemical", "char_span": [107, 119], "ent_id": "D016572", "tok_span": [21, 23]}, {"name": "TMA", "ent_type": "Disease", "char_span": [128, 131], "ent_id": "D057049", "tok_span": [25, 27]}, {"name": "tacrolimus", "ent_type": "Chemical", "char_span": [26, 36], "ent_id": "D016559", "tok_span": [6, 8]}], "relation_list": [{"subject": "cyclosporine", "object": "TMA", "sbj_char_span": [107, 119], "obj_char_span": [128, 131], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 23], "obj_tok_span": [25, 27]}, {"subject": "tacrolimus", "object": "TMA", "sbj_char_span": [26, 36], "obj_char_span": [128, 131], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [25, 27]}], "umls_entity_list": []}, {"text": "With the more widespread application of tacrolimus in organ transplantation, tacrolimus-associated TMA has also been recognized.", "entity_list": [{"name": "TMA", "ent_type": "Disease", "char_span": [99, 102], "ent_id": "D057049", "tok_span": [16, 18]}, {"name": "tacrolimus", "ent_type": "Chemical", "char_span": [77, 87], "ent_id": "D016559", "tok_span": [12, 14]}, {"name": "tacrolimus", "ent_type": "Chemical", "char_span": [40, 50], "ent_id": "D016559", "tok_span": [6, 8]}], "relation_list": [{"subject": "tacrolimus", "object": "TMA", "sbj_char_span": [77, 87], "obj_char_span": [99, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 14], "obj_tok_span": [16, 18]}, {"subject": "tacrolimus", "object": "TMA", "sbj_char_span": [40, 50], "obj_char_span": [99, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "However, literature regarding the incidence of the recurrence of TMA in patients exposed sequentially to cyclosporine and tacrolimus is limited.", "entity_list": [{"name": "cyclosporine", "ent_type": "Chemical", "char_span": [105, 117], "ent_id": "D016572", "tok_span": [17, 19]}, {"name": "tacrolimus", "ent_type": "Chemical", "char_span": [122, 132], "ent_id": "D016559", "tok_span": [20, 22]}, {"name": "TMA", "ent_type": "Disease", "char_span": [65, 68], "ent_id": "D057049", "tok_span": [10, 12]}], "relation_list": [{"subject": "tacrolimus", "object": "TMA", "sbj_char_span": [122, 132], "obj_char_span": [65, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 22], "obj_tok_span": [10, 12]}, {"subject": "cyclosporine", "object": "TMA", "sbj_char_span": [105, 117], "obj_char_span": [65, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 19], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "We report a case of a living donor renal transplant recipient who developed cyclosporine-induced TMA that responded to the withdrawal of cyclosporine in conjunction with plasmapheresis and fresh frozen plasma replacement therapy.", "entity_list": [{"name": "cyclosporine", "ent_type": "Chemical", "char_span": [76, 88], "ent_id": "D016572", "tok_span": [13, 15]}, {"name": "cyclosporine", "ent_type": "Chemical", "char_span": [137, 149], "ent_id": "D016572", "tok_span": [25, 27]}, {"name": "TMA", "ent_type": "Disease", "char_span": [97, 100], "ent_id": "D057049", "tok_span": [17, 19]}], "relation_list": [{"subject": "cyclosporine", "object": "TMA", "sbj_char_span": [137, 149], "obj_char_span": [97, 100], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 27], "obj_tok_span": [17, 19]}, {"subject": "cyclosporine", "object": "TMA", "sbj_char_span": [76, 88], "obj_char_span": [97, 100], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [17, 19]}], "umls_entity_list": []}, {"text": "Introduction of tacrolimus as an alternative immunosuppressive agent resulted in the recurrence of TMA and the subsequent loss of the renal allograft.", "entity_list": [{"name": "tacrolimus", "ent_type": "Chemical", "char_span": [16, 26], "ent_id": "D016559", "tok_span": [2, 4]}, {"name": "TMA", "ent_type": "Disease", "char_span": [99, 102], "ent_id": "D057049", "tok_span": [15, 17]}], "relation_list": [{"subject": "tacrolimus", "object": "TMA", "sbj_char_span": [16, 26], "obj_char_span": [99, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 4], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA.", "entity_list": [{"name": "TMA", "ent_type": "Disease", "char_span": [140, 143], "ent_id": "D057049", "tok_span": [24, 26]}, {"name": "tacrolimus", "ent_type": "Chemical", "char_span": [47, 57], "ent_id": "D016559", "tok_span": [8, 10]}, {"name": "cyclosporine", "ent_type": "Chemical", "char_span": [31, 43], "ent_id": "D016572", "tok_span": [5, 7]}], "relation_list": [{"subject": "tacrolimus", "object": "TMA", "sbj_char_span": [47, 57], "obj_char_span": [140, 143], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [24, 26]}, {"subject": "cyclosporine", "object": "TMA", "sbj_char_span": [31, 43], "obj_char_span": [140, 143], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 7], "obj_tok_span": [24, 26]}], "umls_entity_list": []}, {"text": "Repeated transient anuria following losartan administration in a patient with a solitary kidney.", "entity_list": [{"name": "anuria", "ent_type": "Disease", "char_span": [19, 25], "ent_id": "D001002", "tok_span": [3, 5]}, {"name": "losartan", "ent_type": "Chemical", "char_span": [36, 44], "ent_id": "D019808", "tok_span": [6, 8]}], "relation_list": [{"subject": "losartan", "object": "anuria", "sbj_char_span": [36, 44], "obj_char_span": [19, 25], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration.", "entity_list": [{"name": "losartan", "ent_type": "Chemical", "char_span": [161, 169], "ent_id": "D019808", "tok_span": [30, 32]}, {"name": "hypertensive", "ent_type": "Disease", "char_span": [36, 48], "ent_id": "D006973", "tok_span": [11, 12]}, {"name": "anuria", "ent_type": "Disease", "char_span": [148, 154], "ent_id": "D001002", "tok_span": [27, 29]}, {"name": "chronic renal insufficiency", "ent_type": "Disease", "char_span": [80, 107], "ent_id": "D051436", "tok_span": [18, 21]}], "relation_list": [{"subject": "losartan", "object": "anuria", "sbj_char_span": [161, 169], "obj_char_span": [148, 154], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 32], "obj_tok_span": [27, 29]}], "umls_entity_list": []}, {"text": "Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and amine infusion.", "entity_list": [{"name": "furosemide", "ent_type": "Chemical", "char_span": [122, 132], "ent_id": "D005665", "tok_span": [26, 30]}, {"name": "anuria", "ent_type": "Disease", "char_span": [71, 77], "ent_id": "D001002", "tok_span": [15, 17]}, {"name": "amine", "ent_type": "Chemical", "char_span": [137, 142], "ent_id": "D000588", "tok_span": [31, 32]}, {"name": "losartan", "ent_type": "Chemical", "char_span": [41, 49], "ent_id": "D019808", "tok_span": [9, 11]}], "relation_list": [{"subject": "losartan", "object": "anuria", "sbj_char_span": [41, 49], "obj_char_span": [71, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 11], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "One week later, by mistake, losartan was prescribed again and after the second dose of 50 mg, the patient developed a second episode of transient anuria lasting 10 hours.", "entity_list": [{"name": "anuria", "ent_type": "Disease", "char_span": [146, 152], "ent_id": "D001002", "tok_span": [30, 32]}, {"name": "losartan", "ent_type": "Chemical", "char_span": [28, 36], "ent_id": "D019808", "tok_span": [8, 10]}], "relation_list": [{"subject": "losartan", "object": "anuria", "sbj_char_span": [28, 36], "obj_char_span": [146, 152], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [30, 32]}], "umls_entity_list": []}, {"text": "In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.", "entity_list": [{"name": "acetaminophen", "ent_type": "Chemical", "char_span": [86, 99], "ent_id": "D000082", "tok_span": [14, 17]}, {"name": "amiodarone", "ent_type": "Chemical", "char_span": [124, 134], "ent_id": "D000638", "tok_span": [23, 27]}, {"name": "lung toxicity", "ent_type": "Disease", "char_span": [143, 156], "ent_id": "D008171", "tok_span": [29, 31]}, {"name": "necrotic", "ent_type": "Disease", "char_span": [58, 66], "ent_id": "D009336", "tok_span": [10, 11]}, {"name": "doxorubicin", "ent_type": "Chemical", "char_span": [161, 172], "ent_id": "D004317", "tok_span": [32, 33]}, {"name": "nephrotoxicity", "ent_type": "Disease", "char_span": [108, 122], "ent_id": "D007674", "tok_span": [19, 22]}, {"name": "cardiotoxicity", "ent_type": "Disease", "char_span": [181, 195], "ent_id": "D066126", "tok_span": [35, 37]}, {"name": "IH636 grape seed proanthocyanidin extract", "ent_type": "Chemical", "char_span": [207, 248], "ent_id": "C511402", "tok_span": [40, 51]}], "relation_list": [{"subject": "acetaminophen", "object": "necrotic", "sbj_char_span": [86, 99], "obj_char_span": [58, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [10, 11]}, {"subject": "amiodarone", "object": "lung toxicity", "sbj_char_span": [124, 134], "obj_char_span": [143, 156], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 27], "obj_tok_span": [29, 31]}, {"subject": "amiodarone", "object": "necrotic", "sbj_char_span": [124, 134], "obj_char_span": [58, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 27], "obj_tok_span": [10, 11]}, {"subject": "acetaminophen", "object": "nephrotoxicity", "sbj_char_span": [86, 99], "obj_char_span": [108, 122], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [19, 22]}, {"subject": "doxorubicin", "object": "cardiotoxicity", "sbj_char_span": [161, 172], "obj_char_span": [181, 195], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 33], "obj_tok_span": [35, 37]}, {"subject": "doxorubicin", "object": "necrotic", "sbj_char_span": [161, 172], "obj_char_span": [58, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 33], "obj_tok_span": [10, 11]}], "umls_entity_list": []}, {"text": "This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.", "entity_list": [{"name": "acetaminophen", "ent_type": "Chemical", "char_span": [95, 108], "ent_id": "D000082", "tok_span": [23, 26]}, {"name": "GSPE", "ent_type": "Chemical", "char_span": [78, 82], "ent_id": "C511402", "tok_span": [18, 20]}, {"name": "DOX", "ent_type": "Chemical", "char_span": [196, 199], "ent_id": "D004317", "tok_span": [51, 52]}, {"name": "nephrotoxicity", "ent_type": "Disease", "char_span": [123, 137], "ent_id": "D007674", "tok_span": [32, 35]}, {"name": "IH636 grape seed proanthocyanidin extract", "ent_type": "Chemical", "char_span": [35, 76], "ent_id": "C511402", "tok_span": [6, 17]}, {"name": "AMI", "ent_type": "Chemical", "char_span": [151, 154], "ent_id": "D000638", "tok_span": [41, 42]}, {"name": "cardiotoxicity", "ent_type": "Disease", "char_span": [209, 223], "ent_id": "D066126", "tok_span": [55, 57]}, {"name": "amiodarone", "ent_type": "Chemical", "char_span": [139, 149], "ent_id": "D000638", "tok_span": [36, 40]}, {"name": "lung toxicity", "ent_type": "Disease", "char_span": [164, 177], "ent_id": "D008171", "tok_span": [45, 47]}, {"name": "doxorubicin", "ent_type": "Chemical", "char_span": [183, 194], "ent_id": "D004317", "tok_span": [49, 50]}, {"name": "AAP", "ent_type": "Chemical", "char_span": [110, 113], "ent_id": "D000082", "tok_span": [27, 29]}], "relation_list": [{"subject": "amiodarone", "object": "lung toxicity", "sbj_char_span": [139, 149], "obj_char_span": [164, 177], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 40], "obj_tok_span": [45, 47]}, {"subject": "AAP", "object": "nephrotoxicity", "sbj_char_span": [110, 113], "obj_char_span": [123, 137], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 29], "obj_tok_span": [32, 35]}, {"subject": "DOX", "object": "cardiotoxicity", "sbj_char_span": [196, 199], "obj_char_span": [209, 223], "rel_type": "chemical-induced disease", "sbj_tok_span": [51, 52], "obj_tok_span": [55, 57]}, {"subject": "doxorubicin", "object": "cardiotoxicity", "sbj_char_span": [183, 194], "obj_char_span": [209, 223], "rel_type": "chemical-induced disease", "sbj_tok_span": [49, 50], "obj_tok_span": [55, 57]}, {"subject": "acetaminophen", "object": "nephrotoxicity", "sbj_char_span": [95, 108], "obj_char_span": [123, 137], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [32, 35]}, {"subject": "AMI", "object": "lung toxicity", "sbj_char_span": [151, 154], "obj_char_span": [164, 177], "rel_type": "chemical-induced disease", "sbj_tok_span": [41, 42], "obj_tok_span": [45, 47]}], "umls_entity_list": []}, {"text": "Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.", "entity_list": [{"name": "necrosis", "ent_type": "Disease", "char_span": [95, 103], "ent_id": "D009336", "tok_span": [21, 22]}, {"name": "AAP", "ent_type": "Chemical", "char_span": [39, 42], "ent_id": "D000082", "tok_span": [9, 11]}, {"name": "AMI", "ent_type": "Chemical", "char_span": [44, 47], "ent_id": "D000638", "tok_span": [12, 13]}, {"name": "GSPE", "ent_type": "Chemical", "char_span": [167, 171], "ent_id": "C511402", "tok_span": [32, 34]}, {"name": "DOX", "ent_type": "Chemical", "char_span": [52, 55], "ent_id": "D004317", "tok_span": [14, 15]}], "relation_list": [{"subject": "AAP", "object": "necrosis", "sbj_char_span": [39, 42], "obj_char_span": [95, 103], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 11], "obj_tok_span": [21, 22]}, {"subject": "AMI", "object": "necrosis", "sbj_char_span": [44, 47], "obj_char_span": [95, 103], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [21, 22]}, {"subject": "DOX", "object": "necrosis", "sbj_char_span": [52, 55], "obj_char_span": [95, 103], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [21, 22]}], "umls_entity_list": []}, {"text": "Palpebral twitching in a depressed adolescent on citalopram.", "entity_list": [{"name": "depressed", "ent_type": "Disease", "char_span": [25, 34], "ent_id": "D003866", "tok_span": [7, 8]}, {"name": "citalopram", "ent_type": "Chemical", "char_span": [49, 59], "ent_id": "D015283", "tok_span": [10, 14]}, {"name": "Palpebral twitching", "ent_type": "Disease", "char_span": [0, 19], "ent_id": "D004409", "tok_span": [0, 5]}], "relation_list": [{"subject": "citalopram", "object": "Palpebral twitching", "sbj_char_span": [49, 59], "obj_char_span": [0, 19], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [0, 5]}], "umls_entity_list": []}, {"text": "We report a favorable response to treatment with citalopram by a 15-year-old boy with major depression who exhibited palpebral twitching during his first 2 weeks of treatment.", "entity_list": [{"name": "palpebral twitching", "ent_type": "Disease", "char_span": [117, 136], "ent_id": "D004409", "tok_span": [25, 30]}, {"name": "citalopram", "ent_type": "Chemical", "char_span": [49, 59], "ent_id": "D015283", "tok_span": [8, 12]}, {"name": "major depression", "ent_type": "Disease", "char_span": [86, 102], "ent_id": "D003865", "tok_span": [21, 23]}], "relation_list": [{"subject": "citalopram", "object": "palpebral twitching", "sbj_char_span": [49, 59], "obj_char_span": [117, 136], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [25, 30]}], "umls_entity_list": []}, {"text": "Metamizol potentiates morphine antinociception but not constipation after chronic treatment.", "entity_list": [{"name": "Metamizol", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D004177", "tok_span": [0, 3]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [22, 30], "ent_id": "D009020", "tok_span": [5, 6]}, {"name": "constipation", "ent_type": "Disease", "char_span": [55, 67], "ent_id": "D003248", "tok_span": [12, 15]}], "relation_list": [{"subject": "morphine", "object": "constipation", "sbj_char_span": [22, 30], "obj_char_span": [55, 67], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 6], "obj_tok_span": [12, 15]}], "umls_entity_list": []}, {"text": "This work evaluates the antinociceptive and constipating effects of the combination of 3.2 mg/kg s.c. morphine with 177.8 mg/kg s.c. metamizol in acutely and chronically treated (once a day for 12 days) rats.", "entity_list": [{"name": "metamizol", "ent_type": "Chemical", "char_span": [133, 142], "ent_id": "D004177", "tok_span": [40, 43]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [102, 110], "ent_id": "D009020", "tok_span": [28, 29]}, {"name": "constipating", "ent_type": "Disease", "char_span": [44, 56], "ent_id": "D003248", "tok_span": [10, 13]}], "relation_list": [{"subject": "morphine", "object": "constipating", "sbj_char_span": [102, 110], "obj_char_span": [44, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 29], "obj_tok_span": [10, 13]}], "umls_entity_list": []}, {"text": "In independent groups, morphine inhibited the intestinal transit in 48+/-4% and 38+/-4% after acute and chronic treatment, respectively, suggesting that tolerance did not develop to the constipating effects.", "entity_list": [{"name": "morphine", "ent_type": "Chemical", "char_span": [23, 31], "ent_id": "D009020", "tok_span": [4, 5]}, {"name": "constipating", "ent_type": "Disease", "char_span": [186, 198], "ent_id": "D003248", "tok_span": [39, 42]}], "relation_list": [{"subject": "morphine", "object": "constipating", "sbj_char_span": [23, 31], "obj_char_span": [186, 198], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [39, 42]}], "umls_entity_list": []}, {"text": "The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment, suggesting that metamizol did not potentiate morphine-induced constipation.", "entity_list": [{"name": "morphine", "ent_type": "Chemical", "char_span": [164, 172], "ent_id": "D009020", "tok_span": [27, 28]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [73, 81], "ent_id": "D009020", "tok_span": [10, 11]}, {"name": "metamizol", "ent_type": "Chemical", "char_span": [135, 144], "ent_id": "D004177", "tok_span": [20, 23]}, {"name": "constipation", "ent_type": "Disease", "char_span": [181, 193], "ent_id": "D003248", "tok_span": [30, 33]}], "relation_list": [{"subject": "morphine", "object": "constipation", "sbj_char_span": [164, 172], "obj_char_span": [181, 193], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 28], "obj_tok_span": [30, 33]}, {"subject": "morphine", "object": "constipation", "sbj_char_span": [73, 81], "obj_char_span": [181, 193], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [30, 33]}], "umls_entity_list": []}, {"text": "Ifosfamide encephalopathy presenting with asterixis.", "entity_list": [{"name": "Ifosfamide", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D007069", "tok_span": [0, 5]}, {"name": "asterixis", "ent_type": "Disease", "char_span": [42, 51], "ent_id": "D020820", "tok_span": [9, 12]}, {"name": "encephalopathy", "ent_type": "Disease", "char_span": [11, 25], "ent_id": "D001927", "tok_span": [5, 7]}], "relation_list": [{"subject": "Ifosfamide", "object": "encephalopathy", "sbj_char_span": [0, 10], "obj_char_span": [11, 25], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "We report a case of a 51-year-old man who developed severe, disabling negative myoclonus of the upper and lower extremities after the infusion of ifosfamide for plasmacytoma.", "entity_list": [{"name": "plasmacytoma", "ent_type": "Disease", "char_span": [161, 173], "ent_id": "D010954", "tok_span": [39, 42]}, {"name": "ifosfamide", "ent_type": "Chemical", "char_span": [146, 156], "ent_id": "D007069", "tok_span": [33, 38]}, {"name": "myoclonus", "ent_type": "Disease", "char_span": [79, 88], "ent_id": "D009207", "tok_span": [19, 23]}], "relation_list": [{"subject": "ifosfamide", "object": "myoclonus", "sbj_char_span": [146, 156], "obj_char_span": [79, 88], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 38], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "In the patient described, the presence of asterixis during infusion of ifosfamide, normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of IFX.", "entity_list": [{"name": "myoclonus", "ent_type": "Disease", "char_span": [225, 234], "ent_id": "D009207", "tok_span": [40, 44]}, {"name": "asterixis", "ent_type": "Disease", "char_span": [42, 51], "ent_id": "D020820", "tok_span": [8, 11]}, {"name": "IFX", "ent_type": "Chemical", "char_span": [265, 268], "ent_id": "D007069", "tok_span": [50, 52]}, {"name": "ifosfamide", "ent_type": "Chemical", "char_span": [71, 81], "ent_id": "D007069", "tok_span": [14, 19]}], "relation_list": [{"subject": "ifosfamide", "object": "myoclonus", "sbj_char_span": [71, 81], "obj_char_span": [225, 234], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 19], "obj_tok_span": [40, 44]}, {"subject": "IFX", "object": "myoclonus", "sbj_char_span": [265, 268], "obj_char_span": [225, 234], "rel_type": "chemical-induced disease", "sbj_tok_span": [50, 52], "obj_tok_span": [40, 44]}], "umls_entity_list": []}, {"text": "OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).", "entity_list": [{"name": "dopamine", "ent_type": "Chemical", "char_span": [279, 287], "ent_id": "D004298", "tok_span": [53, 54]}, {"name": "visual field defects", "ent_type": "Disease", "char_span": [97, 117], "ent_id": "D005128", "tok_span": [15, 18]}, {"name": "VFD", "ent_type": "Disease", "char_span": [119, 122], "ent_id": "D005128", "tok_span": [19, 21]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [225, 232], "ent_id": "D003042", "tok_span": [41, 42]}, {"name": "GVG", "ent_type": "Chemical", "char_span": [218, 221], "ent_id": "D020888", "tok_span": [38, 40]}, {"name": "substance abuse", "ent_type": "Disease", "char_span": [55, 70], "ent_id": "D019966", "tok_span": [8, 10]}, {"name": "DA", "ent_type": "Chemical", "char_span": [289, 291], "ent_id": "D004298", "tok_span": [55, 56]}], "relation_list": [{"subject": "GVG", "object": "VFD", "sbj_char_span": [218, 221], "obj_char_span": [119, 122], "rel_type": "chemical-induced disease", "sbj_tok_span": [38, 40], "obj_tok_span": [19, 21]}, {"subject": "GVG", "object": "visual field defects", "sbj_char_span": [218, 221], "obj_char_span": [97, 117], "rel_type": "chemical-induced disease", "sbj_tok_span": [38, 40], "obj_tok_span": [15, 18]}], "umls_entity_list": []}, {"text": "In ICH induction using 0.014-unit collagenase, heparin enhanced the hematoma volume 3.4-fold over that seen in control ICH animals and the bleeding 7.6-fold.", "entity_list": [{"name": "ICH", "ent_type": "Disease", "char_span": [3, 6], "ent_id": "D002543", "tok_span": [1, 3]}, {"name": "bleeding", "ent_type": "Disease", "char_span": [139, 147], "ent_id": "D006470", "tok_span": [35, 36]}, {"name": "ICH", "ent_type": "Disease", "char_span": [119, 122], "ent_id": "D002543", "tok_span": [30, 32]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [47, 54], "ent_id": "D006493", "tok_span": [14, 15]}, {"name": "hematoma", "ent_type": "Disease", "char_span": [68, 76], "ent_id": "D006406", "tok_span": [17, 19]}], "relation_list": [{"subject": "heparin", "object": "hematoma", "sbj_char_span": [47, 54], "obj_char_span": [68, 76], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [17, 19]}], "umls_entity_list": []}, {"text": "We compared the effects of 17beta-estradiol in adult male and ovariectomized female rats subjected to lithium-pilocarpine-induced SE.", "entity_list": [{"name": "SE", "ent_type": "Disease", "char_span": [130, 132], "ent_id": "D013226", "tok_span": [27, 28]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [102, 109], "ent_id": "D008094", "tok_span": [20, 21]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [110, 121], "ent_id": "D010862", "tok_span": [22, 25]}, {"name": "17beta-estradiol", "ent_type": "Chemical", "char_span": [27, 43], "ent_id": "D004958", "tok_span": [5, 9]}], "relation_list": [{"subject": "pilocarpine", "object": "SE", "sbj_char_span": [110, 121], "obj_char_span": [130, 132], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 25], "obj_tok_span": [27, 28]}, {"subject": "lithium", "object": "SE", "sbj_char_span": [102, 109], "obj_char_span": [130, 132], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 21], "obj_tok_span": [27, 28]}], "umls_entity_list": []}, {"text": "Delirium during clozapine treatment: incidence and associated risk factors.", "entity_list": [{"name": "Delirium", "ent_type": "Disease", "char_span": [0, 8], "ent_id": "D003693", "tok_span": [0, 3]}, {"name": "clozapine", "ent_type": "Chemical", "char_span": [16, 25], "ent_id": "D003024", "tok_span": [4, 7]}], "relation_list": [{"subject": "clozapine", "object": "Delirium", "sbj_char_span": [16, 25], "obj_char_span": [0, 8], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "BACKGROUND: Incidence and risk factors for delirium during clozapine treatment require further clarification.", "entity_list": [{"name": "delirium", "ent_type": "Disease", "char_span": [43, 51], "ent_id": "D003693", "tok_span": [7, 10]}, {"name": "clozapine", "ent_type": "Chemical", "char_span": [59, 68], "ent_id": "D003024", "tok_span": [11, 14]}], "relation_list": [{"subject": "clozapine", "object": "delirium", "sbj_char_span": [59, 68], "obj_char_span": [43, 51], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "METHODS: We used computerized pharmacy records to identify all adult psychiatric inpatients treated with clozapine (1995-96), reviewed their medical records to score incidence and severity of delirium, and tested associations with potential risk factors.", "entity_list": [{"name": "delirium", "ent_type": "Disease", "char_span": [192, 200], "ent_id": "D003693", "tok_span": [35, 38]}, {"name": "psychiatric", "ent_type": "Disease", "char_span": [69, 80], "ent_id": "D001523", "tok_span": [11, 12]}, {"name": "clozapine", "ent_type": "Chemical", "char_span": [105, 114], "ent_id": "D003024", "tok_span": [16, 19]}], "relation_list": [{"subject": "clozapine", "object": "delirium", "sbj_char_span": [105, 114], "obj_char_span": [192, 200], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [35, 38]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Delirium was found in 10 % of clozapine-treated inpatients, particularly in older patients exposed to other central anticholinergics.", "entity_list": [{"name": "clozapine", "ent_type": "Chemical", "char_span": [43, 52], "ent_id": "D003024", "tok_span": [11, 14]}, {"name": "Delirium", "ent_type": "Disease", "char_span": [13, 21], "ent_id": "D003693", "tok_span": [2, 5]}], "relation_list": [{"subject": "clozapine", "object": "Delirium", "sbj_char_span": [43, 52], "obj_char_span": [13, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [2, 5]}], "umls_entity_list": []}, {"text": "A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.", "entity_list": [{"name": "tremor", "ent_type": "Disease", "char_span": [85, 91], "ent_id": "D014202", "tok_span": [20, 22]}, {"name": "ketoconazole", "ent_type": "Chemical", "char_span": [122, 134], "ent_id": "D007654", "tok_span": [29, 32]}, {"name": "dysarthria", "ent_type": "Disease", "char_span": [70, 80], "ent_id": "D004401", "tok_span": [16, 19]}, {"name": "weakness of extremities", "ent_type": "Disease", "char_span": [29, 52], "ent_id": "D018908", "tok_span": [8, 11]}, {"name": "legs paralysis", "ent_type": "Disease", "char_span": [54, 68], "ent_id": "D010243", "tok_span": [12, 15]}], "relation_list": [{"subject": "ketoconazole", "object": "dysarthria", "sbj_char_span": [122, 134], "obj_char_span": [70, 80], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 32], "obj_tok_span": [16, 19]}, {"subject": "ketoconazole", "object": "legs paralysis", "sbj_char_span": [122, 134], "obj_char_span": [54, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 32], "obj_tok_span": [12, 15]}, {"subject": "ketoconazole", "object": "weakness of extremities", "sbj_char_span": [122, 134], "obj_char_span": [29, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 32], "obj_tok_span": [8, 11]}, {"subject": "ketoconazole", "object": "tremor", "sbj_char_span": [122, 134], "obj_char_span": [85, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 32], "obj_tok_span": [20, 22]}], "umls_entity_list": []}, {"text": "Capsaicin (0.01-1 mm) applied to oral or nasal mucosa induced increases in dural and cortical blood flow and provoked lacrimation.", "entity_list": [{"name": "Capsaicin", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D002211", "tok_span": [0, 3]}, {"name": "increases in dural and cortical blood flow", "ent_type": "Disease", "char_span": [62, 104], "ent_id": "D006940", "tok_span": [18, 26]}], "relation_list": [{"subject": "Capsaicin", "object": "increases in dural and cortical blood flow", "sbj_char_span": [0, 9], "obj_char_span": [62, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [18, 26]}], "umls_entity_list": []}, {"text": "Similar to rats, systemic pilocarpine injection causes status epilepticus (SE) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice.", "entity_list": [{"name": "SE", "ent_type": "Disease", "char_span": [75, 77], "ent_id": "D013226", "tok_span": [14, 15]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [26, 37], "ent_id": "D010862", "tok_span": [5, 8]}, {"name": "seizures", "ent_type": "Disease", "char_span": [123, 131], "ent_id": "D012640", "tok_span": [22, 23]}, {"name": "status epilepticus", "ent_type": "Disease", "char_span": [55, 73], "ent_id": "D013226", "tok_span": [10, 13]}], "relation_list": [{"subject": "pilocarpine", "object": "status epilepticus", "sbj_char_span": [26, 37], "obj_char_span": [55, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [10, 13]}, {"subject": "pilocarpine", "object": "SE", "sbj_char_span": [26, 37], "obj_char_span": [75, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [14, 15]}, {"subject": "pilocarpine", "object": "seizures", "sbj_char_span": [26, 37], "obj_char_span": [123, 131], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [22, 23]}], "umls_entity_list": []}, {"text": "In Mg(2+)-free bathing medium containing bicuculline, conditions designed to increase excitability in the slices, electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine-treated mice that did not experience SE.", "entity_list": [{"name": "pilocarpine", "ent_type": "Chemical", "char_span": [227, 238], "ent_id": "D010862", "tok_span": [46, 49]}, {"name": "bicuculline", "ent_type": "Chemical", "char_span": [41, 52], "ent_id": "D001640", "tok_span": [12, 16]}, {"name": "SE", "ent_type": "Disease", "char_span": [276, 278], "ent_id": "D013226", "tok_span": [56, 57]}, {"name": "Mg", "ent_type": "Chemical", "char_span": [3, 5], "ent_id": "D008274", "tok_span": [1, 2]}], "relation_list": [{"subject": "pilocarpine", "object": "SE", "sbj_char_span": [227, 238], "obj_char_span": [276, 278], "rel_type": "chemical-induced disease", "sbj_tok_span": [46, 49], "obj_tok_span": [56, 57]}], "umls_entity_list": []}, {"text": "The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine-induced seizures and hypolocomotion in mice.", "entity_list": [{"name": "hypolocomotion", "ent_type": "Disease", "char_span": [111, 125], "ent_id": "D006948", "tok_span": [19, 23]}, {"name": "nicotine", "ent_type": "Chemical", "char_span": [81, 89], "ent_id": "D009538", "tok_span": [14, 15]}, {"name": "seizures", "ent_type": "Disease", "char_span": [98, 106], "ent_id": "D012640", "tok_span": [17, 18]}, {"name": "acetylcholine", "ent_type": "Chemical", "char_span": [31, 44], "ent_id": "D000109", "tok_span": [8, 9]}], "relation_list": [{"subject": "nicotine", "object": "seizures", "sbj_char_span": [81, 89], "obj_char_span": [98, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [17, 18]}], "umls_entity_list": []}, {"text": "Binding of nicotine to nicotinic acetylcholine receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and tremors, to seizures and death. nAChRs are pentameric ion channels usually composed of alpha and beta subunits.", "entity_list": [{"name": "acetylcholine", "ent_type": "Chemical", "char_span": [33, 46], "ent_id": "D000109", "tok_span": [6, 7]}, {"name": "nicotine", "ent_type": "Chemical", "char_span": [11, 19], "ent_id": "D009538", "tok_span": [2, 3]}, {"name": "death", "ent_type": "Disease", "char_span": [184, 189], "ent_id": "D003643", "tok_span": [37, 38]}, {"name": "seizures", "ent_type": "Disease", "char_span": [171, 179], "ent_id": "D012640", "tok_span": [35, 36]}, {"name": "tremors", "ent_type": "Disease", "char_span": [159, 166], "ent_id": "D014202", "tok_span": [31, 33]}], "relation_list": [{"subject": "nicotine", "object": "seizures", "sbj_char_span": [11, 19], "obj_char_span": [171, 179], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 3], "obj_tok_span": [35, 36]}], "umls_entity_list": []}, {"text": "We examined the role of the beta4 subunits in nicotine-induced seizures and hypolocomotion in beta4 homozygous null (beta4 -/-) and alpha3 heterozygous (+/-) mice. beta4 -/- mice were less sensitive to the effects of nicotine both at low doses, measured as decreased exploration in an open field, and at high doses, measured as sensitivity to nicotine-induced seizures.", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [360, 368], "ent_id": "D012640", "tok_span": [82, 83]}, {"name": "nicotine", "ent_type": "Chemical", "char_span": [343, 351], "ent_id": "D009538", "tok_span": [79, 80]}, {"name": "seizures", "ent_type": "Disease", "char_span": [63, 71], "ent_id": "D012640", "tok_span": [13, 14]}, {"name": "nicotine", "ent_type": "Chemical", "char_span": [46, 54], "ent_id": "D009538", "tok_span": [10, 11]}, {"name": "nicotine", "ent_type": "Chemical", "char_span": [217, 225], "ent_id": "D009538", "tok_span": [55, 56]}, {"name": "hypolocomotion", "ent_type": "Disease", "char_span": [76, 90], "ent_id": "D006948", "tok_span": [15, 19]}], "relation_list": [{"subject": "nicotine", "object": "seizures", "sbj_char_span": [46, 54], "obj_char_span": [63, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [13, 14]}, {"subject": "nicotine", "object": "seizures", "sbj_char_span": [343, 351], "obj_char_span": [360, 368], "rel_type": "chemical-induced disease", "sbj_tok_span": [79, 80], "obj_tok_span": [82, 83]}, {"subject": "nicotine", "object": "seizures", "sbj_char_span": [343, 351], "obj_char_span": [63, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [79, 80], "obj_tok_span": [13, 14]}, {"subject": "nicotine", "object": "seizures", "sbj_char_span": [46, 54], "obj_char_span": [360, 368], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [82, 83]}, {"subject": "nicotine", "object": "seizures", "sbj_char_span": [217, 225], "obj_char_span": [360, 368], "rel_type": "chemical-induced disease", "sbj_tok_span": [55, 56], "obj_tok_span": [82, 83]}, {"subject": "nicotine", "object": "seizures", "sbj_char_span": [217, 225], "obj_char_span": [63, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [55, 56], "obj_tok_span": [13, 14]}], "umls_entity_list": []}, {"text": "Using in situ hybridization probes for the alpha3 and alpha5 subunits, we showed that alpha5 mRNA levels are unchanged, whereas alpha3 mRNA levels are selectively decreased in the mitral cell layer of the olfactory bulb, and the inferior and the superior colliculus of beta4 -/- brains. alpha3 +/- mice were partially resistant to nicotine-induced seizures when compared to wild-type littermates. mRNA levels for the alpha5 and the beta4 subunits were unchanged in alpha3 +/- brains.", "entity_list": [{"name": "nicotine", "ent_type": "Chemical", "char_span": [331, 339], "ent_id": "D009538", "tok_span": [69, 70]}, {"name": "seizures", "ent_type": "Disease", "char_span": [348, 356], "ent_id": "D012640", "tok_span": [72, 73]}], "relation_list": [{"subject": "nicotine", "object": "seizures", "sbj_char_span": [331, 339], "obj_char_span": [348, 356], "rel_type": "chemical-induced disease", "sbj_tok_span": [69, 70], "obj_tok_span": [72, 73]}], "umls_entity_list": []}, {"text": "Together, these results suggest that the beta4 and the alpha3 subunits are mediators of nicotine-induced seizures and hypolocomotion.", "entity_list": [{"name": "hypolocomotion", "ent_type": "Disease", "char_span": [118, 132], "ent_id": "D006948", "tok_span": [22, 26]}, {"name": "seizures", "ent_type": "Disease", "char_span": [105, 113], "ent_id": "D012640", "tok_span": [20, 21]}, {"name": "nicotine", "ent_type": "Chemical", "char_span": [88, 96], "ent_id": "D009538", "tok_span": [17, 18]}], "relation_list": [{"subject": "nicotine", "object": "seizures", "sbj_char_span": [88, 96], "obj_char_span": [105, 113], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 18], "obj_tok_span": [20, 21]}], "umls_entity_list": []}, {"text": "Recurrent acute interstitial nephritis induced by azithromycin.", "entity_list": [{"name": "interstitial nephritis", "ent_type": "Disease", "char_span": [16, 38], "ent_id": "D009395", "tok_span": [3, 6]}, {"name": "azithromycin", "ent_type": "Chemical", "char_span": [50, 62], "ent_id": "D017963", "tok_span": [8, 11]}], "relation_list": [{"subject": "azithromycin", "object": "interstitial nephritis", "sbj_char_span": [50, 62], "obj_char_span": [16, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [3, 6]}], "umls_entity_list": []}, {"text": "A 14-year-old girl is reported with recurrent, azithromycin-induced, acute interstitial nephritis.", "entity_list": [{"name": "interstitial nephritis", "ent_type": "Disease", "char_span": [75, 97], "ent_id": "D009395", "tok_span": [19, 22]}, {"name": "azithromycin", "ent_type": "Chemical", "char_span": [47, 59], "ent_id": "D017963", "tok_span": [12, 15]}], "relation_list": [{"subject": "azithromycin", "object": "interstitial nephritis", "sbj_char_span": [47, 59], "obj_char_span": [75, 97], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [19, 22]}], "umls_entity_list": []}, {"text": "Valproate-induced encephalopathy.", "entity_list": [{"name": "Valproate", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D014635", "tok_span": [0, 3]}, {"name": "encephalopathy", "ent_type": "Disease", "char_span": [18, 32], "ent_id": "D001927", "tok_span": [5, 7]}], "relation_list": [{"subject": "Valproate", "object": "encephalopathy", "sbj_char_span": [0, 9], "obj_char_span": [18, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "Valproate-induced encephalopathy is a rare syndrome that may manifest in otherwise normal epileptic individuals.", "entity_list": [{"name": "Valproate", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D014635", "tok_span": [0, 3]}, {"name": "epileptic", "ent_type": "Disease", "char_span": [90, 99], "ent_id": "D004827", "tok_span": [17, 18]}, {"name": "encephalopathy", "ent_type": "Disease", "char_span": [18, 32], "ent_id": "D001927", "tok_span": [5, 7]}], "relation_list": [{"subject": "Valproate", "object": "encephalopathy", "sbj_char_span": [0, 9], "obj_char_span": [18, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "A case of valproate-induced encephalopathy is presented.", "entity_list": [{"name": "valproate", "ent_type": "Chemical", "char_span": [10, 19], "ent_id": "D014635", "tok_span": [3, 6]}, {"name": "encephalopathy", "ent_type": "Disease", "char_span": [28, 42], "ent_id": "D001927", "tok_span": [8, 10]}], "relation_list": [{"subject": "valproate", "object": "encephalopathy", "sbj_char_span": [10, 19], "obj_char_span": [28, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "L-NAME reduced gentamicin-induced hearing loss in the high-frequency range, but gave no protection in the middle or low frequencies.", "entity_list": [{"name": "hearing loss", "ent_type": "Disease", "char_span": [34, 46], "ent_id": "D034381", "tok_span": [9, 11]}, {"name": "L-NAME", "ent_type": "Chemical", "char_span": [0, 6], "ent_id": "D019331", "tok_span": [0, 4]}, {"name": "gentamicin", "ent_type": "Chemical", "char_span": [15, 25], "ent_id": "D005839", "tok_span": [5, 7]}], "relation_list": [{"subject": "gentamicin", "object": "hearing loss", "sbj_char_span": [15, 25], "obj_char_span": [34, 46], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 7], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "Cerebral vasculitis following oral methylphenidate intake in an adult: a case report.", "entity_list": [{"name": "Cerebral vasculitis", "ent_type": "Disease", "char_span": [0, 19], "ent_id": "D020293", "tok_span": [0, 4]}, {"name": "methylphenidate", "ent_type": "Chemical", "char_span": [35, 50], "ent_id": "D008774", "tok_span": [6, 9]}], "relation_list": [{"subject": "methylphenidate", "object": "Cerebral vasculitis", "sbj_char_span": [35, 50], "obj_char_span": [0, 19], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.", "entity_list": [{"name": "methylphenidate", "ent_type": "Chemical", "char_span": [133, 148], "ent_id": "D008774", "tok_span": [26, 29]}, {"name": "Cerebral vasculitis", "ent_type": "Disease", "char_span": [0, 19], "ent_id": "D020293", "tok_span": [0, 4]}, {"name": "amphetamine abuse", "ent_type": "Disease", "char_span": [36, 53], "ent_id": "D019969", "tok_span": [6, 11]}, {"name": "ischaemic stroke", "ent_type": "Disease", "char_span": [92, 108], "ent_id": "D002544", "tok_span": [19, 22]}], "relation_list": [{"subject": "methylphenidate", "object": "Cerebral vasculitis", "sbj_char_span": [133, 148], "obj_char_span": [0, 19], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 29], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "Cerebral haemorrhage induced by warfarin - the influence of drug-drug interactions.", "entity_list": [{"name": "warfarin", "ent_type": "Chemical", "char_span": [32, 40], "ent_id": "D014859", "tok_span": [6, 7]}, {"name": "Cerebral haemorrhage", "ent_type": "Disease", "char_span": [0, 20], "ent_id": "D002543", "tok_span": [0, 4]}], "relation_list": [{"subject": "warfarin", "object": "Cerebral haemorrhage", "sbj_char_span": [32, 40], "obj_char_span": [0, 20], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "PURPOSE: To evaluate the frequency, severity and preventability of warfarin-induced cerebral haemorrhages due to warfarin and warfarin-drug interactions in patients living in the county of Osterg  tland, Sweden.", "entity_list": [{"name": "warfarin", "ent_type": "Chemical", "char_span": [67, 75], "ent_id": "D014859", "tok_span": [12, 13]}, {"name": "warfarin", "ent_type": "Chemical", "char_span": [113, 121], "ent_id": "D014859", "tok_span": [20, 21]}, {"name": "cerebral haemorrhages", "ent_type": "Disease", "char_span": [84, 105], "ent_id": "D002543", "tok_span": [15, 18]}, {"name": "warfarin", "ent_type": "Chemical", "char_span": [126, 134], "ent_id": "D014859", "tok_span": [22, 23]}], "relation_list": [{"subject": "warfarin", "object": "cerebral haemorrhages", "sbj_char_span": [67, 75], "obj_char_span": [84, 105], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [15, 18]}, {"subject": "warfarin", "object": "cerebral haemorrhages", "sbj_char_span": [113, 121], "obj_char_span": [84, 105], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 21], "obj_tok_span": [15, 18]}, {"subject": "warfarin", "object": "cerebral haemorrhages", "sbj_char_span": [126, 134], "obj_char_span": [84, 105], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [15, 18]}], "umls_entity_list": []}, {"text": "Medical records were studied retrospectively to evaluate whether warfarin and warfarin-drug interactions could have caused the cerebral haemorrhage.", "entity_list": [{"name": "warfarin", "ent_type": "Chemical", "char_span": [78, 86], "ent_id": "D014859", "tok_span": [10, 11]}, {"name": "cerebral haemorrhage", "ent_type": "Disease", "char_span": [127, 147], "ent_id": "D002543", "tok_span": [18, 21]}, {"name": "warfarin", "ent_type": "Chemical", "char_span": [65, 73], "ent_id": "D014859", "tok_span": [8, 9]}], "relation_list": [{"subject": "warfarin", "object": "cerebral haemorrhage", "sbj_char_span": [65, 73], "obj_char_span": [127, 147], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [18, 21]}, {"subject": "warfarin", "object": "cerebral haemorrhage", "sbj_char_span": [78, 86], "obj_char_span": [127, 147], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [18, 21]}], "umls_entity_list": []}, {"text": "RESULTS: Among 593 patients with cerebral haemorrhage, 59 (10%) were assessed as related to warfarin treatment.", "entity_list": [{"name": "cerebral haemorrhage", "ent_type": "Disease", "char_span": [33, 53], "ent_id": "D002543", "tok_span": [7, 10]}, {"name": "warfarin", "ent_type": "Chemical", "char_span": [92, 100], "ent_id": "D014859", "tok_span": [21, 22]}], "relation_list": [{"subject": "warfarin", "object": "cerebral haemorrhage", "sbj_char_span": [92, 100], "obj_char_span": [33, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 22], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Warfarin-induced cerebral haemorrhages are a major clinical problem with a high fatality rate.", "entity_list": [{"name": "cerebral haemorrhages", "ent_type": "Disease", "char_span": [30, 51], "ent_id": "D002543", "tok_span": [7, 10]}, {"name": "Warfarin", "ent_type": "Chemical", "char_span": [13, 21], "ent_id": "D014859", "tok_span": [2, 5]}], "relation_list": [{"subject": "Warfarin", "object": "cerebral haemorrhages", "sbj_char_span": [13, 21], "obj_char_span": [30, 51], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "A significant proportion of warfarin-related cerebral haemorrhages might have been prevented if greater caution had been taken when prescribing drugs known to interact with warfarin.", "entity_list": [{"name": "cerebral haemorrhages", "ent_type": "Disease", "char_span": [45, 66], "ent_id": "D002543", "tok_span": [7, 10]}, {"name": "warfarin", "ent_type": "Chemical", "char_span": [173, 181], "ent_id": "D014859", "tok_span": [27, 28]}, {"name": "warfarin", "ent_type": "Chemical", "char_span": [28, 36], "ent_id": "D014859", "tok_span": [4, 5]}], "relation_list": [{"subject": "warfarin", "object": "cerebral haemorrhages", "sbj_char_span": [173, 181], "obj_char_span": [45, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 28], "obj_tok_span": [7, 10]}, {"subject": "warfarin", "object": "cerebral haemorrhages", "sbj_char_span": [28, 36], "obj_char_span": [45, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: The administration of methylprednisolone and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and headache.", "entity_list": [{"name": "gentamicin", "ent_type": "Chemical", "char_span": [58, 68], "ent_id": "D005839", "tok_span": [10, 12]}, {"name": "nausea, vomiting", "ent_type": "Disease", "char_span": [162, 178], "ent_id": "D020250", "tok_span": [32, 35]}, {"name": "headache", "ent_type": "Disease", "char_span": [184, 192], "ent_id": "D006261", "tok_span": [37, 38]}, {"name": "methylprednisolone", "ent_type": "Chemical", "char_span": [35, 53], "ent_id": "D008775", "tok_span": [5, 9]}], "relation_list": [{"subject": "gentamicin", "object": "headache", "sbj_char_span": [58, 68], "obj_char_span": [184, 192], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 12], "obj_tok_span": [37, 38]}, {"subject": "gentamicin", "object": "nausea, vomiting", "sbj_char_span": [58, 68], "obj_char_span": [162, 178], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 12], "obj_tok_span": [32, 35]}, {"subject": "methylprednisolone", "object": "nausea, vomiting", "sbj_char_span": [35, 53], "obj_char_span": [162, 178], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [32, 35]}, {"subject": "methylprednisolone", "object": "headache", "sbj_char_span": [35, 53], "obj_char_span": [184, 192], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [37, 38]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.", "entity_list": [{"name": "diabetes mellitus", "ent_type": "Disease", "char_span": [222, 239], "ent_id": "D003920", "tok_span": [44, 46]}, {"name": "iopamidol", "ent_type": "Chemical", "char_span": [160, 169], "ent_id": "D007479", "tok_span": [27, 31]}, {"name": "nephropathy", "ent_type": "Disease", "char_span": [42, 53], "ent_id": "D007674", "tok_span": [8, 9]}, {"name": "iodixanol", "ent_type": "Chemical", "char_span": [173, 182], "ent_id": "C044834", "tok_span": [32, 35]}], "relation_list": [{"subject": "iopamidol", "object": "nephropathy", "sbj_char_span": [160, 169], "obj_char_span": [42, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 31], "obj_tok_span": [8, 9]}, {"subject": "iodixanol", "object": "nephropathy", "sbj_char_span": [173, 182], "obj_char_span": [42, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 35], "obj_tok_span": [8, 9]}], "umls_entity_list": []}, {"text": "In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats.", "entity_list": [{"name": "cognitive decline", "ent_type": "Disease", "char_span": [81, 98], "ent_id": "D003072", "tok_span": [18, 20]}, {"name": "scopolamine", "ent_type": "Chemical", "char_span": [102, 113], "ent_id": "D012601", "tok_span": [21, 24]}, {"name": "maltolyl p-coumarate", "ent_type": "Chemical", "char_span": [46, 66], "ent_id": "C524754", "tok_span": [8, 16]}, {"name": "amyloid beta peptide(1-42)", "ent_type": "Chemical", "char_span": [135, 161], "ent_id": "C544092", "tok_span": [29, 37]}], "relation_list": [{"subject": "scopolamine", "object": "cognitive decline", "sbj_char_span": [102, 113], "obj_char_span": [81, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [18, 20]}], "umls_entity_list": []}, {"text": "We report 3 cases of serious bleeding complications that appear to be the result of the interaction between warfarin and levofloxacin.", "entity_list": [{"name": "bleeding", "ent_type": "Disease", "char_span": [29, 37], "ent_id": "D006470", "tok_span": [6, 7]}, {"name": "warfarin", "ent_type": "Chemical", "char_span": [108, 116], "ent_id": "D014859", "tok_span": [18, 19]}, {"name": "levofloxacin", "ent_type": "Chemical", "char_span": [121, 133], "ent_id": "D064704", "tok_span": [20, 23]}], "relation_list": [{"subject": "levofloxacin", "object": "bleeding", "sbj_char_span": [121, 133], "obj_char_span": [29, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [6, 7]}, {"subject": "warfarin", "object": "bleeding", "sbj_char_span": [108, 116], "obj_char_span": [29, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [6, 7]}], "umls_entity_list": []}, {"text": "To this end, persistent hyperalgesia was induced by administration of capsaicin in the tail of gonadally intact F344 rats, following which the tail was immersed in a mildly noxious thermal stimulus, and tail-withdrawal latencies measured.", "entity_list": [{"name": "capsaicin", "ent_type": "Chemical", "char_span": [70, 79], "ent_id": "D002211", "tok_span": [14, 17]}, {"name": "hyperalgesia", "ent_type": "Disease", "char_span": [24, 36], "ent_id": "D006930", "tok_span": [5, 9]}], "relation_list": [{"subject": "capsaicin", "object": "hyperalgesia", "sbj_char_span": [70, 79], "obj_char_span": [24, 36], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients.", "entity_list": [{"name": "proteinuria", "ent_type": "Disease", "char_span": [15, 26], "ent_id": "D011507", "tok_span": [2, 3]}, {"name": "sirolimus", "ent_type": "Chemical", "char_span": [43, 52], "ent_id": "D020123", "tok_span": [6, 8]}], "relation_list": [{"subject": "sirolimus", "object": "proteinuria", "sbj_char_span": [43, 52], "obj_char_span": [15, 26], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [2, 3]}], "umls_entity_list": []}, {"text": "The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with Srl has been reported following renal transplantation.", "entity_list": [{"name": "Srl", "ent_type": "Chemical", "char_span": [117, 120], "ent_id": "D020123", "tok_span": [26, 28]}, {"name": "sirolmus", "ent_type": "Chemical", "char_span": [38, 46], "ent_id": "D020123", "tok_span": [8, 11]}, {"name": "proteinuria", "ent_type": "Disease", "char_span": [89, 100], "ent_id": "D011507", "tok_span": [23, 24]}, {"name": "Srl", "ent_type": "Chemical", "char_span": [48, 51], "ent_id": "D020123", "tok_span": [12, 14]}, {"name": "nephrotoxic", "ent_type": "Disease", "char_span": [59, 70], "ent_id": "D007674", "tok_span": [16, 19]}], "relation_list": [{"subject": "sirolmus", "object": "proteinuria", "sbj_char_span": [38, 46], "obj_char_span": [89, 100], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [23, 24]}, {"subject": "Srl", "object": "proteinuria", "sbj_char_span": [48, 51], "obj_char_span": [89, 100], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 14], "obj_tok_span": [23, 24]}, {"subject": "Srl", "object": "proteinuria", "sbj_char_span": [117, 120], "obj_char_span": [89, 100], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 28], "obj_tok_span": [23, 24]}], "umls_entity_list": []}, {"text": "In cardiac transplantation, the incidence of proteinuria associated with Srl is unknown.", "entity_list": [{"name": "proteinuria", "ent_type": "Disease", "char_span": [45, 56], "ent_id": "D011507", "tok_span": [7, 8]}, {"name": "Srl", "ent_type": "Chemical", "char_span": [73, 76], "ent_id": "D020123", "tok_span": [10, 12]}], "relation_list": [{"subject": "Srl", "object": "proteinuria", "sbj_char_span": [73, 76], "obj_char_span": [45, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 12], "obj_tok_span": [7, 8]}], "umls_entity_list": []}, {"text": "Thus, proteinuria may develop in cardiac transplant patients after switch to Srl, which may have an adverse effect on renal function in these patients.", "entity_list": [{"name": "Srl", "ent_type": "Chemical", "char_span": [77, 80], "ent_id": "D020123", "tok_span": [12, 14]}, {"name": "proteinuria", "ent_type": "Disease", "char_span": [6, 17], "ent_id": "D011507", "tok_span": [2, 3]}], "relation_list": [{"subject": "Srl", "object": "proteinuria", "sbj_char_span": [77, 80], "obj_char_span": [6, 17], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 14], "obj_tok_span": [2, 3]}], "umls_entity_list": []}, {"text": "Srl should be used with ACEi/ARB therapy and patients monitored for proteinuria and increased renal dysfunction.", "entity_list": [{"name": "ACEi", "ent_type": "Chemical", "char_span": [24, 28], "ent_id": "D000806", "tok_span": [6, 8]}, {"name": "renal dysfunction", "ent_type": "Disease", "char_span": [94, 111], "ent_id": "D007674", "tok_span": [19, 21]}, {"name": "ARB", "ent_type": "Chemical", "char_span": [29, 32], "ent_id": "D057911", "tok_span": [9, 11]}, {"name": "proteinuria", "ent_type": "Disease", "char_span": [68, 79], "ent_id": "D011507", "tok_span": [16, 17]}, {"name": "Srl", "ent_type": "Chemical", "char_span": [0, 3], "ent_id": "D020123", "tok_span": [0, 2]}], "relation_list": [{"subject": "Srl", "object": "proteinuria", "sbj_char_span": [0, 3], "obj_char_span": [68, 79], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [16, 17]}], "umls_entity_list": []}, {"text": "SAR studies led to compound 14 with excellent potency (K(i) = 0.4 nM), selectivity (A(1)/A(2A) > 100), and efficacy (MED 10 mg/kg p.o.) in the rat haloperidol-induced catalepsy model for Parkinson's disease.", "entity_list": [{"name": "Parkinson's disease", "ent_type": "Disease", "char_span": [187, 206], "ent_id": "D010300", "tok_span": [63, 67]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [147, 158], "ent_id": "D006220", "tok_span": [53, 56]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [167, 176], "ent_id": "D002375", "tok_span": [58, 61]}], "relation_list": [{"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [147, 158], "obj_char_span": [167, 176], "rel_type": "chemical-induced disease", "sbj_tok_span": [53, 56], "obj_tok_span": [58, 61]}], "umls_entity_list": []}, {"text": "Neurosci. 9 (2006), 917] recently identified the microglial-specific fractalkine receptor (CX3CR1) as an important mediator of MPTP-induced neurodegeneration of DA neurons.", "entity_list": [{"name": "DA", "ent_type": "Chemical", "char_span": [161, 163], "ent_id": "D004298", "tok_span": [39, 40]}, {"name": "neurodegeneration", "ent_type": "Disease", "char_span": [140, 157], "ent_id": "D009422", "tok_span": [36, 38]}, {"name": "MPTP", "ent_type": "Chemical", "char_span": [127, 131], "ent_id": "D015632", "tok_span": [32, 34]}], "relation_list": [{"subject": "MPTP", "object": "neurodegeneration", "sbj_char_span": [127, 131], "obj_char_span": [140, 157], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 34], "obj_tok_span": [36, 38]}], "umls_entity_list": []}, {"text": "Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.", "entity_list": [{"name": "CNS damage", "ent_type": "Disease", "char_span": [12, 22], "ent_id": "D009422", "tok_span": [2, 4]}, {"name": "METH", "ent_type": "Chemical", "char_span": [33, 37], "ent_id": "D008694", "tok_span": [6, 8]}, {"name": "MPTP", "ent_type": "Chemical", "char_span": [42, 46], "ent_id": "D015632", "tok_span": [9, 11]}, {"name": "neurotoxicity", "ent_type": "Disease", "char_span": [113, 126], "ent_id": "D020258", "tok_span": [23, 25]}, {"name": "neurotoxicity", "ent_type": "Disease", "char_span": [189, 202], "ent_id": "D020258", "tok_span": [42, 44]}, {"name": "DA", "ent_type": "Chemical", "char_span": [75, 77], "ent_id": "D004298", "tok_span": [16, 17]}, {"name": "METH", "ent_type": "Chemical", "char_span": [176, 180], "ent_id": "D008694", "tok_span": [38, 40]}], "relation_list": [{"subject": "METH", "object": "CNS damage", "sbj_char_span": [176, 180], "obj_char_span": [12, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [38, 40], "obj_tok_span": [2, 4]}, {"subject": "METH", "object": "CNS damage", "sbj_char_span": [33, 37], "obj_char_span": [12, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [2, 4]}, {"subject": "MPTP", "object": "CNS damage", "sbj_char_span": [42, 46], "obj_char_span": [12, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 11], "obj_tok_span": [2, 4]}], "umls_entity_list": []}, {"text": "Recovery of tacrolimus-associated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient--case report and review of the literature.", "entity_list": [{"name": "tacrolimus", "ent_type": "Chemical", "char_span": [12, 22], "ent_id": "D016559", "tok_span": [2, 4]}, {"name": "brachial neuritis", "ent_type": "Disease", "char_span": [34, 51], "ent_id": "D020968", "tok_span": [6, 10]}, {"name": "everolimus", "ent_type": "Chemical", "char_span": [72, 82], "ent_id": "C107135", "tok_span": [13, 16]}], "relation_list": [{"subject": "tacrolimus", "object": "brachial neuritis", "sbj_char_span": [12, 22], "obj_char_span": [34, 51], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 4], "obj_tok_span": [6, 10]}], "umls_entity_list": []}, {"text": "Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.", "entity_list": [{"name": "acute renal failure", "ent_type": "Disease", "char_span": [24, 43], "ent_id": "D058186", "tok_span": [4, 7]}, {"name": "focal segmental glomerulosclerosis", "ent_type": "Disease", "char_span": [117, 151], "ent_id": "D005923", "tok_span": [23, 29]}, {"name": "alendronate", "ent_type": "Chemical", "char_span": [71, 82], "ent_id": "D019386", "tok_span": [13, 17]}, {"name": "proteinuria", "ent_type": "Disease", "char_span": [8, 19], "ent_id": "D011507", "tok_span": [2, 3]}, {"name": "bisphosphonate", "ent_type": "Chemical", "char_span": [55, 69], "ent_id": "D004164", "tok_span": [9, 12]}], "relation_list": [{"subject": "alendronate", "object": "proteinuria", "sbj_char_span": [71, 82], "obj_char_span": [8, 19], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [2, 3]}, {"subject": "alendronate", "object": "acute renal failure", "sbj_char_span": [71, 82], "obj_char_span": [24, 43], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [4, 7]}], "umls_entity_list": []}, {"text": "The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with acute renal failure.", "entity_list": [{"name": "alendronate sodium", "ent_type": "Chemical", "char_span": [109, 127], "ent_id": "D019386", "tok_span": [27, 32]}, {"name": "acute renal failure", "ent_type": "Disease", "char_span": [217, 236], "ent_id": "D058186", "tok_span": [50, 53]}, {"name": "bisphosphonate", "ent_type": "Chemical", "char_span": [93, 107], "ent_id": "D004164", "tok_span": [23, 26]}], "relation_list": [{"subject": "alendronate sodium", "object": "acute renal failure", "sbj_char_span": [109, 127], "obj_char_span": [217, 236], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 32], "obj_tok_span": [50, 53]}], "umls_entity_list": []}, {"text": "Serum- and glucocorticoid-inducible kinase 1 in doxorubicin-induced nephrotic syndrome.", "entity_list": [{"name": "doxorubicin", "ent_type": "Chemical", "char_span": [48, 59], "ent_id": "D004317", "tok_span": [9, 10]}, {"name": "nephrotic syndrome", "ent_type": "Disease", "char_span": [68, 86], "ent_id": "D009404", "tok_span": [12, 15]}], "relation_list": [{"subject": "doxorubicin", "object": "nephrotic syndrome", "sbj_char_span": [48, 59], "obj_char_span": [68, 86], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [12, 15]}], "umls_entity_list": []}, {"text": "Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.", "entity_list": [{"name": "lipidemia", "ent_type": "Disease", "char_span": [179, 188], "ent_id": "D006949", "tok_span": [56, 58]}, {"name": "ascites", "ent_type": "Disease", "char_span": [170, 177], "ent_id": "D001201", "tok_span": [54, 55]}, {"name": "hypoalbuminemia", "ent_type": "Disease", "char_span": [194, 209], "ent_id": "D034141", "tok_span": [60, 63]}, {"name": "nephrotic syndrome", "ent_type": "Disease", "char_span": [146, 164], "ent_id": "D009404", "tok_span": [50, 53]}, {"name": "proteinuria", "ent_type": "Disease", "char_span": [40, 51], "ent_id": "D011507", "tok_span": [7, 8]}, {"name": "Doxorubicin", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D004317", "tok_span": [0, 3]}], "relation_list": [{"subject": "Doxorubicin", "object": "hypoalbuminemia", "sbj_char_span": [0, 11], "obj_char_span": [194, 209], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [60, 63]}, {"subject": "Doxorubicin", "object": "ascites", "sbj_char_span": [0, 11], "obj_char_span": [170, 177], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [54, 55]}, {"subject": "Doxorubicin", "object": "nephrotic syndrome", "sbj_char_span": [0, 11], "obj_char_span": [146, 164], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [50, 53]}, {"subject": "Doxorubicin", "object": "proteinuria", "sbj_char_span": [0, 11], "obj_char_span": [40, 51], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [7, 8]}, {"subject": "Doxorubicin", "object": "lipidemia", "sbj_char_span": [0, 11], "obj_char_span": [179, 188], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [56, 58]}], "umls_entity_list": []}, {"text": "Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during co-trimoxazole treatment for PCP.", "entity_list": [{"name": "HIV-infected", "ent_type": "Disease", "char_span": [56, 68], "ent_id": "D015658", "tok_span": [11, 14]}, {"name": "co-trimoxazole", "ent_type": "Chemical", "char_span": [214, 228], "ent_id": "D015662", "tok_span": [42, 47]}, {"name": "PCP", "ent_type": "Disease", "char_span": [243, 246], "ent_id": "D011020", "tok_span": [49, 50]}, {"name": "intrahepatic cholestasis", "ent_type": "Disease", "char_span": [99, 123], "ent_id": "D002780", "tok_span": [18, 23]}, {"name": "liver abscess", "ent_type": "Disease", "char_span": [162, 175], "ent_id": "D008100", "tok_span": [31, 33]}], "relation_list": [{"subject": "co-trimoxazole", "object": "intrahepatic cholestasis", "sbj_char_span": [214, 228], "obj_char_span": [99, 123], "rel_type": "chemical-induced disease", "sbj_tok_span": [42, 47], "obj_tok_span": [18, 23]}], "umls_entity_list": []}, {"text": "Clinically significant proteinuria following the administration of sirolimus to renal transplant recipients.", "entity_list": [{"name": "proteinuria", "ent_type": "Disease", "char_span": [23, 34], "ent_id": "D011507", "tok_span": [3, 4]}, {"name": "sirolimus", "ent_type": "Chemical", "char_span": [67, 76], "ent_id": "D020123", "tok_span": [8, 10]}], "relation_list": [{"subject": "sirolimus", "object": "proteinuria", "sbj_char_span": [67, 76], "obj_char_span": [23, 34], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [3, 4]}], "umls_entity_list": []}, {"text": "To date there has been little documentation of clinically significant proteinuria linked with the use of sirolimus.", "entity_list": [{"name": "proteinuria", "ent_type": "Disease", "char_span": [70, 81], "ent_id": "D011507", "tok_span": [10, 11]}, {"name": "sirolimus", "ent_type": "Chemical", "char_span": [105, 114], "ent_id": "D020123", "tok_span": [16, 18]}], "relation_list": [{"subject": "sirolimus", "object": "proteinuria", "sbj_char_span": [105, 114], "obj_char_span": [70, 81], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 18], "obj_tok_span": [10, 11]}], "umls_entity_list": []}, {"text": "We have encountered several patients who developed substantial proteinuria associated with sirolimus use.", "entity_list": [{"name": "sirolimus", "ent_type": "Chemical", "char_span": [91, 100], "ent_id": "D020123", "tok_span": [11, 13]}, {"name": "proteinuria", "ent_type": "Disease", "char_span": [63, 74], "ent_id": "D011507", "tok_span": [8, 9]}], "relation_list": [{"subject": "sirolimus", "object": "proteinuria", "sbj_char_span": [91, 100], "obj_char_span": [63, 74], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 13], "obj_tok_span": [8, 9]}], "umls_entity_list": []}, {"text": "In each patient, the close temporal association between the commencement of sirolimus therapy and proteinuria implicated sirolimus as the most likely etiology of the proteinuria.", "entity_list": [{"name": "sirolimus", "ent_type": "Chemical", "char_span": [121, 130], "ent_id": "D020123", "tok_span": [20, 22]}, {"name": "proteinuria", "ent_type": "Disease", "char_span": [166, 177], "ent_id": "D011507", "tok_span": [29, 30]}, {"name": "proteinuria", "ent_type": "Disease", "char_span": [98, 109], "ent_id": "D011507", "tok_span": [18, 19]}, {"name": "sirolimus", "ent_type": "Chemical", "char_span": [76, 85], "ent_id": "D020123", "tok_span": [14, 16]}], "relation_list": [{"subject": "sirolimus", "object": "proteinuria", "sbj_char_span": [121, 130], "obj_char_span": [166, 177], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 22], "obj_tok_span": [29, 30]}, {"subject": "sirolimus", "object": "proteinuria", "sbj_char_span": [76, 85], "obj_char_span": [166, 177], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [29, 30]}, {"subject": "sirolimus", "object": "proteinuria", "sbj_char_span": [121, 130], "obj_char_span": [98, 109], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 22], "obj_tok_span": [18, 19]}, {"subject": "sirolimus", "object": "proteinuria", "sbj_char_span": [76, 85], "obj_char_span": [98, 109], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [18, 19]}], "umls_entity_list": []}, {"text": "In 7 of the 28 patients there was a striking temporal association between the initiation of sirolimus and the development of nephrotic-range proteinuria.", "entity_list": [{"name": "nephrotic", "ent_type": "Disease", "char_span": [125, 134], "ent_id": "D009404", "tok_span": [22, 24]}, {"name": "sirolimus", "ent_type": "Chemical", "char_span": [92, 101], "ent_id": "D020123", "tok_span": [16, 18]}, {"name": "proteinuria", "ent_type": "Disease", "char_span": [141, 152], "ent_id": "D011507", "tok_span": [26, 27]}], "relation_list": [{"subject": "sirolimus", "object": "proteinuria", "sbj_char_span": [92, 101], "obj_char_span": [141, 152], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 18], "obj_tok_span": [26, 27]}], "umls_entity_list": []}, {"text": "Proteinuria correlated most strongly with sirolimus therapy when compared to other demographic and clinical variables.", "entity_list": [{"name": "sirolimus", "ent_type": "Chemical", "char_span": [42, 51], "ent_id": "D020123", "tok_span": [6, 8]}, {"name": "Proteinuria", "ent_type": "Disease", "char_span": [0, 11], "ent_id": "D011507", "tok_span": [0, 2]}], "relation_list": [{"subject": "sirolimus", "object": "Proteinuria", "sbj_char_span": [42, 51], "obj_char_span": [0, 11], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "In most patients, discontinuation of sirolimus resulted in a decrease, but not resolution, of proteinuria.", "entity_list": [{"name": "proteinuria", "ent_type": "Disease", "char_span": [94, 105], "ent_id": "D011507", "tok_span": [18, 19]}, {"name": "sirolimus", "ent_type": "Chemical", "char_span": [37, 46], "ent_id": "D020123", "tok_span": [6, 8]}], "relation_list": [{"subject": "sirolimus", "object": "proteinuria", "sbj_char_span": [37, 46], "obj_char_span": [94, 105], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [18, 19]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Sirolimus induces or aggravates pre-existing proteinuria in an unpredictable subset of renal allograft recipients.", "entity_list": [{"name": "Sirolimus", "ent_type": "Chemical", "char_span": [13, 22], "ent_id": "D020123", "tok_span": [2, 5]}, {"name": "proteinuria", "ent_type": "Disease", "char_span": [58, 69], "ent_id": "D011507", "tok_span": [12, 13]}], "relation_list": [{"subject": "Sirolimus", "object": "proteinuria", "sbj_char_span": [13, 22], "obj_char_span": [58, 69], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [12, 13]}], "umls_entity_list": []}, {"text": "Proteinuria may improve, but does not resolve, when sirolimus is withdrawn.", "entity_list": [{"name": "sirolimus", "ent_type": "Chemical", "char_span": [52, 61], "ent_id": "D020123", "tok_span": [11, 13]}, {"name": "Proteinuria", "ent_type": "Disease", "char_span": [0, 11], "ent_id": "D011507", "tok_span": [0, 2]}], "relation_list": [{"subject": "sirolimus", "object": "Proteinuria", "sbj_char_span": [52, 61], "obj_char_span": [0, 11], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 13], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "OBJECTIVE: The purpose of the present study was to determine the effect of morning-dosed modafinil on sleep and daytime sleepiness in chronic cocaine users.", "entity_list": [{"name": "modafinil", "ent_type": "Chemical", "char_span": [89, 98], "ent_id": "C048833", "tok_span": [18, 22]}, {"name": "daytime sleepiness", "ent_type": "Disease", "char_span": [112, 130], "ent_id": "D012893", "tok_span": [25, 28]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [142, 149], "ent_id": "D003042", "tok_span": [30, 31]}], "relation_list": [{"subject": "cocaine", "object": "daytime sleepiness", "sbj_char_span": [142, 149], "obj_char_span": [112, 130], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 31], "obj_tok_span": [25, 28]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Morning-dosed modafinil promotes nocturnal sleep, normalizes sleep architecture, and decreases daytime sleepiness in abstinent cocaine users.", "entity_list": [{"name": "cocaine", "ent_type": "Chemical", "char_span": [140, 147], "ent_id": "D003042", "tok_span": [29, 30]}, {"name": "daytime sleepiness", "ent_type": "Disease", "char_span": [108, 126], "ent_id": "D012893", "tok_span": [23, 26]}, {"name": "modafinil", "ent_type": "Chemical", "char_span": [27, 36], "ent_id": "C048833", "tok_span": [7, 11]}], "relation_list": [{"subject": "cocaine", "object": "daytime sleepiness", "sbj_char_span": [140, 147], "obj_char_span": [108, 126], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 30], "obj_tok_span": [23, 26]}], "umls_entity_list": []}, {"text": "Extrapyramidal symptoms reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.", "entity_list": [{"name": "haloperidol", "ent_type": "Chemical", "char_span": [115, 126], "ent_id": "D006220", "tok_span": [36, 39]}, {"name": "asenapine", "ent_type": "Chemical", "char_span": [85, 94], "ent_id": "C522667", "tok_span": [25, 28]}, {"name": "Extrapyramidal symptoms", "ent_type": "Disease", "char_span": [0, 23], "ent_id": "D001480", "tok_span": [0, 5]}], "relation_list": [{"subject": "asenapine", "object": "Extrapyramidal symptoms", "sbj_char_span": [85, 94], "obj_char_span": [0, 23], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 28], "obj_tok_span": [0, 5]}, {"subject": "haloperidol", "object": "Extrapyramidal symptoms", "sbj_char_span": [115, 126], "obj_char_span": [0, 23], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 39], "obj_tok_span": [0, 5]}], "umls_entity_list": []}, {"text": "Post hoc analyses indicated that efficacy was similar with asenapine and haloperidol; greater contrasts were seen in AEs, especially extrapyramidal symptoms.", "entity_list": [{"name": "extrapyramidal symptoms", "ent_type": "Disease", "char_span": [133, 156], "ent_id": "D001480", "tok_span": [26, 31]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [73, 84], "ent_id": "D006220", "tok_span": [13, 16]}, {"name": "asenapine", "ent_type": "Chemical", "char_span": [59, 68], "ent_id": "C522667", "tok_span": [9, 12]}], "relation_list": [{"subject": "asenapine", "object": "extrapyramidal symptoms", "sbj_char_span": [59, 68], "obj_char_span": [133, 156], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [26, 31]}, {"subject": "haloperidol", "object": "extrapyramidal symptoms", "sbj_char_span": [73, 84], "obj_char_span": [133, 156], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [26, 31]}], "umls_entity_list": []}, {"text": "Permeability, ultrastructural changes, and distribution of novel proteins in the glomerular barrier in early puromycin aminonucleoside nephrosis.", "entity_list": [{"name": "nephrosis", "ent_type": "Disease", "char_span": [135, 144], "ent_id": "D009401", "tok_span": [24, 26]}, {"name": "puromycin aminonucleoside", "ent_type": "Chemical", "char_span": [109, 134], "ent_id": "D011692", "tok_span": [19, 24]}], "relation_list": [{"subject": "puromycin aminonucleoside", "object": "nephrosis", "sbj_char_span": [109, 134], "obj_char_span": [135, 144], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 24], "obj_tok_span": [24, 26]}], "umls_entity_list": []}, {"text": "Using puromycin aminonucleoside nephrosis (PAN) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin, a-actinin, dendrin, and plekhh2, the last two of which were only recently discovered in podocytes.", "entity_list": [{"name": "puromycin aminonucleoside", "ent_type": "Chemical", "char_span": [6, 31], "ent_id": "D011692", "tok_span": [1, 6]}, {"name": "nephrosis", "ent_type": "Disease", "char_span": [32, 41], "ent_id": "D009401", "tok_span": [6, 8]}], "relation_list": [{"subject": "puromycin aminonucleoside", "object": "nephrosis", "sbj_char_span": [6, 31], "obj_char_span": [32, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 6], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "One of the twins developed complete heart block and dilated cardiomyopathy related to lopinavir/ritonavir therapy, a boosted protease-inhibitor agent, while the other twin developed mild bradycardia.", "entity_list": [{"name": "bradycardia", "ent_type": "Disease", "char_span": [187, 198], "ent_id": "D001919", "tok_span": [36, 40]}, {"name": "dilated cardiomyopathy", "ent_type": "Disease", "char_span": [52, 74], "ent_id": "D002311", "tok_span": [9, 11]}, {"name": "heart block", "ent_type": "Disease", "char_span": [36, 47], "ent_id": "D006327", "tok_span": [6, 8]}, {"name": "lopinavir/ritonavir", "ent_type": "Chemical", "char_span": [86, 105], "ent_id": "C558899", "tok_span": [13, 20]}], "relation_list": [{"subject": "lopinavir/ritonavir", "object": "heart block", "sbj_char_span": [86, 105], "obj_char_span": [36, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 20], "obj_tok_span": [6, 8]}, {"subject": "lopinavir/ritonavir", "object": "dilated cardiomyopathy", "sbj_char_span": [86, 105], "obj_char_span": [52, 74], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 20], "obj_tok_span": [9, 11]}, {"subject": "lopinavir/ritonavir", "object": "bradycardia", "sbj_char_span": [86, 105], "obj_char_span": [187, 198], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 20], "obj_tok_span": [36, 40]}], "umls_entity_list": []}, {"text": "Learning of rats under amnesia caused by pentobarbital.", "entity_list": [{"name": "amnesia", "ent_type": "Disease", "char_span": [23, 30], "ent_id": "D000647", "tok_span": [4, 7]}, {"name": "pentobarbital", "ent_type": "Chemical", "char_span": [41, 54], "ent_id": "D010424", "tok_span": [9, 11]}], "relation_list": [{"subject": "pentobarbital", "object": "amnesia", "sbj_char_span": [41, 54], "obj_char_span": [23, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 11], "obj_tok_span": [4, 7]}], "umls_entity_list": []}, {"text": "Dissociated learning of rats in the normal state and the state of amnesia produced by pentobarbital (15 mg/kg, ip) was carried out.", "entity_list": [{"name": "amnesia", "ent_type": "Disease", "char_span": [66, 73], "ent_id": "D000647", "tok_span": [13, 16]}, {"name": "pentobarbital", "ent_type": "Chemical", "char_span": [86, 99], "ent_id": "D010424", "tok_span": [18, 20]}], "relation_list": [{"subject": "pentobarbital", "object": "amnesia", "sbj_char_span": [86, 99], "obj_char_span": [66, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 20], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "Role of xanthine oxidase in dexamethasone-induced hypertension in rats.\n 1", "entity_list": [{"name": "hypertension", "ent_type": "Disease", "char_span": [50, 62], "ent_id": "D006973", "tok_span": [10, 11]}, {"name": "dexamethasone", "ent_type": "Chemical", "char_span": [28, 41], "ent_id": "D003907", "tok_span": [7, 8]}, {"name": "xanthine", "ent_type": "Chemical", "char_span": [8, 16], "ent_id": "D019820", "tok_span": [2, 5]}], "relation_list": [{"subject": "dexamethasone", "object": "hypertension", "sbj_char_span": [28, 41], "obj_char_span": [50, 62], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [10, 11]}], "umls_entity_list": []}, {"text": "We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT). 3.", "entity_list": [{"name": "xanthine", "ent_type": "Chemical", "char_span": [23, 31], "ent_id": "D019820", "tok_span": [5, 8]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [137, 149], "ent_id": "D006973", "tok_span": [29, 30]}, {"name": "dex", "ent_type": "Chemical", "char_span": [151, 154], "ent_id": "D003907", "tok_span": [31, 32]}, {"name": "HT", "ent_type": "Disease", "char_span": [155, 157], "ent_id": "D006973", "tok_span": [33, 34]}, {"name": "dexamethasone", "ent_type": "Chemical", "char_span": [115, 128], "ent_id": "D003907", "tok_span": [26, 27]}], "relation_list": [{"subject": "dexamethasone", "object": "hypertension", "sbj_char_span": [115, 128], "obj_char_span": [137, 149], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 27], "obj_tok_span": [29, 30]}, {"subject": "dex", "object": "hypertension", "sbj_char_span": [151, 154], "obj_char_span": [137, 149], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 32], "obj_tok_span": [29, 30]}, {"subject": "dex", "object": "HT", "sbj_char_span": [151, 154], "obj_char_span": [155, 157], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 32], "obj_tok_span": [33, 34]}, {"subject": "dexamethasone", "object": "HT", "sbj_char_span": [115, 128], "obj_char_span": [155, 157], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 27], "obj_tok_span": [33, 34]}], "umls_entity_list": []}, {"text": "Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P\" < 0.01).", "entity_list": [{"name": "increased SBP", "ent_type": "Disease", "char_span": [4, 17], "ent_id": "D006973", "tok_span": [1, 3]}, {"name": "decreased thymus (P < 0.001) and bodyweights", "ent_type": "Disease", "char_span": [60, 104], "ent_id": "D015431", "tok_span": [25, 39]}, {"name": "Dex", "ent_type": "Chemical", "char_span": [0, 3], "ent_id": "D003907", "tok_span": [0, 1]}], "relation_list": [{"subject": "Dex", "object": "decreased thymus (P < 0.001) and bodyweights", "sbj_char_span": [0, 3], "obj_char_span": [60, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 1], "obj_tok_span": [25, 39]}, {"subject": "Dex", "object": "increased SBP", "sbj_char_span": [0, 3], "obj_char_span": [4, 17], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 1], "obj_tok_span": [1, 3]}], "umls_entity_list": []}, {"text": "Allopurinol did not prevent dex-HT.", "entity_list": [{"name": "HT", "ent_type": "Disease", "char_span": [32, 34], "ent_id": "D006973", "tok_span": [9, 10]}, {"name": "dex", "ent_type": "Chemical", "char_span": [28, 31], "ent_id": "D003907", "tok_span": [7, 8]}, {"name": "Allopurinol", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D000493", "tok_span": [0, 4]}], "relation_list": [{"subject": "dex", "object": "HT", "sbj_char_span": [28, 31], "obj_char_span": [32, 34], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [9, 10]}], "umls_entity_list": []}, {"text": "Drug-induced parkinsonism was observed in subjects treated with risperidone (42%) and haloperidol (29%) and was observed at occupancy levels above 60%.", "entity_list": [{"name": "Drug-induced parkinsonism", "ent_type": "Disease", "char_span": [0, 25], "ent_id": "D010302", "tok_span": [0, 6]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [86, 97], "ent_id": "D006220", "tok_span": [20, 23]}, {"name": "risperidone", "ent_type": "Chemical", "char_span": [64, 75], "ent_id": "D018967", "tok_span": [12, 15]}], "relation_list": [{"subject": "risperidone", "object": "Drug-induced parkinsonism", "sbj_char_span": [64, 75], "obj_char_span": [0, 25], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [0, 6]}, {"subject": "haloperidol", "object": "Drug-induced parkinsonism", "sbj_char_span": [86, 97], "obj_char_span": [0, 25], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [0, 6]}], "umls_entity_list": []}, {"text": "However, hepatotoxic events have not been widely published with ezetimibe or the combination agent simvastatin-ezetimibe.", "entity_list": [{"name": "hepatotoxic", "ent_type": "Disease", "char_span": [9, 20], "ent_id": "D056486", "tok_span": [2, 4]}, {"name": "simvastatin-ezetimibe", "ent_type": "Chemical", "char_span": [99, 120], "ent_id": "C492458", "tok_span": [20, 28]}, {"name": "ezetimibe", "ent_type": "Chemical", "char_span": [64, 73], "ent_id": "C108606", "tok_span": [11, 16]}], "relation_list": [{"subject": "simvastatin-ezetimibe", "object": "hepatotoxic", "sbj_char_span": [99, 120], "obj_char_span": [9, 20], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 28], "obj_tok_span": [2, 4]}], "umls_entity_list": []}, {"text": "We describe a 70-year-old Hispanic woman who developed fulminant hepatic failure necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg/day to simvastatin 10 mg-ezetimibe 40 mg/day.", "entity_list": [{"name": "simvastatin", "ent_type": "Chemical", "char_span": [148, 159], "ent_id": "D019821", "tok_span": [26, 28]}, {"name": "simvastatin 10 mg-ezetimibe 40 mg", "ent_type": "Chemical", "char_span": [173, 206], "ent_id": "C492458", "tok_span": [33, 45]}, {"name": "fulminant hepatic failure", "ent_type": "Disease", "char_span": [55, 80], "ent_id": "D017114", "tok_span": [12, 17]}], "relation_list": [{"subject": "simvastatin 10 mg-ezetimibe 40 mg", "object": "fulminant hepatic failure", "sbj_char_span": [173, 206], "obj_char_span": [55, 80], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 45], "obj_tok_span": [12, 17]}], "umls_entity_list": []}, {"text": "Simvastatinezetimibe and escitalopram (which she was taking for depression) were discontinued, and other potential causes of hepatotoxicity were excluded.", "entity_list": [{"name": "hepatotoxicity", "ent_type": "Disease", "char_span": [125, 139], "ent_id": "D056486", "tok_span": [27, 29]}, {"name": "Simvastatinezetimibe", "ent_type": "Chemical", "char_span": [0, 20], "ent_id": "C492458", "tok_span": [0, 6]}, {"name": "escitalopram", "ent_type": "Chemical", "char_span": [25, 37], "ent_id": "D015283", "tok_span": [7, 11]}, {"name": "depression", "ent_type": "Disease", "char_span": [64, 74], "ent_id": "D003866", "tok_span": [17, 18]}], "relation_list": [{"subject": "Simvastatinezetimibe", "object": "hepatotoxicity", "sbj_char_span": [0, 20], "obj_char_span": [125, 139], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 6], "obj_tok_span": [27, 29]}], "umls_entity_list": []}, {"text": "We postulate that the mechanism of the simvastatinezetimibe-induced hepatotoxicity is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes.", "entity_list": [{"name": "simvastatin", "ent_type": "Chemical", "char_span": [100, 111], "ent_id": "D019821", "tok_span": [21, 23]}, {"name": "hepatotoxicity", "ent_type": "Disease", "char_span": [68, 82], "ent_id": "D056486", "tok_span": [16, 18]}, {"name": "simvastatinezetimibe", "ent_type": "Chemical", "char_span": [39, 59], "ent_id": "C492458", "tok_span": [8, 14]}, {"name": "ezetimibe", "ent_type": "Chemical", "char_span": [124, 133], "ent_id": "C108606", "tok_span": [25, 30]}], "relation_list": [{"subject": "simvastatinezetimibe", "object": "hepatotoxicity", "sbj_char_span": [39, 59], "obj_char_span": [68, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 14], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "Clinicians should be aware of potential hepatotoxicity with simvastatin-ezetimibe especially in elderly patients and should carefully monitor serum aminotransferase levels when starting therapy and titrating the dosage.", "entity_list": [{"name": "hepatotoxicity", "ent_type": "Disease", "char_span": [40, 54], "ent_id": "D056486", "tok_span": [7, 9]}, {"name": "simvastatin-ezetimibe", "ent_type": "Chemical", "char_span": [60, 81], "ent_id": "C492458", "tok_span": [10, 18]}], "relation_list": [{"subject": "simvastatin-ezetimibe", "object": "hepatotoxicity", "sbj_char_span": [60, 81], "obj_char_span": [40, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 18], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "Dental patients abusing methamphetamine can present with poor oral hygiene, xerostomia, rampant caries (\"meth mouth\"), and excessive tooth wear.", "entity_list": [{"name": "caries", "ent_type": "Disease", "char_span": [96, 102], "ent_id": "D003731", "tok_span": [21, 22]}, {"name": "methamphetamine", "ent_type": "Chemical", "char_span": [24, 39], "ent_id": "D008694", "tok_span": [4, 7]}, {"name": "meth mouth", "ent_type": "Disease", "char_span": [105, 115], "ent_id": "-1", "tok_span": [24, 26]}, {"name": "xerostomia", "ent_type": "Disease", "char_span": [76, 86], "ent_id": "D014987", "tok_span": [14, 18]}, {"name": "tooth wear", "ent_type": "Disease", "char_span": [133, 143], "ent_id": "D057085", "tok_span": [31, 33]}], "relation_list": [{"subject": "methamphetamine", "object": "caries", "sbj_char_span": [24, 39], "obj_char_span": [96, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [21, 22]}], "umls_entity_list": []}, {"text": "She reported her use of methamphetamine for five years and had not experienced any major carious episodes before she started using the drug.", "entity_list": [{"name": "methamphetamine", "ent_type": "Chemical", "char_span": [24, 39], "ent_id": "D008694", "tok_span": [5, 8]}, {"name": "carious episodes", "ent_type": "Disease", "char_span": [89, 105], "ent_id": "D003731", "tok_span": [17, 20]}], "relation_list": [{"subject": "methamphetamine", "object": "carious episodes", "sbj_char_span": [24, 39], "obj_char_span": [89, 105], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [17, 20]}], "umls_entity_list": []}, {"text": "Thyroxine abuse: an unusual case of thyrotoxicosis in pregnancy.", "entity_list": [{"name": "thyrotoxicosis", "ent_type": "Disease", "char_span": [36, 50], "ent_id": "D013971", "tok_span": [10, 14]}, {"name": "Thyroxine", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D013974", "tok_span": [0, 4]}], "relation_list": [{"subject": "Thyroxine", "object": "thyrotoxicosis", "sbj_char_span": [0, 9], "obj_char_span": [36, 50], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "In particular it illustrates the derangements of thyroid function seen in pregnant women with eating disorders and reminds us that when a cause for thyrotoxicosis remains obscure, thyroxine abuse should be considered and explored.", "entity_list": [{"name": "eating disorders", "ent_type": "Disease", "char_span": [94, 110], "ent_id": "D001068", "tok_span": [16, 18]}, {"name": "thyrotoxicosis", "ent_type": "Disease", "char_span": [148, 162], "ent_id": "D013971", "tok_span": [27, 31]}, {"name": "thyroxine", "ent_type": "Chemical", "char_span": [180, 189], "ent_id": "D013974", "tok_span": [35, 38]}], "relation_list": [{"subject": "thyroxine", "object": "thyrotoxicosis", "sbj_char_span": [180, 189], "obj_char_span": [148, 162], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 38], "obj_tok_span": [27, 31]}], "umls_entity_list": []}, {"text": "Lipopolysaccharide pretreatment did not affect the basal body temperature or methamphetamine-elicited hyperthermia three days later.", "entity_list": [{"name": "methamphetamine", "ent_type": "Chemical", "char_span": [77, 92], "ent_id": "D008694", "tok_span": [11, 14]}, {"name": "hyperthermia", "ent_type": "Disease", "char_span": [102, 114], "ent_id": "D005334", "tok_span": [16, 19]}, {"name": "Lipopolysaccharide", "ent_type": "Chemical", "char_span": [0, 18], "ent_id": "D008070", "tok_span": [0, 2]}], "relation_list": [{"subject": "methamphetamine", "object": "hyperthermia", "sbj_char_span": [77, 92], "obj_char_span": [102, 114], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [16, 19]}], "umls_entity_list": []}, {"text": "The effect of the converting enzyme inhibitor (CEI) enalapril was assessed in Munich-Wistar rats with established adriamycin nephrosis.", "entity_list": [{"name": "nephrosis", "ent_type": "Disease", "char_span": [125, 134], "ent_id": "D009401", "tok_span": [29, 31]}, {"name": "enalapril", "ent_type": "Chemical", "char_span": [52, 61], "ent_id": "D004656", "tok_span": [11, 15]}, {"name": "adriamycin", "ent_type": "Chemical", "char_span": [114, 124], "ent_id": "D004317", "tok_span": [25, 29]}], "relation_list": [{"subject": "adriamycin", "object": "nephrosis", "sbj_char_span": [114, 124], "obj_char_span": [125, 134], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 29], "obj_tok_span": [29, 31]}], "umls_entity_list": []}, {"text": "Rats were given a single dose of adriamycin and one month later divided into four groups matched for albuminuria, blood pressure, and plasma albumin concentration.", "entity_list": [{"name": "adriamycin", "ent_type": "Chemical", "char_span": [33, 43], "ent_id": "D004317", "tok_span": [7, 11]}, {"name": "albuminuria", "ent_type": "Disease", "char_span": [101, 112], "ent_id": "D000419", "tok_span": [21, 23]}], "relation_list": [{"subject": "adriamycin", "object": "albuminuria", "sbj_char_span": [33, 43], "obj_char_span": [101, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of renal injury in adriamycin nephrosis.", "entity_list": [{"name": "renal injury", "ent_type": "Disease", "char_span": [106, 118], "ent_id": "D007674", "tok_span": [24, 26]}, {"name": "adriamycin", "ent_type": "Chemical", "char_span": [122, 132], "ent_id": "D004317", "tok_span": [27, 31]}, {"name": "nephrosis", "ent_type": "Disease", "char_span": [133, 142], "ent_id": "D009401", "tok_span": [31, 33]}, {"name": "enalapril", "ent_type": "Chemical", "char_span": [78, 87], "ent_id": "D004656", "tok_span": [17, 21]}], "relation_list": [{"subject": "adriamycin", "object": "nephrosis", "sbj_char_span": [122, 132], "obj_char_span": [133, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 31], "obj_tok_span": [31, 33]}], "umls_entity_list": []}, {"text": "Butyrylcholinesterase gene mutations in patients with prolonged apnea after succinylcholine for electroconvulsive therapy.", "entity_list": [{"name": "succinylcholine", "ent_type": "Chemical", "char_span": [76, 91], "ent_id": "D013390", "tok_span": [14, 17]}, {"name": "apnea", "ent_type": "Disease", "char_span": [64, 69], "ent_id": "D001049", "tok_span": [12, 13]}], "relation_list": [{"subject": "succinylcholine", "object": "apnea", "sbj_char_span": [76, 91], "obj_char_span": [64, 69], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [12, 13]}], "umls_entity_list": []}, {"text": "CONCLUSION: eleven of 13 patients with a prolonged duration of action of succinylcholine had mutations in BCHE, indicating that this is the possible reason for a prolonged period of apnea.", "entity_list": [{"name": "succinylcholine", "ent_type": "Chemical", "char_span": [73, 88], "ent_id": "D013390", "tok_span": [13, 16]}, {"name": "apnea", "ent_type": "Disease", "char_span": [182, 187], "ent_id": "D001049", "tok_span": [34, 35]}], "relation_list": [{"subject": "succinylcholine", "object": "apnea", "sbj_char_span": [73, 88], "obj_char_span": [182, 187], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [34, 35]}], "umls_entity_list": []}, {"text": "Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by MZ use.", "entity_list": [{"name": "hypoxia", "ent_type": "Disease", "char_span": [182, 189], "ent_id": "D000860", "tok_span": [47, 48]}, {"name": "hypoxia", "ent_type": "Disease", "char_span": [100, 107], "ent_id": "D000860", "tok_span": [28, 29]}, {"name": "airway obstruction", "ent_type": "Disease", "char_span": [121, 139], "ent_id": "D000402", "tok_span": [32, 34]}, {"name": "MZ", "ent_type": "Chemical", "char_span": [200, 202], "ent_id": "D008874", "tok_span": [50, 51]}, {"name": "hypoxia", "ent_type": "Disease", "char_span": [5, 12], "ent_id": "D000860", "tok_span": [2, 3]}], "relation_list": [{"subject": "MZ", "object": "hypoxia", "sbj_char_span": [200, 202], "obj_char_span": [182, 189], "rel_type": "chemical-induced disease", "sbj_tok_span": [50, 51], "obj_tok_span": [47, 48]}, {"subject": "MZ", "object": "hypoxia", "sbj_char_span": [200, 202], "obj_char_span": [100, 107], "rel_type": "chemical-induced disease", "sbj_tok_span": [50, 51], "obj_tok_span": [28, 29]}, {"subject": "MZ", "object": "hypoxia", "sbj_char_span": [200, 202], "obj_char_span": [5, 12], "rel_type": "chemical-induced disease", "sbj_tok_span": [50, 51], "obj_tok_span": [2, 3]}], "umls_entity_list": []}, {"text": "The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced convulsions; this effect was less pronounced with bepridil.", "entity_list": [{"name": "convulsions", "ent_type": "Disease", "char_span": [159, 170], "ent_id": "D012640", "tok_span": [31, 34]}, {"name": "bupivacaine", "ent_type": "Chemical", "char_span": [27, 38], "ent_id": "D002045", "tok_span": [6, 10]}, {"name": "bupivacaine", "ent_type": "Chemical", "char_span": [139, 150], "ent_id": "D002045", "tok_span": [25, 29]}, {"name": "calcium", "ent_type": "Chemical", "char_span": [74, 81], "ent_id": "D002118", "tok_span": [15, 16]}, {"name": "bepridil", "ent_type": "Chemical", "char_span": [209, 217], "ent_id": "D015764", "tok_span": [41, 44]}], "relation_list": [{"subject": "bupivacaine", "object": "convulsions", "sbj_char_span": [27, 38], "obj_char_span": [159, 170], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 10], "obj_tok_span": [31, 34]}, {"subject": "bupivacaine", "object": "convulsions", "sbj_char_span": [139, 150], "obj_char_span": [159, 170], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 29], "obj_tok_span": [31, 34]}], "umls_entity_list": []}, {"text": "Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal.", "entity_list": [{"name": "Parkinson's disease", "ent_type": "Disease", "char_span": [43, 62], "ent_id": "D010300", "tok_span": [9, 13]}, {"name": "Selegiline", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D012642", "tok_span": [0, 4]}, {"name": "postural hypotension", "ent_type": "Disease", "char_span": [19, 39], "ent_id": "D007024", "tok_span": [6, 8]}], "relation_list": [{"subject": "Selegiline", "object": "postural hypotension", "sbj_char_span": [0, 10], "obj_char_span": [19, 39], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "Recently, we found that therapy with selegiline and L-dopa was associated with selective systolic orthostatic hypotension which was abolished by withdrawal of selegiline.", "entity_list": [{"name": "selegiline", "ent_type": "Chemical", "char_span": [159, 169], "ent_id": "D012642", "tok_span": [30, 34]}, {"name": "L-dopa", "ent_type": "Chemical", "char_span": [52, 58], "ent_id": "D007980", "tok_span": [12, 16]}, {"name": "systolic orthostatic hypotension", "ent_type": "Disease", "char_span": [89, 121], "ent_id": "D007024", "tok_span": [20, 24]}, {"name": "selegiline", "ent_type": "Chemical", "char_span": [37, 47], "ent_id": "D012642", "tok_span": [7, 11]}], "relation_list": [{"subject": "selegiline", "object": "systolic orthostatic hypotension", "sbj_char_span": [159, 169], "obj_char_span": [89, 121], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 34], "obj_tok_span": [20, 24]}, {"subject": "selegiline", "object": "systolic orthostatic hypotension", "sbj_char_span": [37, 47], "obj_char_span": [89, 121], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "The aims of this study were to confirm our previous findings in a separate cohort of patients and to determine the time course of the cardiovascular consequences of stopping selegiline in the expectation that this might shed light on the mechanisms by which the drug causes orthostatic hypotension.", "entity_list": [{"name": "selegiline", "ent_type": "Chemical", "char_span": [174, 184], "ent_id": "D012642", "tok_span": [29, 33]}, {"name": "orthostatic hypotension", "ent_type": "Disease", "char_span": [274, 297], "ent_id": "D007024", "tok_span": [49, 52]}], "relation_list": [{"subject": "selegiline", "object": "orthostatic hypotension", "sbj_char_span": [174, 184], "obj_char_span": [274, 297], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 33], "obj_tok_span": [49, 52]}], "umls_entity_list": []}, {"text": "RESULTS: Head-up tilt caused systolic orthostatic hypotension which was marked in six of 20 PD patients on selegiline, one of whom lost consciousness with unrecordable blood pressures.", "entity_list": [{"name": "PD", "ent_type": "Disease", "char_span": [92, 94], "ent_id": "D010300", "tok_span": [18, 19]}, {"name": "systolic orthostatic hypotension", "ent_type": "Disease", "char_span": [29, 61], "ent_id": "D007024", "tok_span": [7, 11]}, {"name": "selegiline", "ent_type": "Chemical", "char_span": [107, 117], "ent_id": "D012642", "tok_span": [21, 25]}], "relation_list": [{"subject": "selegiline", "object": "systolic orthostatic hypotension", "sbj_char_span": [107, 117], "obj_char_span": [29, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 25], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "Orthostatic hypotension was ameliorated 4 days after withdrawal of selegiline and totally abolished 7 days after discontinuation of the drug.", "entity_list": [{"name": "Orthostatic hypotension", "ent_type": "Disease", "char_span": [0, 23], "ent_id": "D007024", "tok_span": [0, 3]}, {"name": "selegiline", "ent_type": "Chemical", "char_span": [67, 77], "ent_id": "D012642", "tok_span": [11, 15]}], "relation_list": [{"subject": "selegiline", "object": "Orthostatic hypotension", "sbj_char_span": [67, 77], "obj_char_span": [0, 23], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "Stopping selegiline also significantly reduced the supine systolic and diastolic blood pressures consistent with a previously undescribed supine pressor action.", "entity_list": [{"name": "selegiline", "ent_type": "Chemical", "char_span": [9, 19], "ent_id": "D012642", "tok_span": [3, 7]}, {"name": "reduced the supine systolic and diastolic blood pressures", "ent_type": "Disease", "char_span": [39, 96], "ent_id": "D007024", "tok_span": [9, 17]}], "relation_list": [{"subject": "selegiline", "object": "reduced the supine systolic and diastolic blood pressures", "sbj_char_span": [9, 19], "obj_char_span": [39, 96], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 7], "obj_tok_span": [9, 17]}], "umls_entity_list": []}, {"text": "CONCLUSION: This study confirms our previous finding that selegiline in combination with L-dopa is associated with selective orthostatic hypotension.", "entity_list": [{"name": "orthostatic hypotension", "ent_type": "Disease", "char_span": [125, 148], "ent_id": "D007024", "tok_span": [24, 27]}, {"name": "selegiline", "ent_type": "Chemical", "char_span": [58, 68], "ent_id": "D012642", "tok_span": [9, 13]}, {"name": "L-dopa", "ent_type": "Chemical", "char_span": [89, 95], "ent_id": "D007980", "tok_span": [16, 20]}], "relation_list": [{"subject": "selegiline", "object": "orthostatic hypotension", "sbj_char_span": [58, 68], "obj_char_span": [125, 148], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [24, 27]}], "umls_entity_list": []}, {"text": "Explicit episodic memory for sensory-discriminative components of capsaicin-induced pain: immediate and delayed ratings.", "entity_list": [{"name": "capsaicin", "ent_type": "Chemical", "char_span": [66, 75], "ent_id": "D002211", "tok_span": [10, 13]}, {"name": "pain", "ent_type": "Disease", "char_span": [84, 88], "ent_id": "D010146", "tok_span": [15, 16]}], "relation_list": [{"subject": "capsaicin", "object": "pain", "sbj_char_span": [66, 75], "obj_char_span": [84, 88], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [15, 16]}], "umls_entity_list": []}, {"text": "In order to address long-term pain memory, nine healthy male volunteers received intradermal injections of three doses of capsaicin (0.05, 1 and 20 microg, separated by 15 min breaks), each given three times in a balanced design across three sessions at one week intervals.", "entity_list": [{"name": "pain", "ent_type": "Disease", "char_span": [30, 34], "ent_id": "D010146", "tok_span": [7, 8]}, {"name": "capsaicin", "ent_type": "Chemical", "char_span": [122, 131], "ent_id": "D002211", "tok_span": [23, 26]}], "relation_list": [{"subject": "capsaicin", "object": "pain", "sbj_char_span": [122, 131], "obj_char_span": [30, 34], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [7, 8]}], "umls_entity_list": []}, {"text": "Subjects were able to reliably discriminate pain magnitude and duration across capsaicin doses (both p<0.001), regardless of whether first-time ratings were requested immediately, after one hour or after one day.", "entity_list": [{"name": "capsaicin", "ent_type": "Chemical", "char_span": [79, 88], "ent_id": "D002211", "tok_span": [11, 14]}, {"name": "pain", "ent_type": "Disease", "char_span": [44, 48], "ent_id": "D010146", "tok_span": [6, 7]}], "relation_list": [{"subject": "capsaicin", "object": "pain", "sbj_char_span": [79, 88], "obj_char_span": [44, 48], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [6, 7]}], "umls_entity_list": []}, {"text": "We report a case of severe hypertension with an occluded renal artery to a solitary kidney, who developed sudden deterioration of renal function following treatment with captopril.", "entity_list": [{"name": "captopril", "ent_type": "Chemical", "char_span": [170, 179], "ent_id": "D002216", "tok_span": [28, 31]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [27, 39], "ent_id": "D006973", "tok_span": [6, 7]}, {"name": "sudden deterioration of renal function", "ent_type": "Disease", "char_span": [106, 144], "ent_id": "D058186", "tok_span": [20, 25]}], "relation_list": [{"subject": "captopril", "object": "sudden deterioration of renal function", "sbj_char_span": [170, 179], "obj_char_span": [106, 144], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 31], "obj_tok_span": [20, 25]}], "umls_entity_list": []}, {"text": "This report presents the clinical, laboratory, and light and electron microscopic observations on a patient with chronic active (aggressive) hepatitis caused by the administration of propylthiouracil.", "entity_list": [{"name": "chronic active (aggressive) hepatitis", "ent_type": "Disease", "char_span": [113, 150], "ent_id": "D006521", "tok_span": [18, 24]}, {"name": "propylthiouracil", "ent_type": "Chemical", "char_span": [183, 199], "ent_id": "D011441", "tok_span": [29, 34]}], "relation_list": [{"subject": "propylthiouracil", "object": "chronic active (aggressive) hepatitis", "sbj_char_span": [183, 199], "obj_char_span": [113, 150], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 34], "obj_tok_span": [18, 24]}], "umls_entity_list": []}, {"text": "Capsaicin (10 micro g) was injected into the masseter muscle to induce pain in 11 healthy volunteers.", "entity_list": [{"name": "Capsaicin", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D002211", "tok_span": [0, 3]}, {"name": "pain", "ent_type": "Disease", "char_span": [71, 75], "ent_id": "D010146", "tok_span": [17, 18]}], "relation_list": [{"subject": "Capsaicin", "object": "pain", "sbj_char_span": [0, 9], "obj_char_span": [71, 75], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [17, 18]}], "umls_entity_list": []}, {"text": "Repetitive transcranial magnetic stimulation for levodopa-induced dyskinesias in Parkinson's disease.", "entity_list": [{"name": "dyskinesias", "ent_type": "Disease", "char_span": [66, 77], "ent_id": "D004409", "tok_span": [12, 16]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [49, 57], "ent_id": "D007980", "tok_span": [7, 10]}, {"name": "Parkinson's disease", "ent_type": "Disease", "char_span": [81, 100], "ent_id": "D010300", "tok_span": [17, 21]}], "relation_list": [{"subject": "levodopa", "object": "dyskinesias", "sbj_char_span": [49, 57], "obj_char_span": [66, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [12, 16]}], "umls_entity_list": []}, {"text": "In less than 1 hour after the ingestion of alcohol, he developed malaise with flushing of the face, tachycardia, and dyspnea.", "entity_list": [{"name": "alcohol", "ent_type": "Chemical", "char_span": [43, 50], "ent_id": "D000431", "tok_span": [9, 10]}, {"name": "flushing of the face", "ent_type": "Disease", "char_span": [78, 98], "ent_id": "D005483", "tok_span": [17, 23]}, {"name": "tachycardia", "ent_type": "Disease", "char_span": [100, 111], "ent_id": "D013610", "tok_span": [24, 25]}, {"name": "dyspnea", "ent_type": "Disease", "char_span": [117, 124], "ent_id": "D004417", "tok_span": [27, 29]}], "relation_list": [{"subject": "alcohol", "object": "dyspnea", "sbj_char_span": [43, 50], "obj_char_span": [117, 124], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [27, 29]}, {"subject": "alcohol", "object": "flushing of the face", "sbj_char_span": [43, 50], "obj_char_span": [78, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [17, 23]}, {"subject": "alcohol", "object": "tachycardia", "sbj_char_span": [43, 50], "obj_char_span": [100, 111], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [24, 25]}], "umls_entity_list": []}, {"text": "In the acute experiment TRI (given i.p.) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats.", "entity_list": [{"name": "reserpine", "ent_type": "Chemical", "char_span": [65, 74], "ent_id": "D012110", "tok_span": [17, 20]}, {"name": "TRI", "ent_type": "Chemical", "char_span": [24, 27], "ent_id": "D014299", "tok_span": [4, 5]}, {"name": "5-hydroxytryptophan", "ent_type": "Chemical", "char_span": [123, 142], "ent_id": "D006916", "tok_span": [30, 37]}, {"name": "hypothermia", "ent_type": "Disease", "char_span": [75, 86], "ent_id": "D007035", "tok_span": [20, 22]}], "relation_list": [{"subject": "reserpine", "object": "hypothermia", "sbj_char_span": [65, 74], "obj_char_span": [75, 86], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [20, 22]}], "umls_entity_list": []}, {"text": "TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).", "entity_list": [{"name": "d-amphetamine", "ent_type": "Chemical", "char_span": [78, 91], "ent_id": "D003913", "tok_span": [12, 18]}, {"name": "TRI", "ent_type": "Chemical", "char_span": [0, 3], "ent_id": "D014299", "tok_span": [0, 1]}, {"name": "quinpirole", "ent_type": "Chemical", "char_span": [93, 103], "ent_id": "D019257", "tok_span": [19, 22]}, {"name": "dopamine", "ent_type": "Chemical", "char_span": [146, 154], "ent_id": "D004298", "tok_span": [38, 39]}, {"name": "hyperactivity", "ent_type": "Disease", "char_span": [53, 66], "ent_id": "D006948", "tok_span": [8, 10]}], "relation_list": [{"subject": "d-amphetamine", "object": "hyperactivity", "sbj_char_span": [78, 91], "obj_char_span": [53, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 18], "obj_tok_span": [8, 10]}, {"subject": "quinpirole", "object": "hyperactivity", "sbj_char_span": [93, 103], "obj_char_span": [53, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 22], "obj_tok_span": [8, 10]}, {"subject": "TRI", "object": "hyperactivity", "sbj_char_span": [0, 3], "obj_char_span": [53, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 1], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "Ranitidine-induced acute interstitial nephritis in a cadaveric renal allograft.", "entity_list": [{"name": "interstitial nephritis", "ent_type": "Disease", "char_span": [25, 47], "ent_id": "D009395", "tok_span": [7, 10]}, {"name": "Ranitidine", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D011899", "tok_span": [0, 4]}], "relation_list": [{"subject": "Ranitidine", "object": "interstitial nephritis", "sbj_char_span": [0, 10], "obj_char_span": [25, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "We report a case of ranitidine-induced acute interstitial nephritis in a recipient of a cadaveric renal allograft presenting with acute allograft dysfunction within 48 hours of exposure to the drug.", "entity_list": [{"name": "ranitidine", "ent_type": "Chemical", "char_span": [20, 30], "ent_id": "D011899", "tok_span": [5, 9]}, {"name": "interstitial nephritis", "ent_type": "Disease", "char_span": [45, 67], "ent_id": "D009395", "tok_span": [12, 15]}], "relation_list": [{"subject": "ranitidine", "object": "interstitial nephritis", "sbj_char_span": [20, 30], "obj_char_span": [45, 67], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [12, 15]}], "umls_entity_list": []}, {"text": "Three patients on acetazolamide (15%) developed renal calculi.", "entity_list": [{"name": "renal calculi", "ent_type": "Disease", "char_span": [48, 61], "ent_id": "D007669", "tok_span": [11, 14]}, {"name": "acetazolamide", "ent_type": "Chemical", "char_span": [18, 31], "ent_id": "D000086", "tok_span": [3, 6]}], "relation_list": [{"subject": "acetazolamide", "object": "renal calculi", "sbj_char_span": [18, 31], "obj_char_span": [48, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [11, 14]}], "umls_entity_list": []}, {"text": "Evidence is accumulating that lindane can be toxic to the central nervous system and may be associated with aplastic anaemia.", "entity_list": [{"name": "toxic to the central nervous system", "ent_type": "Disease", "char_span": [45, 80], "ent_id": "D002493", "tok_span": [9, 15]}, {"name": "lindane", "ent_type": "Chemical", "char_span": [30, 37], "ent_id": "D001556", "tok_span": [4, 7]}, {"name": "aplastic anaemia", "ent_type": "Disease", "char_span": [108, 124], "ent_id": "D000741", "tok_span": [20, 24]}], "relation_list": [{"subject": "lindane", "object": "aplastic anaemia", "sbj_char_span": [30, 37], "obj_char_span": [108, 124], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [20, 24]}, {"subject": "lindane", "object": "toxic to the central nervous system", "sbj_char_span": [30, 37], "obj_char_span": [45, 80], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [9, 15]}], "umls_entity_list": []}, {"text": "We report an undiagnosed case of myotonia congenita in a 24-year-old previously healthy primigravida, who developed life threatening masseter spasm following a standard dose of intravenous suxamethonium for induction of anaesthesia.", "entity_list": [{"name": "myotonia congenita", "ent_type": "Disease", "char_span": [33, 51], "ent_id": "D009224", "tok_span": [8, 13]}, {"name": "suxamethonium", "ent_type": "Chemical", "char_span": [189, 202], "ent_id": "D013390", "tok_span": [42, 47]}, {"name": "masseter spasm", "ent_type": "Disease", "char_span": [133, 147], "ent_id": "D014313", "tok_span": [32, 36]}], "relation_list": [{"subject": "suxamethonium", "object": "masseter spasm", "sbj_char_span": [189, 202], "obj_char_span": [133, 147], "rel_type": "chemical-induced disease", "sbj_tok_span": [42, 47], "obj_tok_span": [32, 36]}], "umls_entity_list": []}, {"text": "Furthermore, transient hemoglobinuria was noted approximately 60 minutes postinjection of WR242511 (3.5 or 7.0 mg/kg), and 2 lethalities occurred (one IV and one PO) following the 7.0 mg/kg dose.", "entity_list": [{"name": "hemoglobinuria", "ent_type": "Disease", "char_span": [23, 37], "ent_id": "D006456", "tok_span": [3, 5]}, {"name": "WR242511", "ent_type": "Chemical", "char_span": [90, 98], "ent_id": "C068820", "tok_span": [13, 17]}], "relation_list": [{"subject": "WR242511", "object": "hemoglobinuria", "sbj_char_span": [90, 98], "obj_char_span": [23, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "Atypical sensations following the use of subcutaneous sumatriptan are common, but of uncertain origin.", "entity_list": [{"name": "sumatriptan", "ent_type": "Chemical", "char_span": [54, 65], "ent_id": "D018170", "tok_span": [10, 14]}, {"name": "Atypical sensations", "ent_type": "Disease", "char_span": [0, 19], "ent_id": "D010292", "tok_span": [0, 5]}], "relation_list": [{"subject": "sumatriptan", "object": "Atypical sensations", "sbj_char_span": [54, 65], "obj_char_span": [0, 19], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [0, 5]}], "umls_entity_list": []}, {"text": "Tremor side effects of salbutamol, quantified by a laser pointer technique.", "entity_list": [{"name": "Tremor", "ent_type": "Disease", "char_span": [0, 6], "ent_id": "D014202", "tok_span": [0, 3]}, {"name": "salbutamol", "ent_type": "Chemical", "char_span": [23, 33], "ent_id": "D000420", "tok_span": [6, 10]}], "relation_list": [{"subject": "salbutamol", "object": "Tremor", "sbj_char_span": [23, 33], "obj_char_span": [0, 6], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 10], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "OBJECTIVE: To study tremor side effects of salbutamol an easily applicable, quick and low-priced method is needed.", "entity_list": [{"name": "salbutamol", "ent_type": "Chemical", "char_span": [43, 53], "ent_id": "D000420", "tok_span": [9, 13]}, {"name": "tremor", "ent_type": "Disease", "char_span": [20, 26], "ent_id": "D014202", "tok_span": [4, 6]}], "relation_list": [{"subject": "salbutamol", "object": "tremor", "sbj_char_span": [43, 53], "obj_char_span": [20, 26], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "To determine sensitivity we assessed tremor in 44 patients with obstructive lung disease after administration of cumulative doses of salbutamol.", "entity_list": [{"name": "obstructive lung disease", "ent_type": "Disease", "char_span": [64, 88], "ent_id": "D008173", "tok_span": [11, 14]}, {"name": "salbutamol", "ent_type": "Chemical", "char_span": [133, 143], "ent_id": "D000420", "tok_span": [20, 24]}, {"name": "tremor", "ent_type": "Disease", "char_span": [37, 43], "ent_id": "D014202", "tok_span": [5, 7]}], "relation_list": [{"subject": "salbutamol", "object": "tremor", "sbj_char_span": [133, 143], "obj_char_span": [37, 43], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 24], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "RESULTS: Salbutamol significantly increased tremor severity in patients in a dose-dependent way.", "entity_list": [{"name": "Salbutamol", "ent_type": "Chemical", "char_span": [9, 19], "ent_id": "D000420", "tok_span": [2, 6]}, {"name": "tremor", "ent_type": "Disease", "char_span": [44, 50], "ent_id": "D014202", "tok_span": [8, 10]}], "relation_list": [{"subject": "Salbutamol", "object": "tremor", "sbj_char_span": [9, 19], "obj_char_span": [44, 50], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.", "entity_list": [{"name": "venous thromboembolism", "ent_type": "Disease", "char_span": [23, 45], "ent_id": "D054556", "tok_span": [3, 6]}, {"name": "docetaxel", "ent_type": "Chemical", "char_span": [70, 79], "ent_id": "C067311", "tok_span": [10, 14]}, {"name": "thalidomide", "ent_type": "Chemical", "char_span": [84, 95], "ent_id": "D013792", "tok_span": [15, 18]}, {"name": "prostate cancer", "ent_type": "Disease", "char_span": [145, 160], "ent_id": "D011471", "tok_span": [25, 27]}], "relation_list": [{"subject": "thalidomide", "object": "venous thromboembolism", "sbj_char_span": [84, 95], "obj_char_span": [23, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [3, 6]}, {"subject": "docetaxel", "object": "venous thromboembolism", "sbj_char_span": [70, 79], "obj_char_span": [23, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [3, 6]}], "umls_entity_list": []}, {"text": "STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.", "entity_list": [{"name": "prostate cancer", "ent_type": "Disease", "char_span": [122, 137], "ent_id": "D011471", "tok_span": [22, 24]}, {"name": "thalidomide", "ent_type": "Chemical", "char_span": [199, 210], "ent_id": "D013792", "tok_span": [37, 40]}, {"name": "VTE", "ent_type": "Disease", "char_span": [70, 73], "ent_id": "D054556", "tok_span": [12, 14]}, {"name": "docetaxel", "ent_type": "Chemical", "char_span": [160, 169], "ent_id": "C067311", "tok_span": [28, 32]}, {"name": "venous thromboembolism", "ent_type": "Disease", "char_span": [46, 68], "ent_id": "D054556", "tok_span": [8, 11]}], "relation_list": [{"subject": "docetaxel", "object": "venous thromboembolism", "sbj_char_span": [160, 169], "obj_char_span": [46, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 32], "obj_tok_span": [8, 11]}, {"subject": "docetaxel", "object": "VTE", "sbj_char_span": [160, 169], "obj_char_span": [70, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 32], "obj_tok_span": [12, 14]}, {"subject": "thalidomide", "object": "venous thromboembolism", "sbj_char_span": [199, 210], "obj_char_span": [46, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 40], "obj_tok_span": [8, 11]}, {"subject": "thalidomide", "object": "VTE", "sbj_char_span": [199, 210], "obj_char_span": [70, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 40], "obj_tok_span": [12, 14]}], "umls_entity_list": []}, {"text": "MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).", "entity_list": [{"name": "thalidomide", "ent_type": "Chemical", "char_span": [154, 165], "ent_id": "D013792", "tok_span": [40, 43]}, {"name": "docetaxel", "ent_type": "Chemical", "char_span": [64, 73], "ent_id": "C067311", "tok_span": [15, 19]}, {"name": "VTE", "ent_type": "Disease", "char_span": [90, 93], "ent_id": "D054556", "tok_span": [21, 23]}, {"name": "VTE", "ent_type": "Disease", "char_span": [176, 179], "ent_id": "D054556", "tok_span": [44, 46]}, {"name": "docetaxel", "ent_type": "Chemical", "char_span": [139, 148], "ent_id": "C067311", "tok_span": [35, 39]}], "relation_list": [{"subject": "thalidomide", "object": "VTE", "sbj_char_span": [154, 165], "obj_char_span": [90, 93], "rel_type": "chemical-induced disease", "sbj_tok_span": [40, 43], "obj_tok_span": [21, 23]}, {"subject": "docetaxel", "object": "VTE", "sbj_char_span": [64, 73], "obj_char_span": [90, 93], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 19], "obj_tok_span": [21, 23]}, {"subject": "docetaxel", "object": "VTE", "sbj_char_span": [139, 148], "obj_char_span": [90, 93], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 39], "obj_tok_span": [21, 23]}, {"subject": "docetaxel", "object": "VTE", "sbj_char_span": [64, 73], "obj_char_span": [176, 179], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 19], "obj_tok_span": [44, 46]}, {"subject": "thalidomide", "object": "VTE", "sbj_char_span": [154, 165], "obj_char_span": [176, 179], "rel_type": "chemical-induced disease", "sbj_tok_span": [40, 43], "obj_tok_span": [44, 46]}, {"subject": "docetaxel", "object": "VTE", "sbj_char_span": [139, 148], "obj_char_span": [176, 179], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 39], "obj_tok_span": [44, 46]}], "umls_entity_list": []}, {"text": "CONCLUSION: The addition of thalidomide to docetaxel in the treatment of prostate cancer significantly increases the frequency of VTE.", "entity_list": [{"name": "VTE", "ent_type": "Disease", "char_span": [130, 133], "ent_id": "D054556", "tok_span": [24, 26]}, {"name": "docetaxel", "ent_type": "Chemical", "char_span": [43, 52], "ent_id": "C067311", "tok_span": [9, 13]}, {"name": "thalidomide", "ent_type": "Chemical", "char_span": [28, 39], "ent_id": "D013792", "tok_span": [5, 8]}, {"name": "prostate cancer", "ent_type": "Disease", "char_span": [73, 88], "ent_id": "D011471", "tok_span": [17, 19]}], "relation_list": [{"subject": "thalidomide", "object": "VTE", "sbj_char_span": [28, 39], "obj_char_span": [130, 133], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [24, 26]}, {"subject": "docetaxel", "object": "VTE", "sbj_char_span": [43, 52], "obj_char_span": [130, 133], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [24, 26]}], "umls_entity_list": []}, {"text": "UM-272 (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced ventricular tachycardias.", "entity_list": [{"name": "ouabain", "ent_type": "Chemical", "char_span": [112, 119], "ent_id": "D010042", "tok_span": [33, 36]}, {"name": "ventricular tachycardias", "ent_type": "Disease", "char_span": [128, 152], "ent_id": "D017180", "tok_span": [38, 41]}, {"name": "UM-272", "ent_type": "Chemical", "char_span": [0, 6], "ent_id": "C002616", "tok_span": [0, 4]}, {"name": "N,N-dimethylpropranolol", "ent_type": "Chemical", "char_span": [8, 31], "ent_id": "C002616", "tok_span": [5, 14]}], "relation_list": [{"subject": "ouabain", "object": "ventricular tachycardias", "sbj_char_span": [112, 119], "obj_char_span": [128, 152], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 36], "obj_tok_span": [38, 41]}], "umls_entity_list": []}, {"text": "Severe thrombocytopenia and haemolytic anaemia associated with ciprofloxacin: a case report with fatal outcome.", "entity_list": [{"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [7, 23], "ent_id": "D013921", "tok_span": [1, 3]}, {"name": "haemolytic anaemia", "ent_type": "Disease", "char_span": [28, 46], "ent_id": "D000743", "tok_span": [4, 8]}, {"name": "ciprofloxacin", "ent_type": "Chemical", "char_span": [63, 76], "ent_id": "D002939", "tok_span": [10, 15]}], "relation_list": [{"subject": "ciprofloxacin", "object": "thrombocytopenia", "sbj_char_span": [63, 76], "obj_char_span": [7, 23], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 15], "obj_tok_span": [1, 3]}, {"subject": "ciprofloxacin", "object": "haemolytic anaemia", "sbj_char_span": [63, 76], "obj_char_span": [28, 46], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 15], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "A 30-year old Caucasian man reported with abdominal pain and jaundice after 3-day administration of oral ciprofloxacin for a suspect of urinary tract infection.", "entity_list": [{"name": "urinary tract infection", "ent_type": "Disease", "char_span": [136, 159], "ent_id": "D014552", "tok_span": [31, 34]}, {"name": "ciprofloxacin", "ent_type": "Chemical", "char_span": [105, 118], "ent_id": "D002939", "tok_span": [22, 27]}, {"name": "abdominal pain", "ent_type": "Disease", "char_span": [42, 56], "ent_id": "D015746", "tok_span": [9, 11]}, {"name": "jaundice", "ent_type": "Disease", "char_span": [61, 69], "ent_id": "D007565", "tok_span": [12, 15]}], "relation_list": [{"subject": "ciprofloxacin", "object": "abdominal pain", "sbj_char_span": [105, 118], "obj_char_span": [42, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 27], "obj_tok_span": [9, 11]}, {"subject": "ciprofloxacin", "object": "jaundice", "sbj_char_span": [105, 118], "obj_char_span": [61, 69], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 27], "obj_tok_span": [12, 15]}], "umls_entity_list": []}, {"text": "This case report shows that ciprofloxacin may precipitate life-threatening thrombocytopenia and haemolytic anaemia, even in the early phases of treatment and without apparent previous exposures.", "entity_list": [{"name": "ciprofloxacin", "ent_type": "Chemical", "char_span": [28, 41], "ent_id": "D002939", "tok_span": [5, 10]}, {"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [75, 91], "ent_id": "D013921", "tok_span": [16, 18]}, {"name": "haemolytic anaemia", "ent_type": "Disease", "char_span": [96, 114], "ent_id": "D000743", "tok_span": [19, 23]}], "relation_list": [{"subject": "ciprofloxacin", "object": "thrombocytopenia", "sbj_char_span": [28, 41], "obj_char_span": [75, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 10], "obj_tok_span": [16, 18]}, {"subject": "ciprofloxacin", "object": "haemolytic anaemia", "sbj_char_span": [28, 41], "obj_char_span": [96, 114], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 10], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "Simvastatin-induced bilateral leg compartment syndrome and myonecrosis associated with hypothyroidism.", "entity_list": [{"name": "myonecrosis", "ent_type": "Disease", "char_span": [59, 70], "ent_id": "D009135", "tok_span": [9, 13]}, {"name": "hypothyroidism", "ent_type": "Disease", "char_span": [87, 101], "ent_id": "D007037", "tok_span": [15, 17]}, {"name": "compartment syndrome", "ent_type": "Disease", "char_span": [34, 54], "ent_id": "D003161", "tok_span": [6, 8]}, {"name": "Simvastatin", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D019821", "tok_span": [0, 2]}], "relation_list": [{"subject": "Simvastatin", "object": "compartment syndrome", "sbj_char_span": [0, 11], "obj_char_span": [34, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "A 54-year-old hypothyroid male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis.", "entity_list": [{"name": "compartment syndrome", "ent_type": "Disease", "char_span": [93, 113], "ent_id": "D003161", "tok_span": [20, 22]}, {"name": "myonecrosis", "ent_type": "Disease", "char_span": [118, 129], "ent_id": "D009135", "tok_span": [23, 27]}, {"name": "thyroxine", "ent_type": "Chemical", "char_span": [38, 47], "ent_id": "D013974", "tok_span": [10, 13]}, {"name": "hypothyroid", "ent_type": "Disease", "char_span": [14, 25], "ent_id": "D007037", "tok_span": [6, 8]}, {"name": "simvastatin", "ent_type": "Chemical", "char_span": [52, 63], "ent_id": "D019821", "tok_span": [14, 16]}], "relation_list": [{"subject": "simvastatin", "object": "compartment syndrome", "sbj_char_span": [52, 63], "obj_char_span": [93, 113], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [20, 22]}], "umls_entity_list": []}, {"text": "We report the case of a patient with amoxicillin-clavulanic acid-induced hepatitis with histologic multiple granulomas.", "entity_list": [{"name": "amoxicillin-clavulanic acid", "ent_type": "Chemical", "char_span": [37, 64], "ent_id": "D019980", "tok_span": [8, 17]}, {"name": "granulomas", "ent_type": "Disease", "char_span": [108, 118], "ent_id": "D006099", "tok_span": [23, 25]}, {"name": "hepatitis", "ent_type": "Disease", "char_span": [73, 82], "ent_id": "D056486", "tok_span": [19, 20]}], "relation_list": [{"subject": "amoxicillin-clavulanic acid", "object": "hepatitis", "sbj_char_span": [37, 64], "obj_char_span": [73, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 17], "obj_tok_span": [19, 20]}, {"subject": "amoxicillin-clavulanic acid", "object": "granulomas", "sbj_char_span": [37, 64], "obj_char_span": [108, 118], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 17], "obj_tok_span": [23, 25]}], "umls_entity_list": []}, {"text": "CONCLUSION: Cocaine use predisposed aneurysmal rupture at a significantly earlier age and in much smaller aneurysms.", "entity_list": [{"name": "aneurysmal rupture", "ent_type": "Disease", "char_span": [36, 54], "ent_id": "D017542", "tok_span": [8, 11]}, {"name": "aneurysms", "ent_type": "Disease", "char_span": [106, 115], "ent_id": "D000783", "tok_span": [20, 21]}, {"name": "Cocaine", "ent_type": "Chemical", "char_span": [12, 19], "ent_id": "D003042", "tok_span": [2, 5]}], "relation_list": [{"subject": "Cocaine", "object": "aneurysmal rupture", "sbj_char_span": [12, 19], "obj_char_span": [36, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [8, 11]}], "umls_entity_list": []}, {"text": "The authors present three patients with de novo absence epilepsy after administration of carbamazepine and vigabatrin.", "entity_list": [{"name": "vigabatrin", "ent_type": "Chemical", "char_span": [107, 117], "ent_id": "D020888", "tok_span": [18, 21]}, {"name": "absence epilepsy", "ent_type": "Disease", "char_span": [48, 64], "ent_id": "D004832", "tok_span": [8, 10]}, {"name": "carbamazepine", "ent_type": "Chemical", "char_span": [89, 102], "ent_id": "D002220", "tok_span": [13, 17]}], "relation_list": [{"subject": "vigabatrin", "object": "absence epilepsy", "sbj_char_span": [107, 117], "obj_char_span": [48, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [8, 10]}, {"subject": "carbamazepine", "object": "absence epilepsy", "sbj_char_span": [89, 102], "obj_char_span": [48, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "Procainamide-induced polymorphous ventricular tachycardia.", "entity_list": [{"name": "Procainamide", "ent_type": "Chemical", "char_span": [0, 12], "ent_id": "D011342", "tok_span": [0, 3]}, {"name": "ventricular tachycardia", "ent_type": "Disease", "char_span": [34, 57], "ent_id": "D017180", "tok_span": [7, 9]}], "relation_list": [{"subject": "Procainamide", "object": "ventricular tachycardia", "sbj_char_span": [0, 12], "obj_char_span": [34, 57], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "Seven cases of procainamide-induced polymorphous ventricular tachycardia are presented.", "entity_list": [{"name": "procainamide", "ent_type": "Chemical", "char_span": [15, 27], "ent_id": "D011342", "tok_span": [3, 6]}, {"name": "ventricular tachycardia", "ent_type": "Disease", "char_span": [49, 72], "ent_id": "D017180", "tok_span": [10, 12]}], "relation_list": [{"subject": "procainamide", "object": "ventricular tachycardia", "sbj_char_span": [15, 27], "obj_char_span": [49, 72], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "In four patients, polymorphous ventricular tachycardia appeared after intravenous administration of 200 to 400 mg of procainamide for the treatment of sustained ventricular tachycardia.", "entity_list": [{"name": "procainamide", "ent_type": "Chemical", "char_span": [117, 129], "ent_id": "D011342", "tok_span": [18, 21]}, {"name": "ventricular tachycardia", "ent_type": "Disease", "char_span": [161, 184], "ent_id": "D017180", "tok_span": [26, 28]}, {"name": "ventricular tachycardia", "ent_type": "Disease", "char_span": [31, 54], "ent_id": "D017180", "tok_span": [6, 8]}], "relation_list": [{"subject": "procainamide", "object": "ventricular tachycardia", "sbj_char_span": [117, 129], "obj_char_span": [31, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [6, 8]}, {"subject": "procainamide", "object": "ventricular tachycardia", "sbj_char_span": [117, 129], "obj_char_span": [161, 184], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [26, 28]}], "umls_entity_list": []}, {"text": "In the seventh patient, a permanent ventricular pacemaker was inserted and, despite continuation of procainamide therapy, polymorphous ventricular tachycardia did not reoccur.", "entity_list": [{"name": "ventricular tachycardia", "ent_type": "Disease", "char_span": [135, 158], "ent_id": "D017180", "tok_span": [26, 28]}, {"name": "procainamide", "ent_type": "Chemical", "char_span": [100, 112], "ent_id": "D011342", "tok_span": [19, 22]}], "relation_list": [{"subject": "procainamide", "object": "ventricular tachycardia", "sbj_char_span": [100, 112], "obj_char_span": [135, 158], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 22], "obj_tok_span": [26, 28]}], "umls_entity_list": []}, {"text": "These seven cases demonstrate that procainamide can produce an acquired prolonged Q-T syndrome with polymorphous ventricular tachycardia.", "entity_list": [{"name": "procainamide", "ent_type": "Chemical", "char_span": [35, 47], "ent_id": "D011342", "tok_span": [5, 8]}, {"name": "prolonged Q-T syndrome", "ent_type": "Disease", "char_span": [72, 94], "ent_id": "D008133", "tok_span": [12, 17]}, {"name": "ventricular tachycardia", "ent_type": "Disease", "char_span": [113, 136], "ent_id": "D017180", "tok_span": [20, 22]}], "relation_list": [{"subject": "procainamide", "object": "ventricular tachycardia", "sbj_char_span": [35, 47], "obj_char_span": [113, 136], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [20, 22]}], "umls_entity_list": []}, {"text": "Permeability of the blood-brain barrier was quantitated by clearance of fluorescent-labeled dextran before and during phenylephrine-induced acute hypertension in rats treated with vehicle and Hoe-140 (0.1 microM).", "entity_list": [{"name": "hypertension", "ent_type": "Disease", "char_span": [146, 158], "ent_id": "D006973", "tok_span": [29, 30]}, {"name": "Hoe-140", "ent_type": "Chemical", "char_span": [192, 199], "ent_id": "C065679", "tok_span": [36, 40]}, {"name": "phenylephrine", "ent_type": "Chemical", "char_span": [118, 131], "ent_id": "D010656", "tok_span": [23, 26]}, {"name": "dextran", "ent_type": "Chemical", "char_span": [92, 99], "ent_id": "D003911", "tok_span": [18, 20]}], "relation_list": [{"subject": "phenylephrine", "object": "hypertension", "sbj_char_span": [118, 131], "obj_char_span": [146, 158], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [29, 30]}], "umls_entity_list": []}, {"text": "5-azacytidine potentiates initiation induced by carcinogens in rat liver.", "entity_list": [{"name": "5-azacytidine", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D001374", "tok_span": [0, 5]}, {"name": "initiation induced by carcinogens", "ent_type": "Disease", "char_span": [26, 59], "ent_id": "D011230", "tok_span": [7, 12]}], "relation_list": [{"subject": "5-azacytidine", "object": "initiation induced by carcinogens", "sbj_char_span": [0, 13], "obj_char_span": [26, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [7, 12]}], "umls_entity_list": []}, {"text": "To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).", "entity_list": [{"name": "1,2-dimethylhydrazine", "ent_type": "Chemical", "char_span": [357, 378], "ent_id": "D019813", "tok_span": [97, 104]}, {"name": "initiation of carcinogenic process", "ent_type": "Disease", "char_span": [98, 132], "ent_id": "D011230", "tok_span": [19, 24]}, {"name": "N-methyl-N-nitrosourea", "ent_type": "Chemical", "char_span": [319, 341], "ent_id": "D008770", "tok_span": [81, 90]}, {"name": "benzo[a]-pyrene", "ent_type": "Chemical", "char_span": [290, 305], "ent_id": "D001564", "tok_span": [66, 74]}, {"name": "5-AzC", "ent_type": "Chemical", "char_span": [149, 154], "ent_id": "D001374", "tok_span": [31, 35]}, {"name": "5-azacytidine", "ent_type": "Chemical", "char_span": [134, 147], "ent_id": "D001374", "tok_span": [25, 30]}, {"name": "1,2-DMH", "ent_type": "Chemical", "char_span": [380, 387], "ent_id": "D019813", "tok_span": [105, 111]}], "relation_list": [{"subject": "1,2-DMH", "object": "initiation of carcinogenic process", "sbj_char_span": [380, 387], "obj_char_span": [98, 132], "rel_type": "chemical-induced disease", "sbj_tok_span": [105, 111], "obj_tok_span": [19, 24]}, {"subject": "N-methyl-N-nitrosourea", "object": "initiation of carcinogenic process", "sbj_char_span": [319, 341], "obj_char_span": [98, 132], "rel_type": "chemical-induced disease", "sbj_tok_span": [81, 90], "obj_tok_span": [19, 24]}, {"subject": "5-AzC", "object": "initiation of carcinogenic process", "sbj_char_span": [149, 154], "obj_char_span": [98, 132], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 35], "obj_tok_span": [19, 24]}, {"subject": "benzo[a]-pyrene", "object": "initiation of carcinogenic process", "sbj_char_span": [290, 305], "obj_char_span": [98, 132], "rel_type": "chemical-induced disease", "sbj_tok_span": [66, 74], "obj_tok_span": [19, 24]}, {"subject": "5-azacytidine", "object": "initiation of carcinogenic process", "sbj_char_span": [134, 147], "obj_char_span": [98, 132], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 30], "obj_tok_span": [19, 24]}, {"subject": "1,2-dimethylhydrazine", "object": "initiation of carcinogenic process", "sbj_char_span": [357, 378], "obj_char_span": [98, 132], "rel_type": "chemical-induced disease", "sbj_tok_span": [97, 104], "obj_tok_span": [19, 24]}], "umls_entity_list": []}, {"text": "The patient developed RS during dose reduction of risperidone.", "entity_list": [{"name": "RS", "ent_type": "Disease", "char_span": [22, 24], "ent_id": "D001480", "tok_span": [3, 4]}, {"name": "risperidone", "ent_type": "Chemical", "char_span": [50, 61], "ent_id": "D018967", "tok_span": [8, 11]}], "relation_list": [{"subject": "risperidone", "object": "RS", "sbj_char_span": [50, 61], "obj_char_span": [22, 24], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [3, 4]}], "umls_entity_list": []}, {"text": "The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS.", "entity_list": [{"name": "serotonin", "ent_type": "Chemical", "char_span": [222, 231], "ent_id": "D012701", "tok_span": [40, 41]}, {"name": "risperidone", "ent_type": "Chemical", "char_span": [127, 138], "ent_id": "D018967", "tok_span": [21, 24]}, {"name": "dopamine", "ent_type": "Chemical", "char_span": [152, 160], "ent_id": "D004298", "tok_span": [28, 29]}, {"name": "withdrawal-emergent RS", "ent_type": "Disease", "char_span": [28, 50], "ent_id": "D01337", "tok_span": [4, 8]}, {"name": "RS", "ent_type": "Disease", "char_span": [261, 263], "ent_id": "D001480", "tok_span": [46, 47]}, {"name": "serotonin", "ent_type": "Chemical", "char_span": [142, 151], "ent_id": "D012701", "tok_span": [26, 27]}], "relation_list": [{"subject": "risperidone", "object": "RS", "sbj_char_span": [127, 138], "obj_char_span": [261, 263], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [46, 47]}], "umls_entity_list": []}, {"text": "Verapamil withdrawal as a possible cause of myocardial infarction in a hypertensive woman with a normal coronary angiogram.", "entity_list": [{"name": "Verapamil", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D014700", "tok_span": [0, 3]}, {"name": "myocardial infarction", "ent_type": "Disease", "char_span": [44, 65], "ent_id": "D009203", "tok_span": [9, 11]}, {"name": "hypertensive", "ent_type": "Disease", "char_span": [71, 83], "ent_id": "D006973", "tok_span": [13, 14]}], "relation_list": [{"subject": "Verapamil", "object": "myocardial infarction", "sbj_char_span": [0, 9], "obj_char_span": [44, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "We report a case in which myocardial infarction coincided with the introduction of captopril and the withdrawal of verapamil in a previously asymptomatic woman with severe hypertension.", "entity_list": [{"name": "captopril", "ent_type": "Chemical", "char_span": [83, 92], "ent_id": "D002216", "tok_span": [14, 17]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [172, 184], "ent_id": "D006973", "tok_span": [31, 32]}, {"name": "verapamil", "ent_type": "Chemical", "char_span": [115, 124], "ent_id": "D014700", "tok_span": [21, 24]}, {"name": "myocardial infarction", "ent_type": "Disease", "char_span": [26, 47], "ent_id": "D009203", "tok_span": [6, 8]}], "relation_list": [{"subject": "verapamil", "object": "myocardial infarction", "sbj_char_span": [115, 124], "obj_char_span": [26, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.", "entity_list": [{"name": "leukemoid reaction", "ent_type": "Disease", "char_span": [52, 70], "ent_id": "D007955", "tok_span": [12, 16]}, {"name": "carbamazepine", "ent_type": "Chemical", "char_span": [20, 33], "ent_id": "D002220", "tok_span": [5, 9]}, {"name": "Hypersensitivity", "ent_type": "Disease", "char_span": [0, 16], "ent_id": "D004342", "tok_span": [0, 4]}, {"name": "erythroderma", "ent_type": "Disease", "char_span": [86, 98], "ent_id": "D003873", "tok_span": [20, 24]}, {"name": "renal failure", "ent_type": "Disease", "char_span": [104, 117], "ent_id": "D051437", "tok_span": [26, 28]}, {"name": "eosinophilia", "ent_type": "Disease", "char_span": [72, 84], "ent_id": "D004802", "tok_span": [17, 19]}], "relation_list": [{"subject": "carbamazepine", "object": "renal failure", "sbj_char_span": [20, 33], "obj_char_span": [104, 117], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [26, 28]}, {"subject": "carbamazepine", "object": "leukemoid reaction", "sbj_char_span": [20, 33], "obj_char_span": [52, 70], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [12, 16]}, {"subject": "carbamazepine", "object": "Hypersensitivity", "sbj_char_span": [20, 33], "obj_char_span": [0, 16], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [0, 4]}, {"subject": "carbamazepine", "object": "erythroderma", "sbj_char_span": [20, 33], "obj_char_span": [86, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.", "entity_list": [{"name": "hyponatremia", "ent_type": "Disease", "char_span": [146, 158], "ent_id": "D007010", "tok_span": [31, 35]}, {"name": "eosinophilia", "ent_type": "Disease", "char_span": [132, 144], "ent_id": "D004802", "tok_span": [28, 30]}, {"name": "erythroderma", "ent_type": "Disease", "char_span": [89, 101], "ent_id": "D003873", "tok_span": [16, 20]}, {"name": "leukemoid reaction", "ent_type": "Disease", "char_span": [112, 130], "ent_id": "D007955", "tok_span": [23, 27]}, {"name": "carbamazepine", "ent_type": "Chemical", "char_span": [48, 61], "ent_id": "D002220", "tok_span": [9, 13]}, {"name": "hypersensitivity", "ent_type": "Disease", "char_span": [28, 44], "ent_id": "D004342", "tok_span": [6, 8]}, {"name": "renal failure", "ent_type": "Disease", "char_span": [164, 177], "ent_id": "D051437", "tok_span": [37, 39]}], "relation_list": [{"subject": "carbamazepine", "object": "hypersensitivity", "sbj_char_span": [48, 61], "obj_char_span": [28, 44], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [6, 8]}, {"subject": "carbamazepine", "object": "erythroderma", "sbj_char_span": [48, 61], "obj_char_span": [89, 101], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [16, 20]}, {"subject": "carbamazepine", "object": "hyponatremia", "sbj_char_span": [48, 61], "obj_char_span": [146, 158], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [31, 35]}, {"subject": "carbamazepine", "object": "renal failure", "sbj_char_span": [48, 61], "obj_char_span": [164, 177], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [37, 39]}, {"subject": "carbamazepine", "object": "leukemoid reaction", "sbj_char_span": [48, 61], "obj_char_span": [112, 130], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [23, 27]}], "umls_entity_list": []}, {"text": "Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced hyperactivity, and raised spontaneous nocturnal activity.", "entity_list": [{"name": "locomotor hypoactivity", "ent_type": "Disease", "char_span": [110, 132], "ent_id": "D009069", "tok_span": [29, 32]}, {"name": "nicotine", "ent_type": "Chemical", "char_span": [207, 215], "ent_id": "D009538", "tok_span": [61, 62]}, {"name": "hyperactivity", "ent_type": "Disease", "char_span": [224, 237], "ent_id": "D006948", "tok_span": [64, 66]}, {"name": "nicotine", "ent_type": "Chemical", "char_span": [143, 151], "ent_id": "D009538", "tok_span": [34, 35]}], "relation_list": [{"subject": "nicotine", "object": "hyperactivity", "sbj_char_span": [143, 151], "obj_char_span": [224, 237], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 35], "obj_tok_span": [64, 66]}, {"subject": "nicotine", "object": "hyperactivity", "sbj_char_span": [207, 215], "obj_char_span": [224, 237], "rel_type": "chemical-induced disease", "sbj_tok_span": [61, 62], "obj_tok_span": [64, 66]}], "umls_entity_list": []}, {"text": "Assessment of a new non-invasive index of cardiac performance for detection of dobutamine-induced myocardial ischemia.", "entity_list": [{"name": "dobutamine", "ent_type": "Chemical", "char_span": [79, 89], "ent_id": "D004280", "tok_span": [14, 17]}, {"name": "myocardial ischemia", "ent_type": "Disease", "char_span": [98, 117], "ent_id": "D017202", "tok_span": [19, 21]}], "relation_list": [{"subject": "dobutamine", "object": "myocardial ischemia", "sbj_char_span": [79, 89], "obj_char_span": [98, 117], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [19, 21]}], "umls_entity_list": []}, {"text": "BACKGROUND: Electrocardiography has a very low sensitivity in detecting dobutamine-induced myocardial ischemia.", "entity_list": [{"name": "myocardial ischemia", "ent_type": "Disease", "char_span": [91, 110], "ent_id": "D017202", "tok_span": [17, 19]}, {"name": "dobutamine", "ent_type": "Chemical", "char_span": [72, 82], "ent_id": "D004280", "tok_span": [12, 15]}], "relation_list": [{"subject": "dobutamine", "object": "myocardial ischemia", "sbj_char_span": [72, 82], "obj_char_span": [91, 110], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [17, 19]}], "umls_entity_list": []}, {"text": "OBJECTIVES: To assess the added diagnostic value of a new cardiac performance index (dP/dtejc) measurement, based on brachial artery flow changes, as compared to standard 12-lead ECG, for detecting dobutamine-induced myocardial ischemia, using Tc99m-Sestamibi single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia.", "entity_list": [{"name": "myocardial ischemia", "ent_type": "Disease", "char_span": [217, 236], "ent_id": "D017202", "tok_span": [48, 50]}, {"name": "Tc99m-Sestamibi", "ent_type": "Chemical", "char_span": [244, 259], "ent_id": "D017256", "tok_span": [52, 60]}, {"name": "ischemia", "ent_type": "Disease", "char_span": [375, 383], "ent_id": "D007511", "tok_span": [79, 80]}, {"name": "dobutamine", "ent_type": "Chemical", "char_span": [198, 208], "ent_id": "D004280", "tok_span": [43, 46]}], "relation_list": [{"subject": "dobutamine", "object": "myocardial ischemia", "sbj_char_span": [198, 208], "obj_char_span": [217, 236], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 46], "obj_tok_span": [48, 50]}], "umls_entity_list": []}, {"text": "BACKGROUND: The possible role of alcohol in the development of hepatotoxicity associated with therapeutic doses of paracetamol (acetaminophen) is currently debated.", "entity_list": [{"name": "acetaminophen", "ent_type": "Chemical", "char_span": [128, 141], "ent_id": "D000082", "tok_span": [23, 26]}, {"name": "alcohol", "ent_type": "Chemical", "char_span": [33, 40], "ent_id": "D000431", "tok_span": [6, 7]}, {"name": "hepatotoxicity", "ent_type": "Disease", "char_span": [63, 77], "ent_id": "D056486", "tok_span": [11, 13]}, {"name": "paracetamol", "ent_type": "Chemical", "char_span": [115, 126], "ent_id": "D000082", "tok_span": [18, 22]}], "relation_list": [{"subject": "paracetamol", "object": "hepatotoxicity", "sbj_char_span": [115, 126], "obj_char_span": [63, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 22], "obj_tok_span": [11, 13]}, {"subject": "acetaminophen", "object": "hepatotoxicity", "sbj_char_span": [128, 141], "obj_char_span": [63, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [11, 13]}], "umls_entity_list": []}, {"text": "CASE REPORT: We describe 2 patients who were regular consumers of alcohol and who developed liver failure within 3-5 days after hospitalization and stopping alcohol consumption while being treated with 4 g paracetamol/day.", "entity_list": [{"name": "alcohol", "ent_type": "Chemical", "char_span": [66, 73], "ent_id": "D000431", "tok_span": [12, 13]}, {"name": "liver failure", "ent_type": "Disease", "char_span": [92, 105], "ent_id": "D017093", "tok_span": [16, 18]}, {"name": "alcohol", "ent_type": "Chemical", "char_span": [157, 164], "ent_id": "D000431", "tok_span": [27, 28]}, {"name": "paracetamol", "ent_type": "Chemical", "char_span": [206, 217], "ent_id": "D000082", "tok_span": [35, 39]}], "relation_list": [{"subject": "paracetamol", "object": "liver failure", "sbj_char_span": [206, 217], "obj_char_span": [92, 105], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 39], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "Possible risk factors for the development of hepatotoxicity in patients treated with therapeutic doses of paracetamol are discussed.", "entity_list": [{"name": "paracetamol", "ent_type": "Chemical", "char_span": [106, 117], "ent_id": "D000082", "tok_span": [16, 20]}, {"name": "hepatotoxicity", "ent_type": "Disease", "char_span": [45, 59], "ent_id": "D056486", "tok_span": [7, 9]}], "relation_list": [{"subject": "paracetamol", "object": "hepatotoxicity", "sbj_char_span": [106, 117], "obj_char_span": [45, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 20], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "Cocaine related chest pain: are we seeing the tip of an iceberg?", "entity_list": [{"name": "Cocaine", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "D003042", "tok_span": [0, 3]}, {"name": "chest pain", "ent_type": "Disease", "char_span": [16, 26], "ent_id": "D002637", "tok_span": [4, 6]}], "relation_list": [{"subject": "Cocaine", "object": "chest pain", "sbj_char_span": [0, 7], "obj_char_span": [16, 26], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "In particular, the tendency of cocaine to produce chest pain ought to be in the mind of the emergency nurse when faced with a young victim of chest pain who is otherwise at low risk.", "entity_list": [{"name": "cocaine", "ent_type": "Chemical", "char_span": [31, 38], "ent_id": "D003042", "tok_span": [6, 7]}, {"name": "chest pain", "ent_type": "Disease", "char_span": [50, 60], "ent_id": "D002637", "tok_span": [9, 11]}, {"name": "chest pain", "ent_type": "Disease", "char_span": [142, 152], "ent_id": "D002637", "tok_span": [28, 30]}], "relation_list": [{"subject": "cocaine", "object": "chest pain", "sbj_char_span": [31, 38], "obj_char_span": [50, 60], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [9, 11]}, {"subject": "cocaine", "object": "chest pain", "sbj_char_span": [31, 38], "obj_char_span": [142, 152], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [28, 30]}], "umls_entity_list": []}, {"text": "The mechanism of chest pain related to cocaine use is discussed and treatment dilemmas are discussed.", "entity_list": [{"name": "cocaine", "ent_type": "Chemical", "char_span": [39, 46], "ent_id": "D003042", "tok_span": [7, 8]}, {"name": "chest pain", "ent_type": "Disease", "char_span": [17, 27], "ent_id": "D002637", "tok_span": [3, 5]}], "relation_list": [{"subject": "cocaine", "object": "chest pain", "sbj_char_span": [39, 46], "obj_char_span": [17, 27], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.", "entity_list": [{"name": "atazanavir", "ent_type": "Chemical", "char_span": [107, 117], "ent_id": "C413408", "tok_span": [23, 27]}, {"name": "rhabdomyolysis", "ent_type": "Disease", "char_span": [7, 21], "ent_id": "D012206", "tok_span": [1, 5]}, {"name": "acute renal failure", "ent_type": "Disease", "char_span": [26, 45], "ent_id": "D058186", "tok_span": [6, 9]}, {"name": "simvastatin", "ent_type": "Chemical", "char_span": [78, 89], "ent_id": "D019821", "tok_span": [14, 16]}, {"name": "amiodarone", "ent_type": "Chemical", "char_span": [91, 101], "ent_id": "D000638", "tok_span": [17, 21]}], "relation_list": [{"subject": "simvastatin", "object": "rhabdomyolysis", "sbj_char_span": [78, 89], "obj_char_span": [7, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [1, 5]}, {"subject": "atazanavir", "object": "acute renal failure", "sbj_char_span": [107, 117], "obj_char_span": [26, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 27], "obj_tok_span": [6, 9]}, {"subject": "amiodarone", "object": "rhabdomyolysis", "sbj_char_span": [91, 101], "obj_char_span": [7, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [1, 5]}, {"subject": "simvastatin", "object": "acute renal failure", "sbj_char_span": [78, 89], "obj_char_span": [26, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [6, 9]}, {"subject": "atazanavir", "object": "rhabdomyolysis", "sbj_char_span": [107, 117], "obj_char_span": [7, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 27], "obj_tok_span": [1, 5]}, {"subject": "amiodarone", "object": "acute renal failure", "sbj_char_span": [91, 101], "obj_char_span": [26, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [6, 9]}], "umls_entity_list": []}, {"text": "OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.", "entity_list": [{"name": "acute renal failure", "ent_type": "Disease", "char_span": [132, 151], "ent_id": "D058186", "tok_span": [31, 34]}, {"name": "amiodarone", "ent_type": "Chemical", "char_span": [73, 83], "ent_id": "D000638", "tok_span": [14, 18]}, {"name": "simvastatin", "ent_type": "Chemical", "char_span": [60, 71], "ent_id": "D019821", "tok_span": [11, 13]}, {"name": "rhabdomyolysis", "ent_type": "Disease", "char_span": [113, 127], "ent_id": "D012206", "tok_span": [26, 30]}, {"name": "atazanavir", "ent_type": "Chemical", "char_span": [89, 99], "ent_id": "C413408", "tok_span": [20, 24]}], "relation_list": [{"subject": "simvastatin", "object": "acute renal failure", "sbj_char_span": [60, 71], "obj_char_span": [132, 151], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 13], "obj_tok_span": [31, 34]}, {"subject": "atazanavir", "object": "acute renal failure", "sbj_char_span": [89, 99], "obj_char_span": [132, 151], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 24], "obj_tok_span": [31, 34]}, {"subject": "amiodarone", "object": "rhabdomyolysis", "sbj_char_span": [73, 83], "obj_char_span": [113, 127], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 18], "obj_tok_span": [26, 30]}, {"subject": "atazanavir", "object": "rhabdomyolysis", "sbj_char_span": [89, 99], "obj_char_span": [113, 127], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 24], "obj_tok_span": [26, 30]}, {"subject": "simvastatin", "object": "rhabdomyolysis", "sbj_char_span": [60, 71], "obj_char_span": [113, 127], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 13], "obj_tok_span": [26, 30]}, {"subject": "amiodarone", "object": "acute renal failure", "sbj_char_span": [73, 83], "obj_char_span": [132, 151], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 18], "obj_tok_span": [31, 34]}], "umls_entity_list": []}, {"text": "DISCUSSION: The risk of rhabdomyolysis is increased in the presence of concomitant drugs that inhibit simvastatin metabolism.", "entity_list": [{"name": "simvastatin", "ent_type": "Chemical", "char_span": [102, 113], "ent_id": "D019821", "tok_span": [19, 21]}, {"name": "rhabdomyolysis", "ent_type": "Disease", "char_span": [24, 38], "ent_id": "D012206", "tok_span": [5, 9]}], "relation_list": [{"subject": "simvastatin", "object": "rhabdomyolysis", "sbj_char_span": [102, 113], "obj_char_span": [24, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 21], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "The ocular hypotensive effects were statistically significant for apraclonidine-treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1% apraclonidine.", "entity_list": [{"name": "ocular hypotensive", "ent_type": "Disease", "char_span": [4, 22], "ent_id": "D015814", "tok_span": [1, 4]}, {"name": "apraclonidine", "ent_type": "Chemical", "char_span": [66, 79], "ent_id": "C016986", "tok_span": [9, 13]}, {"name": "apraclonidine", "ent_type": "Chemical", "char_span": [224, 237], "ent_id": "C016986", "tok_span": [35, 39]}], "relation_list": [{"subject": "apraclonidine", "object": "ocular hypotensive", "sbj_char_span": [224, 237], "obj_char_span": [4, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 39], "obj_tok_span": [1, 4]}, {"subject": "apraclonidine", "object": "ocular hypotensive", "sbj_char_span": [66, 79], "obj_char_span": [4, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [1, 4]}], "umls_entity_list": []}, {"text": "Carmofur-induced organic mental disorders.", "entity_list": [{"name": "Carmofur", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "C017367", "tok_span": [0, 4]}, {"name": "organic mental disorders", "ent_type": "Disease", "char_span": [17, 41], "ent_id": "D019965", "tok_span": [6, 9]}], "relation_list": [{"subject": "Carmofur", "object": "organic mental disorders", "sbj_char_span": [0, 8], "obj_char_span": [17, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [6, 9]}], "umls_entity_list": []}, {"text": "Organic mental disorder was observed in a 29-year-old female in the prognostic period after the onset of carmofur-induced leukoencephalopathy.", "entity_list": [{"name": "Organic mental disorder", "ent_type": "Disease", "char_span": [0, 23], "ent_id": "D019965", "tok_span": [0, 3]}, {"name": "leukoencephalopathy", "ent_type": "Disease", "char_span": [122, 141], "ent_id": "D056784", "tok_span": [27, 31]}, {"name": "carmofur", "ent_type": "Chemical", "char_span": [105, 113], "ent_id": "C017367", "tok_span": [21, 25]}], "relation_list": [{"subject": "carmofur", "object": "leukoencephalopathy", "sbj_char_span": [105, 113], "obj_char_span": [122, 141], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 25], "obj_tok_span": [27, 31]}, {"subject": "carmofur", "object": "Organic mental disorder", "sbj_char_span": [105, 113], "obj_char_span": [0, 23], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 25], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "Consequently, carmofur-induced leukoencephalopathy may uncommonly result in organic personality syndrome in the residual state.", "entity_list": [{"name": "carmofur", "ent_type": "Chemical", "char_span": [14, 22], "ent_id": "C017367", "tok_span": [2, 6]}, {"name": "leukoencephalopathy", "ent_type": "Disease", "char_span": [31, 50], "ent_id": "D056784", "tok_span": [8, 12]}, {"name": "organic personality syndrome", "ent_type": "Disease", "char_span": [76, 104], "ent_id": "D010554", "tok_span": [17, 20]}], "relation_list": [{"subject": "carmofur", "object": "leukoencephalopathy", "sbj_char_span": [14, 22], "obj_char_span": [31, 50], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [8, 12]}], "umls_entity_list": []}, {"text": "Previously recognized side effects, particularly tremor and gastrointestinal problems, were more frequent in the mexiletine group than in the placebo group.", "entity_list": [{"name": "mexiletine", "ent_type": "Chemical", "char_span": [113, 123], "ent_id": "D008801", "tok_span": [18, 22]}, {"name": "gastrointestinal problems", "ent_type": "Disease", "char_span": [60, 85], "ent_id": "D012817", "tok_span": [9, 12]}, {"name": "tremor", "ent_type": "Disease", "char_span": [49, 55], "ent_id": "D014202", "tok_span": [6, 8]}], "relation_list": [{"subject": "mexiletine", "object": "tremor", "sbj_char_span": [113, 123], "obj_char_span": [49, 55], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 22], "obj_tok_span": [6, 8]}, {"subject": "mexiletine", "object": "gastrointestinal problems", "sbj_char_span": [113, 123], "obj_char_span": [60, 85], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 22], "obj_tok_span": [9, 12]}], "umls_entity_list": []}, {"text": "Regional localization of the antagonism of amphetamine-induced hyperactivity by intracerebral calcitonin injections.", "entity_list": [{"name": "amphetamine", "ent_type": "Chemical", "char_span": [43, 54], "ent_id": "D000661", "tok_span": [7, 11]}, {"name": "calcitonin", "ent_type": "Chemical", "char_span": [94, 104], "ent_id": "D002116", "tok_span": [19, 22]}, {"name": "hyperactivity", "ent_type": "Disease", "char_span": [63, 76], "ent_id": "D006948", "tok_span": [13, 15]}], "relation_list": [{"subject": "amphetamine", "object": "hyperactivity", "sbj_char_span": [43, 54], "obj_char_span": [63, 76], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "Fatal intracranial bleeding associated with prehospital use of epinephrine.", "entity_list": [{"name": "intracranial bleeding", "ent_type": "Disease", "char_span": [6, 27], "ent_id": "D013345", "tok_span": [2, 4]}, {"name": "epinephrine", "ent_type": "Chemical", "char_span": [63, 74], "ent_id": "D004837", "tok_span": [10, 13]}], "relation_list": [{"subject": "epinephrine", "object": "intracranial bleeding", "sbj_char_span": [63, 74], "obj_char_span": [6, 27], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [2, 4]}], "umls_entity_list": []}, {"text": "Epinephrine has a proven role in cardiac arrest in prehospital care; however, use by paramedics in patients with suspected allergic reaction and severe hypertension should be viewed with caution.", "entity_list": [{"name": "allergic reaction", "ent_type": "Disease", "char_span": [123, 140], "ent_id": "D004342", "tok_span": [26, 28]}, {"name": "Epinephrine", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D004837", "tok_span": [0, 3]}, {"name": "cardiac arrest", "ent_type": "Disease", "char_span": [33, 47], "ent_id": "D006323", "tok_span": [8, 10]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [152, 164], "ent_id": "D006973", "tok_span": [30, 31]}], "relation_list": [{"subject": "Epinephrine", "object": "cardiac arrest", "sbj_char_span": [0, 11], "obj_char_span": [33, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "A case of massive rhabdomyolysis following molindone administration.", "entity_list": [{"name": "rhabdomyolysis", "ent_type": "Disease", "char_span": [18, 32], "ent_id": "D012206", "tok_span": [4, 8]}, {"name": "molindone", "ent_type": "Chemical", "char_span": [43, 52], "ent_id": "D008972", "tok_span": [9, 12]}], "relation_list": [{"subject": "molindone", "object": "rhabdomyolysis", "sbj_char_span": [43, 52], "obj_char_span": [18, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following molindone administration.", "entity_list": [{"name": "molindone", "ent_type": "Chemical", "char_span": [130, 139], "ent_id": "D008972", "tok_span": [22, 25]}, {"name": "rhabdomyolysis", "ent_type": "Disease", "char_span": [70, 84], "ent_id": "D012206", "tok_span": [12, 16]}, {"name": "acute renal failure", "ent_type": "Disease", "char_span": [100, 119], "ent_id": "D058186", "tok_span": [18, 21]}, {"name": "schizophrenic", "ent_type": "Disease", "char_span": [14, 27], "ent_id": "D012559", "tok_span": [4, 6]}], "relation_list": [{"subject": "molindone", "object": "acute renal failure", "sbj_char_span": [130, 139], "obj_char_span": [100, 119], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 25], "obj_tok_span": [18, 21]}, {"subject": "molindone", "object": "rhabdomyolysis", "sbj_char_span": [130, 139], "obj_char_span": [70, 84], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 25], "obj_tok_span": [12, 16]}], "umls_entity_list": []}, {"text": "Preclinical toxicologic investigation suggested that a new calcium channel blocker, Ro 40-5967, induced cardiovascular alterations in rat fetuses exposed to this agent during organogenesis.", "entity_list": [{"name": "cardiovascular alterations", "ent_type": "Disease", "char_span": [104, 130], "ent_id": "D018376", "tok_span": [21, 23]}, {"name": "calcium", "ent_type": "Chemical", "char_span": [59, 66], "ent_id": "D002118", "tok_span": [10, 11]}, {"name": "Ro 40-5967", "ent_type": "Chemical", "char_span": [84, 94], "ent_id": "D020748", "tok_span": [14, 19]}], "relation_list": [{"subject": "Ro 40-5967", "object": "cardiovascular alterations", "sbj_char_span": [84, 94], "obj_char_span": [104, 130], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 19], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "A low incidence of cardiovascular malformations was observed after exposure to each of the four calcium channel blockers, but this incidence was statistically significant only for verapamil and nifedipine.", "entity_list": [{"name": "verapamil", "ent_type": "Chemical", "char_span": [180, 189], "ent_id": "D014700", "tok_span": [27, 30]}, {"name": "calcium", "ent_type": "Chemical", "char_span": [96, 103], "ent_id": "D002118", "tok_span": [15, 16]}, {"name": "nifedipine", "ent_type": "Chemical", "char_span": [194, 204], "ent_id": "D009543", "tok_span": [31, 34]}, {"name": "cardiovascular malformations", "ent_type": "Disease", "char_span": [19, 47], "ent_id": "D018376", "tok_span": [4, 6]}], "relation_list": [{"subject": "verapamil", "object": "cardiovascular malformations", "sbj_char_span": [180, 189], "obj_char_span": [19, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 30], "obj_tok_span": [4, 6]}, {"subject": "nifedipine", "object": "cardiovascular malformations", "sbj_char_span": [194, 204], "obj_char_span": [19, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 34], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "The effects of sevoflurane on lidocaine-induced convulsions.", "entity_list": [{"name": "lidocaine", "ent_type": "Chemical", "char_span": [30, 39], "ent_id": "D008012", "tok_span": [8, 10]}, {"name": "sevoflurane", "ent_type": "Chemical", "char_span": [15, 26], "ent_id": "C009250", "tok_span": [3, 7]}, {"name": "convulsions", "ent_type": "Disease", "char_span": [48, 59], "ent_id": "D012640", "tok_span": [12, 15]}], "relation_list": [{"subject": "lidocaine", "object": "convulsions", "sbj_char_span": [30, 39], "obj_char_span": [48, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [12, 15]}], "umls_entity_list": []}, {"text": "The influence of sevoflurane on lidocaine-induced convulsions was studied in cats.", "entity_list": [{"name": "lidocaine", "ent_type": "Chemical", "char_span": [32, 41], "ent_id": "D008012", "tok_span": [8, 10]}, {"name": "sevoflurane", "ent_type": "Chemical", "char_span": [17, 28], "ent_id": "C009250", "tok_span": [3, 7]}, {"name": "convulsions", "ent_type": "Disease", "char_span": [50, 61], "ent_id": "D012640", "tok_span": [12, 15]}], "relation_list": [{"subject": "lidocaine", "object": "convulsions", "sbj_char_span": [32, 41], "obj_char_span": [50, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [12, 15]}], "umls_entity_list": []}, {"text": "The convulsive threshold (mean +/- SD) was 41.4 +/- 6.5 mg. l(-1) with lidocaine infusion (6 mg.kg(-1).min(-1)), increasing significantly to 66.6 +/- 10.9 mg. l(-1) when the end-tidal concentration of sevoflurane was 0.8%.", "entity_list": [{"name": "convulsive", "ent_type": "Disease", "char_span": [4, 14], "ent_id": "D012640", "tok_span": [1, 3]}, {"name": "lidocaine", "ent_type": "Chemical", "char_span": [71, 80], "ent_id": "D008012", "tok_span": [29, 31]}, {"name": "sevoflurane", "ent_type": "Chemical", "char_span": [201, 212], "ent_id": "C009250", "tok_span": [75, 79]}], "relation_list": [{"subject": "lidocaine", "object": "convulsive", "sbj_char_span": [71, 80], "obj_char_span": [4, 14], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 31], "obj_tok_span": [1, 3]}], "umls_entity_list": []}, {"text": "It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression.", "entity_list": [{"name": "convulsive", "ent_type": "Disease", "char_span": [45, 55], "ent_id": "D012640", "tok_span": [10, 12]}, {"name": "toxicity", "ent_type": "Disease", "char_span": [76, 84], "ent_id": "D064420", "tok_span": [16, 17]}, {"name": "depression", "ent_type": "Disease", "char_span": [126, 136], "ent_id": "D003866", "tok_span": [25, 26]}, {"name": "sevoflurane", "ent_type": "Chemical", "char_span": [21, 32], "ent_id": "C009250", "tok_span": [4, 8]}, {"name": "lidocaine", "ent_type": "Chemical", "char_span": [66, 75], "ent_id": "D008012", "tok_span": [14, 16]}], "relation_list": [{"subject": "lidocaine", "object": "convulsive", "sbj_char_span": [66, 75], "obj_char_span": [45, 55], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Anti-oxidant effects of atorvastatin in dexamethasone-induced hypertension in the rat.\n 1", "entity_list": [{"name": "dexamethasone", "ent_type": "Chemical", "char_span": [40, 53], "ent_id": "D003907", "tok_span": [10, 11]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [62, 74], "ent_id": "D006973", "tok_span": [13, 14]}, {"name": "atorvastatin", "ent_type": "Chemical", "char_span": [24, 36], "ent_id": "C065179", "tok_span": [6, 9]}], "relation_list": [{"subject": "dexamethasone", "object": "hypertension", "sbj_char_span": [40, 53], "obj_char_span": [62, 74], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [13, 14]}], "umls_entity_list": []}, {"text": "Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.", "entity_list": [{"name": "NO", "ent_type": "Chemical", "char_span": [115, 117], "ent_id": "D009569", "tok_span": [18, 19]}, {"name": "nitric oxide", "ent_type": "Chemical", "char_span": [101, 113], "ent_id": "D009569", "tok_span": [15, 17]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [28, 40], "ent_id": "D006973", "tok_span": [7, 8]}, {"name": "O2-", "ent_type": "Chemical", "char_span": [156, 159], "ent_id": "D013481", "tok_span": [25, 28]}, {"name": "Dexamethasone", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D003907", "tok_span": [0, 2]}, {"name": "superoxide", "ent_type": "Chemical", "char_span": [144, 154], "ent_id": "D013481", "tok_span": [23, 24]}, {"name": "Dex", "ent_type": "Chemical", "char_span": [15, 18], "ent_id": "D003907", "tok_span": [3, 4]}], "relation_list": [{"subject": "Dex", "object": "hypertension", "sbj_char_span": [15, 18], "obj_char_span": [28, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [7, 8]}, {"subject": "Dexamethasone", "object": "hypertension", "sbj_char_span": [0, 13], "obj_char_span": [28, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [7, 8]}], "umls_entity_list": []}, {"text": "99mTc-glucarate for detection of isoproterenol-induced myocardial infarction in rats.", "entity_list": [{"name": "myocardial infarction", "ent_type": "Disease", "char_span": [55, 76], "ent_id": "D009203", "tok_span": [16, 18]}, {"name": "isoproterenol", "ent_type": "Chemical", "char_span": [33, 46], "ent_id": "D007545", "tok_span": [10, 14]}, {"name": "99mTc-glucarate", "ent_type": "Chemical", "char_span": [0, 15], "ent_id": "C067171", "tok_span": [0, 7]}], "relation_list": [{"subject": "isoproterenol", "object": "myocardial infarction", "sbj_char_span": [33, 46], "obj_char_span": [55, 76], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "A new infarct-avid radiopharmaceutical based on glucaric acid was prepared in the hospital radiopharmacy of the INCMNSZ. 99mTc-glucarate was easy to prepare, stable for 96 h and was used to study its biodistribution in rats with isoproterenol-induced acute myocardial infarction.", "entity_list": [{"name": "myocardial infarction", "ent_type": "Disease", "char_span": [257, 278], "ent_id": "D009203", "tok_span": [69, 71]}, {"name": "99mTc-glucarate", "ent_type": "Chemical", "char_span": [121, 136], "ent_id": "C067171", "tok_span": [33, 40]}, {"name": "glucaric acid", "ent_type": "Chemical", "char_span": [48, 61], "ent_id": "D005937", "tok_span": [13, 17]}, {"name": "isoproterenol", "ent_type": "Chemical", "char_span": [229, 242], "ent_id": "D007545", "tok_span": [62, 66]}, {"name": "infarct", "ent_type": "Disease", "char_span": [6, 13], "ent_id": "D007238", "tok_span": [2, 3]}], "relation_list": [{"subject": "isoproterenol", "object": "myocardial infarction", "sbj_char_span": [229, 242], "obj_char_span": [257, 278], "rel_type": "chemical-induced disease", "sbj_tok_span": [62, 66], "obj_tok_span": [69, 71]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: The results indicated a favorable therapeutic profile for haloperidol in doses of 2-3 mg/day, although a subgroup developed moderate to severe extrapyramidal signs.", "entity_list": [{"name": "haloperidol", "ent_type": "Chemical", "char_span": [71, 82], "ent_id": "D006220", "tok_span": [10, 13]}, {"name": "extrapyramidal signs", "ent_type": "Disease", "char_span": [156, 176], "ent_id": "D001480", "tok_span": [30, 35]}], "relation_list": [{"subject": "haloperidol", "object": "extrapyramidal signs", "sbj_char_span": [71, 82], "obj_char_span": [156, 176], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [30, 35]}], "umls_entity_list": []}, {"text": "After 1 week of recovery, proteinuria was induced by adriamycin [1.5 mg/kg intravenously (i.v.) n = 18; controls, saline i.v. n = 9].", "entity_list": [{"name": "proteinuria", "ent_type": "Disease", "char_span": [26, 37], "ent_id": "D011507", "tok_span": [6, 7]}, {"name": "adriamycin", "ent_type": "Chemical", "char_span": [53, 63], "ent_id": "D004317", "tok_span": [10, 14]}], "relation_list": [{"subject": "adriamycin", "object": "proteinuria", "sbj_char_span": [53, 63], "obj_char_span": [26, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [6, 7]}], "umls_entity_list": []}, {"text": "RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.", "entity_list": [{"name": "renal interstitial damage", "ent_type": "Disease", "char_span": [74, 99], "ent_id": "D007674", "tok_span": [15, 18]}, {"name": "nephrotic", "ent_type": "Disease", "char_span": [45, 54], "ent_id": "D009404", "tok_span": [10, 12]}, {"name": "adriamycin", "ent_type": "Chemical", "char_span": [25, 35], "ent_id": "D004317", "tok_span": [5, 9]}, {"name": "proteinuria", "ent_type": "Disease", "char_span": [61, 72], "ent_id": "D011507", "tok_span": [13, 14]}, {"name": "focal glomerulosclerosis", "ent_type": "Disease", "char_span": [109, 133], "ent_id": "D005923", "tok_span": [20, 25]}], "relation_list": [{"subject": "adriamycin", "object": "proteinuria", "sbj_char_span": [25, 35], "obj_char_span": [61, 72], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [13, 14]}], "umls_entity_list": []}, {"text": "Baseline renal ACE positively correlated with the relative rise in proteinuria after adriamycin (r = 0.62, P<0.01), renal interstitial alpha-smooth muscle actin (r = 0.49, P<0.05), interstitial macrophage influx (r = 0.56, P<0.05), interstitial collagen III (r = 0.53, P<0.05), glomerular alpha-smooth muscle actin (r = 0.74, P<0.01) and glomerular desmin (r = 0.48, P<0.05).", "entity_list": [{"name": "adriamycin", "ent_type": "Chemical", "char_span": [85, 95], "ent_id": "D004317", "tok_span": [12, 16]}, {"name": "proteinuria", "ent_type": "Disease", "char_span": [67, 78], "ent_id": "D011507", "tok_span": [10, 11]}], "relation_list": [{"subject": "adriamycin", "object": "proteinuria", "sbj_char_span": [85, 95], "obj_char_span": [67, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 16], "obj_tok_span": [10, 11]}], "umls_entity_list": []}, {"text": "In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.", "entity_list": [{"name": "aminoglycoside", "ent_type": "Chemical", "char_span": [232, 246], "ent_id": "D000617", "tok_span": [46, 49]}, {"name": "gentamicin sulfate", "ent_type": "Chemical", "char_span": [109, 127], "ent_id": "D005839", "tok_span": [24, 27]}, {"name": "tobramycin sulfate", "ent_type": "Chemical", "char_span": [131, 149], "ent_id": "D014031", "tok_span": [28, 32]}, {"name": "renal failure", "ent_type": "Disease", "char_span": [255, 268], "ent_id": "D051437", "tok_span": [51, 53]}], "relation_list": [{"subject": "gentamicin sulfate", "object": "renal failure", "sbj_char_span": [109, 127], "obj_char_span": [255, 268], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 27], "obj_tok_span": [51, 53]}, {"subject": "tobramycin sulfate", "object": "renal failure", "sbj_char_span": [131, 149], "obj_char_span": [255, 268], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 32], "obj_tok_span": [51, 53]}], "umls_entity_list": []}, {"text": "Five of 33 (15%) of the tobramycin-treated patients and 16 of 29 (55.2%) of the gentamicin-treated patients had renal failure.", "entity_list": [{"name": "renal failure", "ent_type": "Disease", "char_span": [112, 125], "ent_id": "D051437", "tok_span": [33, 35]}, {"name": "tobramycin", "ent_type": "Chemical", "char_span": [24, 34], "ent_id": "D014031", "tok_span": [9, 12]}, {"name": "gentamicin", "ent_type": "Chemical", "char_span": [80, 90], "ent_id": "D005839", "tok_span": [27, 29]}], "relation_list": [{"subject": "gentamicin", "object": "renal failure", "sbj_char_span": [80, 90], "obj_char_span": [112, 125], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 29], "obj_tok_span": [33, 35]}, {"subject": "tobramycin", "object": "renal failure", "sbj_char_span": [24, 34], "obj_char_span": [112, 125], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [33, 35]}], "umls_entity_list": []}, {"text": "Thus, gentamicin was associated with renal failure more than three times as often as was tobramycin.", "entity_list": [{"name": "gentamicin", "ent_type": "Chemical", "char_span": [6, 16], "ent_id": "D005839", "tok_span": [2, 4]}, {"name": "tobramycin", "ent_type": "Chemical", "char_span": [89, 99], "ent_id": "D014031", "tok_span": [17, 20]}, {"name": "renal failure", "ent_type": "Disease", "char_span": [37, 50], "ent_id": "D051437", "tok_span": [7, 9]}], "relation_list": [{"subject": "gentamicin", "object": "renal failure", "sbj_char_span": [6, 16], "obj_char_span": [37, 50], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 4], "obj_tok_span": [7, 9]}, {"subject": "tobramycin", "object": "renal failure", "sbj_char_span": [89, 99], "obj_char_span": [37, 50], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.", "entity_list": [{"name": "hyperthermia", "ent_type": "Disease", "char_span": [185, 197], "ent_id": "D005334", "tok_span": [37, 40]}, {"name": "MPEP", "ent_type": "Chemical", "char_span": [26, 30], "ent_id": "C121465", "tok_span": [6, 8]}, {"name": "dopamine", "ent_type": "Chemical", "char_span": [150, 158], "ent_id": "D004298", "tok_span": [32, 33]}, {"name": "methamphetamine", "ent_type": "Chemical", "char_span": [66, 81], "ent_id": "D008694", "tok_span": [18, 21]}, {"name": "neurotoxicity", "ent_type": "Disease", "char_span": [103, 116], "ent_id": "D020258", "tok_span": [24, 26]}], "relation_list": [{"subject": "methamphetamine", "object": "hyperthermia", "sbj_char_span": [66, 81], "obj_char_span": [185, 197], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [37, 40]}], "umls_entity_list": []}, {"text": "Moreover, it transiently diminished the methamphetamine (10 mg/kg sc)-induced hyperthermia and reduced basal body temperature.", "entity_list": [{"name": "hyperthermia", "ent_type": "Disease", "char_span": [78, 90], "ent_id": "D005334", "tok_span": [18, 21]}, {"name": "methamphetamine", "ent_type": "Chemical", "char_span": [40, 55], "ent_id": "D008694", "tok_span": [6, 9]}], "relation_list": [{"subject": "methamphetamine", "object": "hyperthermia", "sbj_char_span": [40, 55], "obj_char_span": [78, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [18, 21]}], "umls_entity_list": []}, {"text": "Neuroprotection rendered by MPEP may be associated with the reduction of the methamphetamine-induced dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5, and with a decrease in hyperthermia.", "entity_list": [{"name": "methamphetamine", "ent_type": "Chemical", "char_span": [77, 92], "ent_id": "D008694", "tok_span": [16, 19]}, {"name": "hyperthermia", "ent_type": "Disease", "char_span": [201, 213], "ent_id": "D005334", "tok_span": [45, 48]}, {"name": "dopamine", "ent_type": "Chemical", "char_span": [101, 109], "ent_id": "D004298", "tok_span": [21, 22]}, {"name": "MPEP", "ent_type": "Chemical", "char_span": [28, 32], "ent_id": "C121465", "tok_span": [6, 8]}], "relation_list": [{"subject": "methamphetamine", "object": "hyperthermia", "sbj_char_span": [77, 92], "obj_char_span": [201, 213], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [45, 48]}], "umls_entity_list": []}, {"text": "Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.", "entity_list": [{"name": "desipramine", "ent_type": "Chemical", "char_span": [248, 259], "ent_id": "D003891", "tok_span": [52, 56]}, {"name": "headache", "ent_type": "Disease", "char_span": [186, 194], "ent_id": "D006261", "tok_span": [42, 43]}, {"name": "cinacalcet", "ent_type": "Chemical", "char_span": [263, 273], "ent_id": "C476217", "tok_span": [57, 62]}, {"name": "desipramine", "ent_type": "Chemical", "char_span": [64, 75], "ent_id": "D003891", "tok_span": [9, 13]}, {"name": "cinacalcet", "ent_type": "Chemical", "char_span": [119, 129], "ent_id": "C476217", "tok_span": [22, 27]}, {"name": "nausea", "ent_type": "Disease", "char_span": [175, 181], "ent_id": "D009325", "tok_span": [40, 41]}, {"name": "desipramine", "ent_type": "Chemical", "char_span": [102, 113], "ent_id": "D003891", "tok_span": [17, 21]}], "relation_list": [{"subject": "desipramine", "object": "headache", "sbj_char_span": [64, 75], "obj_char_span": [186, 194], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [42, 43]}, {"subject": "desipramine", "object": "headache", "sbj_char_span": [102, 113], "obj_char_span": [186, 194], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [42, 43]}, {"subject": "cinacalcet", "object": "headache", "sbj_char_span": [119, 129], "obj_char_span": [186, 194], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 27], "obj_tok_span": [42, 43]}, {"subject": "cinacalcet", "object": "headache", "sbj_char_span": [263, 273], "obj_char_span": [186, 194], "rel_type": "chemical-induced disease", "sbj_tok_span": [57, 62], "obj_tok_span": [42, 43]}, {"subject": "desipramine", "object": "nausea", "sbj_char_span": [64, 75], "obj_char_span": [175, 181], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [40, 41]}, {"subject": "desipramine", "object": "nausea", "sbj_char_span": [248, 259], "obj_char_span": [175, 181], "rel_type": "chemical-induced disease", "sbj_tok_span": [52, 56], "obj_tok_span": [40, 41]}, {"subject": "cinacalcet", "object": "nausea", "sbj_char_span": [119, 129], "obj_char_span": [175, 181], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 27], "obj_tok_span": [40, 41]}, {"subject": "cinacalcet", "object": "nausea", "sbj_char_span": [263, 273], "obj_char_span": [175, 181], "rel_type": "chemical-induced disease", "sbj_tok_span": [57, 62], "obj_tok_span": [40, 41]}, {"subject": "desipramine", "object": "nausea", "sbj_char_span": [102, 113], "obj_char_span": [175, 181], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [40, 41]}, {"subject": "desipramine", "object": "headache", "sbj_char_span": [248, 259], "obj_char_span": [186, 194], "rel_type": "chemical-induced disease", "sbj_tok_span": [52, 56], "obj_tok_span": [42, 43]}], "umls_entity_list": []}, {"text": "Proteomic analysis of striatal proteins in the rat model of L-DOPA-induced dyskinesia.", "entity_list": [{"name": "L-DOPA", "ent_type": "Chemical", "char_span": [60, 66], "ent_id": "D007980", "tok_span": [11, 15]}, {"name": "dyskinesia", "ent_type": "Disease", "char_span": [75, 85], "ent_id": "D004409", "tok_span": [17, 21]}], "relation_list": [{"subject": "L-DOPA", "object": "dyskinesia", "sbj_char_span": [60, 66], "obj_char_span": [75, 85], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [17, 21]}], "umls_entity_list": []}, {"text": "L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA.", "entity_list": [{"name": "dyskinesia", "ent_type": "Disease", "char_span": [15, 25], "ent_id": "D004409", "tok_span": [6, 10]}, {"name": "PD", "ent_type": "Disease", "char_span": [100, 102], "ent_id": "D010300", "tok_span": [27, 28]}, {"name": "L-DOPA", "ent_type": "Chemical", "char_span": [146, 152], "ent_id": "D007980", "tok_span": [35, 39]}, {"name": "Parkinson's disease", "ent_type": "Disease", "char_span": [79, 98], "ent_id": "D010300", "tok_span": [22, 26]}, {"name": "L-DOPA", "ent_type": "Chemical", "char_span": [0, 6], "ent_id": "D007980", "tok_span": [0, 4]}, {"name": "LID", "ent_type": "Disease", "char_span": [27, 30], "ent_id": "D004409", "tok_span": [11, 13]}], "relation_list": [{"subject": "L-DOPA", "object": "dyskinesia", "sbj_char_span": [0, 6], "obj_char_span": [15, 25], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [6, 10]}, {"subject": "L-DOPA", "object": "LID", "sbj_char_span": [0, 6], "obj_char_span": [27, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [11, 13]}, {"subject": "L-DOPA", "object": "LID", "sbj_char_span": [146, 152], "obj_char_span": [27, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 39], "obj_tok_span": [11, 13]}, {"subject": "L-DOPA", "object": "dyskinesia", "sbj_char_span": [146, 152], "obj_char_span": [15, 25], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 39], "obj_tok_span": [6, 10]}], "umls_entity_list": []}, {"text": "Rats treated with L-DOPA were allocated to two groups based on the presence or absence of LID.", "entity_list": [{"name": "LID", "ent_type": "Disease", "char_span": [90, 93], "ent_id": "D004409", "tok_span": [19, 21]}, {"name": "L-DOPA", "ent_type": "Chemical", "char_span": [18, 24], "ent_id": "D007980", "tok_span": [3, 7]}], "relation_list": [{"subject": "L-DOPA", "object": "LID", "sbj_char_span": [18, 24], "obj_char_span": [90, 93], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 7], "obj_tok_span": [19, 21]}], "umls_entity_list": []}, {"text": "Valproic acid induced encephalopathy--19 new cases in Germany from 1994 to 2003--a side effect associated to VPA-therapy not only in young children.", "entity_list": [{"name": "VPA", "ent_type": "Chemical", "char_span": [109, 112], "ent_id": "D014635", "tok_span": [25, 27]}, {"name": "Valproic acid", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D014635", "tok_span": [0, 4]}, {"name": "encephalopathy", "ent_type": "Disease", "char_span": [22, 36], "ent_id": "D001927", "tok_span": [5, 7]}], "relation_list": [{"subject": "Valproic acid", "object": "encephalopathy", "sbj_char_span": [0, 13], "obj_char_span": [22, 36], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [5, 7]}, {"subject": "VPA", "object": "encephalopathy", "sbj_char_span": [109, 112], "obj_char_span": [22, 36], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 27], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and VPA-induced encephalopathy.", "entity_list": [{"name": "VPA", "ent_type": "Chemical", "char_span": [148, 151], "ent_id": "D014635", "tok_span": [26, 28]}, {"name": "bone marrow suppression", "ent_type": "Disease", "char_span": [92, 115], "ent_id": "D001855", "tok_span": [15, 18]}, {"name": "pancreatitis", "ent_type": "Disease", "char_span": [78, 90], "ent_id": "D010195", "tok_span": [13, 14]}, {"name": "hepatotoxicity", "ent_type": "Disease", "char_span": [129, 143], "ent_id": "D056486", "tok_span": [23, 25]}, {"name": "VPA", "ent_type": "Chemical", "char_span": [117, 120], "ent_id": "D014635", "tok_span": [19, 21]}, {"name": "encephalopathy", "ent_type": "Disease", "char_span": [160, 174], "ent_id": "D001927", "tok_span": [30, 32]}], "relation_list": [{"subject": "VPA", "object": "pancreatitis", "sbj_char_span": [117, 120], "obj_char_span": [78, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 21], "obj_tok_span": [13, 14]}, {"subject": "VPA", "object": "bone marrow suppression", "sbj_char_span": [148, 151], "obj_char_span": [92, 115], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 28], "obj_tok_span": [15, 18]}, {"subject": "VPA", "object": "hepatotoxicity", "sbj_char_span": [148, 151], "obj_char_span": [129, 143], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 28], "obj_tok_span": [23, 25]}, {"subject": "VPA", "object": "bone marrow suppression", "sbj_char_span": [117, 120], "obj_char_span": [92, 115], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 21], "obj_tok_span": [15, 18]}, {"subject": "VPA", "object": "encephalopathy", "sbj_char_span": [148, 151], "obj_char_span": [160, 174], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 28], "obj_tok_span": [30, 32]}, {"subject": "VPA", "object": "hepatotoxicity", "sbj_char_span": [117, 120], "obj_char_span": [129, 143], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 21], "obj_tok_span": [23, 25]}, {"subject": "VPA", "object": "pancreatitis", "sbj_char_span": [148, 151], "obj_char_span": [78, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 28], "obj_tok_span": [13, 14]}, {"subject": "VPA", "object": "encephalopathy", "sbj_char_span": [117, 120], "obj_char_span": [160, 174], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 21], "obj_tok_span": [30, 32]}], "umls_entity_list": []}, {"text": "The typical signs of VPA-induced encephalopathy are impaired consciousness, sometimes marked EEG background slowing, increased seizure frequency, with or without hyperammonemia.", "entity_list": [{"name": "seizure", "ent_type": "Disease", "char_span": [127, 134], "ent_id": "D012640", "tok_span": [21, 22]}, {"name": "hyperammonemia", "ent_type": "Disease", "char_span": [162, 176], "ent_id": "D022124", "tok_span": [27, 31]}, {"name": "VPA", "ent_type": "Chemical", "char_span": [21, 24], "ent_id": "D014635", "tok_span": [4, 6]}, {"name": "encephalopathy", "ent_type": "Disease", "char_span": [33, 47], "ent_id": "D001927", "tok_span": [8, 10]}, {"name": "impaired consciousness", "ent_type": "Disease", "char_span": [52, 74], "ent_id": "D003244", "tok_span": [11, 13]}], "relation_list": [{"subject": "VPA", "object": "impaired consciousness", "sbj_char_span": [21, 24], "obj_char_span": [52, 74], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 6], "obj_tok_span": [11, 13]}, {"subject": "VPA", "object": "encephalopathy", "sbj_char_span": [21, 24], "obj_char_span": [33, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 6], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "There is still no proof of causative effect of VPA in patients with encephalopathy, but only of an association with an assumed causal relation.", "entity_list": [{"name": "encephalopathy", "ent_type": "Disease", "char_span": [68, 82], "ent_id": "D001927", "tok_span": [14, 16]}, {"name": "VPA", "ent_type": "Chemical", "char_span": [47, 50], "ent_id": "D014635", "tok_span": [9, 11]}], "relation_list": [{"subject": "VPA", "object": "encephalopathy", "sbj_char_span": [47, 50], "obj_char_span": [68, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 11], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "We report 19 patients with VPA-associated encephalopathy in Germany from the years 1994 to 2003, none of whom had been published previously.", "entity_list": [{"name": "encephalopathy", "ent_type": "Disease", "char_span": [42, 56], "ent_id": "D001927", "tok_span": [9, 11]}, {"name": "VPA", "ent_type": "Chemical", "char_span": [27, 30], "ent_id": "D014635", "tok_span": [5, 7]}], "relation_list": [{"subject": "VPA", "object": "encephalopathy", "sbj_char_span": [27, 30], "obj_char_span": [42, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 7], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "Haemolytic-uraemic syndrome after treatment with metronidazole.", "entity_list": [{"name": "Haemolytic-uraemic syndrome", "ent_type": "Disease", "char_span": [0, 27], "ent_id": "D006463", "tok_span": [0, 7]}, {"name": "metronidazole", "ent_type": "Chemical", "char_span": [49, 62], "ent_id": "D008795", "tok_span": [10, 15]}], "relation_list": [{"subject": "metronidazole", "object": "Haemolytic-uraemic syndrome", "sbj_char_span": [49, 62], "obj_char_span": [0, 27], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 15], "obj_tok_span": [0, 7]}], "umls_entity_list": []}, {"text": "This paper describes the clinical features of six children who developed the haemolytic-uraemic syndrome after treatment with metronidazole.", "entity_list": [{"name": "haemolytic-uraemic syndrome", "ent_type": "Disease", "char_span": [77, 104], "ent_id": "D006463", "tok_span": [12, 19]}, {"name": "metronidazole", "ent_type": "Chemical", "char_span": [126, 139], "ent_id": "D008795", "tok_span": [22, 27]}], "relation_list": [{"subject": "metronidazole", "object": "haemolytic-uraemic syndrome", "sbj_char_span": [126, 139], "obj_char_span": [77, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 27], "obj_tok_span": [12, 19]}], "umls_entity_list": []}, {"text": "While the involvement of metronidazole in the aetiology of the haemolytic-uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic-uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic-uraemic syndrome.", "entity_list": [{"name": "metronidazole", "ent_type": "Chemical", "char_span": [25, 38], "ent_id": "D008795", "tok_span": [4, 9]}, {"name": "haemolytic-uraemic syndrome", "ent_type": "Disease", "char_span": [63, 90], "ent_id": "D006463", "tok_span": [15, 22]}, {"name": "metronidazole", "ent_type": "Chemical", "char_span": [299, 312], "ent_id": "D008795", "tok_span": [61, 66]}, {"name": "haemolytic-uraemic syndrome", "ent_type": "Disease", "char_span": [345, 372], "ent_id": "D006463", "tok_span": [72, 79]}, {"name": "haemolytic-uraemic syndrome", "ent_type": "Disease", "char_span": [239, 266], "ent_id": "D006463", "tok_span": [49, 56]}], "relation_list": [{"subject": "metronidazole", "object": "haemolytic-uraemic syndrome", "sbj_char_span": [25, 38], "obj_char_span": [63, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 9], "obj_tok_span": [15, 22]}, {"subject": "metronidazole", "object": "haemolytic-uraemic syndrome", "sbj_char_span": [25, 38], "obj_char_span": [345, 372], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 9], "obj_tok_span": [72, 79]}, {"subject": "metronidazole", "object": "haemolytic-uraemic syndrome", "sbj_char_span": [25, 38], "obj_char_span": [239, 266], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 9], "obj_tok_span": [49, 56]}, {"subject": "metronidazole", "object": "haemolytic-uraemic syndrome", "sbj_char_span": [299, 312], "obj_char_span": [63, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [61, 66], "obj_tok_span": [15, 22]}, {"subject": "metronidazole", "object": "haemolytic-uraemic syndrome", "sbj_char_span": [299, 312], "obj_char_span": [239, 266], "rel_type": "chemical-induced disease", "sbj_tok_span": [61, 66], "obj_tok_span": [49, 56]}, {"subject": "metronidazole", "object": "haemolytic-uraemic syndrome", "sbj_char_span": [299, 312], "obj_char_span": [345, 372], "rel_type": "chemical-induced disease", "sbj_tok_span": [61, 66], "obj_tok_span": [72, 79]}], "umls_entity_list": []}, {"text": "Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion.\n 15 cases of cimetidine-associated mental confusion have been reported", "entity_list": [{"name": "cimetidine", "ent_type": "Chemical", "char_span": [107, 117], "ent_id": "D002927", "tok_span": [20, 23]}, {"name": "confusion", "ent_type": "Disease", "char_span": [136, 145], "ent_id": "D003221", "tok_span": [26, 27]}, {"name": "cimetidine", "ent_type": "Chemical", "char_span": [54, 64], "ent_id": "D002927", "tok_span": [9, 12]}, {"name": "confusion", "ent_type": "Disease", "char_span": [83, 92], "ent_id": "D003221", "tok_span": [15, 16]}], "relation_list": [{"subject": "cimetidine", "object": "confusion", "sbj_char_span": [107, 117], "obj_char_span": [83, 92], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [15, 16]}, {"subject": "cimetidine", "object": "confusion", "sbj_char_span": [54, 64], "obj_char_span": [83, 92], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [15, 16]}, {"subject": "cimetidine", "object": "confusion", "sbj_char_span": [107, 117], "obj_char_span": [136, 145], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [26, 27]}, {"subject": "cimetidine", "object": "confusion", "sbj_char_span": [54, 64], "obj_char_span": [136, 145], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [26, 27]}], "umls_entity_list": []}, {"text": "We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.", "entity_list": [{"name": "EE", "ent_type": "Chemical", "char_span": [69, 71], "ent_id": "D004997", "tok_span": [16, 17]}, {"name": "intrahepatic cholestasis", "ent_type": "Disease", "char_span": [22, 46], "ent_id": "D002780", "tok_span": [5, 10]}, {"name": "ethinyl estradiol", "ent_type": "Chemical", "char_span": [50, 67], "ent_id": "D004997", "tok_span": [11, 15]}, {"name": "extrahepatic cholestasis", "ent_type": "Disease", "char_span": [87, 111], "ent_id": "D001651", "tok_span": [20, 25]}], "relation_list": [{"subject": "EE", "object": "intrahepatic cholestasis", "sbj_char_span": [69, 71], "obj_char_span": [22, 46], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 17], "obj_tok_span": [5, 10]}, {"subject": "ethinyl estradiol", "object": "intrahepatic cholestasis", "sbj_char_span": [50, 67], "obj_char_span": [22, 46], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [5, 10]}], "umls_entity_list": []}, {"text": "Subjects with SNHL were submitted to DFO reduction or temporary withdrawal.", "entity_list": [{"name": "SNHL", "ent_type": "Disease", "char_span": [14, 18], "ent_id": "D006319", "tok_span": [2, 4]}, {"name": "DFO", "ent_type": "Chemical", "char_span": [37, 40], "ent_id": "D003676", "tok_span": [7, 9]}], "relation_list": [{"subject": "DFO", "object": "SNHL", "sbj_char_span": [37, 40], "obj_char_span": [14, 18], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 9], "obj_tok_span": [2, 4]}], "umls_entity_list": []}, {"text": "Since the introduction of angiotensin converting enzyme (ACE) inhibitors into the adjunctive treatment of patients with congestive heart failure, cases of severe hypotension, especially on the first day of treatment, have occasionally been reported.", "entity_list": [{"name": "congestive heart failure", "ent_type": "Disease", "char_span": [120, 144], "ent_id": "D006333", "tok_span": [19, 24]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [162, 173], "ent_id": "D007022", "tok_span": [28, 29]}, {"name": "angiotensin converting enzyme (ACE) inhibitors", "ent_type": "Chemical", "char_span": [26, 72], "ent_id": "D000806", "tok_span": [4, 11]}], "relation_list": [{"subject": "angiotensin converting enzyme (ACE) inhibitors", "object": "hypotension", "sbj_char_span": [26, 72], "obj_char_span": [162, 173], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 11], "obj_tok_span": [28, 29]}], "umls_entity_list": []}, {"text": "To assess the safety of the ACE inhibitor enalapril a multicenter, randomized, prazosin-controlled trial was designed that compared the incidence and severity of symptomatic hypotension on the first day of treatment.", "entity_list": [{"name": "hypotension", "ent_type": "Disease", "char_span": [174, 185], "ent_id": "D007022", "tok_span": [33, 34]}, {"name": "enalapril", "ent_type": "Chemical", "char_span": [42, 51], "ent_id": "D004656", "tok_span": [8, 12]}, {"name": "prazosin", "ent_type": "Chemical", "char_span": [79, 87], "ent_id": "D011224", "tok_span": [17, 20]}, {"name": "ACE inhibitor", "ent_type": "Chemical", "char_span": [28, 41], "ent_id": "D000806", "tok_span": [6, 8]}], "relation_list": [{"subject": "prazosin", "object": "hypotension", "sbj_char_span": [79, 87], "obj_char_span": [174, 185], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [33, 34]}, {"subject": "ACE inhibitor", "object": "hypotension", "sbj_char_span": [28, 41], "obj_char_span": [174, 185], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [33, 34]}], "umls_entity_list": []}, {"text": "Patients who received enalapril experienced clinically and statistically significantly less symptomatic hypotension (5.2%) than the patients who received prazosin (12.9%).", "entity_list": [{"name": "hypotension", "ent_type": "Disease", "char_span": [104, 115], "ent_id": "D007022", "tok_span": [14, 15]}, {"name": "enalapril", "ent_type": "Chemical", "char_span": [22, 31], "ent_id": "D004656", "tok_span": [3, 7]}, {"name": "prazosin", "ent_type": "Chemical", "char_span": [154, 162], "ent_id": "D011224", "tok_span": [26, 29]}], "relation_list": [{"subject": "prazosin", "object": "hypotension", "sbj_char_span": [154, 162], "obj_char_span": [104, 115], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 29], "obj_tok_span": [14, 15]}], "umls_entity_list": []}, {"text": "Antagonism between interleukin 3 and erythropoietin in mice with azidothymidine-induced anemia and in bone marrow endothelial cells.", "entity_list": [{"name": "anemia", "ent_type": "Disease", "char_span": [88, 94], "ent_id": "D000740", "tok_span": [21, 22]}, {"name": "azidothymidine", "ent_type": "Chemical", "char_span": [65, 79], "ent_id": "D015215", "tok_span": [14, 19]}], "relation_list": [{"subject": "azidothymidine", "object": "anemia", "sbj_char_span": [65, 79], "obj_char_span": [88, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 19], "obj_tok_span": [21, 22]}], "umls_entity_list": []}, {"text": "Azidothymidine (AZT)-induced anemia in mice can be reversed by the administration of IGF-IL-3 (fusion protein of insulin-like growth factor II (IGF II) and interleukin 3).", "entity_list": [{"name": "Azidothymidine", "ent_type": "Chemical", "char_span": [0, 14], "ent_id": "D015215", "tok_span": [0, 5]}, {"name": "anemia", "ent_type": "Disease", "char_span": [29, 35], "ent_id": "D000740", "tok_span": [11, 12]}, {"name": "AZT", "ent_type": "Chemical", "char_span": [16, 19], "ent_id": "D015215", "tok_span": [6, 8]}], "relation_list": [{"subject": "Azidothymidine", "object": "anemia", "sbj_char_span": [0, 14], "obj_char_span": [29, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [11, 12]}, {"subject": "AZT", "object": "anemia", "sbj_char_span": [16, 19], "obj_char_span": [29, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [11, 12]}], "umls_entity_list": []}, {"text": "Dose-dependent bradycardia induced by verapamil was potentiated by LNa, LCa, and HCa.", "entity_list": [{"name": "bradycardia", "ent_type": "Disease", "char_span": [15, 26], "ent_id": "D001919", "tok_span": [3, 7]}, {"name": "verapamil", "ent_type": "Chemical", "char_span": [38, 47], "ent_id": "D014700", "tok_span": [9, 12]}], "relation_list": [{"subject": "verapamil", "object": "bradycardia", "sbj_char_span": [38, 47], "obj_char_span": [15, 26], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "Sodium status influences chronic amphotericin B nephrotoxicity in rats.", "entity_list": [{"name": "nephrotoxicity", "ent_type": "Disease", "char_span": [48, 62], "ent_id": "D007674", "tok_span": [8, 11]}, {"name": "Sodium", "ent_type": "Chemical", "char_span": [0, 6], "ent_id": "D012964", "tok_span": [0, 1]}, {"name": "amphotericin B", "ent_type": "Chemical", "char_span": [33, 47], "ent_id": "D000666", "tok_span": [4, 8]}], "relation_list": [{"subject": "amphotericin B", "object": "nephrotoxicity", "sbj_char_span": [33, 47], "obj_char_span": [48, 62], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 8], "obj_tok_span": [8, 11]}], "umls_entity_list": []}, {"text": "The nephrotoxic potential of amphotericin B (5 mg/kg per day intraperitoneally for 3 weeks) has been investigated in salt-depleted, normal-salt, and salt-loaded rats.", "entity_list": [{"name": "nephrotoxic", "ent_type": "Disease", "char_span": [4, 15], "ent_id": "D007674", "tok_span": [1, 4]}, {"name": "amphotericin B", "ent_type": "Chemical", "char_span": [29, 43], "ent_id": "D000666", "tok_span": [6, 10]}], "relation_list": [{"subject": "amphotericin B", "object": "nephrotoxic", "sbj_char_span": [29, 43], "obj_char_span": [4, 15], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 10], "obj_tok_span": [1, 4]}], "umls_entity_list": []}, {"text": "Reversible inferior colliculus lesion in metronidazole-induced encephalopathy: magnetic resonance findings on diffusion-weighted and fluid attenuated inversion recovery imaging.", "entity_list": [{"name": "inferior colliculus lesion", "ent_type": "Disease", "char_span": [11, 37], "ent_id": "D001927", "tok_span": [2, 7]}, {"name": "encephalopathy", "ent_type": "Disease", "char_span": [63, 77], "ent_id": "D001927", "tok_span": [15, 17]}, {"name": "metronidazole", "ent_type": "Chemical", "char_span": [41, 54], "ent_id": "D008795", "tok_span": [8, 13]}], "relation_list": [{"subject": "metronidazole", "object": "encephalopathy", "sbj_char_span": [41, 54], "obj_char_span": [63, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 13], "obj_tok_span": [15, 17]}, {"subject": "metronidazole", "object": "inferior colliculus lesion", "sbj_char_span": [41, 54], "obj_char_span": [11, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 13], "obj_tok_span": [2, 7]}], "umls_entity_list": []}, {"text": "OBJECTIVE: This is to present reversible inferior colliculus lesions in metronidazole-induced encephalopathy, to focus on the diffusion-weighted imaging (DWI) and fluid attenuated inversion recovery (FLAIR) imaging.", "entity_list": [{"name": "metronidazole", "ent_type": "Chemical", "char_span": [72, 85], "ent_id": "D008795", "tok_span": [13, 18]}, {"name": "inferior colliculus lesions", "ent_type": "Disease", "char_span": [41, 68], "ent_id": "D001927", "tok_span": [7, 12]}, {"name": "encephalopathy", "ent_type": "Disease", "char_span": [94, 108], "ent_id": "D001927", "tok_span": [20, 22]}], "relation_list": [{"subject": "metronidazole", "object": "inferior colliculus lesions", "sbj_char_span": [72, 85], "obj_char_span": [41, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 18], "obj_tok_span": [7, 12]}, {"subject": "metronidazole", "object": "encephalopathy", "sbj_char_span": [72, 85], "obj_char_span": [94, 108], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 18], "obj_tok_span": [20, 22]}], "umls_entity_list": []}, {"text": "MATERIALS AND METHODS: From November 2005 to September 2007, 8 patients (5 men and 3 women) were diagnosed as having metronidazole-induced encephalopathy (age range; 43-78 years).", "entity_list": [{"name": "metronidazole", "ent_type": "Chemical", "char_span": [117, 130], "ent_id": "D008795", "tok_span": [24, 29]}, {"name": "encephalopathy", "ent_type": "Disease", "char_span": [139, 153], "ent_id": "D001927", "tok_span": [31, 33]}], "relation_list": [{"subject": "metronidazole", "object": "encephalopathy", "sbj_char_span": [117, 130], "obj_char_span": [139, 153], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 29], "obj_tok_span": [31, 33]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Reversible inferior colliculus lesions could be considered as the characteristic for metronidazole-induced encephalopathy, next to the dentate nucleus involvement.", "entity_list": [{"name": "encephalopathy", "ent_type": "Disease", "char_span": [120, 134], "ent_id": "D001927", "tok_span": [23, 25]}, {"name": "metronidazole", "ent_type": "Chemical", "char_span": [98, 111], "ent_id": "D008795", "tok_span": [16, 21]}, {"name": "inferior colliculus lesions", "ent_type": "Disease", "char_span": [24, 51], "ent_id": "D001927", "tok_span": [4, 9]}], "relation_list": [{"subject": "metronidazole", "object": "encephalopathy", "sbj_char_span": [98, 111], "obj_char_span": [120, 134], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 21], "obj_tok_span": [23, 25]}, {"subject": "metronidazole", "object": "inferior colliculus lesions", "sbj_char_span": [98, 111], "obj_char_span": [24, 51], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 21], "obj_tok_span": [4, 9]}], "umls_entity_list": []}, {"text": "There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the morphine infusion group.", "entity_list": [{"name": "ventricular ectopic beats", "ent_type": "Disease", "char_span": [77, 102], "ent_id": "D018879", "tok_span": [21, 24]}, {"name": "tachyarrhythmias", "ent_type": "Disease", "char_span": [37, 53], "ent_id": "D013610", "tok_span": [7, 12]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [129, 137], "ent_id": "D009020", "tok_span": [34, 35]}], "relation_list": [{"subject": "morphine", "object": "ventricular ectopic beats", "sbj_char_span": [129, 137], "obj_char_span": [77, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 35], "obj_tok_span": [21, 24]}], "umls_entity_list": []}, {"text": "Magnetic resonance volumetry of the cerebellum in epileptic patients after phenytoin overdosages.", "entity_list": [{"name": "phenytoin", "ent_type": "Chemical", "char_span": [75, 84], "ent_id": "D010672", "tok_span": [11, 14]}, {"name": "overdosages", "ent_type": "Disease", "char_span": [85, 96], "ent_id": "D062787", "tok_span": [14, 18]}, {"name": "epileptic", "ent_type": "Disease", "char_span": [50, 59], "ent_id": "D004827", "tok_span": [8, 9]}], "relation_list": [{"subject": "phenytoin", "object": "overdosages", "sbj_char_span": [75, 84], "obj_char_span": [85, 96], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [14, 18]}], "umls_entity_list": []}, {"text": "We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.", "entity_list": [{"name": "phenytoin", "ent_type": "Chemical", "char_span": [112, 121], "ent_id": "D010672", "tok_span": [21, 24]}, {"name": "overdosage", "ent_type": "Disease", "char_span": [27, 37], "ent_id": "D062787", "tok_span": [6, 9]}, {"name": "phenytoin", "ent_type": "Chemical", "char_span": [17, 26], "ent_id": "D010672", "tok_span": [3, 6]}, {"name": "cerebellar atrophy", "ent_type": "Disease", "char_span": [69, 87], "ent_id": "D002526", "tok_span": [14, 16]}, {"name": "cerebellar atrophy", "ent_type": "Disease", "char_span": [155, 173], "ent_id": "D002526", "tok_span": [30, 32]}], "relation_list": [{"subject": "phenytoin", "object": "overdosage", "sbj_char_span": [112, 121], "obj_char_span": [27, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [6, 9]}, {"subject": "phenytoin", "object": "overdosage", "sbj_char_span": [17, 26], "obj_char_span": [27, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [6, 9]}], "umls_entity_list": []}, {"text": "Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings.", "entity_list": [{"name": "cardiomyopathy", "ent_type": "Disease", "char_span": [101, 115], "ent_id": "D009202", "tok_span": [18, 19]}, {"name": "myocardial damage", "ent_type": "Disease", "char_span": [60, 77], "ent_id": "D009202", "tok_span": [12, 14]}, {"name": "doxorubicin", "ent_type": "Chemical", "char_span": [81, 92], "ent_id": "D004317", "tok_span": [15, 16]}], "relation_list": [{"subject": "doxorubicin", "object": "cardiomyopathy", "sbj_char_span": [81, 92], "obj_char_span": [101, 115], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 16], "obj_tok_span": [18, 19]}, {"subject": "doxorubicin", "object": "myocardial damage", "sbj_char_span": [81, 92], "obj_char_span": [60, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 16], "obj_tok_span": [12, 14]}], "umls_entity_list": []}, {"text": "We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.", "entity_list": [{"name": "cardiac disorders", "ent_type": "Disease", "char_span": [239, 256], "ent_id": "D006331", "tok_span": [50, 52]}, {"name": "doxorubicin", "ent_type": "Chemical", "char_span": [111, 122], "ent_id": "D004317", "tok_span": [24, 25]}, {"name": "cardiomyopathy", "ent_type": "Disease", "char_span": [137, 151], "ent_id": "D009202", "tok_span": [30, 31]}, {"name": "DOX", "ent_type": "Chemical", "char_span": [124, 127], "ent_id": "D004317", "tok_span": [26, 27]}, {"name": "myocardial damage", "ent_type": "Disease", "char_span": [75, 92], "ent_id": "D009202", "tok_span": [17, 19]}], "relation_list": [{"subject": "doxorubicin", "object": "myocardial damage", "sbj_char_span": [111, 122], "obj_char_span": [75, 92], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 25], "obj_tok_span": [17, 19]}, {"subject": "doxorubicin", "object": "cardiomyopathy", "sbj_char_span": [111, 122], "obj_char_span": [137, 151], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 25], "obj_tok_span": [30, 31]}, {"subject": "DOX", "object": "myocardial damage", "sbj_char_span": [124, 127], "obj_char_span": [75, 92], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 27], "obj_tok_span": [17, 19]}, {"subject": "DOX", "object": "cardiomyopathy", "sbj_char_span": [124, 127], "obj_char_span": [137, 151], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 27], "obj_tok_span": [30, 31]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Among markers of ischemic injury after DOX in rats, cTnT showed the greatest ability to detect myocardial damage assessed by echocardiographic detection and histological changes.", "entity_list": [{"name": "myocardial damage", "ent_type": "Disease", "char_span": [108, 125], "ent_id": "D009202", "tok_span": [21, 23]}, {"name": "DOX", "ent_type": "Chemical", "char_span": [52, 55], "ent_id": "D004317", "tok_span": [8, 9]}, {"name": "ischemic injury", "ent_type": "Disease", "char_span": [30, 45], "ent_id": "D017202", "tok_span": [5, 7]}], "relation_list": [{"subject": "DOX", "object": "myocardial damage", "sbj_char_span": [52, 55], "obj_char_span": [108, 125], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "The reduction of cyclosporine- or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain.", "entity_list": [{"name": "pain", "ent_type": "Disease", "char_span": [127, 131], "ent_id": "D010146", "tok_span": [22, 23]}, {"name": "tacrolimus", "ent_type": "Chemical", "char_span": [34, 44], "ent_id": "D016559", "tok_span": [7, 9]}, {"name": "cyclosporine", "ent_type": "Chemical", "char_span": [17, 29], "ent_id": "D016572", "tok_span": [3, 5]}, {"name": "calcium", "ent_type": "Chemical", "char_span": [85, 92], "ent_id": "D002118", "tok_span": [15, 16]}], "relation_list": [{"subject": "cyclosporine", "object": "pain", "sbj_char_span": [17, 29], "obj_char_span": [127, 131], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 5], "obj_tok_span": [22, 23]}, {"subject": "tacrolimus", "object": "pain", "sbj_char_span": [34, 44], "obj_char_span": [127, 131], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 9], "obj_tok_span": [22, 23]}], "umls_entity_list": []}, {"text": "The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.", "entity_list": [{"name": "tacrolimus", "ent_type": "Chemical", "char_span": [107, 117], "ent_id": "D016559", "tok_span": [25, 27]}, {"name": "cyclosporine", "ent_type": "Chemical", "char_span": [91, 103], "ent_id": "D016572", "tok_span": [22, 24]}, {"name": "CIPS", "ent_type": "Disease", "char_span": [49, 53], "ent_id": "-1", "tok_span": [11, 13]}, {"name": "Pain", "ent_type": "Disease", "char_span": [34, 38], "ent_id": "D010146", "tok_span": [8, 9]}], "relation_list": [{"subject": "cyclosporine", "object": "Pain", "sbj_char_span": [91, 103], "obj_char_span": [34, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 24], "obj_tok_span": [8, 9]}, {"subject": "tacrolimus", "object": "Pain", "sbj_char_span": [107, 117], "obj_char_span": [34, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 27], "obj_tok_span": [8, 9]}], "umls_entity_list": []}, {"text": "We investigated the safety and efficacy of adding different doses of ephedrine to propofol in order to obtund the hypotensive response.", "entity_list": [{"name": "hypotensive", "ent_type": "Disease", "char_span": [114, 125], "ent_id": "D007022", "tok_span": [24, 26]}, {"name": "ephedrine", "ent_type": "Chemical", "char_span": [69, 78], "ent_id": "D004809", "tok_span": [11, 14]}, {"name": "propofol", "ent_type": "Chemical", "char_span": [82, 90], "ent_id": "D015742", "tok_span": [15, 17]}], "relation_list": [{"subject": "propofol", "object": "hypotensive", "sbj_char_span": [82, 90], "obj_char_span": [114, 125], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 17], "obj_tok_span": [24, 26]}], "umls_entity_list": []}, {"text": "The addition of ephedrine to propofol appears to be an effective method of obtunding the hypotensive response to propofol at all doses used in this study.", "entity_list": [{"name": "ephedrine", "ent_type": "Chemical", "char_span": [16, 25], "ent_id": "D004809", "tok_span": [3, 6]}, {"name": "propofol", "ent_type": "Chemical", "char_span": [113, 121], "ent_id": "D015742", "tok_span": [25, 27]}, {"name": "propofol", "ent_type": "Chemical", "char_span": [29, 37], "ent_id": "D015742", "tok_span": [7, 9]}, {"name": "hypotensive", "ent_type": "Disease", "char_span": [89, 100], "ent_id": "D007022", "tok_span": [21, 23]}], "relation_list": [{"subject": "propofol", "object": "hypotensive", "sbj_char_span": [113, 121], "obj_char_span": [89, 100], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 27], "obj_tok_span": [21, 23]}, {"subject": "propofol", "object": "hypotensive", "sbj_char_span": [29, 37], "obj_char_span": [89, 100], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 9], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "However, marked tachycardia associated with the use of ephedrine in combination with propofol occurred in the majority of patients, occasionally reaching high levels in individual patients.", "entity_list": [{"name": "tachycardia", "ent_type": "Disease", "char_span": [16, 27], "ent_id": "D013610", "tok_span": [3, 4]}, {"name": "propofol", "ent_type": "Chemical", "char_span": [85, 93], "ent_id": "D015742", "tok_span": [15, 17]}, {"name": "ephedrine", "ent_type": "Chemical", "char_span": [55, 64], "ent_id": "D004809", "tok_span": [9, 12]}], "relation_list": [{"subject": "propofol", "object": "tachycardia", "sbj_char_span": [85, 93], "obj_char_span": [16, 27], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 17], "obj_tok_span": [3, 4]}, {"subject": "ephedrine", "object": "tachycardia", "sbj_char_span": [55, 64], "obj_char_span": [16, 27], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [3, 4]}], "umls_entity_list": []}, {"text": "Due to the risk of this tachycardia inducing myocardial ischemia, we would not recommend the use in elderly patients of any of the ephedrine/propofol/mixtures studied.", "entity_list": [{"name": "propofol", "ent_type": "Chemical", "char_span": [141, 149], "ent_id": "D015742", "tok_span": [28, 30]}, {"name": "myocardial ischemia", "ent_type": "Disease", "char_span": [45, 64], "ent_id": "D017202", "tok_span": [8, 10]}, {"name": "tachycardia", "ent_type": "Disease", "char_span": [24, 35], "ent_id": "D013610", "tok_span": [6, 7]}, {"name": "ephedrine", "ent_type": "Chemical", "char_span": [131, 140], "ent_id": "D004809", "tok_span": [24, 27]}], "relation_list": [{"subject": "propofol", "object": "tachycardia", "sbj_char_span": [141, 149], "obj_char_span": [24, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 30], "obj_tok_span": [6, 7]}, {"subject": "ephedrine", "object": "tachycardia", "sbj_char_span": [131, 140], "obj_char_span": [24, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 27], "obj_tok_span": [6, 7]}], "umls_entity_list": []}, {"text": "In six of the probable cases the neurological disturbance consisted of an acute reversible encephalopathy usually related to the ingestion of a high dose of clioquinol over a short period.", "entity_list": [{"name": "clioquinol", "ent_type": "Chemical", "char_span": [157, 167], "ent_id": "D007464", "tok_span": [26, 30]}, {"name": "encephalopathy", "ent_type": "Disease", "char_span": [91, 105], "ent_id": "D001927", "tok_span": [14, 16]}, {"name": "neurological disturbance", "ent_type": "Disease", "char_span": [33, 57], "ent_id": "D009422", "tok_span": [7, 9]}], "relation_list": [{"subject": "clioquinol", "object": "encephalopathy", "sbj_char_span": [157, 167], "obj_char_span": [91, 105], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 30], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "We wanted to study whether tAMCA retains its convulsive action if incorporated into a FS.", "entity_list": [{"name": "tAMCA", "ent_type": "Chemical", "char_span": [27, 32], "ent_id": "D014148", "tok_span": [5, 8]}, {"name": "convulsive", "ent_type": "Disease", "char_span": [45, 55], "ent_id": "D012640", "tok_span": [10, 12]}], "relation_list": [{"subject": "tAMCA", "object": "convulsive", "sbj_char_span": [27, 32], "obj_char_span": [45, 55], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "FINDINGS: FS containing tAMCA caused paroxysmal brain activity which was associated with distinct convulsive behaviours.", "entity_list": [{"name": "convulsive", "ent_type": "Disease", "char_span": [98, 108], "ent_id": "D012640", "tok_span": [21, 23]}, {"name": "tAMCA", "ent_type": "Chemical", "char_span": [24, 29], "ent_id": "D014148", "tok_span": [6, 9]}], "relation_list": [{"subject": "tAMCA", "object": "convulsive", "sbj_char_span": [24, 29], "obj_char_span": [98, 108], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "The degree of these seizures increased with increasing concentration of tAMCA.", "entity_list": [{"name": "tAMCA", "ent_type": "Chemical", "char_span": [72, 77], "ent_id": "D014148", "tok_span": [10, 13]}, {"name": "seizures", "ent_type": "Disease", "char_span": [20, 28], "ent_id": "D012640", "tok_span": [4, 5]}], "relation_list": [{"subject": "tAMCA", "object": "seizures", "sbj_char_span": [72, 77], "obj_char_span": [20, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [4, 5]}], "umls_entity_list": []}, {"text": "Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.", "entity_list": [{"name": "tAMCA", "ent_type": "Chemical", "char_span": [31, 36], "ent_id": "D014148", "tok_span": [10, 13]}, {"name": "generalized seizures", "ent_type": "Disease", "char_span": [44, 64], "ent_id": "D012640", "tok_span": [14, 16]}, {"name": "tAMCA", "ent_type": "Chemical", "char_span": [124, 129], "ent_id": "D014148", "tok_span": [30, 33]}, {"name": "convulsive", "ent_type": "Disease", "char_span": [188, 198], "ent_id": "D012640", "tok_span": [50, 52]}], "relation_list": [{"subject": "tAMCA", "object": "convulsive", "sbj_char_span": [124, 129], "obj_char_span": [188, 198], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 33], "obj_tok_span": [50, 52]}, {"subject": "tAMCA", "object": "generalized seizures", "sbj_char_span": [124, 129], "obj_char_span": [44, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 33], "obj_tok_span": [14, 16]}, {"subject": "tAMCA", "object": "generalized seizures", "sbj_char_span": [31, 36], "obj_char_span": [44, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [14, 16]}, {"subject": "tAMCA", "object": "convulsive", "sbj_char_span": [31, 36], "obj_char_span": [188, 198], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [50, 52]}], "umls_entity_list": []}, {"text": "INTERPRETATION: Tranexamic acid retains its convulsive action within FS.", "entity_list": [{"name": "convulsive", "ent_type": "Disease", "char_span": [44, 54], "ent_id": "D012640", "tok_span": [11, 13]}, {"name": "Tranexamic acid", "ent_type": "Chemical", "char_span": [16, 31], "ent_id": "D014148", "tok_span": [5, 9]}], "relation_list": [{"subject": "Tranexamic acid", "object": "convulsive", "sbj_char_span": [16, 31], "obj_char_span": [44, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [11, 13]}], "umls_entity_list": []}, {"text": "A diet promoting sugar dependency causes behavioral cross-sensitization to a low dose of amphetamine.", "entity_list": [{"name": "amphetamine", "ent_type": "Chemical", "char_span": [89, 100], "ent_id": "D000661", "tok_span": [15, 19]}, {"name": "behavioral cross-sensitization", "ent_type": "Disease", "char_span": [41, 71], "ent_id": "D006948", "tok_span": [6, 10]}, {"name": "sugar dependency", "ent_type": "Disease", "char_span": [17, 33], "ent_id": "D019966", "tok_span": [3, 5]}], "relation_list": [{"subject": "amphetamine", "object": "behavioral cross-sensitization", "sbj_char_span": [89, 100], "obj_char_span": [41, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 19], "obj_tok_span": [6, 10]}], "umls_entity_list": []}, {"text": "The present study examined whether female rats on various regimens of sugar access would show behavioral cross-sensitization to a low dose of amphetamine.", "entity_list": [{"name": "amphetamine", "ent_type": "Chemical", "char_span": [142, 153], "ent_id": "D000661", "tok_span": [24, 28]}, {"name": "behavioral cross-sensitization", "ent_type": "Disease", "char_span": [94, 124], "ent_id": "D006948", "tok_span": [15, 19]}], "relation_list": [{"subject": "amphetamine", "object": "behavioral cross-sensitization", "sbj_char_span": [142, 153], "obj_char_span": [94, 124], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 28], "obj_tok_span": [15, 19]}], "umls_entity_list": []}, {"text": "The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).", "entity_list": [{"name": "sucrose", "ent_type": "Chemical", "char_span": [40, 47], "ent_id": "D013395", "tok_span": [6, 7]}, {"name": "amphetamine", "ent_type": "Chemical", "char_span": [227, 238], "ent_id": "D000661", "tok_span": [47, 51]}, {"name": "amphetamine", "ent_type": "Chemical", "char_span": [89, 100], "ent_id": "D000661", "tok_span": [16, 20]}, {"name": "amphetamine", "ent_type": "Chemical", "char_span": [180, 191], "ent_id": "D000661", "tok_span": [36, 40]}, {"name": "amphetamine", "ent_type": "Chemical", "char_span": [271, 282], "ent_id": "D000661", "tok_span": [58, 62]}, {"name": "sucrose", "ent_type": "Chemical", "char_span": [298, 305], "ent_id": "D013395", "tok_span": [67, 68]}, {"name": "hyperactive", "ent_type": "Disease", "char_span": [62, 73], "ent_id": "D006948", "tok_span": [11, 13]}, {"name": "sucrose", "ent_type": "Chemical", "char_span": [151, 158], "ent_id": "D013395", "tok_span": [30, 31]}], "relation_list": [{"subject": "sucrose", "object": "hyperactive", "sbj_char_span": [298, 305], "obj_char_span": [62, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [67, 68], "obj_tok_span": [11, 13]}, {"subject": "amphetamine", "object": "hyperactive", "sbj_char_span": [227, 238], "obj_char_span": [62, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [47, 51], "obj_tok_span": [11, 13]}, {"subject": "amphetamine", "object": "hyperactive", "sbj_char_span": [89, 100], "obj_char_span": [62, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 20], "obj_tok_span": [11, 13]}, {"subject": "sucrose", "object": "hyperactive", "sbj_char_span": [151, 158], "obj_char_span": [62, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 31], "obj_tok_span": [11, 13]}, {"subject": "amphetamine", "object": "hyperactive", "sbj_char_span": [180, 191], "obj_char_span": [62, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 40], "obj_tok_span": [11, 13]}, {"subject": "amphetamine", "object": "hyperactive", "sbj_char_span": [271, 282], "obj_char_span": [62, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [58, 62], "obj_tok_span": [11, 13]}, {"subject": "sucrose", "object": "hyperactive", "sbj_char_span": [40, 47], "obj_char_span": [62, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [11, 13]}], "umls_entity_list": []}, {"text": "D-penicillamine-induced angiopathy in rats.", "entity_list": [{"name": "angiopathy", "ent_type": "Disease", "char_span": [24, 34], "ent_id": "D001018", "tok_span": [9, 11]}, {"name": "D-penicillamine", "ent_type": "Chemical", "char_span": [0, 15], "ent_id": "D010396", "tok_span": [0, 7]}], "relation_list": [{"subject": "D-penicillamine", "object": "angiopathy", "sbj_char_span": [0, 15], "obj_char_span": [24, 34], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 7], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "On the other hand, BNP did not increase in the patients without heart failure given DNR, even at more than 700 mg/m(2).", "entity_list": [{"name": "DNR", "ent_type": "Chemical", "char_span": [84, 87], "ent_id": "D003630", "tok_span": [17, 19]}, {"name": "heart failure", "ent_type": "Disease", "char_span": [64, 77], "ent_id": "D006333", "tok_span": [14, 16]}], "relation_list": [{"subject": "DNR", "object": "heart failure", "sbj_char_span": [84, 87], "obj_char_span": [64, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 19], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).", "entity_list": [{"name": "choanal atresia", "ent_type": "Disease", "char_span": [229, 244], "ent_id": "D002754", "tok_span": [92, 97]}, {"name": "diaphragmatic hernia", "ent_type": "Disease", "char_span": [337, 357], "ent_id": "D006548", "tok_span": [143, 146]}, {"name": "anencephaly", "ent_type": "Disease", "char_span": [34, 45], "ent_id": "D000757", "tok_span": [7, 10]}, {"name": "coarctation of the aorta", "ent_type": "Disease", "char_span": [174, 198], "ent_id": "D001017", "tok_span": [65, 71]}, {"name": "transverse limb deficiency", "ent_type": "Disease", "char_span": [276, 302], "ent_id": "D017880", "tok_span": [118, 121]}, {"name": "hypoplastic left heart syndrome", "ent_type": "Disease", "char_span": [112, 143], "ent_id": "D018636", "tok_span": [39, 44]}, {"name": "Sulfonamides", "ent_type": "Chemical", "char_span": [0, 12], "ent_id": "D013449", "tok_span": [0, 4]}], "relation_list": [{"subject": "Sulfonamides", "object": "transverse limb deficiency", "sbj_char_span": [0, 12], "obj_char_span": [276, 302], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [118, 121]}, {"subject": "Sulfonamides", "object": "hypoplastic left heart syndrome", "sbj_char_span": [0, 12], "obj_char_span": [112, 143], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [39, 44]}, {"subject": "Sulfonamides", "object": "anencephaly", "sbj_char_span": [0, 12], "obj_char_span": [34, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [7, 10]}, {"subject": "Sulfonamides", "object": "coarctation of the aorta", "sbj_char_span": [0, 12], "obj_char_span": [174, 198], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [65, 71]}, {"subject": "Sulfonamides", "object": "diaphragmatic hernia", "sbj_char_span": [0, 12], "obj_char_span": [337, 357], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [143, 146]}, {"subject": "Sulfonamides", "object": "choanal atresia", "sbj_char_span": [0, 12], "obj_char_span": [229, 244], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [92, 97]}], "umls_entity_list": []}, {"text": "Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).", "entity_list": [{"name": "microphthalmos", "ent_type": "Disease", "char_span": [53, 67], "ent_id": "D008850", "tok_span": [13, 17]}, {"name": "hypoplastic left heart syndrome", "ent_type": "Disease", "char_span": [99, 130], "ent_id": "D018636", "tok_span": [38, 43]}, {"name": "cleft palate", "ent_type": "Disease", "char_span": [232, 244], "ent_id": "D002972", "tok_span": [92, 95]}, {"name": "cleft lip", "ent_type": "Disease", "char_span": [217, 226], "ent_id": "D002971", "tok_span": [89, 91]}, {"name": "atrial septal defects", "ent_type": "Disease", "char_span": [161, 182], "ent_id": "D006344", "tok_span": [64, 67]}, {"name": "anophthalmia", "ent_type": "Disease", "char_span": [37, 49], "ent_id": "D000853", "tok_span": [8, 12]}, {"name": "Nitrofurantoins", "ent_type": "Chemical", "char_span": [0, 15], "ent_id": "D009582", "tok_span": [0, 5]}], "relation_list": [{"subject": "Nitrofurantoins", "object": "atrial septal defects", "sbj_char_span": [0, 15], "obj_char_span": [161, 182], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [64, 67]}, {"subject": "Nitrofurantoins", "object": "anophthalmia", "sbj_char_span": [0, 15], "obj_char_span": [37, 49], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [8, 12]}, {"subject": "Nitrofurantoins", "object": "hypoplastic left heart syndrome", "sbj_char_span": [0, 15], "obj_char_span": [99, 130], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [38, 43]}, {"subject": "Nitrofurantoins", "object": "cleft lip", "sbj_char_span": [0, 15], "obj_char_span": [217, 226], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [89, 91]}, {"subject": "Nitrofurantoins", "object": "cleft palate", "sbj_char_span": [0, 15], "obj_char_span": [232, 244], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [92, 95]}, {"subject": "Nitrofurantoins", "object": "microphthalmos", "sbj_char_span": [0, 15], "obj_char_span": [53, 67], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "Sulfonamides and nitrofurantoins were associated with several birth defects, indicating a need for additional scrutiny.", "entity_list": [{"name": "nitrofurantoins", "ent_type": "Chemical", "char_span": [17, 32], "ent_id": "D009582", "tok_span": [5, 10]}, {"name": "Sulfonamides", "ent_type": "Chemical", "char_span": [0, 12], "ent_id": "D013449", "tok_span": [0, 4]}, {"name": "birth defects", "ent_type": "Disease", "char_span": [62, 75], "ent_id": "D000014", "tok_span": [14, 16]}], "relation_list": [{"subject": "Sulfonamides", "object": "birth defects", "sbj_char_span": [0, 12], "obj_char_span": [62, 75], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [14, 16]}, {"subject": "nitrofurantoins", "object": "birth defects", "sbj_char_span": [17, 32], "obj_char_span": [62, 75], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 10], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.", "entity_list": [{"name": "alkylating agents", "ent_type": "Chemical", "char_span": [121, 138], "ent_id": "D000477", "tok_span": [21, 24]}, {"name": "acute nonlymphocytic leukemia", "ent_type": "Disease", "char_span": [81, 110], "ent_id": "D015470", "tok_span": [13, 18]}, {"name": "non-Hodgkin's lymphoma", "ent_type": "Disease", "char_span": [195, 217], "ent_id": "D008228", "tok_span": [35, 42]}, {"name": "azathioprine", "ent_type": "Chemical", "char_span": [143, 155], "ent_id": "D001379", "tok_span": [25, 29]}, {"name": "alkylating agents", "ent_type": "Chemical", "char_span": [22, 39], "ent_id": "D000477", "tok_span": [3, 6]}], "relation_list": [{"subject": "alkylating agents", "object": "acute nonlymphocytic leukemia", "sbj_char_span": [22, 39], "obj_char_span": [81, 110], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [13, 18]}, {"subject": "alkylating agents", "object": "non-Hodgkin's lymphoma", "sbj_char_span": [22, 39], "obj_char_span": [195, 217], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [35, 42]}, {"subject": "azathioprine", "object": "non-Hodgkin's lymphoma", "sbj_char_span": [143, 155], "obj_char_span": [195, 217], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 29], "obj_tok_span": [35, 42]}, {"subject": "alkylating agents", "object": "non-Hodgkin's lymphoma", "sbj_char_span": [121, 138], "obj_char_span": [195, 217], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [35, 42]}, {"subject": "alkylating agents", "object": "acute nonlymphocytic leukemia", "sbj_char_span": [121, 138], "obj_char_span": [81, 110], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [13, 18]}], "umls_entity_list": []}, {"text": "Patterns of hepatic injury induced by methyldopa.", "entity_list": [{"name": "hepatic injury", "ent_type": "Disease", "char_span": [12, 26], "ent_id": "D056486", "tok_span": [2, 4]}, {"name": "methyldopa", "ent_type": "Chemical", "char_span": [38, 48], "ent_id": "D008750", "tok_span": [6, 9]}], "relation_list": [{"subject": "methyldopa", "object": "hepatic injury", "sbj_char_span": [38, 48], "obj_char_span": [12, 26], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [2, 4]}], "umls_entity_list": []}, {"text": "The remaining patient in the series developed fulminant hepatitis when the drug was accidentally recommenced 1 year after a prior episode of methyldopa-induced hepatitis.", "entity_list": [{"name": "hepatitis", "ent_type": "Disease", "char_span": [160, 169], "ent_id": "D056486", "tok_span": [31, 32]}, {"name": "fulminant hepatitis", "ent_type": "Disease", "char_span": [46, 65], "ent_id": "D017114", "tok_span": [7, 11]}, {"name": "methyldopa", "ent_type": "Chemical", "char_span": [141, 151], "ent_id": "D008750", "tok_span": [26, 29]}], "relation_list": [{"subject": "methyldopa", "object": "hepatitis", "sbj_char_span": [141, 151], "obj_char_span": [160, 169], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 29], "obj_tok_span": [31, 32]}], "umls_entity_list": []}, {"text": "In this latter patient, and in 2 others, the causal relationship between methyldopa and hepatic dysfunction was proved with the recurrence of hepatitis within 2 weeks of re-exposure to the drug.", "entity_list": [{"name": "methyldopa", "ent_type": "Chemical", "char_span": [73, 83], "ent_id": "D008750", "tok_span": [14, 17]}, {"name": "hepatitis", "ent_type": "Disease", "char_span": [142, 151], "ent_id": "D056486", "tok_span": [26, 27]}, {"name": "hepatic dysfunction", "ent_type": "Disease", "char_span": [88, 107], "ent_id": "D008107", "tok_span": [18, 20]}], "relation_list": [{"subject": "methyldopa", "object": "hepatitis", "sbj_char_span": [73, 83], "obj_char_span": [142, 151], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [26, 27]}], "umls_entity_list": []}, {"text": "Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).", "entity_list": [{"name": "seizure", "ent_type": "Disease", "char_span": [118, 125], "ent_id": "D012640", "tok_span": [32, 33]}, {"name": "gamma-HCH", "ent_type": "Chemical", "char_span": [274, 283], "ent_id": "D001556", "tok_span": [68, 72]}, {"name": "lindane", "ent_type": "Chemical", "char_span": [82, 89], "ent_id": "D001556", "tok_span": [23, 26]}, {"name": "PTZ", "ent_type": "Chemical", "char_span": [156, 159], "ent_id": "D010433", "tok_span": [40, 42]}, {"name": "gamma-HCH", "ent_type": "Chemical", "char_span": [29, 38], "ent_id": "D001556", "tok_span": [10, 14]}, {"name": "PTZ", "ent_type": "Chemical", "char_span": [230, 233], "ent_id": "D010433", "tok_span": [58, 60]}, {"name": "gamma-HCH", "ent_type": "Chemical", "char_span": [183, 192], "ent_id": "D001556", "tok_span": [48, 52]}, {"name": "Gamma-hexachlorocyclohexane", "ent_type": "Chemical", "char_span": [0, 27], "ent_id": "D001556", "tok_span": [0, 9]}, {"name": "seizures", "ent_type": "Disease", "char_span": [242, 250], "ent_id": "D012640", "tok_span": [62, 63]}], "relation_list": [{"subject": "PTZ", "object": "seizures", "sbj_char_span": [230, 233], "obj_char_span": [242, 250], "rel_type": "chemical-induced disease", "sbj_tok_span": [58, 60], "obj_tok_span": [62, 63]}, {"subject": "PTZ", "object": "seizure", "sbj_char_span": [156, 159], "obj_char_span": [118, 125], "rel_type": "chemical-induced disease", "sbj_tok_span": [40, 42], "obj_tok_span": [32, 33]}, {"subject": "PTZ", "object": "seizures", "sbj_char_span": [156, 159], "obj_char_span": [242, 250], "rel_type": "chemical-induced disease", "sbj_tok_span": [40, 42], "obj_tok_span": [62, 63]}, {"subject": "PTZ", "object": "seizure", "sbj_char_span": [230, 233], "obj_char_span": [118, 125], "rel_type": "chemical-induced disease", "sbj_tok_span": [58, 60], "obj_tok_span": [32, 33]}], "umls_entity_list": []}, {"text": "Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.", "entity_list": [{"name": "MPA", "ent_type": "Chemical", "char_span": [137, 140], "ent_id": "D015097", "tok_span": [34, 36]}, {"name": "PTZ", "ent_type": "Chemical", "char_span": [24, 27], "ent_id": "D010433", "tok_span": [6, 8]}, {"name": "methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate", "ent_type": "Chemical", "char_span": [162, 216], "ent_id": "C034818", "tok_span": [47, 69]}, {"name": "strychnine", "ent_type": "Chemical", "char_span": [228, 238], "ent_id": "D013331", "tok_span": [75, 79]}, {"name": "Seizure", "ent_type": "Disease", "char_span": [0, 7], "ent_id": "D012640", "tok_span": [0, 3]}, {"name": "STR", "ent_type": "Chemical", "char_span": [240, 243], "ent_id": "D013331", "tok_span": [80, 81]}, {"name": "seizure", "ent_type": "Disease", "char_span": [87, 94], "ent_id": "D012640", "tok_span": [22, 23]}, {"name": "3-mercaptopropionic acid", "ent_type": "Chemical", "char_span": [111, 135], "ent_id": "D015097", "tok_span": [26, 33]}, {"name": "PTX", "ent_type": "Chemical", "char_span": [44, 47], "ent_id": "D010852", "tok_span": [13, 15]}, {"name": "DMCM", "ent_type": "Chemical", "char_span": [218, 222], "ent_id": "C034818", "tok_span": [70, 72]}, {"name": "BCC", "ent_type": "Chemical", "char_span": [156, 159], "ent_id": "D001640", "tok_span": [43, 45]}, {"name": "picrotoxin", "ent_type": "Chemical", "char_span": [32, 42], "ent_id": "D010852", "tok_span": [9, 12]}, {"name": "bicuculline", "ent_type": "Chemical", "char_span": [143, 154], "ent_id": "D001640", "tok_span": [38, 42]}], "relation_list": [{"subject": "PTX", "object": "Seizure", "sbj_char_span": [44, 47], "obj_char_span": [0, 7], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [0, 3]}, {"subject": "PTZ", "object": "seizure", "sbj_char_span": [24, 27], "obj_char_span": [87, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [22, 23]}, {"subject": "MPA", "object": "Seizure", "sbj_char_span": [137, 140], "obj_char_span": [0, 7], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 36], "obj_tok_span": [0, 3]}, {"subject": "BCC", "object": "seizure", "sbj_char_span": [156, 159], "obj_char_span": [87, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 45], "obj_tok_span": [22, 23]}, {"subject": "PTX", "object": "seizure", "sbj_char_span": [44, 47], "obj_char_span": [87, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [22, 23]}, {"subject": "PTZ", "object": "Seizure", "sbj_char_span": [24, 27], "obj_char_span": [0, 7], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [0, 3]}, {"subject": "BCC", "object": "Seizure", "sbj_char_span": [156, 159], "obj_char_span": [0, 7], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 45], "obj_tok_span": [0, 3]}, {"subject": "picrotoxin", "object": "seizure", "sbj_char_span": [32, 42], "obj_char_span": [87, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [22, 23]}, {"subject": "strychnine", "object": "seizure", "sbj_char_span": [228, 238], "obj_char_span": [87, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [75, 79], "obj_tok_span": [22, 23]}, {"subject": "MPA", "object": "seizure", "sbj_char_span": [137, 140], "obj_char_span": [87, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 36], "obj_tok_span": [22, 23]}, {"subject": "picrotoxin", "object": "Seizure", "sbj_char_span": [32, 42], "obj_char_span": [0, 7], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [0, 3]}, {"subject": "STR", "object": "seizure", "sbj_char_span": [240, 243], "obj_char_span": [87, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [80, 81], "obj_tok_span": [22, 23]}, {"subject": "3-mercaptopropionic acid", "object": "seizure", "sbj_char_span": [111, 135], "obj_char_span": [87, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 33], "obj_tok_span": [22, 23]}, {"subject": "methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate", "object": "seizure", "sbj_char_span": [162, 216], "obj_char_span": [87, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [47, 69], "obj_tok_span": [22, 23]}, {"subject": "bicuculline", "object": "Seizure", "sbj_char_span": [143, 154], "obj_char_span": [0, 7], "rel_type": "chemical-induced disease", "sbj_tok_span": [38, 42], "obj_tok_span": [0, 3]}, {"subject": "3-mercaptopropionic acid", "object": "Seizure", "sbj_char_span": [111, 135], "obj_char_span": [0, 7], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 33], "obj_tok_span": [0, 3]}, {"subject": "methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate", "object": "Seizure", "sbj_char_span": [162, 216], "obj_char_span": [0, 7], "rel_type": "chemical-induced disease", "sbj_tok_span": [47, 69], "obj_tok_span": [0, 3]}, {"subject": "STR", "object": "Seizure", "sbj_char_span": [240, 243], "obj_char_span": [0, 7], "rel_type": "chemical-induced disease", "sbj_tok_span": [80, 81], "obj_tok_span": [0, 3]}, {"subject": "DMCM", "object": "Seizure", "sbj_char_span": [218, 222], "obj_char_span": [0, 7], "rel_type": "chemical-induced disease", "sbj_tok_span": [70, 72], "obj_tok_span": [0, 3]}, {"subject": "DMCM", "object": "seizure", "sbj_char_span": [218, 222], "obj_char_span": [87, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [70, 72], "obj_tok_span": [22, 23]}, {"subject": "bicuculline", "object": "seizure", "sbj_char_span": [143, 154], "obj_char_span": [87, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [38, 42], "obj_tok_span": [22, 23]}, {"subject": "strychnine", "object": "Seizure", "sbj_char_span": [228, 238], "obj_char_span": [0, 7], "rel_type": "chemical-induced disease", "sbj_tok_span": [75, 79], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.", "entity_list": [{"name": "seizure", "ent_type": "Disease", "char_span": [170, 177], "ent_id": "D012640", "tok_span": [34, 35]}, {"name": "PTX", "ent_type": "Chemical", "char_span": [107, 110], "ent_id": "D010852", "tok_span": [17, 19]}, {"name": "gamma-HCH", "ent_type": "Chemical", "char_span": [122, 131], "ent_id": "D001556", "tok_span": [22, 26]}, {"name": "seizure", "ent_type": "Disease", "char_span": [71, 78], "ent_id": "D012640", "tok_span": [10, 11]}, {"name": "PTZ", "ent_type": "Chemical", "char_span": [99, 102], "ent_id": "D010433", "tok_span": [14, 16]}], "relation_list": [{"subject": "PTZ", "object": "seizure", "sbj_char_span": [99, 102], "obj_char_span": [170, 177], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [34, 35]}, {"subject": "PTX", "object": "seizure", "sbj_char_span": [107, 110], "obj_char_span": [71, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 19], "obj_tok_span": [10, 11]}, {"subject": "PTX", "object": "seizure", "sbj_char_span": [107, 110], "obj_char_span": [170, 177], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 19], "obj_tok_span": [34, 35]}, {"subject": "PTZ", "object": "seizure", "sbj_char_span": [99, 102], "obj_char_span": [71, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [10, 11]}], "umls_entity_list": []}, {"text": "We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs.", "entity_list": [{"name": "cisplatin", "ent_type": "Chemical", "char_span": [206, 215], "ent_id": "D002945", "tok_span": [36, 37]}, {"name": "peripheral neuropathy", "ent_type": "Disease", "char_span": [50, 71], "ent_id": "D010523", "tok_span": [9, 11]}, {"name": "paclitaxel", "ent_type": "Chemical", "char_span": [191, 201], "ent_id": "D017239", "tok_span": [34, 35]}], "relation_list": [{"subject": "paclitaxel", "object": "peripheral neuropathy", "sbj_char_span": [191, 201], "obj_char_span": [50, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 35], "obj_tok_span": [9, 11]}, {"subject": "cisplatin", "object": "peripheral neuropathy", "sbj_char_span": [206, 215], "obj_char_span": [50, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 37], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.", "entity_list": [{"name": "abnormal liver function", "ent_type": "Disease", "char_span": [188, 211], "ent_id": "D056486", "tok_span": [37, 40]}, {"name": "Ximelagatran", "ent_type": "Chemical", "char_span": [0, 12], "ent_id": "C426686", "tok_span": [0, 4]}, {"name": "embolic events", "ent_type": "Disease", "char_span": [129, 143], "ent_id": "D004617", "tok_span": [26, 29]}, {"name": "vitamin K", "ent_type": "Chemical", "char_span": [81, 90], "ent_id": "D014812", "tok_span": [18, 20]}], "relation_list": [{"subject": "Ximelagatran", "object": "abnormal liver function", "sbj_char_span": [0, 12], "obj_char_span": [188, 211], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [37, 40]}], "umls_entity_list": []}, {"text": "In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment.", "entity_list": [{"name": "cefazedone", "ent_type": "Chemical", "char_span": [82, 92], "ent_id": "C021341", "tok_span": [15, 19]}, {"name": "cefonicid", "ent_type": "Chemical", "char_span": [69, 78], "ent_id": "D015790", "tok_span": [11, 14]}, {"name": "neutropenia", "ent_type": "Disease", "char_span": [153, 164], "ent_id": "D009503", "tok_span": [32, 34]}, {"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [170, 186], "ent_id": "D013921", "tok_span": [36, 38]}, {"name": "anemia", "ent_type": "Disease", "char_span": [145, 151], "ent_id": "D000740", "tok_span": [30, 31]}, {"name": "toxicity", "ent_type": "Disease", "char_span": [17, 25], "ent_id": "D064420", "tok_span": [4, 5]}], "relation_list": [{"subject": "cefazedone", "object": "thrombocytopenia", "sbj_char_span": [82, 92], "obj_char_span": [170, 186], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 19], "obj_tok_span": [36, 38]}, {"subject": "cefonicid", "object": "neutropenia", "sbj_char_span": [69, 78], "obj_char_span": [153, 164], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [32, 34]}, {"subject": "cefonicid", "object": "thrombocytopenia", "sbj_char_span": [69, 78], "obj_char_span": [170, 186], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [36, 38]}, {"subject": "cefazedone", "object": "neutropenia", "sbj_char_span": [82, 92], "obj_char_span": [153, 164], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 19], "obj_tok_span": [32, 34]}, {"subject": "cefonicid", "object": "anemia", "sbj_char_span": [69, 78], "obj_char_span": [145, 151], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [30, 31]}, {"subject": "cefazedone", "object": "anemia", "sbj_char_span": [82, 92], "obj_char_span": [145, 151], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 19], "obj_tok_span": [30, 31]}], "umls_entity_list": []}, {"text": "A nonregenerative anemia was the most compromising of the cytopenias and occurred in approximately 50% of dogs receiving 400-500 mg/kg cefonicid or 540-840 mg/kg cefazedone.", "entity_list": [{"name": "cefazedone", "ent_type": "Chemical", "char_span": [162, 172], "ent_id": "C021341", "tok_span": [42, 46]}, {"name": "cytopenias", "ent_type": "Disease", "char_span": [58, 68], "ent_id": "D006402", "tok_span": [13, 16]}, {"name": "anemia", "ent_type": "Disease", "char_span": [18, 24], "ent_id": "D000740", "tok_span": [5, 6]}, {"name": "cefonicid", "ent_type": "Chemical", "char_span": [135, 144], "ent_id": "D015790", "tok_span": [31, 34]}], "relation_list": [{"subject": "cefazedone", "object": "anemia", "sbj_char_span": [162, 172], "obj_char_span": [18, 24], "rel_type": "chemical-induced disease", "sbj_tok_span": [42, 46], "obj_tok_span": [5, 6]}, {"subject": "cefonicid", "object": "anemia", "sbj_char_span": [135, 144], "obj_char_span": [18, 24], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 34], "obj_tok_span": [5, 6]}], "umls_entity_list": []}, {"text": "A pyridoxine-dependent behavioral disorder unmasked by isoniazid.", "entity_list": [{"name": "behavioral disorder", "ent_type": "Disease", "char_span": [23, 42], "ent_id": "D002653", "tok_span": [7, 9]}, {"name": "pyridoxine", "ent_type": "Chemical", "char_span": [2, 12], "ent_id": "D011736", "tok_span": [1, 5]}, {"name": "isoniazid", "ent_type": "Chemical", "char_span": [55, 64], "ent_id": "D007538", "tok_span": [13, 17]}], "relation_list": [{"subject": "isoniazid", "object": "behavioral disorder", "sbj_char_span": [55, 64], "obj_char_span": [23, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and sleeping difficulties after the therapeutic administration of isoniazid.", "entity_list": [{"name": "irritability", "ent_type": "Disease", "char_span": [67, 79], "ent_id": "D001523", "tok_span": [16, 18]}, {"name": "sleeping difficulties", "ent_type": "Disease", "char_span": [85, 106], "ent_id": "D012893", "tok_span": [20, 23]}, {"name": "isoniazid", "ent_type": "Chemical", "char_span": [147, 156], "ent_id": "D007538", "tok_span": [28, 32]}, {"name": "behavioral deterioration", "ent_type": "Disease", "char_span": [22, 46], "ent_id": "D002653", "tok_span": [8, 10]}, {"name": "hyperkinesis", "ent_type": "Disease", "char_span": [53, 65], "ent_id": "D006948", "tok_span": [12, 15]}], "relation_list": [{"subject": "isoniazid", "object": "behavioral deterioration", "sbj_char_span": [147, 156], "obj_char_span": [22, 46], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 32], "obj_tok_span": [8, 10]}, {"subject": "isoniazid", "object": "hyperkinesis", "sbj_char_span": [147, 156], "obj_char_span": [53, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 32], "obj_tok_span": [12, 15]}], "umls_entity_list": []}, {"text": "NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine (MAP) in mice.", "entity_list": [{"name": "clozapine", "ent_type": "Chemical", "char_span": [12, 21], "ent_id": "D003024", "tok_span": [5, 8]}, {"name": "MAP", "ent_type": "Chemical", "char_span": [86, 89], "ent_id": "D008694", "tok_span": [19, 20]}, {"name": "methamphetamine", "ent_type": "Chemical", "char_span": [69, 84], "ent_id": "D008694", "tok_span": [15, 18]}, {"name": "NRA0160", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "C121249", "tok_span": [0, 4]}, {"name": "hyperactivity", "ent_type": "Disease", "char_span": [44, 57], "ent_id": "D006948", "tok_span": [11, 13]}], "relation_list": [{"subject": "MAP", "object": "hyperactivity", "sbj_char_span": [86, 89], "obj_char_span": [44, 57], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 20], "obj_tok_span": [11, 13]}, {"subject": "methamphetamine", "object": "hyperactivity", "sbj_char_span": [69, 84], "obj_char_span": [44, 57], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [11, 13]}], "umls_entity_list": []}, {"text": "NRA0160 and clozapine significantly induced catalepsy in rats, although their effects did not exceed 50% induction even at the highest dose given.", "entity_list": [{"name": "clozapine", "ent_type": "Chemical", "char_span": [12, 21], "ent_id": "D003024", "tok_span": [5, 8]}, {"name": "NRA0160", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "C121249", "tok_span": [0, 4]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [44, 53], "ent_id": "D002375", "tok_span": [10, 13]}], "relation_list": [{"subject": "clozapine", "object": "catalepsy", "sbj_char_span": [12, 21], "obj_char_span": [44, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [10, 13]}, {"subject": "NRA0160", "object": "catalepsy", "sbj_char_span": [0, 7], "obj_char_span": [44, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [10, 13]}], "umls_entity_list": []}, {"text": "Prolonged cholestasis after troleandomycin-induced acute hepatitis.", "entity_list": [{"name": "cholestasis", "ent_type": "Disease", "char_span": [10, 21], "ent_id": "D002779", "tok_span": [3, 6]}, {"name": "hepatitis", "ent_type": "Disease", "char_span": [57, 66], "ent_id": "D056486", "tok_span": [14, 15]}, {"name": "troleandomycin", "ent_type": "Chemical", "char_span": [28, 42], "ent_id": "D014217", "tok_span": [7, 11]}], "relation_list": [{"subject": "troleandomycin", "object": "hepatitis", "sbj_char_span": [28, 42], "obj_char_span": [57, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [14, 15]}, {"subject": "troleandomycin", "object": "cholestasis", "sbj_char_span": [28, 42], "obj_char_span": [10, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [3, 6]}], "umls_entity_list": []}, {"text": "We report the case of a patient in whom troleandomycin-induced hepatitis was followed by prolonged anicteric cholestasis.", "entity_list": [{"name": "troleandomycin", "ent_type": "Chemical", "char_span": [40, 54], "ent_id": "D014217", "tok_span": [9, 13]}, {"name": "cholestasis", "ent_type": "Disease", "char_span": [109, 120], "ent_id": "D002779", "tok_span": [23, 26]}, {"name": "hepatitis", "ent_type": "Disease", "char_span": [63, 72], "ent_id": "D056486", "tok_span": [15, 16]}], "relation_list": [{"subject": "troleandomycin", "object": "cholestasis", "sbj_char_span": [40, 54], "obj_char_span": [109, 120], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [23, 26]}, {"subject": "troleandomycin", "object": "hepatitis", "sbj_char_span": [40, 54], "obj_char_span": [63, 72], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [15, 16]}], "umls_entity_list": []}, {"text": "Jaundice occurred after administration of troleandomycin for 7 days and was associated with hypereosinophilia.", "entity_list": [{"name": "Jaundice", "ent_type": "Disease", "char_span": [0, 8], "ent_id": "D007565", "tok_span": [0, 3]}, {"name": "hypereosinophilia", "ent_type": "Disease", "char_span": [92, 109], "ent_id": "D004802", "tok_span": [18, 22]}, {"name": "troleandomycin", "ent_type": "Chemical", "char_span": [42, 56], "ent_id": "D014217", "tok_span": [7, 11]}], "relation_list": [{"subject": "troleandomycin", "object": "hypereosinophilia", "sbj_char_span": [42, 56], "obj_char_span": [92, 109], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [18, 22]}, {"subject": "troleandomycin", "object": "Jaundice", "sbj_char_span": [42, 56], "obj_char_span": [0, 8], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "This observation demonstrates that prolonged cholestasis can follow troleandomycin-induced acute hepatitis.", "entity_list": [{"name": "cholestasis", "ent_type": "Disease", "char_span": [45, 56], "ent_id": "D002779", "tok_span": [5, 8]}, {"name": "troleandomycin", "ent_type": "Chemical", "char_span": [68, 82], "ent_id": "D014217", "tok_span": [10, 14]}, {"name": "hepatitis", "ent_type": "Disease", "char_span": [97, 106], "ent_id": "D056486", "tok_span": [17, 18]}], "relation_list": [{"subject": "troleandomycin", "object": "hepatitis", "sbj_char_span": [68, 82], "obj_char_span": [97, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [17, 18]}, {"subject": "troleandomycin", "object": "cholestasis", "sbj_char_span": [68, 82], "obj_char_span": [45, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [5, 8]}], "umls_entity_list": []}, {"text": "Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.", "entity_list": [{"name": "lovastatin", "ent_type": "Chemical", "char_span": [130, 140], "ent_id": "D008148", "tok_span": [26, 28]}, {"name": "myoglobinuria", "ent_type": "Disease", "char_span": [40, 53], "ent_id": "D009212", "tok_span": [8, 11]}, {"name": "niacin", "ent_type": "Chemical", "char_span": [220, 226], "ent_id": "D009525", "tok_span": [45, 47]}, {"name": "gemfibrozil", "ent_type": "Chemical", "char_span": [205, 216], "ent_id": "D015248", "tok_span": [39, 44]}, {"name": "Myopathy", "ent_type": "Disease", "char_span": [0, 8], "ent_id": "D009135", "tok_span": [0, 2]}, {"name": "cyclosporin", "ent_type": "Chemical", "char_span": [192, 203], "ent_id": "D016572", "tok_span": [36, 38]}, {"name": "renal failure", "ent_type": "Disease", "char_span": [85, 98], "ent_id": "D051437", "tok_span": [18, 20]}], "relation_list": [{"subject": "gemfibrozil", "object": "Myopathy", "sbj_char_span": [205, 216], "obj_char_span": [0, 8], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 44], "obj_tok_span": [0, 2]}, {"subject": "cyclosporin", "object": "Myopathy", "sbj_char_span": [192, 203], "obj_char_span": [0, 8], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 38], "obj_tok_span": [0, 2]}, {"subject": "niacin", "object": "Myopathy", "sbj_char_span": [220, 226], "obj_char_span": [0, 8], "rel_type": "chemical-induced disease", "sbj_tok_span": [45, 47], "obj_tok_span": [0, 2]}, {"subject": "lovastatin", "object": "renal failure", "sbj_char_span": [130, 140], "obj_char_span": [85, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 28], "obj_tok_span": [18, 20]}, {"subject": "lovastatin", "object": "myoglobinuria", "sbj_char_span": [130, 140], "obj_char_span": [40, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 28], "obj_tok_span": [8, 11]}], "umls_entity_list": []}, {"text": "Sulfasalazine-induced lupus erythematosus.", "entity_list": [{"name": "Sulfasalazine", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D012460", "tok_span": [0, 3]}, {"name": "lupus erythematosus", "ent_type": "Disease", "char_span": [22, 41], "ent_id": "D008180", "tok_span": [5, 8]}], "relation_list": [{"subject": "Sulfasalazine", "object": "lupus erythematosus", "sbj_char_span": [0, 13], "obj_char_span": [22, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 8]}], "umls_entity_list": []}, {"text": "Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.", "entity_list": [{"name": "cardiac tamponade", "ent_type": "Disease", "char_span": [72, 89], "ent_id": "D002305", "tok_span": [13, 17]}, {"name": "sulfasalazine", "ent_type": "Chemical", "char_span": [179, 192], "ent_id": "D012460", "tok_span": [37, 40]}, {"name": "Pneumonitis", "ent_type": "Disease", "char_span": [0, 11], "ent_id": "D011014", "tok_span": [0, 3]}, {"name": "ulcerative colitis", "ent_type": "Disease", "char_span": [213, 231], "ent_id": "D003093", "tok_span": [43, 46]}, {"name": "pleural effusions", "ent_type": "Disease", "char_span": [23, 40], "ent_id": "D010996", "tok_span": [5, 8]}], "relation_list": [{"subject": "sulfasalazine", "object": "Pneumonitis", "sbj_char_span": [179, 192], "obj_char_span": [0, 11], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 40], "obj_tok_span": [0, 3]}, {"subject": "sulfasalazine", "object": "pleural effusions", "sbj_char_span": [179, 192], "obj_char_span": [23, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 40], "obj_tok_span": [5, 8]}, {"subject": "sulfasalazine", "object": "cardiac tamponade", "sbj_char_span": [179, 192], "obj_char_span": [72, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 40], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.", "entity_list": [{"name": "sulfasalazine", "ent_type": "Chemical", "char_span": [37, 50], "ent_id": "D012460", "tok_span": [7, 10]}, {"name": "serositis", "ent_type": "Disease", "char_span": [88, 97], "ent_id": "D012700", "tok_span": [17, 20]}, {"name": "lupus", "ent_type": "Disease", "char_span": [59, 64], "ent_id": "D008180", "tok_span": [12, 13]}], "relation_list": [{"subject": "sulfasalazine", "object": "lupus", "sbj_char_span": [37, 50], "obj_char_span": [59, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [12, 13]}], "umls_entity_list": []}, {"text": "Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-induced lupus syndrome.", "entity_list": [{"name": "lupus syndrome", "ent_type": "Disease", "char_span": [137, 151], "ent_id": "D008180", "tok_span": [25, 27]}, {"name": "sulfasalazine", "ent_type": "Chemical", "char_span": [19, 32], "ent_id": "D012460", "tok_span": [3, 6]}, {"name": "sulfasalazine", "ent_type": "Chemical", "char_span": [115, 128], "ent_id": "D012460", "tok_span": [20, 23]}, {"name": "inflammatory bowel disease", "ent_type": "Disease", "char_span": [56, 82], "ent_id": "D015212", "tok_span": [10, 13]}], "relation_list": [{"subject": "sulfasalazine", "object": "lupus syndrome", "sbj_char_span": [115, 128], "obj_char_span": [137, 151], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [25, 27]}, {"subject": "sulfasalazine", "object": "lupus syndrome", "sbj_char_span": [19, 32], "obj_char_span": [137, 151], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [25, 27]}], "umls_entity_list": []}, {"text": "Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.", "entity_list": [{"name": "psychosis", "ent_type": "Disease", "char_span": [110, 119], "ent_id": "D011618", "tok_span": [21, 22]}, {"name": "parasomnias", "ent_type": "Disease", "char_span": [143, 154], "ent_id": "D020447", "tok_span": [26, 29]}, {"name": "sleep disturbances", "ent_type": "Disease", "char_span": [121, 139], "ent_id": "D012893", "tok_span": [23, 25]}, {"name": "orthostatic hypotension", "ent_type": "Disease", "char_span": [68, 91], "ent_id": "D007024", "tok_span": [12, 15]}, {"name": "gastrointestinal disorders", "ent_type": "Disease", "char_span": [40, 66], "ent_id": "D005767", "tok_span": [8, 11]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [93, 101], "ent_id": "D007980", "tok_span": [16, 19]}], "relation_list": [{"subject": "levodopa", "object": "gastrointestinal disorders", "sbj_char_span": [93, 101], "obj_char_span": [40, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [8, 11]}, {"subject": "levodopa", "object": "orthostatic hypotension", "sbj_char_span": [93, 101], "obj_char_span": [68, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [12, 15]}, {"subject": "levodopa", "object": "parasomnias", "sbj_char_span": [93, 101], "obj_char_span": [143, 154], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [26, 29]}], "umls_entity_list": []}, {"text": "Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms, and one took a suicidal overdose of nitrazepam.", "entity_list": [{"name": "nitrazepam", "ent_type": "Chemical", "char_span": [123, 133], "ent_id": "D009567", "tok_span": [23, 26]}, {"name": "withdrawal symptoms", "ent_type": "Disease", "char_span": [66, 85], "ent_id": "D013375", "tok_span": [12, 14]}, {"name": "chlormethiazole", "ent_type": "Chemical", "char_span": [38, 53], "ent_id": "D002719", "tok_span": [6, 10]}, {"name": "overdose", "ent_type": "Disease", "char_span": [111, 119], "ent_id": "D062787", "tok_span": [20, 22]}, {"name": "alcohol", "ent_type": "Chemical", "char_span": [58, 65], "ent_id": "D000431", "tok_span": [11, 12]}], "relation_list": [{"subject": "nitrazepam", "object": "overdose", "sbj_char_span": [123, 133], "obj_char_span": [111, 119], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [20, 22]}], "umls_entity_list": []}, {"text": "The patient with nitrazepam overdose and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha coma', showing non-reactive generalized or frontally predominant alpha activity in the EEG.", "entity_list": [{"name": "nitrazepam", "ent_type": "Chemical", "char_span": [17, 27], "ent_id": "D009567", "tok_span": [3, 6]}, {"name": "overdose", "ent_type": "Disease", "char_span": [28, 36], "ent_id": "D062787", "tok_span": [6, 8]}, {"name": "coma", "ent_type": "Disease", "char_span": [124, 128], "ent_id": "D003128", "tok_span": [27, 29]}, {"name": "chlormethiazole", "ent_type": "Chemical", "char_span": [59, 74], "ent_id": "D002719", "tok_span": [13, 17]}], "relation_list": [{"subject": "chlormethiazole", "object": "coma", "sbj_char_span": [59, 74], "obj_char_span": [124, 128], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [27, 29]}, {"subject": "nitrazepam", "object": "overdose", "sbj_char_span": [17, 27], "obj_char_span": [28, 36], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [6, 8]}, {"subject": "nitrazepam", "object": "coma", "sbj_char_span": [17, 27], "obj_char_span": [124, 128], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [27, 29]}], "umls_entity_list": []}, {"text": "RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).", "entity_list": [{"name": "fentanyl", "ent_type": "Chemical", "char_span": [21, 29], "ent_id": "D005283", "tok_span": [5, 8]}, {"name": "fentanyl", "ent_type": "Chemical", "char_span": [233, 241], "ent_id": "D005283", "tok_span": [48, 51]}, {"name": "vomiting", "ent_type": "Disease", "char_span": [137, 145], "ent_id": "D014839", "tok_span": [26, 27]}, {"name": "fentanyl", "ent_type": "Chemical", "char_span": [220, 228], "ent_id": "D005283", "tok_span": [44, 47]}, {"name": "nausea", "ent_type": "Disease", "char_span": [172, 178], "ent_id": "D009325", "tok_span": [33, 34]}, {"name": "dexamethasone", "ent_type": "Chemical", "char_span": [242, 255], "ent_id": "D003907", "tok_span": [52, 53]}, {"name": "postoperative nausea and vomiting", "ent_type": "Disease", "char_span": [70, 103], "ent_id": "D020250", "tok_span": [15, 19]}], "relation_list": [{"subject": "fentanyl", "object": "postoperative nausea and vomiting", "sbj_char_span": [21, 29], "obj_char_span": [70, 103], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [15, 19]}, {"subject": "fentanyl", "object": "postoperative nausea and vomiting", "sbj_char_span": [233, 241], "obj_char_span": [70, 103], "rel_type": "chemical-induced disease", "sbj_tok_span": [48, 51], "obj_tok_span": [15, 19]}, {"subject": "fentanyl", "object": "postoperative nausea and vomiting", "sbj_char_span": [220, 228], "obj_char_span": [70, 103], "rel_type": "chemical-induced disease", "sbj_tok_span": [44, 47], "obj_tok_span": [15, 19]}], "umls_entity_list": []}, {"text": "Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034).", "entity_list": [{"name": "fentanyl", "ent_type": "Chemical", "char_span": [18, 26], "ent_id": "D005283", "tok_span": [3, 6]}, {"name": "nausea", "ent_type": "Disease", "char_span": [150, 156], "ent_id": "D009325", "tok_span": [24, 25]}, {"name": "nausea", "ent_type": "Disease", "char_span": [255, 261], "ent_id": "D009325", "tok_span": [59, 60]}, {"name": "postoperative nausea and vomiting", "ent_type": "Disease", "char_span": [112, 145], "ent_id": "D020250", "tok_span": [19, 23]}], "relation_list": [{"subject": "fentanyl", "object": "postoperative nausea and vomiting", "sbj_char_span": [18, 26], "obj_char_span": [112, 145], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia.", "entity_list": [{"name": "respiratory depression", "ent_type": "Disease", "char_span": [102, 124], "ent_id": "D012131", "tok_span": [21, 23]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [142, 153], "ent_id": "D001919", "tok_span": [26, 30]}, {"name": "Fentanyl", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D005283", "tok_span": [0, 3]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [126, 137], "ent_id": "D007022", "tok_span": [24, 25]}, {"name": "sevoflurane", "ent_type": "Chemical", "char_span": [61, 72], "ent_id": "C009250", "tok_span": [11, 15]}], "relation_list": [{"subject": "Fentanyl", "object": "bradycardia", "sbj_char_span": [0, 8], "obj_char_span": [142, 153], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [26, 30]}, {"subject": "Fentanyl", "object": "respiratory depression", "sbj_char_span": [0, 8], "obj_char_span": [102, 124], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [21, 23]}, {"subject": "Fentanyl", "object": "hypotension", "sbj_char_span": [0, 8], "obj_char_span": [126, 137], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [24, 25]}], "umls_entity_list": []}, {"text": "CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.", "entity_list": [{"name": "fentanyl", "ent_type": "Chemical", "char_span": [15, 23], "ent_id": "D005283", "tok_span": [3, 6]}, {"name": "postoperative pain", "ent_type": "Disease", "char_span": [96, 114], "ent_id": "D010149", "tok_span": [16, 18]}, {"name": "postoperative nausea and vomiting", "ent_type": "Disease", "char_span": [36, 69], "ent_id": "D020250", "tok_span": [8, 12]}, {"name": "sevoflurane", "ent_type": "Chemical", "char_span": [234, 245], "ent_id": "C009250", "tok_span": [39, 43]}], "relation_list": [{"subject": "fentanyl", "object": "postoperative nausea and vomiting", "sbj_char_span": [15, 23], "obj_char_span": [36, 69], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [8, 12]}], "umls_entity_list": []}, {"text": "We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.", "entity_list": [{"name": "myopathy", "ent_type": "Disease", "char_span": [54, 62], "ent_id": "D009135", "tok_span": [10, 12]}, {"name": "tacrolimus", "ent_type": "Chemical", "char_span": [134, 144], "ent_id": "D016559", "tok_span": [22, 24]}, {"name": "mitochondrial dysfunction", "ent_type": "Disease", "char_span": [86, 111], "ent_id": "D028361", "tok_span": [16, 18]}, {"name": "tubular dysfunction", "ent_type": "Disease", "char_span": [30, 49], "ent_id": "D005198", "tok_span": [7, 9]}, {"name": "lamivudine", "ent_type": "Chemical", "char_span": [162, 172], "ent_id": "D019259", "tok_span": [27, 31]}], "relation_list": [{"subject": "lamivudine", "object": "myopathy", "sbj_char_span": [162, 172], "obj_char_span": [54, 62], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 31], "obj_tok_span": [10, 12]}, {"subject": "tacrolimus", "object": "myopathy", "sbj_char_span": [134, 144], "obj_char_span": [54, 62], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 24], "obj_tok_span": [10, 12]}, {"subject": "lamivudine", "object": "tubular dysfunction", "sbj_char_span": [162, 172], "obj_char_span": [30, 49], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 31], "obj_tok_span": [7, 9]}, {"subject": "tacrolimus", "object": "tubular dysfunction", "sbj_char_span": [134, 144], "obj_char_span": [30, 49], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 24], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "Catalepsy was induced by haloperidol (2 mg/kg p.o.), while apomorphine (1.5 mg/kg s.c.) and amphetamine (2 mg/kg s.c.) were used for studying climbing behavior and locomotor activities, respectively. (R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.", "entity_list": [{"name": "catalepsy", "ent_type": "Disease", "char_span": [312, 321], "ent_id": "D002375", "tok_span": [114, 117]}, {"name": "Catalepsy", "ent_type": "Disease", "char_span": [0, 9], "ent_id": "D002375", "tok_span": [0, 3]}, {"name": "apomorphine", "ent_type": "Chemical", "char_span": [59, 70], "ent_id": "D001058", "tok_span": [21, 26]}, {"name": "RAMH", "ent_type": "Chemical", "char_span": [227, 231], "ent_id": "C069357", "tok_span": [76, 78]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [25, 36], "ent_id": "D006220", "tok_span": [6, 9]}, {"name": "THP", "ent_type": "Chemical", "char_span": [269, 272], "ent_id": "C052075", "tok_span": [95, 97]}, {"name": "(R)-alpha-methylhistamine", "ent_type": "Chemical", "char_span": [200, 225], "ent_id": "C069357", "tok_span": [66, 75]}, {"name": "amphetamine", "ent_type": "Chemical", "char_span": [92, 103], "ent_id": "D000661", "tok_span": [39, 43]}, {"name": "thioperamide", "ent_type": "Chemical", "char_span": [255, 267], "ent_id": "C052075", "tok_span": [91, 94]}], "relation_list": [{"subject": "THP", "object": "Catalepsy", "sbj_char_span": [269, 272], "obj_char_span": [0, 9], "rel_type": "chemical-induced disease", "sbj_tok_span": [95, 97], "obj_tok_span": [0, 3]}, {"subject": "THP", "object": "catalepsy", "sbj_char_span": [269, 272], "obj_char_span": [312, 321], "rel_type": "chemical-induced disease", "sbj_tok_span": [95, 97], "obj_tok_span": [114, 117]}, {"subject": "thioperamide", "object": "Catalepsy", "sbj_char_span": [255, 267], "obj_char_span": [0, 9], "rel_type": "chemical-induced disease", "sbj_tok_span": [91, 94], "obj_tok_span": [0, 3]}, {"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [25, 36], "obj_char_span": [312, 321], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [114, 117]}, {"subject": "thioperamide", "object": "catalepsy", "sbj_char_span": [255, 267], "obj_char_span": [312, 321], "rel_type": "chemical-induced disease", "sbj_tok_span": [91, 94], "obj_tok_span": [114, 117]}, {"subject": "haloperidol", "object": "Catalepsy", "sbj_char_span": [25, 36], "obj_char_span": [0, 9], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P < 0.05).", "entity_list": [{"name": "THP", "ent_type": "Chemical", "char_span": [18, 21], "ent_id": "C052075", "tok_span": [2, 4]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [122, 131], "ent_id": "D002375", "tok_span": [38, 41]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [65, 76], "ent_id": "D006220", "tok_span": [26, 29]}], "relation_list": [{"subject": "THP", "object": "catalepsy", "sbj_char_span": [18, 21], "obj_char_span": [122, 131], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 4], "obj_tok_span": [38, 41]}, {"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [65, 76], "obj_char_span": [122, 131], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 29], "obj_tok_span": [38, 41]}], "umls_entity_list": []}, {"text": "On amphetamine-induced hyperactivity, THP (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P < 0.05).", "entity_list": [{"name": "THP", "ent_type": "Chemical", "char_span": [38, 41], "ent_id": "C052075", "tok_span": [10, 12]}, {"name": "hyperactivity", "ent_type": "Disease", "char_span": [23, 36], "ent_id": "D006948", "tok_span": [7, 9]}, {"name": "amphetamine", "ent_type": "Chemical", "char_span": [3, 14], "ent_id": "D000661", "tok_span": [1, 5]}], "relation_list": [{"subject": "amphetamine", "object": "hyperactivity", "sbj_char_span": [3, 14], "obj_char_span": [23, 36], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 5], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.", "entity_list": [{"name": "hyperactivity", "ent_type": "Disease", "char_span": [120, 133], "ent_id": "D006948", "tok_span": [28, 30]}, {"name": "amphetamine", "ent_type": "Chemical", "char_span": [100, 111], "ent_id": "D000661", "tok_span": [22, 26]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [60, 71], "ent_id": "D006220", "tok_span": [12, 15]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [80, 89], "ent_id": "D002375", "tok_span": [17, 20]}, {"name": "apomorphine", "ent_type": "Chemical", "char_span": [147, 158], "ent_id": "D001058", "tok_span": [32, 37]}, {"name": "THP", "ent_type": "Chemical", "char_span": [0, 3], "ent_id": "C052075", "tok_span": [0, 2]}], "relation_list": [{"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [60, 71], "obj_char_span": [80, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [17, 20]}, {"subject": "amphetamine", "object": "hyperactivity", "sbj_char_span": [100, 111], "obj_char_span": [120, 133], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 26], "obj_tok_span": [28, 30]}, {"subject": "THP", "object": "catalepsy", "sbj_char_span": [0, 3], "obj_char_span": [80, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [17, 20]}], "umls_entity_list": []}, {"text": "Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.", "entity_list": [{"name": "nephrotoxicity", "ent_type": "Disease", "char_span": [128, 142], "ent_id": "D007674", "tok_span": [26, 29]}, {"name": "toxicities", "ent_type": "Disease", "char_span": [84, 94], "ent_id": "D064420", "tok_span": [16, 17]}, {"name": "cisplatin", "ent_type": "Chemical", "char_span": [111, 120], "ent_id": "D002945", "tok_span": [19, 20]}, {"name": "neurotoxicity", "ent_type": "Disease", "char_span": [161, 174], "ent_id": "D020258", "tok_span": [34, 36]}, {"name": "breast carcinoma", "ent_type": "Disease", "char_span": [216, 232], "ent_id": "D001943", "tok_span": [45, 47]}, {"name": "ototoxicity", "ent_type": "Disease", "char_span": [144, 155], "ent_id": "D006311", "tok_span": [30, 32]}, {"name": "cisplatin", "ent_type": "Chemical", "char_span": [55, 64], "ent_id": "D002945", "tok_span": [10, 11]}], "relation_list": [{"subject": "cisplatin", "object": "ototoxicity", "sbj_char_span": [111, 120], "obj_char_span": [144, 155], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 20], "obj_tok_span": [30, 32]}, {"subject": "cisplatin", "object": "nephrotoxicity", "sbj_char_span": [55, 64], "obj_char_span": [128, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [26, 29]}, {"subject": "cisplatin", "object": "ototoxicity", "sbj_char_span": [55, 64], "obj_char_span": [144, 155], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [30, 32]}, {"subject": "cisplatin", "object": "nephrotoxicity", "sbj_char_span": [111, 120], "obj_char_span": [128, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 20], "obj_tok_span": [26, 29]}], "umls_entity_list": []}, {"text": "Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.", "entity_list": [{"name": "neuropathy", "ent_type": "Disease", "char_span": [142, 152], "ent_id": "D009422", "tok_span": [28, 29]}, {"name": "amifostine", "ent_type": "Chemical", "char_span": [30, 40], "ent_id": "D004999", "tok_span": [5, 9]}, {"name": "ototoxicity", "ent_type": "Disease", "char_span": [125, 136], "ent_id": "D006311", "tok_span": [24, 26]}, {"name": "nephrotoxicity", "ent_type": "Disease", "char_span": [109, 123], "ent_id": "D007674", "tok_span": [20, 23]}, {"name": "cisplatin", "ent_type": "Chemical", "char_span": [16, 25], "ent_id": "D002945", "tok_span": [3, 4]}, {"name": "cisplatin", "ent_type": "Chemical", "char_span": [91, 100], "ent_id": "D002945", "tok_span": [17, 18]}], "relation_list": [{"subject": "cisplatin", "object": "nephrotoxicity", "sbj_char_span": [91, 100], "obj_char_span": [109, 123], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 18], "obj_tok_span": [20, 23]}, {"subject": "cisplatin", "object": "ototoxicity", "sbj_char_span": [91, 100], "obj_char_span": [125, 136], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 18], "obj_tok_span": [24, 26]}, {"subject": "cisplatin", "object": "nephrotoxicity", "sbj_char_span": [16, 25], "obj_char_span": [109, 123], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [20, 23]}, {"subject": "cisplatin", "object": "ototoxicity", "sbj_char_span": [16, 25], "obj_char_span": [125, 136], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [24, 26]}, {"subject": "cisplatin", "object": "neuropathy", "sbj_char_span": [91, 100], "obj_char_span": [142, 152], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 18], "obj_tok_span": [28, 29]}, {"subject": "cisplatin", "object": "neuropathy", "sbj_char_span": [16, 25], "obj_char_span": [142, 152], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [28, 29]}], "umls_entity_list": []}, {"text": "Warfarin-induced iliopsoas hemorrhage with subsequent femoral nerve palsy.", "entity_list": [{"name": "hemorrhage", "ent_type": "Disease", "char_span": [27, 37], "ent_id": "D006470", "tok_span": [9, 10]}, {"name": "Warfarin", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D014859", "tok_span": [0, 3]}, {"name": "femoral nerve palsy", "ent_type": "Disease", "char_span": [54, 73], "ent_id": "D020428", "tok_span": [12, 15]}], "relation_list": [{"subject": "Warfarin", "object": "femoral nerve palsy", "sbj_char_span": [0, 8], "obj_char_span": [54, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [12, 15]}], "umls_entity_list": []}, {"text": "We present the case of a 28-year-old man on chronic warfarin therapy who sustained a minor muscle tear and developed increasing pain and a flexure contracture of the right hip.", "entity_list": [{"name": "contracture", "ent_type": "Disease", "char_span": [147, 158], "ent_id": "D003286", "tok_span": [30, 32]}, {"name": "warfarin", "ent_type": "Chemical", "char_span": [52, 60], "ent_id": "D014859", "tok_span": [14, 15]}, {"name": "pain", "ent_type": "Disease", "char_span": [128, 132], "ent_id": "D010146", "tok_span": [25, 26]}, {"name": "muscle tear", "ent_type": "Disease", "char_span": [91, 102], "ent_id": "D009135", "tok_span": [20, 22]}], "relation_list": [{"subject": "warfarin", "object": "muscle tear", "sbj_char_span": [52, 60], "obj_char_span": [91, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [20, 22]}], "umls_entity_list": []}, {"text": "Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.", "entity_list": [{"name": "motor and sensory impairment", "ent_type": "Disease", "char_span": [195, 223], "ent_id": "D015417", "tok_span": [37, 41]}, {"name": "femoral nerve palsy", "ent_type": "Disease", "char_span": [22, 41], "ent_id": "D020428", "tok_span": [6, 9]}, {"name": "warfarin", "ent_type": "Chemical", "char_span": [77, 85], "ent_id": "D014859", "tok_span": [15, 16]}, {"name": "pain", "ent_type": "Disease", "char_span": [147, 151], "ent_id": "D010146", "tok_span": [26, 27]}, {"name": "contracture", "ent_type": "Disease", "char_span": [237, 248], "ent_id": "D003286", "tok_span": [45, 47]}, {"name": "peripheral neuropathy", "ent_type": "Disease", "char_span": [94, 115], "ent_id": "D010523", "tok_span": [18, 20]}], "relation_list": [{"subject": "warfarin", "object": "femoral nerve palsy", "sbj_char_span": [77, 85], "obj_char_span": [22, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 16], "obj_tok_span": [6, 9]}], "umls_entity_list": []}, {"text": "Myasthenia gravis caused by penicillamine and chloroquine therapy for rheumatoid arthritis.", "entity_list": [{"name": "chloroquine", "ent_type": "Chemical", "char_span": [46, 57], "ent_id": "D002738", "tok_span": [14, 17]}, {"name": "rheumatoid arthritis", "ent_type": "Disease", "char_span": [70, 90], "ent_id": "D001172", "tok_span": [19, 21]}, {"name": "Myasthenia gravis", "ent_type": "Disease", "char_span": [0, 17], "ent_id": "D009157", "tok_span": [0, 6]}, {"name": "penicillamine", "ent_type": "Chemical", "char_span": [28, 41], "ent_id": "D010396", "tok_span": [8, 13]}], "relation_list": [{"subject": "chloroquine", "object": "Myasthenia gravis", "sbj_char_span": [46, 57], "obj_char_span": [0, 17], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [0, 6]}, {"subject": "penicillamine", "object": "Myasthenia gravis", "sbj_char_span": [28, 41], "obj_char_span": [0, 17], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 13], "obj_tok_span": [0, 6]}], "umls_entity_list": []}, {"text": "We have described a unique patient who had reversible and dose-related myasthenia gravis after penicillamine and chloroquine therapy for rheumatoid arthritis.", "entity_list": [{"name": "penicillamine", "ent_type": "Chemical", "char_span": [95, 108], "ent_id": "D010396", "tok_span": [20, 25]}, {"name": "myasthenia gravis", "ent_type": "Disease", "char_span": [71, 88], "ent_id": "D009157", "tok_span": [13, 19]}, {"name": "chloroquine", "ent_type": "Chemical", "char_span": [113, 124], "ent_id": "D002738", "tok_span": [26, 29]}, {"name": "rheumatoid arthritis", "ent_type": "Disease", "char_span": [137, 157], "ent_id": "D001172", "tok_span": [31, 33]}], "relation_list": [{"subject": "penicillamine", "object": "myasthenia gravis", "sbj_char_span": [95, 108], "obj_char_span": [71, 88], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 25], "obj_tok_span": [13, 19]}, {"subject": "chloroquine", "object": "myasthenia gravis", "sbj_char_span": [113, 124], "obj_char_span": [71, 88], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 29], "obj_tok_span": [13, 19]}], "umls_entity_list": []}, {"text": "Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.", "entity_list": [{"name": "acute tubular necrosis", "ent_type": "Disease", "char_span": [23, 45], "ent_id": "D007683", "tok_span": [3, 6]}, {"name": "gentamicin sulfate", "ent_type": "Chemical", "char_span": [171, 189], "ent_id": "D005839", "tok_span": [28, 31]}, {"name": "oliguric renal failure", "ent_type": "Disease", "char_span": [81, 103], "ent_id": "D00984", "tok_span": [11, 15]}, {"name": "cephalothin sodium", "ent_type": "Chemical", "char_span": [148, 166], "ent_id": "D002512", "tok_span": [23, 27]}], "relation_list": [{"subject": "gentamicin sulfate", "object": "acute tubular necrosis", "sbj_char_span": [171, 189], "obj_char_span": [23, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 31], "obj_tok_span": [3, 6]}, {"subject": "cephalothin sodium", "object": "acute tubular necrosis", "sbj_char_span": [148, 166], "obj_char_span": [23, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 27], "obj_tok_span": [3, 6]}], "umls_entity_list": []}, {"text": "These lemon essential oils showed strong ability to improve memory impaired by scopolamine; however, s-perillyl alcohol relieved the deficit of associative memory in PA only, and did not improve non-associative memory significantly in OFH.", "entity_list": [{"name": "scopolamine", "ent_type": "Chemical", "char_span": [79, 90], "ent_id": "D012601", "tok_span": [13, 16]}, {"name": "deficit of associative memory", "ent_type": "Disease", "char_span": [133, 162], "ent_id": "D008569", "tok_span": [28, 32]}, {"name": "memory impaired", "ent_type": "Disease", "char_span": [60, 75], "ent_id": "D008569", "tok_span": [10, 12]}, {"name": "s-perillyl alcohol", "ent_type": "Chemical", "char_span": [101, 119], "ent_id": "C032208", "tok_span": [19, 25]}], "relation_list": [{"subject": "scopolamine", "object": "memory impaired", "sbj_char_span": [79, 90], "obj_char_span": [60, 75], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [10, 12]}, {"subject": "scopolamine", "object": "deficit of associative memory", "sbj_char_span": [79, 90], "obj_char_span": [133, 162], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.)) and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).", "entity_list": [{"name": "memory deficits", "ent_type": "Disease", "char_span": [115, 130], "ent_id": "D008569", "tok_span": [44, 46]}, {"name": "Ro4368554", "ent_type": "Chemical", "char_span": [6, 15], "ent_id": "C507242", "tok_span": [2, 7]}, {"name": "metrifonate", "ent_type": "Chemical", "char_span": [63, 74], "ent_id": "D014236", "tok_span": [25, 30]}, {"name": "scopolamine", "ent_type": "Chemical", "char_span": [142, 153], "ent_id": "D012601", "tok_span": [48, 51]}, {"name": "TRP", "ent_type": "Chemical", "char_span": [158, 161], "ent_id": "D014364", "tok_span": [52, 53]}], "relation_list": [{"subject": "scopolamine", "object": "memory deficits", "sbj_char_span": [142, 153], "obj_char_span": [115, 130], "rel_type": "chemical-induced disease", "sbj_tok_span": [48, 51], "obj_tok_span": [44, 46]}], "umls_entity_list": []}, {"text": "Lone atrial fibrillation associated with creatine monohydrate supplementation.", "entity_list": [{"name": "atrial fibrillation", "ent_type": "Disease", "char_span": [5, 24], "ent_id": "D001281", "tok_span": [2, 4]}, {"name": "creatine", "ent_type": "Chemical", "char_span": [41, 49], "ent_id": "D003401", "tok_span": [6, 8]}], "relation_list": [{"subject": "creatine", "object": "atrial fibrillation", "sbj_char_span": [41, 49], "obj_char_span": [5, 24], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [2, 4]}], "umls_entity_list": []}, {"text": "RESULTS: Maternal toxicity, intrauterine growth retardation, and increase of external and skeletal variations were found in rats treated with the highest dose of piroxicam.", "entity_list": [{"name": "toxicity", "ent_type": "Disease", "char_span": [18, 26], "ent_id": "D064420", "tok_span": [3, 4]}, {"name": "increase of external and skeletal variations", "ent_type": "Disease", "char_span": [65, 109], "ent_id": "D009139", "tok_span": [11, 17]}, {"name": "intrauterine growth retardation", "ent_type": "Disease", "char_span": [28, 59], "ent_id": "D005317", "tok_span": [5, 9]}, {"name": "piroxicam", "ent_type": "Chemical", "char_span": [162, 171], "ent_id": "D010894", "tok_span": [27, 31]}], "relation_list": [{"subject": "piroxicam", "object": "increase of external and skeletal variations", "sbj_char_span": [162, 171], "obj_char_span": [65, 109], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 31], "obj_tok_span": [11, 17]}, {"subject": "piroxicam", "object": "intrauterine growth retardation", "sbj_char_span": [162, 171], "obj_char_span": [28, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 31], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "Protective efficacy of neuroactive steroids against cocaine kindled-seizures in mice.", "entity_list": [{"name": "cocaine", "ent_type": "Chemical", "char_span": [52, 59], "ent_id": "D003042", "tok_span": [9, 10]}, {"name": "steroids", "ent_type": "Chemical", "char_span": [35, 43], "ent_id": "D013256", "tok_span": [7, 8]}, {"name": "seizures", "ent_type": "Disease", "char_span": [68, 76], "ent_id": "D012640", "tok_span": [13, 14]}], "relation_list": [{"subject": "cocaine", "object": "seizures", "sbj_char_span": [52, 59], "obj_char_span": [68, 76], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [13, 14]}], "umls_entity_list": []}, {"text": "The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (seizure kindling).", "entity_list": [{"name": "GABA", "ent_type": "Chemical", "char_span": [150, 154], "ent_id": "D005680", "tok_span": [27, 28]}, {"name": "seizure", "ent_type": "Disease", "char_span": [288, 295], "ent_id": "D012640", "tok_span": [54, 55]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [264, 271], "ent_id": "D003042", "tok_span": [51, 52]}, {"name": "gamma-aminobutyric acid", "ent_type": "Chemical", "char_span": [125, 148], "ent_id": "D005680", "tok_span": [19, 26]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [233, 240], "ent_id": "D003042", "tok_span": [45, 46]}, {"name": "steroid", "ent_type": "Chemical", "char_span": [88, 95], "ent_id": "D013256", "tok_span": [14, 15]}], "relation_list": [{"subject": "cocaine", "object": "seizure", "sbj_char_span": [264, 271], "obj_char_span": [288, 295], "rel_type": "chemical-induced disease", "sbj_tok_span": [51, 52], "obj_tok_span": [54, 55]}, {"subject": "cocaine", "object": "seizure", "sbj_char_span": [233, 240], "obj_char_span": [288, 295], "rel_type": "chemical-induced disease", "sbj_tok_span": [45, 46], "obj_tok_span": [54, 55]}], "umls_entity_list": []}, {"text": "Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.", "entity_list": [{"name": "3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one", "ent_type": "Chemical", "char_span": [167, 216], "ent_id": "C105051", "tok_span": [55, 74]}, {"name": "seizures", "ent_type": "Disease", "char_span": [361, 369], "ent_id": "D012640", "tok_span": [107, 108]}, {"name": "allopregnanolone", "ent_type": "Chemical", "char_span": [150, 166], "ent_id": "D011280", "tok_span": [50, 55]}, {"name": "3alpha-hydroxy-5alpha-pregnan-20-one", "ent_type": "Chemical", "char_span": [18, 54], "ent_id": "D011280", "tok_span": [6, 20]}, {"name": "pregnanolone", "ent_type": "Chemical", "char_span": [57, 69], "ent_id": "D011280", "tok_span": [22, 25]}, {"name": "3alpha-hydroxy-5beta-pregnan-20-one", "ent_type": "Chemical", "char_span": [71, 106], "ent_id": "D011280", "tok_span": [26, 40]}, {"name": "Allopregnanolone", "ent_type": "Chemical", "char_span": [0, 16], "ent_id": "D011280", "tok_span": [0, 5]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [345, 352], "ent_id": "D003042", "tok_span": [103, 104]}, {"name": "ganaxolone", "ent_type": "Chemical", "char_span": [112, 122], "ent_id": "C105051", "tok_span": [42, 45]}], "relation_list": [{"subject": "cocaine", "object": "seizures", "sbj_char_span": [345, 352], "obj_char_span": [361, 369], "rel_type": "chemical-induced disease", "sbj_tok_span": [103, 104], "obj_tok_span": [107, 108]}], "umls_entity_list": []}, {"text": "Kindled seizures were induced by daily administration of 60 mg/kg cocaine for 5 days.", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [8, 16], "ent_id": "D012640", "tok_span": [2, 3]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [66, 73], "ent_id": "D003042", "tok_span": [13, 14]}], "relation_list": [{"subject": "cocaine", "object": "seizures", "sbj_char_span": [66, 73], "obj_char_span": [8, 16], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 14], "obj_tok_span": [2, 3]}], "umls_entity_list": []}, {"text": "These are nephrotoxic, but SRL seems to act differently displaying only minor nephrotoxic effects, although this question is still open.", "entity_list": [{"name": "nephrotoxic", "ent_type": "Disease", "char_span": [10, 21], "ent_id": "D007674", "tok_span": [2, 5]}, {"name": "nephrotoxic", "ent_type": "Disease", "char_span": [78, 89], "ent_id": "D007674", "tok_span": [16, 19]}, {"name": "SRL", "ent_type": "Chemical", "char_span": [27, 30], "ent_id": "D020123", "tok_span": [7, 9]}], "relation_list": [{"subject": "SRL", "object": "nephrotoxic", "sbj_char_span": [27, 30], "obj_char_span": [78, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 9], "obj_tok_span": [16, 19]}, {"subject": "SRL", "object": "nephrotoxic", "sbj_char_span": [27, 30], "obj_char_span": [10, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 9], "obj_tok_span": [2, 5]}], "umls_entity_list": []}, {"text": "In a number of treatment protocols where SRL was combined with a calcineurin inhibitor indications of a synergistic nephrotoxic effect were described.", "entity_list": [{"name": "nephrotoxic", "ent_type": "Disease", "char_span": [116, 127], "ent_id": "D007674", "tok_span": [21, 24]}, {"name": "SRL", "ent_type": "Chemical", "char_span": [41, 44], "ent_id": "D020123", "tok_span": [7, 9]}], "relation_list": [{"subject": "SRL", "object": "nephrotoxic", "sbj_char_span": [41, 44], "obj_char_span": [116, 127], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 9], "obj_tok_span": [21, 24]}], "umls_entity_list": []}, {"text": "CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.", "entity_list": [{"name": "SRL", "ent_type": "Chemical", "char_span": [109, 112], "ent_id": "D020123", "tok_span": [23, 25]}, {"name": "CsA", "ent_type": "Chemical", "char_span": [76, 79], "ent_id": "D016572", "tok_span": [13, 15]}, {"name": "SRL", "ent_type": "Chemical", "char_span": [85, 88], "ent_id": "D020123", "tok_span": [16, 18]}, {"name": "FK506", "ent_type": "Chemical", "char_span": [98, 103], "ent_id": "D016559", "tok_span": [20, 22]}, {"name": "nephrotoxic", "ent_type": "Disease", "char_span": [54, 65], "ent_id": "D007674", "tok_span": [8, 11]}], "relation_list": [{"subject": "CsA", "object": "nephrotoxic", "sbj_char_span": [76, 79], "obj_char_span": [54, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [8, 11]}, {"subject": "FK506", "object": "nephrotoxic", "sbj_char_span": [98, 103], "obj_char_span": [54, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 22], "obj_tok_span": [8, 11]}, {"subject": "SRL", "object": "nephrotoxic", "sbj_char_span": [109, 112], "obj_char_span": [54, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 25], "obj_tok_span": [8, 11]}, {"subject": "SRL", "object": "nephrotoxic", "sbj_char_span": [85, 88], "obj_char_span": [54, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 18], "obj_tok_span": [8, 11]}], "umls_entity_list": []}, {"text": "Fucoidan-treated rats exhibited evidence of impaired blood clotting and hemodilution, had larger hematomas, and tended to have less inflammation in the vicinity of the hematoma after three days.", "entity_list": [{"name": "hemodilution", "ent_type": "Disease", "char_span": [72, 84], "ent_id": "D020141", "tok_span": [15, 18]}, {"name": "hematomas", "ent_type": "Disease", "char_span": [97, 106], "ent_id": "D006406", "tok_span": [21, 23]}, {"name": "impaired blood clotting", "ent_type": "Disease", "char_span": [44, 67], "ent_id": "D020141", "tok_span": [10, 14]}, {"name": "hematoma", "ent_type": "Disease", "char_span": [168, 176], "ent_id": "D006406", "tok_span": [35, 37]}, {"name": "inflammation", "ent_type": "Disease", "char_span": [132, 144], "ent_id": "D007249", "tok_span": [29, 30]}, {"name": "Fucoidan", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "C007789", "tok_span": [0, 4]}], "relation_list": [{"subject": "Fucoidan", "object": "impaired blood clotting", "sbj_char_span": [0, 8], "obj_char_span": [44, 67], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [10, 14]}, {"subject": "Fucoidan", "object": "hemodilution", "sbj_char_span": [0, 8], "obj_char_span": [72, 84], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [15, 18]}], "umls_entity_list": []}, {"text": "Paracetamol-associated coma, metabolic acidosis, renal and hepatic failure.", "entity_list": [{"name": "metabolic acidosis", "ent_type": "Disease", "char_span": [29, 47], "ent_id": "D000138", "tok_span": [9, 12]}, {"name": "Paracetamol", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D000082", "tok_span": [0, 4]}, {"name": "coma", "ent_type": "Disease", "char_span": [23, 27], "ent_id": "D003128", "tok_span": [6, 8]}, {"name": "renal and hepatic failure", "ent_type": "Disease", "char_span": [49, 74], "ent_id": "D05818", "tok_span": [13, 17]}], "relation_list": [{"subject": "Paracetamol", "object": "metabolic acidosis", "sbj_char_span": [0, 11], "obj_char_span": [29, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [9, 12]}], "umls_entity_list": []}, {"text": "A case of metabolic acidosis, acute renal failure and hepatic failure following paracetamol ingestion is presented.", "entity_list": [{"name": "metabolic acidosis", "ent_type": "Disease", "char_span": [10, 28], "ent_id": "D000138", "tok_span": [3, 6]}, {"name": "acute renal failure and hepatic failure", "ent_type": "Disease", "char_span": [30, 69], "ent_id": "D05818", "tok_span": [7, 13]}, {"name": "paracetamol", "ent_type": "Chemical", "char_span": [80, 91], "ent_id": "D000082", "tok_span": [14, 18]}], "relation_list": [{"subject": "paracetamol", "object": "metabolic acidosis", "sbj_char_span": [80, 91], "obj_char_span": [10, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 18], "obj_tok_span": [3, 6]}], "umls_entity_list": []}, {"text": "In two of the three deaths probably associated with ketoconazole treatment the drug had been continued after the onset of jaundice and other symptoms of hepatitis.", "entity_list": [{"name": "hepatitis", "ent_type": "Disease", "char_span": [153, 162], "ent_id": "D056486", "tok_span": [29, 30]}, {"name": "jaundice", "ent_type": "Disease", "char_span": [122, 130], "ent_id": "D007565", "tok_span": [22, 25]}, {"name": "deaths", "ent_type": "Disease", "char_span": [20, 26], "ent_id": "D003643", "tok_span": [5, 6]}, {"name": "ketoconazole", "ent_type": "Chemical", "char_span": [52, 64], "ent_id": "D007654", "tok_span": [9, 12]}], "relation_list": [{"subject": "ketoconazole", "object": "jaundice", "sbj_char_span": [52, 64], "obj_char_span": [122, 130], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [22, 25]}, {"subject": "ketoconazole", "object": "hepatitis", "sbj_char_span": [52, 64], "obj_char_span": [153, 162], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [29, 30]}], "umls_entity_list": []}, {"text": "Clinical and biochemical monitoring at regular intervals for evidence of hepatitis is advised during long term treatment with ketoconazole to prevent possible serious hepatic injury.", "entity_list": [{"name": "ketoconazole", "ent_type": "Chemical", "char_span": [126, 138], "ent_id": "D007654", "tok_span": [18, 21]}, {"name": "hepatitis", "ent_type": "Disease", "char_span": [73, 82], "ent_id": "D056486", "tok_span": [10, 11]}, {"name": "hepatic injury", "ent_type": "Disease", "char_span": [167, 181], "ent_id": "D056486", "tok_span": [25, 27]}], "relation_list": [{"subject": "ketoconazole", "object": "hepatic injury", "sbj_char_span": [126, 138], "obj_char_span": [167, 181], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [25, 27]}, {"subject": "ketoconazole", "object": "hepatitis", "sbj_char_span": [126, 138], "obj_char_span": [73, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [10, 11]}], "umls_entity_list": []}, {"text": "Combined effects of prolonged prostaglandin E1-induced hypotension and haemodilution on human hepatic function.", "entity_list": [{"name": "hypotension", "ent_type": "Disease", "char_span": [55, 66], "ent_id": "D007022", "tok_span": [9, 10]}, {"name": "prostaglandin E1", "ent_type": "Chemical", "char_span": [30, 46], "ent_id": "D000527", "tok_span": [4, 7]}, {"name": "haemodilution", "ent_type": "Disease", "char_span": [71, 84], "ent_id": "D020141", "tok_span": [11, 14]}], "relation_list": [{"subject": "prostaglandin E1", "object": "hypotension", "sbj_char_span": [30, 46], "obj_char_span": [55, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [9, 10]}], "umls_entity_list": []}, {"text": "Combined effects of prolonged prostaglandin E1 (PGE1)-induced hypotension and haemodilution on hepatic function were studied in 30 patients undergoing hip surgery.", "entity_list": [{"name": "prostaglandin E1", "ent_type": "Chemical", "char_span": [30, 46], "ent_id": "D000527", "tok_span": [4, 7]}, {"name": "PGE1", "ent_type": "Chemical", "char_span": [48, 52], "ent_id": "D000527", "tok_span": [8, 10]}, {"name": "haemodilution", "ent_type": "Disease", "char_span": [78, 91], "ent_id": "D020141", "tok_span": [15, 18]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [62, 73], "ent_id": "D007022", "tok_span": [13, 14]}], "relation_list": [{"subject": "prostaglandin E1", "object": "hypotension", "sbj_char_span": [30, 46], "obj_char_span": [62, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [13, 14]}, {"subject": "PGE1", "object": "hypotension", "sbj_char_span": [48, 52], "obj_char_span": [62, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [13, 14]}], "umls_entity_list": []}, {"text": "Controlled hypotension in groups A and C was induced with PGE1 to maintain mean arterial blood pressure at 55 mmHg for 180 min.", "entity_list": [{"name": "hypotension", "ent_type": "Disease", "char_span": [11, 22], "ent_id": "D007022", "tok_span": [1, 2]}, {"name": "PGE1", "ent_type": "Chemical", "char_span": [58, 62], "ent_id": "D000527", "tok_span": [10, 12]}], "relation_list": [{"subject": "PGE1", "object": "hypotension", "sbj_char_span": [58, 62], "obj_char_span": [11, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 12], "obj_tok_span": [1, 2]}], "umls_entity_list": []}, {"text": "The results suggest that a prolonged combination of more than 120 min of PGE1-induced hypotension and moderate haemodilution would cause impairment of hepatic function.", "entity_list": [{"name": "PGE1", "ent_type": "Chemical", "char_span": [73, 77], "ent_id": "D000527", "tok_span": [13, 15]}, {"name": "haemodilution", "ent_type": "Disease", "char_span": [111, 124], "ent_id": "D020141", "tok_span": [20, 23]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [86, 97], "ent_id": "D007022", "tok_span": [17, 18]}, {"name": "impairment of hepatic function", "ent_type": "Disease", "char_span": [137, 167], "ent_id": "D008107", "tok_span": [25, 29]}], "relation_list": [{"subject": "PGE1", "object": "impairment of hepatic function", "sbj_char_span": [73, 77], "obj_char_span": [137, 167], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [25, 29]}, {"subject": "PGE1", "object": "hypotension", "sbj_char_span": [73, 77], "obj_char_span": [86, 97], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [17, 18]}], "umls_entity_list": []}, {"text": "Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap.", "entity_list": [{"name": "Levodopa", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D007980", "tok_span": [0, 3]}, {"name": "Parkinson's disease", "ent_type": "Disease", "char_span": [46, 65], "ent_id": "D010300", "tok_span": [12, 16]}, {"name": "dyskinesias", "ent_type": "Disease", "char_span": [17, 28], "ent_id": "D004409", "tok_span": [5, 9]}], "relation_list": [{"subject": "Levodopa", "object": "dyskinesias", "sbj_char_span": [0, 8], "obj_char_span": [17, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "Although preclinical and clinical findings suggest pulsatile stimulation of striatal postsynaptic receptors as a key mechanism underlying levodopa-induced dyskinesias, their pathogenesis is still unclear.", "entity_list": [{"name": "levodopa", "ent_type": "Chemical", "char_span": [138, 146], "ent_id": "D007980", "tok_span": [18, 21]}, {"name": "dyskinesias", "ent_type": "Disease", "char_span": [155, 166], "ent_id": "D004409", "tok_span": [23, 27]}], "relation_list": [{"subject": "levodopa", "object": "dyskinesias", "sbj_char_span": [138, 146], "obj_char_span": [155, 166], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [23, 27]}], "umls_entity_list": []}, {"text": "Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms, dopamine receptor subtypes, ionotropic and metabotropic glutamate receptors, and non-dopaminergic neurotransmitter systems in the pathophysiology of levodopa-induced dyskinesias.", "entity_list": [{"name": "dyskinesias", "ent_type": "Disease", "char_span": [314, 325], "ent_id": "D004409", "tok_span": [49, 53]}, {"name": "dopamine", "ent_type": "Chemical", "char_span": [148, 156], "ent_id": "D004298", "tok_span": [21, 22]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [297, 305], "ent_id": "D007980", "tok_span": [44, 47]}, {"name": "glutamate", "ent_type": "Chemical", "char_span": [204, 213], "ent_id": "D018698", "tok_span": [30, 31]}], "relation_list": [{"subject": "levodopa", "object": "dyskinesias", "sbj_char_span": [297, 305], "obj_char_span": [314, 325], "rel_type": "chemical-induced disease", "sbj_tok_span": [44, 47], "obj_tok_span": [49, 53]}], "umls_entity_list": []}, {"text": "In this study, we investigated the therapeutic potential of bone marrow mononuclear cells (BMCs) in a model of epilepsy induced by pilocarpine in rats.", "entity_list": [{"name": "pilocarpine", "ent_type": "Chemical", "char_span": [131, 142], "ent_id": "D010862", "tok_span": [25, 28]}, {"name": "epilepsy", "ent_type": "Disease", "char_span": [111, 119], "ent_id": "D004827", "tok_span": [22, 23]}], "relation_list": [{"subject": "pilocarpine", "object": "epilepsy", "sbj_char_span": [131, 142], "obj_char_span": [111, 119], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 28], "obj_tok_span": [22, 23]}], "umls_entity_list": []}, {"text": "Cardioprotective effect of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.", "entity_list": [{"name": "salvianolic acid A", "ent_type": "Chemical", "char_span": [27, 45], "ent_id": "C066201", "tok_span": [4, 9]}, {"name": "myocardial infarction", "ent_type": "Disease", "char_span": [71, 92], "ent_id": "D009203", "tok_span": [16, 18]}, {"name": "isoproterenol", "ent_type": "Chemical", "char_span": [49, 62], "ent_id": "D007545", "tok_span": [10, 14]}], "relation_list": [{"subject": "isoproterenol", "object": "myocardial infarction", "sbj_char_span": [49, 62], "obj_char_span": [71, 92], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.", "entity_list": [{"name": "myocardial infarction", "ent_type": "Disease", "char_span": [121, 142], "ent_id": "D009203", "tok_span": [24, 26]}, {"name": "isoproterenol", "ent_type": "Chemical", "char_span": [99, 112], "ent_id": "D007545", "tok_span": [18, 22]}, {"name": "salvianolic acid A", "ent_type": "Chemical", "char_span": [77, 95], "ent_id": "C066201", "tok_span": [12, 17]}], "relation_list": [{"subject": "isoproterenol", "object": "myocardial infarction", "sbj_char_span": [99, 112], "obj_char_span": [121, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 22], "obj_tok_span": [24, 26]}], "umls_entity_list": []}, {"text": "The results of our study suggest that salvianolic acid A possessing antioxidant activity has a significant protective effect against isoproterenol-induced myocardial infarction.", "entity_list": [{"name": "isoproterenol", "ent_type": "Chemical", "char_span": [133, 146], "ent_id": "D007545", "tok_span": [21, 25]}, {"name": "myocardial infarction", "ent_type": "Disease", "char_span": [155, 176], "ent_id": "D009203", "tok_span": [27, 29]}, {"name": "salvianolic acid A", "ent_type": "Chemical", "char_span": [38, 56], "ent_id": "C066201", "tok_span": [7, 12]}], "relation_list": [{"subject": "isoproterenol", "object": "myocardial infarction", "sbj_char_span": [133, 146], "obj_char_span": [155, 176], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 25], "obj_tok_span": [27, 29]}], "umls_entity_list": []}, {"text": "Acute effects of N-(2-propylpentanoyl)urea on hippocampal amino acid neurotransmitters in pilocarpine-induced seizure in rats.", "entity_list": [{"name": "amino acid", "ent_type": "Chemical", "char_span": [58, 68], "ent_id": "D000596", "tok_span": [17, 19]}, {"name": "seizure", "ent_type": "Disease", "char_span": [110, 117], "ent_id": "D012640", "tok_span": [27, 28]}, {"name": "N-(2-propylpentanoyl)urea", "ent_type": "Chemical", "char_span": [17, 42], "ent_id": "C108761", "tok_span": [3, 15]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [90, 101], "ent_id": "D010862", "tok_span": [22, 25]}], "relation_list": [{"subject": "pilocarpine", "object": "seizure", "sbj_char_span": [90, 101], "obj_char_span": [110, 117], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 25], "obj_tok_span": [27, 28]}], "umls_entity_list": []}, {"text": "VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced seizure whereas the corresponding value for VPA was 322 mg/kg.", "entity_list": [{"name": "seizure", "ent_type": "Disease", "char_span": [135, 142], "ent_id": "D012640", "tok_span": [34, 35]}, {"name": "VPA", "ent_type": "Chemical", "char_span": [25, 28], "ent_id": "D014635", "tok_span": [6, 8]}, {"name": "VPA", "ent_type": "Chemical", "char_span": [179, 182], "ent_id": "D014635", "tok_span": [40, 42]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [115, 126], "ent_id": "D010862", "tok_span": [29, 32]}, {"name": "VPU", "ent_type": "Chemical", "char_span": [0, 3], "ent_id": "C108761", "tok_span": [0, 2]}], "relation_list": [{"subject": "pilocarpine", "object": "seizure", "sbj_char_span": [115, 126], "obj_char_span": [135, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 32], "obj_tok_span": [34, 35]}], "umls_entity_list": []}, {"text": "Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.", "entity_list": [{"name": "aspartate", "ent_type": "Chemical", "char_span": [256, 265], "ent_id": "D001224", "tok_span": [45, 47]}, {"name": "VPA", "ent_type": "Chemical", "char_span": [34, 37], "ent_id": "D014635", "tok_span": [8, 10]}, {"name": "VPU", "ent_type": "Chemical", "char_span": [26, 29], "ent_id": "C108761", "tok_span": [5, 7]}, {"name": "glutamate", "ent_type": "Chemical", "char_span": [242, 251], "ent_id": "D018698", "tok_span": [43, 44]}, {"name": "amino acid", "ent_type": "Chemical", "char_span": [149, 159], "ent_id": "D000596", "tok_span": [29, 31]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [72, 83], "ent_id": "D010862", "tok_span": [15, 18]}, {"name": "seizure", "ent_type": "Disease", "char_span": [92, 99], "ent_id": "D012640", "tok_span": [20, 21]}], "relation_list": [{"subject": "pilocarpine", "object": "seizure", "sbj_char_span": [72, 83], "obj_char_span": [92, 99], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [20, 21]}], "umls_entity_list": []}, {"text": "Therefore, like VPA, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced seizure in experimental animals.", "entity_list": [{"name": "pilocarpine", "ent_type": "Chemical", "char_span": [67, 78], "ent_id": "D010862", "tok_span": [14, 17]}, {"name": "seizure", "ent_type": "Disease", "char_span": [221, 228], "ent_id": "D012640", "tok_span": [47, 48]}, {"name": "glutamate", "ent_type": "Chemical", "char_span": [100, 109], "ent_id": "D018698", "tok_span": [21, 22]}, {"name": "VPU", "ent_type": "Chemical", "char_span": [38, 41], "ent_id": "C108761", "tok_span": [9, 11]}, {"name": "VPA", "ent_type": "Chemical", "char_span": [16, 19], "ent_id": "D014635", "tok_span": [3, 5]}, {"name": "aspartate", "ent_type": "Chemical", "char_span": [114, 123], "ent_id": "D001224", "tok_span": [23, 25]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [201, 212], "ent_id": "D010862", "tok_span": [42, 45]}], "relation_list": [{"subject": "pilocarpine", "object": "seizure", "sbj_char_span": [67, 78], "obj_char_span": [221, 228], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [47, 48]}, {"subject": "pilocarpine", "object": "seizure", "sbj_char_span": [201, 212], "obj_char_span": [221, 228], "rel_type": "chemical-induced disease", "sbj_tok_span": [42, 45], "obj_tok_span": [47, 48]}], "umls_entity_list": []}, {"text": "Acute hepatitis attack after exposure to telithromycin.", "entity_list": [{"name": "hepatitis", "ent_type": "Disease", "char_span": [6, 15], "ent_id": "D056486", "tok_span": [1, 2]}, {"name": "telithromycin", "ent_type": "Chemical", "char_span": [41, 54], "ent_id": "C106791", "tok_span": [6, 9]}], "relation_list": [{"subject": "telithromycin", "object": "hepatitis", "sbj_char_span": [41, 54], "obj_char_span": [6, 15], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [1, 2]}], "umls_entity_list": []}, {"text": "The patient had suffered a previous episode of \"acute hepatitis of unknown origin,\" that occurred after telithromycin usage.", "entity_list": [{"name": "hepatitis", "ent_type": "Disease", "char_span": [54, 63], "ent_id": "D056486", "tok_span": [10, 11]}, {"name": "telithromycin", "ent_type": "Chemical", "char_span": [104, 117], "ent_id": "C106791", "tok_span": [19, 22]}], "relation_list": [{"subject": "telithromycin", "object": "hepatitis", "sbj_char_span": [104, 117], "obj_char_span": [54, 63], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 22], "obj_tok_span": [10, 11]}], "umls_entity_list": []}, {"text": "Based on a score of 8 on the Naranjo adverse drug reaction probability scale, telithromycin was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced toxic hepatitis.", "entity_list": [{"name": "adverse drug reaction", "ent_type": "Disease", "char_span": [37, 58], "ent_id": "D064420", "tok_span": [11, 14]}, {"name": "toxic hepatitis", "ent_type": "Disease", "char_span": [200, 215], "ent_id": "D056486", "tok_span": [38, 40]}, {"name": "telithromycin", "ent_type": "Chemical", "char_span": [78, 91], "ent_id": "C106791", "tok_span": [17, 20]}, {"name": "hepatitis", "ent_type": "Disease", "char_span": [124, 133], "ent_id": "D056486", "tok_span": [26, 27]}], "relation_list": [{"subject": "telithromycin", "object": "hepatitis", "sbj_char_span": [78, 91], "obj_char_span": [124, 133], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [26, 27]}, {"subject": "telithromycin", "object": "toxic hepatitis", "sbj_char_span": [78, 91], "obj_char_span": [200, 215], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [38, 40]}], "umls_entity_list": []}, {"text": "Recurrence of hepatitis attack might have been avoided if the initial incident had been communicated to the attending physician who prescribed telithromycin the second time.", "entity_list": [{"name": "hepatitis", "ent_type": "Disease", "char_span": [14, 23], "ent_id": "D056486", "tok_span": [4, 5]}, {"name": "telithromycin", "ent_type": "Chemical", "char_span": [143, 156], "ent_id": "C106791", "tok_span": [23, 26]}], "relation_list": [{"subject": "telithromycin", "object": "hepatitis", "sbj_char_span": [143, 156], "obj_char_span": [14, 23], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [4, 5]}], "umls_entity_list": []}, {"text": "CONCLUSION: Here we report a case of acute hepatitis probably associated with the administration of telithromycin.", "entity_list": [{"name": "hepatitis", "ent_type": "Disease", "char_span": [43, 52], "ent_id": "D056486", "tok_span": [9, 10]}, {"name": "telithromycin", "ent_type": "Chemical", "char_span": [100, 113], "ent_id": "C106791", "tok_span": [16, 19]}], "relation_list": [{"subject": "telithromycin", "object": "hepatitis", "sbj_char_span": [100, 113], "obj_char_span": [43, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [9, 10]}], "umls_entity_list": []}, {"text": "Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.", "entity_list": [{"name": "Spironolactone", "ent_type": "Chemical", "char_span": [0, 14], "ent_id": "D013148", "tok_span": [0, 5]}, {"name": "hyperkalemia", "ent_type": "Disease", "char_span": [47, 59], "ent_id": "D006947", "tok_span": [10, 14]}, {"name": "renal insufficiency", "ent_type": "Disease", "char_span": [23, 42], "ent_id": "D051437", "tok_span": [7, 9]}, {"name": "heart failure", "ent_type": "Disease", "char_span": [77, 90], "ent_id": "D006333", "tok_span": [17, 19]}], "relation_list": [{"subject": "Spironolactone", "object": "hyperkalemia", "sbj_char_span": [0, 14], "obj_char_span": [47, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [10, 14]}, {"subject": "Spironolactone", "object": "renal insufficiency", "sbj_char_span": [0, 14], "obj_char_span": [23, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "BACKGROUND: A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia (2%) and renal insufficiency (0%).", "entity_list": [{"name": "heart failure", "ent_type": "Disease", "char_span": [91, 104], "ent_id": "D006333", "tok_span": [16, 18]}, {"name": "hyperkalemia", "ent_type": "Disease", "char_span": [137, 149], "ent_id": "D006947", "tok_span": [24, 28]}, {"name": "spironolactone", "ent_type": "Chemical", "char_span": [73, 87], "ent_id": "D013148", "tok_span": [11, 15]}, {"name": "renal insufficiency", "ent_type": "Disease", "char_span": [159, 178], "ent_id": "D051437", "tok_span": [33, 35]}], "relation_list": [{"subject": "spironolactone", "object": "renal insufficiency", "sbj_char_span": [73, 87], "obj_char_span": [159, 178], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [33, 35]}, {"subject": "spironolactone", "object": "hyperkalemia", "sbj_char_span": [73, 87], "obj_char_span": [137, 149], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [24, 28]}], "umls_entity_list": []}, {"text": "We therefore sought to determine the prevalence and clinical associations of hyperkalemia and renal insufficiency in heart failure patients treated with spironolactone.", "entity_list": [{"name": "renal insufficiency", "ent_type": "Disease", "char_span": [94, 113], "ent_id": "D051437", "tok_span": [16, 18]}, {"name": "heart failure", "ent_type": "Disease", "char_span": [117, 130], "ent_id": "D006333", "tok_span": [19, 21]}, {"name": "hyperkalemia", "ent_type": "Disease", "char_span": [77, 89], "ent_id": "D006947", "tok_span": [11, 15]}, {"name": "spironolactone", "ent_type": "Chemical", "char_span": [153, 167], "ent_id": "D013148", "tok_span": [24, 28]}], "relation_list": [{"subject": "spironolactone", "object": "hyperkalemia", "sbj_char_span": [153, 167], "obj_char_span": [77, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 28], "obj_tok_span": [11, 15]}, {"subject": "spironolactone", "object": "renal insufficiency", "sbj_char_span": [153, 167], "obj_char_span": [94, 113], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 28], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "RESULTS: Sixty-seven of 926 patients (7.2%) required discontinuation of spironolactone due to hyperkalemia (n = 33) or renal failure (n = 34).", "entity_list": [{"name": "renal failure", "ent_type": "Disease", "char_span": [119, 132], "ent_id": "D051437", "tok_span": [34, 36]}, {"name": "spironolactone", "ent_type": "Chemical", "char_span": [72, 86], "ent_id": "D013148", "tok_span": [18, 22]}, {"name": "hyperkalemia", "ent_type": "Disease", "char_span": [94, 106], "ent_id": "D006947", "tok_span": [24, 28]}], "relation_list": [{"subject": "spironolactone", "object": "hyperkalemia", "sbj_char_span": [72, 86], "obj_char_span": [94, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 22], "obj_tok_span": [24, 28]}, {"subject": "spironolactone", "object": "renal failure", "sbj_char_span": [72, 86], "obj_char_span": [119, 132], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 22], "obj_tok_span": [34, 36]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Spironolactone-induced hyperkalemia and renal insufficiency are more common in our clinical experience than reported previously.", "entity_list": [{"name": "Spironolactone", "ent_type": "Chemical", "char_span": [13, 27], "ent_id": "D013148", "tok_span": [2, 7]}, {"name": "renal insufficiency", "ent_type": "Disease", "char_span": [53, 72], "ent_id": "D051437", "tok_span": [14, 16]}, {"name": "hyperkalemia", "ent_type": "Disease", "char_span": [36, 48], "ent_id": "D006947", "tok_span": [9, 13]}], "relation_list": [{"subject": "Spironolactone", "object": "hyperkalemia", "sbj_char_span": [13, 27], "obj_char_span": [36, 48], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 7], "obj_tok_span": [9, 13]}, {"subject": "Spironolactone", "object": "renal insufficiency", "sbj_char_span": [13, 27], "obj_char_span": [53, 72], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 7], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "BACKGROUND: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic.", "entity_list": [{"name": "tacrolimus", "ent_type": "Chemical", "char_span": [56, 66], "ent_id": "D016559", "tok_span": [10, 12]}, {"name": "nephrotoxic", "ent_type": "Disease", "char_span": [88, 99], "ent_id": "D007674", "tok_span": [17, 20]}, {"name": "cyclosporine", "ent_type": "Chemical", "char_span": [39, 51], "ent_id": "D016572", "tok_span": [7, 9]}], "relation_list": [{"subject": "cyclosporine", "object": "nephrotoxic", "sbj_char_span": [39, 51], "obj_char_span": [88, 99], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 9], "obj_tok_span": [17, 20]}, {"subject": "tacrolimus", "object": "nephrotoxic", "sbj_char_span": [56, 66], "obj_char_span": [88, 99], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 12], "obj_tok_span": [17, 20]}], "umls_entity_list": []}, {"text": "BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.", "entity_list": [{"name": "Nimodipine", "ent_type": "Chemical", "char_span": [40, 50], "ent_id": "D009553", "tok_span": [8, 11]}, {"name": "acute stroke", "ent_type": "Disease", "char_span": [197, 209], "ent_id": "D020521", "tok_span": [41, 43]}, {"name": "nimodipine", "ent_type": "Chemical", "char_span": [115, 125], "ent_id": "D009553", "tok_span": [24, 27]}, {"name": "Stroke", "ent_type": "Disease", "char_span": [65, 71], "ent_id": "D020521", "tok_span": [13, 14]}, {"name": "reduction in blood pressure", "ent_type": "Disease", "char_span": [134, 161], "ent_id": "D007022", "tok_span": [29, 33]}], "relation_list": [{"subject": "Nimodipine", "object": "reduction in blood pressure", "sbj_char_span": [40, 50], "obj_char_span": [134, 161], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [29, 33]}, {"subject": "nimodipine", "object": "reduction in blood pressure", "sbj_char_span": [115, 125], "obj_char_span": [134, 161], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 27], "obj_tok_span": [29, 33]}], "umls_entity_list": []}, {"text": "Nimodipine treatment resulted in a statistically significant reduction in systolic BP (SBP) and diastolic BP (DBP) from baseline compared with placebo during the first few days.", "entity_list": [{"name": "Nimodipine", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D009553", "tok_span": [0, 3]}, {"name": "reduction in systolic BP", "ent_type": "Disease", "char_span": [61, 85], "ent_id": "D007022", "tok_span": [9, 13]}], "relation_list": [{"subject": "Nimodipine", "object": "reduction in systolic BP", "sbj_char_span": [0, 10], "obj_char_span": [61, 85], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [9, 13]}], "umls_entity_list": []}, {"text": "Transient neurologic symptoms after spinal anesthesia: a lower incidence with prilocaine and bupivacaine than with lidocaine.", "entity_list": [{"name": "bupivacaine", "ent_type": "Chemical", "char_span": [93, 104], "ent_id": "D002045", "tok_span": [15, 19]}, {"name": "prilocaine", "ent_type": "Chemical", "char_span": [78, 88], "ent_id": "D011318", "tok_span": [12, 14]}, {"name": "Transient neurologic symptoms", "ent_type": "Disease", "char_span": [0, 29], "ent_id": "D009422", "tok_span": [0, 4]}, {"name": "lidocaine", "ent_type": "Chemical", "char_span": [115, 124], "ent_id": "D008012", "tok_span": [21, 23]}], "relation_list": [{"subject": "prilocaine", "object": "Transient neurologic symptoms", "sbj_char_span": [78, 88], "obj_char_span": [0, 29], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 14], "obj_tok_span": [0, 4]}, {"subject": "lidocaine", "object": "Transient neurologic symptoms", "sbj_char_span": [115, 124], "obj_char_span": [0, 29], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 23], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "BACKGROUND: Recent evidence suggests that transient neurologic symptoms (TNSs) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine.", "entity_list": [{"name": "bupivacaine", "ent_type": "Chemical", "char_span": [149, 160], "ent_id": "D002045", "tok_span": [24, 28]}, {"name": "lidocaine", "ent_type": "Chemical", "char_span": [97, 106], "ent_id": "D008012", "tok_span": [15, 17]}, {"name": "TNSs", "ent_type": "Disease", "char_span": [73, 77], "ent_id": "D009422", "tok_span": [10, 12]}, {"name": "transient neurologic symptoms", "ent_type": "Disease", "char_span": [42, 71], "ent_id": "D009422", "tok_span": [6, 9]}], "relation_list": [{"subject": "lidocaine", "object": "TNSs", "sbj_char_span": [97, 106], "obj_char_span": [73, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 17], "obj_tok_span": [10, 12]}, {"subject": "lidocaine", "object": "transient neurologic symptoms", "sbj_char_span": [97, 106], "obj_char_span": [42, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 17], "obj_tok_span": [6, 9]}], "umls_entity_list": []}, {"text": "Accordingly, the present, prospective double-blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of TNSs.", "entity_list": [{"name": "TNSs", "ent_type": "Disease", "char_span": [164, 168], "ent_id": "D009422", "tok_span": [31, 33]}, {"name": "lidocaine", "ent_type": "Chemical", "char_span": [82, 91], "ent_id": "D008012", "tok_span": [14, 16]}, {"name": "prilocaine", "ent_type": "Chemical", "char_span": [66, 76], "ent_id": "D011318", "tok_span": [11, 13]}, {"name": "bupivacaine", "ent_type": "Chemical", "char_span": [96, 107], "ent_id": "D002045", "tok_span": [17, 21]}], "relation_list": [{"subject": "lidocaine", "object": "TNSs", "sbj_char_span": [82, 91], "obj_char_span": [164, 168], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [31, 33]}, {"subject": "prilocaine", "object": "TNSs", "sbj_char_span": [66, 76], "obj_char_span": [164, 168], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 13], "obj_tok_span": [31, 33]}], "umls_entity_list": []}, {"text": "RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.", "entity_list": [{"name": "TNSs", "ent_type": "Disease", "char_span": [61, 65], "ent_id": "D009422", "tok_span": [10, 12]}, {"name": "prilocaine", "ent_type": "Chemical", "char_span": [94, 104], "ent_id": "D011318", "tok_span": [18, 20]}, {"name": "TNSs", "ent_type": "Disease", "char_span": [176, 180], "ent_id": "D009422", "tok_span": [41, 43]}, {"name": "bupivacaine", "ent_type": "Chemical", "char_span": [160, 171], "ent_id": "D002045", "tok_span": [36, 40]}, {"name": "lidocaine", "ent_type": "Chemical", "char_span": [39, 48], "ent_id": "D008012", "tok_span": [7, 9]}], "relation_list": [{"subject": "prilocaine", "object": "TNSs", "sbj_char_span": [94, 104], "obj_char_span": [61, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 20], "obj_tok_span": [10, 12]}, {"subject": "prilocaine", "object": "TNSs", "sbj_char_span": [94, 104], "obj_char_span": [176, 180], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 20], "obj_tok_span": [41, 43]}, {"subject": "lidocaine", "object": "TNSs", "sbj_char_span": [39, 48], "obj_char_span": [61, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 9], "obj_tok_span": [10, 12]}, {"subject": "lidocaine", "object": "TNSs", "sbj_char_span": [39, 48], "obj_char_span": [176, 180], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 9], "obj_tok_span": [41, 43]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Prilocaine may be preferable to lidocaine for short surgical procedures because it has a similar duration of action but a lower incidence of TNSs.", "entity_list": [{"name": "lidocaine", "ent_type": "Chemical", "char_span": [45, 54], "ent_id": "D008012", "tok_span": [9, 11]}, {"name": "Prilocaine", "ent_type": "Chemical", "char_span": [13, 23], "ent_id": "D011318", "tok_span": [2, 5]}, {"name": "TNSs", "ent_type": "Disease", "char_span": [154, 158], "ent_id": "D009422", "tok_span": [28, 30]}], "relation_list": [{"subject": "lidocaine", "object": "TNSs", "sbj_char_span": [45, 54], "obj_char_span": [154, 158], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 11], "obj_tok_span": [28, 30]}, {"subject": "Prilocaine", "object": "TNSs", "sbj_char_span": [13, 23], "obj_char_span": [154, 158], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [28, 30]}], "umls_entity_list": []}, {"text": "The role of nicotine in smoking-related cardiovascular disease.", "entity_list": [{"name": "cardiovascular disease", "ent_type": "Disease", "char_span": [40, 62], "ent_id": "D002318", "tok_span": [8, 10]}, {"name": "nicotine", "ent_type": "Chemical", "char_span": [12, 20], "ent_id": "D009538", "tok_span": [3, 4]}], "relation_list": [{"subject": "nicotine", "object": "cardiovascular disease", "sbj_char_span": [12, 20], "obj_char_span": [40, 62], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "Nicotine activates the sympathetic nervous system and in this way could contribute to cardiovascular disease.", "entity_list": [{"name": "cardiovascular disease", "ent_type": "Disease", "char_span": [86, 108], "ent_id": "D002318", "tok_span": [14, 16]}, {"name": "Nicotine", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D009538", "tok_span": [0, 2]}], "relation_list": [{"subject": "Nicotine", "object": "cardiovascular disease", "sbj_char_span": [0, 8], "obj_char_span": [86, 108], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "Animal studies and mechanistic studies indicate that nicotine could play a role in accelerating atherosclerosis, but evidence among humans is too inadequate to be definitive about such an effect.", "entity_list": [{"name": "atherosclerosis", "ent_type": "Disease", "char_span": [96, 111], "ent_id": "D050197", "tok_span": [14, 15]}, {"name": "nicotine", "ent_type": "Chemical", "char_span": [53, 61], "ent_id": "D009538", "tok_span": [7, 8]}], "relation_list": [{"subject": "nicotine", "object": "atherosclerosis", "sbj_char_span": [53, 61], "obj_char_span": [96, 111], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [14, 15]}], "umls_entity_list": []}, {"text": "Seizure resulting from a venlafaxine overdose.", "entity_list": [{"name": "Seizure", "ent_type": "Disease", "char_span": [0, 7], "ent_id": "D012640", "tok_span": [0, 3]}, {"name": "overdose", "ent_type": "Disease", "char_span": [37, 45], "ent_id": "D062787", "tok_span": [11, 13]}, {"name": "venlafaxine", "ent_type": "Chemical", "char_span": [25, 36], "ent_id": "C047426", "tok_span": [6, 11]}], "relation_list": [{"subject": "venlafaxine", "object": "Seizure", "sbj_char_span": [25, 36], "obj_char_span": [0, 7], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 11], "obj_tok_span": [0, 3]}, {"subject": "venlafaxine", "object": "overdose", "sbj_char_span": [25, 36], "obj_char_span": [37, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 11], "obj_tok_span": [11, 13]}], "umls_entity_list": []}, {"text": "OBJECTIVE: To report a case of venlafaxine overdose.", "entity_list": [{"name": "overdose", "ent_type": "Disease", "char_span": [43, 51], "ent_id": "D062787", "tok_span": [12, 14]}, {"name": "venlafaxine", "ent_type": "Chemical", "char_span": [31, 42], "ent_id": "C047426", "tok_span": [7, 12]}], "relation_list": [{"subject": "venlafaxine", "object": "overdose", "sbj_char_span": [31, 42], "obj_char_span": [43, 51], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 12], "obj_tok_span": [12, 14]}], "umls_entity_list": []}, {"text": "CASE SUMMARY: A 40-year-old woman with major depression took an overdose of venlafaxine in an apparent suicide attempt.", "entity_list": [{"name": "overdose", "ent_type": "Disease", "char_span": [64, 72], "ent_id": "D062787", "tok_span": [15, 17]}, {"name": "major depression", "ent_type": "Disease", "char_span": [39, 55], "ent_id": "D003865", "tok_span": [11, 13]}, {"name": "venlafaxine", "ent_type": "Chemical", "char_span": [76, 87], "ent_id": "C047426", "tok_span": [18, 23]}], "relation_list": [{"subject": "venlafaxine", "object": "overdose", "sbj_char_span": [76, 87], "obj_char_span": [64, 72], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 23], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "After the ingestion of 26 venlafaxine 50-mg tablets, the patient experienced a witnessed generalized seizure.", "entity_list": [{"name": "venlafaxine", "ent_type": "Chemical", "char_span": [26, 37], "ent_id": "C047426", "tok_span": [5, 10]}, {"name": "seizure", "ent_type": "Disease", "char_span": [101, 108], "ent_id": "D012640", "tok_span": [22, 23]}], "relation_list": [{"subject": "venlafaxine", "object": "seizure", "sbj_char_span": [26, 37], "obj_char_span": [101, 108], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 10], "obj_tok_span": [22, 23]}], "umls_entity_list": []}, {"text": "DISCUSSION: To our knowledge, this is the first reported case of venlafaxine overdose that resulted in a generalized seizure.", "entity_list": [{"name": "venlafaxine", "ent_type": "Chemical", "char_span": [65, 76], "ent_id": "C047426", "tok_span": [13, 18]}, {"name": "seizure", "ent_type": "Disease", "char_span": [117, 124], "ent_id": "D012640", "tok_span": [25, 26]}, {"name": "overdose", "ent_type": "Disease", "char_span": [77, 85], "ent_id": "D062787", "tok_span": [18, 20]}], "relation_list": [{"subject": "venlafaxine", "object": "overdose", "sbj_char_span": [65, 76], "obj_char_span": [77, 85], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 18], "obj_tok_span": [18, 20]}, {"subject": "venlafaxine", "object": "seizure", "sbj_char_span": [65, 76], "obj_char_span": [117, 124], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 18], "obj_tok_span": [25, 26]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: The venlafaxine overdose in our patient resulted in a single episode of generalized seizure but elicited no further sequelae.", "entity_list": [{"name": "overdose", "ent_type": "Disease", "char_span": [29, 37], "ent_id": "D062787", "tok_span": [8, 10]}, {"name": "seizure", "ent_type": "Disease", "char_span": [97, 104], "ent_id": "D012640", "tok_span": [20, 21]}, {"name": "venlafaxine", "ent_type": "Chemical", "char_span": [17, 28], "ent_id": "C047426", "tok_span": [3, 8]}], "relation_list": [{"subject": "venlafaxine", "object": "overdose", "sbj_char_span": [17, 28], "obj_char_span": [29, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 8], "obj_tok_span": [8, 10]}, {"subject": "venlafaxine", "object": "seizure", "sbj_char_span": [17, 28], "obj_char_span": [97, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 8], "obj_tok_span": [20, 21]}], "umls_entity_list": []}, {"text": "Two groups of patients receiving tacrolimus were compared over a period of 1 year, one group comprising hypertensive patients who were receiving nifedipine, and the other comprising nonhypertensive patients not receiving nifedipine.", "entity_list": [{"name": "nifedipine", "ent_type": "Chemical", "char_span": [221, 231], "ent_id": "D009543", "tok_span": [37, 40]}, {"name": "hypertensive", "ent_type": "Disease", "char_span": [104, 116], "ent_id": "D006973", "tok_span": [19, 20]}, {"name": "nifedipine", "ent_type": "Chemical", "char_span": [145, 155], "ent_id": "D009543", "tok_span": [24, 27]}, {"name": "tacrolimus", "ent_type": "Chemical", "char_span": [33, 43], "ent_id": "D016559", "tok_span": [5, 7]}], "relation_list": [{"subject": "tacrolimus", "object": "hypertensive", "sbj_char_span": [33, 43], "obj_char_span": [104, 116], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 7], "obj_tok_span": [19, 20]}], "umls_entity_list": []}, {"text": "The observed positive impact of nifedipine on reducing the nephrotoxicity associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population.", "entity_list": [{"name": "nephrotoxicity", "ent_type": "Disease", "char_span": [59, 73], "ent_id": "D007674", "tok_span": [11, 14]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [193, 205], "ent_id": "D006973", "tok_span": [33, 34]}, {"name": "tacrolimus", "ent_type": "Chemical", "char_span": [90, 100], "ent_id": "D016559", "tok_span": [16, 18]}, {"name": "nifedipine", "ent_type": "Chemical", "char_span": [32, 42], "ent_id": "D009543", "tok_span": [5, 8]}], "relation_list": [{"subject": "tacrolimus", "object": "hypertension", "sbj_char_span": [90, 100], "obj_char_span": [193, 205], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 18], "obj_tok_span": [33, 34]}], "umls_entity_list": []}, {"text": "Sinus arrest associated with continuous-infusion cimetidine.", "entity_list": [{"name": "Sinus arrest", "ent_type": "Disease", "char_span": [0, 12], "ent_id": "D054138", "tok_span": [0, 3]}, {"name": "cimetidine", "ent_type": "Chemical", "char_span": [49, 59], "ent_id": "D002927", "tok_span": [8, 11]}], "relation_list": [{"subject": "cimetidine", "object": "Sinus arrest", "sbj_char_span": [49, 59], "obj_char_span": [0, 12], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "The administration of intermittent intravenous infusions of cimetidine is infrequently associated with the development of bradyarrhythmias.", "entity_list": [{"name": "bradyarrhythmias", "ent_type": "Disease", "char_span": [122, 138], "ent_id": "D001919", "tok_span": [19, 24]}, {"name": "cimetidine", "ent_type": "Chemical", "char_span": [60, 70], "ent_id": "D002927", "tok_span": [8, 11]}], "relation_list": [{"subject": "cimetidine", "object": "bradyarrhythmias", "sbj_char_span": [60, 70], "obj_char_span": [122, 138], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [19, 24]}], "umls_entity_list": []}, {"text": "A 40-year-old man with leukemia and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion cimetidine 50 mg/hour.", "entity_list": [{"name": "cimetidine", "ent_type": "Chemical", "char_span": [163, 173], "ent_id": "D002927", "tok_span": [29, 32]}, {"name": "sinus arrest", "ent_type": "Disease", "char_span": [114, 126], "ent_id": "D054138", "tok_span": [22, 24]}, {"name": "leukemia", "ent_type": "Disease", "char_span": [23, 31], "ent_id": "D007938", "tok_span": [8, 9]}, {"name": "cardiac disease", "ent_type": "Disease", "char_span": [50, 65], "ent_id": "D006331", "tok_span": [13, 15]}], "relation_list": [{"subject": "cimetidine", "object": "sinus arrest", "sbj_char_span": [163, 173], "obj_char_span": [114, 126], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 32], "obj_tok_span": [22, 24]}], "umls_entity_list": []}, {"text": "This is the first reported case of sinus arrest associated with continuous-infusion cimetidine.", "entity_list": [{"name": "cimetidine", "ent_type": "Chemical", "char_span": [84, 94], "ent_id": "D002927", "tok_span": [14, 17]}, {"name": "sinus arrest", "ent_type": "Disease", "char_span": [35, 47], "ent_id": "D054138", "tok_span": [7, 9]}], "relation_list": [{"subject": "cimetidine", "object": "sinus arrest", "sbj_char_span": [84, 94], "obj_char_span": [35, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "Composition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid.", "entity_list": [{"name": "octreotide", "ent_type": "Chemical", "char_span": [51, 61], "ent_id": "D015282", "tok_span": [7, 10]}, {"name": "gall bladder stones", "ent_type": "Disease", "char_span": [15, 34], "ent_id": "D042882", "tok_span": [2, 5]}, {"name": "ursodeoxycholic acid", "ent_type": "Chemical", "char_span": [80, 100], "ent_id": "D014580", "tok_span": [14, 20]}], "relation_list": [{"subject": "octreotide", "object": "gall bladder stones", "sbj_char_span": [51, 61], "obj_char_span": [15, 34], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [2, 5]}], "umls_entity_list": []}, {"text": "Octreotide, an effective treatment for acromegaly, induces gall bladder stones in 13-60% of patients.", "entity_list": [{"name": "Octreotide", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D015282", "tok_span": [0, 3]}, {"name": "gall bladder stones", "ent_type": "Disease", "char_span": [59, 78], "ent_id": "D042882", "tok_span": [13, 16]}, {"name": "acromegaly", "ent_type": "Disease", "char_span": [39, 49], "ent_id": "D000172", "tok_span": [8, 11]}], "relation_list": [{"subject": "Octreotide", "object": "gall bladder stones", "sbj_char_span": [0, 10], "obj_char_span": [59, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "Because knowledge of stone composition is essential for studies of their pathogenesis, treatment, and prevention, this was investigated by direct and indirect methods in 14 octreotide treated acromegalic patients with gall stones.", "entity_list": [{"name": "octreotide", "ent_type": "Chemical", "char_span": [173, 183], "ent_id": "D015282", "tok_span": [28, 31]}, {"name": "gall stones", "ent_type": "Disease", "char_span": [218, 229], "ent_id": "D042882", "tok_span": [37, 39]}, {"name": "acromegalic", "ent_type": "Disease", "char_span": [192, 203], "ent_id": "D000172", "tok_span": [32, 35]}], "relation_list": [{"subject": "octreotide", "object": "gall stones", "sbj_char_span": [173, 183], "obj_char_span": [218, 229], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 31], "obj_tok_span": [37, 39]}], "umls_entity_list": []}, {"text": "In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.", "entity_list": [{"name": "gall stone disease", "ent_type": "Disease", "char_span": [135, 153], "ent_id": "D042882", "tok_span": [24, 27]}, {"name": "gall stones", "ent_type": "Disease", "char_span": [226, 237], "ent_id": "D042882", "tok_span": [40, 42]}, {"name": "calcium", "ent_type": "Chemical", "char_span": [249, 256], "ent_id": "D002118", "tok_span": [43, 44]}, {"name": "octreotide", "ent_type": "Chemical", "char_span": [15, 25], "ent_id": "D015282", "tok_span": [3, 6]}, {"name": "gall stones", "ent_type": "Disease", "char_span": [34, 45], "ent_id": "D042882", "tok_span": [7, 9]}, {"name": "cholesterol", "ent_type": "Chemical", "char_span": [81, 92], "ent_id": "D002784", "tok_span": [16, 17]}], "relation_list": [{"subject": "octreotide", "object": "gall stones", "sbj_char_span": [15, 25], "obj_char_span": [226, 237], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [40, 42]}, {"subject": "octreotide", "object": "gall stones", "sbj_char_span": [15, 25], "obj_char_span": [34, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [7, 9]}, {"subject": "octreotide", "object": "gall stone disease", "sbj_char_span": [15, 25], "obj_char_span": [135, 153], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [24, 27]}], "umls_entity_list": []}, {"text": "Cardiovascular complications associated with terbutaline treatment for preterm labor.", "entity_list": [{"name": "terbutaline", "ent_type": "Chemical", "char_span": [45, 56], "ent_id": "D013726", "tok_span": [4, 7]}, {"name": "preterm labor", "ent_type": "Disease", "char_span": [71, 84], "ent_id": "D007752", "tok_span": [9, 11]}, {"name": "Cardiovascular complications", "ent_type": "Disease", "char_span": [0, 28], "ent_id": "D002318", "tok_span": [0, 2]}], "relation_list": [{"subject": "terbutaline", "object": "Cardiovascular complications", "sbj_char_span": [45, 56], "obj_char_span": [0, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Severe cardiovascular complications occurred in eight of 160 patients treated with terbutaline for preterm labor.", "entity_list": [{"name": "cardiovascular complications", "ent_type": "Disease", "char_span": [7, 35], "ent_id": "D002318", "tok_span": [1, 3]}, {"name": "terbutaline", "ent_type": "Chemical", "char_span": [83, 94], "ent_id": "D013726", "tok_span": [11, 14]}, {"name": "preterm labor", "ent_type": "Disease", "char_span": [99, 112], "ent_id": "D007752", "tok_span": [15, 17]}], "relation_list": [{"subject": "terbutaline", "object": "cardiovascular complications", "sbj_char_span": [83, 94], "obj_char_span": [7, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [1, 3]}], "umls_entity_list": []}, {"text": "Of the 20 animals that received subarachnoid injection of 2-chloroprocaine-CE seven (35%) developed hind-limb paralysis.", "entity_list": [{"name": "paralysis", "ent_type": "Disease", "char_span": [110, 119], "ent_id": "D010243", "tok_span": [30, 32]}, {"name": "2-chloroprocaine-CE", "ent_type": "Chemical", "char_span": [58, 77], "ent_id": "C004616", "tok_span": [13, 21]}], "relation_list": [{"subject": "2-chloroprocaine-CE", "object": "paralysis", "sbj_char_span": [58, 77], "obj_char_span": [110, 119], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 21], "obj_tok_span": [30, 32]}], "umls_entity_list": []}, {"text": "Of the 15 spinal cords of the animals that received 2-chloroprocaine-CE, 13 showed subpial necrosis; the nerve roots and subarachnoid vessels were normal.", "entity_list": [{"name": "2-chloroprocaine-CE", "ent_type": "Chemical", "char_span": [52, 71], "ent_id": "C004616", "tok_span": [11, 19]}, {"name": "subpial necrosis", "ent_type": "Disease", "char_span": [83, 99], "ent_id": "D013118", "tok_span": [22, 25]}], "relation_list": [{"subject": "2-chloroprocaine-CE", "object": "subpial necrosis", "sbj_char_span": [52, 71], "obj_char_span": [83, 99], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 19], "obj_tok_span": [22, 25]}], "umls_entity_list": []}, {"text": "Hyperkalemia associated with sulindac therapy.", "entity_list": [{"name": "Hyperkalemia", "ent_type": "Disease", "char_span": [0, 12], "ent_id": "D006947", "tok_span": [0, 4]}, {"name": "sulindac", "ent_type": "Chemical", "char_span": [29, 37], "ent_id": "D013467", "tok_span": [6, 9]}], "relation_list": [{"subject": "sulindac", "object": "Hyperkalemia", "sbj_char_span": [29, 37], "obj_char_span": [0, 12], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "Hyperkalemia has recently been recognized as a complication of nonsteroidal antiinflammatory agents (NSAID) such as indomethacin.", "entity_list": [{"name": "indomethacin", "ent_type": "Chemical", "char_span": [116, 128], "ent_id": "D007213", "tok_span": [24, 27]}, {"name": "Hyperkalemia", "ent_type": "Disease", "char_span": [0, 12], "ent_id": "D006947", "tok_span": [0, 4]}], "relation_list": [{"subject": "indomethacin", "object": "Hyperkalemia", "sbj_char_span": [116, 128], "obj_char_span": [0, 12], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 27], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "We describe 4 patients in whom hyperkalemia ranging from 6.1 to 6.9 mEq/l developed within 3 to 8 days of sulindac administration.", "entity_list": [{"name": "hyperkalemia", "ent_type": "Disease", "char_span": [31, 43], "ent_id": "D006947", "tok_span": [6, 10]}, {"name": "sulindac", "ent_type": "Chemical", "char_span": [106, 114], "ent_id": "D013467", "tok_span": [30, 33]}], "relation_list": [{"subject": "sulindac", "object": "hyperkalemia", "sbj_char_span": [106, 114], "obj_char_span": [31, 43], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 33], "obj_tok_span": [6, 10]}], "umls_entity_list": []}, {"text": "As no other medications known to effect serum potassium had been given concomitantly, this course of events is suggestive of a cause-and-effect relationship between sulindac and hyperkalemia.", "entity_list": [{"name": "hyperkalemia", "ent_type": "Disease", "char_span": [178, 190], "ent_id": "D006947", "tok_span": [34, 38]}, {"name": "sulindac", "ent_type": "Chemical", "char_span": [165, 173], "ent_id": "D013467", "tok_span": [30, 33]}, {"name": "potassium", "ent_type": "Chemical", "char_span": [46, 55], "ent_id": "D011188", "tok_span": [8, 9]}], "relation_list": [{"subject": "sulindac", "object": "hyperkalemia", "sbj_char_span": [165, 173], "obj_char_span": [178, 190], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 33], "obj_tok_span": [34, 38]}], "umls_entity_list": []}, {"text": "Ventricular tachyarrhythmias during cesarean section after ritodrine therapy: interaction with anesthetics.", "entity_list": [{"name": "Ventricular tachyarrhythmias", "ent_type": "Disease", "char_span": [0, 28], "ent_id": "D014693", "tok_span": [0, 8]}, {"name": "ritodrine", "ent_type": "Chemical", "char_span": [59, 68], "ent_id": "D012312", "tok_span": [13, 16]}], "relation_list": [{"subject": "ritodrine", "object": "Ventricular tachyarrhythmias", "sbj_char_span": [59, 68], "obj_char_span": [0, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [0, 8]}], "umls_entity_list": []}, {"text": "Immunohistochemical, electron microscopic and morphometric studies of estrogen-induced rat prolactinomas after bromocriptine treatment.", "entity_list": [{"name": "estrogen", "ent_type": "Chemical", "char_span": [70, 78], "ent_id": "D004967", "tok_span": [10, 11]}, {"name": "bromocriptine", "ent_type": "Chemical", "char_span": [111, 124], "ent_id": "D001971", "tok_span": [18, 22]}, {"name": "prolactinomas", "ent_type": "Disease", "char_span": [91, 104], "ent_id": "D015175", "tok_span": [14, 17]}], "relation_list": [{"subject": "estrogen", "object": "prolactinomas", "sbj_char_span": [70, 78], "obj_char_span": [91, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [14, 17]}], "umls_entity_list": []}, {"text": "To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).", "entity_list": [{"name": "bromocriptine", "ent_type": "Chemical", "char_span": [26, 39], "ent_id": "D001971", "tok_span": [5, 9]}, {"name": "prolactinoma", "ent_type": "Disease", "char_span": [43, 55], "ent_id": "D015175", "tok_span": [10, 13]}, {"name": "bromocriptine", "ent_type": "Chemical", "char_span": [223, 236], "ent_id": "D001971", "tok_span": [46, 50]}, {"name": "prolactinoma", "ent_type": "Disease", "char_span": [173, 185], "ent_id": "D015175", "tok_span": [34, 37]}, {"name": "estrogen", "ent_type": "Chemical", "char_span": [152, 160], "ent_id": "D004967", "tok_span": [30, 31]}], "relation_list": [{"subject": "estrogen", "object": "prolactinoma", "sbj_char_span": [152, 160], "obj_char_span": [43, 55], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 31], "obj_tok_span": [10, 13]}, {"subject": "estrogen", "object": "prolactinoma", "sbj_char_span": [152, 160], "obj_char_span": [173, 185], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 31], "obj_tok_span": [34, 37]}], "umls_entity_list": []}, {"text": "Liver enlargement and muscle wastage occurred in Wistar rats following the subcutaneous administration of prednisolone.", "entity_list": [{"name": "muscle wastage", "ent_type": "Disease", "char_span": [22, 36], "ent_id": "D009133", "tok_span": [3, 6]}, {"name": "prednisolone", "ent_type": "Chemical", "char_span": [106, 118], "ent_id": "D011239", "tok_span": [15, 17]}, {"name": "Liver enlargement", "ent_type": "Disease", "char_span": [0, 17], "ent_id": "D006529", "tok_span": [0, 2]}], "relation_list": [{"subject": "prednisolone", "object": "Liver enlargement", "sbj_char_span": [106, 118], "obj_char_span": [0, 17], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 17], "obj_tok_span": [0, 2]}, {"subject": "prednisolone", "object": "muscle wastage", "sbj_char_span": [106, 118], "obj_char_span": [22, 36], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 17], "obj_tok_span": [3, 6]}], "umls_entity_list": []}, {"text": "Possible intramuscular midazolam-associated cardiorespiratory arrest and death.", "entity_list": [{"name": "death", "ent_type": "Disease", "char_span": [73, 78], "ent_id": "D003643", "tok_span": [13, 14]}, {"name": "midazolam", "ent_type": "Chemical", "char_span": [23, 32], "ent_id": "D008874", "tok_span": [2, 5]}, {"name": "cardiorespiratory arrest", "ent_type": "Disease", "char_span": [44, 68], "ent_id": "D006323", "tok_span": [7, 12]}], "relation_list": [{"subject": "midazolam", "object": "cardiorespiratory arrest", "sbj_char_span": [23, 32], "obj_char_span": [44, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [7, 12]}], "umls_entity_list": []}, {"text": "This report describes the first published case of cardiorespiratory arrest and death associated with intramuscular administration of midazolam.", "entity_list": [{"name": "cardiorespiratory arrest", "ent_type": "Disease", "char_span": [50, 74], "ent_id": "D006323", "tok_span": [8, 13]}, {"name": "midazolam", "ent_type": "Chemical", "char_span": [133, 142], "ent_id": "D008874", "tok_span": [20, 23]}, {"name": "death", "ent_type": "Disease", "char_span": [79, 84], "ent_id": "D003643", "tok_span": [14, 15]}], "relation_list": [{"subject": "midazolam", "object": "cardiorespiratory arrest", "sbj_char_span": [133, 142], "obj_char_span": [50, 74], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [8, 13]}], "umls_entity_list": []}, {"text": "Serial epilepsy caused by levodopa/carbidopa administration in two patients on hemodialysis.", "entity_list": [{"name": "epilepsy", "ent_type": "Disease", "char_span": [7, 15], "ent_id": "D004827", "tok_span": [2, 3]}, {"name": "levodopa/carbidopa", "ent_type": "Chemical", "char_span": [26, 44], "ent_id": "C009265", "tok_span": [5, 12]}], "relation_list": [{"subject": "levodopa/carbidopa", "object": "epilepsy", "sbj_char_span": [26, 44], "obj_char_span": [7, 15], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 12], "obj_tok_span": [2, 3]}], "umls_entity_list": []}, {"text": "The present study was carried out to test the effects of L-alpha-glycerylphosphorylcholine (L-alpha-GFC) on memory impairment induced by scopolamine in man.", "entity_list": [{"name": "scopolamine", "ent_type": "Chemical", "char_span": [137, 148], "ent_id": "D012601", "tok_span": [33, 36]}, {"name": "L-alpha-glycerylphosphorylcholine", "ent_type": "Chemical", "char_span": [57, 90], "ent_id": "D005997", "tok_span": [11, 20]}, {"name": "L-alpha-GFC", "ent_type": "Chemical", "char_span": [92, 103], "ent_id": "D005997", "tok_span": [21, 27]}, {"name": "memory impairment", "ent_type": "Disease", "char_span": [108, 125], "ent_id": "D008569", "tok_span": [29, 31]}], "relation_list": [{"subject": "scopolamine", "object": "memory impairment", "sbj_char_span": [137, 148], "obj_char_span": [108, 125], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 36], "obj_tok_span": [29, 31]}], "umls_entity_list": []}, {"text": "The findings of this study indicate that the drug is able to antagonize impairment of attention and memory induced by scopolamine.", "entity_list": [{"name": "scopolamine", "ent_type": "Chemical", "char_span": [118, 129], "ent_id": "D012601", "tok_span": [21, 24]}, {"name": "impairment of attention and memory", "ent_type": "Disease", "char_span": [72, 106], "ent_id": "D008569", "tok_span": [14, 19]}], "relation_list": [{"subject": "scopolamine", "object": "impairment of attention and memory", "sbj_char_span": [118, 129], "obj_char_span": [72, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [14, 19]}], "umls_entity_list": []}, {"text": "Seizures induced by the cocaine metabolite benzoylecgonine in rats.", "entity_list": [{"name": "Seizures", "ent_type": "Disease", "char_span": [0, 8], "ent_id": "D012640", "tok_span": [0, 3]}, {"name": "benzoylecgonine", "ent_type": "Chemical", "char_span": [43, 58], "ent_id": "C005618", "tok_span": [8, 12]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [24, 31], "ent_id": "D003042", "tok_span": [6, 7]}], "relation_list": [{"subject": "cocaine", "object": "Seizures", "sbj_char_span": [24, 31], "obj_char_span": [0, 8], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [0, 3]}, {"subject": "benzoylecgonine", "object": "Seizures", "sbj_char_span": [43, 58], "obj_char_span": [0, 8], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "The half-life (t1/2) of cocaine is relatively short, but some of the consequences of its use, such as seizures and strokes, can occur hours after exposure.", "entity_list": [{"name": "strokes", "ent_type": "Disease", "char_span": [115, 122], "ent_id": "D020521", "tok_span": [29, 30]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [24, 31], "ent_id": "D003042", "tok_span": [11, 12]}, {"name": "seizures", "ent_type": "Disease", "char_span": [102, 110], "ent_id": "D012640", "tok_span": [27, 28]}], "relation_list": [{"subject": "cocaine", "object": "seizures", "sbj_char_span": [24, 31], "obj_char_span": [102, 110], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [27, 28]}], "umls_entity_list": []}, {"text": "We evaluated the potential of the major metabolite of cocaine, benzoylecgonine (BE), to cause seizures.", "entity_list": [{"name": "BE", "ent_type": "Chemical", "char_span": [80, 82], "ent_id": "C005618", "tok_span": [16, 17]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [54, 61], "ent_id": "D003042", "tok_span": [9, 10]}, {"name": "seizures", "ent_type": "Disease", "char_span": [94, 102], "ent_id": "D012640", "tok_span": [21, 22]}, {"name": "benzoylecgonine", "ent_type": "Chemical", "char_span": [63, 78], "ent_id": "C005618", "tok_span": [11, 15]}], "relation_list": [{"subject": "BE", "object": "seizures", "sbj_char_span": [80, 82], "obj_char_span": [94, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 17], "obj_tok_span": [21, 22]}, {"subject": "benzoylecgonine", "object": "seizures", "sbj_char_span": [63, 78], "obj_char_span": [94, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [21, 22]}, {"subject": "cocaine", "object": "seizures", "sbj_char_span": [54, 61], "obj_char_span": [94, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [21, 22]}], "umls_entity_list": []}, {"text": "BE-Induced seizures occurred more frequently and had significantly longer latencies than those induced by equimolar amounts of cocaine.", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [11, 19], "ent_id": "D012640", "tok_span": [4, 5]}, {"name": "BE", "ent_type": "Chemical", "char_span": [0, 2], "ent_id": "C005618", "tok_span": [0, 1]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [127, 134], "ent_id": "D003042", "tok_span": [22, 23]}], "relation_list": [{"subject": "cocaine", "object": "seizures", "sbj_char_span": [127, 134], "obj_char_span": [11, 19], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [4, 5]}, {"subject": "BE", "object": "seizures", "sbj_char_span": [0, 2], "obj_char_span": [11, 19], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 1], "obj_tok_span": [4, 5]}], "umls_entity_list": []}, {"text": "Whereas cocaine-induced seizures were best characterized as brief, generalized, and tonic and resulted in death, those induced by BE were prolonged, often multiple and mixed in type, and rarely resulted in death.", "entity_list": [{"name": "cocaine", "ent_type": "Chemical", "char_span": [8, 15], "ent_id": "D003042", "tok_span": [1, 2]}, {"name": "death", "ent_type": "Disease", "char_span": [206, 211], "ent_id": "D003643", "tok_span": [38, 39]}, {"name": "BE", "ent_type": "Chemical", "char_span": [130, 132], "ent_id": "C005618", "tok_span": [23, 24]}, {"name": "death", "ent_type": "Disease", "char_span": [106, 111], "ent_id": "D003643", "tok_span": [18, 19]}, {"name": "seizures", "ent_type": "Disease", "char_span": [24, 32], "ent_id": "D012640", "tok_span": [4, 5]}], "relation_list": [{"subject": "cocaine", "object": "seizures", "sbj_char_span": [8, 15], "obj_char_span": [24, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 2], "obj_tok_span": [4, 5]}, {"subject": "BE", "object": "seizures", "sbj_char_span": [130, 132], "obj_char_span": [24, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 24], "obj_tok_span": [4, 5]}], "umls_entity_list": []}, {"text": "BE-Injected rats that did not have seizures had significantly more locomotor activity than cocaine-injected animals without seizures.", "entity_list": [{"name": "cocaine", "ent_type": "Chemical", "char_span": [91, 98], "ent_id": "D003042", "tok_span": [16, 17]}, {"name": "seizures", "ent_type": "Disease", "char_span": [35, 43], "ent_id": "D012640", "tok_span": [9, 10]}, {"name": "BE", "ent_type": "Chemical", "char_span": [0, 2], "ent_id": "C005618", "tok_span": [0, 1]}, {"name": "seizures", "ent_type": "Disease", "char_span": [124, 132], "ent_id": "D012640", "tok_span": [21, 22]}], "relation_list": [{"subject": "cocaine", "object": "seizures", "sbj_char_span": [91, 98], "obj_char_span": [124, 132], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 17], "obj_tok_span": [21, 22]}, {"subject": "cocaine", "object": "seizures", "sbj_char_span": [91, 98], "obj_char_span": [35, 43], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 17], "obj_tok_span": [9, 10]}, {"subject": "BE", "object": "seizures", "sbj_char_span": [0, 2], "obj_char_span": [124, 132], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 1], "obj_tok_span": [21, 22]}, {"subject": "BE", "object": "seizures", "sbj_char_span": [0, 2], "obj_char_span": [35, 43], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 1], "obj_tok_span": [9, 10]}], "umls_entity_list": []}, {"text": "The finding that cocaine- and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a cocaine metabolite, BE.", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [41, 49], "ent_id": "D012640", "tok_span": [9, 10]}, {"name": "BE", "ent_type": "Chemical", "char_span": [194, 196], "ent_id": "C005618", "tok_span": [33, 34]}, {"name": "BE", "ent_type": "Chemical", "char_span": [30, 32], "ent_id": "C005618", "tok_span": [6, 7]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [114, 121], "ent_id": "D003042", "tok_span": [20, 21]}, {"name": "seizures", "ent_type": "Disease", "char_span": [130, 138], "ent_id": "D012640", "tok_span": [23, 24]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [17, 24], "ent_id": "D003042", "tok_span": [3, 4]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [174, 181], "ent_id": "D003042", "tok_span": [30, 31]}], "relation_list": [{"subject": "cocaine", "object": "seizures", "sbj_char_span": [114, 121], "obj_char_span": [41, 49], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 21], "obj_tok_span": [9, 10]}, {"subject": "cocaine", "object": "seizures", "sbj_char_span": [17, 24], "obj_char_span": [130, 138], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [23, 24]}, {"subject": "BE", "object": "seizures", "sbj_char_span": [30, 32], "obj_char_span": [41, 49], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [9, 10]}, {"subject": "cocaine", "object": "seizures", "sbj_char_span": [174, 181], "obj_char_span": [41, 49], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 31], "obj_tok_span": [9, 10]}, {"subject": "cocaine", "object": "seizures", "sbj_char_span": [114, 121], "obj_char_span": [130, 138], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 21], "obj_tok_span": [23, 24]}, {"subject": "BE", "object": "seizures", "sbj_char_span": [194, 196], "obj_char_span": [41, 49], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 34], "obj_tok_span": [9, 10]}, {"subject": "cocaine", "object": "seizures", "sbj_char_span": [174, 181], "obj_char_span": [130, 138], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 31], "obj_tok_span": [23, 24]}, {"subject": "BE", "object": "seizures", "sbj_char_span": [30, 32], "obj_char_span": [130, 138], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [23, 24]}, {"subject": "cocaine", "object": "seizures", "sbj_char_span": [17, 24], "obj_char_span": [41, 49], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [9, 10]}, {"subject": "BE", "object": "seizures", "sbj_char_span": [194, 196], "obj_char_span": [130, 138], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 34], "obj_tok_span": [23, 24]}], "umls_entity_list": []}, {"text": "Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.", "entity_list": [{"name": "amphetamine", "ent_type": "Chemical", "char_span": [19, 30], "ent_id": "D000661", "tok_span": [2, 6]}, {"name": "dopamine", "ent_type": "Chemical", "char_span": [69, 77], "ent_id": "D004298", "tok_span": [12, 13]}, {"name": "amino acid", "ent_type": "Chemical", "char_span": [124, 134], "ent_id": "D000596", "tok_span": [24, 26]}, {"name": "neurotoxicity", "ent_type": "Disease", "char_span": [39, 52], "ent_id": "D020258", "tok_span": [8, 10]}, {"name": "LY274614", "ent_type": "Chemical", "char_span": [100, 108], "ent_id": "C070935", "tok_span": [17, 21]}], "relation_list": [{"subject": "amphetamine", "object": "neurotoxicity", "sbj_char_span": [19, 30], "obj_char_span": [39, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats.", "entity_list": [{"name": "LY274614", "ent_type": "Chemical", "char_span": [168, 176], "ent_id": "C070935", "tok_span": [30, 34]}, {"name": "neurotoxic", "ent_type": "Disease", "char_span": [42, 52], "ent_id": "D020258", "tok_span": [7, 9]}, {"name": "dopamine", "ent_type": "Chemical", "char_span": [118, 126], "ent_id": "D004298", "tok_span": [23, 24]}, {"name": "NMDA", "ent_type": "Chemical", "char_span": [183, 187], "ent_id": "D016202", "tok_span": [36, 37]}, {"name": "amphetamine", "ent_type": "Chemical", "char_span": [63, 74], "ent_id": "D000661", "tok_span": [11, 15]}, {"name": "NMDA", "ent_type": "Chemical", "char_span": [144, 148], "ent_id": "D016202", "tok_span": [26, 27]}], "relation_list": [{"subject": "amphetamine", "object": "neurotoxic", "sbj_char_span": [63, 74], "obj_char_span": [42, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "Neonatal pyridoxine responsive convulsions due to isoniazid therapy.", "entity_list": [{"name": "pyridoxine", "ent_type": "Chemical", "char_span": [9, 19], "ent_id": "D011736", "tok_span": [2, 6]}, {"name": "convulsions", "ent_type": "Disease", "char_span": [31, 42], "ent_id": "D012640", "tok_span": [7, 10]}, {"name": "isoniazid", "ent_type": "Chemical", "char_span": [50, 59], "ent_id": "D007538", "tok_span": [12, 16]}], "relation_list": [{"subject": "isoniazid", "object": "convulsions", "sbj_char_span": [50, 59], "obj_char_span": [31, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 16], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "A 17-day-old infant on isoniazid therapy 13 mg/kg daily from birth because of maternal tuberculosis was admitted after 4 days of clonic fits.", "entity_list": [{"name": "isoniazid", "ent_type": "Chemical", "char_span": [23, 32], "ent_id": "D007538", "tok_span": [8, 12]}, {"name": "clonic fits", "ent_type": "Disease", "char_span": [129, 140], "ent_id": "D012640", "tok_span": [30, 33]}, {"name": "tuberculosis", "ent_type": "Disease", "char_span": [87, 99], "ent_id": "D014376", "tok_span": [23, 24]}], "relation_list": [{"subject": "isoniazid", "object": "clonic fits", "sbj_char_span": [23, 32], "obj_char_span": [129, 140], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [30, 33]}], "umls_entity_list": []}, {"text": "The fits ceased within 4 hours of administering intramuscular pyridoxine, suggesting an aetiology of pyridoxine deficiency secondary to isoniazid medication.", "entity_list": [{"name": "isoniazid", "ent_type": "Chemical", "char_span": [136, 145], "ent_id": "D007538", "tok_span": [28, 32]}, {"name": "fits", "ent_type": "Disease", "char_span": [4, 8], "ent_id": "D012640", "tok_span": [1, 2]}, {"name": "pyridoxine", "ent_type": "Chemical", "char_span": [62, 72], "ent_id": "D011736", "tok_span": [11, 15]}, {"name": "pyridoxine", "ent_type": "Chemical", "char_span": [101, 111], "ent_id": "D011736", "tok_span": [21, 25]}], "relation_list": [{"subject": "isoniazid", "object": "fits", "sbj_char_span": [136, 145], "obj_char_span": [4, 8], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 32], "obj_tok_span": [1, 2]}], "umls_entity_list": []}, {"text": "Nitroglycerin has been shown to reduce ST-segment elevation during acute myocardial infarction, an effect potentiated in the dog by agents that reverse nitroglycerin-induced hypotension.", "entity_list": [{"name": "nitroglycerin", "ent_type": "Chemical", "char_span": [152, 165], "ent_id": "D005996", "tok_span": [29, 32]}, {"name": "Nitroglycerin", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D005996", "tok_span": [0, 4]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [174, 185], "ent_id": "D007022", "tok_span": [34, 35]}, {"name": "acute myocardial infarction", "ent_type": "Disease", "char_span": [67, 94], "ent_id": "D009203", "tok_span": [14, 17]}], "relation_list": [{"subject": "Nitroglycerin", "object": "hypotension", "sbj_char_span": [0, 13], "obj_char_span": [174, 185], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [34, 35]}, {"subject": "nitroglycerin", "object": "hypotension", "sbj_char_span": [152, 165], "obj_char_span": [174, 185], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 32], "obj_tok_span": [34, 35]}], "umls_entity_list": []}, {"text": "Elevation of ADAM10, ADAM17, MMP-2 and MMP-9 expression with media degeneration features CaCl2-induced thoracic aortic aneurysm in a rat model.", "entity_list": [{"name": "CaCl2", "ent_type": "Chemical", "char_span": [89, 94], "ent_id": "D002122", "tok_span": [21, 23]}, {"name": "thoracic aortic aneurysm", "ent_type": "Disease", "char_span": [103, 127], "ent_id": "D017545", "tok_span": [25, 28]}], "relation_list": [{"subject": "CaCl2", "object": "thoracic aortic aneurysm", "sbj_char_span": [89, 94], "obj_char_span": [103, 127], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 23], "obj_tok_span": [25, 28]}], "umls_entity_list": []}, {"text": "PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.", "entity_list": [{"name": "CaCl(2)", "ent_type": "Chemical", "char_span": [113, 120], "ent_id": "D002122", "tok_span": [23, 27]}, {"name": "TAA", "ent_type": "Disease", "char_span": [303, 306], "ent_id": "D017545", "tok_span": [66, 68]}, {"name": "TAA", "ent_type": "Disease", "char_span": [87, 90], "ent_id": "D017545", "tok_span": [16, 18]}, {"name": "calcium chloride", "ent_type": "Chemical", "char_span": [95, 111], "ent_id": "D002122", "tok_span": [20, 22]}, {"name": "arterial injury", "ent_type": "Disease", "char_span": [130, 145], "ent_id": "D014652", "tok_span": [30, 32]}, {"name": "thoracic aortic aneurysm", "ent_type": "Disease", "char_span": [61, 85], "ent_id": "D017545", "tok_span": [12, 15]}], "relation_list": [{"subject": "CaCl(2)", "object": "thoracic aortic aneurysm", "sbj_char_span": [113, 120], "obj_char_span": [61, 85], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 27], "obj_tok_span": [12, 15]}, {"subject": "CaCl(2)", "object": "TAA", "sbj_char_span": [113, 120], "obj_char_span": [87, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 27], "obj_tok_span": [16, 18]}, {"subject": "calcium chloride", "object": "TAA", "sbj_char_span": [95, 111], "obj_char_span": [303, 306], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 22], "obj_tok_span": [66, 68]}, {"subject": "calcium chloride", "object": "thoracic aortic aneurysm", "sbj_char_span": [95, 111], "obj_char_span": [61, 85], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 22], "obj_tok_span": [12, 15]}, {"subject": "CaCl(2)", "object": "TAA", "sbj_char_span": [113, 120], "obj_char_span": [303, 306], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 27], "obj_tok_span": [66, 68]}, {"subject": "calcium chloride", "object": "TAA", "sbj_char_span": [95, 111], "obj_char_span": [87, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 22], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.", "entity_list": [{"name": "TAA", "ent_type": "Disease", "char_span": [37, 40], "ent_id": "D017545", "tok_span": [6, 8]}, {"name": "CaCl(2)", "ent_type": "Chemical", "char_span": [63, 70], "ent_id": "D002122", "tok_span": [13, 17]}], "relation_list": [{"subject": "CaCl(2)", "object": "TAA", "sbj_char_span": [63, 70], "obj_char_span": [37, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "However, a bolus of epinephrine injected through an alternative catheter provoked a hypertensive crisis.", "entity_list": [{"name": "epinephrine", "ent_type": "Chemical", "char_span": [20, 31], "ent_id": "D004837", "tok_span": [5, 8]}, {"name": "hypertensive", "ent_type": "Disease", "char_span": [84, 96], "ent_id": "D006973", "tok_span": [16, 17]}], "relation_list": [{"subject": "epinephrine", "object": "hypertensive", "sbj_char_span": [20, 31], "obj_char_span": [84, 96], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [16, 17]}], "umls_entity_list": []}, {"text": "Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel.", "entity_list": [{"name": "glutamate", "ent_type": "Chemical", "char_span": [10, 19], "ent_id": "D018698", "tok_span": [3, 4]}, {"name": "peripheral neurotoxicity", "ent_type": "Disease", "char_span": [62, 86], "ent_id": "D010523", "tok_span": [9, 12]}, {"name": "paclitaxel", "ent_type": "Chemical", "char_span": [90, 100], "ent_id": "D017239", "tok_span": [13, 14]}], "relation_list": [{"subject": "paclitaxel", "object": "peripheral neurotoxicity", "sbj_char_span": [90, 100], "obj_char_span": [62, 86], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 14], "obj_tok_span": [9, 12]}], "umls_entity_list": []}, {"text": "Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.", "entity_list": [{"name": "glutamate", "ent_type": "Chemical", "char_span": [116, 125], "ent_id": "D018698", "tok_span": [18, 19]}, {"name": "amino acid", "ent_type": "Chemical", "char_span": [150, 160], "ent_id": "D000596", "tok_span": [23, 25]}, {"name": "peripheral neuropathy", "ent_type": "Disease", "char_span": [6, 27], "ent_id": "D010523", "tok_span": [1, 3]}, {"name": "neurotoxicity", "ent_type": "Disease", "char_span": [202, 215], "ent_id": "D020258", "tok_span": [32, 34]}, {"name": "paclitaxel", "ent_type": "Chemical", "char_span": [89, 99], "ent_id": "D017239", "tok_span": [12, 13]}, {"name": "PAC", "ent_type": "Chemical", "char_span": [198, 201], "ent_id": "D017239", "tok_span": [31, 32]}, {"name": "PAC", "ent_type": "Chemical", "char_span": [101, 104], "ent_id": "D017239", "tok_span": [14, 15]}, {"name": "glutamine", "ent_type": "Chemical", "char_span": [161, 170], "ent_id": "D018698", "tok_span": [25, 26]}], "relation_list": [{"subject": "paclitaxel", "object": "peripheral neuropathy", "sbj_char_span": [89, 99], "obj_char_span": [6, 27], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [1, 3]}, {"subject": "PAC", "object": "peripheral neuropathy", "sbj_char_span": [198, 201], "obj_char_span": [6, 27], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 32], "obj_tok_span": [1, 3]}, {"subject": "PAC", "object": "peripheral neuropathy", "sbj_char_span": [101, 104], "obj_char_span": [6, 27], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [1, 3]}], "umls_entity_list": []}, {"text": "This pilot trial aimed to evaluate the role of glutamate supplementation for preventing PAC-induced peripheral neuropathy in a randomized, placebo-controlled, double-blinded clinical and electro-diagnostic study.", "entity_list": [{"name": "peripheral neuropathy", "ent_type": "Disease", "char_span": [100, 121], "ent_id": "D010523", "tok_span": [16, 18]}, {"name": "glutamate", "ent_type": "Chemical", "char_span": [47, 56], "ent_id": "D018698", "tok_span": [9, 10]}, {"name": "PAC", "ent_type": "Chemical", "char_span": [88, 91], "ent_id": "D017239", "tok_span": [13, 14]}], "relation_list": [{"subject": "PAC", "object": "peripheral neuropathy", "sbj_char_span": [88, 91], "obj_char_span": [100, 121], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 14], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "This pilot study leads to the conclusion that glutamate supplementation at the chosen regimen fails to protect against peripheral neurotoxicity of PAC.", "entity_list": [{"name": "peripheral neurotoxicity", "ent_type": "Disease", "char_span": [119, 143], "ent_id": "D010523", "tok_span": [18, 21]}, {"name": "PAC", "ent_type": "Chemical", "char_span": [147, 150], "ent_id": "D017239", "tok_span": [22, 23]}, {"name": "glutamate", "ent_type": "Chemical", "char_span": [46, 55], "ent_id": "D018698", "tok_span": [8, 9]}], "relation_list": [{"subject": "PAC", "object": "peripheral neurotoxicity", "sbj_char_span": [147, 150], "obj_char_span": [119, 143], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [18, 21]}], "umls_entity_list": []}, {"text": "Attentional modulation of perceived pain intensity in capsaicin-induced secondary hyperalgesia.", "entity_list": [{"name": "pain", "ent_type": "Disease", "char_span": [36, 40], "ent_id": "D010146", "tok_span": [6, 7]}, {"name": "capsaicin", "ent_type": "Chemical", "char_span": [54, 63], "ent_id": "D002211", "tok_span": [9, 12]}, {"name": "hyperalgesia", "ent_type": "Disease", "char_span": [82, 94], "ent_id": "D006930", "tok_span": [15, 19]}], "relation_list": [{"subject": "capsaicin", "object": "hyperalgesia", "sbj_char_span": [54, 63], "obj_char_span": [82, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [15, 19]}], "umls_entity_list": []}, {"text": "However, it is not known that how pain intensity ratings are affected by attention in capsaicin-induced secondary hyperalgesia.", "entity_list": [{"name": "hyperalgesia", "ent_type": "Disease", "char_span": [114, 126], "ent_id": "D006930", "tok_span": [22, 26]}, {"name": "capsaicin", "ent_type": "Chemical", "char_span": [86, 95], "ent_id": "D002211", "tok_span": [16, 19]}, {"name": "pain", "ent_type": "Disease", "char_span": [34, 38], "ent_id": "D010146", "tok_span": [8, 9]}], "relation_list": [{"subject": "capsaicin", "object": "hyperalgesia", "sbj_char_span": [86, 95], "obj_char_span": [114, 126], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "Furthermore, it was found that the magnitude of attentional modulation in secondary hyperalgesia is very similar to that of capsaicin-untreated, control condition.", "entity_list": [{"name": "capsaicin", "ent_type": "Chemical", "char_span": [124, 133], "ent_id": "D002211", "tok_span": [23, 26]}, {"name": "hyperalgesia", "ent_type": "Disease", "char_span": [84, 96], "ent_id": "D006930", "tok_span": [13, 17]}], "relation_list": [{"subject": "capsaicin", "object": "hyperalgesia", "sbj_char_span": [124, 133], "obj_char_span": [84, 96], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "Our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin-induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms.", "entity_list": [{"name": "hyperalgesia", "ent_type": "Disease", "char_span": [133, 145], "ent_id": "D006930", "tok_span": [22, 26]}, {"name": "capsaicin", "ent_type": "Chemical", "char_span": [45, 54], "ent_id": "D002211", "tok_span": [7, 10]}, {"name": "capsaicin", "ent_type": "Chemical", "char_span": [105, 114], "ent_id": "D002211", "tok_span": [16, 19]}, {"name": "pain", "ent_type": "Disease", "char_span": [184, 188], "ent_id": "D010146", "tok_span": [31, 32]}], "relation_list": [{"subject": "capsaicin", "object": "hyperalgesia", "sbj_char_span": [105, 114], "obj_char_span": [133, 145], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [22, 26]}, {"subject": "capsaicin", "object": "hyperalgesia", "sbj_char_span": [45, 54], "obj_char_span": [133, 145], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "No changes in haloperidol-induced catalepsy or MK-801-induced locomotion were seen following PD.", "entity_list": [{"name": "haloperidol", "ent_type": "Chemical", "char_span": [14, 25], "ent_id": "D006220", "tok_span": [3, 6]}, {"name": "MK-801", "ent_type": "Chemical", "char_span": [47, 53], "ent_id": "D016291", "tok_span": [12, 16]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [34, 43], "ent_id": "D002375", "tok_span": [8, 11]}], "relation_list": [{"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [14, 25], "obj_char_span": [34, 43], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [8, 11]}], "umls_entity_list": []}, {"text": "Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.", "entity_list": [{"name": "proteinuria", "ent_type": "Disease", "char_span": [8, 19], "ent_id": "D011507", "tok_span": [1, 2]}, {"name": "sirolimus", "ent_type": "Chemical", "char_span": [31, 40], "ent_id": "D020123", "tok_span": [5, 7]}, {"name": "proteinuria", "ent_type": "Disease", "char_span": [135, 146], "ent_id": "D011507", "tok_span": [23, 24]}, {"name": "sirolimus", "ent_type": "Chemical", "char_span": [172, 181], "ent_id": "D020123", "tok_span": [28, 30]}, {"name": "sirolimus", "ent_type": "Chemical", "char_span": [244, 253], "ent_id": "D020123", "tok_span": [39, 41]}], "relation_list": [{"subject": "sirolimus", "object": "proteinuria", "sbj_char_span": [31, 40], "obj_char_span": [8, 19], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 7], "obj_tok_span": [1, 2]}, {"subject": "sirolimus", "object": "proteinuria", "sbj_char_span": [244, 253], "obj_char_span": [135, 146], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 41], "obj_tok_span": [23, 24]}, {"subject": "sirolimus", "object": "proteinuria", "sbj_char_span": [244, 253], "obj_char_span": [8, 19], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 41], "obj_tok_span": [1, 2]}, {"subject": "sirolimus", "object": "proteinuria", "sbj_char_span": [31, 40], "obj_char_span": [135, 146], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 7], "obj_tok_span": [23, 24]}, {"subject": "sirolimus", "object": "proteinuria", "sbj_char_span": [172, 181], "obj_char_span": [135, 146], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 30], "obj_tok_span": [23, 24]}, {"subject": "sirolimus", "object": "proteinuria", "sbj_char_span": [172, 181], "obj_char_span": [8, 19], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 30], "obj_tok_span": [1, 2]}], "umls_entity_list": []}, {"text": "Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.", "entity_list": [{"name": "sulpiride", "ent_type": "Chemical", "char_span": [62, 71], "ent_id": "D013469", "tok_span": [10, 13]}, {"name": "estradiol", "ent_type": "Chemical", "char_span": [188, 197], "ent_id": "D004958", "tok_span": [37, 38]}, {"name": "hyperprolactinemia", "ent_type": "Disease", "char_span": [8, 26], "ent_id": "D006966", "tok_span": [1, 5]}, {"name": "dopamine", "ent_type": "Chemical", "char_span": [42, 50], "ent_id": "D004298", "tok_span": [8, 9]}], "relation_list": [{"subject": "sulpiride", "object": "hyperprolactinemia", "sbj_char_span": [62, 71], "obj_char_span": [8, 26], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [1, 5]}], "umls_entity_list": []}, {"text": "We have previously demonstrated that ritonavir treatment increases atherosclerotic lesion formation in male mice to a greater extent than in female mice.", "entity_list": [{"name": "ritonavir", "ent_type": "Chemical", "char_span": [37, 46], "ent_id": "D019438", "tok_span": [5, 8]}, {"name": "atherosclerotic lesion", "ent_type": "Disease", "char_span": [67, 89], "ent_id": "D050197", "tok_span": [10, 12]}], "relation_list": [{"subject": "ritonavir", "object": "atherosclerotic lesion", "sbj_char_span": [37, 46], "obj_char_span": [67, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "A comparable overexpression of Pgp in the BBB was obtained after pilocarpine-induced seizures in wild-type Wistar rats.", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [85, 93], "ent_id": "D012640", "tok_span": [17, 18]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [65, 76], "ent_id": "D010862", "tok_span": [12, 15]}], "relation_list": [{"subject": "pilocarpine", "object": "seizures", "sbj_char_span": [65, 76], "obj_char_span": [85, 93], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [17, 18]}], "umls_entity_list": []}, {"text": "QTLs for susceptibility to pilocarpine-induced seizures, a model of temporal lobe epilepsy, have not been reported, and CSS have not previously been used to localize seizure susceptibility genes.", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [47, 55], "ent_id": "D012640", "tok_span": [10, 11]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [27, 38], "ent_id": "D010862", "tok_span": [5, 8]}, {"name": "temporal lobe epilepsy", "ent_type": "Disease", "char_span": [68, 90], "ent_id": "D004833", "tok_span": [15, 18]}, {"name": "seizure", "ent_type": "Disease", "char_span": [166, 173], "ent_id": "D012640", "tok_span": [34, 35]}], "relation_list": [{"subject": "pilocarpine", "object": "temporal lobe epilepsy", "sbj_char_span": [27, 38], "obj_char_span": [68, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [15, 18]}], "umls_entity_list": []}, {"text": "In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.", "entity_list": [{"name": "temporal lobe epilepsy", "ent_type": "Disease", "char_span": [298, 320], "ent_id": "D004833", "tok_span": [57, 60]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [277, 288], "ent_id": "D010862", "tok_span": [52, 55]}, {"name": "status epilepticus", "ent_type": "Disease", "char_span": [73, 91], "ent_id": "D013226", "tok_span": [12, 15]}], "relation_list": [{"subject": "pilocarpine", "object": "temporal lobe epilepsy", "sbj_char_span": [277, 288], "obj_char_span": [298, 320], "rel_type": "chemical-induced disease", "sbj_tok_span": [52, 55], "obj_tok_span": [57, 60]}], "umls_entity_list": []}, {"text": "We found that the most-frequent cause of thrombotic microangiopathy was drug related, secondary mainly to cyclosporine.", "entity_list": [{"name": "cyclosporine", "ent_type": "Chemical", "char_span": [106, 118], "ent_id": "D016572", "tok_span": [21, 23]}, {"name": "thrombotic microangiopathy", "ent_type": "Disease", "char_span": [41, 67], "ent_id": "D057049", "tok_span": [9, 14]}], "relation_list": [{"subject": "cyclosporine", "object": "thrombotic microangiopathy", "sbj_char_span": [106, 118], "obj_char_span": [41, 67], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 23], "obj_tok_span": [9, 14]}], "umls_entity_list": []}, {"text": "A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.", "entity_list": [{"name": "myocardial necrosis", "ent_type": "Disease", "char_span": [309, 328], "ent_id": "D009202", "tok_span": [57, 59]}, {"name": "myocardial stunning", "ent_type": "Disease", "char_span": [101, 120], "ent_id": "D017682", "tok_span": [26, 29]}, {"name": "epinephrine", "ent_type": "Chemical", "char_span": [79, 90], "ent_id": "D004837", "tok_span": [22, 25]}, {"name": "left ventricular systolic and diastolic dysfunction", "ent_type": "Disease", "char_span": [206, 257], "ent_id": "D018487", "tok_span": [42, 48]}], "relation_list": [{"subject": "epinephrine", "object": "myocardial stunning", "sbj_char_span": [79, 90], "obj_char_span": [101, 120], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 25], "obj_tok_span": [26, 29]}], "umls_entity_list": []}, {"text": "Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide.", "entity_list": [{"name": "cyclophosphamide", "ent_type": "Chemical", "char_span": [74, 90], "ent_id": "D003520", "tok_span": [17, 20]}, {"name": "Urinary bladder cancer", "ent_type": "Disease", "char_span": [0, 22], "ent_id": "D001749", "tok_span": [0, 4]}, {"name": "Wegener's granulomatosis", "ent_type": "Disease", "char_span": [26, 50], "ent_id": "D014890", "tok_span": [5, 12]}], "relation_list": [{"subject": "cyclophosphamide", "object": "Urinary bladder cancer", "sbj_char_span": [74, 90], "obj_char_span": [0, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "OBJECTIVE: To assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with Wegener's granulomatosis.", "entity_list": [{"name": "cyclophosphamide", "ent_type": "Chemical", "char_span": [86, 102], "ent_id": "D003520", "tok_span": [17, 20]}, {"name": "bladder cancer", "ent_type": "Disease", "char_span": [50, 64], "ent_id": "D001749", "tok_span": [10, 12]}, {"name": "Wegener's granulomatosis", "ent_type": "Disease", "char_span": [121, 145], "ent_id": "D014890", "tok_span": [24, 31]}], "relation_list": [{"subject": "cyclophosphamide", "object": "bladder cancer", "sbj_char_span": [86, 102], "obj_char_span": [50, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Nested within the cohort, a matched case-control study was performed to estimate the association between cyclophosphamide and bladder cancer using odds ratios (ORs) as relative risk.", "entity_list": [{"name": "bladder cancer", "ent_type": "Disease", "char_span": [126, 140], "ent_id": "D001749", "tok_span": [23, 25]}, {"name": "cyclophosphamide", "ent_type": "Chemical", "char_span": [105, 121], "ent_id": "D003520", "tok_span": [19, 22]}], "relation_list": [{"subject": "cyclophosphamide", "object": "bladder cancer", "sbj_char_span": [105, 121], "obj_char_span": [126, 140], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 22], "obj_tok_span": [23, 25]}], "umls_entity_list": []}, {"text": "The risk of bladder cancer doubled for every 10 g increment in cyclophosphamide (OR = 2.0, 95% confidence interval (CI) 0.8 to 4.9).", "entity_list": [{"name": "bladder cancer", "ent_type": "Disease", "char_span": [12, 26], "ent_id": "D001749", "tok_span": [3, 5]}, {"name": "cyclophosphamide", "ent_type": "Chemical", "char_span": [63, 79], "ent_id": "D003520", "tok_span": [12, 15]}], "relation_list": [{"subject": "cyclophosphamide", "object": "bladder cancer", "sbj_char_span": [63, 79], "obj_char_span": [12, 26], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "CONCLUSION: The results indicate a dose-response relationship between cyclophosphamide and the risk of bladder cancer, high cumulative risks in the entire cohort, and also the possibility of risk factors operating even before Wegener's granulomatosis.", "entity_list": [{"name": "cyclophosphamide", "ent_type": "Chemical", "char_span": [70, 86], "ent_id": "D003520", "tok_span": [11, 14]}, {"name": "Wegener's granulomatosis", "ent_type": "Disease", "char_span": [226, 250], "ent_id": "D014890", "tok_span": [39, 46]}, {"name": "bladder cancer", "ent_type": "Disease", "char_span": [103, 117], "ent_id": "D001749", "tok_span": [18, 20]}], "relation_list": [{"subject": "cyclophosphamide", "object": "bladder cancer", "sbj_char_span": [70, 86], "obj_char_span": [103, 117], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [18, 20]}], "umls_entity_list": []}, {"text": "Octreotide-induced hypoxemia and pulmonary hypertension in premature neonates.", "entity_list": [{"name": "Octreotide", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D015282", "tok_span": [0, 3]}, {"name": "hypoxemia", "ent_type": "Disease", "char_span": [19, 28], "ent_id": "D000860", "tok_span": [5, 8]}, {"name": "pulmonary hypertension", "ent_type": "Disease", "char_span": [33, 55], "ent_id": "D006976", "tok_span": [9, 11]}], "relation_list": [{"subject": "Octreotide", "object": "pulmonary hypertension", "sbj_char_span": [0, 10], "obj_char_span": [33, 55], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "Pulmonary hypertension developed after administration of a somatostatin analogue, octreotide, to enhance resolution of the fistula.", "entity_list": [{"name": "octreotide", "ent_type": "Chemical", "char_span": [82, 92], "ent_id": "D015282", "tok_span": [11, 14]}, {"name": "fistula", "ent_type": "Disease", "char_span": [123, 130], "ent_id": "D005402", "tok_span": [20, 21]}, {"name": "Pulmonary hypertension", "ent_type": "Disease", "char_span": [0, 22], "ent_id": "D006976", "tok_span": [0, 2]}], "relation_list": [{"subject": "octreotide", "object": "Pulmonary hypertension", "sbj_char_span": [82, 92], "obj_char_span": [0, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Acute cocaine-induced seizures: differential sensitivity of six inbred mouse strains.", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [22, 30], "ent_id": "D012640", "tok_span": [4, 5]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [6, 13], "ent_id": "D003042", "tok_span": [1, 2]}], "relation_list": [{"subject": "cocaine", "object": "seizures", "sbj_char_span": [6, 13], "obj_char_span": [22, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 2], "obj_tok_span": [4, 5]}], "umls_entity_list": []}, {"text": "Mature male and female mice from six inbred stains were tested for susceptibility to behavioral seizures induced by a single injection of cocaine.", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [96, 104], "ent_id": "D012640", "tok_span": [18, 19]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [138, 145], "ent_id": "D003042", "tok_span": [25, 26]}], "relation_list": [{"subject": "cocaine", "object": "seizures", "sbj_char_span": [138, 145], "obj_char_span": [96, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 26], "obj_tok_span": [18, 19]}], "umls_entity_list": []}, {"text": "Additional studies of these murine strains may be useful for investigating genetic influences on cocaine-induced seizures.", "entity_list": [{"name": "cocaine", "ent_type": "Chemical", "char_span": [97, 104], "ent_id": "D003042", "tok_span": [14, 15]}, {"name": "seizures", "ent_type": "Disease", "char_span": [113, 121], "ent_id": "D012640", "tok_span": [17, 18]}], "relation_list": [{"subject": "cocaine", "object": "seizures", "sbj_char_span": [97, 104], "obj_char_span": [113, 121], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [17, 18]}], "umls_entity_list": []}, {"text": "Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy.", "entity_list": [{"name": "FK506", "ent_type": "Chemical", "char_span": [47, 52], "ent_id": "D016559", "tok_span": [8, 10]}, {"name": "Microangiopathic hemolytic anemia", "ent_type": "Disease", "char_span": [0, 33], "ent_id": "D000743", "tok_span": [0, 6]}, {"name": "tacrolimus", "ent_type": "Chemical", "char_span": [54, 64], "ent_id": "D016559", "tok_span": [11, 13]}], "relation_list": [{"subject": "FK506", "object": "Microangiopathic hemolytic anemia", "sbj_char_span": [47, 52], "obj_char_span": [0, 33], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [0, 6]}, {"subject": "tacrolimus", "object": "Microangiopathic hemolytic anemia", "sbj_char_span": [54, 64], "obj_char_span": [0, 33], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 13], "obj_tok_span": [0, 6]}], "umls_entity_list": []}, {"text": "We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under FK506 (tacrolimus) therapy.", "entity_list": [{"name": "FK506", "ent_type": "Chemical", "char_span": [101, 106], "ent_id": "D016559", "tok_span": [21, 23]}, {"name": "tacrolimus", "ent_type": "Chemical", "char_span": [108, 118], "ent_id": "D016559", "tok_span": [24, 26]}, {"name": "MAHA", "ent_type": "Disease", "char_span": [61, 65], "ent_id": "D000743", "tok_span": [12, 14]}, {"name": "microangiopathic hemolytic anemia", "ent_type": "Disease", "char_span": [26, 59], "ent_id": "D000743", "tok_span": [5, 11]}], "relation_list": [{"subject": "tacrolimus", "object": "MAHA", "sbj_char_span": [108, 118], "obj_char_span": [61, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 26], "obj_tok_span": [12, 14]}, {"subject": "FK506", "object": "microangiopathic hemolytic anemia", "sbj_char_span": [101, 106], "obj_char_span": [26, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 23], "obj_tok_span": [5, 11]}, {"subject": "FK506", "object": "MAHA", "sbj_char_span": [101, 106], "obj_char_span": [61, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 23], "obj_tok_span": [12, 14]}, {"subject": "tacrolimus", "object": "microangiopathic hemolytic anemia", "sbj_char_span": [108, 118], "obj_char_span": [26, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 26], "obj_tok_span": [5, 11]}], "umls_entity_list": []}, {"text": "In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, aspirin, and dipyridamole led to resolution of MAHA.", "entity_list": [{"name": "dipyridamole", "ent_type": "Chemical", "char_span": [139, 151], "ent_id": "D004176", "tok_span": [24, 29]}, {"name": "FK506", "ent_type": "Chemical", "char_span": [34, 39], "ent_id": "D016559", "tok_span": [6, 8]}, {"name": "aspirin", "ent_type": "Chemical", "char_span": [126, 133], "ent_id": "D001241", "tok_span": [21, 22]}, {"name": "corticosteroids", "ent_type": "Chemical", "char_span": [109, 124], "ent_id": "D000305", "tok_span": [19, 20]}, {"name": "MAHA", "ent_type": "Disease", "char_span": [173, 177], "ent_id": "D000743", "tok_span": [33, 35]}], "relation_list": [{"subject": "FK506", "object": "MAHA", "sbj_char_span": [34, 39], "obj_char_span": [173, 177], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [33, 35]}], "umls_entity_list": []}, {"text": "In one patient, reintroduction of FK506 led to rapid recurrence of MAHA.", "entity_list": [{"name": "MAHA", "ent_type": "Disease", "char_span": [67, 71], "ent_id": "D000743", "tok_span": [15, 17]}, {"name": "FK506", "ent_type": "Chemical", "char_span": [34, 39], "ent_id": "D016559", "tok_span": [8, 10]}], "relation_list": [{"subject": "FK506", "object": "MAHA", "sbj_char_span": [34, 39], "obj_char_span": [67, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "FK506-associated MAHA is probably rare but physicians must be aware of this severe complication.", "entity_list": [{"name": "MAHA", "ent_type": "Disease", "char_span": [17, 21], "ent_id": "D000743", "tok_span": [4, 6]}, {"name": "FK506", "ent_type": "Chemical", "char_span": [0, 5], "ent_id": "D016559", "tok_span": [0, 2]}], "relation_list": [{"subject": "FK506", "object": "MAHA", "sbj_char_span": [0, 5], "obj_char_span": [17, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce MAHA.", "entity_list": [{"name": "CyA", "ent_type": "Chemical", "char_span": [106, 109], "ent_id": "D016572", "tok_span": [23, 25]}, {"name": "FK506", "ent_type": "Chemical", "char_span": [51, 56], "ent_id": "D016559", "tok_span": [9, 11]}, {"name": "cyclosporin A", "ent_type": "Chemical", "char_span": [91, 104], "ent_id": "D016572", "tok_span": [19, 22]}, {"name": "MAHA", "ent_type": "Disease", "char_span": [163, 167], "ent_id": "D000743", "tok_span": [37, 39]}], "relation_list": [{"subject": "FK506", "object": "MAHA", "sbj_char_span": [51, 56], "obj_char_span": [163, 167], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 11], "obj_tok_span": [37, 39]}], "umls_entity_list": []}, {"text": "Variant ventricular tachycardia in desipramine toxicity.", "entity_list": [{"name": "ventricular tachycardia", "ent_type": "Disease", "char_span": [8, 31], "ent_id": "D017180", "tok_span": [2, 4]}, {"name": "toxicity", "ent_type": "Disease", "char_span": [47, 55], "ent_id": "D064420", "tok_span": [9, 10]}, {"name": "desipramine", "ent_type": "Chemical", "char_span": [35, 46], "ent_id": "D003891", "tok_span": [5, 9]}], "relation_list": [{"subject": "desipramine", "object": "ventricular tachycardia", "sbj_char_span": [35, 46], "obj_char_span": [8, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [2, 4]}], "umls_entity_list": []}, {"text": "We report a case of variant ventricular tachycardia induced by desipramine toxicity.", "entity_list": [{"name": "toxicity", "ent_type": "Disease", "char_span": [75, 83], "ent_id": "D064420", "tok_span": [14, 15]}, {"name": "desipramine", "ent_type": "Chemical", "char_span": [63, 74], "ent_id": "D003891", "tok_span": [10, 14]}, {"name": "ventricular tachycardia", "ent_type": "Disease", "char_span": [28, 51], "ent_id": "D017180", "tok_span": [6, 8]}], "relation_list": [{"subject": "desipramine", "object": "ventricular tachycardia", "sbj_char_span": [63, 74], "obj_char_span": [28, 51], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "Desipramine-induced delirium at \"subtherapeutic\" concentrations: a case report.", "entity_list": [{"name": "Desipramine", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D003891", "tok_span": [0, 4]}, {"name": "delirium", "ent_type": "Disease", "char_span": [20, 28], "ent_id": "D003693", "tok_span": [6, 9]}], "relation_list": [{"subject": "Desipramine", "object": "delirium", "sbj_char_span": [0, 11], "obj_char_span": [20, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [6, 9]}], "umls_entity_list": []}, {"text": "An elderly patient treated with low dose Desipramine developed a delirium while her plasma level was in the \"subtherapeutic\" range.", "entity_list": [{"name": "delirium", "ent_type": "Disease", "char_span": [65, 73], "ent_id": "D003693", "tok_span": [13, 16]}, {"name": "Desipramine", "ent_type": "Chemical", "char_span": [41, 52], "ent_id": "D003891", "tok_span": [7, 11]}], "relation_list": [{"subject": "Desipramine", "object": "delirium", "sbj_char_span": [41, 52], "obj_char_span": [65, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "Readministration of amantadine, after a drug-free overnight period, increased motility from respective saline control in all strains with exception of the BALB/C mice where suppression of motility occurred.", "entity_list": [{"name": "amantadine", "ent_type": "Chemical", "char_span": [20, 30], "ent_id": "D000547", "tok_span": [3, 7]}, {"name": "suppression of motility", "ent_type": "Disease", "char_span": [173, 196], "ent_id": "D011596", "tok_span": [34, 37]}], "relation_list": [{"subject": "amantadine", "object": "suppression of motility", "sbj_char_span": [20, 30], "obj_char_span": [173, 196], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 7], "obj_tok_span": [34, 37]}], "umls_entity_list": []}, {"text": "The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.", "entity_list": [{"name": "norepinephrine", "ent_type": "Chemical", "char_span": [215, 229], "ent_id": "D009638", "tok_span": [40, 41]}, {"name": "catecholamine", "ent_type": "Chemical", "char_span": [103, 116], "ent_id": "D002395", "tok_span": [19, 21]}, {"name": "amantadine", "ent_type": "Chemical", "char_span": [286, 296], "ent_id": "D000547", "tok_span": [50, 54]}, {"name": "amines", "ent_type": "Chemical", "char_span": [42, 48], "ent_id": "D000588", "tok_span": [7, 8]}, {"name": "behavioral depression", "ent_type": "Disease", "char_span": [254, 275], "ent_id": "D011596", "tok_span": [46, 48]}], "relation_list": [{"subject": "amantadine", "object": "behavioral depression", "sbj_char_span": [286, 296], "obj_char_span": [254, 275], "rel_type": "chemical-induced disease", "sbj_tok_span": [50, 54], "obj_tok_span": [46, 48]}], "umls_entity_list": []}, {"text": "No hepatic preneoplastic nodules or hepatocellular carcinomas developed in rats fed the plain choline-supplemented diet, while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing phenobarbital.", "entity_list": [{"name": "hepatocellular carcinoma", "ent_type": "Disease", "char_span": [160, 184], "ent_id": "D006528", "tok_span": [28, 30]}, {"name": "phenobarbital", "ent_type": "Chemical", "char_span": [236, 249], "ent_id": "D010634", "tok_span": [39, 41]}, {"name": "hepatocellular carcinomas", "ent_type": "Disease", "char_span": [36, 61], "ent_id": "D006528", "tok_span": [7, 9]}, {"name": "choline", "ent_type": "Chemical", "char_span": [94, 101], "ent_id": "D002794", "tok_span": [15, 16]}], "relation_list": [{"subject": "choline", "object": "hepatocellular carcinomas", "sbj_char_span": [94, 101], "obj_char_span": [36, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 16], "obj_tok_span": [7, 9]}, {"subject": "choline", "object": "hepatocellular carcinoma", "sbj_char_span": [94, 101], "obj_char_span": [160, 184], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 16], "obj_tok_span": [28, 30]}], "umls_entity_list": []}, {"text": "The incidence of preneoplastic nodules and of hepatocellular carcinomas was 10% and 37%, respectively, in rats fed the plain choline-devoid diet, and 17% and 30%, in rats fed the phenobarbital-containing choline-devoid diet.", "entity_list": [{"name": "phenobarbital", "ent_type": "Chemical", "char_span": [179, 192], "ent_id": "D010634", "tok_span": [42, 44]}, {"name": "hepatocellular carcinomas", "ent_type": "Disease", "char_span": [46, 71], "ent_id": "D006528", "tok_span": [9, 11]}, {"name": "choline", "ent_type": "Chemical", "char_span": [125, 132], "ent_id": "D002794", "tok_span": [25, 26]}, {"name": "choline", "ent_type": "Chemical", "char_span": [204, 211], "ent_id": "D002794", "tok_span": [46, 47]}], "relation_list": [{"subject": "choline", "object": "hepatocellular carcinomas", "sbj_char_span": [204, 211], "obj_char_span": [46, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [46, 47], "obj_tok_span": [9, 11]}, {"subject": "choline", "object": "hepatocellular carcinomas", "sbj_char_span": [125, 132], "obj_char_span": [46, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 26], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "Doxorubicin is an effective anticancer chemotherapeutic agent known to cause acute and chronic cardiomyopathy.", "entity_list": [{"name": "Doxorubicin", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D004317", "tok_span": [0, 3]}, {"name": "cardiomyopathy", "ent_type": "Disease", "char_span": [95, 109], "ent_id": "D009202", "tok_span": [17, 18]}], "relation_list": [{"subject": "Doxorubicin", "object": "cardiomyopathy", "sbj_char_span": [0, 11], "obj_char_span": [95, 109], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [17, 18]}], "umls_entity_list": []}, {"text": "Effects of aminophylline on the threshold for initiating ventricular fibrillation during respiratory failure.", "entity_list": [{"name": "ventricular fibrillation", "ent_type": "Disease", "char_span": [57, 81], "ent_id": "D014693", "tok_span": [10, 12]}, {"name": "aminophylline", "ent_type": "Chemical", "char_span": [11, 24], "ent_id": "D000628", "tok_span": [2, 5]}, {"name": "respiratory failure", "ent_type": "Disease", "char_span": [89, 108], "ent_id": "D012131", "tok_span": [13, 15]}], "relation_list": [{"subject": "aminophylline", "object": "ventricular fibrillation", "sbj_char_span": [11, 24], "obj_char_span": [57, 81], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "The effects of aminophylline on the ventricular fibrillation threshold during normal acid-base conditions and during respiratory failure were studied in anesthetized open chest dogs.", "entity_list": [{"name": "aminophylline", "ent_type": "Chemical", "char_span": [15, 28], "ent_id": "D000628", "tok_span": [3, 6]}, {"name": "ventricular fibrillation", "ent_type": "Disease", "char_span": [36, 60], "ent_id": "D014693", "tok_span": [8, 10]}, {"name": "respiratory failure", "ent_type": "Disease", "char_span": [117, 136], "ent_id": "D012131", "tok_span": [19, 21]}], "relation_list": [{"subject": "aminophylline", "object": "ventricular fibrillation", "sbj_char_span": [15, 28], "obj_char_span": [36, 60], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.", "entity_list": [{"name": "PO2", "ent_type": "Chemical", "char_span": [165, 168], "ent_id": "C093415", "tok_span": [30, 32]}, {"name": "carbon dioxide", "ent_type": "Chemical", "char_span": [174, 188], "ent_id": "D002245", "tok_span": [34, 36]}, {"name": "ventricular fibrillation", "ent_type": "Disease", "char_span": [42, 66], "ent_id": "D014693", "tok_span": [9, 11]}, {"name": "CO2", "ent_type": "Chemical", "char_span": [190, 193], "ent_id": "D002245", "tok_span": [37, 39]}, {"name": "aminophylline", "ent_type": "Chemical", "char_span": [23, 36], "ent_id": "D000628", "tok_span": [4, 7]}, {"name": "oxygen", "ent_type": "Chemical", "char_span": [157, 163], "ent_id": "D010100", "tok_span": [28, 29]}], "relation_list": [{"subject": "aminophylline", "object": "ventricular fibrillation", "sbj_char_span": [23, 36], "obj_char_span": [42, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.", "entity_list": [{"name": "respiratory failure", "ent_type": "Disease", "char_span": [5, 24], "ent_id": "D012131", "tok_span": [1, 3]}, {"name": "aminophylline", "ent_type": "Chemical", "char_span": [130, 143], "ent_id": "D000628", "tok_span": [38, 41]}, {"name": "ventricular fibrillation", "ent_type": "Disease", "char_span": [184, 208], "ent_id": "D014693", "tok_span": [48, 50]}, {"name": "hypoventilation", "ent_type": "Disease", "char_span": [41, 56], "ent_id": "D007040", "tok_span": [6, 9]}], "relation_list": [{"subject": "aminophylline", "object": "ventricular fibrillation", "sbj_char_span": [130, 143], "obj_char_span": [184, 208], "rel_type": "chemical-induced disease", "sbj_tok_span": [38, 41], "obj_tok_span": [48, 50]}], "umls_entity_list": []}, {"text": "Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).", "entity_list": [{"name": "nausea", "ent_type": "Disease", "char_span": [92, 98], "ent_id": "D009325", "tok_span": [21, 22]}, {"name": "photophobia", "ent_type": "Disease", "char_span": [125, 136], "ent_id": "D020795", "tok_span": [29, 32]}, {"name": "phonophobia", "ent_type": "Disease", "char_span": [110, 121], "ent_id": "D012001", "tok_span": [25, 28]}, {"name": "vomiting", "ent_type": "Disease", "char_span": [100, 108], "ent_id": "D014839", "tok_span": [23, 24]}, {"name": "caffeine", "ent_type": "Chemical", "char_span": [44, 52], "ent_id": "D002110", "tok_span": [13, 14]}, {"name": "ergotamine", "ent_type": "Chemical", "char_span": [33, 43], "ent_id": "D004878", "tok_span": [8, 12]}, {"name": "Rizatriptan", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "C093622", "tok_span": [0, 4]}], "relation_list": [{"subject": "Rizatriptan", "object": "nausea", "sbj_char_span": [0, 11], "obj_char_span": [92, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [21, 22]}], "umls_entity_list": []}, {"text": "The most common adverse events (incidence > or = 5% in one group) after rizatriptan and ergotamine/caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and somnolence (5.5 and 2.3%).", "entity_list": [{"name": "caffeine", "ent_type": "Chemical", "char_span": [99, 107], "ent_id": "D002110", "tok_span": [27, 28]}, {"name": "ergotamine", "ent_type": "Chemical", "char_span": [88, 98], "ent_id": "D004878", "tok_span": [22, 26]}, {"name": "somnolence", "ent_type": "Disease", "char_span": [180, 190], "ent_id": "D006970", "tok_span": [58, 62]}, {"name": "dizziness", "ent_type": "Disease", "char_span": [128, 137], "ent_id": "D004244", "tok_span": [32, 35]}, {"name": "nausea", "ent_type": "Disease", "char_span": [154, 160], "ent_id": "D009325", "tok_span": [46, 47]}, {"name": "rizatriptan", "ent_type": "Chemical", "char_span": [72, 83], "ent_id": "C093622", "tok_span": [17, 21]}], "relation_list": [{"subject": "rizatriptan", "object": "nausea", "sbj_char_span": [72, 83], "obj_char_span": [154, 160], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [46, 47]}, {"subject": "rizatriptan", "object": "dizziness", "sbj_char_span": [72, 83], "obj_char_span": [128, 137], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [32, 35]}], "umls_entity_list": []}, {"text": "Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression.", "entity_list": [{"name": "nephrotoxicity", "ent_type": "Disease", "char_span": [188, 202], "ent_id": "D007674", "tok_span": [31, 34]}, {"name": "bone marrow suppression", "ent_type": "Disease", "char_span": [255, 278], "ent_id": "D001855", "tok_span": [44, 47]}, {"name": "renal failure", "ent_type": "Disease", "char_span": [145, 158], "ent_id": "D051437", "tok_span": [24, 26]}, {"name": "anemia", "ent_type": "Disease", "char_span": [211, 217], "ent_id": "D000740", "tok_span": [36, 37]}, {"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [222, 238], "ent_id": "D013921", "tok_span": [38, 40]}, {"name": "cisplatin", "ent_type": "Chemical", "char_span": [178, 187], "ent_id": "D002945", "tok_span": [30, 31]}], "relation_list": [{"subject": "cisplatin", "object": "nephrotoxicity", "sbj_char_span": [178, 187], "obj_char_span": [188, 202], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 31], "obj_tok_span": [31, 34]}], "umls_entity_list": []}, {"text": "The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain.", "entity_list": [{"name": "neuropathy", "ent_type": "Disease", "char_span": [95, 105], "ent_id": "D009422", "tok_span": [18, 19]}, {"name": "AraG", "ent_type": "Chemical", "char_span": [49, 53], "ent_id": "C104457", "tok_span": [8, 10]}, {"name": "musculoskeletal pain", "ent_type": "Disease", "char_span": [110, 130], "ent_id": "D059352", "tok_span": [20, 22]}], "relation_list": [{"subject": "AraG", "object": "musculoskeletal pain", "sbj_char_span": [49, 53], "obj_char_span": [110, 130], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [20, 22]}, {"subject": "AraG", "object": "neuropathy", "sbj_char_span": [49, 53], "obj_char_span": [95, 105], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [18, 19]}], "umls_entity_list": []}, {"text": "Haematological toxicity was greater for the combination than AraG alone, although median time to neutrophil and platelet recovery was consistent with other salvage therapies.", "entity_list": [{"name": "AraG", "ent_type": "Chemical", "char_span": [61, 65], "ent_id": "C104457", "tok_span": [11, 13]}, {"name": "Haematological toxicity", "ent_type": "Disease", "char_span": [0, 23], "ent_id": "D006402", "tok_span": [0, 5]}], "relation_list": [{"subject": "AraG", "object": "Haematological toxicity", "sbj_char_span": [61, 65], "obj_char_span": [0, 23], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 13], "obj_tok_span": [0, 5]}], "umls_entity_list": []}, {"text": "Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.", "entity_list": [{"name": "neurological toxicity", "ent_type": "Disease", "char_span": [128, 149], "ent_id": "D009422", "tok_span": [26, 28]}, {"name": "cyclophosphamide", "ent_type": "Chemical", "char_span": [101, 117], "ent_id": "D003520", "tok_span": [21, 24]}, {"name": "etoposide", "ent_type": "Chemical", "char_span": [87, 96], "ent_id": "D005047", "tok_span": [17, 20]}, {"name": "AraG", "ent_type": "Chemical", "char_span": [45, 49], "ent_id": "C104457", "tok_span": [7, 9]}], "relation_list": [{"subject": "AraG", "object": "neurological toxicity", "sbj_char_span": [45, 49], "obj_char_span": [128, 149], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 9], "obj_tok_span": [26, 28]}], "umls_entity_list": []}, {"text": "A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.", "entity_list": [{"name": "rheumatoid arthritis", "ent_type": "Disease", "char_span": [177, 197], "ent_id": "D001172", "tok_span": [40, 42]}, {"name": "hepatitis", "ent_type": "Disease", "char_span": [87, 96], "ent_id": "D056486", "tok_span": [19, 20]}, {"name": "dermatitis", "ent_type": "Disease", "char_span": [48, 58], "ent_id": "D003872", "tok_span": [12, 13]}, {"name": "lymphadenopathy", "ent_type": "Disease", "char_span": [67, 82], "ent_id": "D008206", "tok_span": [16, 18]}, {"name": "fever", "ent_type": "Disease", "char_span": [60, 65], "ent_id": "D005334", "tok_span": [14, 15]}, {"name": "sulphasalazine", "ent_type": "Chemical", "char_span": [144, 158], "ent_id": "D012460", "tok_span": [32, 35]}], "relation_list": [{"subject": "sulphasalazine", "object": "hepatitis", "sbj_char_span": [144, 158], "obj_char_span": [87, 96], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 35], "obj_tok_span": [19, 20]}, {"subject": "sulphasalazine", "object": "dermatitis", "sbj_char_span": [144, 158], "obj_char_span": [48, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 35], "obj_tok_span": [12, 13]}, {"subject": "sulphasalazine", "object": "lymphadenopathy", "sbj_char_span": [144, 158], "obj_char_span": [67, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 35], "obj_tok_span": [16, 18]}, {"subject": "sulphasalazine", "object": "fever", "sbj_char_span": [144, 158], "obj_char_span": [60, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 35], "obj_tok_span": [14, 15]}], "umls_entity_list": []}, {"text": "Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.", "entity_list": [{"name": "nitric oxide", "ent_type": "Chemical", "char_span": [37, 49], "ent_id": "D009569", "tok_span": [6, 8]}, {"name": "diabetic neuropathy", "ent_type": "Disease", "char_span": [145, 164], "ent_id": "D003929", "tok_span": [28, 30]}, {"name": "streptozotocin", "ent_type": "Chemical", "char_span": [89, 103], "ent_id": "D013311", "tok_span": [16, 20]}, {"name": "Bradykinin", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D001920", "tok_span": [0, 3]}, {"name": "vincristine", "ent_type": "Chemical", "char_span": [73, 84], "ent_id": "D014750", "tok_span": [11, 15]}, {"name": "hyperalgesia", "ent_type": "Disease", "char_span": [112, 124], "ent_id": "D006930", "tok_span": [21, 25]}], "relation_list": [{"subject": "streptozotocin", "object": "diabetic neuropathy", "sbj_char_span": [89, 103], "obj_char_span": [145, 164], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 20], "obj_tok_span": [28, 30]}, {"subject": "streptozotocin", "object": "hyperalgesia", "sbj_char_span": [89, 103], "obj_char_span": [112, 124], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 20], "obj_tok_span": [21, 25]}, {"subject": "vincristine", "object": "hyperalgesia", "sbj_char_span": [73, 84], "obj_char_span": [112, 124], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [21, 25]}], "umls_entity_list": []}, {"text": "It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by vincristine.", "entity_list": [{"name": "NO", "ent_type": "Chemical", "char_span": [50, 52], "ent_id": "D009569", "tok_span": [9, 10]}, {"name": "hyperalgesia", "ent_type": "Disease", "char_span": [136, 148], "ent_id": "D006930", "tok_span": [26, 30]}, {"name": "vincristine", "ent_type": "Chemical", "char_span": [161, 172], "ent_id": "D014750", "tok_span": [32, 36]}, {"name": "NO", "ent_type": "Chemical", "char_span": [75, 77], "ent_id": "D009569", "tok_span": [13, 14]}, {"name": "bradykinin", "ent_type": "Chemical", "char_span": [109, 119], "ent_id": "D001920", "tok_span": [19, 23]}], "relation_list": [{"subject": "vincristine", "object": "hyperalgesia", "sbj_char_span": [161, 172], "obj_char_span": [136, 148], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 36], "obj_tok_span": [26, 30]}], "umls_entity_list": []}, {"text": "In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.", "entity_list": [{"name": "bradykinin", "ent_type": "Chemical", "char_span": [105, 115], "ent_id": "D001920", "tok_span": [23, 27]}, {"name": "vincristine", "ent_type": "Chemical", "char_span": [128, 139], "ent_id": "D014750", "tok_span": [30, 34]}, {"name": "hyperalgesia", "ent_type": "Disease", "char_span": [148, 160], "ent_id": "D006930", "tok_span": [36, 40]}, {"name": "bradykinin", "ent_type": "Chemical", "char_span": [161, 171], "ent_id": "D001920", "tok_span": [40, 44]}, {"name": "hyperalgesia", "ent_type": "Disease", "char_span": [26, 38], "ent_id": "D006930", "tok_span": [7, 11]}, {"name": "NO", "ent_type": "Chemical", "char_span": [50, 52], "ent_id": "D009569", "tok_span": [13, 14]}, {"name": "streptozotocin", "ent_type": "Chemical", "char_span": [3, 17], "ent_id": "D013311", "tok_span": [1, 5]}, {"name": "NO", "ent_type": "Chemical", "char_span": [200, 202], "ent_id": "D009569", "tok_span": [48, 49]}], "relation_list": [{"subject": "streptozotocin", "object": "hyperalgesia", "sbj_char_span": [3, 17], "obj_char_span": [26, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 5], "obj_tok_span": [7, 11]}, {"subject": "vincristine", "object": "hyperalgesia", "sbj_char_span": [128, 139], "obj_char_span": [26, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 34], "obj_tok_span": [7, 11]}, {"subject": "vincristine", "object": "hyperalgesia", "sbj_char_span": [128, 139], "obj_char_span": [148, 160], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 34], "obj_tok_span": [36, 40]}, {"subject": "streptozotocin", "object": "hyperalgesia", "sbj_char_span": [3, 17], "obj_char_span": [148, 160], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 5], "obj_tok_span": [36, 40]}], "umls_entity_list": []}, {"text": "Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.", "entity_list": [{"name": "hypertension", "ent_type": "Disease", "char_span": [373, 385], "ent_id": "D006973", "tok_span": [66, 67]}, {"name": "diabetes mellitus", "ent_type": "Disease", "char_span": [419, 436], "ent_id": "D003920", "tok_span": [74, 76]}, {"name": "congestive heart failure", "ent_type": "Disease", "char_span": [238, 262], "ent_id": "D006333", "tok_span": [40, 45]}, {"name": "cyclophosphamide", "ent_type": "Chemical", "char_span": [115, 131], "ent_id": "D003520", "tok_span": [19, 22]}, {"name": "anthracyclines", "ent_type": "Chemical", "char_span": [451, 465], "ent_id": "D018943", "tok_span": [80, 83]}, {"name": "CHF", "ent_type": "Disease", "char_span": [264, 267], "ent_id": "D006333", "tok_span": [46, 47]}, {"name": "breast cancer", "ent_type": "Disease", "char_span": [75, 88], "ent_id": "D001943", "tok_span": [11, 13]}], "relation_list": [{"subject": "cyclophosphamide", "object": "CHF", "sbj_char_span": [115, 131], "obj_char_span": [264, 267], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 22], "obj_tok_span": [46, 47]}, {"subject": "cyclophosphamide", "object": "congestive heart failure", "sbj_char_span": [115, 131], "obj_char_span": [238, 262], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 22], "obj_tok_span": [40, 45]}], "umls_entity_list": []}, {"text": "RESULTS: Six of 61 women (10%) developed clinically reversible grade 3 CHF following infusional cyclophosphamide with a median percent decline in ejection fraction of 31%.", "entity_list": [{"name": "cyclophosphamide", "ent_type": "Chemical", "char_span": [96, 112], "ent_id": "D003520", "tok_span": [19, 22]}, {"name": "CHF", "ent_type": "Disease", "char_span": [71, 74], "ent_id": "D006333", "tok_span": [15, 16]}], "relation_list": [{"subject": "cyclophosphamide", "object": "CHF", "sbj_char_span": [96, 112], "obj_char_span": [71, 74], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 22], "obj_tok_span": [15, 16]}], "umls_entity_list": []}, {"text": "Routine EKG monitoring during infusional cyclophosphamide did not predict CHF development.", "entity_list": [{"name": "CHF", "ent_type": "Disease", "char_span": [74, 77], "ent_id": "D006333", "tok_span": [14, 15]}, {"name": "cyclophosphamide", "ent_type": "Chemical", "char_span": [41, 57], "ent_id": "D003520", "tok_span": [8, 11]}], "relation_list": [{"subject": "cyclophosphamide", "object": "CHF", "sbj_char_span": [41, 57], "obj_char_span": [74, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [14, 15]}], "umls_entity_list": []}, {"text": "Inappropriate use of carbamazepine and vigabatrin in typical absence seizures.", "entity_list": [{"name": "vigabatrin", "ent_type": "Chemical", "char_span": [39, 49], "ent_id": "D020888", "tok_span": [11, 14]}, {"name": "absence seizures", "ent_type": "Disease", "char_span": [61, 77], "ent_id": "D004832", "tok_span": [16, 18]}, {"name": "carbamazepine", "ent_type": "Chemical", "char_span": [21, 34], "ent_id": "D002220", "tok_span": [6, 10]}], "relation_list": [{"subject": "vigabatrin", "object": "absence seizures", "sbj_char_span": [39, 49], "obj_char_span": [61, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [16, 18]}, {"subject": "carbamazepine", "object": "absence seizures", "sbj_char_span": [21, 34], "obj_char_span": [61, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 10], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "Carbamazepine and vigabatrin are contraindicated in typical absence seizures.", "entity_list": [{"name": "vigabatrin", "ent_type": "Chemical", "char_span": [18, 28], "ent_id": "D020888", "tok_span": [5, 8]}, {"name": "Carbamazepine", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D002220", "tok_span": [0, 4]}, {"name": "absence seizures", "ent_type": "Disease", "char_span": [60, 76], "ent_id": "D004832", "tok_span": [13, 15]}], "relation_list": [{"subject": "Carbamazepine", "object": "absence seizures", "sbj_char_span": [0, 13], "obj_char_span": [60, 76], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [13, 15]}, {"subject": "vigabatrin", "object": "absence seizures", "sbj_char_span": [18, 28], "obj_char_span": [60, 76], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "Frequency of absences increased in four children treated with carbamazepine and two of these developed myoclonic jerks, which resolved on withdrawal of carbamazepine.", "entity_list": [{"name": "carbamazepine", "ent_type": "Chemical", "char_span": [62, 75], "ent_id": "D002220", "tok_span": [10, 14]}, {"name": "carbamazepine", "ent_type": "Chemical", "char_span": [152, 165], "ent_id": "D002220", "tok_span": [31, 35]}, {"name": "myoclonic jerks", "ent_type": "Disease", "char_span": [103, 118], "ent_id": "D009207", "tok_span": [19, 25]}], "relation_list": [{"subject": "carbamazepine", "object": "myoclonic jerks", "sbj_char_span": [152, 165], "obj_char_span": [103, 118], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 35], "obj_tok_span": [19, 25]}, {"subject": "carbamazepine", "object": "myoclonic jerks", "sbj_char_span": [62, 75], "obj_char_span": [103, 118], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [19, 25]}], "umls_entity_list": []}, {"text": "Hemolytic anemia associated with the use of omeprazole.", "entity_list": [{"name": "Hemolytic anemia", "ent_type": "Disease", "char_span": [0, 16], "ent_id": "D000743", "tok_span": [0, 3]}, {"name": "omeprazole", "ent_type": "Chemical", "char_span": [44, 54], "ent_id": "D009853", "tok_span": [8, 11]}], "relation_list": [{"subject": "omeprazole", "object": "Hemolytic anemia", "sbj_char_span": [44, 54], "obj_char_span": [0, 16], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "We report the first case of a serious short-term adverse reaction with the use of omeprazole: hemolytic anemia.", "entity_list": [{"name": "hemolytic anemia", "ent_type": "Disease", "char_span": [94, 110], "ent_id": "D000743", "tok_span": [21, 24]}, {"name": "omeprazole", "ent_type": "Chemical", "char_span": [82, 92], "ent_id": "D009853", "tok_span": [17, 20]}], "relation_list": [{"subject": "omeprazole", "object": "hemolytic anemia", "sbj_char_span": [82, 92], "obj_char_span": [94, 110], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [21, 24]}], "umls_entity_list": []}, {"text": "The patient developed weakness, lethargy, and shortness of breath 2 days after starting therapy with omeprazole.", "entity_list": [{"name": "lethargy", "ent_type": "Disease", "char_span": [32, 40], "ent_id": "D053609", "tok_span": [5, 8]}, {"name": "omeprazole", "ent_type": "Chemical", "char_span": [101, 111], "ent_id": "D009853", "tok_span": [20, 23]}, {"name": "shortness of breath", "ent_type": "Disease", "char_span": [46, 65], "ent_id": "D004417", "tok_span": [10, 14]}], "relation_list": [{"subject": "omeprazole", "object": "lethargy", "sbj_char_span": [101, 111], "obj_char_span": [32, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [5, 8]}, {"subject": "omeprazole", "object": "shortness of breath", "sbj_char_span": [101, 111], "obj_char_span": [46, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "The mechanism by which omeprazole caused the patient's hemolytic anemia is uncertain, but physicians should be alerted to this possible adverse effect.", "entity_list": [{"name": "omeprazole", "ent_type": "Chemical", "char_span": [23, 33], "ent_id": "D009853", "tok_span": [4, 7]}, {"name": "hemolytic anemia", "ent_type": "Disease", "char_span": [55, 71], "ent_id": "D000743", "tok_span": [12, 15]}], "relation_list": [{"subject": "omeprazole", "object": "hemolytic anemia", "sbj_char_span": [23, 33], "obj_char_span": [55, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [12, 15]}], "umls_entity_list": []}, {"text": "Seven patients developed glucose tolerance curves characteristic of diabetes but these were mild, did not require treatment and returned to normal on ceasing didanosine.", "entity_list": [{"name": "glucose tolerance curves", "ent_type": "Disease", "char_span": [25, 49], "ent_id": "D018149", "tok_span": [3, 6]}, {"name": "didanosine", "ent_type": "Chemical", "char_span": [158, 168], "ent_id": "D016049", "tok_span": [25, 28]}, {"name": "diabetes", "ent_type": "Disease", "char_span": [68, 76], "ent_id": "D003920", "tok_span": [8, 9]}], "relation_list": [{"subject": "didanosine", "object": "glucose tolerance curves", "sbj_char_span": [158, 168], "obj_char_span": [25, 49], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 28], "obj_tok_span": [3, 6]}], "umls_entity_list": []}, {"text": "BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.", "entity_list": [{"name": "sorafenib", "ent_type": "Chemical", "char_span": [137, 146], "ent_id": "C471405", "tok_span": [27, 29]}, {"name": "sunitinib", "ent_type": "Chemical", "char_span": [123, 132], "ent_id": "C473478", "tok_span": [23, 26]}, {"name": "hemolysis", "ent_type": "Disease", "char_span": [178, 187], "ent_id": "D006461", "tok_span": [35, 37]}, {"name": "ribavirin", "ent_type": "Chemical", "char_span": [26, 35], "ent_id": "D012254", "tok_span": [6, 9]}], "relation_list": [{"subject": "sorafenib", "object": "hemolysis", "sbj_char_span": [137, 146], "obj_char_span": [178, 187], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 29], "obj_tok_span": [35, 37]}, {"subject": "sunitinib", "object": "hemolysis", "sbj_char_span": [123, 132], "obj_char_span": [178, 187], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [35, 37]}], "umls_entity_list": []}, {"text": "Based on these data, it can be postulated that (+/-)-PG-9 exerted an antinociceptive effect mediated by a central potentiation of cholinergic transmission. (+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.", "entity_list": [{"name": "dicyclomine", "ent_type": "Chemical", "char_span": [260, 271], "ent_id": "D004025", "tok_span": [82, 86]}, {"name": "amnesia", "ent_type": "Disease", "char_span": [208, 215], "ent_id": "D000647", "tok_span": [62, 65]}, {"name": "PG-9", "ent_type": "Chemical", "char_span": [53, 57], "ent_id": "C087567", "tok_span": [16, 19]}, {"name": "scopolamine", "ent_type": "Chemical", "char_span": [227, 238], "ent_id": "D012601", "tok_span": [67, 70]}, {"name": "PG-9", "ent_type": "Chemical", "char_span": [162, 166], "ent_id": "C087567", "tok_span": [42, 45]}], "relation_list": [{"subject": "dicyclomine", "object": "amnesia", "sbj_char_span": [260, 271], "obj_char_span": [208, 215], "rel_type": "chemical-induced disease", "sbj_tok_span": [82, 86], "obj_tok_span": [62, 65]}, {"subject": "scopolamine", "object": "amnesia", "sbj_char_span": [227, 238], "obj_char_span": [208, 215], "rel_type": "chemical-induced disease", "sbj_tok_span": [67, 70], "obj_tok_span": [62, 65]}], "umls_entity_list": []}, {"text": "The results have shown that the degradation product p-choloroaniline is not a significant factor in chlorhexidine-digluconate associated erosive cystitis.", "entity_list": [{"name": "chlorhexidine-digluconate", "ent_type": "Chemical", "char_span": [100, 125], "ent_id": "C010882", "tok_span": [20, 28]}, {"name": "cystitis", "ent_type": "Disease", "char_span": [145, 153], "ent_id": "D003556", "tok_span": [32, 34]}, {"name": "p-choloroaniline", "ent_type": "Chemical", "char_span": [52, 68], "ent_id": "C004658", "tok_span": [8, 14]}], "relation_list": [{"subject": "chlorhexidine-digluconate", "object": "cystitis", "sbj_char_span": [100, 125], "obj_char_span": [145, 153], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 28], "obj_tok_span": [32, 34]}], "umls_entity_list": []}, {"text": "A high percentage of kanamycin-colistin and povidone-iodine irrigations were associated with erosive cystitis and suggested a possible complication with human usage.", "entity_list": [{"name": "kanamycin", "ent_type": "Chemical", "char_span": [21, 30], "ent_id": "D007612", "tok_span": [4, 6]}, {"name": "colistin", "ent_type": "Chemical", "char_span": [31, 39], "ent_id": "D003091", "tok_span": [7, 10]}, {"name": "povidone-iodine", "ent_type": "Chemical", "char_span": [44, 59], "ent_id": "D011206", "tok_span": [11, 17]}, {"name": "cystitis", "ent_type": "Disease", "char_span": [101, 109], "ent_id": "D003556", "tok_span": [25, 27]}], "relation_list": [{"subject": "colistin", "object": "cystitis", "sbj_char_span": [31, 39], "obj_char_span": [101, 109], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [25, 27]}, {"subject": "povidone-iodine", "object": "cystitis", "sbj_char_span": [44, 59], "obj_char_span": [101, 109], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 17], "obj_tok_span": [25, 27]}, {"subject": "kanamycin", "object": "cystitis", "sbj_char_span": [21, 30], "obj_char_span": [101, 109], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 6], "obj_tok_span": [25, 27]}], "umls_entity_list": []}, {"text": "Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats.", "entity_list": [{"name": "carbamazepine", "ent_type": "Chemical", "char_span": [86, 99], "ent_id": "D002220", "tok_span": [15, 19]}, {"name": "phenobarbitone", "ent_type": "Chemical", "char_span": [67, 81], "ent_id": "D010634", "tok_span": [10, 14]}, {"name": "cognitive dysfunction", "ent_type": "Disease", "char_span": [21, 42], "ent_id": "D003072", "tok_span": [4, 6]}, {"name": "Curcumin", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D003474", "tok_span": [0, 2]}], "relation_list": [{"subject": "carbamazepine", "object": "cognitive dysfunction", "sbj_char_span": [86, 99], "obj_char_span": [21, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 19], "obj_tok_span": [4, 6]}, {"subject": "phenobarbitone", "object": "cognitive dysfunction", "sbj_char_span": [67, 81], "obj_char_span": [21, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "The antiepileptic drugs, phenobarbitone and carbamazepine are well known to cause cognitive impairment on chronic use.", "entity_list": [{"name": "carbamazepine", "ent_type": "Chemical", "char_span": [44, 57], "ent_id": "D002220", "tok_span": [12, 16]}, {"name": "phenobarbitone", "ent_type": "Chemical", "char_span": [25, 39], "ent_id": "D010634", "tok_span": [7, 11]}, {"name": "cognitive impairment", "ent_type": "Disease", "char_span": [82, 102], "ent_id": "D003072", "tok_span": [21, 23]}], "relation_list": [{"subject": "carbamazepine", "object": "cognitive impairment", "sbj_char_span": [44, 57], "obj_char_span": [82, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 16], "obj_tok_span": [21, 23]}, {"subject": "phenobarbitone", "object": "cognitive impairment", "sbj_char_span": [25, 39], "obj_char_span": [82, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "Therefore, the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone- and carbamazepine-induced cognitive impairment and oxidative stress in rats.", "entity_list": [{"name": "carbamazepine", "ent_type": "Chemical", "char_span": [129, 142], "ent_id": "D002220", "tok_span": [23, 27]}, {"name": "curcumin", "ent_type": "Chemical", "char_span": [82, 90], "ent_id": "D003474", "tok_span": [14, 15]}, {"name": "cognitive impairment", "ent_type": "Disease", "char_span": [151, 171], "ent_id": "D003072", "tok_span": [29, 31]}, {"name": "phenobarbitone", "ent_type": "Chemical", "char_span": [109, 123], "ent_id": "D010634", "tok_span": [17, 21]}], "relation_list": [{"subject": "carbamazepine", "object": "cognitive impairment", "sbj_char_span": [129, 142], "obj_char_span": [151, 171], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 27], "obj_tok_span": [29, 31]}, {"subject": "phenobarbitone", "object": "cognitive impairment", "sbj_char_span": [109, 123], "obj_char_span": [151, 171], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [29, 31]}], "umls_entity_list": []}, {"text": "The administration of phenobarbitone and carbamazepine for 21days caused a significant impairment of learning and memory as well as an increased oxidative stress.", "entity_list": [{"name": "carbamazepine", "ent_type": "Chemical", "char_span": [41, 54], "ent_id": "D002220", "tok_span": [8, 12]}, {"name": "phenobarbitone", "ent_type": "Chemical", "char_span": [22, 36], "ent_id": "D010634", "tok_span": [3, 7]}, {"name": "impairment of learning and memory", "ent_type": "Disease", "char_span": [87, 120], "ent_id": "D003072", "tok_span": [18, 23]}], "relation_list": [{"subject": "carbamazepine", "object": "impairment of learning and memory", "sbj_char_span": [41, 54], "obj_char_span": [87, 120], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [18, 23]}, {"subject": "phenobarbitone", "object": "impairment of learning and memory", "sbj_char_span": [22, 36], "obj_char_span": [87, 120], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 7], "obj_tok_span": [18, 23]}], "umls_entity_list": []}, {"text": "These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.", "entity_list": [{"name": "phenobarbitone", "ent_type": "Chemical", "char_span": [152, 166], "ent_id": "D010634", "tok_span": [23, 27]}, {"name": "deterioration of cognitive functions", "ent_type": "Disease", "char_span": [73, 109], "ent_id": "D003072", "tok_span": [12, 16]}, {"name": "curcumin", "ent_type": "Chemical", "char_span": [24, 32], "ent_id": "D003474", "tok_span": [4, 5]}, {"name": "carbamazepine", "ent_type": "Chemical", "char_span": [171, 184], "ent_id": "D002220", "tok_span": [28, 32]}], "relation_list": [{"subject": "carbamazepine", "object": "deterioration of cognitive functions", "sbj_char_span": [171, 184], "obj_char_span": [73, 109], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 32], "obj_tok_span": [12, 16]}, {"subject": "phenobarbitone", "object": "deterioration of cognitive functions", "sbj_char_span": [152, 166], "obj_char_span": [73, 109], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 27], "obj_tok_span": [12, 16]}], "umls_entity_list": []}, {"text": "The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing cognitive impairment associated with these drugs.", "entity_list": [{"name": "phenobarbitone", "ent_type": "Chemical", "char_span": [99, 113], "ent_id": "D010634", "tok_span": [16, 20]}, {"name": "curcumin", "ent_type": "Chemical", "char_span": [26, 34], "ent_id": "D003474", "tok_span": [4, 5]}, {"name": "cognitive impairment", "ent_type": "Disease", "char_span": [154, 174], "ent_id": "D003072", "tok_span": [28, 30]}, {"name": "carbamazepine", "ent_type": "Chemical", "char_span": [118, 131], "ent_id": "D002220", "tok_span": [21, 25]}], "relation_list": [{"subject": "phenobarbitone", "object": "cognitive impairment", "sbj_char_span": [99, 113], "obj_char_span": [154, 174], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 20], "obj_tok_span": [28, 30]}, {"subject": "carbamazepine", "object": "cognitive impairment", "sbj_char_span": [118, 131], "obj_char_span": [154, 174], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 25], "obj_tok_span": [28, 30]}], "umls_entity_list": []}, {"text": "Pyrrolidine dithiocarbamate protects the piriform cortex in the pilocarpine status epilepticus model.", "entity_list": [{"name": "Pyrrolidine dithiocarbamate", "ent_type": "Chemical", "char_span": [0, 27], "ent_id": "C020972", "tok_span": [0, 8]}, {"name": "status epilepticus", "ent_type": "Disease", "char_span": [76, 94], "ent_id": "D013226", "tok_span": [19, 22]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [64, 75], "ent_id": "D010862", "tok_span": [16, 19]}], "relation_list": [{"subject": "pilocarpine", "object": "status epilepticus", "sbj_char_span": [64, 75], "obj_char_span": [76, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [19, 22]}], "umls_entity_list": []}, {"text": "The effect of PDTC on status epilepticus-associated cell loss in the hippocampus and piriform cortex was evaluated in the rat fractionated pilocarpine model.", "entity_list": [{"name": "status epilepticus", "ent_type": "Disease", "char_span": [22, 40], "ent_id": "D013226", "tok_span": [6, 9]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [139, 150], "ent_id": "D010862", "tok_span": [28, 31]}, {"name": "PDTC", "ent_type": "Chemical", "char_span": [14, 18], "ent_id": "C020972", "tok_span": [3, 5]}], "relation_list": [{"subject": "pilocarpine", "object": "status epilepticus", "sbj_char_span": [139, 150], "obj_char_span": [22, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 31], "obj_tok_span": [6, 9]}], "umls_entity_list": []}, {"text": "Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms.", "entity_list": [{"name": "dyskinesias", "ent_type": "Disease", "char_span": [32, 43], "ent_id": "D004409", "tok_span": [7, 11]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [15, 23], "ent_id": "D007980", "tok_span": [2, 5]}, {"name": "parkinsonian", "ent_type": "Disease", "char_span": [47, 59], "ent_id": "D010300", "tok_span": [12, 15]}], "relation_list": [{"subject": "levodopa", "object": "dyskinesias", "sbj_char_span": [15, 23], "obj_char_span": [32, 43], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "Levodopa-induced dyskinesias (LIDs) present a major problem for the long-term management of Parkinson's disease (PD) patients.", "entity_list": [{"name": "Parkinson's disease", "ent_type": "Disease", "char_span": [92, 111], "ent_id": "D010300", "tok_span": [24, 28]}, {"name": "LIDs", "ent_type": "Disease", "char_span": [30, 34], "ent_id": "D004409", "tok_span": [10, 12]}, {"name": "PD", "ent_type": "Disease", "char_span": [113, 115], "ent_id": "D010300", "tok_span": [29, 30]}, {"name": "Levodopa", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D007980", "tok_span": [0, 3]}, {"name": "dyskinesias", "ent_type": "Disease", "char_span": [17, 28], "ent_id": "D004409", "tok_span": [5, 9]}], "relation_list": [{"subject": "Levodopa", "object": "dyskinesias", "sbj_char_span": [0, 8], "obj_char_span": [17, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 9]}, {"subject": "Levodopa", "object": "LIDs", "sbj_char_span": [0, 8], "obj_char_span": [30, 34], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Using macaque monkeys with different types of MPTP-induced parkinsonism, the current study evaluated the degree to which rate of symptom progression, symptom severity, and response to and duration of levodopa therapy may be involved in the development of LIDs.", "entity_list": [{"name": "LIDs", "ent_type": "Disease", "char_span": [255, 259], "ent_id": "D004409", "tok_span": [49, 51]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [200, 208], "ent_id": "D007980", "tok_span": [38, 41]}, {"name": "MPTP", "ent_type": "Chemical", "char_span": [46, 50], "ent_id": "D015632", "tok_span": [8, 10]}, {"name": "parkinsonism", "ent_type": "Disease", "char_span": [59, 71], "ent_id": "D010302", "tok_span": [12, 15]}], "relation_list": [{"subject": "levodopa", "object": "LIDs", "sbj_char_span": [200, 208], "obj_char_span": [255, 259], "rel_type": "chemical-induced disease", "sbj_tok_span": [38, 41], "obj_tok_span": [49, 51]}, {"subject": "MPTP", "object": "parkinsonism", "sbj_char_span": [46, 50], "obj_char_span": [59, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [12, 15]}], "umls_entity_list": []}, {"text": "Monkeys with acute (short-term) MPTP exposure, rapid symptom onset and short symptom duration prior to initiation of levodopa therapy developed dyskinesia between 11 and 24 days of daily levodopa administration.", "entity_list": [{"name": "dyskinesia", "ent_type": "Disease", "char_span": [144, 154], "ent_id": "D004409", "tok_span": [29, 33]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [117, 125], "ent_id": "D007980", "tok_span": [24, 27]}, {"name": "MPTP", "ent_type": "Chemical", "char_span": [32, 36], "ent_id": "D015632", "tok_span": [9, 11]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [187, 195], "ent_id": "D007980", "tok_span": [40, 43]}], "relation_list": [{"subject": "levodopa", "object": "dyskinesia", "sbj_char_span": [117, 125], "obj_char_span": [144, 154], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 27], "obj_tok_span": [29, 33]}, {"subject": "levodopa", "object": "dyskinesia", "sbj_char_span": [187, 195], "obj_char_span": [144, 154], "rel_type": "chemical-induced disease", "sbj_tok_span": [40, 43], "obj_tok_span": [29, 33]}], "umls_entity_list": []}, {"text": "In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).", "entity_list": [{"name": "levodopa", "ent_type": "Chemical", "char_span": [247, 255], "ent_id": "D007980", "tok_span": [55, 58]}, {"name": "MPTP", "ent_type": "Chemical", "char_span": [36, 40], "ent_id": "D015632", "tok_span": [8, 10]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [128, 136], "ent_id": "D007980", "tok_span": [25, 28]}, {"name": "dyskinesia", "ent_type": "Disease", "char_span": [191, 201], "ent_id": "D004409", "tok_span": [42, 46]}, {"name": "LIDs", "ent_type": "Disease", "char_span": [179, 183], "ent_id": "D004409", "tok_span": [34, 36]}], "relation_list": [{"subject": "levodopa", "object": "dyskinesia", "sbj_char_span": [247, 255], "obj_char_span": [191, 201], "rel_type": "chemical-induced disease", "sbj_tok_span": [55, 58], "obj_tok_span": [42, 46]}, {"subject": "levodopa", "object": "LIDs", "sbj_char_span": [128, 136], "obj_char_span": [179, 183], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 28], "obj_tok_span": [34, 36]}, {"subject": "levodopa", "object": "dyskinesia", "sbj_char_span": [128, 136], "obj_char_span": [191, 201], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 28], "obj_tok_span": [42, 46]}, {"subject": "levodopa", "object": "LIDs", "sbj_char_span": [247, 255], "obj_char_span": [179, 183], "rel_type": "chemical-induced disease", "sbj_tok_span": [55, 58], "obj_tok_span": [34, 36]}], "umls_entity_list": []}, {"text": "These data suggest distinct differences in the propensity to develop LIDs in monkeys with different rates of symptom progression or symptom durations prior to levodopa and demonstrate the value of these models for further studying the pathophysiology of LIDs.", "entity_list": [{"name": "LIDs", "ent_type": "Disease", "char_span": [254, 258], "ent_id": "D004409", "tok_span": [41, 43]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [159, 167], "ent_id": "D007980", "tok_span": [25, 28]}, {"name": "LIDs", "ent_type": "Disease", "char_span": [69, 73], "ent_id": "D004409", "tok_span": [10, 12]}], "relation_list": [{"subject": "levodopa", "object": "LIDs", "sbj_char_span": [159, 167], "obj_char_span": [254, 258], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 28], "obj_tok_span": [41, 43]}, {"subject": "levodopa", "object": "LIDs", "sbj_char_span": [159, 167], "obj_char_span": [69, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 28], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Propylthiouracil-induced perinuclear-staining antineutrophil cytoplasmic autoantibody-positive vasculitis in conjunction with pericarditis.", "entity_list": [{"name": "Propylthiouracil", "ent_type": "Chemical", "char_span": [0, 16], "ent_id": "D011441", "tok_span": [0, 5]}, {"name": "pericarditis", "ent_type": "Disease", "char_span": [126, 138], "ent_id": "D010493", "tok_span": [25, 28]}, {"name": "vasculitis", "ent_type": "Disease", "char_span": [95, 105], "ent_id": "D014657", "tok_span": [20, 22]}], "relation_list": [{"subject": "Propylthiouracil", "object": "pericarditis", "sbj_char_span": [0, 16], "obj_char_span": [126, 138], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [25, 28]}], "umls_entity_list": []}, {"text": "OBJECTIVE: To describe a case of propylthiouracil-induced vasculitis manifesting with pericarditis.", "entity_list": [{"name": "pericarditis", "ent_type": "Disease", "char_span": [86, 98], "ent_id": "D010493", "tok_span": [19, 22]}, {"name": "vasculitis", "ent_type": "Disease", "char_span": [58, 68], "ent_id": "D014657", "tok_span": [14, 16]}, {"name": "propylthiouracil", "ent_type": "Chemical", "char_span": [33, 49], "ent_id": "D011441", "tok_span": [7, 12]}], "relation_list": [{"subject": "propylthiouracil", "object": "pericarditis", "sbj_char_span": [33, 49], "obj_char_span": [86, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 12], "obj_tok_span": [19, 22]}], "umls_entity_list": []}, {"text": "METHODS: We present the first case report of a woman with hyperthyroidism treated with propylthiouracil in whom a syndrome of pericarditis, fever, and glomerulonephritis developed.", "entity_list": [{"name": "fever", "ent_type": "Disease", "char_span": [140, 145], "ent_id": "D005334", "tok_span": [32, 33]}, {"name": "hyperthyroidism", "ent_type": "Disease", "char_span": [58, 73], "ent_id": "D006980", "tok_span": [12, 16]}, {"name": "pericarditis", "ent_type": "Disease", "char_span": [126, 138], "ent_id": "D010493", "tok_span": [28, 31]}, {"name": "propylthiouracil", "ent_type": "Chemical", "char_span": [87, 103], "ent_id": "D011441", "tok_span": [18, 23]}, {"name": "glomerulonephritis", "ent_type": "Disease", "char_span": [151, 169], "ent_id": "D005921", "tok_span": [35, 40]}], "relation_list": [{"subject": "propylthiouracil", "object": "glomerulonephritis", "sbj_char_span": [87, 103], "obj_char_span": [151, 169], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 23], "obj_tok_span": [35, 40]}, {"subject": "propylthiouracil", "object": "pericarditis", "sbj_char_span": [87, 103], "obj_char_span": [126, 138], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 23], "obj_tok_span": [28, 31]}, {"subject": "propylthiouracil", "object": "fever", "sbj_char_span": [87, 103], "obj_char_span": [140, 145], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 23], "obj_tok_span": [32, 33]}], "umls_entity_list": []}, {"text": "A literature review revealed no prior reports of pericarditis in anti-MPO pANCA-positive vasculitis associated with propylthio- uracil therapy.", "entity_list": [{"name": "propylthio- uracil", "ent_type": "Chemical", "char_span": [116, 134], "ent_id": "D011441", "tok_span": [25, 32]}, {"name": "pericarditis", "ent_type": "Disease", "char_span": [49, 61], "ent_id": "D010493", "tok_span": [8, 11]}, {"name": "vasculitis", "ent_type": "Disease", "char_span": [89, 99], "ent_id": "D014657", "tok_span": [21, 23]}], "relation_list": [{"subject": "propylthio- uracil", "object": "pericarditis", "sbj_char_span": [116, 134], "obj_char_span": [49, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 32], "obj_tok_span": [8, 11]}], "umls_entity_list": []}, {"text": "CONCLUSION: Pericarditis may be the initial manifestation of drug-induced vasculitis attributable to propylthio- uracil therapy.", "entity_list": [{"name": "propylthio- uracil", "ent_type": "Chemical", "char_span": [101, 119], "ent_id": "D011441", "tok_span": [18, 25]}, {"name": "Pericarditis", "ent_type": "Disease", "char_span": [12, 24], "ent_id": "D010493", "tok_span": [2, 5]}, {"name": "vasculitis", "ent_type": "Disease", "char_span": [74, 84], "ent_id": "D014657", "tok_span": [14, 16]}], "relation_list": [{"subject": "propylthio- uracil", "object": "Pericarditis", "sbj_char_span": [101, 119], "obj_char_span": [12, 24], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 25], "obj_tok_span": [2, 5]}], "umls_entity_list": []}, {"text": "Two mouse lines selected for differential sensitivities to beta-carboline-induced seizures are also differentially sensitive to various pharmacological effects of other GABA(A) receptor ligands.", "entity_list": [{"name": "beta-carboline", "ent_type": "Chemical", "char_span": [59, 73], "ent_id": "C036150", "tok_span": [8, 12]}, {"name": "seizures", "ent_type": "Disease", "char_span": [82, 90], "ent_id": "D012640", "tok_span": [14, 15]}, {"name": "GABA", "ent_type": "Chemical", "char_span": [169, 173], "ent_id": "D005680", "tok_span": [25, 26]}], "relation_list": [{"subject": "beta-carboline", "object": "seizures", "sbj_char_span": [59, 73], "obj_char_span": [82, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [14, 15]}], "umls_entity_list": []}, {"text": "Two mouse lines were selectively bred according to their sensitivity (BS line) or resistance (BR line) to seizures induced by a single i.p. injection of methyl beta-carboline-3-carboxylate (beta-CCM), an inverse agonist of the GABA(A) receptor benzodiazepine site.", "entity_list": [{"name": "GABA", "ent_type": "Chemical", "char_span": [227, 231], "ent_id": "D005680", "tok_span": [55, 56]}, {"name": "benzodiazepine", "ent_type": "Chemical", "char_span": [244, 258], "ent_id": "D001569", "tok_span": [60, 64]}, {"name": "beta-CCM", "ent_type": "Chemical", "char_span": [190, 198], "ent_id": "C036150", "tok_span": [44, 48]}, {"name": "seizures", "ent_type": "Disease", "char_span": [106, 114], "ent_id": "D012640", "tok_span": [22, 23]}, {"name": "methyl beta-carboline-3-carboxylate", "ent_type": "Chemical", "char_span": [153, 188], "ent_id": "C036150", "tok_span": [33, 43]}], "relation_list": [{"subject": "beta-CCM", "object": "seizures", "sbj_char_span": [190, 198], "obj_char_span": [106, 114], "rel_type": "chemical-induced disease", "sbj_tok_span": [44, 48], "obj_tok_span": [22, 23]}, {"subject": "methyl beta-carboline-3-carboxylate", "object": "seizures", "sbj_char_span": [153, 188], "obj_char_span": [106, 114], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 43], "obj_tok_span": [22, 23]}], "umls_entity_list": []}, {"text": "We measured diazepam-induced anxiolysis with the elevated plus-maze test, diazepam-induced sedation by recording the vigilance states, and picrotoxin- and pentylenetetrazol-induced seizures after i.p. injections.", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [181, 189], "ent_id": "D012640", "tok_span": [44, 45]}, {"name": "diazepam", "ent_type": "Chemical", "char_span": [74, 82], "ent_id": "D003975", "tok_span": [18, 21]}, {"name": "picrotoxin", "ent_type": "Chemical", "char_span": [139, 149], "ent_id": "D010852", "tok_span": [33, 36]}, {"name": "diazepam", "ent_type": "Chemical", "char_span": [12, 20], "ent_id": "D003975", "tok_span": [2, 5]}, {"name": "pentylenetetrazol", "ent_type": "Chemical", "char_span": [155, 172], "ent_id": "D010433", "tok_span": [38, 42]}], "relation_list": [{"subject": "pentylenetetrazol", "object": "seizures", "sbj_char_span": [155, 172], "obj_char_span": [181, 189], "rel_type": "chemical-induced disease", "sbj_tok_span": [38, 42], "obj_tok_span": [44, 45]}, {"subject": "picrotoxin", "object": "seizures", "sbj_char_span": [139, 149], "obj_char_span": [181, 189], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 36], "obj_tok_span": [44, 45]}], "umls_entity_list": []}, {"text": "Every patient was screened for testosterone and 451 were screened for prolactin on the basis of low sexual desire, gynecomastia or testosterone less than 4 ng./ml.", "entity_list": [{"name": "gynecomastia", "ent_type": "Disease", "char_span": [115, 127], "ent_id": "D006177", "tok_span": [22, 26]}, {"name": "testosterone", "ent_type": "Chemical", "char_span": [131, 143], "ent_id": "D013739", "tok_span": [27, 28]}, {"name": "testosterone", "ent_type": "Chemical", "char_span": [31, 43], "ent_id": "D013739", "tok_span": [5, 6]}, {"name": "low sexual desire", "ent_type": "Disease", "char_span": [96, 113], "ent_id": "D020018", "tok_span": [18, 21]}], "relation_list": [{"subject": "testosterone", "object": "low sexual desire", "sbj_char_span": [131, 143], "obj_char_span": [96, 113], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 28], "obj_tok_span": [18, 21]}, {"subject": "testosterone", "object": "low sexual desire", "sbj_char_span": [31, 43], "obj_char_span": [96, 113], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 6], "obj_tok_span": [18, 21]}], "umls_entity_list": []}, {"text": "Determining testosterone only in cases of low sexual desire or abnormal physical examination would have missed 40% of the cases with low testosterone, including 37% of those subsequently improved by androgen therapy.", "entity_list": [{"name": "low sexual desire", "ent_type": "Disease", "char_span": [42, 59], "ent_id": "D020018", "tok_span": [7, 10]}, {"name": "testosterone", "ent_type": "Chemical", "char_span": [137, 149], "ent_id": "D013739", "tok_span": [24, 25]}, {"name": "testosterone", "ent_type": "Chemical", "char_span": [12, 24], "ent_id": "D013739", "tok_span": [2, 3]}], "relation_list": [{"subject": "testosterone", "object": "low sexual desire", "sbj_char_span": [12, 24], "obj_char_span": [42, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 3], "obj_tok_span": [7, 10]}, {"subject": "testosterone", "object": "low sexual desire", "sbj_char_span": [137, 149], "obj_char_span": [42, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 25], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "We now advocate that before age 50 years testosterone be determined only in cases of low sexual desire and abnormal physical examination but that it be measured in all men older than 50 years.", "entity_list": [{"name": "testosterone", "ent_type": "Chemical", "char_span": [41, 53], "ent_id": "D013739", "tok_span": [9, 10]}, {"name": "low sexual desire", "ent_type": "Disease", "char_span": [85, 102], "ent_id": "D020018", "tok_span": [16, 19]}], "relation_list": [{"subject": "testosterone", "object": "low sexual desire", "sbj_char_span": [41, 53], "obj_char_span": [85, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [16, 19]}], "umls_entity_list": []}, {"text": "Prolactin should be determined only in cases of low sexual desire, gynecomastia and/or testosterone less than 4 ng./ml.", "entity_list": [{"name": "testosterone", "ent_type": "Chemical", "char_span": [87, 99], "ent_id": "D013739", "tok_span": [20, 21]}, {"name": "low sexual desire", "ent_type": "Disease", "char_span": [48, 65], "ent_id": "D020018", "tok_span": [9, 12]}, {"name": "gynecomastia", "ent_type": "Disease", "char_span": [67, 79], "ent_id": "D006177", "tok_span": [13, 17]}], "relation_list": [{"subject": "testosterone", "object": "low sexual desire", "sbj_char_span": [87, 99], "obj_char_span": [48, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 21], "obj_tok_span": [9, 12]}], "umls_entity_list": []}, {"text": "Thiopentone pretreatment for propofol injection pain in ambulatory patients.", "entity_list": [{"name": "pain", "ent_type": "Disease", "char_span": [48, 52], "ent_id": "D010146", "tok_span": [9, 10]}, {"name": "Thiopentone", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D013874", "tok_span": [0, 4]}, {"name": "propofol", "ent_type": "Chemical", "char_span": [29, 37], "ent_id": "D015742", "tok_span": [6, 8]}], "relation_list": [{"subject": "propofol", "object": "pain", "sbj_char_span": [29, 37], "obj_char_span": [48, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [9, 10]}], "umls_entity_list": []}, {"text": "This study investigated propofol injection pain in patients undergoing ambulatory anaesthesia.", "entity_list": [{"name": "pain", "ent_type": "Disease", "char_span": [43, 47], "ent_id": "D010146", "tok_span": [6, 7]}, {"name": "propofol", "ent_type": "Chemical", "char_span": [24, 32], "ent_id": "D015742", "tok_span": [3, 5]}], "relation_list": [{"subject": "propofol", "object": "pain", "sbj_char_span": [24, 32], "obj_char_span": [43, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 5], "obj_tok_span": [6, 7]}], "umls_entity_list": []}, {"text": "We conclude that lidocaine reduces the incidence and severity of propofol injection pain in ambulatory patients whereas thiopentone only reduces its severity.", "entity_list": [{"name": "thiopentone", "ent_type": "Chemical", "char_span": [120, 131], "ent_id": "D013874", "tok_span": [19, 23]}, {"name": "pain", "ent_type": "Disease", "char_span": [84, 88], "ent_id": "D010146", "tok_span": [14, 15]}, {"name": "propofol", "ent_type": "Chemical", "char_span": [65, 73], "ent_id": "D015742", "tok_span": [11, 13]}, {"name": "lidocaine", "ent_type": "Chemical", "char_span": [17, 26], "ent_id": "D008012", "tok_span": [3, 5]}], "relation_list": [{"subject": "propofol", "object": "pain", "sbj_char_span": [65, 73], "obj_char_span": [84, 88], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 13], "obj_tok_span": [14, 15]}], "umls_entity_list": []}, {"text": "Comparison of i.v. glycopyrrolate and atropine in the prevention of bradycardia and arrhythmias following repeated doses of suxamethonium in children.", "entity_list": [{"name": "atropine", "ent_type": "Chemical", "char_span": [38, 46], "ent_id": "D001285", "tok_span": [11, 14]}, {"name": "glycopyrrolate", "ent_type": "Chemical", "char_span": [19, 33], "ent_id": "D006024", "tok_span": [6, 10]}, {"name": "arrhythmias", "ent_type": "Disease", "char_span": [84, 95], "ent_id": "D001145", "tok_span": [23, 24]}, {"name": "suxamethonium", "ent_type": "Chemical", "char_span": [124, 137], "ent_id": "D013390", "tok_span": [28, 33]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [68, 79], "ent_id": "D001919", "tok_span": [18, 22]}], "relation_list": [{"subject": "suxamethonium", "object": "bradycardia", "sbj_char_span": [124, 137], "obj_char_span": [68, 79], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 33], "obj_tok_span": [18, 22]}], "umls_entity_list": []}, {"text": "The effectiveness of administration of glycopyrrolate 5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v. immediately before the induction of anaesthesia, to prevent arrhythmia and bradycardia following repeated doses of suxamethonium in children, was studied.", "entity_list": [{"name": "glycopyrrolate", "ent_type": "Chemical", "char_span": [39, 53], "ent_id": "D006024", "tok_span": [5, 9]}, {"name": "suxamethonium", "ent_type": "Chemical", "char_span": [238, 251], "ent_id": "D013390", "tok_span": [53, 58]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [198, 209], "ent_id": "D001919", "tok_span": [45, 49]}, {"name": "atropine", "ent_type": "Chemical", "char_span": [83, 91], "ent_id": "D001285", "tok_span": [18, 21]}, {"name": "arrhythmia", "ent_type": "Disease", "char_span": [183, 193], "ent_id": "D001145", "tok_span": [42, 44]}], "relation_list": [{"subject": "suxamethonium", "object": "bradycardia", "sbj_char_span": [238, 251], "obj_char_span": [198, 209], "rel_type": "chemical-induced disease", "sbj_tok_span": [53, 58], "obj_tok_span": [45, 49]}], "umls_entity_list": []}, {"text": "Studies in DBA/2J mice showed that: 1) pretreatment with acetaminophen (100 mg/kg) increased the interval between the administration of caffeine (300 to 450 mg/kg IP) and the onset of fatal convulsions by a factor of about two; and 2) pretreatment with acetaminophen (75 mg/kg) reduced the incidence of audiogenic seizures produced in the presence of caffeine (12.5 to 75 mg/kg IP).", "entity_list": [{"name": "convulsions", "ent_type": "Disease", "char_span": [190, 201], "ent_id": "D012640", "tok_span": [46, 49]}, {"name": "seizures", "ent_type": "Disease", "char_span": [314, 322], "ent_id": "D012640", "tok_span": [76, 77]}, {"name": "caffeine", "ent_type": "Chemical", "char_span": [351, 359], "ent_id": "D002110", "tok_span": [82, 83]}, {"name": "acetaminophen", "ent_type": "Chemical", "char_span": [253, 266], "ent_id": "D000082", "tok_span": [61, 64]}, {"name": "caffeine", "ent_type": "Chemical", "char_span": [136, 144], "ent_id": "D002110", "tok_span": [31, 32]}, {"name": "acetaminophen", "ent_type": "Chemical", "char_span": [57, 70], "ent_id": "D000082", "tok_span": [15, 18]}], "relation_list": [{"subject": "caffeine", "object": "convulsions", "sbj_char_span": [351, 359], "obj_char_span": [190, 201], "rel_type": "chemical-induced disease", "sbj_tok_span": [82, 83], "obj_tok_span": [46, 49]}, {"subject": "caffeine", "object": "convulsions", "sbj_char_span": [136, 144], "obj_char_span": [190, 201], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 32], "obj_tok_span": [46, 49]}, {"subject": "caffeine", "object": "seizures", "sbj_char_span": [136, 144], "obj_char_span": [314, 322], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 32], "obj_tok_span": [76, 77]}, {"subject": "caffeine", "object": "seizures", "sbj_char_span": [351, 359], "obj_char_span": [314, 322], "rel_type": "chemical-induced disease", "sbj_tok_span": [82, 83], "obj_tok_span": [76, 77]}], "umls_entity_list": []}, {"text": "The frequency of sound-induced seizures after 12.5 or 25 mg/kg caffeine was reduced from 50 to 5% by acetaminophen.", "entity_list": [{"name": "caffeine", "ent_type": "Chemical", "char_span": [63, 71], "ent_id": "D002110", "tok_span": [16, 17]}, {"name": "seizures", "ent_type": "Disease", "char_span": [31, 39], "ent_id": "D012640", "tok_span": [6, 7]}, {"name": "acetaminophen", "ent_type": "Chemical", "char_span": [101, 114], "ent_id": "D000082", "tok_span": [25, 28]}], "relation_list": [{"subject": "caffeine", "object": "seizures", "sbj_char_span": [63, 71], "obj_char_span": [31, 39], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 17], "obj_tok_span": [6, 7]}], "umls_entity_list": []}, {"text": "In the absence of caffeine, acetaminophen (up to 300 mg/kg) did not modify the seizures induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice (tests performed by the Anticonvulsant Screening Project of NINCDS).", "entity_list": [{"name": "pentylenetetrezol", "ent_type": "Chemical", "char_span": [161, 178], "ent_id": "D010433", "tok_span": [38, 43]}, {"name": "caffeine", "ent_type": "Chemical", "char_span": [18, 26], "ent_id": "D002110", "tok_span": [4, 5]}, {"name": "seizures", "ent_type": "Disease", "char_span": [79, 87], "ent_id": "D012640", "tok_span": [21, 22]}, {"name": "acetaminophen", "ent_type": "Chemical", "char_span": [28, 41], "ent_id": "D000082", "tok_span": [6, 9]}], "relation_list": [{"subject": "pentylenetetrezol", "object": "seizures", "sbj_char_span": [161, 178], "obj_char_span": [79, 87], "rel_type": "chemical-induced disease", "sbj_tok_span": [38, 43], "obj_tok_span": [21, 22]}, {"subject": "caffeine", "object": "seizures", "sbj_char_span": [18, 26], "obj_char_span": [79, 87], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [21, 22]}], "umls_entity_list": []}, {"text": "Flestolol produced a dose-dependent attenuation of isoproterenol-induced tachycardia.", "entity_list": [{"name": "Flestolol", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "C047847", "tok_span": [0, 4]}, {"name": "isoproterenol", "ent_type": "Chemical", "char_span": [51, 64], "ent_id": "D007545", "tok_span": [11, 15]}, {"name": "tachycardia", "ent_type": "Disease", "char_span": [73, 84], "ent_id": "D013610", "tok_span": [17, 18]}], "relation_list": [{"subject": "isoproterenol", "object": "tachycardia", "sbj_char_span": [51, 64], "obj_char_span": [73, 84], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [17, 18]}], "umls_entity_list": []}, {"text": "Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension.", "entity_list": [{"name": "nephrosclerosis", "ent_type": "Disease", "char_span": [62, 77], "ent_id": "D009400", "tok_span": [11, 14]}, {"name": "nitrendipine", "ent_type": "Chemical", "char_span": [46, 58], "ent_id": "D009568", "tok_span": [7, 10]}, {"name": "renovascular hypertension", "ent_type": "Disease", "char_span": [91, 116], "ent_id": "D006978", "tok_span": [17, 20]}, {"name": "calcium", "ent_type": "Chemical", "char_span": [22, 29], "ent_id": "D002118", "tok_span": [4, 5]}], "relation_list": [{"subject": "nitrendipine", "object": "nephrosclerosis", "sbj_char_span": [46, 58], "obj_char_span": [62, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [11, 14]}], "umls_entity_list": []}, {"text": "The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.", "entity_list": [{"name": "renovascular hypertension", "ent_type": "Disease", "char_span": [274, 299], "ent_id": "D006978", "tok_span": [57, 60]}, {"name": "angiotensin", "ent_type": "Chemical", "char_span": [86, 97], "ent_id": "D000809", "tok_span": [18, 19]}, {"name": "enalapril", "ent_type": "Chemical", "char_span": [126, 135], "ent_id": "D004656", "tok_span": [22, 26]}, {"name": "albuminuria", "ent_type": "Disease", "char_span": [155, 166], "ent_id": "D000419", "tok_span": [30, 32]}, {"name": "calcium", "ent_type": "Chemical", "char_span": [42, 49], "ent_id": "D002118", "tok_span": [10, 11]}, {"name": "nitrendipine", "ent_type": "Chemical", "char_span": [66, 78], "ent_id": "D009568", "tok_span": [13, 16]}], "relation_list": [{"subject": "nitrendipine", "object": "albuminuria", "sbj_char_span": [66, 78], "obj_char_span": [155, 166], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [30, 32]}], "umls_entity_list": []}, {"text": "In contrast, in the nitrendipine-treated group albuminuria increased from 12.8 +/- 2 progressively to 163 +/- 55 compared with 19.2 +/- 9 mg/24 hr in the hypertensive controls.", "entity_list": [{"name": "hypertensive", "ent_type": "Disease", "char_span": [154, 166], "ent_id": "D006973", "tok_span": [44, 45]}, {"name": "nitrendipine", "ent_type": "Chemical", "char_span": [20, 32], "ent_id": "D009568", "tok_span": [5, 8]}, {"name": "albuminuria", "ent_type": "Disease", "char_span": [47, 58], "ent_id": "D000419", "tok_span": [11, 13]}], "relation_list": [{"subject": "nitrendipine", "object": "albuminuria", "sbj_char_span": [20, 32], "obj_char_span": [47, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [11, 13]}], "umls_entity_list": []}, {"text": "Perhexiline maleate and peripheral neuropathy.", "entity_list": [{"name": "Perhexiline maleate", "ent_type": "Chemical", "char_span": [0, 19], "ent_id": "C023470", "tok_span": [0, 6]}, {"name": "peripheral neuropathy", "ent_type": "Disease", "char_span": [24, 45], "ent_id": "D010523", "tok_span": [7, 9]}], "relation_list": [{"subject": "Perhexiline maleate", "object": "peripheral neuropathy", "sbj_char_span": [0, 19], "obj_char_span": [24, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 6], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "Peripheral neuropathy has been noted as a complication of therapy with perhexiline maleate, a drug widely used in France (and in clinical trials in the United States) for the prophylactic treatment of angina pectoris.", "entity_list": [{"name": "angina pectoris", "ent_type": "Disease", "char_span": [201, 216], "ent_id": "D000787", "tok_span": [39, 43]}, {"name": "perhexiline maleate", "ent_type": "Chemical", "char_span": [71, 90], "ent_id": "C023470", "tok_span": [11, 17]}, {"name": "Peripheral neuropathy", "ent_type": "Disease", "char_span": [0, 21], "ent_id": "D010523", "tok_span": [0, 2]}], "relation_list": [{"subject": "perhexiline maleate", "object": "Peripheral neuropathy", "sbj_char_span": [71, 90], "obj_char_span": [0, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 17], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Effect of humoral modulators of morphine-induced increase in locomotor activity of mice.", "entity_list": [{"name": "increase in locomotor activity", "ent_type": "Disease", "char_span": [49, 79], "ent_id": "D006948", "tok_span": [8, 12]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [32, 40], "ent_id": "D009020", "tok_span": [5, 6]}], "relation_list": [{"subject": "morphine", "object": "increase in locomotor activity", "sbj_char_span": [32, 40], "obj_char_span": [49, 79], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 6], "obj_tok_span": [8, 12]}], "umls_entity_list": []}, {"text": "The effect of humoral modulators on the morphine-induced increase in locomotor activity of mice was studied.", "entity_list": [{"name": "increase in locomotor activity", "ent_type": "Disease", "char_span": [57, 87], "ent_id": "D006948", "tok_span": [10, 14]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [40, 48], "ent_id": "D009020", "tok_span": [7, 8]}], "relation_list": [{"subject": "morphine", "object": "increase in locomotor activity", "sbj_char_span": [40, 48], "obj_char_span": [57, 87], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "The subcutaneous administration of 10 mg/kg of morphine-HC1 produced a marked increase in locomotor activity in mice.", "entity_list": [{"name": "increase in locomotor activity", "ent_type": "Disease", "char_span": [78, 108], "ent_id": "D006948", "tok_span": [16, 20]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [47, 55], "ent_id": "D009020", "tok_span": [9, 10]}], "relation_list": [{"subject": "morphine", "object": "increase in locomotor activity", "sbj_char_span": [47, 55], "obj_char_span": [78, 108], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "The morphine-induced hyperactivity was potentiated by scopolamine and attenuated by physostigmine.", "entity_list": [{"name": "scopolamine", "ent_type": "Chemical", "char_span": [54, 65], "ent_id": "D012601", "tok_span": [10, 13]}, {"name": "physostigmine", "ent_type": "Chemical", "char_span": [84, 97], "ent_id": "D010830", "tok_span": [16, 20]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [4, 12], "ent_id": "D009020", "tok_span": [1, 2]}, {"name": "hyperactivity", "ent_type": "Disease", "char_span": [21, 34], "ent_id": "D006948", "tok_span": [4, 6]}], "relation_list": [{"subject": "scopolamine", "object": "hyperactivity", "sbj_char_span": [54, 65], "obj_char_span": [21, 34], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [4, 6]}, {"subject": "morphine", "object": "hyperactivity", "sbj_char_span": [4, 12], "obj_char_span": [21, 34], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 2], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "In contrast, both methscopolamine and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the hyperactivity produced by morphine.", "entity_list": [{"name": "hyperactivity", "ent_type": "Disease", "char_span": [120, 133], "ent_id": "D006948", "tok_span": [29, 31]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [146, 154], "ent_id": "D009020", "tok_span": [33, 34]}, {"name": "neostigmine", "ent_type": "Chemical", "char_span": [38, 49], "ent_id": "D009388", "tok_span": [9, 13]}, {"name": "methscopolamine", "ent_type": "Chemical", "char_span": [18, 33], "ent_id": "D019832", "tok_span": [4, 8]}], "relation_list": [{"subject": "morphine", "object": "hyperactivity", "sbj_char_span": [146, 154], "obj_char_span": [120, 133], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 34], "obj_tok_span": [29, 31]}], "umls_entity_list": []}, {"text": "Mechanisms of FK 506-induced hypertension in the rat.\n -Tacrolimus (FK 506) is a powerful, widely used immunosuppressant", "entity_list": [{"name": "FK 506", "ent_type": "Chemical", "char_span": [68, 74], "ent_id": "D016559", "tok_span": [18, 21]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [29, 41], "ent_id": "D006973", "tok_span": [7, 8]}, {"name": "FK 506", "ent_type": "Chemical", "char_span": [14, 20], "ent_id": "D016559", "tok_span": [2, 5]}, {"name": "Tacrolimus", "ent_type": "Chemical", "char_span": [56, 66], "ent_id": "D016559", "tok_span": [13, 17]}], "relation_list": [{"subject": "FK 506", "object": "hypertension", "sbj_char_span": [14, 20], "obj_char_span": [29, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [7, 8]}, {"subject": "Tacrolimus", "object": "hypertension", "sbj_char_span": [56, 66], "obj_char_span": [29, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [7, 8]}, {"subject": "FK 506", "object": "hypertension", "sbj_char_span": [68, 74], "obj_char_span": [29, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [7, 8]}], "umls_entity_list": []}, {"text": "The clinical utility of FK 506 is complicated by substantial hypertension and nephrotoxicity.", "entity_list": [{"name": "nephrotoxicity", "ent_type": "Disease", "char_span": [78, 92], "ent_id": "D007674", "tok_span": [13, 16]}, {"name": "FK 506", "ent_type": "Chemical", "char_span": [24, 30], "ent_id": "D016559", "tok_span": [4, 7]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [61, 73], "ent_id": "D006973", "tok_span": [11, 12]}], "relation_list": [{"subject": "FK 506", "object": "hypertension", "sbj_char_span": [24, 30], "obj_char_span": [61, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [11, 12]}], "umls_entity_list": []}, {"text": "To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.", "entity_list": [{"name": "FK 506", "ent_type": "Chemical", "char_span": [92, 98], "ent_id": "D016559", "tok_span": [18, 21]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [44, 56], "ent_id": "D006973", "tok_span": [10, 11]}, {"name": "FK 506", "ent_type": "Chemical", "char_span": [29, 35], "ent_id": "D016559", "tok_span": [5, 8]}, {"name": "nitric oxide", "ent_type": "Chemical", "char_span": [231, 243], "ent_id": "D009569", "tok_span": [60, 62]}], "relation_list": [{"subject": "FK 506", "object": "hypertension", "sbj_char_span": [29, 35], "obj_char_span": [44, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [10, 11]}, {"subject": "FK 506", "object": "hypertension", "sbj_char_span": [92, 98], "obj_char_span": [44, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [10, 11]}], "umls_entity_list": []}, {"text": "In addition, the effect of the specific endothelin type A receptor antagonist FR 139317 on FK 506-induced hypertension in rats was studied.", "entity_list": [{"name": "FR 139317", "ent_type": "Chemical", "char_span": [78, 87], "ent_id": "C079574", "tok_span": [14, 18]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [106, 118], "ent_id": "D006973", "tok_span": [24, 25]}, {"name": "FK 506", "ent_type": "Chemical", "char_span": [91, 97], "ent_id": "D016559", "tok_span": [19, 22]}], "relation_list": [{"subject": "FK 506", "object": "hypertension", "sbj_char_span": [91, 97], "obj_char_span": [106, 118], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 22], "obj_tok_span": [24, 25]}], "umls_entity_list": []}, {"text": "The administration of FR 139317 (10 mg. kg-1. d-1) prevented FK 506-induced hypertension in rats.", "entity_list": [{"name": "hypertension", "ent_type": "Disease", "char_span": [76, 88], "ent_id": "D006973", "tok_span": [25, 26]}, {"name": "FK 506", "ent_type": "Chemical", "char_span": [61, 67], "ent_id": "D016559", "tok_span": [20, 23]}, {"name": "FR 139317", "ent_type": "Chemical", "char_span": [22, 31], "ent_id": "C079574", "tok_span": [3, 7]}], "relation_list": [{"subject": "FK 506", "object": "hypertension", "sbj_char_span": [61, 67], "obj_char_span": [76, 88], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [25, 26]}], "umls_entity_list": []}, {"text": "Suxamethonium induced prolonged apnea in a patient receiving electroconvulsive therapy.", "entity_list": [{"name": "Suxamethonium", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D013390", "tok_span": [0, 5]}, {"name": "apnea", "ent_type": "Disease", "char_span": [32, 37], "ent_id": "D001049", "tok_span": [7, 8]}], "relation_list": [{"subject": "Suxamethonium", "object": "apnea", "sbj_char_span": [0, 13], "obj_char_span": [32, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [7, 8]}], "umls_entity_list": []}, {"text": "Suxamethonium causes prolonged apnea in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus (OP) poisons.", "entity_list": [{"name": "Suxamethonium", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D013390", "tok_span": [0, 5]}, {"name": "apnea", "ent_type": "Disease", "char_span": [31, 36], "ent_id": "D001049", "tok_span": [7, 8]}, {"name": "organophosphorus (OP) poisons", "ent_type": "Chemical", "char_span": [105, 134], "ent_id": "D009943", "tok_span": [21, 29]}], "relation_list": [{"subject": "organophosphorus (OP) poisons", "object": "apnea", "sbj_char_span": [105, 134], "obj_char_span": [31, 36], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 29], "obj_tok_span": [7, 8]}, {"subject": "Suxamethonium", "object": "apnea", "sbj_char_span": [0, 13], "obj_char_span": [31, 36], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [7, 8]}], "umls_entity_list": []}, {"text": "Prolonged apnea in our case ensued because the information about suicidal attempt by OP compound was concealed from the treating team.", "entity_list": [{"name": "apnea", "ent_type": "Disease", "char_span": [10, 15], "ent_id": "D001049", "tok_span": [3, 4]}, {"name": "OP compound", "ent_type": "Chemical", "char_span": [85, 96], "ent_id": "D009943", "tok_span": [16, 18]}], "relation_list": [{"subject": "OP compound", "object": "apnea", "sbj_char_span": [85, 96], "obj_char_span": [10, 15], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 18], "obj_tok_span": [3, 4]}], "umls_entity_list": []}, {"text": "Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.", "entity_list": [{"name": "hepatitis-B surface antigen", "ent_type": "Chemical", "char_span": [67, 94], "ent_id": "D006514", "tok_span": [13, 18]}, {"name": "cancer", "ent_type": "Disease", "char_span": [116, 122], "ent_id": "D009369", "tok_span": [26, 27]}, {"name": "HBSAG", "ent_type": "Chemical", "char_span": [96, 101], "ent_id": "D006514", "tok_span": [19, 22]}, {"name": "hepatitis B", "ent_type": "Disease", "char_span": [33, 44], "ent_id": "D006509", "tok_span": [8, 10]}, {"name": "Lamivudine", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D019259", "tok_span": [0, 4]}], "relation_list": [{"subject": "HBSAG", "object": "hepatitis B", "sbj_char_span": [96, 101], "obj_char_span": [33, 44], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 22], "obj_tok_span": [8, 10]}, {"subject": "hepatitis-B surface antigen", "object": "hepatitis B", "sbj_char_span": [67, 94], "obj_char_span": [33, 44], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 18], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "Ginsenoside Rg1 restores the impairment of learning induced by chronic morphine administration in rats.", "entity_list": [{"name": "morphine", "ent_type": "Chemical", "char_span": [71, 79], "ent_id": "D009020", "tok_span": [16, 17]}, {"name": "Ginsenoside Rg1", "ent_type": "Chemical", "char_span": [0, 15], "ent_id": "C035054", "tok_span": [0, 7]}, {"name": "impairment of learning", "ent_type": "Disease", "char_span": [29, 51], "ent_id": "D007859", "tok_span": [10, 13]}], "relation_list": [{"subject": "morphine", "object": "impairment of learning", "sbj_char_span": [71, 79], "obj_char_span": [29, 51], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 17], "obj_tok_span": [10, 13]}], "umls_entity_list": []}, {"text": "The aim of this study was to investigate the effect of Rg1 on learning impairment by chronic morphine administration and the mechanism responsible for this effect.", "entity_list": [{"name": "morphine", "ent_type": "Chemical", "char_span": [93, 101], "ent_id": "D009020", "tok_span": [19, 20]}, {"name": "Rg1", "ent_type": "Chemical", "char_span": [55, 58], "ent_id": "C035054", "tok_span": [11, 14]}, {"name": "learning impairment", "ent_type": "Disease", "char_span": [62, 81], "ent_id": "D007859", "tok_span": [15, 17]}], "relation_list": [{"subject": "morphine", "object": "learning impairment", "sbj_char_span": [93, 101], "obj_char_span": [62, 81], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 20], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "A study on the effect of the duration of subcutaneous heparin injection on bruising and pain.", "entity_list": [{"name": "bruising", "ent_type": "Disease", "char_span": [75, 83], "ent_id": "D003288", "tok_span": [13, 16]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [54, 61], "ent_id": "D006493", "tok_span": [10, 11]}, {"name": "pain", "ent_type": "Disease", "char_span": [88, 92], "ent_id": "D010146", "tok_span": [17, 18]}], "relation_list": [{"subject": "heparin", "object": "bruising", "sbj_char_span": [54, 61], "obj_char_span": [75, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [13, 16]}, {"subject": "heparin", "object": "pain", "sbj_char_span": [54, 61], "obj_char_span": [88, 92], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [17, 18]}], "umls_entity_list": []}, {"text": "AIM: This study was carried out to determine the effect of injection duration on bruising and pain following the administration of the subcutaneous injection of heparin.", "entity_list": [{"name": "bruising", "ent_type": "Disease", "char_span": [81, 89], "ent_id": "D003288", "tok_span": [15, 18]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [161, 168], "ent_id": "D006493", "tok_span": [28, 29]}, {"name": "pain", "ent_type": "Disease", "char_span": [94, 98], "ent_id": "D010146", "tok_span": [19, 20]}], "relation_list": [{"subject": "heparin", "object": "pain", "sbj_char_span": [161, 168], "obj_char_span": [94, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 29], "obj_tok_span": [19, 20]}, {"subject": "heparin", "object": "bruising", "sbj_char_span": [161, 168], "obj_char_span": [81, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 29], "obj_tok_span": [15, 18]}], "umls_entity_list": []}, {"text": "BACKGROUND: Although different methods to prevent bruising and pain following the subcutaneous injection of heparin have been widely studied and described, the effect of injection duration on the occurrence of bruising and pain is little documented.", "entity_list": [{"name": "pain", "ent_type": "Disease", "char_span": [63, 67], "ent_id": "D010146", "tok_span": [11, 12]}, {"name": "bruising", "ent_type": "Disease", "char_span": [50, 58], "ent_id": "D003288", "tok_span": [7, 10]}, {"name": "pain", "ent_type": "Disease", "char_span": [223, 227], "ent_id": "D010146", "tok_span": [38, 39]}, {"name": "bruising", "ent_type": "Disease", "char_span": [210, 218], "ent_id": "D003288", "tok_span": [34, 37]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [108, 115], "ent_id": "D006493", "tok_span": [17, 18]}], "relation_list": [{"subject": "heparin", "object": "pain", "sbj_char_span": [108, 115], "obj_char_span": [223, 227], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 18], "obj_tok_span": [38, 39]}, {"subject": "heparin", "object": "bruising", "sbj_char_span": [108, 115], "obj_char_span": [210, 218], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 18], "obj_tok_span": [34, 37]}, {"subject": "heparin", "object": "pain", "sbj_char_span": [108, 115], "obj_char_span": [63, 67], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 18], "obj_tok_span": [11, 12]}, {"subject": "heparin", "object": "bruising", "sbj_char_span": [108, 115], "obj_char_span": [50, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 18], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "Dimensions of the bruising on the heparin applied areas were measured using transparent millimetric measuring paper.", "entity_list": [{"name": "bruising", "ent_type": "Disease", "char_span": [18, 26], "ent_id": "D003288", "tok_span": [4, 7]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [34, 41], "ent_id": "D006493", "tok_span": [9, 10]}], "relation_list": [{"subject": "heparin", "object": "bruising", "sbj_char_span": [34, 41], "obj_char_span": [18, 26], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [4, 7]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: It was determined that injection duration had an effect on bruising and pain following the subcutaneous administration of heparin.", "entity_list": [{"name": "heparin", "ent_type": "Chemical", "char_span": [135, 142], "ent_id": "D006493", "tok_span": [22, 23]}, {"name": "bruising", "ent_type": "Disease", "char_span": [72, 80], "ent_id": "D003288", "tok_span": [12, 15]}, {"name": "pain", "ent_type": "Disease", "char_span": [85, 89], "ent_id": "D010146", "tok_span": [16, 17]}], "relation_list": [{"subject": "heparin", "object": "bruising", "sbj_char_span": [135, 142], "obj_char_span": [72, 80], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [12, 15]}, {"subject": "heparin", "object": "pain", "sbj_char_span": [135, 142], "obj_char_span": [85, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [16, 17]}], "umls_entity_list": []}, {"text": "Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats.", "entity_list": [{"name": "reserpine", "ent_type": "Chemical", "char_span": [6, 15], "ent_id": "D012110", "tok_span": [1, 4]}, {"name": "orofacial dyskinesia", "ent_type": "Disease", "char_span": [108, 128], "ent_id": "D004409", "tok_span": [21, 27]}, {"name": "glutamate", "ent_type": "Chemical", "char_span": [80, 89], "ent_id": "D018698", "tok_span": [17, 18]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [31, 42], "ent_id": "D006220", "tok_span": [8, 11]}], "relation_list": [{"subject": "haloperidol", "object": "orofacial dyskinesia", "sbj_char_span": [31, 42], "obj_char_span": [108, 128], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [21, 27]}, {"subject": "reserpine", "object": "orofacial dyskinesia", "sbj_char_span": [6, 15], "obj_char_span": [108, 128], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 4], "obj_tok_span": [21, 27]}], "umls_entity_list": []}, {"text": "Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.", "entity_list": [{"name": "haloperidol", "ent_type": "Chemical", "char_span": [15, 26], "ent_id": "D006220", "tok_span": [5, 8]}, {"name": "tardive dyskinesia", "ent_type": "Disease", "char_span": [86, 104], "ent_id": "D004409", "tok_span": [21, 28]}, {"name": "orofacial dyskinesia", "ent_type": "Disease", "char_span": [35, 55], "ent_id": "D004409", "tok_span": [10, 16]}, {"name": "TD", "ent_type": "Disease", "char_span": [106, 108], "ent_id": "D004409", "tok_span": [29, 30]}, {"name": "Reserpine", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D012110", "tok_span": [0, 3]}], "relation_list": [{"subject": "haloperidol", "object": "tardive dyskinesia", "sbj_char_span": [15, 26], "obj_char_span": [86, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [21, 28]}, {"subject": "Reserpine", "object": "TD", "sbj_char_span": [0, 9], "obj_char_span": [106, 108], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [29, 30]}, {"subject": "Reserpine", "object": "orofacial dyskinesia", "sbj_char_span": [0, 9], "obj_char_span": [35, 55], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [10, 16]}, {"subject": "haloperidol", "object": "TD", "sbj_char_span": [15, 26], "obj_char_span": [106, 108], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [29, 30]}, {"subject": "haloperidol", "object": "orofacial dyskinesia", "sbj_char_span": [15, 26], "obj_char_span": [35, 55], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [10, 16]}, {"subject": "Reserpine", "object": "tardive dyskinesia", "sbj_char_span": [0, 9], "obj_char_span": [86, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [21, 28]}], "umls_entity_list": []}, {"text": "In the present study, the authors induced orofacial dyskinesia by acute reserpine and subchronic haloperidol administration to rats.", "entity_list": [{"name": "haloperidol", "ent_type": "Chemical", "char_span": [97, 108], "ent_id": "D006220", "tok_span": [23, 26]}, {"name": "orofacial dyskinesia", "ent_type": "Disease", "char_span": [42, 62], "ent_id": "D004409", "tok_span": [8, 14]}, {"name": "reserpine", "ent_type": "Chemical", "char_span": [72, 81], "ent_id": "D012110", "tok_span": [16, 19]}], "relation_list": [{"subject": "reserpine", "object": "orofacial dyskinesia", "sbj_char_span": [72, 81], "obj_char_span": [42, 62], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [8, 14]}, {"subject": "haloperidol", "object": "orofacial dyskinesia", "sbj_char_span": [97, 108], "obj_char_span": [42, 62], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [8, 14]}], "umls_entity_list": []}, {"text": "Acute psychosis due to treatment with phenytoin in a nonepileptic patient.", "entity_list": [{"name": "phenytoin", "ent_type": "Chemical", "char_span": [38, 47], "ent_id": "D010672", "tok_span": [6, 9]}, {"name": "Acute psychosis", "ent_type": "Disease", "char_span": [0, 15], "ent_id": "D011605", "tok_span": [0, 2]}], "relation_list": [{"subject": "phenytoin", "object": "Acute psychosis", "sbj_char_span": [38, 47], "obj_char_span": [0, 15], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "The case of a nonepileptic patient who developed psychosis following phenytoin treatment for trigeminal neuralgia is described.", "entity_list": [{"name": "phenytoin", "ent_type": "Chemical", "char_span": [69, 78], "ent_id": "D010672", "tok_span": [14, 17]}, {"name": "trigeminal neuralgia", "ent_type": "Disease", "char_span": [93, 113], "ent_id": "D014277", "tok_span": [19, 24]}, {"name": "psychosis", "ent_type": "Disease", "char_span": [49, 58], "ent_id": "D011605", "tok_span": [12, 13]}], "relation_list": [{"subject": "phenytoin", "object": "psychosis", "sbj_char_span": [69, 78], "obj_char_span": [49, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [12, 13]}], "umls_entity_list": []}, {"text": "This case suggests that the psychotic symptoms that occur following phenytoin treatment in some epileptic patients may be the direct result of medication, unrelated to seizures.", "entity_list": [{"name": "phenytoin", "ent_type": "Chemical", "char_span": [68, 77], "ent_id": "D010672", "tok_span": [11, 14]}, {"name": "psychotic symptoms", "ent_type": "Disease", "char_span": [28, 46], "ent_id": "D011605", "tok_span": [5, 8]}, {"name": "seizures", "ent_type": "Disease", "char_span": [168, 176], "ent_id": "D012640", "tok_span": [29, 30]}, {"name": "epileptic", "ent_type": "Disease", "char_span": [96, 105], "ent_id": "D004827", "tok_span": [17, 18]}], "relation_list": [{"subject": "phenytoin", "object": "psychotic symptoms", "sbj_char_span": [68, 77], "obj_char_span": [28, 46], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [5, 8]}], "umls_entity_list": []}, {"text": "In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (GM) nephrotoxicity.", "entity_list": [{"name": "gentamicin", "ent_type": "Chemical", "char_span": [114, 124], "ent_id": "D005839", "tok_span": [22, 24]}, {"name": "acute renal failure", "ent_type": "Disease", "char_span": [83, 102], "ent_id": "D058186", "tok_span": [17, 20]}, {"name": "nephrotoxicity", "ent_type": "Disease", "char_span": [130, 144], "ent_id": "D007674", "tok_span": [27, 30]}, {"name": "gum Arabic", "ent_type": "Chemical", "char_span": [69, 79], "ent_id": "D006170", "tok_span": [13, 16]}, {"name": "GM", "ent_type": "Chemical", "char_span": [126, 128], "ent_id": "D005839", "tok_span": [25, 26]}], "relation_list": [{"subject": "gum Arabic", "object": "acute renal failure", "sbj_char_span": [69, 79], "obj_char_span": [83, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [17, 20]}, {"subject": "gentamicin", "object": "acute renal failure", "sbj_char_span": [114, 124], "obj_char_span": [83, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 24], "obj_tok_span": [17, 20]}, {"subject": "GM", "object": "acute renal failure", "sbj_char_span": [126, 128], "obj_char_span": [83, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 26], "obj_tok_span": [17, 20]}], "umls_entity_list": []}, {"text": "Visual hallucinations associated with zonisamide.", "entity_list": [{"name": "Visual hallucinations", "ent_type": "Disease", "char_span": [0, 21], "ent_id": "D006212", "tok_span": [0, 4]}, {"name": "zonisamide", "ent_type": "Chemical", "char_span": [38, 48], "ent_id": "C022189", "tok_span": [6, 9]}], "relation_list": [{"subject": "zonisamide", "object": "Visual hallucinations", "sbj_char_span": [38, 48], "obj_char_span": [0, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased.", "entity_list": [{"name": "zonisamide", "ent_type": "Chemical", "char_span": [195, 205], "ent_id": "C022189", "tok_span": [33, 36]}, {"name": "visual hallucinations", "ent_type": "Disease", "char_span": [141, 162], "ent_id": "D006212", "tok_span": [24, 28]}, {"name": "visual hallucinations", "ent_type": "Disease", "char_span": [9, 30], "ent_id": "D006212", "tok_span": [1, 5]}], "relation_list": [{"subject": "zonisamide", "object": "visual hallucinations", "sbj_char_span": [195, 205], "obj_char_span": [141, 162], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 36], "obj_tok_span": [24, 28]}, {"subject": "zonisamide", "object": "visual hallucinations", "sbj_char_span": [195, 205], "obj_char_span": [9, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 36], "obj_tok_span": [1, 5]}], "umls_entity_list": []}, {"text": "GLEPP1 receptor tyrosine phosphatase (Ptpro) in rat PAN nephrosis.", "entity_list": [{"name": "nephrosis", "ent_type": "Disease", "char_span": [56, 65], "ent_id": "D009401", "tok_span": [14, 16]}, {"name": "tyrosine", "ent_type": "Chemical", "char_span": [16, 24], "ent_id": "D014443", "tok_span": [5, 6]}, {"name": "PAN", "ent_type": "Chemical", "char_span": [52, 55], "ent_id": "D011692", "tok_span": [13, 14]}], "relation_list": [{"subject": "PAN", "object": "nephrosis", "sbj_char_span": [52, 55], "obj_char_span": [56, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 14], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW).", "entity_list": [{"name": "Puromycin aminonucleoside", "ent_type": "Chemical", "char_span": [0, 25], "ent_id": "D011692", "tok_span": [0, 5]}, {"name": "PAN", "ent_type": "Chemical", "char_span": [114, 117], "ent_id": "D011692", "tok_span": [20, 21]}, {"name": "puromycin aminonucleoside", "ent_type": "Chemical", "char_span": [87, 112], "ent_id": "D011692", "tok_span": [14, 19]}, {"name": "nephrosis", "ent_type": "Disease", "char_span": [26, 35], "ent_id": "D009401", "tok_span": [5, 7]}], "relation_list": [{"subject": "Puromycin aminonucleoside", "object": "nephrosis", "sbj_char_span": [0, 25], "obj_char_span": [26, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [5, 7]}, {"subject": "puromycin aminonucleoside", "object": "nephrosis", "sbj_char_span": [87, 112], "obj_char_span": [26, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 19], "obj_tok_span": [5, 7]}, {"subject": "PAN", "object": "nephrosis", "sbj_char_span": [114, 117], "obj_char_span": [26, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 21], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "Tissues were analyzed at 0, 5, 7, 11, 21, 45, 80 and 126 days after PAN injection so as to include both the acute phase of proteinuria associated with foot process effacement (days 5-11) and the chronic phase of proteinuria associated with glomerulosclerosis (days 45-126).", "entity_list": [{"name": "proteinuria", "ent_type": "Disease", "char_span": [123, 134], "ent_id": "D011507", "tok_span": [33, 34]}, {"name": "glomerulosclerosis", "ent_type": "Disease", "char_span": [240, 258], "ent_id": "D005921", "tok_span": [54, 58]}, {"name": "proteinuria", "ent_type": "Disease", "char_span": [212, 223], "ent_id": "D011507", "tok_span": [51, 52]}, {"name": "PAN", "ent_type": "Chemical", "char_span": [68, 71], "ent_id": "D011692", "tok_span": [22, 23]}], "relation_list": [{"subject": "PAN", "object": "proteinuria", "sbj_char_span": [68, 71], "obj_char_span": [212, 223], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [51, 52]}, {"subject": "PAN", "object": "proteinuria", "sbj_char_span": [68, 71], "obj_char_span": [123, 134], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [33, 34]}], "umls_entity_list": []}, {"text": "Ticlopidine-induced aplastic anemia: report of three Chinese patients and review of the literature.", "entity_list": [{"name": "Ticlopidine", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D013988", "tok_span": [0, 4]}, {"name": "aplastic anemia", "ent_type": "Disease", "char_span": [20, 35], "ent_id": "D000741", "tok_span": [6, 9]}], "relation_list": [{"subject": "Ticlopidine", "object": "aplastic anemia", "sbj_char_span": [0, 11], "obj_char_span": [20, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [6, 9]}], "umls_entity_list": []}, {"text": "In this study, three Chinese patients with ticlopidine-induced aplastic anemia were reported and another 13 patients in the English literature were reviewed.", "entity_list": [{"name": "ticlopidine", "ent_type": "Chemical", "char_span": [43, 54], "ent_id": "D013988", "tok_span": [8, 13]}, {"name": "aplastic anemia", "ent_type": "Disease", "char_span": [63, 78], "ent_id": "D000741", "tok_span": [15, 18]}], "relation_list": [{"subject": "ticlopidine", "object": "aplastic anemia", "sbj_char_span": [43, 54], "obj_char_span": [63, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 13], "obj_tok_span": [15, 18]}], "umls_entity_list": []}, {"text": "Agranulocytosis occurred 3-20 weeks after initiation of ticlopidine, so frequent examination of white cell count during treatment is recommended.", "entity_list": [{"name": "ticlopidine", "ent_type": "Chemical", "char_span": [56, 67], "ent_id": "D013988", "tok_span": [13, 18]}, {"name": "Agranulocytosis", "ent_type": "Disease", "char_span": [0, 15], "ent_id": "D000380", "tok_span": [0, 5]}], "relation_list": [{"subject": "ticlopidine", "object": "Agranulocytosis", "sbj_char_span": [56, 67], "obj_char_span": [0, 15], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 18], "obj_tok_span": [0, 5]}], "umls_entity_list": []}, {"text": "Treatment for ticlopidine-induced aplastic anemia with colony-stimulating factors seemed to have little effect.", "entity_list": [{"name": "ticlopidine", "ent_type": "Chemical", "char_span": [14, 25], "ent_id": "D013988", "tok_span": [2, 7]}, {"name": "aplastic anemia", "ent_type": "Disease", "char_span": [34, 49], "ent_id": "D000741", "tok_span": [9, 12]}], "relation_list": [{"subject": "ticlopidine", "object": "aplastic anemia", "sbj_char_span": [14, 25], "obj_char_span": [34, 49], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 7], "obj_tok_span": [9, 12]}], "umls_entity_list": []}, {"text": "Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial.", "entity_list": [{"name": "morphine", "ent_type": "Chemical", "char_span": [136, 144], "ent_id": "D009020", "tok_span": [33, 34]}, {"name": "scopolamine", "ent_type": "Chemical", "char_span": [20, 31], "ent_id": "D012601", "tok_span": [5, 8]}, {"name": "Amnesia", "ent_type": "Disease", "char_span": [0, 7], "ent_id": "D000647", "tok_span": [0, 3]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [67, 75], "ent_id": "D009020", "tok_span": [15, 16]}, {"name": "cycloheximide", "ent_type": "Chemical", "char_span": [36, 49], "ent_id": "D003513", "tok_span": [9, 12]}, {"name": "naloxone", "ent_type": "Chemical", "char_span": [211, 219], "ent_id": "D009270", "tok_span": [43, 46]}], "relation_list": [{"subject": "cycloheximide", "object": "Amnesia", "sbj_char_span": [36, 49], "obj_char_span": [0, 7], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [0, 3]}, {"subject": "scopolamine", "object": "Amnesia", "sbj_char_span": [20, 31], "obj_char_span": [0, 7], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "Similarly, pre-test scopolamine partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced amnesia.", "entity_list": [{"name": "scopolamine", "ent_type": "Chemical", "char_span": [20, 31], "ent_id": "D012601", "tok_span": [5, 8]}, {"name": "scopolamine", "ent_type": "Chemical", "char_span": [55, 66], "ent_id": "D012601", "tok_span": [11, 14]}, {"name": "cycloheximide", "ent_type": "Chemical", "char_span": [120, 133], "ent_id": "D003513", "tok_span": [28, 31]}, {"name": "cycloheximide", "ent_type": "Chemical", "char_span": [156, 169], "ent_id": "D003513", "tok_span": [35, 38]}, {"name": "amnesia", "ent_type": "Disease", "char_span": [75, 82], "ent_id": "D000647", "tok_span": [16, 19]}, {"name": "amnesia", "ent_type": "Disease", "char_span": [178, 185], "ent_id": "D000647", "tok_span": [40, 43]}], "relation_list": [{"subject": "scopolamine", "object": "amnesia", "sbj_char_span": [55, 66], "obj_char_span": [75, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [16, 19]}, {"subject": "cycloheximide", "object": "amnesia", "sbj_char_span": [120, 133], "obj_char_span": [75, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 31], "obj_tok_span": [16, 19]}, {"subject": "scopolamine", "object": "amnesia", "sbj_char_span": [20, 31], "obj_char_span": [178, 185], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [40, 43]}, {"subject": "scopolamine", "object": "amnesia", "sbj_char_span": [20, 31], "obj_char_span": [75, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [16, 19]}, {"subject": "cycloheximide", "object": "amnesia", "sbj_char_span": [120, 133], "obj_char_span": [178, 185], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 31], "obj_tok_span": [40, 43]}, {"subject": "scopolamine", "object": "amnesia", "sbj_char_span": [55, 66], "obj_char_span": [178, 185], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [40, 43]}, {"subject": "cycloheximide", "object": "amnesia", "sbj_char_span": [156, 169], "obj_char_span": [178, 185], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 38], "obj_tok_span": [40, 43]}, {"subject": "cycloheximide", "object": "amnesia", "sbj_char_span": [156, 169], "obj_char_span": [75, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 38], "obj_tok_span": [16, 19]}], "umls_entity_list": []}, {"text": "Apomorphine, a nonselective dopamine agonist, was selected due to its biphasic behavioral effects, its ability to induce hypothermia, and to produce distinct changes to dopamine turnover in the rodent brain.", "entity_list": [{"name": "hypothermia", "ent_type": "Disease", "char_span": [121, 132], "ent_id": "D007035", "tok_span": [25, 27]}, {"name": "Apomorphine", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D001058", "tok_span": [0, 3]}, {"name": "dopamine agonist", "ent_type": "Chemical", "char_span": [28, 44], "ent_id": "D018491", "tok_span": [8, 10]}, {"name": "dopamine", "ent_type": "Chemical", "char_span": [169, 177], "ent_id": "D004298", "tok_span": [34, 35]}], "relation_list": [{"subject": "Apomorphine", "object": "hypothermia", "sbj_char_span": [0, 11], "obj_char_span": [121, 132], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [25, 27]}], "umls_entity_list": []}, {"text": "In rats, detection of apomorphine-induced hyperactivity was facilitated by a period of acclimatization to the test conditions.", "entity_list": [{"name": "apomorphine", "ent_type": "Chemical", "char_span": [22, 33], "ent_id": "D001058", "tok_span": [5, 10]}, {"name": "hyperactivity", "ent_type": "Disease", "char_span": [42, 55], "ent_id": "D006948", "tok_span": [12, 14]}], "relation_list": [{"subject": "apomorphine", "object": "hyperactivity", "sbj_char_span": [22, 33], "obj_char_span": [42, 55], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 10], "obj_tok_span": [12, 14]}], "umls_entity_list": []}, {"text": "Moreover, test conditions can impact upon other physiological responses to apomorphine such as drug-induced hypothermia.", "entity_list": [{"name": "apomorphine", "ent_type": "Chemical", "char_span": [75, 86], "ent_id": "D001058", "tok_span": [11, 16]}, {"name": "hypothermia", "ent_type": "Disease", "char_span": [108, 119], "ent_id": "D007035", "tok_span": [21, 23]}], "relation_list": [{"subject": "apomorphine", "object": "hypothermia", "sbj_char_span": [75, 86], "obj_char_span": [108, 119], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 16], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "Phenobarbital-induced dyskinesia in a neurologically-impaired child.", "entity_list": [{"name": "neurologically-impaired", "ent_type": "Disease", "char_span": [38, 61], "ent_id": "D009422", "tok_span": [10, 14]}, {"name": "dyskinesia", "ent_type": "Disease", "char_span": [22, 32], "ent_id": "D004409", "tok_span": [4, 8]}, {"name": "Phenobarbital", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D010634", "tok_span": [0, 2]}], "relation_list": [{"subject": "Phenobarbital", "object": "dyskinesia", "sbj_char_span": [0, 13], "obj_char_span": [22, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "A 2-year-old child with known neurologic impairment developed a dyskinesia soon after starting phenobarbital therapy for seizures.", "entity_list": [{"name": "phenobarbital", "ent_type": "Chemical", "char_span": [95, 108], "ent_id": "D010634", "tok_span": [20, 22]}, {"name": "neurologic impairment", "ent_type": "Disease", "char_span": [30, 51], "ent_id": "D009422", "tok_span": [9, 11]}, {"name": "dyskinesia", "ent_type": "Disease", "char_span": [64, 74], "ent_id": "D004409", "tok_span": [13, 17]}, {"name": "seizures", "ent_type": "Disease", "char_span": [121, 129], "ent_id": "D012640", "tok_span": [24, 25]}], "relation_list": [{"subject": "phenobarbital", "object": "dyskinesia", "sbj_char_span": [95, 108], "obj_char_span": [64, 74], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 22], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "On repeat challenge with phenobarbital, the dyskinesia recurred.", "entity_list": [{"name": "phenobarbital", "ent_type": "Chemical", "char_span": [25, 38], "ent_id": "D010634", "tok_span": [4, 6]}, {"name": "dyskinesia", "ent_type": "Disease", "char_span": [44, 54], "ent_id": "D004409", "tok_span": [8, 12]}], "relation_list": [{"subject": "phenobarbital", "object": "dyskinesia", "sbj_char_span": [25, 38], "obj_char_span": [44, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 6], "obj_tok_span": [8, 12]}], "umls_entity_list": []}, {"text": "Ammonia (NH3) was higher in patients who, during continuous therapy, complained of drowsiness (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups.", "entity_list": [{"name": "NH3", "ent_type": "Chemical", "char_span": [9, 12], "ent_id": "D000641", "tok_span": [4, 6]}, {"name": "Ammonia", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "D000641", "tok_span": [0, 3]}, {"name": "drowsiness", "ent_type": "Disease", "char_span": [83, 93], "ent_id": "D006970", "tok_span": [20, 23]}, {"name": "VPA", "ent_type": "Chemical", "char_span": [167, 170], "ent_id": "D014635", "tok_span": [41, 43]}], "relation_list": [{"subject": "NH3", "object": "drowsiness", "sbj_char_span": [9, 12], "obj_char_span": [83, 93], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 6], "obj_tok_span": [20, 23]}, {"subject": "Ammonia", "object": "drowsiness", "sbj_char_span": [0, 7], "obj_char_span": [83, 93], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [20, 23]}, {"subject": "VPA", "object": "drowsiness", "sbj_char_span": [167, 170], "obj_char_span": [83, 93], "rel_type": "chemical-induced disease", "sbj_tok_span": [41, 43], "obj_tok_span": [20, 23]}], "umls_entity_list": []}, {"text": "Calcitonin injection resulted in a potentiation of haloperidol-induced catalepsy and a partial prevention of apomorphine-induced hyperactivity.", "entity_list": [{"name": "apomorphine", "ent_type": "Chemical", "char_span": [109, 120], "ent_id": "D001058", "tok_span": [22, 27]}, {"name": "hyperactivity", "ent_type": "Disease", "char_span": [129, 142], "ent_id": "D006948", "tok_span": [29, 31]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [51, 62], "ent_id": "D006220", "tok_span": [9, 12]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [71, 80], "ent_id": "D002375", "tok_span": [14, 17]}], "relation_list": [{"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [51, 62], "obj_char_span": [71, 80], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [14, 17]}, {"subject": "apomorphine", "object": "hyperactivity", "sbj_char_span": [109, 120], "obj_char_span": [129, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 27], "obj_tok_span": [29, 31]}], "umls_entity_list": []}, {"text": "Development of isoproterenol-induced cardiac hypertrophy.", "entity_list": [{"name": "isoproterenol", "ent_type": "Chemical", "char_span": [15, 28], "ent_id": "D007545", "tok_span": [2, 6]}, {"name": "cardiac hypertrophy", "ent_type": "Disease", "char_span": [37, 56], "ent_id": "D006332", "tok_span": [8, 10]}], "relation_list": [{"subject": "isoproterenol", "object": "cardiac hypertrophy", "sbj_char_span": [15, 28], "obj_char_span": [37, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0.3 mg/kg body weight).", "entity_list": [{"name": "cardiac hypertrophy", "ent_type": "Disease", "char_span": [19, 38], "ent_id": "D006332", "tok_span": [3, 5]}, {"name": "ISO", "ent_type": "Chemical", "char_span": [137, 140], "ent_id": "D007545", "tok_span": [22, 23]}, {"name": "isoproterenol", "ent_type": "Chemical", "char_span": [122, 135], "ent_id": "D007545", "tok_span": [17, 21]}], "relation_list": [{"subject": "isoproterenol", "object": "cardiac hypertrophy", "sbj_char_span": [122, 135], "obj_char_span": [19, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [3, 5]}, {"subject": "ISO", "object": "cardiac hypertrophy", "sbj_char_span": [137, 140], "obj_char_span": [19, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.", "entity_list": [{"name": "carcinogenic", "ent_type": "Disease", "char_span": [3, 15], "ent_id": "D063646", "tok_span": [2, 4]}, {"name": "forestomach carcinogenesis", "ent_type": "Disease", "char_span": [45, 71], "ent_id": "D013274", "tok_span": [10, 14]}, {"name": "butylated hydroxyanisole", "ent_type": "Chemical", "char_span": [103, 127], "ent_id": "D002083", "tok_span": [22, 28]}, {"name": "retinyl acetate", "ent_type": "Chemical", "char_span": [26, 41], "ent_id": "C009166", "tok_span": [6, 9]}], "relation_list": [{"subject": "butylated hydroxyanisole", "object": "forestomach carcinogenesis", "sbj_char_span": [103, 127], "obj_char_span": [45, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 28], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.", "entity_list": [{"name": "retinyl acetate", "ent_type": "Chemical", "char_span": [34, 49], "ent_id": "C009166", "tok_span": [5, 8]}, {"name": "RA", "ent_type": "Chemical", "char_span": [51, 53], "ent_id": "C009166", "tok_span": [9, 10]}, {"name": "butylated hydroxyanisole", "ent_type": "Chemical", "char_span": [58, 82], "ent_id": "D002083", "tok_span": [12, 18]}, {"name": "BHA", "ent_type": "Chemical", "char_span": [84, 87], "ent_id": "D002083", "tok_span": [19, 21]}, {"name": "forestomach tumorigenesis", "ent_type": "Disease", "char_span": [101, 126], "ent_id": "D013274", "tok_span": [25, 29]}], "relation_list": [{"subject": "BHA", "object": "forestomach tumorigenesis", "sbj_char_span": [84, 87], "obj_char_span": [101, 126], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 21], "obj_tok_span": [25, 29]}, {"subject": "butylated hydroxyanisole", "object": "forestomach tumorigenesis", "sbj_char_span": [58, 82], "obj_char_span": [101, 126], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 18], "obj_tok_span": [25, 29]}], "umls_entity_list": []}, {"text": "In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.", "entity_list": [{"name": "RA", "ent_type": "Chemical", "char_span": [148, 150], "ent_id": "C009166", "tok_span": [33, 34]}, {"name": "BHA", "ent_type": "Chemical", "char_span": [19, 22], "ent_id": "D002083", "tok_span": [5, 7]}, {"name": "forestomach tumors", "ent_type": "Disease", "char_span": [211, 229], "ent_id": "D013274", "tok_span": [47, 51]}, {"name": "carcinoma", "ent_type": "Disease", "char_span": [296, 305], "ent_id": "D002277", "tok_span": [70, 71]}, {"name": "carcinoma", "ent_type": "Disease", "char_span": [259, 268], "ent_id": "D002277", "tok_span": [57, 58]}, {"name": "carcinoma", "ent_type": "Disease", "char_span": [336, 345], "ent_id": "D002277", "tok_span": [83, 84]}, {"name": "RA", "ent_type": "Chemical", "char_span": [366, 368], "ent_id": "C009166", "tok_span": [89, 90]}, {"name": "squamous cell papilloma", "ent_type": "Disease", "char_span": [231, 254], "ent_id": "D010212", "tok_span": [52, 56]}], "relation_list": [{"subject": "BHA", "object": "forestomach tumors", "sbj_char_span": [19, 22], "obj_char_span": [211, 229], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 7], "obj_tok_span": [47, 51]}], "umls_entity_list": []}, {"text": "These findings indicate that RA acted as a co-carcinogen in the BHA forestomach carcinogenesis of the rat.", "entity_list": [{"name": "forestomach carcinogenesis", "ent_type": "Disease", "char_span": [68, 94], "ent_id": "D013274", "tok_span": [16, 20]}, {"name": "RA", "ent_type": "Chemical", "char_span": [29, 31], "ent_id": "C009166", "tok_span": [4, 5]}, {"name": "BHA", "ent_type": "Chemical", "char_span": [64, 67], "ent_id": "D002083", "tok_span": [14, 16]}], "relation_list": [{"subject": "BHA", "object": "forestomach carcinogenesis", "sbj_char_span": [64, 67], "obj_char_span": [68, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "Ketanserin pretreatment reverses alfentanil-induced muscle rigidity.", "entity_list": [{"name": "Ketanserin", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D007650", "tok_span": [0, 4]}, {"name": "alfentanil", "ent_type": "Chemical", "char_span": [33, 43], "ent_id": "D015760", "tok_span": [7, 11]}, {"name": "muscle rigidity", "ent_type": "Disease", "char_span": [52, 67], "ent_id": "D009127", "tok_span": [13, 15]}], "relation_list": [{"subject": "alfentanil", "object": "muscle rigidity", "sbj_char_span": [33, 43], "obj_char_span": [52, 67], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "Systemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.", "entity_list": [{"name": "muscle rigidity", "ent_type": "Disease", "char_span": [128, 143], "ent_id": "D009127", "tok_span": [22, 24]}, {"name": "alfentanil", "ent_type": "Chemical", "char_span": [203, 213], "ent_id": "D015760", "tok_span": [36, 40]}, {"name": "ketanserin", "ent_type": "Chemical", "char_span": [27, 37], "ent_id": "D007650", "tok_span": [4, 8]}, {"name": "serotonin", "ent_type": "Chemical", "char_span": [68, 77], "ent_id": "D012701", "tok_span": [15, 16]}], "relation_list": [{"subject": "alfentanil", "object": "muscle rigidity", "sbj_char_span": [203, 213], "obj_char_span": [128, 143], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 40], "obj_tok_span": [22, 24]}], "umls_entity_list": []}, {"text": "Chlordiazepoxide at doses up to 10 mg/kg failed to significantly influence the rigidity produced by alfentanil.", "entity_list": [{"name": "Chlordiazepoxide", "ent_type": "Chemical", "char_span": [0, 16], "ent_id": "D002707", "tok_span": [0, 4]}, {"name": "alfentanil", "ent_type": "Chemical", "char_span": [100, 110], "ent_id": "D015760", "tok_span": [20, 24]}, {"name": "rigidity", "ent_type": "Disease", "char_span": [79, 87], "ent_id": "D009127", "tok_span": [17, 18]}], "relation_list": [{"subject": "alfentanil", "object": "rigidity", "sbj_char_span": [100, 110], "obj_char_span": [79, 87], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 24], "obj_tok_span": [17, 18]}], "umls_entity_list": []}, {"text": "Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by alfentanil were motionless, flaccid, and less responsive to external stimuli than were animals receiving alfentanil alone.", "entity_list": [{"name": "ketanserin", "ent_type": "Chemical", "char_span": [55, 65], "ent_id": "D007650", "tok_span": [9, 13]}, {"name": "rigidity", "ent_type": "Disease", "char_span": [23, 31], "ent_id": "D009127", "tok_span": [4, 5]}, {"name": "alfentanil", "ent_type": "Chemical", "char_span": [214, 224], "ent_id": "D015760", "tok_span": [51, 55]}, {"name": "alfentanil", "ent_type": "Chemical", "char_span": [109, 119], "ent_id": "D015760", "tok_span": [29, 33]}], "relation_list": [{"subject": "alfentanil", "object": "rigidity", "sbj_char_span": [109, 119], "obj_char_span": [23, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 33], "obj_tok_span": [4, 5]}, {"subject": "alfentanil", "object": "rigidity", "sbj_char_span": [214, 224], "obj_char_span": [23, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [51, 55], "obj_tok_span": [4, 5]}], "umls_entity_list": []}, {"text": "Use of glycopyrronium 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, edrophonium-induced bradycardias.", "entity_list": [{"name": "glycopyrronium", "ent_type": "Chemical", "char_span": [7, 21], "ent_id": "D006024", "tok_span": [2, 6]}, {"name": "edrophonium", "ent_type": "Chemical", "char_span": [157, 168], "ent_id": "D004491", "tok_span": [33, 36]}, {"name": "edrophonium", "ent_type": "Chemical", "char_span": [110, 121], "ent_id": "D004491", "tok_span": [23, 26]}, {"name": "bradycardias", "ent_type": "Disease", "char_span": [177, 189], "ent_id": "D001919", "tok_span": [38, 42]}], "relation_list": [{"subject": "edrophonium", "object": "bradycardias", "sbj_char_span": [110, 121], "obj_char_span": [177, 189], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [38, 42]}, {"subject": "edrophonium", "object": "bradycardias", "sbj_char_span": [157, 168], "obj_char_span": [177, 189], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 36], "obj_tok_span": [38, 42]}], "umls_entity_list": []}, {"text": "Involvement of locus coeruleus and noradrenergic neurotransmission in fentanyl-induced muscular rigidity in the rat.", "entity_list": [{"name": "fentanyl", "ent_type": "Chemical", "char_span": [70, 78], "ent_id": "D005283", "tok_span": [15, 18]}, {"name": "muscular rigidity", "ent_type": "Disease", "char_span": [87, 104], "ent_id": "D009127", "tok_span": [20, 22]}], "relation_list": [{"subject": "fentanyl", "object": "muscular rigidity", "sbj_char_span": [70, 78], "obj_char_span": [87, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [20, 22]}], "umls_entity_list": []}, {"text": "Whereas muscular rigidity is a well-known side effect that is associated with high-dose fentanyl anesthesia, a paucity of information exists with regard to its underlying mechanism(s).", "entity_list": [{"name": "muscular rigidity", "ent_type": "Disease", "char_span": [8, 25], "ent_id": "D009127", "tok_span": [1, 3]}, {"name": "fentanyl", "ent_type": "Chemical", "char_span": [88, 96], "ent_id": "D005283", "tok_span": [17, 20]}], "relation_list": [{"subject": "fentanyl", "object": "muscular rigidity", "sbj_char_span": [88, 96], "obj_char_span": [8, 25], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [1, 3]}], "umls_entity_list": []}, {"text": "It is speculated that the induction of muscular rigidity by fentanyl may involve the coerulospinal noradrenergic fibers to the spinal motoneurons.", "entity_list": [{"name": "fentanyl", "ent_type": "Chemical", "char_span": [60, 68], "ent_id": "D005283", "tok_span": [10, 13]}, {"name": "muscular rigidity", "ent_type": "Disease", "char_span": [39, 56], "ent_id": "D009127", "tok_span": [7, 9]}], "relation_list": [{"subject": "fentanyl", "object": "muscular rigidity", "sbj_char_span": [60, 68], "obj_char_span": [39, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection-site pain in the placebo group.", "entity_list": [{"name": "vomiting", "ent_type": "Disease", "char_span": [48, 56], "ent_id": "D014839", "tok_span": [8, 9]}, {"name": "pain", "ent_type": "Disease", "char_span": [111, 115], "ent_id": "D010146", "tok_span": [22, 23]}, {"name": "nausea", "ent_type": "Disease", "char_span": [85, 91], "ent_id": "D009325", "tok_span": [17, 18]}, {"name": "nausea", "ent_type": "Disease", "char_span": [37, 43], "ent_id": "D009325", "tok_span": [6, 7]}, {"name": "flumazenil", "ent_type": "Chemical", "char_span": [64, 74], "ent_id": "D005442", "tok_span": [11, 15]}], "relation_list": [{"subject": "flumazenil", "object": "vomiting", "sbj_char_span": [64, 74], "obj_char_span": [48, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [8, 9]}, {"subject": "flumazenil", "object": "nausea", "sbj_char_span": [64, 74], "obj_char_span": [85, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [17, 18]}, {"subject": "flumazenil", "object": "nausea", "sbj_char_span": [64, 74], "obj_char_span": [37, 43], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [6, 7]}], "umls_entity_list": []}, {"text": "Hepatic adenomas and focal nodular hyperplasia of the liver in young women on oral contraceptives: case reports.", "entity_list": [{"name": "oral contraceptives", "ent_type": "Chemical", "char_span": [78, 97], "ent_id": "D003276", "tok_span": [15, 18]}, {"name": "focal nodular hyperplasia", "ent_type": "Disease", "char_span": [21, 46], "ent_id": "D020518", "tok_span": [4, 8]}, {"name": "adenomas", "ent_type": "Disease", "char_span": [8, 16], "ent_id": "D000236", "tok_span": [2, 3]}], "relation_list": [{"subject": "oral contraceptives", "object": "focal nodular hyperplasia", "sbj_char_span": [78, 97], "obj_char_span": [21, 46], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [4, 8]}, {"subject": "oral contraceptives", "object": "adenomas", "sbj_char_span": [78, 97], "obj_char_span": [8, 16], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [2, 3]}], "umls_entity_list": []}, {"text": "Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives, are reported.", "entity_list": [{"name": "oral contraceptives", "ent_type": "Chemical", "char_span": [104, 123], "ent_id": "D003276", "tok_span": [18, 21]}, {"name": "focal nodular hyperplasia", "ent_type": "Disease", "char_span": [40, 65], "ent_id": "D020518", "tok_span": [8, 12]}, {"name": "adenoma", "ent_type": "Disease", "char_span": [21, 28], "ent_id": "D000236", "tok_span": [4, 5]}], "relation_list": [{"subject": "oral contraceptives", "object": "focal nodular hyperplasia", "sbj_char_span": [104, 123], "obj_char_span": [40, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [8, 12]}, {"subject": "oral contraceptives", "object": "adenoma", "sbj_char_span": [104, 123], "obj_char_span": [21, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [4, 5]}], "umls_entity_list": []}, {"text": "Arterial thromboembolism in patients receiving systemic heparin therapy: a complication associated with heparin-induced thrombocytopenia.", "entity_list": [{"name": "thromboembolism", "ent_type": "Disease", "char_span": [9, 24], "ent_id": "D013923", "tok_span": [2, 4]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [104, 111], "ent_id": "D006493", "tok_span": [15, 16]}, {"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [120, 136], "ent_id": "D013921", "tok_span": [18, 20]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [56, 63], "ent_id": "D006493", "tok_span": [8, 9]}], "relation_list": [{"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [104, 111], "obj_char_span": [120, 136], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 16], "obj_tok_span": [18, 20]}, {"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [56, 63], "obj_char_span": [120, 136], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [18, 20]}], "umls_entity_list": []}, {"text": "Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.", "entity_list": [{"name": "thrombi", "ent_type": "Disease", "char_span": [70, 77], "ent_id": "D013927", "tok_span": [12, 14]}, {"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [191, 207], "ent_id": "D013921", "tok_span": [32, 34]}, {"name": "ischemia", "ent_type": "Disease", "char_span": [90, 98], "ent_id": "D007511", "tok_span": [16, 17]}, {"name": "arterial occlusion", "ent_type": "Disease", "char_span": [32, 50], "ent_id": "D001157", "tok_span": [6, 8]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [153, 160], "ent_id": "D006493", "tok_span": [26, 27]}], "relation_list": [{"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [153, 160], "obj_char_span": [191, 207], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 27], "obj_tok_span": [32, 34]}, {"subject": "heparin", "object": "arterial occlusion", "sbj_char_span": [153, 160], "obj_char_span": [32, 50], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 27], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "The common factor relating thromboembolism and thrombocytopenia is heparin-induced platelet aggregation.", "entity_list": [{"name": "platelet aggregation", "ent_type": "Disease", "char_span": [83, 103], "ent_id": "D001791", "tok_span": [13, 15]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [67, 74], "ent_id": "D006493", "tok_span": [10, 11]}, {"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [47, 63], "ent_id": "D013921", "tok_span": [7, 9]}, {"name": "thromboembolism", "ent_type": "Disease", "char_span": [27, 42], "ent_id": "D013923", "tok_span": [4, 6]}], "relation_list": [{"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [67, 74], "obj_char_span": [47, 63], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "Long-term prognosis for transplant-free survivors of paracetamol-induced acute liver failure.", "entity_list": [{"name": "paracetamol", "ent_type": "Chemical", "char_span": [53, 64], "ent_id": "D000082", "tok_span": [10, 14]}, {"name": "acute liver failure", "ent_type": "Disease", "char_span": [73, 92], "ent_id": "D017114", "tok_span": [16, 19]}], "relation_list": [{"subject": "paracetamol", "object": "acute liver failure", "sbj_char_span": [53, 64], "obj_char_span": [73, 92], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [16, 19]}], "umls_entity_list": []}, {"text": "BACKGROUND: The prognosis for transplant-free survivors of paracetamol-induced acute liver failure remains unknown.", "entity_list": [{"name": "paracetamol", "ent_type": "Chemical", "char_span": [59, 70], "ent_id": "D000082", "tok_span": [10, 14]}, {"name": "acute liver failure", "ent_type": "Disease", "char_span": [79, 98], "ent_id": "D017114", "tok_span": [16, 19]}], "relation_list": [{"subject": "paracetamol", "object": "acute liver failure", "sbj_char_span": [59, 70], "obj_char_span": [79, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [16, 19]}], "umls_entity_list": []}, {"text": "AIM: To examine whether paracetamol-induced acute liver failure increases long-term mortality.", "entity_list": [{"name": "acute liver failure", "ent_type": "Disease", "char_span": [44, 63], "ent_id": "D017114", "tok_span": [11, 14]}, {"name": "paracetamol", "ent_type": "Chemical", "char_span": [24, 35], "ent_id": "D000082", "tok_span": [5, 9]}], "relation_list": [{"subject": "paracetamol", "object": "acute liver failure", "sbj_char_span": [24, 35], "obj_char_span": [44, 63], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [11, 14]}], "umls_entity_list": []}, {"text": "On average, age-specific mortality rates were slightly higher for the 101 patients whose paracetamol-induced liver injury had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.", "entity_list": [{"name": "liver injury", "ent_type": "Disease", "char_span": [109, 121], "ent_id": "D056486", "tok_span": [22, 24]}, {"name": "liver disease", "ent_type": "Disease", "char_span": [301, 314], "ent_id": "D008107", "tok_span": [69, 71]}, {"name": "acute liver failure", "ent_type": "Disease", "char_span": [273, 292], "ent_id": "D017114", "tok_span": [64, 67]}, {"name": "paracetamol", "ent_type": "Chemical", "char_span": [89, 100], "ent_id": "D000082", "tok_span": [16, 20]}, {"name": "acute liver failure", "ent_type": "Disease", "char_span": [136, 155], "ent_id": "D017114", "tok_span": [27, 30]}], "relation_list": [{"subject": "paracetamol", "object": "acute liver failure", "sbj_char_span": [89, 100], "obj_char_span": [273, 292], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 20], "obj_tok_span": [64, 67]}, {"subject": "paracetamol", "object": "acute liver failure", "sbj_char_span": [89, 100], "obj_char_span": [136, 155], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 20], "obj_tok_span": [27, 30]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Paracetamol-induced acute liver failure did not affect long-term mortality.", "entity_list": [{"name": "Paracetamol", "ent_type": "Chemical", "char_span": [13, 24], "ent_id": "D000082", "tok_span": [2, 6]}, {"name": "acute liver failure", "ent_type": "Disease", "char_span": [33, 52], "ent_id": "D017114", "tok_span": [8, 11]}], "relation_list": [{"subject": "Paracetamol", "object": "acute liver failure", "sbj_char_span": [13, 24], "obj_char_span": [33, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [8, 11]}], "umls_entity_list": []}, {"text": "Serotonin 6 receptor gene is associated with methamphetamine-induced psychosis in a Japanese population.", "entity_list": [{"name": "Serotonin", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D012701", "tok_span": [0, 3]}, {"name": "psychosis", "ent_type": "Disease", "char_span": [69, 78], "ent_id": "D011605", "tok_span": [14, 15]}, {"name": "methamphetamine", "ent_type": "Chemical", "char_span": [45, 60], "ent_id": "D008694", "tok_span": [9, 12]}], "relation_list": [{"subject": "methamphetamine", "object": "psychosis", "sbj_char_span": [45, 60], "obj_char_span": [69, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [14, 15]}], "umls_entity_list": []}, {"text": "The symptoms of methamphetamine (METH)-induced psychosis are similar to those of paranoid type schizophrenia.", "entity_list": [{"name": "paranoid type schizophrenia", "ent_type": "Disease", "char_span": [81, 108], "ent_id": "D012563", "tok_span": [18, 23]}, {"name": "methamphetamine", "ent_type": "Chemical", "char_span": [16, 31], "ent_id": "D008694", "tok_span": [3, 6]}, {"name": "METH", "ent_type": "Chemical", "char_span": [33, 37], "ent_id": "D008694", "tok_span": [7, 9]}, {"name": "psychosis", "ent_type": "Disease", "char_span": [47, 56], "ent_id": "D011605", "tok_span": [12, 13]}], "relation_list": [{"subject": "METH", "object": "psychosis", "sbj_char_span": [33, 37], "obj_char_span": [47, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 9], "obj_tok_span": [12, 13]}, {"subject": "methamphetamine", "object": "psychosis", "sbj_char_span": [16, 31], "obj_char_span": [47, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [12, 13]}], "umls_entity_list": []}, {"text": "Therefore, we conducted an analysis of the association of the 5-HT6 gene (HTR6) with METH-induced psychosis.", "entity_list": [{"name": "5-HT", "ent_type": "Chemical", "char_span": [62, 66], "ent_id": "D012701", "tok_span": [11, 14]}, {"name": "METH", "ent_type": "Chemical", "char_span": [85, 89], "ent_id": "D008694", "tok_span": [22, 24]}, {"name": "psychosis", "ent_type": "Disease", "char_span": [98, 107], "ent_id": "D011605", "tok_span": [26, 27]}], "relation_list": [{"subject": "METH", "object": "psychosis", "sbj_char_span": [85, 89], "obj_char_span": [98, 107], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 24], "obj_tok_span": [26, 27]}], "umls_entity_list": []}, {"text": "METHOD: Using five tagging SNPs (rs6693503, rs1805054, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced psychosis patients and 337 controls) in the Japanese population.", "entity_list": [{"name": "METH", "ent_type": "Chemical", "char_span": [165, 169], "ent_id": "D008694", "tok_span": [49, 51]}, {"name": "psychosis", "ent_type": "Disease", "char_span": [178, 187], "ent_id": "D011605", "tok_span": [53, 54]}], "relation_list": [{"subject": "METH", "object": "psychosis", "sbj_char_span": [165, 169], "obj_char_span": [178, 187], "rel_type": "chemical-induced disease", "sbj_tok_span": [49, 51], "obj_tok_span": [53, 54]}], "umls_entity_list": []}, {"text": "RESULTS: rs6693503 was associated with METH-induced psychosis patients in the allele/genotype-wise analysis.", "entity_list": [{"name": "psychosis", "ent_type": "Disease", "char_span": [52, 61], "ent_id": "D011605", "tok_span": [14, 15]}, {"name": "METH", "ent_type": "Chemical", "char_span": [39, 43], "ent_id": "D008694", "tok_span": [10, 12]}], "relation_list": [{"subject": "METH", "object": "psychosis", "sbj_char_span": [39, 43], "obj_char_span": [52, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 12], "obj_tok_span": [14, 15]}], "umls_entity_list": []}, {"text": "In the haplotype-wise analysis, we detected an association between two markers (rs6693503 and rs1805054) and three markers (rs6693503, rs1805054 and rs4912138) in HTR6 and METH-induced psychosis patients, respectively.", "entity_list": [{"name": "METH", "ent_type": "Chemical", "char_span": [172, 176], "ent_id": "D008694", "tok_span": [52, 54]}, {"name": "psychosis", "ent_type": "Disease", "char_span": [185, 194], "ent_id": "D011605", "tok_span": [56, 57]}], "relation_list": [{"subject": "METH", "object": "psychosis", "sbj_char_span": [172, 176], "obj_char_span": [185, 194], "rel_type": "chemical-induced disease", "sbj_tok_span": [52, 54], "obj_tok_span": [56, 57]}], "umls_entity_list": []}, {"text": "CONCLUSION: HTR6 may play an important role in the pathophysiology of METH-induced psychosis in the Japanese population.", "entity_list": [{"name": "psychosis", "ent_type": "Disease", "char_span": [83, 92], "ent_id": "D011605", "tok_span": [18, 19]}, {"name": "METH", "ent_type": "Chemical", "char_span": [70, 74], "ent_id": "D008694", "tok_span": [14, 16]}], "relation_list": [{"subject": "METH", "object": "psychosis", "sbj_char_span": [70, 74], "obj_char_span": [83, 92], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [18, 19]}], "umls_entity_list": []}, {"text": "Effect of increasing intraperitoneal infusion rates on bupropion hydrochloride-induced seizures in mice.", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [87, 95], "ent_id": "D012640", "tok_span": [13, 14]}, {"name": "bupropion hydrochloride", "ent_type": "Chemical", "char_span": [55, 78], "ent_id": "D016642", "tok_span": [7, 11]}], "relation_list": [{"subject": "bupropion hydrochloride", "object": "seizures", "sbj_char_span": [55, 78], "obj_char_span": [87, 95], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [13, 14]}], "umls_entity_list": []}, {"text": "BACKGROUND: It is not known if there is a relationship between input rate and incidence of bupropion-induced seizures.", "entity_list": [{"name": "bupropion", "ent_type": "Chemical", "char_span": [91, 100], "ent_id": "D016642", "tok_span": [17, 20]}, {"name": "seizures", "ent_type": "Disease", "char_span": [109, 117], "ent_id": "D012640", "tok_span": [22, 23]}], "relation_list": [{"subject": "bupropion", "object": "seizures", "sbj_char_span": [91, 100], "obj_char_span": [109, 117], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [22, 23]}], "umls_entity_list": []}, {"text": "METHODS: We investigated the effect of varying the intraperitoneal infusion rates of bupropion HCl 120 mg/kg, a known convulsive dose 50 (CD50), on the incidence and severity of bupropion-induced convulsions in the Swiss albino mice.", "entity_list": [{"name": "convulsive", "ent_type": "Disease", "char_span": [118, 128], "ent_id": "D012640", "tok_span": [24, 26]}, {"name": "bupropion", "ent_type": "Chemical", "char_span": [178, 187], "ent_id": "D016642", "tok_span": [39, 42]}, {"name": "convulsions", "ent_type": "Disease", "char_span": [196, 207], "ent_id": "D012640", "tok_span": [44, 47]}, {"name": "bupropion HCl", "ent_type": "Chemical", "char_span": [85, 98], "ent_id": "D016642", "tok_span": [13, 17]}], "relation_list": [{"subject": "bupropion HCl", "object": "convulsions", "sbj_char_span": [85, 98], "obj_char_span": [196, 207], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [44, 47]}, {"subject": "bupropion", "object": "convulsive", "sbj_char_span": [178, 187], "obj_char_span": [118, 128], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 42], "obj_tok_span": [24, 26]}, {"subject": "bupropion", "object": "convulsions", "sbj_char_span": [178, 187], "obj_char_span": [196, 207], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 42], "obj_tok_span": [44, 47]}, {"subject": "bupropion HCl", "object": "convulsive", "sbj_char_span": [85, 98], "obj_char_span": [118, 128], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [24, 26]}], "umls_entity_list": []}, {"text": "RESULTS: The results showed that IP administration of bupropion HCl 120 mg/kg by bolus injection induced convulsions in 6 out of 10 mice (60% of convulsing mice) in group 1.", "entity_list": [{"name": "bupropion HCl", "ent_type": "Chemical", "char_span": [54, 67], "ent_id": "D016642", "tok_span": [9, 13]}, {"name": "convulsions", "ent_type": "Disease", "char_span": [105, 116], "ent_id": "D012640", "tok_span": [21, 24]}], "relation_list": [{"subject": "bupropion HCl", "object": "convulsions", "sbj_char_span": [54, 67], "obj_char_span": [105, 116], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [21, 24]}], "umls_entity_list": []}, {"text": "Logistic regression analysis revealed that infusion time was significant (p = 0.0004; odds ratio = 0.974) and increasing the IP infusion time of bupropion HCl 120 mg/kg was associated with a 91% reduced odds of convulsions at infusion times of 15 to 90 min compared to bolus injection.", "entity_list": [{"name": "convulsions", "ent_type": "Disease", "char_span": [211, 222], "ent_id": "D012640", "tok_span": [50, 53]}, {"name": "bupropion HCl", "ent_type": "Chemical", "char_span": [145, 158], "ent_id": "D016642", "tok_span": [33, 37]}], "relation_list": [{"subject": "bupropion HCl", "object": "convulsions", "sbj_char_span": [145, 158], "obj_char_span": [211, 222], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 37], "obj_tok_span": [50, 53]}], "umls_entity_list": []}, {"text": "CONCLUSION: In conclusion, the demonstration of an inverse relationship between infusion time of a fixed and convulsive dose of bupropion and the risk of convulsions in a prospective study is novel.", "entity_list": [{"name": "bupropion", "ent_type": "Chemical", "char_span": [128, 137], "ent_id": "D016642", "tok_span": [22, 25]}, {"name": "convulsions", "ent_type": "Disease", "char_span": [154, 165], "ent_id": "D012640", "tok_span": [29, 32]}, {"name": "convulsive", "ent_type": "Disease", "char_span": [109, 119], "ent_id": "D012640", "tok_span": [18, 20]}], "relation_list": [{"subject": "bupropion", "object": "convulsive", "sbj_char_span": [128, 137], "obj_char_span": [109, 119], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 25], "obj_tok_span": [18, 20]}, {"subject": "bupropion", "object": "convulsions", "sbj_char_span": [128, 137], "obj_char_span": [154, 165], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 25], "obj_tok_span": [29, 32]}], "umls_entity_list": []}, {"text": "After a short period of basal activity recording, epileptic focus was induced by injecting 400IU/2 microl penicillin-G potassium into the left lateral ventricle while the cortical activity was continuously recorded.", "entity_list": [{"name": "epileptic", "ent_type": "Disease", "char_span": [50, 59], "ent_id": "D004827", "tok_span": [9, 10]}, {"name": "penicillin-G potassium", "ent_type": "Chemical", "char_span": [106, 128], "ent_id": "D010400", "tok_span": [21, 25]}], "relation_list": [{"subject": "penicillin-G potassium", "object": "epileptic", "sbj_char_span": [106, 128], "obj_char_span": [50, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 25], "obj_tok_span": [9, 10]}], "umls_entity_list": []}, {"text": "Although dexmedetomidine sedation was associated with a 16% incidence of bradycardia, all concomitant mean arterial blood pressures were within 20% of age-adjusted normal range and oxygen saturations were 95% or higher.", "entity_list": [{"name": "dexmedetomidine", "ent_type": "Chemical", "char_span": [9, 24], "ent_id": "D020927", "tok_span": [1, 6]}, {"name": "oxygen", "ent_type": "Chemical", "char_span": [181, 187], "ent_id": "D010100", "tok_span": [37, 38]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [73, 84], "ent_id": "D001919", "tok_span": [15, 19]}], "relation_list": [{"subject": "dexmedetomidine", "object": "bradycardia", "sbj_char_span": [9, 24], "obj_char_span": [73, 84], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 6], "obj_tok_span": [15, 19]}], "umls_entity_list": []}, {"text": "Methamphetamine causes alterations in the MAP kinase-related pathways in the brains of mice that display increased aggressiveness.", "entity_list": [{"name": "Methamphetamine", "ent_type": "Chemical", "char_span": [0, 15], "ent_id": "D008694", "tok_span": [0, 3]}, {"name": "aggressiveness", "ent_type": "Disease", "char_span": [115, 129], "ent_id": "D001523", "tok_span": [20, 22]}], "relation_list": [{"subject": "Methamphetamine", "object": "aggressiveness", "sbj_char_span": [0, 15], "obj_char_span": [115, 129], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [20, 22]}], "umls_entity_list": []}, {"text": "Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders, and are common in methamphetamine (METH) abusers.", "entity_list": [{"name": "Aggressive behaviors", "ent_type": "Disease", "char_span": [0, 20], "ent_id": "D001523", "tok_span": [0, 3]}, {"name": "psychiatric disorders", "ent_type": "Disease", "char_span": [73, 94], "ent_id": "D001523", "tok_span": [12, 14]}, {"name": "METH", "ent_type": "Chemical", "char_span": [131, 135], "ent_id": "D008694", "tok_span": [23, 25]}, {"name": "methamphetamine", "ent_type": "Chemical", "char_span": [114, 129], "ent_id": "D008694", "tok_span": [19, 22]}], "relation_list": [{"subject": "METH", "object": "Aggressive behaviors", "sbj_char_span": [131, 135], "obj_char_span": [0, 20], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 25], "obj_tok_span": [0, 3]}, {"subject": "methamphetamine", "object": "Aggressive behaviors", "sbj_char_span": [114, 129], "obj_char_span": [0, 20], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 22], "obj_tok_span": [0, 3]}, {"subject": "methamphetamine", "object": "psychiatric disorders", "sbj_char_span": [114, 129], "obj_char_span": [73, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 22], "obj_tok_span": [12, 14]}, {"subject": "METH", "object": "psychiatric disorders", "sbj_char_span": [131, 135], "obj_char_span": [73, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 25], "obj_tok_span": [12, 14]}], "umls_entity_list": []}, {"text": "Herein, we report that multiple (but not single) injections of METH significantly increased aggressiveness in male CD-1 mice.", "entity_list": [{"name": "METH", "ent_type": "Chemical", "char_span": [63, 67], "ent_id": "D008694", "tok_span": [13, 15]}, {"name": "aggressiveness", "ent_type": "Disease", "char_span": [92, 106], "ent_id": "D001523", "tok_span": [17, 19]}], "relation_list": [{"subject": "METH", "object": "aggressiveness", "sbj_char_span": [63, 67], "obj_char_span": [92, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [17, 19]}], "umls_entity_list": []}, {"text": "This increase in aggressiveness was not secondary to METH-induced hyperactivity.", "entity_list": [{"name": "METH", "ent_type": "Chemical", "char_span": [53, 57], "ent_id": "D008694", "tok_span": [9, 11]}, {"name": "aggressiveness", "ent_type": "Disease", "char_span": [17, 31], "ent_id": "D001523", "tok_span": [3, 5]}, {"name": "hyperactivity", "ent_type": "Disease", "char_span": [66, 79], "ent_id": "D006948", "tok_span": [13, 15]}], "relation_list": [{"subject": "METH", "object": "aggressiveness", "sbj_char_span": [53, 57], "obj_char_span": [17, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 11], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies.", "entity_list": [{"name": "Lamotrigine", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "C047781", "tok_span": [0, 3]}, {"name": "myoclonus", "ent_type": "Disease", "char_span": [52, 61], "ent_id": "D009207", "tok_span": [10, 14]}, {"name": "idiopathic generalized epilepsies", "ent_type": "Disease", "char_span": [65, 98], "ent_id": "C562694", "tok_span": [15, 19]}], "relation_list": [{"subject": "Lamotrigine", "object": "myoclonus", "sbj_char_span": [0, 11], "obj_char_span": [52, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).", "entity_list": [{"name": "myoclonic jerks", "ent_type": "Disease", "char_span": [140, 155], "ent_id": "D009207", "tok_span": [28, 34]}, {"name": "LTG", "ent_type": "Chemical", "char_span": [85, 88], "ent_id": "C047781", "tok_span": [17, 19]}, {"name": "idiopathic generalized epilepsies", "ent_type": "Disease", "char_span": [19, 52], "ent_id": "C562694", "tok_span": [3, 7]}, {"name": "MJ", "ent_type": "Disease", "char_span": [157, 159], "ent_id": "D009207", "tok_span": [35, 36]}, {"name": "IGE", "ent_type": "Disease", "char_span": [54, 57], "ent_id": "C562694", "tok_span": [8, 10]}, {"name": "lamotrigine", "ent_type": "Chemical", "char_span": [72, 83], "ent_id": "C047781", "tok_span": [13, 16]}], "relation_list": [{"subject": "LTG", "object": "MJ", "sbj_char_span": [85, 88], "obj_char_span": [157, 159], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 19], "obj_tok_span": [35, 36]}, {"subject": "lamotrigine", "object": "myoclonic jerks", "sbj_char_span": [72, 83], "obj_char_span": [140, 155], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [28, 34]}, {"subject": "LTG", "object": "myoclonic jerks", "sbj_char_span": [85, 88], "obj_char_span": [140, 155], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 19], "obj_tok_span": [28, 34]}, {"subject": "lamotrigine", "object": "MJ", "sbj_char_span": [72, 83], "obj_char_span": [157, 159], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [35, 36]}], "umls_entity_list": []}, {"text": "In three patients, LTG exacerbated MJ in a dose-dependent manner with early aggravation during titration.", "entity_list": [{"name": "LTG", "ent_type": "Chemical", "char_span": [19, 22], "ent_id": "C047781", "tok_span": [4, 6]}, {"name": "MJ", "ent_type": "Disease", "char_span": [35, 37], "ent_id": "D009207", "tok_span": [8, 9]}], "relation_list": [{"subject": "LTG", "object": "MJ", "sbj_char_span": [19, 22], "obj_char_span": [35, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 6], "obj_tok_span": [8, 9]}], "umls_entity_list": []}, {"text": "MJ disappeared when LTG dose was decreased by 25 to 50%.", "entity_list": [{"name": "MJ", "ent_type": "Disease", "char_span": [0, 2], "ent_id": "D009207", "tok_span": [0, 1]}, {"name": "LTG", "ent_type": "Chemical", "char_span": [20, 23], "ent_id": "C047781", "tok_span": [3, 5]}], "relation_list": [{"subject": "LTG", "object": "MJ", "sbj_char_span": [20, 23], "obj_char_span": [0, 2], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 5], "obj_tok_span": [0, 1]}], "umls_entity_list": []}, {"text": "In two patients, LTG exacerbated MJ in a delayed but more severe manner, with myoclonic status that only ceased after LTG withdrawal.", "entity_list": [{"name": "LTG", "ent_type": "Chemical", "char_span": [17, 20], "ent_id": "C047781", "tok_span": [4, 6]}, {"name": "myoclonic status", "ent_type": "Disease", "char_span": [78, 94], "ent_id": "D009207", "tok_span": [18, 22]}, {"name": "MJ", "ent_type": "Disease", "char_span": [33, 35], "ent_id": "D009207", "tok_span": [8, 9]}, {"name": "LTG", "ent_type": "Chemical", "char_span": [118, 121], "ent_id": "C047781", "tok_span": [27, 29]}], "relation_list": [{"subject": "LTG", "object": "MJ", "sbj_char_span": [17, 20], "obj_char_span": [33, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 6], "obj_tok_span": [8, 9]}, {"subject": "LTG", "object": "myoclonic status", "sbj_char_span": [118, 121], "obj_char_span": [78, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 29], "obj_tok_span": [18, 22]}, {"subject": "LTG", "object": "MJ", "sbj_char_span": [118, 121], "obj_char_span": [33, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 29], "obj_tok_span": [8, 9]}, {"subject": "LTG", "object": "myoclonic status", "sbj_char_span": [17, 20], "obj_char_span": [78, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 6], "obj_tok_span": [18, 22]}], "umls_entity_list": []}, {"text": "The neural mechanisms and circuitry involved in levodopa-induced dyskinesia are unclear.", "entity_list": [{"name": "dyskinesia", "ent_type": "Disease", "char_span": [65, 75], "ent_id": "D004409", "tok_span": [12, 16]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [48, 56], "ent_id": "D007980", "tok_span": [7, 10]}], "relation_list": [{"subject": "levodopa", "object": "dyskinesia", "sbj_char_span": [48, 56], "obj_char_span": [65, 75], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [12, 16]}], "umls_entity_list": []}, {"text": "Assessment of the onset and persistence of amnesia during procedural sedation with propofol.", "entity_list": [{"name": "amnesia", "ent_type": "Disease", "char_span": [43, 50], "ent_id": "D000647", "tok_span": [7, 10]}, {"name": "propofol", "ent_type": "Chemical", "char_span": [83, 91], "ent_id": "D015742", "tok_span": [14, 16]}], "relation_list": [{"subject": "propofol", "object": "amnesia", "sbj_char_span": [83, 91], "obj_char_span": [43, 50], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.", "entity_list": [{"name": "rubella", "ent_type": "Disease", "char_span": [275, 282], "ent_id": "D012409", "tok_span": [49, 51]}, {"name": "rubella", "ent_type": "Disease", "char_span": [338, 345], "ent_id": "D012409", "tok_span": [60, 62]}, {"name": "hepatitis B", "ent_type": "Disease", "char_span": [61, 72], "ent_id": "D006509", "tok_span": [10, 12]}, {"name": "hepatitis B surface antigen", "ent_type": "Chemical", "char_span": [229, 256], "ent_id": "D006514", "tok_span": [41, 45]}, {"name": "hepatitis B", "ent_type": "Disease", "char_span": [108, 119], "ent_id": "D006509", "tok_span": [19, 21]}, {"name": "rubella", "ent_type": "Disease", "char_span": [357, 364], "ent_id": "D012409", "tok_span": [64, 66]}, {"name": "rubella", "ent_type": "Disease", "char_span": [77, 84], "ent_id": "D012409", "tok_span": [13, 15]}, {"name": "hepatitis B", "ent_type": "Disease", "char_span": [173, 184], "ent_id": "D006509", "tok_span": [30, 32]}], "relation_list": [{"subject": "hepatitis B surface antigen", "object": "hepatitis B", "sbj_char_span": [229, 256], "obj_char_span": [108, 119], "rel_type": "chemical-induced disease", "sbj_tok_span": [41, 45], "obj_tok_span": [19, 21]}, {"subject": "hepatitis B surface antigen", "object": "hepatitis B", "sbj_char_span": [229, 256], "obj_char_span": [61, 72], "rel_type": "chemical-induced disease", "sbj_tok_span": [41, 45], "obj_tok_span": [10, 12]}, {"subject": "hepatitis B surface antigen", "object": "hepatitis B", "sbj_char_span": [229, 256], "obj_char_span": [173, 184], "rel_type": "chemical-induced disease", "sbj_tok_span": [41, 45], "obj_tok_span": [30, 32]}], "umls_entity_list": []}, {"text": "All infants who were born to hepatitis B surface antigen-positive mothers also received hepatitis B immune globulin.", "entity_list": [{"name": "hepatitis B", "ent_type": "Disease", "char_span": [88, 99], "ent_id": "D006509", "tok_span": [15, 17]}, {"name": "hepatitis B surface antigen", "ent_type": "Chemical", "char_span": [29, 56], "ent_id": "D006514", "tok_span": [6, 10]}], "relation_list": [{"subject": "hepatitis B surface antigen", "object": "hepatitis B", "sbj_char_span": [29, 56], "obj_char_span": [88, 99], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 10], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "These findings demonstrate that overexpression of p300 protects cardiac myocytes from doxorubicin-induced apoptosis and reduces the extent of acute heart failure in adult mice in vivo.", "entity_list": [{"name": "doxorubicin", "ent_type": "Chemical", "char_span": [86, 97], "ent_id": "D004317", "tok_span": [12, 13]}, {"name": "heart failure", "ent_type": "Disease", "char_span": [148, 161], "ent_id": "D006333", "tok_span": [22, 24]}], "relation_list": [{"subject": "doxorubicin", "object": "heart failure", "sbj_char_span": [86, 97], "obj_char_span": [148, 161], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [22, 24]}], "umls_entity_list": []}, {"text": "Mitochondrial DNA and its respiratory chain products are defective in doxorubicin nephrosis.", "entity_list": [{"name": "doxorubicin", "ent_type": "Chemical", "char_span": [70, 81], "ent_id": "D004317", "tok_span": [10, 11]}, {"name": "nephrosis", "ent_type": "Disease", "char_span": [82, 91], "ent_id": "D009401", "tok_span": [11, 13]}], "relation_list": [{"subject": "doxorubicin", "object": "nephrosis", "sbj_char_span": [70, 81], "obj_char_span": [82, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [11, 13]}], "umls_entity_list": []}, {"text": "Amphotericin B-induced seizures in a patient with AIDS.", "entity_list": [{"name": "Amphotericin B", "ent_type": "Chemical", "char_span": [0, 14], "ent_id": "D000666", "tok_span": [0, 5]}, {"name": "seizures", "ent_type": "Disease", "char_span": [23, 31], "ent_id": "D012640", "tok_span": [7, 8]}, {"name": "AIDS", "ent_type": "Disease", "char_span": [50, 54], "ent_id": "D000163", "tok_span": [12, 13]}], "relation_list": [{"subject": "Amphotericin B", "object": "seizures", "sbj_char_span": [0, 14], "obj_char_span": [23, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [7, 8]}], "umls_entity_list": []}, {"text": "OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.", "entity_list": [{"name": "seizure", "ent_type": "Disease", "char_span": [52, 59], "ent_id": "D012640", "tok_span": [10, 11]}, {"name": "AIDS", "ent_type": "Disease", "char_span": [75, 79], "ent_id": "D000163", "tok_span": [14, 15]}, {"name": "amphotericin B", "ent_type": "Chemical", "char_span": [97, 111], "ent_id": "D000666", "tok_span": [17, 21]}], "relation_list": [{"subject": "amphotericin B", "object": "seizure", "sbj_char_span": [97, 111], "obj_char_span": [52, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [10, 11]}], "umls_entity_list": []}, {"text": "CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.", "entity_list": [{"name": "amphotericin B", "ent_type": "Chemical", "char_span": [121, 135], "ent_id": "D000666", "tok_span": [22, 26]}, {"name": "seizures", "ent_type": "Disease", "char_span": [152, 160], "ent_id": "D012640", "tok_span": [31, 32]}, {"name": "grand mal seizures", "ent_type": "Disease", "char_span": [71, 89], "ent_id": "D004830", "tok_span": [15, 18]}], "relation_list": [{"subject": "amphotericin B", "object": "seizures", "sbj_char_span": [121, 135], "obj_char_span": [152, 160], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 26], "obj_tok_span": [31, 32]}], "umls_entity_list": []}, {"text": "Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.", "entity_list": [{"name": "amphotercin B", "ent_type": "Chemical", "char_span": [99, 112], "ent_id": "D000666", "tok_span": [19, 23]}, {"name": "phenytoin", "ent_type": "Chemical", "char_span": [26, 35], "ent_id": "D010672", "tok_span": [3, 6]}, {"name": "seizures", "ent_type": "Disease", "char_span": [55, 63], "ent_id": "D012640", "tok_span": [13, 14]}, {"name": "lorazepam", "ent_type": "Chemical", "char_span": [40, 49], "ent_id": "D008140", "tok_span": [7, 11]}], "relation_list": [{"subject": "amphotercin B", "object": "seizures", "sbj_char_span": [99, 112], "obj_char_span": [55, 63], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 23], "obj_tok_span": [13, 14]}], "umls_entity_list": []}, {"text": "The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.", "entity_list": [{"name": "AIDS", "ent_type": "Disease", "char_span": [94, 98], "ent_id": "D000163", "tok_span": [19, 20]}, {"name": "amphotericin B", "ent_type": "Chemical", "char_span": [41, 55], "ent_id": "D000666", "tok_span": [7, 11]}, {"name": "seizures", "ent_type": "Disease", "char_span": [77, 85], "ent_id": "D012640", "tok_span": [16, 17]}], "relation_list": [{"subject": "amphotericin B", "object": "seizures", "sbj_char_span": [41, 55], "obj_char_span": [77, 85], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [16, 17]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Amphotericin B seems to be the probable cause of the seizures.", "entity_list": [{"name": "Amphotericin B", "ent_type": "Chemical", "char_span": [13, 27], "ent_id": "D000666", "tok_span": [2, 7]}, {"name": "seizures", "ent_type": "Disease", "char_span": [66, 74], "ent_id": "D012640", "tok_span": [15, 16]}], "relation_list": [{"subject": "Amphotericin B", "object": "seizures", "sbj_char_span": [13, 27], "obj_char_span": [66, 74], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 7], "obj_tok_span": [15, 16]}], "umls_entity_list": []}, {"text": "To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [29, 37], "ent_id": "D012640", "tok_span": [7, 8]}, {"name": "amphotericin B", "ent_type": "Chemical", "char_span": [54, 68], "ent_id": "D000666", "tok_span": [10, 14]}], "relation_list": [{"subject": "amphotericin B", "object": "seizures", "sbj_char_span": [54, 68], "obj_char_span": [29, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [7, 8]}], "umls_entity_list": []}, {"text": "Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs.", "entity_list": [{"name": "doxorubicin", "ent_type": "Chemical", "char_span": [92, 103], "ent_id": "D004317", "tok_span": [19, 20]}, {"name": "SM-5887", "ent_type": "Chemical", "char_span": [63, 70], "ent_id": "C055866", "tok_span": [10, 14]}, {"name": "cardiomyopathy", "ent_type": "Disease", "char_span": [112, 126], "ent_id": "D009202", "tok_span": [22, 23]}, {"name": "anthracycline", "ent_type": "Chemical", "char_span": [37, 50], "ent_id": "D018943", "tok_span": [6, 8]}], "relation_list": [{"subject": "doxorubicin", "object": "cardiomyopathy", "sbj_char_span": [92, 103], "obj_char_span": [112, 126], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 20], "obj_tok_span": [22, 23]}], "umls_entity_list": []}, {"text": "Animals which received over six courses of doxorubicin demonstrated the electrocardiogram (ECG) changes, decrease of blood pressure and high-grade histopathological cardiomyopathy, while animals which were terminally sacrificed after the SM-5887 administration did not show any changes in ECG, blood pressure and histopathological examinations.", "entity_list": [{"name": "doxorubicin", "ent_type": "Chemical", "char_span": [43, 54], "ent_id": "D004317", "tok_span": [7, 8]}, {"name": "cardiomyopathy", "ent_type": "Disease", "char_span": [165, 179], "ent_id": "D009202", "tok_span": [27, 28]}, {"name": "SM-5887", "ent_type": "Chemical", "char_span": [238, 245], "ent_id": "C055866", "tok_span": [38, 42]}], "relation_list": [{"subject": "doxorubicin", "object": "cardiomyopathy", "sbj_char_span": [43, 54], "obj_char_span": [165, 179], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [27, 28]}], "umls_entity_list": []}, {"text": "To examine a possibly deteriorating cardiotoxic effect of SM-5887, low-grade cardiomyopathy was induced in dogs by four courses of doxorubicin (1.5 mg/kg).", "entity_list": [{"name": "doxorubicin", "ent_type": "Chemical", "char_span": [131, 142], "ent_id": "D004317", "tok_span": [27, 28]}, {"name": "cardiomyopathy", "ent_type": "Disease", "char_span": [77, 91], "ent_id": "D009202", "tok_span": [18, 19]}, {"name": "SM-5887", "ent_type": "Chemical", "char_span": [58, 65], "ent_id": "C055866", "tok_span": [10, 14]}, {"name": "cardiotoxic", "ent_type": "Disease", "char_span": [36, 47], "ent_id": "D066126", "tok_span": [6, 8]}], "relation_list": [{"subject": "doxorubicin", "object": "cardiomyopathy", "sbj_char_span": [131, 142], "obj_char_span": [77, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 28], "obj_tok_span": [18, 19]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: In late-stage Parkinson's disease, pallidotomy significantly reduces levodopa-induced dyskinesias and off-period disability.", "entity_list": [{"name": "dyskinesias", "ent_type": "Disease", "char_span": [99, 110], "ent_id": "D004409", "tok_span": [22, 26]}, {"name": "Parkinson's disease", "ent_type": "Disease", "char_span": [27, 46], "ent_id": "D010300", "tok_span": [6, 10]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [82, 90], "ent_id": "D007980", "tok_span": [17, 20]}], "relation_list": [{"subject": "levodopa", "object": "dyskinesias", "sbj_char_span": [82, 90], "obj_char_span": [99, 110], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "Neuropeptide-Y immunoreactivity in the pilocarpine model of temporal lobe epilepsy.", "entity_list": [{"name": "temporal lobe epilepsy", "ent_type": "Disease", "char_span": [60, 82], "ent_id": "D004833", "tok_span": [13, 16]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [39, 50], "ent_id": "D010862", "tok_span": [8, 11]}], "relation_list": [{"subject": "pilocarpine", "object": "temporal lobe epilepsy", "sbj_char_span": [39, 50], "obj_char_span": [60, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "The results demonstrate that changes in NPY expression, including expression in the granule cells and mossy fibres and the loss of vulnerable NPY neurons, are present in the PILO model of TLE.", "entity_list": [{"name": "PILO", "ent_type": "Chemical", "char_span": [174, 178], "ent_id": "D010862", "tok_span": [33, 35]}, {"name": "TLE", "ent_type": "Disease", "char_span": [188, 191], "ent_id": "D004833", "tok_span": [37, 39]}], "relation_list": [{"subject": "PILO", "object": "TLE", "sbj_char_span": [174, 178], "obj_char_span": [188, 191], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 35], "obj_tok_span": [37, 39]}], "umls_entity_list": []}, {"text": "During the follow-up, 3 patients (12%) developed steroid-induced elevated intraocular pressure (IOP) that resolved after corticosteroid therapy was discontinued.", "entity_list": [{"name": "corticosteroid", "ent_type": "Chemical", "char_span": [121, 135], "ent_id": "D000305", "tok_span": [26, 27]}, {"name": "elevated intraocular pressure", "ent_type": "Disease", "char_span": [65, 94], "ent_id": "D009798", "tok_span": [16, 20]}, {"name": "steroid", "ent_type": "Chemical", "char_span": [49, 56], "ent_id": "D013256", "tok_span": [13, 14]}], "relation_list": [{"subject": "corticosteroid", "object": "elevated intraocular pressure", "sbj_char_span": [121, 135], "obj_char_span": [65, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 27], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "Failure of ancrod in the treatment of heparin-induced arterial thrombosis.", "entity_list": [{"name": "thrombosis", "ent_type": "Disease", "char_span": [63, 73], "ent_id": "D013927", "tok_span": [12, 13]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [38, 45], "ent_id": "D006493", "tok_span": [8, 9]}], "relation_list": [{"subject": "heparin", "object": "thrombosis", "sbj_char_span": [38, 45], "obj_char_span": [63, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [12, 13]}], "umls_entity_list": []}, {"text": "The morbidity and mortality associated with heparin-induced thrombosis remain high despite numerous empirical therapies.", "entity_list": [{"name": "thrombosis", "ent_type": "Disease", "char_span": [60, 70], "ent_id": "D013927", "tok_span": [9, 10]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [44, 51], "ent_id": "D006493", "tok_span": [6, 7]}], "relation_list": [{"subject": "heparin", "object": "thrombosis", "sbj_char_span": [44, 51], "obj_char_span": [60, 70], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [9, 10]}], "umls_entity_list": []}, {"text": "Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.", "entity_list": [{"name": "thrombosis", "ent_type": "Disease", "char_span": [73, 83], "ent_id": "D013927", "tok_span": [12, 13]}, {"name": "thrombosis", "ent_type": "Disease", "char_span": [230, 240], "ent_id": "D013927", "tok_span": [37, 38]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [101, 108], "ent_id": "D006493", "tok_span": [16, 17]}, {"name": "platelet aggregation", "ent_type": "Disease", "char_span": [117, 137], "ent_id": "D001791", "tok_span": [18, 20]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [170, 177], "ent_id": "D006493", "tok_span": [26, 27]}], "relation_list": [{"subject": "heparin", "object": "thrombosis", "sbj_char_span": [170, 177], "obj_char_span": [230, 240], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 27], "obj_tok_span": [37, 38]}, {"subject": "heparin", "object": "thrombosis", "sbj_char_span": [101, 108], "obj_char_span": [73, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 17], "obj_tok_span": [12, 13]}, {"subject": "heparin", "object": "thrombosis", "sbj_char_span": [101, 108], "obj_char_span": [230, 240], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 17], "obj_tok_span": [37, 38]}, {"subject": "heparin", "object": "thrombosis", "sbj_char_span": [170, 177], "obj_char_span": [73, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 27], "obj_tok_span": [12, 13]}], "umls_entity_list": []}, {"text": "The authors present a case of failure of ancrod treatment in a patient with heparin-induced thrombosis.", "entity_list": [{"name": "thrombosis", "ent_type": "Disease", "char_span": [92, 102], "ent_id": "D013927", "tok_span": [18, 19]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [76, 83], "ent_id": "D006493", "tok_span": [15, 16]}], "relation_list": [{"subject": "heparin", "object": "thrombosis", "sbj_char_span": [76, 83], "obj_char_span": [92, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 16], "obj_tok_span": [18, 19]}], "umls_entity_list": []}, {"text": "Seizure after flumazenil administration in a pediatric patient.", "entity_list": [{"name": "Seizure", "ent_type": "Disease", "char_span": [0, 7], "ent_id": "D012640", "tok_span": [0, 3]}, {"name": "flumazenil", "ent_type": "Chemical", "char_span": [14, 24], "ent_id": "D005442", "tok_span": [4, 8]}], "relation_list": [{"subject": "flumazenil", "object": "Seizure", "sbj_char_span": [14, 24], "obj_char_span": [0, 7], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 8], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "We report the occurrence of a generalized tonic-clonic seizure in a pediatric patient following the administration of flumazenil.", "entity_list": [{"name": "flumazenil", "ent_type": "Chemical", "char_span": [118, 128], "ent_id": "D005442", "tok_span": [20, 24]}, {"name": "tonic-clonic seizure", "ent_type": "Disease", "char_span": [42, 62], "ent_id": "D012640", "tok_span": [7, 12]}], "relation_list": [{"subject": "flumazenil", "object": "tonic-clonic seizure", "sbj_char_span": [118, 128], "obj_char_span": [42, 62], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 24], "obj_tok_span": [7, 12]}], "umls_entity_list": []}, {"text": "Remodelling of nerve structure in experimental isoniazid neuropathy in the rat.", "entity_list": [{"name": "isoniazid", "ent_type": "Chemical", "char_span": [47, 56], "ent_id": "D007538", "tok_span": [8, 12]}, {"name": "neuropathy", "ent_type": "Disease", "char_span": [57, 67], "ent_id": "D009422", "tok_span": [12, 13]}], "relation_list": [{"subject": "isoniazid", "object": "neuropathy", "sbj_char_span": [47, 56], "obj_char_span": [57, 67], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [12, 13]}], "umls_entity_list": []}, {"text": "The neuropathy caused by a single dose of isoniazid in rats was studied with a computer-assisted morphometric method.", "entity_list": [{"name": "isoniazid", "ent_type": "Chemical", "char_span": [42, 51], "ent_id": "D007538", "tok_span": [8, 12]}, {"name": "neuropathy", "ent_type": "Disease", "char_span": [4, 14], "ent_id": "D009422", "tok_span": [1, 2]}], "relation_list": [{"subject": "isoniazid", "object": "neuropathy", "sbj_char_span": [42, 51], "obj_char_span": [4, 14], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [1, 2]}], "umls_entity_list": []}, {"text": "Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).", "entity_list": [{"name": "iohexol", "ent_type": "Chemical", "char_span": [108, 115], "ent_id": "D007472", "tok_span": [27, 30]}, {"name": "metrizoate", "ent_type": "Chemical", "char_span": [132, 142], "ent_id": "D008794", "tok_span": [36, 40]}, {"name": "iopentol", "ent_type": "Chemical", "char_span": [90, 98], "ent_id": "C053571", "tok_span": [19, 22]}, {"name": "ventricular fibrillation", "ent_type": "Disease", "char_span": [15, 39], "ent_id": "D014693", "tok_span": [5, 7]}], "relation_list": [{"subject": "metrizoate", "object": "ventricular fibrillation", "sbj_char_span": [132, 142], "obj_char_span": [15, 39], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 40], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "During dipyridamole-induced hyperemia, 12 of the 16 dogs with a partial coronary stenosis had a visible area of hypoperfusion by contrast echocardiography.", "entity_list": [{"name": "dipyridamole", "ent_type": "Chemical", "char_span": [7, 19], "ent_id": "D004176", "tok_span": [1, 6]}, {"name": "hyperemia", "ent_type": "Disease", "char_span": [28, 37], "ent_id": "D006940", "tok_span": [8, 10]}, {"name": "coronary stenosis", "ent_type": "Disease", "char_span": [72, 89], "ent_id": "D023921", "tok_span": [19, 21]}], "relation_list": [{"subject": "dipyridamole", "object": "hyperemia", "sbj_char_span": [7, 19], "obj_char_span": [28, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 6], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "The four dogs without a perfusion defect had a stenosis that resulted in a mild (0% to 50%) reduction in dipyridamole-induced hyperemia.", "entity_list": [{"name": "dipyridamole", "ent_type": "Chemical", "char_span": [105, 117], "ent_id": "D004176", "tok_span": [24, 29]}, {"name": "hyperemia", "ent_type": "Disease", "char_span": [126, 135], "ent_id": "D006940", "tok_span": [31, 33]}], "relation_list": [{"subject": "dipyridamole", "object": "hyperemia", "sbj_char_span": [105, 117], "obj_char_span": [126, 135], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 29], "obj_tok_span": [31, 33]}], "umls_entity_list": []}, {"text": "Thallium-201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole-induced hyperemia; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03).", "entity_list": [{"name": "Thallium", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D013793", "tok_span": [0, 3]}, {"name": "hyperemia", "ent_type": "Disease", "char_span": [103, 112], "ent_id": "D006940", "tok_span": [23, 25]}, {"name": "dipyridamole", "ent_type": "Chemical", "char_span": [82, 94], "ent_id": "D004176", "tok_span": [16, 21]}], "relation_list": [{"subject": "dipyridamole", "object": "hyperemia", "sbj_char_span": [82, 94], "obj_char_span": [103, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 21], "obj_tok_span": [23, 25]}], "umls_entity_list": []}, {"text": "Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).", "entity_list": [{"name": "furosemide", "ent_type": "Chemical", "char_span": [71, 81], "ent_id": "D005665", "tok_span": [10, 14]}, {"name": "creatinine", "ent_type": "Chemical", "char_span": [125, 135], "ent_id": "D003404", "tok_span": [30, 31]}, {"name": "Renal function significantly deteriorated", "ent_type": "Disease", "char_span": [0, 41], "ent_id": "D058186", "tok_span": [0, 5]}], "relation_list": [{"subject": "furosemide", "object": "Renal function significantly deteriorated", "sbj_char_span": [71, 81], "obj_char_span": [0, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [0, 5]}], "umls_entity_list": []}, {"text": "The renal pathology in a case of lithium-induced diabetes insipidus.", "entity_list": [{"name": "lithium", "ent_type": "Chemical", "char_span": [33, 40], "ent_id": "D008094", "tok_span": [7, 8]}, {"name": "diabetes insipidus", "ent_type": "Disease", "char_span": [49, 67], "ent_id": "D003919", "tok_span": [10, 15]}], "relation_list": [{"subject": "lithium", "object": "diabetes insipidus", "sbj_char_span": [33, 40], "obj_char_span": [49, 67], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [10, 15]}], "umls_entity_list": []}, {"text": "A case of lithium-induced diabetes insipidus is reported.", "entity_list": [{"name": "lithium", "ent_type": "Chemical", "char_span": [10, 17], "ent_id": "D008094", "tok_span": [3, 4]}, {"name": "diabetes insipidus", "ent_type": "Disease", "char_span": [26, 44], "ent_id": "D003919", "tok_span": [6, 11]}], "relation_list": [{"subject": "lithium", "object": "diabetes insipidus", "sbj_char_span": [10, 17], "obj_char_span": [26, 44], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [6, 11]}], "umls_entity_list": []}, {"text": "Etiologic factors in the pathogenesis of liver tumors associated with oral contraceptives.", "entity_list": [{"name": "oral contraceptives", "ent_type": "Chemical", "char_span": [70, 89], "ent_id": "D003276", "tok_span": [13, 16]}, {"name": "liver tumors", "ent_type": "Disease", "char_span": [41, 53], "ent_id": "D008113", "tok_span": [9, 11]}], "relation_list": [{"subject": "oral contraceptives", "object": "liver tumors", "sbj_char_span": [70, 89], "obj_char_span": [41, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "Within the last several years, previously rare liver tumors have been seen in young women using oral contraceptive steroids.", "entity_list": [{"name": "oral contraceptive", "ent_type": "Chemical", "char_span": [96, 114], "ent_id": "D003276", "tok_span": [17, 19]}, {"name": "steroids", "ent_type": "Chemical", "char_span": [115, 123], "ent_id": "D013256", "tok_span": [19, 20]}, {"name": "liver tumors", "ent_type": "Disease", "char_span": [47, 59], "ent_id": "D008113", "tok_span": [8, 10]}], "relation_list": [{"subject": "oral contraceptive", "object": "liver tumors", "sbj_char_span": [96, 114], "obj_char_span": [47, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 19], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "The Registry for Liver Tumors Associated with Oral Contraceptives at the University of California, Irvine, has clearly identified 27 cases.", "entity_list": [{"name": "Liver Tumors", "ent_type": "Disease", "char_span": [17, 29], "ent_id": "D008113", "tok_span": [3, 6]}, {"name": "Oral Contraceptives", "ent_type": "Chemical", "char_span": [46, 65], "ent_id": "D003276", "tok_span": [8, 13]}], "relation_list": [{"subject": "Oral Contraceptives", "object": "Liver Tumors", "sbj_char_span": [46, 65], "obj_char_span": [17, 29], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 13], "obj_tok_span": [3, 6]}], "umls_entity_list": []}, {"text": "Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.", "entity_list": [{"name": "sinusoidal obstruction syndrome", "ent_type": "Disease", "char_span": [108, 139], "ent_id": "D006504", "tok_span": [22, 25]}, {"name": "microangiopathy", "ent_type": "Disease", "char_span": [144, 159], "ent_id": "D014652", "tok_span": [26, 29]}, {"name": "Graft-versus-host disease", "ent_type": "Disease", "char_span": [0, 25], "ent_id": "D006086", "tok_span": [0, 7]}, {"name": "tacrolimus", "ent_type": "Chemical", "char_span": [58, 68], "ent_id": "D016559", "tok_span": [13, 15]}, {"name": "everolimus", "ent_type": "Chemical", "char_span": [43, 53], "ent_id": "C107135", "tok_span": [9, 12]}], "relation_list": [{"subject": "everolimus", "object": "sinusoidal obstruction syndrome", "sbj_char_span": [43, 53], "obj_char_span": [108, 139], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [22, 25]}, {"subject": "tacrolimus", "object": "sinusoidal obstruction syndrome", "sbj_char_span": [58, 68], "obj_char_span": [108, 139], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [22, 25]}, {"subject": "tacrolimus", "object": "microangiopathy", "sbj_char_span": [58, 68], "obj_char_span": [144, 159], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [26, 29]}, {"subject": "everolimus", "object": "microangiopathy", "sbj_char_span": [43, 53], "obj_char_span": [144, 159], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [26, 29]}], "umls_entity_list": []}, {"text": "Acute liver failure with concurrent bupropion and carbimazole therapy.", "entity_list": [{"name": "Acute liver failure", "ent_type": "Disease", "char_span": [0, 19], "ent_id": "D017114", "tok_span": [0, 3]}, {"name": "carbimazole", "ent_type": "Chemical", "char_span": [50, 61], "ent_id": "D002231", "tok_span": [9, 13]}, {"name": "bupropion", "ent_type": "Chemical", "char_span": [36, 45], "ent_id": "D016642", "tok_span": [5, 8]}], "relation_list": [{"subject": "carbimazole", "object": "Acute liver failure", "sbj_char_span": [50, 61], "obj_char_span": [0, 19], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [0, 3]}, {"subject": "bupropion", "object": "Acute liver failure", "sbj_char_span": [36, 45], "obj_char_span": [0, 19], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "The likelihood that bupropion induced hepatotoxicity in our patient was possible, based on the Naranjo probability scale.", "entity_list": [{"name": "bupropion", "ent_type": "Chemical", "char_span": [20, 29], "ent_id": "D016642", "tok_span": [3, 6]}, {"name": "hepatotoxicity", "ent_type": "Disease", "char_span": [38, 52], "ent_id": "D056486", "tok_span": [7, 9]}], "relation_list": [{"subject": "bupropion", "object": "hepatotoxicity", "sbj_char_span": [20, 29], "obj_char_span": [38, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.", "entity_list": [{"name": "bupropion", "ent_type": "Chemical", "char_span": [79, 88], "ent_id": "D016642", "tok_span": [12, 15]}, {"name": "acute liver failure", "ent_type": "Disease", "char_span": [155, 174], "ent_id": "D017114", "tok_span": [29, 32]}, {"name": "carbimazole", "ent_type": "Chemical", "char_span": [244, 255], "ent_id": "D002231", "tok_span": [44, 48]}, {"name": "hepatotoxicity", "ent_type": "Disease", "char_span": [53, 67], "ent_id": "D056486", "tok_span": [8, 10]}, {"name": "bupropion", "ent_type": "Chemical", "char_span": [198, 207], "ent_id": "D016642", "tok_span": [36, 39]}], "relation_list": [{"subject": "carbimazole", "object": "hepatotoxicity", "sbj_char_span": [244, 255], "obj_char_span": [53, 67], "rel_type": "chemical-induced disease", "sbj_tok_span": [44, 48], "obj_tok_span": [8, 10]}, {"subject": "bupropion", "object": "acute liver failure", "sbj_char_span": [198, 207], "obj_char_span": [155, 174], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 39], "obj_tok_span": [29, 32]}, {"subject": "carbimazole", "object": "acute liver failure", "sbj_char_span": [244, 255], "obj_char_span": [155, 174], "rel_type": "chemical-induced disease", "sbj_tok_span": [44, 48], "obj_tok_span": [29, 32]}, {"subject": "bupropion", "object": "hepatotoxicity", "sbj_char_span": [198, 207], "obj_char_span": [53, 67], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 39], "obj_tok_span": [8, 10]}, {"subject": "bupropion", "object": "hepatotoxicity", "sbj_char_span": [79, 88], "obj_char_span": [53, 67], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [8, 10]}, {"subject": "bupropion", "object": "acute liver failure", "sbj_char_span": [79, 88], "obj_char_span": [155, 174], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [29, 32]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Clinicians should be aware of the possibility of acute liver insult induced by bupropion given concurrently with other hepatotoxic drugs.", "entity_list": [{"name": "hepatotoxic", "ent_type": "Disease", "char_span": [132, 143], "ent_id": "D056486", "tok_span": [24, 26]}, {"name": "bupropion", "ent_type": "Chemical", "char_span": [92, 101], "ent_id": "D016642", "tok_span": [17, 20]}, {"name": "acute liver insult", "ent_type": "Disease", "char_span": [62, 80], "ent_id": "D017114", "tok_span": [11, 15]}], "relation_list": [{"subject": "bupropion", "object": "hepatotoxic", "sbj_char_span": [92, 101], "obj_char_span": [132, 143], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [24, 26]}, {"subject": "bupropion", "object": "acute liver insult", "sbj_char_span": [92, 101], "obj_char_span": [62, 80], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "Long-term oestrogen-only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.", "entity_list": [{"name": "breast cancer", "ent_type": "Disease", "char_span": [240, 253], "ent_id": "D001943", "tok_span": [49, 51]}, {"name": "stroke", "ent_type": "Disease", "char_span": [89, 95], "ent_id": "D020521", "tok_span": [19, 20]}, {"name": "oestrogen", "ent_type": "Chemical", "char_span": [10, 19], "ent_id": "D004967", "tok_span": [3, 6]}, {"name": "venous thrombo-embolism", "ent_type": "Disease", "char_span": [64, 87], "ent_id": "D054556", "tok_span": [14, 18]}, {"name": "gallbladder disease", "ent_type": "Disease", "char_span": [100, 119], "ent_id": "D005705", "tok_span": [21, 24]}], "relation_list": [{"subject": "oestrogen", "object": "gallbladder disease", "sbj_char_span": [10, 19], "obj_char_span": [100, 119], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [21, 24]}, {"subject": "oestrogen", "object": "stroke", "sbj_char_span": [10, 19], "obj_char_span": [89, 95], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [19, 20]}, {"subject": "oestrogen", "object": "venous thrombo-embolism", "sbj_char_span": [10, 19], "obj_char_span": [64, 87], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [14, 18]}], "umls_entity_list": []}, {"text": "Among women with cardiovascular disease, long-term use of combined continuous HT significantly increased the risk of venous thrombo-embolism.One trial analysed subgroups of 2839 relatively healthy 50 to 59 year old women taking combined continuous HT and 1637 taking oestrogen-only HT, versus similar-sized placebo groups.", "entity_list": [{"name": "cardiovascular disease", "ent_type": "Disease", "char_span": [17, 39], "ent_id": "D002318", "tok_span": [3, 5]}, {"name": "oestrogen", "ent_type": "Chemical", "char_span": [267, 276], "ent_id": "D004967", "tok_span": [47, 50]}, {"name": "venous thrombo-embolism", "ent_type": "Disease", "char_span": [117, 140], "ent_id": "D054556", "tok_span": [19, 23]}], "relation_list": [{"subject": "oestrogen", "object": "venous thrombo-embolism", "sbj_char_span": [267, 276], "obj_char_span": [117, 140], "rel_type": "chemical-induced disease", "sbj_tok_span": [47, 50], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "AIM: Widespread use of mannitol to reduce brain edema and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.", "entity_list": [{"name": "brain tumor", "ent_type": "Disease", "char_span": [80, 91], "ent_id": "D001932", "tok_span": [18, 20]}, {"name": "elevated ICP", "ent_type": "Disease", "char_span": [64, 76], "ent_id": "D019586", "tok_span": [15, 17]}, {"name": "brain edema", "ent_type": "Disease", "char_span": [42, 53], "ent_id": "D001929", "tok_span": [11, 13]}, {"name": "mannitol", "ent_type": "Chemical", "char_span": [23, 31], "ent_id": "D008353", "tok_span": [7, 9]}], "relation_list": [{"subject": "mannitol", "object": "elevated ICP", "sbj_char_span": [23, 31], "obj_char_span": [64, 76], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 9], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "Can lidocaine reduce succinylcholine induced postoperative myalgia?", "entity_list": [{"name": "lidocaine", "ent_type": "Chemical", "char_span": [4, 13], "ent_id": "D008012", "tok_span": [1, 3]}, {"name": "postoperative myalgia", "ent_type": "Disease", "char_span": [45, 66], "ent_id": "D010149", "tok_span": [8, 12]}, {"name": "succinylcholine", "ent_type": "Chemical", "char_span": [21, 36], "ent_id": "D013390", "tok_span": [4, 7]}], "relation_list": [{"subject": "succinylcholine", "object": "postoperative myalgia", "sbj_char_span": [21, 36], "obj_char_span": [45, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [8, 12]}], "umls_entity_list": []}, {"text": "In conclusion, where succinylcholine is used, lidocaine is proven to be the useful pretreatment agent for the reduction of postoperative myalgia.", "entity_list": [{"name": "succinylcholine", "ent_type": "Chemical", "char_span": [21, 36], "ent_id": "D013390", "tok_span": [4, 7]}, {"name": "postoperative myalgia", "ent_type": "Disease", "char_span": [123, 144], "ent_id": "D010149", "tok_span": [24, 28]}, {"name": "lidocaine", "ent_type": "Chemical", "char_span": [46, 55], "ent_id": "D008012", "tok_span": [10, 12]}], "relation_list": [{"subject": "succinylcholine", "object": "postoperative myalgia", "sbj_char_span": [21, 36], "obj_char_span": [123, 144], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [24, 28]}], "umls_entity_list": []}, {"text": "Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of CLZ.", "entity_list": [{"name": "nausea", "ent_type": "Disease", "char_span": [103, 109], "ent_id": "D009325", "tok_span": [18, 19]}, {"name": "CLZ", "ent_type": "Chemical", "char_span": [148, 151], "ent_id": "C045645", "tok_span": [26, 28]}, {"name": "headache", "ent_type": "Disease", "char_span": [37, 45], "ent_id": "D006261", "tok_span": [6, 7]}, {"name": "facial flush", "ent_type": "Disease", "char_span": [79, 91], "ent_id": "D005483", "tok_span": [12, 15]}], "relation_list": [{"subject": "CLZ", "object": "facial flush", "sbj_char_span": [148, 151], "obj_char_span": [79, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 28], "obj_tok_span": [12, 15]}, {"subject": "CLZ", "object": "nausea", "sbj_char_span": [148, 151], "obj_char_span": [103, 109], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 28], "obj_tok_span": [18, 19]}, {"subject": "CLZ", "object": "headache", "sbj_char_span": [148, 151], "obj_char_span": [37, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 28], "obj_tok_span": [6, 7]}], "umls_entity_list": []}, {"text": "The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).", "entity_list": [{"name": "diclofenac", "ent_type": "Chemical", "char_span": [95, 105], "ent_id": "D004008", "tok_span": [18, 22]}, {"name": "GI AEs", "ent_type": "Disease", "char_span": [43, 49], "ent_id": "D005767", "tok_span": [6, 9]}, {"name": "etoricoxib", "ent_type": "Chemical", "char_span": [79, 89], "ent_id": "C422649", "tok_span": [13, 17]}], "relation_list": [{"subject": "diclofenac", "object": "GI AEs", "sbj_char_span": [95, 105], "obj_char_span": [43, 49], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 22], "obj_tok_span": [6, 9]}], "umls_entity_list": []}, {"text": "The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).", "entity_list": [{"name": "oedema", "ent_type": "Disease", "char_span": [247, 253], "ent_id": "D004487", "tok_span": [69, 71]}, {"name": "oedema", "ent_type": "Disease", "char_span": [63, 69], "ent_id": "D004487", "tok_span": [10, 12]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [219, 231], "ent_id": "D006973", "tok_span": [61, 62]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [38, 50], "ent_id": "D006973", "tok_span": [6, 7]}, {"name": "etoricoxib", "ent_type": "Chemical", "char_span": [113, 123], "ent_id": "C422649", "tok_span": [20, 24]}, {"name": "diclofenac", "ent_type": "Chemical", "char_span": [167, 177], "ent_id": "D004008", "tok_span": [38, 42]}], "relation_list": [{"subject": "etoricoxib", "object": "hypertension", "sbj_char_span": [113, 123], "obj_char_span": [38, 50], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 24], "obj_tok_span": [6, 7]}, {"subject": "etoricoxib", "object": "oedema", "sbj_char_span": [113, 123], "obj_char_span": [63, 69], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 24], "obj_tok_span": [10, 12]}, {"subject": "etoricoxib", "object": "hypertension", "sbj_char_span": [113, 123], "obj_char_span": [219, 231], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 24], "obj_tok_span": [61, 62]}, {"subject": "etoricoxib", "object": "oedema", "sbj_char_span": [113, 123], "obj_char_span": [247, 253], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 24], "obj_tok_span": [69, 71]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg. Discontinuations from renovascular AEs, although less common than discontinuations from GI AEs, were significantly higher with etoricoxib.", "entity_list": [{"name": "Etoricoxib", "ent_type": "Chemical", "char_span": [13, 23], "ent_id": "C422649", "tok_span": [2, 6]}, {"name": "GI AEs", "ent_type": "Disease", "char_span": [233, 239], "ent_id": "D005767", "tok_span": [47, 50]}, {"name": "GI AEs", "ent_type": "Disease", "char_span": [105, 111], "ent_id": "D005767", "tok_span": [19, 22]}, {"name": "diclofenac", "ent_type": "Chemical", "char_span": [126, 136], "ent_id": "D004008", "tok_span": [24, 28]}, {"name": "etoricoxib", "ent_type": "Chemical", "char_span": [272, 282], "ent_id": "C422649", "tok_span": [55, 59]}], "relation_list": [{"subject": "diclofenac", "object": "GI AEs", "sbj_char_span": [126, 136], "obj_char_span": [233, 239], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 28], "obj_tok_span": [47, 50]}, {"subject": "diclofenac", "object": "GI AEs", "sbj_char_span": [126, 136], "obj_char_span": [105, 111], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 28], "obj_tok_span": [19, 22]}], "umls_entity_list": []}, {"text": "Similarly, EPS-related adverse events with QTP + Li/DVP (21.4%) were no different than with PBO + Li/DVP (19.2%).", "entity_list": [{"name": "QTP", "ent_type": "Chemical", "char_span": [43, 46], "ent_id": "C069541", "tok_span": [8, 10]}, {"name": "DVP", "ent_type": "Chemical", "char_span": [101, 104], "ent_id": "D014635", "tok_span": [31, 33]}, {"name": "Li", "ent_type": "Chemical", "char_span": [49, 51], "ent_id": "D008094", "tok_span": [11, 12]}, {"name": "DVP", "ent_type": "Chemical", "char_span": [52, 55], "ent_id": "D014635", "tok_span": [13, 15]}, {"name": "Li", "ent_type": "Chemical", "char_span": [98, 100], "ent_id": "D008094", "tok_span": [29, 30]}, {"name": "EPS", "ent_type": "Disease", "char_span": [11, 14], "ent_id": "D001480", "tok_span": [2, 3]}], "relation_list": [{"subject": "Li", "object": "EPS", "sbj_char_span": [49, 51], "obj_char_span": [11, 14], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [2, 3]}, {"subject": "Li", "object": "EPS", "sbj_char_span": [98, 100], "obj_char_span": [11, 14], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 30], "obj_tok_span": [2, 3]}], "umls_entity_list": []}, {"text": "Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.", "entity_list": [{"name": "EPS", "ent_type": "Disease", "char_span": [26, 29], "ent_id": "D001480", "tok_span": [4, 5]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [73, 84], "ent_id": "D006220", "tok_span": [15, 18]}, {"name": "EPS", "ent_type": "Disease", "char_span": [213, 216], "ent_id": "D001480", "tok_span": [46, 47]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [146, 153], "ent_id": "D008094", "tok_span": [34, 35]}], "relation_list": [{"subject": "lithium", "object": "EPS", "sbj_char_span": [146, 153], "obj_char_span": [213, 216], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 35], "obj_tok_span": [46, 47]}, {"subject": "haloperidol", "object": "EPS", "sbj_char_span": [73, 84], "obj_char_span": [26, 29], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [4, 5]}, {"subject": "lithium", "object": "EPS", "sbj_char_span": [146, 153], "obj_char_span": [26, 29], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 35], "obj_tok_span": [4, 5]}, {"subject": "haloperidol", "object": "EPS", "sbj_char_span": [73, 84], "obj_char_span": [213, 216], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [46, 47]}], "umls_entity_list": []}, {"text": "Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.", "entity_list": [{"name": "lithium", "ent_type": "Chemical", "char_span": [251, 258], "ent_id": "D008094", "tok_span": [62, 63]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [168, 175], "ent_id": "D008094", "tok_span": [47, 48]}, {"name": "quetiapine", "ent_type": "Chemical", "char_span": [95, 105], "ent_id": "C069541", "tok_span": [26, 29]}, {"name": "Lithium", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "D008094", "tok_span": [0, 2]}, {"name": "tremor", "ent_type": "Disease", "char_span": [125, 131], "ent_id": "D014202", "tok_span": [37, 39]}, {"name": "tremor", "ent_type": "Disease", "char_span": [222, 228], "ent_id": "D014202", "tok_span": [57, 59]}, {"name": "tremor", "ent_type": "Disease", "char_span": [75, 81], "ent_id": "D014202", "tok_span": [17, 19]}], "relation_list": [{"subject": "Lithium", "object": "tremor", "sbj_char_span": [0, 7], "obj_char_span": [75, 81], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [17, 19]}, {"subject": "Lithium", "object": "tremor", "sbj_char_span": [0, 7], "obj_char_span": [125, 131], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [37, 39]}, {"subject": "lithium", "object": "tremor", "sbj_char_span": [251, 258], "obj_char_span": [75, 81], "rel_type": "chemical-induced disease", "sbj_tok_span": [62, 63], "obj_tok_span": [17, 19]}, {"subject": "lithium", "object": "tremor", "sbj_char_span": [168, 175], "obj_char_span": [222, 228], "rel_type": "chemical-induced disease", "sbj_tok_span": [47, 48], "obj_tok_span": [57, 59]}, {"subject": "lithium", "object": "tremor", "sbj_char_span": [168, 175], "obj_char_span": [125, 131], "rel_type": "chemical-induced disease", "sbj_tok_span": [47, 48], "obj_tok_span": [37, 39]}, {"subject": "Lithium", "object": "tremor", "sbj_char_span": [0, 7], "obj_char_span": [222, 228], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [57, 59]}, {"subject": "lithium", "object": "tremor", "sbj_char_span": [251, 258], "obj_char_span": [125, 131], "rel_type": "chemical-induced disease", "sbj_tok_span": [62, 63], "obj_tok_span": [37, 39]}, {"subject": "lithium", "object": "tremor", "sbj_char_span": [251, 258], "obj_char_span": [222, 228], "rel_type": "chemical-induced disease", "sbj_tok_span": [62, 63], "obj_tok_span": [57, 59]}, {"subject": "lithium", "object": "tremor", "sbj_char_span": [168, 175], "obj_char_span": [75, 81], "rel_type": "chemical-induced disease", "sbj_tok_span": [47, 48], "obj_tok_span": [17, 19]}], "umls_entity_list": []}, {"text": "Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.", "entity_list": [{"name": "extrapyramidal syndrome", "ent_type": "Disease", "char_span": [131, 154], "ent_id": "D001480", "tok_span": [48, 53]}, {"name": "akathisia", "ent_type": "Disease", "char_span": [68, 77], "ent_id": "D017109", "tok_span": [17, 21]}, {"name": "Haloperidol", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D006220", "tok_span": [0, 3]}, {"name": "tremor", "ent_type": "Disease", "char_span": [99, 105], "ent_id": "D014202", "tok_span": [33, 35]}, {"name": "quetiapine", "ent_type": "Chemical", "char_span": [180, 190], "ent_id": "C069541", "tok_span": [65, 68]}], "relation_list": [{"subject": "Haloperidol", "object": "akathisia", "sbj_char_span": [0, 11], "obj_char_span": [68, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [17, 21]}, {"subject": "Haloperidol", "object": "extrapyramidal syndrome", "sbj_char_span": [0, 11], "obj_char_span": [131, 154], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [48, 53]}, {"subject": "Haloperidol", "object": "tremor", "sbj_char_span": [0, 11], "obj_char_span": [99, 105], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [33, 35]}], "umls_entity_list": []}, {"text": "OBJECTIVE: To test the hypothesis that, in lifetime captopril-treated spontaneously hypertensive rats (SHR), the sympathetic nervous system contributes importantly to the hypertensive effect of dietary sodium chloride supplementation.", "entity_list": [{"name": "captopril", "ent_type": "Chemical", "char_span": [52, 61], "ent_id": "D002216", "tok_span": [10, 13]}, {"name": "dietary sodium chloride", "ent_type": "Chemical", "char_span": [194, 217], "ent_id": "D017673", "tok_span": [33, 36]}, {"name": "hypertensive", "ent_type": "Disease", "char_span": [171, 183], "ent_id": "D006973", "tok_span": [30, 31]}, {"name": "hypertensive", "ent_type": "Disease", "char_span": [84, 96], "ent_id": "D006973", "tok_span": [16, 17]}], "relation_list": [{"subject": "dietary sodium chloride", "object": "hypertensive", "sbj_char_span": [194, 217], "obj_char_span": [84, 96], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 36], "obj_tok_span": [16, 17]}, {"subject": "dietary sodium chloride", "object": "hypertensive", "sbj_char_span": [194, 217], "obj_char_span": [171, 183], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 36], "obj_tok_span": [30, 31]}], "umls_entity_list": []}, {"text": "Intravenous infusion of the ganglionic blocker hexamethonium resulted in a rapid decline in MAP that eliminated the dietary sodium chloride-induced increase in MAP in both groups.", "entity_list": [{"name": "increase in MAP", "ent_type": "Disease", "char_span": [148, 163], "ent_id": "D006973", "tok_span": [28, 31]}, {"name": "hexamethonium", "ent_type": "Chemical", "char_span": [47, 60], "ent_id": "D018738", "tok_span": [9, 13]}, {"name": "dietary sodium chloride", "ent_type": "Chemical", "char_span": [116, 139], "ent_id": "D017673", "tok_span": [23, 26]}], "relation_list": [{"subject": "dietary sodium chloride", "object": "increase in MAP", "sbj_char_span": [116, 139], "obj_char_span": [148, 163], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [28, 31]}], "umls_entity_list": []}, {"text": "Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on TOTP-induced neuropathy, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.", "entity_list": [{"name": "TOTP", "ent_type": "Chemical", "char_span": [213, 217], "ent_id": "C025541", "tok_span": [40, 42]}, {"name": "neuropathy", "ent_type": "Disease", "char_span": [116, 126], "ent_id": "D009422", "tok_span": [23, 24]}, {"name": "TOTP", "ent_type": "Chemical", "char_span": [103, 107], "ent_id": "C025541", "tok_span": [19, 21]}, {"name": "corticosterone", "ent_type": "Chemical", "char_span": [62, 76], "ent_id": "D003345", "tok_span": [13, 15]}, {"name": "DFP", "ent_type": "Chemical", "char_span": [221, 224], "ent_id": "D007531", "tok_span": [43, 45]}], "relation_list": [{"subject": "DFP", "object": "neuropathy", "sbj_char_span": [221, 224], "obj_char_span": [116, 126], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 45], "obj_tok_span": [23, 24]}, {"subject": "TOTP", "object": "neuropathy", "sbj_char_span": [103, 107], "obj_char_span": [116, 126], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 21], "obj_tok_span": [23, 24]}, {"subject": "TOTP", "object": "neuropathy", "sbj_char_span": [213, 217], "obj_char_span": [116, 126], "rel_type": "chemical-induced disease", "sbj_tok_span": [40, 42], "obj_tok_span": [23, 24]}], "umls_entity_list": []}, {"text": "Degenerating myelinated fibers were also evident in distal levels of the peripheral nerves of chickens given TOTP or DFP.", "entity_list": [{"name": "TOTP", "ent_type": "Chemical", "char_span": [109, 113], "ent_id": "C025541", "tok_span": [19, 21]}, {"name": "Degenerating myelinated fibers", "ent_type": "Disease", "char_span": [0, 30], "ent_id": "D009410", "tok_span": [0, 6]}, {"name": "DFP", "ent_type": "Chemical", "char_span": [117, 120], "ent_id": "D007531", "tok_span": [22, 24]}], "relation_list": [{"subject": "DFP", "object": "Degenerating myelinated fibers", "sbj_char_span": [117, 120], "obj_char_span": [0, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 24], "obj_tok_span": [0, 6]}, {"subject": "TOTP", "object": "Degenerating myelinated fibers", "sbj_char_span": [109, 113], "obj_char_span": [0, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 21], "obj_tok_span": [0, 6]}], "umls_entity_list": []}, {"text": "Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.", "entity_list": [{"name": "reserpine", "ent_type": "Chemical", "char_span": [298, 307], "ent_id": "D012110", "tok_span": [87, 90]}, {"name": "6-hydroxydopamine", "ent_type": "Chemical", "char_span": [330, 347], "ent_id": "D016627", "tok_span": [97, 104]}, {"name": "MPTP", "ent_type": "Chemical", "char_span": [400, 404], "ent_id": "D015632", "tok_span": [119, 121]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [252, 263], "ent_id": "D006220", "tok_span": [75, 78]}, {"name": "akinesia", "ent_type": "Disease", "char_span": [316, 324], "ent_id": "D004409", "tok_span": [92, 95]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [272, 281], "ent_id": "D002375", "tok_span": [80, 83]}, {"name": "6-OHDA", "ent_type": "Chemical", "char_span": [349, 355], "ent_id": "D016627", "tok_span": [105, 109]}, {"name": "Parkinson's disease", "ent_type": "Disease", "char_span": [198, 217], "ent_id": "D010300", "tok_span": [65, 69]}], "relation_list": [{"subject": "reserpine", "object": "akinesia", "sbj_char_span": [298, 307], "obj_char_span": [316, 324], "rel_type": "chemical-induced disease", "sbj_tok_span": [87, 90], "obj_tok_span": [92, 95]}, {"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [252, 263], "obj_char_span": [272, 281], "rel_type": "chemical-induced disease", "sbj_tok_span": [75, 78], "obj_tok_span": [80, 83]}], "umls_entity_list": []}, {"text": "An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.", "entity_list": [{"name": "delusional parasitosis", "ent_type": "Disease", "char_span": [26, 48], "ent_id": "D063726", "tok_span": [5, 10]}, {"name": "pegylated interferon alpha-2b", "ent_type": "Chemical", "char_span": [89, 118], "ent_id": "C417083", "tok_span": [17, 25]}, {"name": "ribavirin", "ent_type": "Chemical", "char_span": [123, 132], "ent_id": "D012254", "tok_span": [26, 29]}, {"name": "chronic hepatitis C", "ent_type": "Disease", "char_span": [54, 73], "ent_id": "D019698", "tok_span": [12, 15]}], "relation_list": [{"subject": "ribavirin", "object": "delusional parasitosis", "sbj_char_span": [123, 132], "obj_char_span": [26, 48], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 29], "obj_tok_span": [5, 10]}, {"subject": "pegylated interferon alpha-2b", "object": "delusional parasitosis", "sbj_char_span": [89, 118], "obj_char_span": [26, 48], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 25], "obj_tok_span": [5, 10]}], "umls_entity_list": []}, {"text": "We present a 49-year-old woman who developed a delusional parasitosis during treatment with pegylated interferon alpha-2b weekly and ribavirin.", "entity_list": [{"name": "pegylated interferon alpha-2b", "ent_type": "Chemical", "char_span": [92, 121], "ent_id": "C417083", "tok_span": [20, 28]}, {"name": "delusional parasitosis", "ent_type": "Disease", "char_span": [47, 69], "ent_id": "D063726", "tok_span": [12, 17]}, {"name": "ribavirin", "ent_type": "Chemical", "char_span": [133, 142], "ent_id": "D012254", "tok_span": [30, 33]}], "relation_list": [{"subject": "pegylated interferon alpha-2b", "object": "delusional parasitosis", "sbj_char_span": [92, 121], "obj_char_span": [47, 69], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 28], "obj_tok_span": [12, 17]}, {"subject": "ribavirin", "object": "delusional parasitosis", "sbj_char_span": [133, 142], "obj_char_span": [47, 69], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 33], "obj_tok_span": [12, 17]}], "umls_entity_list": []}, {"text": "Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam.", "entity_list": [{"name": "alprazolam", "ent_type": "Chemical", "char_span": [93, 103], "ent_id": "D000525", "tok_span": [16, 20]}, {"name": "neuroleptic malignant syndrome", "ent_type": "Disease", "char_span": [9, 39], "ent_id": "D009459", "tok_span": [1, 7]}, {"name": "paroxetine", "ent_type": "Chemical", "char_span": [78, 88], "ent_id": "D017374", "tok_span": [12, 15]}], "relation_list": [{"subject": "alprazolam", "object": "neuroleptic malignant syndrome", "sbj_char_span": [93, 103], "obj_char_span": [9, 39], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 20], "obj_tok_span": [1, 7]}, {"subject": "paroxetine", "object": "neuroleptic malignant syndrome", "sbj_char_span": [78, 88], "obj_char_span": [9, 39], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [1, 7]}], "umls_entity_list": []}, {"text": "This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.", "entity_list": [{"name": "alprazolam", "ent_type": "Chemical", "char_span": [160, 170], "ent_id": "D000525", "tok_span": [33, 37]}, {"name": "NMS", "ent_type": "Disease", "char_span": [102, 105], "ent_id": "D009459", "tok_span": [20, 22]}, {"name": "NMS", "ent_type": "Disease", "char_span": [72, 75], "ent_id": "D009459", "tok_span": [13, 15]}, {"name": "paroxetine", "ent_type": "Chemical", "char_span": [145, 155], "ent_id": "D017374", "tok_span": [29, 32]}, {"name": "neuroleptic malignant syndrome", "ent_type": "Disease", "char_span": [40, 70], "ent_id": "D009459", "tok_span": [6, 12]}], "relation_list": [{"subject": "paroxetine", "object": "NMS", "sbj_char_span": [145, 155], "obj_char_span": [102, 105], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 32], "obj_tok_span": [20, 22]}, {"subject": "alprazolam", "object": "neuroleptic malignant syndrome", "sbj_char_span": [160, 170], "obj_char_span": [40, 70], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 37], "obj_tok_span": [6, 12]}, {"subject": "alprazolam", "object": "NMS", "sbj_char_span": [160, 170], "obj_char_span": [72, 75], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 37], "obj_tok_span": [13, 15]}, {"subject": "paroxetine", "object": "neuroleptic malignant syndrome", "sbj_char_span": [145, 155], "obj_char_span": [40, 70], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 32], "obj_tok_span": [6, 12]}, {"subject": "paroxetine", "object": "NMS", "sbj_char_span": [145, 155], "obj_char_span": [72, 75], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 32], "obj_tok_span": [13, 15]}, {"subject": "alprazolam", "object": "NMS", "sbj_char_span": [160, 170], "obj_char_span": [102, 105], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 37], "obj_tok_span": [20, 22]}], "umls_entity_list": []}, {"text": "Pilocarpine seizures cause age-dependent impairment in auditory location discrimination.", "entity_list": [{"name": "Pilocarpine", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D010862", "tok_span": [0, 3]}, {"name": "impairment in auditory location discrimination", "ent_type": "Disease", "char_span": [41, 87], "ent_id": "D001308", "tok_span": [8, 13]}, {"name": "seizures", "ent_type": "Disease", "char_span": [12, 20], "ent_id": "D012640", "tok_span": [3, 4]}], "relation_list": [{"subject": "Pilocarpine", "object": "impairment in auditory location discrimination", "sbj_char_span": [0, 11], "obj_char_span": [41, 87], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [8, 13]}], "umls_entity_list": []}, {"text": "Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.", "entity_list": [{"name": "status epilepticus", "ent_type": "Disease", "char_span": [54, 72], "ent_id": "D013226", "tok_span": [11, 14]}, {"name": "status epilepticus", "ent_type": "Disease", "char_span": [34, 52], "ent_id": "D013226", "tok_span": [7, 10]}, {"name": "seizures", "ent_type": "Disease", "char_span": [181, 189], "ent_id": "D012640", "tok_span": [37, 38]}, {"name": "seizures", "ent_type": "Disease", "char_span": [122, 130], "ent_id": "D012640", "tok_span": [25, 26]}, {"name": "Pilocarpine", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D010862", "tok_span": [0, 3]}], "relation_list": [{"subject": "Pilocarpine", "object": "status epilepticus", "sbj_char_span": [0, 11], "obj_char_span": [34, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [7, 10]}, {"subject": "Pilocarpine", "object": "status epilepticus", "sbj_char_span": [0, 11], "obj_char_span": [54, 72], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [11, 14]}], "umls_entity_list": []}, {"text": "Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.", "entity_list": [{"name": "stroke", "ent_type": "Disease", "char_span": [108, 114], "ent_id": "D020521", "tok_span": [16, 17]}, {"name": "heart failure", "ent_type": "Disease", "char_span": [133, 146], "ent_id": "D006333", "tok_span": [20, 22]}, {"name": "myocardial infarction", "ent_type": "Disease", "char_span": [85, 106], "ent_id": "D009203", "tok_span": [13, 15]}, {"name": "cyclooxygenase inhibitors", "ent_type": "Chemical", "char_span": [169, 194], "ent_id": "D016861", "tok_span": [25, 28]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [116, 128], "ent_id": "D006973", "tok_span": [18, 19]}], "relation_list": [{"subject": "cyclooxygenase inhibitors", "object": "myocardial infarction", "sbj_char_span": [169, 194], "obj_char_span": [85, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 28], "obj_tok_span": [13, 15]}, {"subject": "cyclooxygenase inhibitors", "object": "hypertension", "sbj_char_span": [169, 194], "obj_char_span": [116, 128], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 28], "obj_tok_span": [18, 19]}, {"subject": "cyclooxygenase inhibitors", "object": "stroke", "sbj_char_span": [169, 194], "obj_char_span": [108, 114], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 28], "obj_tok_span": [16, 17]}, {"subject": "cyclooxygenase inhibitors", "object": "heart failure", "sbj_char_span": [169, 194], "obj_char_span": [133, 146], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 28], "obj_tok_span": [20, 22]}], "umls_entity_list": []}, {"text": "RESULTS: Patients randomly assigned to enalapril had a 33% greater likelihood of decreased renal function than controls (P =.003).", "entity_list": [{"name": "enalapril", "ent_type": "Chemical", "char_span": [39, 48], "ent_id": "D004656", "tok_span": [6, 10]}, {"name": "decreased renal function", "ent_type": "Disease", "char_span": [81, 105], "ent_id": "D051437", "tok_span": [17, 20]}], "relation_list": [{"subject": "enalapril", "object": "decreased renal function", "sbj_char_span": [39, 48], "obj_char_span": [81, 105], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 10], "obj_tok_span": [17, 20]}], "umls_entity_list": []}, {"text": "By multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective.", "entity_list": [{"name": "diuretic", "ent_type": "Chemical", "char_span": [78, 86], "ent_id": "D004232", "tok_span": [17, 19]}, {"name": "enalapril", "ent_type": "Chemical", "char_span": [50, 59], "ent_id": "D004656", "tok_span": [9, 13]}, {"name": "decreased renal function", "ent_type": "Disease", "char_span": [130, 154], "ent_id": "D051437", "tok_span": [26, 29]}, {"name": "diabetes", "ent_type": "Disease", "char_span": [100, 108], "ent_id": "D003920", "tok_span": [22, 23]}], "relation_list": [{"subject": "enalapril", "object": "decreased renal function", "sbj_char_span": [50, 59], "obj_char_span": [130, 154], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [26, 29]}, {"subject": "diuretic", "object": "decreased renal function", "sbj_char_span": [78, 86], "obj_char_span": [130, 154], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 19], "obj_tok_span": [26, 29]}], "umls_entity_list": []}, {"text": "Older age was associated with a greater risk of developing decreased renal function in both groups, but significantly more so in the enalapril group (enalapril: risk ratio [RR] 1.42 per 10 years, 95% confidence interval [CI] 1.32-1.52 with enalapril; placebo: RR 1.18, 95% CI 1.12-1.25).", "entity_list": [{"name": "decreased renal function", "ent_type": "Disease", "char_span": [59, 83], "ent_id": "D051437", "tok_span": [11, 14]}, {"name": "enalapril", "ent_type": "Chemical", "char_span": [150, 159], "ent_id": "D004656", "tok_span": [30, 34]}, {"name": "enalapril", "ent_type": "Chemical", "char_span": [133, 142], "ent_id": "D004656", "tok_span": [24, 28]}, {"name": "enalapril", "ent_type": "Chemical", "char_span": [240, 249], "ent_id": "D004656", "tok_span": [62, 66]}], "relation_list": [{"subject": "enalapril", "object": "decreased renal function", "sbj_char_span": [150, 159], "obj_char_span": [59, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 34], "obj_tok_span": [11, 14]}, {"subject": "enalapril", "object": "decreased renal function", "sbj_char_span": [133, 142], "obj_char_span": [59, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 28], "obj_tok_span": [11, 14]}, {"subject": "enalapril", "object": "decreased renal function", "sbj_char_span": [240, 249], "obj_char_span": [59, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [62, 66], "obj_tok_span": [11, 14]}], "umls_entity_list": []}, {"text": "Diuretic therapy was likewise associated with a greater risk of decreased renal function in the enalapril group (RR 1.89, 95% CI 1.70-2.08) than in the placebo group (RR 1.35, 95% CI 1.09-1.66).", "entity_list": [{"name": "decreased renal function", "ent_type": "Disease", "char_span": [64, 88], "ent_id": "D051437", "tok_span": [11, 14]}, {"name": "enalapril", "ent_type": "Chemical", "char_span": [96, 105], "ent_id": "D004656", "tok_span": [16, 20]}, {"name": "Diuretic", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D004232", "tok_span": [0, 2]}], "relation_list": [{"subject": "enalapril", "object": "decreased renal function", "sbj_char_span": [96, 105], "obj_char_span": [64, 88], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 20], "obj_tok_span": [11, 14]}, {"subject": "Diuretic", "object": "decreased renal function", "sbj_char_span": [0, 8], "obj_char_span": [64, 88], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [11, 14]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Enalapril use caused a 33% increase in the risk of decreased renal function in patients with CHF.", "entity_list": [{"name": "Enalapril", "ent_type": "Chemical", "char_span": [13, 22], "ent_id": "D004656", "tok_span": [2, 6]}, {"name": "decreased renal function", "ent_type": "Disease", "char_span": [64, 88], "ent_id": "D051437", "tok_span": [16, 19]}, {"name": "CHF", "ent_type": "Disease", "char_span": [106, 109], "ent_id": "D006333", "tok_span": [22, 23]}], "relation_list": [{"subject": "Enalapril", "object": "decreased renal function", "sbj_char_span": [13, 22], "obj_char_span": [64, 88], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [16, 19]}], "umls_entity_list": []}, {"text": "Diabetes was associated with an increased risk of renal impairment in all patients with CHF, but this risk was reduced in the enalapril group compared with the placebo group. beta-Blocker therapy and higher ejection fraction were renoprotective in all patients regardless of therapy.", "entity_list": [{"name": "enalapril", "ent_type": "Chemical", "char_span": [126, 135], "ent_id": "D004656", "tok_span": [23, 27]}, {"name": "renal impairment", "ent_type": "Disease", "char_span": [50, 66], "ent_id": "D051437", "tok_span": [8, 10]}, {"name": "CHF", "ent_type": "Disease", "char_span": [88, 91], "ent_id": "D006333", "tok_span": [14, 15]}, {"name": "Diabetes", "ent_type": "Disease", "char_span": [0, 8], "ent_id": "D003920", "tok_span": [0, 1]}], "relation_list": [{"subject": "enalapril", "object": "renal impairment", "sbj_char_span": [126, 135], "obj_char_span": [50, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 27], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "The possibility of choreoathetoid movements should be considered in patients presenting after pemoline overdose.", "entity_list": [{"name": "choreoathetoid", "ent_type": "Disease", "char_span": [19, 33], "ent_id": "D00281", "tok_span": [3, 9]}, {"name": "pemoline", "ent_type": "Chemical", "char_span": [94, 102], "ent_id": "D010389", "tok_span": [17, 20]}, {"name": "overdose", "ent_type": "Disease", "char_span": [103, 111], "ent_id": "D062787", "tok_span": [20, 22]}], "relation_list": [{"subject": "pemoline", "object": "overdose", "sbj_char_span": [94, 102], "obj_char_span": [103, 111], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [20, 22]}], "umls_entity_list": []}, {"text": "Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.", "entity_list": [{"name": "incoordination", "ent_type": "Disease", "char_span": [172, 186], "ent_id": "D001259", "tok_span": [37, 41]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [91, 99], "ent_id": "D009020", "tok_span": [24, 25]}, {"name": "ammonium acetate", "ent_type": "Chemical", "char_span": [18, 34], "ent_id": "C018824", "tok_span": [3, 5]}, {"name": "NH4Ac", "ent_type": "Chemical", "char_span": [204, 209], "ent_id": "C018824", "tok_span": [47, 50]}, {"name": "NH4Ac", "ent_type": "Chemical", "char_span": [36, 41], "ent_id": "C018824", "tok_span": [6, 9]}, {"name": "diazepam", "ent_type": "Chemical", "char_span": [190, 198], "ent_id": "D003975", "tok_span": [42, 45]}], "relation_list": [{"subject": "NH4Ac", "object": "incoordination", "sbj_char_span": [36, 41], "obj_char_span": [172, 186], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [37, 41]}, {"subject": "diazepam", "object": "incoordination", "sbj_char_span": [190, 198], "obj_char_span": [172, 186], "rel_type": "chemical-induced disease", "sbj_tok_span": [42, 45], "obj_tok_span": [37, 41]}, {"subject": "NH4Ac", "object": "incoordination", "sbj_char_span": [204, 209], "obj_char_span": [172, 186], "rel_type": "chemical-induced disease", "sbj_tok_span": [47, 50], "obj_tok_span": [37, 41]}, {"subject": "ammonium acetate", "object": "incoordination", "sbj_char_span": [18, 34], "obj_char_span": [172, 186], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 5], "obj_tok_span": [37, 41]}], "umls_entity_list": []}, {"text": "Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.", "entity_list": [{"name": "verapamil", "ent_type": "Chemical", "char_span": [5, 14], "ent_id": "D014700", "tok_span": [1, 4]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [63, 71], "ent_id": "D009020", "tok_span": [20, 21]}, {"name": "analgesia", "ent_type": "Disease", "char_span": [72, 81], "ent_id": "D000699", "tok_span": [21, 22]}, {"name": "metrazol", "ent_type": "Chemical", "char_span": [246, 254], "ent_id": "D010433", "tok_span": [62, 65]}, {"name": "diazepam", "ent_type": "Chemical", "char_span": [87, 95], "ent_id": "D003975", "tok_span": [24, 27]}, {"name": "amphetamine", "ent_type": "Chemical", "char_span": [144, 155], "ent_id": "D000661", "tok_span": [37, 41]}, {"name": "incoordination", "ent_type": "Disease", "char_span": [113, 127], "ent_id": "D001259", "tok_span": [30, 34]}, {"name": "NH4Ac", "ent_type": "Chemical", "char_span": [35, 40], "ent_id": "C018824", "tok_span": [15, 18]}, {"name": "verapamil", "ent_type": "Chemical", "char_span": [192, 201], "ent_id": "D014700", "tok_span": [48, 51]}, {"name": "NH4Ac", "ent_type": "Chemical", "char_span": [206, 211], "ent_id": "C018824", "tok_span": [52, 55]}], "relation_list": [{"subject": "NH4Ac", "object": "incoordination", "sbj_char_span": [35, 40], "obj_char_span": [113, 127], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [30, 34]}, {"subject": "NH4Ac", "object": "incoordination", "sbj_char_span": [206, 211], "obj_char_span": [113, 127], "rel_type": "chemical-induced disease", "sbj_tok_span": [52, 55], "obj_tok_span": [30, 34]}, {"subject": "diazepam", "object": "incoordination", "sbj_char_span": [87, 95], "obj_char_span": [113, 127], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 27], "obj_tok_span": [30, 34]}], "umls_entity_list": []}, {"text": "Risk of nephropathy after consumption of nonionic contrast media by children undergoing cardiac angiography: a prospective study.", "entity_list": [{"name": "contrast media", "ent_type": "Chemical", "char_span": [50, 64], "ent_id": "D003287", "tok_span": [8, 10]}, {"name": "nephropathy", "ent_type": "Disease", "char_span": [8, 19], "ent_id": "D007674", "tok_span": [2, 3]}], "relation_list": [{"subject": "contrast media", "object": "nephropathy", "sbj_char_span": [50, 64], "obj_char_span": [8, 19], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [2, 3]}], "umls_entity_list": []}, {"text": "Despite increasing reports on nonionic contrast media-induced nephropathy (CIN) in hospitalized adult patients during cardiac procedures, the studies in pediatrics are limited, with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography.", "entity_list": [{"name": "nephropathy", "ent_type": "Disease", "char_span": [62, 73], "ent_id": "D007674", "tok_span": [10, 11]}, {"name": "contrast media", "ent_type": "Chemical", "char_span": [39, 53], "ent_id": "D003287", "tok_span": [6, 8]}, {"name": "CIN", "ent_type": "Disease", "char_span": [75, 78], "ent_id": "D007674", "tok_span": [12, 13]}], "relation_list": [{"subject": "contrast media", "object": "CIN", "sbj_char_span": [39, 53], "obj_char_span": [75, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [12, 13]}, {"subject": "contrast media", "object": "nephropathy", "sbj_char_span": [39, 53], "obj_char_span": [62, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [10, 11]}], "umls_entity_list": []}, {"text": "This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.", "entity_list": [{"name": "cyanosis", "ent_type": "Disease", "char_span": [262, 270], "ent_id": "D003490", "tok_span": [53, 55]}, {"name": "iohexol", "ent_type": "Chemical", "char_span": [107, 114], "ent_id": "D007472", "tok_span": [22, 25]}, {"name": "CM", "ent_type": "Chemical", "char_span": [88, 90], "ent_id": "D003287", "tok_span": [15, 16]}, {"name": "iopromide", "ent_type": "Chemical", "char_span": [93, 102], "ent_id": "C038192", "tok_span": [18, 21]}, {"name": "CIN", "ent_type": "Disease", "char_span": [51, 54], "ent_id": "D007674", "tok_span": [7, 8]}, {"name": "contrast media", "ent_type": "Chemical", "char_span": [72, 86], "ent_id": "D003287", "tok_span": [12, 14]}, {"name": "CM", "ent_type": "Chemical", "char_span": [239, 241], "ent_id": "D003287", "tok_span": [48, 49]}], "relation_list": [{"subject": "CM", "object": "CIN", "sbj_char_span": [239, 241], "obj_char_span": [51, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [48, 49], "obj_tok_span": [7, 8]}, {"subject": "iopromide", "object": "CIN", "sbj_char_span": [93, 102], "obj_char_span": [51, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [7, 8]}, {"subject": "contrast media", "object": "CIN", "sbj_char_span": [72, 86], "obj_char_span": [51, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 14], "obj_tok_span": [7, 8]}, {"subject": "CM", "object": "CIN", "sbj_char_span": [88, 90], "obj_char_span": [51, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 16], "obj_tok_span": [7, 8]}, {"subject": "iohexol", "object": "CIN", "sbj_char_span": [107, 114], "obj_char_span": [51, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 25], "obj_tok_span": [7, 8]}], "umls_entity_list": []}, {"text": "Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).", "entity_list": [{"name": "CM", "ent_type": "Chemical", "char_span": [90, 92], "ent_id": "D003287", "tok_span": [19, 20]}, {"name": "CIN", "ent_type": "Disease", "char_span": [35, 38], "ent_id": "D007674", "tok_span": [9, 10]}, {"name": "CM", "ent_type": "Chemical", "char_span": [257, 259], "ent_id": "D003287", "tok_span": [52, 53]}, {"name": "CIN", "ent_type": "Disease", "char_span": [217, 220], "ent_id": "D007674", "tok_span": [44, 45]}], "relation_list": [{"subject": "CM", "object": "CIN", "sbj_char_span": [257, 259], "obj_char_span": [35, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [52, 53], "obj_tok_span": [9, 10]}, {"subject": "CM", "object": "CIN", "sbj_char_span": [90, 92], "obj_char_span": [35, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 20], "obj_tok_span": [9, 10]}, {"subject": "CM", "object": "CIN", "sbj_char_span": [257, 259], "obj_char_span": [217, 220], "rel_type": "chemical-induced disease", "sbj_tok_span": [52, 53], "obj_tok_span": [44, 45]}, {"subject": "CM", "object": "CIN", "sbj_char_span": [90, 92], "obj_char_span": [217, 220], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 20], "obj_tok_span": [44, 45]}], "umls_entity_list": []}, {"text": "The incidence depends on dosage but not on the type of consumed nonionic CM, nor on the presence of cyanosis, and although CIN usually is reversible, more concern is needed for the prevention of such a complication in children.", "entity_list": [{"name": "CM", "ent_type": "Chemical", "char_span": [73, 75], "ent_id": "D003287", "tok_span": [14, 15]}, {"name": "CIN", "ent_type": "Disease", "char_span": [123, 126], "ent_id": "D007674", "tok_span": [26, 27]}, {"name": "cyanosis", "ent_type": "Disease", "char_span": [100, 108], "ent_id": "D003490", "tok_span": [21, 23]}], "relation_list": [{"subject": "CM", "object": "CIN", "sbj_char_span": [73, 75], "obj_char_span": [123, 126], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [26, 27]}], "umls_entity_list": []}, {"text": "A case of ventricular tachycardia related to caffeine pretreatment.", "entity_list": [{"name": "caffeine", "ent_type": "Chemical", "char_span": [45, 53], "ent_id": "D002110", "tok_span": [7, 8]}, {"name": "ventricular tachycardia", "ent_type": "Disease", "char_span": [10, 33], "ent_id": "D017180", "tok_span": [3, 5]}], "relation_list": [{"subject": "caffeine", "object": "ventricular tachycardia", "sbj_char_span": [45, 53], "obj_char_span": [10, 33], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "Intravenous caffeine is commonly used to improve seizure duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign ventricular ectopy.", "entity_list": [{"name": "seizure", "ent_type": "Disease", "char_span": [49, 56], "ent_id": "D012640", "tok_span": [9, 10]}, {"name": "caffeine", "ent_type": "Chemical", "char_span": [12, 20], "ent_id": "D002110", "tok_span": [3, 4]}, {"name": "ventricular ectopy", "ent_type": "Disease", "char_span": [178, 196], "ent_id": "D018879", "tok_span": [28, 31]}], "relation_list": [{"subject": "caffeine", "object": "seizure", "sbj_char_span": [12, 20], "obj_char_span": [49, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [9, 10]}, {"subject": "caffeine", "object": "ventricular ectopy", "sbj_char_span": [12, 20], "obj_char_span": [178, 196], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [28, 31]}], "umls_entity_list": []}, {"text": "We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.", "entity_list": [{"name": "ventricular tachycardia", "ent_type": "Disease", "char_span": [133, 156], "ent_id": "D017180", "tok_span": [25, 27]}, {"name": "arrhythmia", "ent_type": "Disease", "char_span": [69, 79], "ent_id": "D001145", "tok_span": [12, 14]}, {"name": "cardiac disease", "ent_type": "Disease", "char_span": [50, 65], "ent_id": "D006331", "tok_span": [9, 11]}, {"name": "caffeine", "ent_type": "Chemical", "char_span": [163, 171], "ent_id": "D002110", "tok_span": [28, 29]}], "relation_list": [{"subject": "caffeine", "object": "ventricular tachycardia", "sbj_char_span": [163, 171], "obj_char_span": [133, 156], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 29], "obj_tok_span": [25, 27]}], "umls_entity_list": []}, {"text": "Optical coherence tomography can measure axonal loss in patients with ethambutol-induced optic neuropathy.", "entity_list": [{"name": "optic neuropathy", "ent_type": "Disease", "char_span": [89, 105], "ent_id": "D009901", "tok_span": [16, 18]}, {"name": "ethambutol", "ent_type": "Chemical", "char_span": [70, 80], "ent_id": "D004977", "tok_span": [10, 14]}], "relation_list": [{"subject": "ethambutol", "object": "optic neuropathy", "sbj_char_span": [70, 80], "obj_char_span": [89, 105], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "PURPOSE: To map and identify the pattern, in vivo, of axonal degeneration in ethambutol-induced optic neuropathy using optical coherence tomography (OCT).", "entity_list": [{"name": "optic neuropathy", "ent_type": "Disease", "char_span": [96, 112], "ent_id": "D009901", "tok_span": [22, 24]}, {"name": "ethambutol", "ent_type": "Chemical", "char_span": [77, 87], "ent_id": "D004977", "tok_span": [16, 20]}, {"name": "axonal degeneration", "ent_type": "Disease", "char_span": [54, 73], "ent_id": "D009410", "tok_span": [13, 15]}], "relation_list": [{"subject": "ethambutol", "object": "optic neuropathy", "sbj_char_span": [77, 87], "obj_char_span": [96, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 20], "obj_tok_span": [22, 24]}], "umls_entity_list": []}, {"text": "A serious complication of ethambutol is an optic neuropathy that impairs visual acuity, contrast sensitivity, and color vision.", "entity_list": [{"name": "optic neuropathy", "ent_type": "Disease", "char_span": [43, 59], "ent_id": "D009901", "tok_span": [10, 12]}, {"name": "ethambutol", "ent_type": "Chemical", "char_span": [26, 36], "ent_id": "D004977", "tok_span": [4, 8]}], "relation_list": [{"subject": "ethambutol", "object": "optic neuropathy", "sbj_char_span": [26, 36], "obj_char_span": [43, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 8], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.", "entity_list": [{"name": "visual deficits", "ent_type": "Disease", "char_span": [124, 139], "ent_id": "D014786", "tok_span": [30, 32]}, {"name": "ethambutol", "ent_type": "Chemical", "char_span": [42, 52], "ent_id": "D004977", "tok_span": [8, 12]}, {"name": "EMB", "ent_type": "Chemical", "char_span": [54, 57], "ent_id": "D004977", "tok_span": [13, 14]}, {"name": "optic neuropathy", "ent_type": "Disease", "char_span": [67, 83], "ent_id": "D009901", "tok_span": [17, 19]}], "relation_list": [{"subject": "ethambutol", "object": "optic neuropathy", "sbj_char_span": [42, 52], "obj_char_span": [67, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [17, 19]}, {"subject": "EMB", "object": "visual deficits", "sbj_char_span": [54, 57], "obj_char_span": [124, 139], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 14], "obj_tok_span": [30, 32]}, {"subject": "ethambutol", "object": "visual deficits", "sbj_char_span": [42, 52], "obj_char_span": [124, 139], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [30, 32]}, {"subject": "EMB", "object": "optic neuropathy", "sbj_char_span": [54, 57], "obj_char_span": [67, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 14], "obj_tok_span": [17, 19]}], "umls_entity_list": []}, {"text": "In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.", "entity_list": [{"name": "EMB", "ent_type": "Chemical", "char_span": [32, 35], "ent_id": "D004977", "tok_span": [6, 7]}, {"name": "optic neuropathy", "ent_type": "Disease", "char_span": [44, 60], "ent_id": "D009901", "tok_span": [9, 11]}, {"name": "visual deficits", "ent_type": "Disease", "char_span": [247, 262], "ent_id": "D014786", "tok_span": [50, 52]}, {"name": "visual deficits", "ent_type": "Disease", "char_span": [298, 313], "ent_id": "D014786", "tok_span": [62, 64]}], "relation_list": [{"subject": "EMB", "object": "visual deficits", "sbj_char_span": [32, 35], "obj_char_span": [298, 313], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [62, 64]}, {"subject": "EMB", "object": "optic neuropathy", "sbj_char_span": [32, 35], "obj_char_span": [44, 60], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [9, 11]}, {"subject": "EMB", "object": "visual deficits", "sbj_char_span": [32, 35], "obj_char_span": [247, 262], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [50, 52]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: The OCT results in these patients with EMB-induced optic neuropathy show considerable loss especially of the temporal fibers.", "entity_list": [{"name": "EMB", "ent_type": "Chemical", "char_span": [52, 55], "ent_id": "D004977", "tok_span": [9, 10]}, {"name": "optic neuropathy", "ent_type": "Disease", "char_span": [64, 80], "ent_id": "D009901", "tok_span": [12, 14]}], "relation_list": [{"subject": "EMB", "object": "optic neuropathy", "sbj_char_span": [52, 55], "obj_char_span": [64, 80], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [12, 14]}], "umls_entity_list": []}, {"text": "Additionally, in terms of management of EMB-induced optic neuropathy, it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.", "entity_list": [{"name": "ethambutol", "ent_type": "Chemical", "char_span": [105, 115], "ent_id": "D004977", "tok_span": [19, 23]}, {"name": "EMB", "ent_type": "Chemical", "char_span": [40, 43], "ent_id": "D004977", "tok_span": [7, 8]}, {"name": "optic neuropathy", "ent_type": "Disease", "char_span": [52, 68], "ent_id": "D009901", "tok_span": [10, 12]}, {"name": "renal impairment", "ent_type": "Disease", "char_span": [140, 156], "ent_id": "D051437", "tok_span": [27, 29]}], "relation_list": [{"subject": "EMB", "object": "optic neuropathy", "sbj_char_span": [40, 43], "obj_char_span": [52, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [10, 12]}, {"subject": "ethambutol", "object": "optic neuropathy", "sbj_char_span": [105, 115], "obj_char_span": [52, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 23], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin (placebo, 1.4% vs. 0%; valdecoxib, 1.7% vs. 0.2%; NSAIDs, 1.9% vs. 0.5%).", "entity_list": [{"name": "aspirin", "ent_type": "Chemical", "char_span": [53, 60], "ent_id": "D001241", "tok_span": [9, 10]}, {"name": "aspirin", "ent_type": "Chemical", "char_span": [84, 91], "ent_id": "D001241", "tok_span": [15, 16]}, {"name": "valdecoxib", "ent_type": "Chemical", "char_span": [115, 125], "ent_id": "C406224", "tok_span": [28, 32]}, {"name": "Thrombotic", "ent_type": "Disease", "char_span": [0, 10], "ent_id": "D013927", "tok_span": [0, 2]}], "relation_list": [{"subject": "aspirin", "object": "Thrombotic", "sbj_char_span": [53, 60], "obj_char_span": [0, 10], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [0, 2]}, {"subject": "aspirin", "object": "Thrombotic", "sbj_char_span": [84, 91], "obj_char_span": [0, 10], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 16], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.", "entity_list": [{"name": "fluoxetine", "ent_type": "Chemical", "char_span": [55, 65], "ent_id": "D005473", "tok_span": [8, 11]}, {"name": "sertraline", "ent_type": "Chemical", "char_span": [67, 77], "ent_id": "D020280", "tok_span": [12, 15]}, {"name": "sexually dysfunctional", "ent_type": "Disease", "char_span": [9, 31], "ent_id": "D020018", "tok_span": [2, 5]}, {"name": "paroxetine", "ent_type": "Chemical", "char_span": [82, 92], "ent_id": "D017374", "tok_span": [17, 20]}, {"name": "ephedrine", "ent_type": "Chemical", "char_span": [193, 202], "ent_id": "D004809", "tok_span": [43, 46]}], "relation_list": [{"subject": "paroxetine", "object": "sexually dysfunctional", "sbj_char_span": [82, 92], "obj_char_span": [9, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [2, 5]}, {"subject": "fluoxetine", "object": "sexually dysfunctional", "sbj_char_span": [55, 65], "obj_char_span": [9, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [2, 5]}, {"subject": "sertraline", "object": "sexually dysfunctional", "sbj_char_span": [67, 77], "obj_char_span": [9, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [2, 5]}], "umls_entity_list": []}, {"text": "We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.", "entity_list": [{"name": "dyskinesias", "ent_type": "Disease", "char_span": [183, 194], "ent_id": "D004409", "tok_span": [53, 57]}, {"name": "MPTP", "ent_type": "Chemical", "char_span": [115, 119], "ent_id": "D015632", "tok_span": [33, 35]}, {"name": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "ent_type": "Chemical", "char_span": [69, 113], "ent_id": "D015632", "tok_span": [12, 32]}, {"name": "dyskinetic", "ent_type": "Disease", "char_span": [225, 235], "ent_id": "D004409", "tok_span": [62, 66]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [166, 174], "ent_id": "D007980", "tok_span": [48, 51]}, {"name": "A-86929", "ent_type": "Chemical", "char_span": [301, 308], "ent_id": "C095427", "tok_span": [86, 91]}, {"name": "[-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol", "ent_type": "Chemical", "char_span": [310, 415], "ent_id": "C095427", "tok_span": [92, 163]}, {"name": "DA", "ent_type": "Chemical", "char_span": [439, 441], "ent_id": "D004298", "tok_span": [169, 170]}], "relation_list": [{"subject": "levodopa", "object": "dyskinesias", "sbj_char_span": [166, 174], "obj_char_span": [183, 194], "rel_type": "chemical-induced disease", "sbj_tok_span": [48, 51], "obj_tok_span": [53, 57]}, {"subject": "levodopa", "object": "dyskinetic", "sbj_char_span": [166, 174], "obj_char_span": [225, 235], "rel_type": "chemical-induced disease", "sbj_tok_span": [48, 51], "obj_tok_span": [62, 66]}], "umls_entity_list": []}, {"text": "Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.", "entity_list": [{"name": "dyskinesias", "ent_type": "Disease", "char_span": [173, 184], "ent_id": "D004409", "tok_span": [44, 48]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [256, 264], "ent_id": "D007980", "tok_span": [63, 66]}, {"name": "parkinsonism", "ent_type": "Disease", "char_span": [79, 91], "ent_id": "D020734", "tok_span": [18, 21]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [95, 103], "ent_id": "D007980", "tok_span": [22, 25]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [156, 164], "ent_id": "D007980", "tok_span": [39, 42]}, {"name": "A-86929", "ent_type": "Chemical", "char_span": [24, 31], "ent_id": "C095427", "tok_span": [3, 8]}, {"name": "LY-171555", "ent_type": "Chemical", "char_span": [219, 228], "ent_id": "C416545", "tok_span": [54, 59]}, {"name": "LY-171555", "ent_type": "Chemical", "char_span": [108, 117], "ent_id": "C416545", "tok_span": [26, 31]}, {"name": "MPTP", "ent_type": "Chemical", "char_span": [66, 70], "ent_id": "D015632", "tok_span": [14, 16]}], "relation_list": [{"subject": "levodopa", "object": "dyskinesias", "sbj_char_span": [256, 264], "obj_char_span": [173, 184], "rel_type": "chemical-induced disease", "sbj_tok_span": [63, 66], "obj_tok_span": [44, 48]}, {"subject": "MPTP", "object": "parkinsonism", "sbj_char_span": [66, 70], "obj_char_span": [79, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [18, 21]}, {"subject": "levodopa", "object": "dyskinesias", "sbj_char_span": [95, 103], "obj_char_span": [173, 184], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 25], "obj_tok_span": [44, 48]}, {"subject": "levodopa", "object": "dyskinesias", "sbj_char_span": [156, 164], "obj_char_span": [173, 184], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 42], "obj_tok_span": [44, 48]}], "umls_entity_list": []}, {"text": "A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the chloroprocaine group, and in 6% of the lidocaine group.", "entity_list": [{"name": "lidocaine", "ent_type": "Chemical", "char_span": [172, 181], "ent_id": "D008012", "tok_span": [49, 51]}, {"name": "chloroprocaine", "ent_type": "Chemical", "char_span": [133, 147], "ent_id": "C004616", "tok_span": [37, 41]}, {"name": "bupivacaine", "ent_type": "Chemical", "char_span": [89, 100], "ent_id": "D002045", "tok_span": [24, 28]}, {"name": "convulsions", "ent_type": "Disease", "char_span": [41, 52], "ent_id": "D012640", "tok_span": [9, 12]}, {"name": "seizures", "ent_type": "Disease", "char_span": [109, 117], "ent_id": "D012640", "tok_span": [30, 31]}], "relation_list": [{"subject": "chloroprocaine", "object": "seizures", "sbj_char_span": [133, 147], "obj_char_span": [109, 117], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 41], "obj_tok_span": [30, 31]}, {"subject": "bupivacaine", "object": "seizures", "sbj_char_span": [89, 100], "obj_char_span": [109, 117], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 28], "obj_tok_span": [30, 31]}, {"subject": "chloroprocaine", "object": "convulsions", "sbj_char_span": [133, 147], "obj_char_span": [41, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 41], "obj_tok_span": [9, 12]}, {"subject": "lidocaine", "object": "seizures", "sbj_char_span": [172, 181], "obj_char_span": [109, 117], "rel_type": "chemical-induced disease", "sbj_tok_span": [49, 51], "obj_tok_span": [30, 31]}, {"subject": "bupivacaine", "object": "convulsions", "sbj_char_span": [89, 100], "obj_char_span": [41, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 28], "obj_tok_span": [9, 12]}, {"subject": "lidocaine", "object": "convulsions", "sbj_char_span": [172, 181], "obj_char_span": [41, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [49, 51], "obj_tok_span": [9, 12]}], "umls_entity_list": []}, {"text": "A patient with sinus bradycardia and atrioventricular block, induced by carbamazepine, prompted an extensive literature review of all previously reported cases.", "entity_list": [{"name": "atrioventricular block", "ent_type": "Disease", "char_span": [37, 59], "ent_id": "D054537", "tok_span": [9, 15]}, {"name": "carbamazepine", "ent_type": "Chemical", "char_span": [72, 85], "ent_id": "D002220", "tok_span": [18, 22]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [21, 32], "ent_id": "D001919", "tok_span": [4, 8]}], "relation_list": [{"subject": "carbamazepine", "object": "bradycardia", "sbj_char_span": [72, 85], "obj_char_span": [21, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 22], "obj_tok_span": [4, 8]}, {"subject": "carbamazepine", "object": "atrioventricular block", "sbj_char_span": [72, 85], "obj_char_span": [37, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 22], "obj_tok_span": [9, 15]}], "umls_entity_list": []}, {"text": "One patient group developed sinus tachycardias in the setting of a massive carbamazepine overdose.", "entity_list": [{"name": "sinus tachycardias", "ent_type": "Disease", "char_span": [28, 46], "ent_id": "D013616", "tok_span": [4, 7]}, {"name": "overdose", "ent_type": "Disease", "char_span": [89, 97], "ent_id": "D062787", "tok_span": [17, 19]}, {"name": "carbamazepine", "ent_type": "Chemical", "char_span": [75, 88], "ent_id": "D002220", "tok_span": [13, 17]}], "relation_list": [{"subject": "carbamazepine", "object": "sinus tachycardias", "sbj_char_span": [75, 88], "obj_char_span": [28, 46], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [4, 7]}], "umls_entity_list": []}, {"text": "The second group consisted almost exclusively of elderly women who developed potentially life-threatening bradyarrhythmias or atrioventricular conduction delay, associated with either therapeutic or modestly elevated carbamazepine serum levels.", "entity_list": [{"name": "atrioventricular conduction delay", "ent_type": "Disease", "char_span": [126, 159], "ent_id": "D054537", "tok_span": [22, 29]}, {"name": "bradyarrhythmias", "ent_type": "Disease", "char_span": [106, 122], "ent_id": "D001919", "tok_span": [16, 21]}, {"name": "carbamazepine", "ent_type": "Chemical", "char_span": [217, 230], "ent_id": "D002220", "tok_span": [38, 42]}], "relation_list": [{"subject": "carbamazepine", "object": "bradyarrhythmias", "sbj_char_span": [217, 230], "obj_char_span": [106, 122], "rel_type": "chemical-induced disease", "sbj_tok_span": [38, 42], "obj_tok_span": [16, 21]}, {"subject": "carbamazepine", "object": "atrioventricular conduction delay", "sbj_char_span": [217, 230], "obj_char_span": [126, 159], "rel_type": "chemical-induced disease", "sbj_tok_span": [38, 42], "obj_tok_span": [22, 29]}], "umls_entity_list": []}, {"text": "Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol-induced catalepsy.", "entity_list": [{"name": "haloperidol", "ent_type": "Chemical", "char_span": [99, 110], "ent_id": "D006220", "tok_span": [18, 21]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [119, 128], "ent_id": "D002375", "tok_span": [23, 26]}, {"name": "NMDA", "ent_type": "Chemical", "char_span": [44, 48], "ent_id": "D016202", "tok_span": [8, 9]}], "relation_list": [{"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [99, 110], "obj_char_span": [119, 128], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [23, 26]}], "umls_entity_list": []}, {"text": "The present study examined the influence of excitatory amino acid-mediated mechanisms in the IC on the catalepsy induced by the dopamine receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.", "entity_list": [{"name": "haloperidol", "ent_type": "Chemical", "char_span": [154, 165], "ent_id": "D006220", "tok_span": [27, 30]}, {"name": "amino acid", "ent_type": "Chemical", "char_span": [55, 65], "ent_id": "D000596", "tok_span": [8, 10]}, {"name": "dopamine", "ent_type": "Chemical", "char_span": [128, 136], "ent_id": "D004298", "tok_span": [24, 25]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [103, 112], "ent_id": "D002375", "tok_span": [18, 21]}], "relation_list": [{"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [154, 165], "obj_char_span": [103, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 30], "obj_tok_span": [18, 21]}], "umls_entity_list": []}, {"text": "Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).", "entity_list": [{"name": "NMDA", "ent_type": "Chemical", "char_span": [101, 105], "ent_id": "D016202", "tok_span": [20, 21]}, {"name": "N-methyl-d-aspartate", "ent_type": "Chemical", "char_span": [230, 250], "ent_id": "D016202", "tok_span": [60, 68]}, {"name": "NMDA", "ent_type": "Chemical", "char_span": [252, 256], "ent_id": "D016202", "tok_span": [69, 70]}, {"name": "AP7", "ent_type": "Chemical", "char_span": [166, 169], "ent_id": "C031231", "tok_span": [40, 42]}, {"name": "MK-801", "ent_type": "Chemical", "char_span": [128, 134], "ent_id": "D016291", "tok_span": [24, 28]}, {"name": "glutamate", "ent_type": "Chemical", "char_span": [91, 100], "ent_id": "D018698", "tok_span": [19, 20]}, {"name": "NMDA", "ent_type": "Chemical", "char_span": [208, 212], "ent_id": "D016202", "tok_span": [57, 58]}, {"name": "Haloperidol", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D006220", "tok_span": [0, 3]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [20, 29], "ent_id": "D002375", "tok_span": [5, 8]}], "relation_list": [{"subject": "Haloperidol", "object": "catalepsy", "sbj_char_span": [0, 11], "obj_char_span": [20, 29], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 8]}], "umls_entity_list": []}, {"text": "The results showed that intracollicular microinjection of MK-801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.", "entity_list": [{"name": "catalepsy", "ent_type": "Disease", "char_span": [149, 158], "ent_id": "D002375", "tok_span": [28, 31]}, {"name": "MK-801", "ent_type": "Chemical", "char_span": [58, 64], "ent_id": "D016291", "tok_span": [10, 14]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [108, 119], "ent_id": "D006220", "tok_span": [22, 25]}, {"name": "AP7", "ent_type": "Chemical", "char_span": [69, 72], "ent_id": "C031231", "tok_span": [15, 17]}], "relation_list": [{"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [108, 119], "obj_char_span": [149, 158], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 25], "obj_tok_span": [28, 31]}], "umls_entity_list": []}, {"text": "These findings suggest that glutamate-mediated mechanisms in the neural circuits at the IC level influence haloperidol-induced catalepsy and participate in the regulation of motor activity.", "entity_list": [{"name": "haloperidol", "ent_type": "Chemical", "char_span": [107, 118], "ent_id": "D006220", "tok_span": [17, 20]}, {"name": "glutamate", "ent_type": "Chemical", "char_span": [28, 37], "ent_id": "D018698", "tok_span": [4, 5]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [127, 136], "ent_id": "D002375", "tok_span": [22, 25]}], "relation_list": [{"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [107, 118], "obj_char_span": [127, 136], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [22, 25]}], "umls_entity_list": []}, {"text": "Here, we show that oral (5 mg/kg) or intrastriatal administration (0.1 and 0.5 nmol) of AMN082 reverses haloperidol-induced catalepsy in rats.", "entity_list": [{"name": "AMN082", "ent_type": "Chemical", "char_span": [88, 94], "ent_id": "C507346", "tok_span": [29, 33]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [104, 115], "ent_id": "D006220", "tok_span": [35, 38]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [124, 133], "ent_id": "D002375", "tok_span": [40, 43]}], "relation_list": [{"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [104, 115], "obj_char_span": [124, 133], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 38], "obj_tok_span": [40, 43]}], "umls_entity_list": []}, {"text": "In addition, AMN082 reduces the duration of haloperidol-induced catalepsy in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice.", "entity_list": [{"name": "haloperidol", "ent_type": "Chemical", "char_span": [44, 55], "ent_id": "D006220", "tok_span": [11, 14]}, {"name": "AMN082", "ent_type": "Chemical", "char_span": [13, 19], "ent_id": "C507346", "tok_span": [3, 7]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [64, 73], "ent_id": "D002375", "tok_span": [16, 19]}], "relation_list": [{"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [44, 55], "obj_char_span": [64, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [16, 19]}], "umls_entity_list": []}, {"text": "Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice.", "entity_list": [{"name": "Nimodipine", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D009553", "tok_span": [0, 3]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [70, 81], "ent_id": "D007022", "tok_span": [13, 14]}, {"name": "nitroglycerin", "ent_type": "Chemical", "char_span": [48, 61], "ent_id": "D005996", "tok_span": [8, 11]}, {"name": "memory impairment", "ent_type": "Disease", "char_span": [20, 37], "ent_id": "D008569", "tok_span": [4, 6]}], "relation_list": [{"subject": "nitroglycerin", "object": "memory impairment", "sbj_char_span": [48, 61], "obj_char_span": [20, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [4, 6]}, {"subject": "nitroglycerin", "object": "hypotension", "sbj_char_span": [48, 61], "obj_char_span": [70, 81], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [13, 14]}], "umls_entity_list": []}, {"text": "We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory.", "entity_list": [{"name": "nimodipine", "ent_type": "Chemical", "char_span": [30, 40], "ent_id": "D009553", "tok_span": [5, 8]}, {"name": "NIMO", "ent_type": "Chemical", "char_span": [42, 46], "ent_id": "D009553", "tok_span": [9, 11]}, {"name": "NTG", "ent_type": "Chemical", "char_span": [92, 95], "ent_id": "D005996", "tok_span": [21, 23]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [105, 116], "ent_id": "D007022", "tok_span": [26, 27]}, {"name": "nitroglycerin", "ent_type": "Chemical", "char_span": [77, 90], "ent_id": "D005996", "tok_span": [17, 20]}], "relation_list": [{"subject": "nitroglycerin", "object": "hypotension", "sbj_char_span": [77, 90], "obj_char_span": [105, 116], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [26, 27]}, {"subject": "NTG", "object": "hypotension", "sbj_char_span": [92, 95], "obj_char_span": [105, 116], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 23], "obj_tok_span": [26, 27]}], "umls_entity_list": []}, {"text": "Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).", "entity_list": [{"name": "NTG", "ent_type": "Chemical", "char_span": [143, 146], "ent_id": "D005996", "tok_span": [28, 30]}, {"name": "NTG", "ent_type": "Chemical", "char_span": [166, 169], "ent_id": "D005996", "tok_span": [36, 38]}, {"name": "hypotensive", "ent_type": "Disease", "char_span": [18, 29], "ent_id": "D007022", "tok_span": [3, 5]}, {"name": "NIMO", "ent_type": "Chemical", "char_span": [149, 153], "ent_id": "D009553", "tok_span": [31, 33]}], "relation_list": [{"subject": "NTG", "object": "hypotensive", "sbj_char_span": [166, 169], "obj_char_span": [18, 29], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 38], "obj_tok_span": [3, 5]}, {"subject": "NTG", "object": "hypotensive", "sbj_char_span": [143, 146], "obj_char_span": [18, 29], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 30], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "CONCLUSION: In a PA retention paradigm, the injection of NTG immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced hypotension had no effect.", "entity_list": [{"name": "hypotension", "ent_type": "Disease", "char_span": [187, 198], "ent_id": "D007022", "tok_span": [32, 33]}, {"name": "NTG", "ent_type": "Chemical", "char_span": [57, 60], "ent_id": "D005996", "tok_span": [11, 13]}], "relation_list": [{"subject": "NTG", "object": "hypotension", "sbj_char_span": [57, 60], "obj_char_span": [187, 198], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 13], "obj_tok_span": [32, 33]}], "umls_entity_list": []}, {"text": "NIMO attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of hypotension.", "entity_list": [{"name": "hypotension", "ent_type": "Disease", "char_span": [128, 139], "ent_id": "D007022", "tok_span": [25, 26]}, {"name": "NTG", "ent_type": "Chemical", "char_span": [78, 81], "ent_id": "D005996", "tok_span": [14, 16]}, {"name": "NIMO", "ent_type": "Chemical", "char_span": [0, 4], "ent_id": "D009553", "tok_span": [0, 2]}], "relation_list": [{"subject": "NTG", "object": "hypotension", "sbj_char_span": [78, 81], "obj_char_span": [128, 139], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [25, 26]}], "umls_entity_list": []}, {"text": "Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.", "entity_list": [{"name": "warfarin", "ent_type": "Chemical", "char_span": [108, 116], "ent_id": "D014859", "tok_span": [20, 21]}, {"name": "gastrointestinal haemorrhage", "ent_type": "Disease", "char_span": [27, 55], "ent_id": "D006471", "tok_span": [7, 11]}, {"name": "haemopericardium", "ent_type": "Disease", "char_span": [6, 22], "ent_id": "D010490", "tok_span": [2, 6]}], "relation_list": [{"subject": "warfarin", "object": "gastrointestinal haemorrhage", "sbj_char_span": [108, 116], "obj_char_span": [27, 55], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 21], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "Isoproterenol induces primary loss of dystrophin in rat hearts: correlation with myocardial injury.", "entity_list": [{"name": "Isoproterenol", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D007545", "tok_span": [0, 4]}, {"name": "myocardial injury", "ent_type": "Disease", "char_span": [81, 98], "ent_id": "D009202", "tok_span": [17, 19]}], "relation_list": [{"subject": "Isoproterenol", "object": "myocardial injury", "sbj_char_span": [0, 13], "obj_char_span": [81, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [17, 19]}], "umls_entity_list": []}, {"text": "The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.", "entity_list": [{"name": "oxygen", "ent_type": "Chemical", "char_span": [87, 93], "ent_id": "D010100", "tok_span": [18, 19]}, {"name": "myocardial damage", "ent_type": "Disease", "char_span": [39, 56], "ent_id": "D009202", "tok_span": [9, 11]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [131, 142], "ent_id": "D007022", "tok_span": [25, 26]}, {"name": "isoproterenol", "ent_type": "Chemical", "char_span": [17, 30], "ent_id": "D007545", "tok_span": [3, 7]}, {"name": "myocardial hyperactivity", "ent_type": "Disease", "char_span": [147, 171], "ent_id": "D009202", "tok_span": [27, 30]}], "relation_list": [{"subject": "isoproterenol", "object": "myocardial hyperactivity", "sbj_char_span": [17, 30], "obj_char_span": [147, 171], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 7], "obj_tok_span": [27, 30]}, {"subject": "isoproterenol", "object": "myocardial damage", "sbj_char_span": [17, 30], "obj_char_span": [39, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 7], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "These changes, related to ischaemic injury, explain the severe alterations in the structural integrity of the sarcolemma of cardiomyocytes and hence severe and irreversible injury induced by isoproterenol.", "entity_list": [{"name": "ischaemic injury", "ent_type": "Disease", "char_span": [26, 42], "ent_id": "D007511", "tok_span": [5, 8]}, {"name": "isoproterenol", "ent_type": "Chemical", "char_span": [191, 204], "ent_id": "D007545", "tok_span": [32, 36]}], "relation_list": [{"subject": "isoproterenol", "object": "ischaemic injury", "sbj_char_span": [191, 204], "obj_char_span": [26, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 36], "obj_tok_span": [5, 8]}], "umls_entity_list": []}, {"text": "High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity.", "entity_list": [{"name": "cardiotoxicity", "ent_type": "Disease", "char_span": [73, 87], "ent_id": "D066126", "tok_span": [14, 16]}, {"name": "doxorubicin", "ent_type": "Chemical", "char_span": [53, 64], "ent_id": "D004317", "tok_span": [11, 12]}, {"name": "obese", "ent_type": "Disease", "char_span": [18, 23], "ent_id": "D009765", "tok_span": [5, 6]}, {"name": "fat", "ent_type": "Chemical", "char_span": [5, 8], "ent_id": "D004041", "tok_span": [1, 2]}], "relation_list": [{"subject": "fat", "object": "obese", "sbj_char_span": [5, 8], "obj_char_span": [18, 23], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 2], "obj_tok_span": [5, 6]}], "umls_entity_list": []}, {"text": "In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.", "entity_list": [{"name": "fat", "ent_type": "Chemical", "char_span": [95, 98], "ent_id": "D004041", "tok_span": [16, 17]}, {"name": "doxorubicin", "ent_type": "Chemical", "char_span": [188, 199], "ent_id": "D004317", "tok_span": [43, 44]}, {"name": "obesity", "ent_type": "Disease", "char_span": [125, 132], "ent_id": "D009765", "tok_span": [24, 25]}, {"name": "cardiotoxicity", "ent_type": "Disease", "char_span": [208, 222], "ent_id": "D066126", "tok_span": [46, 48]}], "relation_list": [{"subject": "fat", "object": "obesity", "sbj_char_span": [95, 98], "obj_char_span": [125, 132], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 17], "obj_tok_span": [24, 25]}], "umls_entity_list": []}, {"text": "A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.", "entity_list": [{"name": "renal or hepatic toxicity", "ent_type": "Disease", "char_span": [236, 261], "ent_id": "D00767", "tok_span": [53, 57]}, {"name": "OB", "ent_type": "Disease", "char_span": [193, 195], "ent_id": "D009765", "tok_span": [44, 45]}, {"name": "doxorubicin", "ent_type": "Chemical", "char_span": [20, 31], "ent_id": "D004317", "tok_span": [9, 10]}, {"name": "obese", "ent_type": "Disease", "char_span": [186, 191], "ent_id": "D009765", "tok_span": [42, 43]}, {"name": "cardiotoxicity", "ent_type": "Disease", "char_span": [104, 118], "ent_id": "D066126", "tok_span": [27, 29]}, {"name": "cardiac dysfunction", "ent_type": "Disease", "char_span": [120, 139], "ent_id": "D006331", "tok_span": [30, 32]}], "relation_list": [{"subject": "doxorubicin", "object": "cardiac dysfunction", "sbj_char_span": [20, 31], "obj_char_span": [120, 139], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [30, 32]}], "umls_entity_list": []}, {"text": "Complete atrioventricular block secondary to lithium therapy.", "entity_list": [{"name": "lithium", "ent_type": "Chemical", "char_span": [45, 52], "ent_id": "D008094", "tok_span": [9, 10]}, {"name": "atrioventricular block", "ent_type": "Disease", "char_span": [9, 31], "ent_id": "D054537", "tok_span": [1, 7]}], "relation_list": [{"subject": "lithium", "object": "atrioventricular block", "sbj_char_span": [45, 52], "obj_char_span": [9, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [1, 7]}], "umls_entity_list": []}, {"text": "Sinus node dysfunction has been reported most frequently among the adverse cardiovascular effects of lithium.", "entity_list": [{"name": "Sinus node dysfunction", "ent_type": "Disease", "char_span": [0, 22], "ent_id": "D012804", "tok_span": [0, 4]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [101, 108], "ent_id": "D008094", "tok_span": [15, 16]}], "relation_list": [{"subject": "lithium", "object": "Sinus node dysfunction", "sbj_char_span": [101, 108], "obj_char_span": [0, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 16], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "In the present case, complete atrioventricular (AV) block with syncopal attacks developed secondary to lithium therapy, necessitating permanent pacemaker implantation.", "entity_list": [{"name": "lithium", "ent_type": "Chemical", "char_span": [103, 110], "ent_id": "D008094", "tok_span": [23, 24]}, {"name": "atrioventricular (AV) block", "ent_type": "Disease", "char_span": [30, 57], "ent_id": "D054537", "tok_span": [6, 15]}, {"name": "syncopal attacks", "ent_type": "Disease", "char_span": [63, 79], "ent_id": "D013575", "tok_span": [16, 20]}], "relation_list": [{"subject": "lithium", "object": "atrioventricular (AV) block", "sbj_char_span": [103, 110], "obj_char_span": [30, 57], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 24], "obj_tok_span": [6, 15]}], "umls_entity_list": []}, {"text": "Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment.", "entity_list": [{"name": "Neuroleptic malignant syndrome", "ent_type": "Disease", "char_span": [0, 30], "ent_id": "D009459", "tok_span": [0, 4]}, {"name": "ziprasidone", "ent_type": "Chemical", "char_span": [42, 53], "ent_id": "C092292", "tok_span": [6, 11]}], "relation_list": [{"subject": "ziprasidone", "object": "Neuroleptic malignant syndrome", "sbj_char_span": [42, 53], "obj_char_span": [0, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 11], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone.", "entity_list": [{"name": "ziprasidone", "ent_type": "Chemical", "char_span": [86, 97], "ent_id": "C092292", "tok_span": [20, 25]}, {"name": "NMS", "ent_type": "Disease", "char_span": [54, 57], "ent_id": "D009459", "tok_span": [12, 14]}, {"name": "neuroleptic malignant syndrome", "ent_type": "Disease", "char_span": [22, 52], "ent_id": "D009459", "tok_span": [5, 11]}], "relation_list": [{"subject": "ziprasidone", "object": "NMS", "sbj_char_span": [86, 97], "obj_char_span": [54, 57], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 25], "obj_tok_span": [12, 14]}, {"subject": "ziprasidone", "object": "neuroleptic malignant syndrome", "sbj_char_span": [86, 97], "obj_char_span": [22, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 25], "obj_tok_span": [5, 11]}], "umls_entity_list": []}, {"text": "Although conventional neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs like ziprasidone may also be a cause.", "entity_list": [{"name": "ziprasidone", "ent_type": "Chemical", "char_span": [110, 121], "ent_id": "C092292", "tok_span": [19, 24]}, {"name": "NMS", "ent_type": "Disease", "char_span": [71, 74], "ent_id": "D009459", "tok_span": [11, 13]}], "relation_list": [{"subject": "ziprasidone", "object": "NMS", "sbj_char_span": [110, 121], "obj_char_span": [71, 74], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 24], "obj_tok_span": [11, 13]}], "umls_entity_list": []}, {"text": "The patient is a 24-year-old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone.", "entity_list": [{"name": "schizophrenia", "ent_type": "Disease", "char_span": [52, 65], "ent_id": "D012559", "tok_span": [14, 15]}, {"name": "ziprasidone", "ent_type": "Chemical", "char_span": [179, 190], "ent_id": "C092292", "tok_span": [40, 45]}, {"name": "NMS", "ent_type": "Disease", "char_span": [102, 105], "ent_id": "D009459", "tok_span": [21, 23]}], "relation_list": [{"subject": "ziprasidone", "object": "NMS", "sbj_char_span": [179, 190], "obj_char_span": [102, 105], "rel_type": "chemical-induced disease", "sbj_tok_span": [40, 45], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "This case is the earliest (second day of treatment) NMS due to ziprasidone reported in the literature.", "entity_list": [{"name": "ziprasidone", "ent_type": "Chemical", "char_span": [63, 74], "ent_id": "C092292", "tok_span": [15, 20]}, {"name": "NMS", "ent_type": "Disease", "char_span": [52, 55], "ent_id": "D009459", "tok_span": [11, 13]}], "relation_list": [{"subject": "ziprasidone", "object": "NMS", "sbj_char_span": [63, 74], "obj_char_span": [52, 55], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 20], "obj_tok_span": [11, 13]}], "umls_entity_list": []}, {"text": "Role of mangiferin on biochemical alterations and antioxidant status in isoproterenol-induced myocardial infarction in rats.", "entity_list": [{"name": "myocardial infarction", "ent_type": "Disease", "char_span": [94, 115], "ent_id": "D009203", "tok_span": [18, 20]}, {"name": "isoproterenol", "ent_type": "Chemical", "char_span": [72, 85], "ent_id": "D007545", "tok_span": [12, 16]}, {"name": "mangiferin", "ent_type": "Chemical", "char_span": [8, 18], "ent_id": "C013592", "tok_span": [2, 5]}], "relation_list": [{"subject": "isoproterenol", "object": "myocardial infarction", "sbj_char_span": [72, 85], "obj_char_span": [94, 115], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 16], "obj_tok_span": [18, 20]}], "umls_entity_list": []}, {"text": "The current study dealt with the protective role of mangiferin, a polyphenol from Mangifera indica Linn. (Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.", "entity_list": [{"name": "mangiferin", "ent_type": "Chemical", "char_span": [52, 62], "ent_id": "C013592", "tok_span": [9, 12]}, {"name": "myocardial infarction", "ent_type": "Disease", "char_span": [154, 175], "ent_id": "D009203", "tok_span": [41, 43]}, {"name": "MI", "ent_type": "Disease", "char_span": [177, 179], "ent_id": "D009203", "tok_span": [44, 45]}, {"name": "isoproterenol", "ent_type": "Chemical", "char_span": [125, 138], "ent_id": "D007545", "tok_span": [31, 35]}, {"name": "ISPH", "ent_type": "Chemical", "char_span": [140, 144], "ent_id": "D007545", "tok_span": [36, 38]}, {"name": "polyphenol", "ent_type": "Chemical", "char_span": [66, 76], "ent_id": "D059808", "tok_span": [14, 16]}], "relation_list": [{"subject": "ISPH", "object": "myocardial infarction", "sbj_char_span": [140, 144], "obj_char_span": [154, 175], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 38], "obj_tok_span": [41, 43]}, {"subject": "isoproterenol", "object": "myocardial infarction", "sbj_char_span": [125, 138], "obj_char_span": [154, 175], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 35], "obj_tok_span": [41, 43]}, {"subject": "isoproterenol", "object": "MI", "sbj_char_span": [125, 138], "obj_char_span": [177, 179], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 35], "obj_tok_span": [44, 45]}, {"subject": "ISPH", "object": "MI", "sbj_char_span": [140, 144], "obj_char_span": [177, 179], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 38], "obj_tok_span": [44, 45]}], "umls_entity_list": []}, {"text": "Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats.", "entity_list": [{"name": "mangiferin", "ent_type": "Chemical", "char_span": [114, 124], "ent_id": "C013592", "tok_span": [18, 21]}, {"name": "ISPH", "ent_type": "Chemical", "char_span": [155, 159], "ent_id": "D007545", "tok_span": [25, 27]}, {"name": "MI", "ent_type": "Disease", "char_span": [168, 170], "ent_id": "D009203", "tok_span": [29, 30]}], "relation_list": [{"subject": "ISPH", "object": "MI", "sbj_char_span": [155, 159], "obj_char_span": [168, 170], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 27], "obj_tok_span": [29, 30]}], "umls_entity_list": []}, {"text": "From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against cardiac damage.", "entity_list": [{"name": "cardiac damage", "ent_type": "Disease", "char_span": [191, 205], "ent_id": "D006331", "tok_span": [34, 36]}, {"name": "ISPH", "ent_type": "Chemical", "char_span": [90, 94], "ent_id": "D007545", "tok_span": [16, 18]}, {"name": "MI", "ent_type": "Disease", "char_span": [103, 105], "ent_id": "D009203", "tok_span": [20, 21]}, {"name": "mangiferin", "ent_type": "Chemical", "char_span": [44, 54], "ent_id": "C013592", "tok_span": [8, 11]}], "relation_list": [{"subject": "ISPH", "object": "MI", "sbj_char_span": [90, 94], "obj_char_span": [103, 105], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 18], "obj_tok_span": [20, 21]}], "umls_entity_list": []}, {"text": "Remifentanil pretreatment reduces myoclonus after etomidate.", "entity_list": [{"name": "etomidate", "ent_type": "Chemical", "char_span": [50, 59], "ent_id": "D005045", "tok_span": [11, 14]}, {"name": "myoclonus", "ent_type": "Disease", "char_span": [34, 43], "ent_id": "D009207", "tok_span": [6, 10]}, {"name": "Remifentanil", "ent_type": "Chemical", "char_span": [0, 12], "ent_id": "C071741", "tok_span": [0, 4]}], "relation_list": [{"subject": "etomidate", "object": "myoclonus", "sbj_char_span": [50, 59], "obj_char_span": [34, 43], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [6, 10]}], "umls_entity_list": []}, {"text": "STUDY OBJECTIVE: The aim of the study was to compare the effect of pretreatment with remifentanil 1 microg/kg and the effect of gender on the incidence of myoclonus after anesthesia induction with etomidate.", "entity_list": [{"name": "remifentanil", "ent_type": "Chemical", "char_span": [85, 97], "ent_id": "C071741", "tok_span": [16, 20]}, {"name": "etomidate", "ent_type": "Chemical", "char_span": [197, 206], "ent_id": "D005045", "tok_span": [42, 45]}, {"name": "myoclonus", "ent_type": "Disease", "char_span": [155, 164], "ent_id": "D009207", "tok_span": [34, 38]}], "relation_list": [{"subject": "etomidate", "object": "myoclonus", "sbj_char_span": [197, 206], "obj_char_span": [155, 164], "rel_type": "chemical-induced disease", "sbj_tok_span": [42, 45], "obj_tok_span": [34, 38]}], "umls_entity_list": []}, {"text": "In the placebo group, male patients were associated with significantly increased incidence of myoclonus after etomidate administration.", "entity_list": [{"name": "myoclonus", "ent_type": "Disease", "char_span": [94, 103], "ent_id": "D009207", "tok_span": [14, 18]}, {"name": "etomidate", "ent_type": "Chemical", "char_span": [110, 119], "ent_id": "D005045", "tok_span": [19, 22]}], "relation_list": [{"subject": "etomidate", "object": "myoclonus", "sbj_char_span": [110, 119], "obj_char_span": [94, 103], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 22], "obj_tok_span": [14, 18]}], "umls_entity_list": []}, {"text": "CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.", "entity_list": [{"name": "remifentanil", "ent_type": "Chemical", "char_span": [30, 42], "ent_id": "C071741", "tok_span": [5, 9]}, {"name": "apnea", "ent_type": "Disease", "char_span": [138, 143], "ent_id": "D001049", "tok_span": [31, 32]}, {"name": "pruritus", "ent_type": "Disease", "char_span": [156, 164], "ent_id": "D011537", "tok_span": [36, 40]}, {"name": "nausea", "ent_type": "Disease", "char_span": [145, 151], "ent_id": "D009325", "tok_span": [33, 34]}, {"name": "etomidate", "ent_type": "Chemical", "char_span": [79, 88], "ent_id": "D005045", "tok_span": [20, 23]}, {"name": "myoclonus", "ent_type": "Disease", "char_span": [63, 72], "ent_id": "D009207", "tok_span": [15, 19]}], "relation_list": [{"subject": "etomidate", "object": "myoclonus", "sbj_char_span": [79, 88], "obj_char_span": [63, 72], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [15, 19]}], "umls_entity_list": []}, {"text": "Men experience increased incidence of myoclonus than women after etomidate administration.", "entity_list": [{"name": "myoclonus", "ent_type": "Disease", "char_span": [38, 47], "ent_id": "D009207", "tok_span": [5, 9]}, {"name": "etomidate", "ent_type": "Chemical", "char_span": [65, 74], "ent_id": "D005045", "tok_span": [12, 15]}], "relation_list": [{"subject": "etomidate", "object": "myoclonus", "sbj_char_span": [65, 74], "obj_char_span": [38, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "Administration of daidzein (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced amnesia, according to the results of a Y-maze test.", "entity_list": [{"name": "daidzein", "ent_type": "Chemical", "char_span": [18, 26], "ent_id": "C004742", "tok_span": [2, 6]}, {"name": "amnesia", "ent_type": "Disease", "char_span": [114, 121], "ent_id": "D000647", "tok_span": [28, 31]}, {"name": "scopolamine", "ent_type": "Chemical", "char_span": [94, 105], "ent_id": "D012601", "tok_span": [23, 26]}], "relation_list": [{"subject": "scopolamine", "object": "amnesia", "sbj_char_span": [94, 105], "obj_char_span": [114, 121], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [28, 31]}], "umls_entity_list": []}, {"text": "These results indicate that daidzein might play a role in acetylcholine biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-induced amnesia.", "entity_list": [{"name": "scopolamine", "ent_type": "Chemical", "char_span": [135, 146], "ent_id": "D012601", "tok_span": [27, 30]}, {"name": "amnesia", "ent_type": "Disease", "char_span": [155, 162], "ent_id": "D000647", "tok_span": [32, 35]}, {"name": "daidzein", "ent_type": "Chemical", "char_span": [28, 36], "ent_id": "C004742", "tok_span": [4, 8]}, {"name": "acetylcholine", "ent_type": "Chemical", "char_span": [58, 71], "ent_id": "D000109", "tok_span": [13, 14]}], "relation_list": [{"subject": "scopolamine", "object": "amnesia", "sbj_char_span": [135, 146], "obj_char_span": [155, 162], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 30], "obj_tok_span": [32, 35]}], "umls_entity_list": []}, {"text": "Possible azithromycin-associated hiccups.", "entity_list": [{"name": "azithromycin", "ent_type": "Chemical", "char_span": [9, 21], "ent_id": "D017963", "tok_span": [1, 4]}, {"name": "hiccups", "ent_type": "Disease", "char_span": [33, 40], "ent_id": "D006606", "tok_span": [6, 9]}], "relation_list": [{"subject": "azithromycin", "object": "hiccups", "sbj_char_span": [9, 21], "obj_char_span": [33, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 4], "obj_tok_span": [6, 9]}], "umls_entity_list": []}, {"text": "OBJECTIVE: To report a case of persistent hiccups associated by azithromycin therapy.", "entity_list": [{"name": "azithromycin", "ent_type": "Chemical", "char_span": [64, 76], "ent_id": "D017963", "tok_span": [13, 16]}, {"name": "hiccups", "ent_type": "Disease", "char_span": [42, 49], "ent_id": "D006606", "tok_span": [8, 11]}], "relation_list": [{"subject": "azithromycin", "object": "hiccups", "sbj_char_span": [64, 76], "obj_char_span": [42, 49], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [8, 11]}], "umls_entity_list": []}, {"text": "CASE SUMMARY: A 76-year-old man presented with persistent hiccups after beginning azithromycin for the treatment of pharyngitis.", "entity_list": [{"name": "azithromycin", "ent_type": "Chemical", "char_span": [82, 94], "ent_id": "D017963", "tok_span": [18, 21]}, {"name": "hiccups", "ent_type": "Disease", "char_span": [58, 65], "ent_id": "D006606", "tok_span": [13, 16]}, {"name": "pharyngitis", "ent_type": "Disease", "char_span": [116, 127], "ent_id": "D010612", "tok_span": [25, 28]}], "relation_list": [{"subject": "azithromycin", "object": "hiccups", "sbj_char_span": [82, 94], "obj_char_span": [58, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "Discontinuation of azithromycin and therapy with baclofen finally resolved hiccups.", "entity_list": [{"name": "baclofen", "ent_type": "Chemical", "char_span": [49, 57], "ent_id": "D001418", "tok_span": [10, 13]}, {"name": "azithromycin", "ent_type": "Chemical", "char_span": [19, 31], "ent_id": "D017963", "tok_span": [4, 7]}, {"name": "hiccups", "ent_type": "Disease", "char_span": [75, 82], "ent_id": "D006606", "tok_span": [15, 18]}], "relation_list": [{"subject": "azithromycin", "object": "hiccups", "sbj_char_span": [19, 31], "obj_char_span": [75, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [15, 18]}, {"subject": "baclofen", "object": "hiccups", "sbj_char_span": [49, 57], "obj_char_span": [75, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [15, 18]}], "umls_entity_list": []}, {"text": "Our hypothesis is that a vagal mechanism mediated by azithromycin could be the pathogenesis of hiccups in our patient.", "entity_list": [{"name": "azithromycin", "ent_type": "Chemical", "char_span": [53, 65], "ent_id": "D017963", "tok_span": [10, 13]}, {"name": "hiccups", "ent_type": "Disease", "char_span": [95, 102], "ent_id": "D006606", "tok_span": [18, 21]}], "relation_list": [{"subject": "azithromycin", "object": "hiccups", "sbj_char_span": [53, 65], "obj_char_span": [95, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [18, 21]}], "umls_entity_list": []}, {"text": "Time trends in warfarin-associated hemorrhage.", "entity_list": [{"name": "warfarin", "ent_type": "Chemical", "char_span": [15, 23], "ent_id": "D014859", "tok_span": [3, 4]}, {"name": "hemorrhage", "ent_type": "Disease", "char_span": [35, 45], "ent_id": "D006470", "tok_span": [6, 7]}], "relation_list": [{"subject": "warfarin", "object": "hemorrhage", "sbj_char_span": [15, 23], "obj_char_span": [35, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [6, 7]}], "umls_entity_list": []}, {"text": "The annual incidence of warfarin-related bleeding at Brigham and Women's Hospital increased from 0.97/1,000 patient admissions in the first time period (January 1995 to October 1998) to 1.19/1,000 patient admissions in the second time period (November 1998 to August 2002) of this study.", "entity_list": [{"name": "bleeding", "ent_type": "Disease", "char_span": [41, 49], "ent_id": "D006470", "tok_span": [7, 8]}, {"name": "warfarin", "ent_type": "Chemical", "char_span": [24, 32], "ent_id": "D014859", "tok_span": [4, 5]}], "relation_list": [{"subject": "warfarin", "object": "bleeding", "sbj_char_span": [24, 32], "obj_char_span": [41, 49], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [7, 8]}], "umls_entity_list": []}, {"text": "Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura.", "entity_list": [{"name": "migraine without aura", "ent_type": "Disease", "char_span": [39, 60], "ent_id": "D020326", "tok_span": [9, 13]}, {"name": "Glyceryl trinitrate", "ent_type": "Chemical", "char_span": [0, 19], "ent_id": "D005996", "tok_span": [0, 6]}, {"name": "migraine with aura", "ent_type": "Disease", "char_span": [77, 95], "ent_id": "D020325", "tok_span": [17, 21]}], "relation_list": [{"subject": "Glyceryl trinitrate", "object": "migraine without aura", "sbj_char_span": [0, 19], "obj_char_span": [39, 60], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 6], "obj_tok_span": [9, 13]}], "umls_entity_list": []}, {"text": "In recent years, increasing evidence has suggested that the messenger molecule nitric oxide (NO) is involved in pain mechanisms of migraine without aura.", "entity_list": [{"name": "migraine without aura", "ent_type": "Disease", "char_span": [131, 152], "ent_id": "D020326", "tok_span": [23, 27]}, {"name": "nitric oxide", "ent_type": "Chemical", "char_span": [79, 91], "ent_id": "D009569", "tok_span": [12, 14]}, {"name": "pain", "ent_type": "Disease", "char_span": [112, 116], "ent_id": "D010146", "tok_span": [20, 21]}, {"name": "NO", "ent_type": "Chemical", "char_span": [93, 95], "ent_id": "D009569", "tok_span": [15, 16]}], "relation_list": [{"subject": "nitric oxide", "object": "migraine without aura", "sbj_char_span": [79, 91], "obj_char_span": [131, 152], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 14], "obj_tok_span": [23, 27]}, {"subject": "NO", "object": "migraine without aura", "sbj_char_span": [93, 95], "obj_char_span": [131, 152], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 16], "obj_tok_span": [23, 27]}], "umls_entity_list": []}, {"text": "Stroke and cocaine or amphetamine use.", "entity_list": [{"name": "Stroke", "ent_type": "Disease", "char_span": [0, 6], "ent_id": "D020521", "tok_span": [0, 1]}, {"name": "amphetamine", "ent_type": "Chemical", "char_span": [22, 33], "ent_id": "D000661", "tok_span": [4, 8]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [11, 18], "ent_id": "D003042", "tok_span": [2, 3]}], "relation_list": [{"subject": "cocaine", "object": "Stroke", "sbj_char_span": [11, 18], "obj_char_span": [0, 6], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 3], "obj_tok_span": [0, 1]}, {"subject": "amphetamine", "object": "Stroke", "sbj_char_span": [22, 33], "obj_char_span": [0, 6], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 8], "obj_tok_span": [0, 1]}], "umls_entity_list": []}, {"text": "The association of cocaine and amphetamine use with hemorrhagic and ischemic stroke is based almost solely on data from case series.", "entity_list": [{"name": "cocaine", "ent_type": "Chemical", "char_span": [19, 26], "ent_id": "D003042", "tok_span": [3, 4]}, {"name": "stroke", "ent_type": "Disease", "char_span": [77, 83], "ent_id": "D020521", "tok_span": [14, 15]}, {"name": "ischemic", "ent_type": "Disease", "char_span": [68, 76], "ent_id": "D007511", "tok_span": [13, 14]}, {"name": "amphetamine", "ent_type": "Chemical", "char_span": [31, 42], "ent_id": "D000661", "tok_span": [5, 9]}], "relation_list": [{"subject": "amphetamine", "object": "stroke", "sbj_char_span": [31, 42], "obj_char_span": [77, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [14, 15]}, {"subject": "cocaine", "object": "stroke", "sbj_char_span": [19, 26], "obj_char_span": [77, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [14, 15]}], "umls_entity_list": []}, {"text": "The limited number of epidemiologic studies of stroke and use of cocaine and/or amphetamine have been done in settings that serve mostly the poor and/or minorities.", "entity_list": [{"name": "cocaine", "ent_type": "Chemical", "char_span": [65, 72], "ent_id": "D003042", "tok_span": [12, 13]}, {"name": "amphetamine", "ent_type": "Chemical", "char_span": [80, 91], "ent_id": "D000661", "tok_span": [16, 20]}, {"name": "stroke", "ent_type": "Disease", "char_span": [47, 53], "ent_id": "D020521", "tok_span": [8, 9]}], "relation_list": [{"subject": "cocaine", "object": "stroke", "sbj_char_span": [65, 72], "obj_char_span": [47, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [8, 9]}, {"subject": "amphetamine", "object": "stroke", "sbj_char_span": [80, 91], "obj_char_span": [47, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 20], "obj_tok_span": [8, 9]}], "umls_entity_list": []}, {"text": "The univariate matched odds ratio for stroke in women who admitted to using cocaine and/or amphetamine was 8.5 (95% confidence interval = 3.6-20.0).", "entity_list": [{"name": "stroke", "ent_type": "Disease", "char_span": [38, 44], "ent_id": "D020521", "tok_span": [6, 7]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [76, 83], "ent_id": "D003042", "tok_span": [13, 14]}, {"name": "amphetamine", "ent_type": "Chemical", "char_span": [91, 102], "ent_id": "D000661", "tok_span": [17, 21]}], "relation_list": [{"subject": "cocaine", "object": "stroke", "sbj_char_span": [76, 83], "obj_char_span": [38, 44], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 14], "obj_tok_span": [6, 7]}, {"subject": "amphetamine", "object": "stroke", "sbj_char_span": [91, 102], "obj_char_span": [38, 44], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [6, 7]}], "umls_entity_list": []}, {"text": "The use of cocaine and/or amphetamine is a strong risk factor for stroke in this socioeconomically heterogeneous, insured urban population.", "entity_list": [{"name": "cocaine", "ent_type": "Chemical", "char_span": [11, 18], "ent_id": "D003042", "tok_span": [3, 4]}, {"name": "amphetamine", "ent_type": "Chemical", "char_span": [26, 37], "ent_id": "D000661", "tok_span": [7, 11]}, {"name": "stroke", "ent_type": "Disease", "char_span": [66, 72], "ent_id": "D020521", "tok_span": [17, 18]}], "relation_list": [{"subject": "cocaine", "object": "stroke", "sbj_char_span": [11, 18], "obj_char_span": [66, 72], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [17, 18]}, {"subject": "amphetamine", "object": "stroke", "sbj_char_span": [26, 37], "obj_char_span": [66, 72], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [17, 18]}], "umls_entity_list": []}, {"text": "Compared with the placebo group, there was a significantly increased risk of vascular events and hypertriglyceridaemia among women on tamoxifen.", "entity_list": [{"name": "hypertriglyceridaemia", "ent_type": "Disease", "char_span": [97, 118], "ent_id": "D015228", "tok_span": [16, 21]}, {"name": "tamoxifen", "ent_type": "Chemical", "char_span": [134, 143], "ent_id": "D013629", "tok_span": [24, 25]}, {"name": "vascular events", "ent_type": "Disease", "char_span": [77, 92], "ent_id": "D014652", "tok_span": [13, 15]}], "relation_list": [{"subject": "tamoxifen", "object": "vascular events", "sbj_char_span": [134, 143], "obj_char_span": [77, 92], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 25], "obj_tok_span": [13, 15]}, {"subject": "tamoxifen", "object": "hypertriglyceridaemia", "sbj_char_span": [134, 143], "obj_char_span": [97, 118], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 25], "obj_tok_span": [16, 21]}], "umls_entity_list": []}, {"text": "A measure of pupillary oscillation as a marker of cocaine-induced paranoia.", "entity_list": [{"name": "cocaine", "ent_type": "Chemical", "char_span": [50, 57], "ent_id": "D003042", "tok_span": [11, 12]}, {"name": "pupillary oscillation", "ent_type": "Disease", "char_span": [13, 34], "ent_id": "D011681", "tok_span": [3, 7]}, {"name": "paranoia", "ent_type": "Disease", "char_span": [66, 74], "ent_id": "D010259", "tok_span": [14, 17]}], "relation_list": [{"subject": "cocaine", "object": "pupillary oscillation", "sbj_char_span": [50, 57], "obj_char_span": [13, 34], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [3, 7]}, {"subject": "cocaine", "object": "paranoia", "sbj_char_span": [50, 57], "obj_char_span": [66, 74], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [14, 17]}], "umls_entity_list": []}, {"text": "Cocaine-induced paranoia (CIP) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.", "entity_list": [{"name": "Cocaine", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "D003042", "tok_span": [0, 3]}, {"name": "paranoia", "ent_type": "Disease", "char_span": [16, 24], "ent_id": "D010259", "tok_span": [5, 8]}, {"name": "paranoia", "ent_type": "Disease", "char_span": [85, 93], "ent_id": "D010259", "tok_span": [21, 24]}, {"name": "CIP", "ent_type": "Disease", "char_span": [26, 29], "ent_id": "D010259", "tok_span": [9, 11]}], "relation_list": [{"subject": "Cocaine", "object": "paranoia", "sbj_char_span": [0, 7], "obj_char_span": [16, 24], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 8]}, {"subject": "Cocaine", "object": "paranoia", "sbj_char_span": [0, 7], "obj_char_span": [85, 93], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [21, 24]}, {"subject": "Cocaine", "object": "CIP", "sbj_char_span": [0, 7], "obj_char_span": [26, 29], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "Seizures induced by combined levomepromazine-fluvoxamine treatment.", "entity_list": [{"name": "Seizures", "ent_type": "Disease", "char_span": [0, 8], "ent_id": "D012640", "tok_span": [0, 3]}, {"name": "levomepromazine", "ent_type": "Chemical", "char_span": [29, 44], "ent_id": "D008728", "tok_span": [6, 10]}, {"name": "fluvoxamine", "ent_type": "Chemical", "char_span": [45, 56], "ent_id": "D016666", "tok_span": [11, 15]}], "relation_list": [{"subject": "levomepromazine", "object": "Seizures", "sbj_char_span": [29, 44], "obj_char_span": [0, 8], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 10], "obj_tok_span": [0, 3]}, {"subject": "fluvoxamine", "object": "Seizures", "sbj_char_span": [45, 56], "obj_char_span": [0, 8], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "We report a case of combined levomepromazine-fluvoxamine treatment-induced seizures.", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [75, 83], "ent_id": "D012640", "tok_span": [18, 19]}, {"name": "levomepromazine", "ent_type": "Chemical", "char_span": [29, 44], "ent_id": "D008728", "tok_span": [6, 10]}, {"name": "fluvoxamine", "ent_type": "Chemical", "char_span": [45, 56], "ent_id": "D016666", "tok_span": [11, 15]}], "relation_list": [{"subject": "fluvoxamine", "object": "seizures", "sbj_char_span": [45, 56], "obj_char_span": [75, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [18, 19]}, {"subject": "levomepromazine", "object": "seizures", "sbj_char_span": [29, 44], "obj_char_span": [75, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 10], "obj_tok_span": [18, 19]}], "umls_entity_list": []}, {"text": "Why may epsilon-aminocaproic acid (EACA) induce myopathy in man?", "entity_list": [{"name": "myopathy", "ent_type": "Disease", "char_span": [48, 56], "ent_id": "D009135", "tok_span": [16, 18]}, {"name": "EACA", "ent_type": "Chemical", "char_span": [35, 39], "ent_id": "D015119", "tok_span": [12, 14]}, {"name": "epsilon-aminocaproic acid", "ent_type": "Chemical", "char_span": [8, 33], "ent_id": "D015119", "tok_span": [2, 11]}], "relation_list": [{"subject": "EACA", "object": "myopathy", "sbj_char_span": [35, 39], "obj_char_span": [48, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 14], "obj_tok_span": [16, 18]}, {"subject": "epsilon-aminocaproic acid", "object": "myopathy", "sbj_char_span": [8, 33], "obj_char_span": [48, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 11], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "Sixty percent of the males developed breast changes or impotence while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine.", "entity_list": [{"name": "cimetidine", "ent_type": "Chemical", "char_span": [78, 88], "ent_id": "D002927", "tok_span": [14, 17]}, {"name": "ranitidine", "ent_type": "Chemical", "char_span": [164, 174], "ent_id": "D011899", "tok_span": [31, 35]}, {"name": "cimetidine", "ent_type": "Chemical", "char_span": [137, 147], "ent_id": "D002927", "tok_span": [25, 28]}, {"name": "impotence", "ent_type": "Disease", "char_span": [55, 64], "ent_id": "D007172", "tok_span": [9, 12]}], "relation_list": [{"subject": "cimetidine", "object": "impotence", "sbj_char_span": [137, 147], "obj_char_span": [55, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 28], "obj_tok_span": [9, 12]}, {"subject": "cimetidine", "object": "impotence", "sbj_char_span": [78, 88], "obj_char_span": [55, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [9, 12]}], "umls_entity_list": []}, {"text": "Reye syndrome may be disappearing from Australia despite a total lack of association with salicylates or aspirin ingestion, since there were no cases found at The Children's Hospital in 1983, 1984, or 1985.", "entity_list": [{"name": "Reye syndrome", "ent_type": "Disease", "char_span": [0, 13], "ent_id": "D012202", "tok_span": [0, 3]}, {"name": "salicylates", "ent_type": "Chemical", "char_span": [90, 101], "ent_id": "D012459", "tok_span": [16, 20]}, {"name": "aspirin", "ent_type": "Chemical", "char_span": [105, 112], "ent_id": "D001241", "tok_span": [21, 22]}], "relation_list": [{"subject": "aspirin", "object": "Reye syndrome", "sbj_char_span": [105, 112], "obj_char_span": [0, 13], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 22], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "A rare case of morbid vasospasm, together with striking angiographic findings, is described secondary to the ingestion of methysergide by a 48-year-old woman.", "entity_list": [{"name": "vasospasm", "ent_type": "Disease", "char_span": [22, 31], "ent_id": "D014652", "tok_span": [7, 10]}, {"name": "methysergide", "ent_type": "Chemical", "char_span": [122, 134], "ent_id": "D008784", "tok_span": [25, 29]}], "relation_list": [{"subject": "methysergide", "object": "vasospasm", "sbj_char_span": [122, 134], "obj_char_span": [22, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 29], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "A discussion of the history of ergot includes its original discovery, the epidemics of gangrene that it has caused through the ages and its past and present role in the management of migraine headache.", "entity_list": [{"name": "migraine headache", "ent_type": "Disease", "char_span": [183, 200], "ent_id": "D008881", "tok_span": [36, 38]}, {"name": "ergot", "ent_type": "Chemical", "char_span": [31, 36], "ent_id": "D004876", "tok_span": [6, 8]}, {"name": "gangrene", "ent_type": "Disease", "char_span": [87, 95], "ent_id": "D005734", "tok_span": [17, 19]}], "relation_list": [{"subject": "ergot", "object": "migraine headache", "sbj_char_span": [31, 36], "obj_char_span": [183, 200], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [36, 38]}], "umls_entity_list": []}, {"text": "Despite the advent of calcium channel blockers and beta-adrenergic antagonists, ergot preparations continue to play a major role in migraine therapy, so that the danger of St. Anthony's fire persists.", "entity_list": [{"name": "St. Anthony's fire", "ent_type": "Disease", "char_span": [172, 190], "ent_id": "D004881", "tok_span": [32, 39]}, {"name": "calcium", "ent_type": "Chemical", "char_span": [22, 29], "ent_id": "D002118", "tok_span": [4, 5]}, {"name": "ergot", "ent_type": "Chemical", "char_span": [80, 85], "ent_id": "D004876", "tok_span": [14, 16]}, {"name": "migraine", "ent_type": "Disease", "char_span": [132, 140], "ent_id": "D008881", "tok_span": [24, 25]}], "relation_list": [{"subject": "ergot", "object": "migraine", "sbj_char_span": [80, 85], "obj_char_span": [132, 140], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [24, 25]}], "umls_entity_list": []}, {"text": "The time course and concentration-effect relationship of terbutaline-induced hypokalemia was studied, using computer-aided pharmacokinetic-dynamic modeling.", "entity_list": [{"name": "hypokalemia", "ent_type": "Disease", "char_span": [77, 88], "ent_id": "D007008", "tok_span": [14, 18]}, {"name": "terbutaline", "ent_type": "Chemical", "char_span": [57, 68], "ent_id": "D013726", "tok_span": [9, 12]}], "relation_list": [{"subject": "terbutaline", "object": "hypokalemia", "sbj_char_span": [57, 68], "obj_char_span": [77, 88], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [14, 18]}], "umls_entity_list": []}, {"text": "In spite of higher terbutaline concentrations after oxprenolol pretreatment, the hypokalemia was almost completely antagonized by the beta 2-blocking action.", "entity_list": [{"name": "terbutaline", "ent_type": "Chemical", "char_span": [19, 30], "ent_id": "D013726", "tok_span": [4, 7]}, {"name": "oxprenolol", "ent_type": "Chemical", "char_span": [52, 62], "ent_id": "D010096", "tok_span": [9, 14]}, {"name": "hypokalemia", "ent_type": "Disease", "char_span": [81, 92], "ent_id": "D007008", "tok_span": [17, 21]}], "relation_list": [{"subject": "terbutaline", "object": "hypokalemia", "sbj_char_span": [19, 30], "obj_char_span": [81, 92], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [17, 21]}], "umls_entity_list": []}, {"text": "Midline B3 serotonin nerves in rat medulla are involved in hypotensive effect of methyldopa.", "entity_list": [{"name": "methyldopa", "ent_type": "Chemical", "char_span": [81, 91], "ent_id": "D008750", "tok_span": [17, 20]}, {"name": "serotonin", "ent_type": "Chemical", "char_span": [11, 20], "ent_id": "D012701", "tok_span": [4, 5]}, {"name": "hypotensive", "ent_type": "Disease", "char_span": [59, 70], "ent_id": "D007022", "tok_span": [13, 15]}], "relation_list": [{"subject": "methyldopa", "object": "hypotensive", "sbj_char_span": [81, 91], "obj_char_span": [59, 70], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "Previous experiments in this laboratory have shown that microinjection of methyldopa onto the ventrolateral cells of the B3 serotonin neurons in the medulla elicits a hypotensive response mediated by a projection descending into the spinal cord.", "entity_list": [{"name": "methyldopa", "ent_type": "Chemical", "char_span": [74, 84], "ent_id": "D008750", "tok_span": [11, 14]}, {"name": "hypotensive", "ent_type": "Disease", "char_span": [167, 178], "ent_id": "D007022", "tok_span": [33, 35]}, {"name": "serotonin", "ent_type": "Chemical", "char_span": [124, 133], "ent_id": "D012701", "tok_span": [24, 25]}], "relation_list": [{"subject": "methyldopa", "object": "hypotensive", "sbj_char_span": [74, 84], "obj_char_span": [167, 178], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [33, 35]}], "umls_entity_list": []}, {"text": "In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.", "entity_list": [{"name": "hypotension", "ent_type": "Disease", "char_span": [171, 182], "ent_id": "D007022", "tok_span": [34, 35]}, {"name": "methyldopa", "ent_type": "Chemical", "char_span": [68, 78], "ent_id": "D008750", "tok_span": [12, 15]}, {"name": "serotonin", "ent_type": "Chemical", "char_span": [269, 278], "ent_id": "D012701", "tok_span": [56, 57]}, {"name": "5,7-dihydroxytryptamine", "ent_type": "Chemical", "char_span": [290, 313], "ent_id": "D015116", "tok_span": [59, 68]}, {"name": "5,7-DHT", "ent_type": "Chemical", "char_span": [315, 322], "ent_id": "D015116", "tok_span": [69, 75]}, {"name": "serotonin", "ent_type": "Chemical", "char_span": [111, 120], "ent_id": "D012701", "tok_span": [23, 24]}, {"name": "stroke", "ent_type": "Disease", "char_span": [31, 37], "ent_id": "D020521", "tok_span": [4, 5]}, {"name": "hypertensive", "ent_type": "Disease", "char_span": [17, 29], "ent_id": "D006973", "tok_span": [2, 3]}], "relation_list": [{"subject": "methyldopa", "object": "hypotension", "sbj_char_span": [68, 78], "obj_char_span": [171, 182], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [34, 35]}], "umls_entity_list": []}, {"text": "It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced hypotension via descending projections, the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.", "entity_list": [{"name": "hypotensive", "ent_type": "Disease", "char_span": [205, 216], "ent_id": "D007022", "tok_span": [40, 42]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [101, 112], "ent_id": "D007022", "tok_span": [22, 23]}, {"name": "methyldopa", "ent_type": "Chemical", "char_span": [227, 237], "ent_id": "D008750", "tok_span": [44, 47]}, {"name": "serotonin", "ent_type": "Chemical", "char_span": [153, 162], "ent_id": "D012701", "tok_span": [29, 30]}, {"name": "methyldopa", "ent_type": "Chemical", "char_span": [82, 92], "ent_id": "D008750", "tok_span": [17, 20]}], "relation_list": [{"subject": "methyldopa", "object": "hypotensive", "sbj_char_span": [227, 237], "obj_char_span": [205, 216], "rel_type": "chemical-induced disease", "sbj_tok_span": [44, 47], "obj_tok_span": [40, 42]}, {"subject": "methyldopa", "object": "hypotension", "sbj_char_span": [82, 92], "obj_char_span": [101, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [22, 23]}, {"subject": "methyldopa", "object": "hypotension", "sbj_char_span": [227, 237], "obj_char_span": [101, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [44, 47], "obj_tok_span": [22, 23]}, {"subject": "methyldopa", "object": "hypotensive", "sbj_char_span": [82, 92], "obj_char_span": [205, 216], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [40, 42]}], "umls_entity_list": []}, {"text": "A single case report suggests that yohimbine may be used to treat the sexual side effects of clomipramine.", "entity_list": [{"name": "clomipramine", "ent_type": "Chemical", "char_span": [93, 105], "ent_id": "D002997", "tok_span": [20, 24]}, {"name": "yohimbine", "ent_type": "Chemical", "char_span": [35, 44], "ent_id": "D015016", "tok_span": [6, 10]}, {"name": "sexual side effects", "ent_type": "Disease", "char_span": [70, 89], "ent_id": "D020018", "tok_span": [16, 19]}], "relation_list": [{"subject": "clomipramine", "object": "sexual side effects", "sbj_char_span": [93, 105], "obj_char_span": [70, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 24], "obj_tok_span": [16, 19]}], "umls_entity_list": []}, {"text": "Hypersensitivity immune reaction as a mechanism for dilevalol-associated hepatitis.", "entity_list": [{"name": "dilevalol", "ent_type": "Chemical", "char_span": [52, 61], "ent_id": "D007741", "tok_span": [10, 13]}, {"name": "Hypersensitivity", "ent_type": "Disease", "char_span": [0, 16], "ent_id": "D004342", "tok_span": [0, 4]}, {"name": "hepatitis", "ent_type": "Disease", "char_span": [73, 82], "ent_id": "D056486", "tok_span": [15, 16]}], "relation_list": [{"subject": "dilevalol", "object": "hepatitis", "sbj_char_span": [52, 61], "obj_char_span": [73, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [15, 16]}, {"subject": "dilevalol", "object": "Hypersensitivity", "sbj_char_span": [52, 61], "obj_char_span": [0, 16], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "OBJECTIVE: To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol-induced liver injury.", "entity_list": [{"name": "dilevalol", "ent_type": "Chemical", "char_span": [46, 55], "ent_id": "D007741", "tok_span": [7, 10]}, {"name": "liver injury", "ent_type": "Disease", "char_span": [162, 174], "ent_id": "D056486", "tok_span": [32, 34]}, {"name": "dilevalol", "ent_type": "Chemical", "char_span": [97, 106], "ent_id": "D007741", "tok_span": [17, 20]}, {"name": "dilevalol", "ent_type": "Chemical", "char_span": [144, 153], "ent_id": "D007741", "tok_span": [27, 30]}], "relation_list": [{"subject": "dilevalol", "object": "liver injury", "sbj_char_span": [46, 55], "obj_char_span": [162, 174], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [32, 34]}, {"subject": "dilevalol", "object": "liver injury", "sbj_char_span": [144, 153], "obj_char_span": [162, 174], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 30], "obj_tok_span": [32, 34]}, {"subject": "dilevalol", "object": "liver injury", "sbj_char_span": [97, 106], "obj_char_span": [162, 174], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [32, 34]}], "umls_entity_list": []}, {"text": "PATIENT: A 58-year-old woman with a clinical diagnosis of dilevalol-induced liver injury.", "entity_list": [{"name": "dilevalol", "ent_type": "Chemical", "char_span": [58, 67], "ent_id": "D007741", "tok_span": [15, 18]}, {"name": "liver injury", "ent_type": "Disease", "char_span": [76, 88], "ent_id": "D056486", "tok_span": [20, 22]}], "relation_list": [{"subject": "dilevalol", "object": "liver injury", "sbj_char_span": [58, 67], "obj_char_span": [76, 88], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [20, 22]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: The methodology used allowed the detection of lymphocyte sensitization to sera containing ex vivo-prepared dilevalol antigens, suggesting the involvement of an immunologic mechanism in dilevalol-induced liver injury.", "entity_list": [{"name": "dilevalol", "ent_type": "Chemical", "char_span": [120, 129], "ent_id": "D007741", "tok_span": [18, 21]}, {"name": "dilevalol", "ent_type": "Chemical", "char_span": [198, 207], "ent_id": "D007741", "tok_span": [33, 36]}, {"name": "liver injury", "ent_type": "Disease", "char_span": [216, 228], "ent_id": "D056486", "tok_span": [38, 40]}], "relation_list": [{"subject": "dilevalol", "object": "liver injury", "sbj_char_span": [120, 129], "obj_char_span": [216, 228], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [38, 40]}, {"subject": "dilevalol", "object": "liver injury", "sbj_char_span": [198, 207], "obj_char_span": [216, 228], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 36], "obj_tok_span": [38, 40]}], "umls_entity_list": []}, {"text": "Reversible myocardial hypertrophy induced by tacrolimus in a pediatric heart transplant recipient: case report.", "entity_list": [{"name": "myocardial hypertrophy", "ent_type": "Disease", "char_span": [11, 33], "ent_id": "D006332", "tok_span": [2, 4]}, {"name": "tacrolimus", "ent_type": "Chemical", "char_span": [45, 55], "ent_id": "D016559", "tok_span": [6, 8]}], "relation_list": [{"subject": "tacrolimus", "object": "myocardial hypertrophy", "sbj_char_span": [45, 55], "obj_char_span": [11, 33], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [2, 4]}], "umls_entity_list": []}, {"text": "Herein we describe transient myocardial hypertrophy induced by tacrolimus after heart transplantation.", "entity_list": [{"name": "tacrolimus", "ent_type": "Chemical", "char_span": [63, 73], "ent_id": "D016559", "tok_span": [8, 10]}, {"name": "myocardial hypertrophy", "ent_type": "Disease", "char_span": [29, 51], "ent_id": "D006332", "tok_span": [4, 6]}], "relation_list": [{"subject": "tacrolimus", "object": "myocardial hypertrophy", "sbj_char_span": [63, 73], "obj_char_span": [29, 51], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "Myocardial hypertrophy completely resolved upon reducing the target concentration of tacrolimus and did not recur, as confirmed at echocardiography and myocardial biopsy.", "entity_list": [{"name": "Myocardial hypertrophy", "ent_type": "Disease", "char_span": [0, 22], "ent_id": "D006332", "tok_span": [0, 3]}, {"name": "tacrolimus", "ent_type": "Chemical", "char_span": [85, 95], "ent_id": "D016559", "tok_span": [11, 13]}], "relation_list": [{"subject": "tacrolimus", "object": "Myocardial hypertrophy", "sbj_char_span": [85, 95], "obj_char_span": [0, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 13], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "Thus, we conclude that tacrolimus induces reversible myocardial hypertrophy.", "entity_list": [{"name": "myocardial hypertrophy", "ent_type": "Disease", "char_span": [53, 75], "ent_id": "D006332", "tok_span": [9, 11]}, {"name": "tacrolimus", "ent_type": "Chemical", "char_span": [23, 33], "ent_id": "D016559", "tok_span": [5, 7]}], "relation_list": [{"subject": "tacrolimus", "object": "myocardial hypertrophy", "sbj_char_span": [23, 33], "obj_char_span": [53, 75], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 7], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "Ten consecutive patients (mean age, 58.4 +/- 6.8 years; 7 men, 3 women) with similar characteristics at the duration of disease (mean disease time, 8.4 +/- 3.5 years), disabling motor fluctuations (Hoehn _ Yahr stage 3-5 in off-drug phases) and levodopa-induced dyskinesias were selected.", "entity_list": [{"name": "levodopa", "ent_type": "Chemical", "char_span": [245, 253], "ent_id": "D007980", "tok_span": [71, 74]}, {"name": "dyskinesias", "ent_type": "Disease", "char_span": [262, 273], "ent_id": "D004409", "tok_span": [76, 80]}], "relation_list": [{"subject": "levodopa", "object": "dyskinesias", "sbj_char_span": [245, 253], "obj_char_span": [262, 273], "rel_type": "chemical-induced disease", "sbj_tok_span": [71, 74], "obj_tok_span": [76, 80]}], "umls_entity_list": []}, {"text": "Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats.", "entity_list": [{"name": "nephrosis", "ent_type": "Disease", "char_span": [64, 73], "ent_id": "D009401", "tok_span": [15, 17]}, {"name": "puromycin aminonucleoside", "ent_type": "Chemical", "char_span": [38, 63], "ent_id": "D011692", "tok_span": [10, 15]}], "relation_list": [{"subject": "puromycin aminonucleoside", "object": "nephrosis", "sbj_char_span": [38, 63], "obj_char_span": [64, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 15], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced nephrosis, which is an experimental model of human nephrotic syndrome.", "entity_list": [{"name": "puromycin aminonucleoside", "ent_type": "Chemical", "char_span": [101, 126], "ent_id": "D011692", "tok_span": [20, 25]}, {"name": "nephrotic syndrome", "ent_type": "Disease", "char_span": [186, 204], "ent_id": "D009404", "tok_span": [37, 40]}, {"name": "nephrosis", "ent_type": "Disease", "char_span": [135, 144], "ent_id": "D009401", "tok_span": [27, 29]}], "relation_list": [{"subject": "puromycin aminonucleoside", "object": "nephrosis", "sbj_char_span": [101, 126], "obj_char_span": [135, 144], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 25], "obj_tok_span": [27, 29]}], "umls_entity_list": []}, {"text": "Reverse or inverted left ventricular apical ballooning syndrome (reverse Takotsubo cardiomyopathy) in a young woman in the setting of amphetamine use.", "entity_list": [{"name": "left ventricular apical ballooning syndrome", "ent_type": "Disease", "char_span": [20, 63], "ent_id": "D054549", "tok_span": [3, 9]}, {"name": "Takotsubo cardiomyopathy", "ent_type": "Disease", "char_span": [73, 97], "ent_id": "D054549", "tok_span": [11, 16]}, {"name": "amphetamine", "ent_type": "Chemical", "char_span": [134, 145], "ent_id": "D000661", "tok_span": [25, 29]}], "relation_list": [{"subject": "amphetamine", "object": "Takotsubo cardiomyopathy", "sbj_char_span": [134, 145], "obj_char_span": [73, 97], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 29], "obj_tok_span": [11, 16]}, {"subject": "amphetamine", "object": "left ventricular apical ballooning syndrome", "sbj_char_span": [134, 145], "obj_char_span": [20, 63], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 29], "obj_tok_span": [3, 9]}], "umls_entity_list": []}, {"text": "In this article, we report an interesting case of a young woman who presented with this rare type of reverse apical ballooning syndrome occurring after amphetamine use.", "entity_list": [{"name": "amphetamine", "ent_type": "Chemical", "char_span": [152, 163], "ent_id": "D000661", "tok_span": [27, 31]}, {"name": "apical ballooning syndrome", "ent_type": "Disease", "char_span": [109, 135], "ent_id": "D054549", "tok_span": [21, 25]}], "relation_list": [{"subject": "amphetamine", "object": "apical ballooning syndrome", "sbj_char_span": [152, 163], "obj_char_span": [109, 135], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 31], "obj_tok_span": [21, 25]}], "umls_entity_list": []}, {"text": "Amphetamine-induced locomotor hyperactivity was similar in all groups.", "entity_list": [{"name": "Amphetamine", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D000661", "tok_span": [0, 5]}, {"name": "locomotor hyperactivity", "ent_type": "Disease", "char_span": [20, 43], "ent_id": "D006948", "tok_span": [7, 10]}], "relation_list": [{"subject": "Amphetamine", "object": "locomotor hyperactivity", "sbj_char_span": [0, 11], "obj_char_span": [20, 43], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "Peripheral iron dextran induced degeneration of dopaminergic neurons in rat substantia nigra.", "entity_list": [{"name": "iron dextran", "ent_type": "Chemical", "char_span": [11, 23], "ent_id": "D007505", "tok_span": [1, 4]}, {"name": "degeneration of dopaminergic neurons", "ent_type": "Disease", "char_span": [32, 68], "ent_id": "D009410", "tok_span": [5, 9]}], "relation_list": [{"subject": "iron dextran", "object": "degeneration of dopaminergic neurons", "sbj_char_span": [11, 23], "obj_char_span": [32, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 4], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.", "entity_list": [{"name": "degeneration of dopaminergic neurons", "ent_type": "Disease", "char_span": [330, 366], "ent_id": "D009410", "tok_span": [60, 64]}, {"name": "iron", "ent_type": "Chemical", "char_span": [51, 55], "ent_id": "D007501", "tok_span": [6, 7]}, {"name": "iron", "ent_type": "Chemical", "char_span": [233, 237], "ent_id": "D007501", "tok_span": [46, 47]}, {"name": "tyrosine", "ent_type": "Chemical", "char_span": [178, 186], "ent_id": "D014443", "tok_span": [34, 35]}, {"name": "iron", "ent_type": "Chemical", "char_span": [381, 385], "ent_id": "D007501", "tok_span": [66, 67]}, {"name": "iron dextran", "ent_type": "Chemical", "char_span": [407, 419], "ent_id": "D007505", "tok_span": [72, 75]}], "relation_list": [{"subject": "iron dextran", "object": "degeneration of dopaminergic neurons", "sbj_char_span": [407, 419], "obj_char_span": [330, 366], "rel_type": "chemical-induced disease", "sbj_tok_span": [72, 75], "obj_tok_span": [60, 64]}], "umls_entity_list": []}, {"text": "These results suggest that peripheral iron dextran can increase the iron level in the SN, where excessive iron causes the degeneration of dopaminergic neurons.", "entity_list": [{"name": "iron", "ent_type": "Chemical", "char_span": [106, 110], "ent_id": "D007501", "tok_span": [19, 20]}, {"name": "iron", "ent_type": "Chemical", "char_span": [68, 72], "ent_id": "D007501", "tok_span": [11, 12]}, {"name": "iron dextran", "ent_type": "Chemical", "char_span": [38, 50], "ent_id": "D007505", "tok_span": [5, 8]}, {"name": "degeneration of dopaminergic neurons", "ent_type": "Disease", "char_span": [122, 158], "ent_id": "D009410", "tok_span": [22, 26]}], "relation_list": [{"subject": "iron dextran", "object": "degeneration of dopaminergic neurons", "sbj_char_span": [38, 50], "obj_char_span": [122, 158], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "The results of skin lesion biopsies were available in 3 patients, confirming LV Cutaneous lesions resolved in all patients after warfarin was discontinued.", "entity_list": [{"name": "warfarin", "ent_type": "Chemical", "char_span": [129, 137], "ent_id": "D014859", "tok_span": [22, 23]}, {"name": "skin lesion", "ent_type": "Disease", "char_span": [15, 26], "ent_id": "D012871", "tok_span": [3, 5]}, {"name": "LV Cutaneous lesions", "ent_type": "Disease", "char_span": [77, 97], "ent_id": "D018366", "tok_span": [13, 17]}], "relation_list": [{"subject": "warfarin", "object": "LV Cutaneous lesions", "sbj_char_span": [129, 137], "obj_char_span": [77, 97], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "Second, we investigated the effect of IT MK-801 (30 mug) on the histopathologic changes in the spinal cord after morphine-induced spastic paraparesis.", "entity_list": [{"name": "spastic paraparesis", "ent_type": "Disease", "char_span": [130, 149], "ent_id": "D020336", "tok_span": [30, 35]}, {"name": "MK-801", "ent_type": "Chemical", "char_span": [41, 47], "ent_id": "D016291", "tok_span": [8, 12]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [113, 121], "ent_id": "D009020", "tok_span": [27, 28]}], "relation_list": [{"subject": "morphine", "object": "spastic paraparesis", "sbj_char_span": [113, 121], "obj_char_span": [130, 149], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 28], "obj_tok_span": [30, 35]}], "umls_entity_list": []}, {"text": "IT MK-801 significantly reduced the number of dark-stained alpha-motoneurons after morphine-induced spastic paraparesis compared with the saline group.", "entity_list": [{"name": "morphine", "ent_type": "Chemical", "char_span": [83, 91], "ent_id": "D009020", "tok_span": [19, 20]}, {"name": "spastic paraparesis", "ent_type": "Disease", "char_span": [100, 119], "ent_id": "D020336", "tok_span": [22, 27]}, {"name": "MK-801", "ent_type": "Chemical", "char_span": [3, 9], "ent_id": "D016291", "tok_span": [1, 5]}], "relation_list": [{"subject": "morphine", "object": "spastic paraparesis", "sbj_char_span": [83, 91], "obj_char_span": [100, 119], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 20], "obj_tok_span": [22, 27]}], "umls_entity_list": []}, {"text": "These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.", "entity_list": [{"name": "glutamate", "ent_type": "Chemical", "char_span": [100, 109], "ent_id": "D018698", "tok_span": [18, 19]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [28, 36], "ent_id": "D009020", "tok_span": [5, 6]}, {"name": "spastic paraparesis", "ent_type": "Disease", "char_span": [45, 64], "ent_id": "D020336", "tok_span": [7, 12]}, {"name": "NMDA", "ent_type": "Chemical", "char_span": [132, 136], "ent_id": "D016202", "tok_span": [24, 25]}], "relation_list": [{"subject": "morphine", "object": "spastic paraparesis", "sbj_char_span": [28, 36], "obj_char_span": [45, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 6], "obj_tok_span": [7, 12]}], "umls_entity_list": []}, {"text": "In contrast, the conduction velocity, the number and size of axons in the optic nerve, and the specific localization of Na(v)1.6 channels in the nodes of Ranvier were unchanged. beta2(-/-) mice displayed increased susceptibility to seizures, as indicated by reduced latency and threshold for pilocarpine-induced seizures, but seemed normal in other neurological tests.", "entity_list": [{"name": "Na", "ent_type": "Chemical", "char_span": [120, 122], "ent_id": "D012964", "tok_span": [23, 24]}, {"name": "seizures", "ent_type": "Disease", "char_span": [312, 320], "ent_id": "D012640", "tok_span": [67, 68]}, {"name": "seizures", "ent_type": "Disease", "char_span": [232, 240], "ent_id": "D012640", "tok_span": [52, 53]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [292, 303], "ent_id": "D010862", "tok_span": [62, 65]}], "relation_list": [{"subject": "pilocarpine", "object": "seizures", "sbj_char_span": [292, 303], "obj_char_span": [312, 320], "rel_type": "chemical-induced disease", "sbj_tok_span": [62, 65], "obj_tok_span": [67, 68]}, {"subject": "pilocarpine", "object": "seizures", "sbj_char_span": [292, 303], "obj_char_span": [232, 240], "rel_type": "chemical-induced disease", "sbj_tok_span": [62, 65], "obj_tok_span": [52, 53]}], "umls_entity_list": []}, {"text": "The objective of this study was to explore the functional anatomy of the globus pallidus internus (GPi) by studying the effects of unilateral pallidotomy on parkinsonian 'off' signs and levodopa-induced dyskinesias (LID).", "entity_list": [{"name": "LID", "ent_type": "Disease", "char_span": [216, 219], "ent_id": "D004409", "tok_span": [53, 55]}, {"name": "parkinsonian", "ent_type": "Disease", "char_span": [157, 169], "ent_id": "D010300", "tok_span": [35, 38]}, {"name": "dyskinesias", "ent_type": "Disease", "char_span": [203, 214], "ent_id": "D004409", "tok_span": [48, 52]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [186, 194], "ent_id": "D007980", "tok_span": [43, 46]}], "relation_list": [{"subject": "levodopa", "object": "LID", "sbj_char_span": [186, 194], "obj_char_span": [216, 219], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 46], "obj_tok_span": [53, 55]}, {"subject": "levodopa", "object": "dyskinesias", "sbj_char_span": [186, 194], "obj_char_span": [203, 214], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 46], "obj_tok_span": [48, 52]}], "umls_entity_list": []}, {"text": "We found significant positive correlations between the preoperative levodopa responsiveness of motor signs and the levodopa responsiveness of scores in timed tests (Core Assessment Program for Intracerebral Transplantations) in the contralateral limbs and the improvement in these scores after surgery, whereas there was no correlation with the improvement in LID.", "entity_list": [{"name": "LID", "ent_type": "Disease", "char_span": [360, 363], "ent_id": "D004409", "tok_span": [60, 62]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [115, 123], "ent_id": "D007980", "tok_span": [17, 20]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [68, 76], "ent_id": "D007980", "tok_span": [8, 11]}], "relation_list": [{"subject": "levodopa", "object": "LID", "sbj_char_span": [115, 123], "obj_char_span": [360, 363], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [60, 62]}, {"subject": "levodopa", "object": "LID", "sbj_char_span": [68, 76], "obj_char_span": [360, 363], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [60, 62]}], "umls_entity_list": []}, {"text": "The differential predictive value of levodopa responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.", "entity_list": [{"name": "parkinsonian", "ent_type": "Disease", "char_span": [190, 202], "ent_id": "D010300", "tok_span": [37, 40]}, {"name": "dyskinesias", "ent_type": "Disease", "char_span": [174, 185], "ent_id": "D004409", "tok_span": [32, 36]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [37, 45], "ent_id": "D007980", "tok_span": [5, 8]}, {"name": "dyskinesias", "ent_type": "Disease", "char_span": [353, 364], "ent_id": "D004409", "tok_span": [67, 71]}, {"name": "LID", "ent_type": "Disease", "char_span": [109, 112], "ent_id": "D004409", "tok_span": [21, 23]}, {"name": "parkinsonian", "ent_type": "Disease", "char_span": [80, 92], "ent_id": "D010300", "tok_span": [13, 16]}, {"name": "parkinsonian", "ent_type": "Disease", "char_span": [324, 336], "ent_id": "D010300", "tok_span": [59, 62]}], "relation_list": [{"subject": "levodopa", "object": "dyskinesias", "sbj_char_span": [37, 45], "obj_char_span": [174, 185], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [32, 36]}, {"subject": "levodopa", "object": "dyskinesias", "sbj_char_span": [37, 45], "obj_char_span": [353, 364], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [67, 71]}, {"subject": "levodopa", "object": "LID", "sbj_char_span": [37, 45], "obj_char_span": [109, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "METHODS: Puromycin aminonucleoside (PAN) was administered to Sprague Dawley rats to induce proteinuria.", "entity_list": [{"name": "Puromycin aminonucleoside", "ent_type": "Chemical", "char_span": [9, 34], "ent_id": "D011692", "tok_span": [2, 7]}, {"name": "proteinuria", "ent_type": "Disease", "char_span": [91, 102], "ent_id": "D011507", "tok_span": [19, 20]}, {"name": "PAN", "ent_type": "Chemical", "char_span": [36, 39], "ent_id": "D011692", "tok_span": [8, 9]}], "relation_list": [{"subject": "Puromycin aminonucleoside", "object": "proteinuria", "sbj_char_span": [9, 34], "obj_char_span": [91, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 7], "obj_tok_span": [19, 20]}, {"subject": "PAN", "object": "proteinuria", "sbj_char_span": [36, 39], "obj_char_span": [91, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [19, 20]}], "umls_entity_list": []}, {"text": "A case of acute inflammatory myopathy associated with the use of pravastatin, a new hydrophilic 3-hydroxy-3 methylglutaril coenzyme A reductase inhibitor, is reported.", "entity_list": [{"name": "inflammatory myopathy", "ent_type": "Disease", "char_span": [16, 37], "ent_id": "D009220", "tok_span": [4, 7]}, {"name": "pravastatin", "ent_type": "Chemical", "char_span": [65, 76], "ent_id": "D017035", "tok_span": [12, 16]}], "relation_list": [{"subject": "pravastatin", "object": "inflammatory myopathy", "sbj_char_span": [65, 76], "obj_char_span": [16, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 16], "obj_tok_span": [4, 7]}], "umls_entity_list": []}, {"text": "Dose-effect and structure-function relationships in doxorubicin cardiomyopathy.", "entity_list": [{"name": "cardiomyopathy", "ent_type": "Disease", "char_span": [64, 78], "ent_id": "D009202", "tok_span": [10, 11]}, {"name": "doxorubicin", "ent_type": "Chemical", "char_span": [52, 63], "ent_id": "D004317", "tok_span": [9, 10]}], "relation_list": [{"subject": "doxorubicin", "object": "cardiomyopathy", "sbj_char_span": [52, 63], "obj_char_span": [64, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [10, 11]}], "umls_entity_list": []}, {"text": "The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.", "entity_list": [{"name": "cardiomyopathy", "ent_type": "Disease", "char_span": [4, 18], "ent_id": "D009202", "tok_span": [1, 2]}, {"name": "CM", "ent_type": "Disease", "char_span": [20, 22], "ent_id": "D009202", "tok_span": [3, 4]}, {"name": "Adriamycin", "ent_type": "Chemical", "char_span": [75, 85], "ent_id": "D004317", "tok_span": [16, 20]}, {"name": "DXR", "ent_type": "Chemical", "char_span": [69, 72], "ent_id": "D004317", "tok_span": [12, 14]}, {"name": "myocardial disease", "ent_type": "Disease", "char_span": [199, 217], "ent_id": "D009202", "tok_span": [38, 40]}, {"name": "doxorubicin", "ent_type": "Chemical", "char_span": [56, 67], "ent_id": "D004317", "tok_span": [10, 11]}], "relation_list": [{"subject": "DXR", "object": "CM", "sbj_char_span": [69, 72], "obj_char_span": [20, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 14], "obj_tok_span": [3, 4]}, {"subject": "doxorubicin", "object": "cardiomyopathy", "sbj_char_span": [56, 67], "obj_char_span": [4, 18], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [1, 2]}, {"subject": "Adriamycin", "object": "cardiomyopathy", "sbj_char_span": [75, 85], "obj_char_span": [4, 18], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 20], "obj_tok_span": [1, 2]}, {"subject": "Adriamycin", "object": "CM", "sbj_char_span": [75, 85], "obj_char_span": [20, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 20], "obj_tok_span": [3, 4]}, {"subject": "doxorubicin", "object": "CM", "sbj_char_span": [56, 67], "obj_char_span": [20, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [3, 4]}, {"subject": "DXR", "object": "myocardial disease", "sbj_char_span": [69, 72], "obj_char_span": [199, 217], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 14], "obj_tok_span": [38, 40]}, {"subject": "doxorubicin", "object": "myocardial disease", "sbj_char_span": [56, 67], "obj_char_span": [199, 217], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [38, 40]}, {"subject": "DXR", "object": "cardiomyopathy", "sbj_char_span": [69, 72], "obj_char_span": [4, 18], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 14], "obj_tok_span": [1, 2]}, {"subject": "Adriamycin", "object": "myocardial disease", "sbj_char_span": [75, 85], "obj_char_span": [199, 217], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 20], "obj_tok_span": [38, 40]}], "umls_entity_list": []}, {"text": "In DXR-CM myocardial damage is proportional to the degree of cytotoxic insult (DXR dose) while myocardial function is preserved until a critical dose or degree of damage is reached, after which myocardial performance deteriorates rapidly.", "entity_list": [{"name": "DXR", "ent_type": "Chemical", "char_span": [79, 82], "ent_id": "D004317", "tok_span": [17, 19]}, {"name": "DXR", "ent_type": "Chemical", "char_span": [3, 6], "ent_id": "D004317", "tok_span": [1, 3]}, {"name": "CM", "ent_type": "Disease", "char_span": [7, 9], "ent_id": "D009202", "tok_span": [4, 5]}, {"name": "myocardial damage", "ent_type": "Disease", "char_span": [10, 27], "ent_id": "D009202", "tok_span": [5, 7]}], "relation_list": [{"subject": "DXR", "object": "myocardial damage", "sbj_char_span": [79, 82], "obj_char_span": [10, 27], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 19], "obj_tok_span": [5, 7]}, {"subject": "DXR", "object": "CM", "sbj_char_span": [3, 6], "obj_char_span": [7, 9], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 3], "obj_tok_span": [4, 5]}, {"subject": "DXR", "object": "CM", "sbj_char_span": [79, 82], "obj_char_span": [7, 9], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 19], "obj_tok_span": [4, 5]}, {"subject": "DXR", "object": "myocardial damage", "sbj_char_span": [3, 6], "obj_char_span": [10, 27], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 3], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol.", "entity_list": [{"name": "aplastic anemia", "ent_type": "Disease", "char_span": [6, 21], "ent_id": "D000741", "tok_span": [2, 5]}, {"name": "chloramphenicol", "ent_type": "Chemical", "char_span": [69, 84], "ent_id": "D002701", "tok_span": [11, 15]}], "relation_list": [{"subject": "chloramphenicol", "object": "aplastic anemia", "sbj_char_span": [69, 84], "obj_char_span": [6, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [2, 5]}], "umls_entity_list": []}, {"text": "A 73-year-old woman died of aplastic anemia less than two months after undergoing cataract extraction and beginning topical therapy with chloramphenicol.", "entity_list": [{"name": "cataract", "ent_type": "Disease", "char_span": [82, 90], "ent_id": "D002386", "tok_span": [18, 19]}, {"name": "aplastic anemia", "ent_type": "Disease", "char_span": [28, 43], "ent_id": "D000741", "tok_span": [9, 12]}, {"name": "chloramphenicol", "ent_type": "Chemical", "char_span": [137, 152], "ent_id": "D002701", "tok_span": [25, 29]}], "relation_list": [{"subject": "chloramphenicol", "object": "aplastic anemia", "sbj_char_span": [137, 152], "obj_char_span": [28, 43], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 29], "obj_tok_span": [9, 12]}], "umls_entity_list": []}, {"text": "The pattern of the aplastic anemia was associated with an idiosyncratic response to chloramphenicol.", "entity_list": [{"name": "aplastic anemia", "ent_type": "Disease", "char_span": [19, 34], "ent_id": "D000741", "tok_span": [4, 7]}, {"name": "chloramphenicol", "ent_type": "Chemical", "char_span": [84, 99], "ent_id": "D002701", "tok_span": [17, 21]}], "relation_list": [{"subject": "chloramphenicol", "object": "aplastic anemia", "sbj_char_span": [84, 99], "obj_char_span": [19, 34], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [4, 7]}], "umls_entity_list": []}, {"text": "This was the second report of fatal aplastic anemia after topical treatment with chloramphenicol for ocular conditions, although two cases of reversible bone marrow hypoplasia have also been reported.", "entity_list": [{"name": "aplastic anemia", "ent_type": "Disease", "char_span": [36, 51], "ent_id": "D000741", "tok_span": [7, 10]}, {"name": "chloramphenicol", "ent_type": "Chemical", "char_span": [81, 96], "ent_id": "D002701", "tok_span": [14, 18]}, {"name": "bone marrow hypoplasia", "ent_type": "Disease", "char_span": [153, 175], "ent_id": "D001855", "tok_span": [27, 31]}], "relation_list": [{"subject": "chloramphenicol", "object": "aplastic anemia", "sbj_char_span": [81, 96], "obj_char_span": [36, 51], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 18], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "Bradycardia due to trihexyphenidyl hydrochloride.", "entity_list": [{"name": "trihexyphenidyl hydrochloride", "ent_type": "Chemical", "char_span": [19, 48], "ent_id": "D014282", "tok_span": [4, 11]}, {"name": "Bradycardia", "ent_type": "Disease", "char_span": [0, 11], "ent_id": "D001919", "tok_span": [0, 2]}], "relation_list": [{"subject": "trihexyphenidyl hydrochloride", "object": "Bradycardia", "sbj_char_span": [19, 48], "obj_char_span": [0, 11], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 11], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Experimental cyclosporine nephrotoxicity: risk of concomitant chemotherapy.", "entity_list": [{"name": "nephrotoxicity", "ent_type": "Disease", "char_span": [26, 40], "ent_id": "D007674", "tok_span": [3, 6]}, {"name": "cyclosporine", "ent_type": "Chemical", "char_span": [13, 25], "ent_id": "D016572", "tok_span": [1, 3]}], "relation_list": [{"subject": "cyclosporine", "object": "nephrotoxicity", "sbj_char_span": [13, 25], "obj_char_span": [26, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 3], "obj_tok_span": [3, 6]}], "umls_entity_list": []}, {"text": "The role of cyclosporine (CSA) alone or in combination with various chemotherapeutics in the development of renal toxicity was evaluated in rats.", "entity_list": [{"name": "renal toxicity", "ent_type": "Disease", "char_span": [108, 122], "ent_id": "D007674", "tok_span": [22, 24]}, {"name": "CSA", "ent_type": "Chemical", "char_span": [26, 29], "ent_id": "D016572", "tok_span": [6, 7]}, {"name": "cyclosporine", "ent_type": "Chemical", "char_span": [12, 24], "ent_id": "D016572", "tok_span": [3, 5]}], "relation_list": [{"subject": "cyclosporine", "object": "renal toxicity", "sbj_char_span": [12, 24], "obj_char_span": [108, 122], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 5], "obj_tok_span": [22, 24]}, {"subject": "CSA", "object": "renal toxicity", "sbj_char_span": [26, 29], "obj_char_span": [108, 122], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [22, 24]}], "umls_entity_list": []}, {"text": "The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.", "entity_list": [{"name": "CSA", "ent_type": "Chemical", "char_span": [31, 34], "ent_id": "D016572", "tok_span": [4, 5]}, {"name": "CSA", "ent_type": "Chemical", "char_span": [255, 258], "ent_id": "D016572", "tok_span": [51, 52]}, {"name": "nephrotoxic", "ent_type": "Disease", "char_span": [77, 88], "ent_id": "D007674", "tok_span": [13, 16]}, {"name": "amphothericin B", "ent_type": "Chemical", "char_span": [143, 158], "ent_id": "D000666", "tok_span": [28, 32]}, {"name": "gentamicin", "ent_type": "Chemical", "char_span": [108, 118], "ent_id": "D005839", "tok_span": [20, 22]}, {"name": "ketoconazole", "ent_type": "Chemical", "char_span": [163, 175], "ent_id": "D007654", "tok_span": [33, 36]}, {"name": "toxicity", "ent_type": "Disease", "char_span": [267, 275], "ent_id": "D064420", "tok_span": [53, 54]}], "relation_list": [{"subject": "CSA", "object": "nephrotoxic", "sbj_char_span": [31, 34], "obj_char_span": [77, 88], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [13, 16]}, {"subject": "CSA", "object": "nephrotoxic", "sbj_char_span": [255, 258], "obj_char_span": [77, 88], "rel_type": "chemical-induced disease", "sbj_tok_span": [51, 52], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "Gentamicin at toxic doses, however, increased CSA nephrotoxicity.", "entity_list": [{"name": "CSA", "ent_type": "Chemical", "char_span": [46, 49], "ent_id": "D016572", "tok_span": [11, 12]}, {"name": "Gentamicin", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D005839", "tok_span": [0, 4]}, {"name": "nephrotoxicity", "ent_type": "Disease", "char_span": [50, 64], "ent_id": "D007674", "tok_span": [12, 15]}], "relation_list": [{"subject": "CSA", "object": "nephrotoxicity", "sbj_char_span": [46, 49], "obj_char_span": [50, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [12, 15]}], "umls_entity_list": []}, {"text": "Thus, the nephrotoxicity induced by CSA has a different pathogenetic mechanism.", "entity_list": [{"name": "nephrotoxicity", "ent_type": "Disease", "char_span": [10, 24], "ent_id": "D007674", "tok_span": [3, 6]}, {"name": "CSA", "ent_type": "Chemical", "char_span": [36, 39], "ent_id": "D016572", "tok_span": [8, 9]}], "relation_list": [{"subject": "CSA", "object": "nephrotoxicity", "sbj_char_span": [36, 39], "obj_char_span": [10, 24], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [3, 6]}], "umls_entity_list": []}, {"text": "Receptor mechanisms of nicotine-induced locomotor hyperactivity in chronic nicotine-treated rats.", "entity_list": [{"name": "nicotine", "ent_type": "Chemical", "char_span": [75, 83], "ent_id": "D009538", "tok_span": [11, 12]}, {"name": "nicotine", "ent_type": "Chemical", "char_span": [23, 31], "ent_id": "D009538", "tok_span": [3, 4]}, {"name": "locomotor hyperactivity", "ent_type": "Disease", "char_span": [40, 63], "ent_id": "D006948", "tok_span": [6, 9]}], "relation_list": [{"subject": "nicotine", "object": "locomotor hyperactivity", "sbj_char_span": [23, 31], "obj_char_span": [40, 63], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [6, 9]}, {"subject": "nicotine", "object": "locomotor hyperactivity", "sbj_char_span": [75, 83], "obj_char_span": [40, 63], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [6, 9]}], "umls_entity_list": []}, {"text": "These results suggest that chronic nicotine-treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum.", "entity_list": [{"name": "nicotine", "ent_type": "Chemical", "char_span": [35, 43], "ent_id": "D009538", "tok_span": [5, 6]}, {"name": "locomotor hyperactivity", "ent_type": "Disease", "char_span": [65, 88], "ent_id": "D006948", "tok_span": [10, 13]}, {"name": "nicotine", "ent_type": "Chemical", "char_span": [104, 112], "ent_id": "D009538", "tok_span": [16, 17]}, {"name": "DA", "ent_type": "Chemical", "char_span": [226, 228], "ent_id": "D004298", "tok_span": [36, 37]}, {"name": "DA", "ent_type": "Chemical", "char_span": [187, 189], "ent_id": "D004298", "tok_span": [30, 31]}], "relation_list": [{"subject": "nicotine", "object": "locomotor hyperactivity", "sbj_char_span": [104, 112], "obj_char_span": [65, 88], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 17], "obj_tok_span": [10, 13]}, {"subject": "nicotine", "object": "locomotor hyperactivity", "sbj_char_span": [35, 43], "obj_char_span": [65, 88], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 6], "obj_tok_span": [10, 13]}], "umls_entity_list": []}, {"text": "Hydrocortisone-induced hypertension in humans: pressor responsiveness and sympathetic function.", "entity_list": [{"name": "hypertension", "ent_type": "Disease", "char_span": [23, 35], "ent_id": "D006973", "tok_span": [6, 7]}, {"name": "Hydrocortisone", "ent_type": "Chemical", "char_span": [0, 14], "ent_id": "D006854", "tok_span": [0, 4]}], "relation_list": [{"subject": "Hydrocortisone", "object": "hypertension", "sbj_char_span": [0, 14], "obj_char_span": [23, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [6, 7]}], "umls_entity_list": []}, {"text": "The rise in resting blood pressure with hydrocortisone is associated with an increased cardiac output (presumably due to increased blood volume).", "entity_list": [{"name": "rise in resting blood pressure", "ent_type": "Disease", "char_span": [4, 34], "ent_id": "D006973", "tok_span": [1, 6]}, {"name": "increased cardiac output", "ent_type": "Disease", "char_span": [77, 101], "ent_id": "D016534", "tok_span": [15, 18]}, {"name": "hydrocortisone", "ent_type": "Chemical", "char_span": [40, 54], "ent_id": "D006854", "tok_span": [7, 11]}], "relation_list": [{"subject": "hydrocortisone", "object": "rise in resting blood pressure", "sbj_char_span": [40, 54], "obj_char_span": [4, 34], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [1, 6]}], "umls_entity_list": []}, {"text": "Although suprofen has been associated with the development of acute renal failure in greater than 100 subjects, the mechanism of damage remains unclear.", "entity_list": [{"name": "suprofen", "ent_type": "Chemical", "char_span": [9, 17], "ent_id": "D013496", "tok_span": [1, 3]}, {"name": "acute renal failure", "ent_type": "Disease", "char_span": [62, 81], "ent_id": "D058186", "tok_span": [10, 13]}], "relation_list": [{"subject": "suprofen", "object": "acute renal failure", "sbj_char_span": [9, 17], "obj_char_span": [62, 81], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 3], "obj_tok_span": [10, 13]}], "umls_entity_list": []}, {"text": "In summary, suprofen causes acute declines in renal function, most likely by directly altering the intrarenal distribution of uric acid.", "entity_list": [{"name": "uric acid", "ent_type": "Chemical", "char_span": [126, 135], "ent_id": "D014527", "tok_span": [22, 25]}, {"name": "acute declines in renal function", "ent_type": "Disease", "char_span": [28, 60], "ent_id": "D058186", "tok_span": [6, 11]}, {"name": "suprofen", "ent_type": "Chemical", "char_span": [12, 20], "ent_id": "D013496", "tok_span": [3, 5]}], "relation_list": [{"subject": "suprofen", "object": "acute declines in renal function", "sbj_char_span": [12, 20], "obj_char_span": [28, 60], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 5], "obj_tok_span": [6, 11]}], "umls_entity_list": []}, {"text": "Cocaine-induced brainstem seizures and behavior.", "entity_list": [{"name": "Cocaine", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "D003042", "tok_span": [0, 3]}, {"name": "seizures", "ent_type": "Disease", "char_span": [26, 34], "ent_id": "D012640", "tok_span": [6, 7]}], "relation_list": [{"subject": "Cocaine", "object": "seizures", "sbj_char_span": [0, 7], "obj_char_span": [26, 34], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [6, 7]}], "umls_entity_list": []}, {"text": "Increased sulfation and decreased 7alpha-hydroxylation of deoxycholic acid in ethinyl estradiol-induced cholestasis in rats.", "entity_list": [{"name": "ethinyl estradiol", "ent_type": "Chemical", "char_span": [78, 95], "ent_id": "D004997", "tok_span": [16, 20]}, {"name": "cholestasis", "ent_type": "Disease", "char_span": [104, 115], "ent_id": "D002779", "tok_span": [22, 25]}, {"name": "deoxycholic acid", "ent_type": "Chemical", "char_span": [58, 74], "ent_id": "D003840", "tok_span": [11, 15]}], "relation_list": [{"subject": "ethinyl estradiol", "object": "cholestasis", "sbj_char_span": [78, 95], "obj_char_span": [104, 115], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 20], "obj_tok_span": [22, 25]}], "umls_entity_list": []}, {"text": "We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure left ventricular end-diastolic volume falls after ouabain administration even when it is initially normal.", "entity_list": [{"name": "coronary artery disease", "ent_type": "Disease", "char_span": [42, 65], "ent_id": "D003324", "tok_span": [7, 10]}, {"name": "ouabain", "ent_type": "Chemical", "char_span": [165, 172], "ent_id": "D010042", "tok_span": [28, 31]}, {"name": "congestive heart failure", "ent_type": "Disease", "char_span": [90, 114], "ent_id": "D006333", "tok_span": [15, 20]}, {"name": "left ventricular end-diastolic volume falls", "ent_type": "Disease", "char_span": [115, 158], "ent_id": "D002303", "tok_span": [20, 27]}], "relation_list": [{"subject": "ouabain", "object": "left ventricular end-diastolic volume falls", "sbj_char_span": [165, 172], "obj_char_span": [115, 158], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 31], "obj_tok_span": [20, 27]}], "umls_entity_list": []}, {"text": "Prolongation of the QT interval related to cisapride-diltiazem interaction.", "entity_list": [{"name": "cisapride", "ent_type": "Chemical", "char_span": [43, 52], "ent_id": "D020117", "tok_span": [9, 13]}, {"name": "diltiazem", "ent_type": "Chemical", "char_span": [53, 62], "ent_id": "D004110", "tok_span": [14, 18]}, {"name": "Prolongation of the QT interval", "ent_type": "Disease", "char_span": [0, 31], "ent_id": "D008133", "tok_span": [0, 7]}], "relation_list": [{"subject": "diltiazem", "object": "Prolongation of the QT interval", "sbj_char_span": [53, 62], "obj_char_span": [0, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 18], "obj_tok_span": [0, 7]}, {"subject": "cisapride", "object": "Prolongation of the QT interval", "sbj_char_span": [43, 52], "obj_char_span": [0, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [0, 7]}], "umls_entity_list": []}, {"text": "Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.", "entity_list": [{"name": "Prolongation of QT interval", "ent_type": "Disease", "char_span": [0, 27], "ent_id": "D008133", "tok_span": [0, 6]}, {"name": "torsades de pointes", "ent_type": "Disease", "char_span": [29, 48], "ent_id": "D016171", "tok_span": [7, 12]}, {"name": "sudden cardiac death", "ent_type": "Disease", "char_span": [54, 74], "ent_id": "D016757", "tok_span": [14, 17]}, {"name": "erythromycin", "ent_type": "Chemical", "char_span": [132, 144], "ent_id": "D004917", "tok_span": [24, 26]}, {"name": "azole", "ent_type": "Chemical", "char_span": [148, 153], "ent_id": "D001393", "tok_span": [27, 29]}], "relation_list": [{"subject": "erythromycin", "object": "torsades de pointes", "sbj_char_span": [132, 144], "obj_char_span": [29, 48], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 26], "obj_tok_span": [7, 12]}, {"subject": "erythromycin", "object": "Prolongation of QT interval", "sbj_char_span": [132, 144], "obj_char_span": [0, 27], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 26], "obj_tok_span": [0, 6]}, {"subject": "erythromycin", "object": "sudden cardiac death", "sbj_char_span": [132, 144], "obj_char_span": [54, 74], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 26], "obj_tok_span": [14, 17]}, {"subject": "azole", "object": "torsades de pointes", "sbj_char_span": [148, 153], "obj_char_span": [29, 48], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 29], "obj_tok_span": [7, 12]}, {"subject": "azole", "object": "sudden cardiac death", "sbj_char_span": [148, 153], "obj_char_span": [54, 74], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 29], "obj_tok_span": [14, 17]}, {"subject": "azole", "object": "Prolongation of QT interval", "sbj_char_span": [148, 153], "obj_char_span": [0, 27], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 29], "obj_tok_span": [0, 6]}], "umls_entity_list": []}, {"text": "Nephrotoxicity occurred in a similar proportion in patients treated with netilmicin and tobramycin (17% vs 11%).", "entity_list": [{"name": "Nephrotoxicity", "ent_type": "Disease", "char_span": [0, 14], "ent_id": "D007674", "tok_span": [0, 3]}, {"name": "netilmicin", "ent_type": "Chemical", "char_span": [73, 83], "ent_id": "D009428", "tok_span": [12, 16]}, {"name": "tobramycin", "ent_type": "Chemical", "char_span": [88, 98], "ent_id": "D014031", "tok_span": [17, 20]}], "relation_list": [{"subject": "netilmicin", "object": "Nephrotoxicity", "sbj_char_span": [73, 83], "obj_char_span": [0, 14], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 16], "obj_tok_span": [0, 3]}, {"subject": "tobramycin", "object": "Nephrotoxicity", "sbj_char_span": [88, 98], "obj_char_span": [0, 14], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.", "entity_list": [{"name": "piperacillin", "ent_type": "Chemical", "char_span": [107, 119], "ent_id": "D010878", "tok_span": [34, 37]}, {"name": "Ototoxicity", "ent_type": "Disease", "char_span": [0, 11], "ent_id": "D006311", "tok_span": [0, 2]}, {"name": "netilmicin", "ent_type": "Chemical", "char_span": [42, 52], "ent_id": "D009428", "tok_span": [13, 17]}, {"name": "piperacillin", "ent_type": "Chemical", "char_span": [57, 69], "ent_id": "D010878", "tok_span": [18, 21]}, {"name": "tobramycin", "ent_type": "Chemical", "char_span": [92, 102], "ent_id": "D014031", "tok_span": [30, 33]}], "relation_list": [{"subject": "piperacillin", "object": "Ototoxicity", "sbj_char_span": [107, 119], "obj_char_span": [0, 11], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 37], "obj_tok_span": [0, 2]}, {"subject": "piperacillin", "object": "Ototoxicity", "sbj_char_span": [57, 69], "obj_char_span": [0, 11], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [0, 2]}, {"subject": "netilmicin", "object": "Ototoxicity", "sbj_char_span": [42, 52], "obj_char_span": [0, 11], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [0, 2]}, {"subject": "tobramycin", "object": "Ototoxicity", "sbj_char_span": [92, 102], "obj_char_span": [0, 11], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 33], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "We conclude that aminoglycoside-associated ototoxicity was less severe and more often reversible with netilmicin than with tobramycin.", "entity_list": [{"name": "aminoglycoside", "ent_type": "Chemical", "char_span": [17, 31], "ent_id": "D000617", "tok_span": [3, 6]}, {"name": "ototoxicity", "ent_type": "Disease", "char_span": [43, 54], "ent_id": "D006311", "tok_span": [8, 10]}, {"name": "netilmicin", "ent_type": "Chemical", "char_span": [102, 112], "ent_id": "D009428", "tok_span": [18, 22]}, {"name": "tobramycin", "ent_type": "Chemical", "char_span": [123, 133], "ent_id": "D014031", "tok_span": [24, 27]}], "relation_list": [{"subject": "tobramycin", "object": "ototoxicity", "sbj_char_span": [123, 133], "obj_char_span": [43, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 27], "obj_tok_span": [8, 10]}, {"subject": "netilmicin", "object": "ototoxicity", "sbj_char_span": [102, 112], "obj_char_span": [43, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 22], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.", "entity_list": [{"name": "bicuculline", "ent_type": "Chemical", "char_span": [206, 217], "ent_id": "D001640", "tok_span": [49, 53]}, {"name": "convulsions", "ent_type": "Disease", "char_span": [125, 136], "ent_id": "D012640", "tok_span": [24, 27]}, {"name": "PGs", "ent_type": "Chemical", "char_span": [51, 54], "ent_id": "D011453", "tok_span": [8, 10]}, {"name": "seizure", "ent_type": "Disease", "char_span": [59, 66], "ent_id": "D012640", "tok_span": [12, 13]}, {"name": "prostaglandins", "ent_type": "Chemical", "char_span": [35, 49], "ent_id": "D011453", "tok_span": [5, 7]}, {"name": "pentetrazol", "ent_type": "Chemical", "char_span": [171, 182], "ent_id": "D010433", "tok_span": [37, 40]}, {"name": "flurothyl", "ent_type": "Chemical", "char_span": [148, 157], "ent_id": "D005481", "tok_span": [29, 32]}, {"name": "PTZ", "ent_type": "Chemical", "char_span": [184, 187], "ent_id": "D010433", "tok_span": [41, 43]}, {"name": "picrotoxin", "ent_type": "Chemical", "char_span": [159, 169], "ent_id": "D010852", "tok_span": [33, 36]}], "relation_list": [{"subject": "pentetrazol", "object": "seizure", "sbj_char_span": [171, 182], "obj_char_span": [59, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 40], "obj_tok_span": [12, 13]}, {"subject": "PTZ", "object": "convulsions", "sbj_char_span": [184, 187], "obj_char_span": [125, 136], "rel_type": "chemical-induced disease", "sbj_tok_span": [41, 43], "obj_tok_span": [24, 27]}, {"subject": "picrotoxin", "object": "seizure", "sbj_char_span": [159, 169], "obj_char_span": [59, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 36], "obj_tok_span": [12, 13]}, {"subject": "bicuculline", "object": "convulsions", "sbj_char_span": [206, 217], "obj_char_span": [125, 136], "rel_type": "chemical-induced disease", "sbj_tok_span": [49, 53], "obj_tok_span": [24, 27]}, {"subject": "PTZ", "object": "seizure", "sbj_char_span": [184, 187], "obj_char_span": [59, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [41, 43], "obj_tok_span": [12, 13]}, {"subject": "flurothyl", "object": "convulsions", "sbj_char_span": [148, 157], "obj_char_span": [125, 136], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 32], "obj_tok_span": [24, 27]}, {"subject": "pentetrazol", "object": "convulsions", "sbj_char_span": [171, 182], "obj_char_span": [125, 136], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 40], "obj_tok_span": [24, 27]}, {"subject": "flurothyl", "object": "seizure", "sbj_char_span": [148, 157], "obj_char_span": [59, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 32], "obj_tok_span": [12, 13]}, {"subject": "picrotoxin", "object": "convulsions", "sbj_char_span": [159, 169], "obj_char_span": [125, 136], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 36], "obj_tok_span": [24, 27]}, {"subject": "bicuculline", "object": "seizure", "sbj_char_span": [206, 217], "obj_char_span": [59, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [49, 53], "obj_tok_span": [12, 13]}], "umls_entity_list": []}, {"text": "These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced convulsions.", "entity_list": [{"name": "convulsions", "ent_type": "Disease", "char_span": [102, 113], "ent_id": "D012640", "tok_span": [24, 27]}, {"name": "convulsions", "ent_type": "Disease", "char_span": [174, 185], "ent_id": "D012640", "tok_span": [47, 50]}, {"name": "bicuculline", "ent_type": "Chemical", "char_span": [154, 165], "ent_id": "D001640", "tok_span": [41, 45]}, {"name": "fluorthyl", "ent_type": "Chemical", "char_span": [75, 84], "ent_id": "D005481", "tok_span": [15, 18]}, {"name": "PGs", "ent_type": "Chemical", "char_span": [27, 30], "ent_id": "D011453", "tok_span": [4, 6]}, {"name": "PTZ", "ent_type": "Chemical", "char_span": [90, 93], "ent_id": "D010433", "tok_span": [20, 22]}, {"name": "picrotoxin", "ent_type": "Chemical", "char_span": [123, 133], "ent_id": "D010852", "tok_span": [30, 33]}], "relation_list": [{"subject": "bicuculline", "object": "convulsions", "sbj_char_span": [154, 165], "obj_char_span": [102, 113], "rel_type": "chemical-induced disease", "sbj_tok_span": [41, 45], "obj_tok_span": [24, 27]}, {"subject": "bicuculline", "object": "convulsions", "sbj_char_span": [154, 165], "obj_char_span": [174, 185], "rel_type": "chemical-induced disease", "sbj_tok_span": [41, 45], "obj_tok_span": [47, 50]}, {"subject": "PTZ", "object": "convulsions", "sbj_char_span": [90, 93], "obj_char_span": [102, 113], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 22], "obj_tok_span": [24, 27]}, {"subject": "fluorthyl", "object": "convulsions", "sbj_char_span": [75, 84], "obj_char_span": [174, 185], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [47, 50]}, {"subject": "picrotoxin", "object": "convulsions", "sbj_char_span": [123, 133], "obj_char_span": [174, 185], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 33], "obj_tok_span": [47, 50]}, {"subject": "fluorthyl", "object": "convulsions", "sbj_char_span": [75, 84], "obj_char_span": [102, 113], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [24, 27]}, {"subject": "picrotoxin", "object": "convulsions", "sbj_char_span": [123, 133], "obj_char_span": [102, 113], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 33], "obj_tok_span": [24, 27]}, {"subject": "PTZ", "object": "convulsions", "sbj_char_span": [90, 93], "obj_char_span": [174, 185], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 22], "obj_tok_span": [47, 50]}], "umls_entity_list": []}, {"text": "Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.", "entity_list": [{"name": "Valproic acid", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D014635", "tok_span": [0, 4]}, {"name": "valproic acid", "ent_type": "Chemical", "char_span": [83, 96], "ent_id": "D014635", "tok_span": [17, 21]}, {"name": "liver toxicity", "ent_type": "Disease", "char_span": [63, 77], "ent_id": "D056486", "tok_span": [13, 15]}], "relation_list": [{"subject": "Valproic acid", "object": "liver toxicity", "sbj_char_span": [0, 13], "obj_char_span": [63, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [13, 15]}, {"subject": "valproic acid", "object": "liver toxicity", "sbj_char_span": [83, 96], "obj_char_span": [63, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "To determine whether there was a temporal relationship between VPA-associated oxidative stress and hepatotoxicity, adult male Sprague-Dawley rats were treated ip with VPA (500 mg/kg) or 0.9% saline (vehicle) once daily for 2, 4, 7, 10, or 14 days.", "entity_list": [{"name": "hepatotoxicity", "ent_type": "Disease", "char_span": [99, 113], "ent_id": "D056486", "tok_span": [16, 18]}, {"name": "VPA", "ent_type": "Chemical", "char_span": [63, 66], "ent_id": "D014635", "tok_span": [9, 11]}, {"name": "VPA", "ent_type": "Chemical", "char_span": [167, 170], "ent_id": "D014635", "tok_span": [30, 32]}], "relation_list": [{"subject": "VPA", "object": "hepatotoxicity", "sbj_char_span": [63, 66], "obj_char_span": [99, 113], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 11], "obj_tok_span": [16, 18]}, {"subject": "VPA", "object": "hepatotoxicity", "sbj_char_span": [167, 170], "obj_char_span": [99, 113], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 32], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.", "entity_list": [{"name": "steatosis", "ent_type": "Disease", "char_span": [159, 168], "ent_id": "D005234", "tok_span": [38, 40]}, {"name": "necrosis", "ent_type": "Disease", "char_span": [149, 157], "ent_id": "D009336", "tok_span": [36, 37]}, {"name": "15-F(2t)-IsoP", "ent_type": "Chemical", "char_span": [106, 119], "ent_id": "C075750", "tok_span": [19, 29]}, {"name": "VPA", "ent_type": "Chemical", "char_span": [38, 41], "ent_id": "D014635", "tok_span": [6, 8]}], "relation_list": [{"subject": "VPA", "object": "steatosis", "sbj_char_span": [38, 41], "obj_char_span": [159, 168], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [38, 40]}, {"subject": "VPA", "object": "necrosis", "sbj_char_span": [38, 41], "obj_char_span": [149, 157], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [36, 37]}], "umls_entity_list": []}, {"text": "CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.", "entity_list": [{"name": "tiapride", "ent_type": "Chemical", "char_span": [157, 165], "ent_id": "D063325", "tok_span": [34, 38]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [54, 66], "ent_id": "D006973", "tok_span": [13, 14]}, {"name": "headache", "ent_type": "Disease", "char_span": [79, 87], "ent_id": "D006261", "tok_span": [16, 17]}, {"name": "vomiting", "ent_type": "Disease", "char_span": [92, 100], "ent_id": "D014839", "tok_span": [18, 19]}, {"name": "amisulpride", "ent_type": "Chemical", "char_span": [134, 145], "ent_id": "C012052", "tok_span": [26, 31]}], "relation_list": [{"subject": "amisulpride", "object": "vomiting", "sbj_char_span": [134, 145], "obj_char_span": [92, 100], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 31], "obj_tok_span": [18, 19]}, {"subject": "tiapride", "object": "hypertension", "sbj_char_span": [157, 165], "obj_char_span": [54, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 38], "obj_tok_span": [13, 14]}, {"subject": "amisulpride", "object": "headache", "sbj_char_span": [134, 145], "obj_char_span": [79, 87], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 31], "obj_tok_span": [16, 17]}, {"subject": "tiapride", "object": "headache", "sbj_char_span": [157, 165], "obj_char_span": [79, 87], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 38], "obj_tok_span": [16, 17]}, {"subject": "tiapride", "object": "vomiting", "sbj_char_span": [157, 165], "obj_char_span": [92, 100], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 38], "obj_tok_span": [18, 19]}, {"subject": "amisulpride", "object": "hypertension", "sbj_char_span": [134, 145], "obj_char_span": [54, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 31], "obj_tok_span": [13, 14]}], "umls_entity_list": []}, {"text": "In our case, use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and tiapride therapy.", "entity_list": [{"name": "hypertensive", "ent_type": "Disease", "char_span": [96, 108], "ent_id": "D006973", "tok_span": [18, 19]}, {"name": "amisulpride", "ent_type": "Chemical", "char_span": [120, 131], "ent_id": "C012052", "tok_span": [21, 26]}, {"name": "tiapride", "ent_type": "Chemical", "char_span": [136, 144], "ent_id": "D063325", "tok_span": [27, 31]}], "relation_list": [{"subject": "amisulpride", "object": "hypertensive", "sbj_char_span": [120, 131], "obj_char_span": [96, 108], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 26], "obj_tok_span": [18, 19]}, {"subject": "tiapride", "object": "hypertensive", "sbj_char_span": [136, 144], "obj_char_span": [96, 108], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 31], "obj_tok_span": [18, 19]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: As of March 24, 2005, this is the first reported case of amisulpride- and tiapride-induced hypertensive crisis in a patient with pheochromocytoma.", "entity_list": [{"name": "tiapride", "ent_type": "Chemical", "char_span": [87, 95], "ent_id": "D063325", "tok_span": [23, 27]}, {"name": "hypertensive", "ent_type": "Disease", "char_span": [104, 116], "ent_id": "D006973", "tok_span": [29, 30]}, {"name": "amisulpride", "ent_type": "Chemical", "char_span": [70, 81], "ent_id": "C012052", "tok_span": [16, 21]}, {"name": "pheochromocytoma", "ent_type": "Disease", "char_span": [142, 158], "ent_id": "D010673", "tok_span": [35, 39]}], "relation_list": [{"subject": "amisulpride", "object": "hypertensive", "sbj_char_span": [70, 81], "obj_char_span": [104, 116], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 21], "obj_tok_span": [29, 30]}, {"subject": "tiapride", "object": "hypertensive", "sbj_char_span": [87, 95], "obj_char_span": [104, 116], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 27], "obj_tok_span": [29, 30]}], "umls_entity_list": []}, {"text": "To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.", "entity_list": [{"name": "psychotic symptoms", "ent_type": "Disease", "char_span": [92, 110], "ent_id": "D011605", "tok_span": [15, 18]}, {"name": "catecholamines", "ent_type": "Chemical", "char_span": [72, 86], "ent_id": "D002395", "tok_span": [11, 13]}, {"name": "amphetamine", "ent_type": "Chemical", "char_span": [185, 196], "ent_id": "D000661", "tok_span": [31, 35]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [201, 208], "ent_id": "D003042", "tok_span": [37, 38]}, {"name": "psychosis", "ent_type": "Disease", "char_span": [217, 226], "ent_id": "D011605", "tok_span": [40, 41]}, {"name": "catecholamine", "ent_type": "Chemical", "char_span": [327, 340], "ent_id": "D002395", "tok_span": [58, 60]}, {"name": "psychiatric", "ent_type": "Disease", "char_span": [135, 146], "ent_id": "D001523", "tok_span": [24, 25]}], "relation_list": [{"subject": "cocaine", "object": "psychosis", "sbj_char_span": [201, 208], "obj_char_span": [217, 226], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 38], "obj_tok_span": [40, 41]}, {"subject": "amphetamine", "object": "psychotic symptoms", "sbj_char_span": [185, 196], "obj_char_span": [92, 110], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 35], "obj_tok_span": [15, 18]}, {"subject": "cocaine", "object": "psychotic symptoms", "sbj_char_span": [201, 208], "obj_char_span": [92, 110], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 38], "obj_tok_span": [15, 18]}, {"subject": "amphetamine", "object": "psychosis", "sbj_char_span": [185, 196], "obj_char_span": [217, 226], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 35], "obj_tok_span": [40, 41]}], "umls_entity_list": []}, {"text": "Methamphetamine or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating.", "entity_list": [{"name": "Methamphetamine", "ent_type": "Chemical", "char_span": [0, 15], "ent_id": "D008694", "tok_span": [0, 3]}, {"name": "hyperkinesia", "ent_type": "Disease", "char_span": [100, 112], "ent_id": "D006948", "tok_span": [20, 24]}, {"name": "amphetamine", "ent_type": "Chemical", "char_span": [19, 30], "ent_id": "D000661", "tok_span": [4, 8]}], "relation_list": [{"subject": "amphetamine", "object": "hyperkinesia", "sbj_char_span": [19, 30], "obj_char_span": [100, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 8], "obj_tok_span": [20, 24]}, {"subject": "Methamphetamine", "object": "hyperkinesia", "sbj_char_span": [0, 15], "obj_char_span": [100, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium.", "entity_list": [{"name": "calcium", "ent_type": "Chemical", "char_span": [100, 107], "ent_id": "D002118", "tok_span": [20, 21]}, {"name": "overdose", "ent_type": "Disease", "char_span": [49, 57], "ent_id": "D062787", "tok_span": [12, 14]}, {"name": "asystolic", "ent_type": "Disease", "char_span": [8, 17], "ent_id": "D006323", "tok_span": [2, 5]}, {"name": "cardiac arrest", "ent_type": "Disease", "char_span": [18, 32], "ent_id": "D006323", "tok_span": [5, 7]}, {"name": "diltiazem", "ent_type": "Chemical", "char_span": [39, 48], "ent_id": "D004110", "tok_span": [8, 12]}], "relation_list": [{"subject": "diltiazem", "object": "overdose", "sbj_char_span": [39, 48], "obj_char_span": [49, 57], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [12, 14]}, {"subject": "diltiazem", "object": "asystolic", "sbj_char_span": [39, 48], "obj_char_span": [8, 17], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [2, 5]}, {"subject": "diltiazem", "object": "cardiac arrest", "sbj_char_span": [39, 48], "obj_char_span": [18, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and alcohol.", "entity_list": [{"name": "paracetamol", "ent_type": "Chemical", "char_span": [74, 85], "ent_id": "D000082", "tok_span": [25, 29]}, {"name": "alcohol", "ent_type": "Chemical", "char_span": [120, 127], "ent_id": "D000431", "tok_span": [39, 40]}, {"name": "isosorbide", "ent_type": "Chemical", "char_span": [96, 106], "ent_id": "D007547", "tok_span": [32, 36]}, {"name": "nitrate", "ent_type": "Chemical", "char_span": [107, 114], "ent_id": "D009566", "tok_span": [36, 37]}, {"name": "overdose", "ent_type": "Disease", "char_span": [31, 39], "ent_id": "D062787", "tok_span": [8, 10]}, {"name": "diltiazem", "ent_type": "Chemical", "char_span": [63, 72], "ent_id": "D004110", "tok_span": [20, 24]}, {"name": "aspirin", "ent_type": "Chemical", "char_span": [87, 94], "ent_id": "D001241", "tok_span": [30, 31]}], "relation_list": [{"subject": "diltiazem", "object": "overdose", "sbj_char_span": [63, 72], "obj_char_span": [31, 39], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 24], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "This case suggests there is a role for aggressive high dose intravenous calcium therapy in severe diltiazem overdose, particularly with the onset of asystole.", "entity_list": [{"name": "calcium", "ent_type": "Chemical", "char_span": [72, 79], "ent_id": "D002118", "tok_span": [12, 13]}, {"name": "asystole", "ent_type": "Disease", "char_span": [149, 157], "ent_id": "D006323", "tok_span": [28, 31]}, {"name": "diltiazem", "ent_type": "Chemical", "char_span": [98, 107], "ent_id": "D004110", "tok_span": [16, 20]}, {"name": "overdose", "ent_type": "Disease", "char_span": [108, 116], "ent_id": "D062787", "tok_span": [20, 22]}], "relation_list": [{"subject": "diltiazem", "object": "asystole", "sbj_char_span": [98, 107], "obj_char_span": [149, 157], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 20], "obj_tok_span": [28, 31]}, {"subject": "diltiazem", "object": "overdose", "sbj_char_span": [98, 107], "obj_char_span": [108, 116], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 20], "obj_tok_span": [20, 22]}], "umls_entity_list": []}, {"text": "It should be considered early in cases of cardiac arrest after diltiazem overdose.", "entity_list": [{"name": "cardiac arrest", "ent_type": "Disease", "char_span": [42, 56], "ent_id": "D006323", "tok_span": [8, 10]}, {"name": "diltiazem", "ent_type": "Chemical", "char_span": [63, 72], "ent_id": "D004110", "tok_span": [11, 15]}, {"name": "overdose", "ent_type": "Disease", "char_span": [73, 81], "ent_id": "D062787", "tok_span": [15, 17]}], "relation_list": [{"subject": "diltiazem", "object": "overdose", "sbj_char_span": [63, 72], "obj_char_span": [73, 81], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [15, 17]}, {"subject": "diltiazem", "object": "cardiac arrest", "sbj_char_span": [63, 72], "obj_char_span": [42, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "Renal papillary necrosis due to naproxen.", "entity_list": [{"name": "Renal papillary necrosis", "ent_type": "Disease", "char_span": [0, 24], "ent_id": "D007681", "tok_span": [0, 3]}, {"name": "naproxen", "ent_type": "Chemical", "char_span": [32, 40], "ent_id": "D009288", "tok_span": [5, 9]}], "relation_list": [{"subject": "naproxen", "object": "Renal papillary necrosis", "sbj_char_span": [32, 40], "obj_char_span": [0, 24], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.", "entity_list": [{"name": "salicylates", "ent_type": "Chemical", "char_span": [122, 133], "ent_id": "D012459", "tok_span": [29, 33]}, {"name": "renal papillary necrosis", "ent_type": "Disease", "char_span": [160, 184], "ent_id": "D007681", "tok_span": [38, 41]}, {"name": "fenoprofen calcium", "ent_type": "Chemical", "char_span": [92, 110], "ent_id": "D005279", "tok_span": [21, 26]}, {"name": "gold", "ent_type": "Chemical", "char_span": [138, 142], "ent_id": "D006046", "tok_span": [34, 35]}, {"name": "RPN", "ent_type": "Disease", "char_span": [186, 189], "ent_id": "D007681", "tok_span": [42, 44]}, {"name": "naproxen", "ent_type": "Chemical", "char_span": [221, 229], "ent_id": "D009288", "tok_span": [50, 54]}, {"name": "rheumatoid arthritis", "ent_type": "Disease", "char_span": [23, 43], "ent_id": "D001172", "tok_span": [8, 10]}, {"name": "sulindac", "ent_type": "Chemical", "char_span": [82, 90], "ent_id": "D013467", "tok_span": [17, 20]}], "relation_list": [{"subject": "naproxen", "object": "renal papillary necrosis", "sbj_char_span": [221, 229], "obj_char_span": [160, 184], "rel_type": "chemical-induced disease", "sbj_tok_span": [50, 54], "obj_tok_span": [38, 41]}, {"subject": "naproxen", "object": "RPN", "sbj_char_span": [221, 229], "obj_char_span": [186, 189], "rel_type": "chemical-induced disease", "sbj_tok_span": [50, 54], "obj_tok_span": [42, 44]}], "umls_entity_list": []}, {"text": "Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.", "entity_list": [{"name": "cardiac failure", "ent_type": "Disease", "char_span": [63, 78], "ent_id": "D006333", "tok_span": [9, 11]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [80, 91], "ent_id": "D007022", "tok_span": [12, 13]}, {"name": "ischaemic heart disease", "ent_type": "Disease", "char_span": [20, 43], "ent_id": "D017202", "tok_span": [3, 7]}, {"name": "verapamil", "ent_type": "Chemical", "char_span": [137, 146], "ent_id": "D014700", "tok_span": [22, 25]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [96, 107], "ent_id": "D001919", "tok_span": [14, 18]}, {"name": "beta-adrenergic blocking drugs", "ent_type": "Chemical", "char_span": [151, 181], "ent_id": "D000319", "tok_span": [26, 32]}], "relation_list": [{"subject": "verapamil", "object": "hypotension", "sbj_char_span": [137, 146], "obj_char_span": [80, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 25], "obj_tok_span": [12, 13]}, {"subject": "verapamil", "object": "cardiac failure", "sbj_char_span": [137, 146], "obj_char_span": [63, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 25], "obj_tok_span": [9, 11]}, {"subject": "beta-adrenergic blocking drugs", "object": "hypotension", "sbj_char_span": [151, 181], "obj_char_span": [80, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 32], "obj_tok_span": [12, 13]}, {"subject": "beta-adrenergic blocking drugs", "object": "bradycardia", "sbj_char_span": [151, 181], "obj_char_span": [96, 107], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 32], "obj_tok_span": [14, 18]}, {"subject": "verapamil", "object": "bradycardia", "sbj_char_span": [137, 146], "obj_char_span": [96, 107], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 25], "obj_tok_span": [14, 18]}, {"subject": "beta-adrenergic blocking drugs", "object": "cardiac failure", "sbj_char_span": [151, 181], "obj_char_span": [63, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 32], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos.", "entity_list": [{"name": "bendrofluazide", "ent_type": "Chemical", "char_span": [40, 54], "ent_id": "D001539", "tok_span": [6, 12]}, {"name": "propranolol", "ent_type": "Chemical", "char_span": [143, 154], "ent_id": "D011433", "tok_span": [29, 33]}, {"name": "impotence", "ent_type": "Disease", "char_span": [84, 93], "ent_id": "D007172", "tok_span": [19, 22]}, {"name": "impotence", "ent_type": "Disease", "char_span": [69, 78], "ent_id": "D007172", "tok_span": [14, 17]}], "relation_list": [{"subject": "bendrofluazide", "object": "impotence", "sbj_char_span": [40, 54], "obj_char_span": [84, 93], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 12], "obj_tok_span": [19, 22]}, {"subject": "propranolol", "object": "impotence", "sbj_char_span": [143, 154], "obj_char_span": [84, 93], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 33], "obj_tok_span": [19, 22]}, {"subject": "bendrofluazide", "object": "impotence", "sbj_char_span": [40, 54], "obj_char_span": [69, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 12], "obj_tok_span": [14, 17]}, {"subject": "propranolol", "object": "impotence", "sbj_char_span": [143, 154], "obj_char_span": [69, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 33], "obj_tok_span": [14, 17]}], "umls_entity_list": []}, {"text": "Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.", "entity_list": [{"name": "bendrofluazide", "ent_type": "Chemical", "char_span": [148, 162], "ent_id": "D001539", "tok_span": [24, 30]}, {"name": "impaired glucose tolerance", "ent_type": "Disease", "char_span": [71, 97], "ent_id": "D018149", "tok_span": [9, 12]}, {"name": "propranolol", "ent_type": "Chemical", "char_span": [236, 247], "ent_id": "D011433", "tok_span": [48, 52]}, {"name": "dyspnoea", "ent_type": "Disease", "char_span": [203, 211], "ent_id": "D004417", "tok_span": [40, 43]}, {"name": "Raynaud's phenomenon", "ent_type": "Disease", "char_span": [178, 198], "ent_id": "D011928", "tok_span": [33, 39]}, {"name": "gout", "ent_type": "Disease", "char_span": [119, 123], "ent_id": "D006073", "tok_span": [17, 19]}], "relation_list": [{"subject": "bendrofluazide", "object": "impaired glucose tolerance", "sbj_char_span": [148, 162], "obj_char_span": [71, 97], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 30], "obj_tok_span": [9, 12]}, {"subject": "propranolol", "object": "Raynaud's phenomenon", "sbj_char_span": [236, 247], "obj_char_span": [178, 198], "rel_type": "chemical-induced disease", "sbj_tok_span": [48, 52], "obj_tok_span": [33, 39]}, {"subject": "propranolol", "object": "dyspnoea", "sbj_char_span": [236, 247], "obj_char_span": [203, 211], "rel_type": "chemical-induced disease", "sbj_tok_span": [48, 52], "obj_tok_span": [40, 43]}, {"subject": "bendrofluazide", "object": "gout", "sbj_char_span": [148, 162], "obj_char_span": [119, 123], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 30], "obj_tok_span": [17, 19]}], "umls_entity_list": []}, {"text": "Use of cidofovir in 1 child was associated with progressive renal failure and neutropenia.", "entity_list": [{"name": "cidofovir", "ent_type": "Chemical", "char_span": [7, 16], "ent_id": "C059262", "tok_span": [2, 6]}, {"name": "neutropenia", "ent_type": "Disease", "char_span": [78, 89], "ent_id": "D009503", "tok_span": [16, 18]}, {"name": "progressive renal failure", "ent_type": "Disease", "char_span": [48, 73], "ent_id": "D058186", "tok_span": [12, 15]}], "relation_list": [{"subject": "cidofovir", "object": "neutropenia", "sbj_char_span": [7, 16], "obj_char_span": [78, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [16, 18]}, {"subject": "cidofovir", "object": "progressive renal failure", "sbj_char_span": [7, 16], "obj_char_span": [48, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [12, 15]}], "umls_entity_list": []}, {"text": "Hepatotoxicity of amiodarone.", "entity_list": [{"name": "amiodarone", "ent_type": "Chemical", "char_span": [18, 28], "ent_id": "D000638", "tok_span": [3, 7]}, {"name": "Hepatotoxicity", "ent_type": "Disease", "char_span": [0, 14], "ent_id": "D056486", "tok_span": [0, 2]}], "relation_list": [{"subject": "amiodarone", "object": "Hepatotoxicity", "sbj_char_span": [18, 28], "obj_char_span": [0, 14], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 7], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "A patient with cholestatic hepatitis due to amiodarone treatment is presented below and a review of the hepatotoxicity of amiodarone is given.", "entity_list": [{"name": "hepatotoxicity", "ent_type": "Disease", "char_span": [104, 118], "ent_id": "D056486", "tok_span": [22, 24]}, {"name": "amiodarone", "ent_type": "Chemical", "char_span": [44, 54], "ent_id": "D000638", "tok_span": [9, 13]}, {"name": "cholestatic hepatitis", "ent_type": "Disease", "char_span": [15, 36], "ent_id": "D00277", "tok_span": [3, 7]}, {"name": "amiodarone", "ent_type": "Chemical", "char_span": [122, 132], "ent_id": "D000638", "tok_span": [25, 29]}], "relation_list": [{"subject": "amiodarone", "object": "hepatotoxicity", "sbj_char_span": [122, 132], "obj_char_span": [104, 118], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 29], "obj_tok_span": [22, 24]}, {"subject": "amiodarone", "object": "hepatotoxicity", "sbj_char_span": [44, 54], "obj_char_span": [104, 118], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [22, 24]}], "umls_entity_list": []}, {"text": "It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.", "entity_list": [{"name": "cirrhosis of the liver", "ent_type": "Disease", "char_span": [194, 216], "ent_id": "D008103", "tok_span": [35, 39]}, {"name": "amiodarone", "ent_type": "Chemical", "char_span": [68, 78], "ent_id": "D000638", "tok_span": [12, 16]}, {"name": "steatosis", "ent_type": "Disease", "char_span": [100, 109], "ent_id": "D005234", "tok_span": [19, 21]}, {"name": "cholestatic hepatitis", "ent_type": "Disease", "char_span": [155, 176], "ent_id": "D00277", "tok_span": [27, 31]}, {"name": "alcoholic hepatitis", "ent_type": "Disease", "char_span": [134, 153], "ent_id": "D006519", "tok_span": [24, 26]}, {"name": "hepatic injury", "ent_type": "Disease", "char_span": [46, 60], "ent_id": "D056486", "tok_span": [8, 10]}], "relation_list": [{"subject": "amiodarone", "object": "steatosis", "sbj_char_span": [68, 78], "obj_char_span": [100, 109], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 16], "obj_tok_span": [19, 21]}, {"subject": "amiodarone", "object": "hepatic injury", "sbj_char_span": [68, 78], "obj_char_span": [46, 60], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 16], "obj_tok_span": [8, 10]}, {"subject": "amiodarone", "object": "cirrhosis of the liver", "sbj_char_span": [68, 78], "obj_char_span": [194, 216], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 16], "obj_tok_span": [35, 39]}], "umls_entity_list": []}, {"text": "Catalepsy induced by combinations of ketamine and morphine: potentiation, antagonism, tolerance and cross-tolerance in the rat.", "entity_list": [{"name": "Catalepsy", "ent_type": "Disease", "char_span": [0, 9], "ent_id": "D002375", "tok_span": [0, 3]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [50, 58], "ent_id": "D009020", "tok_span": [9, 10]}, {"name": "ketamine", "ent_type": "Chemical", "char_span": [37, 45], "ent_id": "D007649", "tok_span": [7, 8]}], "relation_list": [{"subject": "morphine", "object": "Catalepsy", "sbj_char_span": [50, 58], "obj_char_span": [0, 9], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [0, 3]}, {"subject": "ketamine", "object": "Catalepsy", "sbj_char_span": [37, 45], "obj_char_span": [0, 9], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "Previous studies demonstrated that both ketamine and morphine induced analgesia and catalepsy in the rat.", "entity_list": [{"name": "catalepsy", "ent_type": "Disease", "char_span": [84, 93], "ent_id": "D002375", "tok_span": [11, 14]}, {"name": "analgesia", "ent_type": "Disease", "char_span": [70, 79], "ent_id": "D000699", "tok_span": [9, 10]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [53, 61], "ent_id": "D009020", "tok_span": [7, 8]}, {"name": "ketamine", "ent_type": "Chemical", "char_span": [40, 48], "ent_id": "D007649", "tok_span": [5, 6]}], "relation_list": [{"subject": "morphine", "object": "catalepsy", "sbj_char_span": [53, 61], "obj_char_span": [84, 93], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [11, 14]}, {"subject": "ketamine", "object": "catalepsy", "sbj_char_span": [40, 48], "obj_char_span": [84, 93], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 6], "obj_tok_span": [11, 14]}], "umls_entity_list": []}, {"text": "Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the cataleptic response; this augmentation was attributed to residual morphine in the brain.", "entity_list": [{"name": "ketamine", "ent_type": "Chemical", "char_span": [19, 27], "ent_id": "D007649", "tok_span": [4, 5]}, {"name": "cataleptic", "ent_type": "Disease", "char_span": [169, 179], "ent_id": "D002375", "tok_span": [28, 30]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [92, 100], "ent_id": "D009020", "tok_span": [15, 16]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [235, 243], "ent_id": "D009020", "tok_span": [38, 39]}, {"name": "ketamine", "ent_type": "Chemical", "char_span": [135, 143], "ent_id": "D007649", "tok_span": [23, 24]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [56, 64], "ent_id": "D009020", "tok_span": [10, 11]}], "relation_list": [{"subject": "morphine", "object": "cataleptic", "sbj_char_span": [235, 243], "obj_char_span": [169, 179], "rel_type": "chemical-induced disease", "sbj_tok_span": [38, 39], "obj_tok_span": [28, 30]}, {"subject": "morphine", "object": "cataleptic", "sbj_char_span": [56, 64], "obj_char_span": [169, 179], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [28, 30]}, {"subject": "ketamine", "object": "cataleptic", "sbj_char_span": [19, 27], "obj_char_span": [169, 179], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [28, 30]}, {"subject": "morphine", "object": "cataleptic", "sbj_char_span": [92, 100], "obj_char_span": [169, 179], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 16], "obj_tok_span": [28, 30]}, {"subject": "ketamine", "object": "cataleptic", "sbj_char_span": [135, 143], "obj_char_span": [169, 179], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 24], "obj_tok_span": [28, 30]}], "umls_entity_list": []}, {"text": "Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.", "entity_list": [{"name": "tenofovir", "ent_type": "Chemical", "char_span": [45, 54], "ent_id": "C096918", "tok_span": [8, 11]}, {"name": "Acute renal failure", "ent_type": "Disease", "char_span": [0, 19], "ent_id": "D058186", "tok_span": [0, 3]}, {"name": "AIDS", "ent_type": "Disease", "char_span": [37, 41], "ent_id": "D000163", "tok_span": [6, 7]}, {"name": "vancomycin", "ent_type": "Chemical", "char_span": [81, 91], "ent_id": "D014640", "tok_span": [14, 15]}, {"name": "osteomyelitis", "ent_type": "Disease", "char_span": [103, 116], "ent_id": "D010019", "tok_span": [17, 19]}], "relation_list": [{"subject": "vancomycin", "object": "Acute renal failure", "sbj_char_span": [81, 91], "obj_char_span": [0, 19], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal methotrexate for childhood leukaemia.", "entity_list": [{"name": "leukaemia", "ent_type": "Disease", "char_span": [203, 212], "ent_id": "D007938", "tok_span": [33, 35]}, {"name": "leukoencephalopathy", "ent_type": "Disease", "char_span": [24, 43], "ent_id": "D056784", "tok_span": [4, 8]}, {"name": "cerebrovascular accident", "ent_type": "Disease", "char_span": [54, 78], "ent_id": "D002544", "tok_span": [10, 12]}, {"name": "methotrexate", "ent_type": "Chemical", "char_span": [176, 188], "ent_id": "D008727", "tok_span": [29, 31]}], "relation_list": [{"subject": "methotrexate", "object": "leukoencephalopathy", "sbj_char_span": [176, 188], "obj_char_span": [24, 43], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 31], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.", "entity_list": [{"name": "carmofur", "ent_type": "Chemical", "char_span": [160, 168], "ent_id": "C017367", "tok_span": [34, 38]}, {"name": "leukoencephalopathy", "ent_type": "Disease", "char_span": [43, 62], "ent_id": "D056784", "tok_span": [8, 12]}, {"name": "5-fluorouracil", "ent_type": "Chemical", "char_span": [126, 140], "ent_id": "D005472", "tok_span": [26, 31]}, {"name": "methotrexate", "ent_type": "Chemical", "char_span": [88, 100], "ent_id": "D008727", "tok_span": [16, 18]}, {"name": "capecitabine", "ent_type": "Chemical", "char_span": [174, 186], "ent_id": "C110904", "tok_span": [40, 45]}], "relation_list": [{"subject": "5-fluorouracil", "object": "leukoencephalopathy", "sbj_char_span": [126, 140], "obj_char_span": [43, 62], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 31], "obj_tok_span": [8, 12]}, {"subject": "carmofur", "object": "leukoencephalopathy", "sbj_char_span": [160, 168], "obj_char_span": [43, 62], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 38], "obj_tok_span": [8, 12]}, {"subject": "capecitabine", "object": "leukoencephalopathy", "sbj_char_span": [174, 186], "obj_char_span": [43, 62], "rel_type": "chemical-induced disease", "sbj_tok_span": [40, 45], "obj_tok_span": [8, 12]}, {"subject": "methotrexate", "object": "leukoencephalopathy", "sbj_char_span": [88, 100], "obj_char_span": [43, 62], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 18], "obj_tok_span": [8, 12]}], "umls_entity_list": []}, {"text": "Alterations of norepinephrine transporter (NET) function by chronic inhibition of NET in relation to sensitization to seizures induce by cocaine and local anesthetics were studied in mice.", "entity_list": [{"name": "norepinephrine", "ent_type": "Chemical", "char_span": [15, 29], "ent_id": "D009638", "tok_span": [3, 4]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [137, 144], "ent_id": "D003042", "tok_span": [22, 23]}, {"name": "seizures", "ent_type": "Disease", "char_span": [118, 126], "ent_id": "D012640", "tok_span": [19, 20]}], "relation_list": [{"subject": "cocaine", "object": "seizures", "sbj_char_span": [137, 144], "obj_char_span": [118, 126], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [19, 20]}], "umls_entity_list": []}, {"text": "Daily administration of desipramine increased the incidence of appearance of lidocaine-induced convulsions and decreased that of cocaine-induced convulsions.", "entity_list": [{"name": "cocaine", "ent_type": "Chemical", "char_span": [129, 136], "ent_id": "D003042", "tok_span": [24, 25]}, {"name": "convulsions", "ent_type": "Disease", "char_span": [95, 106], "ent_id": "D012640", "tok_span": [17, 20]}, {"name": "desipramine", "ent_type": "Chemical", "char_span": [24, 35], "ent_id": "D003891", "tok_span": [3, 7]}, {"name": "lidocaine", "ent_type": "Chemical", "char_span": [77, 86], "ent_id": "D008012", "tok_span": [13, 15]}, {"name": "convulsions", "ent_type": "Disease", "char_span": [145, 156], "ent_id": "D012640", "tok_span": [27, 30]}], "relation_list": [{"subject": "cocaine", "object": "convulsions", "sbj_char_span": [129, 136], "obj_char_span": [145, 156], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 25], "obj_tok_span": [27, 30]}, {"subject": "lidocaine", "object": "convulsions", "sbj_char_span": [77, 86], "obj_char_span": [145, 156], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [27, 30]}, {"subject": "cocaine", "object": "convulsions", "sbj_char_span": [129, 136], "obj_char_span": [95, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 25], "obj_tok_span": [17, 20]}, {"subject": "lidocaine", "object": "convulsions", "sbj_char_span": [77, 86], "obj_char_span": [95, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [17, 20]}], "umls_entity_list": []}, {"text": "Co-administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and cocaine induced by repeated administration of desipramine.", "entity_list": [{"name": "lidocaine", "ent_type": "Chemical", "char_span": [95, 104], "ent_id": "D008012", "tok_span": [19, 21]}, {"name": "desipramine", "ent_type": "Chemical", "char_span": [36, 47], "ent_id": "D003891", "tok_span": [7, 11]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [109, 116], "ent_id": "D003042", "tok_span": [22, 23]}, {"name": "desipramine", "ent_type": "Chemical", "char_span": [155, 166], "ent_id": "D003891", "tok_span": [28, 32]}, {"name": "lidocaine", "ent_type": "Chemical", "char_span": [21, 30], "ent_id": "D008012", "tok_span": [4, 6]}, {"name": "convulsive", "ent_type": "Disease", "char_span": [72, 82], "ent_id": "D012640", "tok_span": [15, 17]}], "relation_list": [{"subject": "lidocaine", "object": "convulsive", "sbj_char_span": [21, 30], "obj_char_span": [72, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 6], "obj_tok_span": [15, 17]}, {"subject": "lidocaine", "object": "convulsive", "sbj_char_span": [95, 104], "obj_char_span": [72, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 21], "obj_tok_span": [15, 17]}, {"subject": "cocaine", "object": "convulsive", "sbj_char_span": [109, 116], "obj_char_span": [72, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "These results suggest that down-regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine-induced sensitization of lidocaine convulsions.", "entity_list": [{"name": "desipramine", "ent_type": "Chemical", "char_span": [99, 110], "ent_id": "D003891", "tok_span": [15, 19]}, {"name": "desipramine", "ent_type": "Chemical", "char_span": [130, 141], "ent_id": "D003891", "tok_span": [23, 27]}, {"name": "convulsions", "ent_type": "Disease", "char_span": [177, 188], "ent_id": "D012640", "tok_span": [33, 36]}, {"name": "lidocaine", "ent_type": "Chemical", "char_span": [167, 176], "ent_id": "D008012", "tok_span": [31, 33]}], "relation_list": [{"subject": "lidocaine", "object": "convulsions", "sbj_char_span": [167, 176], "obj_char_span": [177, 188], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 33], "obj_tok_span": [33, 36]}], "umls_entity_list": []}, {"text": "Desipramine-induced sensitization of lidocaine seizures may have a mechanism distinct from kindling resulting from repeated administration of cocaine.", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [47, 55], "ent_id": "D012640", "tok_span": [10, 11]}, {"name": "lidocaine", "ent_type": "Chemical", "char_span": [37, 46], "ent_id": "D008012", "tok_span": [8, 10]}, {"name": "Desipramine", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D003891", "tok_span": [0, 4]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [142, 149], "ent_id": "D003042", "tok_span": [24, 25]}], "relation_list": [{"subject": "cocaine", "object": "seizures", "sbj_char_span": [142, 149], "obj_char_span": [47, 55], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 25], "obj_tok_span": [10, 11]}, {"subject": "lidocaine", "object": "seizures", "sbj_char_span": [37, 46], "obj_char_span": [47, 55], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [10, 11]}], "umls_entity_list": []}, {"text": "Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.", "entity_list": [{"name": "ribavirin", "ent_type": "Chemical", "char_span": [41, 50], "ent_id": "D012254", "tok_span": [12, 15]}, {"name": "ribavirin", "ent_type": "Chemical", "char_span": [108, 117], "ent_id": "D012254", "tok_span": [26, 29]}, {"name": "chronic hepatitis C", "ent_type": "Disease", "char_span": [181, 200], "ent_id": "D019698", "tok_span": [40, 43]}, {"name": "Viramidine", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "C026956", "tok_span": [0, 3]}, {"name": "hemolytic anemia", "ent_type": "Disease", "char_span": [147, 163], "ent_id": "D000743", "tok_span": [34, 37]}], "relation_list": [{"subject": "ribavirin", "object": "hemolytic anemia", "sbj_char_span": [108, 117], "obj_char_span": [147, 163], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 29], "obj_tok_span": [34, 37]}, {"subject": "ribavirin", "object": "hemolytic anemia", "sbj_char_span": [41, 50], "obj_char_span": [147, 163], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [34, 37]}], "umls_entity_list": []}, {"text": "Calcium carbonate toxicity: the updated milk-alkali syndrome; report of 3 cases and review of the literature.", "entity_list": [{"name": "milk-alkali syndrome", "ent_type": "Disease", "char_span": [40, 60], "ent_id": "D006934", "tok_span": [6, 11]}, {"name": "toxicity", "ent_type": "Disease", "char_span": [18, 26], "ent_id": "D064420", "tok_span": [2, 3]}, {"name": "Calcium carbonate", "ent_type": "Chemical", "char_span": [0, 17], "ent_id": "D002119", "tok_span": [0, 2]}], "relation_list": [{"subject": "Calcium carbonate", "object": "milk-alkali syndrome", "sbj_char_span": [0, 17], "obj_char_span": [40, 60], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [6, 11]}], "umls_entity_list": []}, {"text": "OBJECTIVE: To describe 3 patients with calcium carbonate-induced hypercalcemia and gain insights into the cause and management of the milk-alkali syndrome.", "entity_list": [{"name": "hypercalcemia", "ent_type": "Disease", "char_span": [65, 78], "ent_id": "D006934", "tok_span": [11, 14]}, {"name": "milk-alkali syndrome", "ent_type": "Disease", "char_span": [134, 154], "ent_id": "D006934", "tok_span": [24, 29]}, {"name": "calcium carbonate", "ent_type": "Chemical", "char_span": [39, 56], "ent_id": "D002119", "tok_span": [7, 9]}], "relation_list": [{"subject": "calcium carbonate", "object": "hypercalcemia", "sbj_char_span": [39, 56], "obj_char_span": [65, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 9], "obj_tok_span": [11, 14]}, {"subject": "calcium carbonate", "object": "milk-alkali syndrome", "sbj_char_span": [39, 56], "obj_char_span": [134, 154], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 9], "obj_tok_span": [24, 29]}], "umls_entity_list": []}, {"text": "The 2 patients with the higher serum calcium concentrations received pamidronate intravenously (60 and 30 mg, respectively), which caused severe hypocalcemia.", "entity_list": [{"name": "hypocalcemia", "ent_type": "Disease", "char_span": [145, 157], "ent_id": "D006996", "tok_span": [27, 30]}, {"name": "calcium", "ent_type": "Chemical", "char_span": [37, 44], "ent_id": "D002118", "tok_span": [7, 8]}, {"name": "pamidronate", "ent_type": "Chemical", "char_span": [69, 80], "ent_id": "C019248", "tok_span": [10, 14]}], "relation_list": [{"subject": "pamidronate", "object": "hypocalcemia", "sbj_char_span": [69, 80], "obj_char_span": [145, 157], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [27, 30]}], "umls_entity_list": []}, {"text": "CONCLUSION: Milk-alkali syndrome may be a common cause of unexplained hypercalcemia and can be precipitated by small amounts of orally ingested calcium carbonate in susceptible persons.", "entity_list": [{"name": "calcium carbonate", "ent_type": "Chemical", "char_span": [144, 161], "ent_id": "D002119", "tok_span": [30, 32]}, {"name": "Milk-alkali syndrome", "ent_type": "Disease", "char_span": [12, 32], "ent_id": "D006934", "tok_span": [2, 8]}, {"name": "hypercalcemia", "ent_type": "Disease", "char_span": [70, 83], "ent_id": "D006934", "tok_span": [16, 19]}], "relation_list": [{"subject": "calcium carbonate", "object": "Milk-alkali syndrome", "sbj_char_span": [144, 161], "obj_char_span": [12, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 32], "obj_tok_span": [2, 8]}, {"subject": "calcium carbonate", "object": "hypercalcemia", "sbj_char_span": [144, 161], "obj_char_span": [70, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 32], "obj_tok_span": [16, 19]}], "umls_entity_list": []}, {"text": "Pamidronate treatment is associated with considerable risk for hypocalcemia, even in cases of initially severe hypercalcemia.", "entity_list": [{"name": "hypocalcemia", "ent_type": "Disease", "char_span": [63, 75], "ent_id": "D006996", "tok_span": [11, 14]}, {"name": "hypercalcemia", "ent_type": "Disease", "char_span": [111, 124], "ent_id": "D006934", "tok_span": [21, 24]}, {"name": "Pamidronate", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "C019248", "tok_span": [0, 4]}], "relation_list": [{"subject": "Pamidronate", "object": "hypocalcemia", "sbj_char_span": [0, 11], "obj_char_span": [63, 75], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [11, 14]}], "umls_entity_list": []}, {"text": "Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: clinical and economic implications.", "entity_list": [{"name": "ribavirin", "ent_type": "Chemical", "char_span": [26, 35], "ent_id": "D012254", "tok_span": [3, 6]}, {"name": "hepatitis C", "ent_type": "Disease", "char_span": [81, 92], "ent_id": "D006526", "tok_span": [15, 17]}, {"name": "hemolytic anemia", "ent_type": "Disease", "char_span": [44, 60], "ent_id": "D000743", "tok_span": [8, 11]}], "relation_list": [{"subject": "ribavirin", "object": "hemolytic anemia", "sbj_char_span": [26, 35], "obj_char_span": [44, 60], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [8, 11]}], "umls_entity_list": []}, {"text": "Combination therapy is associated with a clinically important adverse effect: ribavirin-induced hemolytic anemia (RIHA).", "entity_list": [{"name": "RIHA", "ent_type": "Disease", "char_span": [114, 118], "ent_id": "D000743", "tok_span": [21, 23]}, {"name": "hemolytic anemia", "ent_type": "Disease", "char_span": [96, 112], "ent_id": "D000743", "tok_span": [17, 20]}, {"name": "ribavirin", "ent_type": "Chemical", "char_span": [78, 87], "ent_id": "D012254", "tok_span": [12, 15]}], "relation_list": [{"subject": "ribavirin", "object": "RIHA", "sbj_char_span": [78, 87], "obj_char_span": [114, 118], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [21, 23]}, {"subject": "ribavirin", "object": "hemolytic anemia", "sbj_char_span": [78, 87], "obj_char_span": [96, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [17, 20]}], "umls_entity_list": []}, {"text": "The standard of care for management of RIHA is reduction or discontinuation of the ribavirin dosage.", "entity_list": [{"name": "ribavirin", "ent_type": "Chemical", "char_span": [83, 92], "ent_id": "D012254", "tok_span": [15, 18]}, {"name": "RIHA", "ent_type": "Disease", "char_span": [39, 43], "ent_id": "D000743", "tok_span": [7, 9]}], "relation_list": [{"subject": "ribavirin", "object": "RIHA", "sbj_char_span": [83, 92], "obj_char_span": [39, 43], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "Questions remain about the optimal dose of ribavirin and the incidence of RIHA in a real-world population.", "entity_list": [{"name": "ribavirin", "ent_type": "Chemical", "char_span": [43, 52], "ent_id": "D012254", "tok_span": [7, 10]}, {"name": "RIHA", "ent_type": "Disease", "char_span": [74, 78], "ent_id": "D000743", "tok_span": [14, 16]}], "relation_list": [{"subject": "ribavirin", "object": "RIHA", "sbj_char_span": [43, 52], "obj_char_span": [74, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "Effects of amine pretreatment on ketamine catatonia in pinealectomized or hypophysectomized animals.", "entity_list": [{"name": "catatonia", "ent_type": "Disease", "char_span": [42, 51], "ent_id": "D002389", "tok_span": [6, 9]}, {"name": "ketamine", "ent_type": "Chemical", "char_span": [33, 41], "ent_id": "D007649", "tok_span": [5, 6]}, {"name": "amine", "ent_type": "Chemical", "char_span": [11, 16], "ent_id": "D000588", "tok_span": [2, 3]}], "relation_list": [{"subject": "ketamine", "object": "catatonia", "sbj_char_span": [33, 41], "obj_char_span": [42, 51], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 6], "obj_tok_span": [6, 9]}], "umls_entity_list": []}, {"text": "The present studies were designed to clarify the role of catecholamines and pineal idolamines on ketamine-induced catatonia in the intact, pinealectomized or hypophysectomized chick and rat.", "entity_list": [{"name": "catatonia", "ent_type": "Disease", "char_span": [114, 123], "ent_id": "D002389", "tok_span": [23, 26]}, {"name": "ketamine", "ent_type": "Chemical", "char_span": [97, 105], "ent_id": "D007649", "tok_span": [20, 21]}, {"name": "catecholamines", "ent_type": "Chemical", "char_span": [57, 71], "ent_id": "D002395", "tok_span": [10, 12]}], "relation_list": [{"subject": "ketamine", "object": "catatonia", "sbj_char_span": [97, 105], "obj_char_span": [114, 123], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 21], "obj_tok_span": [23, 26]}], "umls_entity_list": []}, {"text": "In the pinealectomized chick, pretreatment with dopamine increased the duration of catatonia (DOC) after ketamine, but pretreatment with norepinephrine did not.", "entity_list": [{"name": "ketamine", "ent_type": "Chemical", "char_span": [105, 113], "ent_id": "D007649", "tok_span": [23, 24]}, {"name": "dopamine", "ent_type": "Chemical", "char_span": [48, 56], "ent_id": "D004298", "tok_span": [11, 12]}, {"name": "norepinephrine", "ent_type": "Chemical", "char_span": [137, 151], "ent_id": "D009638", "tok_span": [28, 29]}, {"name": "catatonia", "ent_type": "Disease", "char_span": [83, 92], "ent_id": "D002389", "tok_span": [16, 19]}], "relation_list": [{"subject": "dopamine", "object": "catatonia", "sbj_char_span": [48, 56], "obj_char_span": [83, 92], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [16, 19]}, {"subject": "ketamine", "object": "catatonia", "sbj_char_span": [105, 113], "obj_char_span": [83, 92], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 24], "obj_tok_span": [16, 19]}], "umls_entity_list": []}, {"text": "Furthermore, dopamine appeared to act on systems more closely involved with the induction of ketamine catatonia rather than directly on the pituitary.", "entity_list": [{"name": "catatonia", "ent_type": "Disease", "char_span": [102, 111], "ent_id": "D002389", "tok_span": [16, 19]}, {"name": "dopamine", "ent_type": "Chemical", "char_span": [13, 21], "ent_id": "D004298", "tok_span": [2, 3]}, {"name": "ketamine", "ent_type": "Chemical", "char_span": [93, 101], "ent_id": "D007649", "tok_span": [15, 16]}], "relation_list": [{"subject": "dopamine", "object": "catatonia", "sbj_char_span": [13, 21], "obj_char_span": [102, 111], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 3], "obj_tok_span": [16, 19]}, {"subject": "ketamine", "object": "catatonia", "sbj_char_span": [93, 101], "obj_char_span": [102, 111], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 16], "obj_tok_span": [16, 19]}], "umls_entity_list": []}, {"text": "Drowsiness and altered taste perception were increased significantly over placebo only in the high-dose azelastine group.", "entity_list": [{"name": "altered taste perception", "ent_type": "Disease", "char_span": [15, 39], "ent_id": "D013651", "tok_span": [4, 7]}, {"name": "Drowsiness", "ent_type": "Disease", "char_span": [0, 10], "ent_id": "D006970", "tok_span": [0, 3]}, {"name": "azelastine", "ent_type": "Chemical", "char_span": [104, 114], "ent_id": "C020976", "tok_span": [18, 22]}], "relation_list": [{"subject": "azelastine", "object": "altered taste perception", "sbj_char_span": [104, 114], "obj_char_span": [15, 39], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 22], "obj_tok_span": [4, 7]}, {"subject": "azelastine", "object": "Drowsiness", "sbj_char_span": [104, 114], "obj_char_span": [0, 10], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 22], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-sodium bicarbonate powders for more than 20 years.", "entity_list": [{"name": "hypercalcaemia", "ent_type": "Disease", "char_span": [18, 32], "ent_id": "D006934", "tok_span": [4, 7]}, {"name": "nephrolithiasis", "ent_type": "Disease", "char_span": [54, 69], "ent_id": "D053040", "tok_span": [11, 15]}, {"name": "calcium carbon-ate", "ent_type": "Chemical", "char_span": [139, 157], "ent_id": "D002119", "tok_span": [26, 30]}, {"name": "sodium bicarbonate", "ent_type": "Chemical", "char_span": [158, 176], "ent_id": "D017693", "tok_span": [31, 33]}], "relation_list": [{"subject": "sodium bicarbonate", "object": "hypercalcaemia", "sbj_char_span": [158, 176], "obj_char_span": [18, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 33], "obj_tok_span": [4, 7]}, {"subject": "sodium bicarbonate", "object": "nephrolithiasis", "sbj_char_span": [158, 176], "obj_char_span": [54, 69], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 33], "obj_tok_span": [11, 15]}, {"subject": "calcium carbon-ate", "object": "nephrolithiasis", "sbj_char_span": [139, 157], "obj_char_span": [54, 69], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 30], "obj_tok_span": [11, 15]}, {"subject": "calcium carbon-ate", "object": "hypercalcaemia", "sbj_char_span": [139, 157], "obj_char_span": [18, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 30], "obj_tok_span": [4, 7]}], "umls_entity_list": []}, {"text": "The long-term use of nondepolarizing neuromuscular blocking agents (ND-NMBA) has recently been implicated as a cause of prolonged muscle weakness, although the site of the lesion and the predisposing factors have been unclear.", "entity_list": [{"name": "ND-NMBA", "ent_type": "Chemical", "char_span": [68, 75], "ent_id": "D003473", "tok_span": [14, 18]}, {"name": "nondepolarizing neuromuscular blocking agents", "ent_type": "Chemical", "char_span": [21, 66], "ent_id": "D003473", "tok_span": [6, 13]}, {"name": "muscle weakness", "ent_type": "Disease", "char_span": [130, 145], "ent_id": "D018908", "tok_span": [28, 30]}], "relation_list": [{"subject": "ND-NMBA", "object": "muscle weakness", "sbj_char_span": [68, 75], "obj_char_span": [130, 145], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 18], "obj_tok_span": [28, 30]}, {"subject": "nondepolarizing neuromuscular blocking agents", "object": "muscle weakness", "sbj_char_span": [21, 66], "obj_char_span": [130, 145], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 13], "obj_tok_span": [28, 30]}], "umls_entity_list": []}, {"text": "We report 3 patients (age 37-52 years) with acute respiratory insufficiency who developed prolonged weakness following the discontinuation of ND-NMBAs.", "entity_list": [{"name": "weakness", "ent_type": "Disease", "char_span": [100, 108], "ent_id": "D018908", "tok_span": [18, 19]}, {"name": "ND-NMBAs", "ent_type": "Chemical", "char_span": [142, 150], "ent_id": "D003473", "tok_span": [23, 28]}, {"name": "respiratory insufficiency", "ent_type": "Disease", "char_span": [50, 75], "ent_id": "D012131", "tok_span": [13, 15]}], "relation_list": [{"subject": "ND-NMBAs", "object": "weakness", "sbj_char_span": [142, 150], "obj_char_span": [100, 108], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 28], "obj_tok_span": [18, 19]}], "umls_entity_list": []}, {"text": "The weakness in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to corticosteroids).", "entity_list": [{"name": "ND-NMBA", "ent_type": "Chemical", "char_span": [106, 113], "ent_id": "D003473", "tok_span": [19, 23]}, {"name": "pathology at both the neuromuscular junction", "ent_type": "Disease", "char_span": [41, 85], "ent_id": "D009468", "tok_span": [8, 14]}, {"name": "corticosteroids", "ent_type": "Chemical", "char_span": [146, 161], "ent_id": "D000305", "tok_span": [31, 32]}, {"name": "weakness", "ent_type": "Disease", "char_span": [4, 12], "ent_id": "D018908", "tok_span": [1, 2]}], "relation_list": [{"subject": "ND-NMBA", "object": "weakness", "sbj_char_span": [106, 113], "obj_char_span": [4, 12], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 23], "obj_tok_span": [1, 2]}, {"subject": "ND-NMBA", "object": "pathology at both the neuromuscular junction", "sbj_char_span": [106, 113], "obj_char_span": [41, 85], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 23], "obj_tok_span": [8, 14]}], "umls_entity_list": []}, {"text": "Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins?", "entity_list": [{"name": "tachykinins", "ent_type": "Chemical", "char_span": [89, 100], "ent_id": "D015320", "tok_span": [19, 23]}, {"name": "Prostaglandin E2", "ent_type": "Chemical", "char_span": [0, 16], "ent_id": "D015232", "tok_span": [0, 6]}, {"name": "bladder hyperactivity", "ent_type": "Disease", "char_span": [25, 46], "ent_id": "D053201", "tok_span": [8, 11]}], "relation_list": [{"subject": "Prostaglandin E2", "object": "bladder hyperactivity", "sbj_char_span": [0, 16], "obj_char_span": [25, 46], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 6], "obj_tok_span": [8, 11]}], "umls_entity_list": []}, {"text": "Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.", "entity_list": [{"name": "amiloride", "ent_type": "Chemical", "char_span": [12, 21], "ent_id": "D000584", "tok_span": [2, 6]}, {"name": "ventricular ectopic beats", "ent_type": "Disease", "char_span": [104, 129], "ent_id": "D018879", "tok_span": [20, 23]}, {"name": "chlorthalidone", "ent_type": "Chemical", "char_span": [37, 51], "ent_id": "D002752", "tok_span": [9, 12]}], "relation_list": [{"subject": "chlorthalidone", "object": "ventricular ectopic beats", "sbj_char_span": [37, 51], "obj_char_span": [104, 129], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [20, 23]}], "umls_entity_list": []}, {"text": "GABA involvement in naloxone induced reversal of respiratory paralysis produced by thiopental.", "entity_list": [{"name": "thiopental", "ent_type": "Chemical", "char_span": [83, 93], "ent_id": "D013874", "tok_span": [14, 17]}, {"name": "naloxone", "ent_type": "Chemical", "char_span": [20, 28], "ent_id": "D009270", "tok_span": [3, 6]}, {"name": "GABA", "ent_type": "Chemical", "char_span": [0, 4], "ent_id": "D005680", "tok_span": [0, 1]}, {"name": "respiratory paralysis", "ent_type": "Disease", "char_span": [49, 70], "ent_id": "D012133", "tok_span": [9, 12]}], "relation_list": [{"subject": "thiopental", "object": "respiratory paralysis", "sbj_char_span": [83, 93], "obj_char_span": [49, 70], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [9, 12]}], "umls_entity_list": []}, {"text": "In this study naloxone reversed respiratory paralysis induced by thiopental in rats. 25 mg/kg, i.v. thiopental produced anesthesia without altering respiratory rate, increased GABA, decreased glutamate, and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem.", "entity_list": [{"name": "thiopental", "ent_type": "Chemical", "char_span": [100, 110], "ent_id": "D013874", "tok_span": [27, 30]}, {"name": "glycine", "ent_type": "Chemical", "char_span": [237, 244], "ent_id": "D005998", "tok_span": [51, 52]}, {"name": "thiopental", "ent_type": "Chemical", "char_span": [65, 75], "ent_id": "D013874", "tok_span": [12, 15]}, {"name": "respiratory paralysis", "ent_type": "Disease", "char_span": [32, 53], "ent_id": "D012133", "tok_span": [7, 10]}, {"name": "glutamate", "ent_type": "Chemical", "char_span": [192, 201], "ent_id": "D018698", "tok_span": [41, 42]}, {"name": "naloxone", "ent_type": "Chemical", "char_span": [14, 22], "ent_id": "D009270", "tok_span": [3, 6]}, {"name": "aspartate", "ent_type": "Chemical", "char_span": [224, 233], "ent_id": "D001224", "tok_span": [48, 50]}, {"name": "GABA", "ent_type": "Chemical", "char_span": [176, 180], "ent_id": "D005680", "tok_span": [38, 39]}], "relation_list": [{"subject": "thiopental", "object": "respiratory paralysis", "sbj_char_span": [100, 110], "obj_char_span": [32, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 30], "obj_tok_span": [7, 10]}, {"subject": "thiopental", "object": "respiratory paralysis", "sbj_char_span": [65, 75], "obj_char_span": [32, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves GABA in its action.", "entity_list": [{"name": "GABA", "ent_type": "Chemical", "char_span": [95, 99], "ent_id": "D005680", "tok_span": [18, 19]}, {"name": "naloxone", "ent_type": "Chemical", "char_span": [19, 27], "ent_id": "D009270", "tok_span": [3, 6]}, {"name": "thiopental", "ent_type": "Chemical", "char_span": [71, 81], "ent_id": "D013874", "tok_span": [13, 16]}, {"name": "respiratory paralysis", "ent_type": "Disease", "char_span": [37, 58], "ent_id": "D012133", "tok_span": [8, 11]}], "relation_list": [{"subject": "thiopental", "object": "respiratory paralysis", "sbj_char_span": [71, 81], "obj_char_span": [37, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [8, 11]}], "umls_entity_list": []}, {"text": "Prostaglandin D2 (0.5-3 ng/mouse) had a hyperalgesic action on the response to a hot plate during a 3-60 min period after injection.", "entity_list": [{"name": "Prostaglandin D2", "ent_type": "Chemical", "char_span": [0, 16], "ent_id": "D015230", "tok_span": [0, 6]}, {"name": "hyperalgesic", "ent_type": "Disease", "char_span": [40, 52], "ent_id": "D006930", "tok_span": [18, 22]}], "relation_list": [{"subject": "Prostaglandin D2", "object": "hyperalgesic", "sbj_char_span": [0, 16], "obj_char_span": [40, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 6], "obj_tok_span": [18, 22]}], "umls_entity_list": []}, {"text": "Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.", "entity_list": [{"name": "hyperalgesic", "ent_type": "Disease", "char_span": [26, 38], "ent_id": "D006930", "tok_span": [8, 12]}, {"name": "prostaglandin D2", "ent_type": "Chemical", "char_span": [133, 149], "ent_id": "D015230", "tok_span": [38, 41]}, {"name": "Prostaglandin E2", "ent_type": "Chemical", "char_span": [0, 16], "ent_id": "D015232", "tok_span": [0, 6]}, {"name": "pg", "ent_type": "Chemical", "char_span": [60, 62], "ent_id": "D011453", "tok_span": [17, 18]}], "relation_list": [{"subject": "prostaglandin D2", "object": "hyperalgesic", "sbj_char_span": [133, 149], "obj_char_span": [26, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [38, 41], "obj_tok_span": [8, 12]}, {"subject": "Prostaglandin E2", "object": "hyperalgesic", "sbj_char_span": [0, 16], "obj_char_span": [26, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 6], "obj_tok_span": [8, 12]}], "umls_entity_list": []}, {"text": "The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.", "entity_list": [{"name": "prostaglandin D2", "ent_type": "Chemical", "char_span": [27, 43], "ent_id": "D015230", "tok_span": [7, 10]}, {"name": "hyperalgesic", "ent_type": "Disease", "char_span": [4, 16], "ent_id": "D006930", "tok_span": [1, 5]}, {"name": "AH6809", "ent_type": "Chemical", "char_span": [155, 161], "ent_id": "C053876", "tok_span": [32, 35]}], "relation_list": [{"subject": "prostaglandin D2", "object": "hyperalgesic", "sbj_char_span": [27, 43], "obj_char_span": [4, 16], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [1, 5]}], "umls_entity_list": []}, {"text": "Conversely, prostaglandin E2-induced hyperalgesia was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist.", "entity_list": [{"name": "AH6809", "ent_type": "Chemical", "char_span": [65, 71], "ent_id": "C053876", "tok_span": [14, 17]}, {"name": "hyperalgesia", "ent_type": "Disease", "char_span": [37, 49], "ent_id": "D006930", "tok_span": [7, 11]}, {"name": "prostaglandin E2", "ent_type": "Chemical", "char_span": [12, 28], "ent_id": "D015232", "tok_span": [2, 5]}], "relation_list": [{"subject": "prostaglandin E2", "object": "hyperalgesia", "sbj_char_span": [12, 28], "obj_char_span": [37, 49], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert hyperalgesia in the spinal cord, but in different ways.", "entity_list": [{"name": "prostaglandin D2", "ent_type": "Chemical", "char_span": [36, 52], "ent_id": "D015230", "tok_span": [5, 8]}, {"name": "hyperalgesia", "ent_type": "Disease", "char_span": [80, 92], "ent_id": "D006930", "tok_span": [13, 17]}, {"name": "prostaglandin E2", "ent_type": "Chemical", "char_span": [57, 73], "ent_id": "D015232", "tok_span": [9, 12]}], "relation_list": [{"subject": "prostaglandin D2", "object": "hyperalgesia", "sbj_char_span": [36, 52], "obj_char_span": [80, 92], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [13, 17]}, {"subject": "prostaglandin E2", "object": "hyperalgesia", "sbj_char_span": [57, 73], "obj_char_span": [80, 92], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "Swallowing-induced atrial tachyarrhythmia triggered by salbutamol: case report and review of the literature.", "entity_list": [{"name": "atrial tachyarrhythmia", "ent_type": "Disease", "char_span": [19, 41], "ent_id": "D013617", "tok_span": [5, 11]}, {"name": "salbutamol", "ent_type": "Chemical", "char_span": [55, 65], "ent_id": "D000420", "tok_span": [13, 17]}], "relation_list": [{"subject": "salbutamol", "object": "atrial tachyarrhythmia", "sbj_char_span": [55, 65], "obj_char_span": [19, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [5, 11]}], "umls_entity_list": []}, {"text": "CONCLUSION: Salbutamol is presented here as a possible trigger for SIAT.", "entity_list": [{"name": "Salbutamol", "ent_type": "Chemical", "char_span": [12, 22], "ent_id": "D000420", "tok_span": [2, 6]}, {"name": "SIAT", "ent_type": "Disease", "char_span": [67, 71], "ent_id": "D013617", "tok_span": [14, 16]}], "relation_list": [{"subject": "Salbutamol", "object": "SIAT", "sbj_char_span": [12, 22], "obj_char_span": [67, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "The nephroprotective effect of coenzyme Q10 was investigated in mice with acute renal injury induced by a single i.p. injection of cisplatin (5 mg/kg).", "entity_list": [{"name": "coenzyme Q10", "ent_type": "Chemical", "char_span": [31, 43], "ent_id": "C024989", "tok_span": [8, 13]}, {"name": "cisplatin", "ent_type": "Chemical", "char_span": [131, 140], "ent_id": "D002945", "tok_span": [31, 32]}, {"name": "acute renal injury", "ent_type": "Disease", "char_span": [74, 92], "ent_id": "D058186", "tok_span": [18, 21]}], "relation_list": [{"subject": "cisplatin", "object": "acute renal injury", "sbj_char_span": [131, 140], "obj_char_span": [74, 92], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 32], "obj_tok_span": [18, 21]}], "umls_entity_list": []}, {"text": "Metformin treatment fully blocked gentamicin-mediated acute renal failure.", "entity_list": [{"name": "acute renal failure", "ent_type": "Disease", "char_span": [54, 73], "ent_id": "D058186", "tok_span": [9, 12]}, {"name": "gentamicin", "ent_type": "Chemical", "char_span": [34, 44], "ent_id": "D005839", "tok_span": [5, 7]}, {"name": "Metformin", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D008687", "tok_span": [0, 2]}], "relation_list": [{"subject": "gentamicin", "object": "acute renal failure", "sbj_char_span": [34, 44], "obj_char_span": [54, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 7], "obj_tok_span": [9, 12]}], "umls_entity_list": []}, {"text": "PATIENTS AND METHODS: We performed a double-blind, randomized controlled trial at an academic medical center of elderly patients (>or=65 years) without preoperative delirium or severe dementia who underwent hip fracture repair under spinal anesthesia with propofol sedation.", "entity_list": [{"name": "dementia", "ent_type": "Disease", "char_span": [184, 192], "ent_id": "D003704", "tok_span": [37, 38]}, {"name": "hip fracture", "ent_type": "Disease", "char_span": [207, 219], "ent_id": "D006620", "tok_span": [40, 42]}, {"name": "propofol", "ent_type": "Chemical", "char_span": [256, 264], "ent_id": "D015742", "tok_span": [47, 49]}, {"name": "delirium", "ent_type": "Disease", "char_span": [165, 173], "ent_id": "D003693", "tok_span": [32, 35]}], "relation_list": [{"subject": "propofol", "object": "delirium", "sbj_char_span": [256, 264], "obj_char_span": [165, 173], "rel_type": "chemical-induced disease", "sbj_tok_span": [47, 49], "obj_tok_span": [32, 35]}], "umls_entity_list": []}, {"text": "Sorafenib-induced acute myocardial infarction due to coronary artery spasm.", "entity_list": [{"name": "coronary artery spasm", "ent_type": "Disease", "char_span": [53, 74], "ent_id": "D003329", "tok_span": [9, 13]}, {"name": "myocardial infarction", "ent_type": "Disease", "char_span": [24, 45], "ent_id": "D009203", "tok_span": [5, 7]}, {"name": "Sorafenib", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "C471405", "tok_span": [0, 2]}], "relation_list": [{"subject": "Sorafenib", "object": "coronary artery spasm", "sbj_char_span": [0, 9], "obj_char_span": [53, 74], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [9, 13]}], "umls_entity_list": []}, {"text": "We report the first case of sorafenib-induced coronary artery spasm.", "entity_list": [{"name": "coronary artery spasm", "ent_type": "Disease", "char_span": [46, 67], "ent_id": "D003329", "tok_span": [10, 14]}, {"name": "sorafenib", "ent_type": "Chemical", "char_span": [28, 37], "ent_id": "C471405", "tok_span": [6, 8]}], "relation_list": [{"subject": "sorafenib", "object": "coronary artery spasm", "sbj_char_span": [28, 37], "obj_char_span": [46, 67], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "RESULTS: The results indicate that ciprofloxacin- and norfloxacin-treated rats showed anxious behaviour in comparison to control rats in all the parameters studied.", "entity_list": [{"name": "norfloxacin", "ent_type": "Chemical", "char_span": [54, 65], "ent_id": "D009643", "tok_span": [13, 15]}, {"name": "anxious behaviour", "ent_type": "Disease", "char_span": [86, 103], "ent_id": "D001008", "tok_span": [19, 22]}, {"name": "ciprofloxacin", "ent_type": "Chemical", "char_span": [35, 48], "ent_id": "D002939", "tok_span": [6, 11]}], "relation_list": [{"subject": "norfloxacin", "object": "anxious behaviour", "sbj_char_span": [54, 65], "obj_char_span": [86, 103], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [19, 22]}, {"subject": "ciprofloxacin", "object": "anxious behaviour", "sbj_char_span": [35, 48], "obj_char_span": [86, 103], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 11], "obj_tok_span": [19, 22]}], "umls_entity_list": []}, {"text": "Myocardial Fas ligand expression increases susceptibility to AZT-induced cardiomyopathy.", "entity_list": [{"name": "AZT", "ent_type": "Chemical", "char_span": [61, 64], "ent_id": "D015215", "tok_span": [8, 10]}, {"name": "cardiomyopathy", "ent_type": "Disease", "char_span": [73, 87], "ent_id": "D009202", "tok_span": [12, 13]}], "relation_list": [{"subject": "AZT", "object": "cardiomyopathy", "sbj_char_span": [61, 64], "obj_char_span": [73, 87], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [12, 13]}], "umls_entity_list": []}, {"text": "METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).", "entity_list": [{"name": "DCM", "ent_type": "Disease", "char_span": [222, 225], "ent_id": "D002311", "tok_span": [57, 58]}, {"name": "AZT", "ent_type": "Chemical", "char_span": [395, 398], "ent_id": "D015215", "tok_span": [94, 96]}, {"name": "zidovudine", "ent_type": "Chemical", "char_span": [73, 83], "ent_id": "D015215", "tok_span": [13, 18]}, {"name": "3'-azido-2',3'-deoxythymidine", "ent_type": "Chemical", "char_span": [85, 114], "ent_id": "D015215", "tok_span": [19, 35]}, {"name": "AZT", "ent_type": "Chemical", "char_span": [116, 119], "ent_id": "D015215", "tok_span": [36, 38]}], "relation_list": [{"subject": "AZT", "object": "DCM", "sbj_char_span": [116, 119], "obj_char_span": [222, 225], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 38], "obj_tok_span": [57, 58]}, {"subject": "AZT", "object": "DCM", "sbj_char_span": [395, 398], "obj_char_span": [222, 225], "rel_type": "chemical-induced disease", "sbj_tok_span": [94, 96], "obj_tok_span": [57, 58]}, {"subject": "zidovudine", "object": "DCM", "sbj_char_span": [73, 83], "obj_char_span": [222, 225], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 18], "obj_tok_span": [57, 58]}, {"subject": "3'-azido-2',3'-deoxythymidine", "object": "DCM", "sbj_char_span": [85, 114], "obj_char_span": [222, 225], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 35], "obj_tok_span": [57, 58]}], "umls_entity_list": []}, {"text": "In contrast, AZT-treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.", "entity_list": [{"name": "cardiac dilation", "ent_type": "Disease", "char_span": [48, 64], "ent_id": "D002311", "tok_span": [12, 14]}, {"name": "AZT", "ent_type": "Chemical", "char_span": [13, 16], "ent_id": "D015215", "tok_span": [3, 5]}], "relation_list": [{"subject": "AZT", "object": "cardiac dilation", "sbj_char_span": [13, 16], "obj_char_span": [48, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 5], "obj_tok_span": [12, 14]}], "umls_entity_list": []}, {"text": "Valproate-induced chorea and encephalopathy in atypical nonketotic hyperglycinemia.", "entity_list": [{"name": "Valproate", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D014635", "tok_span": [0, 3]}, {"name": "encephalopathy", "ent_type": "Disease", "char_span": [29, 43], "ent_id": "D001927", "tok_span": [8, 10]}, {"name": "nonketotic hyperglycinemia", "ent_type": "Disease", "char_span": [56, 82], "ent_id": "D020158", "tok_span": [12, 18]}, {"name": "chorea", "ent_type": "Disease", "char_span": [18, 24], "ent_id": "D002819", "tok_span": [5, 7]}], "relation_list": [{"subject": "Valproate", "object": "encephalopathy", "sbj_char_span": [0, 9], "obj_char_span": [29, 43], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [8, 10]}, {"subject": "Valproate", "object": "chorea", "sbj_char_span": [0, 9], "obj_char_span": [18, 24], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.", "entity_list": [{"name": "encephalopathy", "ent_type": "Disease", "char_span": [168, 182], "ent_id": "D001927", "tok_span": [29, 31]}, {"name": "mental retardation", "ent_type": "Disease", "char_span": [61, 79], "ent_id": "D008607", "tok_span": [10, 12]}, {"name": "chorea", "ent_type": "Disease", "char_span": [187, 193], "ent_id": "D002819", "tok_span": [32, 34]}, {"name": "valproate", "ent_type": "Chemical", "char_span": [222, 231], "ent_id": "D014635", "tok_span": [38, 41]}, {"name": "language delay", "ent_type": "Disease", "char_span": [42, 56], "ent_id": "D007805", "tok_span": [7, 9]}, {"name": "nonketotic hyperglycinemia", "ent_type": "Disease", "char_span": [103, 129], "ent_id": "D020158", "tok_span": [18, 24]}], "relation_list": [{"subject": "valproate", "object": "chorea", "sbj_char_span": [222, 231], "obj_char_span": [187, 193], "rel_type": "chemical-induced disease", "sbj_tok_span": [38, 41], "obj_tok_span": [32, 34]}, {"subject": "valproate", "object": "encephalopathy", "sbj_char_span": [222, 231], "obj_char_span": [168, 182], "rel_type": "chemical-induced disease", "sbj_tok_span": [38, 41], "obj_tok_span": [29, 31]}], "umls_entity_list": []}, {"text": "Microinjection of ritanserin into the CA1 region of hippocampus improves scopolamine-induced amnesia in adult male rats.", "entity_list": [{"name": "scopolamine", "ent_type": "Chemical", "char_span": [73, 84], "ent_id": "D012601", "tok_span": [15, 18]}, {"name": "amnesia", "ent_type": "Disease", "char_span": [93, 100], "ent_id": "D000647", "tok_span": [20, 23]}, {"name": "ritanserin", "ent_type": "Chemical", "char_span": [18, 28], "ent_id": "D016713", "tok_span": [3, 7]}], "relation_list": [{"subject": "scopolamine", "object": "amnesia", "sbj_char_span": [73, 84], "obj_char_span": [93, 100], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [20, 23]}], "umls_entity_list": []}, {"text": "The effect of ritanserin (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-induced amnesia in Morris water maze (MWM) was investigated.", "entity_list": [{"name": "scopolamine", "ent_type": "Chemical", "char_span": [47, 58], "ent_id": "D012601", "tok_span": [15, 18]}, {"name": "ritanserin", "ent_type": "Chemical", "char_span": [14, 24], "ent_id": "D016713", "tok_span": [3, 7]}, {"name": "amnesia", "ent_type": "Disease", "char_span": [103, 110], "ent_id": "D000647", "tok_span": [27, 30]}], "relation_list": [{"subject": "scopolamine", "object": "amnesia", "sbj_char_span": [47, 58], "obj_char_span": [103, 110], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [27, 30]}], "umls_entity_list": []}, {"text": "Our findings show that microinjection of ritanserin into the CA1 region of the hippocampus improves the scopolamine-induced amnesia.", "entity_list": [{"name": "scopolamine", "ent_type": "Chemical", "char_span": [104, 115], "ent_id": "D012601", "tok_span": [21, 24]}, {"name": "ritanserin", "ent_type": "Chemical", "char_span": [41, 51], "ent_id": "D016713", "tok_span": [7, 11]}, {"name": "amnesia", "ent_type": "Disease", "char_span": [124, 131], "ent_id": "D000647", "tok_span": [26, 29]}], "relation_list": [{"subject": "scopolamine", "object": "amnesia", "sbj_char_span": [104, 115], "obj_char_span": [124, 131], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [26, 29]}], "umls_entity_list": []}, {"text": "With this model, we were able to identify diffuse cortical hypoxia in the puromycin aminonucleoside-induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model.", "entity_list": [{"name": "hypoxia", "ent_type": "Disease", "char_span": [59, 66], "ent_id": "D000860", "tok_span": [11, 12]}, {"name": "nephrotic syndrome", "ent_type": "Disease", "char_span": [108, 126], "ent_id": "D009404", "tok_span": [21, 24]}, {"name": "hypoxia", "ent_type": "Disease", "char_span": [151, 158], "ent_id": "D000860", "tok_span": [28, 29]}, {"name": "puromycin aminonucleoside", "ent_type": "Chemical", "char_span": [74, 99], "ent_id": "D011692", "tok_span": [14, 19]}], "relation_list": [{"subject": "puromycin aminonucleoside", "object": "hypoxia", "sbj_char_span": [74, 99], "obj_char_span": [151, 158], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 19], "obj_tok_span": [28, 29]}, {"subject": "puromycin aminonucleoside", "object": "nephrotic syndrome", "sbj_char_span": [74, 99], "obj_char_span": [108, 126], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 19], "obj_tok_span": [21, 24]}, {"subject": "puromycin aminonucleoside", "object": "hypoxia", "sbj_char_span": [74, 99], "obj_char_span": [59, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 19], "obj_tok_span": [11, 12]}], "umls_entity_list": []}, {"text": "Expression of the hypoxia-responsive transgene increased throughout the observation period, reaching 2.2-fold at 2 weeks in the puromycin aminonucleoside model and 2.6-fold at 4 weeks in the remnant kidney model, whereas that of vascular endothelial growth factor showed a mild decrease, reflecting distinct behaviors of the two genes.", "entity_list": [{"name": "puromycin aminonucleoside", "ent_type": "Chemical", "char_span": [128, 153], "ent_id": "D011692", "tok_span": [24, 29]}, {"name": "hypoxia", "ent_type": "Disease", "char_span": [18, 25], "ent_id": "D000860", "tok_span": [3, 4]}], "relation_list": [{"subject": "puromycin aminonucleoside", "object": "hypoxia", "sbj_char_span": [128, 153], "obj_char_span": [18, 25], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 29], "obj_tok_span": [3, 4]}], "umls_entity_list": []}, {"text": "However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.", "entity_list": [{"name": "heart damage", "ent_type": "Disease", "char_span": [138, 150], "ent_id": "D006331", "tok_span": [28, 30]}, {"name": "mitoxantrone", "ent_type": "Chemical", "char_span": [77, 89], "ent_id": "D008942", "tok_span": [15, 20]}, {"name": "cyclophosphamide", "ent_type": "Chemical", "char_span": [34, 50], "ent_id": "D003520", "tok_span": [6, 9]}, {"name": "anthracyclines", "ent_type": "Chemical", "char_span": [54, 68], "ent_id": "D018943", "tok_span": [10, 13]}, {"name": "systemic sclerosis", "ent_type": "Disease", "char_span": [165, 183], "ent_id": "D012595", "tok_span": [34, 36]}], "relation_list": [{"subject": "mitoxantrone", "object": "heart damage", "sbj_char_span": [77, 89], "obj_char_span": [138, 150], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 20], "obj_tok_span": [28, 30]}, {"subject": "cyclophosphamide", "object": "heart damage", "sbj_char_span": [34, 50], "obj_char_span": [138, 150], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [28, 30]}], "umls_entity_list": []}, {"text": "Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.", "entity_list": [{"name": "fenoldopam", "ent_type": "Chemical", "char_span": [180, 190], "ent_id": "D018818", "tok_span": [41, 46]}, {"name": "tumor", "ent_type": "Disease", "char_span": [110, 115], "ent_id": "D009369", "tok_span": [22, 23]}, {"name": "arteritis", "ent_type": "Disease", "char_span": [151, 160], "ent_id": "D001167", "tok_span": [35, 37]}, {"name": "theophylline", "ent_type": "Chemical", "char_span": [195, 207], "ent_id": "D013806", "tok_span": [47, 50]}, {"name": "nitric oxide", "ent_type": "Chemical", "char_span": [47, 59], "ent_id": "D009569", "tok_span": [7, 9]}], "relation_list": [{"subject": "fenoldopam", "object": "arteritis", "sbj_char_span": [180, 190], "obj_char_span": [151, 160], "rel_type": "chemical-induced disease", "sbj_tok_span": [41, 46], "obj_tok_span": [35, 37]}, {"subject": "theophylline", "object": "arteritis", "sbj_char_span": [195, 207], "obj_char_span": [151, 160], "rel_type": "chemical-induced disease", "sbj_tok_span": [47, 50], "obj_tok_span": [35, 37]}], "umls_entity_list": []}, {"text": "Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).", "entity_list": [{"name": "nitric oxide", "ent_type": "Chemical", "char_span": [144, 156], "ent_id": "D009569", "tok_span": [30, 32]}, {"name": "Arteritis", "ent_type": "Disease", "char_span": [0, 9], "ent_id": "D001167", "tok_span": [0, 2]}, {"name": "theophylline", "ent_type": "Chemical", "char_span": [58, 70], "ent_id": "D013806", "tok_span": [15, 18]}, {"name": "fenoldopam", "ent_type": "Chemical", "char_span": [43, 53], "ent_id": "D018818", "tok_span": [9, 14]}, {"name": "tumor", "ent_type": "Disease", "char_span": [216, 221], "ent_id": "D009369", "tok_span": [46, 47]}], "relation_list": [{"subject": "theophylline", "object": "Arteritis", "sbj_char_span": [58, 70], "obj_char_span": [0, 9], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [0, 2]}, {"subject": "fenoldopam", "object": "Arteritis", "sbj_char_span": [43, 53], "obj_char_span": [0, 9], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 14], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Topiramate-induced nephrolithiasis.", "entity_list": [{"name": "nephrolithiasis", "ent_type": "Disease", "char_span": [19, 34], "ent_id": "D053040", "tok_span": [6, 10]}, {"name": "Topiramate", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "C052342", "tok_span": [0, 4]}], "relation_list": [{"subject": "Topiramate", "object": "nephrolithiasis", "sbj_char_span": [0, 10], "obj_char_span": [19, 34], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [6, 10]}], "umls_entity_list": []}, {"text": "We report the first two cases of topiramate-induced nephrolithiasis in the urologic literature.", "entity_list": [{"name": "topiramate", "ent_type": "Chemical", "char_span": [33, 43], "ent_id": "C052342", "tok_span": [7, 11]}, {"name": "nephrolithiasis", "ent_type": "Disease", "char_span": [52, 67], "ent_id": "D053040", "tok_span": [13, 17]}], "relation_list": [{"subject": "topiramate", "object": "nephrolithiasis", "sbj_char_span": [33, 43], "obj_char_span": [52, 67], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?", "entity_list": [{"name": "Spironolactone", "ent_type": "Chemical", "char_span": [0, 14], "ent_id": "D013148", "tok_span": [0, 5]}, {"name": "amphotericin B", "ent_type": "Chemical", "char_span": [57, 71], "ent_id": "D000666", "tok_span": [15, 19]}, {"name": "cancer", "ent_type": "Disease", "char_span": [95, 101], "ent_id": "D009369", "tok_span": [26, 27]}, {"name": "hypokalemia", "ent_type": "Disease", "char_span": [80, 91], "ent_id": "D007008", "tok_span": [21, 25]}], "relation_list": [{"subject": "amphotericin B", "object": "hypokalemia", "sbj_char_span": [57, 71], "obj_char_span": [80, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 19], "obj_tok_span": [21, 25]}], "umls_entity_list": []}, {"text": "This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.", "entity_list": [{"name": "neutropenic", "ent_type": "Disease", "char_span": [127, 138], "ent_id": "D009503", "tok_span": [25, 27]}, {"name": "AmB", "ent_type": "Chemical", "char_span": [151, 154], "ent_id": "D000666", "tok_span": [29, 31]}, {"name": "potassium", "ent_type": "Chemical", "char_span": [74, 83], "ent_id": "D011188", "tok_span": [15, 16]}, {"name": "spironolactone", "ent_type": "Chemical", "char_span": [49, 63], "ent_id": "D013148", "tok_span": [9, 13]}, {"name": "hypokalemia", "ent_type": "Disease", "char_span": [112, 123], "ent_id": "D007008", "tok_span": [20, 24]}], "relation_list": [{"subject": "AmB", "object": "hypokalemia", "sbj_char_span": [151, 154], "obj_char_span": [112, 123], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 31], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.", "entity_list": [{"name": "AmB", "ent_type": "Chemical", "char_span": [170, 173], "ent_id": "D000666", "tok_span": [30, 32]}, {"name": "hypokalemia", "ent_type": "Disease", "char_span": [96, 107], "ent_id": "D007008", "tok_span": [16, 20]}, {"name": "spironolactone", "ent_type": "Chemical", "char_span": [35, 49], "ent_id": "D013148", "tok_span": [6, 10]}, {"name": "potassium", "ent_type": "Chemical", "char_span": [61, 70], "ent_id": "D011188", "tok_span": [12, 13]}, {"name": "neutropenic", "ent_type": "Disease", "char_span": [146, 157], "ent_id": "D009503", "tok_span": [26, 28]}, {"name": "potassium", "ent_type": "Chemical", "char_span": [128, 137], "ent_id": "D011188", "tok_span": [23, 24]}], "relation_list": [{"subject": "AmB", "object": "hypokalemia", "sbj_char_span": [170, 173], "obj_char_span": [96, 107], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 32], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "Here we analyze the occurrence of seizures and neurotoxicity in D2R -/- mice treated with the cholinergic agonist pilocarpine.", "entity_list": [{"name": "neurotoxicity", "ent_type": "Disease", "char_span": [47, 60], "ent_id": "D020258", "tok_span": [8, 10]}, {"name": "seizures", "ent_type": "Disease", "char_span": [34, 42], "ent_id": "D012640", "tok_span": [6, 7]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [114, 125], "ent_id": "D010862", "tok_span": [23, 26]}], "relation_list": [{"subject": "pilocarpine", "object": "seizures", "sbj_char_span": [114, 125], "obj_char_span": [34, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [6, 7]}], "umls_entity_list": []}, {"text": "However, pilocarpine-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA.", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [29, 37], "ent_id": "D012640", "tok_span": [7, 8]}, {"name": "KA", "ent_type": "Chemical", "char_span": [128, 130], "ent_id": "D007608", "tok_span": [29, 30]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [9, 20], "ent_id": "D010862", "tok_span": [2, 5]}], "relation_list": [{"subject": "pilocarpine", "object": "seizures", "sbj_char_span": [9, 20], "obj_char_span": [29, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [7, 8]}, {"subject": "KA", "object": "seizures", "sbj_char_span": [128, 130], "obj_char_span": [29, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 30], "obj_tok_span": [7, 8]}], "umls_entity_list": []}, {"text": "Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children.", "entity_list": [{"name": "hyperprolactinemia", "ent_type": "Disease", "char_span": [33, 51], "ent_id": "D006966", "tok_span": [7, 11]}, {"name": "risperidone", "ent_type": "Chemical", "char_span": [13, 24], "ent_id": "D018967", "tok_span": [2, 5]}, {"name": "dopamine", "ent_type": "Chemical", "char_span": [59, 67], "ent_id": "D004298", "tok_span": [13, 14]}], "relation_list": [{"subject": "risperidone", "object": "hyperprolactinemia", "sbj_char_span": [13, 24], "obj_char_span": [33, 51], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "BACKGROUND: Risperidone, a potent antagonist of both serotonergic (5HT2A) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children.", "entity_list": [{"name": "hyperprolactinemia", "ent_type": "Disease", "char_span": [123, 141], "ent_id": "D006966", "tok_span": [27, 31]}, {"name": "Risperidone", "ent_type": "Chemical", "char_span": [12, 23], "ent_id": "D018967", "tok_span": [2, 5]}], "relation_list": [{"subject": "Risperidone", "object": "hyperprolactinemia", "sbj_char_span": [12, 23], "obj_char_span": [123, 141], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [27, 31]}], "umls_entity_list": []}, {"text": "We report the successful treatment of risperidone-induced hyperprolactinemia with cabergoline in youth.", "entity_list": [{"name": "hyperprolactinemia", "ent_type": "Disease", "char_span": [58, 76], "ent_id": "D006966", "tok_span": [11, 15]}, {"name": "cabergoline", "ent_type": "Chemical", "char_span": [82, 93], "ent_id": "C047047", "tok_span": [16, 19]}, {"name": "risperidone", "ent_type": "Chemical", "char_span": [38, 49], "ent_id": "D018967", "tok_span": [6, 9]}], "relation_list": [{"subject": "risperidone", "object": "hyperprolactinemia", "sbj_char_span": [38, 49], "obj_char_span": [58, 76], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "METHODS: We undertook a retrospective case review of four children with risperidone-induced hyperprolactinemia treated with cabergoline.", "entity_list": [{"name": "risperidone", "ent_type": "Chemical", "char_span": [72, 83], "ent_id": "D018967", "tok_span": [14, 17]}, {"name": "cabergoline", "ent_type": "Chemical", "char_span": [124, 135], "ent_id": "C047047", "tok_span": [25, 28]}, {"name": "hyperprolactinemia", "ent_type": "Disease", "char_span": [92, 110], "ent_id": "D006966", "tok_span": [19, 23]}], "relation_list": [{"subject": "risperidone", "object": "hyperprolactinemia", "sbj_char_span": [72, 83], "obj_char_span": [92, 110], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Cabergoline may be useful for the treatment of risperidone-induced hyperprolactinemia in youth; however, further research is needed.", "entity_list": [{"name": "Cabergoline", "ent_type": "Chemical", "char_span": [13, 24], "ent_id": "C047047", "tok_span": [2, 5]}, {"name": "hyperprolactinemia", "ent_type": "Disease", "char_span": [80, 98], "ent_id": "D006966", "tok_span": [17, 21]}, {"name": "risperidone", "ent_type": "Chemical", "char_span": [60, 71], "ent_id": "D018967", "tok_span": [12, 15]}], "relation_list": [{"subject": "risperidone", "object": "hyperprolactinemia", "sbj_char_span": [60, 71], "obj_char_span": [80, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [17, 21]}], "umls_entity_list": []}, {"text": "Cholestatic jaundice associated with the use of metformin.", "entity_list": [{"name": "metformin", "ent_type": "Chemical", "char_span": [48, 57], "ent_id": "D008687", "tok_span": [12, 13]}, {"name": "Cholestatic jaundice", "ent_type": "Disease", "char_span": [0, 20], "ent_id": "D041781", "tok_span": [0, 7]}], "relation_list": [{"subject": "metformin", "object": "Cholestatic jaundice", "sbj_char_span": [48, 57], "obj_char_span": [0, 20], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [0, 7]}], "umls_entity_list": []}, {"text": "We report a patient who developed cholestatic jaundice shortly after initiation of treatment with metformin hydrochloride.", "entity_list": [{"name": "cholestatic jaundice", "ent_type": "Disease", "char_span": [34, 54], "ent_id": "D041781", "tok_span": [6, 12]}, {"name": "metformin hydrochloride", "ent_type": "Chemical", "char_span": [98, 121], "ent_id": "D008687", "tok_span": [18, 20]}], "relation_list": [{"subject": "metformin hydrochloride", "object": "cholestatic jaundice", "sbj_char_span": [98, 121], "obj_char_span": [34, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 20], "obj_tok_span": [6, 12]}], "umls_entity_list": []}, {"text": "Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction.", "entity_list": [{"name": "visual field constriction", "ent_type": "Disease", "char_span": [142, 167], "ent_id": "D014786", "tok_span": [30, 34]}, {"name": "vigabatrin", "ent_type": "Chemical", "char_span": [120, 130], "ent_id": "D020888", "tok_span": [25, 28]}], "relation_list": [{"subject": "vigabatrin", "object": "visual field constriction", "sbj_char_span": [120, 130], "obj_char_span": [142, 167], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 28], "obj_tok_span": [30, 34]}], "umls_entity_list": []}, {"text": "PURPOSE: Symptomatic visual field constriction thought to be associated with vigabatrin has been reported.", "entity_list": [{"name": "vigabatrin", "ent_type": "Chemical", "char_span": [77, 87], "ent_id": "D020888", "tok_span": [13, 16]}, {"name": "visual field constriction", "ent_type": "Disease", "char_span": [21, 46], "ent_id": "D014786", "tok_span": [4, 8]}], "relation_list": [{"subject": "vigabatrin", "object": "visual field constriction", "sbj_char_span": [77, 87], "obj_char_span": [21, 46], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "The current study investigated the visual fields and visual electrophysiology of eight patients with known vigabatrin-attributed visual field loss, three of whom were reported previously.", "entity_list": [{"name": "visual field loss", "ent_type": "Disease", "char_span": [129, 146], "ent_id": "D014786", "tok_span": [21, 24]}, {"name": "vigabatrin", "ent_type": "Chemical", "char_span": [107, 117], "ent_id": "D020888", "tok_span": [16, 19]}], "relation_list": [{"subject": "vigabatrin", "object": "visual field loss", "sbj_char_span": [107, 117], "obj_char_span": [129, 146], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [21, 24]}], "umls_entity_list": []}, {"text": "CONCLUSION: Marked visual field constriction appears to be associated with vigabatrin therapy.", "entity_list": [{"name": "vigabatrin", "ent_type": "Chemical", "char_span": [75, 85], "ent_id": "D020888", "tok_span": [13, 16]}, {"name": "visual field constriction", "ent_type": "Disease", "char_span": [19, 44], "ent_id": "D014786", "tok_span": [4, 8]}], "relation_list": [{"subject": "vigabatrin", "object": "visual field constriction", "sbj_char_span": [75, 85], "obj_char_span": [19, 44], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.", "entity_list": [{"name": "nephrotoxicity", "ent_type": "Disease", "char_span": [51, 65], "ent_id": "D007674", "tok_span": [11, 14]}, {"name": "PTLD", "ent_type": "Disease", "char_span": [179, 183], "ent_id": "D008232", "tok_span": [47, 49]}, {"name": "CsA", "ent_type": "Chemical", "char_span": [40, 43], "ent_id": "D016572", "tok_span": [6, 8]}, {"name": "Tac", "ent_type": "Chemical", "char_span": [85, 88], "ent_id": "D016559", "tok_span": [22, 24]}, {"name": "Tac", "ent_type": "Chemical", "char_span": [47, 50], "ent_id": "D016559", "tok_span": [9, 11]}, {"name": "CsA", "ent_type": "Chemical", "char_span": [78, 81], "ent_id": "D016572", "tok_span": [19, 21]}, {"name": "facial dysmorphism", "ent_type": "Disease", "char_span": [110, 128], "ent_id": "-1", "tok_span": [30, 36]}, {"name": "toxicity", "ent_type": "Disease", "char_span": [89, 97], "ent_id": "D064420", "tok_span": [24, 25]}, {"name": "hepatotoxicity", "ent_type": "Disease", "char_span": [207, 221], "ent_id": "D056486", "tok_span": [57, 59]}, {"name": "posttransplant lymphoproliferative disorder", "ent_type": "Disease", "char_span": [134, 177], "ent_id": "D008232", "tok_span": [40, 46]}], "relation_list": [{"subject": "CsA", "object": "nephrotoxicity", "sbj_char_span": [40, 43], "obj_char_span": [51, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [11, 14]}, {"subject": "Tac", "object": "nephrotoxicity", "sbj_char_span": [85, 88], "obj_char_span": [51, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 24], "obj_tok_span": [11, 14]}, {"subject": "CsA", "object": "nephrotoxicity", "sbj_char_span": [78, 81], "obj_char_span": [51, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 21], "obj_tok_span": [11, 14]}, {"subject": "Tac", "object": "nephrotoxicity", "sbj_char_span": [47, 50], "obj_char_span": [51, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 11], "obj_tok_span": [11, 14]}], "umls_entity_list": []}, {"text": "Worsening of levodopa-induced dyskinesias by motor and mental tasks.", "entity_list": [{"name": "levodopa", "ent_type": "Chemical", "char_span": [13, 21], "ent_id": "D007980", "tok_span": [4, 7]}, {"name": "dyskinesias", "ent_type": "Disease", "char_span": [30, 41], "ent_id": "D004409", "tok_span": [9, 13]}], "relation_list": [{"subject": "levodopa", "object": "dyskinesias", "sbj_char_span": [13, 21], "obj_char_span": [30, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [9, 13]}], "umls_entity_list": []}, {"text": "Ten patients who had Parkinson's disease with disabling dyskinesia were included in this study to evaluate the role of mental (mental calculation) and motor (flexion/extension of right fingers, flexion/extension of left fingers, flexion/extension of the neck, speaking aloud) tasks on the worsening of peak-dose dyskinesia following administration of an effective single dose of apomorphine.", "entity_list": [{"name": "dyskinesia", "ent_type": "Disease", "char_span": [312, 322], "ent_id": "D004409", "tok_span": [66, 70]}, {"name": "Parkinson's disease", "ent_type": "Disease", "char_span": [21, 40], "ent_id": "D010300", "tok_span": [4, 8]}, {"name": "apomorphine", "ent_type": "Chemical", "char_span": [379, 390], "ent_id": "D001058", "tok_span": [78, 83]}, {"name": "dyskinesia", "ent_type": "Disease", "char_span": [56, 66], "ent_id": "D004409", "tok_span": [11, 15]}], "relation_list": [{"subject": "apomorphine", "object": "dyskinesia", "sbj_char_span": [379, 390], "obj_char_span": [56, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [78, 83], "obj_tok_span": [11, 15]}, {"subject": "apomorphine", "object": "dyskinesia", "sbj_char_span": [379, 390], "obj_char_span": [312, 322], "rel_type": "chemical-induced disease", "sbj_tok_span": [78, 83], "obj_tok_span": [66, 70]}], "umls_entity_list": []}, {"text": "Structural and functional impairment of mitochondria in adriamycin-induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression.", "entity_list": [{"name": "cardiomyopathy", "ent_type": "Disease", "char_span": [75, 89], "ent_id": "D009202", "tok_span": [13, 14]}, {"name": "Structural and functional impairment of mitochondria", "ent_type": "Disease", "char_span": [0, 52], "ent_id": "D028361", "tok_span": [0, 6]}, {"name": "adriamycin", "ent_type": "Chemical", "char_span": [56, 66], "ent_id": "D004317", "tok_span": [7, 11]}], "relation_list": [{"subject": "adriamycin", "object": "Structural and functional impairment of mitochondria", "sbj_char_span": [56, 66], "obj_char_span": [0, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [0, 6]}], "umls_entity_list": []}, {"text": "Our results indicated that 1) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.", "entity_list": [{"name": "bradycardia", "ent_type": "Disease", "char_span": [108, 119], "ent_id": "D001919", "tok_span": [17, 21]}, {"name": "swelling", "ent_type": "Disease", "char_span": [295, 303], "ent_id": "D004487", "tok_span": [60, 61]}, {"name": "ADR", "ent_type": "Chemical", "char_span": [53, 56], "ent_id": "D004317", "tok_span": [10, 12]}, {"name": "cardiovascular arrhythmias", "ent_type": "Disease", "char_span": [64, 90], "ent_id": "D001145", "tok_span": [13, 15]}], "relation_list": [{"subject": "ADR", "object": "bradycardia", "sbj_char_span": [53, 56], "obj_char_span": [108, 119], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 12], "obj_tok_span": [17, 21]}], "umls_entity_list": []}, {"text": "Knowing that heart mitochondria represent almost 40% of heart muscle by weight, we conclude that the deteriorating effects of ADR on cardiovascular function involve mitochondrial structural and functional impairment.", "entity_list": [{"name": "ADR", "ent_type": "Chemical", "char_span": [126, 129], "ent_id": "D004317", "tok_span": [23, 25]}, {"name": "mitochondrial structural and functional impairment", "ent_type": "Disease", "char_span": [165, 215], "ent_id": "D028361", "tok_span": [29, 34]}], "relation_list": [{"subject": "ADR", "object": "mitochondrial structural and functional impairment", "sbj_char_span": [126, 129], "obj_char_span": [165, 215], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 25], "obj_tok_span": [29, 34]}], "umls_entity_list": []}, {"text": "Enhanced bradycardia induced by beta-adrenoceptor antagonists in rats pretreated with isoniazid.", "entity_list": [{"name": "bradycardia", "ent_type": "Disease", "char_span": [9, 20], "ent_id": "D001919", "tok_span": [1, 5]}, {"name": "isoniazid", "ent_type": "Chemical", "char_span": [86, 95], "ent_id": "D007538", "tok_span": [17, 21]}], "relation_list": [{"subject": "isoniazid", "object": "bradycardia", "sbj_char_span": [86, 95], "obj_char_span": [9, 20], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [1, 5]}], "umls_entity_list": []}, {"text": "High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).", "entity_list": [{"name": "gamma-aminobutyric acid", "ent_type": "Chemical", "char_span": [190, 213], "ent_id": "D005680", "tok_span": [33, 40]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [33, 44], "ent_id": "D007022", "tok_span": [8, 9]}, {"name": "GABA", "ent_type": "Chemical", "char_span": [215, 219], "ent_id": "D005680", "tok_span": [41, 42]}, {"name": "isoniazid", "ent_type": "Chemical", "char_span": [14, 23], "ent_id": "D007538", "tok_span": [3, 7]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [119, 130], "ent_id": "D001919", "tok_span": [20, 24]}, {"name": "tachycardia", "ent_type": "Disease", "char_span": [104, 115], "ent_id": "D013610", "tok_span": [18, 19]}], "relation_list": [{"subject": "isoniazid", "object": "bradycardia", "sbj_char_span": [14, 23], "obj_char_span": [119, 130], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 7], "obj_tok_span": [20, 24]}, {"subject": "isoniazid", "object": "hypotension", "sbj_char_span": [14, 23], "obj_char_span": [33, 44], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 7], "obj_tok_span": [8, 9]}], "umls_entity_list": []}, {"text": "In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.", "entity_list": [{"name": "bradycardia", "ent_type": "Disease", "char_span": [63, 74], "ent_id": "D001919", "tok_span": [14, 18]}, {"name": "isoniazid", "ent_type": "Chemical", "char_span": [50, 59], "ent_id": "D007538", "tok_span": [9, 13]}, {"name": "chloralose", "ent_type": "Chemical", "char_span": [158, 168], "ent_id": "D002698", "tok_span": [34, 37]}, {"name": "urethane", "ent_type": "Chemical", "char_span": [169, 177], "ent_id": "D014520", "tok_span": [38, 40]}], "relation_list": [{"subject": "isoniazid", "object": "bradycardia", "sbj_char_span": [50, 59], "obj_char_span": [63, 74], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [14, 18]}], "umls_entity_list": []}, {"text": "Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.", "entity_list": [{"name": "bradycardia", "ent_type": "Disease", "char_span": [34, 45], "ent_id": "D001919", "tok_span": [6, 10]}, {"name": "clonidine", "ent_type": "Chemical", "char_span": [116, 125], "ent_id": "D003000", "tok_span": [34, 36]}, {"name": "labetalol", "ent_type": "Chemical", "char_span": [75, 84], "ent_id": "D007741", "tok_span": [21, 24]}, {"name": "carbachol", "ent_type": "Chemical", "char_span": [158, 167], "ent_id": "D002217", "tok_span": [45, 48]}, {"name": "hexamethonium", "ent_type": "Chemical", "char_span": [141, 154], "ent_id": "D018738", "tok_span": [40, 44]}, {"name": "atenolol", "ent_type": "Chemical", "char_span": [89, 97], "ent_id": "D001262", "tok_span": [25, 29]}, {"name": "pindolol", "ent_type": "Chemical", "char_span": [65, 73], "ent_id": "D010869", "tok_span": [16, 20]}, {"name": "Isoniazid", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D007538", "tok_span": [0, 4]}, {"name": "propranolol", "ent_type": "Chemical", "char_span": [52, 63], "ent_id": "D011433", "tok_span": [11, 15]}], "relation_list": [{"subject": "Isoniazid", "object": "bradycardia", "sbj_char_span": [0, 9], "obj_char_span": [34, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [6, 10]}], "umls_entity_list": []}, {"text": "Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)\n OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.", "entity_list": [{"name": "folic acid", "ent_type": "Chemical", "char_span": [61, 71], "ent_id": "D005492", "tok_span": [14, 17]}, {"name": "folic acid", "ent_type": "Chemical", "char_span": [121, 131], "ent_id": "D005492", "tok_span": [27, 30]}, {"name": "epilepsy", "ent_type": "Disease", "char_span": [282, 290], "ent_id": "D004827", "tok_span": [54, 55]}, {"name": "SLE", "ent_type": "Disease", "char_span": [56, 59], "ent_id": "D008180", "tok_span": [12, 13]}, {"name": "epileptic", "ent_type": "Disease", "char_span": [175, 184], "ent_id": "D004827", "tok_span": [37, 38]}, {"name": "birth defects", "ent_type": "Disease", "char_span": [264, 277], "ent_id": "D000014", "tok_span": [51, 53]}, {"name": "folic acid", "ent_type": "Chemical", "char_span": [26, 36], "ent_id": "D005492", "tok_span": [6, 9]}, {"name": "epilepsy", "ent_type": "Disease", "char_span": [76, 84], "ent_id": "D004827", "tok_span": [18, 19]}], "relation_list": [{"subject": "folic acid", "object": "SLE", "sbj_char_span": [121, 131], "obj_char_span": [56, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 30], "obj_tok_span": [12, 13]}, {"subject": "folic acid", "object": "SLE", "sbj_char_span": [26, 36], "obj_char_span": [56, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [12, 13]}, {"subject": "folic acid", "object": "SLE", "sbj_char_span": [61, 71], "obj_char_span": [56, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [12, 13]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [214, 222], "ent_id": "D012640", "tok_span": [44, 45]}, {"name": "folic acid", "ent_type": "Chemical", "char_span": [180, 190], "ent_id": "D005492", "tok_span": [37, 40]}, {"name": "epileptic", "ent_type": "Disease", "char_span": [17, 26], "ent_id": "D004827", "tok_span": [3, 4]}, {"name": "autoimmune disease", "ent_type": "Disease", "char_span": [46, 64], "ent_id": "D001327", "tok_span": [8, 10]}, {"name": "lupus", "ent_type": "Disease", "char_span": [88, 93], "ent_id": "D008180", "tok_span": [15, 16]}], "relation_list": [{"subject": "folic acid", "object": "seizures", "sbj_char_span": [180, 190], "obj_char_span": [214, 222], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 40], "obj_tok_span": [44, 45]}, {"subject": "folic acid", "object": "lupus", "sbj_char_span": [180, 190], "obj_char_span": [88, 93], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 40], "obj_tok_span": [15, 16]}], "umls_entity_list": []}, {"text": "Clarithromycin-induced ventricular tachycardia.", "entity_list": [{"name": "Clarithromycin", "ent_type": "Chemical", "char_span": [0, 14], "ent_id": "D017291", "tok_span": [0, 3]}, {"name": "ventricular tachycardia", "ent_type": "Disease", "char_span": [23, 46], "ent_id": "D017180", "tok_span": [5, 7]}], "relation_list": [{"subject": "Clarithromycin", "object": "ventricular tachycardia", "sbj_char_span": [0, 14], "obj_char_span": [23, 46], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "Although the side-effect profile of erythromycin is established, including gastroenteritis and interactions with other drugs subject to hepatic mixed-function oxidase metabolism, experience with the newer macrolides is still being recorded.", "entity_list": [{"name": "gastroenteritis", "ent_type": "Disease", "char_span": [75, 90], "ent_id": "D005759", "tok_span": [13, 16]}, {"name": "macrolides", "ent_type": "Chemical", "char_span": [205, 215], "ent_id": "D018942", "tok_span": [34, 37]}, {"name": "erythromycin", "ent_type": "Chemical", "char_span": [36, 48], "ent_id": "D004917", "tok_span": [7, 9]}], "relation_list": [{"subject": "erythromycin", "object": "gastroenteritis", "sbj_char_span": [36, 48], "obj_char_span": [75, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 9], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "Persistent nephrogenic diabetes insipidus following lithium therapy.", "entity_list": [{"name": "lithium", "ent_type": "Chemical", "char_span": [52, 59], "ent_id": "D008094", "tok_span": [10, 11]}, {"name": "nephrogenic diabetes insipidus", "ent_type": "Disease", "char_span": [11, 41], "ent_id": "D018500", "tok_span": [2, 9]}], "relation_list": [{"subject": "lithium", "object": "nephrogenic diabetes insipidus", "sbj_char_span": [52, 59], "obj_char_span": [11, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [2, 9]}], "umls_entity_list": []}, {"text": "Ten years previously he had been diagnosed to have lithium-induced nephrogenic diabetes insipidus, and lithium therapy had been discontinued.", "entity_list": [{"name": "nephrogenic diabetes insipidus", "ent_type": "Disease", "char_span": [67, 97], "ent_id": "D018500", "tok_span": [12, 19]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [51, 58], "ent_id": "D008094", "tok_span": [9, 10]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [103, 110], "ent_id": "D008094", "tok_span": [21, 22]}], "relation_list": [{"subject": "lithium", "object": "nephrogenic diabetes insipidus", "sbj_char_span": [51, 58], "obj_char_span": [67, 97], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [12, 19]}, {"subject": "lithium", "object": "nephrogenic diabetes insipidus", "sbj_char_span": [103, 110], "obj_char_span": [67, 97], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 22], "obj_tok_span": [12, 19]}], "umls_entity_list": []}, {"text": "He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion, with clear evidence of nephrogenic diabetes insipidus.", "entity_list": [{"name": "nephrogenic diabetes insipidus", "ent_type": "Disease", "char_span": [191, 221], "ent_id": "D018500", "tok_span": [36, 43]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [54, 61], "ent_id": "D008094", "tok_span": [11, 12]}, {"name": "polyuric", "ent_type": "Disease", "char_span": [24, 32], "ent_id": "D011141", "tok_span": [6, 8]}, {"name": "vasopressin", "ent_type": "Chemical", "char_span": [145, 156], "ent_id": "D014667", "tok_span": [27, 30]}], "relation_list": [{"subject": "lithium", "object": "nephrogenic diabetes insipidus", "sbj_char_span": [54, 61], "obj_char_span": [191, 221], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [36, 43]}, {"subject": "lithium", "object": "polyuric", "sbj_char_span": [54, 61], "obj_char_span": [24, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "Lithium induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after lithium was stopped.", "entity_list": [{"name": "lithium", "ent_type": "Chemical", "char_span": [161, 168], "ent_id": "D008094", "tok_span": [30, 31]}, {"name": "nephrogenic diabetes insipidus", "ent_type": "Disease", "char_span": [16, 46], "ent_id": "D018500", "tok_span": [3, 10]}, {"name": "polyuria", "ent_type": "Disease", "char_span": [106, 114], "ent_id": "D011141", "tok_span": [20, 22]}, {"name": "Lithium", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "D008094", "tok_span": [0, 2]}], "relation_list": [{"subject": "lithium", "object": "nephrogenic diabetes insipidus", "sbj_char_span": [161, 168], "obj_char_span": [16, 46], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 31], "obj_tok_span": [3, 10]}, {"subject": "Lithium", "object": "nephrogenic diabetes insipidus", "sbj_char_span": [0, 7], "obj_char_span": [16, 46], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [3, 10]}, {"subject": "lithium", "object": "polyuria", "sbj_char_span": [161, 168], "obj_char_span": [106, 114], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 31], "obj_tok_span": [20, 22]}, {"subject": "Lithium", "object": "polyuria", "sbj_char_span": [0, 7], "obj_char_span": [106, 114], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [20, 22]}], "umls_entity_list": []}, {"text": "We discuss the possible renal mechanisms and the implications for management of patients with lithium-induced nephrogenic diabetes insipidus.", "entity_list": [{"name": "lithium", "ent_type": "Chemical", "char_span": [94, 101], "ent_id": "D008094", "tok_span": [14, 15]}, {"name": "nephrogenic diabetes insipidus", "ent_type": "Disease", "char_span": [110, 140], "ent_id": "D018500", "tok_span": [17, 24]}], "relation_list": [{"subject": "lithium", "object": "nephrogenic diabetes insipidus", "sbj_char_span": [94, 101], "obj_char_span": [110, 140], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [17, 24]}], "umls_entity_list": []}, {"text": "Venous complications of midazolam versus diazepam.", "entity_list": [{"name": "Venous complications", "ent_type": "Disease", "char_span": [0, 20], "ent_id": "D014652", "tok_span": [0, 3]}, {"name": "diazepam", "ent_type": "Chemical", "char_span": [41, 49], "ent_id": "D003975", "tok_span": [8, 11]}, {"name": "midazolam", "ent_type": "Chemical", "char_span": [24, 33], "ent_id": "D008874", "tok_span": [4, 7]}], "relation_list": [{"subject": "diazepam", "object": "Venous complications", "sbj_char_span": [41, 49], "obj_char_span": [0, 20], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [0, 3]}, {"subject": "midazolam", "object": "Venous complications", "sbj_char_span": [24, 33], "obj_char_span": [0, 20], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "Although some studies have suggested fewer venous complications are associated with midazolam than with diazepam for endoscopic procedures, this variable has not been well documented.", "entity_list": [{"name": "midazolam", "ent_type": "Chemical", "char_span": [84, 93], "ent_id": "D008874", "tok_span": [11, 14]}, {"name": "venous complications", "ent_type": "Disease", "char_span": [43, 63], "ent_id": "D014652", "tok_span": [6, 8]}, {"name": "diazepam", "ent_type": "Chemical", "char_span": [104, 112], "ent_id": "D003975", "tok_span": [16, 19]}], "relation_list": [{"subject": "midazolam", "object": "venous complications", "sbj_char_span": [84, 93], "obj_char_span": [43, 63], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [6, 8]}, {"subject": "diazepam", "object": "venous complications", "sbj_char_span": [104, 112], "obj_char_span": [43, 63], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "We prospectively evaluated the incidence of venous complications after intravenous injection of diazepam or midazolam in 122 consecutive patients undergoing colonoscopy and esophagogastroduodenoscopy.", "entity_list": [{"name": "venous complications", "ent_type": "Disease", "char_span": [44, 64], "ent_id": "D014652", "tok_span": [6, 8]}, {"name": "midazolam", "ent_type": "Chemical", "char_span": [108, 117], "ent_id": "D008874", "tok_span": [16, 19]}, {"name": "diazepam", "ent_type": "Chemical", "char_span": [96, 104], "ent_id": "D003975", "tok_span": [12, 15]}], "relation_list": [{"subject": "diazepam", "object": "venous complications", "sbj_char_span": [96, 104], "obj_char_span": [44, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [6, 8]}, {"subject": "midazolam", "object": "venous complications", "sbj_char_span": [108, 117], "obj_char_span": [44, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "Overall, venous complications were more frequent with diazepam (22 of 62 patients) than with midazolam (4 of 60 patients) (p < 0.001).", "entity_list": [{"name": "venous complications", "ent_type": "Disease", "char_span": [9, 29], "ent_id": "D014652", "tok_span": [2, 4]}, {"name": "midazolam", "ent_type": "Chemical", "char_span": [93, 102], "ent_id": "D008874", "tok_span": [19, 22]}, {"name": "diazepam", "ent_type": "Chemical", "char_span": [54, 62], "ent_id": "D003975", "tok_span": [8, 11]}], "relation_list": [{"subject": "midazolam", "object": "venous complications", "sbj_char_span": [93, 102], "obj_char_span": [9, 29], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 22], "obj_tok_span": [2, 4]}, {"subject": "diazepam", "object": "venous complications", "sbj_char_span": [54, 62], "obj_char_span": [9, 29], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [2, 4]}], "umls_entity_list": []}, {"text": "Tetany and rhabdomyolysis due to surreptitious furosemide--importance of magnesium supplementation.", "entity_list": [{"name": "furosemide", "ent_type": "Chemical", "char_span": [47, 57], "ent_id": "D005665", "tok_span": [13, 17]}, {"name": "rhabdomyolysis", "ent_type": "Disease", "char_span": [11, 25], "ent_id": "D012206", "tok_span": [3, 7]}, {"name": "magnesium", "ent_type": "Chemical", "char_span": [73, 82], "ent_id": "D008274", "tok_span": [21, 22]}, {"name": "Tetany", "ent_type": "Disease", "char_span": [0, 6], "ent_id": "D013746", "tok_span": [0, 2]}], "relation_list": [{"subject": "furosemide", "object": "rhabdomyolysis", "sbj_char_span": [47, 57], "obj_char_span": [11, 25], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [3, 7]}, {"subject": "furosemide", "object": "Tetany", "sbj_char_span": [47, 57], "obj_char_span": [0, 6], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Loss of glutamate decarboxylase mRNA-containing neurons in the rat dentate gyrus following pilocarpine-induced seizures.", "entity_list": [{"name": "pilocarpine", "ent_type": "Chemical", "char_span": [91, 102], "ent_id": "D010862", "tok_span": [17, 20]}, {"name": "seizures", "ent_type": "Disease", "char_span": [111, 119], "ent_id": "D012640", "tok_span": [22, 23]}, {"name": "glutamate", "ent_type": "Chemical", "char_span": [8, 17], "ent_id": "D018698", "tok_span": [2, 3]}], "relation_list": [{"subject": "pilocarpine", "object": "seizures", "sbj_char_span": [91, 102], "obj_char_span": [111, 119], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [22, 23]}], "umls_entity_list": []}, {"text": "Sprague-Dawley rats were injected intraperitoneally with pilocarpine, and the hippocampal formation was studied histologically at 1, 2, 4, and 8 week intervals after pilocarpine-induced seizures.", "entity_list": [{"name": "pilocarpine", "ent_type": "Chemical", "char_span": [57, 68], "ent_id": "D010862", "tok_span": [10, 13]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [166, 177], "ent_id": "D010862", "tok_span": [33, 36]}, {"name": "seizures", "ent_type": "Disease", "char_span": [186, 194], "ent_id": "D012640", "tok_span": [38, 39]}], "relation_list": [{"subject": "pilocarpine", "object": "seizures", "sbj_char_span": [57, 68], "obj_char_span": [186, 194], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [38, 39]}, {"subject": "pilocarpine", "object": "seizures", "sbj_char_span": [166, 177], "obj_char_span": [186, 194], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 36], "obj_tok_span": [38, 39]}], "umls_entity_list": []}, {"text": "Protective effect of misoprostol on indomethacin induced renal dysfunction in elderly patients.", "entity_list": [{"name": "misoprostol", "ent_type": "Chemical", "char_span": [21, 32], "ent_id": "D016595", "tok_span": [5, 8]}, {"name": "indomethacin", "ent_type": "Chemical", "char_span": [36, 48], "ent_id": "D007213", "tok_span": [9, 12]}, {"name": "renal dysfunction", "ent_type": "Disease", "char_span": [57, 74], "ent_id": "D007674", "tok_span": [13, 15]}], "relation_list": [{"subject": "indomethacin", "object": "renal dysfunction", "sbj_char_span": [36, 48], "obj_char_span": [57, 74], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "CONCLUSION: Hospitalized elderly patients are at risk for developing indomethacin related renal dysfunction.", "entity_list": [{"name": "indomethacin", "ent_type": "Chemical", "char_span": [69, 81], "ent_id": "D007213", "tok_span": [11, 14]}, {"name": "renal dysfunction", "ent_type": "Disease", "char_span": [90, 107], "ent_id": "D007674", "tok_span": [15, 17]}], "relation_list": [{"subject": "indomethacin", "object": "renal dysfunction", "sbj_char_span": [69, 81], "obj_char_span": [90, 107], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats.", "entity_list": [{"name": "ouabain", "ent_type": "Chemical", "char_span": [91, 98], "ent_id": "D010042", "tok_span": [22, 25]}, {"name": "pindolol", "ent_type": "Chemical", "char_span": [67, 75], "ent_id": "D010869", "tok_span": [16, 20]}, {"name": "arrhythmia", "ent_type": "Disease", "char_span": [99, 109], "ent_id": "D001145", "tok_span": [25, 27]}, {"name": "propranolol", "ent_type": "Chemical", "char_span": [51, 62], "ent_id": "D011433", "tok_span": [11, 15]}], "relation_list": [{"subject": "ouabain", "object": "arrhythmia", "sbj_char_span": [91, 98], "obj_char_span": [99, 109], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 25], "obj_tok_span": [25, 27]}], "umls_entity_list": []}, {"text": "Chorea associated with oral contraception.", "entity_list": [{"name": "oral contraception", "ent_type": "Chemical", "char_span": [23, 41], "ent_id": "D003276", "tok_span": [4, 7]}, {"name": "Chorea", "ent_type": "Disease", "char_span": [0, 6], "ent_id": "D002819", "tok_span": [0, 2]}], "relation_list": [{"subject": "oral contraception", "object": "Chorea", "sbj_char_span": [23, 41], "obj_char_span": [0, 6], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Three patients developed chorea while receiving oral contraceptives.", "entity_list": [{"name": "oral contraceptives", "ent_type": "Chemical", "char_span": [48, 67], "ent_id": "D003276", "tok_span": [7, 10]}, {"name": "chorea", "ent_type": "Disease", "char_span": [25, 31], "ent_id": "D002819", "tok_span": [3, 5]}], "relation_list": [{"subject": "oral contraceptives", "object": "chorea", "sbj_char_span": [48, 67], "obj_char_span": [25, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "The third patient had acute amphetamine-induced chorea after prolonged oral contraception.", "entity_list": [{"name": "oral contraception", "ent_type": "Chemical", "char_span": [71, 89], "ent_id": "D003276", "tok_span": [15, 18]}, {"name": "chorea", "ent_type": "Disease", "char_span": [48, 54], "ent_id": "D002819", "tok_span": [11, 13]}, {"name": "amphetamine", "ent_type": "Chemical", "char_span": [28, 39], "ent_id": "D000661", "tok_span": [5, 9]}], "relation_list": [{"subject": "amphetamine", "object": "chorea", "sbj_char_span": [28, 39], "obj_char_span": [48, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [11, 13]}, {"subject": "oral contraception", "object": "chorea", "sbj_char_span": [71, 89], "obj_char_span": [48, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [11, 13]}], "umls_entity_list": []}, {"text": "Ammonia coma was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1.7 mmol NH4CL.", "entity_list": [{"name": "Ammonia", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "D000641", "tok_span": [0, 3]}, {"name": "NH4CL", "ent_type": "Chemical", "char_span": [101, 106], "ent_id": "D000643", "tok_span": [23, 26]}, {"name": "coma", "ent_type": "Disease", "char_span": [8, 12], "ent_id": "D003128", "tok_span": [3, 5]}], "relation_list": [{"subject": "NH4CL", "object": "coma", "sbj_char_span": [101, 106], "obj_char_span": [8, 12], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "Heparin-induced thrombocytopenia after liver transplantation.", "entity_list": [{"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [16, 32], "ent_id": "D013921", "tok_span": [4, 6]}, {"name": "Heparin", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "D006493", "tok_span": [0, 2]}], "relation_list": [{"subject": "Heparin", "object": "thrombocytopenia", "sbj_char_span": [0, 7], "obj_char_span": [16, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "Heparin-induced thrombocytopenia (HIT) is an adverse immune-mediated reaction to heparin, resulting in platelet count decreases of more than 50%.", "entity_list": [{"name": "heparin", "ent_type": "Chemical", "char_span": [81, 88], "ent_id": "D006493", "tok_span": [18, 19]}, {"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [16, 32], "ent_id": "D013921", "tok_span": [4, 6]}, {"name": "HIT", "ent_type": "Disease", "char_span": [34, 37], "ent_id": "D013921", "tok_span": [7, 9]}, {"name": "Heparin", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "D006493", "tok_span": [0, 2]}], "relation_list": [{"subject": "heparin", "object": "HIT", "sbj_char_span": [81, 88], "obj_char_span": [34, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [7, 9]}, {"subject": "Heparin", "object": "HIT", "sbj_char_span": [0, 7], "obj_char_span": [34, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [7, 9]}, {"subject": "Heparin", "object": "thrombocytopenia", "sbj_char_span": [0, 7], "obj_char_span": [16, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [4, 6]}, {"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [81, 88], "obj_char_span": [16, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "The frequencies of HIT after liver transplantation and platelet factor 4/heparin-reactive antibody (HIT antibody) positivity in liver transplantation patients, however, are unknown.", "entity_list": [{"name": "HIT", "ent_type": "Disease", "char_span": [100, 103], "ent_id": "D013921", "tok_span": [18, 20]}, {"name": "HIT", "ent_type": "Disease", "char_span": [19, 22], "ent_id": "D013921", "tok_span": [3, 5]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [73, 80], "ent_id": "D006493", "tok_span": [13, 14]}], "relation_list": [{"subject": "heparin", "object": "HIT", "sbj_char_span": [73, 80], "obj_char_span": [19, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 14], "obj_tok_span": [3, 5]}, {"subject": "heparin", "object": "HIT", "sbj_char_span": [73, 80], "obj_char_span": [100, 103], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 14], "obj_tok_span": [18, 20]}], "umls_entity_list": []}, {"text": "None of the subjects/patients developed UFH-related HIT.", "entity_list": [{"name": "HIT", "ent_type": "Disease", "char_span": [52, 55], "ent_id": "D013921", "tok_span": [11, 13]}, {"name": "UFH", "ent_type": "Chemical", "char_span": [40, 43], "ent_id": "D006493", "tok_span": [7, 9]}], "relation_list": [{"subject": "UFH", "object": "HIT", "sbj_char_span": [40, 43], "obj_char_span": [52, 55], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 9], "obj_tok_span": [11, 13]}], "umls_entity_list": []}, {"text": "PTU-associated vasculitis in a girl with Turner Syndrome and Graves' disease.", "entity_list": [{"name": "vasculitis", "ent_type": "Disease", "char_span": [15, 25], "ent_id": "D014657", "tok_span": [4, 6]}, {"name": "Turner Syndrome", "ent_type": "Disease", "char_span": [41, 56], "ent_id": "D014424", "tok_span": [10, 12]}, {"name": "Graves' disease", "ent_type": "Disease", "char_span": [61, 76], "ent_id": "D006111", "tok_span": [13, 17]}, {"name": "PTU", "ent_type": "Chemical", "char_span": [0, 3], "ent_id": "D011441", "tok_span": [0, 2]}], "relation_list": [{"subject": "PTU", "object": "vasculitis", "sbj_char_span": [0, 3], "obj_char_span": [15, 25], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "The diagnosis of propylthiouracil (PTU)-associated vasculitis was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of PTU.", "entity_list": [{"name": "vasculitis", "ent_type": "Disease", "char_span": [51, 61], "ent_id": "D014657", "tok_span": [14, 16]}, {"name": "PTU", "ent_type": "Chemical", "char_span": [245, 248], "ent_id": "D011441", "tok_span": [48, 50]}, {"name": "PTU", "ent_type": "Chemical", "char_span": [35, 38], "ent_id": "D011441", "tok_span": [9, 11]}, {"name": "propylthiouracil", "ent_type": "Chemical", "char_span": [17, 33], "ent_id": "D011441", "tok_span": [3, 8]}], "relation_list": [{"subject": "propylthiouracil", "object": "vasculitis", "sbj_char_span": [17, 33], "obj_char_span": [51, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 8], "obj_tok_span": [14, 16]}, {"subject": "PTU", "object": "vasculitis", "sbj_char_span": [35, 38], "obj_char_span": [51, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 11], "obj_tok_span": [14, 16]}, {"subject": "PTU", "object": "vasculitis", "sbj_char_span": [245, 248], "obj_char_span": [51, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [48, 50], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "Succinylcholine-induced masseter muscle rigidity during bronchoscopic removal of a tracheal foreign body.", "entity_list": [{"name": "masseter muscle rigidity", "ent_type": "Disease", "char_span": [24, 48], "ent_id": "D014313", "tok_span": [6, 10]}, {"name": "Succinylcholine", "ent_type": "Chemical", "char_span": [0, 15], "ent_id": "D013390", "tok_span": [0, 4]}], "relation_list": [{"subject": "Succinylcholine", "object": "masseter muscle rigidity", "sbj_char_span": [0, 15], "obj_char_span": [24, 48], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [6, 10]}], "umls_entity_list": []}, {"text": "Here, we describe a case of severe masseter muscle rigidity (jaw of steel) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.", "entity_list": [{"name": "succinylcholine", "ent_type": "Chemical", "char_span": [81, 96], "ent_id": "D013390", "tok_span": [18, 21]}, {"name": "masseter muscle rigidity", "ent_type": "Disease", "char_span": [35, 59], "ent_id": "D014313", "tok_span": [8, 12]}, {"name": "jaw of steel", "ent_type": "Disease", "char_span": [61, 73], "ent_id": "D014313", "tok_span": [13, 16]}, {"name": "Sch", "ent_type": "Chemical", "char_span": [98, 101], "ent_id": "D013390", "tok_span": [22, 23]}], "relation_list": [{"subject": "succinylcholine", "object": "masseter muscle rigidity", "sbj_char_span": [81, 96], "obj_char_span": [35, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [8, 12]}, {"subject": "succinylcholine", "object": "jaw of steel", "sbj_char_span": [81, 96], "obj_char_span": [61, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [13, 16]}, {"subject": "Sch", "object": "masseter muscle rigidity", "sbj_char_span": [98, 101], "obj_char_span": [35, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [8, 12]}, {"subject": "Sch", "object": "jaw of steel", "sbj_char_span": [98, 101], "obj_char_span": [61, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "Minor neurological dysfunction, cognitive development, and somatic development at the age of 3 to 7 years after dexamethasone treatment in very-low birth-weight infants.", "entity_list": [{"name": "neurological dysfunction", "ent_type": "Disease", "char_span": [6, 30], "ent_id": "D009422", "tok_span": [2, 4]}, {"name": "dexamethasone", "ent_type": "Chemical", "char_span": [112, 125], "ent_id": "D003907", "tok_span": [20, 21]}], "relation_list": [{"subject": "dexamethasone", "object": "neurological dysfunction", "sbj_char_span": [112, 125], "obj_char_span": [6, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 21], "obj_tok_span": [2, 4]}], "umls_entity_list": []}, {"text": "The objective of this study was to assess minor neurological dysfunction, cognitive development, and somatic development after dexamethasone therapy in very-low-birthweight infants.", "entity_list": [{"name": "dexamethasone", "ent_type": "Chemical", "char_span": [127, 140], "ent_id": "D003907", "tok_span": [19, 20]}, {"name": "neurological dysfunction", "ent_type": "Disease", "char_span": [48, 72], "ent_id": "D009422", "tok_span": [9, 11]}], "relation_list": [{"subject": "dexamethasone", "object": "neurological dysfunction", "sbj_char_span": [127, 140], "obj_char_span": [48, 72], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 20], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "After dexamethasone treatment, children showed a higher rate of minor neurological dysfunctions.", "entity_list": [{"name": "neurological dysfunctions", "ent_type": "Disease", "char_span": [70, 95], "ent_id": "D009422", "tok_span": [11, 14]}, {"name": "dexamethasone", "ent_type": "Chemical", "char_span": [6, 19], "ent_id": "D003907", "tok_span": [1, 2]}], "relation_list": [{"subject": "dexamethasone", "object": "neurological dysfunctions", "sbj_char_span": [6, 19], "obj_char_span": [70, 95], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 2], "obj_tok_span": [11, 14]}], "umls_entity_list": []}, {"text": "Force overflow and levodopa-induced dyskinesias in Parkinson's disease.", "entity_list": [{"name": "levodopa", "ent_type": "Chemical", "char_span": [19, 27], "ent_id": "D007980", "tok_span": [3, 6]}, {"name": "dyskinesias", "ent_type": "Disease", "char_span": [36, 47], "ent_id": "D004409", "tok_span": [8, 12]}, {"name": "Parkinson's disease", "ent_type": "Disease", "char_span": [51, 70], "ent_id": "D010300", "tok_span": [13, 17]}], "relation_list": [{"subject": "levodopa", "object": "dyskinesias", "sbj_char_span": [19, 27], "obj_char_span": [36, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [8, 12]}], "umls_entity_list": []}, {"text": "We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of levodopa therapy, particularly to levodopa-induced dyskinesias (LID).", "entity_list": [{"name": "dyskinesias", "ent_type": "Disease", "char_span": [164, 175], "ent_id": "D004409", "tok_span": [31, 35]}, {"name": "Parkinson's disease", "ent_type": "Disease", "char_span": [46, 65], "ent_id": "D010300", "tok_span": [8, 12]}, {"name": "LID", "ent_type": "Disease", "char_span": [177, 180], "ent_id": "D004409", "tok_span": [36, 38]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [147, 155], "ent_id": "D007980", "tok_span": [26, 29]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [113, 121], "ent_id": "D007980", "tok_span": [19, 22]}], "relation_list": [{"subject": "levodopa", "object": "LID", "sbj_char_span": [147, 155], "obj_char_span": [177, 180], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 29], "obj_tok_span": [36, 38]}, {"subject": "levodopa", "object": "LID", "sbj_char_span": [113, 121], "obj_char_span": [177, 180], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 22], "obj_tok_span": [36, 38]}, {"subject": "levodopa", "object": "dyskinesias", "sbj_char_span": [113, 121], "obj_char_span": [164, 175], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 22], "obj_tok_span": [31, 35]}, {"subject": "levodopa", "object": "dyskinesias", "sbj_char_span": [147, 155], "obj_char_span": [164, 175], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 29], "obj_tok_span": [31, 35]}], "umls_entity_list": []}, {"text": "We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.", "entity_list": [{"name": "Parkinson's disease", "ent_type": "Disease", "char_span": [60, 79], "ent_id": "D010300", "tok_span": [12, 16]}, {"name": "dyskinesias", "ent_type": "Disease", "char_span": [124, 135], "ent_id": "D004409", "tok_span": [31, 35]}, {"name": "LID", "ent_type": "Disease", "char_span": [159, 162], "ent_id": "D004409", "tok_span": [41, 43]}, {"name": "Parkinson's disease", "ent_type": "Disease", "char_span": [137, 156], "ent_id": "D010300", "tok_span": [36, 40]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [107, 115], "ent_id": "D007980", "tok_span": [26, 29]}, {"name": "Parkinson's disease", "ent_type": "Disease", "char_span": [25, 44], "ent_id": "D010300", "tok_span": [5, 9]}, {"name": "LID", "ent_type": "Disease", "char_span": [82, 85], "ent_id": "D004409", "tok_span": [17, 19]}], "relation_list": [{"subject": "levodopa", "object": "LID", "sbj_char_span": [107, 115], "obj_char_span": [159, 162], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 29], "obj_tok_span": [41, 43]}, {"subject": "levodopa", "object": "LID", "sbj_char_span": [107, 115], "obj_char_span": [82, 85], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 29], "obj_tok_span": [17, 19]}, {"subject": "levodopa", "object": "dyskinesias", "sbj_char_span": [107, 115], "obj_char_span": [124, 135], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 29], "obj_tok_span": [31, 35]}], "umls_entity_list": []}, {"text": "The motor score of the Unified Parkinson's Disease Rating Scale, a dyskinesia score and force in a grip-lift paradigm were assessed ON and OFF levodopa.", "entity_list": [{"name": "Parkinson's Disease", "ent_type": "Disease", "char_span": [31, 50], "ent_id": "D010300", "tok_span": [8, 12]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [143, 151], "ent_id": "D007980", "tok_span": [35, 38]}, {"name": "dyskinesia", "ent_type": "Disease", "char_span": [67, 77], "ent_id": "D004409", "tok_span": [16, 20]}], "relation_list": [{"subject": "levodopa", "object": "dyskinesia", "sbj_char_span": [143, 151], "obj_char_span": [67, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 38], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "In Parkinson's disease + LID, the force involved in pressing down the object before lifting was significantly increased by levodopa (by 61%, P < 0.05).", "entity_list": [{"name": "levodopa", "ent_type": "Chemical", "char_span": [123, 131], "ent_id": "D007980", "tok_span": [23, 26]}, {"name": "LID", "ent_type": "Disease", "char_span": [25, 28], "ent_id": "D004409", "tok_span": [6, 8]}, {"name": "Parkinson's disease", "ent_type": "Disease", "char_span": [3, 22], "ent_id": "D010300", "tok_span": [1, 5]}], "relation_list": [{"subject": "levodopa", "object": "LID", "sbj_char_span": [123, 131], "obj_char_span": [25, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "Postinfarction ventricular septal defect associated with long-term steroid therapy.", "entity_list": [{"name": "ventricular septal defect", "ent_type": "Disease", "char_span": [15, 40], "ent_id": "D018658", "tok_span": [4, 7]}, {"name": "steroid", "ent_type": "Chemical", "char_span": [67, 74], "ent_id": "D013256", "tok_span": [12, 13]}], "relation_list": [{"subject": "steroid", "object": "ventricular septal defect", "sbj_char_span": [67, 74], "obj_char_span": [15, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [4, 7]}], "umls_entity_list": []}, {"text": "Two cases of postinfarction ventricular septal rupture in patients on long-term steroid therapy are presented and the favourable outcome in both cases described.", "entity_list": [{"name": "steroid", "ent_type": "Chemical", "char_span": [80, 87], "ent_id": "D013256", "tok_span": [16, 17]}, {"name": "ventricular septal rupture", "ent_type": "Disease", "char_span": [28, 54], "ent_id": "D018658", "tok_span": [7, 10]}], "relation_list": [{"subject": "steroid", "object": "ventricular septal rupture", "sbj_char_span": [80, 87], "obj_char_span": [28, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 17], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "A possible association between steroid therapy and subsequent postinfarction septal rupture is discussed.", "entity_list": [{"name": "septal rupture", "ent_type": "Disease", "char_span": [77, 91], "ent_id": "D018658", "tok_span": [12, 14]}, {"name": "steroid", "ent_type": "Chemical", "char_span": [31, 38], "ent_id": "D013256", "tok_span": [4, 5]}], "relation_list": [{"subject": "steroid", "object": "septal rupture", "sbj_char_span": [31, 38], "obj_char_span": [77, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [12, 14]}], "umls_entity_list": []}, {"text": "Angioedema associated with droperidol administration.", "entity_list": [{"name": "droperidol", "ent_type": "Chemical", "char_span": [27, 37], "ent_id": "D004329", "tok_span": [6, 10]}, {"name": "Angioedema", "ent_type": "Disease", "char_span": [0, 10], "ent_id": "D000799", "tok_span": [0, 4]}], "relation_list": [{"subject": "droperidol", "object": "Angioedema", "sbj_char_span": [27, 37], "obj_char_span": [0, 10], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 10], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol.", "entity_list": [{"name": "angioedema", "ent_type": "Disease", "char_span": [96, 106], "ent_id": "D000799", "tok_span": [22, 26]}, {"name": "drug allergies", "ent_type": "Disease", "char_span": [73, 87], "ent_id": "D004342", "tok_span": [17, 20]}, {"name": "droperidol", "ent_type": "Chemical", "char_span": [228, 238], "ent_id": "D004329", "tok_span": [46, 50]}, {"name": "tongue swelling", "ent_type": "Disease", "char_span": [124, 139], "ent_id": "D01406", "tok_span": [28, 30]}], "relation_list": [{"subject": "droperidol", "object": "angioedema", "sbj_char_span": [228, 238], "obj_char_span": [96, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [46, 50], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "Clarithromycin-associated visual hallucinations in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis.", "entity_list": [{"name": "Clarithromycin", "ent_type": "Chemical", "char_span": [0, 14], "ent_id": "D017291", "tok_span": [0, 3]}, {"name": "chronic renal failure", "ent_type": "Disease", "char_span": [66, 87], "ent_id": "D007676", "tok_span": [13, 16]}, {"name": "visual hallucinations", "ent_type": "Disease", "char_span": [26, 47], "ent_id": "D006212", "tok_span": [5, 9]}], "relation_list": [{"subject": "Clarithromycin", "object": "visual hallucinations", "sbj_char_span": [0, 14], "obj_char_span": [26, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic, clarithromycin.", "entity_list": [{"name": "visual hallucinations", "ent_type": "Disease", "char_span": [32, 53], "ent_id": "D006212", "tok_span": [6, 10]}, {"name": "clarithromycin", "ent_type": "Chemical", "char_span": [114, 128], "ent_id": "D017291", "tok_span": [21, 24]}, {"name": "macrolide", "ent_type": "Chemical", "char_span": [92, 101], "ent_id": "D018942", "tok_span": [16, 19]}], "relation_list": [{"subject": "clarithromycin", "object": "visual hallucinations", "sbj_char_span": [114, 128], "obj_char_span": [32, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [6, 10]}], "umls_entity_list": []}, {"text": "A 3 times higher proteinuria appeared in animals treated with DXNP than in those treated with DX.", "entity_list": [{"name": "proteinuria", "ent_type": "Disease", "char_span": [17, 28], "ent_id": "D011507", "tok_span": [4, 5]}, {"name": "DX", "ent_type": "Chemical", "char_span": [94, 96], "ent_id": "D004317", "tok_span": [18, 20]}], "relation_list": [{"subject": "DX", "object": "proteinuria", "sbj_char_span": [94, 96], "obj_char_span": [17, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 20], "obj_tok_span": [4, 5]}], "umls_entity_list": []}, {"text": "Proteinuria appeared in all series, but was 2-5 times more intense (p > 0.001) and prolonged after doxorubicin treatment (400-700 mg/day), without significant difference between DXNP and DX.", "entity_list": [{"name": "DX", "ent_type": "Chemical", "char_span": [187, 189], "ent_id": "D004317", "tok_span": [45, 47]}, {"name": "doxorubicin", "ent_type": "Chemical", "char_span": [99, 110], "ent_id": "D004317", "tok_span": [26, 27]}, {"name": "Proteinuria", "ent_type": "Disease", "char_span": [0, 11], "ent_id": "D011507", "tok_span": [0, 2]}], "relation_list": [{"subject": "DX", "object": "Proteinuria", "sbj_char_span": [187, 189], "obj_char_span": [0, 11], "rel_type": "chemical-induced disease", "sbj_tok_span": [45, 47], "obj_tok_span": [0, 2]}, {"subject": "doxorubicin", "object": "Proteinuria", "sbj_char_span": [99, 110], "obj_char_span": [0, 11], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 27], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Etoposide-related myocardial infarction.", "entity_list": [{"name": "Etoposide", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D005047", "tok_span": [0, 3]}, {"name": "myocardial infarction", "ent_type": "Disease", "char_span": [18, 39], "ent_id": "D009203", "tok_span": [5, 7]}], "relation_list": [{"subject": "Etoposide", "object": "myocardial infarction", "sbj_char_span": [0, 9], "obj_char_span": [18, 39], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide, in a man with no risk factors for coronary heart disease.", "entity_list": [{"name": "etoposide", "ent_type": "Chemical", "char_span": [84, 93], "ent_id": "D005047", "tok_span": [11, 14]}, {"name": "coronary heart disease", "ent_type": "Disease", "char_span": [129, 151], "ent_id": "D003327", "tok_span": [23, 26]}, {"name": "myocardial infarction", "ent_type": "Disease", "char_span": [20, 41], "ent_id": "D009203", "tok_span": [4, 6]}], "relation_list": [{"subject": "etoposide", "object": "myocardial infarction", "sbj_char_span": [84, 93], "obj_char_span": [20, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "Subjective assessment of sexual dysfunction of patients on long-term administration of digoxin.", "entity_list": [{"name": "digoxin", "ent_type": "Chemical", "char_span": [87, 94], "ent_id": "D004077", "tok_span": [14, 16]}, {"name": "sexual dysfunction", "ent_type": "Disease", "char_span": [25, 43], "ent_id": "D020018", "tok_span": [4, 6]}], "relation_list": [{"subject": "digoxin", "object": "sexual dysfunction", "sbj_char_span": [87, 94], "obj_char_span": [25, 43], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "Fatal aplastic anemia due to indomethacin--lymphocyte transformation tests in vitro.", "entity_list": [{"name": "indomethacin", "ent_type": "Chemical", "char_span": [29, 41], "ent_id": "D007213", "tok_span": [7, 10]}, {"name": "aplastic anemia", "ent_type": "Disease", "char_span": [6, 21], "ent_id": "D000741", "tok_span": [2, 5]}], "relation_list": [{"subject": "indomethacin", "object": "aplastic anemia", "sbj_char_span": [29, 41], "obj_char_span": [6, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [2, 5]}], "umls_entity_list": []}, {"text": "Although indomethacin has been implicated as a possible cause of aplastic anemia on the basis of a few clinical observations, its role has not been definitely established.", "entity_list": [{"name": "indomethacin", "ent_type": "Chemical", "char_span": [9, 21], "ent_id": "D007213", "tok_span": [1, 4]}, {"name": "aplastic anemia", "ent_type": "Disease", "char_span": [65, 80], "ent_id": "D000741", "tok_span": [12, 15]}], "relation_list": [{"subject": "indomethacin", "object": "aplastic anemia", "sbj_char_span": [9, 21], "obj_char_span": [65, 80], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 4], "obj_tok_span": [12, 15]}], "umls_entity_list": []}, {"text": "A case of fatal aplastic anemia is described in which no drugs other than allopurinol and indomethacin were given.", "entity_list": [{"name": "aplastic anemia", "ent_type": "Disease", "char_span": [16, 31], "ent_id": "D000741", "tok_span": [4, 7]}, {"name": "indomethacin", "ent_type": "Chemical", "char_span": [90, 102], "ent_id": "D007213", "tok_span": [20, 23]}, {"name": "allopurinol", "ent_type": "Chemical", "char_span": [74, 85], "ent_id": "D000493", "tok_span": [15, 19]}], "relation_list": [{"subject": "indomethacin", "object": "aplastic anemia", "sbj_char_span": [90, 102], "obj_char_span": [16, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [4, 7]}], "umls_entity_list": []}, {"text": "A positive lymphocyte transformation test with indomethacin in vitro further substantiates the potential role of this drug in causing aplastic anemia in a susceptible patient.", "entity_list": [{"name": "aplastic anemia", "ent_type": "Disease", "char_span": [134, 149], "ent_id": "D000741", "tok_span": [22, 25]}, {"name": "indomethacin", "ent_type": "Chemical", "char_span": [47, 59], "ent_id": "D007213", "tok_span": [6, 9]}], "relation_list": [{"subject": "indomethacin", "object": "aplastic anemia", "sbj_char_span": [47, 59], "obj_char_span": [134, 149], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [22, 25]}], "umls_entity_list": []}, {"text": "Plasma and urinary lipids and lipoproteins during the development of nephrotic syndrome induced in the rat by puromycin aminonucleoside.", "entity_list": [{"name": "nephrotic syndrome", "ent_type": "Disease", "char_span": [69, 87], "ent_id": "D009404", "tok_span": [11, 14]}, {"name": "puromycin aminonucleoside", "ent_type": "Chemical", "char_span": [110, 135], "ent_id": "D011692", "tok_span": [19, 24]}], "relation_list": [{"subject": "puromycin aminonucleoside", "object": "nephrotic syndrome", "sbj_char_span": [110, 135], "obj_char_span": [69, 87], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 24], "obj_tok_span": [11, 14]}], "umls_entity_list": []}, {"text": "This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.", "entity_list": [{"name": "puromycin aminonucleoside", "ent_type": "Chemical", "char_span": [125, 150], "ent_id": "D011692", "tok_span": [20, 25]}, {"name": "nephrotic syndrome", "ent_type": "Disease", "char_span": [163, 181], "ent_id": "D009404", "tok_span": [28, 31]}, {"name": "nephrotic syndrome", "ent_type": "Disease", "char_span": [95, 113], "ent_id": "D009404", "tok_span": [15, 18]}, {"name": "aminonucleoside", "ent_type": "Chemical", "char_span": [219, 234], "ent_id": "D011692", "tok_span": [43, 46]}], "relation_list": [{"subject": "puromycin aminonucleoside", "object": "nephrotic syndrome", "sbj_char_span": [125, 150], "obj_char_span": [163, 181], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 25], "obj_tok_span": [28, 31]}, {"subject": "aminonucleoside", "object": "nephrotic syndrome", "sbj_char_span": [219, 234], "obj_char_span": [95, 113], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 46], "obj_tok_span": [15, 18]}, {"subject": "aminonucleoside", "object": "nephrotic syndrome", "sbj_char_span": [219, 234], "obj_char_span": [163, 181], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 46], "obj_tok_span": [28, 31]}, {"subject": "puromycin aminonucleoside", "object": "nephrotic syndrome", "sbj_char_span": [125, 150], "obj_char_span": [95, 113], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 25], "obj_tok_span": [15, 18]}], "umls_entity_list": []}, {"text": "The purpose of the present study was to investigate the changes in plasma and urinary lipoproteins during the administration of puromycin aminonucleoside (20 mg/kg for 7 days) and the subsequent development of nephrotic syndrome.", "entity_list": [{"name": "puromycin aminonucleoside", "ent_type": "Chemical", "char_span": [128, 153], "ent_id": "D011692", "tok_span": [21, 26]}, {"name": "nephrotic syndrome", "ent_type": "Disease", "char_span": [210, 228], "ent_id": "D009404", "tok_span": [40, 43]}], "relation_list": [{"subject": "puromycin aminonucleoside", "object": "nephrotic syndrome", "sbj_char_span": [128, 153], "obj_char_span": [210, 228], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 26], "obj_tok_span": [40, 43]}], "umls_entity_list": []}, {"text": "Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.", "entity_list": [{"name": "fulminant hepatic failure", "ent_type": "Disease", "char_span": [128, 153], "ent_id": "D017114", "tok_span": [26, 31]}, {"name": "paracetamol", "ent_type": "Chemical", "char_span": [160, 171], "ent_id": "D000082", "tok_span": [32, 36]}, {"name": "overdose", "ent_type": "Disease", "char_span": [172, 180], "ent_id": "D062787", "tok_span": [36, 38]}, {"name": "viral hepatitis", "ent_type": "Disease", "char_span": [274, 289], "ent_id": "D006525", "tok_span": [54, 56]}, {"name": "fulminant hepatic failure", "ent_type": "Disease", "char_span": [241, 266], "ent_id": "D017114", "tok_span": [47, 52]}], "relation_list": [{"subject": "paracetamol", "object": "fulminant hepatic failure", "sbj_char_span": [160, 171], "obj_char_span": [128, 153], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 36], "obj_tok_span": [26, 31]}, {"subject": "paracetamol", "object": "fulminant hepatic failure", "sbj_char_span": [160, 171], "obj_char_span": [241, 266], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 36], "obj_tok_span": [47, 52]}], "umls_entity_list": []}, {"text": "Transketolase abnormality in tolazamide-induced Wernicke's encephalopathy.", "entity_list": [{"name": "Wernicke's encephalopathy", "ent_type": "Disease", "char_span": [48, 73], "ent_id": "D014899", "tok_span": [13, 20]}, {"name": "tolazamide", "ent_type": "Chemical", "char_span": [29, 39], "ent_id": "D014042", "tok_span": [6, 11]}], "relation_list": [{"subject": "tolazamide", "object": "Wernicke's encephalopathy", "sbj_char_span": [29, 39], "obj_char_span": [48, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 11], "obj_tok_span": [13, 20]}], "umls_entity_list": []}, {"text": "We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.", "entity_list": [{"name": "Wernicke's encephalopathy", "ent_type": "Disease", "char_span": [108, 133], "ent_id": "D014899", "tok_span": [22, 29]}, {"name": "TPP", "ent_type": "Chemical", "char_span": [274, 277], "ent_id": "D013835", "tok_span": [62, 64]}, {"name": "Wernicke-Korsakoff syndrome", "ent_type": "Disease", "char_span": [321, 348], "ent_id": "D020915", "tok_span": [75, 84]}, {"name": "thiamine", "ent_type": "Chemical", "char_span": [13, 21], "ent_id": "D013831", "tok_span": [3, 5]}, {"name": "tolazamide", "ent_type": "Chemical", "char_span": [152, 162], "ent_id": "D014042", "tok_span": [32, 37]}, {"name": "diabetic", "ent_type": "Disease", "char_span": [77, 85], "ent_id": "D003920", "tok_span": [18, 19]}, {"name": "thiamine pyrophosphate", "ent_type": "Chemical", "char_span": [250, 272], "ent_id": "D013835", "tok_span": [57, 61]}], "relation_list": [{"subject": "tolazamide", "object": "Wernicke's encephalopathy", "sbj_char_span": [152, 162], "obj_char_span": [108, 133], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 37], "obj_tok_span": [22, 29]}], "umls_entity_list": []}, {"text": "These data suggest a similarity between postalcoholic Wernicke-Korsakoff syndrome and the patient with tolazamide-induced Wernicke's encephalopathy from the standpoint of transketolase abnormality.", "entity_list": [{"name": "Wernicke's encephalopathy", "ent_type": "Disease", "char_span": [122, 147], "ent_id": "D014899", "tok_span": [30, 37]}, {"name": "Wernicke-Korsakoff syndrome", "ent_type": "Disease", "char_span": [54, 81], "ent_id": "D020915", "tok_span": [10, 19]}, {"name": "tolazamide", "ent_type": "Chemical", "char_span": [103, 113], "ent_id": "D014042", "tok_span": [23, 28]}], "relation_list": [{"subject": "tolazamide", "object": "Wernicke's encephalopathy", "sbj_char_span": [103, 113], "obj_char_span": [122, 147], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 28], "obj_tok_span": [30, 37]}], "umls_entity_list": []}, {"text": "Mechanisms of myocardial ischemia induced by epinephrine: comparison with exercise-induced ischemia.", "entity_list": [{"name": "myocardial ischemia", "ent_type": "Disease", "char_span": [14, 33], "ent_id": "D017202", "tok_span": [2, 4]}, {"name": "ischemia", "ent_type": "Disease", "char_span": [91, 99], "ent_id": "D007511", "tok_span": [15, 16]}, {"name": "epinephrine", "ent_type": "Chemical", "char_span": [45, 56], "ent_id": "D004837", "tok_span": [6, 9]}], "relation_list": [{"subject": "epinephrine", "object": "myocardial ischemia", "sbj_char_span": [45, 56], "obj_char_span": [14, 33], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [2, 4]}], "umls_entity_list": []}, {"text": "The role of epinephrine in eliciting myocardial ischemia was examined in patients with coronary artery disease.", "entity_list": [{"name": "epinephrine", "ent_type": "Chemical", "char_span": [12, 23], "ent_id": "D004837", "tok_span": [3, 6]}, {"name": "myocardial ischemia", "ent_type": "Disease", "char_span": [37, 56], "ent_id": "D017202", "tok_span": [9, 11]}, {"name": "coronary artery disease", "ent_type": "Disease", "char_span": [87, 110], "ent_id": "D003324", "tok_span": [16, 19]}], "relation_list": [{"subject": "epinephrine", "object": "myocardial ischemia", "sbj_char_span": [12, 23], "obj_char_span": [37, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and angina.", "entity_list": [{"name": "epinephrine", "ent_type": "Chemical", "char_span": [5, 16], "ent_id": "D004837", "tok_span": [1, 4]}, {"name": "depression", "ent_type": "Disease", "char_span": [86, 96], "ent_id": "D003866", "tok_span": [14, 15]}, {"name": "myocardial ischemia", "ent_type": "Disease", "char_span": [39, 58], "ent_id": "D017202", "tok_span": [7, 9]}, {"name": "angina", "ent_type": "Disease", "char_span": [101, 107], "ent_id": "D000787", "tok_span": [16, 17]}], "relation_list": [{"subject": "epinephrine", "object": "myocardial ischemia", "sbj_char_span": [5, 16], "obj_char_span": [39, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 4], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "However, the mechanisms of myocardial ischemia induced by epinephrine were significantly different from those of exercise.", "entity_list": [{"name": "epinephrine", "ent_type": "Chemical", "char_span": [58, 69], "ent_id": "D004837", "tok_span": [9, 12]}, {"name": "myocardial ischemia", "ent_type": "Disease", "char_span": [27, 46], "ent_id": "D017202", "tok_span": [5, 7]}], "relation_list": [{"subject": "epinephrine", "object": "myocardial ischemia", "sbj_char_span": [58, 69], "obj_char_span": [27, 46], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "Exercise-induced myocardial ischemia was marked predominantly by increased heart rate and rate-pressure product with a minor contribution of end-diastolic volume, while epinephrine-induced ischemia was characterized by a marked increase in contractility and a less pronounced increase in heart rate and rate-pressure product.", "entity_list": [{"name": "ischemia", "ent_type": "Disease", "char_span": [189, 197], "ent_id": "D007511", "tok_span": [33, 34]}, {"name": "epinephrine", "ent_type": "Chemical", "char_span": [169, 180], "ent_id": "D004837", "tok_span": [28, 31]}, {"name": "myocardial ischemia", "ent_type": "Disease", "char_span": [17, 36], "ent_id": "D017202", "tok_span": [3, 5]}], "relation_list": [{"subject": "epinephrine", "object": "myocardial ischemia", "sbj_char_span": [169, 180], "obj_char_span": [17, 36], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 31], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "Transient contralateral rotation following unilateral substantia nigra lesion reflects susceptibility of the nigrostriatal system to exhaustion by amphetamine.", "entity_list": [{"name": "contralateral rotation", "ent_type": "Disease", "char_span": [10, 32], "ent_id": "D009069", "tok_span": [2, 4]}, {"name": "amphetamine", "ent_type": "Chemical", "char_span": [147, 158], "ent_id": "D000661", "tok_span": [24, 28]}, {"name": "substantia nigra lesion", "ent_type": "Disease", "char_span": [54, 77], "ent_id": "-1", "tok_span": [6, 11]}], "relation_list": [{"subject": "amphetamine", "object": "contralateral rotation", "sbj_char_span": [147, 158], "obj_char_span": [10, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 28], "obj_tok_span": [2, 4]}], "umls_entity_list": []}, {"text": "In order to clarify the nature of this initial contralateral rotation we examined the effect of the duration of recovery period after the lesion, on amphetamine-induced rotational behavior.", "entity_list": [{"name": "amphetamine", "ent_type": "Chemical", "char_span": [149, 160], "ent_id": "D000661", "tok_span": [26, 30]}, {"name": "rotational behavior", "ent_type": "Disease", "char_span": [169, 188], "ent_id": "D009069", "tok_span": [32, 34]}, {"name": "contralateral rotation", "ent_type": "Disease", "char_span": [47, 69], "ent_id": "D009069", "tok_span": [9, 11]}], "relation_list": [{"subject": "amphetamine", "object": "rotational behavior", "sbj_char_span": [149, 160], "obj_char_span": [169, 188], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 30], "obj_tok_span": [32, 34]}, {"subject": "amphetamine", "object": "contralateral rotation", "sbj_char_span": [149, 160], "obj_char_span": [47, 69], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 30], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "A substantial degree of contralateral preference was still evident when amphetamine was administered for the first time 24 days after lesioning, indicating involvement of spared cells in the contralateral rotation.", "entity_list": [{"name": "contralateral rotation", "ent_type": "Disease", "char_span": [191, 213], "ent_id": "D009069", "tok_span": [34, 36]}, {"name": "amphetamine", "ent_type": "Chemical", "char_span": [72, 83], "ent_id": "D000661", "tok_span": [10, 14]}], "relation_list": [{"subject": "amphetamine", "object": "contralateral rotation", "sbj_char_span": [72, 83], "obj_char_span": [191, 213], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [34, 36]}], "umls_entity_list": []}, {"text": "However, regardless of the duration of recovery (and irrespective of either lesion volume, amphetamine dose, or post-lesion motor exercise), amphetamine-induced rotation tended to become gradually more ipsilateral as the observation session progressed, and all rats circled ipsilaterally to the lesion in response to further amphetamine injections.", "entity_list": [{"name": "amphetamine", "ent_type": "Chemical", "char_span": [141, 152], "ent_id": "D000661", "tok_span": [30, 34]}, {"name": "rotation", "ent_type": "Disease", "char_span": [161, 169], "ent_id": "D009069", "tok_span": [36, 37]}, {"name": "amphetamine", "ent_type": "Chemical", "char_span": [91, 102], "ent_id": "D000661", "tok_span": [16, 20]}, {"name": "amphetamine", "ent_type": "Chemical", "char_span": [325, 336], "ent_id": "D000661", "tok_span": [63, 67]}], "relation_list": [{"subject": "amphetamine", "object": "rotation", "sbj_char_span": [325, 336], "obj_char_span": [161, 169], "rel_type": "chemical-induced disease", "sbj_tok_span": [63, 67], "obj_tok_span": [36, 37]}, {"subject": "amphetamine", "object": "rotation", "sbj_char_span": [91, 102], "obj_char_span": [161, 169], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 20], "obj_tok_span": [36, 37]}, {"subject": "amphetamine", "object": "rotation", "sbj_char_span": [141, 152], "obj_char_span": [161, 169], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 34], "obj_tok_span": [36, 37]}], "umls_entity_list": []}, {"text": "These findings suggest that amphetamine has an irreversible effect on the post-lesion DA pool contributing to contralateral rotation.", "entity_list": [{"name": "amphetamine", "ent_type": "Chemical", "char_span": [28, 39], "ent_id": "D000661", "tok_span": [4, 8]}, {"name": "contralateral rotation", "ent_type": "Disease", "char_span": [110, 132], "ent_id": "D009069", "tok_span": [21, 23]}], "relation_list": [{"subject": "amphetamine", "object": "contralateral rotation", "sbj_char_span": [28, 39], "obj_char_span": [110, 132], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 8], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "It has been suggested that adenylate cyclase inhibition may be important in the development of both nephrogenic diabetes insipidus and hypothyroidism during lithium treatment.", "entity_list": [{"name": "hypothyroidism", "ent_type": "Disease", "char_span": [135, 149], "ent_id": "D007037", "tok_span": [25, 27]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [157, 164], "ent_id": "D008094", "tok_span": [28, 29]}, {"name": "nephrogenic diabetes insipidus", "ent_type": "Disease", "char_span": [100, 130], "ent_id": "D018500", "tok_span": [17, 24]}], "relation_list": [{"subject": "lithium", "object": "hypothyroidism", "sbj_char_span": [157, 164], "obj_char_span": [135, 149], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 29], "obj_tok_span": [25, 27]}], "umls_entity_list": []}, {"text": "Hypothyroidism developed in eight patients while they were taking lithium.", "entity_list": [{"name": "lithium", "ent_type": "Chemical", "char_span": [66, 73], "ent_id": "D008094", "tok_span": [12, 13]}, {"name": "Hypothyroidism", "ent_type": "Disease", "char_span": [0, 14], "ent_id": "D007037", "tok_span": [0, 4]}], "relation_list": [{"subject": "lithium", "object": "Hypothyroidism", "sbj_char_span": [66, 73], "obj_char_span": [0, 14], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "The anaemia induced by 3'-azido-3'dideoxythymidine (AZT) is poorly understood.", "entity_list": [{"name": "anaemia", "ent_type": "Disease", "char_span": [4, 11], "ent_id": "D000740", "tok_span": [1, 3]}, {"name": "3'-azido-3'dideoxythymidine", "ent_type": "Chemical", "char_span": [23, 50], "ent_id": "D015215", "tok_span": [5, 19]}, {"name": "AZT", "ent_type": "Chemical", "char_span": [52, 55], "ent_id": "D015215", "tok_span": [20, 22]}], "relation_list": [{"subject": "AZT", "object": "anaemia", "sbj_char_span": [52, 55], "obj_char_span": [4, 11], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 22], "obj_tok_span": [1, 3]}, {"subject": "3'-azido-3'dideoxythymidine", "object": "anaemia", "sbj_char_span": [23, 50], "obj_char_span": [4, 11], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 19], "obj_tok_span": [1, 3]}], "umls_entity_list": []}, {"text": "We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).", "entity_list": [{"name": "infection", "ent_type": "Disease", "char_span": [37, 46], "ent_id": "D007239", "tok_span": [9, 10]}, {"name": "anaemia", "ent_type": "Disease", "char_span": [141, 148], "ent_id": "D000740", "tok_span": [39, 41]}, {"name": "leukaemia", "ent_type": "Disease", "char_span": [89, 98], "ent_id": "D007938", "tok_span": [24, 26]}, {"name": "AIDS", "ent_type": "Disease", "char_span": [31, 35], "ent_id": "D000163", "tok_span": [7, 8]}, {"name": "AZT", "ent_type": "Chemical", "char_span": [129, 132], "ent_id": "D015215", "tok_span": [35, 37]}], "relation_list": [{"subject": "AZT", "object": "anaemia", "sbj_char_span": [129, 132], "obj_char_span": [141, 148], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 37], "obj_tok_span": [39, 41]}], "umls_entity_list": []}, {"text": "AZT produced anaemia in both groups, in a dose-dependent fashion.", "entity_list": [{"name": "anaemia", "ent_type": "Disease", "char_span": [13, 20], "ent_id": "D000740", "tok_span": [3, 5]}, {"name": "AZT", "ent_type": "Chemical", "char_span": [0, 3], "ent_id": "D015215", "tok_span": [0, 2]}], "relation_list": [{"subject": "AZT", "object": "anaemia", "sbj_char_span": [0, 3], "obj_char_span": [13, 20], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "Despite the anaemia, the number of splenic and bone marrow BFU-e in AZT treated mice increased up to five-fold over levels observed in infected untreated animals after 15 d of treatment.", "entity_list": [{"name": "anaemia", "ent_type": "Disease", "char_span": [12, 19], "ent_id": "D000740", "tok_span": [2, 4]}, {"name": "AZT", "ent_type": "Chemical", "char_span": [68, 71], "ent_id": "D015215", "tok_span": [17, 19]}], "relation_list": [{"subject": "AZT", "object": "anaemia", "sbj_char_span": [68, 71], "obj_char_span": [12, 19], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 19], "obj_tok_span": [2, 4]}], "umls_entity_list": []}, {"text": "The mean plasma levels of EPO observed in AZT treated mice were appropriate for the degree of anaemia observed when compared with phenylhydrazine (PHZ) treated mice.", "entity_list": [{"name": "anaemia", "ent_type": "Disease", "char_span": [94, 101], "ent_id": "D000740", "tok_span": [19, 21]}, {"name": "phenylhydrazine", "ent_type": "Chemical", "char_span": [130, 145], "ent_id": "C030299", "tok_span": [25, 28]}, {"name": "AZT", "ent_type": "Chemical", "char_span": [42, 45], "ent_id": "D015215", "tok_span": [9, 11]}, {"name": "PHZ", "ent_type": "Chemical", "char_span": [147, 150], "ent_id": "C030299", "tok_span": [29, 31]}], "relation_list": [{"subject": "AZT", "object": "anaemia", "sbj_char_span": [42, 45], "obj_char_span": [94, 101], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 11], "obj_tok_span": [19, 21]}], "umls_entity_list": []}, {"text": "The numbers of BFU-e and the percentage of bone marrow erythroblasts observed were comparable in AZT and PHZ treated mice with similar degrees of anaemia.", "entity_list": [{"name": "AZT", "ent_type": "Chemical", "char_span": [97, 100], "ent_id": "D015215", "tok_span": [20, 22]}, {"name": "PHZ", "ent_type": "Chemical", "char_span": [105, 108], "ent_id": "C030299", "tok_span": [23, 25]}, {"name": "anaemia", "ent_type": "Disease", "char_span": [146, 153], "ent_id": "D000740", "tok_span": [31, 33]}], "relation_list": [{"subject": "AZT", "object": "anaemia", "sbj_char_span": [97, 100], "obj_char_span": [146, 153], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 22], "obj_tok_span": [31, 33]}], "umls_entity_list": []}, {"text": "However, reticulocytosis was inappropriate for the degree of anaemia observed in AZT treated infected mice.", "entity_list": [{"name": "anaemia", "ent_type": "Disease", "char_span": [61, 68], "ent_id": "D000740", "tok_span": [12, 14]}, {"name": "AZT", "ent_type": "Chemical", "char_span": [81, 84], "ent_id": "D015215", "tok_span": [16, 18]}, {"name": "reticulocytosis", "ent_type": "Disease", "char_span": [9, 24], "ent_id": "D045262", "tok_span": [2, 6]}], "relation_list": [{"subject": "AZT", "object": "anaemia", "sbj_char_span": [81, 84], "obj_char_span": [61, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 18], "obj_tok_span": [12, 14]}], "umls_entity_list": []}, {"text": "AZT-induced peripheral anaemia in the face of increased numbers of BFU-e and increased levels of plasma EPO suggest a lesion in terminal differentiation.", "entity_list": [{"name": "anaemia", "ent_type": "Disease", "char_span": [23, 30], "ent_id": "D000740", "tok_span": [5, 7]}, {"name": "AZT", "ent_type": "Chemical", "char_span": [0, 3], "ent_id": "D015215", "tok_span": [0, 2]}], "relation_list": [{"subject": "AZT", "object": "anaemia", "sbj_char_span": [0, 3], "obj_char_span": [23, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "Detection of abnormal cardiac adrenergic neuron activity in adriamycin-induced cardiomyopathy with iodine-125-metaiodobenzylguanidine.", "entity_list": [{"name": "adriamycin", "ent_type": "Chemical", "char_span": [60, 70], "ent_id": "D004317", "tok_span": [9, 13]}, {"name": "iodine-125-metaiodobenzylguanidine", "ent_type": "Chemical", "char_span": [99, 133], "ent_id": "D019797", "tok_span": [17, 29]}, {"name": "cardiomyopathy", "ent_type": "Disease", "char_span": [79, 93], "ent_id": "D009202", "tok_span": [15, 16]}], "relation_list": [{"subject": "adriamycin", "object": "cardiomyopathy", "sbj_char_span": [60, 70], "obj_char_span": [79, 93], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [15, 16]}], "umls_entity_list": []}, {"text": "Using a rat model of adriamycin-induced cardiomyopathy, we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose-dependently in adriamycin cardiomyopathy.", "entity_list": [{"name": "cardiomyopathy", "ent_type": "Disease", "char_span": [191, 205], "ent_id": "D009202", "tok_span": [39, 40]}, {"name": "cardiomyopathy", "ent_type": "Disease", "char_span": [40, 54], "ent_id": "D009202", "tok_span": [11, 12]}, {"name": "adriamycin", "ent_type": "Chemical", "char_span": [180, 190], "ent_id": "D004317", "tok_span": [35, 39]}, {"name": "adriamycin", "ent_type": "Chemical", "char_span": [21, 31], "ent_id": "D004317", "tok_span": [5, 9]}], "relation_list": [{"subject": "adriamycin", "object": "cardiomyopathy", "sbj_char_span": [21, 31], "obj_char_span": [191, 205], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [39, 40]}, {"subject": "adriamycin", "object": "cardiomyopathy", "sbj_char_span": [180, 190], "obj_char_span": [40, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 39], "obj_tok_span": [11, 12]}, {"subject": "adriamycin", "object": "cardiomyopathy", "sbj_char_span": [180, 190], "obj_char_span": [191, 205], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 39], "obj_tok_span": [39, 40]}, {"subject": "adriamycin", "object": "cardiomyopathy", "sbj_char_span": [21, 31], "obj_char_span": [40, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [11, 12]}], "umls_entity_list": []}, {"text": "The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal vacuolar degeneration) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin-induced cardiomyopathy.", "entity_list": [{"name": "MIBG", "ent_type": "Chemical", "char_span": [168, 172], "ent_id": "D019797", "tok_span": [26, 28]}, {"name": "adriamycin", "ent_type": "Chemical", "char_span": [226, 236], "ent_id": "D004317", "tok_span": [40, 44]}, {"name": "vacuolar degeneration", "ent_type": "Disease", "char_span": [130, 151], "ent_id": "C536522", "tok_span": [20, 23]}, {"name": "myocardial impairment", "ent_type": "Disease", "char_span": [88, 109], "ent_id": "D009202", "tok_span": [14, 16]}, {"name": "cardiomyopathy", "ent_type": "Disease", "char_span": [245, 259], "ent_id": "D009202", "tok_span": [46, 47]}], "relation_list": [{"subject": "adriamycin", "object": "cardiomyopathy", "sbj_char_span": [226, 236], "obj_char_span": [245, 259], "rel_type": "chemical-induced disease", "sbj_tok_span": [40, 44], "obj_tok_span": [46, 47]}, {"subject": "adriamycin", "object": "myocardial impairment", "sbj_char_span": [226, 236], "obj_char_span": [88, 109], "rel_type": "chemical-induced disease", "sbj_tok_span": [40, 44], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "Amnestic syndrome associated with propranolol toxicity: a case report.", "entity_list": [{"name": "toxicity", "ent_type": "Disease", "char_span": [46, 54], "ent_id": "D064420", "tok_span": [10, 11]}, {"name": "propranolol", "ent_type": "Chemical", "char_span": [34, 45], "ent_id": "D011433", "tok_span": [6, 10]}, {"name": "Amnestic syndrome", "ent_type": "Disease", "char_span": [0, 17], "ent_id": "D000647", "tok_span": [0, 4]}], "relation_list": [{"subject": "propranolol", "object": "Amnestic syndrome", "sbj_char_span": [34, 45], "obj_char_span": [0, 17], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 10], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "Bilateral vagotomy and sympathectomy or prior administration of a ganglion blocker failed to inhibit the occurrence of the ketamine-induced tachycardia, while it was completely abolished in the reserpinized dogs or by a prior injection of a beta-blocking agent into the SA node artery.", "entity_list": [{"name": "tachycardia", "ent_type": "Disease", "char_span": [140, 151], "ent_id": "D013610", "tok_span": [25, 26]}, {"name": "ketamine", "ent_type": "Chemical", "char_span": [123, 131], "ent_id": "D007649", "tok_span": [22, 23]}], "relation_list": [{"subject": "ketamine", "object": "tachycardia", "sbj_char_span": [123, 131], "obj_char_span": [140, 151], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [25, 26]}], "umls_entity_list": []}, {"text": "The use of serum cholinesterase in succinylcholine apnoea.", "entity_list": [{"name": "apnoea", "ent_type": "Disease", "char_span": [51, 57], "ent_id": "D001049", "tok_span": [11, 14]}, {"name": "succinylcholine", "ent_type": "Chemical", "char_span": [35, 50], "ent_id": "D013390", "tok_span": [8, 11]}], "relation_list": [{"subject": "succinylcholine", "object": "apnoea", "sbj_char_span": [35, 50], "obj_char_span": [51, 57], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [11, 14]}], "umls_entity_list": []}, {"text": "Fifteen patients demonstrating unexpected prolonged apnoea lasting several hours after succinylcholine have been treated by a new preparation of human serum cholinesterase.", "entity_list": [{"name": "succinylcholine", "ent_type": "Chemical", "char_span": [87, 102], "ent_id": "D013390", "tok_span": [13, 16]}, {"name": "apnoea", "ent_type": "Disease", "char_span": [52, 58], "ent_id": "D001049", "tok_span": [6, 9]}], "relation_list": [{"subject": "succinylcholine", "object": "apnoea", "sbj_char_span": [87, 102], "obj_char_span": [52, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [6, 9]}], "umls_entity_list": []}, {"text": "The use of serum cholinesterase in succinylcholine apnoea provided considerable relief to both patient and anaesthetist.", "entity_list": [{"name": "apnoea", "ent_type": "Disease", "char_span": [51, 57], "ent_id": "D001049", "tok_span": [11, 14]}, {"name": "succinylcholine", "ent_type": "Chemical", "char_span": [35, 50], "ent_id": "D013390", "tok_span": [8, 11]}], "relation_list": [{"subject": "succinylcholine", "object": "apnoea", "sbj_char_span": [35, 50], "obj_char_span": [51, 57], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [11, 14]}], "umls_entity_list": []}, {"text": "Orthostatic hypotension occurs following alpha 2-adrenoceptor blockade in chronic prazosin-pretreated conscious spontaneously hypertensive rats.\n 1", "entity_list": [{"name": "prazosin", "ent_type": "Chemical", "char_span": [82, 90], "ent_id": "D011224", "tok_span": [14, 17]}, {"name": "Orthostatic hypotension", "ent_type": "Disease", "char_span": [0, 23], "ent_id": "D007024", "tok_span": [0, 3]}, {"name": "hypertensive", "ent_type": "Disease", "char_span": [126, 138], "ent_id": "D006973", "tok_span": [21, 22]}], "relation_list": [{"subject": "prazosin", "object": "Orthostatic hypotension", "sbj_char_span": [82, 90], "obj_char_span": [0, 23], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6). 3.", "entity_list": [{"name": "rauwolscine", "ent_type": "Chemical", "char_span": [142, 153], "ent_id": "D015016", "tok_span": [37, 42]}, {"name": "orthostatic hypotension", "ent_type": "Disease", "char_span": [34, 57], "ent_id": "D007024", "tok_span": [8, 11]}, {"name": "prazosin", "ent_type": "Chemical", "char_span": [82, 90], "ent_id": "D011224", "tok_span": [16, 19]}], "relation_list": [{"subject": "prazosin", "object": "orthostatic hypotension", "sbj_char_span": [82, 90], "obj_char_span": [34, 57], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [8, 11]}], "umls_entity_list": []}, {"text": "Head-up tilts in these rats did not produce orthostatic hypotension when performed either prior to or after acute dosing of prazosin (0.1 mg kg-1 i.p.).", "entity_list": [{"name": "orthostatic hypotension", "ent_type": "Disease", "char_span": [44, 67], "ent_id": "D007024", "tok_span": [11, 14]}, {"name": "prazosin", "ent_type": "Chemical", "char_span": [124, 132], "ent_id": "D011224", "tok_span": [24, 27]}], "relation_list": [{"subject": "prazosin", "object": "orthostatic hypotension", "sbj_char_span": [124, 132], "obj_char_span": [44, 67], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 27], "obj_tok_span": [11, 14]}], "umls_entity_list": []}, {"text": "The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.", "entity_list": [{"name": "noradrenaline", "ent_type": "Chemical", "char_span": [175, 188], "ent_id": "D009638", "tok_span": [62, 65]}, {"name": "Abbott-53693", "ent_type": "Chemical", "char_span": [126, 138], "ent_id": "C056299", "tok_span": [40, 46]}, {"name": "cirazoline", "ent_type": "Chemical", "char_span": [61, 71], "ent_id": "C014282", "tok_span": [15, 18]}, {"name": "prazosin", "ent_type": "Chemical", "char_span": [282, 290], "ent_id": "D011224", "tok_span": [92, 95]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [26, 37], "ent_id": "D001919", "tok_span": [5, 9]}], "relation_list": [{"subject": "Abbott-53693", "object": "bradycardia", "sbj_char_span": [126, 138], "obj_char_span": [26, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [40, 46], "obj_tok_span": [5, 9]}, {"subject": "cirazoline", "object": "bradycardia", "sbj_char_span": [61, 71], "obj_char_span": [26, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [5, 9]}, {"subject": "noradrenaline", "object": "bradycardia", "sbj_char_span": [175, 188], "obj_char_span": [26, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [62, 65], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "Both the pressor and bradycardia effects of cirazoline were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4).", "entity_list": [{"name": "prazosin", "ent_type": "Chemical", "char_span": [81, 89], "ent_id": "D011224", "tok_span": [18, 21]}, {"name": "cirazoline", "ent_type": "Chemical", "char_span": [44, 54], "ent_id": "C014282", "tok_span": [11, 14]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [21, 32], "ent_id": "D001919", "tok_span": [5, 9]}], "relation_list": [{"subject": "cirazoline", "object": "bradycardia", "sbj_char_span": [44, 54], "obj_char_span": [21, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "On the other hand, the pressor effects of Abbott-53693 were similar in both groups of SHR, but the accompanying bradycardia was greater in SHR with chronic prazosin treatment than without such treatment.", "entity_list": [{"name": "prazosin", "ent_type": "Chemical", "char_span": [156, 164], "ent_id": "D011224", "tok_span": [37, 40]}, {"name": "Abbott-53693", "ent_type": "Chemical", "char_span": [42, 54], "ent_id": "C056299", "tok_span": [10, 16]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [112, 123], "ent_id": "D001919", "tok_span": [27, 31]}], "relation_list": [{"subject": "Abbott-53693", "object": "bradycardia", "sbj_char_span": [42, 54], "obj_char_span": [112, 123], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 16], "obj_tok_span": [27, 31]}], "umls_entity_list": []}, {"text": "Furthermore, the bradycardia that accompanied the noradrenaline-induced pressor effect in SHR was similar with and without chronic prazosin treatment despite a 47-71% reduction of the pressor effect in chronic alpha 1-receptor blocked SHR.", "entity_list": [{"name": "noradrenaline", "ent_type": "Chemical", "char_span": [50, 63], "ent_id": "D009638", "tok_span": [10, 13]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [17, 28], "ent_id": "D001919", "tok_span": [3, 7]}, {"name": "prazosin", "ent_type": "Chemical", "char_span": [131, 139], "ent_id": "D011224", "tok_span": [26, 29]}], "relation_list": [{"subject": "noradrenaline", "object": "bradycardia", "sbj_char_span": [50, 63], "obj_char_span": [17, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "Chloroquine related complete heart block with blindness: case report.", "entity_list": [{"name": "Chloroquine", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D002738", "tok_span": [0, 3]}, {"name": "blindness", "ent_type": "Disease", "char_span": [46, 55], "ent_id": "D001766", "tok_span": [8, 10]}, {"name": "heart block", "ent_type": "Disease", "char_span": [29, 40], "ent_id": "D006327", "tok_span": [5, 7]}], "relation_list": [{"subject": "Chloroquine", "object": "blindness", "sbj_char_span": [0, 11], "obj_char_span": [46, 55], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.", "entity_list": [{"name": "dizziness", "ent_type": "Disease", "char_span": [156, 165], "ent_id": "D004244", "tok_span": [31, 34]}, {"name": "syncopal attacks", "ent_type": "Disease", "char_span": [181, 197], "ent_id": "D013575", "tok_span": [37, 41]}, {"name": "deterioration of vision", "ent_type": "Disease", "char_span": [101, 124], "ent_id": "D015354", "tok_span": [18, 21]}, {"name": "chloroquine", "ent_type": "Chemical", "char_span": [52, 63], "ent_id": "D002738", "tok_span": [11, 14]}, {"name": "dyspnoea", "ent_type": "Disease", "char_span": [146, 154], "ent_id": "D004417", "tok_span": [27, 30]}, {"name": "fatiguability", "ent_type": "Disease", "char_span": [131, 144], "ent_id": "D005221", "tok_span": [23, 26]}], "relation_list": [{"subject": "chloroquine", "object": "syncopal attacks", "sbj_char_span": [52, 63], "obj_char_span": [181, 197], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [37, 41]}, {"subject": "chloroquine", "object": "dyspnoea", "sbj_char_span": [52, 63], "obj_char_span": [146, 154], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [27, 30]}, {"subject": "chloroquine", "object": "fatiguability", "sbj_char_span": [52, 63], "obj_char_span": [131, 144], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [23, 26]}, {"subject": "chloroquine", "object": "dizziness", "sbj_char_span": [52, 63], "obj_char_span": [156, 165], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [31, 34]}], "umls_entity_list": []}, {"text": "Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.", "entity_list": [{"name": "heart block", "ent_type": "Disease", "char_span": [143, 154], "ent_id": "D006327", "tok_span": [22, 24]}, {"name": "heart failure", "ent_type": "Disease", "char_span": [114, 127], "ent_id": "D006333", "tok_span": [17, 19]}, {"name": "retinopathy", "ent_type": "Disease", "char_span": [61, 72], "ent_id": "D012164", "tok_span": [10, 11]}, {"name": "chloroquine", "ent_type": "Chemical", "char_span": [49, 60], "ent_id": "D002738", "tok_span": [7, 10]}, {"name": "right bundle branch block", "ent_type": "Disease", "char_span": [160, 185], "ent_id": "D002037", "tok_span": [25, 29]}], "relation_list": [{"subject": "chloroquine", "object": "retinopathy", "sbj_char_span": [49, 60], "obj_char_span": [61, 72], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [10, 11]}, {"subject": "chloroquine", "object": "right bundle branch block", "sbj_char_span": [49, 60], "obj_char_span": [160, 185], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [25, 29]}, {"subject": "chloroquine", "object": "heart failure", "sbj_char_span": [49, 60], "obj_char_span": [114, 127], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [17, 19]}], "umls_entity_list": []}, {"text": "The heart block was treated by pacemaker insertion and the heart failure resolved spontaneously following chloroquine discontinuation.", "entity_list": [{"name": "heart block", "ent_type": "Disease", "char_span": [4, 15], "ent_id": "D006327", "tok_span": [1, 3]}, {"name": "heart failure", "ent_type": "Disease", "char_span": [59, 72], "ent_id": "D006333", "tok_span": [12, 14]}, {"name": "chloroquine", "ent_type": "Chemical", "char_span": [106, 117], "ent_id": "D002738", "tok_span": [17, 20]}], "relation_list": [{"subject": "chloroquine", "object": "heart failure", "sbj_char_span": [106, 117], "obj_char_span": [59, 72], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [12, 14]}], "umls_entity_list": []}, {"text": "The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine.", "entity_list": [{"name": "bupivacaine", "ent_type": "Chemical", "char_span": [122, 133], "ent_id": "D002045", "tok_span": [26, 30]}, {"name": "levobupivacaine", "ent_type": "Chemical", "char_span": [24, 39], "ent_id": "C476513", "tok_span": [4, 10]}, {"name": "ropivacaine", "ent_type": "Chemical", "char_span": [44, 55], "ent_id": "C037663", "tok_span": [11, 15]}, {"name": "seizures", "ent_type": "Disease", "char_span": [70, 78], "ent_id": "D012640", "tok_span": [17, 18]}], "relation_list": [{"subject": "levobupivacaine", "object": "seizures", "sbj_char_span": [24, 39], "obj_char_span": [70, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 10], "obj_tok_span": [17, 18]}, {"subject": "ropivacaine", "object": "seizures", "sbj_char_span": [44, 55], "obj_char_span": [70, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [17, 18]}], "umls_entity_list": []}, {"text": "The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.", "entity_list": [{"name": "dysrhythmias", "ent_type": "Disease", "char_span": [54, 66], "ent_id": "D001145", "tok_span": [12, 16]}, {"name": "asystole", "ent_type": "Disease", "char_span": [71, 79], "ent_id": "D006323", "tok_span": [17, 20]}, {"name": "levobupivacaine", "ent_type": "Chemical", "char_span": [24, 39], "ent_id": "C476513", "tok_span": [4, 10]}, {"name": "bupivacaine", "ent_type": "Chemical", "char_span": [173, 184], "ent_id": "D002045", "tok_span": [39, 43]}, {"name": "ropivacaine", "ent_type": "Chemical", "char_span": [125, 136], "ent_id": "C037663", "tok_span": [27, 31]}], "relation_list": [{"subject": "levobupivacaine", "object": "asystole", "sbj_char_span": [24, 39], "obj_char_span": [71, 79], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 10], "obj_tok_span": [17, 20]}, {"subject": "ropivacaine", "object": "dysrhythmias", "sbj_char_span": [125, 136], "obj_char_span": [54, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 31], "obj_tok_span": [12, 16]}, {"subject": "levobupivacaine", "object": "dysrhythmias", "sbj_char_span": [24, 39], "obj_char_span": [54, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 10], "obj_tok_span": [12, 16]}, {"subject": "ropivacaine", "object": "asystole", "sbj_char_span": [125, 136], "obj_char_span": [71, 79], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 31], "obj_tok_span": [17, 20]}], "umls_entity_list": []}, {"text": "We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.", "entity_list": [{"name": "bupivacaine", "ent_type": "Chemical", "char_span": [106, 117], "ent_id": "D002045", "tok_span": [23, 27]}, {"name": "levobupivacaine", "ent_type": "Chemical", "char_span": [277, 292], "ent_id": "C476513", "tok_span": [59, 65]}, {"name": "cardiac arrest", "ent_type": "Disease", "char_span": [182, 196], "ent_id": "D006323", "tok_span": [41, 43]}, {"name": "ropivacaine", "ent_type": "Chemical", "char_span": [90, 101], "ent_id": "C037663", "tok_span": [18, 22]}, {"name": "toxicity", "ent_type": "Disease", "char_span": [30, 38], "ent_id": "D064420", "tok_span": [5, 6]}, {"name": "ropivacaine", "ent_type": "Chemical", "char_span": [162, 173], "ent_id": "C037663", "tok_span": [35, 39]}, {"name": "bupivacaine", "ent_type": "Chemical", "char_span": [262, 273], "ent_id": "D002045", "tok_span": [54, 58]}, {"name": "levobupivacaine", "ent_type": "Chemical", "char_span": [42, 57], "ent_id": "C476513", "tok_span": [7, 13]}], "relation_list": [{"subject": "ropivacaine", "object": "cardiac arrest", "sbj_char_span": [90, 101], "obj_char_span": [182, 196], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 22], "obj_tok_span": [41, 43]}, {"subject": "levobupivacaine", "object": "cardiac arrest", "sbj_char_span": [277, 292], "obj_char_span": [182, 196], "rel_type": "chemical-induced disease", "sbj_tok_span": [59, 65], "obj_tok_span": [41, 43]}, {"subject": "ropivacaine", "object": "cardiac arrest", "sbj_char_span": [162, 173], "obj_char_span": [182, 196], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 39], "obj_tok_span": [41, 43]}, {"subject": "levobupivacaine", "object": "cardiac arrest", "sbj_char_span": [42, 57], "obj_char_span": [182, 196], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 13], "obj_tok_span": [41, 43]}], "umls_entity_list": []}, {"text": "BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.", "entity_list": [{"name": "suppression of bone turnover", "ent_type": "Disease", "char_span": [180, 208], "ent_id": "D001851", "tok_span": [33, 37]}, {"name": "hypercalcemia", "ent_type": "Disease", "char_span": [152, 165], "ent_id": "D006934", "tok_span": [26, 29]}, {"name": "Calcitriol", "ent_type": "Chemical", "char_span": [12, 22], "ent_id": "D002117", "tok_span": [2, 5]}, {"name": "adynamic bone disease", "ent_type": "Disease", "char_span": [228, 249], "ent_id": "D001851", "tok_span": [42, 46]}, {"name": "renal failure", "ent_type": "Disease", "char_span": [101, 114], "ent_id": "D051437", "tok_span": [18, 20]}], "relation_list": [{"subject": "Calcitriol", "object": "suppression of bone turnover", "sbj_char_span": [12, 22], "obj_char_span": [180, 208], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [33, 37]}, {"subject": "Calcitriol", "object": "hypercalcemia", "sbj_char_span": [12, 22], "obj_char_span": [152, 165], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [26, 29]}, {"subject": "Calcitriol", "object": "adynamic bone disease", "sbj_char_span": [12, 22], "obj_char_span": [228, 249], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [42, 46]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.", "entity_list": [{"name": "adynamic bone disease", "ent_type": "Disease", "char_span": [323, 344], "ent_id": "D001851", "tok_span": [58, 62]}, {"name": "low bone turnover", "ent_type": "Disease", "char_span": [259, 276], "ent_id": "D001851", "tok_span": [45, 48]}, {"name": "OCT", "ent_type": "Chemical", "char_span": [53, 56], "ent_id": "C051883", "tok_span": [8, 9]}, {"name": "renal insufficiency", "ent_type": "Disease", "char_span": [143, 162], "ent_id": "D051437", "tok_span": [23, 25]}, {"name": "hypercalcemia", "ent_type": "Disease", "char_span": [103, 116], "ent_id": "D006934", "tok_span": [16, 19]}, {"name": "secondary hyperparathyroidism", "ent_type": "Disease", "char_span": [202, 231], "ent_id": "D006962", "tok_span": [35, 40]}], "relation_list": [{"subject": "OCT", "object": "hypercalcemia", "sbj_char_span": [53, 56], "obj_char_span": [103, 116], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [16, 19]}], "umls_entity_list": []}, {"text": "Cerebral hemorrhage associated with phenylpropanolamine in combination with caffeine.", "entity_list": [{"name": "caffeine", "ent_type": "Chemical", "char_span": [76, 84], "ent_id": "D002110", "tok_span": [12, 13]}, {"name": "Cerebral hemorrhage", "ent_type": "Disease", "char_span": [0, 19], "ent_id": "D002543", "tok_span": [0, 3]}, {"name": "phenylpropanolamine", "ent_type": "Chemical", "char_span": [36, 55], "ent_id": "D010665", "tok_span": [5, 9]}], "relation_list": [{"subject": "phenylpropanolamine", "object": "Cerebral hemorrhage", "sbj_char_span": [36, 55], "obj_char_span": [0, 19], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [0, 3]}, {"subject": "caffeine", "object": "Cerebral hemorrhage", "sbj_char_span": [76, 84], "obj_char_span": [0, 19], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "Phenylpropanolamine (PPA) is a drug that has been associated with serious side effects including stroke.", "entity_list": [{"name": "Phenylpropanolamine", "ent_type": "Chemical", "char_span": [0, 19], "ent_id": "D010665", "tok_span": [0, 5]}, {"name": "stroke", "ent_type": "Disease", "char_span": [97, 103], "ent_id": "D020521", "tok_span": [21, 22]}, {"name": "PPA", "ent_type": "Chemical", "char_span": [21, 24], "ent_id": "D010665", "tok_span": [6, 8]}], "relation_list": [{"subject": "PPA", "object": "stroke", "sbj_char_span": [21, 24], "obj_char_span": [97, 103], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [21, 22]}, {"subject": "Phenylpropanolamine", "object": "stroke", "sbj_char_span": [0, 19], "obj_char_span": [97, 103], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [21, 22]}], "umls_entity_list": []}, {"text": "In order to determine if PPA/caffeine can lead to stroke in normotensive and/or hypertensive rats, we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days.", "entity_list": [{"name": "hypertensive", "ent_type": "Disease", "char_span": [80, 92], "ent_id": "D006973", "tok_span": [21, 22]}, {"name": "stroke", "ent_type": "Disease", "char_span": [50, 56], "ent_id": "D020521", "tok_span": [12, 13]}, {"name": "caffeine", "ent_type": "Chemical", "char_span": [29, 37], "ent_id": "D002110", "tok_span": [8, 9]}, {"name": "PPA", "ent_type": "Chemical", "char_span": [25, 28], "ent_id": "D010665", "tok_span": [5, 7]}], "relation_list": [{"subject": "caffeine", "object": "hypertensive", "sbj_char_span": [29, 37], "obj_char_span": [80, 92], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [21, 22]}, {"subject": "PPA", "object": "stroke", "sbj_char_span": [25, 28], "obj_char_span": [50, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 7], "obj_tok_span": [12, 13]}, {"subject": "PPA", "object": "hypertensive", "sbj_char_span": [25, 28], "obj_char_span": [80, 92], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 7], "obj_tok_span": [21, 22]}], "umls_entity_list": []}, {"text": "A single PPA/caffeine administration (same dose) lead to acute hypertension in both the normotensive and hypertensive animals.", "entity_list": [{"name": "PPA", "ent_type": "Chemical", "char_span": [9, 12], "ent_id": "D010665", "tok_span": [2, 4]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [63, 75], "ent_id": "D006973", "tok_span": [14, 15]}, {"name": "caffeine", "ent_type": "Chemical", "char_span": [13, 21], "ent_id": "D002110", "tok_span": [5, 6]}, {"name": "hypertensive", "ent_type": "Disease", "char_span": [105, 117], "ent_id": "D006973", "tok_span": [23, 24]}], "relation_list": [{"subject": "caffeine", "object": "hypertension", "sbj_char_span": [13, 21], "obj_char_span": [63, 75], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 6], "obj_tok_span": [14, 15]}, {"subject": "PPA", "object": "hypertension", "sbj_char_span": [9, 12], "obj_char_span": [63, 75], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 4], "obj_tok_span": [14, 15]}, {"subject": "caffeine", "object": "hypertensive", "sbj_char_span": [13, 21], "obj_char_span": [105, 117], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 6], "obj_tok_span": [23, 24]}, {"subject": "PPA", "object": "hypertensive", "sbj_char_span": [9, 12], "obj_char_span": [105, 117], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 4], "obj_tok_span": [23, 24]}], "umls_entity_list": []}, {"text": "These results suggest that PPA/caffeine can lead to cerebral hemorrhage in previously hypertensive animals when administered in greater than the allowed dosage.", "entity_list": [{"name": "PPA", "ent_type": "Chemical", "char_span": [27, 30], "ent_id": "D010665", "tok_span": [4, 6]}, {"name": "caffeine", "ent_type": "Chemical", "char_span": [31, 39], "ent_id": "D002110", "tok_span": [7, 8]}, {"name": "cerebral hemorrhage", "ent_type": "Disease", "char_span": [52, 71], "ent_id": "D002543", "tok_span": [11, 13]}, {"name": "hypertensive", "ent_type": "Disease", "char_span": [86, 98], "ent_id": "D006973", "tok_span": [15, 16]}], "relation_list": [{"subject": "PPA", "object": "hypertensive", "sbj_char_span": [27, 30], "obj_char_span": [86, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 6], "obj_tok_span": [15, 16]}, {"subject": "PPA", "object": "cerebral hemorrhage", "sbj_char_span": [27, 30], "obj_char_span": [52, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 6], "obj_tok_span": [11, 13]}, {"subject": "caffeine", "object": "hypertensive", "sbj_char_span": [31, 39], "obj_char_span": [86, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [15, 16]}, {"subject": "caffeine", "object": "cerebral hemorrhage", "sbj_char_span": [31, 39], "obj_char_span": [52, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [11, 13]}], "umls_entity_list": []}, {"text": "Anesthetized rats received the tricyclic antidepressant desipramine IP to produce hypotension, QRS prolongation, and bradycardia.", "entity_list": [{"name": "bradycardia", "ent_type": "Disease", "char_span": [117, 128], "ent_id": "D001919", "tok_span": [23, 27]}, {"name": "desipramine", "ent_type": "Chemical", "char_span": [56, 67], "ent_id": "D003891", "tok_span": [8, 12]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [82, 93], "ent_id": "D007022", "tok_span": [15, 16]}], "relation_list": [{"subject": "desipramine", "object": "hypotension", "sbj_char_span": [56, 67], "obj_char_span": [82, 93], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [15, 16]}, {"subject": "desipramine", "object": "bradycardia", "sbj_char_span": [56, 67], "obj_char_span": [117, 128], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [23, 27]}], "umls_entity_list": []}, {"text": "The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups.", "entity_list": [{"name": "CaCl2", "ent_type": "Chemical", "char_span": [84, 89], "ent_id": "D002122", "tok_span": [24, 26]}, {"name": "seizures", "ent_type": "Disease", "char_span": [57, 65], "ent_id": "D012640", "tok_span": [14, 15]}, {"name": "ventricular arrhythmias", "ent_type": "Disease", "char_span": [17, 40], "ent_id": "D001145", "tok_span": [3, 5]}], "relation_list": [{"subject": "CaCl2", "object": "ventricular arrhythmias", "sbj_char_span": [84, 89], "obj_char_span": [17, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 26], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "The DLT included hypercalcemia, and may be predicted by serum cis-RA levels.", "entity_list": [{"name": "hypercalcemia", "ent_type": "Disease", "char_span": [17, 30], "ent_id": "D006934", "tok_span": [4, 7]}, {"name": "cis-RA", "ent_type": "Chemical", "char_span": [62, 68], "ent_id": "D015474", "tok_span": [14, 17]}], "relation_list": [{"subject": "cis-RA", "object": "hypercalcemia", "sbj_char_span": [62, 68], "obj_char_span": [17, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [4, 7]}], "umls_entity_list": []}, {"text": "The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.", "entity_list": [{"name": "carbachol", "ent_type": "Chemical", "char_span": [292, 301], "ent_id": "D002217", "tok_span": [74, 77]}, {"name": "eserine", "ent_type": "Chemical", "char_span": [306, 313], "ent_id": "D010830", "tok_span": [78, 81]}, {"name": "calcium chloride", "ent_type": "Chemical", "char_span": [14, 30], "ent_id": "D002122", "tok_span": [3, 5]}, {"name": "tremor", "ent_type": "Disease", "char_span": [244, 250], "ent_id": "D014202", "tok_span": [62, 64]}, {"name": "mydriasis", "ent_type": "Disease", "char_span": [233, 242], "ent_id": "D015878", "tok_span": [58, 61]}, {"name": "clonic-tonic convulsions", "ent_type": "Disease", "char_span": [255, 279], "ent_id": "D004830", "tok_span": [65, 72]}], "relation_list": [{"subject": "carbachol", "object": "clonic-tonic convulsions", "sbj_char_span": [292, 301], "obj_char_span": [255, 279], "rel_type": "chemical-induced disease", "sbj_tok_span": [74, 77], "obj_tok_span": [65, 72]}, {"subject": "carbachol", "object": "mydriasis", "sbj_char_span": [292, 301], "obj_char_span": [233, 242], "rel_type": "chemical-induced disease", "sbj_tok_span": [74, 77], "obj_tok_span": [58, 61]}, {"subject": "carbachol", "object": "tremor", "sbj_char_span": [292, 301], "obj_char_span": [244, 250], "rel_type": "chemical-induced disease", "sbj_tok_span": [74, 77], "obj_tok_span": [62, 64]}, {"subject": "eserine", "object": "tremor", "sbj_char_span": [306, 313], "obj_char_span": [244, 250], "rel_type": "chemical-induced disease", "sbj_tok_span": [78, 81], "obj_tok_span": [62, 64]}, {"subject": "eserine", "object": "mydriasis", "sbj_char_span": [306, 313], "obj_char_span": [233, 242], "rel_type": "chemical-induced disease", "sbj_tok_span": [78, 81], "obj_tok_span": [58, 61]}, {"subject": "eserine", "object": "clonic-tonic convulsions", "sbj_char_span": [306, 313], "obj_char_span": [255, 279], "rel_type": "chemical-induced disease", "sbj_tok_span": [78, 81], "obj_tok_span": [65, 72]}], "umls_entity_list": []}, {"text": "On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.", "entity_list": [{"name": "carbachol", "ent_type": "Chemical", "char_span": [76, 85], "ent_id": "D002217", "tok_span": [21, 24]}, {"name": "tremor", "ent_type": "Disease", "char_span": [30, 36], "ent_id": "D014202", "tok_span": [9, 11]}, {"name": "calcium chloride", "ent_type": "Chemical", "char_span": [132, 148], "ent_id": "D002122", "tok_span": [33, 35]}, {"name": "clonic-tonic convulsions", "ent_type": "Disease", "char_span": [41, 65], "ent_id": "D004830", "tok_span": [12, 19]}, {"name": "eserine", "ent_type": "Chemical", "char_span": [90, 97], "ent_id": "D010830", "tok_span": [25, 28]}, {"name": "mydriasis", "ent_type": "Disease", "char_span": [19, 28], "ent_id": "D015878", "tok_span": [5, 8]}], "relation_list": [{"subject": "carbachol", "object": "mydriasis", "sbj_char_span": [76, 85], "obj_char_span": [19, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [5, 8]}, {"subject": "carbachol", "object": "tremor", "sbj_char_span": [76, 85], "obj_char_span": [30, 36], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [9, 11]}, {"subject": "eserine", "object": "mydriasis", "sbj_char_span": [90, 97], "obj_char_span": [19, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 28], "obj_tok_span": [5, 8]}, {"subject": "carbachol", "object": "clonic-tonic convulsions", "sbj_char_span": [76, 85], "obj_char_span": [41, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [12, 19]}, {"subject": "eserine", "object": "tremor", "sbj_char_span": [90, 97], "obj_char_span": [30, 36], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 28], "obj_tok_span": [9, 11]}, {"subject": "eserine", "object": "clonic-tonic convulsions", "sbj_char_span": [90, 97], "obj_char_span": [41, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 28], "obj_tok_span": [12, 19]}], "umls_entity_list": []}, {"text": "It is apparent that calcium chloride can \"dissociate\" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.", "entity_list": [{"name": "carbachol", "ent_type": "Chemical", "char_span": [180, 189], "ent_id": "D002217", "tok_span": [39, 42]}, {"name": "clonic-tonic convulsions", "ent_type": "Disease", "char_span": [145, 169], "ent_id": "D004830", "tok_span": [30, 37]}, {"name": "tremor", "ent_type": "Disease", "char_span": [134, 140], "ent_id": "D014202", "tok_span": [27, 29]}, {"name": "calcium chloride", "ent_type": "Chemical", "char_span": [20, 36], "ent_id": "D002122", "tok_span": [4, 6]}, {"name": "mydriasis", "ent_type": "Disease", "char_span": [123, 132], "ent_id": "D015878", "tok_span": [23, 26]}, {"name": "eserine", "ent_type": "Chemical", "char_span": [194, 201], "ent_id": "D010830", "tok_span": [43, 46]}], "relation_list": [{"subject": "carbachol", "object": "clonic-tonic convulsions", "sbj_char_span": [180, 189], "obj_char_span": [145, 169], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 42], "obj_tok_span": [30, 37]}, {"subject": "eserine", "object": "mydriasis", "sbj_char_span": [194, 201], "obj_char_span": [123, 132], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 46], "obj_tok_span": [23, 26]}, {"subject": "carbachol", "object": "tremor", "sbj_char_span": [180, 189], "obj_char_span": [134, 140], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 42], "obj_tok_span": [27, 29]}, {"subject": "eserine", "object": "clonic-tonic convulsions", "sbj_char_span": [194, 201], "obj_char_span": [145, 169], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 46], "obj_tok_span": [30, 37]}, {"subject": "eserine", "object": "tremor", "sbj_char_span": [194, 201], "obj_char_span": [134, 140], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 46], "obj_tok_span": [27, 29]}, {"subject": "carbachol", "object": "mydriasis", "sbj_char_span": [180, 189], "obj_char_span": [123, 132], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 42], "obj_tok_span": [23, 26]}], "umls_entity_list": []}, {"text": "Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.", "entity_list": [{"name": "polymyositis", "ent_type": "Disease", "char_span": [56, 68], "ent_id": "D017285", "tok_span": [12, 16]}, {"name": "penicillamine", "ent_type": "Chemical", "char_span": [134, 147], "ent_id": "D010396", "tok_span": [30, 35]}, {"name": "rheumatoid arthritis", "ent_type": "Disease", "char_span": [173, 193], "ent_id": "D001172", "tok_span": [39, 41]}, {"name": "systemic lupus erythematosus", "ent_type": "Disease", "char_span": [26, 54], "ent_id": "D008180", "tok_span": [7, 11]}, {"name": "Skin rashes", "ent_type": "Disease", "char_span": [0, 11], "ent_id": "D005076", "tok_span": [0, 4]}, {"name": "proteinuria", "ent_type": "Disease", "char_span": [13, 24], "ent_id": "D011507", "tok_span": [5, 6]}, {"name": "myasthenia gravis", "ent_type": "Disease", "char_span": [73, 90], "ent_id": "D009157", "tok_span": [17, 23]}], "relation_list": [{"subject": "penicillamine", "object": "proteinuria", "sbj_char_span": [134, 147], "obj_char_span": [13, 24], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 35], "obj_tok_span": [5, 6]}, {"subject": "penicillamine", "object": "Skin rashes", "sbj_char_span": [134, 147], "obj_char_span": [0, 11], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 35], "obj_tok_span": [0, 4]}, {"subject": "penicillamine", "object": "polymyositis", "sbj_char_span": [134, 147], "obj_char_span": [56, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 35], "obj_tok_span": [12, 16]}, {"subject": "penicillamine", "object": "myasthenia gravis", "sbj_char_span": [134, 147], "obj_char_span": [73, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 35], "obj_tok_span": [17, 23]}, {"subject": "penicillamine", "object": "systemic lupus erythematosus", "sbj_char_span": [134, 147], "obj_char_span": [26, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 35], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "Although most patients were receiving several drugs, Mellaril (thioridazine) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman.", "entity_list": [{"name": "ventricular tachycardia", "ent_type": "Disease", "char_span": [122, 145], "ent_id": "D017180", "tok_span": [26, 28]}, {"name": "thioridazine", "ent_type": "Chemical", "char_span": [63, 75], "ent_id": "D013881", "tok_span": [12, 17]}, {"name": "Mellaril", "ent_type": "Chemical", "char_span": [53, 61], "ent_id": "D013881", "tok_span": [8, 11]}], "relation_list": [{"subject": "Mellaril", "object": "ventricular tachycardia", "sbj_char_span": [53, 61], "obj_char_span": [122, 145], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [26, 28]}, {"subject": "thioridazine", "object": "ventricular tachycardia", "sbj_char_span": [63, 75], "obj_char_span": [122, 145], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 17], "obj_tok_span": [26, 28]}], "umls_entity_list": []}, {"text": "Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.", "entity_list": [{"name": "left bundle branch block", "ent_type": "Disease", "char_span": [65, 89], "ent_id": "D002037", "tok_span": [22, 26]}, {"name": "amitriptyline", "ent_type": "Chemical", "char_span": [36, 49], "ent_id": "D000639", "tok_span": [14, 19]}, {"name": "Elavil", "ent_type": "Chemical", "char_span": [28, 34], "ent_id": "D000639", "tok_span": [10, 13]}, {"name": "Aventyl", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "D009661", "tok_span": [0, 3]}, {"name": "nortriptyline", "ent_type": "Chemical", "char_span": [9, 22], "ent_id": "D009661", "tok_span": [4, 8]}], "relation_list": [{"subject": "Aventyl", "object": "left bundle branch block", "sbj_char_span": [0, 7], "obj_char_span": [65, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [22, 26]}, {"subject": "amitriptyline", "object": "left bundle branch block", "sbj_char_span": [36, 49], "obj_char_span": [65, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 19], "obj_tok_span": [22, 26]}, {"subject": "nortriptyline", "object": "left bundle branch block", "sbj_char_span": [9, 22], "obj_char_span": [65, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 8], "obj_tok_span": [22, 26]}, {"subject": "Elavil", "object": "left bundle branch block", "sbj_char_span": [28, 34], "obj_char_span": [65, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "Serotonergic drugs, benzodiazepines and baclofen block muscimol-induced myoclonic jerks in a strain of mice.", "entity_list": [{"name": "benzodiazepines", "ent_type": "Chemical", "char_span": [20, 35], "ent_id": "D001569", "tok_span": [5, 10]}, {"name": "muscimol", "ent_type": "Chemical", "char_span": [55, 63], "ent_id": "D009118", "tok_span": [15, 18]}, {"name": "myoclonic jerks", "ent_type": "Disease", "char_span": [72, 87], "ent_id": "D009207", "tok_span": [20, 26]}, {"name": "baclofen", "ent_type": "Chemical", "char_span": [40, 48], "ent_id": "D001418", "tok_span": [11, 14]}], "relation_list": [{"subject": "muscimol", "object": "myoclonic jerks", "sbj_char_span": [55, 63], "obj_char_span": [72, 87], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [20, 26]}], "umls_entity_list": []}, {"text": "In male Swiss mice, muscimol produced myoclonic jerks.", "entity_list": [{"name": "myoclonic jerks", "ent_type": "Disease", "char_span": [38, 53], "ent_id": "D009207", "tok_span": [9, 15]}, {"name": "muscimol", "ent_type": "Chemical", "char_span": [20, 28], "ent_id": "D009118", "tok_span": [5, 8]}], "relation_list": [{"subject": "muscimol", "object": "myoclonic jerks", "sbj_char_span": [20, 28], "obj_char_span": [38, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [9, 15]}], "umls_entity_list": []}, {"text": "Considering the fact that 5-HTP and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus, the muscimol-induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition.", "entity_list": [{"name": "myoclonus", "ent_type": "Disease", "char_span": [151, 160], "ent_id": "D009207", "tok_span": [37, 41]}, {"name": "myoclonus", "ent_type": "Disease", "char_span": [119, 128], "ent_id": "D009207", "tok_span": [26, 30]}, {"name": "benzodiazepines", "ent_type": "Chemical", "char_span": [40, 55], "ent_id": "D001569", "tok_span": [10, 15]}, {"name": "muscimol", "ent_type": "Chemical", "char_span": [134, 142], "ent_id": "D009118", "tok_span": [32, 35]}, {"name": "5-HTP", "ent_type": "Chemical", "char_span": [26, 31], "ent_id": "D006916", "tok_span": [4, 8]}], "relation_list": [{"subject": "muscimol", "object": "myoclonus", "sbj_char_span": [134, 142], "obj_char_span": [151, 160], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 35], "obj_tok_span": [37, 41]}, {"subject": "muscimol", "object": "myoclonus", "sbj_char_span": [134, 142], "obj_char_span": [119, 128], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 35], "obj_tok_span": [26, 30]}], "umls_entity_list": []}, {"text": "Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats.", "entity_list": [{"name": "crocin", "ent_type": "Chemical", "char_span": [53, 59], "ent_id": "C029036", "tok_span": [13, 15]}, {"name": "Alzheimer's disease", "ent_type": "Disease", "char_span": [102, 121], "ent_id": "D000544", "tok_span": [24, 28]}, {"name": "streptozocin", "ent_type": "Chemical", "char_span": [63, 75], "ent_id": "D013311", "tok_span": [16, 19]}], "relation_list": [{"subject": "streptozocin", "object": "Alzheimer's disease", "sbj_char_span": [63, 75], "obj_char_span": [102, 121], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [24, 28]}], "umls_entity_list": []}, {"text": "In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.", "entity_list": [{"name": "streptozocin", "ent_type": "Chemical", "char_span": [117, 129], "ent_id": "D013311", "tok_span": [29, 32]}, {"name": "Alzheimer's disease", "ent_type": "Disease", "char_span": [56, 75], "ent_id": "D000544", "tok_span": [13, 17]}, {"name": "STZ", "ent_type": "Chemical", "char_span": [131, 134], "ent_id": "D013311", "tok_span": [33, 35]}, {"name": "crocins", "ent_type": "Chemical", "char_span": [36, 43], "ent_id": "C029036", "tok_span": [8, 11]}], "relation_list": [{"subject": "STZ", "object": "Alzheimer's disease", "sbj_char_span": [131, 134], "obj_char_span": [56, 75], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 35], "obj_tok_span": [13, 17]}, {"subject": "streptozocin", "object": "Alzheimer's disease", "sbj_char_span": [117, 129], "obj_char_span": [56, 75], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 32], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "In Alzheimer's disease groups, rats were injected with STZ-icv bilaterally (3 mg/kg) in first day and 3 days later, a similar STZ-icv application was repeated.", "entity_list": [{"name": "STZ", "ent_type": "Chemical", "char_span": [126, 129], "ent_id": "D013311", "tok_span": [34, 36]}, {"name": "Alzheimer's disease", "ent_type": "Disease", "char_span": [3, 22], "ent_id": "D000544", "tok_span": [1, 5]}, {"name": "STZ", "ent_type": "Chemical", "char_span": [55, 58], "ent_id": "D013311", "tok_span": [11, 13]}], "relation_list": [{"subject": "STZ", "object": "Alzheimer's disease", "sbj_char_span": [55, 58], "obj_char_span": [3, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 13], "obj_tok_span": [1, 5]}, {"subject": "STZ", "object": "Alzheimer's disease", "sbj_char_span": [126, 129], "obj_char_span": [3, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 36], "obj_tok_span": [1, 5]}], "umls_entity_list": []}, {"text": "CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.", "entity_list": [{"name": "cognitive deficits", "ent_type": "Disease", "char_span": [108, 126], "ent_id": "D003072", "tok_span": [22, 24]}, {"name": "STZ", "ent_type": "Chemical", "char_span": [137, 140], "ent_id": "D013311", "tok_span": [26, 28]}, {"name": "crocin", "ent_type": "Chemical", "char_span": [70, 76], "ent_id": "C029036", "tok_span": [10, 12]}, {"name": "Alzheimer's disease", "ent_type": "Disease", "char_span": [226, 245], "ent_id": "D000544", "tok_span": [45, 49]}, {"name": "neurodegenerative diseases", "ent_type": "Disease", "char_span": [191, 217], "ent_id": "D019636", "tok_span": [40, 43]}], "relation_list": [{"subject": "STZ", "object": "Alzheimer's disease", "sbj_char_span": [137, 140], "obj_char_span": [226, 245], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 28], "obj_tok_span": [45, 49]}, {"subject": "STZ", "object": "cognitive deficits", "sbj_char_span": [137, 140], "obj_char_span": [108, 126], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 28], "obj_tok_span": [22, 24]}], "umls_entity_list": []}, {"text": "Continuous topical use of immunomodulators such as tacrolimus or pimecrolimus should be regarded as a potential cause of rosaceiform dermatitis, although many cases have not been reported.", "entity_list": [{"name": "tacrolimus", "ent_type": "Chemical", "char_span": [51, 61], "ent_id": "D016559", "tok_span": [8, 10]}, {"name": "dermatitis", "ent_type": "Disease", "char_span": [133, 143], "ent_id": "D003872", "tok_span": [28, 29]}, {"name": "pimecrolimus", "ent_type": "Chemical", "char_span": [65, 77], "ent_id": "C117268", "tok_span": [11, 16]}], "relation_list": [{"subject": "pimecrolimus", "object": "dermatitis", "sbj_char_span": [65, 77], "obj_char_span": [133, 143], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 16], "obj_tok_span": [28, 29]}], "umls_entity_list": []}, {"text": "Tacrine, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed hippocampal damage.", "entity_list": [{"name": "Tacrine", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "D013619", "tok_span": [0, 3]}, {"name": "seizures", "ent_type": "Disease", "char_span": [78, 86], "ent_id": "D012640", "tok_span": [18, 19]}, {"name": "LiCl", "ent_type": "Chemical", "char_span": [25, 29], "ent_id": "D018021", "tok_span": [6, 8]}, {"name": "hippocampal damage", "ent_type": "Disease", "char_span": [99, 117], "ent_id": "D001930", "tok_span": [21, 23]}], "relation_list": [{"subject": "Tacrine", "object": "seizures", "sbj_char_span": [0, 7], "obj_char_span": [78, 86], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [18, 19]}, {"subject": "LiCl", "object": "seizures", "sbj_char_span": [25, 29], "obj_char_span": [78, 86], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [18, 19]}, {"subject": "Tacrine", "object": "hippocampal damage", "sbj_char_span": [0, 7], "obj_char_span": [99, 117], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [21, 23]}, {"subject": "LiCl", "object": "hippocampal damage", "sbj_char_span": [25, 29], "obj_char_span": [99, 117], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "In addition, tacrine-loaded nanoparticles administration induced damage of neuronal cells in CA1 field of the hippocampus in all treated animals, while the saline solution of tacrine only in 60% of animals.", "entity_list": [{"name": "damage of neuronal cells", "ent_type": "Disease", "char_span": [65, 89], "ent_id": "D001930", "tok_span": [10, 14]}, {"name": "tacrine", "ent_type": "Chemical", "char_span": [13, 20], "ent_id": "D013619", "tok_span": [3, 5]}, {"name": "tacrine", "ent_type": "Chemical", "char_span": [175, 182], "ent_id": "D013619", "tok_span": [31, 33]}], "relation_list": [{"subject": "tacrine", "object": "damage of neuronal cells", "sbj_char_span": [175, 182], "obj_char_span": [65, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 33], "obj_tok_span": [10, 14]}, {"subject": "tacrine", "object": "damage of neuronal cells", "sbj_char_span": [13, 20], "obj_char_span": [65, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 5], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism, using both aconitine-induced rat and ouabain-induced guinea pig arrhythmia models.", "entity_list": [{"name": "ouabain", "ent_type": "Chemical", "char_span": [144, 151], "ent_id": "D010042", "tok_span": [28, 31]}, {"name": "aconitine", "ent_type": "Chemical", "char_span": [118, 127], "ent_id": "D000157", "tok_span": [21, 24]}, {"name": "arrhythmia", "ent_type": "Disease", "char_span": [171, 181], "ent_id": "D001145", "tok_span": [35, 37]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [51, 62], "ent_id": "D010862", "tok_span": [9, 12]}], "relation_list": [{"subject": "aconitine", "object": "arrhythmia", "sbj_char_span": [118, 127], "obj_char_span": [171, 181], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [35, 37]}, {"subject": "ouabain", "object": "arrhythmia", "sbj_char_span": [144, 151], "obj_char_span": [171, 181], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 31], "obj_tok_span": [35, 37]}], "umls_entity_list": []}, {"text": "The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.", "entity_list": [{"name": "aconitine", "ent_type": "Chemical", "char_span": [282, 291], "ent_id": "D000157", "tok_span": [55, 58]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [29, 40], "ent_id": "D010862", "tok_span": [5, 8]}, {"name": "arrhythmias", "ent_type": "Disease", "char_span": [72, 83], "ent_id": "D001145", "tok_span": [12, 13]}, {"name": "arrhythmia", "ent_type": "Disease", "char_span": [164, 174], "ent_id": "D001145", "tok_span": [25, 27]}, {"name": "Ca", "ent_type": "Chemical", "char_span": [251, 253], "ent_id": "D002118", "tok_span": [43, 44]}, {"name": "ouabain", "ent_type": "Chemical", "char_span": [295, 302], "ent_id": "D010042", "tok_span": [59, 62]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [352, 363], "ent_id": "D010862", "tok_span": [69, 72]}, {"name": "arrhythmic", "ent_type": "Disease", "char_span": [217, 227], "ent_id": "D001145", "tok_span": [35, 37]}, {"name": "ventricular tachycardia and fibrillation", "ent_type": "Disease", "char_span": [114, 154], "ent_id": "D01718", "tok_span": [19, 23]}], "relation_list": [{"subject": "aconitine", "object": "arrhythmia", "sbj_char_span": [282, 291], "obj_char_span": [164, 174], "rel_type": "chemical-induced disease", "sbj_tok_span": [55, 58], "obj_tok_span": [25, 27]}, {"subject": "ouabain", "object": "arrhythmias", "sbj_char_span": [295, 302], "obj_char_span": [72, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [59, 62], "obj_tok_span": [12, 13]}, {"subject": "ouabain", "object": "arrhythmic", "sbj_char_span": [295, 302], "obj_char_span": [217, 227], "rel_type": "chemical-induced disease", "sbj_tok_span": [59, 62], "obj_tok_span": [35, 37]}, {"subject": "aconitine", "object": "arrhythmic", "sbj_char_span": [282, 291], "obj_char_span": [217, 227], "rel_type": "chemical-induced disease", "sbj_tok_span": [55, 58], "obj_tok_span": [35, 37]}, {"subject": "ouabain", "object": "arrhythmia", "sbj_char_span": [295, 302], "obj_char_span": [164, 174], "rel_type": "chemical-induced disease", "sbj_tok_span": [59, 62], "obj_tok_span": [25, 27]}, {"subject": "aconitine", "object": "arrhythmias", "sbj_char_span": [282, 291], "obj_char_span": [72, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [55, 58], "obj_tok_span": [12, 13]}], "umls_entity_list": []}, {"text": "These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR.", "entity_list": [{"name": "pilocarpine", "ent_type": "Chemical", "char_span": [24, 35], "ent_id": "D010862", "tok_span": [4, 7]}, {"name": "aconitine", "ent_type": "Chemical", "char_span": [119, 128], "ent_id": "D000157", "tok_span": [23, 26]}, {"name": "arrhythmic", "ent_type": "Disease", "char_span": [71, 81], "ent_id": "D001145", "tok_span": [14, 16]}, {"name": "ouabain", "ent_type": "Chemical", "char_span": [132, 139], "ent_id": "D010042", "tok_span": [27, 30]}], "relation_list": [{"subject": "ouabain", "object": "arrhythmic", "sbj_char_span": [132, 139], "obj_char_span": [71, 81], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 30], "obj_tok_span": [14, 16]}, {"subject": "aconitine", "object": "arrhythmic", "sbj_char_span": [119, 128], "obj_char_span": [71, 81], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "Dual effects of melatonin on barbiturate-induced narcosis in rats.", "entity_list": [{"name": "melatonin", "ent_type": "Chemical", "char_span": [16, 25], "ent_id": "D008550", "tok_span": [3, 4]}, {"name": "barbiturate", "ent_type": "Chemical", "char_span": [29, 40], "ent_id": "C032232", "tok_span": [5, 8]}, {"name": "narcosis", "ent_type": "Disease", "char_span": [49, 57], "ent_id": "D053608", "tok_span": [10, 12]}], "relation_list": [{"subject": "melatonin", "object": "narcosis", "sbj_char_span": [16, 25], "obj_char_span": [49, 57], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Melatonin affects the circadian sleep/wake cycle, but it is not clear whether it may influence drug-induced narcosis.", "entity_list": [{"name": "narcosis", "ent_type": "Disease", "char_span": [108, 116], "ent_id": "D053608", "tok_span": [22, 24]}, {"name": "Melatonin", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D008550", "tok_span": [0, 2]}], "relation_list": [{"subject": "Melatonin", "object": "narcosis", "sbj_char_span": [0, 9], "obj_char_span": [108, 116], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [22, 24]}], "umls_entity_list": []}, {"text": "Melatonin pre-treatment affected in a dual manner barbiturate narcosis, however, no dose-effect correlation was found.", "entity_list": [{"name": "barbiturate", "ent_type": "Chemical", "char_span": [50, 61], "ent_id": "C032232", "tok_span": [10, 13]}, {"name": "narcosis", "ent_type": "Disease", "char_span": [62, 70], "ent_id": "D053608", "tok_span": [13, 15]}, {"name": "Melatonin", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D008550", "tok_span": [0, 2]}], "relation_list": [{"subject": "Melatonin", "object": "narcosis", "sbj_char_span": [0, 9], "obj_char_span": [62, 70], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "In contrast, the highest dose of melatonin (50 mg/kg) caused a paradoxical increase in the latency and produced a sustained reduction of the duration of narcosis, and a reduction in mortality rate.", "entity_list": [{"name": "melatonin", "ent_type": "Chemical", "char_span": [33, 42], "ent_id": "D008550", "tok_span": [7, 8]}, {"name": "narcosis", "ent_type": "Disease", "char_span": [153, 161], "ent_id": "D053608", "tok_span": [31, 33]}], "relation_list": [{"subject": "melatonin", "object": "narcosis", "sbj_char_span": [33, 42], "obj_char_span": [153, 161], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [31, 33]}], "umls_entity_list": []}, {"text": "Melatonin 0.5 and 5 mg/kg influenced the duration but not the latency of ketamine- or diazepam-induced narcosis.", "entity_list": [{"name": "narcosis", "ent_type": "Disease", "char_span": [103, 111], "ent_id": "D053608", "tok_span": [26, 28]}, {"name": "ketamine", "ent_type": "Chemical", "char_span": [73, 81], "ent_id": "D007649", "tok_span": [18, 19]}, {"name": "diazepam", "ent_type": "Chemical", "char_span": [86, 94], "ent_id": "D003975", "tok_span": [21, 24]}, {"name": "Melatonin", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D008550", "tok_span": [0, 2]}], "relation_list": [{"subject": "diazepam", "object": "narcosis", "sbj_char_span": [86, 94], "obj_char_span": [103, 111], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [26, 28]}, {"subject": "ketamine", "object": "narcosis", "sbj_char_span": [73, 81], "obj_char_span": [103, 111], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [26, 28]}, {"subject": "Melatonin", "object": "narcosis", "sbj_char_span": [0, 9], "obj_char_span": [103, 111], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [26, 28]}], "umls_entity_list": []}, {"text": "Thus, the dual action of melatonin on pharmacological narcosis seems to be specific for the barbiturate mechanism of action.", "entity_list": [{"name": "barbiturate", "ent_type": "Chemical", "char_span": [92, 103], "ent_id": "C032232", "tok_span": [17, 20]}, {"name": "melatonin", "ent_type": "Chemical", "char_span": [25, 34], "ent_id": "D008550", "tok_span": [6, 7]}, {"name": "narcosis", "ent_type": "Disease", "char_span": [54, 62], "ent_id": "D053608", "tok_span": [9, 11]}], "relation_list": [{"subject": "melatonin", "object": "narcosis", "sbj_char_span": [25, 34], "obj_char_span": [54, 62], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "Effects of NIK-247 on cholinesterase and scopolamine-induced amnesia.", "entity_list": [{"name": "NIK-247", "ent_type": "Chemical", "char_span": [11, 18], "ent_id": "C049860", "tok_span": [2, 6]}, {"name": "scopolamine", "ent_type": "Chemical", "char_span": [41, 52], "ent_id": "D012601", "tok_span": [11, 14]}, {"name": "amnesia", "ent_type": "Disease", "char_span": [61, 68], "ent_id": "D000647", "tok_span": [16, 19]}], "relation_list": [{"subject": "scopolamine", "object": "amnesia", "sbj_char_span": [41, 52], "obj_char_span": [61, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [16, 19]}, {"subject": "NIK-247", "object": "amnesia", "sbj_char_span": [11, 18], "obj_char_span": [61, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [16, 19]}], "umls_entity_list": []}, {"text": "The effects of NIK-247 on cholinesterase, scopolamine-induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.", "entity_list": [{"name": "scopolamine", "ent_type": "Chemical", "char_span": [42, 53], "ent_id": "D012601", "tok_span": [12, 15]}, {"name": "E-2020", "ent_type": "Chemical", "char_span": [189, 195], "ent_id": "C076946", "tok_span": [41, 45]}, {"name": "amnesia", "ent_type": "Disease", "char_span": [62, 69], "ent_id": "D000647", "tok_span": [17, 20]}, {"name": "NIK-247", "ent_type": "Chemical", "char_span": [15, 22], "ent_id": "C049860", "tok_span": [3, 7]}, {"name": "tacrine", "ent_type": "Chemical", "char_span": [177, 184], "ent_id": "D013619", "tok_span": [38, 40]}], "relation_list": [{"subject": "scopolamine", "object": "amnesia", "sbj_char_span": [42, 53], "obj_char_span": [62, 69], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [17, 20]}, {"subject": "NIK-247", "object": "amnesia", "sbj_char_span": [15, 22], "obj_char_span": [62, 69], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 7], "obj_tok_span": [17, 20]}, {"subject": "tacrine", "object": "amnesia", "sbj_char_span": [177, 184], "obj_char_span": [62, 69], "rel_type": "chemical-induced disease", "sbj_tok_span": [38, 40], "obj_tok_span": [17, 20]}, {"subject": "E-2020", "object": "amnesia", "sbj_char_span": [189, 195], "obj_char_span": [62, 69], "rel_type": "chemical-induced disease", "sbj_tok_span": [41, 45], "obj_tok_span": [17, 20]}], "umls_entity_list": []}, {"text": "All compounds at 0.1-1 mg/kg p.o. significantly improved the amnesia induced by scopolamine (0.5 mg/kg s.c.) in rats performing a passive avoidance task.", "entity_list": [{"name": "scopolamine", "ent_type": "Chemical", "char_span": [80, 91], "ent_id": "D012601", "tok_span": [23, 26]}, {"name": "amnesia", "ent_type": "Disease", "char_span": [61, 68], "ent_id": "D000647", "tok_span": [18, 21]}], "relation_list": [{"subject": "scopolamine", "object": "amnesia", "sbj_char_span": [80, 91], "obj_char_span": [61, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [18, 21]}], "umls_entity_list": []}, {"text": "These findings suggest that NIK-247 at a low dose (0.1-1 mg/kg p.o.) improves scopolamine-induced amnesia but does not affect spontaneous movement.", "entity_list": [{"name": "scopolamine", "ent_type": "Chemical", "char_span": [78, 89], "ent_id": "D012601", "tok_span": [27, 30]}, {"name": "NIK-247", "ent_type": "Chemical", "char_span": [28, 35], "ent_id": "C049860", "tok_span": [4, 8]}, {"name": "amnesia", "ent_type": "Disease", "char_span": [98, 105], "ent_id": "D000647", "tok_span": [32, 35]}], "relation_list": [{"subject": "NIK-247", "object": "amnesia", "sbj_char_span": [28, 35], "obj_char_span": [98, 105], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 8], "obj_tok_span": [32, 35]}, {"subject": "scopolamine", "object": "amnesia", "sbj_char_span": [78, 89], "obj_char_span": [98, 105], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 30], "obj_tok_span": [32, 35]}], "umls_entity_list": []}, {"text": "Nightmares and hallucinations after long-term intake of tramadol combined with antidepressants.", "entity_list": [{"name": "hallucinations", "ent_type": "Disease", "char_span": [15, 29], "ent_id": "D006212", "tok_span": [5, 8]}, {"name": "tramadol", "ent_type": "Chemical", "char_span": [56, 64], "ent_id": "D014147", "tok_span": [14, 18]}], "relation_list": [{"subject": "tramadol", "object": "hallucinations", "sbj_char_span": [56, 64], "obj_char_span": [15, 29], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 18], "obj_tok_span": [5, 8]}], "umls_entity_list": []}, {"text": "Fifty-six days after initiation of the treatment the patient presented hallucinations that only stopped after the withdrawal of psycho-active drugs and tramadol.", "entity_list": [{"name": "tramadol", "ent_type": "Chemical", "char_span": [152, 160], "ent_id": "D014147", "tok_span": [27, 31]}, {"name": "hallucinations", "ent_type": "Disease", "char_span": [71, 85], "ent_id": "D006212", "tok_span": [12, 15]}], "relation_list": [{"subject": "tramadol", "object": "hallucinations", "sbj_char_span": [152, 160], "obj_char_span": [71, 85], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 31], "obj_tok_span": [12, 15]}], "umls_entity_list": []}, {"text": "BMT was used to treat severe aplastic anemia which was caused by gold in one case and D-penicillamine in the other.", "entity_list": [{"name": "aplastic anemia", "ent_type": "Disease", "char_span": [29, 44], "ent_id": "D000741", "tok_span": [7, 10]}, {"name": "gold", "ent_type": "Chemical", "char_span": [65, 69], "ent_id": "D006046", "tok_span": [14, 15]}, {"name": "D-penicillamine", "ent_type": "Chemical", "char_span": [86, 101], "ent_id": "D010396", "tok_span": [19, 26]}], "relation_list": [{"subject": "gold", "object": "aplastic anemia", "sbj_char_span": [65, 69], "obj_char_span": [29, 44], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [7, 10]}, {"subject": "D-penicillamine", "object": "aplastic anemia", "sbj_char_span": [86, 101], "obj_char_span": [29, 44], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 26], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.", "entity_list": [{"name": "hexachloro-1:3-butadiene", "ent_type": "Chemical", "char_span": [147, 171], "ent_id": "C001335", "tok_span": [24, 35]}, {"name": "PAN", "ent_type": "Chemical", "char_span": [207, 210], "ent_id": "D011692", "tok_span": [46, 47]}, {"name": "Acute experimental models of renal damage", "ent_type": "Disease", "char_span": [0, 41], "ent_id": "D058186", "tok_span": [0, 6]}, {"name": "2-bromoethylamine", "ent_type": "Chemical", "char_span": [217, 234], "ent_id": "C004504", "tok_span": [50, 57]}, {"name": "BEA", "ent_type": "Chemical", "char_span": [236, 239], "ent_id": "C004504", "tok_span": [58, 60]}, {"name": "HCBD", "ent_type": "Chemical", "char_span": [173, 177], "ent_id": "C001335", "tok_span": [36, 38]}, {"name": "puromycin aminonucleoside", "ent_type": "Chemical", "char_span": [180, 205], "ent_id": "D011692", "tok_span": [40, 45]}], "relation_list": [{"subject": "hexachloro-1:3-butadiene", "object": "Acute experimental models of renal damage", "sbj_char_span": [147, 171], "obj_char_span": [0, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 35], "obj_tok_span": [0, 6]}, {"subject": "2-bromoethylamine", "object": "Acute experimental models of renal damage", "sbj_char_span": [217, 234], "obj_char_span": [0, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [50, 57], "obj_tok_span": [0, 6]}, {"subject": "HCBD", "object": "Acute experimental models of renal damage", "sbj_char_span": [173, 177], "obj_char_span": [0, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 38], "obj_tok_span": [0, 6]}, {"subject": "BEA", "object": "Acute experimental models of renal damage", "sbj_char_span": [236, 239], "obj_char_span": [0, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [58, 60], "obj_tok_span": [0, 6]}, {"subject": "PAN", "object": "Acute experimental models of renal damage", "sbj_char_span": [207, 210], "obj_char_span": [0, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [46, 47], "obj_tok_span": [0, 6]}, {"subject": "puromycin aminonucleoside", "object": "Acute experimental models of renal damage", "sbj_char_span": [180, 205], "obj_char_span": [0, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [40, 45], "obj_tok_span": [0, 6]}], "umls_entity_list": []}, {"text": "Neuromuscular blockade with magnesium sulfate and nifedipine.", "entity_list": [{"name": "nifedipine", "ent_type": "Chemical", "char_span": [50, 60], "ent_id": "D009543", "tok_span": [9, 12]}, {"name": "magnesium sulfate", "ent_type": "Chemical", "char_span": [28, 45], "ent_id": "D008278", "tok_span": [6, 8]}, {"name": "Neuromuscular blockade", "ent_type": "Disease", "char_span": [0, 22], "ent_id": "D020879", "tok_span": [0, 5]}], "relation_list": [{"subject": "nifedipine", "object": "Neuromuscular blockade", "sbj_char_span": [50, 60], "obj_char_span": [0, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [0, 5]}, {"subject": "magnesium sulfate", "object": "Neuromuscular blockade", "sbj_char_span": [28, 45], "obj_char_span": [0, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [0, 5]}], "umls_entity_list": []}, {"text": "A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of magnesium sulfate was administered.", "entity_list": [{"name": "magnesium sulfate", "ent_type": "Chemical", "char_span": [98, 115], "ent_id": "D008278", "tok_span": [18, 20]}, {"name": "neuromuscular blockade", "ent_type": "Disease", "char_span": [59, 81], "ent_id": "D020879", "tok_span": [12, 14]}, {"name": "nifedipine", "ent_type": "Chemical", "char_span": [38, 48], "ent_id": "D009543", "tok_span": [8, 11]}], "relation_list": [{"subject": "nifedipine", "object": "neuromuscular blockade", "sbj_char_span": [38, 48], "obj_char_span": [59, 81], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [12, 14]}, {"subject": "magnesium sulfate", "object": "neuromuscular blockade", "sbj_char_span": [98, 115], "obj_char_span": [59, 81], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 20], "obj_tok_span": [12, 14]}], "umls_entity_list": []}, {"text": "Myocardial infarction in pregnancy associated with clomiphene citrate for ovulation induction: a case report.", "entity_list": [{"name": "Myocardial infarction", "ent_type": "Disease", "char_span": [0, 21], "ent_id": "D009203", "tok_span": [0, 3]}, {"name": "clomiphene citrate", "ent_type": "Chemical", "char_span": [51, 69], "ent_id": "D002996", "tok_span": [7, 12]}], "relation_list": [{"subject": "clomiphene citrate", "object": "Myocardial infarction", "sbj_char_span": [51, 69], "obj_char_span": [0, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 12], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "Thromboembolism is a rare but life-threatening complication that has been reported after ovulation induction with CC.", "entity_list": [{"name": "Thromboembolism", "ent_type": "Disease", "char_span": [0, 15], "ent_id": "D013923", "tok_span": [0, 4]}, {"name": "CC", "ent_type": "Chemical", "char_span": [114, 116], "ent_id": "D002996", "tok_span": [22, 23]}], "relation_list": [{"subject": "CC", "object": "Thromboembolism", "sbj_char_span": [114, 116], "obj_char_span": [0, 15], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "CONCLUSION: This appears to be the first reported case documenting a possible association between CC and myocardial infarction.", "entity_list": [{"name": "CC", "ent_type": "Chemical", "char_span": [98, 100], "ent_id": "D002996", "tok_span": [16, 17]}, {"name": "myocardial infarction", "ent_type": "Disease", "char_span": [105, 126], "ent_id": "D009203", "tok_span": [18, 20]}], "relation_list": [{"subject": "CC", "object": "myocardial infarction", "sbj_char_span": [98, 100], "obj_char_span": [105, 126], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 17], "obj_tok_span": [18, 20]}], "umls_entity_list": []}, {"text": "Hepatonecrosis and cholangitis related to long-term phenobarbital therapy: an autopsy report of two patients.", "entity_list": [{"name": "phenobarbital", "ent_type": "Chemical", "char_span": [52, 65], "ent_id": "D010634", "tok_span": [13, 15]}, {"name": "cholangitis", "ent_type": "Disease", "char_span": [19, 30], "ent_id": "D002761", "tok_span": [5, 8]}, {"name": "Hepatonecrosis", "ent_type": "Disease", "char_span": [0, 14], "ent_id": "-1", "tok_span": [0, 4]}], "relation_list": [{"subject": "phenobarbital", "object": "cholangitis", "sbj_char_span": [52, 65], "obj_char_span": [19, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [5, 8]}], "umls_entity_list": []}, {"text": "Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.", "entity_list": [{"name": "PB", "ent_type": "Chemical", "char_span": [15, 17], "ent_id": "D010634", "tok_span": [3, 4]}, {"name": "liver disease", "ent_type": "Disease", "char_span": [201, 214], "ent_id": "D008107", "tok_span": [36, 38]}, {"name": "PB", "ent_type": "Chemical", "char_span": [81, 83], "ent_id": "D010634", "tok_span": [17, 18]}, {"name": "Phenobarbital", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D010634", "tok_span": [0, 2]}], "relation_list": [{"subject": "PB", "object": "liver disease", "sbj_char_span": [81, 83], "obj_char_span": [201, 214], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 18], "obj_tok_span": [36, 38]}, {"subject": "Phenobarbital", "object": "liver disease", "sbj_char_span": [0, 13], "obj_char_span": [201, 214], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [36, 38]}, {"subject": "PB", "object": "liver disease", "sbj_char_span": [15, 17], "obj_char_span": [201, 214], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [36, 38]}], "umls_entity_list": []}, {"text": "Our findings illustrate that PB may be associated with chronic liver damage, which may lead to more serious and deleterious consequences.", "entity_list": [{"name": "PB", "ent_type": "Chemical", "char_span": [29, 31], "ent_id": "D010634", "tok_span": [4, 5]}, {"name": "liver damage", "ent_type": "Disease", "char_span": [63, 75], "ent_id": "D008107", "tok_span": [10, 12]}], "relation_list": [{"subject": "PB", "object": "liver damage", "sbj_char_span": [29, 31], "obj_char_span": [63, 75], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Ethambutol-associated optic neuropathy.", "entity_list": [{"name": "Ethambutol", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D004977", "tok_span": [0, 4]}, {"name": "optic neuropathy", "ent_type": "Disease", "char_span": [22, 38], "ent_id": "D009901", "tok_span": [6, 8]}], "relation_list": [{"subject": "Ethambutol", "object": "optic neuropathy", "sbj_char_span": [0, 10], "obj_char_span": [22, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "INTRODUCTION: Ethambutol is used in the treatment of tuberculosis, which is still prevalent in Southeast Asia, and can be associated with permanent visual loss.", "entity_list": [{"name": "Ethambutol", "ent_type": "Chemical", "char_span": [14, 24], "ent_id": "D004977", "tok_span": [2, 6]}, {"name": "visual loss", "ent_type": "Disease", "char_span": [148, 159], "ent_id": "D014786", "tok_span": [30, 32]}, {"name": "tuberculosis", "ent_type": "Disease", "char_span": [53, 65], "ent_id": "D014376", "tok_span": [12, 13]}], "relation_list": [{"subject": "Ethambutol", "object": "visual loss", "sbj_char_span": [14, 24], "obj_char_span": [148, 159], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [30, 32]}], "umls_entity_list": []}, {"text": "CLINICAL PICTURE: Three patients with ethambutol-associated toxic optic neuropathy are described.", "entity_list": [{"name": "ethambutol", "ent_type": "Chemical", "char_span": [38, 48], "ent_id": "D004977", "tok_span": [10, 14]}, {"name": "optic neuropathy", "ent_type": "Disease", "char_span": [66, 82], "ent_id": "D009901", "tok_span": [17, 19]}], "relation_list": [{"subject": "ethambutol", "object": "optic neuropathy", "sbj_char_span": [38, 48], "obj_char_span": [66, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [17, 19]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Ethambutol usage is associated with permanent visual loss and should be avoided if possible or used with caution and proper ophthalmological follow-up.", "entity_list": [{"name": "Ethambutol", "ent_type": "Chemical", "char_span": [13, 23], "ent_id": "D004977", "tok_span": [2, 6]}, {"name": "visual loss", "ent_type": "Disease", "char_span": [59, 70], "ent_id": "D014786", "tok_span": [11, 13]}], "relation_list": [{"subject": "Ethambutol", "object": "visual loss", "sbj_char_span": [13, 23], "obj_char_span": [59, 70], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [11, 13]}], "umls_entity_list": []}, {"text": "Tolerability of nimesulide and paracetamol in patients with NSAID-induced urticaria/angioedema.", "entity_list": [{"name": "angioedema", "ent_type": "Disease", "char_span": [84, 94], "ent_id": "D000799", "tok_span": [24, 28]}, {"name": "paracetamol", "ent_type": "Chemical", "char_span": [31, 42], "ent_id": "D000082", "tok_span": [9, 13]}, {"name": "urticaria", "ent_type": "Disease", "char_span": [74, 83], "ent_id": "D014581", "tok_span": [20, 23]}, {"name": "NSAID", "ent_type": "Chemical", "char_span": [60, 65], "ent_id": "D000894", "tok_span": [16, 18]}, {"name": "nimesulide", "ent_type": "Chemical", "char_span": [16, 26], "ent_id": "C012655", "tok_span": [4, 8]}], "relation_list": [{"subject": "NSAID", "object": "angioedema", "sbj_char_span": [60, 65], "obj_char_span": [84, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 18], "obj_tok_span": [24, 28]}, {"subject": "paracetamol", "object": "angioedema", "sbj_char_span": [31, 42], "obj_char_span": [84, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [24, 28]}, {"subject": "nimesulide", "object": "angioedema", "sbj_char_span": [16, 26], "obj_char_span": [84, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 8], "obj_tok_span": [24, 28]}], "umls_entity_list": []}, {"text": "In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well-documented history of NSAID-induced urticaria/angioedema.", "entity_list": [{"name": "NSAID", "ent_type": "Chemical", "char_span": [169, 174], "ent_id": "D000894", "tok_span": [34, 36]}, {"name": "urticaria", "ent_type": "Disease", "char_span": [183, 192], "ent_id": "D014581", "tok_span": [38, 41]}, {"name": "paracetamol", "ent_type": "Chemical", "char_span": [77, 88], "ent_id": "D000082", "tok_span": [15, 19]}, {"name": "nimesulide", "ent_type": "Chemical", "char_span": [62, 72], "ent_id": "C012655", "tok_span": [10, 14]}, {"name": "angioedema", "ent_type": "Disease", "char_span": [193, 203], "ent_id": "D000799", "tok_span": [42, 46]}], "relation_list": [{"subject": "paracetamol", "object": "angioedema", "sbj_char_span": [77, 88], "obj_char_span": [193, 203], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 19], "obj_tok_span": [42, 46]}, {"subject": "nimesulide", "object": "angioedema", "sbj_char_span": [62, 72], "obj_char_span": [193, 203], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [42, 46]}, {"subject": "NSAID", "object": "angioedema", "sbj_char_span": [169, 174], "obj_char_span": [193, 203], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 36], "obj_tok_span": [42, 46]}], "umls_entity_list": []}, {"text": "A single-placebo-controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID-induced urticaria/angioedema.", "entity_list": [{"name": "angioedema", "ent_type": "Disease", "char_span": [154, 164], "ent_id": "D000799", "tok_span": [37, 41]}, {"name": "paracetamol", "ent_type": "Chemical", "char_span": [72, 83], "ent_id": "D000082", "tok_span": [15, 19]}, {"name": "NSAID", "ent_type": "Chemical", "char_span": [130, 135], "ent_id": "D000894", "tok_span": [29, 31]}, {"name": "urticaria", "ent_type": "Disease", "char_span": [144, 153], "ent_id": "D014581", "tok_span": [33, 36]}, {"name": "nimesulide", "ent_type": "Chemical", "char_span": [58, 68], "ent_id": "C012655", "tok_span": [10, 14]}], "relation_list": [{"subject": "paracetamol", "object": "angioedema", "sbj_char_span": [72, 83], "obj_char_span": [154, 164], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 19], "obj_tok_span": [37, 41]}, {"subject": "NSAID", "object": "angioedema", "sbj_char_span": [130, 135], "obj_char_span": [154, 164], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 31], "obj_tok_span": [37, 41]}, {"subject": "nimesulide", "object": "angioedema", "sbj_char_span": [58, 68], "obj_char_span": [154, 164], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [37, 41]}], "umls_entity_list": []}, {"text": "Furthermore, 18.28% of patients with a history of chronic urticaria and 11.8% of subjects with an history of NSAID-induced urticaria/angioedema or angioedema alone (with or without chronic urticaria) resulted to be intolerant to alternative drugs.", "entity_list": [{"name": "urticaria", "ent_type": "Disease", "char_span": [123, 132], "ent_id": "D014581", "tok_span": [31, 34]}, {"name": "angioedema", "ent_type": "Disease", "char_span": [133, 143], "ent_id": "D000799", "tok_span": [35, 39]}, {"name": "urticaria", "ent_type": "Disease", "char_span": [189, 198], "ent_id": "D014581", "tok_span": [50, 53]}, {"name": "urticaria", "ent_type": "Disease", "char_span": [58, 67], "ent_id": "D014581", "tok_span": [13, 16]}, {"name": "angioedema", "ent_type": "Disease", "char_span": [147, 157], "ent_id": "D000799", "tok_span": [40, 44]}, {"name": "NSAID", "ent_type": "Chemical", "char_span": [109, 114], "ent_id": "D000894", "tok_span": [27, 29]}], "relation_list": [{"subject": "NSAID", "object": "angioedema", "sbj_char_span": [109, 114], "obj_char_span": [133, 143], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 29], "obj_tok_span": [35, 39]}, {"subject": "NSAID", "object": "angioedema", "sbj_char_span": [109, 114], "obj_char_span": [147, 157], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 29], "obj_tok_span": [40, 44]}], "umls_entity_list": []}, {"text": "Taken together, our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria/angioedema caused by NSAIDs.", "entity_list": [{"name": "urticaria", "ent_type": "Disease", "char_span": [116, 125], "ent_id": "D014581", "tok_span": [24, 27]}, {"name": "NSAIDs", "ent_type": "Chemical", "char_span": [147, 153], "ent_id": "D000894", "tok_span": [34, 36]}, {"name": "angioedema", "ent_type": "Disease", "char_span": [126, 136], "ent_id": "D000799", "tok_span": [28, 32]}, {"name": "paracetamol", "ent_type": "Chemical", "char_span": [76, 87], "ent_id": "D000082", "tok_span": [16, 20]}, {"name": "nimesulide", "ent_type": "Chemical", "char_span": [61, 71], "ent_id": "C012655", "tok_span": [11, 15]}], "relation_list": [{"subject": "paracetamol", "object": "angioedema", "sbj_char_span": [76, 87], "obj_char_span": [126, 136], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 20], "obj_tok_span": [28, 32]}, {"subject": "NSAIDs", "object": "angioedema", "sbj_char_span": [147, 153], "obj_char_span": [126, 136], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 36], "obj_tok_span": [28, 32]}, {"subject": "nimesulide", "object": "angioedema", "sbj_char_span": [61, 71], "obj_char_span": [126, 136], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "However, the risk of reaction to these alternative study drugs is statistically increased by a history of chronic urticaria and, above all, by a history of NSAID-induced angioedema.", "entity_list": [{"name": "urticaria", "ent_type": "Disease", "char_span": [114, 123], "ent_id": "D014581", "tok_span": [19, 22]}, {"name": "angioedema", "ent_type": "Disease", "char_span": [170, 180], "ent_id": "D000799", "tok_span": [35, 39]}, {"name": "NSAID", "ent_type": "Chemical", "char_span": [156, 161], "ent_id": "D000894", "tok_span": [31, 33]}], "relation_list": [{"subject": "NSAID", "object": "angioedema", "sbj_char_span": [156, 161], "obj_char_span": [170, 180], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 33], "obj_tok_span": [35, 39]}], "umls_entity_list": []}, {"text": "Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs.", "entity_list": [{"name": "atrial fibrillation", "ent_type": "Disease", "char_span": [24, 43], "ent_id": "D001281", "tok_span": [6, 8]}, {"name": "verapamil", "ent_type": "Chemical", "char_span": [11, 20], "ent_id": "D014700", "tok_span": [2, 5]}], "relation_list": [{"subject": "verapamil", "object": "atrial fibrillation", "sbj_char_span": [11, 20], "obj_char_span": [24, 43], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "METHODS: To evaluate the potential mechanisms of AF promotion by Ca(2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs.", "entity_list": [{"name": "chloralose", "ent_type": "Chemical", "char_span": [128, 138], "ent_id": "D002698", "tok_span": [27, 30]}, {"name": "verapamil", "ent_type": "Chemical", "char_span": [106, 115], "ent_id": "D014700", "tok_span": [21, 24]}, {"name": "AF", "ent_type": "Disease", "char_span": [49, 51], "ent_id": "D001281", "tok_span": [8, 9]}, {"name": "Ca", "ent_type": "Chemical", "char_span": [65, 67], "ent_id": "D002118", "tok_span": [11, 12]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [119, 127], "ent_id": "D009020", "tok_span": [25, 26]}], "relation_list": [{"subject": "verapamil", "object": "AF", "sbj_char_span": [106, 115], "obj_char_span": [49, 51], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [8, 9]}], "umls_entity_list": []}, {"text": "RESULTS: Verapamil caused AF promotion in six dogs, increasing mean duration of AF induced by burst pacing, from 8+/-4 s (mean+/-S.E.) to 95+/-39 s (P<0.01 vs. control) at a loading dose of 0.1 mg/kg and 228+/-101 s (P<0.0005 vs. control) at a dose of 0.2 mg/kg.", "entity_list": [{"name": "AF", "ent_type": "Disease", "char_span": [26, 28], "ent_id": "D001281", "tok_span": [6, 7]}, {"name": "Verapamil", "ent_type": "Chemical", "char_span": [9, 18], "ent_id": "D014700", "tok_span": [2, 5]}, {"name": "AF", "ent_type": "Disease", "char_span": [80, 82], "ent_id": "D001281", "tok_span": [16, 17]}], "relation_list": [{"subject": "Verapamil", "object": "AF", "sbj_char_span": [9, 18], "obj_char_span": [26, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [6, 7]}, {"subject": "Verapamil", "object": "AF", "sbj_char_span": [9, 18], "obj_char_span": [80, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [16, 17]}], "umls_entity_list": []}, {"text": "In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).", "entity_list": [{"name": "verapamil", "ent_type": "Chemical", "char_span": [22, 31], "ent_id": "D014700", "tok_span": [4, 7]}, {"name": "AF", "ent_type": "Disease", "char_span": [288, 290], "ent_id": "D001281", "tok_span": [79, 80]}], "relation_list": [{"subject": "verapamil", "object": "AF", "sbj_char_span": [22, 31], "obj_char_span": [288, 290], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [79, 80]}], "umls_entity_list": []}, {"text": "Diltiazem did not affect ERP, AF cycle length or AF duration, but produced conduction acceleration similar to that caused by verapamil (n=5).", "entity_list": [{"name": "AF", "ent_type": "Disease", "char_span": [30, 32], "ent_id": "D001281", "tok_span": [9, 10]}, {"name": "Diltiazem", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D004110", "tok_span": [0, 4]}, {"name": "AF", "ent_type": "Disease", "char_span": [49, 51], "ent_id": "D001281", "tok_span": [13, 14]}, {"name": "verapamil", "ent_type": "Chemical", "char_span": [125, 134], "ent_id": "D014700", "tok_span": [25, 28]}], "relation_list": [{"subject": "verapamil", "object": "AF", "sbj_char_span": [125, 134], "obj_char_span": [30, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 28], "obj_tok_span": [9, 10]}, {"subject": "verapamil", "object": "AF", "sbj_char_span": [125, 134], "obj_char_span": [49, 51], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 28], "obj_tok_span": [13, 14]}], "umls_entity_list": []}, {"text": "In the presence of autonomic blockade, verapamil failed to promote AF and increased, rather than decreasing, refractoriness.", "entity_list": [{"name": "verapamil", "ent_type": "Chemical", "char_span": [39, 48], "ent_id": "D014700", "tok_span": [7, 10]}, {"name": "AF", "ent_type": "Disease", "char_span": [67, 69], "ent_id": "D001281", "tok_span": [13, 14]}], "relation_list": [{"subject": "verapamil", "object": "AF", "sbj_char_span": [39, 48], "obj_char_span": [67, 69], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [13, 14]}], "umls_entity_list": []}, {"text": "Epicardial mapping suggested that verapamil promoted AF by increasing the number of simultaneous wavefronts reflected by separate zones of reactivation in each cycle.", "entity_list": [{"name": "AF", "ent_type": "Disease", "char_span": [53, 55], "ent_id": "D001281", "tok_span": [9, 10]}, {"name": "verapamil", "ent_type": "Chemical", "char_span": [34, 43], "ent_id": "D014700", "tok_span": [5, 8]}], "relation_list": [{"subject": "verapamil", "object": "AF", "sbj_char_span": [34, 43], "obj_char_span": [53, 55], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [9, 10]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Verapamil promotes AF in normal dogs by promoting multiple circuit reentry, an effect dependent on intact autonomic tone and not shared by diltiazem.", "entity_list": [{"name": "diltiazem", "ent_type": "Chemical", "char_span": [152, 161], "ent_id": "D004110", "tok_span": [28, 32]}, {"name": "AF", "ent_type": "Disease", "char_span": [32, 34], "ent_id": "D001281", "tok_span": [6, 7]}, {"name": "Verapamil", "ent_type": "Chemical", "char_span": [13, 22], "ent_id": "D014700", "tok_span": [2, 5]}], "relation_list": [{"subject": "Verapamil", "object": "AF", "sbj_char_span": [13, 22], "obj_char_span": [32, 34], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [6, 7]}], "umls_entity_list": []}, {"text": "Hypotension, bradycardia, and asystole after high-dose intravenous methylprednisolone in a monitored patient.", "entity_list": [{"name": "bradycardia", "ent_type": "Disease", "char_span": [13, 24], "ent_id": "D001919", "tok_span": [3, 7]}, {"name": "methylprednisolone", "ent_type": "Chemical", "char_span": [67, 85], "ent_id": "D008775", "tok_span": [17, 21]}, {"name": "asystole", "ent_type": "Disease", "char_span": [30, 38], "ent_id": "D006323", "tok_span": [9, 12]}, {"name": "Hypotension", "ent_type": "Disease", "char_span": [0, 11], "ent_id": "D007022", "tok_span": [0, 2]}], "relation_list": [{"subject": "methylprednisolone", "object": "Hypotension", "sbj_char_span": [67, 85], "obj_char_span": [0, 11], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [0, 2]}, {"subject": "methylprednisolone", "object": "asystole", "sbj_char_span": [67, 85], "obj_char_span": [30, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [9, 12]}, {"subject": "methylprednisolone", "object": "bradycardia", "sbj_char_span": [67, 85], "obj_char_span": [13, 24], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "We report a case of hypotension, bradycardia, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.", "entity_list": [{"name": "methylprednisolone", "ent_type": "Chemical", "char_span": [105, 123], "ent_id": "D008775", "tok_span": [23, 27]}, {"name": "asystole", "ent_type": "Disease", "char_span": [50, 58], "ent_id": "D006323", "tok_span": [13, 16]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [33, 44], "ent_id": "D001919", "tok_span": [7, 11]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [20, 31], "ent_id": "D007022", "tok_span": [5, 6]}], "relation_list": [{"subject": "methylprednisolone", "object": "asystole", "sbj_char_span": [105, 123], "obj_char_span": [50, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 27], "obj_tok_span": [13, 16]}, {"subject": "methylprednisolone", "object": "hypotension", "sbj_char_span": [105, 123], "obj_char_span": [20, 31], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 27], "obj_tok_span": [5, 6]}, {"subject": "methylprednisolone", "object": "bradycardia", "sbj_char_span": [105, 123], "obj_char_span": [33, 44], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 27], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "Lifetime treatment of mice with azidothymidine (AZT) produces myelodysplasia.", "entity_list": [{"name": "myelodysplasia", "ent_type": "Disease", "char_span": [62, 76], "ent_id": "D009190", "tok_span": [16, 20]}, {"name": "AZT", "ent_type": "Chemical", "char_span": [48, 51], "ent_id": "D015215", "tok_span": [12, 14]}, {"name": "azidothymidine", "ent_type": "Chemical", "char_span": [32, 46], "ent_id": "D015215", "tok_span": [6, 11]}], "relation_list": [{"subject": "AZT", "object": "myelodysplasia", "sbj_char_span": [48, 51], "obj_char_span": [62, 76], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 14], "obj_tok_span": [16, 20]}, {"subject": "azidothymidine", "object": "myelodysplasia", "sbj_char_span": [32, 46], "obj_char_span": [62, 76], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 11], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy.", "entity_list": [{"name": "AIDS", "ent_type": "Disease", "char_span": [39, 43], "ent_id": "D000163", "tok_span": [10, 11]}, {"name": "AZT", "ent_type": "Chemical", "char_span": [66, 69], "ent_id": "D015215", "tok_span": [15, 17]}, {"name": "macrocytic anemia", "ent_type": "Disease", "char_span": [18, 35], "ent_id": "D000748", "tok_span": [5, 9]}, {"name": "AZT", "ent_type": "Chemical", "char_span": [0, 3], "ent_id": "D015215", "tok_span": [0, 2]}], "relation_list": [{"subject": "AZT", "object": "macrocytic anemia", "sbj_char_span": [0, 3], "obj_char_span": [18, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [5, 9]}, {"subject": "AZT", "object": "macrocytic anemia", "sbj_char_span": [66, 69], "obj_char_span": [18, 35], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 17], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "Above mentioned AZT incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells, which is known to be seen commonly in the myelodysplastic syndrome.", "entity_list": [{"name": "AZT", "ent_type": "Chemical", "char_span": [16, 19], "ent_id": "D015215", "tok_span": [2, 4]}, {"name": "myelodysplastic syndrome", "ent_type": "Disease", "char_span": [167, 191], "ent_id": "D009190", "tok_span": [30, 35]}], "relation_list": [{"subject": "AZT", "object": "myelodysplastic syndrome", "sbj_char_span": [16, 19], "obj_char_span": [167, 191], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 4], "obj_tok_span": [30, 35]}], "umls_entity_list": []}, {"text": "Influence of diet free of NAD-precursors on acetaminophen hepatotoxicity in mice.", "entity_list": [{"name": "hepatotoxicity", "ent_type": "Disease", "char_span": [58, 72], "ent_id": "D056486", "tok_span": [12, 14]}, {"name": "NAD", "ent_type": "Chemical", "char_span": [26, 29], "ent_id": "D009243", "tok_span": [5, 6]}, {"name": "acetaminophen", "ent_type": "Chemical", "char_span": [44, 57], "ent_id": "D000082", "tok_span": [9, 12]}], "relation_list": [{"subject": "acetaminophen", "object": "hepatotoxicity", "sbj_char_span": [44, 57], "obj_char_span": [58, 72], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [12, 14]}], "umls_entity_list": []}, {"text": "Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.", "entity_list": [{"name": "hepatitis", "ent_type": "Disease", "char_span": [196, 205], "ent_id": "D056486", "tok_span": [50, 51]}, {"name": "AAP", "ent_type": "Chemical", "char_span": [191, 194], "ent_id": "D000082", "tok_span": [46, 48]}, {"name": "nicotinic acid amide", "ent_type": "Chemical", "char_span": [58, 78], "ent_id": "D009536", "tok_span": [9, 13]}, {"name": "poly(ADP-ribose)", "ent_type": "Chemical", "char_span": [105, 121], "ent_id": "D011064", "tok_span": [18, 25]}, {"name": "liver injury", "ent_type": "Disease", "char_span": [239, 251], "ent_id": "D056486", "tok_span": [59, 61]}, {"name": "acetaminophen", "ent_type": "Chemical", "char_span": [176, 189], "ent_id": "D000082", "tok_span": [42, 45]}, {"name": "AAP", "ent_type": "Chemical", "char_span": [227, 230], "ent_id": "D000082", "tok_span": [55, 57]}], "relation_list": [{"subject": "AAP", "object": "liver injury", "sbj_char_span": [227, 230], "obj_char_span": [239, 251], "rel_type": "chemical-induced disease", "sbj_tok_span": [55, 57], "obj_tok_span": [59, 61]}, {"subject": "AAP", "object": "liver injury", "sbj_char_span": [191, 194], "obj_char_span": [239, 251], "rel_type": "chemical-induced disease", "sbj_tok_span": [46, 48], "obj_tok_span": [59, 61]}, {"subject": "acetaminophen", "object": "liver injury", "sbj_char_span": [176, 189], "obj_char_span": [239, 251], "rel_type": "chemical-induced disease", "sbj_tok_span": [42, 45], "obj_tok_span": [59, 61]}, {"subject": "AAP", "object": "hepatitis", "sbj_char_span": [191, 194], "obj_char_span": [196, 205], "rel_type": "chemical-induced disease", "sbj_tok_span": [46, 48], "obj_tok_span": [50, 51]}, {"subject": "AAP", "object": "hepatitis", "sbj_char_span": [227, 230], "obj_char_span": [196, 205], "rel_type": "chemical-induced disease", "sbj_tok_span": [55, 57], "obj_tok_span": [50, 51]}, {"subject": "acetaminophen", "object": "hepatitis", "sbj_char_span": [176, 189], "obj_char_span": [196, 205], "rel_type": "chemical-induced disease", "sbj_tok_span": [42, 45], "obj_tok_span": [50, 51]}], "umls_entity_list": []}, {"text": "The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals.", "entity_list": [{"name": "AAP", "ent_type": "Chemical", "char_span": [139, 142], "ent_id": "D000082", "tok_span": [28, 30]}, {"name": "hepatitis", "ent_type": "Disease", "char_span": [143, 152], "ent_id": "D056486", "tok_span": [30, 31]}, {"name": "ethanol", "ent_type": "Chemical", "char_span": [197, 204], "ent_id": "D000431", "tok_span": [37, 38]}, {"name": "NAD", "ent_type": "Chemical", "char_span": [75, 78], "ent_id": "D009243", "tok_span": [13, 14]}], "relation_list": [{"subject": "AAP", "object": "hepatitis", "sbj_char_span": [139, 142], "obj_char_span": [143, 152], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 30], "obj_tok_span": [30, 31]}, {"subject": "ethanol", "object": "hepatitis", "sbj_char_span": [197, 204], "obj_char_span": [143, 152], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 38], "obj_tok_span": [30, 31]}], "umls_entity_list": []}, {"text": "In these animals, only minor increases of serum transaminase activities were measured in the presence of AAP, and unlike the exacerbation caused by ethanol in mice on a standard diet, the liver damage was inhibited by 50% by ethanol.", "entity_list": [{"name": "ethanol", "ent_type": "Chemical", "char_span": [225, 232], "ent_id": "D000431", "tok_span": [45, 46]}, {"name": "ethanol", "ent_type": "Chemical", "char_span": [148, 155], "ent_id": "D000431", "tok_span": [28, 29]}, {"name": "AAP", "ent_type": "Chemical", "char_span": [105, 108], "ent_id": "D000082", "tok_span": [18, 20]}, {"name": "liver damage", "ent_type": "Disease", "char_span": [188, 200], "ent_id": "D056486", "tok_span": [37, 39]}], "relation_list": [{"subject": "ethanol", "object": "liver damage", "sbj_char_span": [225, 232], "obj_char_span": [188, 200], "rel_type": "chemical-induced disease", "sbj_tok_span": [45, 46], "obj_tok_span": [37, 39]}, {"subject": "ethanol", "object": "liver damage", "sbj_char_span": [148, 155], "obj_char_span": [188, 200], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 29], "obj_tok_span": [37, 39]}, {"subject": "AAP", "object": "liver damage", "sbj_char_span": [105, 108], "obj_char_span": [188, 200], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 20], "obj_tok_span": [37, 39]}], "umls_entity_list": []}, {"text": "A further 64% reduction of hepatitis was observed, when NAA was given to ethanol/AAP-mice.", "entity_list": [{"name": "ethanol", "ent_type": "Chemical", "char_span": [73, 80], "ent_id": "D000431", "tok_span": [16, 17]}, {"name": "AAP", "ent_type": "Chemical", "char_span": [81, 84], "ent_id": "D000082", "tok_span": [18, 20]}, {"name": "hepatitis", "ent_type": "Disease", "char_span": [27, 36], "ent_id": "D056486", "tok_span": [6, 7]}, {"name": "NAA", "ent_type": "Chemical", "char_span": [56, 59], "ent_id": "D009536", "tok_span": [11, 13]}], "relation_list": [{"subject": "AAP", "object": "hepatitis", "sbj_char_span": [81, 84], "obj_char_span": [27, 36], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 20], "obj_tok_span": [6, 7]}, {"subject": "ethanol", "object": "hepatitis", "sbj_char_span": [73, 80], "obj_char_span": [27, 36], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 17], "obj_tok_span": [6, 7]}], "umls_entity_list": []}, {"text": "Our results provide evidence that the AAP-induced hepatitis and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.", "entity_list": [{"name": "AAP", "ent_type": "Chemical", "char_span": [38, 41], "ent_id": "D000082", "tok_span": [6, 8]}, {"name": "hepatitis", "ent_type": "Disease", "char_span": [50, 59], "ent_id": "D056486", "tok_span": [10, 11]}, {"name": "NAA", "ent_type": "Chemical", "char_span": [151, 154], "ent_id": "D009536", "tok_span": [29, 31]}, {"name": "NAD", "ent_type": "Chemical", "char_span": [205, 208], "ent_id": "D009243", "tok_span": [41, 42]}, {"name": "ethanol", "ent_type": "Chemical", "char_span": [84, 91], "ent_id": "D000431", "tok_span": [16, 17]}], "relation_list": [{"subject": "ethanol", "object": "hepatitis", "sbj_char_span": [84, 91], "obj_char_span": [50, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 17], "obj_tok_span": [10, 11]}, {"subject": "AAP", "object": "hepatitis", "sbj_char_span": [38, 41], "obj_char_span": [50, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [10, 11]}], "umls_entity_list": []}, {"text": "We see the main application of NAA as for the combinational use in pharmaceutical preparations of acetaminophen in order to avoid hepatic damage in patients treated with this widely used analgesic.", "entity_list": [{"name": "acetaminophen", "ent_type": "Chemical", "char_span": [98, 111], "ent_id": "D000082", "tok_span": [18, 21]}, {"name": "hepatic damage", "ent_type": "Disease", "char_span": [130, 144], "ent_id": "D056486", "tok_span": [25, 27]}, {"name": "NAA", "ent_type": "Chemical", "char_span": [31, 34], "ent_id": "D009536", "tok_span": [6, 8]}], "relation_list": [{"subject": "acetaminophen", "object": "hepatic damage", "sbj_char_span": [98, 111], "obj_char_span": [130, 144], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [25, 27]}], "umls_entity_list": []}, {"text": "Using two-stage coronary ligation-, digitalis-, and adrenaline-induced canine ventricular arrhythmias, antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined.", "entity_list": [{"name": "cibenzoline", "ent_type": "Chemical", "char_span": [129, 140], "ent_id": "C032151", "tok_span": [27, 30]}, {"name": "arrhythmia", "ent_type": "Disease", "char_span": [211, 221], "ent_id": "D001145", "tok_span": [40, 42]}, {"name": "digitalis", "ent_type": "Chemical", "char_span": [36, 45], "ent_id": "D004071", "tok_span": [8, 10]}, {"name": "adrenaline", "ent_type": "Chemical", "char_span": [52, 62], "ent_id": "D004837", "tok_span": [13, 15]}, {"name": "ventricular arrhythmias", "ent_type": "Disease", "char_span": [78, 101], "ent_id": "D001145", "tok_span": [18, 20]}], "relation_list": [{"subject": "digitalis", "object": "arrhythmia", "sbj_char_span": [36, 45], "obj_char_span": [211, 221], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [40, 42]}, {"subject": "adrenaline", "object": "arrhythmia", "sbj_char_span": [52, 62], "obj_char_span": [211, 221], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [40, 42]}, {"subject": "digitalis", "object": "ventricular arrhythmias", "sbj_char_span": [36, 45], "obj_char_span": [78, 101], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [18, 20]}, {"subject": "adrenaline", "object": "ventricular arrhythmias", "sbj_char_span": [52, 62], "obj_char_span": [78, 101], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [18, 20]}], "umls_entity_list": []}, {"text": "Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).", "entity_list": [{"name": "digitalis", "ent_type": "Chemical", "char_span": [167, 176], "ent_id": "D004071", "tok_span": [30, 32]}, {"name": "adrenaline", "ent_type": "Chemical", "char_span": [182, 192], "ent_id": "D004837", "tok_span": [34, 36]}, {"name": "Cibenzoline", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "C032151", "tok_span": [0, 3]}, {"name": "arrhythmias", "ent_type": "Disease", "char_span": [31, 42], "ent_id": "D001145", "tok_span": [6, 7]}, {"name": "arrhythmias", "ent_type": "Disease", "char_span": [96, 107], "ent_id": "D001145", "tok_span": [15, 16]}], "relation_list": [{"subject": "digitalis", "object": "arrhythmias", "sbj_char_span": [167, 176], "obj_char_span": [31, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 32], "obj_tok_span": [6, 7]}, {"subject": "adrenaline", "object": "arrhythmias", "sbj_char_span": [182, 192], "obj_char_span": [96, 107], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 36], "obj_tok_span": [15, 16]}, {"subject": "digitalis", "object": "arrhythmias", "sbj_char_span": [167, 176], "obj_char_span": [96, 107], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 32], "obj_tok_span": [15, 16]}, {"subject": "adrenaline", "object": "arrhythmias", "sbj_char_span": [182, 192], "obj_char_span": [31, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 36], "obj_tok_span": [6, 7]}], "umls_entity_list": []}, {"text": "The concentration for adrenaline-induced arrhythmia was significantly higher than those for the other types of arrhythmias.", "entity_list": [{"name": "arrhythmia", "ent_type": "Disease", "char_span": [41, 51], "ent_id": "D001145", "tok_span": [7, 9]}, {"name": "adrenaline", "ent_type": "Chemical", "char_span": [22, 32], "ent_id": "D004837", "tok_span": [3, 5]}, {"name": "arrhythmias", "ent_type": "Disease", "char_span": [111, 122], "ent_id": "D001145", "tok_span": [19, 20]}], "relation_list": [{"subject": "adrenaline", "object": "arrhythmia", "sbj_char_span": [22, 32], "obj_char_span": [41, 51], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 5], "obj_tok_span": [7, 9]}, {"subject": "adrenaline", "object": "arrhythmias", "sbj_char_span": [22, 32], "obj_char_span": [111, 122], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 5], "obj_tok_span": [19, 20]}], "umls_entity_list": []}, {"text": "Immunopathology of penicillamine-induced glomerular disease.", "entity_list": [{"name": "glomerular disease", "ent_type": "Disease", "char_span": [41, 59], "ent_id": "D007674", "tok_span": [10, 12]}, {"name": "penicillamine", "ent_type": "Chemical", "char_span": [19, 32], "ent_id": "D010396", "tok_span": [3, 8]}], "relation_list": [{"subject": "penicillamine", "object": "glomerular disease", "sbj_char_span": [19, 32], "obj_char_span": [41, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 8], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Four patients with rheumatoid arthritis developed heavy proteinuria after five to 12 months of treatment with D-penicillamine.", "entity_list": [{"name": "D-penicillamine", "ent_type": "Chemical", "char_span": [110, 125], "ent_id": "D010396", "tok_span": [16, 23]}, {"name": "proteinuria", "ent_type": "Disease", "char_span": [56, 67], "ent_id": "D011507", "tok_span": [7, 8]}, {"name": "rheumatoid arthritis", "ent_type": "Disease", "char_span": [19, 39], "ent_id": "D001172", "tok_span": [3, 5]}], "relation_list": [{"subject": "D-penicillamine", "object": "proteinuria", "sbj_char_span": [110, 125], "obj_char_span": [56, 67], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 23], "obj_tok_span": [7, 8]}], "umls_entity_list": []}, {"text": "Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated intracerebral hemorrhage.", "entity_list": [{"name": "warfarin", "ent_type": "Chemical", "char_span": [80, 88], "ent_id": "D014859", "tok_span": [12, 13]}, {"name": "hemorrhage", "ent_type": "Disease", "char_span": [42, 52], "ent_id": "D006470", "tok_span": [5, 6]}, {"name": "intracerebral hemorrhage", "ent_type": "Disease", "char_span": [100, 124], "ent_id": "D002543", "tok_span": [15, 19]}], "relation_list": [{"subject": "warfarin", "object": "intracerebral hemorrhage", "sbj_char_span": [80, 88], "obj_char_span": [100, 124], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [15, 19]}], "umls_entity_list": []}, {"text": "Warfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke.", "entity_list": [{"name": "Warfarin", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D014859", "tok_span": [0, 3]}, {"name": "ICH", "ent_type": "Disease", "char_span": [48, 51], "ent_id": "D002543", "tok_span": [12, 14]}, {"name": "stroke", "ent_type": "Disease", "char_span": [73, 79], "ent_id": "D020521", "tok_span": [20, 21]}, {"name": "intracerebral hemorrhage", "ent_type": "Disease", "char_span": [20, 44], "ent_id": "D002543", "tok_span": [5, 9]}], "relation_list": [{"subject": "Warfarin", "object": "intracerebral hemorrhage", "sbj_char_span": [0, 8], "obj_char_span": [20, 44], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 9]}, {"subject": "Warfarin", "object": "ICH", "sbj_char_span": [0, 8], "obj_char_span": [48, 51], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [12, 14]}], "umls_entity_list": []}, {"text": "This study examined the utility of biometry for detecting alcohol-related fetal growth impairment.", "entity_list": [{"name": "alcohol", "ent_type": "Chemical", "char_span": [58, 65], "ent_id": "D000431", "tok_span": [10, 11]}, {"name": "growth impairment", "ent_type": "Disease", "char_span": [80, 97], "ent_id": "D006130", "tok_span": [14, 16]}], "relation_list": [{"subject": "alcohol", "object": "growth impairment", "sbj_char_span": [58, 65], "obj_char_span": [80, 97], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers.", "entity_list": [{"name": "decreased cranial to body growth", "ent_type": "Disease", "char_span": [124, 156], "ent_id": "D006130", "tok_span": [21, 26]}, {"name": "reduced cerebellar growth", "ent_type": "Disease", "char_span": [87, 112], "ent_id": "D006130", "tok_span": [15, 18]}, {"name": "alcohol", "ent_type": "Chemical", "char_span": [4, 11], "ent_id": "D000431", "tok_span": [1, 2]}], "relation_list": [{"subject": "alcohol", "object": "decreased cranial to body growth", "sbj_char_span": [4, 11], "obj_char_span": [124, 156], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 2], "obj_tok_span": [21, 26]}, {"subject": "alcohol", "object": "reduced cerebellar growth", "sbj_char_span": [4, 11], "obj_char_span": [87, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 2], "obj_tok_span": [15, 18]}], "umls_entity_list": []}, {"text": "Absence of acute cerebral vasoconstriction after cocaine-associated subarachnoid hemorrhage.", "entity_list": [{"name": "subarachnoid hemorrhage", "ent_type": "Disease", "char_span": [68, 91], "ent_id": "D013345", "tok_span": [11, 17]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [49, 56], "ent_id": "D003042", "tok_span": [8, 9]}], "relation_list": [{"subject": "cocaine", "object": "subarachnoid hemorrhage", "sbj_char_span": [49, 56], "obj_char_span": [68, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [11, 17]}], "umls_entity_list": []}, {"text": "Information on these effects could be obtained from angiograms of patients with cocaine-associated subarachnoid hemorrhage (SAH) who underwent angiography shortly after cocaine use.", "entity_list": [{"name": "subarachnoid hemorrhage", "ent_type": "Disease", "char_span": [99, 122], "ent_id": "D013345", "tok_span": [16, 22]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [169, 176], "ent_id": "D003042", "tok_span": [31, 32]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [80, 87], "ent_id": "D003042", "tok_span": [13, 14]}, {"name": "SAH", "ent_type": "Disease", "char_span": [124, 127], "ent_id": "D013345", "tok_span": [23, 25]}], "relation_list": [{"subject": "cocaine", "object": "subarachnoid hemorrhage", "sbj_char_span": [80, 87], "obj_char_span": [99, 122], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 14], "obj_tok_span": [16, 22]}, {"subject": "cocaine", "object": "subarachnoid hemorrhage", "sbj_char_span": [169, 176], "obj_char_span": [99, 122], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 32], "obj_tok_span": [16, 22]}, {"subject": "cocaine", "object": "SAH", "sbj_char_span": [80, 87], "obj_char_span": [124, 127], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 14], "obj_tok_span": [23, 25]}, {"subject": "cocaine", "object": "SAH", "sbj_char_span": [169, 176], "obj_char_span": [124, 127], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 32], "obj_tok_span": [23, 25]}], "umls_entity_list": []}, {"text": "METHODS: We screened patients with SAH retrospectively and identified those with positive urine toxicology for cocaine or its metabolites.", "entity_list": [{"name": "cocaine", "ent_type": "Chemical", "char_span": [111, 118], "ent_id": "D003042", "tok_span": [18, 19]}, {"name": "SAH", "ent_type": "Disease", "char_span": [35, 38], "ent_id": "D013345", "tok_span": [6, 8]}], "relation_list": [{"subject": "cocaine", "object": "SAH", "sbj_char_span": [111, 118], "obj_char_span": [35, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "CONCLUSION: No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after aneurysmal SAH associated with cocaine use.", "entity_list": [{"name": "cocaine", "ent_type": "Chemical", "char_span": [240, 247], "ent_id": "D003042", "tok_span": [37, 38]}, {"name": "SAH", "ent_type": "Disease", "char_span": [220, 223], "ent_id": "D013345", "tok_span": [33, 35]}, {"name": "aneurysmal", "ent_type": "Disease", "char_span": [209, 219], "ent_id": "D017542", "tok_span": [31, 33]}, {"name": "vasculitis", "ent_type": "Disease", "char_span": [139, 149], "ent_id": "D014657", "tok_span": [20, 22]}], "relation_list": [{"subject": "cocaine", "object": "SAH", "sbj_char_span": [240, 247], "obj_char_span": [220, 223], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 38], "obj_tok_span": [33, 35]}, {"subject": "cocaine", "object": "aneurysmal", "sbj_char_span": [240, 247], "obj_char_span": [209, 219], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 38], "obj_tok_span": [31, 33]}], "umls_entity_list": []}, {"text": "The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.", "entity_list": [{"name": "muscular dystrophy", "ent_type": "Disease", "char_span": [139, 157], "ent_id": "D009136", "tok_span": [25, 28]}, {"name": "doxorubicin", "ent_type": "Chemical", "char_span": [213, 224], "ent_id": "D004317", "tok_span": [37, 38]}, {"name": "myotonic dystrophy", "ent_type": "Disease", "char_span": [89, 107], "ent_id": "D009223", "tok_span": [14, 18]}, {"name": "gastric lymphoma", "ent_type": "Disease", "char_span": [68, 84], "ent_id": "C535648", "tok_span": [11, 13]}, {"name": "atrial fibrillation", "ent_type": "Disease", "char_span": [170, 189], "ent_id": "D001281", "tok_span": [31, 33]}], "relation_list": [{"subject": "doxorubicin", "object": "atrial fibrillation", "sbj_char_span": [213, 224], "obj_char_span": [170, 189], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 38], "obj_tok_span": [31, 33]}], "umls_entity_list": []}, {"text": "Haloperidol (1 mg/kg ip) induced parkinsonian-like muscle rigidity, measured as an increased resistance of a rat's hind foot to passive flexion and extension at the ankle joint. (RS)-1-aminoindan-1,5-dicarboxylic acid (AIDA; 0.5-15 microg/0.5 microl), a potent and selective mGluR1 antagonist, or (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-APDC; 7.5-15 microg/0.5 microl), a selective group II agonist, was injected bilaterally into the striatum of haloperidol-treated animals.", "entity_list": [{"name": "parkinsonian", "ent_type": "Disease", "char_span": [33, 45], "ent_id": "D010300", "tok_span": [11, 14]}, {"name": "(RS)-1-aminoindan-1,5-dicarboxylic acid", "ent_type": "Chemical", "char_span": [178, 217], "ent_id": "C095756", "tok_span": [41, 59]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [458, 469], "ent_id": "D006220", "tok_span": [148, 151]}, {"name": "(2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate", "ent_type": "Chemical", "char_span": [297, 341], "ent_id": "C097299", "tok_span": [88, 110]}, {"name": "muscle rigidity", "ent_type": "Disease", "char_span": [51, 66], "ent_id": "D009127", "tok_span": [16, 18]}, {"name": "AIDA", "ent_type": "Chemical", "char_span": [219, 223], "ent_id": "C095756", "tok_span": [60, 62]}, {"name": "2R,4R-APDC", "ent_type": "Chemical", "char_span": [343, 353], "ent_id": "C097299", "tok_span": [111, 119]}, {"name": "Haloperidol", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D006220", "tok_span": [0, 3]}], "relation_list": [{"subject": "Haloperidol", "object": "muscle rigidity", "sbj_char_span": [0, 11], "obj_char_span": [51, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [16, 18]}, {"subject": "haloperidol", "object": "muscle rigidity", "sbj_char_span": [458, 469], "obj_char_span": [51, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [148, 151], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "AIDA in doses of 7.5-15 microg/0.5 microl diminished the haloperidol-induced muscle rigidity.", "entity_list": [{"name": "muscle rigidity", "ent_type": "Disease", "char_span": [77, 92], "ent_id": "D009127", "tok_span": [24, 26]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [57, 68], "ent_id": "D006220", "tok_span": [19, 22]}, {"name": "AIDA", "ent_type": "Chemical", "char_span": [0, 4], "ent_id": "C095756", "tok_span": [0, 2]}], "relation_list": [{"subject": "haloperidol", "object": "muscle rigidity", "sbj_char_span": [57, 68], "obj_char_span": [77, 92], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 22], "obj_tok_span": [24, 26]}], "umls_entity_list": []}, {"text": "Calcitonin gene-related peptide levels during nitric oxide-induced headache in patients with chronic tension-type headache.", "entity_list": [{"name": "headache", "ent_type": "Disease", "char_span": [67, 75], "ent_id": "D006261", "tok_span": [13, 14]}, {"name": "nitric oxide", "ent_type": "Chemical", "char_span": [46, 58], "ent_id": "D009569", "tok_span": [9, 11]}, {"name": "tension-type headache", "ent_type": "Disease", "char_span": [101, 122], "ent_id": "D018781", "tok_span": [18, 22]}], "relation_list": [{"subject": "nitric oxide", "object": "headache", "sbj_char_span": [46, 58], "obj_char_span": [67, 75], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 11], "obj_tok_span": [13, 14]}], "umls_entity_list": []}, {"text": "It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).", "entity_list": [{"name": "primary headaches", "ent_type": "Disease", "char_span": [64, 81], "ent_id": "D051270", "tok_span": [13, 16]}, {"name": "headache", "ent_type": "Disease", "char_span": [52, 60], "ent_id": "D006261", "tok_span": [11, 12]}, {"name": "NO", "ent_type": "Chemical", "char_span": [40, 42], "ent_id": "D009569", "tok_span": [8, 9]}, {"name": "nitric oxide", "ent_type": "Chemical", "char_span": [26, 38], "ent_id": "D009569", "tok_span": [5, 7]}], "relation_list": [{"subject": "nitric oxide", "object": "headache", "sbj_char_span": [26, 38], "obj_char_span": [52, 60], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 7], "obj_tok_span": [11, 12]}, {"subject": "NO", "object": "headache", "sbj_char_span": [40, 42], "obj_char_span": [52, 60], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [11, 12]}], "umls_entity_list": []}, {"text": "In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.", "entity_list": [{"name": "glyceryl trinitrate", "ent_type": "Chemical", "char_span": [107, 126], "ent_id": "D005996", "tok_span": [20, 25]}, {"name": "GTN", "ent_type": "Chemical", "char_span": [128, 131], "ent_id": "D005996", "tok_span": [26, 28]}, {"name": "NO", "ent_type": "Chemical", "char_span": [98, 100], "ent_id": "D009569", "tok_span": [18, 19]}, {"name": "headache", "ent_type": "Disease", "char_span": [74, 82], "ent_id": "D006261", "tok_span": [14, 15]}, {"name": "tension-type headache", "ent_type": "Disease", "char_span": [161, 182], "ent_id": "D018781", "tok_span": [34, 38]}], "relation_list": [{"subject": "GTN", "object": "headache", "sbj_char_span": [128, 131], "obj_char_span": [74, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 28], "obj_tok_span": [14, 15]}, {"subject": "NO", "object": "headache", "sbj_char_span": [98, 100], "obj_char_span": [74, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [14, 15]}, {"subject": "glyceryl trinitrate", "object": "headache", "sbj_char_span": [107, 126], "obj_char_span": [74, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 25], "obj_tok_span": [14, 15]}], "umls_entity_list": []}, {"text": "The subjects were randomly allocated to receive 0.5 microg/kg/min GTN or placebo over 20 min on two headache-free days.", "entity_list": [{"name": "GTN", "ent_type": "Chemical", "char_span": [66, 69], "ent_id": "D005996", "tok_span": [16, 18]}, {"name": "headache", "ent_type": "Disease", "char_span": [100, 108], "ent_id": "D006261", "tok_span": [25, 26]}], "relation_list": [{"subject": "GTN", "object": "headache", "sbj_char_span": [66, 69], "obj_char_span": [100, 108], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 18], "obj_tok_span": [25, 26]}], "umls_entity_list": []}, {"text": "Both patients and controls developed significantly stronger immediate headache on the GTN day than on the placebo day and the headache was significantly more pronounced in patients than in controls.", "entity_list": [{"name": "GTN", "ent_type": "Chemical", "char_span": [86, 89], "ent_id": "D005996", "tok_span": [11, 13]}, {"name": "headache", "ent_type": "Disease", "char_span": [126, 134], "ent_id": "D006261", "tok_span": [21, 22]}, {"name": "headache", "ent_type": "Disease", "char_span": [70, 78], "ent_id": "D006261", "tok_span": [8, 9]}], "relation_list": [{"subject": "GTN", "object": "headache", "sbj_char_span": [86, 89], "obj_char_span": [126, 134], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 13], "obj_tok_span": [21, 22]}, {"subject": "GTN", "object": "headache", "sbj_char_span": [86, 89], "obj_char_span": [70, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 13], "obj_tok_span": [8, 9]}], "umls_entity_list": []}, {"text": "The present study indicates that NO-induced immediate headache is not associated with release of CGRP.", "entity_list": [{"name": "headache", "ent_type": "Disease", "char_span": [54, 62], "ent_id": "D006261", "tok_span": [9, 10]}, {"name": "NO", "ent_type": "Chemical", "char_span": [33, 35], "ent_id": "D009569", "tok_span": [5, 6]}], "relation_list": [{"subject": "NO", "object": "headache", "sbj_char_span": [33, 35], "obj_char_span": [54, 62], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 6], "obj_tok_span": [9, 10]}], "umls_entity_list": []}, {"text": "Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography.", "entity_list": [{"name": "dobutamine", "ent_type": "Chemical", "char_span": [56, 66], "ent_id": "D004280", "tok_span": [10, 13]}, {"name": "Myocardial ischemia", "ent_type": "Disease", "char_span": [0, 19], "ent_id": "D017202", "tok_span": [0, 3]}, {"name": "coronary artery spasm", "ent_type": "Disease", "char_span": [27, 48], "ent_id": "D003329", "tok_span": [5, 9]}], "relation_list": [{"subject": "dobutamine", "object": "coronary artery spasm", "sbj_char_span": [56, 66], "obj_char_span": [27, 48], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "The aim of the present study is to examine whether myocardial ischemia due to coronary spasm is induced by dobutamine.", "entity_list": [{"name": "dobutamine", "ent_type": "Chemical", "char_span": [107, 117], "ent_id": "D004280", "tok_span": [20, 23]}, {"name": "myocardial ischemia", "ent_type": "Disease", "char_span": [51, 70], "ent_id": "D017202", "tok_span": [10, 12]}, {"name": "coronary spasm", "ent_type": "Disease", "char_span": [78, 92], "ent_id": "D003329", "tok_span": [14, 17]}], "relation_list": [{"subject": "dobutamine", "object": "coronary spasm", "sbj_char_span": [107, 117], "obj_char_span": [78, 92], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [14, 17]}], "umls_entity_list": []}, {"text": "These findings indicate that dobutamine can provoke coronary spasm in some patients with coronary spastic angina.", "entity_list": [{"name": "dobutamine", "ent_type": "Chemical", "char_span": [29, 39], "ent_id": "D004280", "tok_span": [4, 7]}, {"name": "coronary spastic angina", "ent_type": "Disease", "char_span": [89, 112], "ent_id": "D000788", "tok_span": [17, 21]}, {"name": "coronary spasm", "ent_type": "Disease", "char_span": [52, 66], "ent_id": "D003329", "tok_span": [10, 13]}], "relation_list": [{"subject": "dobutamine", "object": "coronary spasm", "sbj_char_span": [29, 39], "obj_char_span": [52, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [10, 13]}, {"subject": "dobutamine", "object": "coronary spastic angina", "sbj_char_span": [29, 39], "obj_char_span": [89, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [17, 21]}], "umls_entity_list": []}, {"text": "Nitric oxide synthase expression in the course of lead-induced hypertension.", "entity_list": [{"name": "Nitric oxide", "ent_type": "Chemical", "char_span": [0, 12], "ent_id": "D009569", "tok_span": [0, 3]}, {"name": "lead", "ent_type": "Chemical", "char_span": [50, 54], "ent_id": "D007854", "tok_span": [9, 10]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [63, 75], "ent_id": "D006973", "tok_span": [12, 13]}], "relation_list": [{"subject": "lead", "object": "hypertension", "sbj_char_span": [50, 54], "obj_char_span": [63, 75], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [12, 13]}], "umls_entity_list": []}, {"text": "We recently showed elevated reactive oxygen species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with lead-induced hypertension.", "entity_list": [{"name": "NO", "ent_type": "Chemical", "char_span": [124, 126], "ent_id": "D009569", "tok_span": [24, 25]}, {"name": "oxygen", "ent_type": "Chemical", "char_span": [37, 43], "ent_id": "D010100", "tok_span": [5, 6]}, {"name": "NO", "ent_type": "Chemical", "char_span": [88, 90], "ent_id": "D009569", "tok_span": [15, 16]}, {"name": "nitrotyrosine", "ent_type": "Chemical", "char_span": [144, 157], "ent_id": "C002744", "tok_span": [28, 31]}, {"name": "lead", "ent_type": "Chemical", "char_span": [190, 194], "ent_id": "D007854", "tok_span": [37, 38]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [203, 215], "ent_id": "D006973", "tok_span": [40, 41]}], "relation_list": [{"subject": "lead", "object": "hypertension", "sbj_char_span": [190, 194], "obj_char_span": [203, 215], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 38], "obj_tok_span": [40, 41]}], "umls_entity_list": []}, {"text": "This study was designed to discern whether the reduction in urinary NOx in lead-induced hypertension is, in part, due to depressed NO synthase (NOS) expression.", "entity_list": [{"name": "NO", "ent_type": "Chemical", "char_span": [131, 133], "ent_id": "D009569", "tok_span": [26, 27]}, {"name": "lead", "ent_type": "Chemical", "char_span": [75, 79], "ent_id": "D007854", "tok_span": [14, 15]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [88, 100], "ent_id": "D006973", "tok_span": [17, 18]}], "relation_list": [{"subject": "lead", "object": "hypertension", "sbj_char_span": [75, 79], "obj_char_span": [88, 100], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [17, 18]}], "umls_entity_list": []}, {"text": "In conclusion, lead-induced hypertension in this model was associated with a compensatory upregulation of renal and vascular eNOS and iNOS expression.", "entity_list": [{"name": "lead", "ent_type": "Chemical", "char_span": [15, 19], "ent_id": "D007854", "tok_span": [3, 4]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [28, 40], "ent_id": "D006973", "tok_span": [6, 7]}], "relation_list": [{"subject": "lead", "object": "hypertension", "sbj_char_span": [15, 19], "obj_char_span": [28, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [6, 7]}], "umls_entity_list": []}, {"text": "This is, in part, due to ROS-mediated NO inactivation, lead-associated inhibition of NOS activity, and perhaps stimulatory actions of increased shear stress associated with hypertension.", "entity_list": [{"name": "hypertension", "ent_type": "Disease", "char_span": [173, 185], "ent_id": "D006973", "tok_span": [33, 34]}, {"name": "NO", "ent_type": "Chemical", "char_span": [38, 40], "ent_id": "D009569", "tok_span": [11, 12]}, {"name": "lead", "ent_type": "Chemical", "char_span": [55, 59], "ent_id": "D007854", "tok_span": [14, 15]}], "relation_list": [{"subject": "lead", "object": "hypertension", "sbj_char_span": [55, 59], "obj_char_span": [173, 185], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [33, 34]}], "umls_entity_list": []}, {"text": "However, the use of CBDCA higher-intensity schedules and the association with other neurotoxic drugs in polychemotherapy may cause some concern about its safety with respect to peripheral nervous system damage.", "entity_list": [{"name": "peripheral nervous system damage", "ent_type": "Disease", "char_span": [177, 209], "ent_id": "D010523", "tok_span": [34, 38]}, {"name": "CBDCA", "ent_type": "Chemical", "char_span": [20, 25], "ent_id": "D016190", "tok_span": [5, 8]}, {"name": "neurotoxic", "ent_type": "Disease", "char_span": [84, 94], "ent_id": "D020258", "tok_span": [17, 19]}], "relation_list": [{"subject": "CBDCA", "object": "peripheral nervous system damage", "sbj_char_span": [20, 25], "obj_char_span": [177, 209], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [34, 38]}], "umls_entity_list": []}, {"text": "RESULTS: CBDCA administration induced dose-dependent peripheral neurotoxicity.", "entity_list": [{"name": "CBDCA", "ent_type": "Chemical", "char_span": [9, 14], "ent_id": "D016190", "tok_span": [2, 5]}, {"name": "peripheral neurotoxicity", "ent_type": "Disease", "char_span": [53, 77], "ent_id": "D010523", "tok_span": [10, 13]}], "relation_list": [{"subject": "CBDCA", "object": "peripheral neurotoxicity", "sbj_char_span": [9, 14], "obj_char_span": [53, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [10, 13]}], "umls_entity_list": []}, {"text": "We have investigated the association between endometrial cancer and tamoxifen use or other treatments in women treated for breast cancer in a case-control study.", "entity_list": [{"name": "breast cancer", "ent_type": "Disease", "char_span": [123, 136], "ent_id": "D001943", "tok_span": [18, 20]}, {"name": "tamoxifen", "ent_type": "Chemical", "char_span": [68, 77], "ent_id": "D013629", "tok_span": [9, 10]}, {"name": "endometrial cancer", "ent_type": "Disease", "char_span": [45, 63], "ent_id": "D016889", "tok_span": [6, 8]}], "relation_list": [{"subject": "tamoxifen", "object": "endometrial cancer", "sbj_char_span": [68, 77], "obj_char_span": [45, 63], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "Women who had received tamoxifen were significantly more likely to have endometrial cancer diagnosed than those who had not (crude relative risk = 4.9, p = 0.0001).", "entity_list": [{"name": "tamoxifen", "ent_type": "Chemical", "char_span": [23, 32], "ent_id": "D013629", "tok_span": [4, 5]}, {"name": "endometrial cancer", "ent_type": "Disease", "char_span": [72, 90], "ent_id": "D016889", "tok_span": [11, 13]}], "relation_list": [{"subject": "tamoxifen", "object": "endometrial cancer", "sbj_char_span": [23, 32], "obj_char_span": [72, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [11, 13]}], "umls_entity_list": []}, {"text": "Women who had endometrial cancer and had received tamoxifen had more advanced disease and poorer prognosis than those with endometrial cancer who had not received this treatment.", "entity_list": [{"name": "endometrial cancer", "ent_type": "Disease", "char_span": [123, 141], "ent_id": "D016889", "tok_span": [19, 21]}, {"name": "advanced disease", "ent_type": "Disease", "char_span": [69, 85], "ent_id": "D020178", "tok_span": [11, 13]}, {"name": "endometrial cancer", "ent_type": "Disease", "char_span": [14, 32], "ent_id": "D016889", "tok_span": [3, 5]}, {"name": "tamoxifen", "ent_type": "Chemical", "char_span": [50, 59], "ent_id": "D013629", "tok_span": [8, 9]}], "relation_list": [{"subject": "tamoxifen", "object": "endometrial cancer", "sbj_char_span": [50, 59], "obj_char_span": [14, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [3, 5]}, {"subject": "tamoxifen", "object": "endometrial cancer", "sbj_char_span": [50, 59], "obj_char_span": [123, 141], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [19, 21]}], "umls_entity_list": []}, {"text": "Our results suggest a causal role of tamoxifen in endometrial cancer, particularly when used as currently proposed for breast cancer prevention.", "entity_list": [{"name": "breast cancer", "ent_type": "Disease", "char_span": [119, 132], "ent_id": "D001943", "tok_span": [19, 21]}, {"name": "tamoxifen", "ent_type": "Chemical", "char_span": [37, 46], "ent_id": "D013629", "tok_span": [7, 8]}, {"name": "endometrial cancer", "ent_type": "Disease", "char_span": [50, 68], "ent_id": "D016889", "tok_span": [9, 11]}], "relation_list": [{"subject": "tamoxifen", "object": "endometrial cancer", "sbj_char_span": [37, 46], "obj_char_span": [50, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "Endometrial cancers diagnosed in women treated with tamoxifen have poorer prognosis.", "entity_list": [{"name": "tamoxifen", "ent_type": "Chemical", "char_span": [52, 61], "ent_id": "D013629", "tok_span": [9, 10]}, {"name": "Endometrial cancers", "ent_type": "Disease", "char_span": [0, 19], "ent_id": "D016889", "tok_span": [0, 4]}], "relation_list": [{"subject": "tamoxifen", "object": "Endometrial cancers", "sbj_char_span": [52, 61], "obj_char_span": [0, 19], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "Granulosa cell tumor of the ovary associated with antecedent tamoxifen use.", "entity_list": [{"name": "Granulosa cell tumor of the ovary", "ent_type": "Disease", "char_span": [0, 33], "ent_id": "C537296", "tok_span": [0, 8]}, {"name": "tamoxifen", "ent_type": "Chemical", "char_span": [61, 70], "ent_id": "D013629", "tok_span": [11, 12]}], "relation_list": [{"subject": "tamoxifen", "object": "Granulosa cell tumor of the ovary", "sbj_char_span": [61, 70], "obj_char_span": [0, 33], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [0, 8]}], "umls_entity_list": []}, {"text": "CONCLUSION: Patients with tamoxifen-induced liver dysfunction may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism.", "entity_list": [{"name": "tamoxifen", "ent_type": "Chemical", "char_span": [139, 148], "ent_id": "D013629", "tok_span": [23, 24]}, {"name": "tamoxifen", "ent_type": "Chemical", "char_span": [26, 35], "ent_id": "D013629", "tok_span": [4, 5]}, {"name": "liver dysfunction", "ent_type": "Disease", "char_span": [44, 61], "ent_id": "D017093", "tok_span": [7, 9]}, {"name": "granulosa cell tumors", "ent_type": "Disease", "char_span": [91, 112], "ent_id": "D006106", "tok_span": [15, 19]}], "relation_list": [{"subject": "tamoxifen", "object": "liver dysfunction", "sbj_char_span": [26, 35], "obj_char_span": [44, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [7, 9]}, {"subject": "tamoxifen", "object": "liver dysfunction", "sbj_char_span": [139, 148], "obj_char_span": [44, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 24], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.", "entity_list": [{"name": "adenomyosis", "ent_type": "Disease", "char_span": [18, 29], "ent_id": "D062788", "tok_span": [4, 7]}, {"name": "adenomyosis", "ent_type": "Disease", "char_span": [147, 158], "ent_id": "D062788", "tok_span": [31, 34]}, {"name": "serotonin", "ent_type": "Chemical", "char_span": [114, 123], "ent_id": "D012701", "tok_span": [24, 25]}, {"name": "hyperprolactinemia", "ent_type": "Disease", "char_span": [46, 64], "ent_id": "D006966", "tok_span": [11, 15]}, {"name": "fluoxetine hydrochloride", "ent_type": "Chemical", "char_span": [76, 100], "ent_id": "D005473", "tok_span": [17, 21]}], "relation_list": [{"subject": "fluoxetine hydrochloride", "object": "adenomyosis", "sbj_char_span": [76, 100], "obj_char_span": [18, 29], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [4, 7]}, {"subject": "fluoxetine hydrochloride", "object": "hyperprolactinemia", "sbj_char_span": [76, 100], "obj_char_span": [46, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [11, 15]}, {"subject": "fluoxetine hydrochloride", "object": "adenomyosis", "sbj_char_span": [76, 100], "obj_char_span": [147, 158], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [31, 34]}], "umls_entity_list": []}, {"text": "OBJECTIVE: The aim of this study was to investigate whether fluoxetine given to castrated and noncastrated rats caused hyperprolactinemia and its effects with respect to adenomyosis.", "entity_list": [{"name": "fluoxetine", "ent_type": "Chemical", "char_span": [60, 70], "ent_id": "D005473", "tok_span": [11, 14]}, {"name": "hyperprolactinemia", "ent_type": "Disease", "char_span": [119, 137], "ent_id": "D006966", "tok_span": [24, 28]}, {"name": "adenomyosis", "ent_type": "Disease", "char_span": [170, 181], "ent_id": "D062788", "tok_span": [34, 37]}], "relation_list": [{"subject": "fluoxetine", "object": "hyperprolactinemia", "sbj_char_span": [60, 70], "obj_char_span": [119, 137], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [24, 28]}, {"subject": "fluoxetine", "object": "adenomyosis", "sbj_char_span": [60, 70], "obj_char_span": [170, 181], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [34, 37]}], "umls_entity_list": []}, {"text": "DESIGN: Fluoxetine, a serotonin reuptake inhibitor, was given to Wistar Albino rats for 98 days to produce hyperprolactinemia.", "entity_list": [{"name": "serotonin", "ent_type": "Chemical", "char_span": [22, 31], "ent_id": "D012701", "tok_span": [7, 8]}, {"name": "Fluoxetine", "ent_type": "Chemical", "char_span": [8, 18], "ent_id": "D005473", "tok_span": [2, 5]}, {"name": "hyperprolactinemia", "ent_type": "Disease", "char_span": [107, 125], "ent_id": "D006966", "tok_span": [25, 29]}], "relation_list": [{"subject": "Fluoxetine", "object": "hyperprolactinemia", "sbj_char_span": [8, 18], "obj_char_span": [107, 125], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [25, 29]}], "umls_entity_list": []}, {"text": "Histological studies revealed 11 cases of adenomyosis, all within the noncastrated group receiving fluoxetine.", "entity_list": [{"name": "fluoxetine", "ent_type": "Chemical", "char_span": [99, 109], "ent_id": "D005473", "tok_span": [18, 21]}, {"name": "adenomyosis", "ent_type": "Disease", "char_span": [42, 53], "ent_id": "D062788", "tok_span": [6, 9]}], "relation_list": [{"subject": "fluoxetine", "object": "adenomyosis", "sbj_char_span": [99, 109], "obj_char_span": [42, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [6, 9]}], "umls_entity_list": []}, {"text": "Effects of deliberate hypotension induced by labetalol with isoflurane on neuropsychological function.", "entity_list": [{"name": "labetalol", "ent_type": "Chemical", "char_span": [45, 54], "ent_id": "D007741", "tok_span": [7, 10]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [22, 33], "ent_id": "D007022", "tok_span": [4, 5]}, {"name": "isoflurane", "ent_type": "Chemical", "char_span": [60, 70], "ent_id": "D007530", "tok_span": [11, 13]}], "relation_list": [{"subject": "isoflurane", "object": "hypotension", "sbj_char_span": [60, 70], "obj_char_span": [22, 33], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 13], "obj_tok_span": [4, 5]}, {"subject": "labetalol", "object": "hypotension", "sbj_char_span": [45, 54], "obj_char_span": [22, 33], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [4, 5]}], "umls_entity_list": []}, {"text": "Twenty-four patients were anaesthetized for middle-ear surgery with deliberate hypotension induced by labetalol with isoflurane (hypotensive group).", "entity_list": [{"name": "labetalol", "ent_type": "Chemical", "char_span": [102, 111], "ent_id": "D007741", "tok_span": [18, 21]}, {"name": "isoflurane", "ent_type": "Chemical", "char_span": [117, 127], "ent_id": "D007530", "tok_span": [22, 24]}, {"name": "hypotensive", "ent_type": "Disease", "char_span": [129, 140], "ent_id": "D007022", "tok_span": [25, 27]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [79, 90], "ent_id": "D007022", "tok_span": [15, 16]}], "relation_list": [{"subject": "labetalol", "object": "hypotension", "sbj_char_span": [102, 111], "obj_char_span": [79, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [15, 16]}, {"subject": "isoflurane", "object": "hypotensive", "sbj_char_span": [117, 127], "obj_char_span": [129, 140], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 24], "obj_tok_span": [25, 27]}, {"subject": "labetalol", "object": "hypotensive", "sbj_char_span": [102, 111], "obj_char_span": [129, 140], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [25, 27]}, {"subject": "isoflurane", "object": "hypotension", "sbj_char_span": [117, 127], "obj_char_span": [79, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 24], "obj_tok_span": [15, 16]}], "umls_entity_list": []}, {"text": "The results indicate that hypotension induced by labetalol with isoflurane has no significant harmful effects on mental functions compared to normotensive anaesthesia.", "entity_list": [{"name": "labetalol", "ent_type": "Chemical", "char_span": [49, 58], "ent_id": "D007741", "tok_span": [7, 10]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [26, 37], "ent_id": "D007022", "tok_span": [4, 5]}, {"name": "isoflurane", "ent_type": "Chemical", "char_span": [64, 74], "ent_id": "D007530", "tok_span": [11, 13]}], "relation_list": [{"subject": "isoflurane", "object": "hypotension", "sbj_char_span": [64, 74], "obj_char_span": [26, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 13], "obj_tok_span": [4, 5]}, {"subject": "labetalol", "object": "hypotension", "sbj_char_span": [49, 58], "obj_char_span": [26, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [4, 5]}], "umls_entity_list": []}, {"text": "Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although apnoea occurred less often in the midazolam group it lasted longer.", "entity_list": [{"name": "midazolam", "ent_type": "Chemical", "char_span": [132, 141], "ent_id": "D008874", "tok_span": [28, 31]}, {"name": "apnoea", "ent_type": "Disease", "char_span": [98, 104], "ent_id": "D001049", "tok_span": [20, 23]}, {"name": "midazolam", "ent_type": "Chemical", "char_span": [67, 76], "ent_id": "D008874", "tok_span": [12, 15]}], "relation_list": [{"subject": "midazolam", "object": "apnoea", "sbj_char_span": [67, 76], "obj_char_span": [98, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [20, 23]}, {"subject": "midazolam", "object": "apnoea", "sbj_char_span": [132, 141], "obj_char_span": [98, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 31], "obj_tok_span": [20, 23]}], "umls_entity_list": []}, {"text": "Cardiotoxic and possible leukemogenic effects of adriamycin in nonhuman primates.\n 10 monkeys (macaques) received adriamycin by monthly intravenous injections at 12 mg/m2 (1 mg/kg). 8 of the 10 monkeys developed congestive heart failure at an average cumulative adriamycin dose (310 mg/m2) well below that considered the safe upper limit (550 mg/m2) in man", "entity_list": [{"name": "adriamycin", "ent_type": "Chemical", "char_span": [262, 272], "ent_id": "D004317", "tok_span": [61, 65]}, {"name": "Cardiotoxic", "ent_type": "Disease", "char_span": [0, 11], "ent_id": "D066126", "tok_span": [0, 2]}, {"name": "adriamycin", "ent_type": "Chemical", "char_span": [114, 124], "ent_id": "D004317", "tok_span": [25, 29]}, {"name": "congestive heart failure", "ent_type": "Disease", "char_span": [212, 236], "ent_id": "D006333", "tok_span": [52, 57]}, {"name": "adriamycin", "ent_type": "Chemical", "char_span": [49, 59], "ent_id": "D004317", "tok_span": [9, 13]}], "relation_list": [{"subject": "adriamycin", "object": "congestive heart failure", "sbj_char_span": [262, 272], "obj_char_span": [212, 236], "rel_type": "chemical-induced disease", "sbj_tok_span": [61, 65], "obj_tok_span": [52, 57]}, {"subject": "adriamycin", "object": "congestive heart failure", "sbj_char_span": [114, 124], "obj_char_span": [212, 236], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 29], "obj_tok_span": [52, 57]}, {"subject": "adriamycin", "object": "congestive heart failure", "sbj_char_span": [49, 59], "obj_char_span": [212, 236], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [52, 57]}], "umls_entity_list": []}, {"text": "Histologically, the myocardial lesions resembled those found in human anthracycline-induced cardiomyopathy. 1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg/m2 of adriamycin; the 10th monkey is alive and well 26 months after the last dose of drug.", "entity_list": [{"name": "acute myeloblastic leukemia", "ent_type": "Disease", "char_span": [138, 165], "ent_id": "D015470", "tok_span": [24, 28]}, {"name": "cardiomyopathy", "ent_type": "Disease", "char_span": [92, 106], "ent_id": "D009202", "tok_span": [16, 17]}, {"name": "myocardial lesions", "ent_type": "Disease", "char_span": [20, 38], "ent_id": "D001768", "tok_span": [4, 6]}, {"name": "adriamycin", "ent_type": "Chemical", "char_span": [195, 205], "ent_id": "D004317", "tok_span": [36, 40]}, {"name": "anthracycline", "ent_type": "Chemical", "char_span": [70, 83], "ent_id": "D018943", "tok_span": [12, 14]}], "relation_list": [{"subject": "adriamycin", "object": "acute myeloblastic leukemia", "sbj_char_span": [195, 205], "obj_char_span": [138, 165], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 40], "obj_tok_span": [24, 28]}], "umls_entity_list": []}, {"text": "Doxorubicin cardiomyopathy in children with left-sided Wilms tumor.", "entity_list": [{"name": "Wilms tumor", "ent_type": "Disease", "char_span": [55, 66], "ent_id": "D009396", "tok_span": [11, 14]}, {"name": "Doxorubicin", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D004317", "tok_span": [0, 3]}, {"name": "cardiomyopathy", "ent_type": "Disease", "char_span": [12, 26], "ent_id": "D009202", "tok_span": [3, 4]}], "relation_list": [{"subject": "Doxorubicin", "object": "cardiomyopathy", "sbj_char_span": [0, 11], "obj_char_span": [12, 26], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [3, 4]}], "umls_entity_list": []}, {"text": "Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin.", "entity_list": [{"name": "tumor", "ent_type": "Disease", "char_span": [122, 127], "ent_id": "D009369", "tok_span": [19, 20]}, {"name": "Wilms tumor", "ent_type": "Disease", "char_span": [18, 29], "ent_id": "D009396", "tok_span": [3, 6]}, {"name": "cardiomyopathy", "ent_type": "Disease", "char_span": [82, 96], "ent_id": "D009202", "tok_span": [14, 15]}, {"name": "anthracycline", "ent_type": "Chemical", "char_span": [68, 81], "ent_id": "D018943", "tok_span": [12, 14]}, {"name": "doxorubicin", "ent_type": "Chemical", "char_span": [159, 170], "ent_id": "D004317", "tok_span": [25, 26]}], "relation_list": [{"subject": "doxorubicin", "object": "cardiomyopathy", "sbj_char_span": [159, 170], "obj_char_span": [82, 96], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 26], "obj_tok_span": [14, 15]}], "umls_entity_list": []}, {"text": "The cardiomyopathy is attributed 1) to the fact that radiation fields for left Wilms tumor include the lower portion of the heart and 2) to the interaction of doxorubicin and irradiation on cardiac muscle.", "entity_list": [{"name": "doxorubicin", "ent_type": "Chemical", "char_span": [159, 170], "ent_id": "D004317", "tok_span": [31, 32]}, {"name": "cardiomyopathy", "ent_type": "Disease", "char_span": [4, 18], "ent_id": "D009202", "tok_span": [1, 2]}, {"name": "Wilms tumor", "ent_type": "Disease", "char_span": [79, 90], "ent_id": "D009396", "tok_span": [14, 17]}], "relation_list": [{"subject": "doxorubicin", "object": "cardiomyopathy", "sbj_char_span": [159, 170], "obj_char_span": [4, 18], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 32], "obj_tok_span": [1, 2]}], "umls_entity_list": []}, {"text": "Conventional LW rats, implanted with testosterone at age 4 months, developed a higher incidence of prostate cancer after an average interval of 14 months: 24% had developed gross tumors, and 40% when it included microscopic tumors.", "entity_list": [{"name": "tumors", "ent_type": "Disease", "char_span": [179, 185], "ent_id": "D009369", "tok_span": [32, 33]}, {"name": "testosterone", "ent_type": "Chemical", "char_span": [37, 49], "ent_id": "D013739", "tok_span": [6, 7]}, {"name": "tumors", "ent_type": "Disease", "char_span": [224, 230], "ent_id": "D009369", "tok_span": [41, 42]}, {"name": "prostate cancer", "ent_type": "Disease", "char_span": [99, 114], "ent_id": "D011471", "tok_span": [17, 19]}], "relation_list": [{"subject": "testosterone", "object": "prostate cancer", "sbj_char_span": [37, 49], "obj_char_span": [99, 114], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [17, 19]}], "umls_entity_list": []}, {"text": "Preliminary results indicate that testosterone-treated LW rats that were fed the same diet, which was supplemented with corn oil up to 20% fat, developed prostate cancer after intervals of 6-12 months.", "entity_list": [{"name": "testosterone", "ent_type": "Chemical", "char_span": [34, 46], "ent_id": "D013739", "tok_span": [4, 5]}, {"name": "prostate cancer", "ent_type": "Disease", "char_span": [154, 169], "ent_id": "D011471", "tok_span": [29, 31]}], "relation_list": [{"subject": "testosterone", "object": "prostate cancer", "sbj_char_span": [34, 46], "obj_char_span": [154, 169], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [29, 31]}], "umls_entity_list": []}, {"text": "Conventional SD rats fed diet L-485 and treated with testosterone developed only prostatitis.", "entity_list": [{"name": "testosterone", "ent_type": "Chemical", "char_span": [53, 65], "ent_id": "D013739", "tok_span": [12, 13]}, {"name": "prostatitis", "ent_type": "Disease", "char_span": [81, 92], "ent_id": "D011472", "tok_span": [15, 17]}], "relation_list": [{"subject": "testosterone", "object": "prostatitis", "sbj_char_span": [53, 65], "obj_char_span": [81, 92], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "Mitomycin C associated hemolytic uremic syndrome.", "entity_list": [{"name": "Mitomycin C", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D016685", "tok_span": [0, 3]}, {"name": "hemolytic uremic syndrome", "ent_type": "Disease", "char_span": [23, 48], "ent_id": "D006463", "tok_span": [4, 9]}], "relation_list": [{"subject": "Mitomycin C", "object": "hemolytic uremic syndrome", "sbj_char_span": [0, 11], "obj_char_span": [23, 48], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [4, 9]}], "umls_entity_list": []}, {"text": "Mitomycin C associated Hemolytic Uremic Syndrome (HUS) is a potentially fatal but uncommon condition that is not yet widely recognised.", "entity_list": [{"name": "Mitomycin C", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D016685", "tok_span": [0, 3]}, {"name": "HUS", "ent_type": "Disease", "char_span": [50, 53], "ent_id": "D006463", "tok_span": [10, 12]}, {"name": "Hemolytic Uremic Syndrome", "ent_type": "Disease", "char_span": [23, 48], "ent_id": "D006463", "tok_span": [4, 9]}], "relation_list": [{"subject": "Mitomycin C", "object": "Hemolytic Uremic Syndrome", "sbj_char_span": [0, 11], "obj_char_span": [23, 48], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [4, 9]}, {"subject": "Mitomycin C", "object": "HUS", "sbj_char_span": [0, 11], "obj_char_span": [50, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.", "entity_list": [{"name": "mitomycin C", "ent_type": "Chemical", "char_span": [113, 124], "ent_id": "D016685", "tok_span": [18, 21]}, {"name": "renal failure", "ent_type": "Disease", "char_span": [83, 96], "ent_id": "D051437", "tok_span": [14, 16]}, {"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [50, 66], "ent_id": "D013921", "tok_span": [10, 12]}, {"name": "hemolytic anemia", "ent_type": "Disease", "char_span": [32, 48], "ent_id": "D000743", "tok_span": [6, 9]}], "relation_list": [{"subject": "mitomycin C", "object": "renal failure", "sbj_char_span": [113, 124], "obj_char_span": [83, 96], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.", "entity_list": [{"name": "renal failure", "ent_type": "Disease", "char_span": [4, 17], "ent_id": "D051437", "tok_span": [1, 3]}, {"name": "mitomycin C", "ent_type": "Chemical", "char_span": [65, 76], "ent_id": "D016685", "tok_span": [14, 17]}, {"name": "renal failure", "ent_type": "Disease", "char_span": [131, 144], "ent_id": "D051437", "tok_span": [26, 28]}, {"name": "pulmonary edema", "ent_type": "Disease", "char_span": [148, 163], "ent_id": "D011654", "tok_span": [29, 31]}], "relation_list": [{"subject": "mitomycin C", "object": "renal failure", "sbj_char_span": [65, 76], "obj_char_span": [131, 144], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [26, 28]}, {"subject": "mitomycin C", "object": "renal failure", "sbj_char_span": [65, 76], "obj_char_span": [4, 17], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [1, 3]}], "umls_entity_list": []}, {"text": "We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.", "entity_list": [{"name": "pulmonary edema", "ent_type": "Disease", "char_span": [202, 217], "ent_id": "D011654", "tok_span": [35, 37]}, {"name": "renal failure", "ent_type": "Disease", "char_span": [119, 132], "ent_id": "D051437", "tok_span": [20, 22]}, {"name": "mitomycin C", "ent_type": "Chemical", "char_span": [178, 189], "ent_id": "D016685", "tok_span": [29, 32]}, {"name": "gastric adenocarcinoma", "ent_type": "Disease", "char_span": [82, 104], "ent_id": "D013274", "tok_span": [16, 18]}, {"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [137, 153], "ent_id": "D013921", "tok_span": [23, 25]}], "relation_list": [{"subject": "mitomycin C", "object": "renal failure", "sbj_char_span": [178, 189], "obj_char_span": [119, 132], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 32], "obj_tok_span": [20, 22]}], "umls_entity_list": []}, {"text": "We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5-FU infusion for treatment of solid tumors in order to assess the incidence of ischemic ST changes.", "entity_list": [{"name": "5-FU", "ent_type": "Chemical", "char_span": [90, 94], "ent_id": "D005472", "tok_span": [11, 14]}, {"name": "ischemic", "ent_type": "Disease", "char_span": [170, 178], "ent_id": "D007511", "tok_span": [27, 28]}, {"name": "tumors", "ent_type": "Disease", "char_span": [127, 133], "ent_id": "D009369", "tok_span": [19, 20]}], "relation_list": [{"subject": "5-FU", "object": "ischemic", "sbj_char_span": [90, 94], "obj_char_span": [170, 178], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [27, 28]}], "umls_entity_list": []}, {"text": "Anginal episodes were rare: only one patient had angina (during 5-FU infusion).", "entity_list": [{"name": "angina", "ent_type": "Disease", "char_span": [49, 55], "ent_id": "D000787", "tok_span": [10, 11]}, {"name": "5-FU", "ent_type": "Chemical", "char_span": [64, 68], "ent_id": "D005472", "tok_span": [13, 16]}, {"name": "Anginal", "ent_type": "Disease", "char_span": [0, 7], "ent_id": "D000787", "tok_span": [0, 2]}], "relation_list": [{"subject": "5-FU", "object": "angina", "sbj_char_span": [64, 68], "obj_char_span": [49, 55], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [10, 11]}, {"subject": "5-FU", "object": "Anginal", "sbj_char_span": [64, 68], "obj_char_span": [0, 7], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "The incidence of ischemic episodes per patient per hour was 0.05 +/- 0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).", "entity_list": [{"name": "5-FU", "ent_type": "Chemical", "char_span": [83, 87], "ent_id": "D005472", "tok_span": [21, 24]}, {"name": "5-FU", "ent_type": "Chemical", "char_span": [289, 293], "ent_id": "D005472", "tok_span": [89, 92]}, {"name": "ischemic", "ent_type": "Disease", "char_span": [17, 25], "ent_id": "D007511", "tok_span": [3, 4]}, {"name": "5-FU", "ent_type": "Chemical", "char_span": [234, 238], "ent_id": "D005472", "tok_span": [70, 73]}, {"name": "5-FU", "ent_type": "Chemical", "char_span": [120, 124], "ent_id": "D005472", "tok_span": [36, 39]}], "relation_list": [{"subject": "5-FU", "object": "ischemic", "sbj_char_span": [234, 238], "obj_char_span": [17, 25], "rel_type": "chemical-induced disease", "sbj_tok_span": [70, 73], "obj_tok_span": [3, 4]}, {"subject": "5-FU", "object": "ischemic", "sbj_char_span": [289, 293], "obj_char_span": [17, 25], "rel_type": "chemical-induced disease", "sbj_tok_span": [89, 92], "obj_tok_span": [3, 4]}, {"subject": "5-FU", "object": "ischemic", "sbj_char_span": [120, 124], "obj_char_span": [17, 25], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 39], "obj_tok_span": [3, 4]}, {"subject": "5-FU", "object": "ischemic", "sbj_char_span": [83, 87], "obj_char_span": [17, 25], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [3, 4]}], "umls_entity_list": []}, {"text": "We conclude that 5-FU infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia, particularly among patients with coronary artery disease.", "entity_list": [{"name": "5-FU", "ent_type": "Chemical", "char_span": [17, 21], "ent_id": "D005472", "tok_span": [3, 6]}, {"name": "ischemia", "ent_type": "Disease", "char_span": [118, 126], "ent_id": "D007511", "tok_span": [20, 21]}, {"name": "coronary artery disease", "ent_type": "Disease", "char_span": [161, 184], "ent_id": "D003324", "tok_span": [26, 29]}], "relation_list": [{"subject": "5-FU", "object": "ischemia", "sbj_char_span": [17, 21], "obj_char_span": [118, 126], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [20, 21]}], "umls_entity_list": []}, {"text": "Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function.", "entity_list": [{"name": "anuria", "ent_type": "Disease", "char_span": [7, 13], "ent_id": "D001002", "tok_span": [2, 4]}, {"name": "impaired renal function", "ent_type": "Disease", "char_span": [96, 119], "ent_id": "D007674", "tok_span": [21, 24]}, {"name": "breast cancer", "ent_type": "Disease", "char_span": [66, 79], "ent_id": "D001943", "tok_span": [16, 18]}, {"name": "ifosfamide", "ent_type": "Chemical", "char_span": [37, 47], "ent_id": "D007069", "tok_span": [8, 13]}], "relation_list": [{"subject": "ifosfamide", "object": "anuria", "sbj_char_span": [37, 47], "obj_char_span": [7, 13], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 13], "obj_tok_span": [2, 4]}, {"subject": "ifosfamide", "object": "impaired renal function", "sbj_char_span": [37, 47], "obj_char_span": [96, 119], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 13], "obj_tok_span": [21, 24]}], "umls_entity_list": []}, {"text": "A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.", "entity_list": [{"name": "renal failure", "ent_type": "Disease", "char_span": [120, 133], "ent_id": "D051437", "tok_span": [22, 24]}, {"name": "breast cancer", "ent_type": "Disease", "char_span": [37, 50], "ent_id": "D001943", "tok_span": [10, 12]}, {"name": "anuria", "ent_type": "Disease", "char_span": [139, 145], "ent_id": "D001002", "tok_span": [25, 27]}, {"name": "ifosfamide", "ent_type": "Chemical", "char_span": [174, 184], "ent_id": "D007069", "tok_span": [37, 42]}, {"name": "cisplatin", "ent_type": "Chemical", "char_span": [76, 85], "ent_id": "D002945", "tok_span": [16, 17]}], "relation_list": [{"subject": "ifosfamide", "object": "anuria", "sbj_char_span": [174, 184], "obj_char_span": [139, 145], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 42], "obj_tok_span": [25, 27]}], "umls_entity_list": []}, {"text": "Ifosfamide is a known nephrotoxic drug with demonstrated tubulopathies.", "entity_list": [{"name": "Ifosfamide", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D007069", "tok_span": [0, 5]}, {"name": "tubulopathies", "ent_type": "Disease", "char_span": [57, 70], "ent_id": "D007674", "tok_span": [14, 18]}, {"name": "nephrotoxic", "ent_type": "Disease", "char_span": [22, 33], "ent_id": "D007674", "tok_span": [8, 11]}], "relation_list": [{"subject": "Ifosfamide", "object": "nephrotoxic", "sbj_char_span": [0, 10], "obj_char_span": [22, 33], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [8, 11]}, {"subject": "Ifosfamide", "object": "tubulopathies", "sbj_char_span": [0, 10], "obj_char_span": [57, 70], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [14, 18]}], "umls_entity_list": []}, {"text": "We strongly suspect that this lethal anuria was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension.", "entity_list": [{"name": "cisplatin", "ent_type": "Chemical", "char_span": [122, 131], "ent_id": "D002945", "tok_span": [25, 26]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [193, 204], "ent_id": "D007022", "tok_span": [35, 36]}, {"name": "ifosfamide", "ent_type": "Chemical", "char_span": [62, 72], "ent_id": "D007069", "tok_span": [12, 17]}, {"name": "anuria", "ent_type": "Disease", "char_span": [37, 43], "ent_id": "D001002", "tok_span": [6, 8]}], "relation_list": [{"subject": "ifosfamide", "object": "anuria", "sbj_char_span": [62, 72], "obj_char_span": [37, 43], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 17], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "We recommend careful use of ifosfamide in patients pretreated with nephrotoxic chemotherapy and inadequate renal perfusion.", "entity_list": [{"name": "ifosfamide", "ent_type": "Chemical", "char_span": [28, 38], "ent_id": "D007069", "tok_span": [5, 10]}, {"name": "nephrotoxic", "ent_type": "Disease", "char_span": [67, 78], "ent_id": "D007674", "tok_span": [14, 17]}], "relation_list": [{"subject": "ifosfamide", "object": "nephrotoxic", "sbj_char_span": [28, 38], "obj_char_span": [67, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 10], "obj_tok_span": [14, 17]}], "umls_entity_list": []}, {"text": "Central vein thrombosis and topical dipivalyl epinephrine.", "entity_list": [{"name": "vein thrombosis", "ent_type": "Disease", "char_span": [8, 23], "ent_id": "D020246", "tok_span": [1, 3]}, {"name": "dipivalyl epinephrine", "ent_type": "Chemical", "char_span": [36, 57], "ent_id": "C015173", "tok_span": [5, 11]}], "relation_list": [{"subject": "dipivalyl epinephrine", "object": "vein thrombosis", "sbj_char_span": [36, 57], "obj_char_span": [8, 23], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 11], "obj_tok_span": [1, 3]}], "umls_entity_list": []}, {"text": "A report is given on an 83-year-old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with dipivalyl epinephrine for advanced glaucoma discovered in the other eye.", "entity_list": [{"name": "dipivalyl epinephrine", "ent_type": "Chemical", "char_span": [151, 172], "ent_id": "C015173", "tok_span": [29, 35]}, {"name": "vein thrombosis", "ent_type": "Disease", "char_span": [64, 79], "ent_id": "D020246", "tok_span": [15, 17]}, {"name": "glaucoma", "ent_type": "Disease", "char_span": [186, 194], "ent_id": "D005901", "tok_span": [37, 38]}], "relation_list": [{"subject": "dipivalyl epinephrine", "object": "vein thrombosis", "sbj_char_span": [151, 172], "obj_char_span": [64, 79], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 35], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "Amelioration of bendrofluazide-induced hypokalemia by timolol.", "entity_list": [{"name": "hypokalemia", "ent_type": "Disease", "char_span": [39, 50], "ent_id": "D007008", "tok_span": [12, 16]}, {"name": "bendrofluazide", "ent_type": "Chemical", "char_span": [16, 30], "ent_id": "D001539", "tok_span": [4, 10]}, {"name": "timolol", "ent_type": "Chemical", "char_span": [54, 61], "ent_id": "D013999", "tok_span": [17, 20]}], "relation_list": [{"subject": "bendrofluazide", "object": "hypokalemia", "sbj_char_span": [16, 30], "obj_char_span": [39, 50], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 10], "obj_tok_span": [12, 16]}], "umls_entity_list": []}, {"text": "The beta adrenergic blocking drug, timolol, tended to correct the hypokalemia of short-term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant.", "entity_list": [{"name": "bendrofluazide", "ent_type": "Chemical", "char_span": [92, 106], "ent_id": "D001539", "tok_span": [23, 29]}, {"name": "timolol", "ent_type": "Chemical", "char_span": [35, 42], "ent_id": "D013999", "tok_span": [7, 10]}, {"name": "hypokalemia", "ent_type": "Disease", "char_span": [66, 77], "ent_id": "D007008", "tok_span": [15, 19]}], "relation_list": [{"subject": "bendrofluazide", "object": "hypokalemia", "sbj_char_span": [92, 106], "obj_char_span": [66, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 29], "obj_tok_span": [15, 19]}], "umls_entity_list": []}, {"text": "OBJECTIVE: The aim of the present study was to investigate the effect of risperidone-induced hyperprolactinemia on trabecular bone mineral density (BMD) in children and adolescents.", "entity_list": [{"name": "risperidone", "ent_type": "Chemical", "char_span": [73, 84], "ent_id": "D018967", "tok_span": [14, 17]}, {"name": "hyperprolactinemia", "ent_type": "Disease", "char_span": [93, 111], "ent_id": "D006966", "tok_span": [19, 23]}], "relation_list": [{"subject": "risperidone", "object": "hyperprolactinemia", "sbj_char_span": [73, 84], "obj_char_span": [93, 111], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "RESULTS: Hyperprolactinemia was present in 49% of 83 boys (n = 41) treated with risperidone for a mean of 2.9 years.", "entity_list": [{"name": "risperidone", "ent_type": "Chemical", "char_span": [80, 91], "ent_id": "D018967", "tok_span": [21, 24]}, {"name": "Hyperprolactinemia", "ent_type": "Disease", "char_span": [9, 27], "ent_id": "D006966", "tok_span": [2, 6]}], "relation_list": [{"subject": "risperidone", "object": "Hyperprolactinemia", "sbj_char_span": [80, 91], "obj_char_span": [9, 27], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [2, 6]}], "umls_entity_list": []}, {"text": "Of 13 documented fractures, 3 occurred after risperidone and SSRIs were started, and none occurred in patients with hyperprolactinemia.", "entity_list": [{"name": "fractures", "ent_type": "Disease", "char_span": [17, 26], "ent_id": "D050723", "tok_span": [3, 4]}, {"name": "hyperprolactinemia", "ent_type": "Disease", "char_span": [116, 134], "ent_id": "D006966", "tok_span": [24, 28]}, {"name": "risperidone", "ent_type": "Chemical", "char_span": [45, 56], "ent_id": "D018967", "tok_span": [8, 11]}], "relation_list": [{"subject": "risperidone", "object": "hyperprolactinemia", "sbj_char_span": [45, 56], "obj_char_span": [116, 134], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [24, 28]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: This is the first study to link risperidone-induced hyperprolactinemia and SSRI treatment to lower BMD in children and adolescents.", "entity_list": [{"name": "hyperprolactinemia", "ent_type": "Disease", "char_span": [65, 83], "ent_id": "D006966", "tok_span": [14, 18]}, {"name": "risperidone", "ent_type": "Chemical", "char_span": [45, 56], "ent_id": "D018967", "tok_span": [9, 12]}], "relation_list": [{"subject": "risperidone", "object": "hyperprolactinemia", "sbj_char_span": [45, 56], "obj_char_span": [65, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [14, 18]}], "umls_entity_list": []}, {"text": "Seizures associated with levofloxacin: case presentation and literature review.", "entity_list": [{"name": "Seizures", "ent_type": "Disease", "char_span": [0, 8], "ent_id": "D012640", "tok_span": [0, 3]}, {"name": "levofloxacin", "ent_type": "Chemical", "char_span": [25, 37], "ent_id": "D064704", "tok_span": [5, 8]}], "relation_list": [{"subject": "levofloxacin", "object": "Seizures", "sbj_char_span": [25, 37], "obj_char_span": [0, 8], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "PURPOSE: We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-induced seizures.", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [54, 62], "ent_id": "D012640", "tok_span": [11, 12]}, {"name": "levofloxacin", "ent_type": "Chemical", "char_span": [267, 279], "ent_id": "D064704", "tok_span": [55, 58]}, {"name": "levofloxacin", "ent_type": "Chemical", "char_span": [103, 115], "ent_id": "D064704", "tok_span": [17, 20]}, {"name": "seizures", "ent_type": "Disease", "char_span": [288, 296], "ent_id": "D012640", "tok_span": [60, 61]}], "relation_list": [{"subject": "levofloxacin", "object": "seizures", "sbj_char_span": [103, 115], "obj_char_span": [54, 62], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [11, 12]}, {"subject": "levofloxacin", "object": "seizures", "sbj_char_span": [267, 279], "obj_char_span": [54, 62], "rel_type": "chemical-induced disease", "sbj_tok_span": [55, 58], "obj_tok_span": [11, 12]}, {"subject": "levofloxacin", "object": "seizures", "sbj_char_span": [103, 115], "obj_char_span": [288, 296], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [60, 61]}, {"subject": "levofloxacin", "object": "seizures", "sbj_char_span": [267, 279], "obj_char_span": [288, 296], "rel_type": "chemical-induced disease", "sbj_tok_span": [55, 58], "obj_tok_span": [60, 61]}], "umls_entity_list": []}, {"text": "RESULTS: Six cases of levofloxacin-induced seizures have been reported in the literature.", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [43, 51], "ent_id": "D012640", "tok_span": [10, 11]}, {"name": "levofloxacin", "ent_type": "Chemical", "char_span": [22, 34], "ent_id": "D064704", "tok_span": [5, 8]}], "relation_list": [{"subject": "levofloxacin", "object": "seizures", "sbj_char_span": [22, 34], "obj_char_span": [43, 51], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [10, 11]}], "umls_entity_list": []}, {"text": "A 2-wk administration of LiCl (4 mmol.kg(-1).day(-1) ip) in mPGES-1 +/+ mice led to a marked polyuria with hyposmotic urine.", "entity_list": [{"name": "polyuria", "ent_type": "Disease", "char_span": [93, 101], "ent_id": "D011141", "tok_span": [39, 41]}, {"name": "LiCl", "ent_type": "Chemical", "char_span": [25, 29], "ent_id": "D018021", "tok_span": [6, 8]}], "relation_list": [{"subject": "LiCl", "object": "polyuria", "sbj_char_span": [25, 29], "obj_char_span": [93, 101], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [39, 41]}], "umls_entity_list": []}, {"text": "Recently, a number of commercial lots of heparin products were found to be contaminated with an oversulfated chondroitin sulfate (OSCS) derivative that could elicit a hypotensive response in pigs following a single high-dose infusion.", "entity_list": [{"name": "hypotensive", "ent_type": "Disease", "char_span": [167, 178], "ent_id": "D007022", "tok_span": [33, 35]}, {"name": "chondroitin sulfate", "ent_type": "Chemical", "char_span": [109, 128], "ent_id": "D002809", "tok_span": [20, 24]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [41, 48], "ent_id": "D006493", "tok_span": [8, 9]}], "relation_list": [{"subject": "chondroitin sulfate", "object": "hypotensive", "sbj_char_span": [109, 128], "obj_char_span": [167, 178], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 24], "obj_tok_span": [33, 35]}], "umls_entity_list": []}, {"text": "Doxorubicin cardiomyopathy-induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor.", "entity_list": [{"name": "Doxorubicin", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D004317", "tok_span": [0, 3]}, {"name": "inflammation", "ent_type": "Disease", "char_span": [35, 47], "ent_id": "D007249", "tok_span": [6, 7]}, {"name": "cardiomyopathy", "ent_type": "Disease", "char_span": [12, 26], "ent_id": "D009202", "tok_span": [3, 4]}], "relation_list": [{"subject": "Doxorubicin", "object": "cardiomyopathy", "sbj_char_span": [0, 11], "obj_char_span": [12, 26], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [3, 4]}], "umls_entity_list": []}, {"text": "To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.", "entity_list": [{"name": "inflammation", "ent_type": "Disease", "char_span": [173, 185], "ent_id": "D007249", "tok_span": [44, 45]}, {"name": "DOX", "ent_type": "Chemical", "char_span": [219, 222], "ent_id": "D004317", "tok_span": [50, 51]}, {"name": "DOX", "ent_type": "Chemical", "char_span": [88, 91], "ent_id": "D004317", "tok_span": [21, 22]}, {"name": "cardiomyopathy", "ent_type": "Disease", "char_span": [92, 106], "ent_id": "D009202", "tok_span": [22, 23]}, {"name": "cardiomyopathy", "ent_type": "Disease", "char_span": [231, 245], "ent_id": "D009202", "tok_span": [53, 54]}], "relation_list": [{"subject": "DOX", "object": "cardiomyopathy", "sbj_char_span": [219, 222], "obj_char_span": [231, 245], "rel_type": "chemical-induced disease", "sbj_tok_span": [50, 51], "obj_tok_span": [53, 54]}, {"subject": "DOX", "object": "cardiomyopathy", "sbj_char_span": [219, 222], "obj_char_span": [92, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [50, 51], "obj_tok_span": [22, 23]}, {"subject": "DOX", "object": "cardiomyopathy", "sbj_char_span": [88, 91], "obj_char_span": [92, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 22], "obj_tok_span": [22, 23]}, {"subject": "DOX", "object": "cardiomyopathy", "sbj_char_span": [88, 91], "obj_char_span": [231, 245], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 22], "obj_tok_span": [53, 54]}], "umls_entity_list": []}, {"text": "These findings suggest that B1R is detrimental in DOX cardiomyopathy in that it mediates the inflammatory response and apoptosis.", "entity_list": [{"name": "DOX", "ent_type": "Chemical", "char_span": [50, 53], "ent_id": "D004317", "tok_span": [10, 11]}, {"name": "cardiomyopathy", "ent_type": "Disease", "char_span": [54, 68], "ent_id": "D009202", "tok_span": [11, 12]}], "relation_list": [{"subject": "DOX", "object": "cardiomyopathy", "sbj_char_span": [50, 53], "obj_char_span": [54, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [11, 12]}], "umls_entity_list": []}, {"text": "These insights might have useful implications for future studies utilizing B1R antagonists for treatment of human DOX cardiomyopathy.", "entity_list": [{"name": "DOX", "ent_type": "Chemical", "char_span": [114, 117], "ent_id": "D004317", "tok_span": [18, 19]}, {"name": "cardiomyopathy", "ent_type": "Disease", "char_span": [118, 132], "ent_id": "D009202", "tok_span": [19, 20]}], "relation_list": [{"subject": "DOX", "object": "cardiomyopathy", "sbj_char_span": [114, 117], "obj_char_span": [118, 132], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [19, 20]}], "umls_entity_list": []}, {"text": "Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events.", "entity_list": [{"name": "arthritis", "ent_type": "Disease", "char_span": [61, 70], "ent_id": "D001168", "tok_span": [9, 10]}, {"name": "sulfasalazine", "ent_type": "Chemical", "char_span": [31, 44], "ent_id": "D012460", "tok_span": [4, 7]}, {"name": "Hepatotoxicity", "ent_type": "Disease", "char_span": [0, 14], "ent_id": "D056486", "tok_span": [0, 2]}], "relation_list": [{"subject": "sulfasalazine", "object": "Hepatotoxicity", "sbj_char_span": [31, 44], "obj_char_span": [0, 14], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Patients', who had hepatotoxicity on sulfasalazine and met a definition of a serious ADR, were identified.", "entity_list": [{"name": "sulfasalazine", "ent_type": "Chemical", "char_span": [37, 50], "ent_id": "D012460", "tok_span": [8, 11]}, {"name": "hepatotoxicity", "ent_type": "Disease", "char_span": [19, 33], "ent_id": "D056486", "tok_span": [5, 7]}], "relation_list": [{"subject": "sulfasalazine", "object": "hepatotoxicity", "sbj_char_span": [37, 50], "obj_char_span": [19, 33], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "The likely frequency of hepatotoxicity with sulfasalazine was estimated by making a series of conservative assumptions.", "entity_list": [{"name": "sulfasalazine", "ent_type": "Chemical", "char_span": [44, 57], "ent_id": "D012460", "tok_span": [7, 10]}, {"name": "hepatotoxicity", "ent_type": "Disease", "char_span": [24, 38], "ent_id": "D056486", "tok_span": [4, 6]}], "relation_list": [{"subject": "sulfasalazine", "object": "hepatotoxicity", "sbj_char_span": [44, 57], "obj_char_span": [24, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "The likely frequency of serious hepatotoxicity with sulfasalazine was estimated at 0.4% of treated patients.", "entity_list": [{"name": "sulfasalazine", "ent_type": "Chemical", "char_span": [52, 65], "ent_id": "D012460", "tok_span": [8, 11]}, {"name": "hepatotoxicity", "ent_type": "Disease", "char_span": [32, 46], "ent_id": "D056486", "tok_span": [5, 7]}], "relation_list": [{"subject": "sulfasalazine", "object": "hepatotoxicity", "sbj_char_span": [52, 65], "obj_char_span": [32, 46], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "CONCLUSION: Serious hepatotoxicity associated with sulfasalazine appears to be under-appreciated and intensive monitoring and vigilance in the first 6 weeks of treatment is especially important.", "entity_list": [{"name": "sulfasalazine", "ent_type": "Chemical", "char_span": [51, 64], "ent_id": "D012460", "tok_span": [8, 11]}, {"name": "hepatotoxicity", "ent_type": "Disease", "char_span": [20, 34], "ent_id": "D056486", "tok_span": [4, 6]}], "relation_list": [{"subject": "sulfasalazine", "object": "hepatotoxicity", "sbj_char_span": [51, 64], "obj_char_span": [20, 34], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "An evaluation of amikacin nephrotoxicity in the hematology/oncology population.", "entity_list": [{"name": "amikacin", "ent_type": "Chemical", "char_span": [17, 25], "ent_id": "D000583", "tok_span": [3, 6]}, {"name": "nephrotoxicity", "ent_type": "Disease", "char_span": [26, 40], "ent_id": "D007674", "tok_span": [6, 9]}], "relation_list": [{"subject": "amikacin", "object": "nephrotoxicity", "sbj_char_span": [17, 25], "obj_char_span": [26, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [6, 9]}], "umls_entity_list": []}, {"text": "To evaluate amikacin-associated nephrotoxicity in an adult hematology/oncology population, a prospective, randomized, open-label trial was conducted at a university-affiliated medical center.", "entity_list": [{"name": "nephrotoxicity", "ent_type": "Disease", "char_span": [32, 46], "ent_id": "D007674", "tok_span": [7, 10]}, {"name": "amikacin", "ent_type": "Chemical", "char_span": [12, 20], "ent_id": "D000583", "tok_span": [2, 5]}], "relation_list": [{"subject": "amikacin", "object": "nephrotoxicity", "sbj_char_span": [12, 20], "obj_char_span": [32, 46], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "The occurrence of nephrotoxicity by means of an increase in serum creatinine and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed.", "entity_list": [{"name": "nephrotoxicity", "ent_type": "Disease", "char_span": [18, 32], "ent_id": "D007674", "tok_span": [3, 6]}, {"name": "amikacin", "ent_type": "Chemical", "char_span": [108, 116], "ent_id": "D000583", "tok_span": [19, 22]}, {"name": "creatinine", "ent_type": "Chemical", "char_span": [66, 76], "ent_id": "D003404", "tok_span": [13, 14]}], "relation_list": [{"subject": "amikacin", "object": "nephrotoxicity", "sbj_char_span": [108, 116], "obj_char_span": [18, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 22], "obj_tok_span": [3, 6]}], "umls_entity_list": []}, {"text": "In contrast, no evidence of memory impairment was observed in moderate MDMA users.", "entity_list": [{"name": "MDMA", "ent_type": "Chemical", "char_span": [71, 75], "ent_id": "D018817", "tok_span": [12, 14]}, {"name": "memory impairment", "ent_type": "Disease", "char_span": [28, 45], "ent_id": "D008569", "tok_span": [6, 8]}], "relation_list": [{"subject": "MDMA", "object": "memory impairment", "sbj_char_span": [71, 75], "obj_char_span": [28, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 14], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "While the use of MDMA in quantities that may be considered \"moderate\" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.", "entity_list": [{"name": "MDMA", "ent_type": "Chemical", "char_span": [17, 21], "ent_id": "D018817", "tok_span": [4, 6]}, {"name": "MDMA", "ent_type": "Chemical", "char_span": [135, 139], "ent_id": "D018817", "tok_span": [26, 28]}, {"name": "memory impairments", "ent_type": "Disease", "char_span": [169, 187], "ent_id": "D008569", "tok_span": [34, 36]}, {"name": "impaired memory functioning", "ent_type": "Disease", "char_span": [93, 120], "ent_id": "D008569", "tok_span": [19, 22]}], "relation_list": [{"subject": "MDMA", "object": "memory impairments", "sbj_char_span": [135, 139], "obj_char_span": [169, 187], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 28], "obj_tok_span": [34, 36]}, {"subject": "MDMA", "object": "impaired memory functioning", "sbj_char_span": [17, 21], "obj_char_span": [93, 120], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 6], "obj_tok_span": [19, 22]}, {"subject": "MDMA", "object": "memory impairments", "sbj_char_span": [17, 21], "obj_char_span": [169, 187], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 6], "obj_tok_span": [34, 36]}, {"subject": "MDMA", "object": "impaired memory functioning", "sbj_char_span": [135, 139], "obj_char_span": [93, 120], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 28], "obj_tok_span": [19, 22]}], "umls_entity_list": []}, {"text": "Aging process of epithelial cells of the rat prostate lateral lobe in experimental hyperprolactinemia induced by haloperidol.", "entity_list": [{"name": "haloperidol", "ent_type": "Chemical", "char_span": [113, 124], "ent_id": "D006220", "tok_span": [19, 22]}, {"name": "hyperprolactinemia", "ent_type": "Disease", "char_span": [83, 101], "ent_id": "D006966", "tok_span": [13, 17]}], "relation_list": [{"subject": "haloperidol", "object": "hyperprolactinemia", "sbj_char_span": [113, 124], "obj_char_span": [83, 101], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 22], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "The aim of the study was to examine the influence of hyperprolactinemia, induced by haloperidol (HAL) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe.", "entity_list": [{"name": "haloperidol", "ent_type": "Chemical", "char_span": [84, 95], "ent_id": "D006220", "tok_span": [18, 21]}, {"name": "HAL", "ent_type": "Chemical", "char_span": [97, 100], "ent_id": "D006220", "tok_span": [22, 24]}, {"name": "hyperprolactinemia", "ent_type": "Disease", "char_span": [53, 71], "ent_id": "D006966", "tok_span": [11, 15]}], "relation_list": [{"subject": "haloperidol", "object": "hyperprolactinemia", "sbj_char_span": [84, 95], "obj_char_span": [53, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [11, 15]}, {"subject": "HAL", "object": "hyperprolactinemia", "sbj_char_span": [97, 100], "obj_char_span": [53, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 24], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?", "entity_list": [{"name": "vitamin C", "ent_type": "Chemical", "char_span": [18, 27], "ent_id": "D001205", "tok_span": [2, 4]}, {"name": "diabetes", "ent_type": "Disease", "char_span": [79, 87], "ent_id": "D003920", "tok_span": [11, 12]}, {"name": "cardiovascular disease", "ent_type": "Disease", "char_span": [37, 59], "ent_id": "D002318", "tok_span": [5, 7]}], "relation_list": [{"subject": "vitamin C", "object": "cardiovascular disease", "sbj_char_span": [18, 27], "obj_char_span": [37, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 4], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "OBJECTIVE: The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease.", "entity_list": [{"name": "cardiovascular disease", "ent_type": "Disease", "char_span": [97, 119], "ent_id": "D002318", "tok_span": [16, 18]}, {"name": "vitamin C", "ent_type": "Chemical", "char_span": [61, 70], "ent_id": "D001205", "tok_span": [10, 12]}], "relation_list": [{"subject": "vitamin C", "object": "cardiovascular disease", "sbj_char_span": [61, 70], "obj_char_span": [97, 119], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 12], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.", "entity_list": [{"name": "diabetic", "ent_type": "Disease", "char_span": [219, 227], "ent_id": "D003920", "tok_span": [47, 48]}, {"name": "cardiovascular disease", "ent_type": "Disease", "char_span": [82, 104], "ent_id": "D002318", "tok_span": [14, 16]}, {"name": "stroke", "ent_type": "Disease", "char_span": [155, 161], "ent_id": "D020521", "tok_span": [33, 34]}, {"name": "coronary artery disease", "ent_type": "Disease", "char_span": [116, 139], "ent_id": "D003324", "tok_span": [23, 26]}, {"name": "vitamin C", "ent_type": "Chemical", "char_span": [40, 49], "ent_id": "D001205", "tok_span": [7, 9]}], "relation_list": [{"subject": "vitamin C", "object": "cardiovascular disease", "sbj_char_span": [40, 49], "obj_char_span": [82, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 9], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.", "entity_list": [{"name": "beta-carotene", "ent_type": "Chemical", "char_span": [161, 174], "ent_id": "D019207", "tok_span": [29, 33]}, {"name": "cardiovascular disease", "ent_type": "Disease", "char_span": [213, 235], "ent_id": "D002318", "tok_span": [40, 42]}, {"name": "diabetes", "ent_type": "Disease", "char_span": [75, 83], "ent_id": "D003920", "tok_span": [12, 13]}, {"name": "vitamin C", "ent_type": "Chemical", "char_span": [330, 339], "ent_id": "D001205", "tok_span": [78, 80]}, {"name": "vitamin E", "ent_type": "Chemical", "char_span": [146, 155], "ent_id": "D014810", "tok_span": [25, 27]}, {"name": "cardiovascular disease", "ent_type": "Disease", "char_span": [30, 52], "ent_id": "D002318", "tok_span": [5, 7]}, {"name": "folate", "ent_type": "Chemical", "char_span": [138, 144], "ent_id": "D005492", "tok_span": [23, 24]}, {"name": "diabetes", "ent_type": "Disease", "char_span": [113, 121], "ent_id": "D003920", "tok_span": [18, 19]}], "relation_list": [{"subject": "vitamin C", "object": "cardiovascular disease", "sbj_char_span": [330, 339], "obj_char_span": [213, 235], "rel_type": "chemical-induced disease", "sbj_tok_span": [78, 80], "obj_tok_span": [40, 42]}, {"subject": "vitamin C", "object": "cardiovascular disease", "sbj_char_span": [330, 339], "obj_char_span": [30, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [78, 80], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "Vitamin C intake was unrelated to mortality from cardiovascular disease in the nondiabetic subjects at baseline.", "entity_list": [{"name": "cardiovascular disease", "ent_type": "Disease", "char_span": [49, 71], "ent_id": "D002318", "tok_span": [8, 10]}, {"name": "Vitamin C", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D001205", "tok_span": [0, 2]}], "relation_list": [{"subject": "Vitamin C", "object": "cardiovascular disease", "sbj_char_span": [0, 9], "obj_char_span": [49, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "CONCLUSION: A high vitamin C intake from supplements is associated with an increased risk of cardiovascular disease mortality in postmenopausal women with diabetes.", "entity_list": [{"name": "vitamin C", "ent_type": "Chemical", "char_span": [19, 28], "ent_id": "D001205", "tok_span": [4, 6]}, {"name": "cardiovascular disease", "ent_type": "Disease", "char_span": [93, 115], "ent_id": "D002318", "tok_span": [16, 18]}, {"name": "diabetes", "ent_type": "Disease", "char_span": [155, 163], "ent_id": "D003920", "tok_span": [23, 24]}], "relation_list": [{"subject": "vitamin C", "object": "cardiovascular disease", "sbj_char_span": [19, 28], "obj_char_span": [93, 115], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 6], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).", "entity_list": [{"name": "ethinylestradiol", "ent_type": "Chemical", "char_span": [118, 134], "ent_id": "D004997", "tok_span": [24, 30]}, {"name": "COCs", "ent_type": "Chemical", "char_span": [194, 198], "ent_id": "D003277", "tok_span": [46, 48]}, {"name": "CPA", "ent_type": "Chemical", "char_span": [136, 139], "ent_id": "D017373", "tok_span": [31, 33]}, {"name": "combined oral contraceptives", "ent_type": "Chemical", "char_span": [164, 192], "ent_id": "D003277", "tok_span": [41, 45]}, {"name": "VTE", "ent_type": "Disease", "char_span": [73, 76], "ent_id": "D054556", "tok_span": [12, 14]}, {"name": "cyproterone acetate", "ent_type": "Chemical", "char_span": [93, 112], "ent_id": "D017373", "tok_span": [18, 23]}, {"name": "EE", "ent_type": "Chemical", "char_span": [140, 142], "ent_id": "D004997", "tok_span": [34, 35]}, {"name": "venous thromboembolism", "ent_type": "Disease", "char_span": [49, 71], "ent_id": "D054556", "tok_span": [8, 11]}], "relation_list": [{"subject": "combined oral contraceptives", "object": "VTE", "sbj_char_span": [164, 192], "obj_char_span": [73, 76], "rel_type": "chemical-induced disease", "sbj_tok_span": [41, 45], "obj_tok_span": [12, 14]}, {"subject": "COCs", "object": "venous thromboembolism", "sbj_char_span": [194, 198], "obj_char_span": [49, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [46, 48], "obj_tok_span": [8, 11]}, {"subject": "combined oral contraceptives", "object": "venous thromboembolism", "sbj_char_span": [164, 192], "obj_char_span": [49, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [41, 45], "obj_tok_span": [8, 11]}, {"subject": "COCs", "object": "VTE", "sbj_char_span": [194, 198], "obj_char_span": [73, 76], "rel_type": "chemical-induced disease", "sbj_tok_span": [46, 48], "obj_tok_span": [12, 14]}], "umls_entity_list": []}, {"text": "RESULTS: During the time frame of the study, 330 women were found to have had VTE while on COCs.", "entity_list": [{"name": "COCs", "ent_type": "Chemical", "char_span": [91, 95], "ent_id": "D003277", "tok_span": [21, 23]}, {"name": "VTE", "ent_type": "Disease", "char_span": [78, 81], "ent_id": "D054556", "tok_span": [17, 19]}], "relation_list": [{"subject": "COCs", "object": "VTE", "sbj_char_span": [91, 95], "obj_char_span": [78, 81], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 23], "obj_tok_span": [17, 19]}], "umls_entity_list": []}, {"text": "The corresponding absolute risk of VTE was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/EE.", "entity_list": [{"name": "COCs", "ent_type": "Chemical", "char_span": [106, 110], "ent_id": "D003277", "tok_span": [31, 33]}, {"name": "COCs", "ent_type": "Chemical", "char_span": [197, 201], "ent_id": "D003277", "tok_span": [63, 65]}, {"name": "levonorgestrel", "ent_type": "Chemical", "char_span": [171, 185], "ent_id": "D016912", "tok_span": [56, 61]}, {"name": "EE", "ent_type": "Chemical", "char_span": [274, 276], "ent_id": "D004997", "tok_span": [93, 94]}, {"name": "VTE", "ent_type": "Disease", "char_span": [35, 38], "ent_id": "D054556", "tok_span": [5, 7]}, {"name": "CPA", "ent_type": "Chemical", "char_span": [270, 273], "ent_id": "D017373", "tok_span": [90, 92]}], "relation_list": [{"subject": "COCs", "object": "VTE", "sbj_char_span": [106, 110], "obj_char_span": [35, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 33], "obj_tok_span": [5, 7]}, {"subject": "COCs", "object": "VTE", "sbj_char_span": [197, 201], "obj_char_span": [35, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [63, 65], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "CONCLUSION: Our results suggest the absolute risk of VTE among Danish women on COCs is similar to that among women taking CPA/EE.", "entity_list": [{"name": "CPA", "ent_type": "Chemical", "char_span": [122, 125], "ent_id": "D017373", "tok_span": [24, 26]}, {"name": "EE", "ent_type": "Chemical", "char_span": [126, 128], "ent_id": "D004997", "tok_span": [27, 28]}, {"name": "COCs", "ent_type": "Chemical", "char_span": [79, 83], "ent_id": "D003277", "tok_span": [15, 17]}, {"name": "VTE", "ent_type": "Disease", "char_span": [53, 56], "ent_id": "D054556", "tok_span": [9, 11]}], "relation_list": [{"subject": "COCs", "object": "VTE", "sbj_char_span": [79, 83], "obj_char_span": [53, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 17], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.", "entity_list": [{"name": "convulsions", "ent_type": "Disease", "char_span": [193, 204], "ent_id": "D012640", "tok_span": [47, 50]}, {"name": "phenobarbital", "ent_type": "Chemical", "char_span": [224, 237], "ent_id": "D010634", "tok_span": [53, 55]}, {"name": "lindane", "ent_type": "Chemical", "char_span": [368, 375], "ent_id": "D001556", "tok_span": [93, 96]}, {"name": "3-methylcholanthrene", "ent_type": "Chemical", "char_span": [64, 84], "ent_id": "D008748", "tok_span": [9, 15]}, {"name": "ethanol", "ent_type": "Chemical", "char_span": [274, 281], "ent_id": "D000431", "tok_span": [73, 74]}, {"name": "MC", "ent_type": "Chemical", "char_span": [86, 88], "ent_id": "D008748", "tok_span": [16, 17]}, {"name": "convulsions", "ent_type": "Disease", "char_span": [384, 395], "ent_id": "D012640", "tok_span": [97, 100]}, {"name": "lindane", "ent_type": "Chemical", "char_span": [177, 184], "ent_id": "D001556", "tok_span": [43, 46]}], "relation_list": [{"subject": "lindane", "object": "convulsions", "sbj_char_span": [368, 375], "obj_char_span": [384, 395], "rel_type": "chemical-induced disease", "sbj_tok_span": [93, 96], "obj_tok_span": [97, 100]}, {"subject": "lindane", "object": "convulsions", "sbj_char_span": [177, 184], "obj_char_span": [384, 395], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 46], "obj_tok_span": [97, 100]}, {"subject": "lindane", "object": "convulsions", "sbj_char_span": [177, 184], "obj_char_span": [193, 204], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 46], "obj_tok_span": [47, 50]}, {"subject": "lindane", "object": "convulsions", "sbj_char_span": [368, 375], "obj_char_span": [193, 204], "rel_type": "chemical-induced disease", "sbj_tok_span": [93, 96], "obj_tok_span": [47, 50]}], "umls_entity_list": []}, {"text": "Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.", "entity_list": [{"name": "ethanol", "ent_type": "Chemical", "char_span": [224, 231], "ent_id": "D000431", "tok_span": [46, 47]}, {"name": "lindane", "ent_type": "Chemical", "char_span": [174, 181], "ent_id": "D001556", "tok_span": [34, 37]}, {"name": "lindane", "ent_type": "Chemical", "char_span": [150, 157], "ent_id": "D001556", "tok_span": [29, 32]}, {"name": "convulsions", "ent_type": "Disease", "char_span": [100, 111], "ent_id": "D012640", "tok_span": [20, 23]}, {"name": "toxicity", "ent_type": "Disease", "char_span": [294, 302], "ent_id": "D064420", "tok_span": [61, 62]}, {"name": "lindane", "ent_type": "Chemical", "char_span": [48, 55], "ent_id": "D001556", "tok_span": [10, 13]}, {"name": "cobalt chloride", "ent_type": "Chemical", "char_span": [71, 86], "ent_id": "C018021", "tok_span": [16, 18]}], "relation_list": [{"subject": "lindane", "object": "convulsions", "sbj_char_span": [48, 55], "obj_char_span": [100, 111], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [20, 23]}, {"subject": "lindane", "object": "convulsions", "sbj_char_span": [150, 157], "obj_char_span": [100, 111], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 32], "obj_tok_span": [20, 23]}, {"subject": "lindane", "object": "convulsions", "sbj_char_span": [174, 181], "obj_char_span": [100, 111], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 37], "obj_tok_span": [20, 23]}], "umls_entity_list": []}, {"text": "Seizure associated with sleep deprivation and sustained-release bupropion.", "entity_list": [{"name": "Seizure", "ent_type": "Disease", "char_span": [0, 7], "ent_id": "D012640", "tok_span": [0, 3]}, {"name": "bupropion", "ent_type": "Chemical", "char_span": [64, 73], "ent_id": "D016642", "tok_span": [11, 14]}, {"name": "sleep deprivation", "ent_type": "Disease", "char_span": [24, 41], "ent_id": "D012892", "tok_span": [5, 7]}], "relation_list": [{"subject": "bupropion", "object": "Seizure", "sbj_char_span": [64, 73], "obj_char_span": [0, 7], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "This case report describes a generalized seizure associated with sustained-release bupropion use and sleep deprivation.", "entity_list": [{"name": "seizure", "ent_type": "Disease", "char_span": [41, 48], "ent_id": "D012640", "tok_span": [6, 7]}, {"name": "sleep deprivation", "ent_type": "Disease", "char_span": [101, 118], "ent_id": "D012892", "tok_span": [17, 19]}, {"name": "bupropion", "ent_type": "Chemical", "char_span": [83, 92], "ent_id": "D016642", "tok_span": [12, 15]}], "relation_list": [{"subject": "bupropion", "object": "seizure", "sbj_char_span": [83, 92], "obj_char_span": [41, 48], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [6, 7]}], "umls_entity_list": []}, {"text": "After 5 weeks of bupropion use, the subject experienced a generalized tonic clonic seizure after staying up nearly all night packing and moving to a new residence.", "entity_list": [{"name": "bupropion", "ent_type": "Chemical", "char_span": [17, 26], "ent_id": "D016642", "tok_span": [4, 7]}, {"name": "seizure", "ent_type": "Disease", "char_span": [83, 90], "ent_id": "D012640", "tok_span": [17, 18]}], "relation_list": [{"subject": "bupropion", "object": "seizure", "sbj_char_span": [17, 26], "obj_char_span": [83, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [17, 18]}], "umls_entity_list": []}, {"text": "We suggest that sleep deprivation may add to the risk of bupropion-associated seizures.", "entity_list": [{"name": "bupropion", "ent_type": "Chemical", "char_span": [57, 66], "ent_id": "D016642", "tok_span": [11, 14]}, {"name": "sleep deprivation", "ent_type": "Disease", "char_span": [16, 33], "ent_id": "D012892", "tok_span": [3, 5]}, {"name": "seizures", "ent_type": "Disease", "char_span": [78, 86], "ent_id": "D012640", "tok_span": [16, 17]}], "relation_list": [{"subject": "bupropion", "object": "seizures", "sbj_char_span": [57, 66], "obj_char_span": [78, 86], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [16, 17]}], "umls_entity_list": []}, {"text": "METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.", "entity_list": [{"name": "nephrotoxic", "ent_type": "Disease", "char_span": [95, 106], "ent_id": "D007674", "tok_span": [17, 20]}, {"name": "iohexol", "ent_type": "Chemical", "char_span": [246, 253], "ent_id": "D007472", "tok_span": [56, 59]}, {"name": "iodixanol", "ent_type": "Chemical", "char_span": [169, 178], "ent_id": "C044834", "tok_span": [36, 39]}], "relation_list": [{"subject": "iohexol", "object": "nephrotoxic", "sbj_char_span": [246, 253], "obj_char_span": [95, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [56, 59], "obj_tok_span": [17, 20]}], "umls_entity_list": []}, {"text": "Experimental cranial pain elicited by capsaicin: a PET study.", "entity_list": [{"name": "capsaicin", "ent_type": "Chemical", "char_span": [38, 47], "ent_id": "D002211", "tok_span": [5, 8]}, {"name": "pain", "ent_type": "Disease", "char_span": [21, 25], "ent_id": "D010146", "tok_span": [2, 3]}], "relation_list": [{"subject": "capsaicin", "object": "pain", "sbj_char_span": [38, 47], "obj_char_span": [21, 25], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [2, 3]}], "umls_entity_list": []}, {"text": "A small amount of capsaicin was administered subcutaneously in the right forehead to evoke a burning painful sensation in the first division of the trigeminal nerve.", "entity_list": [{"name": "capsaicin", "ent_type": "Chemical", "char_span": [18, 27], "ent_id": "D002211", "tok_span": [4, 7]}, {"name": "painful", "ent_type": "Disease", "char_span": [101, 108], "ent_id": "D010146", "tok_span": [21, 22]}], "relation_list": [{"subject": "capsaicin", "object": "painful", "sbj_char_span": [18, 27], "obj_char_span": [101, 108], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [21, 22]}], "umls_entity_list": []}, {"text": "Neuroleptic malignant syndrome with risperidone.", "entity_list": [{"name": "risperidone", "ent_type": "Chemical", "char_span": [36, 47], "ent_id": "D018967", "tok_span": [5, 8]}, {"name": "Neuroleptic malignant syndrome", "ent_type": "Disease", "char_span": [0, 30], "ent_id": "D009459", "tok_span": [0, 4]}], "relation_list": [{"subject": "risperidone", "object": "Neuroleptic malignant syndrome", "sbj_char_span": [36, 47], "obj_char_span": [0, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "A 73-year-old woman developed neuroleptic malignant syndrome after monotherapy with risperidone.", "entity_list": [{"name": "risperidone", "ent_type": "Chemical", "char_span": [84, 95], "ent_id": "D018967", "tok_span": [17, 20]}, {"name": "neuroleptic malignant syndrome", "ent_type": "Disease", "char_span": [30, 60], "ent_id": "D009459", "tok_span": [8, 14]}], "relation_list": [{"subject": "risperidone", "object": "neuroleptic malignant syndrome", "sbj_char_span": [84, 95], "obj_char_span": [30, 60], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [8, 14]}], "umls_entity_list": []}, {"text": "It appears that the protection from extrapyramidal side effects observed with risperidone does not ensure protection from neuroleptic malignant syndrome.", "entity_list": [{"name": "risperidone", "ent_type": "Chemical", "char_span": [78, 89], "ent_id": "D018967", "tok_span": [14, 17]}, {"name": "neuroleptic malignant syndrome", "ent_type": "Disease", "char_span": [122, 152], "ent_id": "D009459", "tok_span": [22, 28]}], "relation_list": [{"subject": "risperidone", "object": "neuroleptic malignant syndrome", "sbj_char_span": [78, 89], "obj_char_span": [122, 152], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [22, 28]}], "umls_entity_list": []}, {"text": "NS was induced by a single injection of puromycin amino-nucleoside (PAN).", "entity_list": [{"name": "NS", "ent_type": "Disease", "char_span": [0, 2], "ent_id": "D009404", "tok_span": [0, 1]}, {"name": "puromycin amino-nucleoside", "ent_type": "Chemical", "char_span": [40, 66], "ent_id": "D011692", "tok_span": [8, 14]}, {"name": "PAN", "ent_type": "Chemical", "char_span": [68, 71], "ent_id": "D011692", "tok_span": [15, 16]}], "relation_list": [{"subject": "puromycin amino-nucleoside", "object": "NS", "sbj_char_span": [40, 66], "obj_char_span": [0, 2], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 14], "obj_tok_span": [0, 1]}, {"subject": "PAN", "object": "NS", "sbj_char_span": [68, 71], "obj_char_span": [0, 2], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 16], "obj_tok_span": [0, 1]}], "umls_entity_list": []}, {"text": "Although a great urinary excretion and half-normal plasma levels of Ao were observed on day 6 after PAN injection, when NS was clearly established, hepatic Ao mRNA levels did not change.", "entity_list": [{"name": "PAN", "ent_type": "Chemical", "char_span": [100, 103], "ent_id": "D011692", "tok_span": [20, 21]}, {"name": "NS", "ent_type": "Disease", "char_span": [120, 122], "ent_id": "D009404", "tok_span": [24, 25]}], "relation_list": [{"subject": "PAN", "object": "NS", "sbj_char_span": [100, 103], "obj_char_span": [120, 122], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 21], "obj_tok_span": [24, 25]}], "umls_entity_list": []}, {"text": "These data suggest that the hepatic and extrahepatic Ao mRNA levels are unaltered during the development of the acute NS induced by PAN.", "entity_list": [{"name": "PAN", "ent_type": "Chemical", "char_span": [132, 135], "ent_id": "D011692", "tok_span": [26, 27]}, {"name": "NS", "ent_type": "Disease", "char_span": [118, 120], "ent_id": "D009404", "tok_span": [23, 24]}], "relation_list": [{"subject": "PAN", "object": "NS", "sbj_char_span": [132, 135], "obj_char_span": [118, 120], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 27], "obj_tok_span": [23, 24]}], "umls_entity_list": []}, {"text": "Cyclophosphamide associated bladder cancer--a highly aggressive disease: analysis of 12 cases.", "entity_list": [{"name": "bladder cancer", "ent_type": "Disease", "char_span": [28, 42], "ent_id": "D001749", "tok_span": [3, 5]}, {"name": "Cyclophosphamide", "ent_type": "Chemical", "char_span": [0, 16], "ent_id": "D003520", "tok_span": [0, 2]}], "relation_list": [{"subject": "Cyclophosphamide", "object": "bladder cancer", "sbj_char_span": [0, 16], "obj_char_span": [28, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "MATERIALS AND METHODS: The medical records of 6 men and 6 women (mean age 55 years) with cyclophosphamide associated bladder cancer were reviewed.", "entity_list": [{"name": "bladder cancer", "ent_type": "Disease", "char_span": [117, 131], "ent_id": "D001749", "tok_span": [24, 26]}, {"name": "cyclophosphamide", "ent_type": "Chemical", "char_span": [89, 105], "ent_id": "D003520", "tok_span": [20, 23]}], "relation_list": [{"subject": "cyclophosphamide", "object": "bladder cancer", "sbj_char_span": [89, 105], "obj_char_span": [117, 131], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [24, 26]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Cyclophosphamide associated bladder tumor is an aggressive disease.", "entity_list": [{"name": "Cyclophosphamide", "ent_type": "Chemical", "char_span": [13, 29], "ent_id": "D003520", "tok_span": [2, 4]}, {"name": "bladder tumor", "ent_type": "Disease", "char_span": [41, 54], "ent_id": "D001749", "tok_span": [5, 7]}], "relation_list": [{"subject": "Cyclophosphamide", "object": "bladder tumor", "sbj_char_span": [13, 29], "obj_char_span": [41, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 4], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "Leg and back pain after spinal anaesthesia involving hyperbaric 5% lignocaine.", "entity_list": [{"name": "lignocaine", "ent_type": "Chemical", "char_span": [67, 77], "ent_id": "D008012", "tok_span": [13, 15]}, {"name": "Leg and back pain", "ent_type": "Disease", "char_span": [0, 17], "ent_id": "D001416", "tok_span": [0, 4]}], "relation_list": [{"subject": "lignocaine", "object": "Leg and back pain", "sbj_char_span": [67, 77], "obj_char_span": [0, 17], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "Leg and/or back pain is associated with the intrathecal use of hyperbaric 5% lignocaine.", "entity_list": [{"name": "lignocaine", "ent_type": "Chemical", "char_span": [77, 87], "ent_id": "D008012", "tok_span": [20, 22]}, {"name": "Leg and/or back pain", "ent_type": "Disease", "char_span": [0, 20], "ent_id": "D001416", "tok_span": [0, 6]}], "relation_list": [{"subject": "lignocaine", "object": "Leg and/or back pain", "sbj_char_span": [77, 87], "obj_char_span": [0, 20], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 22], "obj_tok_span": [0, 6]}], "umls_entity_list": []}, {"text": "Acute blood pressure elevations with caffeine in men with borderline systemic hypertension.", "entity_list": [{"name": "hypertension", "ent_type": "Disease", "char_span": [78, 90], "ent_id": "D006973", "tok_span": [11, 12]}, {"name": "caffeine", "ent_type": "Chemical", "char_span": [37, 45], "ent_id": "D002110", "tok_span": [5, 6]}], "relation_list": [{"subject": "caffeine", "object": "hypertension", "sbj_char_span": [37, 45], "obj_char_span": [78, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 6], "obj_tok_span": [11, 12]}], "umls_entity_list": []}, {"text": "Whether the vasoconstrictive actions of caffeine are enhanced in hypertensive persons has not been demonstrated.", "entity_list": [{"name": "hypertensive", "ent_type": "Disease", "char_span": [65, 77], "ent_id": "D006973", "tok_span": [11, 12]}, {"name": "caffeine", "ent_type": "Chemical", "char_span": [40, 48], "ent_id": "D002110", "tok_span": [7, 8]}], "relation_list": [{"subject": "caffeine", "object": "hypertensive", "sbj_char_span": [40, 48], "obj_char_span": [65, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [11, 12]}], "umls_entity_list": []}, {"text": "Consequently, whereas all participants exhibited normotensive levels during the resting predrug baseline, 33% of borderline subjects achieved hypertensive BP levels after caffeine ingestion.", "entity_list": [{"name": "caffeine", "ent_type": "Chemical", "char_span": [171, 179], "ent_id": "D002110", "tok_span": [29, 30]}, {"name": "hypertensive", "ent_type": "Disease", "char_span": [142, 154], "ent_id": "D006973", "tok_span": [25, 26]}], "relation_list": [{"subject": "caffeine", "object": "hypertensive", "sbj_char_span": [171, 179], "obj_char_span": [142, 154], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 30], "obj_tok_span": [25, 26]}], "umls_entity_list": []}, {"text": "Thus, in borderline hypertensive men, exaggerated responses to caffeine were: selective for diastolic BP, consistent with greater vasoconstriction, replicated in 2 protocols, and representative of nearly all borderline hypertensives.", "entity_list": [{"name": "caffeine", "ent_type": "Chemical", "char_span": [63, 71], "ent_id": "D002110", "tok_span": [11, 12]}, {"name": "hypertensive", "ent_type": "Disease", "char_span": [20, 32], "ent_id": "D006973", "tok_span": [4, 5]}, {"name": "hypertensives", "ent_type": "Disease", "char_span": [219, 232], "ent_id": "D006973", "tok_span": [36, 38]}], "relation_list": [{"subject": "caffeine", "object": "hypertensives", "sbj_char_span": [63, 71], "obj_char_span": [219, 232], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [36, 38]}, {"subject": "caffeine", "object": "hypertensive", "sbj_char_span": [63, 71], "obj_char_span": [20, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [4, 5]}], "umls_entity_list": []}, {"text": "Hallucinations and ifosfamide-induced neurotoxicity.", "entity_list": [{"name": "ifosfamide", "ent_type": "Chemical", "char_span": [19, 29], "ent_id": "D007069", "tok_span": [4, 9]}, {"name": "Hallucinations", "ent_type": "Disease", "char_span": [0, 14], "ent_id": "D006212", "tok_span": [0, 3]}, {"name": "neurotoxicity", "ent_type": "Disease", "char_span": [38, 51], "ent_id": "D020258", "tok_span": [11, 13]}], "relation_list": [{"subject": "ifosfamide", "object": "Hallucinations", "sbj_char_span": [19, 29], "obj_char_span": [0, 14], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 9], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "BACKGROUND: Hallucinations as a symptom of central neurotoxicity are a known but poorly described side effect of ifosfamide.", "entity_list": [{"name": "ifosfamide", "ent_type": "Chemical", "char_span": [113, 123], "ent_id": "D007069", "tok_span": [21, 26]}, {"name": "Hallucinations", "ent_type": "Disease", "char_span": [12, 26], "ent_id": "D006212", "tok_span": [2, 5]}, {"name": "neurotoxicity", "ent_type": "Disease", "char_span": [51, 64], "ent_id": "D020258", "tok_span": [10, 12]}], "relation_list": [{"subject": "ifosfamide", "object": "Hallucinations", "sbj_char_span": [113, 123], "obj_char_span": [12, 26], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 26], "obj_tok_span": [2, 5]}], "umls_entity_list": []}, {"text": "Most cases of ifosfamide-induced hallucinations have been reported with other mental status changes.", "entity_list": [{"name": "ifosfamide", "ent_type": "Chemical", "char_span": [14, 24], "ent_id": "D007069", "tok_span": [3, 8]}, {"name": "hallucinations", "ent_type": "Disease", "char_span": [33, 47], "ent_id": "D006212", "tok_span": [10, 13]}], "relation_list": [{"subject": "ifosfamide", "object": "hallucinations", "sbj_char_span": [14, 24], "obj_char_span": [33, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 8], "obj_tok_span": [10, 13]}], "umls_entity_list": []}, {"text": "METHODS: The authors interviewed six persons with ifosfamide-induced hallucinations in the presence of a clear sensorium.", "entity_list": [{"name": "ifosfamide", "ent_type": "Chemical", "char_span": [50, 60], "ent_id": "D007069", "tok_span": [8, 13]}, {"name": "hallucinations", "ent_type": "Disease", "char_span": [69, 83], "ent_id": "D006212", "tok_span": [15, 18]}], "relation_list": [{"subject": "ifosfamide", "object": "hallucinations", "sbj_char_span": [50, 60], "obj_char_span": [69, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 13], "obj_tok_span": [15, 18]}], "umls_entity_list": []}, {"text": "The clinician should be alerted for possible ifosfamide-induced hallucinations, which may occur without other signs of neurotoxicity. \"Eyes-closed\" hallucinatory experiences appear to be an unusual feature of this presentation.", "entity_list": [{"name": "neurotoxicity", "ent_type": "Disease", "char_span": [119, 132], "ent_id": "D020258", "tok_span": [26, 28]}, {"name": "ifosfamide", "ent_type": "Chemical", "char_span": [45, 55], "ent_id": "D007069", "tok_span": [8, 13]}, {"name": "hallucinations", "ent_type": "Disease", "char_span": [64, 78], "ent_id": "D006212", "tok_span": [15, 18]}, {"name": "hallucinatory", "ent_type": "Disease", "char_span": [148, 161], "ent_id": "D006212", "tok_span": [35, 39]}], "relation_list": [{"subject": "ifosfamide", "object": "hallucinatory", "sbj_char_span": [45, 55], "obj_char_span": [148, 161], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 13], "obj_tok_span": [35, 39]}, {"subject": "ifosfamide", "object": "hallucinations", "sbj_char_span": [45, 55], "obj_char_span": [64, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 13], "obj_tok_span": [15, 18]}], "umls_entity_list": []}, {"text": "Chlorpropamide-induced optic neuropathy.", "entity_list": [{"name": "Chlorpropamide", "ent_type": "Chemical", "char_span": [0, 14], "ent_id": "D002747", "tok_span": [0, 3]}, {"name": "optic neuropathy", "ent_type": "Disease", "char_span": [23, 39], "ent_id": "D009901", "tok_span": [5, 7]}], "relation_list": [{"subject": "Chlorpropamide", "object": "optic neuropathy", "sbj_char_span": [0, 14], "obj_char_span": [23, 39], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.", "entity_list": [{"name": "chlorpropamide", "ent_type": "Chemical", "char_span": [59, 73], "ent_id": "D002747", "tok_span": [14, 17]}, {"name": "toxic optic neuropathy", "ent_type": "Disease", "char_span": [92, 114], "ent_id": "D009901", "tok_span": [24, 27]}, {"name": "Diabenese", "ent_type": "Chemical", "char_span": [75, 84], "ent_id": "D002747", "tok_span": [18, 21]}, {"name": "adult-onset diabetes", "ent_type": "Disease", "char_span": [25, 45], "ent_id": "D003924", "tok_span": [8, 12]}, {"name": "chlorpropamide", "ent_type": "Chemical", "char_span": [153, 167], "ent_id": "D002747", "tok_span": [32, 35]}], "relation_list": [{"subject": "chlorpropamide", "object": "toxic optic neuropathy", "sbj_char_span": [59, 73], "obj_char_span": [92, 114], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [24, 27]}, {"subject": "Diabenese", "object": "toxic optic neuropathy", "sbj_char_span": [75, 84], "obj_char_span": [92, 114], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [24, 27]}, {"subject": "chlorpropamide", "object": "toxic optic neuropathy", "sbj_char_span": [153, 167], "obj_char_span": [92, 114], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 35], "obj_tok_span": [24, 27]}], "umls_entity_list": []}, {"text": "Levodopa-induced dyskinesia and thalamotomy.", "entity_list": [{"name": "Levodopa", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D007980", "tok_span": [0, 3]}, {"name": "dyskinesia", "ent_type": "Disease", "char_span": [17, 27], "ent_id": "D004409", "tok_span": [5, 9]}], "relation_list": [{"subject": "Levodopa", "object": "dyskinesia", "sbj_char_span": [0, 8], "obj_char_span": [17, 27], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "Levodopa-induced dyskinesia of the limbs in thirteen cases of Parkinsonism, which was choreic, ballistic or dystonic in type, was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus, but much less by the ventralis intermedius nucleus.", "entity_list": [{"name": "Levodopa", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D007980", "tok_span": [0, 3]}, {"name": "dystonic", "ent_type": "Disease", "char_span": [108, 116], "ent_id": "D020821", "tok_span": [30, 32]}, {"name": "dyskinesia", "ent_type": "Disease", "char_span": [17, 27], "ent_id": "D004409", "tok_span": [5, 9]}, {"name": "Parkinsonism", "ent_type": "Disease", "char_span": [62, 74], "ent_id": "D010302", "tok_span": [18, 20]}], "relation_list": [{"subject": "Levodopa", "object": "dyskinesia", "sbj_char_span": [0, 8], "obj_char_span": [17, 27], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "Control of levodopa-induced dyskinesias by thalamic lesions in the course of routine treatment of Parkinsonism is discussed.", "entity_list": [{"name": "Parkinsonism", "ent_type": "Disease", "char_span": [98, 110], "ent_id": "D010302", "tok_span": [22, 24]}, {"name": "dyskinesias", "ent_type": "Disease", "char_span": [28, 39], "ent_id": "D004409", "tok_span": [7, 11]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [11, 19], "ent_id": "D007980", "tok_span": [2, 5]}, {"name": "thalamic lesions", "ent_type": "Disease", "char_span": [43, 59], "ent_id": "D013786", "tok_span": [12, 15]}], "relation_list": [{"subject": "levodopa", "object": "dyskinesias", "sbj_char_span": [11, 19], "obj_char_span": [28, 39], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "Factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin.", "entity_list": [{"name": "nephrotoxicity", "ent_type": "Disease", "char_span": [24, 38], "ent_id": "D007674", "tok_span": [3, 6]}, {"name": "amikacin", "ent_type": "Chemical", "char_span": [82, 90], "ent_id": "D000583", "tok_span": [12, 15]}], "relation_list": [{"subject": "amikacin", "object": "nephrotoxicity", "sbj_char_span": [82, 90], "obj_char_span": [24, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [3, 6]}], "umls_entity_list": []}, {"text": "Data from 60 patients treated with amikacin were analyzed for factors associated with nephrotoxicity.", "entity_list": [{"name": "nephrotoxicity", "ent_type": "Disease", "char_span": [86, 100], "ent_id": "D007674", "tok_span": [15, 18]}, {"name": "amikacin", "ent_type": "Chemical", "char_span": [35, 43], "ent_id": "D000583", "tok_span": [6, 9]}], "relation_list": [{"subject": "amikacin", "object": "nephrotoxicity", "sbj_char_span": [35, 43], "obj_char_span": [86, 100], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [15, 18]}], "umls_entity_list": []}, {"text": "Group II also showed a significant decrease of chronic nephrotoxicity secondary to long-term therapy with cyclosporine.", "entity_list": [{"name": "cyclosporine", "ent_type": "Chemical", "char_span": [106, 118], "ent_id": "D016572", "tok_span": [19, 21]}, {"name": "nephrotoxicity", "ent_type": "Disease", "char_span": [55, 69], "ent_id": "D007674", "tok_span": [9, 12]}], "relation_list": [{"subject": "cyclosporine", "object": "nephrotoxicity", "sbj_char_span": [106, 118], "obj_char_span": [55, 69], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 21], "obj_tok_span": [9, 12]}], "umls_entity_list": []}, {"text": "We think that even these lower dosages of cyclosporine can cause chronic nephrotoxicity and that further modification of the immunosuppressive regimen is required to completely abolish this toxic side effect.", "entity_list": [{"name": "cyclosporine", "ent_type": "Chemical", "char_span": [42, 54], "ent_id": "D016572", "tok_span": [9, 11]}, {"name": "nephrotoxicity", "ent_type": "Disease", "char_span": [73, 87], "ent_id": "D007674", "tok_span": [14, 17]}], "relation_list": [{"subject": "cyclosporine", "object": "nephrotoxicity", "sbj_char_span": [42, 54], "obj_char_span": [73, 87], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 11], "obj_tok_span": [14, 17]}], "umls_entity_list": []}, {"text": "Reversible cholestasis with bile duct injury following azathioprine therapy.", "entity_list": [{"name": "azathioprine", "ent_type": "Chemical", "char_span": [55, 67], "ent_id": "D001379", "tok_span": [10, 14]}, {"name": "cholestasis", "ent_type": "Disease", "char_span": [11, 22], "ent_id": "D002779", "tok_span": [2, 5]}, {"name": "bile duct injury", "ent_type": "Disease", "char_span": [28, 44], "ent_id": "D002779", "tok_span": [6, 9]}], "relation_list": [{"subject": "azathioprine", "object": "bile duct injury", "sbj_char_span": [55, 67], "obj_char_span": [28, 44], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [6, 9]}, {"subject": "azathioprine", "object": "cholestasis", "sbj_char_span": [55, 67], "obj_char_span": [11, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [2, 5]}], "umls_entity_list": []}, {"text": "A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy.", "entity_list": [{"name": "cholestasis", "ent_type": "Disease", "char_span": [151, 162], "ent_id": "D002779", "tok_span": [29, 32]}, {"name": "polymyositis", "ent_type": "Disease", "char_span": [36, 48], "ent_id": "D017285", "tok_span": [10, 14]}, {"name": "liver disease", "ent_type": "Disease", "char_span": [82, 95], "ent_id": "D008107", "tok_span": [19, 21]}, {"name": "azathioprine", "ent_type": "Chemical", "char_span": [192, 204], "ent_id": "D001379", "tok_span": [37, 41]}], "relation_list": [{"subject": "azathioprine", "object": "cholestasis", "sbj_char_span": [192, 204], "obj_char_span": [151, 162], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 41], "obj_tok_span": [29, 32]}], "umls_entity_list": []}, {"text": "It is believed that this is the first reported case of reversible azathioprine-induced cholestasis associated with histological evidence of bile duct injury.", "entity_list": [{"name": "azathioprine", "ent_type": "Chemical", "char_span": [66, 78], "ent_id": "D001379", "tok_span": [12, 16]}, {"name": "bile duct injury", "ent_type": "Disease", "char_span": [140, 156], "ent_id": "D002779", "tok_span": [26, 29]}, {"name": "cholestasis", "ent_type": "Disease", "char_span": [87, 98], "ent_id": "D002779", "tok_span": [18, 21]}], "relation_list": [{"subject": "azathioprine", "object": "bile duct injury", "sbj_char_span": [66, 78], "obj_char_span": [140, 156], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 16], "obj_tok_span": [26, 29]}, {"subject": "azathioprine", "object": "cholestasis", "sbj_char_span": [66, 78], "obj_char_span": [87, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 16], "obj_tok_span": [18, 21]}], "umls_entity_list": []}, {"text": "Renal function and hemodynamics during prolonged isoflurane-induced hypotension in humans.", "entity_list": [{"name": "hypotension", "ent_type": "Disease", "char_span": [68, 79], "ent_id": "D007022", "tok_span": [11, 12]}, {"name": "isoflurane", "ent_type": "Chemical", "char_span": [49, 59], "ent_id": "D007530", "tok_span": [7, 9]}], "relation_list": [{"subject": "isoflurane", "object": "hypotension", "sbj_char_span": [49, 59], "obj_char_span": [68, 79], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 9], "obj_tok_span": [11, 12]}], "umls_entity_list": []}, {"text": "The effect of isoflurane-induced hypotension on glomerular function and renal blood flow was investigated in 20 human subjects.", "entity_list": [{"name": "hypotension", "ent_type": "Disease", "char_span": [33, 44], "ent_id": "D007022", "tok_span": [7, 8]}, {"name": "isoflurane", "ent_type": "Chemical", "char_span": [14, 24], "ent_id": "D007530", "tok_span": [3, 5]}], "relation_list": [{"subject": "isoflurane", "object": "hypotension", "sbj_char_span": [14, 24], "obj_char_span": [33, 44], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 5], "obj_tok_span": [7, 8]}], "umls_entity_list": []}, {"text": "Hypotension was induced for 236.9 +/- 15.1 min by increasing the isoflurane inspired concentration to maintain a mean arterial pressure of 59.8 +/- 0.4 mmHg.", "entity_list": [{"name": "isoflurane", "ent_type": "Chemical", "char_span": [65, 75], "ent_id": "D007530", "tok_span": [19, 21]}, {"name": "Hypotension", "ent_type": "Disease", "char_span": [0, 11], "ent_id": "D007022", "tok_span": [0, 2]}], "relation_list": [{"subject": "isoflurane", "object": "Hypotension", "sbj_char_span": [65, 75], "obj_char_span": [0, 11], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 21], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "We conclude that renal compensatory mechanisms are preserved during isoflurane-induced hypotension and that renal function and hemodynamics quickly return to normal when normotension is resumed.", "entity_list": [{"name": "hypotension", "ent_type": "Disease", "char_span": [87, 98], "ent_id": "D007022", "tok_span": [13, 14]}, {"name": "isoflurane", "ent_type": "Chemical", "char_span": [68, 78], "ent_id": "D007530", "tok_span": [9, 11]}], "relation_list": [{"subject": "isoflurane", "object": "hypotension", "sbj_char_span": [68, 78], "obj_char_span": [87, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 11], "obj_tok_span": [13, 14]}], "umls_entity_list": []}, {"text": "The drug effect studied was the antagonism by metoprolol of terbutaline-induced hypokalemia.", "entity_list": [{"name": "terbutaline", "ent_type": "Chemical", "char_span": [60, 71], "ent_id": "D013726", "tok_span": [13, 16]}, {"name": "metoprolol", "ent_type": "Chemical", "char_span": [46, 56], "ent_id": "D008790", "tok_span": [9, 12]}, {"name": "hypokalemia", "ent_type": "Disease", "char_span": [80, 91], "ent_id": "D007008", "tok_span": [18, 22]}], "relation_list": [{"subject": "terbutaline", "object": "hypokalemia", "sbj_char_span": [60, 71], "obj_char_span": [80, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [18, 22]}], "umls_entity_list": []}, {"text": "Cefotetan-induced immune hemolytic anemia.", "entity_list": [{"name": "hemolytic anemia", "ent_type": "Disease", "char_span": [25, 41], "ent_id": "D000743", "tok_span": [7, 10]}, {"name": "Cefotetan", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D015313", "tok_span": [0, 4]}], "relation_list": [{"subject": "Cefotetan", "object": "hemolytic anemia", "sbj_char_span": [0, 9], "obj_char_span": [25, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "Acute renal failure subsequent to the administration of rifampicin.", "entity_list": [{"name": "Acute renal failure", "ent_type": "Disease", "char_span": [0, 19], "ent_id": "D058186", "tok_span": [0, 3]}, {"name": "rifampicin", "ent_type": "Chemical", "char_span": [56, 66], "ent_id": "D012293", "tok_span": [8, 11]}], "relation_list": [{"subject": "rifampicin", "object": "Acute renal failure", "sbj_char_span": [56, 66], "obj_char_span": [0, 19], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "Serotonin syndrome from venlafaxine-tranylcypromine interaction.", "entity_list": [{"name": "venlafaxine", "ent_type": "Chemical", "char_span": [24, 35], "ent_id": "C047426", "tok_span": [5, 10]}, {"name": "Serotonin syndrome", "ent_type": "Disease", "char_span": [0, 18], "ent_id": "D020230", "tok_span": [0, 4]}, {"name": "tranylcypromine", "ent_type": "Chemical", "char_span": [36, 51], "ent_id": "D014191", "tok_span": [11, 16]}], "relation_list": [{"subject": "venlafaxine", "object": "Serotonin syndrome", "sbj_char_span": [24, 35], "obj_char_span": [0, 18], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 10], "obj_tok_span": [0, 4]}, {"subject": "tranylcypromine", "object": "Serotonin syndrome", "sbj_char_span": [36, 51], "obj_char_span": [0, 18], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 16], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.", "entity_list": [{"name": "depression", "ent_type": "Disease", "char_span": [135, 145], "ent_id": "D003866", "tok_span": [36, 37]}, {"name": "tranylcypromine", "ent_type": "Chemical", "char_span": [115, 130], "ent_id": "D014191", "tok_span": [30, 35]}, {"name": "venlafaxine", "ent_type": "Chemical", "char_span": [12, 23], "ent_id": "C047426", "tok_span": [3, 8]}, {"name": "serotonin syndrome", "ent_type": "Disease", "char_span": [62, 80], "ent_id": "D020230", "tok_span": [17, 19]}], "relation_list": [{"subject": "tranylcypromine", "object": "serotonin syndrome", "sbj_char_span": [115, 130], "obj_char_span": [62, 80], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 35], "obj_tok_span": [17, 19]}, {"subject": "venlafaxine", "object": "serotonin syndrome", "sbj_char_span": [12, 23], "obj_char_span": [62, 80], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 8], "obj_tok_span": [17, 19]}], "umls_entity_list": []}, {"text": "A group of four monkeys was rendered parkinsonian with the toxin MPTP.", "entity_list": [{"name": "MPTP", "ent_type": "Chemical", "char_span": [65, 69], "ent_id": "D015632", "tok_span": [13, 15]}, {"name": "parkinsonian", "ent_type": "Disease", "char_span": [37, 49], "ent_id": "D020734", "tok_span": [7, 10]}], "relation_list": [{"subject": "MPTP", "object": "parkinsonian", "sbj_char_span": [65, 69], "obj_char_span": [37, 49], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice.", "entity_list": [{"name": "pilocarpine", "ent_type": "Chemical", "char_span": [37, 48], "ent_id": "D010862", "tok_span": [5, 8]}, {"name": "steroids", "ent_type": "Chemical", "char_span": [12, 20], "ent_id": "D013256", "tok_span": [2, 3]}, {"name": "status epilepticus", "ent_type": "Disease", "char_span": [94, 112], "ent_id": "D013226", "tok_span": [20, 23]}, {"name": "kainic acid", "ent_type": "Chemical", "char_span": [54, 65], "ent_id": "D007608", "tok_span": [10, 14]}, {"name": "seizures", "ent_type": "Disease", "char_span": [81, 89], "ent_id": "D012640", "tok_span": [18, 19]}], "relation_list": [{"subject": "pilocarpine", "object": "seizures", "sbj_char_span": [37, 48], "obj_char_span": [81, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [18, 19]}, {"subject": "pilocarpine", "object": "status epilepticus", "sbj_char_span": [37, 48], "obj_char_span": [94, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [20, 23]}, {"subject": "kainic acid", "object": "seizures", "sbj_char_span": [54, 65], "obj_char_span": [81, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [18, 19]}, {"subject": "kainic acid", "object": "status epilepticus", "sbj_char_span": [54, 65], "obj_char_span": [94, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [20, 23]}], "umls_entity_list": []}, {"text": "Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.", "entity_list": [{"name": "pilocarpine", "ent_type": "Chemical", "char_span": [231, 242], "ent_id": "D010862", "tok_span": [55, 58]}, {"name": "progesterone", "ent_type": "Chemical", "char_span": [44, 56], "ent_id": "D011374", "tok_span": [5, 6]}, {"name": "N-methyl-D-aspartate", "ent_type": "Chemical", "char_span": [262, 282], "ent_id": "D016202", "tok_span": [66, 74]}, {"name": "kainic acid", "ent_type": "Chemical", "char_span": [245, 256], "ent_id": "D007608", "tok_span": [60, 64]}, {"name": "deoxycorticosterone", "ent_type": "Chemical", "char_span": [96, 115], "ent_id": "D003900", "tok_span": [19, 24]}, {"name": "NMDA", "ent_type": "Chemical", "char_span": [284, 288], "ent_id": "D016202", "tok_span": [75, 76]}, {"name": "3 alpha-hydroxy pregnane-20-ones", "ent_type": "Chemical", "char_span": [58, 90], "ent_id": "D011374", "tok_span": [7, 17]}, {"name": "3 alpha-hydroxy pregnane-21-diol-20-ones", "ent_type": "Chemical", "char_span": [117, 157], "ent_id": "D003900", "tok_span": [25, 40]}, {"name": "seizures", "ent_type": "Disease", "char_span": [298, 306], "ent_id": "D012640", "tok_span": [79, 80]}], "relation_list": [{"subject": "kainic acid", "object": "seizures", "sbj_char_span": [245, 256], "obj_char_span": [298, 306], "rel_type": "chemical-induced disease", "sbj_tok_span": [60, 64], "obj_tok_span": [79, 80]}, {"subject": "pilocarpine", "object": "seizures", "sbj_char_span": [231, 242], "obj_char_span": [298, 306], "rel_type": "chemical-induced disease", "sbj_tok_span": [55, 58], "obj_tok_span": [79, 80]}], "umls_entity_list": []}, {"text": "Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).", "entity_list": [{"name": "status epilepticus", "ent_type": "Disease", "char_span": [209, 227], "ent_id": "D013226", "tok_span": [53, 56]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [145, 156], "ent_id": "D010862", "tok_span": [31, 34]}, {"name": "seizures", "ent_type": "Disease", "char_span": [196, 204], "ent_id": "D012640", "tok_span": [51, 52]}, {"name": "Steroids", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D013256", "tok_span": [0, 2]}], "relation_list": [{"subject": "pilocarpine", "object": "seizures", "sbj_char_span": [145, 156], "obj_char_span": [196, 204], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 34], "obj_tok_span": [51, 52]}, {"subject": "pilocarpine", "object": "status epilepticus", "sbj_char_span": [145, 156], "obj_char_span": [209, 227], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 34], "obj_tok_span": [53, 56]}], "umls_entity_list": []}, {"text": "Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.", "entity_list": [{"name": "pilocarpine", "ent_type": "Chemical", "char_span": [121, 132], "ent_id": "D010862", "tok_span": [21, 24]}, {"name": "steroids", "ent_type": "Chemical", "char_span": [25, 33], "ent_id": "D013256", "tok_span": [4, 5]}, {"name": "seizure", "ent_type": "Disease", "char_span": [287, 294], "ent_id": "D012640", "tok_span": [54, 55]}, {"name": "clonazepam", "ent_type": "Chemical", "char_span": [312, 322], "ent_id": "D002998", "tok_span": [58, 61]}, {"name": "clonazepam", "ent_type": "Chemical", "char_span": [88, 98], "ent_id": "D002998", "tok_span": [15, 18]}, {"name": "steroids", "ent_type": "Chemical", "char_span": [357, 365], "ent_id": "D013256", "tok_span": [67, 68]}, {"name": "toxicity", "ent_type": "Disease", "char_span": [390, 398], "ent_id": "D064420", "tok_span": [72, 73]}, {"name": "seizures", "ent_type": "Disease", "char_span": [133, 141], "ent_id": "D012640", "tok_span": [24, 25]}, {"name": "benzodiazepine", "ent_type": "Chemical", "char_span": [73, 87], "ent_id": "D001569", "tok_span": [11, 15]}, {"name": "steroids", "ent_type": "Chemical", "char_span": [143, 151], "ent_id": "D013256", "tok_span": [26, 27]}], "relation_list": [{"subject": "pilocarpine", "object": "seizure", "sbj_char_span": [121, 132], "obj_char_span": [287, 294], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [54, 55]}, {"subject": "pilocarpine", "object": "seizures", "sbj_char_span": [121, 132], "obj_char_span": [133, 141], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [24, 25]}], "umls_entity_list": []}, {"text": "Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.", "entity_list": [{"name": "kainic acid", "ent_type": "Chemical", "char_span": [148, 159], "ent_id": "D007608", "tok_span": [34, 38]}, {"name": "seizures", "ent_type": "Disease", "char_span": [128, 136], "ent_id": "D012640", "tok_span": [31, 32]}, {"name": "seizures", "ent_type": "Disease", "char_span": [221, 229], "ent_id": "D012640", "tok_span": [57, 58]}, {"name": "Steroids", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D013256", "tok_span": [0, 2]}], "relation_list": [{"subject": "kainic acid", "object": "seizures", "sbj_char_span": [148, 159], "obj_char_span": [221, 229], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 38], "obj_tok_span": [57, 58]}, {"subject": "kainic acid", "object": "seizures", "sbj_char_span": [148, 159], "obj_char_span": [128, 136], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 38], "obj_tok_span": [31, 32]}], "umls_entity_list": []}, {"text": "However, when a second dose of the steroid was administered 1 hr after the first dose, complete protection from the kainic acid-induced limbic seizures and status epilepticus was obtained.", "entity_list": [{"name": "kainic acid", "ent_type": "Chemical", "char_span": [116, 127], "ent_id": "D007608", "tok_span": [22, 26]}, {"name": "status epilepticus", "ent_type": "Disease", "char_span": [156, 174], "ent_id": "D013226", "tok_span": [32, 35]}, {"name": "seizures", "ent_type": "Disease", "char_span": [143, 151], "ent_id": "D012640", "tok_span": [30, 31]}, {"name": "steroid", "ent_type": "Chemical", "char_span": [35, 42], "ent_id": "D013256", "tok_span": [8, 9]}], "relation_list": [{"subject": "kainic acid", "object": "status epilepticus", "sbj_char_span": [116, 127], "obj_char_span": [156, 174], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 26], "obj_tok_span": [32, 35]}, {"subject": "kainic acid", "object": "seizures", "sbj_char_span": [116, 127], "obj_char_span": [143, 151], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 26], "obj_tok_span": [30, 31]}], "umls_entity_list": []}, {"text": "We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.", "entity_list": [{"name": "steroids", "ent_type": "Chemical", "char_span": [29, 37], "ent_id": "D013256", "tok_span": [5, 6]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [81, 92], "ent_id": "D010862", "tok_span": [12, 15]}, {"name": "status epilepticus", "ent_type": "Disease", "char_span": [131, 149], "ent_id": "D013226", "tok_span": [25, 28]}, {"name": "seizures", "ent_type": "Disease", "char_span": [118, 126], "ent_id": "D012640", "tok_span": [23, 24]}, {"name": "status epilepticus", "ent_type": "Disease", "char_span": [215, 233], "ent_id": "D013226", "tok_span": [43, 46]}, {"name": "kainic acid", "ent_type": "Chemical", "char_span": [98, 109], "ent_id": "D007608", "tok_span": [17, 21]}], "relation_list": [{"subject": "kainic acid", "object": "status epilepticus", "sbj_char_span": [98, 109], "obj_char_span": [215, 233], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [43, 46]}, {"subject": "kainic acid", "object": "status epilepticus", "sbj_char_span": [98, 109], "obj_char_span": [131, 149], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [25, 28]}, {"subject": "pilocarpine", "object": "status epilepticus", "sbj_char_span": [81, 92], "obj_char_span": [131, 149], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [25, 28]}, {"subject": "pilocarpine", "object": "status epilepticus", "sbj_char_span": [81, 92], "obj_char_span": [215, 233], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [43, 46]}, {"subject": "kainic acid", "object": "seizures", "sbj_char_span": [98, 109], "obj_char_span": [118, 126], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [23, 24]}, {"subject": "pilocarpine", "object": "seizures", "sbj_char_span": [81, 92], "obj_char_span": [118, 126], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [23, 24]}], "umls_entity_list": []}, {"text": "In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.", "entity_list": [{"name": "fluphenazine enanthate", "ent_type": "Chemical", "char_span": [116, 138], "ent_id": "C017610", "tok_span": [25, 31]}, {"name": "ethopropazine", "ent_type": "Chemical", "char_span": [30, 43], "ent_id": "C084820", "tok_span": [7, 10]}, {"name": "parkinsonism", "ent_type": "Disease", "char_span": [92, 104], "ent_id": "D010302", "tok_span": [20, 23]}, {"name": "benztropine", "ent_type": "Chemical", "char_span": [60, 71], "ent_id": "D001590", "tok_span": [13, 16]}, {"name": "schizophrenic", "ent_type": "Disease", "char_span": [145, 158], "ent_id": "D012559", "tok_span": [33, 35]}], "relation_list": [{"subject": "fluphenazine enanthate", "object": "parkinsonism", "sbj_char_span": [116, 138], "obj_char_span": [92, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 31], "obj_tok_span": [20, 23]}], "umls_entity_list": []}, {"text": "However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.", "entity_list": [{"name": "tardive dyskinesia", "ent_type": "Disease", "char_span": [68, 86], "ent_id": "D004409", "tok_span": [12, 19]}, {"name": "ethopropazine", "ent_type": "Chemical", "char_span": [198, 211], "ent_id": "C084820", "tok_span": [37, 40]}, {"name": "depression", "ent_type": "Disease", "char_span": [182, 192], "ent_id": "D003866", "tok_span": [35, 36]}, {"name": "procyclindine", "ent_type": "Chemical", "char_span": [122, 135], "ent_id": "D011352", "tok_span": [24, 28]}, {"name": "anxiety", "ent_type": "Disease", "char_span": [170, 177], "ent_id": "D001008", "tok_span": [33, 34]}, {"name": "benztropine", "ent_type": "Chemical", "char_span": [9, 20], "ent_id": "D001590", "tok_span": [2, 5]}], "relation_list": [{"subject": "benztropine", "object": "anxiety", "sbj_char_span": [9, 20], "obj_char_span": [170, 177], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [33, 34]}, {"subject": "benztropine", "object": "tardive dyskinesia", "sbj_char_span": [9, 20], "obj_char_span": [68, 86], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [12, 19]}, {"subject": "benztropine", "object": "depression", "sbj_char_span": [9, 20], "obj_char_span": [182, 192], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [35, 36]}], "umls_entity_list": []}, {"text": "The concentrations of dopamine (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment. alpha-TC and DFO attenuated the MA-induced hyperthermia as well as the alterations in the locomotor activity.", "entity_list": [{"name": "alpha-TC", "ent_type": "Chemical", "char_span": [145, 153], "ent_id": "D024502", "tok_span": [23, 26]}, {"name": "DA", "ent_type": "Chemical", "char_span": [32, 34], "ent_id": "D004298", "tok_span": [5, 6]}, {"name": "alpha-TC", "ent_type": "Chemical", "char_span": [176, 184], "ent_id": "D024502", "tok_span": [31, 34]}, {"name": "MA", "ent_type": "Chemical", "char_span": [99, 101], "ent_id": "D008694", "tok_span": [15, 16]}, {"name": "serotonin", "ent_type": "Chemical", "char_span": [37, 46], "ent_id": "D012701", "tok_span": [8, 9]}, {"name": "MA", "ent_type": "Chemical", "char_span": [208, 210], "ent_id": "D008694", "tok_span": [39, 40]}, {"name": "hyperthermia", "ent_type": "Disease", "char_span": [219, 231], "ent_id": "D005334", "tok_span": [42, 45]}, {"name": "DFO", "ent_type": "Chemical", "char_span": [189, 192], "ent_id": "D003676", "tok_span": [35, 37]}, {"name": "dopamine", "ent_type": "Chemical", "char_span": [22, 30], "ent_id": "D004298", "tok_span": [3, 4]}, {"name": "DFO", "ent_type": "Chemical", "char_span": [158, 161], "ent_id": "D003676", "tok_span": [27, 29]}], "relation_list": [{"subject": "MA", "object": "hyperthermia", "sbj_char_span": [99, 101], "obj_char_span": [219, 231], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 16], "obj_tok_span": [42, 45]}, {"subject": "MA", "object": "hyperthermia", "sbj_char_span": [208, 210], "obj_char_span": [219, 231], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 40], "obj_tok_span": [42, 45]}], "umls_entity_list": []}, {"text": "This suggests that alpha-TC and DFO ameliorate the MA-induced neuronal damage by decreasing the level of oxidative stress.", "entity_list": [{"name": "MA", "ent_type": "Chemical", "char_span": [51, 53], "ent_id": "D008694", "tok_span": [12, 13]}, {"name": "alpha-TC", "ent_type": "Chemical", "char_span": [19, 27], "ent_id": "D024502", "tok_span": [3, 6]}, {"name": "neuronal damage", "ent_type": "Disease", "char_span": [62, 77], "ent_id": "D009422", "tok_span": [15, 17]}, {"name": "DFO", "ent_type": "Chemical", "char_span": [32, 35], "ent_id": "D003676", "tok_span": [7, 9]}], "relation_list": [{"subject": "MA", "object": "neuronal damage", "sbj_char_span": [51, 53], "obj_char_span": [62, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "Reserpine (1 mg/kg), administered once every other day for 4 days, produced increases in orofacial dyskinesia, tongue protrusion and vacuous chewing in mice, which are signs indicative of tardive dyskinesia.", "entity_list": [{"name": "Reserpine", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D012110", "tok_span": [0, 3]}, {"name": "orofacial dyskinesia", "ent_type": "Disease", "char_span": [89, 109], "ent_id": "D009069", "tok_span": [22, 28]}, {"name": "tardive dyskinesia", "ent_type": "Disease", "char_span": [188, 206], "ent_id": "D004409", "tok_span": [45, 52]}], "relation_list": [{"subject": "Reserpine", "object": "tardive dyskinesia", "sbj_char_span": [0, 9], "obj_char_span": [188, 206], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [45, 52]}], "umls_entity_list": []}, {"text": "Reserpine also produced tremor and catalepsy, which are signs suggestive of Parkinson's disease.", "entity_list": [{"name": "Reserpine", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D012110", "tok_span": [0, 3]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [35, 44], "ent_id": "D002375", "tok_span": [8, 11]}, {"name": "Parkinson's disease", "ent_type": "Disease", "char_span": [76, 95], "ent_id": "D010300", "tok_span": [17, 21]}, {"name": "tremor", "ent_type": "Disease", "char_span": [24, 30], "ent_id": "D014202", "tok_span": [5, 7]}], "relation_list": [{"subject": "Reserpine", "object": "catalepsy", "sbj_char_span": [0, 9], "obj_char_span": [35, 44], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [8, 11]}, {"subject": "Reserpine", "object": "tremor", "sbj_char_span": [0, 9], "obj_char_span": [24, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "MK-801 (0.1 mg/kg), administered 30 min before the observation test, prevented the vacuous chewing movements, tongue protrusions and catalepsy induced by reserpine.", "entity_list": [{"name": "catalepsy", "ent_type": "Disease", "char_span": [133, 142], "ent_id": "D002375", "tok_span": [33, 36]}, {"name": "MK-801", "ent_type": "Chemical", "char_span": [0, 6], "ent_id": "D016291", "tok_span": [0, 4]}, {"name": "reserpine", "ent_type": "Chemical", "char_span": [154, 163], "ent_id": "D012110", "tok_span": [38, 41]}], "relation_list": [{"subject": "reserpine", "object": "catalepsy", "sbj_char_span": [154, 163], "obj_char_span": [133, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [38, 41], "obj_tok_span": [33, 36]}], "umls_entity_list": []}, {"text": "However, MK-801 injection produced a significant increase of tremor in reserpine-treated mice.", "entity_list": [{"name": "MK-801", "ent_type": "Chemical", "char_span": [9, 15], "ent_id": "D016291", "tok_span": [2, 6]}, {"name": "tremor", "ent_type": "Disease", "char_span": [61, 67], "ent_id": "D014202", "tok_span": [12, 14]}, {"name": "reserpine", "ent_type": "Chemical", "char_span": [71, 80], "ent_id": "D012110", "tok_span": [15, 18]}], "relation_list": [{"subject": "reserpine", "object": "tremor", "sbj_char_span": [71, 80], "obj_char_span": [61, 67], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [12, 14]}], "umls_entity_list": []}, {"text": "On the other hand, reserpine induced increases in tremor and catalepsy compared to control mice.", "entity_list": [{"name": "reserpine", "ent_type": "Chemical", "char_span": [19, 28], "ent_id": "D012110", "tok_span": [5, 8]}, {"name": "tremor", "ent_type": "Disease", "char_span": [50, 56], "ent_id": "D014202", "tok_span": [11, 13]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [61, 70], "ent_id": "D002375", "tok_span": [14, 17]}], "relation_list": [{"subject": "reserpine", "object": "catalepsy", "sbj_char_span": [19, 28], "obj_char_span": [61, 70], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [14, 17]}, {"subject": "reserpine", "object": "tremor", "sbj_char_span": [19, 28], "obj_char_span": [50, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [11, 13]}], "umls_entity_list": []}, {"text": "MK-801 (0.1 mg/kg) administration attenuated the catalepsy and tremor induced by reserpine.", "entity_list": [{"name": "tremor", "ent_type": "Disease", "char_span": [63, 69], "ent_id": "D014202", "tok_span": [19, 21]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [49, 58], "ent_id": "D002375", "tok_span": [15, 18]}, {"name": "MK-801", "ent_type": "Chemical", "char_span": [0, 6], "ent_id": "D016291", "tok_span": [0, 4]}, {"name": "reserpine", "ent_type": "Chemical", "char_span": [81, 90], "ent_id": "D012110", "tok_span": [23, 26]}], "relation_list": [{"subject": "reserpine", "object": "catalepsy", "sbj_char_span": [81, 90], "obj_char_span": [49, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [15, 18]}, {"subject": "reserpine", "object": "tremor", "sbj_char_span": [81, 90], "obj_char_span": [63, 69], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [19, 21]}], "umls_entity_list": []}, {"text": "Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.", "entity_list": [{"name": "reserpine", "ent_type": "Chemical", "char_span": [272, 281], "ent_id": "D012110", "tok_span": [66, 69]}, {"name": "MK-801", "ent_type": "Chemical", "char_span": [196, 202], "ent_id": "D016291", "tok_span": [44, 48]}, {"name": "reserpine", "ent_type": "Chemical", "char_span": [18, 27], "ent_id": "D012110", "tok_span": [3, 6]}, {"name": "tremor", "ent_type": "Disease", "char_span": [166, 172], "ent_id": "D014202", "tok_span": [36, 38]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [177, 186], "ent_id": "D002375", "tok_span": [39, 42]}], "relation_list": [{"subject": "reserpine", "object": "catalepsy", "sbj_char_span": [18, 27], "obj_char_span": [177, 186], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [39, 42]}, {"subject": "reserpine", "object": "catalepsy", "sbj_char_span": [272, 281], "obj_char_span": [177, 186], "rel_type": "chemical-induced disease", "sbj_tok_span": [66, 69], "obj_tok_span": [39, 42]}, {"subject": "reserpine", "object": "tremor", "sbj_char_span": [18, 27], "obj_char_span": [166, 172], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [36, 38]}, {"subject": "reserpine", "object": "tremor", "sbj_char_span": [272, 281], "obj_char_span": [166, 172], "rel_type": "chemical-induced disease", "sbj_tok_span": [66, 69], "obj_tok_span": [36, 38]}], "umls_entity_list": []}, {"text": "These results show that reserpine produces different and abnormal movements, which are related to dose and schedule employed and can be considered as parkinsonian-like and tardive dsykinesia signs.", "entity_list": [{"name": "reserpine", "ent_type": "Chemical", "char_span": [24, 33], "ent_id": "D012110", "tok_span": [4, 7]}, {"name": "tardive dsykinesia", "ent_type": "Disease", "char_span": [172, 190], "ent_id": "D004409", "tok_span": [32, 39]}, {"name": "parkinsonian", "ent_type": "Disease", "char_span": [150, 162], "ent_id": "D010300", "tok_span": [26, 29]}, {"name": "abnormal movements", "ent_type": "Disease", "char_span": [57, 75], "ent_id": "D004409", "tok_span": [10, 12]}], "relation_list": [{"subject": "reserpine", "object": "abnormal movements", "sbj_char_span": [24, 33], "obj_char_span": [57, 75], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [10, 12]}, {"subject": "reserpine", "object": "tardive dsykinesia", "sbj_char_span": [24, 33], "obj_char_span": [172, 190], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [32, 39]}], "umls_entity_list": []}, {"text": "OBJECTIVE: In this study the effect of glyceryl trinitrate on the prostigmine-morphine-induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia.", "entity_list": [{"name": "sphincter of Oddi spasm", "ent_type": "Disease", "char_span": [95, 118], "ent_id": "D04662", "tok_span": [22, 29]}, {"name": "sphincter of Oddi dyskinesia", "ent_type": "Disease", "char_span": [162, 190], "ent_id": "D046628", "tok_span": [36, 45]}, {"name": "glyceryl trinitrate", "ent_type": "Chemical", "char_span": [39, 58], "ent_id": "D005996", "tok_span": [8, 13]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [78, 86], "ent_id": "D009020", "tok_span": [19, 20]}, {"name": "prostigmine", "ent_type": "Chemical", "char_span": [66, 77], "ent_id": "D009388", "tok_span": [15, 18]}], "relation_list": [{"subject": "morphine", "object": "sphincter of Oddi dyskinesia", "sbj_char_span": [78, 86], "obj_char_span": [162, 190], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 20], "obj_tok_span": [36, 45]}, {"subject": "prostigmine", "object": "sphincter of Oddi dyskinesia", "sbj_char_span": [66, 77], "obj_char_span": [162, 190], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [36, 45]}], "umls_entity_list": []}, {"text": "RESULTS: Prostigmine-morphine provocation caused significant increases in the time to peak activity (Tmax) over the hepatic hilum (HH: 34.33 +/- 5.05 vs. 22.77 +/- 3.26) and the common bile duct (CBD: 60.44 +/- 5.99 vs. 40.0 +/- 2.88) and in the half-time of excretion (T1/2) over the liver parenchyma (LP: 120.04 +/- 16.01 vs. 27.37 +/- 2.19), HH (117.61 +/- 14.71 vs. 31.85 +/- 3.99) and CBD (158.11 +/- 9.18 vs. 40.1 +/- 6.24), indicating a complete spasm at the level of the sphincter of Oddi.", "entity_list": [{"name": "Prostigmine", "ent_type": "Chemical", "char_span": [9, 20], "ent_id": "D009388", "tok_span": [2, 6]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [21, 29], "ent_id": "D009020", "tok_span": [7, 8]}, {"name": "spasm", "ent_type": "Disease", "char_span": [453, 458], "ent_id": "D013035", "tok_span": [178, 180]}], "relation_list": [{"subject": "morphine", "object": "spasm", "sbj_char_span": [21, 29], "obj_char_span": [453, 458], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [178, 180]}, {"subject": "Prostigmine", "object": "spasm", "sbj_char_span": [9, 20], "obj_char_span": [453, 458], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [178, 180]}], "umls_entity_list": []}, {"text": "Since glyceryl trinitrate is able to overcome even the drastic effect of morphine, it might be of relevance in the treatment of sphincter of Oddi dyskinesia.", "entity_list": [{"name": "morphine", "ent_type": "Chemical", "char_span": [73, 81], "ent_id": "D009020", "tok_span": [16, 17]}, {"name": "glyceryl trinitrate", "ent_type": "Chemical", "char_span": [6, 25], "ent_id": "D005996", "tok_span": [1, 6]}, {"name": "sphincter of Oddi dyskinesia", "ent_type": "Disease", "char_span": [128, 156], "ent_id": "D046628", "tok_span": [27, 36]}], "relation_list": [{"subject": "morphine", "object": "sphincter of Oddi dyskinesia", "sbj_char_span": [73, 81], "obj_char_span": [128, 156], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 17], "obj_tok_span": [27, 36]}], "umls_entity_list": []}, {"text": "Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), methylprednisolone (M), or triamcinolone (T) 80 mg/kg/d for 5 d. Nutritional intake, measured daily in 15 animals, showed a significant reduction of food intake in the steroid-treated groups (-50 and -79% in M and T, respectively).", "entity_list": [{"name": "T", "ent_type": "Chemical", "char_span": [131, 132], "ent_id": "D014221", "tok_span": [32, 33]}, {"name": "methylprednisolone", "ent_type": "Chemical", "char_span": [89, 107], "ent_id": "D008775", "tok_span": [18, 22]}, {"name": "steroid", "ent_type": "Chemical", "char_span": [257, 264], "ent_id": "D013256", "tok_span": [63, 64]}, {"name": "M", "ent_type": "Chemical", "char_span": [297, 298], "ent_id": "D008775", "tok_span": [75, 76]}, {"name": "reduction of food intake", "ent_type": "Disease", "char_span": [225, 249], "ent_id": "D000855", "tok_span": [57, 61]}, {"name": "M", "ent_type": "Chemical", "char_span": [109, 110], "ent_id": "D008775", "tok_span": [23, 24]}, {"name": "T", "ent_type": "Chemical", "char_span": [303, 304], "ent_id": "D014221", "tok_span": [77, 78]}, {"name": "triamcinolone", "ent_type": "Chemical", "char_span": [116, 129], "ent_id": "D014221", "tok_span": [27, 31]}], "relation_list": [{"subject": "M", "object": "reduction of food intake", "sbj_char_span": [109, 110], "obj_char_span": [225, 249], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 24], "obj_tok_span": [57, 61]}, {"subject": "T", "object": "reduction of food intake", "sbj_char_span": [131, 132], "obj_char_span": [225, 249], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 33], "obj_tok_span": [57, 61]}, {"subject": "M", "object": "reduction of food intake", "sbj_char_span": [297, 298], "obj_char_span": [225, 249], "rel_type": "chemical-induced disease", "sbj_tok_span": [75, 76], "obj_tok_span": [57, 61]}, {"subject": "methylprednisolone", "object": "reduction of food intake", "sbj_char_span": [89, 107], "obj_char_span": [225, 249], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 22], "obj_tok_span": [57, 61]}, {"subject": "triamcinolone", "object": "reduction of food intake", "sbj_char_span": [116, 129], "obj_char_span": [225, 249], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 31], "obj_tok_span": [57, 61]}, {"subject": "T", "object": "reduction of food intake", "sbj_char_span": [303, 304], "obj_char_span": [225, 249], "rel_type": "chemical-induced disease", "sbj_tok_span": [77, 78], "obj_tok_span": [57, 61]}], "umls_entity_list": []}, {"text": "ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with T, whereas histologic examinations revealed a normal muscular pattern with absence of necrosis.", "entity_list": [{"name": "atrophy", "ent_type": "Disease", "char_span": [153, 160], "ent_id": "D009133", "tok_span": [34, 35]}, {"name": "atrophy", "ent_type": "Disease", "char_span": [91, 98], "ent_id": "D009133", "tok_span": [22, 23]}, {"name": "necrosis", "ent_type": "Disease", "char_span": [252, 260], "ent_id": "D009336", "tok_span": [49, 50]}, {"name": "T", "ent_type": "Chemical", "char_span": [166, 167], "ent_id": "D014221", "tok_span": [36, 37]}, {"name": "steroid", "ent_type": "Chemical", "char_span": [106, 113], "ent_id": "D013256", "tok_span": [25, 26]}], "relation_list": [{"subject": "T", "object": "atrophy", "sbj_char_span": [166, 167], "obj_char_span": [91, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 37], "obj_tok_span": [22, 23]}, {"subject": "T", "object": "atrophy", "sbj_char_span": [166, 167], "obj_char_span": [153, 160], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 37], "obj_tok_span": [34, 35]}], "umls_entity_list": []}, {"text": "Finally, a pair-fed (PF) study, performed in 18 rats (C, T, and PF), showed that muscle atrophy was considerably less pronounced in PF animals than in T-treated animals.", "entity_list": [{"name": "muscle atrophy", "ent_type": "Disease", "char_span": [81, 95], "ent_id": "D009133", "tok_span": [26, 28]}, {"name": "T", "ent_type": "Chemical", "char_span": [151, 152], "ent_id": "D014221", "tok_span": [37, 38]}, {"name": "T", "ent_type": "Chemical", "char_span": [57, 58], "ent_id": "D014221", "tok_span": [18, 19]}], "relation_list": [{"subject": "T", "object": "muscle atrophy", "sbj_char_span": [151, 152], "obj_char_span": [81, 95], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 38], "obj_tok_span": [26, 28]}, {"subject": "T", "object": "muscle atrophy", "sbj_char_span": [57, 58], "obj_char_span": [81, 95], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [26, 28]}], "umls_entity_list": []}, {"text": "Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment.", "entity_list": [{"name": "cardiogenic shock", "ent_type": "Disease", "char_span": [11, 28], "ent_id": "D012770", "tok_span": [4, 7]}, {"name": "metoprolol", "ent_type": "Chemical", "char_span": [77, 87], "ent_id": "D008790", "tok_span": [17, 20]}, {"name": "heart block", "ent_type": "Disease", "char_span": [42, 53], "ent_id": "D006327", "tok_span": [9, 11]}, {"name": "verapamil", "ent_type": "Chemical", "char_span": [60, 69], "ent_id": "D014700", "tok_span": [12, 15]}], "relation_list": [{"subject": "metoprolol", "object": "heart block", "sbj_char_span": [77, 87], "obj_char_span": [42, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [9, 11]}, {"subject": "verapamil", "object": "heart block", "sbj_char_span": [60, 69], "obj_char_span": [42, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "A seventy-eight-year-old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained-release verapamil with concomitant use of metoprolol.", "entity_list": [{"name": "verapamil", "ent_type": "Chemical", "char_span": [149, 158], "ent_id": "D014700", "tok_span": [28, 31]}, {"name": "metoprolol", "ent_type": "Chemical", "char_span": [183, 193], "ent_id": "D008790", "tok_span": [35, 38]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [82, 93], "ent_id": "D007022", "tok_span": [17, 18]}, {"name": "heart block", "ent_type": "Disease", "char_span": [55, 66], "ent_id": "D006327", "tok_span": [13, 15]}], "relation_list": [{"subject": "verapamil", "object": "hypotension", "sbj_char_span": [149, 158], "obj_char_span": [82, 93], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 31], "obj_tok_span": [17, 18]}, {"subject": "verapamil", "object": "heart block", "sbj_char_span": [149, 158], "obj_char_span": [55, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 31], "obj_tok_span": [13, 15]}, {"subject": "metoprolol", "object": "hypotension", "sbj_char_span": [183, 193], "obj_char_span": [82, 93], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 38], "obj_tok_span": [17, 18]}, {"subject": "metoprolol", "object": "heart block", "sbj_char_span": [183, 193], "obj_char_span": [55, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 38], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.", "entity_list": [{"name": "hyperalgesia", "ent_type": "Disease", "char_span": [141, 153], "ent_id": "D006930", "tok_span": [29, 33]}, {"name": "prostaglandin E2", "ent_type": "Chemical", "char_span": [116, 132], "ent_id": "D015232", "tok_span": [24, 27]}], "relation_list": [{"subject": "prostaglandin E2", "object": "hyperalgesia", "sbj_char_span": [116, 132], "obj_char_span": [141, 153], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 27], "obj_tok_span": [29, 33]}], "umls_entity_list": []}, {"text": "Morphine did not, however, alter the hyperalgesia induced by 8-bromo cyclic adenosine monophosphate.", "entity_list": [{"name": "hyperalgesia", "ent_type": "Disease", "char_span": [37, 49], "ent_id": "D006930", "tok_span": [9, 13]}, {"name": "8-bromo cyclic adenosine monophosphate", "ent_type": "Chemical", "char_span": [61, 99], "ent_id": "D015124", "tok_span": [15, 26]}, {"name": "Morphine", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D009020", "tok_span": [0, 2]}], "relation_list": [{"subject": "8-bromo cyclic adenosine monophosphate", "object": "hyperalgesia", "sbj_char_span": [61, 99], "obj_char_span": [37, 49], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 26], "obj_tok_span": [9, 13]}], "umls_entity_list": []}, {"text": "Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.\n BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.", "entity_list": [{"name": "chronic hepatitis C", "ent_type": "Disease", "char_span": [125, 144], "ent_id": "D019698", "tok_span": [24, 27]}, {"name": "interferon", "ent_type": "Chemical", "char_span": [96, 106], "ent_id": "D007372", "tok_span": [18, 19]}, {"name": "ribavirin", "ent_type": "Chemical", "char_span": [19, 28], "ent_id": "D012254", "tok_span": [5, 8]}, {"name": "hemolysis", "ent_type": "Disease", "char_span": [56, 65], "ent_id": "D006461", "tok_span": [12, 14]}, {"name": "Hemolytic anemia", "ent_type": "Disease", "char_span": [159, 175], "ent_id": "D000743", "tok_span": [30, 33]}, {"name": "ribavirin", "ent_type": "Chemical", "char_span": [256, 265], "ent_id": "D012254", "tok_span": [47, 50]}, {"name": "interferon", "ent_type": "Chemical", "char_span": [241, 251], "ent_id": "D007372", "tok_span": [45, 46]}, {"name": "ribavirin", "ent_type": "Chemical", "char_span": [111, 120], "ent_id": "D012254", "tok_span": [20, 23]}], "relation_list": [{"subject": "ribavirin", "object": "Hemolytic anemia", "sbj_char_span": [111, 120], "obj_char_span": [159, 175], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [30, 33]}, {"subject": "interferon", "object": "Hemolytic anemia", "sbj_char_span": [96, 106], "obj_char_span": [159, 175], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [30, 33]}, {"subject": "ribavirin", "object": "Hemolytic anemia", "sbj_char_span": [256, 265], "obj_char_span": [159, 175], "rel_type": "chemical-induced disease", "sbj_tok_span": [47, 50], "obj_tok_span": [30, 33]}, {"subject": "interferon", "object": "Hemolytic anemia", "sbj_char_span": [241, 251], "obj_char_span": [159, 175], "rel_type": "chemical-induced disease", "sbj_tok_span": [45, 46], "obj_tok_span": [30, 33]}, {"subject": "ribavirin", "object": "Hemolytic anemia", "sbj_char_span": [19, 28], "obj_char_span": [159, 175], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [30, 33]}], "umls_entity_list": []}, {"text": "Because of ribavirin-related hemolytic anemia, dose reduction is a common event in this therapy.", "entity_list": [{"name": "hemolytic anemia", "ent_type": "Disease", "char_span": [29, 45], "ent_id": "D000743", "tok_span": [7, 10]}, {"name": "ribavirin", "ent_type": "Chemical", "char_span": [11, 20], "ent_id": "D012254", "tok_span": [2, 5]}], "relation_list": [{"subject": "ribavirin", "object": "hemolytic anemia", "sbj_char_span": [11, 20], "obj_char_span": [29, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside-induced nephrotic syndrome in rats.", "entity_list": [{"name": "puromycin aminonucleoside", "ent_type": "Chemical", "char_span": [68, 93], "ent_id": "D011692", "tok_span": [12, 17]}, {"name": "nephrotic syndrome", "ent_type": "Disease", "char_span": [102, 120], "ent_id": "D009404", "tok_span": [19, 22]}], "relation_list": [{"subject": "puromycin aminonucleoside", "object": "nephrotic syndrome", "sbj_char_span": [68, 93], "obj_char_span": [102, 120], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 17], "obj_tok_span": [19, 22]}], "umls_entity_list": []}, {"text": "After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.", "entity_list": [{"name": "ascites", "ent_type": "Disease", "char_span": [128, 135], "ent_id": "D001201", "tok_span": [21, 22]}, {"name": "PAN", "ent_type": "Chemical", "char_span": [14, 17], "ent_id": "D011692", "tok_span": [4, 5]}, {"name": "proteinuria", "ent_type": "Disease", "char_span": [48, 59], "ent_id": "D011507", "tok_span": [8, 9]}, {"name": "hypoalbuminemia", "ent_type": "Disease", "char_span": [61, 76], "ent_id": "D034141", "tok_span": [10, 13]}, {"name": "sodium", "ent_type": "Chemical", "char_span": [96, 102], "ent_id": "D012964", "tok_span": [16, 17]}], "relation_list": [{"subject": "PAN", "object": "hypoalbuminemia", "sbj_char_span": [14, 17], "obj_char_span": [61, 76], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [10, 13]}, {"subject": "PAN", "object": "proteinuria", "sbj_char_span": [14, 17], "obj_char_span": [48, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [8, 9]}, {"subject": "PAN", "object": "ascites", "sbj_char_span": [14, 17], "obj_char_span": [128, 135], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [21, 22]}], "umls_entity_list": []}, {"text": "In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the sodium retention associated with PAN-induced nephrotic syndrome.", "entity_list": [{"name": "PAN", "ent_type": "Chemical", "char_span": [229, 232], "ent_id": "D011692", "tok_span": [42, 43]}, {"name": "nephrotic syndrome", "ent_type": "Disease", "char_span": [241, 259], "ent_id": "D009404", "tok_span": [45, 48]}, {"name": "sodium", "ent_type": "Chemical", "char_span": [196, 202], "ent_id": "D012964", "tok_span": [38, 39]}], "relation_list": [{"subject": "PAN", "object": "nephrotic syndrome", "sbj_char_span": [229, 232], "obj_char_span": [241, 259], "rel_type": "chemical-induced disease", "sbj_tok_span": [42, 43], "obj_tok_span": [45, 48]}], "umls_entity_list": []}, {"text": "We have studied the role of NO and its association with apoptosis in an experimental model of nephrotic syndrome induced by a single injection of adriamycin (ADR).", "entity_list": [{"name": "adriamycin", "ent_type": "Chemical", "char_span": [146, 156], "ent_id": "D004317", "tok_span": [26, 30]}, {"name": "NO", "ent_type": "Chemical", "char_span": [28, 30], "ent_id": "D009569", "tok_span": [6, 7]}, {"name": "nephrotic syndrome", "ent_type": "Disease", "char_span": [94, 112], "ent_id": "D009404", "tok_span": [17, 20]}, {"name": "ADR", "ent_type": "Chemical", "char_span": [158, 161], "ent_id": "D004317", "tok_span": [31, 33]}], "relation_list": [{"subject": "ADR", "object": "nephrotic syndrome", "sbj_char_span": [158, 161], "obj_char_span": [94, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 33], "obj_tok_span": [17, 20]}, {"subject": "adriamycin", "object": "nephrotic syndrome", "sbj_char_span": [146, 156], "obj_char_span": [94, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 30], "obj_tok_span": [17, 20]}], "umls_entity_list": []}, {"text": "Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.", "entity_list": [{"name": "catalepsy", "ent_type": "Disease", "char_span": [92, 101], "ent_id": "D002375", "tok_span": [24, 27]}, {"name": "carteolol", "ent_type": "Chemical", "char_span": [26, 35], "ent_id": "D002354", "tok_span": [5, 9]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [72, 83], "ent_id": "D006220", "tok_span": [19, 22]}, {"name": "propranolol", "ent_type": "Chemical", "char_span": [163, 174], "ent_id": "D011433", "tok_span": [38, 42]}, {"name": "biperiden", "ent_type": "Chemical", "char_span": [179, 188], "ent_id": "D001712", "tok_span": [43, 46]}], "relation_list": [{"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [72, 83], "obj_char_span": [92, 101], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 22], "obj_tok_span": [24, 27]}], "umls_entity_list": []}, {"text": "Carteolol, as well as propranolol and biperiden, inhibited the haloperidol-induced catalepsy.", "entity_list": [{"name": "catalepsy", "ent_type": "Disease", "char_span": [83, 92], "ent_id": "D002375", "tok_span": [24, 27]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [63, 74], "ent_id": "D006220", "tok_span": [19, 22]}, {"name": "propranolol", "ent_type": "Chemical", "char_span": [22, 33], "ent_id": "D011433", "tok_span": [8, 12]}, {"name": "biperiden", "ent_type": "Chemical", "char_span": [38, 47], "ent_id": "D001712", "tok_span": [13, 16]}, {"name": "Carteolol", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D002354", "tok_span": [0, 4]}], "relation_list": [{"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [63, 74], "obj_char_span": [83, 92], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 22], "obj_tok_span": [24, 27]}], "umls_entity_list": []}, {"text": "These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.", "entity_list": [{"name": "catalepsy", "ent_type": "Disease", "char_span": [75, 84], "ent_id": "D002375", "tok_span": [15, 18]}, {"name": "carteolol", "ent_type": "Chemical", "char_span": [36, 45], "ent_id": "D002354", "tok_span": [5, 9]}, {"name": "dopamine", "ent_type": "Chemical", "char_span": [281, 289], "ent_id": "D004298", "tok_span": [58, 59]}, {"name": "akathisia", "ent_type": "Disease", "char_span": [185, 194], "ent_id": "D017109", "tok_span": [38, 42]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [55, 66], "ent_id": "D006220", "tok_span": [10, 13]}], "relation_list": [{"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [55, 66], "obj_char_span": [75, 84], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [15, 18]}], "umls_entity_list": []}, {"text": "Penicillamine-induced rapidly progressive glomerulonephritis in a patient with rheumatoid arthritis.", "entity_list": [{"name": "Penicillamine", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D010396", "tok_span": [0, 5]}, {"name": "glomerulonephritis", "ent_type": "Disease", "char_span": [42, 60], "ent_id": "D005921", "tok_span": [9, 14]}, {"name": "rheumatoid arthritis", "ent_type": "Disease", "char_span": [79, 99], "ent_id": "D001172", "tok_span": [18, 20]}], "relation_list": [{"subject": "Penicillamine", "object": "glomerulonephritis", "sbj_char_span": [0, 13], "obj_char_span": [42, 60], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [9, 14]}], "umls_entity_list": []}, {"text": "A 67-year-old woman with rheumatoid arthritis presented rapidly progressive glomerulonephritis (RPGN) after 5 months of D-penicillamine (250 mg/day) treatment.", "entity_list": [{"name": "glomerulonephritis", "ent_type": "Disease", "char_span": [76, 94], "ent_id": "D005921", "tok_span": [13, 18]}, {"name": "rheumatoid arthritis", "ent_type": "Disease", "char_span": [25, 45], "ent_id": "D001172", "tok_span": [8, 10]}, {"name": "RPGN", "ent_type": "Disease", "char_span": [96, 100], "ent_id": "D005921", "tok_span": [19, 21]}, {"name": "D-penicillamine", "ent_type": "Chemical", "char_span": [120, 135], "ent_id": "D010396", "tok_span": [26, 33]}], "relation_list": [{"subject": "D-penicillamine", "object": "RPGN", "sbj_char_span": [120, 135], "obj_char_span": [96, 100], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 33], "obj_tok_span": [19, 21]}, {"subject": "D-penicillamine", "object": "glomerulonephritis", "sbj_char_span": [120, 135], "obj_char_span": [76, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 33], "obj_tok_span": [13, 18]}], "umls_entity_list": []}, {"text": "This new case of RPGN in the course of D-penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and proteinuria in these patients.", "entity_list": [{"name": "proteinuria", "ent_type": "Disease", "char_span": [166, 177], "ent_id": "D011507", "tok_span": [33, 34]}, {"name": "D-penicillamine", "ent_type": "Chemical", "char_span": [39, 54], "ent_id": "D010396", "tok_span": [10, 17]}, {"name": "RPGN", "ent_type": "Disease", "char_span": [17, 21], "ent_id": "D005921", "tok_span": [4, 6]}], "relation_list": [{"subject": "D-penicillamine", "object": "RPGN", "sbj_char_span": [39, 54], "obj_char_span": [17, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 17], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment.", "entity_list": [{"name": "isoniazid", "ent_type": "Chemical", "char_span": [58, 67], "ent_id": "D007538", "tok_span": [12, 16]}, {"name": "Bilateral optic neuropathy", "ent_type": "Disease", "char_span": [0, 26], "ent_id": "D009901", "tok_span": [0, 4]}, {"name": "ethambutol", "ent_type": "Chemical", "char_span": [43, 53], "ent_id": "D004977", "tok_span": [7, 11]}], "relation_list": [{"subject": "ethambutol", "object": "Bilateral optic neuropathy", "sbj_char_span": [43, 53], "obj_char_span": [0, 26], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [0, 4]}, {"subject": "isoniazid", "object": "Bilateral optic neuropathy", "sbj_char_span": [58, 67], "obj_char_span": [0, 26], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 16], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "Thromboembolic and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors: summary report of a ten-year study.", "entity_list": [{"name": "oral contraceptive", "ent_type": "Chemical", "char_span": [42, 60], "ent_id": "D003276", "tok_span": [8, 10]}, {"name": "Thromboembolic", "ent_type": "Disease", "char_span": [0, 14], "ent_id": "D013923", "tok_span": [0, 4]}, {"name": "blood coagulation", "ent_type": "Disease", "char_span": [111, 128], "ent_id": "D001778", "tok_span": [17, 19]}], "relation_list": [{"subject": "oral contraceptive", "object": "blood coagulation", "sbj_char_span": [42, 60], "obj_char_span": [111, 128], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [17, 19]}], "umls_entity_list": []}, {"text": "Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine.", "entity_list": [{"name": "sevoflurane", "ent_type": "Chemical", "char_span": [57, 68], "ent_id": "C009250", "tok_span": [9, 13]}, {"name": "cerebral palsy", "ent_type": "Disease", "char_span": [31, 45], "ent_id": "D002547", "tok_span": [6, 8]}, {"name": "clonidine", "ent_type": "Chemical", "char_span": [112, 121], "ent_id": "D003000", "tok_span": [18, 20]}, {"name": "Cardiac arrest", "ent_type": "Disease", "char_span": [0, 14], "ent_id": "D006323", "tok_span": [0, 2]}], "relation_list": [{"subject": "clonidine", "object": "Cardiac arrest", "sbj_char_span": [112, 121], "obj_char_span": [0, 14], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 20], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "There are no previous reports of clonidine-associated cardiac arrest in a child undergoing induction of anesthesia.", "entity_list": [{"name": "cardiac arrest", "ent_type": "Disease", "char_span": [54, 68], "ent_id": "D006323", "tok_span": [10, 12]}, {"name": "clonidine", "ent_type": "Chemical", "char_span": [33, 42], "ent_id": "D003000", "tok_span": [6, 8]}], "relation_list": [{"subject": "clonidine", "object": "cardiac arrest", "sbj_char_span": [33, 42], "obj_char_span": [54, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Earlier studies have demonstrated that antagonism of sigma1 receptors attenuates the convulsive, lethal, locomotor stimulatory and rewarding actions of cocaine in mice.", "entity_list": [{"name": "cocaine", "ent_type": "Chemical", "char_span": [152, 159], "ent_id": "D003042", "tok_span": [27, 28]}, {"name": "convulsive", "ent_type": "Disease", "char_span": [85, 95], "ent_id": "D012640", "tok_span": [14, 16]}], "relation_list": [{"subject": "cocaine", "object": "convulsive", "sbj_char_span": [152, 159], "obj_char_span": [85, 95], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 28], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "In behavioral studies, pretreatment of Swiss Webster mice with UMB24 or (+/-)-SM 21 significantly attenuated cocaine-induced convulsions and locomotor activity, but not lethality.", "entity_list": [{"name": "SM 21", "ent_type": "Chemical", "char_span": [78, 83], "ent_id": "C107044", "tok_span": [21, 23]}, {"name": "UMB24", "ent_type": "Chemical", "char_span": [63, 68], "ent_id": "C519696", "tok_span": [11, 14]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [109, 116], "ent_id": "D003042", "tok_span": [25, 26]}, {"name": "convulsions", "ent_type": "Disease", "char_span": [125, 136], "ent_id": "D012640", "tok_span": [28, 31]}], "relation_list": [{"subject": "cocaine", "object": "convulsions", "sbj_char_span": [109, 116], "obj_char_span": [125, 136], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 26], "obj_tok_span": [28, 31]}], "umls_entity_list": []}, {"text": "Methimazole-induced cholestatic jaundice.", "entity_list": [{"name": "cholestatic jaundice", "ent_type": "Disease", "char_span": [20, 40], "ent_id": "D041781", "tok_span": [6, 12]}, {"name": "Methimazole", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D008713", "tok_span": [0, 4]}], "relation_list": [{"subject": "Methimazole", "object": "cholestatic jaundice", "sbj_char_span": [0, 11], "obj_char_span": [20, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [6, 12]}], "umls_entity_list": []}, {"text": "A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.", "entity_list": [{"name": "propranolol", "ent_type": "Chemical", "char_span": [104, 115], "ent_id": "D011433", "tok_span": [30, 34]}, {"name": "hyperthyroidism", "ent_type": "Disease", "char_span": [145, 160], "ent_id": "D006980", "tok_span": [43, 47]}, {"name": "itching", "ent_type": "Disease", "char_span": [44, 51], "ent_id": "D011537", "tok_span": [13, 15]}, {"name": "jaundice", "ent_type": "Disease", "char_span": [31, 39], "ent_id": "D007565", "tok_span": [9, 12]}, {"name": "methimazole", "ent_type": "Chemical", "char_span": [76, 87], "ent_id": "D008713", "tok_span": [19, 23]}], "relation_list": [{"subject": "methimazole", "object": "itching", "sbj_char_span": [76, 87], "obj_char_span": [44, 51], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 23], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "Ciprofloxacin-induced acute interstitial nephritis and autoimmune hemolytic anemia.", "entity_list": [{"name": "Ciprofloxacin", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D002939", "tok_span": [0, 5]}, {"name": "autoimmune hemolytic anemia", "ent_type": "Disease", "char_span": [55, 82], "ent_id": "D000744", "tok_span": [12, 16]}, {"name": "interstitial nephritis", "ent_type": "Disease", "char_span": [28, 50], "ent_id": "D009395", "tok_span": [8, 11]}], "relation_list": [{"subject": "Ciprofloxacin", "object": "interstitial nephritis", "sbj_char_span": [0, 13], "obj_char_span": [28, 50], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [8, 11]}], "umls_entity_list": []}, {"text": "Ciprofloxacin has been associated with several side effects including interstitial nephritis and hemolytic anemia.", "entity_list": [{"name": "Ciprofloxacin", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D002939", "tok_span": [0, 5]}, {"name": "interstitial nephritis", "ent_type": "Disease", "char_span": [70, 92], "ent_id": "D009395", "tok_span": [13, 16]}, {"name": "hemolytic anemia", "ent_type": "Disease", "char_span": [97, 113], "ent_id": "D000743", "tok_span": [17, 20]}], "relation_list": [{"subject": "Ciprofloxacin", "object": "hemolytic anemia", "sbj_char_span": [0, 13], "obj_char_span": [97, 113], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [17, 20]}, {"subject": "Ciprofloxacin", "object": "interstitial nephritis", "sbj_char_span": [0, 13], "obj_char_span": [70, 92], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "In this report, we describe a case of ciprofloxacin-induced interstitial nephritis and autoimmune hemolytic anemia.", "entity_list": [{"name": "interstitial nephritis", "ent_type": "Disease", "char_span": [60, 82], "ent_id": "D009395", "tok_span": [16, 19]}, {"name": "autoimmune hemolytic anemia", "ent_type": "Disease", "char_span": [87, 114], "ent_id": "D000744", "tok_span": [20, 24]}, {"name": "ciprofloxacin", "ent_type": "Chemical", "char_span": [38, 51], "ent_id": "D002939", "tok_span": [9, 14]}], "relation_list": [{"subject": "ciprofloxacin", "object": "interstitial nephritis", "sbj_char_span": [38, 51], "obj_char_span": [60, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 14], "obj_tok_span": [16, 19]}], "umls_entity_list": []}, {"text": "Contribution of sodium valproate to the syndrome of inappropriate secretion of antidiuretic hormone.", "entity_list": [{"name": "syndrome of inappropriate secretion of antidiuretic hormone", "ent_type": "Disease", "char_span": [40, 99], "ent_id": "D007177", "tok_span": [10, 19]}, {"name": "sodium valproate", "ent_type": "Chemical", "char_span": [16, 32], "ent_id": "D014635", "tok_span": [4, 8]}], "relation_list": [{"subject": "sodium valproate", "object": "syndrome of inappropriate secretion of antidiuretic hormone", "sbj_char_span": [16, 32], "obj_char_span": [40, 99], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 8], "obj_tok_span": [10, 19]}], "umls_entity_list": []}, {"text": "We report the case of a 62-year-old man who was administered sodium valproate (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).", "entity_list": [{"name": "sodium valproate", "ent_type": "Chemical", "char_span": [61, 77], "ent_id": "D014635", "tok_span": [15, 19]}, {"name": "syndrome of inappropriate secretion of antidiuretic hormone", "ent_type": "Disease", "char_span": [119, 178], "ent_id": "D007177", "tok_span": [28, 37]}, {"name": "VPA", "ent_type": "Chemical", "char_span": [79, 82], "ent_id": "D014635", "tok_span": [20, 22]}, {"name": "SIADH", "ent_type": "Disease", "char_span": [180, 185], "ent_id": "D007177", "tok_span": [38, 41]}], "relation_list": [{"subject": "VPA", "object": "SIADH", "sbj_char_span": [79, 82], "obj_char_span": [180, 185], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 22], "obj_tok_span": [38, 41]}, {"subject": "sodium valproate", "object": "SIADH", "sbj_char_span": [61, 77], "obj_char_span": [180, 185], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 19], "obj_tok_span": [38, 41]}, {"subject": "sodium valproate", "object": "syndrome of inappropriate secretion of antidiuretic hormone", "sbj_char_span": [61, 77], "obj_char_span": [119, 178], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 19], "obj_tok_span": [28, 37]}, {"subject": "VPA", "object": "syndrome of inappropriate secretion of antidiuretic hormone", "sbj_char_span": [79, 82], "obj_char_span": [119, 178], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 22], "obj_tok_span": [28, 37]}], "umls_entity_list": []}, {"text": "We consider this episode of SIADH to be the result of a combination of factors including a weakness of the central nervous system and the long-term administration of VPA.", "entity_list": [{"name": "SIADH", "ent_type": "Disease", "char_span": [28, 33], "ent_id": "D007177", "tok_span": [5, 8]}, {"name": "VPA", "ent_type": "Chemical", "char_span": [166, 169], "ent_id": "D014635", "tok_span": [32, 34]}, {"name": "weakness of the central nervous system", "ent_type": "Disease", "char_span": [91, 129], "ent_id": "D002493", "tok_span": [19, 25]}], "relation_list": [{"subject": "VPA", "object": "SIADH", "sbj_char_span": [166, 169], "obj_char_span": [28, 33], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 34], "obj_tok_span": [5, 8]}], "umls_entity_list": []}, {"text": "Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure.", "entity_list": [{"name": "heart failure", "ent_type": "Disease", "char_span": [72, 85], "ent_id": "D006333", "tok_span": [15, 17]}, {"name": "Vasopressin", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D014667", "tok_span": [0, 3]}, {"name": "milrinone", "ent_type": "Chemical", "char_span": [32, 41], "ent_id": "D020105", "tok_span": [7, 10]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [50, 61], "ent_id": "D007022", "tok_span": [12, 13]}], "relation_list": [{"subject": "Vasopressin", "object": "hypotension", "sbj_char_span": [0, 11], "obj_char_span": [50, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [12, 13]}, {"subject": "milrinone", "object": "hypotension", "sbj_char_span": [32, 41], "obj_char_span": [50, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [12, 13]}], "umls_entity_list": []}, {"text": "The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension.", "entity_list": [{"name": "milrinone", "ent_type": "Chemical", "char_span": [48, 57], "ent_id": "D020105", "tok_span": [10, 13]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [160, 171], "ent_id": "D007022", "tok_span": [29, 30]}, {"name": "heart failure", "ent_type": "Disease", "char_span": [85, 98], "ent_id": "D006333", "tok_span": [18, 20]}], "relation_list": [{"subject": "milrinone", "object": "hypotension", "sbj_char_span": [48, 57], "obj_char_span": [160, 171], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [29, 30]}], "umls_entity_list": []}, {"text": "In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.", "entity_list": [{"name": "milrinone", "ent_type": "Chemical", "char_span": [83, 92], "ent_id": "D020105", "tok_span": [14, 17]}, {"name": "vasopressin", "ent_type": "Chemical", "char_span": [107, 118], "ent_id": "D014667", "tok_span": [21, 24]}, {"name": "milrinone", "ent_type": "Chemical", "char_span": [186, 195], "ent_id": "D020105", "tok_span": [34, 37]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [50, 61], "ent_id": "D007022", "tok_span": [10, 11]}, {"name": "heart failure", "ent_type": "Disease", "char_span": [31, 44], "ent_id": "D006333", "tok_span": [7, 9]}], "relation_list": [{"subject": "milrinone", "object": "hypotension", "sbj_char_span": [186, 195], "obj_char_span": [50, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 37], "obj_tok_span": [10, 11]}, {"subject": "milrinone", "object": "hypotension", "sbj_char_span": [83, 92], "obj_char_span": [50, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [10, 11]}, {"subject": "vasopressin", "object": "hypotension", "sbj_char_span": [107, 118], "obj_char_span": [50, 61], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [10, 11]}], "umls_entity_list": []}, {"text": "Two halogenated anesthetics, enflurane and isoflurane, have been associated with an allergic-type hepatic injury both alone and following previous exposure to halothane.", "entity_list": [{"name": "hepatic injury", "ent_type": "Disease", "char_span": [98, 112], "ent_id": "D056486", "tok_span": [22, 24]}, {"name": "enflurane", "ent_type": "Chemical", "char_span": [29, 38], "ent_id": "D004737", "tok_span": [7, 10]}, {"name": "halothane", "ent_type": "Chemical", "char_span": [159, 168], "ent_id": "D006221", "tok_span": [31, 34]}, {"name": "isoflurane", "ent_type": "Chemical", "char_span": [43, 53], "ent_id": "D007530", "tok_span": [11, 13]}], "relation_list": [{"subject": "halothane", "object": "hepatic injury", "sbj_char_span": [159, 168], "obj_char_span": [98, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 34], "obj_tok_span": [22, 24]}, {"subject": "isoflurane", "object": "hepatic injury", "sbj_char_span": [43, 53], "obj_char_span": [98, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 13], "obj_tok_span": [22, 24]}, {"subject": "enflurane", "object": "hepatic injury", "sbj_char_span": [29, 38], "obj_char_span": [98, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [22, 24]}], "umls_entity_list": []}, {"text": "Halothane hepatitis appears to involve an aberrant immune response.", "entity_list": [{"name": "Halothane", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D006221", "tok_span": [0, 3]}, {"name": "hepatitis", "ent_type": "Disease", "char_span": [10, 19], "ent_id": "D056486", "tok_span": [3, 4]}], "relation_list": [{"subject": "Halothane", "object": "hepatitis", "sbj_char_span": [0, 9], "obj_char_span": [10, 19], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [3, 4]}], "umls_entity_list": []}, {"text": "An antibody response to a protein-bound biotransformation product (trifluoroacetyl adduct) has been detected on halothane hepatitis patients.", "entity_list": [{"name": "hepatitis", "ent_type": "Disease", "char_span": [122, 131], "ent_id": "D056486", "tok_span": [29, 30]}, {"name": "trifluoroacetyl", "ent_type": "Chemical", "char_span": [67, 82], "ent_id": "D014269", "tok_span": [13, 19]}, {"name": "halothane", "ent_type": "Chemical", "char_span": [112, 121], "ent_id": "D006221", "tok_span": [26, 29]}], "relation_list": [{"subject": "halothane", "object": "hepatitis", "sbj_char_span": [112, 121], "obj_char_span": [122, 131], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 29], "obj_tok_span": [29, 30]}], "umls_entity_list": []}, {"text": "This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration.", "entity_list": [{"name": "hypersensitivity", "ent_type": "Disease", "char_span": [113, 129], "ent_id": "D004342", "tok_span": [22, 24]}, {"name": "hepatitis", "ent_type": "Disease", "char_span": [169, 178], "ent_id": "D056486", "tok_span": [32, 33]}, {"name": "isoflurane", "ent_type": "Chemical", "char_span": [86, 96], "ent_id": "D007530", "tok_span": [17, 19]}, {"name": "enflurane", "ent_type": "Chemical", "char_span": [69, 78], "ent_id": "D004737", "tok_span": [11, 14]}, {"name": "halothane", "ent_type": "Chemical", "char_span": [209, 218], "ent_id": "D006221", "tok_span": [38, 41]}, {"name": "halothane", "ent_type": "Chemical", "char_span": [159, 168], "ent_id": "D006221", "tok_span": [29, 32]}], "relation_list": [{"subject": "halothane", "object": "hepatitis", "sbj_char_span": [159, 168], "obj_char_span": [169, 178], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 32], "obj_tok_span": [32, 33]}, {"subject": "isoflurane", "object": "hepatitis", "sbj_char_span": [86, 96], "obj_char_span": [169, 178], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 19], "obj_tok_span": [32, 33]}, {"subject": "enflurane", "object": "hepatitis", "sbj_char_span": [69, 78], "obj_char_span": [169, 178], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [32, 33]}, {"subject": "halothane", "object": "hepatitis", "sbj_char_span": [209, 218], "obj_char_span": [169, 178], "rel_type": "chemical-induced disease", "sbj_tok_span": [38, 41], "obj_tok_span": [32, 33]}], "umls_entity_list": []}, {"text": "Papillomas of the transitional epithelium of the bladder developed in all paracetamol-treated groups, and three rats bore bladder carcinomas.", "entity_list": [{"name": "bladder carcinomas", "ent_type": "Disease", "char_span": [122, 140], "ent_id": "D001749", "tok_span": [25, 27]}, {"name": "Papillomas", "ent_type": "Disease", "char_span": [0, 10], "ent_id": "D010212", "tok_span": [0, 3]}, {"name": "paracetamol", "ent_type": "Chemical", "char_span": [74, 85], "ent_id": "D000082", "tok_span": [13, 17]}], "relation_list": [{"subject": "paracetamol", "object": "bladder carcinomas", "sbj_char_span": [74, 85], "obj_char_span": [122, 140], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [25, 27]}], "umls_entity_list": []}, {"text": "Additionally, 20 to 25% of paracetamol-treated rats developed hyperplasia of the bladder epithelium, which was not coincident with the presence of bladder calculi.", "entity_list": [{"name": "bladder calculi", "ent_type": "Disease", "char_span": [147, 162], "ent_id": "D001744", "tok_span": [30, 33]}, {"name": "paracetamol", "ent_type": "Chemical", "char_span": [27, 38], "ent_id": "D000082", "tok_span": [7, 11]}, {"name": "hyperplasia", "ent_type": "Disease", "char_span": [62, 73], "ent_id": "D006965", "tok_span": [15, 16]}], "relation_list": [{"subject": "paracetamol", "object": "hyperplasia", "sbj_char_span": [27, 38], "obj_char_span": [62, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [15, 16]}], "umls_entity_list": []}, {"text": "An electron microscope study of the livers of paracetamol-treated rats revealed ultrastructural changes in the hepatocytes that resemble those that result from exposure to a variety of known hepatocarcinogens.", "entity_list": [{"name": "paracetamol", "ent_type": "Chemical", "char_span": [46, 57], "ent_id": "D000082", "tok_span": [8, 12]}, {"name": "hepatocarcinogens", "ent_type": "Disease", "char_span": [191, 208], "ent_id": "D008113", "tok_span": [34, 37]}], "relation_list": [{"subject": "paracetamol", "object": "hepatocarcinogens", "sbj_char_span": [46, 57], "obj_char_span": [191, 208], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [34, 37]}], "umls_entity_list": []}, {"text": "In addition to muscle damage, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus epinephrine.", "entity_list": [{"name": "mepivacaine", "ent_type": "Chemical", "char_span": [108, 119], "ent_id": "D008619", "tok_span": [20, 24]}, {"name": "epinephrine", "ent_type": "Chemical", "char_span": [139, 150], "ent_id": "D004837", "tok_span": [28, 31]}, {"name": "lidocaine", "ent_type": "Chemical", "char_span": [124, 133], "ent_id": "D008012", "tok_span": [25, 27]}, {"name": "muscle damage", "ent_type": "Disease", "char_span": [15, 28], "ent_id": "D009135", "tok_span": [3, 5]}], "relation_list": [{"subject": "mepivacaine", "object": "muscle damage", "sbj_char_span": [108, 119], "obj_char_span": [15, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 24], "obj_tok_span": [3, 5]}, {"subject": "lidocaine", "object": "muscle damage", "sbj_char_span": [124, 133], "obj_char_span": [15, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 27], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "The novel anxiolytic drug, buspirone, reverses catalepsy induced by haloperidol.", "entity_list": [{"name": "catalepsy", "ent_type": "Disease", "char_span": [47, 56], "ent_id": "D002375", "tok_span": [13, 16]}, {"name": "buspirone", "ent_type": "Chemical", "char_span": [27, 36], "ent_id": "D002065", "tok_span": [7, 10]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [68, 79], "ent_id": "D006220", "tok_span": [18, 21]}], "relation_list": [{"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [68, 79], "obj_char_span": [47, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 21], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "A series of aryl-piperazine analogues of buspirone and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced catalepsy.", "entity_list": [{"name": "5-hydroxytryptaminergic agonists", "ent_type": "Chemical", "char_span": [61, 93], "ent_id": "D058825", "tok_span": [15, 22]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [135, 146], "ent_id": "D006220", "tok_span": [29, 32]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [155, 164], "ent_id": "D002375", "tok_span": [33, 36]}, {"name": "aryl-piperazine", "ent_type": "Chemical", "char_span": [12, 27], "ent_id": "-1", "tok_span": [3, 8]}, {"name": "buspirone", "ent_type": "Chemical", "char_span": [41, 50], "ent_id": "D002065", "tok_span": [10, 13]}], "relation_list": [{"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [135, 146], "obj_char_span": [155, 164], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 32], "obj_tok_span": [33, 36]}], "umls_entity_list": []}, {"text": "Diazepam facilitates reflex bradycardia in conscious rats.", "entity_list": [{"name": "Diazepam", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D003975", "tok_span": [0, 3]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [28, 39], "ent_id": "D001919", "tok_span": [5, 9]}], "relation_list": [{"subject": "Diazepam", "object": "bradycardia", "sbj_char_span": [0, 8], "obj_char_span": [28, 39], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "Also, reflex bradycardia was produced in rats by intravenous infusion of adrenaline (1.25-2.5 micrograms kg-1).", "entity_list": [{"name": "bradycardia", "ent_type": "Disease", "char_span": [13, 24], "ent_id": "D001919", "tok_span": [3, 7]}, {"name": "adrenaline", "ent_type": "Chemical", "char_span": [73, 83], "ent_id": "D004837", "tok_span": [15, 17]}], "relation_list": [{"subject": "adrenaline", "object": "bradycardia", "sbj_char_span": [73, 83], "obj_char_span": [13, 24], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 17], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "Intravenous pretreatment of the rats with diazepam, although causing no change in the adrenaline-induced pressor effect, did enhance the adrenaline-induced reflex bradycardia.", "entity_list": [{"name": "adrenaline", "ent_type": "Chemical", "char_span": [86, 96], "ent_id": "D004837", "tok_span": [18, 20]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [163, 174], "ent_id": "D001919", "tok_span": [34, 38]}, {"name": "diazepam", "ent_type": "Chemical", "char_span": [42, 50], "ent_id": "D003975", "tok_span": [8, 11]}, {"name": "adrenaline", "ent_type": "Chemical", "char_span": [137, 147], "ent_id": "D004837", "tok_span": [29, 31]}], "relation_list": [{"subject": "diazepam", "object": "bradycardia", "sbj_char_span": [42, 50], "obj_char_span": [163, 174], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [34, 38]}, {"subject": "adrenaline", "object": "bradycardia", "sbj_char_span": [86, 96], "obj_char_span": [163, 174], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 20], "obj_tok_span": [34, 38]}, {"subject": "adrenaline", "object": "bradycardia", "sbj_char_span": [137, 147], "obj_char_span": [163, 174], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 31], "obj_tok_span": [34, 38]}], "umls_entity_list": []}, {"text": "However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).", "entity_list": [{"name": "adrenaline", "ent_type": "Chemical", "char_span": [37, 47], "ent_id": "D004837", "tok_span": [8, 10]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [63, 74], "ent_id": "D001919", "tok_span": [13, 17]}, {"name": "GABA", "ent_type": "Chemical", "char_span": [244, 248], "ent_id": "D005680", "tok_span": [50, 51]}, {"name": "picrotoxin", "ent_type": "Chemical", "char_span": [143, 153], "ent_id": "D010852", "tok_span": [29, 32]}, {"name": "diazepam", "ent_type": "Chemical", "char_span": [13, 21], "ent_id": "D003975", "tok_span": [3, 6]}, {"name": "chloride", "ent_type": "Chemical", "char_span": [171, 179], "ent_id": "D002712", "tok_span": [36, 37]}, {"name": "chloride", "ent_type": "Chemical", "char_span": [249, 257], "ent_id": "D002712", "tok_span": [52, 53]}, {"name": "benzodiazepine", "ent_type": "Chemical", "char_span": [229, 243], "ent_id": "D001569", "tok_span": [45, 49]}], "relation_list": [{"subject": "diazepam", "object": "bradycardia", "sbj_char_span": [13, 21], "obj_char_span": [63, 74], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [13, 17]}, {"subject": "adrenaline", "object": "bradycardia", "sbj_char_span": [37, 47], "obj_char_span": [63, 74], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "The data indicate that diazepam acts through the benzodiazepine-GABA-chloride channel macromolecular complex within the central nervous system to facilitate reflex bradycardia mediated through baroreceptor reflexes in response to an acute increase in arterial pressure.", "entity_list": [{"name": "diazepam", "ent_type": "Chemical", "char_span": [23, 31], "ent_id": "D003975", "tok_span": [4, 7]}, {"name": "GABA", "ent_type": "Chemical", "char_span": [64, 68], "ent_id": "D005680", "tok_span": [15, 16]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [164, 175], "ent_id": "D001919", "tok_span": [30, 34]}, {"name": "benzodiazepine", "ent_type": "Chemical", "char_span": [49, 63], "ent_id": "D001569", "tok_span": [10, 14]}, {"name": "chloride", "ent_type": "Chemical", "char_span": [69, 77], "ent_id": "D002712", "tok_span": [17, 18]}], "relation_list": [{"subject": "diazepam", "object": "bradycardia", "sbj_char_span": [23, 31], "obj_char_span": [164, 175], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [30, 34]}], "umls_entity_list": []}, {"text": "Chronic carbamazepine inhibits the development of local anesthetic seizures kindled by cocaine and lidocaine.", "entity_list": [{"name": "lidocaine", "ent_type": "Chemical", "char_span": [99, 108], "ent_id": "D008012", "tok_span": [17, 19]}, {"name": "seizures", "ent_type": "Disease", "char_span": [67, 75], "ent_id": "D012640", "tok_span": [11, 12]}, {"name": "carbamazepine", "ent_type": "Chemical", "char_span": [8, 21], "ent_id": "D002220", "tok_span": [1, 5]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [87, 94], "ent_id": "D003042", "tok_span": [15, 16]}], "relation_list": [{"subject": "cocaine", "object": "seizures", "sbj_char_span": [87, 94], "obj_char_span": [67, 75], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 16], "obj_tok_span": [11, 12]}, {"subject": "lidocaine", "object": "seizures", "sbj_char_span": [99, 108], "obj_char_span": [67, 75], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 19], "obj_tok_span": [11, 12]}], "umls_entity_list": []}, {"text": "Chronic oral CBZ inhibited the development of both lidocaine- and cocaine-induced seizures, but had little effect on the fully developed local anesthetic seizures.", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [154, 162], "ent_id": "D012640", "tok_span": [28, 29]}, {"name": "CBZ", "ent_type": "Chemical", "char_span": [13, 16], "ent_id": "D002220", "tok_span": [2, 4]}, {"name": "lidocaine", "ent_type": "Chemical", "char_span": [51, 60], "ent_id": "D008012", "tok_span": [9, 11]}, {"name": "seizures", "ent_type": "Disease", "char_span": [82, 90], "ent_id": "D012640", "tok_span": [16, 17]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [66, 73], "ent_id": "D003042", "tok_span": [13, 14]}], "relation_list": [{"subject": "cocaine", "object": "seizures", "sbj_char_span": [66, 73], "obj_char_span": [154, 162], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 14], "obj_tok_span": [28, 29]}, {"subject": "cocaine", "object": "seizures", "sbj_char_span": [66, 73], "obj_char_span": [82, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 14], "obj_tok_span": [16, 17]}, {"subject": "lidocaine", "object": "seizures", "sbj_char_span": [51, 60], "obj_char_span": [154, 162], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 11], "obj_tok_span": [28, 29]}, {"subject": "lidocaine", "object": "seizures", "sbj_char_span": [51, 60], "obj_char_span": [82, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 11], "obj_tok_span": [16, 17]}], "umls_entity_list": []}, {"text": "Chronic CBZ also decreased the incidence of seizure-related mortality in the cocaine-injected rats.", "entity_list": [{"name": "CBZ", "ent_type": "Chemical", "char_span": [8, 11], "ent_id": "D002220", "tok_span": [1, 3]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [77, 84], "ent_id": "D003042", "tok_span": [14, 15]}, {"name": "seizure", "ent_type": "Disease", "char_span": [44, 51], "ent_id": "D012640", "tok_span": [8, 9]}], "relation_list": [{"subject": "cocaine", "object": "seizure", "sbj_char_span": [77, 84], "obj_char_span": [44, 51], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [8, 9]}], "umls_entity_list": []}, {"text": "Acute CBZ over a range of doses (15-50 mg/kg) had no effect on completed lidocaine-kindled or acute cocaine-induced seizures.", "entity_list": [{"name": "lidocaine", "ent_type": "Chemical", "char_span": [73, 82], "ent_id": "D008012", "tok_span": [21, 23]}, {"name": "CBZ", "ent_type": "Chemical", "char_span": [6, 9], "ent_id": "D002220", "tok_span": [1, 3]}, {"name": "seizures", "ent_type": "Disease", "char_span": [116, 124], "ent_id": "D012640", "tok_span": [31, 32]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [100, 107], "ent_id": "D003042", "tok_span": [28, 29]}], "relation_list": [{"subject": "cocaine", "object": "seizures", "sbj_char_span": [100, 107], "obj_char_span": [116, 124], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 29], "obj_tok_span": [31, 32]}, {"subject": "lidocaine", "object": "seizures", "sbj_char_span": [73, 82], "obj_char_span": [116, 124], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 23], "obj_tok_span": [31, 32]}], "umls_entity_list": []}, {"text": "Repeated i.p. injection of CBZ (15 mg/kg) also was without effect on the development of lidocaine- or cocaine-kindled seizures.", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [118, 126], "ent_id": "D012640", "tok_span": [32, 33]}, {"name": "lidocaine", "ent_type": "Chemical", "char_span": [88, 97], "ent_id": "D008012", "tok_span": [24, 26]}, {"name": "CBZ", "ent_type": "Chemical", "char_span": [27, 30], "ent_id": "D002220", "tok_span": [8, 10]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [102, 109], "ent_id": "D003042", "tok_span": [28, 29]}], "relation_list": [{"subject": "cocaine", "object": "seizures", "sbj_char_span": [102, 109], "obj_char_span": [118, 126], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 29], "obj_tok_span": [32, 33]}, {"subject": "lidocaine", "object": "seizures", "sbj_char_span": [88, 97], "obj_char_span": [118, 126], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 26], "obj_tok_span": [32, 33]}], "umls_entity_list": []}, {"text": "D-Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients; none developed renal insufficiency.", "entity_list": [{"name": "proteinuria", "ent_type": "Disease", "char_span": [77, 88], "ent_id": "D011507", "tok_span": [18, 19]}, {"name": "nephrotic syndrome", "ent_type": "Disease", "char_span": [23, 41], "ent_id": "D009404", "tok_span": [8, 11]}, {"name": "renal insufficiency", "ent_type": "Disease", "char_span": [125, 144], "ent_id": "D051437", "tok_span": [26, 28]}, {"name": "D-Penicillamine", "ent_type": "Chemical", "char_span": [0, 15], "ent_id": "D010396", "tok_span": [0, 7]}], "relation_list": [{"subject": "D-Penicillamine", "object": "proteinuria", "sbj_char_span": [0, 15], "obj_char_span": [77, 88], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 7], "obj_tok_span": [18, 19]}, {"subject": "D-Penicillamine", "object": "nephrotic syndrome", "sbj_char_span": [0, 15], "obj_char_span": [23, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 7], "obj_tok_span": [8, 11]}], "umls_entity_list": []}, {"text": "Preservation of renal blood flow during hypotension induced with fenoldopam in dogs.", "entity_list": [{"name": "hypotension", "ent_type": "Disease", "char_span": [40, 51], "ent_id": "D007022", "tok_span": [7, 8]}, {"name": "fenoldopam", "ent_type": "Chemical", "char_span": [65, 75], "ent_id": "D018818", "tok_span": [10, 15]}], "relation_list": [{"subject": "fenoldopam", "object": "hypotension", "sbj_char_span": [65, 75], "obj_char_span": [40, 51], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 15], "obj_tok_span": [7, 8]}], "umls_entity_list": []}, {"text": "The hypothesis that fenoldopam could be used to induce hypotension and preserve blood flow to the kidney was tested.", "entity_list": [{"name": "hypotension", "ent_type": "Disease", "char_span": [55, 66], "ent_id": "D007022", "tok_span": [13, 14]}, {"name": "fenoldopam", "ent_type": "Chemical", "char_span": [20, 30], "ent_id": "D018818", "tok_span": [3, 8]}], "relation_list": [{"subject": "fenoldopam", "object": "hypotension", "sbj_char_span": [20, 30], "obj_char_span": [55, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 8], "obj_tok_span": [13, 14]}], "umls_entity_list": []}, {"text": "Renal blood flow (RBF) increased during fenoldopam-induced hypotension 11 +/- 7 per cent and decreased 21 +/- 8 per cent during sodium nitroprusside-induced hypotension (P less than 0.01).", "entity_list": [{"name": "sodium", "ent_type": "Chemical", "char_span": [128, 134], "ent_id": "D012964", "tok_span": [33, 34]}, {"name": "nitroprusside", "ent_type": "Chemical", "char_span": [135, 148], "ent_id": "D009599", "tok_span": [34, 38]}, {"name": "fenoldopam", "ent_type": "Chemical", "char_span": [40, 50], "ent_id": "D018818", "tok_span": [8, 13]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [157, 168], "ent_id": "D007022", "tok_span": [40, 41]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [59, 70], "ent_id": "D007022", "tok_span": [15, 16]}], "relation_list": [{"subject": "nitroprusside", "object": "hypotension", "sbj_char_span": [135, 148], "obj_char_span": [59, 70], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 38], "obj_tok_span": [15, 16]}, {"subject": "nitroprusside", "object": "hypotension", "sbj_char_span": [135, 148], "obj_char_span": [157, 168], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 38], "obj_tok_span": [40, 41]}, {"subject": "fenoldopam", "object": "hypotension", "sbj_char_span": [40, 50], "obj_char_span": [157, 168], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 13], "obj_tok_span": [40, 41]}, {"subject": "fenoldopam", "object": "hypotension", "sbj_char_span": [40, 50], "obj_char_span": [59, 70], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 13], "obj_tok_span": [15, 16]}], "umls_entity_list": []}, {"text": "Sodium nitroprusside is a non-selective arteriolar and venous vasodilator that can produce redistribution of blood flow away from the kidney during induced hypotension.", "entity_list": [{"name": "hypotension", "ent_type": "Disease", "char_span": [156, 167], "ent_id": "D007022", "tok_span": [29, 30]}, {"name": "nitroprusside", "ent_type": "Chemical", "char_span": [7, 20], "ent_id": "D009599", "tok_span": [1, 5]}], "relation_list": [{"subject": "nitroprusside", "object": "hypotension", "sbj_char_span": [7, 20], "obj_char_span": [156, 167], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 5], "obj_tok_span": [29, 30]}], "umls_entity_list": []}, {"text": "Digitalis arrhythmia, which is suppressed by Na channel blockers, was induced by intermittent intravenous (i.v.) injection of ouabain in pentobarbital-anesthetized dogs.", "entity_list": [{"name": "arrhythmia", "ent_type": "Disease", "char_span": [10, 20], "ent_id": "D001145", "tok_span": [2, 4]}, {"name": "pentobarbital", "ent_type": "Chemical", "char_span": [137, 150], "ent_id": "D010424", "tok_span": [30, 32]}, {"name": "Na", "ent_type": "Chemical", "char_span": [45, 47], "ent_id": "D012964", "tok_span": [9, 10]}, {"name": "ouabain", "ent_type": "Chemical", "char_span": [126, 133], "ent_id": "D010042", "tok_span": [26, 29]}, {"name": "Digitalis", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D004070", "tok_span": [0, 2]}], "relation_list": [{"subject": "ouabain", "object": "arrhythmia", "sbj_char_span": [126, 133], "obj_char_span": [10, 20], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 29], "obj_tok_span": [2, 4]}], "umls_entity_list": []}, {"text": "Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.", "entity_list": [{"name": "adrenaline", "ent_type": "Chemical", "char_span": [82, 92], "ent_id": "D004837", "tok_span": [17, 19]}, {"name": "Ca", "ent_type": "Chemical", "char_span": [46, 48], "ent_id": "D002118", "tok_span": [10, 11]}, {"name": "halothane", "ent_type": "Chemical", "char_span": [105, 114], "ent_id": "D006221", "tok_span": [21, 24]}, {"name": "Adrenaline arrhythmia", "ent_type": "Disease", "char_span": [0, 21], "ent_id": "D001145", "tok_span": [0, 5]}], "relation_list": [{"subject": "adrenaline", "object": "Adrenaline arrhythmia", "sbj_char_span": [82, 92], "obj_char_span": [0, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 19], "obj_tok_span": [0, 5]}], "umls_entity_list": []}, {"text": "Ten and 5 mg/kg i.v. (+)-cibenzoline suppressed digitalis- and adrenaline-induced arrhythmias, respectively.", "entity_list": [{"name": "cibenzoline", "ent_type": "Chemical", "char_span": [25, 36], "ent_id": "C032151", "tok_span": [14, 17]}, {"name": "adrenaline", "ent_type": "Chemical", "char_span": [63, 73], "ent_id": "D004837", "tok_span": [22, 24]}, {"name": "arrhythmias", "ent_type": "Disease", "char_span": [82, 93], "ent_id": "D001145", "tok_span": [26, 27]}, {"name": "digitalis", "ent_type": "Chemical", "char_span": [48, 57], "ent_id": "D004070", "tok_span": [18, 20]}], "relation_list": [{"subject": "adrenaline", "object": "arrhythmias", "sbj_char_span": [63, 73], "obj_char_span": [82, 93], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 24], "obj_tok_span": [26, 27]}], "umls_entity_list": []}, {"text": "The minimum effective plasma concentrations of (+)-cibenzoline for digitalis- and adrenaline-induced arrhythmias were 1.4 +/- 0.4 and 2.0 +/- 0.6 micrograms/ml, respectively (mean +/- SD, n = 6).", "entity_list": [{"name": "cibenzoline", "ent_type": "Chemical", "char_span": [51, 62], "ent_id": "C032151", "tok_span": [10, 13]}, {"name": "adrenaline", "ent_type": "Chemical", "char_span": [82, 92], "ent_id": "D004837", "tok_span": [18, 20]}, {"name": "arrhythmias", "ent_type": "Disease", "char_span": [101, 112], "ent_id": "D001145", "tok_span": [22, 23]}, {"name": "digitalis", "ent_type": "Chemical", "char_span": [67, 76], "ent_id": "D004070", "tok_span": [14, 16]}], "relation_list": [{"subject": "adrenaline", "object": "arrhythmias", "sbj_char_span": [82, 92], "obj_char_span": [101, 112], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 20], "obj_tok_span": [22, 23]}], "umls_entity_list": []}, {"text": "A lower dose of 1 mg/kg i.v. of (-)-cibenzoline suppressed the digitalis-induced arrhythmia, whereas 5 mg/kg i.v. was needed to suppress adrenaline-induced arrhythmias.", "entity_list": [{"name": "digitalis", "ent_type": "Chemical", "char_span": [63, 72], "ent_id": "D004070", "tok_span": [22, 24]}, {"name": "arrhythmias", "ent_type": "Disease", "char_span": [156, 167], "ent_id": "D001145", "tok_span": [46, 47]}, {"name": "arrhythmia", "ent_type": "Disease", "char_span": [81, 91], "ent_id": "D001145", "tok_span": [26, 28]}, {"name": "adrenaline", "ent_type": "Chemical", "char_span": [137, 147], "ent_id": "D004837", "tok_span": [42, 44]}, {"name": "cibenzoline", "ent_type": "Chemical", "char_span": [36, 47], "ent_id": "C032151", "tok_span": [17, 20]}], "relation_list": [{"subject": "adrenaline", "object": "arrhythmias", "sbj_char_span": [137, 147], "obj_char_span": [156, 167], "rel_type": "chemical-induced disease", "sbj_tok_span": [42, 44], "obj_tok_span": [46, 47]}, {"subject": "adrenaline", "object": "arrhythmia", "sbj_char_span": [137, 147], "obj_char_span": [81, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [42, 44], "obj_tok_span": [26, 28]}], "umls_entity_list": []}, {"text": "The minimum effective plasma concentrations of (-)-cibenzoline for digitalis- and adrenaline-induced arrhythmia were 0.06 +/- 0.04 and 0.7 +/- 0.1 micrograms/ml, respectively (mean +/- SD, n = 6).", "entity_list": [{"name": "cibenzoline", "ent_type": "Chemical", "char_span": [51, 62], "ent_id": "C032151", "tok_span": [10, 13]}, {"name": "adrenaline", "ent_type": "Chemical", "char_span": [82, 92], "ent_id": "D004837", "tok_span": [18, 20]}, {"name": "arrhythmia", "ent_type": "Disease", "char_span": [101, 111], "ent_id": "D001145", "tok_span": [22, 24]}, {"name": "digitalis", "ent_type": "Chemical", "char_span": [67, 76], "ent_id": "D004070", "tok_span": [14, 16]}], "relation_list": [{"subject": "adrenaline", "object": "arrhythmia", "sbj_char_span": [82, 92], "obj_char_span": [101, 111], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 20], "obj_tok_span": [22, 24]}], "umls_entity_list": []}, {"text": "Effect of methanolic extract of Hibiscus rosa sinensis (100-300 mg/kg) was studied on reserpine-induced orofacial dyskinesia and neurochemical alterations.", "entity_list": [{"name": "dyskinesia", "ent_type": "Disease", "char_span": [114, 124], "ent_id": "D004409", "tok_span": [32, 36]}, {"name": "reserpine", "ent_type": "Chemical", "char_span": [86, 95], "ent_id": "D012110", "tok_span": [25, 28]}, {"name": "Hibiscus rosa sinensis", "ent_type": "Chemical", "char_span": [32, 54], "ent_id": "D010936", "tok_span": [6, 14]}], "relation_list": [{"subject": "reserpine", "object": "dyskinesia", "sbj_char_span": [86, 95], "obj_char_span": [114, 124], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 28], "obj_tok_span": [32, 36]}], "umls_entity_list": []}, {"text": "The results of the present study suggested that Hibiscus rosa sinensis had a protective role against reserpine-induced orofacial dyskinesia and oxidative stress.", "entity_list": [{"name": "dyskinesia", "ent_type": "Disease", "char_span": [129, 139], "ent_id": "D004409", "tok_span": [28, 32]}, {"name": "reserpine", "ent_type": "Chemical", "char_span": [101, 110], "ent_id": "D012110", "tok_span": [21, 24]}, {"name": "Hibiscus rosa sinensis", "ent_type": "Chemical", "char_span": [48, 70], "ent_id": "D010936", "tok_span": [8, 16]}], "relation_list": [{"subject": "reserpine", "object": "dyskinesia", "sbj_char_span": [101, 110], "obj_char_span": [129, 139], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "5 flourouracil-induced apical ballooning syndrome: a case report.", "entity_list": [{"name": "apical ballooning syndrome", "ent_type": "Disease", "char_span": [23, 49], "ent_id": "D054549", "tok_span": [6, 10]}, {"name": "5 flourouracil", "ent_type": "Chemical", "char_span": [0, 14], "ent_id": "D005472", "tok_span": [0, 4]}], "relation_list": [{"subject": "5 flourouracil", "object": "apical ballooning syndrome", "sbj_char_span": [0, 14], "obj_char_span": [23, 49], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [6, 10]}], "umls_entity_list": []}, {"text": "Reduction of pain during induction with target-controlled propofol and remifentanil.", "entity_list": [{"name": "propofol", "ent_type": "Chemical", "char_span": [58, 66], "ent_id": "D015742", "tok_span": [9, 11]}, {"name": "remifentanil", "ent_type": "Chemical", "char_span": [71, 83], "ent_id": "C071741", "tok_span": [12, 16]}, {"name": "pain", "ent_type": "Disease", "char_span": [13, 17], "ent_id": "D010146", "tok_span": [2, 3]}], "relation_list": [{"subject": "propofol", "object": "pain", "sbj_char_span": [58, 66], "obj_char_span": [13, 17], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 11], "obj_tok_span": [2, 3]}], "umls_entity_list": []}, {"text": "BACKGROUND: Pain on injection of propofol is unpleasant.", "entity_list": [{"name": "Pain", "ent_type": "Disease", "char_span": [12, 16], "ent_id": "D010146", "tok_span": [2, 3]}, {"name": "propofol", "ent_type": "Chemical", "char_span": [33, 41], "ent_id": "D015742", "tok_span": [6, 8]}], "relation_list": [{"subject": "propofol", "object": "Pain", "sbj_char_span": [33, 41], "obj_char_span": [12, 16], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [2, 3]}], "umls_entity_list": []}, {"text": "We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used.", "entity_list": [{"name": "propofol", "ent_type": "Chemical", "char_span": [108, 116], "ent_id": "D015742", "tok_span": [20, 22]}, {"name": "pain", "ent_type": "Disease", "char_span": [39, 43], "ent_id": "D010146", "tok_span": [6, 7]}, {"name": "propofol", "ent_type": "Chemical", "char_span": [21, 29], "ent_id": "D015742", "tok_span": [3, 5]}, {"name": "remifentanil", "ent_type": "Chemical", "char_span": [75, 87], "ent_id": "C071741", "tok_span": [13, 17]}], "relation_list": [{"subject": "propofol", "object": "pain", "sbj_char_span": [21, 29], "obj_char_span": [39, 43], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 5], "obj_tok_span": [6, 7]}, {"subject": "propofol", "object": "pain", "sbj_char_span": [108, 116], "obj_char_span": [39, 43], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 22], "obj_tok_span": [6, 7]}], "umls_entity_list": []}, {"text": "Remifentanil-related complications were assessed during the remifentanil infusion, and pain caused by propofol was evaluated using a four-point scale during the propofol infusion.", "entity_list": [{"name": "propofol", "ent_type": "Chemical", "char_span": [161, 169], "ent_id": "D015742", "tok_span": [33, 35]}, {"name": "propofol", "ent_type": "Chemical", "char_span": [102, 110], "ent_id": "D015742", "tok_span": [21, 23]}, {"name": "pain", "ent_type": "Disease", "char_span": [87, 91], "ent_id": "D010146", "tok_span": [18, 19]}, {"name": "Remifentanil", "ent_type": "Chemical", "char_span": [0, 12], "ent_id": "C071741", "tok_span": [0, 4]}, {"name": "remifentanil", "ent_type": "Chemical", "char_span": [60, 72], "ent_id": "C071741", "tok_span": [11, 15]}], "relation_list": [{"subject": "propofol", "object": "pain", "sbj_char_span": [102, 110], "obj_char_span": [87, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 23], "obj_tok_span": [18, 19]}, {"subject": "propofol", "object": "pain", "sbj_char_span": [161, 169], "obj_char_span": [87, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 35], "obj_tok_span": [18, 19]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).", "entity_list": [{"name": "propofol", "ent_type": "Chemical", "char_span": [111, 119], "ent_id": "D015742", "tok_span": [22, 24]}, {"name": "propofol", "ent_type": "Chemical", "char_span": [57, 65], "ent_id": "D015742", "tok_span": [10, 12]}, {"name": "remifentanil", "ent_type": "Chemical", "char_span": [70, 82], "ent_id": "C071741", "tok_span": [13, 17]}, {"name": "pain", "ent_type": "Disease", "char_span": [129, 133], "ent_id": "D010146", "tok_span": [25, 26]}, {"name": "remifentanil", "ent_type": "Chemical", "char_span": [208, 220], "ent_id": "C071741", "tok_span": [35, 39]}], "relation_list": [{"subject": "propofol", "object": "pain", "sbj_char_span": [57, 65], "obj_char_span": [129, 133], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 12], "obj_tok_span": [25, 26]}, {"subject": "propofol", "object": "pain", "sbj_char_span": [111, 119], "obj_char_span": [129, 133], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 24], "obj_tok_span": [25, 26]}], "umls_entity_list": []}, {"text": "Epidemiological data suggest that fluoxetine exposure prenatally increases the prevalence of persistent pulmonary hypertension syndrome of the newborn.", "entity_list": [{"name": "pulmonary hypertension syndrome", "ent_type": "Disease", "char_span": [104, 135], "ent_id": "D006976", "tok_span": [17, 20]}, {"name": "fluoxetine", "ent_type": "Chemical", "char_span": [34, 44], "ent_id": "D005473", "tok_span": [6, 9]}], "relation_list": [{"subject": "fluoxetine", "object": "pulmonary hypertension syndrome", "sbj_char_span": [34, 44], "obj_char_span": [104, 135], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [17, 20]}], "umls_entity_list": []}, {"text": "The mechanism responsible for this effect is unclear and paradoxical, considering the current evidence of a pulmonary hypertension protective fluoxetine effect in adult rodents.", "entity_list": [{"name": "fluoxetine", "ent_type": "Chemical", "char_span": [142, 152], "ent_id": "D005473", "tok_span": [21, 24]}, {"name": "pulmonary hypertension", "ent_type": "Disease", "char_span": [108, 130], "ent_id": "D006976", "tok_span": [18, 20]}], "relation_list": [{"subject": "fluoxetine", "object": "pulmonary hypertension", "sbj_char_span": [142, 152], "obj_char_span": [108, 130], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [18, 20]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: In contrast to the adult, fluoxetine exposure in utero induces pulmonary hypertension in the fetal rat as a result of a developmentally regulated increase in pulmonary vascular smooth muscle proliferation.", "entity_list": [{"name": "pulmonary hypertension", "ent_type": "Disease", "char_span": [76, 98], "ent_id": "D006976", "tok_span": [16, 18]}, {"name": "fluoxetine", "ent_type": "Chemical", "char_span": [39, 49], "ent_id": "D005473", "tok_span": [8, 11]}], "relation_list": [{"subject": "fluoxetine", "object": "pulmonary hypertension", "sbj_char_span": [39, 49], "obj_char_span": [76, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.", "entity_list": [{"name": "QT prolongation", "ent_type": "Disease", "char_span": [12, 27], "ent_id": "D008133", "tok_span": [3, 6]}, {"name": "methadone", "ent_type": "Chemical", "char_span": [56, 65], "ent_id": "D008691", "tok_span": [10, 13]}, {"name": "heroin", "ent_type": "Chemical", "char_span": [70, 76], "ent_id": "D003932", "tok_span": [14, 16]}, {"name": "Syncope", "ent_type": "Disease", "char_span": [0, 7], "ent_id": "D013575", "tok_span": [0, 2]}], "relation_list": [{"subject": "methadone", "object": "QT prolongation", "sbj_char_span": [56, 65], "obj_char_span": [12, 27], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [3, 6]}, {"subject": "methadone", "object": "Syncope", "sbj_char_span": [56, 65], "obj_char_span": [0, 7], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.", "entity_list": [{"name": "syncope", "ent_type": "Disease", "char_span": [106, 113], "ent_id": "D013575", "tok_span": [22, 24]}, {"name": "heroin", "ent_type": "Chemical", "char_span": [3, 9], "ent_id": "D003932", "tok_span": [1, 3]}, {"name": "TdP", "ent_type": "Disease", "char_span": [177, 180], "ent_id": "D016171", "tok_span": [35, 38]}, {"name": "methadone", "ent_type": "Chemical", "char_span": [306, 315], "ent_id": "D008691", "tok_span": [65, 68]}], "relation_list": [{"subject": "methadone", "object": "syncope", "sbj_char_span": [306, 315], "obj_char_span": [106, 113], "rel_type": "chemical-induced disease", "sbj_tok_span": [65, 68], "obj_tok_span": [22, 24]}], "umls_entity_list": []}, {"text": "The association between opioid dose and QT, and methadone dose and reporting of syncope was assessed using multivariate linear regression and logistic regression, respectively.", "entity_list": [{"name": "syncope", "ent_type": "Disease", "char_span": [80, 87], "ent_id": "D013575", "tok_span": [16, 18]}, {"name": "methadone", "ent_type": "Chemical", "char_span": [48, 57], "ent_id": "D008691", "tok_span": [9, 12]}], "relation_list": [{"subject": "methadone", "object": "syncope", "sbj_char_span": [48, 57], "obj_char_span": [80, 87], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "Among the subjects treated with methadone, 28% men and 32% women had prolonged QTc interval.", "entity_list": [{"name": "methadone", "ent_type": "Chemical", "char_span": [32, 41], "ent_id": "D008691", "tok_span": [5, 8]}, {"name": "prolonged QTc interval", "ent_type": "Disease", "char_span": [69, 91], "ent_id": "D008133", "tok_span": [17, 21]}], "relation_list": [{"subject": "methadone", "object": "prolonged QTc interval", "sbj_char_span": [32, 41], "obj_char_span": [69, 91], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [17, 21]}], "umls_entity_list": []}, {"text": "A 50 mg higher methadone dose was associated with a 1.2 (95% CI 1.1 to 1.4) times higher odds for syncope.", "entity_list": [{"name": "methadone", "ent_type": "Chemical", "char_span": [15, 24], "ent_id": "D008691", "tok_span": [4, 7]}, {"name": "syncope", "ent_type": "Disease", "char_span": [98, 105], "ent_id": "D013575", "tok_span": [31, 33]}], "relation_list": [{"subject": "methadone", "object": "syncope", "sbj_char_span": [15, 24], "obj_char_span": [98, 105], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [31, 33]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts.", "entity_list": [{"name": "heroin", "ent_type": "Chemical", "char_span": [109, 115], "ent_id": "D003932", "tok_span": [21, 23]}, {"name": "QT prolongation", "ent_type": "Disease", "char_span": [42, 57], "ent_id": "D008133", "tok_span": [8, 11]}, {"name": "Methadone", "ent_type": "Chemical", "char_span": [13, 22], "ent_id": "D008691", "tok_span": [2, 5]}, {"name": "syncope", "ent_type": "Disease", "char_span": [82, 89], "ent_id": "D013575", "tok_span": [15, 17]}], "relation_list": [{"subject": "Methadone", "object": "syncope", "sbj_char_span": [13, 22], "obj_char_span": [82, 89], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [15, 17]}, {"subject": "Methadone", "object": "QT prolongation", "sbj_char_span": [13, 22], "obj_char_span": [42, 57], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [8, 11]}], "umls_entity_list": []}, {"text": "Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia.", "entity_list": [{"name": "acute myeloid leukemia", "ent_type": "Disease", "char_span": [91, 113], "ent_id": "D015470", "tok_span": [17, 20]}, {"name": "cytosine arabinoside", "ent_type": "Chemical", "char_span": [42, 62], "ent_id": "D003561", "tok_span": [7, 12]}, {"name": "Peripheral neuropathy", "ent_type": "Disease", "char_span": [0, 21], "ent_id": "D010523", "tok_span": [0, 2]}], "relation_list": [{"subject": "cytosine arabinoside", "object": "Peripheral neuropathy", "sbj_char_span": [42, 62], "obj_char_span": [0, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 12], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Although the mechanisms of peripheral neuropathy are still unclear, high-dose cytosine arabinoside is a therapy that is potentially toxic to the peripheral nervous system, and auto/alloimmunity may play an important role in these mechanisms.", "entity_list": [{"name": "cytosine arabinoside", "ent_type": "Chemical", "char_span": [78, 98], "ent_id": "D003561", "tok_span": [13, 18]}, {"name": "peripheral neuropathy", "ent_type": "Disease", "char_span": [27, 48], "ent_id": "D010523", "tok_span": [4, 6]}], "relation_list": [{"subject": "cytosine arabinoside", "object": "peripheral neuropathy", "sbj_char_span": [78, 98], "obj_char_span": [27, 48], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 18], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "Atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat.", "entity_list": [{"name": "hypertension", "ent_type": "Disease", "char_span": [58, 70], "ent_id": "D006973", "tok_span": [9, 10]}, {"name": "Atorvastatin", "ent_type": "Chemical", "char_span": [0, 12], "ent_id": "C065179", "tok_span": [0, 3]}, {"name": "dexamethasone", "ent_type": "Chemical", "char_span": [36, 49], "ent_id": "D003907", "tok_span": [6, 7]}], "relation_list": [{"subject": "dexamethasone", "object": "hypertension", "sbj_char_span": [36, 49], "obj_char_span": [58, 70], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [9, 10]}], "umls_entity_list": []}, {"text": "To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.", "entity_list": [{"name": "hypertension", "ent_type": "Disease", "char_span": [90, 102], "ent_id": "D006973", "tok_span": [21, 22]}, {"name": "dexamethasone", "ent_type": "Chemical", "char_span": [62, 75], "ent_id": "D003907", "tok_span": [15, 16]}, {"name": "atorvastatin", "ent_type": "Chemical", "char_span": [37, 49], "ent_id": "C065179", "tok_span": [6, 9]}, {"name": "atorva", "ent_type": "Chemical", "char_span": [51, 57], "ent_id": "C065179", "tok_span": [10, 13]}, {"name": "atorva", "ent_type": "Chemical", "char_span": [150, 156], "ent_id": "C065179", "tok_span": [33, 36]}, {"name": "dex", "ent_type": "Chemical", "char_span": [77, 80], "ent_id": "D003907", "tok_span": [17, 18]}], "relation_list": [{"subject": "dex", "object": "hypertension", "sbj_char_span": [77, 80], "obj_char_span": [90, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 18], "obj_tok_span": [21, 22]}, {"subject": "dexamethasone", "object": "hypertension", "sbj_char_span": [62, 75], "obj_char_span": [90, 102], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 16], "obj_tok_span": [21, 22]}], "umls_entity_list": []}, {"text": "Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).", "entity_list": [{"name": "dex", "ent_type": "Chemical", "char_span": [16, 19], "ent_id": "D003907", "tok_span": [4, 5]}, {"name": "atorva", "ent_type": "Chemical", "char_span": [160, 166], "ent_id": "C065179", "tok_span": [60, 63]}, {"name": "hypertension", "ent_type": "Disease", "char_span": [28, 40], "ent_id": "D006973", "tok_span": [7, 8]}, {"name": "dex", "ent_type": "Chemical", "char_span": [169, 172], "ent_id": "D003907", "tok_span": [64, 65]}, {"name": "superoxide", "ent_type": "Chemical", "char_span": [113, 123], "ent_id": "D013481", "tok_span": [38, 39]}, {"name": "dex", "ent_type": "Chemical", "char_span": [140, 143], "ent_id": "D003907", "tok_span": [49, 50]}, {"name": "Atorva", "ent_type": "Chemical", "char_span": [0, 6], "ent_id": "C065179", "tok_span": [0, 3]}], "relation_list": [{"subject": "dex", "object": "hypertension", "sbj_char_span": [140, 143], "obj_char_span": [28, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [49, 50], "obj_tok_span": [7, 8]}, {"subject": "dex", "object": "hypertension", "sbj_char_span": [16, 19], "obj_char_span": [28, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [7, 8]}, {"subject": "dex", "object": "hypertension", "sbj_char_span": [169, 172], "obj_char_span": [28, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [64, 65], "obj_tok_span": [7, 8]}], "umls_entity_list": []}, {"text": "Thus, atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat.", "entity_list": [{"name": "hypertension", "ent_type": "Disease", "char_span": [64, 76], "ent_id": "D006973", "tok_span": [11, 12]}, {"name": "atorvastatin", "ent_type": "Chemical", "char_span": [6, 18], "ent_id": "C065179", "tok_span": [2, 5]}, {"name": "dexamethasone", "ent_type": "Chemical", "char_span": [42, 55], "ent_id": "D003907", "tok_span": [8, 9]}], "relation_list": [{"subject": "dexamethasone", "object": "hypertension", "sbj_char_span": [42, 55], "obj_char_span": [64, 76], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [11, 12]}], "umls_entity_list": []}, {"text": "Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.", "entity_list": [{"name": "carrageenan", "ent_type": "Chemical", "char_span": [115, 126], "ent_id": "D002351", "tok_span": [27, 32]}, {"name": "thermal hyperalgesia", "ent_type": "Disease", "char_span": [135, 155], "ent_id": "D006930", "tok_span": [34, 39]}, {"name": "formalin", "ent_type": "Chemical", "char_span": [85, 93], "ent_id": "D005557", "tok_span": [19, 20]}, {"name": "capsaicin", "ent_type": "Chemical", "char_span": [161, 170], "ent_id": "D002211", "tok_span": [41, 44]}, {"name": "mechanical hyperalgesia", "ent_type": "Disease", "char_span": [179, 202], "ent_id": "D006930", "tok_span": [46, 51]}, {"name": "pain", "ent_type": "Disease", "char_span": [67, 71], "ent_id": "D010146", "tok_span": [15, 16]}], "relation_list": [{"subject": "carrageenan", "object": "mechanical hyperalgesia", "sbj_char_span": [115, 126], "obj_char_span": [179, 202], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 32], "obj_tok_span": [46, 51]}, {"subject": "carrageenan", "object": "thermal hyperalgesia", "sbj_char_span": [115, 126], "obj_char_span": [135, 155], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 32], "obj_tok_span": [34, 39]}, {"subject": "capsaicin", "object": "thermal hyperalgesia", "sbj_char_span": [161, 170], "obj_char_span": [135, 155], "rel_type": "chemical-induced disease", "sbj_tok_span": [41, 44], "obj_tok_span": [34, 39]}, {"subject": "capsaicin", "object": "mechanical hyperalgesia", "sbj_char_span": [161, 170], "obj_char_span": [179, 202], "rel_type": "chemical-induced disease", "sbj_tok_span": [41, 44], "obj_tok_span": [46, 51]}], "umls_entity_list": []}, {"text": "Anemia was induced using a single dose of carboplatin (50 mg/kg i.v.) resulting in a long-lasting reduction (30%) of the hemoglobin concentration.", "entity_list": [{"name": "carboplatin", "ent_type": "Chemical", "char_span": [42, 53], "ent_id": "D016190", "tok_span": [9, 12]}, {"name": "Anemia", "ent_type": "Disease", "char_span": [0, 6], "ent_id": "D000740", "tok_span": [0, 2]}], "relation_list": [{"subject": "carboplatin", "object": "Anemia", "sbj_char_span": [42, 53], "obj_char_span": [0, 6], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "In a second group, the development of anemia was prevented by rHuEPO (1000 IU/kg) administered s.c. three times/week starting 7 days before carboplatin application.", "entity_list": [{"name": "carboplatin", "ent_type": "Chemical", "char_span": [140, 151], "ent_id": "D016190", "tok_span": [35, 38]}, {"name": "anemia", "ent_type": "Disease", "char_span": [38, 44], "ent_id": "D000740", "tok_span": [8, 9]}], "relation_list": [{"subject": "carboplatin", "object": "anemia", "sbj_char_span": [140, 151], "obj_char_span": [38, 44], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 38], "obj_tok_span": [8, 9]}], "umls_entity_list": []}, {"text": "The role of nitrergic system in lidocaine-induced convulsion in the mouse.", "entity_list": [{"name": "convulsion", "ent_type": "Disease", "char_span": [50, 60], "ent_id": "D012640", "tok_span": [11, 13]}, {"name": "lidocaine", "ent_type": "Chemical", "char_span": [32, 41], "ent_id": "D008012", "tok_span": [7, 9]}], "relation_list": [{"subject": "lidocaine", "object": "convulsion", "sbj_char_span": [32, 41], "obj_char_span": [50, 60], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 9], "obj_tok_span": [11, 13]}], "umls_entity_list": []}, {"text": "The effects of N-nitro-L-arginine-methyl ester (L-NAME) a nitric oxide (NO) synthase inhibitor and L-arginine, a NO precursor, were investigated on lidocaine-induced convulsions.", "entity_list": [{"name": "NO", "ent_type": "Chemical", "char_span": [113, 115], "ent_id": "D009569", "tok_span": [33, 34]}, {"name": "L-NAME", "ent_type": "Chemical", "char_span": [48, 54], "ent_id": "D019331", "tok_span": [14, 18]}, {"name": "L-arginine", "ent_type": "Chemical", "char_span": [99, 109], "ent_id": "D001120", "tok_span": [28, 31]}, {"name": "lidocaine", "ent_type": "Chemical", "char_span": [148, 157], "ent_id": "D008012", "tok_span": [39, 41]}, {"name": "N-nitro-L-arginine-methyl ester", "ent_type": "Chemical", "char_span": [15, 46], "ent_id": "D019331", "tok_span": [3, 13]}, {"name": "convulsions", "ent_type": "Disease", "char_span": [166, 177], "ent_id": "D012640", "tok_span": [43, 46]}, {"name": "nitric oxide", "ent_type": "Chemical", "char_span": [58, 70], "ent_id": "D009569", "tok_span": [20, 22]}, {"name": "NO", "ent_type": "Chemical", "char_span": [72, 74], "ent_id": "D009569", "tok_span": [23, 24]}], "relation_list": [{"subject": "lidocaine", "object": "convulsions", "sbj_char_span": [148, 157], "obj_char_span": [166, 177], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 41], "obj_tok_span": [43, 46]}], "umls_entity_list": []}, {"text": "L-NAME (100 mg/kg, i.p.) and diazepam (2 mg/kg) significantly decreased the incidence of lidocaine (50 mg/kg)-induced convulsions.", "entity_list": [{"name": "lidocaine", "ent_type": "Chemical", "char_span": [89, 98], "ent_id": "D008012", "tok_span": [30, 32]}, {"name": "L-NAME", "ent_type": "Chemical", "char_span": [0, 6], "ent_id": "D019331", "tok_span": [0, 4]}, {"name": "diazepam", "ent_type": "Chemical", "char_span": [29, 37], "ent_id": "D003975", "tok_span": [16, 19]}, {"name": "convulsions", "ent_type": "Disease", "char_span": [118, 129], "ent_id": "D012640", "tok_span": [40, 43]}], "relation_list": [{"subject": "lidocaine", "object": "convulsions", "sbj_char_span": [89, 98], "obj_char_span": [118, 129], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 32], "obj_tok_span": [40, 43]}], "umls_entity_list": []}, {"text": "In contrast, the L-arginine treatment increased the incidence of lidocaine (80 mg/kg, i.p.)-induced convulsions significantly.", "entity_list": [{"name": "L-arginine", "ent_type": "Chemical", "char_span": [17, 27], "ent_id": "D001120", "tok_span": [4, 7]}, {"name": "lidocaine", "ent_type": "Chemical", "char_span": [65, 74], "ent_id": "D008012", "tok_span": [12, 14]}, {"name": "convulsions", "ent_type": "Disease", "char_span": [100, 111], "ent_id": "D012640", "tok_span": [27, 30]}], "relation_list": [{"subject": "lidocaine", "object": "convulsions", "sbj_char_span": [65, 74], "obj_char_span": [100, 111], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 14], "obj_tok_span": [27, 30]}], "umls_entity_list": []}, {"text": "These results may suggest that NO is a proconvulsant mediator in lidocaine-induced convulsions.", "entity_list": [{"name": "lidocaine", "ent_type": "Chemical", "char_span": [65, 74], "ent_id": "D008012", "tok_span": [15, 17]}, {"name": "convulsions", "ent_type": "Disease", "char_span": [83, 94], "ent_id": "D012640", "tok_span": [19, 22]}, {"name": "NO", "ent_type": "Chemical", "char_span": [31, 33], "ent_id": "D009569", "tok_span": [5, 6]}], "relation_list": [{"subject": "lidocaine", "object": "convulsions", "sbj_char_span": [65, 74], "obj_char_span": [83, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 17], "obj_tok_span": [19, 22]}], "umls_entity_list": []}, {"text": "Effect of intravenous metoprolol or intravenous metoprolol plus glucagon on dobutamine-induced myocardial ischemia.", "entity_list": [{"name": "dobutamine", "ent_type": "Chemical", "char_span": [76, 86], "ent_id": "D004280", "tok_span": [14, 17]}, {"name": "metoprolol", "ent_type": "Chemical", "char_span": [22, 32], "ent_id": "D008790", "tok_span": [3, 6]}, {"name": "myocardial ischemia", "ent_type": "Disease", "char_span": [95, 114], "ent_id": "D017202", "tok_span": [19, 21]}, {"name": "metoprolol", "ent_type": "Chemical", "char_span": [48, 58], "ent_id": "D008790", "tok_span": [8, 11]}], "relation_list": [{"subject": "dobutamine", "object": "myocardial ischemia", "sbj_char_span": [76, 86], "obj_char_span": [95, 114], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [19, 21]}], "umls_entity_list": []}, {"text": "CONCLUSION: During dobutamine stress testing, metoprolol attenuates or eliminates evidence of myocardial ischemia.", "entity_list": [{"name": "dobutamine", "ent_type": "Chemical", "char_span": [19, 29], "ent_id": "D004280", "tok_span": [3, 6]}, {"name": "myocardial ischemia", "ent_type": "Disease", "char_span": [94, 113], "ent_id": "D017202", "tok_span": [18, 20]}, {"name": "metoprolol", "ent_type": "Chemical", "char_span": [46, 56], "ent_id": "D008790", "tok_span": [9, 12]}], "relation_list": [{"subject": "dobutamine", "object": "myocardial ischemia", "sbj_char_span": [19, 29], "obj_char_span": [94, 113], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [18, 20]}], "umls_entity_list": []}, {"text": "Prednisolone-induced muscle dysfunction is caused more by atrophy than by altered acetylcholine receptor expression.", "entity_list": [{"name": "Prednisolone", "ent_type": "Chemical", "char_span": [0, 12], "ent_id": "D011239", "tok_span": [0, 3]}, {"name": "atrophy", "ent_type": "Disease", "char_span": [58, 65], "ent_id": "D001284", "tok_span": [11, 12]}, {"name": "acetylcholine", "ent_type": "Chemical", "char_span": [82, 95], "ent_id": "D000109", "tok_span": [15, 16]}, {"name": "muscle dysfunction", "ent_type": "Disease", "char_span": [21, 39], "ent_id": "D018908", "tok_span": [5, 7]}], "relation_list": [{"subject": "Prednisolone", "object": "muscle dysfunction", "sbj_char_span": [0, 12], "obj_char_span": [21, 39], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "Our results suggest that the neuromuscular dysfunction after prednisolone is dose-dependent, and derives primarily from muscle atrophy and derives less so from changes in AChR expression.", "entity_list": [{"name": "muscle atrophy", "ent_type": "Disease", "char_span": [120, 134], "ent_id": "D009133", "tok_span": [19, 21]}, {"name": "prednisolone", "ent_type": "Chemical", "char_span": [61, 73], "ent_id": "D011239", "tok_span": [8, 10]}, {"name": "neuromuscular dysfunction", "ent_type": "Disease", "char_span": [29, 54], "ent_id": "D009468", "tok_span": [5, 7]}], "relation_list": [{"subject": "prednisolone", "object": "muscle atrophy", "sbj_char_span": [61, 73], "obj_char_span": [120, 134], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [19, 21]}], "umls_entity_list": []}, {"text": "Rapid reversal of life-threatening diltiazem-induced tetany with calcium chloride.", "entity_list": [{"name": "calcium chloride", "ent_type": "Chemical", "char_span": [65, 81], "ent_id": "D002122", "tok_span": [16, 18]}, {"name": "diltiazem", "ent_type": "Chemical", "char_span": [35, 44], "ent_id": "D004110", "tok_span": [7, 11]}, {"name": "tetany", "ent_type": "Disease", "char_span": [53, 59], "ent_id": "D013746", "tok_span": [13, 15]}], "relation_list": [{"subject": "diltiazem", "object": "tetany", "sbj_char_span": [35, 44], "obj_char_span": [53, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "We describe a patient who developed tetany with sudden respiratory arrest after the infusion of intravenous diltiazem.", "entity_list": [{"name": "respiratory arrest", "ent_type": "Disease", "char_span": [55, 73], "ent_id": "D012131", "tok_span": [10, 12]}, {"name": "tetany", "ent_type": "Disease", "char_span": [36, 42], "ent_id": "D013746", "tok_span": [6, 8]}, {"name": "diltiazem", "ent_type": "Chemical", "char_span": [108, 117], "ent_id": "D004110", "tok_span": [17, 21]}], "relation_list": [{"subject": "diltiazem", "object": "tetany", "sbj_char_span": [108, 117], "obj_char_span": [36, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "The emergency physician should be aware that life-threatening tetany may accompany the administration of intravenous diltiazem and that calcium chloride may be a rapid and effective remedy.", "entity_list": [{"name": "diltiazem", "ent_type": "Chemical", "char_span": [117, 126], "ent_id": "D004110", "tok_span": [20, 24]}, {"name": "calcium chloride", "ent_type": "Chemical", "char_span": [136, 152], "ent_id": "D002122", "tok_span": [26, 28]}, {"name": "tetany", "ent_type": "Disease", "char_span": [62, 68], "ent_id": "D013746", "tok_span": [11, 13]}], "relation_list": [{"subject": "diltiazem", "object": "tetany", "sbj_char_span": [117, 126], "obj_char_span": [62, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 24], "obj_tok_span": [11, 13]}], "umls_entity_list": []}, {"text": "Maximal platelet aggregation induced by 6 microM of adenosine diphosphate decreased after administration of ketoprofen.", "entity_list": [{"name": "platelet aggregation", "ent_type": "Disease", "char_span": [8, 28], "ent_id": "D001791", "tok_span": [2, 4]}, {"name": "ketoprofen", "ent_type": "Chemical", "char_span": [108, 118], "ent_id": "D007660", "tok_span": [17, 20]}, {"name": "adenosine diphosphate", "ent_type": "Chemical", "char_span": [52, 73], "ent_id": "D000244", "tok_span": [10, 13]}], "relation_list": [{"subject": "ketoprofen", "object": "platelet aggregation", "sbj_char_span": [108, 118], "obj_char_span": [8, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [2, 4]}], "umls_entity_list": []}, {"text": "One patient in the ketoprofen group developed a postoperative intracranial hematoma.", "entity_list": [{"name": "ketoprofen", "ent_type": "Chemical", "char_span": [19, 29], "ent_id": "D007660", "tok_span": [4, 7]}, {"name": "hematoma", "ent_type": "Disease", "char_span": [75, 83], "ent_id": "D006406", "tok_span": [12, 14]}], "relation_list": [{"subject": "ketoprofen", "object": "hematoma", "sbj_char_span": [19, 29], "obj_char_span": [75, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [12, 14]}], "umls_entity_list": []}, {"text": "Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial.", "entity_list": [{"name": "methylprednisolone", "ent_type": "Chemical", "char_span": [9, 27], "ent_id": "D008775", "tok_span": [2, 6]}, {"name": "myalgia", "ent_type": "Disease", "char_span": [60, 67], "ent_id": "D063806", "tok_span": [14, 17]}, {"name": "iron dextran", "ent_type": "Chemical", "char_span": [120, 132], "ent_id": "D007505", "tok_span": [25, 28]}, {"name": "arthralgia", "ent_type": "Disease", "char_span": [49, 59], "ent_id": "D018771", "tok_span": [10, 13]}], "relation_list": [{"subject": "iron dextran", "object": "arthralgia", "sbj_char_span": [120, 132], "obj_char_span": [49, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 28], "obj_tok_span": [10, 13]}], "umls_entity_list": []}, {"text": "A case of polymyositis in a patient with primary biliary cirrhosis treated with D-penicillamine.", "entity_list": [{"name": "primary biliary cirrhosis", "ent_type": "Disease", "char_span": [41, 66], "ent_id": "D008105", "tok_span": [11, 14]}, {"name": "D-penicillamine", "ent_type": "Chemical", "char_span": [80, 95], "ent_id": "D010396", "tok_span": [16, 23]}, {"name": "polymyositis", "ent_type": "Disease", "char_span": [10, 22], "ent_id": "D017285", "tok_span": [3, 7]}], "relation_list": [{"subject": "D-penicillamine", "object": "polymyositis", "sbj_char_span": [80, 95], "obj_char_span": [10, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 23], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "Polymyositis/dermatomyositis can develop as one of the autoimmune complications of D-penicillamine treatment, but its exact pathogenesis remains unclear.", "entity_list": [{"name": "D-penicillamine", "ent_type": "Chemical", "char_span": [83, 98], "ent_id": "D010396", "tok_span": [18, 25]}, {"name": "Polymyositis", "ent_type": "Disease", "char_span": [0, 12], "ent_id": "D017285", "tok_span": [0, 4]}, {"name": "dermatomyositis", "ent_type": "Disease", "char_span": [13, 28], "ent_id": "D003882", "tok_span": [5, 9]}], "relation_list": [{"subject": "D-penicillamine", "object": "Polymyositis", "sbj_char_span": [83, 98], "obj_char_span": [0, 12], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 25], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "We report a patient with primary biliary cirrhosis, who developed polymyositis while receiving D-penicillamine therapy.", "entity_list": [{"name": "primary biliary cirrhosis", "ent_type": "Disease", "char_span": [25, 50], "ent_id": "D008105", "tok_span": [5, 8]}, {"name": "polymyositis", "ent_type": "Disease", "char_span": [66, 78], "ent_id": "D017285", "tok_span": [11, 15]}, {"name": "D-penicillamine", "ent_type": "Chemical", "char_span": [95, 110], "ent_id": "D010396", "tok_span": [17, 24]}], "relation_list": [{"subject": "D-penicillamine", "object": "polymyositis", "sbj_char_span": [95, 110], "obj_char_span": [66, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 24], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "Patients receiving D-penicillamine therapy should be followed carefully for the development of autoimmune complications like polymyositis/dermatomyositis.", "entity_list": [{"name": "D-penicillamine", "ent_type": "Chemical", "char_span": [19, 34], "ent_id": "D010396", "tok_span": [2, 9]}, {"name": "polymyositis", "ent_type": "Disease", "char_span": [125, 137], "ent_id": "D017285", "tok_span": [21, 25]}, {"name": "dermatomyositis", "ent_type": "Disease", "char_span": [138, 153], "ent_id": "D003882", "tok_span": [26, 30]}], "relation_list": [{"subject": "D-penicillamine", "object": "polymyositis", "sbj_char_span": [19, 34], "obj_char_span": [125, 137], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 9], "obj_tok_span": [21, 25]}], "umls_entity_list": []}, {"text": "Photodistributed nifedipine-induced facial telangiectasia.", "entity_list": [{"name": "nifedipine", "ent_type": "Chemical", "char_span": [17, 27], "ent_id": "D009543", "tok_span": [5, 8]}, {"name": "telangiectasia", "ent_type": "Disease", "char_span": [43, 57], "ent_id": "D013684", "tok_span": [11, 15]}], "relation_list": [{"subject": "nifedipine", "object": "telangiectasia", "sbj_char_span": [17, 27], "obj_char_span": [43, 57], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "Five months after starting nifedipine (Adalat), two patients developed photodistributed facial telangiectasia, which became more noticeable with time.", "entity_list": [{"name": "nifedipine", "ent_type": "Chemical", "char_span": [27, 37], "ent_id": "D009543", "tok_span": [4, 7]}, {"name": "Adalat", "ent_type": "Chemical", "char_span": [39, 45], "ent_id": "D009543", "tok_span": [8, 10]}, {"name": "telangiectasia", "ent_type": "Disease", "char_span": [95, 109], "ent_id": "D013684", "tok_span": [20, 24]}], "relation_list": [{"subject": "nifedipine", "object": "telangiectasia", "sbj_char_span": [27, 37], "obj_char_span": [95, 109], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [20, 24]}, {"subject": "Adalat", "object": "telangiectasia", "sbj_char_span": [39, 45], "obj_char_span": [95, 109], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "One commenced the closely related drug amlodipine 3 years later, with recurrence of telangiectasia.", "entity_list": [{"name": "telangiectasia", "ent_type": "Disease", "char_span": [84, 98], "ent_id": "D013684", "tok_span": [18, 22]}, {"name": "amlodipine", "ent_type": "Chemical", "char_span": [39, 49], "ent_id": "D017311", "tok_span": [7, 11]}], "relation_list": [{"subject": "amlodipine", "object": "telangiectasia", "sbj_char_span": [39, 49], "obj_char_span": [84, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [18, 22]}], "umls_entity_list": []}, {"text": "Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase.", "entity_list": [{"name": "Nephrotoxicity", "ent_type": "Disease", "char_span": [0, 14], "ent_id": "D007674", "tok_span": [0, 3]}, {"name": "FK506", "ent_type": "Chemical", "char_span": [36, 41], "ent_id": "D016559", "tok_span": [8, 10]}, {"name": "cyclosporin A", "ent_type": "Chemical", "char_span": [18, 31], "ent_id": "D016572", "tok_span": [4, 7]}], "relation_list": [{"subject": "FK506", "object": "Nephrotoxicity", "sbj_char_span": [36, 41], "obj_char_span": [0, 14], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [0, 3]}, {"subject": "cyclosporin A", "object": "Nephrotoxicity", "sbj_char_span": [18, 31], "obj_char_span": [0, 14], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "These results suggest that the nephrotoxic effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase.", "entity_list": [{"name": "FK506", "ent_type": "Chemical", "char_span": [62, 67], "ent_id": "D016559", "tok_span": [13, 15]}, {"name": "nephrotoxic", "ent_type": "Disease", "char_span": [31, 42], "ent_id": "D007674", "tok_span": [5, 8]}, {"name": "CsA", "ent_type": "Chemical", "char_span": [54, 57], "ent_id": "D016572", "tok_span": [10, 12]}], "relation_list": [{"subject": "CsA", "object": "nephrotoxic", "sbj_char_span": [54, 57], "obj_char_span": [31, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 12], "obj_tok_span": [5, 8]}, {"subject": "FK506", "object": "nephrotoxic", "sbj_char_span": [62, 67], "obj_char_span": [31, 42], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [5, 8]}], "umls_entity_list": []}, {"text": "Massive cerebral edema associated with fulminant hepatic failure in acetaminophen overdose: possible role of cranial decompression.", "entity_list": [{"name": "cerebral edema", "ent_type": "Disease", "char_span": [8, 22], "ent_id": "D001929", "tok_span": [2, 4]}, {"name": "overdose", "ent_type": "Disease", "char_span": [82, 90], "ent_id": "D062787", "tok_span": [15, 17]}, {"name": "hepatic failure", "ent_type": "Disease", "char_span": [49, 64], "ent_id": "D017093", "tok_span": [9, 11]}, {"name": "acetaminophen", "ent_type": "Chemical", "char_span": [68, 81], "ent_id": "D000082", "tok_span": [12, 15]}], "relation_list": [{"subject": "acetaminophen", "object": "cerebral edema", "sbj_char_span": [68, 81], "obj_char_span": [8, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [2, 4]}, {"subject": "acetaminophen", "object": "hepatic failure", "sbj_char_span": [68, 81], "obj_char_span": [49, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "We present a patient with fatal acetaminophen-induced fulminant hepatic failure, with signs and symptoms of cerebral edema, unresponsive to conventional medical therapy.", "entity_list": [{"name": "cerebral edema", "ent_type": "Disease", "char_span": [108, 122], "ent_id": "D001929", "tok_span": [22, 24]}, {"name": "fulminant hepatic failure", "ent_type": "Disease", "char_span": [54, 79], "ent_id": "D017093", "tok_span": [11, 16]}, {"name": "acetaminophen", "ent_type": "Chemical", "char_span": [32, 45], "ent_id": "D000082", "tok_span": [6, 9]}], "relation_list": [{"subject": "acetaminophen", "object": "cerebral edema", "sbj_char_span": [32, 45], "obj_char_span": [108, 122], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [22, 24]}, {"subject": "acetaminophen", "object": "fulminant hepatic failure", "sbj_char_span": [32, 45], "obj_char_span": [54, 79], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [11, 16]}], "umls_entity_list": []}, {"text": "The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with gentamicin (5 mg/kg/day) and penicillin are presented.", "entity_list": [{"name": "gentamicin", "ent_type": "Chemical", "char_span": [105, 115], "ent_id": "D005839", "tok_span": [18, 20]}, {"name": "penicillin", "ent_type": "Chemical", "char_span": [134, 144], "ent_id": "D010406", "tok_span": [29, 30]}, {"name": "acute renal failure", "ent_type": "Disease", "char_span": [66, 85], "ent_id": "D058186", "tok_span": [12, 15]}], "relation_list": [{"subject": "gentamicin", "object": "acute renal failure", "sbj_char_span": [105, 115], "obj_char_span": [66, 85], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 20], "obj_tok_span": [12, 15]}], "umls_entity_list": []}, {"text": "After the end of the treatment, the number and the size of induced PAS positive preneoplastic foci was significantly reduced when PB was given simultaneously with DEN for 4 and 6 weeks.", "entity_list": [{"name": "preneoplastic foci", "ent_type": "Disease", "char_span": [80, 98], "ent_id": "D011230", "tok_span": [16, 20]}, {"name": "DEN", "ent_type": "Chemical", "char_span": [163, 166], "ent_id": "D004052", "tok_span": [29, 30]}, {"name": "PB", "ent_type": "Chemical", "char_span": [130, 132], "ent_id": "D010634", "tok_span": [24, 25]}], "relation_list": [{"subject": "DEN", "object": "preneoplastic foci", "sbj_char_span": [163, 166], "obj_char_span": [80, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 30], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "Post-operative rigidity after fentanyl administration.", "entity_list": [{"name": "rigidity", "ent_type": "Disease", "char_span": [15, 23], "ent_id": "D009127", "tok_span": [3, 4]}, {"name": "fentanyl", "ent_type": "Chemical", "char_span": [30, 38], "ent_id": "D005283", "tok_span": [5, 8]}], "relation_list": [{"subject": "fentanyl", "object": "rigidity", "sbj_char_span": [30, 38], "obj_char_span": [15, 23], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [3, 4]}], "umls_entity_list": []}, {"text": "A case of thoraco-abdominal rigidity leading to respiratory failure is described in the post-operative period in an elderly patient who received a moderate dose of fentanyl.", "entity_list": [{"name": "fentanyl", "ent_type": "Chemical", "char_span": [164, 172], "ent_id": "D005283", "tok_span": [30, 33]}, {"name": "rigidity", "ent_type": "Disease", "char_span": [28, 36], "ent_id": "D009127", "tok_span": [7, 8]}, {"name": "respiratory failure", "ent_type": "Disease", "char_span": [48, 67], "ent_id": "D012131", "tok_span": [10, 12]}], "relation_list": [{"subject": "fentanyl", "object": "rigidity", "sbj_char_span": [164, 172], "obj_char_span": [28, 36], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 33], "obj_tok_span": [7, 8]}], "umls_entity_list": []}, {"text": "Postpartum psychosis induced by bromocriptine.", "entity_list": [{"name": "psychosis", "ent_type": "Disease", "char_span": [11, 20], "ent_id": "D011605", "tok_span": [2, 3]}, {"name": "bromocriptine", "ent_type": "Chemical", "char_span": [32, 45], "ent_id": "D001971", "tok_span": [5, 9]}], "relation_list": [{"subject": "bromocriptine", "object": "psychosis", "sbj_char_span": [32, 45], "obj_char_span": [11, 20], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [2, 3]}], "umls_entity_list": []}, {"text": "Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis, having received bromocriptine for inhibition of lactation.", "entity_list": [{"name": "psychosis", "ent_type": "Disease", "char_span": [86, 95], "ent_id": "D011605", "tok_span": [14, 15]}, {"name": "bromocriptine", "ent_type": "Chemical", "char_span": [113, 126], "ent_id": "D001971", "tok_span": [18, 22]}, {"name": "inhibition of lactation", "ent_type": "Disease", "char_span": [131, 154], "ent_id": "D007775", "tok_span": [23, 26]}, {"name": "psychiatric", "ent_type": "Disease", "char_span": [40, 51], "ent_id": "D001523", "tok_span": [8, 9]}], "relation_list": [{"subject": "bromocriptine", "object": "psychosis", "sbj_char_span": [113, 126], "obj_char_span": [86, 95], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 22], "obj_tok_span": [14, 15]}], "umls_entity_list": []}, {"text": "Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson's disease.", "entity_list": [{"name": "Parkinson's disease", "ent_type": "Disease", "char_span": [104, 123], "ent_id": "D010300", "tok_span": [19, 23]}, {"name": "Bromocriptine", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D001971", "tok_span": [0, 4]}, {"name": "psychosis", "ent_type": "Disease", "char_span": [59, 68], "ent_id": "D011605", "tok_span": [12, 13]}], "relation_list": [{"subject": "Bromocriptine", "object": "psychosis", "sbj_char_span": [0, 13], "obj_char_span": [59, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [12, 13]}], "umls_entity_list": []}, {"text": "These cases demonstrate that bromocriptine may cause psychosis even when given in low doses.", "entity_list": [{"name": "psychosis", "ent_type": "Disease", "char_span": [53, 62], "ent_id": "D011605", "tok_span": [10, 11]}, {"name": "bromocriptine", "ent_type": "Chemical", "char_span": [29, 42], "ent_id": "D001971", "tok_span": [4, 8]}], "relation_list": [{"subject": "bromocriptine", "object": "psychosis", "sbj_char_span": [29, 42], "obj_char_span": [53, 62], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 8], "obj_tok_span": [10, 11]}], "umls_entity_list": []}, {"text": "One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.", "entity_list": [{"name": "MMC", "ent_type": "Chemical", "char_span": [62, 65], "ent_id": "D016685", "tok_span": [13, 15]}, {"name": "doxorubicin", "ent_type": "Chemical", "char_span": [86, 97], "ent_id": "D004317", "tok_span": [22, 23]}, {"name": "cardiac failure", "ent_type": "Disease", "char_span": [30, 45], "ent_id": "D006333", "tok_span": [5, 7]}], "relation_list": [{"subject": "MMC", "object": "cardiac failure", "sbj_char_span": [62, 65], "obj_char_span": [30, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [5, 7]}, {"subject": "doxorubicin", "object": "cardiac failure", "sbj_char_span": [86, 97], "obj_char_span": [30, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).", "entity_list": [{"name": "glycosuria", "ent_type": "Disease", "char_span": [93, 103], "ent_id": "D006029", "tok_span": [22, 24]}, {"name": "acute renal failure", "ent_type": "Disease", "char_span": [222, 241], "ent_id": "D058186", "tok_span": [51, 54]}, {"name": "diabetes mellitus", "ent_type": "Disease", "char_span": [41, 58], "ent_id": "D003920", "tok_span": [9, 11]}, {"name": "DM", "ent_type": "Disease", "char_span": [60, 62], "ent_id": "D003920", "tok_span": [12, 13]}, {"name": "gentamicin", "ent_type": "Chemical", "char_span": [203, 213], "ent_id": "D005839", "tok_span": [47, 49]}, {"name": "ARF", "ent_type": "Disease", "char_span": [243, 246], "ent_id": "D058186", "tok_span": [55, 57]}, {"name": "streptozotocin", "ent_type": "Chemical", "char_span": [18, 32], "ent_id": "D013311", "tok_span": [3, 7]}], "relation_list": [{"subject": "gentamicin", "object": "ARF", "sbj_char_span": [203, 213], "obj_char_span": [243, 246], "rel_type": "chemical-induced disease", "sbj_tok_span": [47, 49], "obj_tok_span": [55, 57]}, {"subject": "streptozotocin", "object": "DM", "sbj_char_span": [18, 32], "obj_char_span": [60, 62], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 7], "obj_tok_span": [12, 13]}, {"subject": "gentamicin", "object": "acute renal failure", "sbj_char_span": [203, 213], "obj_char_span": [222, 241], "rel_type": "chemical-induced disease", "sbj_tok_span": [47, 49], "obj_tok_span": [51, 54]}, {"subject": "streptozotocin", "object": "diabetes mellitus", "sbj_char_span": [18, 32], "obj_char_span": [41, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 7], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).", "entity_list": [{"name": "gentamicin", "ent_type": "Chemical", "char_span": [31, 41], "ent_id": "D005839", "tok_span": [8, 10]}, {"name": "P", "ent_type": "Chemical", "char_span": [13, 14], "ent_id": "D010695", "tok_span": [4, 5]}, {"name": "tubular necrosis", "ent_type": "Disease", "char_span": [155, 171], "ent_id": "D009956", "tok_span": [52, 54]}, {"name": "ARF", "ent_type": "Disease", "char_span": [42, 45], "ent_id": "D058186", "tok_span": [11, 13]}, {"name": "P", "ent_type": "Chemical", "char_span": [85, 86], "ent_id": "D010695", "tok_span": [26, 27]}], "relation_list": [{"subject": "gentamicin", "object": "ARF", "sbj_char_span": [31, 41], "obj_char_span": [42, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 10], "obj_tok_span": [11, 13]}], "umls_entity_list": []}, {"text": "Tiapride in levodopa-induced involuntary movements.", "entity_list": [{"name": "levodopa", "ent_type": "Chemical", "char_span": [12, 20], "ent_id": "D007980", "tok_span": [5, 8]}, {"name": "Tiapride", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D063325", "tok_span": [0, 4]}, {"name": "involuntary movements", "ent_type": "Disease", "char_span": [29, 50], "ent_id": "D004409", "tok_span": [10, 13]}], "relation_list": [{"subject": "levodopa", "object": "involuntary movements", "sbj_char_span": [12, 20], "obj_char_span": [29, 50], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [10, 13]}], "umls_entity_list": []}, {"text": "Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.", "entity_list": [{"name": "idiopathic Parkinson's disease", "ent_type": "Disease", "char_span": [157, 187], "ent_id": "D010300", "tok_span": [34, 39]}, {"name": "metoclopramide", "ent_type": "Chemical", "char_span": [64, 78], "ent_id": "D008787", "tok_span": [13, 18]}, {"name": "involuntary movements", "ent_type": "Disease", "char_span": [115, 136], "ent_id": "D004409", "tok_span": [27, 30]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [88, 96], "ent_id": "D007980", "tok_span": [20, 23]}, {"name": "Tiapride", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D063325", "tok_span": [0, 4]}, {"name": "benzamide", "ent_type": "Chemical", "char_span": [24, 33], "ent_id": "C037689", "tok_span": [7, 9]}], "relation_list": [{"subject": "levodopa", "object": "involuntary movements", "sbj_char_span": [88, 96], "obj_char_span": [115, 136], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [27, 30]}], "umls_entity_list": []}, {"text": "These results fail to support the notion that levodopa-induced dyskinesias are caused by overstimulation of a separate group of dopamine receptors.", "entity_list": [{"name": "dyskinesias", "ent_type": "Disease", "char_span": [63, 74], "ent_id": "D004409", "tok_span": [13, 17]}, {"name": "dopamine", "ent_type": "Chemical", "char_span": [128, 136], "ent_id": "D004298", "tok_span": [28, 29]}, {"name": "levodopa", "ent_type": "Chemical", "char_span": [46, 54], "ent_id": "D007980", "tok_span": [8, 11]}], "relation_list": [{"subject": "levodopa", "object": "dyskinesias", "sbj_char_span": [46, 54], "obj_char_span": [63, 74], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "Ketamine elicited psychosis like psychopathology.", "entity_list": [{"name": "Ketamine", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D007649", "tok_span": [0, 4]}, {"name": "psychosis", "ent_type": "Disease", "char_span": [18, 27], "ent_id": "D011605", "tok_span": [5, 6]}], "relation_list": [{"subject": "Ketamine", "object": "psychosis", "sbj_char_span": [0, 8], "obj_char_span": [18, 27], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [5, 6]}], "umls_entity_list": []}, {"text": "Dopamine is not essential for the development of methamphetamine-induced neurotoxicity.", "entity_list": [{"name": "methamphetamine", "ent_type": "Chemical", "char_span": [49, 64], "ent_id": "D008694", "tok_span": [11, 14]}, {"name": "neurotoxicity", "ent_type": "Disease", "char_span": [73, 86], "ent_id": "D020258", "tok_span": [16, 18]}, {"name": "Dopamine", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D004298", "tok_span": [0, 4]}], "relation_list": [{"subject": "methamphetamine", "object": "neurotoxicity", "sbj_char_span": [49, 64], "obj_char_span": [73, 86], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.", "entity_list": [{"name": "DA", "ent_type": "Chemical", "char_span": [155, 157], "ent_id": "D004298", "tok_span": [33, 34]}, {"name": "L-dihydroxyphenylalanine", "ent_type": "Chemical", "char_span": [51, 75], "ent_id": "D007980", "tok_span": [9, 15]}, {"name": "METH", "ent_type": "Chemical", "char_span": [142, 146], "ent_id": "D008694", "tok_span": [29, 31]}, {"name": "alpha-methyl-para-tyrosine", "ent_type": "Chemical", "char_span": [112, 138], "ent_id": "D019805", "tok_span": [21, 28]}, {"name": "neurotoxicity", "ent_type": "Disease", "char_span": [158, 171], "ent_id": "D020258", "tok_span": [34, 36]}], "relation_list": [{"subject": "METH", "object": "neurotoxicity", "sbj_char_span": [142, 146], "obj_char_span": [158, 171], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 31], "obj_tok_span": [34, 36]}], "umls_entity_list": []}, {"text": "Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.", "entity_list": [{"name": "METH", "ent_type": "Chemical", "char_span": [140, 144], "ent_id": "D008694", "tok_span": [28, 30]}, {"name": "METH", "ent_type": "Chemical", "char_span": [86, 90], "ent_id": "D008694", "tok_span": [15, 17]}, {"name": "DA", "ent_type": "Chemical", "char_span": [75, 77], "ent_id": "D004298", "tok_span": [13, 14]}, {"name": "neurotoxicity", "ent_type": "Disease", "char_span": [91, 104], "ent_id": "D020258", "tok_span": [17, 19]}], "relation_list": [{"subject": "METH", "object": "neurotoxicity", "sbj_char_span": [140, 144], "obj_char_span": [91, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 30], "obj_tok_span": [17, 19]}, {"subject": "METH", "object": "neurotoxicity", "sbj_char_span": [86, 90], "obj_char_span": [91, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 17], "obj_tok_span": [17, 19]}], "umls_entity_list": []}, {"text": "Taken together, these findings demonstrate that DA is not essential for the development of METH-induced dopaminergic neurotoxicity and suggest that mechanisms independent of DA warrant more intense investigation.", "entity_list": [{"name": "DA", "ent_type": "Chemical", "char_span": [174, 176], "ent_id": "D004298", "tok_span": [28, 29]}, {"name": "DA", "ent_type": "Chemical", "char_span": [48, 50], "ent_id": "D004298", "tok_span": [7, 8]}, {"name": "neurotoxicity", "ent_type": "Disease", "char_span": [117, 130], "ent_id": "D020258", "tok_span": [20, 22]}, {"name": "METH", "ent_type": "Chemical", "char_span": [91, 95], "ent_id": "D008694", "tok_span": [15, 17]}], "relation_list": [{"subject": "METH", "object": "neurotoxicity", "sbj_char_span": [91, 95], "obj_char_span": [117, 130], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 17], "obj_tok_span": [20, 22]}], "umls_entity_list": []}, {"text": "The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy.", "entity_list": [{"name": "streptozotocin", "ent_type": "Chemical", "char_span": [31, 45], "ent_id": "D013311", "tok_span": [7, 11]}, {"name": "diabetic nephropathy", "ent_type": "Disease", "char_span": [54, 74], "ent_id": "D003928", "tok_span": [13, 15]}], "relation_list": [{"subject": "streptozotocin", "object": "diabetic nephropathy", "sbj_char_span": [31, 45], "obj_char_span": [54, 74], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "RESEARCH DESIGN AND METHODS: We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients, a streptozotocin-induced diabetic nephropathy model in Nrf2(-/-) mice, and cultured human mesangial cells.", "entity_list": [{"name": "diabetic nephropathy", "ent_type": "Disease", "char_span": [136, 156], "ent_id": "D003928", "tok_span": [22, 24]}, {"name": "diabetic nephropathy", "ent_type": "Disease", "char_span": [192, 212], "ent_id": "D003928", "tok_span": [33, 35]}, {"name": "diabetic nephropathy", "ent_type": "Disease", "char_span": [76, 96], "ent_id": "D003928", "tok_span": [14, 16]}, {"name": "streptozotocin", "ent_type": "Chemical", "char_span": [169, 183], "ent_id": "D013311", "tok_span": [27, 31]}], "relation_list": [{"subject": "streptozotocin", "object": "diabetic nephropathy", "sbj_char_span": [169, 183], "obj_char_span": [76, 96], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 31], "obj_tok_span": [14, 16]}, {"subject": "streptozotocin", "object": "diabetic nephropathy", "sbj_char_span": [169, 183], "obj_char_span": [192, 212], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 31], "obj_tok_span": [33, 35]}, {"subject": "streptozotocin", "object": "diabetic nephropathy", "sbj_char_span": [169, 183], "obj_char_span": [136, 156], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 31], "obj_tok_span": [22, 24]}], "umls_entity_list": []}, {"text": "High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [66, 74], "ent_id": "D012640", "tok_span": [14, 15]}, {"name": "tranexamic Acid", "ent_type": "Chemical", "char_span": [10, 25], "ent_id": "D014148", "tok_span": [3, 7]}], "relation_list": [{"subject": "tranexamic Acid", "object": "seizures", "sbj_char_span": [10, 25], "obj_char_span": [66, 74], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 7], "obj_tok_span": [14, 15]}], "umls_entity_list": []}, {"text": "The purpose of this review was to perform a retrospective analysis to examine whether there was a relation between TXA usage and seizures after cardiac surgery.", "entity_list": [{"name": "TXA", "ent_type": "Chemical", "char_span": [115, 118], "ent_id": "D014148", "tok_span": [19, 21]}, {"name": "seizures", "ent_type": "Disease", "char_span": [129, 137], "ent_id": "D012640", "tok_span": [23, 24]}], "relation_list": [{"subject": "TXA", "object": "seizures", "sbj_char_span": [115, 118], "obj_char_span": [129, 137], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 21], "obj_tok_span": [23, 24]}], "umls_entity_list": []}, {"text": "All 24 patients with seizures received high doses of TXA intraoperatively ranging from 61 to 259 mg/kg, had a mean age of 69.9 years, and 21 of 24 had undergone open chamber rather than coronary bypass procedures.", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [21, 29], "ent_id": "D012640", "tok_span": [4, 5]}, {"name": "TXA", "ent_type": "Chemical", "char_span": [53, 56], "ent_id": "D014148", "tok_span": [9, 11]}], "relation_list": [{"subject": "TXA", "object": "seizures", "sbj_char_span": [53, 56], "obj_char_span": [21, 29], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 11], "obj_tok_span": [4, 5]}], "umls_entity_list": []}, {"text": "CONCLUSION: Our results suggest that use of high-dose TXA in older patients in conjunction with cardiopulmonary bypass and open-chamber cardiac surgery is associated with clinical seizures in susceptible patients.", "entity_list": [{"name": "seizures", "ent_type": "Disease", "char_span": [180, 188], "ent_id": "D012640", "tok_span": [31, 32]}, {"name": "TXA", "ent_type": "Chemical", "char_span": [54, 57], "ent_id": "D014148", "tok_span": [11, 13]}], "relation_list": [{"subject": "TXA", "object": "seizures", "sbj_char_span": [54, 57], "obj_char_span": [180, 188], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 13], "obj_tok_span": [31, 32]}], "umls_entity_list": []}, {"text": "Recurrent dysosmia induced by pyrazinamide.", "entity_list": [{"name": "dysosmia", "ent_type": "Disease", "char_span": [10, 18], "ent_id": "D000857", "tok_span": [2, 5]}, {"name": "pyrazinamide", "ent_type": "Chemical", "char_span": [30, 42], "ent_id": "D011718", "tok_span": [7, 11]}], "relation_list": [{"subject": "pyrazinamide", "object": "dysosmia", "sbj_char_span": [30, 42], "obj_char_span": [10, 18], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [2, 5]}], "umls_entity_list": []}, {"text": "We report a case of reversible olfactory disorder related to pyrazinamide in a woman, with a positive rechallenge.", "entity_list": [{"name": "pyrazinamide", "ent_type": "Chemical", "char_span": [61, 73], "ent_id": "D011718", "tok_span": [10, 14]}, {"name": "olfactory disorder", "ent_type": "Disease", "char_span": [31, 49], "ent_id": "D000857", "tok_span": [6, 8]}], "relation_list": [{"subject": "pyrazinamide", "object": "olfactory disorder", "sbj_char_span": [61, 73], "obj_char_span": [31, 49], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "Dysosmia disappeared completely after pyrazinamide withdrawal and recurred after its rechallenge.", "entity_list": [{"name": "Dysosmia", "ent_type": "Disease", "char_span": [0, 8], "ent_id": "D000857", "tok_span": [0, 3]}, {"name": "pyrazinamide", "ent_type": "Chemical", "char_span": [38, 50], "ent_id": "D011718", "tok_span": [6, 10]}], "relation_list": [{"subject": "pyrazinamide", "object": "Dysosmia", "sbj_char_span": [38, 50], "obj_char_span": [0, 8], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 10], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "There was no significant difference in the proportion of subjects in the DFMO plus sulindac group who experienced clinically significant hearing loss compared with the placebo group.", "entity_list": [{"name": "hearing loss", "ent_type": "Disease", "char_span": [137, 149], "ent_id": "D034381", "tok_span": [23, 25]}, {"name": "DFMO", "ent_type": "Chemical", "char_span": [73, 77], "ent_id": "D000518", "tok_span": [12, 14]}, {"name": "sulindac", "ent_type": "Chemical", "char_span": [83, 91], "ent_id": "D013467", "tok_span": [15, 18]}], "relation_list": [{"subject": "sulindac", "object": "hearing loss", "sbj_char_span": [83, 91], "obj_char_span": [137, 149], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [23, 25]}], "umls_entity_list": []}, {"text": "Increased mental slowing associated with the APOE epsilon4 allele after trihexyphenidyl oral anticholinergic challenge in healthy elderly.", "entity_list": [{"name": "mental slowing", "ent_type": "Disease", "char_span": [10, 24], "ent_id": "D003072", "tok_span": [1, 3]}, {"name": "trihexyphenidyl", "ent_type": "Chemical", "char_span": [72, 87], "ent_id": "D014282", "tok_span": [14, 20]}], "relation_list": [{"subject": "trihexyphenidyl", "object": "mental slowing", "sbj_char_span": [72, 87], "obj_char_span": [10, 24], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 20], "obj_tok_span": [1, 3]}], "umls_entity_list": []}, {"text": "RESULTS: A 2.0-mg oral dose of trihexyphenidyl resulted in increased subjective ratings of mental slowness in carriers of the APOE epsilon4 allele only.", "entity_list": [{"name": "trihexyphenidyl", "ent_type": "Chemical", "char_span": [31, 46], "ent_id": "D014282", "tok_span": [11, 17]}, {"name": "mental slowness", "ent_type": "Disease", "char_span": [91, 106], "ent_id": "D003072", "tok_span": [23, 26]}], "relation_list": [{"subject": "trihexyphenidyl", "object": "mental slowness", "sbj_char_span": [31, 46], "obj_char_span": [91, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 17], "obj_tok_span": [23, 26]}], "umls_entity_list": []}, {"text": "Drug effects as determined by difference scores between 2.0 mg trihexyphenidyl and placebo on ratings of mental slowness significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only.", "entity_list": [{"name": "mental slowness", "ent_type": "Disease", "char_span": [105, 120], "ent_id": "D003072", "tok_span": [23, 26]}, {"name": "trihexyphenidyl", "ent_type": "Chemical", "char_span": [63, 78], "ent_id": "D014282", "tok_span": [12, 18]}], "relation_list": [{"subject": "trihexyphenidyl", "object": "mental slowness", "sbj_char_span": [63, 78], "obj_char_span": [105, 120], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 18], "obj_tok_span": [23, 26]}], "umls_entity_list": []}, {"text": "CONCLUSION: The epsilon4 allele in healthy elderly was associated with increased subjective mental slowing after trihexyphenidyl anticholinergic challenge.", "entity_list": [{"name": "mental slowing", "ent_type": "Disease", "char_span": [92, 106], "ent_id": "D003072", "tok_span": [16, 18]}, {"name": "trihexyphenidyl", "ent_type": "Chemical", "char_span": [113, 128], "ent_id": "D014282", "tok_span": [19, 25]}], "relation_list": [{"subject": "trihexyphenidyl", "object": "mental slowing", "sbj_char_span": [113, 128], "obj_char_span": [92, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 25], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "T alone had no effect on locomotion, irritability, or sexual behavior but increased partner preference and aggression.", "entity_list": [{"name": "irritability", "ent_type": "Disease", "char_span": [37, 49], "ent_id": "D001523", "tok_span": [8, 10]}, {"name": "T", "ent_type": "Chemical", "char_span": [0, 1], "ent_id": "D013739", "tok_span": [0, 1]}, {"name": "aggression", "ent_type": "Disease", "char_span": [107, 117], "ent_id": "D001523", "tok_span": [19, 20]}], "relation_list": [{"subject": "T", "object": "aggression", "sbj_char_span": [0, 1], "obj_char_span": [107, 117], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 1], "obj_tok_span": [19, 20]}, {"subject": "T", "object": "irritability", "sbj_char_span": [0, 1], "obj_char_span": [37, 49], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 1], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel.", "entity_list": [{"name": "brain edema", "ent_type": "Disease", "char_span": [93, 104], "ent_id": "D001929", "tok_span": [16, 18]}, {"name": "paclitaxel", "ent_type": "Chemical", "char_span": [45, 55], "ent_id": "D017239", "tok_span": [9, 10]}, {"name": "paclitaxel", "ent_type": "Chemical", "char_span": [166, 176], "ent_id": "D017239", "tok_span": [30, 31]}], "relation_list": [{"subject": "paclitaxel", "object": "brain edema", "sbj_char_span": [166, 176], "obj_char_span": [93, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 31], "obj_tok_span": [16, 18]}, {"subject": "paclitaxel", "object": "brain edema", "sbj_char_span": [45, 55], "obj_char_span": [93, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "Methylphenidate-induced obsessive-compulsive symptoms in an elderly man.", "entity_list": [{"name": "Methylphenidate", "ent_type": "Chemical", "char_span": [0, 15], "ent_id": "D008774", "tok_span": [0, 3]}, {"name": "obsessive-compulsive symptoms", "ent_type": "Disease", "char_span": [24, 53], "ent_id": "D009771", "tok_span": [5, 11]}], "relation_list": [{"subject": "Methylphenidate", "object": "obsessive-compulsive symptoms", "sbj_char_span": [0, 15], "obj_char_span": [24, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 11]}], "umls_entity_list": []}, {"text": "Significant obsessive-compulsive behavior ensued but diminished over several weeks when methylphenidate was replaced by fluvoxamine.", "entity_list": [{"name": "methylphenidate", "ent_type": "Chemical", "char_span": [88, 103], "ent_id": "D008774", "tok_span": [15, 18]}, {"name": "obsessive-compulsive behavior", "ent_type": "Disease", "char_span": [12, 41], "ent_id": "D009771", "tok_span": [1, 7]}, {"name": "fluvoxamine", "ent_type": "Chemical", "char_span": [120, 131], "ent_id": "D016666", "tok_span": [21, 25]}], "relation_list": [{"subject": "methylphenidate", "object": "obsessive-compulsive behavior", "sbj_char_span": [88, 103], "obj_char_span": [12, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [1, 7]}], "umls_entity_list": []}, {"text": "Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest.", "entity_list": [{"name": "metoclopramide", "ent_type": "Chemical", "char_span": [33, 47], "ent_id": "D008787", "tok_span": [4, 9]}, {"name": "metoclopramide", "ent_type": "Chemical", "char_span": [88, 102], "ent_id": "D008787", "tok_span": [17, 22]}, {"name": "cardiac arrest", "ent_type": "Disease", "char_span": [128, 142], "ent_id": "D006323", "tok_span": [26, 28]}, {"name": "Cardiac arrest", "ent_type": "Disease", "char_span": [0, 14], "ent_id": "D006323", "tok_span": [0, 2]}], "relation_list": [{"subject": "metoclopramide", "object": "Cardiac arrest", "sbj_char_span": [88, 102], "obj_char_span": [0, 14], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 22], "obj_tok_span": [0, 2]}, {"subject": "metoclopramide", "object": "cardiac arrest", "sbj_char_span": [33, 47], "obj_char_span": [128, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 9], "obj_tok_span": [26, 28]}, {"subject": "metoclopramide", "object": "cardiac arrest", "sbj_char_span": [88, 102], "obj_char_span": [128, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 22], "obj_tok_span": [26, 28]}, {"subject": "metoclopramide", "object": "Cardiac arrest", "sbj_char_span": [33, 47], "obj_char_span": [0, 14], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 9], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "We describe a patient where intravenous injection of metoclopramide was immediately followed by asystole repeatedly.", "entity_list": [{"name": "metoclopramide", "ent_type": "Chemical", "char_span": [53, 67], "ent_id": "D008787", "tok_span": [8, 13]}, {"name": "asystole", "ent_type": "Disease", "char_span": [96, 104], "ent_id": "D006323", "tok_span": [17, 20]}], "relation_list": [{"subject": "metoclopramide", "object": "asystole", "sbj_char_span": [53, 67], "obj_char_span": [96, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 13], "obj_tok_span": [17, 20]}], "umls_entity_list": []}, {"text": "The patient received metoclopramide 10 mg i.v. five times during 48 h. After interviewing the attending nurses and reviewing the written documentation, it is clear that every administration of metoclopramide was immediately (within s) followed by asystole.", "entity_list": [{"name": "asystole", "ent_type": "Disease", "char_span": [247, 255], "ent_id": "D006323", "tok_span": [52, 55]}, {"name": "metoclopramide", "ent_type": "Chemical", "char_span": [193, 207], "ent_id": "D008787", "tok_span": [39, 44]}, {"name": "metoclopramide", "ent_type": "Chemical", "char_span": [21, 35], "ent_id": "D008787", "tok_span": [3, 8]}], "relation_list": [{"subject": "metoclopramide", "object": "asystole", "sbj_char_span": [193, 207], "obj_char_span": [247, 255], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 44], "obj_tok_span": [52, 55]}, {"subject": "metoclopramide", "object": "asystole", "sbj_char_span": [21, 35], "obj_char_span": [247, 255], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 8], "obj_tok_span": [52, 55]}], "umls_entity_list": []}, {"text": "We interpret this as episodes of cardiac arrest caused by metoclopramide.", "entity_list": [{"name": "cardiac arrest", "ent_type": "Disease", "char_span": [33, 47], "ent_id": "D006323", "tok_span": [6, 8]}, {"name": "metoclopramide", "ent_type": "Chemical", "char_span": [58, 72], "ent_id": "D008787", "tok_span": [10, 15]}], "relation_list": [{"subject": "metoclopramide", "object": "cardiac arrest", "sbj_char_span": [58, 72], "obj_char_span": [33, 47], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 15], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures.", "entity_list": [{"name": "cefotetan", "ent_type": "Chemical", "char_span": [67, 76], "ent_id": "D015313", "tok_span": [10, 13]}, {"name": "hemolytic anemia", "ent_type": "Disease", "char_span": [14, 30], "ent_id": "D000743", "tok_span": [2, 5]}], "relation_list": [{"subject": "cefotetan", "object": "hemolytic anemia", "sbj_char_span": [67, 76], "obj_char_span": [14, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [2, 5]}], "umls_entity_list": []}, {"text": "Second- and third-generation cephalosporins, especially cefotetan, are increasingly associated with severe, sometimes fatal immune hemolytic anemia.", "entity_list": [{"name": "cefotetan", "ent_type": "Chemical", "char_span": [56, 65], "ent_id": "D015313", "tok_span": [11, 14]}, {"name": "hemolytic anemia", "ent_type": "Disease", "char_span": [131, 147], "ent_id": "D000743", "tok_span": [24, 27]}, {"name": "cephalosporins", "ent_type": "Chemical", "char_span": [29, 43], "ent_id": "D002511", "tok_span": [6, 9]}], "relation_list": [{"subject": "cefotetan", "object": "hemolytic anemia", "sbj_char_span": [56, 65], "obj_char_span": [131, 147], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [24, 27]}], "umls_entity_list": []}, {"text": "We noticed that 10 of our 35 cases of cefotetan-induced hemolytic anemias were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures.", "entity_list": [{"name": "hemolytic anemias", "ent_type": "Disease", "char_span": [56, 73], "ent_id": "D000743", "tok_span": [14, 18]}, {"name": "cefotetan", "ent_type": "Chemical", "char_span": [108, 117], "ent_id": "D015313", "tok_span": [24, 27]}, {"name": "cefotetan", "ent_type": "Chemical", "char_span": [38, 47], "ent_id": "D015313", "tok_span": [9, 12]}], "relation_list": [{"subject": "cefotetan", "object": "hemolytic anemias", "sbj_char_span": [108, 117], "obj_char_span": [56, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 27], "obj_tok_span": [14, 18]}, {"subject": "cefotetan", "object": "hemolytic anemias", "sbj_char_span": [38, 47], "obj_char_span": [56, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [14, 18]}], "umls_entity_list": []}, {"text": "Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.", "entity_list": [{"name": "cauda equina syndrome", "ent_type": "Disease", "char_span": [103, 124], "ent_id": "D011128", "tok_span": [23, 28]}, {"name": "lignocaine", "ent_type": "Chemical", "char_span": [66, 76], "ent_id": "D008012", "tok_span": [14, 16]}, {"name": "Cauda equina syndrome", "ent_type": "Disease", "char_span": [0, 21], "ent_id": "D011128", "tok_span": [0, 5]}], "relation_list": [{"subject": "lignocaine", "object": "Cauda equina syndrome", "sbj_char_span": [66, 76], "obj_char_span": [0, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [0, 5]}, {"subject": "lignocaine", "object": "cauda equina syndrome", "sbj_char_span": [66, 76], "obj_char_span": [103, 124], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [23, 28]}], "umls_entity_list": []}, {"text": "Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia.", "entity_list": [{"name": "dyskinesia", "ent_type": "Disease", "char_span": [85, 95], "ent_id": "D004409", "tok_span": [20, 24]}, {"name": "L-dopa", "ent_type": "Chemical", "char_span": [60, 66], "ent_id": "D007980", "tok_span": [11, 15]}, {"name": "parkinsonian", "ent_type": "Disease", "char_span": [33, 45], "ent_id": "D020734", "tok_span": [6, 9]}], "relation_list": [{"subject": "L-dopa", "object": "dyskinesia", "sbj_char_span": [60, 66], "obj_char_span": [85, 95], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.", "entity_list": [{"name": "dyskinesia", "ent_type": "Disease", "char_span": [276, 286], "ent_id": "D004409", "tok_span": [59, 63]}, {"name": "dyskinesia", "ent_type": "Disease", "char_span": [334, 344], "ent_id": "D004409", "tok_span": [76, 80]}, {"name": "L-dopa", "ent_type": "Chemical", "char_span": [220, 226], "ent_id": "D007980", "tok_span": [44, 48]}, {"name": "L-dopa", "ent_type": "Chemical", "char_span": [261, 267], "ent_id": "D007980", "tok_span": [54, 58]}, {"name": "parkinsonian", "ent_type": "Disease", "char_span": [195, 207], "ent_id": "D020734", "tok_span": [39, 42]}], "relation_list": [{"subject": "L-dopa", "object": "dyskinesia", "sbj_char_span": [261, 267], "obj_char_span": [276, 286], "rel_type": "chemical-induced disease", "sbj_tok_span": [54, 58], "obj_tok_span": [59, 63]}, {"subject": "L-dopa", "object": "dyskinesia", "sbj_char_span": [261, 267], "obj_char_span": [334, 344], "rel_type": "chemical-induced disease", "sbj_tok_span": [54, 58], "obj_tok_span": [76, 80]}, {"subject": "L-dopa", "object": "dyskinesia", "sbj_char_span": [220, 226], "obj_char_span": [276, 286], "rel_type": "chemical-induced disease", "sbj_tok_span": [44, 48], "obj_tok_span": [59, 63]}, {"subject": "L-dopa", "object": "dyskinesia", "sbj_char_span": [220, 226], "obj_char_span": [334, 344], "rel_type": "chemical-induced disease", "sbj_tok_span": [44, 48], "obj_tok_span": [76, 80]}], "umls_entity_list": []}, {"text": "These results are compatible with the hypothesis that an hyperkinetic abnormal involuntary movement, like L-dopa-induced peak dose dyskinesia, is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop.", "entity_list": [{"name": "L-dopa", "ent_type": "Chemical", "char_span": [106, 112], "ent_id": "D007980", "tok_span": [19, 23]}, {"name": "hyperkinetic", "ent_type": "Disease", "char_span": [57, 69], "ent_id": "D006948", "tok_span": [9, 13]}, {"name": "dyskinesia", "ent_type": "Disease", "char_span": [131, 141], "ent_id": "D004409", "tok_span": [27, 31]}, {"name": "abnormal involuntary movement", "ent_type": "Disease", "char_span": [70, 99], "ent_id": "D004409", "tok_span": [13, 17]}], "relation_list": [{"subject": "L-dopa", "object": "dyskinesia", "sbj_char_span": [106, 112], "obj_char_span": [131, 141], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 23], "obj_tok_span": [27, 31]}, {"subject": "L-dopa", "object": "abnormal involuntary movement", "sbj_char_span": [106, 112], "obj_char_span": [70, 99], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 23], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "Dexamethasone-induced ocular hypertension in perfusion-cultured human eyes.", "entity_list": [{"name": "ocular hypertension", "ent_type": "Disease", "char_span": [22, 41], "ent_id": "D009798", "tok_span": [4, 6]}, {"name": "Dexamethasone", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D003907", "tok_span": [0, 2]}], "relation_list": [{"subject": "Dexamethasone", "object": "ocular hypertension", "sbj_char_span": [0, 13], "obj_char_span": [22, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "In contrast, the dexamethasone-treated hypertensive eyes had thickened trabecular beams, decreased intertrabecular spaces, thickened juxtacanalicular tissue, activated trabecular meshwork cells, and increased amounts of amorphogranular extracellular material, especially in the juxtacanalicular tissue and beneath the endothelial lining of the canal of Schlemm.", "entity_list": [{"name": "dexamethasone", "ent_type": "Chemical", "char_span": [17, 30], "ent_id": "D003907", "tok_span": [4, 5]}, {"name": "hypertensive eyes", "ent_type": "Disease", "char_span": [39, 56], "ent_id": "D009798", "tok_span": [7, 9]}], "relation_list": [{"subject": "dexamethasone", "object": "hypertensive eyes", "sbj_char_span": [17, 30], "obj_char_span": [39, 56], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "CONCLUSION: Dexamethasone treatment of isolated, perfusion-cultured human eyes led to the generation of ocular hypertension in approximately 30% of the dexamethasone-treated eyes.", "entity_list": [{"name": "Dexamethasone", "ent_type": "Chemical", "char_span": [12, 25], "ent_id": "D003907", "tok_span": [2, 4]}, {"name": "ocular hypertension", "ent_type": "Disease", "char_span": [104, 123], "ent_id": "D009798", "tok_span": [18, 20]}, {"name": "dexamethasone", "ent_type": "Chemical", "char_span": [152, 165], "ent_id": "D003907", "tok_span": [26, 27]}], "relation_list": [{"subject": "Dexamethasone", "object": "ocular hypertension", "sbj_char_span": [12, 25], "obj_char_span": [104, 123], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 4], "obj_tok_span": [18, 20]}, {"subject": "dexamethasone", "object": "ocular hypertension", "sbj_char_span": [152, 165], "obj_char_span": [104, 123], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 27], "obj_tok_span": [18, 20]}], "umls_entity_list": []}, {"text": "Cognitive deterioration from long-term abuse of dextromethorphan: a case report.", "entity_list": [{"name": "dextromethorphan", "ent_type": "Chemical", "char_span": [48, 64], "ent_id": "D003915", "tok_span": [8, 13]}, {"name": "Cognitive deterioration", "ent_type": "Disease", "char_span": [0, 23], "ent_id": "D003072", "tok_span": [0, 2]}], "relation_list": [{"subject": "dextromethorphan", "object": "Cognitive deterioration", "sbj_char_span": [48, 64], "obj_char_span": [0, 23], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 13], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "This report describes a case of cognitive deterioration resulting from prolonged use of DM.", "entity_list": [{"name": "cognitive deterioration", "ent_type": "Disease", "char_span": [32, 55], "ent_id": "D003072", "tok_span": [6, 8]}, {"name": "DM", "ent_type": "Chemical", "char_span": [88, 90], "ent_id": "D003915", "tok_span": [13, 14]}], "relation_list": [{"subject": "DM", "object": "cognitive deterioration", "sbj_char_span": [88, 90], "obj_char_span": [32, 55], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 14], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "Complete heart block following a single dose of trazodone.", "entity_list": [{"name": "heart block", "ent_type": "Disease", "char_span": [9, 20], "ent_id": "D006327", "tok_span": [1, 3]}, {"name": "trazodone", "ent_type": "Chemical", "char_span": [48, 57], "ent_id": "D014196", "tok_span": [8, 12]}], "relation_list": [{"subject": "trazodone", "object": "heart block", "sbj_char_span": [48, 57], "obj_char_span": [9, 20], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [1, 3]}], "umls_entity_list": []}, {"text": "Forty minutes after receiving a single starting dose of trazodone, a patient developed complete heart block.", "entity_list": [{"name": "trazodone", "ent_type": "Chemical", "char_span": [56, 65], "ent_id": "D014196", "tok_span": [9, 13]}, {"name": "heart block", "ent_type": "Disease", "char_span": [96, 107], "ent_id": "D006327", "tok_span": [18, 20]}], "relation_list": [{"subject": "trazodone", "object": "heart block", "sbj_char_span": [56, 65], "obj_char_span": [96, 107], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [18, 20]}], "umls_entity_list": []}, {"text": "Quinidine phenylethylbarbiturate-induced fulminant hepatitis in a pregnant woman.", "entity_list": [{"name": "hepatitis", "ent_type": "Disease", "char_span": [51, 60], "ent_id": "D056486", "tok_span": [14, 15]}, {"name": "Quinidine phenylethylbarbiturate", "ent_type": "Chemical", "char_span": [0, 32], "ent_id": "C033457", "tok_span": [0, 9]}], "relation_list": [{"subject": "Quinidine phenylethylbarbiturate", "object": "hepatitis", "sbj_char_span": [0, 32], "obj_char_span": [51, 60], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 9], "obj_tok_span": [14, 15]}], "umls_entity_list": []}, {"text": "We report the case of a 19-year-old Laotian patient affected by fulminant hepatitis during the third trimester of her pregnancy after a 1-month administration of quinidine phenylethylbarbiturate.", "entity_list": [{"name": "hepatitis", "ent_type": "Disease", "char_span": [74, 83], "ent_id": "D056486", "tok_span": [20, 21]}, {"name": "quinidine phenylethylbarbiturate", "ent_type": "Chemical", "char_span": [162, 194], "ent_id": "C033457", "tok_span": [35, 42]}], "relation_list": [{"subject": "quinidine phenylethylbarbiturate", "object": "hepatitis", "sbj_char_span": [162, 194], "obj_char_span": [74, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [35, 42], "obj_tok_span": [20, 21]}], "umls_entity_list": []}, {"text": "Quinidine itself or phenylethylbarbiturate may be responsible for fulminant hepatitis in this patient.", "entity_list": [{"name": "hepatitis", "ent_type": "Disease", "char_span": [76, 85], "ent_id": "D056486", "tok_span": [18, 19]}, {"name": "Quinidine", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D011802", "tok_span": [0, 4]}, {"name": "phenylethylbarbiturate", "ent_type": "Chemical", "char_span": [20, 42], "ent_id": "C033457", "tok_span": [6, 11]}], "relation_list": [{"subject": "phenylethylbarbiturate", "object": "hepatitis", "sbj_char_span": [20, 42], "obj_char_span": [76, 85], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 11], "obj_tok_span": [18, 19]}], "umls_entity_list": []}, {"text": "The epidemiology of the acute flank pain syndrome from suprofen.", "entity_list": [{"name": "suprofen", "ent_type": "Chemical", "char_span": [55, 63], "ent_id": "D013496", "tok_span": [9, 11]}, {"name": "flank pain", "ent_type": "Disease", "char_span": [30, 40], "ent_id": "D021501", "tok_span": [5, 7]}], "relation_list": [{"subject": "suprofen", "object": "flank pain", "sbj_char_span": [55, 63], "obj_char_span": [30, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 11], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "Hemolytic-uremic syndrome associated with ingestion of quinine.", "entity_list": [{"name": "Hemolytic-uremic syndrome", "ent_type": "Disease", "char_span": [0, 25], "ent_id": "D006463", "tok_span": [0, 6]}, {"name": "quinine", "ent_type": "Chemical", "char_span": [55, 62], "ent_id": "D011803", "tok_span": [10, 12]}], "relation_list": [{"subject": "quinine", "object": "Hemolytic-uremic syndrome", "sbj_char_span": [55, 62], "obj_char_span": [0, 25], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 12], "obj_tok_span": [0, 6]}], "umls_entity_list": []}, {"text": "Hemolytic-uremic syndrome following quinine ingestion is a newly described phenomenon, with just two previous descriptions of 4 cases in the literature.", "entity_list": [{"name": "Hemolytic-uremic syndrome", "ent_type": "Disease", "char_span": [0, 25], "ent_id": "D006463", "tok_span": [0, 6]}, {"name": "quinine", "ent_type": "Chemical", "char_span": [36, 43], "ent_id": "D011803", "tok_span": [7, 9]}], "relation_list": [{"subject": "quinine", "object": "Hemolytic-uremic syndrome", "sbj_char_span": [36, 43], "obj_char_span": [0, 25], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 9], "obj_tok_span": [0, 6]}], "umls_entity_list": []}, {"text": "Quinine-associated hemolytic-uremic syndrome probably occurs more often than is recognized.", "entity_list": [{"name": "hemolytic-uremic syndrome", "ent_type": "Disease", "char_span": [19, 44], "ent_id": "D006463", "tok_span": [4, 10]}, {"name": "Quinine", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "D011803", "tok_span": [0, 2]}], "relation_list": [{"subject": "Quinine", "object": "hemolytic-uremic syndrome", "sbj_char_span": [0, 7], "obj_char_span": [19, 44], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [4, 10]}], "umls_entity_list": []}, {"text": "Changes in peroxisomes in preneoplastic liver and hepatoma of mice induced by alpha-benzene hexachloride.", "entity_list": [{"name": "alpha-benzene hexachloride", "ent_type": "Chemical", "char_span": [78, 104], "ent_id": "D001556", "tok_span": [16, 23]}, {"name": "hepatoma", "ent_type": "Disease", "char_span": [50, 58], "ent_id": "D006528", "tok_span": [10, 12]}], "relation_list": [{"subject": "alpha-benzene hexachloride", "object": "hepatoma", "sbj_char_span": [78, 104], "obj_char_span": [50, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 23], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Peroxisomes in hepatomas and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm alpha-benzene hexachloride were examined histochemically and electron microscopically.", "entity_list": [{"name": "alpha-benzene hexachloride", "ent_type": "Chemical", "char_span": [97, 123], "ent_id": "D001556", "tok_span": [21, 28]}, {"name": "liver lesions", "ent_type": "Disease", "char_span": [56, 69], "ent_id": "D017093", "tok_span": [13, 15]}, {"name": "hepatomas", "ent_type": "Disease", "char_span": [15, 24], "ent_id": "D006528", "tok_span": [5, 7]}], "relation_list": [{"subject": "alpha-benzene hexachloride", "object": "hepatomas", "sbj_char_span": [97, 123], "obj_char_span": [15, 24], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 28], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "Quinidine hepatitis.", "entity_list": [{"name": "hepatitis", "ent_type": "Disease", "char_span": [10, 19], "ent_id": "D056486", "tok_span": [4, 5]}, {"name": "Quinidine", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D011802", "tok_span": [0, 4]}], "relation_list": [{"subject": "Quinidine", "object": "hepatitis", "sbj_char_span": [0, 9], "obj_char_span": [10, 19], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [4, 5]}], "umls_entity_list": []}, {"text": "We concluded that this patient had quinidine hepatotoxicity and believe that this is the first case reported with liver biopsy documentation.", "entity_list": [{"name": "hepatotoxicity", "ent_type": "Disease", "char_span": [45, 59], "ent_id": "D056486", "tok_span": [8, 10]}, {"name": "quinidine", "ent_type": "Chemical", "char_span": [35, 44], "ent_id": "D011802", "tok_span": [6, 8]}], "relation_list": [{"subject": "quinidine", "object": "hepatotoxicity", "sbj_char_span": [35, 44], "obj_char_span": [45, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).", "entity_list": [{"name": "CS", "ent_type": "Chemical", "char_span": [102, 104], "ent_id": "-1", "tok_span": [27, 28]}, {"name": "carbon tetrachloride", "ent_type": "Chemical", "char_span": [189, 209], "ent_id": "D002251", "tok_span": [43, 48]}, {"name": "hepatotoxic", "ent_type": "Disease", "char_span": [166, 177], "ent_id": "D056486", "tok_span": [39, 41]}, {"name": "CCl4", "ent_type": "Chemical", "char_span": [211, 215], "ent_id": "D002251", "tok_span": [49, 52]}, {"name": "cholesteryl hemisuccinate", "ent_type": "Chemical", "char_span": [64, 89], "ent_id": "C013440", "tok_span": [15, 23]}, {"name": "tris salt", "ent_type": "Chemical", "char_span": [91, 100], "ent_id": "-1", "tok_span": [24, 26]}], "relation_list": [{"subject": "CCl4", "object": "hepatotoxic", "sbj_char_span": [211, 215], "obj_char_span": [166, 177], "rel_type": "chemical-induced disease", "sbj_tok_span": [49, 52], "obj_tok_span": [39, 41]}, {"subject": "carbon tetrachloride", "object": "hepatotoxic", "sbj_char_span": [189, 209], "obj_char_span": [166, 177], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 48], "obj_tok_span": [39, 41]}], "umls_entity_list": []}, {"text": "A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.", "entity_list": [{"name": "acetaminophen", "ent_type": "Chemical", "char_span": [168, 181], "ent_id": "D000082", "tok_span": [46, 49]}, {"name": "adriamycin", "ent_type": "Chemical", "char_span": [262, 272], "ent_id": "D004317", "tok_span": [66, 70]}, {"name": "CCl4", "ent_type": "Chemical", "char_span": [155, 159], "ent_id": "D002251", "tok_span": [38, 41]}, {"name": "CS", "ent_type": "Chemical", "char_span": [64, 66], "ent_id": "-1", "tok_span": [15, 16]}, {"name": "galactosamine", "ent_type": "Chemical", "char_span": [186, 199], "ent_id": "D005688", "tok_span": [50, 54]}, {"name": "cardiotoxic", "ent_type": "Disease", "char_span": [239, 250], "ent_id": "D066126", "tok_span": [61, 63]}, {"name": "hepatotoxic", "ent_type": "Disease", "char_span": [132, 143], "ent_id": "D056486", "tok_span": [34, 36]}, {"name": "CHCl3", "ent_type": "Chemical", "char_span": [161, 166], "ent_id": "D002725", "tok_span": [42, 45]}], "relation_list": [{"subject": "adriamycin", "object": "cardiotoxic", "sbj_char_span": [262, 272], "obj_char_span": [239, 250], "rel_type": "chemical-induced disease", "sbj_tok_span": [66, 70], "obj_tok_span": [61, 63]}, {"subject": "acetaminophen", "object": "hepatotoxic", "sbj_char_span": [168, 181], "obj_char_span": [132, 143], "rel_type": "chemical-induced disease", "sbj_tok_span": [46, 49], "obj_tok_span": [34, 36]}, {"subject": "CCl4", "object": "hepatotoxic", "sbj_char_span": [155, 159], "obj_char_span": [132, 143], "rel_type": "chemical-induced disease", "sbj_tok_span": [38, 41], "obj_tok_span": [34, 36]}, {"subject": "CHCl3", "object": "hepatotoxic", "sbj_char_span": [161, 166], "obj_char_span": [132, 143], "rel_type": "chemical-induced disease", "sbj_tok_span": [42, 45], "obj_tok_span": [34, 36]}, {"subject": "galactosamine", "object": "hepatotoxic", "sbj_char_span": [186, 199], "obj_char_span": [132, 143], "rel_type": "chemical-induced disease", "sbj_tok_span": [50, 54], "obj_tok_span": [34, 36]}], "umls_entity_list": []}, {"text": "The mechanism of CS protection does not appear to be dependent on the inhibition of chemical bioactivation to a toxic reactive intermediate (in light of the protection observed against galactosamine hepatotoxicity).", "entity_list": [{"name": "CS", "ent_type": "Chemical", "char_span": [17, 19], "ent_id": "-1", "tok_span": [3, 4]}, {"name": "galactosamine", "ent_type": "Chemical", "char_span": [185, 198], "ent_id": "D005688", "tok_span": [31, 35]}, {"name": "hepatotoxicity", "ent_type": "Disease", "char_span": [199, 213], "ent_id": "D056486", "tok_span": [35, 37]}], "relation_list": [{"subject": "galactosamine", "object": "hepatotoxicity", "sbj_char_span": [185, 198], "obj_char_span": [199, 213], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 35], "obj_tok_span": [35, 37]}], "umls_entity_list": []}, {"text": "Cutaneous leucocytoclastic vasculitis associated with oxacillin.", "entity_list": [{"name": "Cutaneous leucocytoclastic vasculitis", "ent_type": "Disease", "char_span": [0, 37], "ent_id": "D018366", "tok_span": [0, 8]}, {"name": "oxacillin", "ent_type": "Chemical", "char_span": [54, 63], "ent_id": "D010068", "tok_span": [10, 13]}], "relation_list": [{"subject": "oxacillin", "object": "Cutaneous leucocytoclastic vasculitis", "sbj_char_span": [54, 63], "obj_char_span": [0, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [0, 8]}], "umls_entity_list": []}, {"text": "A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.", "entity_list": [{"name": "renal failure", "ent_type": "Disease", "char_span": [117, 130], "ent_id": "D051437", "tok_span": [25, 27]}, {"name": "oxacillin", "ent_type": "Chemical", "char_span": [39, 48], "ent_id": "D010068", "tok_span": [11, 14]}, {"name": "purpuric lesions", "ent_type": "Disease", "char_span": [164, 180], "ent_id": "D011693", "tok_span": [34, 38]}, {"name": "Staphylococcus aureus bacteremia", "ent_type": "Disease", "char_span": [73, 105], "ent_id": "D01320", "tok_span": [19, 23]}], "relation_list": [{"subject": "oxacillin", "object": "renal failure", "sbj_char_span": [39, 48], "obj_char_span": [117, 130], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [25, 27]}], "umls_entity_list": []}, {"text": "Oxacillin should be included among the drugs that can cause leucocytoclastic vasculitis.", "entity_list": [{"name": "Oxacillin", "ent_type": "Chemical", "char_span": [0, 9], "ent_id": "D010068", "tok_span": [0, 3]}, {"name": "leucocytoclastic vasculitis", "ent_type": "Disease", "char_span": [60, 87], "ent_id": "D018366", "tok_span": [12, 18]}], "relation_list": [{"subject": "Oxacillin", "object": "leucocytoclastic vasculitis", "sbj_char_span": [0, 9], "obj_char_span": [60, 87], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [12, 18]}], "umls_entity_list": []}, {"text": "Pretreatment with naloxazone significantly blocked morphine analgesia, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.", "entity_list": [{"name": "catalepsy", "ent_type": "Disease", "char_span": [71, 80], "ent_id": "D002375", "tok_span": [11, 14]}, {"name": "analgesia", "ent_type": "Disease", "char_span": [60, 69], "ent_id": "D000699", "tok_span": [9, 10]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [51, 59], "ent_id": "D009020", "tok_span": [8, 9]}, {"name": "naloxazone", "ent_type": "Chemical", "char_span": [18, 28], "ent_id": "C024224", "tok_span": [3, 6]}, {"name": "hypothermia", "ent_type": "Disease", "char_span": [85, 96], "ent_id": "D007035", "tok_span": [15, 17]}], "relation_list": [{"subject": "morphine", "object": "catalepsy", "sbj_char_span": [51, 59], "obj_char_span": [71, 80], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [11, 14]}, {"subject": "morphine", "object": "hypothermia", "sbj_char_span": [51, 59], "obj_char_span": [85, 96], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.", "entity_list": [{"name": "hypotension", "ent_type": "Disease", "char_span": [67, 78], "ent_id": "D007022", "tok_span": [11, 12]}, {"name": "respiratory depression", "ent_type": "Disease", "char_span": [83, 105], "ent_id": "D012131", "tok_span": [13, 15]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [50, 58], "ent_id": "D009020", "tok_span": [8, 9]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [132, 143], "ent_id": "D001919", "tok_span": [20, 24]}, {"name": "naloxazone", "ent_type": "Chemical", "char_span": [10, 20], "ent_id": "C024224", "tok_span": [2, 5]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [115, 123], "ent_id": "D009020", "tok_span": [17, 18]}], "relation_list": [{"subject": "morphine", "object": "bradycardia", "sbj_char_span": [115, 123], "obj_char_span": [132, 143], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 18], "obj_tok_span": [20, 24]}, {"subject": "morphine", "object": "bradycardia", "sbj_char_span": [50, 58], "obj_char_span": [132, 143], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [20, 24]}, {"subject": "morphine", "object": "hypotension", "sbj_char_span": [115, 123], "obj_char_span": [67, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 18], "obj_tok_span": [11, 12]}, {"subject": "morphine", "object": "hypotension", "sbj_char_span": [50, 58], "obj_char_span": [67, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 9], "obj_tok_span": [11, 12]}], "umls_entity_list": []}, {"text": "EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.", "entity_list": [{"name": "dexrazoxane", "ent_type": "Chemical", "char_span": [109, 120], "ent_id": "D064730", "tok_span": [17, 20]}, {"name": "doxorubicin", "ent_type": "Chemical", "char_span": [288, 299], "ent_id": "D004317", "tok_span": [50, 51]}, {"name": "hematologic toxicity", "ent_type": "Disease", "char_span": [58, 78], "ent_id": "D006402", "tok_span": [10, 13]}, {"name": "dexrazoxane", "ent_type": "Chemical", "char_span": [304, 315], "ent_id": "D064730", "tok_span": [54, 57]}, {"name": "etoposide", "ent_type": "Chemical", "char_span": [259, 268], "ent_id": "D005047", "tok_span": [41, 44]}, {"name": "daunorubicin", "ent_type": "Chemical", "char_span": [270, 282], "ent_id": "D003630", "tok_span": [45, 48]}], "relation_list": [{"subject": "doxorubicin", "object": "hematologic toxicity", "sbj_char_span": [288, 299], "obj_char_span": [58, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [50, 51], "obj_tok_span": [10, 13]}, {"subject": "etoposide", "object": "hematologic toxicity", "sbj_char_span": [259, 268], "obj_char_span": [58, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [41, 44], "obj_tok_span": [10, 13]}, {"subject": "daunorubicin", "object": "hematologic toxicity", "sbj_char_span": [270, 282], "obj_char_span": [58, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [45, 48], "obj_tok_span": [10, 13]}], "umls_entity_list": []}, {"text": "RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.", "entity_list": [{"name": "myelosuppression", "ent_type": "Disease", "char_span": [47, 63], "ent_id": "D001855", "tok_span": [12, 16]}, {"name": "dexrazoxane", "ent_type": "Chemical", "char_span": [27, 38], "ent_id": "D064730", "tok_span": [8, 11]}, {"name": "doxorubicin", "ent_type": "Chemical", "char_span": [292, 303], "ent_id": "D004317", "tok_span": [62, 63]}, {"name": "etoposide", "ent_type": "Chemical", "char_span": [102, 111], "ent_id": "D005047", "tok_span": [24, 27]}, {"name": "dexrazoxane", "ent_type": "Chemical", "char_span": [198, 209], "ent_id": "D064730", "tok_span": [43, 46]}, {"name": "myelosuppression", "ent_type": "Disease", "char_span": [226, 242], "ent_id": "D001855", "tok_span": [48, 52]}, {"name": "cytotoxicity", "ent_type": "Disease", "char_span": [274, 286], "ent_id": "D064420", "tok_span": [60, 61]}, {"name": "daunorubicin", "ent_type": "Chemical", "char_span": [85, 97], "ent_id": "D003630", "tok_span": [20, 23]}, {"name": "weight loss", "ent_type": "Disease", "char_span": [244, 255], "ent_id": "D015431", "tok_span": [53, 55]}, {"name": "weight loss", "ent_type": "Disease", "char_span": [68, 79], "ent_id": "D015431", "tok_span": [17, 19]}], "relation_list": [{"subject": "doxorubicin", "object": "weight loss", "sbj_char_span": [292, 303], "obj_char_span": [68, 79], "rel_type": "chemical-induced disease", "sbj_tok_span": [62, 63], "obj_tok_span": [17, 19]}, {"subject": "daunorubicin", "object": "weight loss", "sbj_char_span": [85, 97], "obj_char_span": [68, 79], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [17, 19]}, {"subject": "etoposide", "object": "weight loss", "sbj_char_span": [102, 111], "obj_char_span": [68, 79], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 27], "obj_tok_span": [17, 19]}, {"subject": "etoposide", "object": "weight loss", "sbj_char_span": [102, 111], "obj_char_span": [244, 255], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 27], "obj_tok_span": [53, 55]}, {"subject": "doxorubicin", "object": "weight loss", "sbj_char_span": [292, 303], "obj_char_span": [244, 255], "rel_type": "chemical-induced disease", "sbj_tok_span": [62, 63], "obj_tok_span": [53, 55]}, {"subject": "daunorubicin", "object": "weight loss", "sbj_char_span": [85, 97], "obj_char_span": [244, 255], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 23], "obj_tok_span": [53, 55]}], "umls_entity_list": []}, {"text": "Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.", "entity_list": [{"name": "hematologic toxicity", "ent_type": "Disease", "char_span": [166, 186], "ent_id": "D006402", "tok_span": [29, 32]}, {"name": "metastases", "ent_type": "Disease", "char_span": [39, 49], "ent_id": "D009362", "tok_span": [6, 7]}, {"name": "etoposide", "ent_type": "Chemical", "char_span": [90, 99], "ent_id": "D005047", "tok_span": [15, 18]}, {"name": "dexrazoxane", "ent_type": "Chemical", "char_span": [60, 71], "ent_id": "D064730", "tok_span": [8, 11]}], "relation_list": [{"subject": "etoposide", "object": "hematologic toxicity", "sbj_char_span": [90, 99], "obj_char_span": [166, 186], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 18], "obj_tok_span": [29, 32]}], "umls_entity_list": []}, {"text": "The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).", "entity_list": [{"name": "cycloheximide", "ent_type": "Chemical", "char_span": [800, 813], "ent_id": "D003513", "tok_span": [174, 177]}, {"name": "scopolamine", "ent_type": "Chemical", "char_span": [436, 447], "ent_id": "D012601", "tok_span": [98, 101]}, {"name": "amnesia", "ent_type": "Disease", "char_span": [537, 544], "ent_id": "D000647", "tok_span": [121, 124]}, {"name": "hypercapnia", "ent_type": "Disease", "char_span": [1178, 1189], "ent_id": "D006935", "tok_span": [249, 252]}, {"name": "Ro 13-5057", "ent_type": "Chemical", "char_span": [26, 36], "ent_id": "C036466", "tok_span": [9, 14]}, {"name": "aniracetam", "ent_type": "Chemical", "char_span": [14, 24], "ent_id": "C036466", "tok_span": [3, 8]}, {"name": "cycloheximide", "ent_type": "Chemical", "char_span": [1012, 1025], "ent_id": "D003513", "tok_span": [213, 216]}, {"name": "chloramphenicol", "ent_type": "Chemical", "char_span": [781, 796], "ent_id": "D002701", "tok_span": [169, 173]}, {"name": "hypercapnia", "ent_type": "Disease", "char_span": [324, 335], "ent_id": "D006935", "tok_span": [74, 77]}, {"name": "amnesia", "ent_type": "Disease", "char_span": [467, 474], "ent_id": "D000647", "tok_span": [106, 109]}, {"name": "impaired cognitive functions", "ent_type": "Disease", "char_span": [112, 140], "ent_id": "D003072", "tok_span": [34, 37]}, {"name": "1-anisoyl-2-pyrrolidinone", "ent_type": "Chemical", "char_span": [38, 63], "ent_id": "C036466", "tok_span": [15, 26]}], "relation_list": [{"subject": "scopolamine", "object": "amnesia", "sbj_char_span": [436, 447], "obj_char_span": [467, 474], "rel_type": "chemical-induced disease", "sbj_tok_span": [98, 101], "obj_tok_span": [106, 109]}, {"subject": "scopolamine", "object": "amnesia", "sbj_char_span": [436, 447], "obj_char_span": [537, 544], "rel_type": "chemical-induced disease", "sbj_tok_span": [98, 101], "obj_tok_span": [121, 124]}], "umls_entity_list": []}, {"text": "Nicotine potentiation of morphine-induced catalepsy in mice.", "entity_list": [{"name": "catalepsy", "ent_type": "Disease", "char_span": [42, 51], "ent_id": "D002375", "tok_span": [7, 10]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [25, 33], "ent_id": "D009020", "tok_span": [4, 5]}, {"name": "Nicotine", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D009538", "tok_span": [0, 2]}], "relation_list": [{"subject": "morphine", "object": "catalepsy", "sbj_char_span": [25, 33], "obj_char_span": [42, 51], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [7, 10]}, {"subject": "Nicotine", "object": "catalepsy", "sbj_char_span": [0, 8], "obj_char_span": [42, 51], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "In the present study, effects of nicotine on catalepsy induced by morphine in mice have been investigated.", "entity_list": [{"name": "nicotine", "ent_type": "Chemical", "char_span": [33, 41], "ent_id": "D009538", "tok_span": [7, 8]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [66, 74], "ent_id": "D009020", "tok_span": [14, 15]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [45, 54], "ent_id": "D002375", "tok_span": [9, 12]}], "relation_list": [{"subject": "morphine", "object": "catalepsy", "sbj_char_span": [66, 74], "obj_char_span": [45, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [9, 12]}, {"subject": "nicotine", "object": "catalepsy", "sbj_char_span": [33, 41], "obj_char_span": [45, 54], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [9, 12]}], "umls_entity_list": []}, {"text": "Morphine but not nicotine induced a dose-dependent catalepsy.", "entity_list": [{"name": "nicotine", "ent_type": "Chemical", "char_span": [17, 25], "ent_id": "D009538", "tok_span": [4, 5]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [51, 60], "ent_id": "D002375", "tok_span": [10, 13]}, {"name": "Morphine", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D009020", "tok_span": [0, 2]}], "relation_list": [{"subject": "nicotine", "object": "catalepsy", "sbj_char_span": [17, 25], "obj_char_span": [51, 60], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [10, 13]}, {"subject": "Morphine", "object": "catalepsy", "sbj_char_span": [0, 8], "obj_char_span": [51, 60], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [10, 13]}], "umls_entity_list": []}, {"text": "Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.", "entity_list": [{"name": "atropine", "ent_type": "Chemical", "char_span": [34, 42], "ent_id": "D001285", "tok_span": [5, 8]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [102, 111], "ent_id": "D002375", "tok_span": [26, 29]}, {"name": "mecamylamine", "ent_type": "Chemical", "char_span": [54, 66], "ent_id": "D008464", "tok_span": [13, 17]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [140, 148], "ent_id": "D009020", "tok_span": [34, 35]}, {"name": "hexamethonium", "ent_type": "Chemical", "char_span": [72, 85], "ent_id": "D018738", "tok_span": [19, 23]}, {"name": "nicotine", "ent_type": "Chemical", "char_span": [154, 162], "ent_id": "D009538", "tok_span": [36, 37]}, {"name": "naloxone", "ent_type": "Chemical", "char_span": [44, 52], "ent_id": "D009270", "tok_span": [9, 12]}], "relation_list": [{"subject": "nicotine", "object": "catalepsy", "sbj_char_span": [154, 162], "obj_char_span": [102, 111], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 37], "obj_tok_span": [26, 29]}, {"subject": "morphine", "object": "catalepsy", "sbj_char_span": [140, 148], "obj_char_span": [102, 111], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 35], "obj_tok_span": [26, 29]}], "umls_entity_list": []}, {"text": "Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased catalepsy induced by morphine plus nicotine.", "entity_list": [{"name": "morphine", "ent_type": "Chemical", "char_span": [111, 119], "ent_id": "D009020", "tok_span": [27, 28]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [90, 99], "ent_id": "D002375", "tok_span": [22, 25]}, {"name": "atropine", "ent_type": "Chemical", "char_span": [37, 45], "ent_id": "D001285", "tok_span": [7, 10]}, {"name": "nicotine", "ent_type": "Chemical", "char_span": [125, 133], "ent_id": "D009538", "tok_span": [29, 30]}, {"name": "naloxone", "ent_type": "Chemical", "char_span": [66, 74], "ent_id": "D009270", "tok_span": [17, 20]}, {"name": "hexamethonium", "ent_type": "Chemical", "char_span": [47, 60], "ent_id": "D018738", "tok_span": [11, 15]}], "relation_list": [{"subject": "nicotine", "object": "catalepsy", "sbj_char_span": [125, 133], "obj_char_span": [90, 99], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 30], "obj_tok_span": [22, 25]}, {"subject": "morphine", "object": "catalepsy", "sbj_char_span": [111, 119], "obj_char_span": [90, 99], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 28], "obj_tok_span": [22, 25]}], "umls_entity_list": []}, {"text": "It was concluded that morphine catalepsy can be elicited by opioid and cholinergic receptors, and the potentiation of morphine induced by nicotine may also be mediated through cholinergic receptor mechanisms.", "entity_list": [{"name": "catalepsy", "ent_type": "Disease", "char_span": [31, 40], "ent_id": "D002375", "tok_span": [5, 8]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [22, 30], "ent_id": "D009020", "tok_span": [4, 5]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [118, 126], "ent_id": "D009020", "tok_span": [21, 22]}, {"name": "nicotine", "ent_type": "Chemical", "char_span": [138, 146], "ent_id": "D009538", "tok_span": [24, 25]}], "relation_list": [{"subject": "nicotine", "object": "catalepsy", "sbj_char_span": [138, 146], "obj_char_span": [31, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 25], "obj_tok_span": [5, 8]}, {"subject": "morphine", "object": "catalepsy", "sbj_char_span": [118, 126], "obj_char_span": [31, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 22], "obj_tok_span": [5, 8]}, {"subject": "morphine", "object": "catalepsy", "sbj_char_span": [22, 30], "obj_char_span": [31, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [5, 8]}], "umls_entity_list": []}, {"text": "CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.", "entity_list": [{"name": "MBC", "ent_type": "Disease", "char_span": [247, 250], "ent_id": "D001943", "tok_span": [41, 43]}, {"name": "neutropenia", "ent_type": "Disease", "char_span": [118, 129], "ent_id": "D009503", "tok_span": [19, 21]}, {"name": "cardiotoxicity", "ent_type": "Disease", "char_span": [91, 105], "ent_id": "D066126", "tok_span": [14, 16]}, {"name": "cyclophosphamide", "ent_type": "Chemical", "char_span": [204, 220], "ent_id": "D003520", "tok_span": [32, 35]}, {"name": "doxorubicin", "ent_type": "Chemical", "char_span": [53, 64], "ent_id": "D004317", "tok_span": [10, 11]}, {"name": "Myocet", "ent_type": "Chemical", "char_span": [12, 18], "ent_id": "D004317", "tok_span": [2, 5]}], "relation_list": [{"subject": "Myocet", "object": "neutropenia", "sbj_char_span": [12, 18], "obj_char_span": [118, 129], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [19, 21]}, {"subject": "doxorubicin", "object": "neutropenia", "sbj_char_span": [53, 64], "obj_char_span": [118, 129], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [19, 21]}, {"subject": "cyclophosphamide", "object": "neutropenia", "sbj_char_span": [204, 220], "obj_char_span": [118, 129], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 35], "obj_tok_span": [19, 21]}], "umls_entity_list": []}, {"text": "Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human immunodeficiency virus activity.", "entity_list": [{"name": "immunodeficiency", "ent_type": "Disease", "char_span": [104, 120], "ent_id": "D007153", "tok_span": [24, 26]}, {"name": "marrow suppression", "ent_type": "Disease", "char_span": [52, 70], "ent_id": "D001855", "tok_span": [16, 18]}, {"name": "Benzylacyclouridine", "ent_type": "Chemical", "char_span": [0, 19], "ent_id": "C034753", "tok_span": [0, 7]}, {"name": "azidothymidine", "ent_type": "Chemical", "char_span": [29, 43], "ent_id": "D015215", "tok_span": [9, 14]}], "relation_list": [{"subject": "azidothymidine", "object": "marrow suppression", "sbj_char_span": [29, 43], "obj_char_span": [52, 70], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 14], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.", "entity_list": [{"name": "Urd", "ent_type": "Chemical", "char_span": [59, 62], "ent_id": "D014529", "tok_span": [8, 10]}, {"name": "BAU", "ent_type": "Chemical", "char_span": [115, 118], "ent_id": "C034753", "tok_span": [23, 25]}, {"name": "benzylacyclouridine", "ent_type": "Chemical", "char_span": [94, 113], "ent_id": "C034753", "tok_span": [15, 22]}, {"name": "anemia", "ent_type": "Disease", "char_span": [152, 158], "ent_id": "D000740", "tok_span": [36, 37]}, {"name": "leukopenia", "ent_type": "Disease", "char_span": [163, 173], "ent_id": "D007970", "tok_span": [38, 40]}, {"name": "AZT", "ent_type": "Chemical", "char_span": [140, 143], "ent_id": "D015215", "tok_span": [32, 34]}, {"name": "toxicities", "ent_type": "Disease", "char_span": [24, 34], "ent_id": "D064420", "tok_span": [4, 5]}], "relation_list": [{"subject": "AZT", "object": "leukopenia", "sbj_char_span": [140, 143], "obj_char_span": [163, 173], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 34], "obj_tok_span": [38, 40]}, {"subject": "AZT", "object": "anemia", "sbj_char_span": [140, 143], "obj_char_span": [152, 158], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 34], "obj_tok_span": [36, 37]}], "umls_entity_list": []}, {"text": "In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.", "entity_list": [{"name": "leukopenia", "ent_type": "Disease", "char_span": [224, 234], "ent_id": "D007970", "tok_span": [56, 58]}, {"name": "AZT", "ent_type": "Chemical", "char_span": [143, 146], "ent_id": "D015215", "tok_span": [34, 36]}, {"name": "anemia", "ent_type": "Disease", "char_span": [213, 219], "ent_id": "D000740", "tok_span": [54, 55]}, {"name": "anemic", "ent_type": "Disease", "char_span": [17, 23], "ent_id": "D000740", "tok_span": [3, 5]}, {"name": "leukopenic", "ent_type": "Disease", "char_span": [28, 38], "ent_id": "D007970", "tok_span": [6, 9]}, {"name": "AZT", "ent_type": "Chemical", "char_span": [201, 204], "ent_id": "D015215", "tok_span": [50, 52]}, {"name": "megaloblastosis", "ent_type": "Disease", "char_span": [367, 382], "ent_id": "-1", "tok_span": [95, 100]}, {"name": "AZT", "ent_type": "Chemical", "char_span": [64, 67], "ent_id": "D015215", "tok_span": [13, 15]}, {"name": "BAU", "ent_type": "Chemical", "char_span": [158, 161], "ent_id": "C034753", "tok_span": [38, 40]}], "relation_list": [{"subject": "AZT", "object": "anemic", "sbj_char_span": [201, 204], "obj_char_span": [17, 23], "rel_type": "chemical-induced disease", "sbj_tok_span": [50, 52], "obj_tok_span": [3, 5]}, {"subject": "AZT", "object": "anemia", "sbj_char_span": [64, 67], "obj_char_span": [213, 219], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [54, 55]}, {"subject": "AZT", "object": "anemic", "sbj_char_span": [64, 67], "obj_char_span": [17, 23], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [3, 5]}, {"subject": "AZT", "object": "leukopenia", "sbj_char_span": [64, 67], "obj_char_span": [224, 234], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [56, 58]}, {"subject": "AZT", "object": "anemia", "sbj_char_span": [201, 204], "obj_char_span": [213, 219], "rel_type": "chemical-induced disease", "sbj_tok_span": [50, 52], "obj_tok_span": [54, 55]}, {"subject": "AZT", "object": "leukopenia", "sbj_char_span": [143, 146], "obj_char_span": [224, 234], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 36], "obj_tok_span": [56, 58]}, {"subject": "AZT", "object": "anemia", "sbj_char_span": [143, 146], "obj_char_span": [213, 219], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 36], "obj_tok_span": [54, 55]}, {"subject": "AZT", "object": "leukopenic", "sbj_char_span": [64, 67], "obj_char_span": [28, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [6, 9]}, {"subject": "AZT", "object": "leukopenia", "sbj_char_span": [201, 204], "obj_char_span": [224, 234], "rel_type": "chemical-induced disease", "sbj_tok_span": [50, 52], "obj_tok_span": [56, 58]}, {"subject": "AZT", "object": "anemic", "sbj_char_span": [143, 146], "obj_char_span": [17, 23], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 36], "obj_tok_span": [3, 5]}, {"subject": "AZT", "object": "leukopenic", "sbj_char_span": [143, 146], "obj_char_span": [28, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [34, 36], "obj_tok_span": [6, 9]}, {"subject": "AZT", "object": "leukopenic", "sbj_char_span": [201, 204], "obj_char_span": [28, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [50, 52], "obj_tok_span": [6, 9]}], "umls_entity_list": []}, {"text": "When coadministered with AZT from the onset of drug administration, BAU reduced AZT-induced marrow toxicity.", "entity_list": [{"name": "AZT", "ent_type": "Chemical", "char_span": [25, 28], "ent_id": "D015215", "tok_span": [4, 6]}, {"name": "AZT", "ent_type": "Chemical", "char_span": [80, 83], "ent_id": "D015215", "tok_span": [16, 18]}, {"name": "BAU", "ent_type": "Chemical", "char_span": [68, 71], "ent_id": "C034753", "tok_span": [13, 15]}, {"name": "marrow toxicity", "ent_type": "Disease", "char_span": [92, 107], "ent_id": "D001855", "tok_span": [20, 22]}], "relation_list": [{"subject": "AZT", "object": "marrow toxicity", "sbj_char_span": [80, 83], "obj_char_span": [92, 107], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 18], "obj_tok_span": [20, 22]}, {"subject": "AZT", "object": "marrow toxicity", "sbj_char_span": [25, 28], "obj_char_span": [92, 107], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 6], "obj_tok_span": [20, 22]}], "umls_entity_list": []}, {"text": "Cyclophosphamide-induced cystitis in freely-moving conscious rats: behavioral approach to a new model of visceral pain.", "entity_list": [{"name": "cystitis", "ent_type": "Disease", "char_span": [25, 33], "ent_id": "D003556", "tok_span": [4, 6]}, {"name": "visceral pain", "ent_type": "Disease", "char_span": [105, 118], "ent_id": "D059265", "tok_span": [20, 22]}, {"name": "Cyclophosphamide", "ent_type": "Chemical", "char_span": [0, 16], "ent_id": "D003520", "tok_span": [0, 2]}], "relation_list": [{"subject": "Cyclophosphamide", "object": "cystitis", "sbj_char_span": [0, 16], "obj_char_span": [25, 33], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce cystitis.", "entity_list": [{"name": "CP", "ent_type": "Chemical", "char_span": [18, 20], "ent_id": "D003520", "tok_span": [3, 4]}, {"name": "cystitis", "ent_type": "Disease", "char_span": [158, 166], "ent_id": "D003556", "tok_span": [32, 34]}, {"name": "acrolein", "ent_type": "Chemical", "char_span": [129, 137], "ent_id": "D000171", "tok_span": [24, 27]}, {"name": "Cyclophosphamide", "ent_type": "Chemical", "char_span": [0, 16], "ent_id": "D003520", "tok_span": [0, 2]}], "relation_list": [{"subject": "CP", "object": "cystitis", "sbj_char_span": [18, 20], "obj_char_span": [158, 166], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 4], "obj_tok_span": [32, 34]}, {"subject": "Cyclophosphamide", "object": "cystitis", "sbj_char_span": [0, 16], "obj_char_span": [158, 166], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [32, 34]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Overall, these results indicate that this experimental model of CP-induced cystitis may be an interesting new behavioral model of inflammatory visceral pain, allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them.", "entity_list": [{"name": "CP", "ent_type": "Chemical", "char_span": [77, 79], "ent_id": "D003520", "tok_span": [12, 13]}, {"name": "cystitis", "ent_type": "Disease", "char_span": [88, 96], "ent_id": "D003556", "tok_span": [15, 17]}, {"name": "visceral pain", "ent_type": "Disease", "char_span": [156, 169], "ent_id": "D059265", "tok_span": [26, 28]}, {"name": "painful syndromes", "ent_type": "Disease", "char_span": [212, 229], "ent_id": "D010146", "tok_span": [35, 37]}], "relation_list": [{"subject": "CP", "object": "painful syndromes", "sbj_char_span": [77, 79], "obj_char_span": [212, 229], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [35, 37]}, {"subject": "CP", "object": "cystitis", "sbj_char_span": [77, 79], "obj_char_span": [88, 96], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine.", "entity_list": [{"name": "cancer", "ent_type": "Disease", "char_span": [39, 45], "ent_id": "D009369", "tok_span": [11, 12]}, {"name": "Hyperalgesia", "ent_type": "Disease", "char_span": [0, 12], "ent_id": "D006930", "tok_span": [0, 4]}, {"name": "myoclonus", "ent_type": "Disease", "char_span": [17, 26], "ent_id": "D009207", "tok_span": [5, 9]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [91, 99], "ent_id": "D009020", "tok_span": [17, 18]}], "relation_list": [{"subject": "morphine", "object": "Hyperalgesia", "sbj_char_span": [91, 99], "obj_char_span": [0, 12], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 18], "obj_tok_span": [0, 4]}, {"subject": "morphine", "object": "myoclonus", "sbj_char_span": [91, 99], "obj_char_span": [17, 26], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 18], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "Eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia.", "entity_list": [{"name": "morphine", "ent_type": "Chemical", "char_span": [99, 107], "ent_id": "D009020", "tok_span": [16, 17]}, {"name": "hyperalgesia", "ent_type": "Disease", "char_span": [118, 130], "ent_id": "D006930", "tok_span": [18, 22]}, {"name": "cancer", "ent_type": "Disease", "char_span": [6, 12], "ent_id": "D009369", "tok_span": [1, 2]}], "relation_list": [{"subject": "morphine", "object": "hyperalgesia", "sbj_char_span": [99, 107], "obj_char_span": [118, 130], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 17], "obj_tok_span": [18, 22]}], "umls_entity_list": []}, {"text": "Although only few clinical descriptions of the relationship between hyperalgesia/myoclonus and high doses of morphine are available, experimental support from animal studies indicates that morphine, or its metabolites, plays a causative role for the observed behavioural syndrome.", "entity_list": [{"name": "hyperalgesia", "ent_type": "Disease", "char_span": [68, 80], "ent_id": "D006930", "tok_span": [9, 13]}, {"name": "myoclonus", "ent_type": "Disease", "char_span": [81, 90], "ent_id": "D009207", "tok_span": [14, 18]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [189, 197], "ent_id": "D009020", "tok_span": [33, 34]}, {"name": "morphine", "ent_type": "Chemical", "char_span": [109, 117], "ent_id": "D009020", "tok_span": [22, 23]}], "relation_list": [{"subject": "morphine", "object": "hyperalgesia", "sbj_char_span": [189, 197], "obj_char_span": [68, 80], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 34], "obj_tok_span": [9, 13]}, {"subject": "morphine", "object": "myoclonus", "sbj_char_span": [189, 197], "obj_char_span": [81, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 34], "obj_tok_span": [14, 18]}, {"subject": "morphine", "object": "hyperalgesia", "sbj_char_span": [109, 117], "obj_char_span": [68, 80], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [9, 13]}, {"subject": "morphine", "object": "myoclonus", "sbj_char_span": [109, 117], "obj_char_span": [81, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 23], "obj_tok_span": [14, 18]}], "umls_entity_list": []}, {"text": "Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.", "entity_list": [{"name": "Thrombophlebitis", "ent_type": "Disease", "char_span": [0, 16], "ent_id": "D013924", "tok_span": [0, 4]}, {"name": "nephrotoxicity", "ent_type": "Disease", "char_span": [74, 88], "ent_id": "D007674", "tok_span": [13, 16]}, {"name": "aminoglycoside", "ent_type": "Chemical", "char_span": [144, 158], "ent_id": "D000617", "tok_span": [25, 28]}, {"name": "vancomycin", "ent_type": "Chemical", "char_span": [164, 174], "ent_id": "D014640", "tok_span": [29, 30]}, {"name": "ototoxicity", "ent_type": "Disease", "char_span": [93, 104], "ent_id": "D006311", "tok_span": [17, 19]}], "relation_list": [{"subject": "vancomycin", "object": "Thrombophlebitis", "sbj_char_span": [164, 174], "obj_char_span": [0, 16], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 30], "obj_tok_span": [0, 4]}, {"subject": "vancomycin", "object": "ototoxicity", "sbj_char_span": [164, 174], "obj_char_span": [93, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 30], "obj_tok_span": [17, 19]}], "umls_entity_list": []}, {"text": "Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced catalepsy.", "entity_list": [{"name": "fluphenazine", "ent_type": "Chemical", "char_span": [20, 32], "ent_id": "D005476", "tok_span": [5, 8]}, {"name": "sulpiride", "ent_type": "Chemical", "char_span": [77, 86], "ent_id": "D013469", "tok_span": [21, 24]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [95, 104], "ent_id": "D002375", "tok_span": [25, 28]}, {"name": "SCH 23390", "ent_type": "Chemical", "char_span": [49, 58], "ent_id": "C534628", "tok_span": [13, 16]}, {"name": "Dopamine", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D004298", "tok_span": [0, 4]}], "relation_list": [{"subject": "SCH 23390", "object": "catalepsy", "sbj_char_span": [49, 58], "obj_char_span": [95, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [25, 28]}, {"subject": "sulpiride", "object": "catalepsy", "sbj_char_span": [77, 86], "obj_char_span": [95, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 24], "obj_tok_span": [25, 28]}, {"subject": "fluphenazine", "object": "catalepsy", "sbj_char_span": [20, 32], "obj_char_span": [95, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [25, 28]}], "umls_entity_list": []}, {"text": "Combination of SCH 23390 with sulpiride did not induce catalepsy potentiation. 3.", "entity_list": [{"name": "catalepsy", "ent_type": "Disease", "char_span": [55, 64], "ent_id": "D002375", "tok_span": [13, 16]}, {"name": "SCH 23390", "ent_type": "Chemical", "char_span": [15, 24], "ent_id": "C534628", "tok_span": [3, 6]}, {"name": "sulpiride", "ent_type": "Chemical", "char_span": [30, 39], "ent_id": "D013469", "tok_span": [7, 10]}], "relation_list": [{"subject": "sulpiride", "object": "catalepsy", "sbj_char_span": [30, 39], "obj_char_span": [55, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [13, 16]}, {"subject": "SCH 23390", "object": "catalepsy", "sbj_char_span": [15, 24], "obj_char_span": [55, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride. 4.", "entity_list": [{"name": "SKF 38393", "ent_type": "Chemical", "char_span": [12, 21], "ent_id": "D015647", "tok_span": [4, 9]}, {"name": "quinpirole", "ent_type": "Chemical", "char_span": [37, 47], "ent_id": "D019257", "tok_span": [14, 17]}, {"name": "fluphenazine", "ent_type": "Chemical", "char_span": [83, 95], "ent_id": "D005476", "tok_span": [24, 27]}, {"name": "catalepsy", "ent_type": "Disease", "char_span": [62, 71], "ent_id": "D002375", "tok_span": [19, 22]}, {"name": "SCH 23390", "ent_type": "Chemical", "char_span": [97, 106], "ent_id": "C534628", "tok_span": [28, 31]}, {"name": "sulpiride", "ent_type": "Chemical", "char_span": [110, 119], "ent_id": "D013469", "tok_span": [32, 35]}], "relation_list": [{"subject": "sulpiride", "object": "catalepsy", "sbj_char_span": [110, 119], "obj_char_span": [62, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 35], "obj_tok_span": [19, 22]}, {"subject": "SCH 23390", "object": "catalepsy", "sbj_char_span": [97, 106], "obj_char_span": [62, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 31], "obj_tok_span": [19, 22]}, {"subject": "fluphenazine", "object": "catalepsy", "sbj_char_span": [83, 95], "obj_char_span": [62, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 27], "obj_tok_span": [19, 22]}], "umls_entity_list": []}, {"text": "Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw edema model, respectively.", "entity_list": [{"name": "carrageenan", "ent_type": "Chemical", "char_span": [117, 128], "ent_id": "D002351", "tok_span": [20, 25]}, {"name": "edema", "ent_type": "Disease", "char_span": [145, 150], "ent_id": "D004487", "tok_span": [30, 31]}, {"name": "acetic acid", "ent_type": "Chemical", "char_span": [71, 82], "ent_id": "D019342", "tok_span": [10, 12]}, {"name": "writhing", "ent_type": "Disease", "char_span": [91, 99], "ent_id": "D010146", "tok_span": [13, 15]}], "relation_list": [{"subject": "carrageenan", "object": "edema", "sbj_char_span": [117, 128], "obj_char_span": [145, 150], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 25], "obj_tok_span": [30, 31]}, {"subject": "carrageenan", "object": "writhing", "sbj_char_span": [117, 128], "obj_char_span": [91, 99], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 25], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "It is likely that the hypersensitivity (eosinophilic) myocarditis was related to dobutamine infusion therapy.", "entity_list": [{"name": "eosinophilic", "ent_type": "Disease", "char_span": [40, 52], "ent_id": "D004802", "tok_span": [8, 10]}, {"name": "myocarditis", "ent_type": "Disease", "char_span": [54, 65], "ent_id": "D009205", "tok_span": [11, 13]}, {"name": "dobutamine", "ent_type": "Chemical", "char_span": [81, 91], "ent_id": "D004280", "tok_span": [16, 19]}, {"name": "hypersensitivity", "ent_type": "Disease", "char_span": [22, 38], "ent_id": "D004342", "tok_span": [5, 7]}], "relation_list": [{"subject": "dobutamine", "object": "hypersensitivity", "sbj_char_span": [81, 91], "obj_char_span": [22, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [5, 7]}, {"subject": "dobutamine", "object": "myocarditis", "sbj_char_span": [81, 91], "obj_char_span": [54, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [11, 13]}, {"subject": "dobutamine", "object": "eosinophilic", "sbj_char_span": [81, 91], "obj_char_span": [40, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "All- trans-retinoic acid-induced erythema nodosum in patients with acute promyelocytic leukemia.", "entity_list": [{"name": "erythema nodosum", "ent_type": "Disease", "char_span": [33, 49], "ent_id": "D004893", "tok_span": [9, 13]}, {"name": "acute promyelocytic leukemia", "ent_type": "Disease", "char_span": [67, 95], "ent_id": "D015473", "tok_span": [16, 21]}, {"name": "All- trans-retinoic acid", "ent_type": "Chemical", "char_span": [0, 24], "ent_id": "D014212", "tok_span": [0, 7]}], "relation_list": [{"subject": "All- trans-retinoic acid", "object": "erythema nodosum", "sbj_char_span": [0, 24], "obj_char_span": [33, 49], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 7], "obj_tok_span": [9, 13]}], "umls_entity_list": []}, {"text": "Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.", "entity_list": [{"name": "ATRA", "ent_type": "Chemical", "char_span": [59, 63], "ent_id": "D014212", "tok_span": [15, 17]}, {"name": "acute promyelocytic leukemia", "ent_type": "Disease", "char_span": [69, 97], "ent_id": "D015473", "tok_span": [19, 24]}, {"name": "APL", "ent_type": "Disease", "char_span": [99, 102], "ent_id": "D015473", "tok_span": [25, 27]}, {"name": "Erythema nodosum", "ent_type": "Disease", "char_span": [0, 16], "ent_id": "D004893", "tok_span": [0, 5]}, {"name": "all- trans-retinoic acid", "ent_type": "Chemical", "char_span": [33, 57], "ent_id": "D014212", "tok_span": [7, 14]}], "relation_list": [{"subject": "ATRA", "object": "Erythema nodosum", "sbj_char_span": [59, 63], "obj_char_span": [0, 16], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 17], "obj_tok_span": [0, 5]}, {"subject": "all- trans-retinoic acid", "object": "Erythema nodosum", "sbj_char_span": [33, 57], "obj_char_span": [0, 16], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 14], "obj_tok_span": [0, 5]}], "umls_entity_list": []}, {"text": "We describe four patients with classic APL who developed erythema nodosum during ATRA therapy.", "entity_list": [{"name": "erythema nodosum", "ent_type": "Disease", "char_span": [57, 73], "ent_id": "D004893", "tok_span": [10, 14]}, {"name": "ATRA", "ent_type": "Chemical", "char_span": [81, 85], "ent_id": "D014212", "tok_span": [15, 17]}, {"name": "APL", "ent_type": "Disease", "char_span": [39, 42], "ent_id": "D015473", "tok_span": [6, 8]}], "relation_list": [{"subject": "ATRA", "object": "erythema nodosum", "sbj_char_span": [81, 85], "obj_char_span": [57, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 17], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.", "entity_list": [{"name": "ATRA", "ent_type": "Chemical", "char_span": [133, 137], "ent_id": "D014212", "tok_span": [29, 31]}, {"name": "painful", "ent_type": "Disease", "char_span": [30, 37], "ent_id": "D010146", "tok_span": [5, 6]}, {"name": "erythematous nodules", "ent_type": "Disease", "char_span": [38, 58], "ent_id": "D004893", "tok_span": [6, 9]}, {"name": "Fever", "ent_type": "Disease", "char_span": [0, 5], "ent_id": "D005334", "tok_span": [0, 2]}], "relation_list": [{"subject": "ATRA", "object": "erythematous nodules", "sbj_char_span": [133, 137], "obj_char_span": [38, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 31], "obj_tok_span": [6, 9]}, {"subject": "ATRA", "object": "Fever", "sbj_char_span": [133, 137], "obj_char_span": [0, 5], "rel_type": "chemical-induced disease", "sbj_tok_span": [29, 31], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "ATRA seemed to be the most possible etiology of erythema nodosum in our patients.", "entity_list": [{"name": "erythema nodosum", "ent_type": "Disease", "char_span": [48, 64], "ent_id": "D004893", "tok_span": [10, 14]}, {"name": "ATRA", "ent_type": "Chemical", "char_span": [0, 4], "ent_id": "D014212", "tok_span": [0, 2]}], "relation_list": [{"subject": "ATRA", "object": "erythema nodosum", "sbj_char_span": [0, 4], "obj_char_span": [48, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "Short-term use of steroid is very effective in ATRA-induced erythema nodosum.", "entity_list": [{"name": "erythema nodosum", "ent_type": "Disease", "char_span": [60, 76], "ent_id": "D004893", "tok_span": [14, 18]}, {"name": "steroid", "ent_type": "Chemical", "char_span": [18, 25], "ent_id": "D013256", "tok_span": [5, 6]}, {"name": "ATRA", "ent_type": "Chemical", "char_span": [47, 51], "ent_id": "D014212", "tok_span": [10, 12]}], "relation_list": [{"subject": "ATRA", "object": "erythema nodosum", "sbj_char_span": [47, 51], "obj_char_span": [60, 76], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 12], "obj_tok_span": [14, 18]}], "umls_entity_list": []}, {"text": "Delayed-onset heparin-induced thrombocytopenia.", "entity_list": [{"name": "heparin", "ent_type": "Chemical", "char_span": [14, 21], "ent_id": "D006493", "tok_span": [4, 5]}, {"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [30, 46], "ent_id": "D013921", "tok_span": [7, 9]}], "relation_list": [{"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [14, 21], "obj_char_span": [30, 46], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 5], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "BACKGROUND: Heparin-induced thrombocytopenia presents 5 to 12 days after heparin exposure, with or without arterial or venous thromboemboli.", "entity_list": [{"name": "Heparin", "ent_type": "Chemical", "char_span": [12, 19], "ent_id": "D006493", "tok_span": [2, 4]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [73, 80], "ent_id": "D006493", "tok_span": [14, 15]}, {"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [28, 44], "ent_id": "D013921", "tok_span": [6, 8]}, {"name": "arterial or venous thromboemboli", "ent_type": "Disease", "char_span": [107, 139], "ent_id": "D00115", "tok_span": [20, 25]}], "relation_list": [{"subject": "Heparin", "object": "thrombocytopenia", "sbj_char_span": [12, 19], "obj_char_span": [28, 44], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 4], "obj_tok_span": [6, 8]}, {"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [73, 80], "obj_char_span": [28, 44], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "Delayed recognition and treatment of heparin-induced thrombocytopenia contribute to poor patient outcomes.", "entity_list": [{"name": "heparin", "ent_type": "Chemical", "char_span": [37, 44], "ent_id": "D006493", "tok_span": [6, 7]}, {"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [53, 69], "ent_id": "D013921", "tok_span": [9, 11]}], "relation_list": [{"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [37, 44], "obj_char_span": [53, 69], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "OBJECTIVE: To describe and increase awareness of a clinical scenario in which the onset or manifestations of heparin-induced thrombocytopenia are delayed.", "entity_list": [{"name": "heparin", "ent_type": "Chemical", "char_span": [109, 116], "ent_id": "D006493", "tok_span": [18, 19]}, {"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [125, 141], "ent_id": "D013921", "tok_span": [21, 23]}], "relation_list": [{"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [109, 116], "obj_char_span": [125, 141], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "PATIENTS: 14 patients seen over a 3-year period in whom heparin-induced thrombocytopenia became apparent on delayed presentation with thromboembolic complications.", "entity_list": [{"name": "thromboembolic", "ent_type": "Disease", "char_span": [134, 148], "ent_id": "D013923", "tok_span": [25, 27]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [56, 63], "ent_id": "D006493", "tok_span": [14, 15]}, {"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [72, 88], "ent_id": "D013921", "tok_span": [17, 19]}], "relation_list": [{"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [56, 63], "obj_char_span": [72, 88], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [17, 19]}], "umls_entity_list": []}, {"text": "RESULTS: Patients went home after hospitalizations that had included heparin exposure--in most cases, with no thrombocytopenia recognized--only to return to the hospital (median, day 14) with thromboembolic complications.", "entity_list": [{"name": "heparin", "ent_type": "Chemical", "char_span": [69, 76], "ent_id": "D006493", "tok_span": [11, 12]}, {"name": "thromboembolic", "ent_type": "Disease", "char_span": [192, 206], "ent_id": "D013923", "tok_span": [39, 41]}, {"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [110, 126], "ent_id": "D013921", "tok_span": [21, 23]}], "relation_list": [{"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [69, 76], "obj_char_span": [110, 126], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Delayed-onset heparin-induced thrombocytopenia is increasingly being recognized.", "entity_list": [{"name": "heparin", "ent_type": "Chemical", "char_span": [27, 34], "ent_id": "D006493", "tok_span": [6, 7]}, {"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [43, 59], "ent_id": "D013921", "tok_span": [9, 11]}], "relation_list": [{"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [27, 34], "obj_char_span": [43, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "To avoid disastrous outcomes, physicians must consider heparin-induced thrombocytopenia whenever a recently hospitalized patient returns with thromboembolism; therapy with alternative anticoagulants, not heparin, should be initiated.", "entity_list": [{"name": "thromboembolism", "ent_type": "Disease", "char_span": [142, 157], "ent_id": "D013923", "tok_span": [22, 24]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [55, 62], "ent_id": "D006493", "tok_span": [10, 11]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [204, 211], "ent_id": "D006493", "tok_span": [32, 33]}, {"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [71, 87], "ent_id": "D013921", "tok_span": [13, 15]}], "relation_list": [{"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [55, 62], "obj_char_span": [71, 87], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [13, 15]}, {"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [204, 211], "obj_char_span": [71, 87], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 33], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).", "entity_list": [{"name": "amlodipine", "ent_type": "Chemical", "char_span": [239, 249], "ent_id": "D017311", "tok_span": [75, 79]}, {"name": "valsartan", "ent_type": "Chemical", "char_span": [191, 200], "ent_id": "C081489", "tok_span": [56, 60]}, {"name": "amlodipine", "ent_type": "Chemical", "char_span": [73, 83], "ent_id": "D017311", "tok_span": [13, 17]}, {"name": "edema", "ent_type": "Disease", "char_span": [40, 45], "ent_id": "D004487", "tok_span": [7, 8]}, {"name": "valsartan", "ent_type": "Chemical", "char_span": [147, 156], "ent_id": "C081489", "tok_span": [36, 40]}, {"name": "amlodipine", "ent_type": "Chemical", "char_span": [211, 221], "ent_id": "D017311", "tok_span": [63, 67]}, {"name": "amlodipine", "ent_type": "Chemical", "char_span": [172, 182], "ent_id": "D017311", "tok_span": [48, 52]}], "relation_list": [{"subject": "valsartan", "object": "edema", "sbj_char_span": [191, 200], "obj_char_span": [40, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [56, 60], "obj_tok_span": [7, 8]}, {"subject": "amlodipine", "object": "edema", "sbj_char_span": [73, 83], "obj_char_span": [40, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [7, 8]}, {"subject": "amlodipine", "object": "edema", "sbj_char_span": [211, 221], "obj_char_span": [40, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [63, 67], "obj_tok_span": [7, 8]}, {"subject": "valsartan", "object": "edema", "sbj_char_span": [147, 156], "obj_char_span": [40, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [36, 40], "obj_tok_span": [7, 8]}, {"subject": "amlodipine", "object": "edema", "sbj_char_span": [172, 182], "obj_char_span": [40, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [48, 52], "obj_tok_span": [7, 8]}, {"subject": "amlodipine", "object": "edema", "sbj_char_span": [239, 249], "obj_char_span": [40, 45], "rel_type": "chemical-induced disease", "sbj_tok_span": [75, 79], "obj_tok_span": [7, 8]}], "umls_entity_list": []}, {"text": "Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner.", "entity_list": [{"name": "CGS 21680", "ent_type": "Chemical", "char_span": [197, 206], "ent_id": "C061282", "tok_span": [48, 52]}, {"name": "KF17837", "ent_type": "Chemical", "char_span": [23, 30], "ent_id": "C081198", "tok_span": [3, 7]}, {"name": "cataleptic", "ent_type": "Disease", "char_span": [88, 98], "ent_id": "D002375", "tok_span": [27, 29]}, {"name": "adenosine", "ent_type": "Chemical", "char_span": [165, 174], "ent_id": "D000241", "tok_span": [41, 42]}], "relation_list": [{"subject": "CGS 21680", "object": "cataleptic", "sbj_char_span": [197, 206], "obj_char_span": [88, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [48, 52], "obj_tok_span": [27, 29]}], "umls_entity_list": []}, {"text": "KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.).", "entity_list": [{"name": "catalepsy", "ent_type": "Disease", "char_span": [25, 34], "ent_id": "D002375", "tok_span": [7, 10]}, {"name": "reserpine", "ent_type": "Chemical", "char_span": [80, 89], "ent_id": "D012110", "tok_span": [27, 30]}, {"name": "KF17837", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "C081198", "tok_span": [0, 4]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [46, 57], "ent_id": "D006220", "tok_span": [12, 15]}], "relation_list": [{"subject": "reserpine", "object": "catalepsy", "sbj_char_span": [80, 89], "obj_char_span": [25, 34], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 30], "obj_tok_span": [7, 10]}, {"subject": "haloperidol", "object": "catalepsy", "sbj_char_span": [46, 57], "obj_char_span": [25, 34], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "A repeated treatment with fluvoxamine (twice daily for 14 days) potentiated in mice and in rats (weaker) the amphetamine-induced hyperactivity.", "entity_list": [{"name": "amphetamine", "ent_type": "Chemical", "char_span": [109, 120], "ent_id": "D000661", "tok_span": [26, 30]}, {"name": "hyperactivity", "ent_type": "Disease", "char_span": [129, 142], "ent_id": "D006948", "tok_span": [32, 34]}, {"name": "fluvoxamine", "ent_type": "Chemical", "char_span": [26, 37], "ent_id": "D016666", "tok_span": [4, 8]}], "relation_list": [{"subject": "fluvoxamine", "object": "hyperactivity", "sbj_char_span": [26, 37], "obj_char_span": [129, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 8], "obj_tok_span": [32, 34]}, {"subject": "amphetamine", "object": "hyperactivity", "sbj_char_span": [109, 120], "obj_char_span": [129, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 30], "obj_tok_span": [32, 34]}], "umls_entity_list": []}, {"text": "The hyperactivity induced by nomifensine in mice remained unaffected by fluvoxamine.", "entity_list": [{"name": "hyperactivity", "ent_type": "Disease", "char_span": [4, 17], "ent_id": "D006948", "tok_span": [1, 3]}, {"name": "fluvoxamine", "ent_type": "Chemical", "char_span": [72, 83], "ent_id": "D016666", "tok_span": [14, 18]}, {"name": "nomifensine", "ent_type": "Chemical", "char_span": [29, 40], "ent_id": "D009627", "tok_span": [5, 9]}], "relation_list": [{"subject": "nomifensine", "object": "hyperactivity", "sbj_char_span": [29, 40], "obj_char_span": [4, 17], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 9], "obj_tok_span": [1, 3]}, {"subject": "fluvoxamine", "object": "hyperactivity", "sbj_char_span": [72, 83], "obj_char_span": [4, 17], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 18], "obj_tok_span": [1, 3]}], "umls_entity_list": []}, {"text": "This is a case report of myxedema coma secondary to amiodarone-induced hypothyroidism in a patient with severe congestive heart failure (CHF).", "entity_list": [{"name": "CHF", "ent_type": "Disease", "char_span": [137, 140], "ent_id": "D006333", "tok_span": [32, 33]}, {"name": "myxedema coma", "ent_type": "Disease", "char_span": [25, 38], "ent_id": "D00923", "tok_span": [6, 11]}, {"name": "hypothyroidism", "ent_type": "Disease", "char_span": [71, 85], "ent_id": "D007037", "tok_span": [19, 21]}, {"name": "amiodarone", "ent_type": "Chemical", "char_span": [52, 62], "ent_id": "D000638", "tok_span": [13, 17]}, {"name": "congestive heart failure", "ent_type": "Disease", "char_span": [111, 135], "ent_id": "D006333", "tok_span": [26, 31]}], "relation_list": [{"subject": "amiodarone", "object": "hypothyroidism", "sbj_char_span": [52, 62], "obj_char_span": [71, 85], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [19, 21]}], "umls_entity_list": []}, {"text": "Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels.", "entity_list": [{"name": "amiodarone", "ent_type": "Chemical", "char_span": [21, 31], "ent_id": "D000638", "tok_span": [4, 8]}, {"name": "hypothyroidism", "ent_type": "Disease", "char_span": [80, 94], "ent_id": "D007037", "tok_span": [15, 17]}, {"name": "CHF", "ent_type": "Disease", "char_span": [14, 17], "ent_id": "D006333", "tok_span": [2, 3]}], "relation_list": [{"subject": "amiodarone", "object": "hypothyroidism", "sbj_char_span": [21, 31], "obj_char_span": [80, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 8], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.", "entity_list": [{"name": "yohimbine", "ent_type": "Chemical", "char_span": [13, 22], "ent_id": "D015016", "tok_span": [2, 6]}, {"name": "startle", "ent_type": "Disease", "char_span": [103, 110], "ent_id": "D012021", "tok_span": [22, 24]}, {"name": "PTZ", "ent_type": "Chemical", "char_span": [139, 142], "ent_id": "D010433", "tok_span": [33, 35]}, {"name": "startle", "ent_type": "Disease", "char_span": [42, 49], "ent_id": "D012021", "tok_span": [8, 10]}, {"name": "mCPP", "ent_type": "Chemical", "char_span": [78, 82], "ent_id": "C015068", "tok_span": [17, 20]}, {"name": "startle", "ent_type": "Disease", "char_span": [163, 170], "ent_id": "D012021", "tok_span": [37, 39]}], "relation_list": [{"subject": "mCPP", "object": "startle", "sbj_char_span": [78, 82], "obj_char_span": [163, 170], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [37, 39]}, {"subject": "mCPP", "object": "startle", "sbj_char_span": [78, 82], "obj_char_span": [103, 110], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [22, 24]}, {"subject": "yohimbine", "object": "startle", "sbj_char_span": [13, 22], "obj_char_span": [42, 49], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [8, 10]}, {"subject": "PTZ", "object": "startle", "sbj_char_span": [139, 142], "obj_char_span": [103, 110], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 35], "obj_tok_span": [22, 24]}, {"subject": "mCPP", "object": "startle", "sbj_char_span": [78, 82], "obj_char_span": [42, 49], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [8, 10]}, {"subject": "yohimbine", "object": "startle", "sbj_char_span": [13, 22], "obj_char_span": [163, 170], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [37, 39]}, {"subject": "PTZ", "object": "startle", "sbj_char_span": [139, 142], "obj_char_span": [163, 170], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 35], "obj_tok_span": [37, 39]}, {"subject": "yohimbine", "object": "startle", "sbj_char_span": [13, 22], "obj_char_span": [103, 110], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 6], "obj_tok_span": [22, 24]}, {"subject": "PTZ", "object": "startle", "sbj_char_span": [139, 142], "obj_char_span": [42, 49], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 35], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.", "entity_list": [{"name": "ulcerative colitis", "ent_type": "Disease", "char_span": [25, 43], "ent_id": "D003093", "tok_span": [8, 11]}, {"name": "urinary abnormalities", "ent_type": "Disease", "char_span": [99, 120], "ent_id": "D001745", "tok_span": [21, 23]}, {"name": "red eyes", "ent_type": "Disease", "char_span": [54, 62], "ent_id": "D005128", "tok_span": [12, 14]}, {"name": "sulphasalazine", "ent_type": "Chemical", "char_span": [141, 155], "ent_id": "D012460", "tok_span": [28, 31]}, {"name": "pleural effusion", "ent_type": "Disease", "char_span": [64, 80], "ent_id": "D010996", "tok_span": [15, 17]}, {"name": "eosinophilia", "ent_type": "Disease", "char_span": [82, 94], "ent_id": "D004802", "tok_span": [18, 20]}], "relation_list": [{"subject": "sulphasalazine", "object": "pleural effusion", "sbj_char_span": [141, 155], "obj_char_span": [64, 80], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 31], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.", "entity_list": [{"name": "fever", "ent_type": "Disease", "char_span": [75, 80], "ent_id": "D005334", "tok_span": [11, 12]}, {"name": "pleural effusions", "ent_type": "Disease", "char_span": [150, 167], "ent_id": "D010996", "tok_span": [29, 32]}, {"name": "pleural effusion", "ent_type": "Disease", "char_span": [296, 312], "ent_id": "D010996", "tok_span": [64, 66]}, {"name": "red eyes", "ent_type": "Disease", "char_span": [82, 90], "ent_id": "D005128", "tok_span": [13, 15]}, {"name": "sulphasalazine", "ent_type": "Chemical", "char_span": [22, 36], "ent_id": "D012460", "tok_span": [3, 6]}, {"name": "chest pain", "ent_type": "Disease", "char_span": [92, 102], "ent_id": "D002637", "tok_span": [16, 18]}, {"name": "steroid", "ent_type": "Chemical", "char_span": [182, 189], "ent_id": "D013256", "tok_span": [35, 36]}], "relation_list": [{"subject": "sulphasalazine", "object": "pleural effusion", "sbj_char_span": [22, 36], "obj_char_span": [296, 312], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [64, 66]}, {"subject": "sulphasalazine", "object": "pleural effusions", "sbj_char_span": [22, 36], "obj_char_span": [150, 167], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [29, 32]}, {"subject": "sulphasalazine", "object": "fever", "sbj_char_span": [22, 36], "obj_char_span": [75, 80], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [11, 12]}], "umls_entity_list": []}, {"text": "Following phenytoin administration, the patient developed acute severe bradycardia, refractory to atropine and adrenaline.", "entity_list": [{"name": "atropine", "ent_type": "Chemical", "char_span": [98, 106], "ent_id": "D001285", "tok_span": [18, 21]}, {"name": "phenytoin", "ent_type": "Chemical", "char_span": [10, 19], "ent_id": "D010672", "tok_span": [1, 4]}, {"name": "bradycardia", "ent_type": "Disease", "char_span": [71, 82], "ent_id": "D001919", "tok_span": [11, 15]}, {"name": "adrenaline", "ent_type": "Chemical", "char_span": [111, 121], "ent_id": "D004837", "tok_span": [22, 24]}], "relation_list": [{"subject": "phenytoin", "object": "bradycardia", "sbj_char_span": [10, 19], "obj_char_span": [71, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [1, 4], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "Amisulpride related tic-like symptoms in an adolescent schizophrenic.", "entity_list": [{"name": "Amisulpride", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "C012052", "tok_span": [0, 5]}, {"name": "tic-like symptoms", "ent_type": "Disease", "char_span": [20, 37], "ent_id": "D013981", "tok_span": [6, 10]}, {"name": "schizophrenic", "ent_type": "Disease", "char_span": [55, 68], "ent_id": "D012559", "tok_span": [13, 15]}], "relation_list": [{"subject": "Amisulpride", "object": "tic-like symptoms", "sbj_char_span": [0, 11], "obj_char_span": [20, 37], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [6, 10]}], "umls_entity_list": []}, {"text": "The tic-like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day.", "entity_list": [{"name": "amisulpride", "ent_type": "Chemical", "char_span": [71, 82], "ent_id": "C012052", "tok_span": [13, 18]}, {"name": "tic-like symptoms", "ent_type": "Disease", "char_span": [4, 21], "ent_id": "D013981", "tok_span": [1, 5]}], "relation_list": [{"subject": "amisulpride", "object": "tic-like symptoms", "sbj_char_span": [71, 82], "obj_char_span": [4, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 18], "obj_tok_span": [1, 5]}], "umls_entity_list": []}, {"text": "Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.", "entity_list": [{"name": "quetiapine", "ent_type": "Chemical", "char_span": [185, 195], "ent_id": "C069541", "tok_span": [28, 31]}, {"name": "tic-like symptoms", "ent_type": "Disease", "char_span": [67, 84], "ent_id": "D013981", "tok_span": [10, 14]}, {"name": "amisulpride", "ent_type": "Chemical", "char_span": [211, 222], "ent_id": "C012052", "tok_span": [37, 42]}, {"name": "clozapine", "ent_type": "Chemical", "char_span": [197, 206], "ent_id": "D003024", "tok_span": [32, 35]}], "relation_list": [{"subject": "amisulpride", "object": "tic-like symptoms", "sbj_char_span": [211, 222], "obj_char_span": [67, 84], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 42], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces developmental anomalies when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.", "entity_list": [{"name": "acetylsalicylic acid", "ent_type": "Chemical", "char_span": [9, 29], "ent_id": "D001241", "tok_span": [4, 9]}, {"name": "Aspirin", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "D001241", "tok_span": [0, 3]}, {"name": "ASA", "ent_type": "Chemical", "char_span": [31, 34], "ent_id": "D001241", "tok_span": [10, 11]}, {"name": "developmental anomalies", "ent_type": "Disease", "char_span": [96, 119], "ent_id": "D000014", "tok_span": [24, 26]}], "relation_list": [{"subject": "Aspirin", "object": "developmental anomalies", "sbj_char_span": [0, 7], "obj_char_span": [96, 119], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [24, 26]}, {"subject": "ASA", "object": "developmental anomalies", "sbj_char_span": [31, 34], "obj_char_span": [96, 119], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [24, 26]}, {"subject": "acetylsalicylic acid", "object": "developmental anomalies", "sbj_char_span": [9, 29], "obj_char_span": [96, 119], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 9], "obj_tok_span": [24, 26]}], "umls_entity_list": []}, {"text": "Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.", "entity_list": [{"name": "ASA", "ent_type": "Chemical", "char_span": [383, 386], "ent_id": "D001241", "tok_span": [71, 72]}, {"name": "ASA", "ent_type": "Chemical", "char_span": [108, 111], "ent_id": "D001241", "tok_span": [21, 22]}, {"name": "gastrointestinal toxicity", "ent_type": "Disease", "char_span": [297, 322], "ent_id": "D005767", "tok_span": [59, 62]}, {"name": "malformations", "ent_type": "Disease", "char_span": [364, 377], "ent_id": "D000014", "tok_span": [69, 70]}], "relation_list": [{"subject": "ASA", "object": "malformations", "sbj_char_span": [383, 386], "obj_char_span": [364, 377], "rel_type": "chemical-induced disease", "sbj_tok_span": [71, 72], "obj_tok_span": [69, 70]}, {"subject": "ASA", "object": "malformations", "sbj_char_span": [108, 111], "obj_char_span": [364, 377], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 22], "obj_tok_span": [69, 70]}], "umls_entity_list": []}, {"text": "RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.", "entity_list": [{"name": "MDs", "ent_type": "Disease", "char_span": [119, 122], "ent_id": "D009436", "tok_span": [21, 23]}, {"name": "DH", "ent_type": "Disease", "char_span": [158, 160], "ent_id": "D065630", "tok_span": [31, 32]}, {"name": "ventricular septal defects", "ent_type": "Disease", "char_span": [64, 90], "ent_id": "D006345", "tok_span": [10, 13]}, {"name": "VSDs", "ent_type": "Disease", "char_span": [172, 176], "ent_id": "D006345", "tok_span": [38, 40]}, {"name": "ASA", "ent_type": "Chemical", "char_span": [281, 284], "ent_id": "D001241", "tok_span": [64, 65]}, {"name": "VSDs", "ent_type": "Disease", "char_span": [92, 96], "ent_id": "D006345", "tok_span": [14, 16]}, {"name": "malformations", "ent_type": "Disease", "char_span": [254, 267], "ent_id": "D000014", "tok_span": [60, 61]}, {"name": "diaphragmatic hernia", "ent_type": "Disease", "char_span": [136, 156], "ent_id": "D065630", "tok_span": [27, 30]}, {"name": "MDs", "ent_type": "Disease", "char_span": [163, 166], "ent_id": "D009436", "tok_span": [34, 36]}, {"name": "malformations", "ent_type": "Disease", "char_span": [321, 334], "ent_id": "D000014", "tok_span": [71, 72]}, {"name": "midline defects", "ent_type": "Disease", "char_span": [102, 117], "ent_id": "D009436", "tok_span": [18, 20]}], "relation_list": [{"subject": "ASA", "object": "malformations", "sbj_char_span": [281, 284], "obj_char_span": [321, 334], "rel_type": "chemical-induced disease", "sbj_tok_span": [64, 65], "obj_tok_span": [71, 72]}, {"subject": "ASA", "object": "malformations", "sbj_char_span": [281, 284], "obj_char_span": [254, 267], "rel_type": "chemical-induced disease", "sbj_tok_span": [64, 65], "obj_tok_span": [60, 61]}, {"subject": "ASA", "object": "VSDs", "sbj_char_span": [281, 284], "obj_char_span": [92, 96], "rel_type": "chemical-induced disease", "sbj_tok_span": [64, 65], "obj_tok_span": [14, 16]}, {"subject": "ASA", "object": "VSDs", "sbj_char_span": [281, 284], "obj_char_span": [172, 176], "rel_type": "chemical-induced disease", "sbj_tok_span": [64, 65], "obj_tok_span": [38, 40]}, {"subject": "ASA", "object": "diaphragmatic hernia", "sbj_char_span": [281, 284], "obj_char_span": [136, 156], "rel_type": "chemical-induced disease", "sbj_tok_span": [64, 65], "obj_tok_span": [27, 30]}, {"subject": "ASA", "object": "DH", "sbj_char_span": [281, 284], "obj_char_span": [158, 160], "rel_type": "chemical-induced disease", "sbj_tok_span": [64, 65], "obj_tok_span": [31, 32]}, {"subject": "ASA", "object": "ventricular septal defects", "sbj_char_span": [281, 284], "obj_char_span": [64, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [64, 65], "obj_tok_span": [10, 13]}], "umls_entity_list": []}, {"text": "Variations and malformations were similar when ASA was administered as a single dose or during the period of organogenesis (GDs 6 to 17).", "entity_list": [{"name": "malformations", "ent_type": "Disease", "char_span": [15, 28], "ent_id": "D000014", "tok_span": [3, 4]}, {"name": "ASA", "ent_type": "Chemical", "char_span": [47, 50], "ent_id": "D001241", "tok_span": [7, 8]}], "relation_list": [{"subject": "ASA", "object": "malformations", "sbj_char_span": [47, 50], "obj_char_span": [15, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [3, 4]}], "umls_entity_list": []}, {"text": "It was also evident that, by titrating the dose to achieve a maximum tolerated dose, malformations that normally occur at low incidence, as reported from previous single dose studies, could also be induced with ASA given at multiple doses.", "entity_list": [{"name": "ASA", "ent_type": "Chemical", "char_span": [211, 214], "ent_id": "D001241", "tok_span": [39, 40]}, {"name": "malformations", "ent_type": "Disease", "char_span": [85, 98], "ent_id": "D000014", "tok_span": [18, 19]}], "relation_list": [{"subject": "ASA", "object": "malformations", "sbj_char_span": [211, 214], "obj_char_span": [85, 98], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 40], "obj_tok_span": [18, 19]}], "umls_entity_list": []}, {"text": "Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block.", "entity_list": [{"name": "Torsade de pointes", "ent_type": "Disease", "char_span": [0, 18], "ent_id": "D016171", "tok_span": [0, 6]}, {"name": "left bundle branch block", "ent_type": "Disease", "char_span": [91, 115], "ent_id": "D002037", "tok_span": [21, 25]}, {"name": "metoclopramide", "ent_type": "Chemical", "char_span": [30, 44], "ent_id": "D008787", "tok_span": [8, 13]}], "relation_list": [{"subject": "metoclopramide", "object": "Torsade de pointes", "sbj_char_span": [30, 44], "obj_char_span": [0, 18], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 13], "obj_tok_span": [0, 6]}], "umls_entity_list": []}, {"text": "We report on a 92-year-old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide.", "entity_list": [{"name": "left bundle branch block", "ent_type": "Disease", "char_span": [59, 83], "ent_id": "D002037", "tok_span": [14, 18]}, {"name": "metoclopramide", "ent_type": "Chemical", "char_span": [162, 176], "ent_id": "D008787", "tok_span": [31, 36]}, {"name": "torsade de pointes", "ent_type": "Disease", "char_span": [98, 116], "ent_id": "D016171", "tok_span": [20, 25]}], "relation_list": [{"subject": "metoclopramide", "object": "torsade de pointes", "sbj_char_span": [162, 176], "obj_char_span": [98, 116], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 36], "obj_tok_span": [20, 25]}], "umls_entity_list": []}, {"text": "This patient also developed torsade de pointes when cisapride and erythromycin were given simultaneously.", "entity_list": [{"name": "cisapride", "ent_type": "Chemical", "char_span": [52, 61], "ent_id": "D020117", "tok_span": [10, 14]}, {"name": "erythromycin", "ent_type": "Chemical", "char_span": [66, 78], "ent_id": "D004917", "tok_span": [15, 17]}, {"name": "torsade de pointes", "ent_type": "Disease", "char_span": [28, 46], "ent_id": "D016171", "tok_span": [4, 9]}], "relation_list": [{"subject": "erythromycin", "object": "torsade de pointes", "sbj_char_span": [66, 78], "obj_char_span": [28, 46], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 17], "obj_tok_span": [4, 9]}, {"subject": "cisapride", "object": "torsade de pointes", "sbj_char_span": [52, 61], "obj_char_span": [28, 46], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 14], "obj_tok_span": [4, 9]}], "umls_entity_list": []}, {"text": "This is the first documentation that metoclopramide provokes torsade de pointes clinically.", "entity_list": [{"name": "torsade de pointes", "ent_type": "Disease", "char_span": [61, 79], "ent_id": "D016171", "tok_span": [13, 18]}, {"name": "metoclopramide", "ent_type": "Chemical", "char_span": [37, 51], "ent_id": "D008787", "tok_span": [6, 11]}], "relation_list": [{"subject": "metoclopramide", "object": "torsade de pointes", "sbj_char_span": [37, 51], "obj_char_span": [61, 79], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 11], "obj_tok_span": [13, 18]}], "umls_entity_list": []}, {"text": "Metoclopramide should be used cautiously in patients with a risk of torsade de pointes.", "entity_list": [{"name": "Metoclopramide", "ent_type": "Chemical", "char_span": [0, 14], "ent_id": "D008787", "tok_span": [0, 5]}, {"name": "torsade de pointes", "ent_type": "Disease", "char_span": [68, 86], "ent_id": "D016171", "tok_span": [17, 22]}], "relation_list": [{"subject": "Metoclopramide", "object": "torsade de pointes", "sbj_char_span": [0, 14], "obj_char_span": [68, 86], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 5], "obj_tok_span": [17, 22]}], "umls_entity_list": []}, {"text": "In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa-induced dyskinesias.", "entity_list": [{"name": "levodopa", "ent_type": "Chemical", "char_span": [171, 179], "ent_id": "D007980", "tok_span": [28, 31]}, {"name": "dyskinesias", "ent_type": "Disease", "char_span": [188, 199], "ent_id": "D004409", "tok_span": [33, 37]}, {"name": "apomorphine", "ent_type": "Chemical", "char_span": [97, 108], "ent_id": "D001058", "tok_span": [13, 18]}], "relation_list": [{"subject": "levodopa", "object": "dyskinesias", "sbj_char_span": [171, 179], "obj_char_span": [188, 199], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 31], "obj_tok_span": [33, 37]}], "umls_entity_list": []}, {"text": "Fatal excited delirium following cocaine use: epidemiologic findings provide new evidence for mechanisms of cocaine toxicity.", "entity_list": [{"name": "delirium", "ent_type": "Disease", "char_span": [14, 22], "ent_id": "D003693", "tok_span": [3, 6]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [108, 115], "ent_id": "D003042", "tok_span": [19, 20]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [33, 40], "ent_id": "D003042", "tok_span": [7, 8]}, {"name": "toxicity", "ent_type": "Disease", "char_span": [116, 124], "ent_id": "D064420", "tok_span": [20, 21]}], "relation_list": [{"subject": "cocaine", "object": "delirium", "sbj_char_span": [108, 115], "obj_char_span": [14, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 20], "obj_tok_span": [3, 6]}, {"subject": "cocaine", "object": "delirium", "sbj_char_span": [33, 40], "obj_char_span": [14, 22], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [3, 6]}], "umls_entity_list": []}, {"text": "We describe an outbreak of deaths from cocaine-induced excited delirium (EDDs) in Dade County, Florida between 1979 and 1990.", "entity_list": [{"name": "delirium", "ent_type": "Disease", "char_span": [63, 71], "ent_id": "D003693", "tok_span": [11, 14]}, {"name": "EDDs", "ent_type": "Disease", "char_span": [73, 77], "ent_id": "D003693", "tok_span": [15, 17]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [39, 46], "ent_id": "D003042", "tok_span": [7, 8]}], "relation_list": [{"subject": "cocaine", "object": "delirium", "sbj_char_span": [39, 46], "obj_char_span": [63, 71], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [11, 14]}, {"subject": "cocaine", "object": "EDDs", "sbj_char_span": [39, 46], "obj_char_span": [73, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 8], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "From a registry of all cocaine-related deaths in Dade County, Florida, from 1969-1990, 58 EDDs were compared with 125 victims of accidental cocaine overdose without excited delirium.", "entity_list": [{"name": "cocaine", "ent_type": "Chemical", "char_span": [140, 147], "ent_id": "D003042", "tok_span": [33, 34]}, {"name": "delirium", "ent_type": "Disease", "char_span": [173, 181], "ent_id": "D003693", "tok_span": [38, 41]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [23, 30], "ent_id": "D003042", "tok_span": [5, 6]}, {"name": "EDDs", "ent_type": "Disease", "char_span": [90, 94], "ent_id": "D003693", "tok_span": [23, 25]}, {"name": "overdose", "ent_type": "Disease", "char_span": [148, 156], "ent_id": "D062787", "tok_span": [34, 36]}], "relation_list": [{"subject": "cocaine", "object": "EDDs", "sbj_char_span": [23, 30], "obj_char_span": [90, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 6], "obj_tok_span": [23, 25]}, {"subject": "cocaine", "object": "delirium", "sbj_char_span": [23, 30], "obj_char_span": [173, 181], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 6], "obj_tok_span": [38, 41]}, {"subject": "cocaine", "object": "delirium", "sbj_char_span": [140, 147], "obj_char_span": [173, 181], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 34], "obj_tok_span": [38, 41]}, {"subject": "cocaine", "object": "EDDs", "sbj_char_span": [140, 147], "obj_char_span": [90, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 34], "obj_tok_span": [23, 25]}], "umls_entity_list": []}, {"text": "EDDs had concentrations of cocaine and benzoylecgonine in autopsy blood that were similar to those for controls.", "entity_list": [{"name": "benzoylecgonine", "ent_type": "Chemical", "char_span": [39, 54], "ent_id": "C005618", "tok_span": [7, 11]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [27, 34], "ent_id": "D003042", "tok_span": [5, 6]}, {"name": "EDDs", "ent_type": "Disease", "char_span": [0, 4], "ent_id": "D003693", "tok_span": [0, 2]}], "relation_list": [{"subject": "cocaine", "object": "EDDs", "sbj_char_span": [27, 34], "obj_char_span": [0, 4], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 6], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.", "entity_list": [{"name": "sudden death", "ent_type": "Disease", "char_span": [250, 262], "ent_id": "D003645", "tok_span": [47, 49]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [153, 160], "ent_id": "D003042", "tok_span": [24, 25]}, {"name": "agitation", "ent_type": "Disease", "char_span": [182, 191], "ent_id": "D011595", "tok_span": [29, 31]}, {"name": "delirium", "ent_type": "Disease", "char_span": [193, 201], "ent_id": "D003693", "tok_span": [32, 35]}, {"name": "cocaine", "ent_type": "Chemical", "char_span": [80, 87], "ent_id": "D003042", "tok_span": [12, 13]}, {"name": "rhabdomyolysis", "ent_type": "Disease", "char_span": [230, 244], "ent_id": "D012206", "tok_span": [41, 45]}], "relation_list": [{"subject": "cocaine", "object": "sudden death", "sbj_char_span": [153, 160], "obj_char_span": [250, 262], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 25], "obj_tok_span": [47, 49]}, {"subject": "cocaine", "object": "delirium", "sbj_char_span": [80, 87], "obj_char_span": [193, 201], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [32, 35]}, {"subject": "cocaine", "object": "rhabdomyolysis", "sbj_char_span": [153, 160], "obj_char_span": [230, 244], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 25], "obj_tok_span": [41, 45]}, {"subject": "cocaine", "object": "delirium", "sbj_char_span": [153, 160], "obj_char_span": [193, 201], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 25], "obj_tok_span": [32, 35]}, {"subject": "cocaine", "object": "rhabdomyolysis", "sbj_char_span": [80, 87], "obj_char_span": [230, 244], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [41, 45]}, {"subject": "cocaine", "object": "sudden death", "sbj_char_span": [80, 87], "obj_char_span": [250, 262], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [47, 49]}], "umls_entity_list": []}, {"text": "Heparin-induced thrombocytopenia, thrombosis, and hemorrhage.", "entity_list": [{"name": "hemorrhage", "ent_type": "Disease", "char_span": [50, 60], "ent_id": "D006470", "tok_span": [10, 11]}, {"name": "thrombosis", "ent_type": "Disease", "char_span": [34, 44], "ent_id": "D013927", "tok_span": [7, 8]}, {"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [16, 32], "ent_id": "D013921", "tok_span": [4, 6]}, {"name": "Heparin", "ent_type": "Chemical", "char_span": [0, 7], "ent_id": "D006493", "tok_span": [0, 2]}], "relation_list": [{"subject": "Heparin", "object": "hemorrhage", "sbj_char_span": [0, 7], "obj_char_span": [50, 60], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [10, 11]}, {"subject": "Heparin", "object": "thrombocytopenia", "sbj_char_span": [0, 7], "obj_char_span": [16, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 2], "obj_tok_span": [4, 6]}], "umls_entity_list": []}, {"text": "Sixty-two patients with a heparin-induced thrombocytopenia are reported.", "entity_list": [{"name": "heparin", "ent_type": "Chemical", "char_span": [26, 33], "ent_id": "D006493", "tok_span": [6, 7]}, {"name": "thrombocytopenia", "ent_type": "Disease", "char_span": [42, 58], "ent_id": "D013921", "tok_span": [9, 11]}], "relation_list": [{"subject": "heparin", "object": "thrombocytopenia", "sbj_char_span": [26, 33], "obj_char_span": [42, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "Clinical manifestations of this disorder include hemorrhage or, more frequently, thromboembolic events in patients receiving heparin.", "entity_list": [{"name": "hemorrhage", "ent_type": "Disease", "char_span": [49, 59], "ent_id": "D006470", "tok_span": [6, 7]}, {"name": "heparin", "ent_type": "Chemical", "char_span": [125, 132], "ent_id": "D006493", "tok_span": [18, 19]}, {"name": "thromboembolic", "ent_type": "Disease", "char_span": [81, 95], "ent_id": "D013923", "tok_span": [12, 14]}], "relation_list": [{"subject": "heparin", "object": "thromboembolic", "sbj_char_span": [125, 132], "obj_char_span": [81, 95], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [12, 14]}, {"subject": "heparin", "object": "hemorrhage", "sbj_char_span": [125, 132], "obj_char_span": [49, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 19], "obj_tok_span": [6, 7]}], "umls_entity_list": []}, {"text": "We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.", "entity_list": [{"name": "metastasis", "ent_type": "Disease", "char_span": [61, 71], "ent_id": "D009362", "tok_span": [12, 13]}, {"name": "5-FU", "ent_type": "Chemical", "char_span": [119, 123], "ent_id": "D005472", "tok_span": [24, 27]}, {"name": "5-fluorouracil", "ent_type": "Chemical", "char_span": [103, 117], "ent_id": "D005472", "tok_span": [18, 23]}, {"name": "colon carcinoma", "ent_type": "Disease", "char_span": [35, 50], "ent_id": "D003110", "tok_span": [8, 10]}, {"name": "chest pain", "ent_type": "Disease", "char_span": [86, 96], "ent_id": "D002637", "tok_span": [15, 17]}], "relation_list": [{"subject": "5-fluorouracil", "object": "chest pain", "sbj_char_span": [103, 117], "obj_char_span": [86, 96], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 23], "obj_tok_span": [15, 17]}, {"subject": "5-FU", "object": "chest pain", "sbj_char_span": [119, 123], "obj_char_span": [86, 96], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 27], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.", "entity_list": [{"name": "thiosulphate", "ent_type": "Chemical", "char_span": [185, 197], "ent_id": "-1", "tok_span": [46, 51]}, {"name": "dermatitis", "ent_type": "Disease", "char_span": [58, 68], "ent_id": "D003872", "tok_span": [10, 11]}, {"name": "dermatitis", "ent_type": "Disease", "char_span": [162, 172], "ent_id": "D003872", "tok_span": [42, 43]}, {"name": "Tiopronin", "ent_type": "Chemical", "char_span": [76, 85], "ent_id": "D008625", "tok_span": [13, 17]}, {"name": "D-Penicillamine", "ent_type": "Chemical", "char_span": [89, 104], "ent_id": "D010396", "tok_span": [19, 26]}, {"name": "nephritis", "ent_type": "Disease", "char_span": [44, 53], "ent_id": "D009393", "tok_span": [7, 9]}, {"name": "gold", "ent_type": "Chemical", "char_span": [180, 184], "ent_id": "D006046", "tok_span": [45, 46]}], "relation_list": [{"subject": "gold", "object": "dermatitis", "sbj_char_span": [180, 184], "obj_char_span": [58, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [45, 46], "obj_tok_span": [10, 11]}, {"subject": "gold", "object": "dermatitis", "sbj_char_span": [180, 184], "obj_char_span": [162, 172], "rel_type": "chemical-induced disease", "sbj_tok_span": [45, 46], "obj_tok_span": [42, 43]}, {"subject": "Tiopronin", "object": "dermatitis", "sbj_char_span": [76, 85], "obj_char_span": [162, 172], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [42, 43]}, {"subject": "Tiopronin", "object": "dermatitis", "sbj_char_span": [76, 85], "obj_char_span": [58, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [10, 11]}, {"subject": "Tiopronin", "object": "nephritis", "sbj_char_span": [76, 85], "obj_char_span": [44, 53], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 17], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group.", "entity_list": [{"name": "RA", "ent_type": "Disease", "char_span": [81, 83], "ent_id": "D001172", "tok_span": [14, 15]}, {"name": "Tiopronin", "ent_type": "Chemical", "char_span": [99, 108], "ent_id": "D008625", "tok_span": [18, 22]}, {"name": "nephritis", "ent_type": "Disease", "char_span": [117, 126], "ent_id": "D009393", "tok_span": [23, 25]}], "relation_list": [{"subject": "Tiopronin", "object": "nephritis", "sbj_char_span": [99, 108], "obj_char_span": [117, 126], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 22], "obj_tok_span": [23, 25]}], "umls_entity_list": []}, {"text": "Transient hemiparesis: a rare manifestation of diphenylhydantoin toxicity.", "entity_list": [{"name": "diphenylhydantoin", "ent_type": "Chemical", "char_span": [47, 64], "ent_id": "D010672", "tok_span": [11, 17]}, {"name": "toxicity", "ent_type": "Disease", "char_span": [65, 73], "ent_id": "D064420", "tok_span": [17, 18]}, {"name": "hemiparesis", "ent_type": "Disease", "char_span": [10, 21], "ent_id": "D010291", "tok_span": [2, 6]}], "relation_list": [{"subject": "diphenylhydantoin", "object": "hemiparesis", "sbj_char_span": [47, 64], "obj_char_span": [10, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 17], "obj_tok_span": [2, 6]}], "umls_entity_list": []}, {"text": "Among the common side effects of diphenylhydantoin (DPH) overdose, the most frequently encountered neurological signs are those of cerebellar dysfunction.", "entity_list": [{"name": "DPH", "ent_type": "Chemical", "char_span": [52, 55], "ent_id": "D010672", "tok_span": [13, 15]}, {"name": "overdose", "ent_type": "Disease", "char_span": [57, 65], "ent_id": "D062787", "tok_span": [16, 18]}, {"name": "diphenylhydantoin", "ent_type": "Chemical", "char_span": [33, 50], "ent_id": "D010672", "tok_span": [6, 12]}, {"name": "cerebellar dysfunction", "ent_type": "Disease", "char_span": [131, 153], "ent_id": "D002526", "tok_span": [28, 30]}], "relation_list": [{"subject": "DPH", "object": "overdose", "sbj_char_span": [52, 55], "obj_char_span": [57, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [16, 18]}, {"subject": "diphenylhydantoin", "object": "cerebellar dysfunction", "sbj_char_span": [33, 50], "obj_char_span": [131, 153], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 12], "obj_tok_span": [28, 30]}, {"subject": "DPH", "object": "cerebellar dysfunction", "sbj_char_span": [52, 55], "obj_char_span": [131, 153], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [28, 30]}, {"subject": "diphenylhydantoin", "object": "overdose", "sbj_char_span": [33, 50], "obj_char_span": [57, 65], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 12], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "Two patients are presented who suffered progressive hemiparesis due to DPH overdose.", "entity_list": [{"name": "DPH", "ent_type": "Chemical", "char_span": [71, 74], "ent_id": "D010672", "tok_span": [13, 15]}, {"name": "overdose", "ent_type": "Disease", "char_span": [75, 83], "ent_id": "D062787", "tok_span": [15, 17]}, {"name": "hemiparesis", "ent_type": "Disease", "char_span": [52, 63], "ent_id": "D010291", "tok_span": [7, 11]}], "relation_list": [{"subject": "DPH", "object": "hemiparesis", "sbj_char_span": [71, 74], "obj_char_span": [52, 63], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [7, 11]}, {"subject": "DPH", "object": "overdose", "sbj_char_span": [71, 74], "obj_char_span": [75, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 15], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).", "entity_list": [{"name": "PGF2alpha", "ent_type": "Chemical", "char_span": [31, 40], "ent_id": "D015237", "tok_span": [9, 13]}, {"name": "OAB", "ent_type": "Disease", "char_span": [87, 90], "ent_id": "D053201", "tok_span": [19, 21]}, {"name": "PGE2", "ent_type": "Chemical", "char_span": [22, 26], "ent_id": "D015232", "tok_span": [6, 8]}], "relation_list": [{"subject": "PGE2", "object": "OAB", "sbj_char_span": [22, 26], "obj_char_span": [87, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [19, 21]}, {"subject": "PGF2alpha", "object": "OAB", "sbj_char_span": [31, 40], "obj_char_span": [87, 90], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 13], "obj_tok_span": [19, 21]}], "umls_entity_list": []}, {"text": "In patients with OAB urinary PGE2 positively correlated with volume at first desire to void and maximum cystometric capacity (p <0.05).", "entity_list": [{"name": "OAB", "ent_type": "Disease", "char_span": [17, 20], "ent_id": "D053201", "tok_span": [3, 5]}, {"name": "PGE2", "ent_type": "Chemical", "char_span": [29, 33], "ent_id": "D015232", "tok_span": [6, 8]}], "relation_list": [{"subject": "PGE2", "object": "OAB", "sbj_char_span": [29, 33], "obj_char_span": [17, 20], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "Urinary NGF, PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB.", "entity_list": [{"name": "OAB", "ent_type": "Disease", "char_span": [94, 97], "ent_id": "D053201", "tok_span": [22, 24]}, {"name": "PGF2alpha", "ent_type": "Chemical", "char_span": [13, 22], "ent_id": "D015237", "tok_span": [4, 8]}, {"name": "PGI2", "ent_type": "Chemical", "char_span": [27, 31], "ent_id": "D011464", "tok_span": [9, 12]}], "relation_list": [{"subject": "PGF2alpha", "object": "OAB", "sbj_char_span": [13, 22], "obj_char_span": [94, 97], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 8], "obj_tok_span": [22, 24]}], "umls_entity_list": []}, {"text": "Acute low back pain during intravenous administration of amiodarone: a report of two cases.", "entity_list": [{"name": "low back pain", "ent_type": "Disease", "char_span": [6, 19], "ent_id": "D017116", "tok_span": [1, 4]}, {"name": "amiodarone", "ent_type": "Chemical", "char_span": [57, 67], "ent_id": "D000638", "tok_span": [8, 12]}], "relation_list": [{"subject": "amiodarone", "object": "low back pain", "sbj_char_span": [57, 67], "obj_char_span": [6, 19], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 12], "obj_tok_span": [1, 4]}], "umls_entity_list": []}, {"text": "We briefly describe two patients suffering from recent-onset atrial fibrillation, who experienced an acute devastating low back pain a few minutes after initiation of intravenous amiodarone loading.", "entity_list": [{"name": "amiodarone", "ent_type": "Chemical", "char_span": [179, 189], "ent_id": "D000638", "tok_span": [30, 34]}, {"name": "low back pain", "ent_type": "Disease", "char_span": [119, 132], "ent_id": "D017116", "tok_span": [20, 23]}, {"name": "atrial fibrillation", "ent_type": "Disease", "char_span": [61, 80], "ent_id": "D001281", "tok_span": [10, 12]}], "relation_list": [{"subject": "amiodarone", "object": "low back pain", "sbj_char_span": [179, 189], "obj_char_span": [119, 132], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 34], "obj_tok_span": [20, 23]}], "umls_entity_list": []}, {"text": "Postoperative myalgia after succinylcholine: no evidence for an inflammatory origin.", "entity_list": [{"name": "succinylcholine", "ent_type": "Chemical", "char_span": [28, 43], "ent_id": "D013390", "tok_span": [5, 8]}, {"name": "Postoperative myalgia", "ent_type": "Disease", "char_span": [0, 21], "ent_id": "D010149", "tok_span": [0, 4]}], "relation_list": [{"subject": "succinylcholine", "object": "Postoperative myalgia", "sbj_char_span": [28, 43], "obj_char_span": [0, 21], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [0, 4]}], "umls_entity_list": []}, {"text": "A common side effect associated with succinylcholine is postoperative myalgia.", "entity_list": [{"name": "postoperative myalgia", "ent_type": "Disease", "char_span": [56, 77], "ent_id": "D010149", "tok_span": [10, 14]}, {"name": "succinylcholine", "ent_type": "Chemical", "char_span": [37, 52], "ent_id": "D013390", "tok_span": [6, 9]}], "relation_list": [{"subject": "succinylcholine", "object": "postoperative myalgia", "sbj_char_span": [37, 52], "obj_char_span": [56, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "The incidence and severity of succinylcholine-associated myalgia was determined in 64 patients pretreated with saline or dexamethasone before succinylcholine (n = 32 for each).", "entity_list": [{"name": "succinylcholine", "ent_type": "Chemical", "char_span": [142, 157], "ent_id": "D013390", "tok_span": [24, 27]}, {"name": "succinylcholine", "ent_type": "Chemical", "char_span": [30, 45], "ent_id": "D013390", "tok_span": [5, 8]}, {"name": "dexamethasone", "ent_type": "Chemical", "char_span": [121, 134], "ent_id": "D003907", "tok_span": [22, 23]}, {"name": "myalgia", "ent_type": "Disease", "char_span": [57, 64], "ent_id": "D063806", "tok_span": [10, 13]}], "relation_list": [{"subject": "succinylcholine", "object": "myalgia", "sbj_char_span": [30, 45], "obj_char_span": [57, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [10, 13]}, {"subject": "succinylcholine", "object": "myalgia", "sbj_char_span": [142, 157], "obj_char_span": [57, 64], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 27], "obj_tok_span": [10, 13]}], "umls_entity_list": []}, {"text": "In conclusion, there is no evidence for an inflammatory origin of succinylcholine-associated myalgia.", "entity_list": [{"name": "myalgia", "ent_type": "Disease", "char_span": [93, 100], "ent_id": "D063806", "tok_span": [17, 20]}, {"name": "succinylcholine", "ent_type": "Chemical", "char_span": [66, 81], "ent_id": "D013390", "tok_span": [12, 15]}], "relation_list": [{"subject": "succinylcholine", "object": "myalgia", "sbj_char_span": [66, 81], "obj_char_span": [93, 100], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [17, 20]}], "umls_entity_list": []}, {"text": "IMPLICATIONS: Administration of dexamethasone before succinylcholine was not effective in decreasing the incidence or the severity of succinylcholine-induced postoperative myalgia.", "entity_list": [{"name": "succinylcholine", "ent_type": "Chemical", "char_span": [53, 68], "ent_id": "D013390", "tok_span": [10, 13]}, {"name": "postoperative myalgia", "ent_type": "Disease", "char_span": [158, 179], "ent_id": "D010149", "tok_span": [29, 33]}, {"name": "succinylcholine", "ent_type": "Chemical", "char_span": [134, 149], "ent_id": "D013390", "tok_span": [24, 27]}, {"name": "dexamethasone", "ent_type": "Chemical", "char_span": [32, 45], "ent_id": "D003907", "tok_span": [8, 9]}], "relation_list": [{"subject": "succinylcholine", "object": "postoperative myalgia", "sbj_char_span": [134, 149], "obj_char_span": [158, 179], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 27], "obj_tok_span": [29, 33]}, {"subject": "succinylcholine", "object": "postoperative myalgia", "sbj_char_span": [53, 68], "obj_char_span": [158, 179], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [29, 33]}], "umls_entity_list": []}, {"text": "Pretreatment with dexamethasone is not justified to prevent postoperative myalgia after succinylcholine.", "entity_list": [{"name": "succinylcholine", "ent_type": "Chemical", "char_span": [88, 103], "ent_id": "D013390", "tok_span": [14, 17]}, {"name": "postoperative myalgia", "ent_type": "Disease", "char_span": [60, 81], "ent_id": "D010149", "tok_span": [9, 13]}, {"name": "dexamethasone", "ent_type": "Chemical", "char_span": [18, 31], "ent_id": "D003907", "tok_span": [3, 4]}], "relation_list": [{"subject": "succinylcholine", "object": "postoperative myalgia", "sbj_char_span": [88, 103], "obj_char_span": [60, 81], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 17], "obj_tok_span": [9, 13]}], "umls_entity_list": []}, {"text": "Levodopa-induced oromandibular dystonia in progressive supranuclear palsy.", "entity_list": [{"name": "Levodopa", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D007980", "tok_span": [0, 3]}, {"name": "progressive supranuclear palsy", "ent_type": "Disease", "char_span": [43, 73], "ent_id": "D013494", "tok_span": [13, 18]}, {"name": "dystonia", "ent_type": "Disease", "char_span": [31, 39], "ent_id": "D004421", "tok_span": [10, 12]}], "relation_list": [{"subject": "Levodopa", "object": "dystonia", "sbj_char_span": [0, 8], "obj_char_span": [31, 39], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Protective effect of edaravone against streptomycin-induced vestibulotoxicity in the guinea pig.", "entity_list": [{"name": "streptomycin", "ent_type": "Chemical", "char_span": [39, 51], "ent_id": "D013307", "tok_span": [10, 11]}, {"name": "vestibulotoxicity", "ent_type": "Disease", "char_span": [60, 77], "ent_id": "D015837", "tok_span": [13, 19]}, {"name": "edaravone", "ent_type": "Chemical", "char_span": [21, 30], "ent_id": "C005435", "tok_span": [5, 9]}], "relation_list": [{"subject": "streptomycin", "object": "vestibulotoxicity", "sbj_char_span": [39, 51], "obj_char_span": [60, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 11], "obj_tok_span": [13, 19]}], "umls_entity_list": []}, {"text": "This study investigated alleviation of streptomycin-induced vestibulotoxicity by edaravone in guinea pigs.", "entity_list": [{"name": "vestibulotoxicity", "ent_type": "Disease", "char_span": [60, 77], "ent_id": "D015837", "tok_span": [9, 15]}, {"name": "edaravone", "ent_type": "Chemical", "char_span": [81, 90], "ent_id": "C005435", "tok_span": [16, 20]}, {"name": "streptomycin", "ent_type": "Chemical", "char_span": [39, 51], "ent_id": "D013307", "tok_span": [6, 7]}], "relation_list": [{"subject": "streptomycin", "object": "vestibulotoxicity", "sbj_char_span": [39, 51], "obj_char_span": [60, 77], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [9, 15]}], "umls_entity_list": []}, {"text": "These results suggest that edaravone suppresses streptomycin-induced vestibulotoxicity.", "entity_list": [{"name": "streptomycin", "ent_type": "Chemical", "char_span": [48, 60], "ent_id": "D013307", "tok_span": [9, 10]}, {"name": "edaravone", "ent_type": "Chemical", "char_span": [27, 36], "ent_id": "C005435", "tok_span": [4, 8]}, {"name": "vestibulotoxicity", "ent_type": "Disease", "char_span": [69, 86], "ent_id": "D015837", "tok_span": [12, 18]}], "relation_list": [{"subject": "streptomycin", "object": "vestibulotoxicity", "sbj_char_span": [48, 60], "obj_char_span": [69, 86], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 10], "obj_tok_span": [12, 18]}], "umls_entity_list": []}, {"text": "Diazepam, unless contraindicated or risky, remains the only necessary complementary drug to ketamine as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative hallucinations.", "entity_list": [{"name": "Diazepam", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D003975", "tok_span": [0, 3]}, {"name": "hallucinations", "ent_type": "Disease", "char_span": [215, 229], "ent_id": "D006212", "tok_span": [34, 37]}, {"name": "ketamine", "ent_type": "Chemical", "char_span": [92, 100], "ent_id": "D007649", "tok_span": [17, 18]}], "relation_list": [{"subject": "ketamine", "object": "hallucinations", "sbj_char_span": [92, 100], "obj_char_span": [215, 229], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 18], "obj_tok_span": [34, 37]}], "umls_entity_list": []}, {"text": "The memory-enhancing effects of PREGS and its analogs were tested in the passive avoidance task using the model of scopolamine-induced amnesia.", "entity_list": [{"name": "amnesia", "ent_type": "Disease", "char_span": [135, 142], "ent_id": "D000647", "tok_span": [27, 30]}, {"name": "scopolamine", "ent_type": "Chemical", "char_span": [115, 126], "ent_id": "D012601", "tok_span": [22, 25]}, {"name": "PREGS", "ent_type": "Chemical", "char_span": [32, 37], "ent_id": "C018370", "tok_span": [6, 8]}], "relation_list": [{"subject": "scopolamine", "object": "amnesia", "sbj_char_span": [115, 126], "obj_char_span": [135, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 25], "obj_tok_span": [27, 30]}], "umls_entity_list": []}, {"text": "Moreover, enantioselectivity was demonstrated by the ability of natural PREGS to be an order of magnitude more effective than its synthetic enantiomer in reversing scopolamine-induced amnesia.", "entity_list": [{"name": "amnesia", "ent_type": "Disease", "char_span": [184, 191], "ent_id": "D000647", "tok_span": [35, 38]}, {"name": "PREGS", "ent_type": "Chemical", "char_span": [72, 77], "ent_id": "C018370", "tok_span": [12, 14]}, {"name": "scopolamine", "ent_type": "Chemical", "char_span": [164, 175], "ent_id": "D012601", "tok_span": [30, 33]}], "relation_list": [{"subject": "scopolamine", "object": "amnesia", "sbj_char_span": [164, 175], "obj_char_span": [184, 191], "rel_type": "chemical-induced disease", "sbj_tok_span": [30, 33], "obj_tok_span": [35, 38]}], "umls_entity_list": []}, {"text": "METHODS: Following Food and Drug Administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials: an open-label, dose-escalating trial with intrathecal adenosine doses of 0.25-2.0 mg and a double-blind, placebo-controlled trial of adenosine, 2 mg. Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.", "entity_list": [{"name": "allodynia", "ent_type": "Disease", "char_span": [465, 474], "ent_id": "D006930", "tok_span": [95, 98]}, {"name": "adenosine", "ent_type": "Chemical", "char_span": [214, 223], "ent_id": "D000241", "tok_span": [39, 40]}, {"name": "mechanical hyperalgesia", "ent_type": "Disease", "char_span": [437, 460], "ent_id": "D006930", "tok_span": [89, 94]}, {"name": "adenosine", "ent_type": "Chemical", "char_span": [293, 302], "ent_id": "D000241", "tok_span": [61, 62]}, {"name": "pain", "ent_type": "Disease", "char_span": [377, 381], "ent_id": "D010146", "tok_span": [78, 79]}, {"name": "capsaicin", "ent_type": "Chemical", "char_span": [493, 502], "ent_id": "D002211", "tok_span": [102, 105]}], "relation_list": [{"subject": "capsaicin", "object": "allodynia", "sbj_char_span": [493, 502], "obj_char_span": [465, 474], "rel_type": "chemical-induced disease", "sbj_tok_span": [102, 105], "obj_tok_span": [95, 98]}, {"subject": "capsaicin", "object": "mechanical hyperalgesia", "sbj_char_span": [493, 502], "obj_char_span": [437, 460], "rel_type": "chemical-induced disease", "sbj_tok_span": [102, 105], "obj_tok_span": [89, 94]}], "umls_entity_list": []}, {"text": "RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).", "entity_list": [{"name": "pain", "ent_type": "Disease", "char_span": [41, 45], "ent_id": "D010146", "tok_span": [8, 9]}, {"name": "Adenosine", "ent_type": "Chemical", "char_span": [9, 18], "ent_id": "D000241", "tok_span": [2, 4]}, {"name": "allodynia", "ent_type": "Disease", "char_span": [142, 151], "ent_id": "D006930", "tok_span": [26, 29]}, {"name": "mechanical hyperalgesia", "ent_type": "Disease", "char_span": [114, 137], "ent_id": "D006930", "tok_span": [20, 25]}, {"name": "adenosine", "ent_type": "Chemical", "char_span": [239, 248], "ent_id": "D000241", "tok_span": [49, 50]}, {"name": "capsaicin", "ent_type": "Chemical", "char_span": [169, 178], "ent_id": "D002211", "tok_span": [33, 36]}], "relation_list": [{"subject": "capsaicin", "object": "allodynia", "sbj_char_span": [169, 178], "obj_char_span": [142, 151], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 36], "obj_tok_span": [26, 29]}, {"subject": "capsaicin", "object": "mechanical hyperalgesia", "sbj_char_span": [169, 178], "obj_char_span": [114, 137], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 36], "obj_tok_span": [20, 25]}], "umls_entity_list": []}, {"text": "All patients having first-degree relatives affected by thyroid illness had accelerated onset of hypothyroidism (3.7 years after onset of lithium therapy) compared with patients without a family history (8.6 years after onset of lithium therapy).", "entity_list": [{"name": "lithium", "ent_type": "Chemical", "char_span": [228, 235], "ent_id": "D008094", "tok_span": [43, 44]}, {"name": "hypothyroidism", "ent_type": "Disease", "char_span": [96, 110], "ent_id": "D007037", "tok_span": [15, 17]}, {"name": "thyroid illness", "ent_type": "Disease", "char_span": [55, 70], "ent_id": "D013959", "tok_span": [9, 11]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [137, 144], "ent_id": "D008094", "tok_span": [25, 26]}], "relation_list": [{"subject": "lithium", "object": "hypothyroidism", "sbj_char_span": [137, 144], "obj_char_span": [96, 110], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 26], "obj_tok_span": [15, 17]}, {"subject": "lithium", "object": "hypothyroidism", "sbj_char_span": [228, 235], "obj_char_span": [96, 110], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 44], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Familial thyroid illness is a risk factor for hypothyroidism and hypercalcemia during lithium therapy.", "entity_list": [{"name": "hypercalcemia", "ent_type": "Disease", "char_span": [78, 91], "ent_id": "D006934", "tok_span": [16, 19]}, {"name": "lithium", "ent_type": "Chemical", "char_span": [99, 106], "ent_id": "D008094", "tok_span": [20, 21]}, {"name": "thyroid illness", "ent_type": "Disease", "char_span": [22, 37], "ent_id": "D013959", "tok_span": [6, 8]}, {"name": "hypothyroidism", "ent_type": "Disease", "char_span": [59, 73], "ent_id": "D007037", "tok_span": [13, 15]}], "relation_list": [{"subject": "lithium", "object": "hypothyroidism", "sbj_char_span": [99, 106], "obj_char_span": [59, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 21], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.", "entity_list": [{"name": "sirolimus", "ent_type": "Chemical", "char_span": [46, 55], "ent_id": "D020123", "tok_span": [6, 8]}, {"name": "capillary leak syndrome", "ent_type": "Disease", "char_span": [107, 130], "ent_id": "D019559", "tok_span": [18, 21]}, {"name": "rapamycin", "ent_type": "Chemical", "char_span": [66, 75], "ent_id": "D020123", "tok_span": [11, 12]}, {"name": "psoriasis", "ent_type": "Disease", "char_span": [81, 90], "ent_id": "D011565", "tok_span": [14, 15]}, {"name": "toxicity", "ent_type": "Disease", "char_span": [9, 17], "ent_id": "D064420", "tok_span": [2, 3]}], "relation_list": [{"subject": "sirolimus", "object": "capillary leak syndrome", "sbj_char_span": [46, 55], "obj_char_span": [107, 130], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [18, 21]}, {"subject": "rapamycin", "object": "capillary leak syndrome", "sbj_char_span": [66, 75], "obj_char_span": [107, 130], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 12], "obj_tok_span": [18, 21]}], "umls_entity_list": []}, {"text": "After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis.", "entity_list": [{"name": "capillary leak syndrome", "ent_type": "Disease", "char_span": [47, 70], "ent_id": "D019559", "tok_span": [7, 10]}, {"name": "psoriasis", "ent_type": "Disease", "char_span": [25, 34], "ent_id": "D011565", "tok_span": [4, 5]}, {"name": "sirolimus", "ent_type": "Chemical", "char_span": [101, 110], "ent_id": "D020123", "tok_span": [14, 16]}], "relation_list": [{"subject": "sirolimus", "object": "capillary leak syndrome", "sbj_char_span": [101, 110], "obj_char_span": [47, 70], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "OBSERVATIONS: A keratome skin specimen from 1 patient with sirolimus-induced capillary leak syndrome had a 2.3-fold increase in percentage of apoptotic cells (to 48%) compared with an unaffected sirolimus-treated patient with psoriasis (21%).", "entity_list": [{"name": "psoriasis", "ent_type": "Disease", "char_span": [226, 235], "ent_id": "D011565", "tok_span": [49, 50]}, {"name": "sirolimus", "ent_type": "Chemical", "char_span": [195, 204], "ent_id": "D020123", "tok_span": [43, 45]}, {"name": "sirolimus", "ent_type": "Chemical", "char_span": [59, 68], "ent_id": "D020123", "tok_span": [14, 16]}, {"name": "capillary leak syndrome", "ent_type": "Disease", "char_span": [77, 100], "ent_id": "D019559", "tok_span": [18, 21]}], "relation_list": [{"subject": "sirolimus", "object": "capillary leak syndrome", "sbj_char_span": [195, 204], "obj_char_span": [77, 100], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 45], "obj_tok_span": [18, 21]}, {"subject": "sirolimus", "object": "capillary leak syndrome", "sbj_char_span": [59, 68], "obj_char_span": [77, 100], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 16], "obj_tok_span": [18, 21]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Severe adverse effects of sirolimus include fever, anemia, and capillary leak syndrome.", "entity_list": [{"name": "fever", "ent_type": "Disease", "char_span": [57, 62], "ent_id": "D005334", "tok_span": [9, 10]}, {"name": "anemia", "ent_type": "Disease", "char_span": [64, 70], "ent_id": "D000740", "tok_span": [11, 12]}, {"name": "sirolimus", "ent_type": "Chemical", "char_span": [39, 48], "ent_id": "D020123", "tok_span": [6, 8]}, {"name": "capillary leak syndrome", "ent_type": "Disease", "char_span": [76, 99], "ent_id": "D019559", "tok_span": [14, 17]}], "relation_list": [{"subject": "sirolimus", "object": "capillary leak syndrome", "sbj_char_span": [39, 48], "obj_char_span": [76, 99], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 8], "obj_tok_span": [14, 17]}], "umls_entity_list": []}, {"text": "Muscle rigidity was induced by haloperidol (2.5 mg/kg i.p.). 5,7-dichlorokynurenic acid (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced muscle rigidity (MMG) and the enhanced electromyographic activity (EMG). 5,7-DCKA injected bilaterally in a dose of 4.5 microg/0.5 microl into the intermediate-caudal region of the striatum of rats not pretreated with haloperidol had no effect on the muscle tone.", "entity_list": [{"name": "haloperidol", "ent_type": "Chemical", "char_span": [31, 42], "ent_id": "D006220", "tok_span": [5, 8]}, {"name": "Muscle rigidity", "ent_type": "Disease", "char_span": [0, 15], "ent_id": "D009127", "tok_span": [0, 2]}, {"name": "5,7-dichlorokynurenic acid", "ent_type": "Chemical", "char_span": [61, 87], "ent_id": "C066192", "tok_span": [21, 31]}, {"name": "5,7-DCKA", "ent_type": "Chemical", "char_span": [354, 362], "ent_id": "C066192", "tok_span": [101, 107]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [499, 510], "ent_id": "D006220", "tok_span": [138, 141]}, {"name": "muscle rigidity", "ent_type": "Disease", "char_span": [281, 296], "ent_id": "D009127", "tok_span": [84, 86]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [261, 272], "ent_id": "D006220", "tok_span": [79, 82]}, {"name": "5,7-DCKA", "ent_type": "Chemical", "char_span": [89, 97], "ent_id": "C066192", "tok_span": [32, 38]}, {"name": "glycine", "ent_type": "Chemical", "char_span": [112, 119], "ent_id": "D005998", "tok_span": [42, 43]}], "relation_list": [{"subject": "haloperidol", "object": "muscle rigidity", "sbj_char_span": [261, 272], "obj_char_span": [281, 296], "rel_type": "chemical-induced disease", "sbj_tok_span": [79, 82], "obj_tok_span": [84, 86]}, {"subject": "haloperidol", "object": "Muscle rigidity", "sbj_char_span": [499, 510], "obj_char_span": [0, 15], "rel_type": "chemical-induced disease", "sbj_tok_span": [138, 141], "obj_tok_span": [0, 2]}, {"subject": "haloperidol", "object": "Muscle rigidity", "sbj_char_span": [31, 42], "obj_char_span": [0, 15], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [0, 2]}, {"subject": "haloperidol", "object": "muscle rigidity", "sbj_char_span": [31, 42], "obj_char_span": [281, 296], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [84, 86]}, {"subject": "haloperidol", "object": "Muscle rigidity", "sbj_char_span": [261, 272], "obj_char_span": [0, 15], "rel_type": "chemical-induced disease", "sbj_tok_span": [79, 82], "obj_tok_span": [0, 2]}, {"subject": "haloperidol", "object": "muscle rigidity", "sbj_char_span": [499, 510], "obj_char_span": [281, 296], "rel_type": "chemical-induced disease", "sbj_tok_span": [138, 141], "obj_tok_span": [84, 86]}], "umls_entity_list": []}, {"text": "Myopathy, defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg).", "entity_list": [{"name": "creatine", "ent_type": "Chemical", "char_span": [42, 50], "ent_id": "D003401", "tok_span": [8, 10]}, {"name": "lovastatin", "ent_type": "Chemical", "char_span": [185, 195], "ent_id": "D008148", "tok_span": [33, 35]}, {"name": "Myopathy", "ent_type": "Disease", "char_span": [0, 8], "ent_id": "D009135", "tok_span": [0, 2]}], "relation_list": [{"subject": "lovastatin", "object": "Myopathy", "sbj_char_span": [185, 195], "obj_char_span": [0, 8], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 35], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.", "entity_list": [{"name": "quipazine", "ent_type": "Chemical", "char_span": [86, 95], "ent_id": "D011814", "tok_span": [21, 25]}, {"name": "REM sleep deprivation", "ent_type": "Disease", "char_span": [15, 36], "ent_id": "D012892", "tok_span": [3, 6]}, {"name": "head twitches", "ent_type": "Disease", "char_span": [104, 117], "ent_id": "D009069", "tok_span": [27, 31]}, {"name": "apomorphine", "ent_type": "Chemical", "char_span": [47, 58], "ent_id": "D001058", "tok_span": [11, 16]}, {"name": "REMD", "ent_type": "Disease", "char_span": [38, 42], "ent_id": "D012892", "tok_span": [7, 9]}, {"name": "aggressiveness", "ent_type": "Disease", "char_span": [67, 81], "ent_id": "D001523", "tok_span": [18, 20]}], "relation_list": [{"subject": "apomorphine", "object": "aggressiveness", "sbj_char_span": [47, 58], "obj_char_span": [67, 81], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 16], "obj_tok_span": [18, 20]}, {"subject": "quipazine", "object": "head twitches", "sbj_char_span": [86, 95], "obj_char_span": [104, 117], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 25], "obj_tok_span": [27, 31]}], "umls_entity_list": []}, {"text": "Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced head twitches.", "entity_list": [{"name": "REMD", "ent_type": "Disease", "char_span": [114, 118], "ent_id": "D012892", "tok_span": [25, 27]}, {"name": "apomorphine", "ent_type": "Chemical", "char_span": [33, 44], "ent_id": "D001058", "tok_span": [8, 13]}, {"name": "head twitches", "ent_type": "Disease", "char_span": [184, 197], "ent_id": "D009069", "tok_span": [45, 49]}, {"name": "REMD", "ent_type": "Disease", "char_span": [160, 164], "ent_id": "D012892", "tok_span": [36, 38]}, {"name": "REMD", "ent_type": "Disease", "char_span": [18, 22], "ent_id": "D012892", "tok_span": [5, 7]}, {"name": "quipazine", "ent_type": "Chemical", "char_span": [166, 175], "ent_id": "D011814", "tok_span": [39, 43]}, {"name": "aggressiveness", "ent_type": "Disease", "char_span": [53, 67], "ent_id": "D001523", "tok_span": [15, 17]}], "relation_list": [{"subject": "apomorphine", "object": "aggressiveness", "sbj_char_span": [33, 44], "obj_char_span": [53, 67], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 13], "obj_tok_span": [15, 17]}, {"subject": "quipazine", "object": "head twitches", "sbj_char_span": [166, 175], "obj_char_span": [184, 197], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 43], "obj_tok_span": [45, 49]}], "umls_entity_list": []}, {"text": "The incidence of parkinsonism was higher at higher doses of haloperidol and in younger patients.", "entity_list": [{"name": "parkinsonism", "ent_type": "Disease", "char_span": [17, 29], "ent_id": "D010302", "tok_span": [3, 6]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [60, 71], "ent_id": "D006220", "tok_span": [12, 15]}], "relation_list": [{"subject": "haloperidol", "object": "parkinsonism", "sbj_char_span": [60, 71], "obj_char_span": [17, 29], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 15], "obj_tok_span": [3, 6]}], "umls_entity_list": []}, {"text": "Hepatic veno-occlusive disease caused by 6-thioguanine.", "entity_list": [{"name": "Hepatic veno-occlusive disease", "ent_type": "Disease", "char_span": [0, 30], "ent_id": "D006504", "tok_span": [0, 8]}, {"name": "6-thioguanine", "ent_type": "Chemical", "char_span": [41, 54], "ent_id": "D013866", "tok_span": [10, 16]}], "relation_list": [{"subject": "6-thioguanine", "object": "Hepatic veno-occlusive disease", "sbj_char_span": [41, 54], "obj_char_span": [0, 30], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 16], "obj_tok_span": [0, 8]}], "umls_entity_list": []}, {"text": "Clinically reversible veno-occlusive disease of the liver developed in a 23-year-old man with acute lymphocytic leukemia after 10 months of maintenance therapy with 6-thioguanine.", "entity_list": [{"name": "acute lymphocytic leukemia", "ent_type": "Disease", "char_span": [94, 120], "ent_id": "D054198", "tok_span": [22, 26]}, {"name": "veno-occlusive disease of the liver", "ent_type": "Disease", "char_span": [22, 57], "ent_id": "D006504", "tok_span": [3, 12]}, {"name": "6-thioguanine", "ent_type": "Chemical", "char_span": [165, 178], "ent_id": "D013866", "tok_span": [33, 39]}], "relation_list": [{"subject": "6-thioguanine", "object": "veno-occlusive disease of the liver", "sbj_char_span": [165, 178], "obj_char_span": [22, 57], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 39], "obj_tok_span": [3, 12]}], "umls_entity_list": []}, {"text": "This case presented a unique opportunity to observe the histologic features of clinically reversible hepatic veno-occlusive disease over time, and may be the first case of veno-occlusive related solely to 6-thioguanine.", "entity_list": [{"name": "6-thioguanine", "ent_type": "Chemical", "char_span": [205, 218], "ent_id": "D013866", "tok_span": [39, 45]}, {"name": "hepatic veno-occlusive disease", "ent_type": "Disease", "char_span": [101, 131], "ent_id": "D006504", "tok_span": [14, 21]}], "relation_list": [{"subject": "6-thioguanine", "object": "hepatic veno-occlusive disease", "sbj_char_span": [205, 218], "obj_char_span": [101, 131], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 45], "obj_tok_span": [14, 21]}], "umls_entity_list": []}, {"text": "Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.", "entity_list": [{"name": "sodium 2-mercaptoethane sulphonate", "ent_type": "Chemical", "char_span": [78, 112], "ent_id": "D015080", "tok_span": [17, 27]}, {"name": "urothelial toxicity", "ent_type": "Disease", "char_span": [32, 51], "ent_id": "D001745", "tok_span": [9, 13]}, {"name": "MESNA", "ent_type": "Chemical", "char_span": [114, 119], "ent_id": "D015080", "tok_span": [28, 30]}, {"name": "ifosfamide", "ent_type": "Chemical", "char_span": [13, 23], "ent_id": "D007069", "tok_span": [2, 7]}, {"name": "lung cancer", "ent_type": "Disease", "char_span": [149, 160], "ent_id": "D008175", "tok_span": [37, 39]}], "relation_list": [{"subject": "ifosfamide", "object": "urothelial toxicity", "sbj_char_span": [13, 23], "obj_char_span": [32, 51], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 7], "obj_tok_span": [9, 13]}], "umls_entity_list": []}, {"text": "The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.", "entity_list": [{"name": "IF", "ent_type": "Chemical", "char_span": [251, 253], "ent_id": "D007069", "tok_span": [56, 57]}, {"name": "lung cancer", "ent_type": "Disease", "char_span": [218, 229], "ent_id": "D008175", "tok_span": [51, 53]}, {"name": "ifosfamide", "ent_type": "Chemical", "char_span": [149, 159], "ent_id": "D007069", "tok_span": [31, 36]}, {"name": "MESNA", "ent_type": "Chemical", "char_span": [103, 108], "ent_id": "D015080", "tok_span": [21, 23]}, {"name": "thiol", "ent_type": "Chemical", "char_span": [52, 57], "ent_id": "D013438", "tok_span": [8, 9]}, {"name": "IF", "ent_type": "Chemical", "char_span": [161, 163], "ent_id": "D007069", "tok_span": [37, 38]}, {"name": "sodium 2-mercaptoethane sulphonate", "ent_type": "Chemical", "char_span": [67, 101], "ent_id": "D015080", "tok_span": [10, 20]}, {"name": "urothelial toxicity", "ent_type": "Disease", "char_span": [118, 137], "ent_id": "D001745", "tok_span": [25, 29]}], "relation_list": [{"subject": "IF", "object": "urothelial toxicity", "sbj_char_span": [161, 163], "obj_char_span": [118, 137], "rel_type": "chemical-induced disease", "sbj_tok_span": [37, 38], "obj_tok_span": [25, 29]}, {"subject": "ifosfamide", "object": "urothelial toxicity", "sbj_char_span": [149, 159], "obj_char_span": [118, 137], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 36], "obj_tok_span": [25, 29]}, {"subject": "IF", "object": "urothelial toxicity", "sbj_char_span": [251, 253], "obj_char_span": [118, 137], "rel_type": "chemical-induced disease", "sbj_tok_span": [56, 57], "obj_tok_span": [25, 29]}], "umls_entity_list": []}, {"text": "Production of autochthonous prostate cancer in Lobund-Wistar rats by treatments with N-nitroso-N-methylurea and testosterone.", "entity_list": [{"name": "testosterone", "ent_type": "Chemical", "char_span": [112, 124], "ent_id": "D013739", "tok_span": [29, 30]}, {"name": "prostate cancer", "ent_type": "Disease", "char_span": [28, 43], "ent_id": "D011471", "tok_span": [7, 9]}, {"name": "N-nitroso-N-methylurea", "ent_type": "Chemical", "char_span": [85, 107], "ent_id": "D008770", "tok_span": [19, 28]}], "relation_list": [{"subject": "N-nitroso-N-methylurea", "object": "prostate cancer", "sbj_char_span": [85, 107], "obj_char_span": [28, 43], "rel_type": "chemical-induced disease", "sbj_tok_span": [19, 28], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.", "entity_list": [{"name": "prostate adenocarcinomas", "ent_type": "Disease", "char_span": [75, 99], "ent_id": "D011471", "tok_span": [22, 25]}, {"name": "testosterone propionate", "ent_type": "Chemical", "char_span": [175, 198], "ent_id": "D043343", "tok_span": [52, 56]}, {"name": "tumor", "ent_type": "Disease", "char_span": [236, 241], "ent_id": "D009369", "tok_span": [73, 74]}, {"name": "TP", "ent_type": "Chemical", "char_span": [201, 203], "ent_id": "D043343", "tok_span": [58, 59]}, {"name": "N-nitroso-N-methylurea", "ent_type": "Chemical", "char_span": [132, 154], "ent_id": "D008770", "tok_span": [32, 41]}, {"name": "PAs", "ent_type": "Disease", "char_span": [101, 104], "ent_id": "D011471", "tok_span": [26, 28]}], "relation_list": [{"subject": "TP", "object": "prostate adenocarcinomas", "sbj_char_span": [201, 203], "obj_char_span": [75, 99], "rel_type": "chemical-induced disease", "sbj_tok_span": [58, 59], "obj_tok_span": [22, 25]}, {"subject": "testosterone propionate", "object": "prostate adenocarcinomas", "sbj_char_span": [175, 198], "obj_char_span": [75, 99], "rel_type": "chemical-induced disease", "sbj_tok_span": [52, 56], "obj_tok_span": [22, 25]}, {"subject": "TP", "object": "PAs", "sbj_char_span": [201, 203], "obj_char_span": [101, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [58, 59], "obj_tok_span": [26, 28]}, {"subject": "N-nitroso-N-methylurea", "object": "PAs", "sbj_char_span": [132, 154], "obj_char_span": [101, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 41], "obj_tok_span": [26, 28]}, {"subject": "N-nitroso-N-methylurea", "object": "prostate adenocarcinomas", "sbj_char_span": [132, 154], "obj_char_span": [75, 99], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 41], "obj_tok_span": [22, 25]}, {"subject": "testosterone propionate", "object": "PAs", "sbj_char_span": [175, 198], "obj_char_span": [101, 104], "rel_type": "chemical-induced disease", "sbj_tok_span": [52, 56], "obj_tok_span": [26, 28]}], "umls_entity_list": []}, {"text": "Within the same timeframe, no L-W rat developed a similar palpable PA when treated only with TP.", "entity_list": [{"name": "TP", "ent_type": "Chemical", "char_span": [93, 95], "ent_id": "D043343", "tok_span": [21, 22]}, {"name": "PA", "ent_type": "Disease", "char_span": [67, 69], "ent_id": "D011471", "tok_span": [16, 17]}], "relation_list": [{"subject": "TP", "object": "PA", "sbj_char_span": [93, 95], "obj_char_span": [67, 69], "rel_type": "chemical-induced disease", "sbj_tok_span": [21, 22], "obj_tok_span": [16, 17]}], "umls_entity_list": []}, {"text": "In L-W rats, TP acted as a tumor enhancement agent, with primary emphasis on the development of prostate cancer.", "entity_list": [{"name": "tumor", "ent_type": "Disease", "char_span": [27, 32], "ent_id": "D009369", "tok_span": [10, 11]}, {"name": "TP", "ent_type": "Chemical", "char_span": [13, 15], "ent_id": "D043343", "tok_span": [6, 7]}, {"name": "prostate cancer", "ent_type": "Disease", "char_span": [96, 111], "ent_id": "D011471", "tok_span": [21, 23]}], "relation_list": [{"subject": "TP", "object": "prostate cancer", "sbj_char_span": [13, 15], "obj_char_span": [96, 111], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "A dystonia-like syndrome after neuropeptide (MSH/ACTH) stimulation of the rat locus ceruleus.", "entity_list": [{"name": "dystonia", "ent_type": "Disease", "char_span": [2, 10], "ent_id": "D004421", "tok_span": [1, 3]}, {"name": "ACTH", "ent_type": "Chemical", "char_span": [49, 53], "ent_id": "D000324", "tok_span": [13, 14]}, {"name": "MSH", "ent_type": "Chemical", "char_span": [45, 48], "ent_id": "D009074", "tok_span": [10, 12]}], "relation_list": [{"subject": "ACTH", "object": "dystonia", "sbj_char_span": [49, 53], "obj_char_span": [2, 10], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 14], "obj_tok_span": [1, 3]}, {"subject": "MSH", "object": "dystonia", "sbj_char_span": [45, 48], "obj_char_span": [2, 10], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 12], "obj_tok_span": [1, 3]}], "umls_entity_list": []}, {"text": "In the present study, the authors determined if treatment with D-MED prevents the muscle rigidity caused by high-dose alfentanil anesthesia in the rat.", "entity_list": [{"name": "alfentanil", "ent_type": "Chemical", "char_span": [118, 128], "ent_id": "D015760", "tok_span": [23, 27]}, {"name": "D-MED", "ent_type": "Chemical", "char_span": [63, 68], "ent_id": "D020927", "tok_span": [11, 14]}, {"name": "muscle rigidity", "ent_type": "Disease", "char_span": [82, 97], "ent_id": "D009127", "tok_span": [16, 18]}], "relation_list": [{"subject": "alfentanil", "object": "muscle rigidity", "sbj_char_span": [118, 128], "obj_char_span": [82, 97], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 27], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "In contrast, D-MED prevented alfentanil-induced muscle rigidity in a dose-dependent fashion.", "entity_list": [{"name": "D-MED", "ent_type": "Chemical", "char_span": [13, 18], "ent_id": "D020927", "tok_span": [3, 6]}, {"name": "alfentanil", "ent_type": "Chemical", "char_span": [29, 39], "ent_id": "D015760", "tok_span": [7, 11]}, {"name": "muscle rigidity", "ent_type": "Disease", "char_span": [48, 63], "ent_id": "D009127", "tok_span": [13, 15]}], "relation_list": [{"subject": "alfentanil", "object": "muscle rigidity", "sbj_char_span": [29, 39], "obj_char_span": [48, 63], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.", "entity_list": [{"name": "renal disease", "ent_type": "Disease", "char_span": [113, 126], "ent_id": "D007674", "tok_span": [22, 24]}, {"name": "imipenem/cilastatin", "ent_type": "Chemical", "char_span": [179, 198], "ent_id": "C044650", "tok_span": [31, 39]}, {"name": "CVA", "ent_type": "Disease", "char_span": [74, 77], "ent_id": "D020521", "tok_span": [12, 14]}, {"name": "head trauma", "ent_type": "Disease", "char_span": [82, 93], "ent_id": "D006259", "tok_span": [16, 18]}, {"name": "seizures", "ent_type": "Disease", "char_span": [137, 145], "ent_id": "D012640", "tok_span": [25, 26]}, {"name": "cerebral vascular accident", "ent_type": "Disease", "char_span": [46, 72], "ent_id": "D020521", "tok_span": [8, 11]}], "relation_list": [{"subject": "imipenem/cilastatin", "object": "seizures", "sbj_char_span": [179, 198], "obj_char_span": [137, 145], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 39], "obj_tok_span": [25, 26]}], "umls_entity_list": []}, {"text": "The ability of insulin treatment to reverse or prevent the changes in urinary bladder function caused by streptozotocin-induced diabetes mellitus.\n 1", "entity_list": [{"name": "diabetes mellitus", "ent_type": "Disease", "char_span": [128, 145], "ent_id": "D003920", "tok_span": [23, 25]}, {"name": "streptozotocin", "ent_type": "Chemical", "char_span": [105, 119], "ent_id": "D013311", "tok_span": [17, 21]}], "relation_list": [{"subject": "streptozotocin", "object": "diabetes mellitus", "sbj_char_span": [105, 119], "obj_char_span": [128, 145], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 21], "obj_tok_span": [23, 25]}], "umls_entity_list": []}, {"text": "The effects of insulin treatment on in vivo and in vitro urinary bladder function in streptozotocin-diabetic rats were investigated. 2.", "entity_list": [{"name": "streptozotocin", "ent_type": "Chemical", "char_span": [85, 99], "ent_id": "D013311", "tok_span": [15, 19]}, {"name": "diabetic", "ent_type": "Disease", "char_span": [100, 108], "ent_id": "D003920", "tok_span": [20, 21]}], "relation_list": [{"subject": "streptozotocin", "object": "diabetic", "sbj_char_span": [85, 99], "obj_char_span": [100, 108], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 19], "obj_tok_span": [20, 21]}], "umls_entity_list": []}, {"text": "The data indicate that the effects of streptozotocin-induced diabetes on urinary bladder function are both prevented and reversed by insulin treatment.", "entity_list": [{"name": "diabetes", "ent_type": "Disease", "char_span": [61, 69], "ent_id": "D003920", "tok_span": [13, 14]}, {"name": "streptozotocin", "ent_type": "Chemical", "char_span": [38, 52], "ent_id": "D013311", "tok_span": [7, 11]}], "relation_list": [{"subject": "streptozotocin", "object": "diabetes", "sbj_char_span": [38, 52], "obj_char_span": [61, 69], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 11], "obj_tok_span": [13, 14]}], "umls_entity_list": []}, {"text": "The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.", "entity_list": [{"name": "hypertension", "ent_type": "Disease", "char_span": [45, 57], "ent_id": "D006973", "tok_span": [9, 10]}, {"name": "edema", "ent_type": "Disease", "char_span": [103, 108], "ent_id": "D004487", "tok_span": [21, 22]}, {"name": "neuronal dysfunction", "ent_type": "Disease", "char_span": [244, 264], "ent_id": "D009410", "tok_span": [48, 50]}, {"name": "phenylephrine", "ent_type": "Chemical", "char_span": [23, 36], "ent_id": "D010656", "tok_span": [4, 7]}, {"name": "ischemic", "ent_type": "Disease", "char_span": [178, 186], "ent_id": "D007511", "tok_span": [36, 37]}, {"name": "edema", "ent_type": "Disease", "char_span": [148, 153], "ent_id": "D004487", "tok_span": [30, 31]}, {"name": "MCAO", "ent_type": "Disease", "char_span": [79, 83], "ent_id": "D020244", "tok_span": [15, 17]}, {"name": "ischemic", "ent_type": "Disease", "char_span": [116, 124], "ent_id": "D007511", "tok_span": [24, 25]}], "relation_list": [{"subject": "phenylephrine", "object": "hypertension", "sbj_char_span": [23, 36], "obj_char_span": [45, 57], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [9, 10]}], "umls_entity_list": []}, {"text": "Amiodarone is an effective antiarrhythmic agent whose utility is limited by many side-effects, the most problematic being pneumonitis.", "entity_list": [{"name": "Amiodarone", "ent_type": "Chemical", "char_span": [0, 10], "ent_id": "D000638", "tok_span": [0, 4]}, {"name": "pneumonitis", "ent_type": "Disease", "char_span": [122, 133], "ent_id": "D011014", "tok_span": [26, 29]}], "relation_list": [{"subject": "Amiodarone", "object": "pneumonitis", "sbj_char_span": [0, 10], "obj_char_span": [122, 133], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [26, 29]}], "umls_entity_list": []}, {"text": "Light chain proteinuria and cellular mediated immunity in rifampin treated patients with tuberculosis.", "entity_list": [{"name": "tuberculosis", "ent_type": "Disease", "char_span": [89, 101], "ent_id": "D014376", "tok_span": [14, 15]}, {"name": "proteinuria", "ent_type": "Disease", "char_span": [12, 23], "ent_id": "D011507", "tok_span": [2, 3]}, {"name": "rifampin", "ent_type": "Chemical", "char_span": [58, 66], "ent_id": "D012293", "tok_span": [8, 11]}], "relation_list": [{"subject": "rifampin", "object": "proteinuria", "sbj_char_span": [58, 66], "obj_char_span": [12, 23], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [2, 3]}], "umls_entity_list": []}, {"text": "Light chain proteinuria was found in 9 of 17 tuberculosis patients treated with rifampin.", "entity_list": [{"name": "tuberculosis", "ent_type": "Disease", "char_span": [45, 57], "ent_id": "D014376", "tok_span": [9, 10]}, {"name": "rifampin", "ent_type": "Chemical", "char_span": [80, 88], "ent_id": "D012293", "tok_span": [13, 16]}, {"name": "proteinuria", "ent_type": "Disease", "char_span": [12, 23], "ent_id": "D011507", "tok_span": [2, 3]}], "relation_list": [{"subject": "rifampin", "object": "proteinuria", "sbj_char_span": [80, 88], "obj_char_span": [12, 23], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 16], "obj_tok_span": [2, 3]}], "umls_entity_list": []}, {"text": "Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.", "entity_list": [{"name": "hypertension", "ent_type": "Disease", "char_span": [104, 116], "ent_id": "D006973", "tok_span": [17, 18]}, {"name": "potassium", "ent_type": "Chemical", "char_span": [8, 17], "ent_id": "D011188", "tok_span": [1, 2]}, {"name": "hypokalaemia", "ent_type": "Disease", "char_span": [27, 39], "ent_id": "D007008", "tok_span": [4, 8]}, {"name": "sodium", "ent_type": "Chemical", "char_span": [143, 149], "ent_id": "D012964", "tok_span": [23, 24]}, {"name": "chlorthalidone", "ent_type": "Chemical", "char_span": [47, 61], "ent_id": "D002752", "tok_span": [9, 12]}], "relation_list": [{"subject": "chlorthalidone", "object": "hypokalaemia", "sbj_char_span": [47, 61], "obj_char_span": [27, 39], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "In this study we postulated that during acute renal failure induced by gentamicin the transient or dynamic response of blood vessels could be affected, and that antioxidants can prevent the changes in dynamic responses of blood vessels.", "entity_list": [{"name": "acute renal failure", "ent_type": "Disease", "char_span": [40, 59], "ent_id": "D058186", "tok_span": [7, 10]}, {"name": "gentamicin", "ent_type": "Chemical", "char_span": [71, 81], "ent_id": "D005839", "tok_span": [12, 14]}], "relation_list": [{"subject": "gentamicin", "object": "acute renal failure", "sbj_char_span": [71, 81], "obj_char_span": [40, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 14], "obj_tok_span": [7, 10]}], "umls_entity_list": []}, {"text": "Oxytocin is a commonly used uterotonic that can cause significant and even fatal hypotension, particularly when given as a bolus.", "entity_list": [{"name": "Oxytocin", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D010121", "tok_span": [0, 3]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [81, 92], "ent_id": "D007022", "tok_span": [16, 17]}], "relation_list": [{"subject": "Oxytocin", "object": "hypotension", "sbj_char_span": [0, 8], "obj_char_span": [81, 92], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [16, 17]}], "umls_entity_list": []}, {"text": "Oxytocin-induced hypotension at cesarean delivery may be incorrectly attributed to blood loss.", "entity_list": [{"name": "Oxytocin", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D010121", "tok_span": [0, 3]}, {"name": "blood loss", "ent_type": "Disease", "char_span": [83, 93], "ent_id": "D006473", "tok_span": [15, 17]}, {"name": "hypotension", "ent_type": "Disease", "char_span": [17, 28], "ent_id": "D007022", "tok_span": [5, 6]}], "relation_list": [{"subject": "Oxytocin", "object": "hypotension", "sbj_char_span": [0, 8], "obj_char_span": [17, 28], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 6]}], "umls_entity_list": []}, {"text": "Hypotension in response to oxytocin was associated with a decrease in systemic vascular resistance and a compensatory increase in stroke volume, heart rate and cardiac output.", "entity_list": [{"name": "oxytocin", "ent_type": "Chemical", "char_span": [27, 35], "ent_id": "D010121", "tok_span": [5, 8]}, {"name": "stroke", "ent_type": "Disease", "char_span": [130, 136], "ent_id": "D020521", "tok_span": [22, 23]}, {"name": "Hypotension", "ent_type": "Disease", "char_span": [0, 11], "ent_id": "D007022", "tok_span": [0, 2]}], "relation_list": [{"subject": "oxytocin", "object": "Hypotension", "sbj_char_span": [27, 35], "obj_char_span": [0, 11], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout (VIP-/-) mice with cyclophosphamide (CYP)-induced cystitis.", "entity_list": [{"name": "cyclophosphamide", "ent_type": "Chemical", "char_span": [114, 130], "ent_id": "D003520", "tok_span": [24, 27]}, {"name": "cystitis", "ent_type": "Disease", "char_span": [145, 153], "ent_id": "D003556", "tok_span": [32, 34]}, {"name": "CYP", "ent_type": "Chemical", "char_span": [132, 135], "ent_id": "D003520", "tok_span": [28, 29]}], "relation_list": [{"subject": "cyclophosphamide", "object": "cystitis", "sbj_char_span": [114, 130], "obj_char_span": [145, 153], "rel_type": "chemical-induced disease", "sbj_tok_span": [24, 27], "obj_tok_span": [32, 34]}, {"subject": "CYP", "object": "cystitis", "sbj_char_span": [132, 135], "obj_char_span": [145, 153], "rel_type": "chemical-induced disease", "sbj_tok_span": [28, 29], "obj_tok_span": [32, 34]}], "umls_entity_list": []}, {"text": "VIP(-/-) mice exhibit altered bladder function and neurochemical properties in micturition pathways after cyclophosphamide (CYP)-induced cystitis.", "entity_list": [{"name": "cystitis", "ent_type": "Disease", "char_span": [137, 145], "ent_id": "D003556", "tok_span": [30, 32]}, {"name": "cyclophosphamide", "ent_type": "Chemical", "char_span": [106, 122], "ent_id": "D003520", "tok_span": [22, 25]}, {"name": "CYP", "ent_type": "Chemical", "char_span": [124, 127], "ent_id": "D003520", "tok_span": [26, 27]}], "relation_list": [{"subject": "cyclophosphamide", "object": "cystitis", "sbj_char_span": [106, 122], "obj_char_span": [137, 145], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 25], "obj_tok_span": [30, 32]}, {"subject": "CYP", "object": "cystitis", "sbj_char_span": [124, 127], "obj_char_span": [137, 145], "rel_type": "chemical-induced disease", "sbj_tok_span": [26, 27], "obj_tok_span": [30, 32]}], "umls_entity_list": []}, {"text": "A mouse inflammatory cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type (WT) and VIP(-/-) mice with or without CYP-induced cystitis (150 mg/kg; i.p.; 48 h).", "entity_list": [{"name": "CYP", "ent_type": "Chemical", "char_span": [181, 184], "ent_id": "D003520", "tok_span": [39, 40]}, {"name": "cystitis", "ent_type": "Disease", "char_span": [193, 201], "ent_id": "D003556", "tok_span": [42, 44]}], "relation_list": [{"subject": "CYP", "object": "cystitis", "sbj_char_span": [181, 184], "obj_char_span": [193, 201], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 40], "obj_tok_span": [42, 44]}], "umls_entity_list": []}, {"text": "OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.", "entity_list": [{"name": "elevated intraocular pressure", "ent_type": "Disease", "char_span": [53, 82], "ent_id": "D009798", "tok_span": [9, 13]}, {"name": "fluocinolone acetonide", "ent_type": "Chemical", "char_span": [131, 153], "ent_id": "D005446", "tok_span": [25, 31]}, {"name": "uveitis", "ent_type": "Disease", "char_span": [106, 113], "ent_id": "D014605", "tok_span": [19, 22]}, {"name": "FA", "ent_type": "Chemical", "char_span": [155, 157], "ent_id": "D005446", "tok_span": [32, 33]}], "relation_list": [{"subject": "fluocinolone acetonide", "object": "elevated intraocular pressure", "sbj_char_span": [131, 153], "obj_char_span": [53, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 31], "obj_tok_span": [9, 13]}, {"subject": "FA", "object": "elevated intraocular pressure", "sbj_char_span": [155, 157], "obj_char_span": [53, 82], "rel_type": "chemical-induced disease", "sbj_tok_span": [32, 33], "obj_tok_span": [9, 13]}], "umls_entity_list": []}, {"text": "Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.", "entity_list": [{"name": "levodopa", "ent_type": "Chemical", "char_span": [122, 130], "ent_id": "D007980", "tok_span": [27, 30]}, {"name": "dyskinesias", "ent_type": "Disease", "char_span": [139, 150], "ent_id": "D004409", "tok_span": [32, 36]}, {"name": "bradykinesia", "ent_type": "Disease", "char_span": [30, 42], "ent_id": "D018476", "tok_span": [6, 11]}, {"name": "rigidity", "ent_type": "Disease", "char_span": [47, 55], "ent_id": "D009127", "tok_span": [12, 13]}], "relation_list": [{"subject": "levodopa", "object": "dyskinesias", "sbj_char_span": [122, 130], "obj_char_span": [139, 150], "rel_type": "chemical-induced disease", "sbj_tok_span": [27, 30], "obj_tok_span": [32, 36]}], "umls_entity_list": []}, {"text": "Case report: Dexatrim (Phenylpropanolamine) as a cause of myocardial infarction.", "entity_list": [{"name": "Dexatrim", "ent_type": "Chemical", "char_span": [13, 21], "ent_id": "D010665", "tok_span": [3, 6]}, {"name": "myocardial infarction", "ent_type": "Disease", "char_span": [58, 79], "ent_id": "D009203", "tok_span": [17, 19]}, {"name": "Phenylpropanolamine", "ent_type": "Chemical", "char_span": [23, 42], "ent_id": "D010665", "tok_span": [7, 12]}], "relation_list": [{"subject": "Phenylpropanolamine", "object": "myocardial infarction", "sbj_char_span": [23, 42], "obj_char_span": [58, 79], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 12], "obj_tok_span": [17, 19]}, {"subject": "Dexatrim", "object": "myocardial infarction", "sbj_char_span": [13, 21], "obj_char_span": [58, 79], "rel_type": "chemical-induced disease", "sbj_tok_span": [3, 6], "obj_tok_span": [17, 19]}], "umls_entity_list": []}, {"text": "Risperidone-associated, benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse.", "entity_list": [{"name": "Risperidone", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D018967", "tok_span": [0, 3]}, {"name": "visual disturbances", "ent_type": "Disease", "char_span": [41, 60], "ent_id": "D010468", "tok_span": [8, 10]}, {"name": "LSD", "ent_type": "Chemical", "char_span": [110, 113], "ent_id": "D008238", "tok_span": [19, 21]}, {"name": "schizophrenic", "ent_type": "Disease", "char_span": [64, 77], "ent_id": "D012559", "tok_span": [11, 13]}], "relation_list": [{"subject": "Risperidone", "object": "visual disturbances", "sbj_char_span": [0, 11], "obj_char_span": [41, 60], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "They both reported short episodes of transient visual disturbances, which appeared immediately after starting treatment with risperidone.", "entity_list": [{"name": "risperidone", "ent_type": "Chemical", "char_span": [125, 136], "ent_id": "D018967", "tok_span": [17, 20]}, {"name": "visual disturbances", "ent_type": "Disease", "char_span": [47, 66], "ent_id": "D010468", "tok_span": [7, 9]}], "relation_list": [{"subject": "risperidone", "object": "visual disturbances", "sbj_char_span": [125, 136], "obj_char_span": [47, 66], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "Risperidone administration was continued and the visual disturbances gradually wore off.", "entity_list": [{"name": "Risperidone", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D018967", "tok_span": [0, 3]}, {"name": "visual disturbances", "ent_type": "Disease", "char_span": [49, 68], "ent_id": "D010468", "tok_span": [8, 10]}], "relation_list": [{"subject": "Risperidone", "object": "visual disturbances", "sbj_char_span": [0, 11], "obj_char_span": [49, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure.", "entity_list": [{"name": "poly(ADP-ribose)", "ent_type": "Chemical", "char_span": [14, 30], "ent_id": "D011064", "tok_span": [2, 9]}, {"name": "doxorubicin", "ent_type": "Chemical", "char_span": [72, 83], "ent_id": "D004317", "tok_span": [14, 15]}, {"name": "heart failure", "ent_type": "Disease", "char_span": [92, 105], "ent_id": "D006333", "tok_span": [17, 19]}], "relation_list": [{"subject": "doxorubicin", "object": "heart failure", "sbj_char_span": [72, 83], "obj_char_span": [92, 105], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 15], "obj_tok_span": [17, 19]}], "umls_entity_list": []}, {"text": "Fluconazole-induced torsade de pointes.", "entity_list": [{"name": "Fluconazole", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D015725", "tok_span": [0, 3]}, {"name": "torsade de pointes", "ent_type": "Disease", "char_span": [20, 38], "ent_id": "D016171", "tok_span": [5, 10]}], "relation_list": [{"subject": "Fluconazole", "object": "torsade de pointes", "sbj_char_span": [0, 11], "obj_char_span": [20, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 10]}], "umls_entity_list": []}, {"text": "OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.", "entity_list": [{"name": "torsade de pointes", "ent_type": "Disease", "char_span": [55, 73], "ent_id": "D016171", "tok_span": [12, 17]}, {"name": "fluconazole", "ent_type": "Chemical", "char_span": [92, 103], "ent_id": "D015725", "tok_span": [23, 26]}, {"name": "fluconazole", "ent_type": "Chemical", "char_span": [32, 43], "ent_id": "D015725", "tok_span": [7, 10]}, {"name": "TDP", "ent_type": "Disease", "char_span": [75, 78], "ent_id": "D016171", "tok_span": [18, 20]}, {"name": "TDP", "ent_type": "Disease", "char_span": [122, 125], "ent_id": "D016171", "tok_span": [31, 33]}], "relation_list": [{"subject": "fluconazole", "object": "TDP", "sbj_char_span": [92, 103], "obj_char_span": [122, 125], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [31, 33]}, {"subject": "fluconazole", "object": "TDP", "sbj_char_span": [32, 43], "obj_char_span": [75, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [18, 20]}, {"subject": "fluconazole", "object": "torsade de pointes", "sbj_char_span": [92, 103], "obj_char_span": [55, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [12, 17]}, {"subject": "fluconazole", "object": "torsade de pointes", "sbj_char_span": [32, 43], "obj_char_span": [55, 73], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [12, 17]}, {"subject": "fluconazole", "object": "TDP", "sbj_char_span": [32, 43], "obj_char_span": [122, 125], "rel_type": "chemical-induced disease", "sbj_tok_span": [7, 10], "obj_tok_span": [31, 33]}, {"subject": "fluconazole", "object": "TDP", "sbj_char_span": [92, 103], "obj_char_span": [75, 78], "rel_type": "chemical-induced disease", "sbj_tok_span": [23, 26], "obj_tok_span": [18, 20]}], "umls_entity_list": []}, {"text": "CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.", "entity_list": [{"name": "TDP", "ent_type": "Disease", "char_span": [384, 387], "ent_id": "D016171", "tok_span": [76, 78]}, {"name": "TDP", "ent_type": "Disease", "char_span": [106, 109], "ent_id": "D016171", "tok_span": [25, 27]}, {"name": "TDP", "ent_type": "Disease", "char_span": [197, 200], "ent_id": "D016171", "tok_span": [44, 46]}, {"name": "coronary artery disease", "ent_type": "Disease", "char_span": [212, 235], "ent_id": "D003324", "tok_span": [48, 51]}, {"name": "congestive heart failure", "ent_type": "Disease", "char_span": [253, 277], "ent_id": "D006333", "tok_span": [54, 59]}, {"name": "cardiomyopathy", "ent_type": "Disease", "char_span": [237, 251], "ent_id": "D009202", "tok_span": [52, 53]}, {"name": "fluconazole", "ent_type": "Chemical", "char_span": [143, 154], "ent_id": "D015725", "tok_span": [33, 36]}, {"name": "fluconazole", "ent_type": "Chemical", "char_span": [368, 379], "ent_id": "D015725", "tok_span": [72, 75]}], "relation_list": [{"subject": "fluconazole", "object": "TDP", "sbj_char_span": [143, 154], "obj_char_span": [197, 200], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 36], "obj_tok_span": [44, 46]}, {"subject": "fluconazole", "object": "TDP", "sbj_char_span": [143, 154], "obj_char_span": [384, 387], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 36], "obj_tok_span": [76, 78]}, {"subject": "fluconazole", "object": "TDP", "sbj_char_span": [143, 154], "obj_char_span": [106, 109], "rel_type": "chemical-induced disease", "sbj_tok_span": [33, 36], "obj_tok_span": [25, 27]}, {"subject": "fluconazole", "object": "TDP", "sbj_char_span": [368, 379], "obj_char_span": [197, 200], "rel_type": "chemical-induced disease", "sbj_tok_span": [72, 75], "obj_tok_span": [44, 46]}, {"subject": "fluconazole", "object": "TDP", "sbj_char_span": [368, 379], "obj_char_span": [384, 387], "rel_type": "chemical-induced disease", "sbj_tok_span": [72, 75], "obj_tok_span": [76, 78]}, {"subject": "fluconazole", "object": "TDP", "sbj_char_span": [368, 379], "obj_char_span": [106, 109], "rel_type": "chemical-induced disease", "sbj_tok_span": [72, 75], "obj_tok_span": [25, 27]}], "umls_entity_list": []}, {"text": "The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.", "entity_list": [{"name": "fluconazole", "ent_type": "Chemical", "char_span": [312, 323], "ent_id": "D015725", "tok_span": [55, 58]}, {"name": "fluconazole", "ent_type": "Chemical", "char_span": [22, 33], "ent_id": "D015725", "tok_span": [5, 8]}, {"name": "NSVT", "ent_type": "Disease", "char_span": [168, 172], "ent_id": "D017180", "tok_span": [28, 30]}, {"name": "TDP", "ent_type": "Disease", "char_span": [4, 7], "ent_id": "D016171", "tok_span": [1, 3]}, {"name": "ventricular tachycardia", "ent_type": "Disease", "char_span": [143, 166], "ent_id": "D017180", "tok_span": [25, 27]}, {"name": "premature ventricular contractions", "ent_type": "Disease", "char_span": [91, 125], "ent_id": "D018879", "tok_span": [18, 21]}, {"name": "TDP", "ent_type": "Disease", "char_span": [347, 350], "ent_id": "D016171", "tok_span": [62, 64]}], "relation_list": [{"subject": "fluconazole", "object": "TDP", "sbj_char_span": [22, 33], "obj_char_span": [4, 7], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [1, 3]}, {"subject": "fluconazole", "object": "TDP", "sbj_char_span": [312, 323], "obj_char_span": [347, 350], "rel_type": "chemical-induced disease", "sbj_tok_span": [55, 58], "obj_tok_span": [62, 64]}, {"subject": "fluconazole", "object": "TDP", "sbj_char_span": [312, 323], "obj_char_span": [4, 7], "rel_type": "chemical-induced disease", "sbj_tok_span": [55, 58], "obj_tok_span": [1, 3]}, {"subject": "fluconazole", "object": "TDP", "sbj_char_span": [22, 33], "obj_char_span": [347, 350], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [62, 64]}], "umls_entity_list": []}, {"text": "In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.", "entity_list": [{"name": "premature ventricular contractions", "ent_type": "Disease", "char_span": [136, 170], "ent_id": "D018879", "tok_span": [26, 29]}, {"name": "QT prolongation", "ent_type": "Disease", "char_span": [74, 89], "ent_id": "D008133", "tok_span": [13, 16]}, {"name": "NSVT", "ent_type": "Disease", "char_span": [127, 131], "ent_id": "D017180", "tok_span": [23, 25]}, {"name": "fluconazole", "ent_type": "Chemical", "char_span": [257, 268], "ent_id": "D015725", "tok_span": [42, 45]}, {"name": "TDP", "ent_type": "Disease", "char_span": [93, 96], "ent_id": "D016171", "tok_span": [17, 19]}], "relation_list": [{"subject": "fluconazole", "object": "TDP", "sbj_char_span": [257, 268], "obj_char_span": [93, 96], "rel_type": "chemical-induced disease", "sbj_tok_span": [42, 45], "obj_tok_span": [17, 19]}], "umls_entity_list": []}, {"text": "CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause prolongation of the QT interval, leading to TDP.", "entity_list": [{"name": "prolongation of the QT interval", "ent_type": "Disease", "char_span": [87, 118], "ent_id": "D008133", "tok_span": [19, 25]}, {"name": "fluconazole", "ent_type": "Chemical", "char_span": [45, 56], "ent_id": "D015725", "tok_span": [8, 11]}, {"name": "TDP", "ent_type": "Disease", "char_span": [131, 134], "ent_id": "D016171", "tok_span": [28, 30]}], "relation_list": [{"subject": "fluconazole", "object": "TDP", "sbj_char_span": [45, 56], "obj_char_span": [131, 134], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [28, 30]}], "umls_entity_list": []}, {"text": "In the NASCIS, there was no mention regarding the possibility of acute corticosteroid myopathy that high-dose methylprednisolone may cause.", "entity_list": [{"name": "methylprednisolone", "ent_type": "Chemical", "char_span": [110, 128], "ent_id": "D008775", "tok_span": [22, 26]}, {"name": "myopathy", "ent_type": "Disease", "char_span": [86, 94], "ent_id": "D009135", "tok_span": [16, 18]}, {"name": "corticosteroid", "ent_type": "Chemical", "char_span": [71, 85], "ent_id": "D000305", "tok_span": [15, 16]}], "relation_list": [{"subject": "methylprednisolone", "object": "myopathy", "sbj_char_span": [110, 128], "obj_char_span": [86, 94], "rel_type": "chemical-induced disease", "sbj_tok_span": [22, 26], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.", "entity_list": [{"name": "spinal cord injury", "ent_type": "Disease", "char_span": [244, 262], "ent_id": "D013119", "tok_span": [46, 49]}, {"name": "myopathy", "ent_type": "Disease", "char_span": [17, 25], "ent_id": "D009135", "tok_span": [3, 5]}, {"name": "steroid", "ent_type": "Chemical", "char_span": [9, 16], "ent_id": "D013256", "tok_span": [2, 3]}, {"name": "methylprednisolone", "ent_type": "Chemical", "char_span": [211, 229], "ent_id": "D008775", "tok_span": [39, 43]}, {"name": "myopathy", "ent_type": "Disease", "char_span": [170, 178], "ent_id": "D009135", "tok_span": [31, 33]}, {"name": "steroid", "ent_type": "Chemical", "char_span": [162, 169], "ent_id": "D013256", "tok_span": [30, 31]}], "relation_list": [{"subject": "methylprednisolone", "object": "myopathy", "sbj_char_span": [211, 229], "obj_char_span": [17, 25], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 43], "obj_tok_span": [3, 5]}, {"subject": "methylprednisolone", "object": "myopathy", "sbj_char_span": [211, 229], "obj_char_span": [170, 178], "rel_type": "chemical-induced disease", "sbj_tok_span": [39, 43], "obj_tok_span": [31, 33]}], "umls_entity_list": []}, {"text": "To our knowledge, this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute corticosteroid myopathy.", "entity_list": [{"name": "methylprednisolone", "ent_type": "Chemical", "char_span": [84, 102], "ent_id": "D008775", "tok_span": [14, 18]}, {"name": "myopathy", "ent_type": "Disease", "char_span": [156, 164], "ent_id": "D009135", "tok_span": [27, 29]}, {"name": "corticosteroid", "ent_type": "Chemical", "char_span": [141, 155], "ent_id": "D000305", "tok_span": [26, 27]}], "relation_list": [{"subject": "methylprednisolone", "object": "myopathy", "sbj_char_span": [84, 102], "obj_char_span": [156, 164], "rel_type": "chemical-induced disease", "sbj_tok_span": [14, 18], "obj_tok_span": [27, 29]}], "umls_entity_list": []}, {"text": "OUTCOME MEASURES: Pupil size at time points after administration of tropicamide and pilocarpine; scopolamine-induced impairment in word recall.", "entity_list": [{"name": "impairment in word recall", "ent_type": "Disease", "char_span": [117, 142], "ent_id": "D008569", "tok_span": [30, 34]}, {"name": "tropicamide", "ent_type": "Chemical", "char_span": [68, 79], "ent_id": "D014331", "tok_span": [16, 20]}, {"name": "pilocarpine", "ent_type": "Chemical", "char_span": [84, 95], "ent_id": "D010862", "tok_span": [21, 24]}, {"name": "scopolamine", "ent_type": "Chemical", "char_span": [97, 108], "ent_id": "D012601", "tok_span": [25, 28]}], "relation_list": [{"subject": "scopolamine", "object": "impairment in word recall", "sbj_char_span": [97, 108], "obj_char_span": [117, 142], "rel_type": "chemical-induced disease", "sbj_tok_span": [25, 28], "obj_tok_span": [30, 34]}], "umls_entity_list": []}, {"text": "Compared with the young group, the elderly group had greater scopolamine-induced impairment in word recall 60, 90 and 120 minutes after administration (p < 0.05).", "entity_list": [{"name": "scopolamine", "ent_type": "Chemical", "char_span": [61, 72], "ent_id": "D012601", "tok_span": [11, 14]}, {"name": "impairment in word recall", "ent_type": "Disease", "char_span": [81, 106], "ent_id": "D008569", "tok_span": [16, 20]}], "relation_list": [{"subject": "scopolamine", "object": "impairment in word recall", "sbj_char_span": [61, 72], "obj_char_span": [81, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 14], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "Acetazolamide-induced Gerstmann syndrome.", "entity_list": [{"name": "Acetazolamide", "ent_type": "Chemical", "char_span": [0, 13], "ent_id": "D000086", "tok_span": [0, 3]}, {"name": "Gerstmann syndrome", "ent_type": "Disease", "char_span": [22, 40], "ent_id": "D005862", "tok_span": [5, 9]}], "relation_list": [{"subject": "Acetazolamide", "object": "Gerstmann syndrome", "sbj_char_span": [0, 13], "obj_char_span": [22, 40], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "We report a case of acetazolamide-induced Gerstmann syndrome in a patient with normal renal function, to highlight predisposing factors that are frequently overlooked.", "entity_list": [{"name": "Gerstmann syndrome", "ent_type": "Disease", "char_span": [42, 60], "ent_id": "D005862", "tok_span": [10, 14]}, {"name": "acetazolamide", "ent_type": "Chemical", "char_span": [20, 33], "ent_id": "D000086", "tok_span": [5, 8]}], "relation_list": [{"subject": "acetazolamide", "object": "Gerstmann syndrome", "sbj_char_span": [20, 33], "obj_char_span": [42, 60], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "Hypomania-like syndrome induced by olanzapine.", "entity_list": [{"name": "Hypomania", "ent_type": "Disease", "char_span": [0, 9], "ent_id": "D001714", "tok_span": [0, 3]}, {"name": "olanzapine", "ent_type": "Chemical", "char_span": [35, 45], "ent_id": "C076029", "tok_span": [8, 11]}], "relation_list": [{"subject": "olanzapine", "object": "Hypomania", "sbj_char_span": [35, 45], "obj_char_span": [0, 9], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "We report a female patient with a diagnosis of a not otherwise specified psychotic disorder (DSM-IV) who developed hypomania shortly after the introduction of olanzapine treatment.", "entity_list": [{"name": "psychotic disorder", "ent_type": "Disease", "char_span": [73, 91], "ent_id": "D011618", "tok_span": [13, 16]}, {"name": "hypomania", "ent_type": "Disease", "char_span": [115, 124], "ent_id": "D001714", "tok_span": [23, 26]}, {"name": "olanzapine", "ent_type": "Chemical", "char_span": [159, 169], "ent_id": "C076029", "tok_span": [31, 34]}], "relation_list": [{"subject": "olanzapine", "object": "hypomania", "sbj_char_span": [159, 169], "obj_char_span": [115, 124], "rel_type": "chemical-induced disease", "sbj_tok_span": [31, 34], "obj_tok_span": [23, 26]}], "umls_entity_list": []}, {"text": "In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.", "entity_list": [{"name": "paracetamol", "ent_type": "Chemical", "char_span": [76, 87], "ent_id": "D000082", "tok_span": [15, 19]}, {"name": "overdose", "ent_type": "Disease", "char_span": [88, 96], "ent_id": "D062787", "tok_span": [19, 21]}, {"name": "ALF", "ent_type": "Disease", "char_span": [65, 68], "ent_id": "D017114", "tok_span": [11, 13]}, {"name": "oxygen", "ent_type": "Chemical", "char_span": [22, 28], "ent_id": "D010100", "tok_span": [5, 6]}], "relation_list": [{"subject": "paracetamol", "object": "ALF", "sbj_char_span": [76, 87], "obj_char_span": [65, 68], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 19], "obj_tok_span": [11, 13]}], "umls_entity_list": []}, {"text": "These results demonstrate a neutrophil defect in ALF due to paracetamol overdose, that is complement dependent but independent of serum complement, possibly connected to the complement receptor.", "entity_list": [{"name": "overdose", "ent_type": "Disease", "char_span": [72, 80], "ent_id": "D062787", "tok_span": [15, 17]}, {"name": "ALF", "ent_type": "Disease", "char_span": [49, 52], "ent_id": "D017114", "tok_span": [7, 9]}, {"name": "paracetamol", "ent_type": "Chemical", "char_span": [60, 71], "ent_id": "D000082", "tok_span": [11, 15]}], "relation_list": [{"subject": "paracetamol", "object": "ALF", "sbj_char_span": [60, 71], "obj_char_span": [49, 52], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 15], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol.", "entity_list": [{"name": "sertraline", "ent_type": "Chemical", "char_span": [21, 31], "ent_id": "D020280", "tok_span": [5, 8]}, {"name": "haloperidol", "ent_type": "Chemical", "char_span": [89, 100], "ent_id": "D006220", "tok_span": [17, 20]}, {"name": "cognitive impairment", "ent_type": "Disease", "char_span": [63, 83], "ent_id": "D003072", "tok_span": [14, 16]}], "relation_list": [{"subject": "haloperidol", "object": "cognitive impairment", "sbj_char_span": [89, 100], "obj_char_span": [63, 83], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "RESULTS: Impairment of cognitive function was observed 6 to 8 hours after administration of haloperidol on Day 2 but was not evident 23 hours after dosing.", "entity_list": [{"name": "haloperidol", "ent_type": "Chemical", "char_span": [92, 103], "ent_id": "D006220", "tok_span": [17, 20]}, {"name": "Impairment of cognitive function", "ent_type": "Disease", "char_span": [9, 41], "ent_id": "D003072", "tok_span": [2, 8]}], "relation_list": [{"subject": "haloperidol", "object": "Impairment of cognitive function", "sbj_char_span": [92, 103], "obj_char_span": [9, 41], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [2, 8]}], "umls_entity_list": []}, {"text": "CONCLUSION: Haloperidol produced a clear profile of cognitive impairment that was not worsened by concomitant sertraline administration.", "entity_list": [{"name": "cognitive impairment", "ent_type": "Disease", "char_span": [52, 72], "ent_id": "D003072", "tok_span": [10, 12]}, {"name": "Haloperidol", "ent_type": "Chemical", "char_span": [12, 23], "ent_id": "D006220", "tok_span": [2, 5]}, {"name": "sertraline", "ent_type": "Chemical", "char_span": [110, 120], "ent_id": "D020280", "tok_span": [19, 22]}], "relation_list": [{"subject": "Haloperidol", "object": "cognitive impairment", "sbj_char_span": [12, 23], "obj_char_span": [52, 72], "rel_type": "chemical-induced disease", "sbj_tok_span": [2, 5], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Five patients with cancer who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed.", "entity_list": [{"name": "cancer", "ent_type": "Disease", "char_span": [19, 25], "ent_id": "D009369", "tok_span": [3, 4]}, {"name": "ciprofloxacin", "ent_type": "Chemical", "char_span": [89, 102], "ent_id": "D002939", "tok_span": [13, 18]}, {"name": "acute renal failure", "ent_type": "Disease", "char_span": [40, 59], "ent_id": "D058186", "tok_span": [6, 9]}], "relation_list": [{"subject": "ciprofloxacin", "object": "acute renal failure", "sbj_char_span": [89, 102], "obj_char_span": [40, 59], "rel_type": "chemical-induced disease", "sbj_tok_span": [13, 18], "obj_tok_span": [6, 9]}], "umls_entity_list": []}, {"text": "An improvement in renal function that followed the discontinuation of the offending antibiotic supports the presumptive diagnosis of ciprofloxacin-induced acute renal failure.", "entity_list": [{"name": "ciprofloxacin", "ent_type": "Chemical", "char_span": [133, 146], "ent_id": "D002939", "tok_span": [20, 25]}, {"name": "acute renal failure", "ent_type": "Disease", "char_span": [155, 174], "ent_id": "D058186", "tok_span": [27, 30]}], "relation_list": [{"subject": "ciprofloxacin", "object": "acute renal failure", "sbj_char_span": [133, 146], "obj_char_span": [155, 174], "rel_type": "chemical-induced disease", "sbj_tok_span": [20, 25], "obj_tok_span": [27, 30]}], "umls_entity_list": []}, {"text": "Pentamidine isethionate has been associated with ventricular tachyarrhythmias, including torsade de pointes.", "entity_list": [{"name": "Pentamidine isethionate", "ent_type": "Chemical", "char_span": [0, 23], "ent_id": "D010419", "tok_span": [0, 8]}, {"name": "ventricular tachyarrhythmias", "ent_type": "Disease", "char_span": [49, 77], "ent_id": "D017180", "tok_span": [12, 18]}, {"name": "torsade de pointes", "ent_type": "Disease", "char_span": [89, 107], "ent_id": "D016171", "tok_span": [20, 25]}], "relation_list": [{"subject": "Pentamidine isethionate", "object": "torsade de pointes", "sbj_char_span": [0, 23], "obj_char_span": [89, 107], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 8], "obj_tok_span": [20, 25]}], "umls_entity_list": []}, {"text": "Pentamidine-induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.", "entity_list": [{"name": "magnesium", "ent_type": "Chemical", "char_span": [63, 72], "ent_id": "D008274", "tok_span": [16, 17]}, {"name": "Pentamidine", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D010419", "tok_span": [0, 4]}, {"name": "torsade de pointes", "ent_type": "Disease", "char_span": [20, 38], "ent_id": "D016171", "tok_span": [6, 11]}, {"name": "hypomagnesemia", "ent_type": "Disease", "char_span": [84, 98], "ent_id": "C537153", "tok_span": [19, 23]}], "relation_list": [{"subject": "Pentamidine", "object": "torsade de pointes", "sbj_char_span": [0, 11], "obj_char_span": [20, 38], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 4], "obj_tok_span": [6, 11]}], "umls_entity_list": []}, {"text": "Torsade de pointes occurred after an average of 10 days of treatment with pentamidine.", "entity_list": [{"name": "Torsade de pointes", "ent_type": "Disease", "char_span": [0, 18], "ent_id": "D016171", "tok_span": [0, 6]}, {"name": "pentamidine", "ent_type": "Chemical", "char_span": [74, 85], "ent_id": "D010419", "tok_span": [16, 19]}], "relation_list": [{"subject": "pentamidine", "object": "Torsade de pointes", "sbj_char_span": [74, 85], "obj_char_span": [0, 18], "rel_type": "chemical-induced disease", "sbj_tok_span": [16, 19], "obj_tok_span": [0, 6]}], "umls_entity_list": []}, {"text": "Torsade de pointes can be treated when recognized early, possibly without discontinuation of pentamidine.", "entity_list": [{"name": "Torsade de pointes", "ent_type": "Disease", "char_span": [0, 18], "ent_id": "D016171", "tok_span": [0, 6]}, {"name": "pentamidine", "ent_type": "Chemical", "char_span": [93, 104], "ent_id": "D010419", "tok_span": [17, 20]}], "relation_list": [{"subject": "pentamidine", "object": "Torsade de pointes", "sbj_char_span": [93, 104], "obj_char_span": [0, 18], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 20], "obj_tok_span": [0, 6]}], "umls_entity_list": []}, {"text": "Time dependence of plasma malondialdehyde, oxypurines, and nucleosides during incomplete cerebral ischemia in the rat.", "entity_list": [{"name": "oxypurines", "ent_type": "Chemical", "char_span": [43, 53], "ent_id": "-1", "tok_span": [9, 13]}, {"name": "nucleosides", "ent_type": "Chemical", "char_span": [59, 70], "ent_id": "D009705", "tok_span": [15, 18]}, {"name": "malondialdehyde", "ent_type": "Chemical", "char_span": [26, 41], "ent_id": "D008315", "tok_span": [4, 8]}, {"name": "cerebral ischemia", "ent_type": "Disease", "char_span": [89, 106], "ent_id": "D002545", "tok_span": [20, 22]}], "relation_list": [{"subject": "malondialdehyde", "object": "cerebral ischemia", "sbj_char_span": [26, 41], "obj_char_span": [89, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 8], "obj_tok_span": [20, 22]}], "umls_entity_list": []}, {"text": "A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops, presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis.", "entity_list": [{"name": "muscle weakness", "ent_type": "Disease", "char_span": [129, 144], "ent_id": "D018908", "tok_span": [23, 25]}, {"name": "echothiophate iodide", "ent_type": "Chemical", "char_span": [66, 86], "ent_id": "D004456", "tok_span": [11, 16]}, {"name": "myasthenia gravis", "ent_type": "Disease", "char_span": [186, 203], "ent_id": "D009157", "tok_span": [32, 38]}], "relation_list": [{"subject": "echothiophate iodide", "object": "muscle weakness", "sbj_char_span": [66, 86], "obj_char_span": [129, 144], "rel_type": "chemical-induced disease", "sbj_tok_span": [11, 16], "obj_tok_span": [23, 25]}], "umls_entity_list": []}, {"text": "Acute renal failure in high dose carboplatin chemotherapy.", "entity_list": [{"name": "Acute renal failure", "ent_type": "Disease", "char_span": [0, 19], "ent_id": "D058186", "tok_span": [0, 3]}, {"name": "carboplatin", "ent_type": "Chemical", "char_span": [33, 44], "ent_id": "D016190", "tok_span": [6, 9]}], "relation_list": [{"subject": "carboplatin", "object": "Acute renal failure", "sbj_char_span": [33, 44], "obj_char_span": [0, 19], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 9], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "Carboplatin has been reported to cause acute renal failure when administered in high doses to adult patients.", "entity_list": [{"name": "Carboplatin", "ent_type": "Chemical", "char_span": [0, 11], "ent_id": "D016190", "tok_span": [0, 3]}, {"name": "acute renal failure", "ent_type": "Disease", "char_span": [39, 58], "ent_id": "D058186", "tok_span": [8, 11]}], "relation_list": [{"subject": "Carboplatin", "object": "acute renal failure", "sbj_char_span": [0, 11], "obj_char_span": [39, 58], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [8, 11]}], "umls_entity_list": []}, {"text": "She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.", "entity_list": [{"name": "ovarian failure", "ent_type": "Disease", "char_span": [8, 23], "ent_id": "D010049", "tok_span": [2, 4]}, {"name": "estrogens", "ent_type": "Chemical", "char_span": [113, 122], "ent_id": "D004967", "tok_span": [17, 19]}, {"name": "endometrial cancer", "ent_type": "Disease", "char_span": [169, 187], "ent_id": "D016889", "tok_span": [27, 29]}, {"name": "Hodgkin disease", "ent_type": "Disease", "char_span": [73, 88], "ent_id": "D006689", "tok_span": [10, 13]}], "relation_list": [{"subject": "estrogens", "object": "endometrial cancer", "sbj_char_span": [113, 122], "obj_char_span": [169, 187], "rel_type": "chemical-induced disease", "sbj_tok_span": [17, 19], "obj_tok_span": [27, 29]}], "umls_entity_list": []}, {"text": "Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically.", "entity_list": [{"name": "estrogens", "ent_type": "Chemical", "char_span": [27, 36], "ent_id": "D004967", "tok_span": [4, 6]}, {"name": "endometrial carcinoma", "ent_type": "Disease", "char_span": [110, 131], "ent_id": "D016889", "tok_span": [18, 20]}, {"name": "cancer", "ent_type": "Disease", "char_span": [63, 69], "ent_id": "D009369", "tok_span": [10, 11]}, {"name": "ovarian failure", "ent_type": "Disease", "char_span": [41, 56], "ent_id": "D010049", "tok_span": [7, 9]}], "relation_list": [{"subject": "estrogens", "object": "endometrial carcinoma", "sbj_char_span": [27, 36], "obj_char_span": [110, 131], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 6], "obj_tok_span": [18, 20]}], "umls_entity_list": []}, {"text": "Induction of the obstructive sleep apnea syndrome in a woman by exogenous androgen administration.", "entity_list": [{"name": "androgen", "ent_type": "Chemical", "char_span": [74, 82], "ent_id": "D000728", "tok_span": [12, 13]}, {"name": "obstructive sleep apnea syndrome", "ent_type": "Disease", "char_span": [17, 49], "ent_id": "D020181", "tok_span": [3, 7]}], "relation_list": [{"subject": "androgen", "object": "obstructive sleep apnea syndrome", "sbj_char_span": [74, 82], "obj_char_span": [17, 49], "rel_type": "chemical-induced disease", "sbj_tok_span": [12, 13], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54-yr-old woman who had developed physical changes and the syndrome of obstructive sleep apnea while being administered exogenous androgens.", "entity_list": [{"name": "syndrome of obstructive sleep apnea", "ent_type": "Disease", "char_span": [167, 202], "ent_id": "D020181", "tok_span": [34, 39]}, {"name": "androgens", "ent_type": "Chemical", "char_span": [238, 247], "ent_id": "D000728", "tok_span": [43, 45]}], "relation_list": [{"subject": "androgens", "object": "syndrome of obstructive sleep apnea", "sbj_char_span": [238, 247], "obj_char_span": [167, 202], "rel_type": "chemical-induced disease", "sbj_tok_span": [43, 45], "obj_tok_span": [34, 39]}], "umls_entity_list": []}, {"text": "A rechallenge with androgen produced symptoms of obstructive sleep apnea that abated upon withdrawal of the hormone.", "entity_list": [{"name": "androgen", "ent_type": "Chemical", "char_span": [19, 27], "ent_id": "D000728", "tok_span": [6, 7]}, {"name": "obstructive sleep apnea", "ent_type": "Disease", "char_span": [49, 72], "ent_id": "D020181", "tok_span": [10, 13]}], "relation_list": [{"subject": "androgen", "object": "obstructive sleep apnea", "sbj_char_span": [19, 27], "obj_char_span": [49, 72], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 7], "obj_tok_span": [10, 13]}], "umls_entity_list": []}, {"text": "Development of the obstructive sleep apnea syndrome must be considered a possible side effect of androgen therapy.", "entity_list": [{"name": "obstructive sleep apnea syndrome", "ent_type": "Disease", "char_span": [19, 51], "ent_id": "D020181", "tok_span": [3, 7]}, {"name": "androgen", "ent_type": "Chemical", "char_span": [97, 105], "ent_id": "D000728", "tok_span": [15, 16]}], "relation_list": [{"subject": "androgen", "object": "obstructive sleep apnea syndrome", "sbj_char_span": [97, 105], "obj_char_span": [19, 51], "rel_type": "chemical-induced disease", "sbj_tok_span": [15, 16], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "Effect of captopril on pre-existing and aminonucleoside-induced proteinuria in spontaneously hypertensive rats.", "entity_list": [{"name": "aminonucleoside", "ent_type": "Chemical", "char_span": [40, 55], "ent_id": "D011692", "tok_span": [10, 13]}, {"name": "hypertensive", "ent_type": "Disease", "char_span": [93, 105], "ent_id": "D006973", "tok_span": [18, 19]}, {"name": "captopril", "ent_type": "Chemical", "char_span": [10, 19], "ent_id": "D002216", "tok_span": [2, 5]}, {"name": "proteinuria", "ent_type": "Disease", "char_span": [64, 75], "ent_id": "D011507", "tok_span": [15, 16]}], "relation_list": [{"subject": "aminonucleoside", "object": "proteinuria", "sbj_char_span": [40, 55], "obj_char_span": [64, 75], "rel_type": "chemical-induced disease", "sbj_tok_span": [10, 13], "obj_tok_span": [15, 16]}], "umls_entity_list": []}, {"text": "Also, captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR.", "entity_list": [{"name": "captopril", "ent_type": "Chemical", "char_span": [6, 15], "ent_id": "D002216", "tok_span": [2, 5]}, {"name": "puromycin aminonucleoside", "ent_type": "Chemical", "char_span": [107, 132], "ent_id": "D011692", "tok_span": [18, 23]}, {"name": "proteinuria", "ent_type": "Disease", "char_span": [84, 95], "ent_id": "D011507", "tok_span": [15, 16]}], "relation_list": [{"subject": "puromycin aminonucleoside", "object": "proteinuria", "sbj_char_span": [107, 132], "obj_char_span": [84, 95], "rel_type": "chemical-induced disease", "sbj_tok_span": [18, 23], "obj_tok_span": [15, 16]}], "umls_entity_list": []}, {"text": "In one patient, enflurane administered during a donor nephrectomy resulted in unexpected partial motor seizures.", "entity_list": [{"name": "enflurane", "ent_type": "Chemical", "char_span": [16, 25], "ent_id": "D004737", "tok_span": [4, 7]}, {"name": "seizures", "ent_type": "Disease", "char_span": [103, 111], "ent_id": "D012640", "tok_span": [18, 19]}], "relation_list": [{"subject": "enflurane", "object": "seizures", "sbj_char_span": [16, 25], "obj_char_span": [103, 111], "rel_type": "chemical-induced disease", "sbj_tok_span": [4, 7], "obj_tok_span": [18, 19]}], "umls_entity_list": []}, {"text": "Epileptic foci delineated and activated by enflurane were surgically ablated and the patients are now seizure-free.", "entity_list": [{"name": "Epileptic", "ent_type": "Disease", "char_span": [0, 9], "ent_id": "D004827", "tok_span": [0, 3]}, {"name": "seizure", "ent_type": "Disease", "char_span": [102, 109], "ent_id": "D012640", "tok_span": [21, 22]}, {"name": "enflurane", "ent_type": "Chemical", "char_span": [43, 52], "ent_id": "D004737", "tok_span": [9, 12]}], "relation_list": [{"subject": "enflurane", "object": "seizure", "sbj_char_span": [43, 52], "obj_char_span": [102, 109], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [21, 22]}], "umls_entity_list": []}, {"text": "Reversible cerebral lesions associated with tiazofurin usage: MR demonstration.", "entity_list": [{"name": "cerebral lesions", "ent_type": "Disease", "char_span": [11, 27], "ent_id": "D001927", "tok_span": [2, 4]}, {"name": "tiazofurin", "ent_type": "Chemical", "char_span": [44, 54], "ent_id": "C033706", "tok_span": [6, 10]}], "relation_list": [{"subject": "tiazofurin", "object": "cerebral lesions", "sbj_char_span": [44, 54], "obj_char_span": [11, 27], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 10], "obj_tok_span": [2, 4]}], "umls_entity_list": []}, {"text": "Enhanced stimulus-induced neurotransmitter overflow in epinephrine-induced hypertensive rats is not mediated by prejunctional beta-adrenoceptor activation.", "entity_list": [{"name": "hypertensive", "ent_type": "Disease", "char_span": [75, 87], "ent_id": "D006973", "tok_span": [13, 14]}, {"name": "epinephrine", "ent_type": "Chemical", "char_span": [55, 66], "ent_id": "D004837", "tok_span": [8, 11]}], "relation_list": [{"subject": "epinephrine", "object": "hypertensive", "sbj_char_span": [55, 66], "obj_char_span": [75, 87], "rel_type": "chemical-induced disease", "sbj_tok_span": [8, 11], "obj_tok_span": [13, 14]}], "umls_entity_list": []}, {"text": "We used chloroquine or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs.", "entity_list": [{"name": "hydroxychloroquine", "ent_type": "Chemical", "char_span": [23, 41], "ent_id": "D006886", "tok_span": [6, 10]}, {"name": "chloroquine", "ent_type": "Chemical", "char_span": [8, 19], "ent_id": "D002738", "tok_span": [2, 5]}, {"name": "chorioretinopathy", "ent_type": "Disease", "char_span": [89, 106], "ent_id": "D012164", "tok_span": [21, 25]}], "relation_list": [{"subject": "hydroxychloroquine", "object": "chorioretinopathy", "sbj_char_span": [23, 41], "obj_char_span": [89, 106], "rel_type": "chemical-induced disease", "sbj_tok_span": [6, 10], "obj_tok_span": [21, 25]}], "umls_entity_list": []}, {"text": "Water intoxication associated with oxytocin administration during saline-induced abortion.", "entity_list": [{"name": "Water intoxication", "ent_type": "Disease", "char_span": [0, 18], "ent_id": "D014869", "tok_span": [0, 3]}, {"name": "oxytocin", "ent_type": "Chemical", "char_span": [35, 43], "ent_id": "D010121", "tok_span": [5, 8]}, {"name": "abortion", "ent_type": "Disease", "char_span": [81, 89], "ent_id": "D000031", "tok_span": [13, 14]}], "relation_list": [{"subject": "oxytocin", "object": "Water intoxication", "sbj_char_span": [35, 43], "obj_char_span": [0, 18], "rel_type": "chemical-induced disease", "sbj_tok_span": [5, 8], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "Four cases of water intoxication in connection with oxytocin administration during saline-induced abortions are described.", "entity_list": [{"name": "water intoxication", "ent_type": "Disease", "char_span": [14, 32], "ent_id": "D014869", "tok_span": [3, 6]}, {"name": "oxytocin", "ent_type": "Chemical", "char_span": [52, 60], "ent_id": "D010121", "tok_span": [9, 12]}, {"name": "abortions", "ent_type": "Disease", "char_span": [98, 107], "ent_id": "D000031", "tok_span": [17, 19]}], "relation_list": [{"subject": "oxytocin", "object": "water intoxication", "sbj_char_span": [52, 60], "obj_char_span": [14, 32], "rel_type": "chemical-induced disease", "sbj_tok_span": [9, 12], "obj_tok_span": [3, 6]}], "umls_entity_list": []}, {"text": "Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.", "entity_list": [{"name": "water intoxication", "ent_type": "Disease", "char_span": [184, 202], "ent_id": "D014869", "tok_span": [35, 38]}, {"name": "headaches", "ent_type": "Disease", "char_span": [323, 332], "ent_id": "D006261", "tok_span": [63, 65]}, {"name": "abortions", "ent_type": "Disease", "char_span": [52, 61], "ent_id": "D000031", "tok_span": [10, 12]}, {"name": "asthenia", "ent_type": "Disease", "char_span": [287, 295], "ent_id": "D001247", "tok_span": [55, 57]}, {"name": "Oxytocin", "ent_type": "Chemical", "char_span": [0, 8], "ent_id": "D010121", "tok_span": [0, 3]}, {"name": "irritability", "ent_type": "Disease", "char_span": [306, 318], "ent_id": "D001523", "tok_span": [59, 61]}], "relation_list": [{"subject": "Oxytocin", "object": "water intoxication", "sbj_char_span": [0, 8], "obj_char_span": [184, 202], "rel_type": "chemical-induced disease", "sbj_tok_span": [0, 3], "obj_tok_span": [35, 38]}], "umls_entity_list": []}]